<SEC-DOCUMENT>0001558370-23-001580.txt : 20230221
<SEC-HEADER>0001558370-23-001580.hdr.sgml : 20230221
<ACCEPTANCE-DATETIME>20230221091555
ACCESSION NUMBER:		0001558370-23-001580
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		95
CONFORMED PERIOD OF REPORT:	20221231
FILED AS OF DATE:		20230221
DATE AS OF CHANGE:		20230221

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			TACTILE SYSTEMS TECHNOLOGY INC
		CENTRAL INDEX KEY:			0001027838
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37799
		FILM NUMBER:		23645632

	BUSINESS ADDRESS:	
		STREET 1:		1331 TYLER STREET NE STE 200
		CITY:			MINNEAPOLIS
		STATE:			MN
		ZIP:			55413
		BUSINESS PHONE:		866-435-3948

	MAIL ADDRESS:	
		STREET 1:		1331 TYLER STREET NE STE 200
		CITY:			MINNEAPOLIS
		STATE:			MN
		ZIP:			55413
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>tcmd-20221231x10k.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='UTF-8'?>

      <!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 10.2.0.4 -->
      <!-- Based on: iXBRL 1.1 -->
      <!-- Created on: 2/21/2023 1:38:18 PM -->
      <!-- iXBRL Library version: 1.0.8405.27969 -->
      <!-- iXBRL Service Job ID: d2c20843-56d7-44e8-a409-077b0f6e8eb1 -->

  <html xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:tcmd="http://www.tactilemedical.com/20221231" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:srt="http://fasb.org/srt/2022" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xbrldi="http://xbrl.org/2006/xbrldi"><head><meta content="text/html" http-equiv="content-type" /><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" xs:nil="true" contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw" name="us-gaap:CommitmentsAndContingencies" id="Hidden_aRe_ITIiPkGRhMbMyQyrwA"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" xs:nil="true" contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q" name="us-gaap:CommitmentsAndContingencies" id="Hidden_9qaF8uEvyEKyjx097znuhA"></ix:nonFraction><ix:nonNumeric contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw" name="us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="Hidden_2RBFup1GF0aYmRp6sPf_WA">http://fasb.org/us-gaap/2022#OperatingLeaseRightOfUseAsset</ix:nonNumeric><ix:nonNumeric contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="Hidden_AJFhMV1JPUOJ0hFVR48KjQ">http://fasb.org/us-gaap/2022#OperatingLeaseLiabilityCurrent</ix:nonNumeric><ix:nonNumeric contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw" name="us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="Hidden_Ez5Qhbo3AU2e7FSsdfdH2g">http://fasb.org/us-gaap/2022#OperatingLeaseLiabilityNoncurrent</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ" contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" id="Hidden_SRrXC5R_mkC7J8odlogKhQ">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ" contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" id="Hidden_Z0qGnwbWkUSwt3t7s-ACpQ">0</ix:nonFraction><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" name="dei:EntityCentralIndexKey" id="Tc_luXDnhlF3kmZqciYOqfRYg_5_1">0001027838</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" name="dei:DocumentFiscalYearFocus" id="Tc_1AtDzqSotkqOz95i38e_og_7_1">2022</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" name="dei:DocumentFiscalPeriodFocus" id="Tc_n2c0akmvl0i_ROFdpuXG-Q_8_1">FY</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" name="dei:EntityFilerCategory" id="Hidden_WgadwSncGUeeRkl-6pghrg">Accelerated Filer</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" xs:nil="true" contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw" name="us-gaap:PreferredStockValue" id="Hidden_3S7QxW9bN0-5rDK2dHG7WQ"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" xs:nil="true" contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q" name="us-gaap:PreferredStockValue" id="Hidden_FZYePmsfUEaYRZiApBW7xw"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ" contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" id="Hidden__bCQNAsLokuxTIDsHWGXFQ">20252677</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ" contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" id="Hidden_xOwJC91HdkeMBD-SeycYHA">19877786</ix:nonFraction><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_nUg2v2mfW0uAzRdSMTamQQ" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Hidden_-K2S-WgBSE6sH7tBYgqsYw">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_tcmd_GarmentsMember_srt_RangeAxis_srt_MinimumMember_k8qNoq95Rky9-_sJro6IyA" name="tcmd:TermOfProductWarranty" id="Hidden_y-RzrDjl6U6YAkZa8g5tjg">P1Y</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_tcmd_ControllersMember_srt_RangeAxis_srt_MinimumMember_QvX9jbOWVkiQmu6BazrG2Q" name="tcmd:TermOfProductWarranty" id="Hidden_2vCz5hZwoEmnfJJOj_Lktg">P1Y</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_nUg2v2mfW0uAzRdSMTamQQ" name="tcmd:PeriodForConsiderationPaymentAfterShipmentDate" id="Hidden_29m0XALLYEGpUDkg67Logg">P2D</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_tcmd_GarmentsMember_srt_RangeAxis_srt_MinimumMember_k8qNoq95Rky9-_sJro6IyA" name="tcmd:TermOfProductWarranty" id="Hidden_9oGSvawUkUuA-bl9OI56kg">P1Y</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_segment_zejw3MrZOkWEznPtKLNRGQ" contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" decimals="INF" name="us-gaap:NumberOfReportableSegments" id="Hidden_hf125MM_GkGhx3Sj6QqkPA">1</ix:nonFraction><ix:nonNumeric contextRef="As_Of_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember_lOgwHc6a7keMQ5U8kHbmZA" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="Hidden_cPi9QUIkvEuGhENNTJkqkw">P1Y</ix:nonNumeric><ix:nonNumeric contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q" name="us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="Hidden_tKPJpXeds0SiabhmYWAMEg">http://fasb.org/us-gaap/2022#OperatingLeaseRightOfUseAsset</ix:nonNumeric><ix:nonNumeric contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="Hidden_tyE6-ij7k06Rv5IRQ6iD1Q">http://fasb.org/us-gaap/2022#OperatingLeaseLiabilityCurrent</ix:nonNumeric><ix:nonNumeric contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q" name="us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="Hidden_hRi5aCIDPEGUkAgK0iaGvw">http://fasb.org/us-gaap/2022#OperatingLeaseLiabilityNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_Apyhw0rpjEqZ3vFtmoPsAg" name="tcmd:NumberOfConsecutiveTradingDaysInWhichStockPriceExceedCertainPercentageOfClosingPriceOfCommonStockRequiredForAwardToBeGranted" id="Hidden_94egicmKoESPdhUuU5X_1w">P20D</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_L2H-B4harkuWLN7SUIOPRQ" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Hidden_6Mhakd_sLkqC71m6G0M6Og">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_L2H-B4harkuWLN7SUIOPRQ" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="Hidden_tp1Se7X6AEitbPWWRbR6bw">P7Y</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_6-UgFP9YHkKs37vGGIhEVw" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Hidden_EUn6f84eb0OJm-52SjcRtw">P4Y6M</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_SKlrM8781Eet0zFbC3ewTw" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Hidden_M9XtAoRCQE23lB3X4M3v9w">P4Y6M</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_KSWzHsfkUUCC4ceQE_HELQ" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Hidden_iCRDlIEFVkGCl5KX7TVfHQ">P4Y6M</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_tcmd_TimeBasedRestrictedStockUnitsRsusMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_UQNyJOFH5UKq1kC0uw2-mQ" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Hidden_fHxG8ZvlB0ieDTwHUV85QA">P1Y</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_tcmd_PerformanceBasedStockSettledRestrictedStockUnitsMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_-dmVAO8GPEe-d87xbGyf8Q" decimals="4" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" id="Hidden_sHnOWzszGUy7ZkN0NmbHuA">0.3333</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_tcmd_PerformanceBasedStockSettledRestrictedStockUnitsMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_9JG89pH7v0yNuwlry2fC6A" decimals="4" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" id="Hidden_v4hPxGJ7JkKjemco7Ewk7A">0.6667</ix:nonFraction><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_nUg2v2mfW0uAzRdSMTamQQ" name="tcmd:RentToPurchaseArrangementsRentalPeriod" id="Hidden_8JEPt4Tv9EexWjz9141gSw">P3M</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" name="dei:AmendmentFlag" id="Narr_P_FZjDXiJE6os7CzioOzvg">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="tcmd-20221231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_CnxzEZbj2keHiRpKCxnEuw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_CdFl24OyvE-vHZl3Dyt3tg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_IoIhyk8NdE6DGInICUHwgg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_TR941NiDcUCdRWACyKn3Wg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_-1H3pbcbgE2pDEcuUUIOQA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_dQSyY2Nl1EyEQUyJvn7F7A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_H3RLfzlePUicZ6gsHqIN-g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_JAb6JFyA10K9maMFF2T0yQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_BPwmELKt2UWgprqGAT1saQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_iD4fs-NVZUqKbPMH2pu8Tg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_SzV_dAN03kCUiZaHywHGxw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_bAXadoBqGUyVY6l0rjAY1g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_dwEtqEfNw0CpirbkcmdKtw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_jyxtNFkIQECm4cCy3eQwzQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_BMz7mX7-OUWrFBdwQYForQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Qp36H0EGtUGt3jcLLgZfHw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_831Iwe84l0uIaFkRq3YMEA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_2_2016_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_G1Q8otm7u0SlPI0I3gLpyg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-08-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_RangeAxis_srt_MinimumMember_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_MEZgTABuGkCMjTedZP40gQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_VEK6kkacQUeh0rcfcqChxQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_c4XlEVcSZkGUgY9pO9GVYw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MinimumMember_1ONqRYxs-E23uhkk4rcXew"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MaximumMember_AgQnIK2l2UG-kwV420MM5g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember___xLca8jWE2AqShfBEgmlw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_YXF4jcKSZ0az4v_DZj-Otw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_1_1_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_EmployeeStockMember_oauLVrUQf0Cdq6kFtZ4aEg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_1_1_2021_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_GIA9oCLf2kOobzBosxqDOQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tcmd:EquityIncentivePlan2016Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_N_-EN94zSkyi4738ywQnkQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_cTbUJaM5EEi7_dTn33kCIQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_X4ApOCKa20aLE0iARpjyBw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_KSWzHsfkUUCC4ceQE_HELQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_AwardTypeAxis_tcmd_TimeBasedRestrictedStockUnitsRsusMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_Rx5oCF5RME-QoxzFqBAV1g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tcmd:TimeBasedRestrictedStockUnitsRsusMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tcmd:EquityIncentivePlan2016Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_AwardTypeAxis_tcmd_TimeBasedRestrictedStockUnitsRsusMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_IaK_VsGjOEiqSEoE-zGXOw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tcmd:TimeBasedRestrictedStockUnitsRsusMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tcmd:EquityIncentivePlan2016Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_AwardTypeAxis_tcmd_TimeBasedRestrictedStockUnitsRsusMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_RfN-hRdVK0WQ7dibE-9y_A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tcmd:TimeBasedRestrictedStockUnitsRsusMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tcmd:EquityIncentivePlan2016Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_AwardTypeAxis_tcmd_PerformanceBasedStockSettledRestrictedStockUnitsMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_yXZPu2ZWyESDFq8L-JZCHg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tcmd:PerformanceBasedStockSettledRestrictedStockUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tcmd:EquityIncentivePlan2016Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_AwardTypeAxis_tcmd_PerformanceBasedStockSettledRestrictedStockUnitsMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_vFDEcLAy5EyVpxGp-lSAGQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tcmd:PerformanceBasedStockSettledRestrictedStockUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tcmd:EquityIncentivePlan2016Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_tcmd_PerformanceBasedStockSettledRestrictedStockUnitsMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_9JG89pH7v0yNuwlry2fC6A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tcmd:PerformanceBasedStockSettledRestrictedStockUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tcmd:EquityIncentivePlan2016Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_tcmd_PerformanceBasedStockSettledRestrictedStockUnitsMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_-dmVAO8GPEe-d87xbGyf8Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tcmd:PerformanceBasedStockSettledRestrictedStockUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tcmd:EquityIncentivePlan2016Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_tcmd_TimeBasedRestrictedStockUnitsRsusMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_UQNyJOFH5UKq1kC0uw2-mQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tcmd:TimeBasedRestrictedStockUnitsRsusMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tcmd:EquityIncentivePlan2016Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_tcmd_TimeBasedRestrictedStockUnitsRsusMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_8RJLAbFs-0aC61lHpsR90Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tcmd:TimeBasedRestrictedStockUnitsRsusMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tcmd:EquityIncentivePlan2016Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_L2H-B4harkuWLN7SUIOPRQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_x68hCF8ixkS5q2MJuoiIYA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_tcmd_TimeBasedRestrictedStockUnitsRsusMember_OqoDokUrok2FtqlOs8iQLQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tcmd:TimeBasedRestrictedStockUnitsRsusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_tcmd_PerformanceBasedStockSettledRestrictedStockUnitsMember_jgqU-RDfJkWBTKO22fvJHw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tcmd:PerformanceBasedStockSettledRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_tcmd_VeteransAdministrationMember_UImO_mSEIUWRj4_3Jkesdw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">tcmd:VeteransAdministrationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_tcmd_PrivateInsurersMember_Gl5_xQhWx0SDBOy0s9jDJA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">tcmd:PrivateInsurersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_tcmd_MedicareMember_K5sCGhJDSUOfkdarnEOQWg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">tcmd:MedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_tcmd_DurableMedicalEquipmentDistributorsMember_VSaj6O2pMU2ypZXriiw1kg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">tcmd:DurableMedicalEquipmentDistributorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_tcmd_VeteransAdministrationMember_QGri6VTOrky2n0lhb6O-wg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">tcmd:VeteransAdministrationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_tcmd_PrivateInsurersMember_7J0YXfLIgU2pD3Cizu1_Aw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">tcmd:PrivateInsurersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_tcmd_MedicareMember_rK1KRWcE20Ot8cBmMKEQsA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">tcmd:MedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_tcmd_DurableMedicalEquipmentDistributorsMember_FRHWIP8w2UG8vVzzhUcyKg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">tcmd:DurableMedicalEquipmentDistributorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_srt_MajorCustomersAxis_tcmd_VeteransAdministrationMember_nKPbjM6STkCgVrqDgy_u8Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">tcmd:VeteransAdministrationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_srt_MajorCustomersAxis_tcmd_PrivateInsurersMember_6NttS8BSLkSGb2rID11mYQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">tcmd:PrivateInsurersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_srt_MajorCustomersAxis_tcmd_MedicareMember__J8_VCY0Ok-NPKhYcRHpiw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">tcmd:MedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_8_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_BusinessAcquisitionAxis_tcmd_AfflovestPMember_jLq6gqZQRUe0_w5vfb9Asg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tcmd:AfflovestPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ToolsDiesAndMoldsMember_NTOCOwxcN0WCHhE4s7Z6xg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ToolsDiesAndMoldsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_MA9Tzfj_Zkq7UAzFHCpHMQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdsAndLeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_wBBLS9cO1EGcEb4aYAZlcA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_Yh5OMODH40SC-Um87PF3UA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember_jGU_hCQP7EaA8kqaHpKwsg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_tcmd_DemoEquipmentMember_r01Fmv-tlE2ZfmS0SxVG8g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">tcmd:DemoEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ToolsDiesAndMoldsMember_Pvs6l_E6h0O5TC299fq4Bg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ToolsDiesAndMoldsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_MU5-dZQMLEOZnQDTmaetLQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdsAndLeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_cb8KtxnOaUusasmEVS4S6w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_Uf5xoWiQAkuLZI9kCZLPRA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember_Ko8IgMBkWUy1Erw3_JKPQg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_tcmd_DemoEquipmentMember_3j_rU49gBEimc7YFgpwKEw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">tcmd:DemoEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_CreditFacilityAxis_tcmd_TermLoanMember_VIrloQlsfEmn_JzIEt95jA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">tcmd:TermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_i_HrmJK0qEam7JhO2g89aw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_fVykz_MeNEanAhnkwaVQuw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_8_2021_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_4ewNm1bD10K5QwII7IVr3g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_pmPeDzOSDEq1hwWSnhZm1A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember_lOgwHc6a7keMQ5U8kHbmZA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_CBz12HaJ3EelHnd3ISwWrQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember_bxiv0zaNYUqU9S4A8vYbgw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_VehiclesMember_WEhReoFIrk61ZFxikX2DoA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_RangeAxis_srt_MinimumMember_EXKUiZxnk0qVwfOmUunwkw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_lwkNBH8qPUKwpTFPfFM4eg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_8_2021_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember_cbYze6WHq0-MzNMIXQ6G8Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember_IyWAZ3ta8E2Ea1SMrdPPBQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_PatentsMember_LNA_h_4RnkaxxN0_I1BWbQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember_aBd3a_ELrEOm_yysA0S0ag"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_PatentsMember_m8rPRrVCGkCmV2jH3V3EGA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_BusinessAcquisitionAxis_tcmd_AfflovestPMember_0vr8lFFgNk-hj48fe5kJDg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tcmd:AfflovestPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_9_8_2021_To_9_8_2021_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_9xTBZJ8BSEyOBEAowNs5qA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-08</xbrli:startDate><xbrli:endDate>2021-09-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_8_2021_To_9_8_2021_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_CustomerRelationshipsMember_vwfc8GlHbEG6FpxSb_48hw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-08</xbrli:startDate><xbrli:endDate>2021-09-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_CustomerContractsMember_zWlWYJGY4UyP-QjMu9VYLA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_PatentsMember_bHnLKkfY50SShKWlCELEaA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_lM7vBgl8SkW3zbCRJ6akww"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_CustomerRelationshipsMember_jYH-emDiWkiQNaMDqVEM4w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_tcmd_DefensiveIntangibleAssetsMember_6NFOXe0OVEae4LCvhvDg5A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">tcmd:DefensiveIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_PatentsMember_nZCthuPEmEK_vsD9bnMPZg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_TEkHdFvt00SmYBkAMY4_HQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_CustomerRelationshipsMember_64UYdGsGlUaBziSx02KLVQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_CustomerContractsMember_8VJEgmF_UkWBYfqLoC4C3A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_tcmd_DefensiveIntangibleAssetsMember_62-asFO7iEyeD8pb1fZgLA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">tcmd:DefensiveIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_8_2021_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_1vdqkBPIV06qt_Sb8l9xvw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_8_2021_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_CustomerRelationshipsMember_W5D5EY3MR0edt8BoVhmVUQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_PatentsMember_EzMi2_I88kuyRc4Rc_5PoQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_lL8SrIZbB0O4E4gu1p47vA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_CustomerRelationshipsMember_Y08o1mZ38kCDCzt3GAQN8A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_CustomerContractsMember_YzWU1KiStEOVgQlfeA7jcw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_tcmd_DefensiveIntangibleAssetsMember_LZ89k11DfEu3IXN3jY-Q_A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">tcmd:DefensiveIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_PatentsMember_JkjaHeEoUE2DyDTDEjvMwQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_iZuKEYAKNU6aSfE3kxIqUw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_CustomerRelationshipsMember_dmnRIghXk0SjwOQAgPqgtg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_CustomerContractsMember_fTqSuCd94keomoVYMmQiIw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_tcmd_DefensiveIntangibleAssetsMember_QV0b5loORke7y1IpAQUFJQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">tcmd:DefensiveIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_AwardTypeAxis_tcmd_TimeBasedRestrictedStockUnitsRsusMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_qc0c3k5OY0eKiJM_sgU8nA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tcmd:TimeBasedRestrictedStockUnitsRsusMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tcmd:EquityIncentivePlan2016Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_Un8xxO7K-UGnIxffkFMjsw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_AwardTypeAxis_tcmd_PerformanceBasedStockSettledRestrictedStockUnitsMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_GskkIzSZ40CADy7RgEQqjw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tcmd:PerformanceBasedStockSettledRestrictedStockUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tcmd:EquityIncentivePlan2016Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_RetirementPlanNameAxis_tcmd_DefinedContribution401kRetirementPlanMember_tDmbZG8x90OrgLeuanK9nw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">tcmd:DefinedContribution401kRetirementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_RetirementPlanNameAxis_tcmd_DefinedContribution401kRetirementPlanMember_zWNpuLNXTEuhSfDngvS76w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">tcmd:DefinedContribution401kRetirementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_RetirementPlanNameAxis_tcmd_DefinedContribution401kRetirementPlanMember_tGvCSx6Y1EuXw-i1zDT2EA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">tcmd:DefinedContribution401kRetirementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_WDmzwEjdBUiA-CU6PKMNzQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_CreditFacilityAxis_tcmd_TermLoanMember_3Cnmib--SkSEPm4Zq4wPzQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">tcmd:TermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_8_2021_us-gaap_CreditFacilityAxis_tcmd_TermLoanMember_oz1r9Y66CkacJQ3itM6kfg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">tcmd:TermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_VariableRateAxis_us-gaap_LondonInterbankOfferedRateLIBORMember_qtvC3cCEtUGvoYG_aiVd5w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_VariableRateAxis_us-gaap_BaseRateMember_RkYOxE7JdkmHm__eg3-sdw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_VariableRateAxis_us-gaap_LondonInterbankOfferedRateLIBORMember_5Ok3Lj-bZEKdl_78m7_07g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_VariableRateAxis_us-gaap_BaseRateMember_cKhsiHfOCE28P3WddmWqow"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_VariableRateAxis_us-gaap_LondonInterbankOfferedRateLIBORMember_27-_EKPJYUWpaRUxj1OYBQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_VariableRateAxis_us-gaap_FederalFundsEffectiveSwapRateMember_Ox5KmpqBekOgFh1i9iNuQg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:FederalFundsEffectiveSwapRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_VariableRateAxis_us-gaap_BaseRateMember_bmZqSyyD0UC5KiXp5eY0wA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_VariableRateAxis_us-gaap_LondonInterbankOfferedRateLIBORMember_6BVYYrgoDEySTxjBn4sZ3A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_SP3wyCMXCU2i6drZEHq64A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_tcmd_RentalProductServiceMember_UQEeT0sALU2WyRpN4h-d1g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tcmd:RentalProductServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_hfu9P6iNKUi9O4wj8Mt1eQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_tcmd_RentalProductServiceMember_SHuwLl4tzECMukntSz1kJw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tcmd:RentalProductServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember_cRwZGotvHkm9Z1U4mHwTFw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_srt_ProductOrServiceAxis_tcmd_RentalProductServiceMember_NFKOoDrORk2r6CW4q3szBw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tcmd:RentalProductServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_CostOfGoodsTotalMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_SupplierConcentrationRiskMember_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_tcmd_VendorOneMember_vviffeAE5EGD7qLxiUROxg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfGoodsTotalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">tcmd:VendorOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_tcmd_InsuranceCompanyTwoMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_YhUWFBciaEqXEvSlvrAhSQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">tcmd:InsuranceCompanyTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_tcmd_InsuranceCompanyTwoMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_xVT-UB4QW0Gw2arUgYbYcQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">tcmd:InsuranceCompanyTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_tcmd_InsuranceCompanyOneMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_0HtNQF4hrEWyegzUln8uIA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">tcmd:InsuranceCompanyOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_tcmd_InsuranceCompanyOneMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_N4xxMFKVj0S35nREv_ENMA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">tcmd:InsuranceCompanyOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_CostOfGoodsTotalMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_SupplierConcentrationRiskMember_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_tcmd_VendorTwoMember_ofzmjVvnsUW7aaWOzboUlQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfGoodsTotalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">tcmd:VendorTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_tcmd_InsuranceCompanyTwoMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_3m0fCb_Nf0uWfI863PsLKw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">tcmd:InsuranceCompanyTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_tcmd_InsuranceCompanyTwoMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_vLNz00UhJUufY_Zqk3iO2A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">tcmd:InsuranceCompanyTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_tcmd_InsuranceCompanyOneMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_qYkwWgdcNkuDHHwGOvxkhQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">tcmd:InsuranceCompanyOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_tcmd_InsuranceCompanyOneMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_1-eh01sLXEOTZIQ08pcPiw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">tcmd:InsuranceCompanyOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_WCG-z2RnpUGRHcHammTWIw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_YaY3_P_Sw02KL1vnK5w7IQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_CN1dmz1V3Ue1flAlam2dNQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_aFuDPm3quE6OkMXnwfeySg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_EmployeeStockMember_h6LWksYkZk-wYDJVCmudqg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_27_2017_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_EmployeeStockMember_1JhNvac8pkCgs2t4mxK9oQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-04-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_q95ww8WB7U-18mlScI3MCA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_3ga0jBjg6EKA4-znaQ36NQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_9V6sgB50n0-ZfOQSvVu1Mw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_8_2021_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_tcmd_AssetAcquisitionEarnoutPaymentsRevenueTargetsFromOctoberTwoThousandTwentyOneToSeptemberTwoThousandTwentyTwoMember_us-gaap_BusinessAcquisitionAxis_tcmd_AfflovestPMember_u62XShicPUa52TcVaICEVA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">tcmd:AssetAcquisitionEarnoutPaymentsRevenueTargetsFromOctoberTwoThousandTwentyOneToSeptemberTwoThousandTwentyTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tcmd:AfflovestPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_9_8_2021_To_9_8_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_BusinessAcquisitionAxis_tcmd_AfflovestPMember_cXLgD3w8o0mAJ_EMBbTfZg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tcmd:AfflovestPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-08</xbrli:startDate><xbrli:endDate>2021-09-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_8_2021_To_9_8_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_0hChIJ5gE0K__CcmmMTvmQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-08</xbrli:startDate><xbrli:endDate>2021-09-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2021_To_12_31_2021_us-gaap_BusinessAcquisitionAxis_tcmd_AfflovestPMember_C1E4O7zjlUGPDClD_oKeEg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tcmd:AfflovestPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2020_To_12_31_2020_us-gaap_BusinessAcquisitionAxis_tcmd_AfflovestPMember_jQCcMt5pY0Os-LuUZm0lRA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tcmd:AfflovestPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_uLFZTWJi2k6g6WI1HfkiNA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_vevcUAPFYESbYWLi7G0kaQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_KVbTIgc1_EmIcfBzONO5-g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_91EX6xEDf0-UcTWUZJ8XyA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_8_2021_us-gaap_BusinessAcquisitionAxis_tcmd_AfflovestPMember_3FbjYCEqNkWAlMK4QIberg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tcmd:AfflovestPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2018_us-gaap_PropertyPlantAndEquipmentByTypeAxis_tcmd_CorporateHeadQuarterSecondLeaseMember_kJI6F8P6zkKbLuYO9IJnVw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">tcmd:CorporateHeadQuarterSecondLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_31_2018_us-gaap_PropertyPlantAndEquipmentByTypeAxis_tcmd_CorporateHeadQuarterInitialLeaseMember_iOfecFzhU0CEX9fKgtv8qA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">tcmd:CorporateHeadQuarterInitialLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_zrOdl-ZHU0eDIaMQWN19yQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_PerformanceSharesMember_2SwhGbNgwU-bMQqkqXN2dA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_Qq8im1g0PUaVhc7NKNKkWg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_tcmd_EmployeeStockPurchasePlanMember_4b4qjiA0fk6pyDx0k4A_zw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tcmd:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_CIZJzOcjHUyKmot1xYLGwA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_PerformanceSharesMember_rMVulEGBZE-wAbQ2SAc66Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_ghRyW-vZS0uZBW3nKbbR-g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_tcmd_EmployeeStockPurchasePlanMember_f1tc7L44FUqMy8SxWvmMoQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tcmd:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_t1GQxjJoS0WeSfGLeyxUPw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_PerformanceSharesMember_c5JOwteMr0ax5Sb2--bJyg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_bg4XNhQ5v0uWr2dXSfREiw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_tcmd_EmployeeStockPurchasePlanMember_C8tXw8ygUkKbK1P0V6S3LQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tcmd:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingAndMarketingExpenseMember_6DUS8nZX1k2uITtnX1jELw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_WkeJd_L3IEm8ahIsJkn_Ww"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_Ny2qblOYAkWwzAuljmv4Ow"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_6-UgFP9YHkKs37vGGIhEVw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_1cM49KVdP0WP3FTRdFVJvA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_tcmd_TwoThousandEighteenAndTwoThousandTwentyPerformanceBasedRestrictedStockUnitsMember_WZVx9pkMD0SJKZFhIdnWjQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tcmd:TwoThousandEighteenAndTwoThousandTwentyPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingAndMarketingExpenseMember_tE0YJWqzRkusl6_G8TxGpA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_NHelbVJut0SpZ1MaGzM82w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_oF6quC9QMU-Gu_UPthtpzw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_SKlrM8781Eet0zFbC3ewTw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_EmployeeStockMember_5xoE_s_XYkyuIAK5oWCe8Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_-Mhsa97jY0mecFzNVd7m8w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_tcmd_TwoThousandEighteenAndTwoThousandTwentyPerformanceBasedRestrictedStockUnitsMember_HDcRO5L1FU2oWQGAEeWYwA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tcmd:TwoThousandEighteenAndTwoThousandTwentyPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingAndMarketingExpenseMember_LOcVV8870UGUDxZpsZpW1A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_2oRfq2ewaUy6AGWg2Xby5A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_DbypvZkVpEePjQqYGvgkEw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_qOmCDKQT9Eyfuidf3pzRYg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_EmployeeStockMember_8hDu8hXfJECRLadm6BTlqQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_jRQ3JtT1NE2Wt3xFenHFEw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_AggAm3MT3EmHS5mE0Dp2Yg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Yly5bMDTYE-lx-OvMp67yw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_dZyQCZO280GpmViirHXo1g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_tcmd_GarmentsMember_srt_RangeAxis_srt_MinimumMember_k8qNoq95Rky9-_sJro6IyA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tcmd:GarmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_tcmd_GarmentsMember_srt_RangeAxis_srt_MaximumMember_fiHw-QVcjESriGs85ZfH7w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tcmd:GarmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_tcmd_ControllersMember_srt_RangeAxis_srt_MinimumMember_QvX9jbOWVkiQmu6BazrG2Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tcmd:ControllersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_tcmd_ControllersMember_srt_RangeAxis_srt_MaximumMember_wiN7jXmrnkGpVKBXgBLvJA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tcmd:ControllersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_2_2016_To_8_2_2016_jh5ft8WN0USibAdtcwGHiA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2016-08-02</xbrli:startDate><xbrli:endDate>2016-08-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_tcmd_TimeBasedRestrictedStockUnitsRsusMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_Nb-WbjXmjUKf3z1gH8kH5Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tcmd:TimeBasedRestrictedStockUnitsRsusMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tcmd:EquityIncentivePlan2016Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_tcmd_TimeBasedRestrictedStockUnitsRsusMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_YpNaI4H08kWMKCFdksUPJg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tcmd:TimeBasedRestrictedStockUnitsRsusMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tcmd:EquityIncentivePlan2016Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_tcmd_TimeBasedRestrictedStockUnitsRsusMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_-BKViJhhwkykuZDgY3GR5A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tcmd:TimeBasedRestrictedStockUnitsRsusMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tcmd:EquityIncentivePlan2016Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_AwardTypeAxis_tcmd_PerformanceBasedStockSettledRestrictedStockUnitsMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_WpTm0Lj5Q0WDgY5zSwuAIg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tcmd:PerformanceBasedStockSettledRestrictedStockUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tcmd:EquityIncentivePlan2016Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_MJZ8uZEAPEmYMAtcEg9uBg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tcmd:EquityIncentivePlan2016Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_8_2_2016_To_8_2_2016_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_F3xqjLu7uEyeSRqBJT0RuA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-08-02</xbrli:startDate><xbrli:endDate>2016-08-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_2_2016_To_8_2_2016_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_QQrwNskzWkG7CPUnrW9tVw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-08-02</xbrli:startDate><xbrli:endDate>2016-08-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_nUg2v2mfW0uAzRdSMTamQQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_VpuMgvUm10Cec1Yu-NEe1Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_tcmd_PerformanceBasedStockSettledRestrictedStockUnitsMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_CmpNEKSSE0O0i2jPBWOaAg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tcmd:PerformanceBasedStockSettledRestrictedStockUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tcmd:EquityIncentivePlan2016Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_tcmd_PerformanceBasedStockSettledRestrictedStockUnitsMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_Hlc6i7-A9EusSlzegAjTIQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tcmd:PerformanceBasedStockSettledRestrictedStockUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tcmd:EquityIncentivePlan2016Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_tcmd_FlexitouchSystemMember_CGH6jrZrrEuNDGgcZtJaOQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tcmd:FlexitouchSystemMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_tcmd_AfflovestMember_dBqlEgBFb02-NFr9MvkVnw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tcmd:AfflovestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_tcmd_FlexitouchSystemMember_DXKUE6FvQUC574PEnBV1Ow"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tcmd:FlexitouchSystemMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_tcmd_AfflovestMember__lGIQFNyT06Uzw8ThGA7KA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tcmd:AfflovestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_srt_ProductOrServiceAxis_tcmd_FlexitouchSystemMember_H2Jxo4pTn0OGkO2d39JE6g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tcmd:FlexitouchSystemMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_tcmd_VendorOneMember_X8R2b_l6g02zwqRLkFf0tg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">tcmd:VendorOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_VehiclesMember_2k-hdZ3H2UWc6uo6P8NZ5Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_Apyhw0rpjEqZ3vFtmoPsAg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_21_2022_m22jugRAaEmtVeWbOHw3dw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-11-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_9_8_2021_To_9_8_2021_JHuv2YIhr0-DMtiV3Vl0PA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-08</xbrli:startDate><xbrli:endDate>2021-09-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_2_2016_To_8_2_2016_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_oNbQsAMXk0uBUzklZFhmAA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-08-02</xbrli:startDate><xbrli:endDate>2016-08-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_tcmd_PerformanceBasedStockSettledRestrictedStockUnitsMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_UgLe632XY0y4wqXfkaKIqg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tcmd:PerformanceBasedStockSettledRestrictedStockUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tcmd:EquityIncentivePlan2016Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_tcmd_PerformanceBasedStockSettledRestrictedStockUnitsMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_7x_jPqkWGkShM1NIyefKfQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tcmd:PerformanceBasedStockSettledRestrictedStockUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tcmd:EquityIncentivePlan2016Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_tcmd_PerformanceBasedStockSettledRestrictedStockUnitsMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_rm8GPwYY40y-DieCnmoBug"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tcmd:PerformanceBasedStockSettledRestrictedStockUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tcmd:EquityIncentivePlan2016Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_EmployeeStockMember_cKXRqo7dk0-EdILU7PZBhg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_22_2022_To_2_22_2022_us-gaap_CreditFacilityAxis_tcmd_TermLoanMember_L6c2GMdVeE2wHtiYF_EBdA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">tcmd:TermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-22</xbrli:startDate><xbrli:endDate>2022-02-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_8_2021_8l4xBubq7Umd0Y3dMd0UnQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-09-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_RangeAxis_srt_MaximumMember__4L7Euy5PkiEdMffnWdNng"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_4_2022_srt_StatementScenarioAxis_tcmd_SecondEarnOutAmendmentMember_us-gaap_BusinessAcquisitionAxis_tcmd_AfflovestPMember_la2cedehBk-qL-iSyE1pIA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">tcmd:SecondEarnOutAmendmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tcmd:AfflovestPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_4_2022_srt_StatementScenarioAxis_tcmd_EarnOutPeriodOnOrBeforeNovember282022Member_us-gaap_BusinessAcquisitionAxis_tcmd_AfflovestPMember_YJ8bNR_NZ0CvMpF7RV_aqw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">tcmd:EarnOutPeriodOnOrBeforeNovember282022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tcmd:AfflovestPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_4_2022_srt_StatementScenarioAxis_tcmd_EarnOutPeriodOnOrBeforeMay262023Member_us-gaap_BusinessAcquisitionAxis_tcmd_AfflovestPMember_en0im7ZgS0KUsbPg8tTm6A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">tcmd:EarnOutPeriodOnOrBeforeMay262023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tcmd:AfflovestPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_4_2022_us-gaap_BusinessAcquisitionAxis_tcmd_AfflovestPMember_mDniF7LA_kiQpOIIlQZs3g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tcmd:AfflovestPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_8_2021_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_tcmd_AssetAcquisitionEarnoutPaymentsRevenueTargetsFromOctoberTwoThousandTwentyTwoToSeptemberTwoThousandTwentyThreeMember_us-gaap_BusinessAcquisitionAxis_tcmd_AfflovestPMember_o1oljgm50kqF7GpMnEHq0g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">tcmd:AssetAcquisitionEarnoutPaymentsRevenueTargetsFromOctoberTwoThousandTwentyTwoToSeptemberTwoThousandTwentyThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tcmd:AfflovestPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_11_4_2022_To_11_4_2022_srt_StatementScenarioAxis_tcmd_SecondEarnOutAmendmentMember_us-gaap_BusinessAcquisitionAxis_tcmd_AfflovestPMember_AEZMhjNrNkqvyABhlnwRPg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">tcmd:SecondEarnOutAmendmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tcmd:AfflovestPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-04</xbrli:startDate><xbrli:endDate>2022-11-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_4_2022_To_11_4_2022_us-gaap_BusinessAcquisitionAxis_tcmd_AfflovestPMember_pimwAjq0t0WJdAD0aYSTWA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tcmd:AfflovestPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-04</xbrli:startDate><xbrli:endDate>2022-11-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_8_2021_To_9_8_2021_srt_StatementScenarioAxis_tcmd_AssetAcquisitionEarnoutPaymentsRevenueTargetsFromOctoberTwoThousandTwentyTwoToSeptemberTwoThousandTwentyThreeMember_us-gaap_BusinessAcquisitionAxis_tcmd_AfflovestPMember_HRn8Gvyx7UuDkFsUjw2MWw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">tcmd:AssetAcquisitionEarnoutPaymentsRevenueTargetsFromOctoberTwoThousandTwentyTwoToSeptemberTwoThousandTwentyThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tcmd:AfflovestPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-08</xbrli:startDate><xbrli:endDate>2021-09-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_8_2021_To_9_8_2021_srt_StatementScenarioAxis_tcmd_AssetAcquisitionEarnoutPaymentsRevenueTargetsFromOctoberTwoThousandTwentyOneToSeptemberTwoThousandTwentyTwoMember_us-gaap_BusinessAcquisitionAxis_tcmd_AfflovestPMember_ekMNWGfKGkOGXb6VuFuvcQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">tcmd:AssetAcquisitionEarnoutPaymentsRevenueTargetsFromOctoberTwoThousandTwentyOneToSeptemberTwoThousandTwentyTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tcmd:AfflovestPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-08</xbrli:startDate><xbrli:endDate>2021-09-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_8_2021_To_9_8_2021_us-gaap_BusinessAcquisitionAxis_tcmd_AfflovestPMember_9xzfRGshm0aKb9OM49UhSQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tcmd:AfflovestPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-08</xbrli:startDate><xbrli:endDate>2021-09-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_4VmedOiWwk-TuOc3qFFccg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_26fO_zM0qkaf9YFqHV50Wg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_tcmd_CorporateHeadQuarterThirdLeaseMember_i4Zbs1u8B0-YqSUpBTf3Hg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">tcmd:CorporateHeadQuarterThirdLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_tcmd_CorporateHeadQuarterSecondLeaseMember_RayR2gEiIEWjwHNeeJouhw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">tcmd:CorporateHeadQuarterSecondLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_2_2016_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_Y9mdYePcDUyiYIOsBHbTDA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-08-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_JtERcFin0ki2oKH5VRLp_g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_17_2023_bjzkG-0zVU2f6CDXzJQEcA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-02-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_sqft_pFxGS_NorEW8LBFrHYvkFg"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_item_-67QV0kzWUGc8AbcCukKig"><xbrli:measure>tcmd:item</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="Unit_Standard_segment_zejw3MrZOkWEznPtKLNRGQ"><xbrli:measure>tcmd:segment</xbrli:measure></xbrli:unit></ix:resources></ix:header></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:7.2pt;min-height:20.15pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:5.75pt;"><a id="_463ef978_4097_4362_99ce_8b0008a9f792"></a><div style="padding-top:1.0px;border-top:3.0pt solid #000000;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1pt;padding-top:1pt;text-align:center;background:#ffffff;border-top:1.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:15pt;text-align:center;background:#ffffff;margin:0pt;"><b style="font-size:13pt;font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:15pt;text-align:center;background:#ffffff;margin:0pt;"><b style="font-size:13pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:center;background:#ffffff;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">Washington, D.C. 20549</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:8pt;text-align:center;background:#ffffff;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><div style="font-family:'Arial','Helvetica','sans-serif';font-size:5.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;background:#ffffff;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:13.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:13pt;line-height:15pt;text-align:center;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">FORM&#160;</b><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" name="dei:DocumentType" id="Narr__7E1bFZR7UOxQE8r3H_TYg"><b style="font-weight:bold;">10-K</b></ix:nonNumeric></p><div style="font-family:'Arial','Helvetica','sans-serif';font-size:5.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;background:#ffffff;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:13.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;line-height:9pt;padding-top:6pt;text-align:center;background:#ffffff;margin:0pt;"><span style="font-size:7.5pt;">(Mark One)</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:9pt;padding-left:24.5pt;text-align:center;text-indent:-24.5pt;background:#ffffff;margin:0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:24.5pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" name="dei:DocumentAnnualReport" id="Narr_hIv00jI6VEWI16Kfvrpu4w"><b style="font-family:'Segoe UI Symbol';font-size:8pt;font-style:normal;font-weight:bold;">&#9746;</b></ix:nonNumeric></span><b style="font-size:7.5pt;font-weight:bold;">ANNUAL REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF&#160;1934</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:8pt;text-align:center;background:#ffffff;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:9pt;text-align:center;background:#ffffff;margin:0pt;"><span style="font-size:7.5pt;">For the fiscal year ended </span><ix:nonNumeric format="ixt:datemonthdayyearen" contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" name="dei:DocumentPeriodEndDate" id="Narr_cnvhmtJwOUyEUM6FEIfMEg"><ix:nonNumeric format="ixt:datemonthdayen" contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" name="dei:CurrentFiscalYearEndDate" id="Narr_Ztz7VCzIZkuRojT1-ls1qg"><span style="font-size:7.5pt;">December&#160;31</span></ix:nonNumeric><span style="font-size:7.5pt;">,&#160;2022</span></ix:nonNumeric></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:8pt;text-align:center;background:#ffffff;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;line-height:9pt;text-align:center;background:#ffffff;margin:0pt;"><span style="font-size:7.5pt;">OR</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:8pt;text-align:center;background:#ffffff;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:9pt;padding-left:24.5pt;text-align:center;text-indent:-24.5pt;background:#ffffff;margin:0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:24.5pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" name="dei:DocumentTransitionReport" id="Narr_ztRMj6qtRECsLNvcNhe8Xw"><span style="font-family:'Segoe UI Symbol';font-size:8pt;font-style:normal;font-weight:normal;">&#9744;</span></ix:nonNumeric></span><b style="font-size:7.5pt;font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF&#160;1934</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:8pt;text-align:center;background:#ffffff;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;line-height:9pt;text-align:center;background:#ffffff;margin:0pt;"><span style="font-size:7.5pt;">For the transition period from&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; to</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:8pt;text-align:center;background:#ffffff;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:9pt;text-align:center;background:#ffffff;margin:0pt 0pt 6pt 0pt;"><span style="font-size:7.5pt;">Commission file number:</span><b style="font-size:7.5pt;font-weight:bold;"> </b><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" name="dei:EntityFileNumber" id="Narr_gWKz5doJ8U2tjLI7bpmPkQ"><b style="font-size:7.5pt;font-weight:bold;">001-37799</b></ix:nonNumeric></p><div style="font-family:'Arial','Helvetica','sans-serif';font-size:5.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:43.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:15pt;line-height:15pt;text-align:center;background:#ffffff;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" name="dei:EntityRegistrantName" id="Narr__2MCmtYy-ke_SrPh6ryM7w"><b style="font-weight:bold;">Tactile Systems Technology, Inc.</b></ix:nonNumeric></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;line-height:9pt;text-align:center;background:#ffffff;margin:0pt;"><span style="font-size:7.5pt;">(Exact name of registrant as specified in its charter)</span></p><div style="font-family:'Arial','Helvetica','sans-serif';font-size:5.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;background:#ffffff;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:43.0%;border:none;margin:0 auto;"></div></div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:33.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;background:#ffffff;margin:0pt;"><ix:nonNumeric format="ixt-sec:stateprovnameen" contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" name="dei:EntityIncorporationStateCountryCode" id="Narr_2rD9p0g7GU6jYXBSUwmlcg"><b style="font-size:7.5pt;font-weight:bold;">Delaware</b></ix:nonNumeric></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;line-height:9pt;text-align:center;background:#ffffff;margin:0pt;"><span style="font-size:7.5pt;">(State or other jurisdiction of</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;line-height:9pt;text-align:center;background:#ffffff;margin:0pt;"><span style="font-size:7.5pt;">incorporation or organization)</span></p></td><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;background:#ffffff;margin:6pt 0pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" name="dei:EntityAddressAddressLine1" id="Narr_1MEtQ8s2cEue92ldbY1WQQ"><b style="font-size:7.5pt;font-weight:bold;">3701 Wayzata Blvd, Suite 300</b></ix:nonNumeric></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;background:#ffffff;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" name="dei:EntityAddressCityOrTown" id="Narr_q4jMHmRRQUujxCJz-sVu1Q"><b style="font-size:7.5pt;font-weight:bold;">Minneapolis</b></ix:nonNumeric><b style="font-size:7.5pt;font-weight:bold;">, </b><ix:nonNumeric format="ixt-sec:stateprovnameen" contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" name="dei:EntityAddressStateOrProvince" id="Narr_q8TnKHhDjUSoiDHoCsdwHQ"><b style="font-size:7.5pt;font-weight:bold;">Minnesota</b></ix:nonNumeric><b style="font-size:7.5pt;font-weight:bold;"> </b><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" name="dei:EntityAddressPostalZipCode" id="Narr_p3hPBP1_W0WyVyUfIEJAdg"><b style="font-size:7.5pt;font-weight:bold;">55416</b></ix:nonNumeric></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;line-height:9pt;text-align:center;background:#ffffff;margin:0pt;"><span style="font-size:7.5pt;">(Address and zip code of principal executive offices)</span></p></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;background:#ffffff;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" name="dei:EntityTaxIdentificationNumber" id="Narr_t8jtNcMvG06b9xFfrpFLuA"><b style="font-size:7.5pt;font-weight:bold;">41-1801204</b></ix:nonNumeric></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;line-height:9pt;text-align:center;background:#ffffff;margin:0pt;"><span style="font-size:7.5pt;">(I.R.S. Employer</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;line-height:9pt;text-align:center;background:#ffffff;margin:0pt;"><span style="font-size:7.5pt;">Identification No.)</span></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:9pt;text-align:center;background:#ffffff;margin:6pt 0pt 0pt 0pt;"><b style="font-size:7.5pt;font-weight:bold;white-space:pre-wrap;"> (</b><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" name="dei:CityAreaCode" id="Narr_Y_a8vsaeEkCQcVUOEaQVRA"><b style="font-size:7.5pt;font-weight:bold;">612</b></ix:nonNumeric><b style="font-size:7.5pt;font-weight:bold;">) </b><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" name="dei:LocalPhoneNumber" id="Narr_mt1MRhdWgk2lWfGkf7M8SQ"><b style="font-size:7.5pt;font-weight:bold;">355-5100</b></ix:nonNumeric></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:center;background:#ffffff;margin:0pt;"><span style="font-size:7.5pt;">(Registrant&#8217;s telephone number, including area code)</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;line-height:9pt;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">Securities registered pursuant to Section 12(b) of the Act:</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:8pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><a id="_c6b382f3_bab0_408a_8153_68ea3ee53a73"></a><div style="margin-left:0pt;"><a id="Tc_94t5bM3fo0WaSxx6cv0QQw_1_0"></a><a id="Tc_LYr3VQ4YA0iqP2zTdzQwcA_1_1"></a><a id="Tc_Swvr1a7epkWNHIS_byUqXg_1_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;width:98.84%;"><tr style="height:1pt;"><td style="vertical-align:top;width:38.4%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:21.23%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:40.35%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:38.4%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt 0pt 2.2pt 0pt;"><b style="font-size:7.5pt;font-weight:bold;">Title of each class</b></p></td><td style="vertical-align:top;width:21.23%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt 0pt 2.2pt 0pt;"><b style="font-size:7.5pt;font-weight:bold;">Trading Symbol(s)</b></p></td><td style="vertical-align:top;width:40.35%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt 0pt 2.2pt 0pt;"><b style="font-size:7.5pt;font-weight:bold;">Name of each exchange on which registered</b></p></td></tr><tr><td style="vertical-align:top;width:38.4%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" name="dei:Security12bTitle" id="Tc_0cFJOkfnk0GejTYGQTUOKw_2_0"><span style="font-size:7.5pt;">Common Stock, Par Value $0.001 Per Share</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:21.23%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 2.2pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" name="dei:TradingSymbol" id="Tc_TN2IvGZJJUKSjoQKhzCgfA_2_1"><span style="font-size:7.5pt;">TCMD</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:40.35%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 2.2pt 0pt;"><ix:nonNumeric format="ixt-sec:exchnameen" contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" name="dei:SecurityExchangeName" id="Tc_YLnAstMN9Eyq2hgvdUypeg_2_2"><span style="font-size:7.5pt;">The Nasdaq Stock Market LLC</span></ix:nonNumeric></p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;line-height:9pt;text-align:center;margin:0pt 0pt 8pt 0pt;"><b style="font-size:7.5pt;font-weight:bold;">Securities registered pursuant to Section 12(g) of the Act:</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">None</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt 0pt 8pt 0pt;"><span style="font-size:7.5pt;">(Title of class)</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:9pt;margin:0pt 0pt 8pt 0pt;"><span style="font-size:7pt;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act.&#160;Yes&#160;&#160;&#160;</span><span style="font-family:'Times New Roman';font-size:7pt;">&#9723;</span><span style="font-size:7pt;">&#160;&#160;</span><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" name="dei:EntityWellKnownSeasonedIssuer" id="Narr_gRFd10SMPkmdLqNi1EkhmA"><span style="font-size:7pt;">No</span></ix:nonNumeric><span style="font-size:7pt;">&#160;&#160;&#160;</span><span style="font-family:'Times New Roman';font-size:7pt;">&#8999;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:9pt;margin:0pt 0pt 8pt 0pt;"><span style="font-size:7pt;">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or Section 15(d) of the Act.&#160;Yes&#160;&#160;&#160;</span><span style="font-family:'Times New Roman';font-size:7pt;">&#9723;</span><span style="font-size:7pt;">&#160;&#160;</span><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" name="dei:EntityVoluntaryFilers" id="Narr_PnG9uN-hzUSpt_6ESFNIHA"><span style="font-size:7pt;">No</span></ix:nonNumeric><span style="font-size:7pt;">&#160;&#160;&#160;</span><span style="font-family:'Times New Roman';font-size:7pt;">&#8999;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:9pt;margin:0pt 0pt 8pt 0pt;"><span style="font-size:7pt;">Indicate by check mark whether the registrant: (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.&#160;</span><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" name="dei:EntityCurrentReportingStatus" id="Narr_54mZyRDF0UmHnBDvxH7kFQ"><span style="font-size:7pt;">Yes</span></ix:nonNumeric><span style="font-size:7pt;">&#160;&#160;&#160;</span><span style="font-family:'Times New Roman';font-size:7pt;">&#8999;</span><span style="font-size:7pt;">&#160;&#160; No&#160;&#160;&#160;</span><span style="font-family:'Times New Roman';font-size:7pt;">&#9723;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:9pt;margin:0pt 0pt 8pt 0pt;"><span style="font-size:7pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation&#160;S-T (&#167;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files).&#160;</span><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" name="dei:EntityInteractiveDataCurrent" id="Narr_6UVDu1YrGUOmDPkJ0zgpKw"><span style="font-size:7pt;">Yes</span></ix:nonNumeric><span style="font-size:7pt;">&#160;&#160;&#160;</span><span style="font-family:'Times New Roman';font-size:7pt;">&#8999;</span><span style="font-size:7pt;">&#160;&#160;No&#160;&#160;&#160;</span><span style="font-family:'Times New Roman';font-size:7pt;">&#9723;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;line-height:9pt;margin:0pt 0pt 8pt 0pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act. </p><a id="_4008cd27_7a9a_4fb0_a5e9_4672618d64c2"></a><a id="Tc_uzev18xNWk69asi5aMX2qQ_3_0"></a><a id="Tc_6sol7fFRcUedFX27SYIDHQ_3_1"></a><a id="Tc_-KBuzjL-nU2Ll9LXtgWTJQ_3_6"></a><a id="Tc_zu8vu-tujUWxWuvqKCmsAA_5_0"></a><a id="Tc_1lJSp44TOECWruVcUizzgQ_5_1"></a><a id="Tc_RW-fOlvgYkO6M-buIFvORg_5_5"></a><a id="Tc_UHyqr2h7fESUzWzHNXt1rg_7_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:20%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:0.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:0.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:21.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:20%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:0.99%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:52%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:0.99%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:21.99%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:20%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:0.99%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:52%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:0.99%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:21.99%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:20%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;">Large&#160;accelerated&#160;filer&#160;</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-family:'Times New Roman';">&#9723;</span></p></td><td style="vertical-align:bottom;width:0.99%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:52%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:0.99%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:21.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_WgadwSncGUeeRkl-6pghrg;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;font-style:normal;font-weight:normal;">Accelerated&#160;filer</span></span></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-family:'Times New Roman';">&#8999;</span></p></td></tr><tr><td style="vertical-align:bottom;width:20%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:4pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:4pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:4pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:4pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:4pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:21.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:4pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:4pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:20%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;">Non-accelerated&#160;filer&#160;</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="font-family:'Times New Roman';">&#9723;</span></p></td><td style="vertical-align:bottom;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:52%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:21.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;">Smaller&#160;reporting&#160;company&#160;</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" name="dei:EntitySmallBusiness" id="Tc_Xa3Hbi4Pq0CueH6i2SloFw_5_6"><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9744;</span></ix:nonNumeric></p></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:20%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:21.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:20%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;">Emerging growth company</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" name="dei:EntityEmergingGrowthCompany" id="Tc_V8S6WXcMSUWtTpc_lqlM3w_7_1"><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9744;</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:21.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;line-height:9pt;margin:0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#160;<span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Segoe UI Symbol';font-size:4pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:9pt;margin:0pt;"><span style="font-size:7pt;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. </span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" name="dei:IcfrAuditorAttestationFlag" id="Narr_t2O1KDtGfEufwvD4fe4R2A"><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9746;</span></ix:nonNumeric></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;line-height:9pt;margin:0pt;">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. <span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;line-height:9pt;margin:0pt;">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). <span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:9pt;margin:0pt 0pt 8pt 0pt;"><span style="font-size:7pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Act).&#160;Yes&#160;&#160;&#160;</span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" name="dei:EntityShellCompany" id="Narr_-nmHNvf9tkCxV96amA5x-Q"><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9744;</span></ix:nonNumeric><span style="font-size:7pt;">&#160;&#160;No&#160;&#160;&#160;</span><span style="font-family:'Times New Roman';font-size:7pt;">&#8999;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;line-height:9pt;padding-bottom:1pt;border-bottom:1px solid #000000;margin:0pt 0pt 8pt 0pt;">The aggregate market value of the voting and non-voting common equity held by non-affiliates of the registrant, based on $7.30, the closing price of the shares of common stock on June 30, 2022 (the last business day of the registrant&#8217;s most recently completed second fiscal quarter) as reported by The Nasdaq Stock Market LLC<span style="font-size:7.5pt;"> on such date, was </span>$<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" format="ixt:numdotdecimal" scale="0" contextRef="As_Of_6_30_2022_JtERcFin0ki2oKH5VRLp_g" decimals="0" name="dei:EntityPublicFloat" id="Narr_8OC5AcAmIE6VAwQQ6emUQA">146,541,485</ix:nonFraction>. The number of shares of registrant&#8217;s Common Stock outstanding as of February 17, 2023 was <ix:nonFraction unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ" format="ixt:numdotdecimal" scale="0" contextRef="As_Of_2_17_2023_bjzkG-0zVU2f6CDXzJQEcA" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" id="Narr_lncCeyF52Umn_If-YmdgmA">20,250,951</ix:nonFraction>.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;">Portions of the Registrant&#8217;s Definitive Proxy Statement relating to the Annual Meeting of Stockholders, scheduled to be held on May 8, 2023 are incorporated by reference into Part&#160;III of this Report.</p><div style="padding-bottom:1.0px;border-bottom:3.0pt solid #000000;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:1pt;border-bottom:1.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:5pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Arial','Helvetica','sans-serif';line-height:0pt;text-align:center;background:#ffffff;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_25454e47_51a7_4c0f_b97f_d975ab0efb14"></a><a id="Toc"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;background:#ffffff;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">TABLE OF CONTENTS</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:82.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;white-space:nowrap;width:4.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:top;width:82.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;background:#ffffff;margin:0pt;"><a href="#PARTIFINANCIALINFORMATION_582439"><b style="font-style:normal;font-weight:bold;">PART&#160;I</b></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.97%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:82.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;background:#ffffff;margin:0pt;"><a href="#Item1_Business"><span style="font-style:normal;font-weight:normal;">Item&#160;1.</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:82.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><a href="#Item1_Business"><span style="font-style:normal;font-weight:normal;">Business</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">5</p></td></tr><tr><td style="vertical-align:top;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;background:#ffffff;margin:0pt;"><a href="#Item1ARiskFactors_367271"><span style="font-style:normal;font-weight:normal;">Item 1A.</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:82.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><a href="#Item1ARiskFactors_367271"><span style="font-style:normal;font-weight:normal;">Risk Factors</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">29</p></td></tr><tr><td style="vertical-align:top;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;background:#ffffff;margin:0pt;"><a href="#Item1BUnresolvedStaffComments_540074"><span style="font-style:normal;font-weight:normal;">Item 1B.</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:82.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><a href="#Item1BUnresolvedStaffComments_540074"><span style="font-style:normal;font-weight:normal;">Unresolved Staff Comments</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">68</p></td></tr><tr><td style="vertical-align:top;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;background:#ffffff;margin:0pt;"><a href="#Item2Properties_393200"><span style="font-style:normal;font-weight:normal;">Item 2.</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:82.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><a href="#Item2Properties_393200"><span style="font-style:normal;font-weight:normal;">Properties</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">68</p></td></tr><tr><td style="vertical-align:top;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;background:#ffffff;margin:0pt;"><a href="#Item3LegalProceedings_92048"><span style="font-style:normal;font-weight:normal;">Item 3.</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:82.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><a href="#Item3LegalProceedings_92048"><span style="font-style:normal;font-weight:normal;">Legal Proceedings</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">68</p></td></tr><tr><td style="vertical-align:top;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;background:#ffffff;margin:0pt;"><a href="#Item4MineSafetyDisclosures_923755"><span style="font-style:normal;font-weight:normal;">Item 4.</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:82.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><a href="#Item4MineSafetyDisclosures_923755"><span style="font-style:normal;font-weight:normal;">Mine Safety Disclosures</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">68</p></td></tr><tr><td style="vertical-align:top;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:82.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:82.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;background:#ffffff;margin:0pt;"><a href="#PARTII_338450"><b style="font-style:normal;font-weight:bold;">PART II</b></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:82.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;background:#ffffff;margin:0pt;"><a href="#Item5MarketForRegistrantsCommonEquityRel"><span style="font-style:normal;font-weight:normal;">Item 5.</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:82.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><a href="#Item5MarketForRegistrantsCommonEquityRel"><span style="font-style:normal;font-weight:normal;">Market For Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">69</p></td></tr><tr><td style="vertical-align:top;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;background:#ffffff;margin:0pt;"><a href="#Item6SelectedFinancialData_879996"><span style="font-style:normal;font-weight:normal;">Item 6.</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:82.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><a href="#Item6SelectedFinancialData_879996"><span style="font-style:normal;font-weight:normal;">Selected Financial Data</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">71</p></td></tr><tr><td style="vertical-align:top;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;background:#ffffff;margin:0pt;"><a href="#Item7ManagementsDiscussionandAnalyisofFi"><span style="font-style:normal;font-weight:normal;">Item&#160;7.</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:82.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><a href="#Item7ManagementsDiscussionandAnalyisofFi"><span style="font-style:normal;font-weight:normal;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">71</p></td></tr><tr><td style="vertical-align:top;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;background:#ffffff;margin:0pt;"><a href="#Item7AQuantitativeandQualitativeDisclosu"><span style="font-style:normal;font-weight:normal;">Item&#160;7A.</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:82.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><a href="#Item7AQuantitativeandQualitativeDisclosu"><span style="font-style:normal;font-weight:normal;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">83</p></td></tr><tr><td style="vertical-align:top;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;background:#ffffff;margin:0pt;"><a href="#Item8FinancialStatementsandSupplementary"><span style="font-style:normal;font-weight:normal;">Item 8.</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:82.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><a href="#Item8FinancialStatementsandSupplementary"><span style="font-style:normal;font-weight:normal;">Financial Statements and Supplementary Data</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">85</p></td></tr><tr><td style="vertical-align:top;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;background:#ffffff;margin:0pt;"><a href="#Item9ChangesinandDisagreementsWithAccoun"><span style="font-style:normal;font-weight:normal;">Item 9.</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:82.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><a href="#Item9ChangesinandDisagreementsWithAccoun"><span style="font-style:normal;font-weight:normal;">Changes in and Disagreements With Accountants on Accounting and Financial Disclosure</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">118</p></td></tr><tr><td style="vertical-align:top;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;background:#ffffff;margin:0pt;"><a href="#Item9AControlsandProcedures_324410"><span style="font-style:normal;font-weight:normal;">Item&#160;9A.</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:82.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><a href="#Item9AControlsandProcedures_324410"><span style="font-style:normal;font-weight:normal;">Controls and Procedures</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">118</p></td></tr><tr><td style="vertical-align:top;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;background:#ffffff;margin:0pt;"><a href="#Item9BOtherInformation_904802"><span style="font-style:normal;font-weight:normal;">Item 9B.</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:82.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><a href="#Item9BOtherInformation_904802"><span style="font-style:normal;font-weight:normal;">Other Information</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">122</p></td></tr><tr><td style="vertical-align:top;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;background:#ffffff;margin:0pt;"><a style="font-size:10pt;" href="#ITEM9CDisclosureregarding"><span style="font-style:normal;font-weight:normal;">Item 9C</span></a>.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:82.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><a href="#ITEM9CDisclosureregarding"><span style="font-style:normal;font-weight:normal;">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">122</p></td></tr><tr><td style="vertical-align:top;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:6pt;padding-left:7.2pt;text-indent:-7.2pt;background:#ffffff;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:82.28%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:82.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;background:#ffffff;margin:0pt;"><a href="#PARTIII_933629"><b style="font-style:normal;font-weight:bold;">PART&#160;III</b></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:6pt;padding-left:7.2pt;text-indent:-7.2pt;background:#ffffff;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:82.28%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;background:#ffffff;margin:0pt;"><a href="#Item10DirectorsExecutiveOfficersandCorpo"><span style="font-style:normal;font-weight:normal;">Item&#160;10.</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:82.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><a href="#Item10DirectorsExecutiveOfficersandCorpo"><span style="font-style:normal;font-weight:normal;">Directors, Executive Officers and Corporate Governance</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">123</p></td></tr><tr><td style="vertical-align:top;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;background:#ffffff;margin:0pt;"><a href="#Item11ExecutiveCompensation_884168"><span style="font-style:normal;font-weight:normal;">Item&#160;11.</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:82.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><a href="#Item11ExecutiveCompensation_884168"><span style="font-style:normal;font-weight:normal;">Executive Compensation </span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">124</p></td></tr><tr><td style="vertical-align:top;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;background:#ffffff;margin:0pt;"><a href="#ITEM_12_SECURITY_OWNERSHIP_CERTAIN_BENEF"><span style="font-style:normal;font-weight:normal;">Item&#160;12.</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:82.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><a href="#ITEM_12_SECURITY_OWNERSHIP_CERTAIN_BENEF"><span style="font-style:normal;font-weight:normal;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">124</p></td></tr><tr><td style="vertical-align:top;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;background:#ffffff;margin:0pt;"><a href="#ITEM_13_CERTAIN_RELATIONSHIPS_RELATED_TR"><span style="font-style:normal;font-weight:normal;">Item&#160;13.</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:82.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><a href="#ITEM_13_CERTAIN_RELATIONSHIPS_RELATED_TR"><span style="font-style:normal;font-weight:normal;">Certain Relationships and Related Transactions, and Director Independence</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">124</p></td></tr><tr><td style="vertical-align:top;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;background:#ffffff;margin:0pt;"><a href="#ITEM_14_PRINCIPAL_ACCOUNTING_FEES_SERVIC"><span style="font-style:normal;font-weight:normal;">Item&#160;14.</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:82.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><a href="#ITEM_14_PRINCIPAL_ACCOUNTING_FEES_SERVIC"><span style="font-style:normal;font-weight:normal;">Principal Accountant Fees and Services</span></a> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">124</p></td></tr><tr><td style="vertical-align:top;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:82.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:82.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;background:#ffffff;margin:0pt;"><a href="#PARTIV_90088"><b style="font-style:normal;font-weight:bold;">PART IV</b></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:82.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;background:#ffffff;margin:0pt;"><a href="#Item15ExhibitsFinancialStatementSchedule"><span style="font-style:normal;font-weight:normal;">Item 15.</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:82.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><a href="#Item15ExhibitsFinancialStatementSchedule"><span style="font-style:normal;font-weight:normal;">Exhibits, Financial Statement Schedules</span></a> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">125</p></td></tr><tr><td style="vertical-align:top;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;background:#ffffff;margin:0pt;"><a href="#Item16Form10KSummary_290554"><span style="font-style:normal;font-weight:normal;">Item 16.</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:82.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><a href="#Item16Form10KSummary_290554"><span style="font-style:normal;font-weight:normal;">Form 10-K Summary</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">129</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;background:#ffffff;margin:0pt;"><span style="font-size:10pt;font-weight:bold;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;line-height:0pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;"><span style="font-size:0pt;font-weight:bold;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">i</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_fea8c62f_561c_4554_ac6a_d7bc8d5a3e55"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:center;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">SPECIAL NOTE REGARDING FORWARD-LOOKING INFORMATION</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">This Annual Report on Form 10-K contains forward-looking statements regarding us, our business prospects and our results of operations that are subject to certain risks and uncertainties posed by many factors and events that could cause our actual business, prospects and results of operations to differ materially from those that may be anticipated by such forward-looking statements.&#160;Factors that could cause or contribute to such differences include, but are not limited to, those described in Part I, Item 1A. &#8220;Risk Factors&#8221; and elsewhere in this report.&#160;Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this report.&#160;Readers are urged to carefully review and consider the various disclosures made by us in this report and in our other reports filed with the Securities and Exchange Commission, or the SEC, that advise interested parties of the risks and factors that may affect our business.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">All statements, other than statements of historical facts, contained in this Annual Report on Form 10-K, including statements regarding our business, operations and financial performance and condition, as well as our plans, objectives and expectations for our business, operations and financial performance and condition, are forward-looking statements. In some cases, you can identify forward-looking statements by the following words: &quot;anticipate,&quot; &quot;believe,&quot; &quot;continue,&quot; &quot;could,&quot; &quot;estimate,&quot; &quot;expect,&quot; &quot;intend,&quot; &quot;may,&quot; &quot;might,&quot; &quot;ongoing,&quot; &quot;plan,&quot; &quot;potential,&quot; &quot;predict,&quot; &quot;project,&quot; &quot;should,&quot; &quot;target,&quot; &quot;will,&quot; &quot;would,&quot; or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our results, levels of activity, performance or achievements to be materially different from the information expressed or implied by the forward-looking statements in this Annual Report on Form 10-K. These risks, uncertainties and other factors include, but are not limited to:</p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:23.05pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 12pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 12pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the impacts of inflation, rising interest rates or a recession;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:23.05pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 12pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 12pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the adequacy of our liquidity to pursue our business objectives; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:23.05pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 12pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 12pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to obtain reimbursement from third-party payers for our products; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:23.05pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 12pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 12pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">adverse economic conditions or intense competition; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:23.05pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 12pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 12pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">price increases for supplies and components; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:23.05pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 12pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 12pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">wage and component price inflation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:23.05pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 12pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 12pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">loss of a key supplier; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:23.05pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 12pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 12pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">entry of new competitors and products; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:23.05pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 12pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 12pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">compliance with and changes in federal, state and local government regulation; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:23.05pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 12pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 12pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">loss or retirement of key executives, including prior to identifying a successor; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:23.05pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 12pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 12pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">technological obsolescence of our products; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:23.05pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 12pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 12pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">technical problems with our research and products; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:23.05pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 12pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 12pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to expand our business through strategic acquisitions; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:23.05pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 12pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 12pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to integrate acquisitions and related businesses; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:23.05pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 12pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 12pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the impacts of the COVID-19 pandemic on our business, financial condition and results of operations, and our inability to mitigate such impacts;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:23.05pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 12pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 12pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the effects of current and future U.S. and foreign trade policy and tariff actions; and</span></td></tr></table></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">1</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:23.05pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the inability to carry out research, development and commercialization plans.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:14pt 0pt 0pt 0pt;">You should read the matters described in Part I, Item 1A. &quot;Risk Factors&quot; and the other cautionary statements made in this Annual Report on Form 10-K. We cannot assure you that the forward-looking statements in this report will prove to be accurate and therefore you are encouraged not to place undue reliance on forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. You are urged to carefully review and consider the various disclosures made by us in this report and in other filings with the SEC that advise of the risks and factors that may affect our business. Other than as required by law, we expressly disclaim any intent or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments that we may make.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:14pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_e0c67bf6_d86d_41b8_bb60_6918ef2852c9"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:center;background:#ffffff;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">RISK FACTORS SUMMARY</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-indent:36pt;background:#ffffff;margin:0pt;">Our business, financial condition, and operating results may be affected by a number of factors, whether currently known or unknown. Any one or more of such factors could directly or indirectly cause our actual results of operations and financial condition to vary materially from past or anticipated future results of operations and financial condition. Any of these factors, in whole or in part, could materially and adversely affect our business, financial condition, results of operations, and stock price. We have provided a summary of some of these risks below, with a more detailed explanation of the risks applicable to us in Part I, Item 1A. &#8220;Risk Factors&#8221; and elsewhere in this report:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Risks Related to Our Business, Operations and Strategy </i></p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 12pt 0pt;">-</td><td style="padding:0pt 0pt 12pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Current or worsening economic conditions, including inflation, rising interest rates or a recession, could adversely affect our business and financial condition.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 12pt 0pt;">-</td><td style="padding:0pt 0pt 12pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">If we are unable to achieve and maintain adequate levels of coverage or reimbursement for our products, our business and results of operations will be adversely affected.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 12pt 0pt;">-</td><td style="padding:0pt 0pt 12pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Changes to the level of Medicare coverage or coverage criteria for our products could have an adverse effect on our business and results of operations.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 12pt 0pt;">-</td><td style="padding:0pt 0pt 12pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">We utilize third-party, single-source suppliers for some components and materials used in our products, and the loss of any of these suppliers could have an adverse impact on our business.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 12pt 0pt;">-</td><td style="padding:0pt 0pt 12pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Our revenue is primarily generated from our lymphedema products and we are therefore highly dependent on these products.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 12pt 0pt;">-</td><td style="padding:0pt 0pt 12pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">We are increasingly dependent on sophisticated information technology and if we fail to effectively maintain or protect our information systems or data, including from cyber-attacks or data breaches, our business could be adversely affected.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 12pt 0pt;">-</td><td style="padding:0pt 0pt 12pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Consolidation in the healthcare industry could lead to demands for price concessions, which may impact our ability to sell our products at prices necessary to support our current business strategies.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 12pt 0pt;">-</td><td style="padding:0pt 0pt 12pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Our long-term growth depends on awareness and adoption of our products.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 12pt 0pt;">-</td><td style="padding:0pt 0pt 12pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">If we are unable to expand, manage and maintain our direct sales and marketing organizations, as well as our relationships with distributors, we may not be able to generate anticipated revenue.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 12pt 0pt;">-</td><td style="padding:0pt 0pt 12pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Physicians and payers may require additional clinical studies prior to prescribing our products or prior to providing or maintaining coverage and reimbursement for our products. Any subsequent clinical studies that are conducted and published may not be positive or consistent with our existing data, which would adversely affect the rate of adoption of our products.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">-</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">The COVID-19 pandemic has had, and may continue to have, an adverse effect on our business, financial condition and results of operations.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Government Regulation, Compliance and Legal Risks</i></p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 12pt 0pt;">-</td><td style="padding:0pt 0pt 12pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">We are subject to extensive federal and state regulation, and if we fail to comply with applicable regulations, we could be required to repay amounts previously received, and could suffer severe criminal or civil sanctions or be required to make significant changes to our operations that could adversely affect our business, financial condition and operating results.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 12pt 0pt;">-</td><td style="padding:0pt 0pt 12pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">We are subject to significant regulation by numerous government agencies, including the FDA. We cannot market or commercially distribute our products without obtaining and maintaining necessary regulatory clearances or approvals.</span></td></tr></table></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 12pt 0pt;">-</td><td style="padding:0pt 0pt 12pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">If clinical studies of our future products do not produce results necessary to support regulatory clearance or approval in the United States or, with respect to our current or future products, elsewhere, we will be unable to expand the indications for or commercialize these products.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 12pt 0pt;">-</td><td style="padding:0pt 0pt 12pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">If the third parties on which we rely to conduct our clinical trials and to assist us with pre-clinical development do not perform as contractually required or expected, we may not be able to obtain regulatory clearance or approval for or commercialize our products.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 12pt 0pt;">-</td><td style="padding:0pt 0pt 12pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">If we fail to comply with state and federal fraud and abuse laws, including anti-kickback, false claims and anti-inducement laws, we could face substantial penalties and our business, operations and financial condition could be adversely affected.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 12pt 0pt;">-</td><td style="padding:0pt 0pt 12pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Failure to maintain the licenses and accreditations necessary to operate under our direct-to-patient and -provider model would adversely affect our business.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">-</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Our products are currently made available to authorized users of the Department of Veterans Affairs Federal Supply Schedule and if we were no longer eligible to sell our products through such channel, our business may be adversely affected.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Financial Condition, Credit and Tax Risks</i></p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">-</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">If we fail to maintain proper and effective internal control over financial reporting, our ability to produce accurate and timely financial statements could be impaired, which could harm our operating results, investors&#39; views of us and, as a result, the value of our common stock.</span></td></tr></table><div style="margin-top:12pt;"></div><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">-</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">The level of our indebtedness under our credit facility may adversely impact us, and the phase-out, replacement or unavailability of LIBOR and/or other interest rate benchmarks could adversely affect our indebtedness.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:12pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">-</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Our credit facility contains covenants that restrict </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">our business and financing activities, and the property that secures our obligations under the credit facility may be subject to foreclosure.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Risks Related to Ownership of Our Common Stock</i></p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">-</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">The trading price of the shares of our common stock has been and could continue to be highly volatile, and purchasers of our common stock may not be able to resell their shares of our common stock at or above the price at which they purchased their shares and could incur substantial losses.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="PARTIFINANCIALINFORMATION_582439"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">PART I</b></p><a id="_f9321ffc_b910_4a07_978b_aeafc9492bb1"></a><a id="_Hlk62208653"></a><a id="Item1_Business"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:14pt;background:#ffffff;margin:14pt 0pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;">Item 1.  Business.</b></p><a id="_ecac16a4_f266_4cef_9202_e73e21f56018"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Overview</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">Tactile Systems Technology, Inc. (&#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221;) is a medical technology company that develops and provides innovative medical devices for the treatment of underserved chronic diseases. We were originally incorporated in Minnesota under the name Tactile Systems Technology, Inc. on January 30, 1995. During 2006, we established a merger corporation and subsequently, on July 21, 2006, merged with and into this merger corporation resulting in us being reincorporated as a Delaware corporation. The resulting corporation assumed the name Tactile Systems Technology, Inc. and in September 2013, we began doing business as &#8220;Tactile Medical&#8221;. Our mission is to help people suffering from chronic diseases live better and care for themselves at home. We focus our efforts on advancing the standard of care in treating underserved chronic diseases in the home to improve patient outcomes and quality of life and help control rising healthcare expenditures. Our areas of therapeutic focus are (1) vascular disease, with a goal of advancing the standard of care in treating lymphedema and chronic venous insufficiency, (2) oncology, where lymphedema is a common consequence among cancer survivors and (3) providing airway clearance therapy for those suffering from chronic respiratory conditions. We possess a unique, scalable platform to deliver at-home healthcare solutions throughout the United States. This evolving home care delivery model is recognized by policymakers and insurance payers as a key for controlling rising healthcare costs. Our solutions deliver cost-effective, clinically proven, long-term treatment for people with these chronic diseases.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">We employ a direct-to-patient and -provider model within our lymphedema portfolio, through which we obtain patient referrals from clinicians, manage insurance claims on behalf of our patients and their clinicians, deliver our solutions directly to patients and train them on the proper use of our solutions. This model allows us to engage directly with patients and clinicians, which are both critical audiences to which we can provide clinical evidence and education. For our respiratory therapy products, we have a durable medical equipment (&#8220;DME&#8221;) distribution model, utilizing mature comprehensive respiratory DME providers to service patients. We sell the AffloVest product to accredited DME providers. They gather and submit documentation for payer reimbursement, train patients on use of the device, and provide ongoing patient support. For the year ended December 31, 2022, we generated revenue of $246.8 million and had a net loss of $17.9 million. Our revenue increased 19% during the year ended December 31, 2022, compared to the year ended December 31, 2021. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">Lymphedema is a type of chronic swelling, or edema, which occurs in the arms, legs, neck, trunk or other body parts when the lymphatic vessels are unable to adequately drain protein-rich lymph fluid from these regions. Lymphedema is progressive in nature, worsens over time, and has no known cure. Chronic venous insufficiency is a condition that occurs when the venous wall and/or valves in the veins are not working effectively, making it difficult for blood to return to the heart from the affected region(s). Phlebolymphedema is the convergence of lymphedema and chronic venous insufficiency. When the venous system does not effectively transfer blood from the lower limbs, it can result in venous hypertension and the development of painful, slow-healing wounds on the lower leg called venous leg ulcers. Venous hypertension can also lead to a marked increase in fluid build-up in the limbs, overwhelming the lymphatic system and causing lymphedema. Our proprietary Flexitouch and Entre systems are clinically proven at-home solutions for patients with vascular disorders such as lymphedema. Patients with lymphedema or chronic venous insufficiency are typically treated by vascular surgeons, vascular medicine physicians, oncology care teams, wound physicians, nurses and therapists. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">Our current lymphedema products are the Flexitouch and Entre systems. A predecessor to our Flexitouch system received 510(k) clearance from the U.S. Food and Drug Administration (the &#8220;FDA&#8221;) in July 2002, and we introduced the system to address the many limitations of self-administered home-based manual lymphatic drainage therapy. We began selling our more advanced Flexitouch system after receiving 510(k) clearance from the FDA in October 2006. In September 2016, we received 510(k) clearance from the FDA for the Flexitouch system in treating lymphedema of the head and neck. In June 2017, we announced that we received 510(k) clearance from the FDA for the Flexitouch Plus, the third-generation version of our Flexitouch system. In December 2020, we received 510(k) clearance for two new indications for our Flexitouch Plus system: phlebolymphedema and lipedema. We introduced our Entre system in the United States in February </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">5</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;">2013. The Entre system is sold or rented to patients who need a simple pump or who do not yet qualify for insurance reimbursement for an advanced compression device such as our Flexitouch system. Sales and rentals of our lymphedema products generated $212.3 million, or 86%, of our revenue in 2022, and $202.9 million, or 98%, of our revenue in 2021.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">On September 8, 2021, we acquired the assets of the AffloVest airway clearance product line from International Biophysics Corporation (&#8220;IBC&#8221;), a privately-held company which developed and manufactured AffloVest. AffloVest is a portable, wearable vest that provides airway clearance to&#160;treat patients with chronic respiratory conditions such as bronchiectasis or conditions resulting from neuromuscular disorders. The AffloVest product line generated $34.5 million, or 14%, of our revenue in 2022 and $5.1 million, or 2%, of our revenue in 2021.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:14pt;padding-top:2pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">To support the growth of our business, we invest in our commercial infrastructure, consisting of our direct sales force, DME sales team, patient training resources, reimbursement capabilities and clinical expertise. We are a national, accredited provider of home medical equipment services approved for coverage by private payers, Medicare, the Veterans Administration and certain Medicaid programs in the United States. Our field commercial team is focused on increasing clinician awareness of our lymphedema solutions. As of December 31, 2022, we employed a field staff of 287, which consisted of 250 field sales representatives and 24 field managers for our lymphedema products, as well as a team of 13 supporting our airway clearance products. This compares to a field staff of 262 as of December 31, 2021, which consisted of approximately 233 field sales representatives and 19 field managers for our lymphedema products, as well as a team of 10 supporting our airway clearance products.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:14pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="color:#ff0000;"> </span>In concert with COVID-19 social distancing requirements and recommendations, beginning in 2020, our patient training model includes both in-person training and virtual patient training options. This provides additional options for us to connect with patients to ensure they receive the appropriate training, while protecting the health and limiting the exposure of both our trainers and patients. In 2022, we provided patient training primarily through a team of employee trainers to educate patients on the proper use of our solutions.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:14pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">Our reimbursement function includes payer relations and reimbursement operations. Our payer relations function focuses on payer policy development, education, contract negotiations, and data analysis. Our reimbursement operations function is responsible for verifying patient insurance benefits, individual patient case development, prior authorization submissions, case follow-up, and appeals when necessary. Our clinical function, consisting of a scientific advisory board, in-house therapists and nurses, and our Chief Medical Officer, serves as a resource to clinicians and patients and guides our development of clinical evidence in support of our products. We believe these investments are critical to driving payer, clinician and patient adoption of our technologies, and together with our commercial infrastructure, represent a significant competitive advantage. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:14pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">Health insurance coverage for our Flexitouch and Entre systems is in place with private payers, Medicare, the Veterans Administration and certain Medicaid programs. Based on our estimates, we are contracted or enrolled as an in-network provider with payers covering nearly 275 million lives in the United States. In 2022 we served over 65,000 patients with our compression therapy devices and cumulatively have served over 395,000 patients since they launched. This compares to over 330,000 patients cumulatively as of December 31, 2021.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:14pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">AffloVest also benefits from a relatively mature reimbursement landscape. Health insurance coverage is in place for High Frequency Chest Wall Oscillation (&#8220;HFCWO&#8221;) vest therapy with Medicare and most private insurers. Respiratory DME partners serve the role of receiving prescriptions, verifying coverage criteria, shipping, billing and training the patient.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:14pt;text-align:justify;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Coronavirus (COVID-19)</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">The United States economy in general and our business specifically have been negatively affected by the COVID-19 pandemic. We have seen adverse impacts as it relates to the decline in the number of patients that healthcare facilities and clinics are able to treat due to enhanced safety protocols, including during most of 2021 and the first quarter of 2022.&#160;We have also seen staffing challenges, both in our organization and at the </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">6</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">clinics we serve, as another lingering consequence of the COVID-19 pandemic. While we saw some level of recovery in 2022 after the first quarter, ongoing consequences of the pandemic remain uncertain. There are no reliable estimates of how long the pandemic will last, whether any recovery will be sustained or will reverse course, the severity of any resurgence of COVID-19 or variant strains of the virus, the effectiveness of vaccines and attitudes towards receiving them, or what ultimate effects the pandemic will have. For that reason, we are unable to reasonably estimate the long-term impact of the pandemic on our business at this time.</p><a id="_5770fe09_9eab_4b4c_882b_5221c1250c10"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:10pt;text-align:justify;text-indent:-10pt;margin:14pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Overview of Lymphedema and Chronic Venous Insufficiency </b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:10pt;text-align:justify;text-indent:-10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Lymphedema</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The lymphatic system, a fundamental part of the cardiovascular system, consists of lymph vessels and lymph organs that protect the body against harmful bacteria and transport lymph fluid from the body&#8217;s tissues back to the cardiovascular system. Lymph vessels are thin-walled capillaries that absorb fluids, bacteria and proteins, and propel them to lymph nodes, small lymph organs that filter and process the lymph fluid by eliminating waste and bacteria. Lymph nodes are located in several areas of the body, including superficial and deep lymph nodes under each arm, at the hip, in the groin, above the collar bones in the neck, in the abdomen, tonsils and spleen, and in bone marrow. Lymph vessels and lymph nodes work together with larger lymph structures to help maintain a normal healthy fluid balance.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Lymphedema occurs when there is impairment to the lymphatic system, disrupting normal transport of lymph fluid within the body and causes severe and debilitating symptoms, including swelling, decreased mobility, skin breakdown, pain, increased risk of serious infection and marked psychosocial impairment, resulting in significant negative implications for a patient&#39;s health. When the lymphatic system becomes overwhelmed, damaged, or blocked for an extended period of time, lasting swelling (referred to as chronic edema) occurs. Symptoms related to lymphedema can present anywhere in the body, including the head, neck, arms, legs, trunk and genitals. For most patients with lymphedema, it has a negative impact on their quality of life. Performing daily activities of cooking, shopping, cleaning and yard work can often become difficult, if not impossible, for patients who suffer from lymphedema. For patients with head and neck lymphedema, critical functions such as swallowing, breathing and range of motion can be negatively impacted. Over time, the accumulation of lymph fluid can result in significant changes in the structure of the tissues, causing thickening and hardening of the skin, referred to as fibrosis. Recurrent skin infections such as erysipelas and cellulitis, a more serious skin infection, are common complications of lymphedema.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Lymphedema worsens over time if not properly treated, and currently has no known cure. When untreated, lymphedema can become painful and debilitating. The symptoms of lymphedema can be managed however, and patients who are educated about effective treatment options can improve their quality of life.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Misdiagnosis of lymphedema is common, and often patients do not get the medical care they need until significant symptoms have occurred. Proper diagnosis of lymphedema may require evaluation by a physician or other healthcare provider with knowledge of lymphedema and its visible symptoms. While not required to develop a lymphedema diagnosis, some clinicians may choose to perform diagnostic testing. Diagnostic tests for lymphedema include history and physical examination, soft tissue and vascular imaging, lymph node imaging, volume measurements, changes in electrical conductance, changes in biomechanical properties, genetic testing and blood tests for other conditions that have similar symptoms to lymphedema. The International Society of Lymphology categorizes the progression of lymphedema from Stage 0, the least severe stage, to Stage 3, the most severe stage. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:14pt 0pt 0pt 0pt;">&#160;<span style="font-size:10pt;font-style:italic;font-weight:bold;">Chronic Venous Insufficiency and Phlebolymphedema </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:14pt 0pt 0pt 0pt;">The most common form of lymphedema in the Western world is phelobolymphedema, a mixed etiology swelling due to chronic venous insufficiency (&#8220;CVI&#8221;) and lymphatic insufficiency. The inability of the lymphatic system to adequately drain the interstitial fluid that accumulates in severe chronic venous hypertension causes this &#8216;combined&#8217; condition, phlebolymphedema. CVI is prevalent among patients who are obese or pregnant and may also be caused by high blood pressure, trauma, lack of exercise, smoking, deep vein thrombosis and inflammation of the vein walls. As the valves deteriorate, blood is no longer able to effectively travel in the </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">7</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">normal direction, leading to increased pressure in the vascular system, stretching and dilating vessels, which exacerbates the problem. Prolonged or untreated chronic venous insufficiency may cause an increase in the buildup of interstitial fluid (the fluid surrounding cells), which in turn, can cause skin and tissue changes that can permanently damage the lymphatic system. As hypertension increases, more fluid is pushed out of the vascular system leading to swelling, progressive tissue breakdown, skin infections and venous leg ulcers. Ulcers develop in areas with edema as swelling interferes with the movement of oxygen and nutrients through tissues, and if left untreated, these ulcers can quickly become infected or even gangrenous. Physicians diagnose chronic venous insufficiency based on appearance, symptoms and imaging techniques and classify it based upon a scale endorsed by the Society for Vascular Surgery. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Market Opportunity </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Lymphedema and CVI are costly and lifelong conditions with debilitating physical and psychological impacts on patients. Based on a study performed by Dr. Steven Dean et al., it is estimated that more than 16 million people in the United States are living with lymphedema due to CVI. This, in addition to the estimated five million individuals living in the U.S. with cancer-related and primary lymphedema, increases the prevalence estimates to over 20 million individuals. For people with cancer, the build-up of lymph fluid can be caused by surgery, especially when lymph nodes are removed, radiation therapy that can damage lymph nodes and vessels, infections that damage surrounding tissue or cause scarring, and other conditions.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the fourth quarter of 2016 we expanded the indications for use of the Flexitouch system. We received U.S. FDA clearance to market a first-of-its-kind system to treat patients suffering from lymphedema of the head and neck, a frequent consequence of head and neck cancer and its treatment. Patient symptoms often include significant skin changes, pain and discomfort, as well as difficulty breathing and swallowing. The American Cancer Society estimates that there are 430,000 survivors of head and neck cancers in the United States, and more than 65,000 new patients are diagnosed each year. In a 2016 clinical publication, researchers at Vanderbilt University School of Medicine estimated that more than 75% of patients with head and neck cancer develop lymphedema requiring treatment. Our Flexitouch head and neck system is the only pneumatic compression device with an indication to treat patients suffering from debilitating head and neck lymphedema. We estimate the market opportunity for our Flexitouch head and neck system is approximately $1 billion in the United States, which is based on 75% of the total number of patients suffering from cancers of the head and neck and our average selling price per device. In June 2020, a study published in Supportive Care in Cancer recognized the effectiveness of Flexitouch in treating patients with head and neck related lymphedema. The study, led by Vanderbilt University was a pilot randomized clinical trial reflecting statistically significant reductions in swelling, pain and improvements in the ability to swallow. In addition, in September 2021, we initiated a randomized, controlled clinical trial evaluating the effectiveness of our Flexitouch&#160;Plus system for the treatment of head and neck lymphedema. We believe this study will represent the largest randomized, controlled clinical trial ever conducted for the treatment of head and neck cancer-related lymphedema. The trial will consist of approximately 250 subjects enrolled at ten clinical sites and will span three years.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Current Treatment and Limitations </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A traditional treatment for lymphedema is complete decongestive therapy consisting of manual lymphatic drainage, which is a specialized application of gentle pressure to the skin applied by a trained therapist that encourages drainage of lymph fluid, as well as decongestive exercises, skin care and compression with multilayered bandages, compression garments or pumps. Typically, this therapy begins with clinic visits three to five times per week for four to eight weeks, which is costly, inconvenient for the patient, and time consuming. Access to therapy clinics can also be limited, leading to many patients not completing their prescribed in-clinic treatments. Following the in-clinic visits, typically clinical improvement plateaus or reimbursement for the therapy ends, and patients transition to self-administered home-based care. Manual lymphatic drainage is difficult for patients to self-administer due to limited range of motion and treatment techniques that are difficult to replicate, and pump-based compression using simple pumps can be uncomfortable and has not demonstrated the clinical and economic benefits of our Flexitouch advanced pneumatic pump. To address these limitations, our at-home Flexitouch system was developed to provide automated lymphatic drainage therapy through an advanced, easy-to-use, self-applied at-home system. Peer-reviewed, published studies have shown that our Flexitouch system provides improved quality of life and clinical outcomes and delivers significant cost savings to payers and patients. </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">8</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_Hlk32494920"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The standard of care treatment for CVI is compression therapy. Compression stockings and wraps are typically used to provide added pressure, increasing the effectiveness of the calf-muscle pump in returning blood to the heart, but these products can be challenging for patients to apply. As the disease progresses, patients may develop a venous leg ulcer, which is commonly treated using multilayered bandages to minimize swelling and enhance blood flow. A clinician applies these typically non-removable bandages to patients at a precise pressure and patients wear the bandages between weekly visits to the wound clinic during which they are then removed and reapplied. Treatment typically occurs for several months and impairs patient quality of life by limiting bathing, range of motion, comfort and other activities of daily living. Treatment efficacy is inconsistent because bandages can lose their precise pressure between treatments. Enhancing standard of care treatments for CVI with our pneumatic compression systems has been proven to reduce the recurrence of ulcer formations as well as recurrent skin infections (cellulitis) leading to better patient quality of life and lower overall cost of clinical care.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In 2022, three independent societies&#8217; consensus endorsements were published in <i style="font-style:italic;">Phlebology: The Journal of Venous Disease</i>. Experts from the American Venous Forum, American Venous and Lymphatic Society and Society for Vascular Medicine provided the consensus guidance on diagnosis and patient treatment pathways for lymphedema. Over a majority of the panel (92%) agreed with the statement that sequential pneumatic compression should be recommended for lymphedema patients, with 34% strongly agreeing. In addition, 72% of the panel agreed with the statement that all patients with CVI (stages C3-C6) should be considered as lymphedema patients, with 38% strongly agreeing.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Overview of Bronchiectasis and Cystic Fibrosis </b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Bronchiectasis is a COPD-associated condition where the lung&#8217;s bronchi become inflamed, widened, permanently damaged and scarred. As more of the bronchial wall thickens, mucus gets trapped, creating a breeding ground for infection. The inability to fully clear mucus and pathogens from the lungs can result in a chronic cycle of infections and inflammation. Airway clearance therapies help break this vicious cycle and need to be used regularly to maintain a healthy respiratory system.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Cystic fibrosis is an inherited disease that causes thickened mucus to form in the lungs, pancreas and other organs. In the lungs, this mucus blocks the airways, creating lung damage and making it hard to breathe. There is no cure for COPD or cystic fibrosis.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Market Opportunity</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:14pt 0pt 0pt 0pt;">Bronchiectasis is one of the most common respiratory diseases with over 500,000 U.S. adults diagnosed and is estimated to be growing in the high single-digits annually. More than 16 million people in the U.S. are living with COPD and it is estimated that over 4 million of them may be affected by bronchiectasis. High frequency chest wall oscillation is used to treat bronchiectasis and over 40 other International Classification of Disease (&#8220;ICD&#8221;)-10 diagnosis codes.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:14pt 0pt 0pt 0pt;">Over 30,000 people in the U.S. struggle with the effects of cystic fibrosis every day. Cystic fibrosis treatment includes airway clearance therapy, of which HFCWO is the standard of care. The Cystic Fibrosis Foundation Patient Registry reports 77% of cystic fibrosis patients use HFCWO.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:14pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">Current Treatment and Limitations</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="letter-spacing:0.05pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Airway clearance therapy (&#8220;ACT&#8221;) utilizes physical or mechanical means of percussion or vibration to mobilize mucus and phlegm to facilitate airway clearance by coughing. ACT options include huff coughing, chest physiotherapy performed by a therapist or caregiver, active cycle breathing, positive expiratory pressure devices and HFCWO vests. These treatments need to be performed daily to support bronchial hygiene for at-risk respiratory patients. Adherence to treatments and effectiveness of treatments are a significant challenge for patients with these chronic conditions.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="color:#ff0000;letter-spacing:0.05pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">AffloVest is a HFCWO therapy vest that has eight anatomically positioned oscillating motors that create individual pressure waveforms to target all lobes of the lungs to loosen, thin and mobilize lung secretions.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">9</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="color:#ff0000;font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_1a220878_9f26_4a66_9102_5fc2bce64ff4"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:10.1pt;text-align:justify;text-indent:-10.1pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Our Strategy</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our goal is to become a leader in the at-home treatment of underserved chronic diseases. We intend to leverage our established product, service and fulfillment platforms to be a global provider of clinically proven easy-to-use and cost-effective solutions. The key elements of our strategy include: </p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23.05pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;">Increase awareness of our solutions and establish them as the standards of care.</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"> We believe that many patients with lymphedema, chronic venous insufficiency and chronic respiratory conditions remain undiagnosed or undertreated. We intend to further educate physicians, nurses, therapists, patients, payers and DME providers to raise awareness of these diseases, the associated health burdens of such diseases on patients and society, and the clinical and economic benefits of using our products. Further, we intend to continue promoting this awareness through training and educating clinicians, advertising campaigns, exhibiting at tradeshows and physician meetings and publishing additional clinical and economic outcome data demonstrating the benefits of our solutions. Our ongoing marketing initiatives focus on increasing referrals from physicians trained in the diagnosis and treatment of venous and lymphatic diseases, oncology and chronic respiratory conditions. In addition, we plan to launch more extensive direct-to-provider and patient marketing programs that we believe will further increase awareness of our solutions. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23.05pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;">Utilize direct sales and customer support teams.</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"> We rely on a large direct sales force and marketing organization to drive greater product adoption by patients suffering from lymphedema and CVI and their clinicians. We also intend to expand and support our respiratory DME channels, in an effort to help demonstrate HFCWO as a staple among the host of treatments they bring to chronic respiratory patients. We intend to strengthen our distribution network by continuing to recruit, train and retain talented sales representatives. With an expanded sales force, our goal is to expand the existing prescriber base. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23.05pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;">Demonstrate ongoing innovation to grow our technology platform and expand adoption of our therapies.</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"> We are actively developing new products and features for our portfolio in order to expand the number of patients using our products and allow us to enter new clinical adjacencies. We pursue both internal research, design and development, and also work with external collaborators to expand our product offerings. In addition, we evaluate opportunities to license or acquire additional technologies and products to expand our total addressable market opportunity. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23.05pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;">Continue the development of clinical and economic outcome data.</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"> A key part of our success is our ability to demonstrate the effectiveness of our products through clinical and economic outcome data. We intend to invest in additional studies to support peer-reviewed, published articles that evidence the clinical and economic benefits of our solutions as compared to traditional treatments. We intend to use these data to continue to educate clinicians, payers and patients on the proven advantages of our products compared to other therapies and expand our network of key opinion leader advocates. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23.05pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;">Expand third-party reimbursement.</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"> Most of our products are covered under existing reimbursement codes, and we have secured coverage for our solutions with commercial payers, Medicare, the Veterans Administration and certain Medicaid programs. Our team has experienced significant success in obtaining positive coverage policies from payers by developing direct relationships with payer decision-makers, leveraging our relationships with physician societies and key opinion leaders, providing clinical data, demonstrating the efficacy of our products and educating payers on the limitations of traditional treatments. We intend to continue this strategic approach to further expand coverage for our solutions, as well as to meet payer-specific requirements on behalf of patients.</span></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#ff0000;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">10</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_47c7fcd6_e830_40dd_9934_99d86ec2c3a0"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:10.1pt;text-align:justify;text-indent:-10.1pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Our Products </b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We market Flexitouch and Entre systems as at-home therapies for the treatment of lymphedema and chronic venous insufficiency. We market AffloVest as an at-home therapy intended to promote airway clearance. These products have received 510(k) clearance from the FDA to be marketed in the United States. We believe our products have unique features and benefits that address the shortcomings of traditional treatments, are more cost-effective and enable more consistent and effective therapy, leading to enhanced patient quality of life, improved clinical outcomes and reduced cost of care. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:10pt;text-align:justify;text-indent:-10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Flexitouch System </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our Flexitouch Plus system is a fully automated, programmable, advanced pneumatic compression device, or APCD, designed for treatment of lymphedema in the home setting. Our Flexitouch system has received 510(k) clearance for the treatment of lymphedema, phlebolymphedema, lipedema, certain types of other edema, venous insufficiencies and certain types of leg ulcers. We introduced our first-generation Flexitouch system in the United States in 2003, our second-generation Flexitouch system in 2006, and our third-generation Flexitouch system, the Flexitouch Plus, in 2018. The mechanism of action of our patented Flexitouch Plus system is designed to stimulate the lymphatic system similar to manual lymphatic drainage therapy, the current standard of care in patient treatment. By automating this technique, we believe our system offers an effective, cost-efficient, convenient and accessible at-home treatment for patients. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our Flexitouch Plus system consists of an electronic controller unit that offers 17 treatment settings and multiple contoured garment configurations for the trunk, chest, head, neck and the arm or leg. Our Flexitouch Plus is the only pneumatic compression system offering the flexibility for treating upper and lower extremities, the trunk and chest, and the head and neck. The electronic controller is a pneumatic compressor with four connector outlets. Each connector has eight outflow ports into which the garment hoses are connected. Our unique garments contain up to 32 air chambers, are made of a soft, pliable fabric and are designed with zippers and hook-and-loop fasteners to fit snugly around affected areas for maximum comfort and optimum pressure delivery. The garments come in a variety of sizes that can be easily adjusted to patients of all sizes. When our system is activated, air passes through the hoses, delivering sequential inflation and deflation to the garments and applying gentle pressure to the skin. The inflation sequence is designed to stimulate the lymphatic system, moving lymph fluid from the impaired areas toward healthy regions of the body. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The electronic controller unit adjusts the amount of pressure and the timing of the pressure and release cycles. This unit is lightweight and easily portable, providing maximum convenience for at-home treatment. A typical therapy session using our Flexitouch Plus system lasts up to one hour, with additional treatment options available if prescribed by a clinician. Beginning in November 2022, Flexitouch Plus controllers include Bluetooth capability that enables therapy data from the controller to be reported through Kylee, a companion application.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:10pt;text-align:justify;text-indent:-10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Entre System </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We introduced our Entre system in the United States in February 2013 to offer a lightweight, portable pneumatic compression solution for patients with cognitive or dexterity issues who need a basic (simple) pump or for patients who do not yet qualify for insurance coverage of an advanced compression device such as our Flexitouch Plus system. Our Entre system is a basic pneumatic compression device used for the at-home treatment of venous disorders including lymphedema and chronic venous insufficiency, including venous leg ulcers. Our Entre system is a pump with garments covering the arm or leg with eight chambers that inflate in sequence and remain inflated for a preset time period. All chambers deflate at once. Our Entre system moves fluid from fingers or toes toward areas closer to the trunk. The system can be programmed to a variety of pressures delivering a prescribed treatment customized to meet the patient&#39;s needs.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Kylee</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"></span>In 2022, we introduced Kylee&#8482;, a free mobile application to help patients learn about lymphedema, track their symptoms and treatment, and share their progress with their doctor. The purpose behind Kylee is to help support and encourage patients to embrace self-care and become more educated about their condition. Our customers can use Kylee to track their orders for our devices and view onboarding tutorials for using the </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">11</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">device. Once a patient starts using the device, they can use Kylee to record their treatments and symptoms, and capture photos of their condition for sharing with their healthcare team. Flexitouch Plus controllers include Bluetooth technology, which is now viewable using Kylee. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">AffloVest</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;margin:0pt;">We acquired the AffloVest business in September 2021. The AffloVest is the first truly portable high-frequency chest wall oscillation (HFCWO) vest. The device is battery-powered and affords patients the ability to ambulate while receiving treatment, as well as increases the likelihood that their treatment will travel with them. The AffloVest treats patients with retained pulmonary secretions resulting from bronchiectasis, cystic fibrosis and a host of neuromuscular disorders. The AffloVest offers various treatment modes and intensities. The user can set and store their personalized default treatment settings. Our AffloVest system has received 510(k) clearance as a HFCWO device and is intended for promoting airway clearance and improvement of bronchial drainage by enhancing mobilization of bronchial secretions where manipulation of the thorax is the physician&#8217;s choice of treatment.</p><a id="_de757e6a_a777_4f3c_b29b_cca6d46e7325"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Clinical Results and Studies</b> </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;padding-left:10pt;text-align:justify;text-indent:-10pt;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Overview </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">A key part of our success is our ability to demonstrate the effectiveness of our products by funding studies that generate clinical and economic outcome data supporting our products. We have developed a significant body of clinical data supporting the efficacy and safety of our products. We intend to continue to invest in additional studies to support peer-reviewed, published articles that evidence the clinical and economic benefits of our solutions as compared to traditional treatments. To date, more than 25 studies regarding the safety and efficacy of our products have been completed, in which over 2,100 subjects have been included. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;padding-left:10pt;text-align:justify;text-indent:-10pt;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Economic Impact of our Flexitouch System in Patients with Phlebolymphedema </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">A retrospective longitudinal matched case-control analysis of de-identified private insurance claims published by the Journal of Vascular Surgery in 2018 indicated significant benefits attributable to our Flexitouch system as compared to alternative compression therapies currently employed to help reduce the notable economic burden of phlebolymphedema (chronic venous insufficiency-related lymphedema). The study used administrative claims data from Blue Health Intelligence for the years 2012 through 2016. Patients were required to be continuously enrolled in the health plan for at least 18 months, diagnosed with phlebolymphedema, and had received at least one claim for conservative therapy either alone or in addition to a pneumatic compression device, or PCD. The main outcomes included direct phlebolymphedema- and sequelae-related medical resource utilization and costs. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">Prior to case matching, 1,065 patients met these criteria. After case matching, the study included: 86 patients using conservative therapy matched with 87 patients on Flexitouch; 34 patients on simple PCDs, or SPCDs, matched with 23 patients on Flexitouch; and 69 patients on other advanced PCDs, or APCDs, matched with 67 patients on Flexitouch. Compared with conservative therapy alone, Flexitouch patients were associated with 69% lower per patient per year total phlebolymphedema- and sequelae-related costs net of any PCD-related costs ($3,839 vs $12,253; P=0.001). This was driven by 59% fewer mean annual hospitalizations (0.13 vs 0.32; P&lt;0.001) corresponding to 82% lower inpatient costs and 55% lower outpatient hospital costs. Flexitouch patients were also associated with 52% lower outpatient physical therapy and occupational therapy costs and 56% lower other outpatient-related costs. Compared with SPCDs, Flexitouch was associated with 85% lower total costs ($1,153 vs $7,449; P=0.008) driven by 93% lower inpatient costs ($297 vs $4,215; P=0.002), 84% lower outpatient hospital costs ($368 vs $2,347; P=0.020), and 85% lower other outpatient-related costs ($353 vs $2,313; P=0.023). Compared with other APCDs, Flexitouch was associated with 53% lower total costs ($3,973 vs $8,436; P=0.032) because of lower outpatient costs and lower rates of cellulitis infections (22.4% vs 44.9% of patients; P=0.02).</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">12</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;padding-left:10pt;text-align:justify;text-indent:-10pt;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Impact on Clinical Outcomes and Healthcare Costs with Use of our Flexitouch System </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">A retrospective study published by the American Medical Association in <i style="font-style:italic;">JAMA Dermatology</i> demonstrated significant improvement in key clinical endpoints and immediate cost reductions for individuals with lymphedema following receipt of our Flexitouch system. The study was conducted in the United States and included 718 patients with a lymphedema diagnosis who had continuous insurance coverage during the 12 months prior to and the 12 months after receiving our Flexitouch system from 2007 through 2013. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">The study evaluated a broad, clinically relevant set of healthcare use outcomes for each patient for the 12 months before and the 12 months after receipt of our Flexitouch system, including cellulitis infections, inpatient hospitalizations, physical therapy and outpatient hospital visits. Receipt of our Flexitouch system was associated with a significant decline in the rate of cellulitis diagnosis in the cancer-related lymphedema patients of 79% (from 21.1% to 4.5%; p&lt;0.001) and in the non-cancer-related lymphedema patients of 75% (from 28.8% to 7.3%; p&lt;0.001). The inpatient hospitalization rate declined 22% in the cancer-related group (from 2.7% to 2.1%; p=0.63) and declined 54% in the non-cancer-related group (from 7.0% to 3.2%; p=0.02). The manual therapy rate decreased 30% in the cancer-related lymphedema patients (from 35.6% to 24.9%; p=0.001) and decreased 34% in the non-cancer-related lymphedema patients (from 32.3% to 21.2%; p=0.001). In addition, outpatient hospital visits declined 29% in the cancer-related patients (from 58.6% to 41.4%; p&lt;0.001) and 40% in the non-cancer-related patients (from 52.6% to 31.4%; p&lt;0.001). </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The study also reviewed lymphedema-related healthcare costs for each patient in the study for the 12 months before and the 12 months after receipt of our Flexitouch system. Among the cancer-related lymphedema patients, total costs per patient, excluding durable medical equipment costs, were reduced by 37%, from $2,597 to $1,642 (p=0.002) following receipt of our Flexitouch system. The greatest contributor to this change was a 54% reduction in outpatient hospital costs from $1,517 to $694 (p&lt;0.001). Total costs per non-cancer-related lymphedema patient, excluding durable medical equipment costs, were reduced by 36% from $2,937 to $1,883 (p=0.007). Outpatient hospital costs for the non-cancer patients declined by 65% from $1,726 to $606 (p&lt;0.001). </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:10pt;text-align:justify;text-indent:-10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Flexitouch System Impact on Limb Volume and Patient-Reported Outcomes </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A prospective study published in the <i style="font-style:italic;">European Journal of Vascular and Endovascular Surgery</i> demonstrated that use of our Flexitouch system is associated with statistically significant reduction in limb volume, improvement in quality of life and no significant adverse effects. The study was conducted in the United States and collected data from a patient registry required by a third-party payer for 196 patients with lower extremity lymphedema who were prescribed our Flexitouch system from January 2009 to May 2012. The primary objective of the study was to examine the effectiveness of our Flexitouch system in reducing lower extremity limb volume, with a secondary objective of evaluating clinician-assessed and patient-reported outcomes. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Use of our Flexitouch system was associated with a statistically significant reduction in limb volume with 88% of patients experiencing a reduction in limb volume and with 35% enjoying a substantial reduction in limb volume of greater than 10%. Twelve percent of patients experienced an increase in limb volume. Clinician assessment indicated that the majority of patients experienced improvement in the condition of their skin. Eighty-six percent of the patients exhibited a reduction in skin hardening (fibrosis) based on manual assessment of the skin. Based on clinical observation of function, 85% of patients demonstrated an increased ability to perform activities of daily living. Additionally, 77% of patients demonstrated improved range of motion.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"> <span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Patients reported a significant increase in their ability to control lymphedema through treatment with our Flexitouch system, with an increase in function and a reduction in pain. Of the 98 patients who responded, 66% reported being &quot;very satisfied&quot; with the treatment by our Flexitouch system and 29, or 30%, of patients reported being &quot;satisfied&quot; with the treatment by our Flexitouch system.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:10pt;text-align:justify;text-indent:-10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Comparison of our Flexitouch System with Simple Pneumatic Compression Devices </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">A prospective, randomized controlled trial published in <i style="font-style:italic;">Supportive Care in Cancer</i> demonstrated that our Flexitouch system provides better clinical outcomes as compared to those achieved with a simple </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">13</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">pneumatic compression device for home-based treatment of breast cancer-related lymphedema. The study was conducted in the United States and involved 36 patients. The number of participants in this study is considered to be a small sample size and a limitation of the study. However, it is one of the only published randomized controlled trials comparing PCDs, and we believe is currently the only published study of PCDs that reported comprehensively on adverse events. The patients were randomized to our Flexitouch system or a simple pneumatic compression device used for home treatment of one-hour per day for 12 weeks. The simple pneumatic compression device used in the study was a Bio Compression 2004 Sequential Circulator pneumatic compression device. The primary objective of the study was to determine whether our Flexitouch system provides better outcomes, as measured by arm edema and tissue water reductions, compared to a simple pneumatic compression device in patients with arm lymphedema. The study does not reflect a comparison of our Flexitouch system to a product that is billed under the same Healthcare Common Procedure Coding System, or HCPCS, Code as our Flexitouch system. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Thirty-six patients with unilateral upper extremity lymphedema with at least 5% arm edema volume at the time of enrollment completed treatments over the 12-week period, with 26 patients being evaluated for edema volume change and 28 patients being evaluated for changes in arm tissue water content. Arm edema volumes were determined from arm girth measurements and suitable model calculations, and tissue water was determined based on measurements of the arm tissue. The patients were randomized into two groups of 18 patients each, with one group receiving treatment with our Flexitouch system and the other group receiving treatment using a simple pneumatic compression device. The group using our Flexitouch system experienced an average reduction in edema of 29% compared to a 16% increase in the group using a simple pneumatic compression device. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:10.1pt;text-align:justify;text-indent:-10.1pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Study of Patient-Reported Satisfaction with Use of our Flexitouch System </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A retrospective study published in the <i style="font-style:italic;">Oncology Nursing Forum</i> demonstrated that patients using our Flexitouch system were satisfied with the device and perceived it to be beneficial in managing their lymphedema. The study was conducted in the United States and involved 155 patients with lymphedema whose treatment was initiated from March 2004 to May 2006. The primary objective of the study was to compare treatment protocol adherence, satisfaction and perceived changes in emotional and functional status between patients with cancer-related lymphedema and non-cancer-related lymphedema using our Flexitouch system. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Ninety percent of the 155 study patients reported being &quot;satisfied&quot; with our Flexitouch system. Of these patients, more than 65% reported being &quot;extremely satisfied.&quot; Further, 95% of patients reported a positive limb volume outcome, which was defined as a patient perceiving that limb volume had been maintained or reduced with device use. Of these patients, 42% reported limb volume decreases as much as 20%, and an additional 20% reported decreases of less than 20%. In addition, clinically and statistically significant improvements occurred in all areas of physical and emotional health (p&lt;0.006). </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:10.1pt;text-align:justify;text-indent:-10.1pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Flexitouch System Impact on Patient-Reported Improved Quality-of-Life </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A prospective observational study published in <i style="font-style:italic;">Annals of Vascular Surgery</i> demonstrated that use of our Flexitouch system is associated with patient-reported overall improvement in quality-of-life and lower extremity-related symptoms. The study was conducted in the United States and collected data from patients presenting for treatment of lower-extremity lymphedema from March 2011 to September 2014. A total of 100 consecutive patients with lower-extremity lymphedema met inclusion criteria and were included in the study. The primary objective of the study was to demonstrate improved quality-of-life in patients with lower-extremity lymphedema with Flexitouch system treatment. The secondary objective was to demonstrate reduced infectious complications of lymphedema with Flexitouch system treatment, and to determine the incidence of concomitant venous insufficiency in patients with lymphedema. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Use of our Flexitouch system was associated with overall improvement in lower extremity-related symptoms, with 54% of patients reporting greatly improved symptom control after use of our Flexitouch system, 35% moderately improved and 11% mildly improved. In the year before use of our Flexitouch system, 15% of the patients reported 26 episodes of cellulitis, which decreased to five episodes after initiation of the Flexitouch system (<i style="font-style:italic;">P</i>=0.002) in subsequent median follow-up of 12.7 months. Eight percent of patients reported skin ulceration of the affected extremity in the year before presentation for treatment. The number of lower-extremity </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">14</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">ulcers pre- and post-Flexitouch system use decreased from seven to two (<i style="font-style:italic;">P</i>=0.007). Overall, 46% of the patients had complete limb girth measurements at the ankle and calf, and there was a statistically significant decreased overall limb girth after Flexitouch system treatment in pre- and post-ankle (28.3 cm vs. 27.5 cm, <i style="font-style:italic;">P</i>=0.01), and calf mean girths (44.7 cm vs. 43.8 cm, <i style="font-style:italic;">P</i>=0.018). In addition, venous reflux was present in 18% of patients, 14% and 4% within the superficial and deep venous system respectively. In patients with venous reflux, moderate to great improvement in symptoms was reported in 7% and 11%, respectively compared with 28% and 43% in patients without venous reflux (<i style="font-style:italic;">P</i>=0.257).</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt -36pt;"><span style="font-style:italic;font-weight:bold;">Advanced Pneumatic Compression for Treatment of Lymphedema of the Head and Neck</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">An open label, randomized wait-list controlled trial published in the <i style="font-style:italic;">Supportive Care in Cancer</i> journal supported the safety and feasibility of the Flexitouch system APCD for the treatment of secondary lymphedema in head and neck cancer, or HNC, patients. This study was conducted in the United States and included 49 head and neck cancer patients. Eligible patients had completed treatment for HNC, were disease free, and had lymphedema at enrollment. Participants were randomized to wait-list lymphedema self-management (standard of care) or lymphedema self-management plus the use of the APCD bib. Safety (CTCAE V4.0) and feasibility were primary endpoints; secondary endpoints included efficacy measure by objective examination and patient reported outcomes (symptoms, quality of life, function) adherence barriers, and satisfaction. Assessments were conducted at baseline and weeks 4 and 8.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">No device-related serious adverse events were reported. Most patients used the APCD once per day, instead of the prescribed twice per day, citing time related factors as barriers to use. Patients in the intervention group reported improvement in perceived ability to control lymphedema (baseline: 5/19, 26% good or excellent; 8 weeks: 16/19, 84% good or excellent, p=0.003) and visible external swelling (front view p&lt;0.001, right view p=0.004, left p=0.005), as well as less reported pain. Relative to patients in the control group, at 8-weeks patients using the Flexitouch system had statistically significant reductions in the reported severity of soft tissue (p=0.008, d =&#8722;0.86) and neurological symptoms (p=0.047, d=&#8722;0.60) clusters on the Lymphedema Symptom Intensity and Distress Survey-Head and Neck. Relative to patients in the control group, patients using the Flexitouch system had statistically significant improvement in swallowing solids (p=0.016) and mucous related symptoms (p=0.050, d=&#8722;0.80 and &#8722;0.57 respectively) on the Vanderbilt Head and Neck Symptom Survey plus General Symptom Survey.<span style="font-family:'Times New Roman','Times','serif';font-size:12pt;"> </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">AffloVest Clinical Evidence</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The use of the AffloVest in patients with cystic fibrosis (&#8220;CF&#8221;) has been studied and reported on in non-peer reviewed journals. In 2016, a prospective study was conducted of 25 patients who were asked to augment their current airway treatment regimen with the AffloVest. These patients ranged from 11 to 18 years old and used AffloVest&#160;for periods of one month to almost a full year. Twelve patients demonstrated measurable improvement in multiple lung function tests: Forced Vital Capacity (&#8220;FVC&#8221;) increased 15.22%, Forced Expiratory Volume 1 (&#8220;FEV1&#8221;) increased 17.41% and Forced Expiratory Flow (&#8220;FEF&#8221;) 25-75% increased 11.21% respectively. Eleven of the 12 patients who demonstrated positive improvement in their lung scores, and in whom those scores were maintained for nearly one year, had been using air bladder style vests previously. The remaining 13 patients saw no significant increase, and no decrease, in lung function.<span style="font-family:'Times New Roman','Times','serif';font-size:12pt;"> </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">A prospective, single-site study was published in <i style="font-style:italic;">Respiratory Therapy</i> in 2018 and compared the impact of traditional compressor/bladder-style HFCWO vests with that of the mobile, battery-powered AffloVest on lung function measures in 32 healthy patients. The results showed no significant difference between the technologies in increased airflow in the lungs during treatment. AffloVest performed favorably to traditional vests in that it produced no significant decline in forced vital capacity or forced expiratory volume, while the traditional vests did show statistically significant declines in these measures.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In 2020, a chart review study of 30 patients compared the need for antibiotic therapy due to exacerbation, based on the number of prescriptions, emergency room visits and hospitalizations in the period approximately six months before each patient started AffloVest HFCWO therapy compared to the period six months after initiating AffloVest HFCWO therapy. The results showed a 96.2% reduction in hospitalizations, 82.4% reduction in emergency room visits, and 87.3% reduction in antibiotic usage for the post-AffloVest group.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">15</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:194.25pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;margin:0pt;">The AffloVest has a history of clinical evidence, and Tactile Medical is committed to supporting additional studies to further support the benefits of this differentiated HFCWO technology. </p><a id="_04d0856e_8ad8_42c9_bfdb_c4903ff5e69c"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Sales and Marketing </b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Unlike many of our competitors, we utilize a direct-to-patient and -provider model to market our lymphedema products directly to patients and clinics, providing high-quality customer service and capturing both the manufacturer and distributor margins. The direct channel allows us to focus on two of our primary call points, vascular and oncology. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For AffloVest, we utilize the respiratory DME channel as our go-to-market method. Our utilization of DME representatives gives us access to a larger channel than competitors that market and sell directly. The respiratory DME channel also already serves the chronic respiratory community, enabling them to identify candidates who are regularly on other respiratory therapies (such as oxygen, nebulizers, non-invasive ventilators, etc.) and who might benefit from the use of our AffloVest. The below chart reflects these models:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#ff0000;"><img src="tcmd-20221231x10k005.jpg" alt="Graphic" style="display:inline-block;height:136.5pt;width:367.5pt;" /></span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#ff0000;"> </span>Our direct-to-patient and -provider lymphedema business is composed of a direct sales force, patient training and support, reimbursement capabilities and medical expertise to educate, expand awareness, coordinate referrals and obtain payment for our products.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The chart below describes our U.S. direct-to-patient and -provider model for our lymphedema business. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#ff0000;"><img src="tcmd-20221231x10k006.jpg" alt="Graphic" style="display:inline-block;height:194.25pt;width:417.75pt;" /></span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">We sell the AffloVest to DME providers in the U.S. that service patients and bill third-party payers for the product. The DME providers obtain the prescription and coordinate with patients and payers to determine insurance eligibility and payment. These DME providers are staffed by trained respiratory therapists who are required in some states to set up patients on at-home prescription respiratory therapies like AffloVest. We </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">16</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:222pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">market to, and educate, DME providers and clinicians about the AffloVest advantages. As of December 31, 2022, we also employed a small group of respiratory specialists, who educate DME provider representatives, provide product demonstrations for targeted clinicians and support technical questions related to the AffloVest. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The chart below describes our DME model.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#ff0000;"><img src="tcmd-20221231x10k007.jpg" alt="Graphic" style="display:inline-block;height:222pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:306.89pt;" /></span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2022, we employed a field staff of 287 Tactile employees, made up of sales representatives, as well as managers, who provide support throughout the United States for our lymphedema and respiratory therapies.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;margin:0pt;">Our marketing team leads our efforts in brand development, product messaging, tradeshow attendance, medical educational forums, website development, social media and advertising.</p><a id="_0e194e50_ac42_4740_a1ee_7cd4e58f2184"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;padding-left:10pt;text-align:justify;text-indent:-10pt;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Reimbursement, Payer Relations and Customer Support Process</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">Private insurers and other payers represented approximately 57% and 68% of our revenue in 2022 and 2021, respectively, while Medicare represented approximately 19% and 17% of our revenue in 2022 and 2021, respectively, Veterans Administration hospitals represented approximately 10% and 13% of our revenue in 2022 and 2021, respectively, and DME distributors represented approximately 14% and 2% of our revenue in 2022 and 2021, respectively. When we sell our solutions directly to patients, we generally bill third-party payers, such as commercial insurance or Medicare, on behalf of our patients and bill the patient for their copayment obligations and deductibles.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As a nationwide provider, we have developed a broad expertise in obtaining billing codes, in-network contracts, developing coverage policies, overcoming payer barriers and obtaining authorization and payment from payers across all regions of the United States. Our model utilizes our strategic and operational reimbursement proficiency to meet the varying requirements of hundreds of payers across the country. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our reimbursement function includes payer relations and reimbursement operations. Our payer relations function focuses on payer policy development and education for our entire portfolio, as well as contract negotiations for our direct business, and data analysis. Our reimbursement operations function is responsible for verifying patient insurance benefits, individual patient case development, prior authorization submissions, case follow-up, and appeals when necessary. The reimbursement operations function is organized into &#8220;regional payer lanes&#8221; so that each case is handled throughout the process by experts in specific payer requirements.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">17</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have strong and established payer relationships, including most of the largest private payers in the United States. Based on our estimates, we are contracted or enrolled as an in-network provider with payers covering nearly 275 million lives. These contracts allow us to be an in-network provider for patients, enabling them to access our systems at a competitive rate and copay comparable to other suppliers and easing our administrative burden in processing authorizations and claims. We have enjoyed a consistent commercial payer approval rate of greater than 80% for the last six years, and a greater than 90% Medicare claims submitted approval rate for the last six years (post-arbitration and based on the number of claims, not dollar amount of claims, submitted across all our products). We began doing business with Medicare in 2007. We have an in-depth understanding of specific payer coverage criteria, and our submission materials are tailored to address an individual payer&#39;s distinct requirements. Our dedicated customer service team is available to answer patient questions regarding reimbursement, account status, device operation and troubleshooting during normal business hours. We receive no additional reimbursement for patient support, but provide high-quality customer service and continuity to enhance patient comfort, satisfaction, compliance and safety with our products. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:14pt 0pt 0pt 0pt;">Our Flexitouch Plus system controller is reimbursed under HCPCS code E0652, and our Entre system controller is reimbursed under HCPCS code E0651. Garments that cover various parts of the body are used with these systems and billed using HCPCS codes E0667, E0668 and E0669. Our head and neck garments do not currently have billing codes assigned. To date, over 1,100 payers have paid for our products.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:14pt;text-align:justify;text-indent:36pt;margin:14pt 0pt 0pt 0pt;">Our respiratory DME partners contract directly with commercial payers and regularly serve as a consolidated source for various respiratory-related therapies. The DME distributor obtains the prescription and, in coordination with the patient and payer, determines insurance eligibility and payment. The AffloVest is reimbursed under HCPCS code E0483, high frequency chest wall oscillation for bronchiectasis, and over 40 other ICD-10 diagnosis codes. </p><a id="_a7f3d433_16b8_4116_82b0_fbda489a43b8"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Research and Clinical Operations</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-top:2pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">We are committed to ongoing research and development as part of our efforts to be at the forefront of physician and patient preference in the area of chronic disease, especially lymphedema, cancer-related lymphedema, chronic venous insufficiency, bronchiectasis and other chronic respiratory conditions. Our research and development and clinical operations functions include scientists, clinical monitors and project managers with expertise in pneumatics, electronics, garment design, embedded software, mechanical design, sensors, manufacturing technologies and clinical trial management. Our current research and development efforts are focused primarily on increasing efficacy, improving design for ease-of-use, enhancing clinical functionality and reducing production costs of our solutions. Our clinical development efforts are focused on further differentiating our products from our competitors. We coordinate our development efforts with our intellectual property strategies in order to enhance our ability to obtain patent and other intellectual property protection. Our research and development expenses, including spending on our clinical evidence development efforts, totaled $7.1 million and $5.7 million for the years ended December 31, 2022 and 2021, respectively.</p><a id="_a407e884_7734_4dac_884e_fc7ac2d00f5f"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;padding-bottom:12pt;text-align:justify;margin:14pt 0pt 0pt 0pt;"><span style="color:#ff0000;">&#160;</span><b style="font-size:10pt;font-weight:bold;">Manufacturing and Quality Assurance</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">Our manufacturing and quality assurance model combines our internal manufacturing resources and expertise, including assembly, quality assurance, material procurement and inventory control, with approved third-party manufacturers and suppliers of system components. Our internal manufacturing activities, located in Minneapolis, Minnesota, include quality inspection, assembly, packaging, warehousing and shipping of our products. We outsource the manufacture of components, which are produced to our specifications and shipped to our facilities for inspection and final assembly. We use third-party manufacturers and suppliers worldwide to source our components, maintaining dual-source vendors of critical components whenever possible, and leveraging competitive bids among third-party manufacturers and suppliers to control costs. Quality control, risk management, efficiency and the ability to respond quickly to changing requirements are the primary goals of our manufacturing operations. We believe our manufacturing model permits us to operate with low capital expenditure requirements. We carefully manage our supply chain in an effort to take costs out of the manufacturing process. </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">18</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">We manage our arrangements with our third-party manufacturers and suppliers to adjust delivery schedules and quantities of components to match our changing manufacturing requirements. We forecast our component needs based on historical trends, current utilization patterns and sales forecasts of future demand. We establish our relationships with our third-party manufacturers and suppliers through supplier contracts and purchase orders. In most cases, these supplier relationships may be terminated by either party upon reasonable notice. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">In order to mitigate against the risks related to a single source of supply, we qualify alternative suppliers, when possible, and develop contingency plans for responding to disruptions, including maintaining adequate inventory of any single source components, along with requiring each supplier to maintain specified quantities of inventory. To date, we have not experienced material delays in obtaining any of our components, nor has the ready supply of finished products to our patients or clinicians been adversely impacted by component supply issues. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">We have implemented a quality management system designed to comply with FDA regulations and International Standards Organization, or ISO, standards governing medical device products. In the United States, we and some of our manufacturers are required to manufacture our products in compliance with the FDA&#39;s Quality System Regulation, which covers the methods and documentation of the design, testing, control, manufacturing, labeling, quality assurance, packaging, storage and shipping for our products. We maintain a quality management system to control compliance with such requirements and have procedures in place designed to ensure that all products and materials purchased by us conform to our requirements and FDA regulations. Our quality management system has been certified to ISO 13485:2003 in 2012, 2014 and 2017, and to ISO 13485:2016 in 2019, 2020, 2021 and 2022. In 2021, we also received our Medical Device Single Audit Program (&#8220;MDSAP&#8221;) certification. An MDSAP allows an MDSAP-recognized Auditing Organization to conduct a single regulatory audit of a medical device manufacturer that satisfies the relevant requirements of the regulatory authorities participating in the program. Many of our manufacturers&#8217; quality management systems also have been certified to ISO.</p><a id="_b8f78de8_efc7_4cf6_8a69_590b8da08bd9"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Order Fulfillment and Patient Education </b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">With respect to our Flexitouch and Entre systems, once we have a complete patient order and appropriate documentation from the payer, we package and ship the system, configured to their physician&#39;s prescription, directly to the patient. We utilize third-party carriers for delivery and pick up of our devices. After delivery and when requested by our patient, we coordinate a virtual or at-home visit from one of our&#160;trainers to provide education and instruction on use and care of their therapy system. These trainers are&#160;professionally trained and&#160;instructed on proper use of our products. Patient visits are coordinated from our offices in Minneapolis and training sessions are assigned by our staff. Additional materials including training videos and support content is available on our website to support patients and their training needs. Kylee&#8482; allows patients to manage their conditions by tracking treatments and symptoms, as well as having direct access to educational resources.&#160;</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;margin:0pt;">Our AffloVest product is packaged and shipped to the DME provider or drop-shipped directly to a patient, as directed. We utilize third-party carriers for delivery and pick up of our AffloVest products. In situations in which the product is shipped to the DME provider, they are responsible for completing the delivery to the patient. Upon receipt of the product, patients are able to utilize materials included with the product to complete self-training or engage with the DME provider for additional support. </p><a id="_c0384c68_0aa5_4e24_9900_d7f6b4ae857c"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Competition </b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">The pneumatic compression pump market is composed of a number of manufacturers and distributors of pneumatic compression pumps. Our most significant manufacturing competitors are Bio Compression Systems, Inc. and Lympha Press USA. Other competitors are Koya Medical, Inc. and Aria Health. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">&#160;<span style="font-size:10pt;">Given the growth of the pneumatic compression pump market, we expect that the industry will become increasingly competitive in the future. Manufacturing companies compete for sales to patients primarily based on product features and service. </span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">19</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We believe we are the only pneumatic compression home-therapy device company with a meaningful U.S. market position supported by a direct sales force. We believe our manufacturing competitors&#39; complete reliance on DME distribution intermediaries compresses their margins and limits their ability to invest in clinical evidence and product features that address consumer preferences. To pursue a direct-to-patient and -provider sales model, our manufacturing competitors would need to meet national accreditation and state-by-state licensing requirements, secure Medicare billing privileges, as well as compete directly with the home medical equipment providers that many rely on across their entire home care businesses. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We anticipate that, given the size of the available market, we will face increased competition in the future as existing companies and competitors develop new or improved products and distribution strategies and as new companies enter the market with new technologies and distribution strategies. Our ability to compete successfully and to increase our market share is dependent upon our reputation for providing responsive, professional and high-quality products and services and achieving strong customer satisfaction. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;margin:0pt;">Competitors within the airway clearance market consist largely of three other HFCWO vest manufacturers: Baxter (formerly Hill-Rom), Philips Medical and Electromed. While we believe AffloVest&#8217;s portability and our use of DME distributors are differentiators, we anticipate that given the size of the airway clearance market, we will continue to see vigorous competition. We intend to further expand and support our respiratory DME relationships, as well as invest in product development to better support this still-underserved area.</p><a id="_94270cc3_f62f_4478_ae6e_7962cbd76d64"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Government Regulation </b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our systems are medical devices subject to extensive and ongoing regulation by numerous governmental authorities, principally the FDA, and corresponding state and foreign regulatory agencies. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:10pt;text-align:justify;text-indent:-10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">FDA Regulation </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the United States, the FDA regulates medical devices, including the following activities that we perform, or that are performed on our behalf with respect to our devices: product design and development, pre-clinical and clinical testing, manufacturing, labeling, storage, premarket clearance or approval, record keeping, product marketing, advertising and promotion, sales and distribution, and post-marketing surveillance. Failure to comply with applicable U.S. requirements may subject us to a variety of administrative or judicial sanctions, such as warning letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, civil penalties and criminal prosecution. The FDA can also refuse to clear or approve pending applications.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Unless an exemption applies, each medical device we seek to distribute commercially in the United States requires marketing authorization from the FDA prior to distribution. The two primary types of FDA marketing authorization applicable to a device are premarket notification, also called 510(k) clearance, and premarket approval. The type of marketing authorization is generally linked to the classification of the device, which is based on the degree of risk the FDA determines to be associated with a device and the level of regulatory control deemed necessary to ensure the device&#39;s safety and effectiveness. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our Flexitouch, Entre and AffloVest systems (all models) are Class II devices under the FDA classification system requiring 510(k) clearance. We obtained 510(k) clearance for our Flexitouch system in October 2006 and for a discontinued predecessor system in July 2002. In September 2016, we received 510(k) clearance from the FDA for the Flexitouch system for treating lymphedema of the head and neck. In June 2017, we announced that we received 510(k) clearance from the FDA for the Flexitouch Plus, the third-generation version of our Flexitouch system. In December 2020, we received 510(k) clearance for two new indications for our Flexitouch Plus system: phlebolymphedema and lipedema. We obtained 510(k) clearance for our Entre system in May 2015. 510(k) clearance for the AffloVest system was obtained in 2013. All of our Class II devices have obtained 510(k) clearance and that status remains current as of the date of this filing.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">After a device receives 510(k) clearance or a premarket approval, in general any modification that could significantly affect its safety or effectiveness, or that would constitute a major change in its intended use, will </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">20</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">require a new clearance or approval. Thus, modifications to our existing devices will be evaluated to ensure ongoing compliance to the FDA requirements.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Further, even after a device receives clearance or approval by the FDA and is placed on the market, numerous regulatory requirements apply. These include:</p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23.05pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">establishment registration and device listing; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23.05pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">quality system regulation, which requires manufacturers, including third-party manufacturers, to follow stringent design, testing, control, documentation and other quality assurance procedures during all aspects of the manufacturing process; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23.05pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">labeling regulations and the FDA prohibitions against the promotion of products for un-cleared, unapproved or &quot;off-label&quot; uses, and other requirements related to promotional activities; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23.05pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">medical device reporting regulations, which require that manufacturers report to the FDA if their device may have caused or contributed to a death or serious injury or malfunctioned in a way that would likely cause or contribute to a death or serious injury if the malfunction were to recur; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23.05pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">corrections and removals reporting regulations, which require that manufacturers report to the FDA field corrections and product recalls or removals if undertaken to reduce a risk to health posed by the device or to remedy a violation that may present a risk to health; and </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23.05pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">post-market surveillance regulations, which apply when necessary to protect the public health or to provide additional safety and effectiveness data for the device. </span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Any new Class II devices developed by us will be submitted to the FDA as required by the 510(k) process. Under this process, when a 510(k) clearance is required, we must submit a premarket notification to the FDA demonstrating that our proposed device is &quot;substantially equivalent&quot; to a previously cleared and legally marketed 510(k) device or a device that was in commercial distribution before May&#160;28, 1976 for which the FDA has not yet called for the submission of a premarket approval application, which is commonly known as the &quot;predicate device.&quot; In 2019, the FDA released an optional Safety and Performance Based Pathway for 510(k) clearance, which allows a submitter to demonstrate that an eligible new device of a well-understood type meets FDA-identified performance criteria to demonstrate that the device is as safe and effective as a legally marketed device. If the FDA determines that the device, or its intended use, is not substantially equivalent to a previously-cleared device or use, the FDA will issue a not substantially equivalent decision. This means the device cannot be cleared through the 510(k) process and will require marketing authorization through the premarket approval pathway. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A premarket approval application must be submitted to the FDA if the device cannot be cleared through the 510(k) process. The premarket approval application process is much more demanding than the 510(k) premarket notification process and requires the payment of significant user fees. A premarket approval application must be supported by valid scientific evidence, which typically requires extensive data, including but not limited to technical, pre-clinical, clinical trials, manufacturing and labeling to demonstrate to the FDA&#39;s satisfaction reasonable evidence of safety and effectiveness of the device. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Failure to comply with applicable regulatory requirements can result in enforcement action by the FDA, which may include any of the following sanctions: Warning Letters, fines, injunctions, civil or criminal penalties, recall or seizure of our products, operating restrictions, partial suspension or total shutdown of production, denying our request for 510(k) clearance or premarket approval of new products, rescinding previously granted 510(k) clearances or withdrawing previously granted premarket approvals. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are also subject to announced and unannounced inspections by the FDA, and these inspections may include the manufacturing facilities of our subcontractors. We were audited three times since January 2010 by the FDA and found to be in compliance with the Quality System Regulation. We cannot assure you that we can maintain a comparable level of regulatory compliance in the future at our facilities. </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">21</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:10pt;text-align:justify;text-indent:-10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">FTC Regulation </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Device advertising and promotional activity in certain circumstances is also subject to scrutiny by the Federal Trade Commission, as well as similar state consumer protection agencies, which enforce laws related to false and deceptive trade practices. A company that is found to have advertised its product in violation of these laws may be subject to liability, including monetary penalties. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:10pt;text-align:justify;text-indent:-10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Centers for Medicare and Medicaid Services </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Centers for Medicare and Medicaid Services, or CMS, requires providers of products or services to attain and maintain accreditation in order to participate in federally funded healthcare programs. To attain and maintain accreditation, companies are required to institute policies and procedures that, among other things, formalize the interaction of the company with patients. Accrediting bodies that are approved (&#8220;deemed&#8221;) by CMS will perform audits of these policies and procedures every three years. Should a company fall out of compliance with the requirements of the accrediting body, expulsion from the Medicare program could follow. In May 2008, we became a Durable, Medical Equipment, Prosthetics, Orthotics, and Supplies accredited supplier by the Accreditation Commission for Health Care. This accreditation must be renewed every three years through a recredentialing process that includes an on-site review. We last renewed our accreditation with our accrediting body in May 2020.&#160;Maintaining our accreditation and Medicare enrollment requires that we comply with numerous business and customer support standards. If we are deemed out of compliance with accreditation standards, our enrollment status in the Medicare program could be jeopardized, up to and including termination. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:10pt;text-align:justify;text-indent:-10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Licensure </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Several states require that durable medical equipment providers be licensed in order to sell products to patients in that state. Certain of these states require that durable medical equipment providers maintain an in-state location. Most of our state licenses are renewed on an annual or bi-annual basis. In addition, we are subject to certain state laws regarding professional licensure. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:10pt;text-align:justify;text-indent:-10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Fraud and Abuse Regulations </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Federal Anti-Kickback and Self-Referral Laws.</span>&#160;&#160;&#160;&#160;The Federal Anti-Kickback Statute, among other things, prohibits the knowing and willful offer, payment, solicitation or receipt of any form of remuneration, whether directly or indirectly and overtly or covertly, in return for, or to induce the referral of an individual for the:</p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">furnishing or arranging for the furnishing of items or services reimbursable in whole or in part under Medicare, Medicaid or other federal healthcare programs; or </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">purchase, lease, or order of, or the arrangement or recommendation of the purchasing, leasing, or ordering of any item or service reimbursable in whole or in part under Medicare, Medicaid or other federal healthcare programs. </span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Federal Anti-Kickback Statute applies to certain arrangements with healthcare providers, product end users and other parties, including marketing arrangements and discounts and other financial incentives offered to our clinicians in connection with the sales of our products. The statute is very broad, but includes statutory safe harbors (such as a discount safe harbor) to ensure that if a company tailors its conduct in accordance with a safe harbor, it will not violate the statute.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Noncompliance with the Federal Anti-Kickback Statute can result in civil, administrative and criminal penalties, restrictions on our ability to operate in certain jurisdictions, and exclusion from participation in Medicare, Medicaid or other federal healthcare programs. In addition, to the extent we are found to not be in compliance, we may be required to curtail or restructure our operations. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Ethics in Patient Referrals Act, commonly known as the &quot;Stark Law,&quot; prohibits a physician from making referrals for certain &quot;designated health services&quot; payable by Medicare to an entity, including a company </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">22</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">that furnishes durable medical equipment, in which the physician or an immediate family member of such physician has an ownership or investment interest or with which the physician has entered into a compensation arrangement unless an exception applies. Violation of the Stark Law could result in denial of payment, disgorgement of reimbursements received under a noncompliant arrangement, civil penalties and exclusion from Medicare or other governmental programs. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Additionally, because some of these laws continue to evolve, we lack definitive guidance as to the application of certain key aspects of these laws as they relate to our arrangements with providers with respect to patient training. We cannot predict the final form that these regulations will take or the effect that the final regulations will have on us. As a result, our provider arrangements may ultimately be found to be non-compliant with applicable federal law. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">False statements.</span>&#160;&#160;&#160;&#160;The federal false statements statute prohibits knowingly and willfully falsifying, concealing, or omitting a material fact or making any materially false statement in connection with the delivery of healthcare benefits, items, or services. In addition to criminal penalties, violation of this statute may result in collateral administrative sanctions, including exclusion from participation in Medicare, Medicaid and other federal health care programs. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Federal False Claims Act and Civil Monetary Penalties Law.</span>&#160;&#160;&#160;&#160;The Federal False Claims Act provides, in part, that the federal government may bring a lawsuit against any person whom it believes has knowingly presented, or caused to be presented, any false or fraudulent request for payment from the federal government, or who has made a false statement or used a false record to get a claim paid or to avoid, decrease or conceal an obligation to pay money to the federal government or knowingly retained an overpayment. In addition, amendments to the Federal False Claims Act have made it easier for private parties to bring whistleblower lawsuits against companies. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Civil Monetary Penalties Law provides, in part, that the federal government may seek civil monetary penalties against any person that, like under the Federal False Claims Act, presents or causes to be presented claims to a Federal health care program that the person knows or should know is for an item or services that was not provided as claimed or is false or fraudulent or that has made a false statement or used a false record to get a claim paid. The federal government may also seek civil monetary penalties for a wide variety of other conduct, including offering remuneration to influence a Medicare or Medicaid beneficiary&#39;s selection of providers and violations of the Federal Anti-Kickback Statute. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If we are found to be in violation of the Federal False Claims Act or the Civil Monetary Penalties laws, penalties include fines for each false claim violation of the Federal False Claims Act and varying amounts based on the type of violation of the Civil Monetary Penalties Law, plus up to three times the amount of damages that the federal government sustained because of the act of that person. In addition, the federal government may also seek exclusion from participation in all federal health care programs. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, we bill Medicare Part&#160;B and other insurers directly for each sale to patients. As a result, we must comply with all laws, rules and regulations associated with filing claims with the Medicare program, including the Social Security Act, Medicare regulations, the Federal False Claims Act and the Civil Monetary Penalties Law, as well as a variety of additional federal and state laws. During an audit, insurers typically expect to find explicit documentation in the medical record to support a claim. Physicians and other clinicians, who are responsible for prescribing our products for patients, are expected to create and maintain the medical records that form the basis for the claims we submit to Medicare and other insurers. Any failure to properly document the medical records for patients using our products could invalidate claims, impair our ability to collect submitted claims and subject us to overpayment liabilities, Federal False Claims Act liabilities and other penalties including exclusion from the Medicare, Medicaid or private insurance programs. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">State fraud and abuse provisions.</span> &#160; &#160;Many states have also adopted some form of anti-kickback and anti-referral laws and false claims acts that apply regardless of payer, in addition to items and services reimbursed under Medicaid and other state programs. In some states, these laws apply, and we believe that we are in compliance with such laws. Nevertheless, a determination of liability under such laws could result in fines and penalties and restrictions on our ability to operate in these jurisdictions.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">23</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The U.S. Foreign Corrupt Practices Act and Other Anti-Corruption Laws.</span>&#160;&#160;&#160;&#160;We may be subject to a variety of domestic and foreign anti-corruption laws with respect to our regulatory compliance efforts and operations. The U.S. Foreign Corrupt Practices Act, commonly known as the FCPA, is a criminal statute that prohibits an individual or business from paying, offering, promising or authorizing the provision of money (such as a bribe or kickback) or anything else of value (such as an improper gift, hospitality, or favor), directly or indirectly, to any foreign official, political party or candidate for the purpose of influencing any act or decision in order to assist the individual or business in obtaining, retaining, or directing business or other advantages (such as favorable regulatory rulings). In addition to the FCPA, there are other federal and state anti-corruption laws to which we may be subject, including, the U.S. domestic bribery statute contained in 18 USC &#167; 201 (which prohibits bribing U.S. government officials) and the U.S. Travel Act (which in some instances addresses private-sector or commercial bribery both within and outside the United States). Also, a number of other countries have their own domestic and international anti-corruption laws, such as the UK Bribery Act 2010. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We could be held liable under the FCPA and other anti-corruption laws for the illegal activities of our employees, representatives, contractors, collaborators, agents, subsidiaries, or affiliates, even if we did not explicitly authorize such activity. Although we will seek to comply with anti-corruption laws, there can be no assurance that all of our employees, representatives, contractors, collaborators, agents, subsidiaries or affiliates will comply with these laws at all times. Violation of these laws could subject us to whistleblower complaints, investigations, sanctions, settlements, prosecution, other enforcement actions, disgorgement of profits, significant fines, damages, other civil and criminal penalties or injunctions, suspension and/or debarment from contracting with certain governments or other persons, the loss of export privileges, reputational harm, adverse media coverage and other collateral consequences. In addition, our directors, officers, employees, and other representatives who engage in violations of the FCPA and certain other anti-corruption statutes may face imprisonment, fines and penalties. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">State and federal transparency/reporting requirements.</span>&#160;&#160;&#160;&#160;As part of the Patient Protection and Affordable Care Act, or ACA, the Federal government has created a transparency program known as Open Payments (the Physician Payments Sunshine Act) which requires manufacturers of drugs, devices, biologicals and medical supplies to report annually to the CMS, an agency within the U.S. Department of Health and Human Services, or HHS, information related to payments and other transfers of value provided to physicians and teaching hospitals (&#8220;covered recipients&#8221;) and certain ownership and investment interests held by physicians and their immediate family members. Beginning in 2021, tracking and reporting was expanded to include additional covered recipients, namely physician assistants, nurse practitioners, clinical nurse specialists, certified registered nurse anesthetists and certified nurse-midwives. Failure to submit timely, accurate and complete information may result in civil monetary penalties of up to an aggregate of $150,000 per year and up to an aggregate of $1.0&#160;million per year for &quot;knowing failures to report.&quot; Certain states require implementation of commercial compliance programs and compliance with the device industry&#39;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, impose restrictions on marketing practices, and/or prohibition and tracking and reporting of gifts, compensation and other remuneration or items of value provided to physicians and other healthcare professionals and entities. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The laws described above impact the kinds of financial arrangements we may have with hospitals, healthcare professionals or other potential purchasers of our products. If our operations are found to be in violation of any of the laws or regulations described above or others that apply to us, we may be subject to penalties, including potentially significant criminal, civil and/or administrative penalties, damages, fines, disgorgement, exclusion from participation in government healthcare programs, contractual damages, reputational harm, administrative burdens, diminished profits and future earnings, and the curtailment or restructuring of our operations. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">HIPAA.</span>&#160;&#160;&#160;&#160;The Health Insurance Portability and Accountability Act of 1996, or HIPAA, established uniform standards governing the conduct of certain electronic healthcare transactions and protecting the security and privacy of individually identifiable health information maintained or transmitted by healthcare providers, health plans and healthcare clearinghouses, which are referred to as covered entities. The standards promulgated under HIPAA&#39;s regulations include those that:</p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23.05pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">restrict the use and disclosure of individually identifiable health information, or &quot;protected health information&quot;; </span></td></tr></table></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">24</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23.05pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">establish standards for common electronic healthcare transactions, such as claims information, plan eligibility, payment information and the use of electronic signatures; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23.05pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">require covered entities to implement and maintain certain security measures to safeguard certain electronic health information, including the adoption of administrative, physical and technical safeguards to protect such information; and </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23.05pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">require covered entitles to provide notification to affected individuals, the Department of Health and Human Services and the media in the event of a breach of unsecured protected health information. </span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The American Recovery and Reinvestment Act of 2009, or ARRA, expanded HIPAA&#39;s privacy and security standards. ARRA includes the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH, which, among other things, made HIPAA&#39;s privacy and security standards directly applicable to business associates of covered entities. A business associate is a person or entity that performs certain functions or activities on behalf of a covered entity that involve the use or disclosure of protected health information. As a result, business associates are now subject to significant civil and criminal penalties for failure to comply with applicable standards. Moreover, HITECH creates a new requirement to report certain breaches of unsecured, individually identifiable health information and imposes penalties on entities that fail to do so. HITECH also increased the civil and criminal penalties that may be imposed against covered entities, business associates and possibly other persons and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorney fees and costs associated with pursuing federal civil actions.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The 2013 final HITECH omnibus rule, or the HITECH Final Rule, modifies the breach reporting standard in a manner that makes more data security incidents qualify as reportable breaches. The costs of complying with privacy and security related legal and regulatory requirements are burdensome. The HITECH Final Rule will continue to be subject to interpretation by various courts and other governmental authorities, thus creating potentially complex compliance issues for us, as well as referring providers.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition to federal regulations issued under HIPAA, several states have enacted privacy and security statutes or regulations that, in certain cases, are more stringent than those issued under HIPAA. In those cases, it may be necessary to modify our planned operations and procedures to comply with the more stringent state laws. Most states have also adopted breach notification laws that require notification to affected individuals and certain state agencies if there is a security breach of certain individually-identifiable information. If we suffer a privacy or security breach, we could be required to expend significant resources to provide notification to the affected individuals and address the breach, as well as reputational harm associated with the breach. If we fail to comply with applicable state laws and regulations, we could be subject to additional sanctions. Any liability from failure to comply with the requirements of HIPAA, HITECH or state privacy and security statutes or regulations could adversely affect our financial condition. The costs of complying with privacy and security related legal and regulatory requirements are burdensome and could have a material adverse effect on our business, financial condition and results of operations. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:10pt;text-align:justify;text-indent:-10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Environmental Regulation </b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our research and development and manufacturing processes and operations may involve the controlled use of hazardous materials, including flammables, toxics and corrosives and produce hazardous chemical waste products. We are subject to numerous foreign, federal, state, and local environmental, health and safety laws and regulations relating to, among other matters, safe working conditions, product stewardship and end-of-life handling or disposition of products, and environmental protection, including those governing the generation, storage, handling, use, transportation and disposal of hazardous or potentially hazardous materials. Some of these laws and regulations require us to obtain licenses or permits to conduct our operations. Environmental laws and regulations are complex, change frequently and have tended to become more stringent over time. </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">25</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:10pt;text-align:justify;text-indent:-10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Foreign Government Regulation </b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">International sales of medical devices are subject to foreign governmental regulations, which vary substantially from country to country. The time required to obtain clearance or approval by a foreign country may be longer or shorter than that required for FDA clearance or approval, and the requirements may be different. Many countries also impose product standards, packaging requirements, environmental requirements, labeling requirements, and import restrictions on medical devices. Each country has its own tariff regulations, duties and tax requirements. Failure to comply with applicable foreign regulatory requirements may subject a company to fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions, criminal prosecution or other consequences. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The European Union is the primary regulator in Europe, which has adopted numerous directives/regulations and has promulgated standards regulating the design, manufacture, clinical trials, labeling and adverse event reporting for medical devices. Medical devices that comply with the requirements of applicable directives/regulations will be entitled to bear the CE conformity marking, indicating that the device conforms with the essential requirements of the applicable directives/regulations and, accordingly, can be commercially distributed throughout the member states of the European Union, and other countries that comply with or mirror these directives. At this time, we have no products that are CE marked. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;margin:0pt;">In March 2012, we received our Medical Device License in Canada for our Flexitouch (classic) system and in June 2021 for our Flexitouch (Plus) system. In October 2021, we discontinued our Flexitouch (classic) system Medical Device License in Canada, but our Flexitouch (Plus) system License remains current as of the date of this filing. </p><a id="_10eb8a8d_5337_4890_b398_c9e1dc6860a5"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Third-Party Reimbursement</b> </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">In the United States and elsewhere, sales of medical devices depend in significant part on the availability of coverage and reimbursement to providers and patients from third-party payers. Third-party payers include private insurance plans and governmental programs. As with other medical devices, reimbursement for our products can differ significantly from payer to payer, and our products are not universally covered by third- party commercial payers. Further, third-party payers continually review existing technologies for continued coverage and can, with limited notice, deny or reverse coverage for existing products. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;padding-top:2pt;text-align:justify;text-indent:36pt;margin:0pt;">&#160;<span style="font-size:10pt;">Two principal governmental third-party payers in the United States are Medicare and Medicaid. Medicare is a federal program that provides certain medical insurance benefits to persons age 65 and over, certain disabled persons and others. In contrast, Medicaid is a medical assistance program jointly funded by federal and state governments to serve certain individuals and families with low incomes and who meet other eligibility requirements. Each state administers its own Medicaid program which determines the benefits made available to the Medicaid recipients in that state. The Medicare and Medicaid statutory framework is subject to administrative rulings, interpretations and discretion that affect the amount and timing of reimbursement made under Medicare and Medicaid. </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:14pt 0pt 12pt 0pt;">CMS, which is the agency within the Department of Health and Human Services that administers both Medicare and Medicaid, has the authority to decline to cover particular products or services if it determines that they are not &quot;reasonable and necessary&quot; for the treatment of Medicare beneficiaries. A coverage determination for a product, which establishes the indications that will be covered, and any restrictions or limitations, can be developed at the national level by CMS through a National Coverage Determination, or NCD, or at the local level through a Local Coverage Determination, or LCD, by a regional Medicare Administrative Contractor, which is a private contractor that processes and pays claims on behalf of CMS for the geographic area where the services were rendered. Obtaining a coverage determination, whether an NCD or LCD, is a time-consuming, expensive and highly uncertain endeavor, especially for a new device. Under a NCD that has been effective since January 14, 2002, pneumatic compression devices, or PCDs, including our products, are covered for the treatment of lymphedema or for the treatment of chronic venous insufficiency with venous stasis ulcers. A LCD, administered by the four Medicare Administrative Contractors responsible for processing durable medical equipment claims, sets forth additional coverage criteria that impacts Medicare coverage for our products. Our Medicare business was 19% of revenue in 2022 compared to 17% in 2021.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">26</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Because Medicare criteria is extensive, we have a team dedicated to educating prescribers to help them understand how Medicare policy affects their patients and the medical record documentation needed to meet Medicare requirements. We maintain open communication with physician key opinion leaders and with Medicare contractors to provide data as it becomes available that could potentially influence coverage decisions. We also continue to closely monitor our Medicare business to identify trends that could have a negative impact on certain Medicare patients&#39; access to our products, which in turn could have an adverse effect on our business and results of operations. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Commercial payers that reimburse for our products do so in a variety of ways, depending on the insurance plan&#39;s policies, employer and benefit manager input, and contracts with their provider network. Moreover, Medicaid programs and some commercial insurance plans, especially Medicare Advantage plans (commercial insurers that are administering Medicare benefits to certain beneficiaries), are frequently influenced by Medicare coverage determinations. In working with payers who follow Medicare criteria, we have focused on clear communications with insurers to ensure mutual understanding of criteria interpretation, which differs significantly among the plans from very restrictive to quite lenient, and we then work closely with prescribers to educate them accordingly. While this approach has had positive impact, we do not know if or when additional payers may adopt the LCD criteria nor do we know how they will choose to interpret it.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;margin:0pt;">We believe a reduction or elimination of coverage or reimbursement of our products by Medicare would likely cause some commercial third-party payers to implement similar reductions in their coverage or reimbursement of our products. If we are unable to expand coverage of our products by additional commercial payers, or if third-party payers that currently cover or reimburse for our products reverse or limit their coverage or reimbursement levels in the future, our business and results of operations could be adversely affected. </p><a id="_a678baa0_6870_4ad9_bcba_201ee84cdfa2"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Intellectual Property </b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our intellectual property consists of patented designs and methods and proprietary know-how. In addition to the patented designs and methods discussed below, we have made significant investments in proprietary know-how, including the manufacture of fabrics and garments used in our systems and the algorithms used to manage the inflation and deflation of our systems and other functions of the controllers. To maintain and protect our proprietary technologies and products, we rely on a combination of patent, copyright, trademark, trade secret and other intellectual property laws, and confidentiality provisions in our contracts. We have a policy to enter into confidentiality agreements with employees, consultants, third parties and our advisors to protect our intellectual property and maintain our competitive position. We also require our employees and consultants to sign agreements requiring that they assign to us their interest in intellectual property such as patents and copyrights arising from their work for us. We also require all employees to sign an agreement not to compete unfairly with us during their employment and upon termination of their employment through the misuse of confidential information, soliciting employees, and soliciting customers. Despite any measures taken to protect our intellectual property, unauthorized parties may attempt to copy aspects of our systems or to obtain and use information that we regard as proprietary. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:10pt;text-align:justify;text-indent:-10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Patents </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our patent portfolio consists of three sets of patents, including patents relating to our Flexitouch system and other wearable compression-related technologies. As of December 31, 2022, we owned about 188 issued patents globally, of which 62 were issued U.S. patents. As of December 31, 2022, we owned about 30 pending patent applications pending globally, of which 9 were pending patent applications in the United States. Our U.S. issued patents have varying patent terms, expiring between 2023 and through at least 2040, subject to payment of required maintenance fees, annuities and other charges. U.S. patents covering various aspects of our Flexitouch system expired in 2017.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:10pt;text-align:justify;text-indent:-10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Trademarks </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">We have registered the trademarks Tactile Medical, Flexitouch, the Flexitouch logo design, Entre, AffloVest, and AffloVest Pro with the United States Patent and Trademark Office on the Principal Register. We rely in the United States on common law rights to the Tactile Medical design trademark. The Tactile Medical </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">27</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;">trademark is registered in Australia and Japan, and the AffloVest trademark is registered in Australia, the European Union, New Zealand and the United Kingdom.</p><a id="_fef20b77_ab57_4a7d_9daa_128f99f1c48d"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:14pt;text-align:justify;background:#ffffff;margin:14pt 0pt 0pt 0pt;"><b style="font-weight:bold;">Seasonality</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:14pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">Our business is affected by seasonality. See &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations &#8211; Seasonality.&#8221;</p><a id="_08899566_104a_4239_a04e_905bc3354992"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Human Capital Resources </b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">As a company, our focus is on developing and selling solutions that help increase clinical efficacy, reduce overall healthcare costs and improve the quality of life for patients with chronic conditions by treating them at home. We believe the strength of our employees is the cornerstone to achieving these goals. As of December 31, 2022, we had 982 employees. We have 566 employees who are based throughout the United States, as well as 416 employees who are primarily based in our corporate/manufacturing locations in the Minneapolis metropolitan area. Our employees are our most important resource and they set the foundation for our ability to achieve our strategic objectives. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The success and growth of our business depends, in large part, on our ability to attract, retain and develop a diverse population of talented and high-performing employees at all levels of our organization, including the individuals who comprise our workforce as well as executive officers and other key personnel. To succeed in a competitive labor market, we have developed key recruitment and retention strategies, objectives and measures that we focus on as part of the overall management of our business. These strategies, objectives and measures form the pillars of our human capital management framework and are advanced through the following programs, policies and initiatives: </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Total Rewards:</span> Rewarding and supporting our employees is essential to Company morale. To maintain a competitive salary and benefits package, we utilize an independent third party to evaluate employee compensation. We continue to explore and utilize benefits options in line with our growing and diverse workforce to attract and retain top talent. These benefits include but are not limited to retirement savings, an employee stock purchase plan, a variety of health insurance options, including dental and vision, discounts on healthy foods and fitness memberships, disability insurance, paid maternity/paternity leave, and a company volunteer program implemented in 2022 providing employees paid time to give back to the community. Our Remote Work Policy also allows for a flexible work schedule and location, depending on business needs and the specific role. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Diversity, Equity, and Inclusion</span><b style="font-weight:bold;">:</b> We consider diversity, equity, inclusion, and employee engagement as cornerstones to the future growth of the business. Our diverse and inclusive workplace encourages different perspectives and ideas, which we believe enables better business decisions and rapid innovation. We are committed to constructive and critical self-evaluation that leads to concrete steps that continually enhance and strengthen our corporate culture. Based on employee feedback, we have assessed our company practices and developed goals to guide our diversity, equity, and inclusion initiatives including:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Increased diversity awareness programs for all areas of our organization; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Increased focus on enhancing inclusiveness in our culture and understanding unintentional bias.</span></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#ff0000;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Fair Labor Practices:</span> We seek fair labor practices throughout our business, including from our partners and key suppliers who share our values for human rights, dignity, and respect. We have adopted a Human Rights Policy formalizing this commitment and implemented a Supplier Code of Conduct, requiring from our suppliers the same commitment to human rights, fair labor practices, and anticorruption that we value here at Tactile Medical. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><span style="color:#ff0000;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Health and Safety</span><b style="font-weight:bold;">:</b> The health and safety of our employees is a vital aspect to the success of the Company. We provide all employees training on workplace safety and require employees to follow standards and practices supporting a safe and healthy work environment. </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">28</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Talent and Retention:</span> In 2022, we continued to focus on recruitment, hiring, and retention to ensure high quality talent and a strong fit for specific roles and the Company. Our recruitment efforts are expanding through strong recruiting and hiring processes, as well as utilization and enhancements of our recruiting platform we implemented in 2021. The company intranet facilitates employee inclusion, provides resources, and advances transparent communication efforts. We have also implemented an internal platform for employees to acknowledge achievements of colleagues and highlight company values, encouraging a culture of collaboration and positive reinforcement. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#ff0000;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span>We continue to be diligent and remain focused on our employee engagement strategies, including through exit interview analyses, talent management and retention risk analyses and an employee engagement survey that we rolled out in December 2022.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#ff0000;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Available Information</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">We file annual, quarterly and current reports, proxy statements and other information with the SEC. The SEC maintains an Internet site that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC at http://www.sec.gov.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:10pt;text-align:justify;text-indent:36pt;margin:0pt;">We also make financial information, news releases and other information available on our corporate website at www.tactilemedical.com. Our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and any amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934 are available free of charge on this website as soon as reasonably practicable after we electronically file these reports and amendments with, or furnish them to, the SEC. The information contained on or connected to our website is not incorporated by reference into this Annual Report on Form 10-K and should not be considered part of this or any other report filed with the SEC.</p><a id="_a4d0897f_60ef_4496_8ec2_ebeb333e402f"></a><a id="Item1ARiskFactors_367271"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Item 1A. &#160;Risk Factors.</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">Risk factors which could cause actual results to differ from our expectations and which could negatively impact our financial condition and results of operations are discussed below and elsewhere in this report.&#160;Additional risks and uncertainties not presently known to us or that are currently not believed to be significant to our business may also affect our actual results and could harm our business, financial condition and results of operations.&#160;If any of the risks or uncertainties described below or any additional risks and uncertainties actually occur, our business, results of operations and financial condition could be materially and adversely affected.</p><a id="_b474fc0b_e33e_48bb_b531_97d6329c68c4"></a><a id="_Hlk64033942"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Risks Related to Our Business, Operations and Strategy</b><b style="font-weight:bold;"> </b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Current or worsening economic conditions, including inflation, rising interest rates or a recession, could adversely affect our business and financial condition.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-top:14pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">General global economic downturns and macroeconomic trends, including heightened inflation, capital market volatility, interest rate fluctuations, and economic slowdown or recession, may result in unfavorable conditions that could negatively affect demand for our products and exacerbate some of the other risks that affect our business, financial condition and results of operations. Further, current or worsening economic conditions may adversely impact payment terms or rates, and the amount spent on healthcare generally, which could result in decreased demand for our products.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:14pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we are unable to achieve and maintain adequate levels of coverage or reimbursement for our products, our business and results of operations will be adversely affected. </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Any decline in the amount payers are willing to pay for our products could create pricing pressure for us. If we are forced to lower the price we charge for our products, our gross margins will decrease, which will adversely affect our business, financial condition and results of operations. Also, insurance benefit levels vary substantially by health plan, meaning that some patients have high annual out-of-pocket medical costs, which may make it difficult for those patients to afford our products.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">29</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Third-party payers, whether foreign or domestic, or governmental or commercial, are developing increasingly sophisticated methods of controlling healthcare costs. In the United States, no uniform policy of coverage and reimbursement for our products exists among third-party payers. Therefore, reimbursement for our products can differ significantly from payer to payer and our products are not universally covered by third-party commercial payers. In addition, payers, including Medicare, continually review existing technologies for continued coverage and can, without notice, deny or reverse coverage for existing products. We believe a reduction or elimination of coverage or reimbursement of our products by Medicare would likely cause many commercial third-party payers to implement similar reductions or elimination of their coverage or reimbursement of our products. If we are unable to expand coverage of our products by additional commercial payers, or if third-party payers that currently cover or reimburse for our products reverse or limit their coverage or reimbursement levels in the future, our business and results of operations could be adversely affected. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Further, we believe that future coverage and reimbursement may be subject to increased restrictions, such as additional preauthorization requirements. If we are unable to satisfy any new preauthorization requirements or adjust to any future new restrictions on our products, third-party coverage and reimbursement may be limited in the future, which could have an adverse impact on our business. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, payers often conduct routine audits and request customer records and other documents to support our claims submitted for payment. Recent increases in the frequency and scope of such audits, as well as findings as a result of such audits, could lead to our inability to collect receivables, or require us to repay amounts previously received, which could adversely affect our business and results of operations.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Changes to the level of Medicare coverage or coverage criteria for our products could have an adverse effect on our business and results of operations. </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Determinations of which products or services will be reimbursed under Medicare can be developed at the national level through a National Coverage Determination, or NCD, by CMS, or at the local level through a Local Coverage Determination, or LCD, by the four regional Medicare Administrative Contractors, which are private contractors that process and pay claims on behalf of CMS for different regions. These NCDs and LCDs may be subject to review and revision from time to time, which revisions may not be favorable for coverage of our products.<span style="font-size:12pt;"> </span>Additional NCDs or LCDs, or changes in NCDs or LCDs for our products, could have adverse effects on our business. Further, we believe that a reduction or elimination of coverage or reimbursement of our products by Medicare would likely cause some commercial third-party payers to implement similar reductions in their coverage or reimbursement of our products. Given the evolving nature of the healthcare industry and ongoing healthcare cost reforms, we are and will continue to be subject to changes in the level of Medicare coverage for our products, and unfavorable coverage determinations at the national or local level could adversely affect our business and results of operations.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We utilize third-party, single-source suppliers for some components and materials used in our products, and the loss of any of these suppliers could have an adverse impact on our business. </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We rely on third-party manufacturers and suppliers to supply all components and materials used in our Flexitouch, Entre and AffloVest systems. Our ability to supply our products commercially depends, in part, on our ability to obtain components and materials in accordance with our specifications and with regulatory requirements and in sufficient quantities to meet demand for our products. Our ability to obtain components and materials may be affected by matters outside our control, including that our suppliers may cancel our arrangements on short notice, we may be relatively less important as a customer to certain suppliers and our suppliers may have disruptions to their operations.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If we are required to establish additional or replacement suppliers for any of our components or materials, it may not be accomplished quickly and our operations could be disrupted. Even if we are able to find replacement suppliers, the replacement suppliers would need to be qualified and may require additional regulatory authority approval, which could result in further delay. In the event of a supply disruption, our product inventories may be insufficient to supply our patients. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">If our third-party suppliers fail to deliver the required commercial quantities of materials on a timely basis and at commercially reasonable prices, and we are unable to find one or more replacement suppliers </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">30</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">capable of production at a substantially equivalent cost in substantially equivalent volumes and quality on a timely basis, the continued commercialization of our products, the supply of our products to customers and the development of any future products would be delayed, limited or prevented, which could have an adverse impact on our business.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our revenue is primarily generated from our lymphedema products and we are therefore highly dependent on these products. </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our lymphedema products accounted for 86% and 98% of our revenue for the years ended December&#160;31, 2022 and 2021, respectively. We expect that sales of our lymphedema products will continue to account for a majority of our revenue going forward. Therefore, our ability to execute our growth strategy will depend not only upon increasing awareness of lymphedema, but also on the adoption of our products to treat this condition. Many physicians and clinicians may have experience with, and/or invested substantial resources in, developing expertise in traditional or alternative treatments for lymphedema, which may make them less willing to adopt our products. If our lymphedema products fail to achieve wide market acceptance for any reason, our business, financial condition and results of operations could be adversely affected. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:10pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">We are increasingly dependent on sophisticated information technology and if we fail to effectively maintain or protect our information systems or data, including from cyber-attacks or data breaches, our business could be adversely affected. </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:10pt 0pt 0pt 0pt;">We are increasingly dependent on sophisticated information technology for our products and infrastructure. In some cases, we have outsourced elements of our operations to third parties, and, as a result, we manage a number of third-party vendors who may or could have access to our intellectual property, proprietary business information, personal information of patients and employees and other confidential information. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:10pt 0pt 0pt 0pt;">Our information systems, and those of third-party vendors with whom we contract, require an ongoing commitment of significant resources to maintain, protect and enhance existing systems and develop new systems to keep pace with continuing changes in information technology, evolving systems and regulatory standards and the increasing need to protect patient, customer and employee information, including personally-identifiable information. In addition, given their size and complexity, these systems could be vulnerable to service interruptions or to security breaches from inadvertent or intentional actions by our employees, third-party vendors and/or business partners, or from cyber-attacks by malicious third parties attempting to gain unauthorized access to our products, systems or confidential information (including, but not limited to, intellectual property, proprietary business information and personal information of our patients, customers and employees). </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:10pt 0pt 0pt 0pt;">We are subject to cyber-attacks, including state-sponsored cyber-attacks, industrial espionage, insider threats, computer denial-of-service attacks, computer viruses, ransomware and other malware, phishing attacks, payment fraud or other cyber incidents. Cyber incidents are becoming more sophisticated, frequent and adaptive. If we fail to maintain or protect our information systems and data integrity effectively, we could:</p><div style="margin-top:6pt;"></div><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">lose&#160;existing&#160;customers;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">have&#160;difficulty&#160;attracting&#160;new&#160;customers;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">have&#160;problems&#160;in&#160;determining&#160;product&#160;cost&#160;estimates&#160;and&#160;establishing appropriate&#160;pricing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">suffer outages or disruptions in our operations or supply chain;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">have&#160;difficulty&#160;preventing,&#160;detecting,&#160;and&#160;controlling&#160;fraud;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">have&#160;disputes&#160;with&#160;customers,&#160;physicians,&#160;and&#160;other&#160;healthcare professionals; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">have&#160;regulatory&#160;sanctions&#160;or&#160;penalties&#160;imposed;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">incur&#160;increased&#160;operating&#160;expenses;</span></td></tr></table></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">31</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">be subject to issues with product functionality that may result in a loss of data, risk to patient safety, field actions and/or product recalls;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">incur&#160;expenses&#160;or&#160;lose&#160;revenue&#160;as&#160;a&#160;result&#160;of&#160;a&#160;data&#160;privacy&#160;breach;&#160;or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">suffer&#160;other&#160;adverse&#160;consequences.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We cannot assure you that cyber-attacks or data breaches will not occur or that systems issues will not arise in the future. Any significant breakdown, intrusion, breach, interruption, corruption or destruction of these systems could have a material adverse effect on our business and reputation. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, we accept payments for many of our sales through credit and debit card transactions, which are handled through a third-party payment processor. As a result, we are subject to a number of risks related to credit and debit card payments, including that we pay interchange and other fees, which may increase over time and could require us to either increase the prices we charge for our products or experience an increase in our costs and expenses. In addition, as part of the payment processing process, we transmit our patients&#39; and clinicians&#39; credit and debit card information to our third-party payment processor. We may in the future become subject to lawsuits or other proceedings for purportedly fraudulent transactions arising out of the actual or alleged theft of our patients&#39; credit or debit card information if the security of our third-party credit card payment processor is breached. We and our third-party credit card payment processor are also subject to payment card association operating rules, certification requirements and rules governing electronic funds transfers, which could change or be reinterpreted to make it difficult or impossible for us to comply. Failure to comply with these rules or requirements may result in fines and higher transaction fees, or we may lose the ability to accept credit and debit card payments from our patients, and there may be an adverse impact on our business. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Consolidation in the healthcare industry could lead to demands for price concessions, which may impact our ability to sell our products at prices necessary to support our current business strategies. </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Healthcare costs have risen significantly over the past decade, which has resulted in or led to numerous cost reform initiatives by legislators, regulators and third-party payers. Cost reform has triggered a consolidation trend in the healthcare industry to aggregate purchasing power, which may create more requests for pricing concessions in the future. We expect that market demand, government regulation, third-party coverage and reimbursement policies and societal pressures will continue to change the healthcare industry worldwide, resulting in further business consolidations and alliances among our payers, which may exert increasing downward pressure on the prices of our products in the future.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our long-term growth depends on awareness and adoption of our products. </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A primary growth strategy is to establish our products as the standard of care for the treatment of chronic diseases. In order to achieve this growth strategy, we must:</p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">increase clinician and consumer awareness of these diseases, which are often underserved; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">introduce the clinical and economic benefits of our solutions to physicians, therapists and other clinicians across several specialties and in various clinical settings; and </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">demonstrate consistent coverage and reimbursement for our solutions by private payers, Medicare, the Veterans Administration and certain Medicaid programs. </span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Clinicians may not adopt our solutions as the standard of care for lymphedema, chronic venous insufficiency and chronic respiratory conditions or may not prescribe our products for a number of reasons, including:</p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">our inability to educate a sufficient number of clinicians on these diseases or our products; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the unavailability or inadequacy of insurance coverage or reimbursement for our products; </span></td></tr></table></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">32</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">failure of evidence supporting clinical benefits or cost-effectiveness of our products over existing alternatives to convince clinicians to change their treatment methods; and </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">resistance from clinicians to replace traditional treatments with our solutions. </span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We believe recommendations and support of our products by key opinion leaders can influence market acceptance and adoption. If these key opinion leaders choose to not support our products, our ability to achieve broad market acceptance for our products may be impaired. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we are unable to expand, manage and maintain our direct sales and marketing organizations, as well as our relationships with distributors, we may not be able to generate anticipated revenue. </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our operating results are directly dependent upon the sales and marketing efforts of our employees and upon our relationships with our distributors and their sales and marketing efforts. If our direct sales force or our distributors fail to adequately promote, market and sell our products, our sales may suffer.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During most of 2020, 2021 and the first quarter of 2022, our direct sales force for our lymphedema product line experienced increased turnover and difficulty in recruiting qualified replacements. Although we saw some level of recovery in 2022 after the first quarter, we cannot assure you that this recovery will continue or that we will be able to recruit and retain quality candidates for our direct sales force. For our respiratory therapy products, we rely on DME providers for all aspects of sales, reimbursement, training and support. Our ability to continue to market, distribute, and sell our airway clearance products may be at risk if key or multiple of the DME providers choose to stop selling our products or if we are unable to enter into relationships with new distributors. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our future success will depend largely on our ability to hire, train, retain and motivate skilled sales personnel with significant technical knowledge of lymphedema and chronic venous insufficiency, and our ability to maintain and expand relationships with our current, and enter into relationships with new, distributors of our airway clearance products. Failure to do so would prevent us from building awareness of our solutions, expanding our business and maintaining or generating additional sales. If we are unable to maintain or expand our sales and marketing capabilities and our distributor relationships, we may not be able to effectively commercialize our products, which could have an adverse impact on our business.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Physicians and payers may require additional clinical studies prior to prescribing our products or prior to providing or maintaining coverage and reimbursement for our products. Any subsequent clinical studies that are conducted and published may not be positive or consistent with our existing data, which would adversely affect the rate of adoption of our products. </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our success depends in large part on the medical and third-party payer community&#39;s acceptance of our products as being useful in treating patients with lymphedema, chronic venous insufficiency or chronic respiratory conditions. While the results of our studies collectively indicate a favorable safety and efficacy profile, the study designs and results may not be viewed as compelling to physicians and insurers. In particular, payers and physicians may see limitations in the design and results of the studies because certain studies were not specifically based on our products, involved a limited number of total subjects or subjects outside the control group and made &quot;quality of life&quot; conclusions based upon criteria contained in patient questionnaires that required subjective conclusions. Certain physicians and insurers may also prefer to see longer-term efficacy data than we have produced or are able to produce. If physicians or insurers do not find our data compelling or wish to wait for additional or independently-performed studies, they may choose not to prescribe or to provide coverage and reimbursement for our products. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We cannot assure you that any data that we or others generate will be consistent with that observed in the existing studies or that results will be maintained beyond the time points studied. We also cannot assure you that any data that may be collected will be compelling to the medical community because the data may not be scientifically meaningful or may not demonstrate that our products are attractive alternatives to traditional treatments. If subsequent studies are not positive or consistent with our existing data, adoption of our products may suffer and, accordingly, our business could be adversely impacted.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">33</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:14pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">The COVID-19 pandemic has had, and may continue to have, an adverse effect on our business, financial condition and results of operations.</span> </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">The United States economy in general and our business specifically have been negatively affected by the COVID-19 pandemic. We have seen adverse impacts as it relates to the decline in the number of patients that healthcare facilities and clinics are able to treat due to enhanced safety protocols particularly during most of 2020 and 2021, and during the first quarter of 2022.&#160;We have also seen staffing challenges, both in our organization and at the clinics we serve, as another lingering consequence of the COVID-19 pandemic. While we saw some level of recovery in 2022 after the first quarter, ongoing consequences of the pandemic remain uncertain. There are no reliable estimates of how long the pandemic will last, whether any recovery will be sustained or will reverse course, the severity of any resurgence of COVID-19 or variant strains of the virus, the effectiveness of vaccines and attitudes towards receiving them, or what ultimate effects the pandemic will have. For that reason, we are unable to reasonably estimate the long-term impact of the pandemic on our business at this time. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:14pt 0pt 0pt 0pt;">Further, the extent to which the COVID-19 pandemic, including any resurgence or variant strains of the virus, will impact our business, financial condition and results of operations in the future will depend on future developments, which are highly uncertain and cannot be predicted, including, but not limited to, the duration, spread, severity, and impact of the COVID-19 pandemic, the effects of the COVID-19 pandemic on our clinician customers and their patients, our suppliers and our payers, the remedial actions, any vaccine mandates and stimulus measures adopted by governmental authorities, and to what extent normal economic and operating conditions can resume. Even after the COVID-19 pandemic has subsided, we may continue to experience adverse impacts to our business as a result of any related economic recession or depression that has occurred or may occur in the future.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:14pt 0pt 12pt 0pt;">Given the evolving health, economic, social and governmental impacts of the COVID-19 pandemic, the potential impact that the COVID-19 pandemic could have on us remains uncertain, but it could have a material adverse effect on our business, financial condition and results of operations.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">U.S. patent protection covering various aspects of our Flexitouch system expired in 2017, and thus may subject us to increased competition and reduce or eliminate our opportunity to generate product revenue. </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">U.S. patents covering various aspects of our Flexitouch system expired in 2017. Given the expiration of these patents, third parties may be permitted to incorporate aspects of our Flexitouch system into their products or create substantially similar or generic versions of our Flexitouch system. This could subject us to increased competition from products attempting to replicate our technology. Moreover, these competitors could sell their competing products for a substantially lower price, which could substantially limit our opportunity to increase or maintain revenue from our Flexitouch system and, in fact, our revenue could be substantially reduced, causing a material adverse effect on our business. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Changes in government trade policies, including additional tariffs and the resulting consequences, may have a material adverse impact on our business and results of operations.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The United States government from time to time has adopted new approaches to trade policy, including in some cases renegotiating or terminating certain existing bilateral or multi-lateral trade agreements, or imposing tariffs on certain foreign goods, including certain raw materials that are included in our products. Changes in U.S. trade policy have and could continue to result in one or more of its trading partners adopting responsive or retaliatory trade policies, making it more difficult or costly for us to export our products to those countries in the future or import our products or raw materials utilized in making our products. These measures have resulted in, and in the future could result in, increased costs for our goods imported into the United States. Since our prices are often fixed due to the reimbursement policies of, and arrangements with, third-party payers, this could result in lower margins on our products.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">There is also a concern that the imposition of additional tariffs by the United States could result in the adoption of tariffs by other countries. The resulting trade war could have a significant adverse effect on world </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">34</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">trade and the world economy. To the extent that trade tariffs and other restrictions imposed by the United States increase the price of, or limit the amount of, the raw materials and products we import into the United States, the costs of our raw materials may be adversely affected and the demand from our customers for products and services may be diminished, which could adversely affect our revenue and profitability. In addition, our margins could be significantly impacted.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We cannot predict future trade policy or the terms of any renegotiated trade agreements and their impact on our business. The adoption and expansion of trade restrictions, the occurrence of a trade war, or other governmental action related to tariffs or trade agreements or policies have the potential to adversely impact demand for our products, our costs, our customers, our suppliers and the United States economy, which in turn could adversely impact our business, financial condition and results of operations.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Increases in our operating costs could have an adverse effect on our financial condition and results of operations. </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Reimbursement rates are established by fee schedules mandated by private payers, Medicare, the Veterans Administration, and certain Medicaid programs. Although Medicare and certain private payers index their reimbursement rate off of a subset of cost of living, the Veterans Administration, certain Medicaid programs and other private payers are more likely to remain constant or slightly decrease their reimbursement rates. As a result, we may not be able to offset the effects of general inflation on our operating costs through increases in prices for our products. In particular, labor and related costs account for a significant portion of our operating costs and we compete with other healthcare providers to attract and retain qualified or skilled personnel and with various industries for administrative and service employees. This competitive environment could result in increased labor costs. Failure to control our operating costs, particularly labor and related costs, could adversely affect our financial conditions and results of operations. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our operating costs may fluctuate significantly in the future as a result of a variety of factors, many of which are outside of our control. These factors include:</p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">increased sales and marketing costs to increase awareness of our products; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">costs to develop new and enhanced features for current products and research and development costs for new products; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the time, resources and expense required to develop and conduct clinical trials and seek additional regulatory clearances and approvals for additional treatment indications for our products and for any additional products we develop or acquire; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs of preparing, filing, prosecuting, defending and enforcing patent claims and other patent related costs, including litigation costs and the results of such litigation; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">any product liability or other lawsuits related to our products and the costs associated with defending them or the costs related to the results of such lawsuits; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs to attract and retain personnel with the skills required for effective operations; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs associated with being a public company; and </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">costs associated with entering and maintaining international markets. </span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our failure to anticipate and minimize the impact of these costs could adversely affect our business and results of operations. </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">35</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We compete and may compete in the future against other companies, some of which have longer operating histories, more established products or greater resources than we do, which may harm our business. </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The medical device industry is highly competitive. Our success depends, in part, upon our ability to maintain a competitive position in the development of technologies and solutions for the at-home treatment of lymphedema, chronic venous insufficiency and chronic respiratory conditions or for market adjacencies. Any product we develop will have to compete for market acceptance and market share. We face significant competition, and we expect the intensity of competition will increase over time. Our primary competitors are Bio Compression Systems,&#160;Inc., Lympha Press USA, Hill-Rom, Philips Medical and Electromed. Other competitors include Airos Medical, Inc. and NormaTec Industries. Many of the companies developing or marketing competing products enjoy several competitive advantages, including:</p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">significantly greater name recognition; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">established relations with healthcare professionals, customers and third-party payers; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">established distribution networks; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">additional lines of products, and the ability to offer rebates or bundle products to offer higher discounts or other incentives to gain a competitive advantage; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">greater history in conducting research and development, manufacturing, marketing and obtaining regulatory approval for homecare devices; and </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">greater financial and human resources for product development, sales and marketing, patent litigation and customer financing. </span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our competitors may develop and patent processes or products earlier than us, obtain regulatory clearance or approvals for competing devices more rapidly than us or develop more effective or less expensive products or technologies that render our technology or products obsolete or less competitive. We also face fierce competition in recruiting and retaining qualified sales, scientific, reimbursement and management personnel, particularly those with direct-to-patient and -provider experience. If our competitors are more successful than us in these matters, our business may be harmed. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our long-term growth depends on our ability to develop and commercialize additional products. </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The medical device industry is highly competitive and subject to rapid change and technological advancements. Therefore, it is important to our business that we continue to enhance our product offerings and introduce new products. Developing products is expensive and time-consuming and could divert management&#39;s attention away from our business. We may not be successful in developing new products or enhancements to existing products. Further, we may expend financial, management and operational resources on products that we are not able to successfully commercialize. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our ability to develop and commercialize additional products or enhancements to existing products will depend on several factors, including our ability to:</p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">properly identify and anticipate physician and patient needs; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">develop and introduce new products or product enhancements in a timely manner; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">avoid infringing upon the intellectual property rights of third parties; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">demonstrate the safety and efficacy of new products with data from clinical studies; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">obtain the necessary regulatory clearances or approvals for new products or product enhancements; </span></td></tr></table></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">36</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">be fully FDA-compliant with the development, manufacturing and marketing of new devices or modified products; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">provide adequate training to potential users of our products; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">secure adequate coverage and reimbursement for our products; and </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">develop and maintain an effective and dedicated sales and marketing team, as well as relationships with distributors. </span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If we are unsuccessful in developing and commercializing new products, our ability to increase our revenue may be impaired. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">It is difficult to forecast future performance and our financial results may vary from forecasts and may fluctuate from quarter to quarter. </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A number of factors over which we have limited control, such as seasonal variations in revenue, may contribute to fluctuations in our financial results. In the first quarter of each year, when most patients have started a new insurance year and have not yet met their annual out-of-pocket payment obligations, we experience substantially reduced demand for our products. We typically experience higher revenue in the third and fourth quarters when more patients have met their annual insurance deductibles, thereby reducing their out-of-pocket costs for our products, and because patients desire to exhaust their flexible spending accounts at year end. This seasonality applies only to purchases and rentals of our products by patients covered by commercial insurance and is not relevant to Medicare, Medicaid or the Veterans Administration, as those payers either do not have plans that have declining deductibles over the course of the plan year and/or do not have plans that include patient deductibles for purchases or rentals of our products. To the extent that the prevalence of high deductible insurance plans and higher copay and coinsurance plans continue to grow in the private payer market, the seasonal variations in our revenue could become even more pronounced.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Other factors that may cause fluctuation in our quarterly results or variations from our forecasts include:</p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">physician adoption of our products; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">timing of new product offerings, acquisitions, licenses or other significant events by us or our competitors; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">unanticipated pricing pressure; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the hiring, retention and continued productivity of our sales representatives; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to expand the geographic reach of our distribution, sales and marketing efforts; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to obtain regulatory clearance or approval for our products in development or for our current products outside the United States; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the impact of results from clinical research and trials on our existing products and products in development; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">delays in receipt of anticipated purchase orders; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">delays in, or failure of, component deliveries from our suppliers; and </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">positive or negative coverage in the media or clinical publications of our products or products of our competitors or our industry. </span></td></tr></table><div style="margin-top:12pt;"></div></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">37</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the event our actual revenue and operating results do not meet our forecasts or the forecasts or estimates of the research analysts that cover us for a particular period, the market price of our common stock may decline substantially. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If physicians fail to properly document medical records for patients using our products, our business could be adversely impacted. </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We bill Medicare Part&#160;B and other insurers directly for sales and rentals of lymphedema products. As a result, we must comply with all laws, rules and regulations associated with filing claims with the Medicare program, including the Social Security Act, Medicare regulations, the Federal False Claims Act and the Civil Monetary Penalties Law, as well as a variety of additional federal and state laws. During an audit, insurers typically expect to find explicit documentation in the medical record to support a claim. Physicians and other clinicians, who are responsible for prescribing our products for patients, are expected to create and maintain the medical records that form the basis for the claims we submit to Medicare and other insurers. Any failure to properly document the medical records for patients using our products could invalidate claims, impair our ability to collect submitted claims and subject us to overpayment liabilities, False Claims Act liabilities and other penalties including exclusion from the Medicare, Medicaid or private insurance programs. Our reimbursement operations group is responsible for verifying and managing patient claims for our lymphedema products. This group works with physicians and other clinicians to educate physicians and other clinicians on their record keeping responsibilities. From time to time our reimbursement operations group identifies situations where the documentation is missing, incomplete or could be questioned by Medicare or other insurers, and revises its procedures to strengthen our controls, audits and oversight compliance systems based on our experience with Medicare contractors, Medicaid, insurers, physicians and other clinicians. If our procedures are not sufficient to detect deficiencies in the medical records of patients or such procedures are not updated in a timely manner before claims are submitted to Medicare or other insurers, or if the Medicare program or other insurer disagrees with the way the medical necessity support for prescribing our products has been documented, we could face potential liabilities for submitting claims based on inadequate records. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The size of the market for our products is an estimate, and may be smaller than we believe. </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our estimate of the total addressable market for our products is based on a number of internal and third-party estimates. In addition, our internal estimates are based in large part on current trends in diagnosing lymphedema, chronic venous insufficiency and chronic respiratory conditions. While we believe these factors have historically provided and may continue to provide us with effective tools in estimating the total market for lymphedema, chronic venous insufficiency, chronic respiratory conditions and our products, these estimates may not be correct and the conditions supporting our estimates may change at any time, thereby reducing the predictive accuracy of these underlying factors. As a result, our estimates of the total addressable market for our products may prove to be incorrect. If the actual number of patients who would benefit from our products and the total addressable market for our products is smaller than we have estimated, our future growth could be adversely impacted. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may be unable to manage our growth effectively. </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our past growth has provided, and our future growth may create, challenges to our organization. We intend to continue to grow and may experience periods of rapid growth and expansion. Future growth will impose significant added responsibilities on management, including the need to identify, recruit, train, integrate, retain and motivate additional employees. In addition, rapid and significant growth will place a strain on our administrative personnel, information technology systems and other operational infrastructure. Any failure by us to manage our growth effectively could have an adverse effect on our ability to achieve our development and commercialization goals. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Successful growth is also dependent upon our ability to implement appropriate financial and management controls, systems and procedures. In order to manage our operations and growth, we will need to continue to improve our operational and management controls, reporting and information technology systems and financial internal control procedures. If we are unable to manage our growth effectively, it may be difficult for us to execute our business strategy and there could be an adverse impact on our business. </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">38</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our ability to maintain our competitive position depends on our ability to attract, integrate and retain key executives and highly qualified personnel. </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We believe that our continued success depends to a significant extent upon the efforts and abilities of our executive officers and other key personnel. Our executive officers and other key personnel are critical to the strategic direction and overall management of our company as well as our research and development process.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our future success also depends on our ability to continue to attract and retain additional executive officers and other key employees. We invest significant time and expense in training our employees, which increases their value to competitors who may seek to recruit them. Many of our competitors have greater resources than we have that allows them to offer more competitive remuneration, which could adversely impact our ability to attract and retain experienced executives and other key employees. We carry a &quot;key person&quot; insurance policy only on our Chief Executive Officer. The replacement of any of our key personnel likely would involve significant time and costs and may significantly delay or prevent the achievement of our business objectives and would harm our business. Our productivity may be adversely affected if we do not integrate and train our new employees quickly and effectively. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Changes in reimbursement coding could impair our ability to receive reimbursement for our products. </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">HCPCS is a standardized system used by all U.S. insurance payers to provide descriptions of healthcare equipment, supplies and services. HCPCS codes are used by payers to identify what services are being billed and to assign payment rates to those specific services. HCPCS codes for durable medical equipment are assigned and managed by CMS and a Medicare contractor responsible for Pricing, Data Analysis and Coding, or PDAC. New products and product revisions must go through a coding verification process to confirm the products meet the requested HCPCS definitions. CMS or its contractor can review and revise coding assignments if they believe a product no longer meets the assigned HCPCS definition. If the PDAC contractor determines one of our products does not meet the current HCPCS definition, it could remove all coding or assign a different HCPCS code with a lesser payment rate. This could have an adverse impact on our reimbursement rates, results of operations and cash flows. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If the quality of our products does not meet the expectations of physicians or patients, then our brand and reputation could suffer and our business could be adversely impacted. </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the course of conducting our business, we must adequately address quality issues that may arise with our products, as well as defects in third-party components included in our products. There can be no assurance that our internal procedures to minimize risks that may arise from quality issues will be able to eliminate or mitigate occurrences of these issues and associated liabilities. If the quality of our products does not meet the expectations of physicians or patients, then our brand and reputation could suffer and our business could be adversely impacted. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If our facilities are damaged or become inoperable, we will be unable to continue to research, develop, manufacture and commercialize our products and, as a result, there will be an adverse impact on our business until we are able to secure a new facility. </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We do not have redundant facilities. We perform substantially all of our research and development, assembly and back office activity and maintain all our finished goods inventory at one location in Minneapolis, Minnesota. Our facilities and equipment would be costly to replace and could require substantial lead time to repair or replace. The facilities may be harmed or rendered inoperable by natural or man-made disasters (such as tornadoes, flooding, fire and power outages), vulnerabilities in our technology or cyber-attacks against our information systems (such as ransomware), which may render it difficult or impossible for us to perform our research, development, manufacturing and commercialization activities for some period of time. The inability to perform those activities, combined with our limited inventory of reserve raw materials and finished product, may result in the inability to continue manufacturing our products during such periods and the loss of customers or harm to our reputation. Our insurance for damage to our property and the disruption of our business may not be sufficient to cover all of our potential losses, and this insurance may not continue to be available to us on acceptable terms, or at all. </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">39</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may be adversely affected by natural disasters and other catastrophic events, and by man-made problems such as terrorism or violence, that could disrupt our business operations.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Natural disasters or other catastrophic events may also cause damage or disruption to our operations, including causing delays in completing sales, continuing production or performing other critical functions of our business, which could have an adverse effect on our business, operating results and financial condition. Our business operations are subject to interruption by natural disasters, fire, power shortages, pandemics and other events beyond our control. In addition, acts of terrorism, violence and other geo-political unrest could cause disruptions in our business or the businesses of our partners or the economy as a whole. In the event of a natural disaster, including a major earthquake, blizzard or hurricane, or a catastrophic event such as a fire, power loss, or telecommunications failure, we may be unable to continue our operations for a period of time in the affected area, which could have an adverse effect on our future operating results.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Acquisition activity involves substantial risks, and we may not be able to successfully integrate newly acquired companies or businesses. </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have acquired, and may in the future acquire, companies, businesses, products, services and technologies. Acquisitions involve significant risks and uncertainties, including:</p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23.05pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">incurring significantly higher than anticipated capital expenditures and operating expenses;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23.05pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">failing to assimilate the operations, customers and personnel of the acquired company or business;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23.05pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">disrupting our ongoing business;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23.05pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">dissipating our management resources;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23.05pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">dilution to existing stockholders from the issuance of equity securities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23.05pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">liabilities or other problems associated with the acquired business;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23.05pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">failing to achieve the anticipated benefits of the acquisition;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23.05pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">incurring debt on terms unfavorable to us or that we are unable to repay;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23.05pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">becoming subject to adverse tax consequences, substantial depreciation or deferred compensation charges;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23.05pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">improper compliance with laws and regulations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23.05pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">failing to maintain uniform standards, controls and policies; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23.05pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">impairing relationships with employees and business partners as a result of changes in management.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Fully integrating an acquired company or business into our operations may take a significant amount of time. We cannot assure you that we will be successful in overcoming these risks or any other problems encountered with acquisitions. To the extent we do not successfully avoid or overcome the risks or problems related to any acquisitions, our results of operations and financial condition could be adversely affected. Future acquisitions also could impact our financial position and capital needs, and could cause substantial fluctuations in our quarterly and yearly results of operations. Acquisitions could include significant goodwill and intangible assets, which may result in future impairment charges that would reduce our stated earnings. </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">40</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we commercialize any products outside of the United States, a variety of risks associated with international operations could impact our strategy and adversely affect our future growth. </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If we expand internationally, we would be subject to additional risks related to entering into international markets, including:</p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">difficulty obtaining approvals under foreign regulatory requirements, such as more stringent requirements for regulatory clearance of products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">difficulty successfully training patients and physicians on using our products; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">difficulty hiring a qualified direct-sales force or finding and entering into commercially acceptable agreements with suitable third-parties to market our products; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">reduced protection for intellectual property rights; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">increased or different tariffs, trade barriers and regulatory requirements; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">economic weakness, including inflation, or political instability in particular foreign economies and markets; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">foreign taxes, including withholding of payroll taxes; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">foreign currency fluctuations, which could result in increased operating expenses and reduced revenue, and other obligations incident to doing business in another country; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">workforce uncertainty in countries where labor unrest is more common than in the United States; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">complex data privacy requirements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">international regulators and third-party payers may require additional clinical studies prior to approving or allowing reimbursement for our products; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">disadvantages of competing against companies from countries that are not subject to U.S. laws and regulations, including the U.S. Foreign Corrupt Practices Act, regulations of the U.S. Office of Foreign Assets Controls and U.S. anti-money laundering regulations, as well as exposure of our foreign operations to liability under these regulatory regimes; and </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">business interruptions resulting from geopolitical actions, including war and terrorism, or natural disasters including earthquakes, typhoons, floods and fires. </span></td></tr></table><div style="margin-top:12pt;"><a id="_e544212b_22f0_4590_a37e_897e302bf871"></a></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Government Regulation, Compliance and Legal Risks </b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We are subject to extensive federal and state regulation, and if we fail to comply with applicable regulations, we could be required to repay amounts previously received, and could suffer severe criminal or civil sanctions or be required to make significant changes to our operations that could adversely affect our business, financial condition and operating results. </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The federal government and all states in which we currently operate regulate various aspects of our business. Our operations also are subject to state laws governing, among other things, distribution of medical equipment and certain types of home health activities, and we are required to obtain and maintain licenses in many states to act as a durable medical equipment supplier. </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">41</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As a healthcare provider participating in governmental healthcare programs, we are subject to complex laws and regulations directed at preventing fraud and abuse, which subject our marketing, billing, documentation and other practices to government scrutiny. To ensure compliance with Medicare, Medicaid and other regulations, government agencies or their contractors often conduct routine audits and request customer records and other documents to support our claims submitted for payment of services rendered. Medicare has engaged a variety of contractors to audit claims submitted to the government, including Medicare Administrative Contractors, Recovery Audit Contractors, Supplemental Medical Review Contractors and Unified Program Integrity Contractors. Recovery Audit Contractors are compensated based on a percentage of overpayments recovered from providers. Unified Program Integrity Contractors focus on potential fraud and frequently make referrals to the Office of Inspector General or the Department of Justice to pursue criminal or civil action against providers. The increased number of Medicare contractors, with their focus on recovering overpayments and identifying fraud, creates increased risk to providers like us that submit claims to federal government programs. The Office of Inspector General and the Department of Justice also initiate their own investigations into possible violations of applicable laws and regulations. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Violations of federal and state regulations can result in severe criminal, civil and administrative penalties and sanctions, including debarment, suspension or exclusion from Medicare, Medicaid and other government reimbursement programs, any of which would have a material adverse effect on our business. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Changes in healthcare laws and regulations and new interpretations of existing laws and regulations may affect permissible activities, the relative costs associated with doing business, and reimbursement amounts paid by federal, state and other third-party payers. There have been and will continue to be regulatory initiatives affecting our business and we cannot predict the extent to which future legislation and regulatory changes could have a material adverse effect on our business, financial condition and results of operations. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We are subject to significant regulation by numerous government agencies, including the FDA. We cannot market or commercially distribute our products without obtaining and maintaining necessary regulatory clearances or approvals. </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our products are medical devices subject to extensive regulation in the United States. The FDA and other U.S. and foreign governmental agencies regulate, among other things, with respect to medical devices:</p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">design, development and manufacturing; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">establishment registration and product listing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">testing, labeling, content and language of instructions for use and storage; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">clinical trials; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">product safety; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">marketing, sales and distribution; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">unique device identifiers; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">premarket clearance and approval; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">record keeping procedures; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">advertising and promotion; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">recalls and field safety corrective actions; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">post-market surveillance, including reporting of deaths or serious injuries and malfunctions that, if they were to recur, could lead to death or serious injury; </span></td></tr></table></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">42</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">post-market approval studies; and </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">product import and export. </span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Unless an exemption applies, each medical device we seek to distribute commercially in the United States requires marketing authorization from the FDA prior to distribution. The two primary types of FDA marketing authorization applicable to a device are premarket notification, also called 510(k) clearance, and premarket approval. The type of marketing authorization is generally linked to the classification of the device. When a 510(k) clearance is required, we must submit a premarket notification to the FDA demonstrating that our proposed device is &quot;substantially equivalent&quot; to a legally marketed device previously found substantially equivalent through a 510(k) premarket notification, a legally marketed device which has been reclassified from high to low or moderate risk or a legally marketed device in commercial distribution before May 28, 1976 for which the FDA does not require the submission of a premarket approval application. Such a device is commonly known as a &#8216;&#8216;predicate device.&#8217;&#8217; In 2019, the FDA released an optional Safety and Performance Based Pathway for 510(k) clearance, which allows a submitter to demonstrate that an eligible new device of a well-understood type meets FDA-identified performance criteria to demonstrate that the device is as safe and effective as a legally marketed device. The FDA may require further information, including clinical data, to make a determination regarding substantial equivalence. A medical device may be found not to be equivalent if it has different intended uses from the predicate device or possesses different technological characteristics from the predicate device which raise new questions of safety and effectiveness. A premarket approval application must be submitted to the FDA if the device cannot be cleared through the 510(k) process. The premarket approval application process is much more demanding than the 510(k) premarket notification process and requires the payment of significant user fees. A premarket approval application must be supported by valid scientific evidence, which typically requires extensive data to demonstrate the reasonable assurance of safety and effectiveness of the device. The approval process involves FDA review of information, including but not limited to, technical, pre-clinical (bench and/or animal), clinical trials, manufacturing and labeling. The FDA clearance and approval processes frequently take longer than anticipated due to increasing FDA demands for clarification of data or new data requirements. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If there is no predicate device that would permit the device to be cleared through the 510(k) path, then the FDA will automatically classify the device as a Class&#160;III high risk premarket approval device. In the event of this possibility, the sponsor can request a risk-based classification determination for the device in accordance with the de novo process, which is a route to market for novel medical devices that are low to moderate risk and are not substantially equivalent to a predicate device. A company files&#160;a de novo request when it does not have a predicate to which it can claim substantial equivalence. The FDA reviews the request for a de novo decision and grants or denies the request. If the request is granted, the FDA issues an order indicating that the device may legally be marketed and the device is classified as a Class&#160;I or II device, depending on risk. Once a device is classified through the de novo process, future devices from the company or a competitor may use that device as a 510(k) predicate. The advantage of the de novo process is that it generally requires less data than a premarket approval. The disadvantage is that it may require more data than a 510(k) and most often will include human clinical data. The FDA is increasingly moving devices with slightly different proposed indication statements or different technological features off the 510(k) path and on to the de novo path resulting in more time and expense for the company. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Both the 510(k) and premarket approval processes can be expensive and lengthy and require the payment of significant fees, unless an exemption applies. The FDA&#39;s 510(k) clearance process usually takes from approximately three to 12&#160;months, but may take longer. The process of obtaining a premarket approval is much more costly and uncertain than the 510(k) clearance process and generally takes from approximately one to five years, or longer, from the time the application is submitted to the FDA until an approval is obtained. The process of obtaining regulatory clearances or approvals to market a medical device can be costly and time consuming, and we may not be able to obtain these clearances or approvals on a timely basis, if at all. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In the United States, our currently commercialized products are marketed pursuant to premarket clearance under Section&#160;510(k) of the Federal Food, Drug and Cosmetic Act, or FDCA. If the FDA requires us to go through a lengthier, more rigorous examination for future products or modifications to existing products than we had expected, our product introductions or modifications could be delayed or canceled, which could cause our sales to decline. In addition, the FDA may determine that future products will require the more costly, </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">43</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">lengthy and uncertain premarket approval process. Although we do not currently market any devices under a premarket approval, the FDA may demand that we obtain a premarket approval prior to marketing certain of our future products. In addition, if the FDA disagrees with our determination that a product we currently market is subject to an exemption from premarket review, the FDA may require us to submit a 510(k) or premarket approval application in order to continue marketing the product. Further, even with respect to those future products where a premarket approval is not required, we cannot assure you that we will be able to obtain the 510(k) clearances required with respect to those products. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The FDA can delay, limit or deny clearance or approval of a device for many reasons, including:</p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">for non-premarket approval devices, failure of the applicant to demonstrate to the FDA&#39;s satisfaction that its products meet the definition of &quot;substantial equivalence&quot; or meet the standard for the FDA to grant a petition for de novo classification; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">failure of the applicant to demonstrate that there is reasonable assurance that the medical device is safe or effective under the conditions of use prescribed, recommended or suggested in the proposed labeling; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">insufficient data from the pre-clinical studies and clinical trials; or </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the manufacturing processes, methods, controls or facilities used for the manufacture, processing, packing or installation of the device do not meet applicable requirements. </span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Any delay in, or failure to receive or maintain, clearances or approvals for our products could prevent us from generating revenue from these products or achieving profitability. Additionally, the FDA and other governmental authorities have broad enforcement powers. Our failure to comply with applicable regulatory requirements could lead governmental authorities or a court to take action against us, including, but not limited to:</p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">issuing untitled (notice of violation) letters or public warning letters to us; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">imposing fines and penalties on us; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">obtaining an injunction or administrative detention preventing us from manufacturing or selling our products; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">seizing products to prevent sale or transport or export; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">bringing civil or criminal charges against us; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">recalling our products or mandating a product correction; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">detaining our products at U.S. Customs; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">delaying the introduction of our products into the market; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">delaying pending requests for clearance or approval of new uses or modifications to our existing products; and </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">withdrawing or denying approvals or clearances for our products. </span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If we fail to obtain and maintain regulatory clearances or approvals, our ability to sell our products and generate revenue will be materially harmed. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In addition, the FDA may change its clearance and approval policies, adopt additional regulations or revise existing regulations, or take other actions which may prevent or delay approval or clearance of our </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">44</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">products under development or impact our ability to modify our currently approved or cleared products on a timely basis. For example, in response to industry and healthcare provider concerns regarding the predictability, consistency and rigor of the 510(k) regulatory pathway, the FDA published new guidance on the 510(k) regulatory pathway in 2014, which altered the manner in which the 510(k) regulatory pathway is administered and interpreted. The FDA intends these reform actions to improve the efficiency and transparency of the clearance process, as well as bolster patient safety. This new guidance could impose additional regulatory requirements upon us which could delay our ability to obtain new 510(k) clearances, increase the costs of compliance or restrict our ability to maintain our current clearances. In addition, as part of the Food and Drug Administration Safety and Innovation Act, Congress reauthorized the Medical Device User Fee Amendments with various FDA performance goal commitments and enacted several &quot;Medical Device Regulatory Improvements&quot; and miscellaneous reforms which are further intended to clarify and improve medical device regulation both pre- and post-market. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Medical devices may only be promoted and sold for the indications for which they are approved or cleared. In addition, even if the FDA has approved or cleared a product, it can take action affecting such product approvals or clearances if serious safety or other problems develop in the marketplace. Delays in obtaining clearances or approvals could adversely affect our ability to introduce new products or modifications to our existing products in a timely manner, which would delay or prevent commercial sales of our products. Additionally, the FDA and other regulatory authorities have broad enforcement powers. Regulatory enforcement or inquiries, or other increased scrutiny on us, could affect the perceived safety and efficacy of our products and dissuade patients and clinicians from using our products. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If clinical studies of our future products do not produce results necessary to support regulatory clearance or approval in the United States or, with respect to our current or future products, elsewhere, we will be unable to expand the indications for or commercialize these products. </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We will likely need to conduct additional clinical studies in the future to support new indications for our products or for clearances of new product lines, or for the approval of the use of our products in some foreign countries. Clinical testing can take many years, can be expensive and carries uncertain outcomes. The initiation and completion of any of these studies may be prevented, delayed, or halted for numerous reasons. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Clinical failure can occur at any stage of testing. Our clinical studies may produce negative, unanticipated or inconclusive results, and we may decide, or regulators may require us, to conduct additional clinical and non-clinical testing in addition to those we have planned. Our failure to adequately demonstrate the safety and efficacy of any of our devices would prevent receipt of regulatory clearance or approval and, ultimately, the commercialization of that device or indication for use. Even if our products are cleared in the United States, commercialization of our products in foreign countries would require approval by regulatory authorities in those countries. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different from, and greater than, those in the United States, including additional pre-clinical studies or clinical trials. Any of these occurrences could have an adverse impact on our business. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If the third parties on which we rely to conduct our clinical trials and to assist us with pre-clinical development do not perform as contractually required or expected, we may not be able to obtain regulatory clearance or approval for or commercialize our products. </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We often must rely on third parties, such as contract research organizations, medical institutions, clinical investigators and contract laboratories, to conduct our clinical trials and to assist us with pre-clinical development. If these third parties do not successfully carry out their contractual duties or regulatory obligations, have difficulty recruiting sufficient subjects for clinical studies or fail to meet expected deadlines, if these third parties need to be replaced, or if the quality or accuracy of the data they obtain is compromised due to the failure to adhere to our clinical protocols or regulatory requirements or for other reasons, our pre-clinical development activities or clinical trials may be extended, delayed, suspended or terminated, and we may not be able to obtain regulatory approval for, or successfully commercialize, our products on a timely basis, if at all, and our business, operating results and prospects may be adversely affected. Furthermore, our third-party clinical trial investigators may be delayed in conducting our clinical trials for reasons outside of their control. </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">45</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we fail to comply with state and federal fraud and abuse laws, including anti-kickback, false claims and anti-inducement laws, we could face substantial penalties and our business, operations and financial condition could be adversely affected. </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Federal Anti-Kickback Statute prohibits, among other things, knowingly and willfully offering, paying, soliciting or receiving remuneration, whether directly or indirectly and overtly or covertly, to induce or in return for purchasing, leasing, ordering, or arranging for the purchase, lease or order of any healthcare item or service reimbursable under Medicare, Medicaid, or other federal financed healthcare programs. The statutory exceptions and regulatory safe harbors protecting certain common activities from prosecution are drawn narrowly, and any remuneration to or from a prescriber or purchaser of healthcare products or services may be subject to scrutiny if they do not qualify for an exception or safe harbor. Our practices may not in all cases meet all of the criteria for safe harbor protection from anti-kickback liability. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Federal false claims laws prohibit, in part, any person from knowingly presenting or causing to be presented a false claim for payment to the federal government, or knowingly making or causing to be made a false statement to obtain payment. The majority of states also have statutes or regulations similar to the Federal Anti-Kickback Statute and Federal False Claims Act, which apply to items or services reimbursed under Medicaid and other state programs, or, in several states, apply regardless of payer. These false claims statutes allow any person to bring suit in the name of the government alleging false and fraudulent claims presented to or paid by the government (or other violations of the statutes) and to share in any amounts paid by the entity to the government in fines or settlement. Such suits, known as <i style="font-style:italic;">qui tam</i> actions, have increased significantly in the healthcare industry in recent years.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Sanctions under these federal and state laws may include civil monetary penalties, exclusion of a manufacturer&#39;s products from reimbursement under government programs, criminal fines and imprisonment. In addition, the ACA, among other things, amended the intent requirement of the Federal Anti-Kickback Statute and criminal healthcare fraud statutes. A person or entity does not need to have actual knowledge of this statute or specific intent to violate it. In addition, the ACA provides that the government may assert that a claim, including items or services resulting from a violation of the Federal Anti-Kickback Statute, constitutes a false or fraudulent claim for purposes of the false claims statutes. Because of the breadth of these laws and the narrowness of the safe harbors and exceptions, some of our business activities could be subject to challenge under one or more of such laws. Such a challenge, regardless of the outcome, could have a material adverse effect on our business, business relationships, reputation, financial condition and results of operations. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, there has been a recent trend of increased federal and state regulation of payments made to physicians. The ACA imposed new reporting and disclosure requirements on device and drug manufacturers for any &quot;transfer of value&quot; made or distributed to prescribers and other healthcare providers. Device and drug manufacturers are also required to report and disclose any investment interests held by physicians and their immediate family members during the preceding calendar year. Failure to submit required information may result in civil monetary penalties of up to an aggregate of $150,000 per year (and up to an aggregate of $1.0&#160;million per year for &quot;knowing failures to report&quot;), for all payments, transfers of value or ownership or investment interests not reported in an annual submission. Manufacturers are required to collect data and are required to submit their data reports to CMS for each calendar year by the 90th&#160;day of the subsequent calendar year. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Certain states mandate implementation of compliance programs and/or the tracking and reporting of gifts, compensation and other remuneration to physicians or other healthcare professionals. The shifting compliance environment and the need to build and maintain robust and expandable systems to comply with different compliance and/or reporting requirements in multiple jurisdictions increase the possibility that a healthcare company may violate one or more of the requirements. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Federal Civil Monetary Penalties Law prohibits, in part, the offering or giving of remuneration to a Medicare or Medicaid beneficiary that the person knows or should know is likely to influence the beneficiary&#39;s selection of a particular supplier of items or services reimbursable by a Federal or state governmental program. We sometimes offer customers various discounts and other financial incentives in connection with the sales of our products. While it is our intent to comply with all applicable laws, the government may find that our marketing activities violate the Civil Monetary Penalties Law. If we are found to be in noncompliance, we could be subject </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">46</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">to civil money penalties of up to $20,000 for each wrongful act, assessment of three times the amount claimed for each item or service and exclusion from the Federal healthcare programs. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The scope and enforcement of each of these laws is uncertain and subject to rapid change in the current environment of healthcare reform, especially in light of the lack of applicable precedent and regulations. If our operations are found to be in violation of any of the laws described above or any other government regulations that apply to us, we may be subject to penalties, including civil and criminal penalties, damages, fines and the curtailment, restructuring, or restricting of our operations. Any penalties, damages, fines, curtailment or restructuring of our operations could harm our ability to operate our business and our financial results. Responding to any action or threat of action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management&#39;s attention from operation of our business. Moreover, achieving and sustaining compliance with applicable federal and state fraud laws may prove costly. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Failure to maintain the licenses and accreditations necessary to operate under our direct-to-patient and -provider model would adversely affect our business. </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">To continue operating our business under our direct-to-patient and -provider model, we must maintain our Durable Medical Equipment certification from the Accreditation Commission for Health Care. In May 2008, we became a Durable, Medical Equipment, Prosthetics, Orthotics, and Supplies accredited supplier by the Accreditation Commission for Health Care. This accreditation status must be renewed every three years through a recredentialing process that includes an on-site review. We last renewed our accreditation with our accrediting body in May 2020. If we are deemed out of compliance with accreditation standards, our enrollment status in the Medicare program could be jeopardized, up to and including termination. In addition to maintaining our Durable Medical Equipment certification from the Accreditation Commission for Health Care, we also must maintain certain state-required licenses. If we were found to be noncompliant, we could lose our licensure in that state. Losing our licensure could subject us to financial penalties and/or prohibit us from selling our current or future products to patients in such state and our business, financial condition and results of operations could be adversely affected as a result of any such prohibition. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our products are currently made available to authorized users of the Department of Veterans Affairs Federal Supply Schedule and if we were no longer eligible to sell our products through such channel, our business may be adversely affected. </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our Flexitouch and Entre systems are eligible for reimbursement by the Department of Veterans Affairs and included on the Federal Supply Schedule pricing program, established by Section&#160;603 of the Veterans Health Care Act of 1992.<b style="font-weight:bold;"> </b>To be eligible for this program, we must comply with additional laws and requirements applicable to our operations and manufacturing processes. If we were to lose eligibility for reimbursement by the Department of Veterans Affairs, our business, financial condition and results of operations could be adversely affected.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we modify our FDA cleared devices, we may need to seek additional clearances or approvals, which, if not granted, would prevent us from selling our modified products. </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The FDA regulations require the submission and clearance of a new 510(k) premarket notification, or possibly, premarket approval, for significant changes or modifications made in the design, components, method of manufacture or intended use of a device including changes or modifications to a 510(k)-cleared device that could significantly affect the device&#39;s safety or effectiveness, or would constitute a major change or modification in the device&#39;s intended use. The FDA requires each manufacturer to make this determination, but the FDA may review any manufacturer&#39;s decision. The FDA may not agree with our decisions regarding whether new clearances or approvals are necessary. We have modified some of our 510(k) cleared products, and have determined based on our review of the applicable FDA guidance that in certain instances new 510(k) clearances or premarket approval are not required. If the FDA disagrees with our determination and requires us to submit new 510(k) notifications or premarket approval for modifications to our previously cleared products for which we have concluded that new clearances or approvals are unnecessary, we may be required to cease marketing or to recall the modified product until we obtain clearance or approval, and we may be subject to significant regulatory fines or penalties. </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">47</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Furthermore, the FDA&#39;s ongoing review of the 510(k) program may make it more difficult for us to make modifications to our previously cleared products, either by imposing more strict requirements on when a manufacturer must submit a new 510(k) for a modification to a previously cleared product, or by applying more onerous review criteria to such submissions. If the FDA requires us to cease marketing a modified device until we obtain a new 510(k) clearance or premarket approval, our business, financial condition, operating results and future growth prospects could be materially adversely affected. Further in this situation, our products could be subject to recall. Any recall or FDA requirement that we seek additional approvals or clearances could result in significant delays, fines, increased costs associated with modification of a product, loss of revenue and potential operating restrictions imposed by the FDA. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The misuse or off-label use of our products may harm our image in the marketplace, result in injuries that lead to product liability suits or result in costly investigations, fines or sanctions by regulatory bodies if we are deemed to have engaged in the promotion of these uses, any of which could be costly to our business. </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The products we currently market have been cleared by the FDA for specific treatments. We train our employees and distributors in appropriate and lawful promotion of our products, within our approved indications and to be truthful and not misleading. We cannot, however, prevent a physician from using our products off-label, when in the physician&#39;s independent professional medical judgment, he or she deems it appropriate. The FDA does not restrict or regulate a physician&#39;s choice of treatment. There may be increased risk of injury to patients if physicians use our products off-label. Furthermore, the use of our products for indications other than those cleared by the governing regulatory body may not effectively treat such conditions, which could harm our reputation in the marketplace among physicians and patients. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If the FDA determines that our promotional materials, activity, communications or training constitute promotion of or encourage off-label uses, it could request that we modify our training or promotional materials or subject us to regulatory or enforcement actions, including the issuance of untitled letters, warning letters, injunctions, seizures, civil fines or criminal penalties. It is also possible that other federal, state or foreign enforcement authorities might take action if they consider our business activities to constitute promotion of an off-label use, which could result in significant penalties, including, but not limited to, criminal, civil and administrative penalties, damages, fines, disgorgement, exclusion from participation in government healthcare programs, and the curtailment of our operations. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, physicians or patients may misuse our products or use improper techniques, potentially leading to injury and an increased risk of product liability. If our products are misused or used with improper technique, we may become subject to costly litigation by our clinicians or their patients. We can be subject to lawsuits, whether or not our product is proven to be defective and whether or not our employees have adequately trained the physicians. Product liability claims could divert management&#39;s attention from our core business, be expensive to defend and result in sizeable damage awards against us that may not be covered by insurance. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our products may cause or contribute to adverse medical events that we are required to report to the FDA, and if we fail to do so, we would be subject to sanctions that would materially harm our business. </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our marketed products are subject to Medical Device Reporting, or MDR, obligations, which require that we report to the FDA any incident in which our products may have caused or contributed to a death or serious injury, or in which our products malfunctioned and, if the malfunction were to recur, it could likely cause or contribute to a death or serious injury. The timing of our obligation to report under the MDR regulations is triggered by the date we become aware of the adverse event as well as the nature of the event. We may fail to report adverse events of which we become aware within the prescribed timeframe. We may also fail to recognize that we have become aware of a reportable adverse event, especially if it is not reported to us as an adverse event or if it is an adverse event that is unexpected or removed in time from the use of our products. If we fail to comply with our reporting obligations, the FDA could take action including warning letters, untitled letters, administrative actions, criminal prosecution, imposition of civil monetary penalties, revocation of our device clearances, seizure of our products, or delay in clearance of future products. </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">48</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our products may in the future be subject to product recalls. A recall of our products, either voluntarily or at the direction of the FDA or another governmental authority, or the discovery of serious safety issues with our products, could have a significant adverse impact on us. </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The FDA and similar foreign governmental authorities have the authority to require the recall of commercialized products in the event of material deficiencies or defects in their design or manufacture. The FDA&#39;s authority to require a recall must be based on a finding that there is reasonable probability that the device would cause serious, adverse health consequences or death. We may also choose to voluntarily recall a product if any material deficiency is found. A government-mandated or voluntary recall could occur as a result of an unacceptable risk to health, component failures, malfunctions, manufacturing errors, design or labeling defects or other deficiencies and issues. Recalls of any of our products would divert managerial and financial resources and have an adverse effect on our reputation and business, which could impair our ability to produce our products in a cost-effective and timely manner in order to meet our patients&#39; demands. We may also be subject to liability claims, be required to bear other costs, or take other actions that may have a negative impact on our future sales and our ability to generate profits. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Companies are required to maintain certain records of recalls and corrections, even if they are not reportable to the FDA. We may initiate voluntary recalls or corrections for our products in the future that we determine do not require notification of the FDA. If the FDA disagrees with our determinations, they could require us to report those actions as recalls and we may be subject to enforcement action. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we or our component manufacturers fail to comply with the FDA&#39;s Quality System Regulation, our manufacturing operations could be interrupted, and our product sales and operating results could suffer. </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We and many of our component manufacturers are required to comply with the FDA&#39;s Quality System Regulation, or QSR, which covers the procedures and documentation of the design, testing, production, control, quality assurance, labeling, packaging, sterilization, storage and shipping of our devices. The FDA audits compliance with the QSR through periodic announced and unannounced inspections of manufacturing and other facilities. We and our component manufacturers have been, and anticipate in the future being, subject to such inspections. We cannot provide assurance that any future inspection will not result in adverse findings with respect to our QSR compliance. If our manufacturing facilities or those of any of our component manufacturers or suppliers are found to be in violation of applicable laws and regulations, or we or our manufacturers or suppliers fail to take satisfactory corrective action in response to an adverse inspection, the FDA could take enforcement action, including one or more of the following non-exclusive sanctions:</p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23.05pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">untitled letters, warning letters, fines, injunctions, consent decrees and civil penalties; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">customer notifications or repair, replacement, refunds, recall, detention or seizure of our products; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">operating restrictions or partial suspension or total shutdown of production; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">refusing or delaying our requests for 510(k) clearance or premarket approval of new products or modified products; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">withdrawing 510(k) clearances or premarket approvals that have already been granted; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">refusal to grant export approval for our products; or </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">criminal prosecution. </span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Any of these sanctions could adversely affect our business, financial condition and results of operations. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">For any products that we sell outside the United States, those products and our operations would also be required to comply with standards set by foreign law, treaties and industrial standards bodies, such as the </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">49</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">International Organization for Standardization, or ISO, and domestic regulatory authorities within foreign countries. Foreign regulatory bodies may evaluate our products or the testing that our products undergo against these or other standards. The specific standards, types of evaluation and scope of review differ among foreign regulatory bodies. If we fail to adequately comply with any of these standards, a foreign regulatory body may take adverse actions similar to those within the power of the FDA. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Any of these actions could prevent us from marketing, distributing or selling our products and would likely harm our business. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Future regulatory actions may adversely affect our ability to sell our products profitably. </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">From time to time, legislation is drafted and introduced that could significantly change the statutory provisions governing the clearance or approval, manufacture and marketing of a medical device. In addition, FDA and other regulations and guidance are often revised or reinterpreted in ways that may significantly affect our business and our products, and new regulations or guidance documents may be promulgated. It is impossible to predict whether legislative changes will be enacted or regulations, guidance or interpretations changed or added, and what the impact of such changes or additions, if any, may be. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Healthcare regulatory reform may affect our ability to sell our products profitably</span><b style="font-weight:bold;">. </b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the United States, the legislative landscape, particularly as it relates to healthcare regulation and reimbursement coverage, continues to evolve. In March 2010 the ACA was passed and substantially changed healthcare financing by both governmental and private insurers. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Other legislative changes have been proposed and adopted in the United States since the ACA was enacted. The Budget Control Act of 2011 requires, among other things, mandatory across-the-board reductions in Federal spending, also known as sequestration. The American Taxpayer Relief Act of 2012 postponed sequestration for two months. As required by law, a sequestration order was issued on March 1, 2013. As a result of the sequestration order, Medicare Fee-for-Service claims with dates-of-service or dates-of-discharge on or after April 1, 2013 will continue to incur a 2% reduction in the Medicare payment until further notice. Claims for durable medical equipment, prosthetics, orthotics and supplies, including claims under the DME Competitive Bidding Program, are reduced by 2% based upon whether the date-of-service, or the start date for rental equipment or multi-day supplies, is on or after April 1, 2013. This 2% reduction based on the sequestration was suspended in 2020 due to the public health emergency, and Congress extended the sequestration moratorium through March 31, 2021. From April 1, 2021 through June 30, 2021, the reduction went back into effect at a 1% reduction level, and beginning July 1, 2021, the reduction returned to a 2% reduction level. We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our products or additional pricing pressures. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">There have been judicial and Congressional challenges to certain aspects of the ACA. Additional state and federal health care reform measures that may be adopted in the future could have a material adverse effect on our industry generally and on our customers. Any changes in, or uncertainty with respect to future reimbursement rates, or changes in hospital admission rates could impact our customers&#39; demand for our products and services, which in turn could impact our ability to successfully commercialize our products, or could limit or eliminate our spending on certain development projects. These changes could adversely affect our business and results of operations.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">There have been, and we expect there will continue to be, a number of legislative and regulatory changes to the healthcare system that could affect our future revenue and profitability and the future revenue and profitability of our customers. Federal and state lawmakers regularly propose and, at times, enact legislation that results in significant changes to the healthcare system, some of which are intended to contain or reduce the costs of medical products and services. Such uncertainty and any changes could negatively impact our ability to successfully commercialize our products or product candidates and could result in reduced demand for our products and additional pricing pressures.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">50</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">While our products are not currently subject to the competitive bidding process under Medicare, if our products were to become subject to such process in the future, it could negatively affect our business and financial condition. </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 required the Secretary of Health and Human Services to establish and implement programs under which competitive acquisition areas are established throughout the United States for purposes of awarding contracts for the furnishing of competitively priced items of durable medical equipment. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">CMS, the agency responsible for administering the Medicare program, conducts a competition for each competitive acquisition area under which providers submit bids to supply certain covered items of durable medical equipment. Successful bidders must meet certain program quality standards in order to be awarded a contract and only successful bidders can supply the covered items to Medicare beneficiaries in the acquisition area. There are, however, regulations in place that allow non-contracted providers to continue to provide products and services to their existing customers at the new competitive bidding payment amounts. The contracts are expected to be re-bid every three years. CMS is required to award contracts to multiple entities submitting bids in each area for an item or service, but has the authority to limit the number of contractors in a competitive acquisition area to the number it determines to be necessary to meet projected demand. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Although we continue to monitor developments regarding the implementation of the competitive bidding program, we cannot predict the outcome of the competitive bidding program on our business when fully implemented, nor the Medicare payment rates that will be in effect in future years for the items subjected to competitive bidding, including our products. We expect that payment rates will continue to fluctuate, and a large negative payment adjustment could adversely affect our business, financial conditions and results of operations. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We are subject to additional federal, state and foreign laws and regulations relating to our healthcare business; our failure to comply with those laws could have an adverse impact on our business. </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are subject to healthcare fraud and abuse regulation and enforcement by federal and state governments, which could adversely impact our business. Healthcare fraud and abuse and health information privacy and security laws potentially applicable to our operations include:</p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23.05pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the federal Anti-Kickback Statute, which applies to our marketing practices, educational programs, pricing policies and relationships with healthcare providers, by prohibiting, among other things, soliciting, receiving, offering or providing remuneration, whether directly or indirectly and overtly or covertly, intended to induce the referral of an individual for (i)&#160;the furnishing or the arranging for the furnishing of items or services reimbursable under a federal healthcare program, such as Medicare or Medicaid; or (ii)&#160;the purchase, lease or order of, or the arrangement or recommendation of the purchasing, leasing or ordering of, of an item or service reimbursable under a federal healthcare program. Courts have ruled that a person or entity does not need to have actual knowledge of this statute or specific intent to violate it to have committed a violation; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23.05pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">federal civil and criminal false claims laws and civil monetary penalty laws, including civil whistleblower or </span><i style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:normal;">qui tam</i><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"> actions that prohibit, among other things, knowingly presenting, or causing to be presented, claims for payment or approval to the federal government that are false or fraudulent, knowingly making a false statement material to an obligation to pay or transmit money or property to the federal government, knowingly concealing or knowingly and improperly avoiding or decreasing an obligation to pay or transmit money or property to the federal government or knowingly offering remuneration to influence a Medicare or Medicaid beneficiary&#39;s selection of health care providers. The government may assert that a claim, including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the false claims statutes; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23.05pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">HIPAA and its implementing regulations, which created federal criminal laws that prohibit, among other things, executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters; </span></td></tr></table></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">51</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23.05pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">HIPAA, as amended by HITECH, also imposes certain regulatory and contractual requirements regarding the privacy, security and transmission of individually identifiable health information; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23.05pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">federal Open Payments (the Physician Payments Sunshine Act) requirements imposed by the ACA on device manufacturers regarding certain &quot;transfers of value&quot; made or distributed to physicians, certain other healthcare providers, and teaching hospitals. Failure to submit required information may result in civil monetary penalties of up to an aggregate of $150,000 per year (or up to an aggregate of $1.0&#160;million per year for &quot;knowing failures&quot;), for all payments, transfers of value or ownership or investment interests that are not timely, accurately and completely reported in an annual submission. Manufacturers must report detailed payment data and submit legal attestation to the accuracy of such data for each calendar year by the 90th&#160;day of the subsequent calendar year; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23.05pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers; and </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23.05pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">state law equivalents of each of the above federal laws, such as anti-kickback and false claims laws that may apply to items or services reimbursed by any third-party payer, including commercial insurers; state laws that require device companies to comply with the industry&#39;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government or otherwise restrict payments that may be made to healthcare providers; state laws that require device manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures; and state laws governing the privacy and security of certain health information, many of which differ from each other in significant ways and often are not preempted by HIPAA. </span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The risk of our being found in violation of these laws and regulations is increased by the fact that many of them have not been fully interpreted by the regulatory authorities or the courts, and their provisions are open to a variety of interpretations. We are unable to predict what additional federal or state legislation or regulatory initiatives may be enacted in the future regarding our business or the healthcare industry in general, or what effect such legislation or regulations may have on us. Federal or state governments may impose additional restrictions or adopt interpretations of existing laws that could have a material adverse effect on us. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Because of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available under such laws, some of our business activities, including certain sales and marketing practices and financial arrangements, including the provision of stock options as partial compensation for consulting services, with physicians, some of whom use or purchase our products, and other customers, could be subject to challenge under one or more of such laws. Responding to any action or threat of action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management&#39;s attention from the operation of our business. If our operations are found to be in violation of any of the laws described above or any other governmental regulations that apply to us, we may be subject to penalties, including civil and criminal penalties, damages, fines, exclusion from governmental healthcare programs, disgorgement, contractual damages, reputational harm, diminished profits and future earnings, and the curtailment or restructuring of our operations, any of which could adversely impact our business. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Failure to comply with regulations affecting the transmission, security and privacy of health information could result in significant penalties. </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Numerous federal and state laws and regulations, including HIPAA and the HITECH Act, govern the collection, dissemination, security, use and confidentiality of patient-identifiable health information or more broadly personally identifiable information. HIPAA and the HITECH Act require us to comply with standards for the use and disclosure of health information within our company and with third parties. The Privacy Standards and Security Standards under HIPAA establish a set of basic national privacy and security standards for the protection of individually identifiable health information by health plans, healthcare clearinghouses and certain healthcare providers, referred to as covered entities, and the business associates with whom such covered entities contract for services. Notably, whereas HIPAA previously directly regulated only these covered entities, the HITECH Act, which was signed into law as part of the stimulus package in February 2009, makes certain </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">52</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">of HIPAA&#39;s privacy and security standards also directly applicable to covered entities&#39; business associates. As a result, both covered entities and business associates are subject to significant civil and criminal penalties for failure to comply with Privacy Standards and Security Standards. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">HIPAA and the HITECH Act also include standards for common healthcare electronic transactions and code sets, such as claims information, plan eligibility, payment information and the use of electronic signatures, and privacy and electronic security of individually identifiable health information. Covered entities, such as healthcare providers, are required to conform to such transaction set standards pursuant to HIPAA. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">HIPAA requires healthcare providers like us to develop and maintain policies and procedures with respect to protected health information that is used or disclosed, including the adoption of administrative, physical and technical safeguards to protect such information. The HITECH Act expands the notification requirement for breaches of patient-identifiable health information, restricts certain disclosures and sales of patient-identifiable health information and provides a tiered system for civil monetary penalties for HIPAA violations. The HITECH Act also increased the civil and criminal penalties that may be imposed against covered entities, business associates and possibly other persons and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorney fees and costs associated with pursuing federal civil actions. Additionally, certain states have adopted comparable privacy and data security laws and regulations, some of which may be more stringent than HIPAA. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If we do not comply with existing or new laws and regulations related to patient health information, we could be subject to criminal or civil sanctions. New health information standards, whether implemented pursuant to HIPAA, the HITECH Act, state or federal congressional action or otherwise, could have a significant effect on the manner in which we handle healthcare related data and communicate with payers, and the cost of complying with these standards could be significant. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The 2013 final HITECH omnibus rule, or the HITECH Final Rule, modified the breach reporting standard in a manner that makes more data security incidents qualify as reportable breaches. Any liability from a failure to comply with the requirements of HIPAA or the HITECH Act could adversely affect our financial condition. The costs of complying with privacy and security related legal and regulatory requirements are burdensome and could have a material adverse effect on our results of operations. The HITECH Final Rule is subject to interpretation by various courts and other governmental authorities, thus creating potentially complex compliance issues for us, as well as our clients and strategic partners. In addition, we are unable to predict what changes to the HIPAA Privacy Standards and Security Standards might be made in the future or how those changes could affect our business. Any new legislation or regulation in the area of privacy and security of personal information, including personal health information, could also adversely affect our business operations. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, the FDA has issued guidance to which we may be subject concerning data security for medical devices.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Additionally, the Federal Trade Commission has issued and several states have issued or are considering new regulations to require holders of certain types of personally identifiable information to implement formal policies and programs to prevent, detect and mitigate the risk of identity theft and other unauthorized access to or use of such information. Further, the U.S. Congress and a number of states have considered or are considering prohibitions or limitations on the disclosure of medical or other information to individuals or entities located outside of the United States. We may need to comply with applicable laws in those jurisdictions that regulate the use and disclosure of individually identifiable information. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Failure to comply with privacy and data security laws and regulations could subject us to substantial penalties and our business, operations and financial condition could be adversely affected. </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In addition to the HIPAA and HITECH Act regulations described above, a number of U.S. states have also enacted data privacy and data security laws and regulations that govern the collection, use, disclosure, transfer, storage, disposal, and protection of sensitive personal information, such as social security numbers, medical and financial information and other personal information. These laws and regulations may be more restrictive and not preempted by U.S. federal laws. For example, several U.S. territories and all 50 states now </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">53</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">have data breach laws that require timely notification to individual victims, and at times regulators, if a company has experienced the unauthorized access or acquisition of sensitive personal data. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Other state laws contain additional disclosure obligations for businesses that collect personal information about residents and afford those individuals additional rights relating to their personal information that may affect our ability to use personal information or share it with our business partners. For example, California has laws that g<span style="background:#ffffff;">ive California residents certain privacy rights in the collection and disclosure of their personal information and requires businesses to make certain disclosures and take certain other acts in furtherance of those rights, and has recently created a new agency, the California Privacy Protection Agency, authorized to implement and enforce California&#8217;s privacy laws, which could result in increased privacy and information security regulatory actions. Other U.S. states, such as Virginia, Utah, Connecticut, and Colorado, have passed consumer privacy laws that become effective in 2023. </span>We will continue to monitor and assess the impact of these state laws, which may impose substantial penalties for violations, impose significant costs for investigations and compliance, allow private class-action litigation and carry significant potential liability for our business. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We face the risk of product liability claims that could be expensive, divert management&#39;s attention and harm our reputation and business. We may not be able to maintain adequate product liability insurance. </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our business exposes us to the risk of product liability claims that are inherent in the testing, manufacturing and marketing of medical devices. This risk exists even if a device is cleared or approved for commercial sale by the FDA and manufactured in facilities licensed and regulated by the FDA or an applicable foreign regulatory authority. Our products are designed to affect, and any future products will be designed to affect, important bodily functions and processes. Any side effects, manufacturing defects, misuse or abuse associated with our products or our products in development could result in patient injury or death. The medical device industry has historically been subject to extensive litigation over product liability claims, and we cannot offer any assurance that we will not face product liability suits. We may be subject to product liability claims if our products cause, or merely appear to have caused, patient injury or death. In addition, an injury that is caused by the activities of our suppliers, such as those who provide us with components and materials, may be the basis for a claim against us. Product liability claims may be brought against us by patients, clinicians or others selling or otherwise coming into contact with our products, among others. If we cannot successfully defend ourselves against product liability claims, we will incur substantial liabilities and reputational harm. In addition, regardless of merit or eventual outcome, product liability claims may result in:</p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23.05pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">costs of litigation; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">distraction of management&#39;s attention from our primary business; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the inability to commercialize our existing or new products; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">decreased demand for our products or products in development; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">damage to our business reputation; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">product recalls or withdrawals from the market; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">withdrawal of clinical trial participants; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">substantial monetary awards to patients or other claimants; or </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">loss of revenue. </span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">While we may attempt to manage our product liability exposure by proactively recalling or withdrawing from the market any defective products, any recall or market withdrawal of our products would delay the supply of those products to our distributors, clinicians and patients and may impact our reputation. We can provide no assurance that we will be successful in initiating appropriate market recall or market withdrawal efforts that may </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">54</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">be required in the future or that these efforts will have the intended effect of preventing product malfunctions and the accompanying product liability that may result. Such recalls and withdrawals may also be used by our competitors to harm our reputation for safety or be perceived by patients as a safety risk when considering the use of our products, either of which could have an adverse impact on our business. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, our product liability insurance is subject to deductibles and coverage limitations. Our current product liability insurance may not continue to be available to us on acceptable terms, if at all, and, if available, coverage may not be adequate to protect us against any future product liability claims. If we are unable to obtain insurance at an acceptable cost or on acceptable terms or otherwise protect against potential product liability claims, we could be exposed to significant liabilities. A product liability claim, recall or other claim with respect to uninsured liabilities or for amounts in excess of insured liabilities could have an adverse impact on our business.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our employees, distributors, independent contractors, consultants, collaborators and suppliers may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements and insider trading. </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are exposed to the risk that our employees, distributors and other third parties, in spite of our compliance training and programs, may engage in fraudulent conduct or other illegal activity. Misconduct by employees, distributors and other third parties could include intentional, reckless and/or negligent conduct or disclosure of unauthorized activities to us that violate FDA regulations, including those laws requiring the reporting of true, complete and accurate information to the FDA, manufacturing standards, federal and state healthcare fraud and abuse laws and regulations, or laws that require the reporting of financial information or data accurately. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws intended to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Activities subject to these laws also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. It is not always possible to identify and deter employee and other third-party misconduct, and the steps we take to detect, prevent and remedy any such activity may not protect us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws. If any such actions are threatened or instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant civil, criminal and administrative penalties, damages, monetary fines, disgorgement, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings and curtailment or restructuring of our operations, any of which could adversely affect our ability to operate.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may be unable to obtain or maintain international regulatory registrations or approvals for our current or future products and indications, which could adversely impact our business. </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Sales of our devices outside the United States are subject to foreign regulatory requirements that vary widely from country to country. In addition, the FDA regulates exports of medical devices from the United States. Complying with international regulatory requirements can be an expensive and time-consuming process and approval is not certain. The time required to obtain registration or approvals, if required by other countries, may be longer than that required for FDA clearance, and requirements for such registrations or approvals may significantly differ from FDA requirements. In certain countries we intend to rely upon third-party distributors to obtain all required regulatory registrations and approvals, and these distributors may be unable to obtain or maintain such registrations or approvals. Our distributors in these countries may also incur significant costs in attempting to obtain and in maintaining foreign regulatory approvals or registrations, which could increase the difficulty of attracting and retaining qualified distributors. If we are unable to obtain or maintain international registrations or approvals, or if distributors experience delays in receiving, or fail to receive, necessary registrations or approvals to market our products outside the United States, we may be unable to market our products or enhancements in certain international markets effectively, or at all. </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">55</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our operations involve the use of hazardous and toxic materials, and we must comply with environmental, health and safety laws and regulations, which can be expensive, and could have an adverse impact on our business. </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:14pt;text-align:justify;text-indent:36pt;margin:14pt 0pt 0pt 0pt;">Our operations use or generate small volumes of hazardous or toxic materials. We are therefore subject to a variety of federal, state and local regulations relating to the use, handling, storage, disposal and human exposure to hazardous and toxic materials. Liability under environmental laws can be joint and several and without regard to comparative fault, and environmental laws could become more stringent over time, imposing greater compliance costs and increasing risks and penalties associated with violations, which could have an adverse impact on our business. There can be no assurance that violations of environmental, health and safety laws will not occur in the future as a result of human error, accident, equipment failure or other causes. The failure to comply with past, present or future laws could result in the imposition of fines, third-party property damage and personal injury claims, investigation and remediation costs, the suspension of production or a cessation of operations. We also expect that our operations will be affected by other new environmental and health and safety laws and regulations on an ongoing basis. Although we cannot predict the ultimate impact of any such new laws and regulations, they will likely result in additional costs, and may require us to change how we manufacture our products, which could have an adverse impact on our business.</p><a id="_ab45748c_25bf_42ea_a1f5_13f9a09d5604"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Financial Condition, Credit and Tax Risks </b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we fail to maintain proper and effective internal control over financial reporting, our ability to produce accurate and timely financial statements could be impaired, which could harm our operating results, investors&#39; views of us and, as a result, the value of our common stock. </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to Section&#160;404 of the Sarbanes-Oxley Act, our management is required to report upon the effectiveness of our internal control over financial reporting, and our independent registered public accounting firm is required to attest to the effectiveness of our internal control over financial reporting. The rules governing the standards that must be met for our management and our independent registered public accounting firm to assess our internal control over financial reporting are complex and require significant documentation, testing and possible remediation. In connection with our and our independent registered public accounting firm&#8217;s evaluations of our internal control over financial reporting, we may need to upgrade our systems, including information technology; implement additional financial and management controls, reporting systems and procedures; and hire additional accounting and finance staff. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Any failure to implement required new or improved controls, or difficulties encountered in their implementation, could cause us to fail to meet our reporting obligations. In addition, any testing by us or our independent registered public accounting firm conducted in connection with Section&#160;404 of the Sarbanes-Oxley Act may reveal deficiencies in our internal control over financial reporting that are deemed to be material weaknesses or that may require prospective or retroactive changes to our financial statements or identify other areas for further attention or improvement. Inferior internal controls could also cause investors to lose confidence in our reported financial information, which could have a negative effect on the trading price of our common stock. Internal control deficiencies could also result in a restatement of our financial results in the future. We could become subject to stockholder or other third-party litigation, as well as investigations by the SEC, the stock exchange on which our securities are listed, or other regulatory authorities, which could require additional financial and management resources and could result in fines, trading suspensions, payment of damages or other remedies.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:12pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">The level of our indebtedness under our credit facility may adversely impact us, and the phase-out, replacement or unavailability of LIBOR and/or other interest rate benchmarks could adversely affect our indebtedness. </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:14pt 0pt 0pt 0pt;">Our level of debt under our credit facility could, among other things:</p><div style="margin-top:6pt;"></div><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:14pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">require us to dedicate a large portion of our cash flow from operations to the servicing and repayment of our debt, thereby reducing funds available for working capital, capital expenditures, research and development expenditures and other general corporate requirements;</span></td></tr></table></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">56</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:3pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">limit our ability to obtain additional financing to fund future working capital, capital expenditures, research and development expenditures and other general corporate requirements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:3pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">limit our flexibility in planning for, or reacting to, changes in our business and the industry in which we operate;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:3pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">restrict our ability to make strategic acquisitions or dispositions or to exploit business opportunities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:3pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">place us at a competitive disadvantage compared to our competitors that have less debt; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:3pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:24.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">adversely affect the market price of our common stock.</span></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">Further, our ability to make scheduled payments of the principal of, to pay interest on or to refinance our indebtedness depends on our future performance, which is subject to economic, financial, competitive and other factors beyond our control.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">In addition, our financial condition, results of operations and cash flows could be affected by changes in interest rates and actions taken by the Federal Reserve or changes in the London Interbank Offered Rate (&quot;LIBOR&quot;) or its replacement. Future increases in market interest rates would increase our interest expense. Alternative, successor, or replacement rates following the planned phase-out of LIBOR in June 2023 may not be similar to, or produce the same value or economic equivalence of, or have the same volume or liquidity as did, LIBOR (the current benchmark rate under our Credit Agreement), which may increase our overall interest expense. In addition, the credit spread adjustments on any benchmark replacement to LIBOR under our credit facility may not produce substantially the same rate as current LIBOR based loans. The potential effect of the phase-out or replacement of LIBOR on our cost of capital cannot yet be determined and any increase in the interest we pay and a corresponding increase in our costs of capital or otherwise could have a material adverse impact on our financial condition, results of operations or cash flows.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Our credit facility contains covenants that restrict our business and financing activities, and the property that secures our obligations under the credit facility may be subject to foreclosure.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">Our credit facility contains a number of restrictions and covenants, which, among other things, restrict our ability to acquire or merge with another entity, dispose of our assets, make investments, loans or guarantees, incur additional indebtedness, create liens or other encumbrances, or pay dividends or make other distributions. The credit facility also requires us to maintain compliance with a maximum leverage ratio, a minimum fixed charge coverage ratio, a minimum EBITDA covenant and a minimum liquidity covenant. These provisions impose significant operating and financial restrictions on us and may limit our ability to compete effectively, take advantage of new business opportunities or take other actions that may be in our best interests. Our ability to obtain additional or other financing or to dispose of certain assets could also be negatively impacted because we have pledged substantially all of our assets as collateral in connection with the credit facility. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">Our ability to comply with the provisions under the Credit Agreement may be affected by events beyond our control and our inability to comply with any of these provisions could result in a default under the Credit Agreement. If such a default occurs, the lenders may elect to declare all borrowings outstanding, together with accrued interest and other fees, to be immediately due and payable, and they would have the right to terminate any commitments they have to provide further borrowings. If we are unable to repay outstanding borrowings when due, the lenders under the Credit Agreement also have the right to proceed against the collateral, including substantially all of our assets, granted to them to secure the indebtedness under the facility. If our indebtedness under the Credit Agreement were to be accelerated, we cannot assure you that our assets would be sufficient to repay in full that indebtedness. The occurrence of any of these events could have a material adverse effect on our business, financial condition, results of operations and liquidity.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may need substantial additional funding and may be unable to raise capital when needed, which could force us to delay or reduce our commercialization efforts or product development programs. </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">We believe our cash, cash equivalents and cash flows from operations will be sufficient to meet our working capital, capital expenditure and debt repayment and related interest payment requirements for at least the next twelve months. However, we have based these estimates on assumptions that may prove to be </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">57</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">incorrect, and we could spend our available financial resources much faster than we currently expect. Any future funding requirements will depend on many factors, including:</p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23.05pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">market acceptance of our products; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the scope, rate of progress and cost of our clinical studies; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the cost of our research and development activities; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the cost of filing and prosecuting patent applications and defending and enforcing our patent or other intellectual property rights; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the cost of defending, in litigation or otherwise, any claims that we infringe third-party patents or other intellectual property rights; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the cost and timing of additional regulatory clearances or approvals; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the cost and timing of establishing additional sales, marketing and distribution capabilities; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">costs associated with any product recall that may occur; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the effect of competing technological and market developments; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the extent to which we acquire or invest in products, technologies and businesses; and </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs of operating as a public company. </span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If we raise additional funds by issuing equity securities, our stockholders may experience dilution. Any future debt financing into which we enter may impose upon us covenants that restrict our operations, including limitations on our ability to incur liens or additional debt, pay dividends, repurchase our common stock, make certain investments and engage in certain merger, consolidation or asset sale transactions. Any debt financing or additional equity that we raise may contain terms that are not favorable to us or our stockholders. If we raise additional funds through collaboration and licensing arrangements with third parties, it may be necessary to relinquish some rights to our technologies or our products, or grant licenses on terms that are not favorable to us. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:14pt;text-align:justify;text-indent:36pt;margin:14pt 0pt 0pt 0pt;">Furthermore, we cannot be certain that additional funding will be available on acceptable terms, if at all. If we do not have, or are not able to obtain, sufficient funds, we may have to delay development or commercialization of our products or license to third parties the rights to commercialize products or technologies that we would otherwise seek to commercialize. We also may have to reduce marketing, customer support or other resources devoted to our products or cease operations. Any of these factors could harm our operating results.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">A reclassification of our independent contractor trainers could require us to pay retroactive taxes and penalties, which could have a material adverse effect on our business, financial condition and operating results.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">Prior to the inactivation of our independent contractor home trainers in May 2020, we contracted with over 560 licensed healthcare practitioners as home trainers, who educate our patients on the proper use of our solutions. We have since reactivated a small number of healthcare practitioners in the same capacity as previously noted. Because we consider these licensed practitioners to be independent contractors, as opposed to employees, under federal and applicable state laws, we do not withhold federal or state income or other employment related taxes or make federal or state unemployment tax or Federal Insurance Contributions Act payments. Our contracts with these independent contractors obligate them to pay these taxes. The classification of healthcare practitioners as independent contractors depends on the facts and circumstances of the relationship. Recently, there has been increased focus on the tests and standards related to classifying </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">58</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;">individuals as employees or independent contractors, including through judicial decisions, legislative proposals and private lawsuits in certain jurisdictions. For example, California enacted a law (AB 5), which took effect January 1, 2020. AB 5 significantly limits the types of workers who may be able to be classified as independent contractors under California law, including requiring the worker to perform work that is outside the usual course of the hiring company&#8217;s business in order to be classified as an independent contractor. In addition, in October 2022, the U.S. Department of Labor published a Notice of Proposed Rulemaking that would rescind the current federal independent contractor rule (adopted by the Trump administration in 2021) and would apply a non-exhaustive six factor totality-of-the-circumstances analysis, and could, if enacted in its current form, result in the need to reclassify certain types of workers.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">Other state legislatures and Congress are considering, and may enact, laws or regulations narrowing the scope of workers who may be classified as independent contractors. As a result, there is significant uncertainty regarding what the state and federal worker classification regulatory landscape may look like in coming years. In the event federal or state taxing or other regulatory authorities, or a court, were to determine that the healthcare practitioners with whom we contract should be classified as employees, we might be liable for unpaid past taxes and other costs and subject to penalties. We also could, among other things, be required to withhold income taxes, to withhold and pay Social Security, Medicare and similar taxes, to pay unemployment and other related payroll taxes and to provide certain employee benefits, including workers&#8217; compensation coverage and group medical benefits, or be forced to change our business model as it relates to the trainers to avoid various types of liability exposure associated with worker misclassification claims pursued by governmental agencies or through private legal action. As a result, any determination that the trainers are our employees could have a material adverse effect on our business, financial condition and results of operations.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-top:2pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We may be subject to liabilities related to state income, sales and use taxes, which could adversely affect our financial condition and results of operations and could decrease demand for our products.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:14pt 0pt 0pt 0pt;">State income tax and sales and use tax laws, statutes, rules and regulations vary greatly by jurisdiction and are complex and subject to uncertainty. If it is determined that certain of these tax rules apply to us, we could be required to pay substantial tax amounts, and significant penalties and interest for past amounts that may have been due, in addition to taxes going forward. These tax assessments, penalties and interest, and future requirements, may adversely affect our financial condition and results of operations. In addition, the imposition of sales and use taxes on our products going forward would effectively increase the cost of our products to our customers and may adversely affect demand for our products</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:14pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may be unable to collect all of our Medicare accounts receivable. </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:14pt;text-align:justify;text-indent:36pt;margin:14pt 0pt 0pt 0pt;">At December 31, 2022, we had approximately $33.2&#160;million of accounts receivable for sales of our Flexitouch system to patients covered by Medicare. A portion of the related claims to Medicare are initially denied and enter the appeals process, where many are ultimately reviewed by an Administrative Law Judge. The appeal process can be lengthy, lasting several years in most cases. At December 31, 2022, we classified $23.1&#160;million of our Medicare accounts receivable&#160;related to Flexitouch system sales as long-term assets on our balance sheet due to the estimated amount of receivables that will be paid more than one year from December 31, 2022, as a result of delays with the Administrative Law Judge appeal process. A significant increase in Medicare denial of submitted claims or an increase in the proportion of Medicare denials that are upheld by an Administrative Law Judge could adversely affect our results of operations or cause us to reduce the carrying value of our Medicare accounts receivable related to Flexitouch system sales.</p><a id="_6abeb734_c84d_4f3c_b46d_3b1a552f7569"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to Our Intellectual Property </b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may not be able to protect our intellectual property rights throughout the world. </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Filing, prosecuting and defending patents on products in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States may be less extensive than those in the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. For example, many foreign countries have compulsory licensing laws, under which a patent owner must grant licenses to third </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">59</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">parties. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products, and further, competitors may export otherwise infringing products to territories where we have patent protection but enforcement rights are not as strong as those in the United States. These products may compete with our products in jurisdictions where we do not have any issued patents, and our patent claims or other intellectual property rights may not be effective or sufficient to prevent them from so competing. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries do not favor the enforcement of patents and other intellectual property protection, which could make it difficult for us to stop the infringement of our patents generally. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing, and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The patent protection for our products may expire before we are able to maximize their commercial value, which may subject us to increased competition and reduce or eliminate our opportunity to generate product revenue. </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The patents related to our products have varying expiration dates and, when these patents expire, we may be subject to increased competition and we may not be able to recover our development costs or market any of our approved products profitably. For instance, many U.S. patents covering various aspects of our Flexitouch system expired in 2017. Upon expiration of our patents, we may be subject to increased competition and our opportunity to establish or maintain product revenue could be substantially reduced or eliminated. Further, we may not have sufficient time to recover our development costs prior to the expiration of our U.S. and foreign patents. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may not identify relevant patents or may incorrectly interpret the relevance, scope or expiration of a patent, which may adversely affect our ability to develop and market our products. </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We cannot guarantee that any of our patent searches or analyses, including but not limited to the identification of relevant patents, the scope of patent claims or the expiration of relevant patents, are complete or thorough, nor can we be certain that we have identified each and every patent and pending application in the United States and abroad that is relevant to or necessary for the commercialization of our products in any jurisdiction. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The scope of a patent claim is determined by an interpretation of the law, the written disclosure in a patent and the patent family&#39;s prosecution history. Our interpretation of the relevance or the scope of a patent or a pending application may be incorrect, which may negatively impact our ability to market our products. We may incorrectly determine that our products are not covered by a third-party patent. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Many patents may cover a marketed product, including but not limited to patents covering the product or portions thereof, methods of use or methods relating to the product, and production processes of or for the product. The identification of all patents and their expiration dates relevant to the production and sale of a therapeutic product is extraordinarily complex and requires sophisticated legal knowledge in the relevant jurisdiction. It may be impossible to identify all patents in all jurisdictions relevant to a marketed product. Our determination of the expiration date of any patent in the United States or abroad that we consider relevant may be incorrect, which may negatively impact our ability to develop and market our products. </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">60</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Obtaining and maintaining our patent protection depends on compliance with various procedural, documentary, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements. </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The United States Patent and Trademark Office, or USPTO, and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent prosecution process. Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on any issued patent and/or pending patent applications are due to be paid to the USPTO and foreign patent agencies in several stages over the lifetime of a patent or patent application. We have systems in place to remind us to pay these fees, and we employ an outside firm and rely on our outside counsel to pay these fees. While an inadvertent lapse may sometimes be cured by payment of a late fee or by other means in accordance with the applicable rules, there are many situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. If we fail to maintain the patents and patent applications directed to our products, our competitors might be able to enter the market earlier than should otherwise have been the case, which may have a material adverse effect on our business. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may become involved in lawsuits to protect our patents or other intellectual property rights, which could be expensive, time-consuming and ultimately unsuccessful. </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Competitors may infringe our patents or other intellectual property rights. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time consuming. In addition, in an infringement proceeding, a court may decide that a patent of ours is not valid or is unenforceable or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in any litigation or defense proceedings could put one or more of our patents at risk of being invalidated or interpreted narrowly and could put our patent applications at risk of not issuing. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Various proceedings brought before the USPTO may be necessary to determine the priority of inventions with respect to our patents and patent applications or those of our current or future collaborators. An unfavorable outcome could require us to cease using the technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if a prevailing party does not offer us a license on terms that are acceptable to us. Litigation or other proceedings may fail and, even if successful, may result in substantial costs and distraction of our management and other employees. We may not be able to prevent misappropriation of our proprietary rights, particularly in countries where the laws may not protect those rights as fully as in the United States. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential and proprietary information could be compromised by disclosure during this type of litigation. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Third-party claims of intellectual property infringement or misappropriation may adversely affect our business and could prevent us from developing or commercializing our products. </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Our commercial success depends in part on us not infringing the patents and proprietary rights of third parties. There is a substantial amount of litigation, both within and outside the United States, involving patent and other intellectual property rights in the medical device industry, including patent infringement lawsuits, interferences, oppositions, <i style="font-style:italic;">ex-parte</i> review and <i style="font-style:italic;">inter partes</i> reexamination and post-grant review proceedings before the USPTO and corresponding foreign patent offices. Numerous U.S. and foreign issued patents and pending patent applications owned by third parties exist in the fields in which we are developing and may develop our products. As the medical device industry expands and more patents are issued, the risk increases </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">61</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">that our products may be subject to claims of infringement of the patent rights of third parties. If a third-party claims that we infringe on their intellectual property or technology, we could face a number of issues, including:</p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23.05pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">infringement and other intellectual property claims which, with or without merit, can be expensive and time-consuming to litigate and can divert management&#39;s attention from our core business; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23.05pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">substantial damages for past infringement, which we may have to pay if a court decides that our product infringes on a competitor&#39;s patent; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23.05pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">a court prohibiting us from selling or licensing our product, unless the patent holder licenses the patent to us; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23.05pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">if a license is available from a patent holder, we may have to pay substantial royalties or grant cross licenses to our patents; and </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23.05pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">redesigning our products and processes so they do not infringe, which may not be possible or could require substantial funds and time. </span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Third parties may assert that we are employing their proprietary technology without authorization. There may be third-party patents or patent applications with claims to products, materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our products, that we failed to identify. For example, applications filed before November&#160;29, 2000 and certain applications filed after that date that will not be filed outside the United States may remain confidential until issued as patents. Except for the preceding exceptions, patent applications in the United States and elsewhere are generally published only after a waiting period of approximately 18&#160;months after the earliest filing. Therefore, patent applications covering our technology or our products could have been filed by others without our knowledge. Additionally, pending patent applications that have been published can, subject to certain limitations, be later amended in a manner that could cover our technologies, our products or the use or manufacture of our products. We may also face a claim of misappropriation, if a third party believes that we inappropriately obtained and used trade secrets of such third parties. If we are found to have misappropriated a third party&#39;s trade secrets, we may be prevented from further using such trade secrets, limiting our ability to develop our products, and we may be required to pay damages. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If any third-party patents were held by a court of competent jurisdiction to cover aspects of our products, materials, formulations, methods of manufacture or methods for treatment, the holders of any such patents would be able to block our ability to develop and commercialize the applicable product candidate until such patent expired or unless we obtain a license. These licenses may not be available on acceptable terms, if at all. Even if we were able to obtain a license, the rights may be nonexclusive, which could result in our competitors gaining access to the same intellectual property. Ultimately, we could be prevented from commercializing a product, or be forced to cease some aspect of our business operations, if, as a result of actual or threatened patent infringement claims, we are unable to enter into licenses on acceptable terms. In addition, during the course of any patent or other intellectual property litigation, there could be public announcements of the results of hearings, rulings on motions and other interim proceedings in the litigation. If securities analysts or investors regard these announcements as negative, the perceived value of our products, programs, or intellectual property could be diminished. Accordingly, the market price of our common stock may decline. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Parties making claims against us may obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize one or more of our products. Defending against claims of patent infringement or misappropriation of trade secrets could be costly and time-consuming, regardless of the outcome. Thus, even if we were to ultimately prevail, or to settle at an early stage, such litigation could burden us with substantial unanticipated costs. In addition, litigation or threatened litigation could result in significant demands on the time and attention of our management team, distracting them from the pursuit of other company business. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys&#39; fees for willful infringement, pay royalties, redesign our infringing products and processes or obtain one or more licenses from third parties, which may be impossible or require substantial time and monetary expenditure. In addition, the uncertainties associated with </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">62</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">litigation could have a material adverse effect on our ability to raise the funds necessary to continue our clinical trials, continue our research programs, license necessary technology from third parties, or enter into development collaborations that would help us bring our products to market. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our products. </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As is the case with other medical device companies, our success is heavily dependent on intellectual property, particularly on obtaining and enforcing patents. Obtaining and enforcing patents in the medical device industry involves both technological and legal complexity, and therefore is costly, time-consuming and inherently uncertain. In addition, the United States has enacted and is currently implementing wide-ranging patent reform legislation. Further, several judicial rulings have either narrowed the scope of patent protection available in certain circumstances or weakened the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Depending on decisions by the U.S. Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Because of the expense and uncertainty of litigation, we may not be in a position to enforce our intellectual property rights against third parties. </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have become aware from time to time that third parties may be infringing on our patents or other intellectual property rights. Because of the expense and uncertainty of litigation, we have concluded in the past and may conclude in the future that even if a third party is infringing our patents or other intellectual property rights, the risk-adjusted cost of bringing and enforcing such a claim or action may be too high or not in the best interest of our company or our stockholders. In such cases, we may decide that the more prudent course of action is to simply monitor the situation or initiate or seek some other non-litigious action or solution. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Intellectual property rights do not address all potential threats to our competitive advantage. </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The degree of future protection afforded by our intellectual property rights is uncertain, because intellectual property rights have limitations and may not adequately protect our business or permit us to maintain our competitive advantage. The following examples are illustrative:</p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">others may be able to make products that are similar to our products but that are not covered by the claims of the patents that we own or license from others; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">others may independently develop similar or alternative technologies or otherwise circumvent any of our technologies without infringing our intellectual property rights; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">we might not have been the first to conceive and reduce to practice the inventions covered by the patents or patent applications that we own, license or will own or license; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">we might not have been the first to file patent applications covering certain subject matter of the patents or patent applications that we own or for which we have obtained a license, or will own or for which we will obtain a license; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">it is possible that our pending patent applications will not result in issued patents; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">issued patents that we own may not provide us with any competitive advantage, or may be held invalid or unenforceable, as a result of legal challenges by our competitors; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">our competitors might conduct research and development activities in countries where we do not have patent rights, or in countries where research and development safe harbor laws exist, and then use </span></td></tr></table></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">63</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"></td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the information learned from such activities to develop competitive products for sale in our major commercial markets;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">ownership of our patents or patent applications may be challenged by third parties; and </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the patents of third parties or pending or future applications of third parties, if issued, may have an adverse effect on our business. </span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Confidentiality agreements with employees and others may not adequately prevent disclosure of trade secrets and protect other proprietary information. </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We consider proprietary trade secrets and/or confidential know-how to be important to our business. We may rely on trade secrets and/or confidential know-how to protect our technology, especially where patent protection is believed by us to be of limited value. However, trade secrets and/or confidential know-how can be difficult to maintain as confidential. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">To protect this type of information against disclosure or appropriation by competitors, our policy is to require our employees, consultants, contractors and advisors to enter into confidentiality agreements with us. However, current or former employees, consultants, contractors and advisors may unintentionally or willfully disclose our confidential information to competitors, and confidentiality agreements may not provide an adequate remedy in the event of unauthorized disclosure of confidential information. Enforcing a claim that a third party obtained illegally and is using trade secrets and/or confidential know-how is expensive, time consuming and unpredictable. The enforceability of confidentiality agreements may vary from jurisdiction to jurisdiction. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Failure to obtain or maintain trade secrets and/or confidential know-how trade protection could adversely affect our competitive position. Moreover, our competitors may independently develop substantially equivalent proprietary information and may even apply for patent protection in respect of the same. If successful in obtaining such patent protection, our competitors could limit our use of our trade secrets and/or confidential know-how. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may need to license certain intellectual property from third parties, and such licenses may not be available or may not be available on commercially reasonable terms. </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A third party may hold intellectual property, including patent rights that are important or necessary to the development or commercialization of any future products. It may be necessary for us to use the patented or proprietary technology of third parties to commercialize our products, in which case we would be required to obtain a license from these third parties. Such a license may not be available on commercially reasonable terms or at all, which could materially harm our business. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties. </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have received, and may receive in the future, confidential and proprietary information from third parties. In addition, we employ, and may employ in the future, individuals who were previously employed at other medical device companies. We may be subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise improperly used or disclosed confidential information of these third parties or our employees&#39; former employers. Further, we may be subject to ownership disputes in the future, arising, for example, from conflicting obligations of consultants or others who are involved in developing our products. We may also be subject to claims that former employees, consultants, independent contractors, collaborators or other third parties have an ownership interest in our patents or other intellectual property. Litigation may be necessary to defend against these and other claims challenging our right to and use of confidential and proprietary information. If we fail in defending any such claims, in addition to paying monetary damages, we may lose our rights therein. Such an outcome could have a material adverse effect on our business. Even if we are successful in defending against these claims, litigation could result in substantial cost and be a distraction to our management and employees. </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">64</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property. </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We may also be subject to claims that former employees, collaborators or other third parties have an ownership interest in our patents or other intellectual property. We may be subject to ownership disputes in the future, arising, for example, from conflicting obligations of consultants or others who are involved in developing our products. Litigation may be necessary to defend against these and other claims challenging inventorship or ownership. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed. </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Because we rely on third parties to assist with research and development and to manufacture our products, we must, at times, share trade secrets with them. We seek to protect our proprietary technology in part by entering into confidentiality agreements and, if applicable, material transfer agreements, consulting agreements or other similar agreements with our advisors, employees, third-party contractors and consultants, prior to beginning research or disclosing proprietary information. These agreements typically limit the rights of the third parties to use or disclose our confidential information, including our trade secrets. Despite the contractual provisions employed when working with third parties, the need to share trade secrets and other confidential information increases the risk that such trade secrets become known by our competitors, are inadvertently incorporated into the technology of others, or are disclosed or used in violation of these agreements. Given that our proprietary position is based, in part, on our know-how and trade secrets, a competitor&#39;s discovery of our trade secrets or other unauthorized use or disclosure would impair our competitive position and may have a material adverse effect on our business. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, these agreements typically restrict the ability of our advisors, employees, third-party contractors and consultants to publish data potentially relating to our trade secrets, although our agreements may contain certain limited publication rights. For example, any academic institution that we may collaborate with in the future will usually expect to be granted rights to publish data arising out of such collaboration, provided that we are notified in advance and given the opportunity to delay publication for a limited time period in order for us to secure patent protection of intellectual property rights arising from the collaboration, in addition to the opportunity to remove confidential or trade secret information from any such publication. In the future, we may also conduct joint research and development programs that may require us to share trade secrets under the terms of our research and development or similar agreements. Despite our efforts to protect our trade secrets, our competitors may discover our trade secrets, either through breach of our agreements with third parties, independent development or publication of information by any of our third-party collaborators. A competitor&#39;s discovery of our trade secrets would impair our competitive position and have an adverse impact on our business. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If our trademarks and trade names are not adequately protected, then we may not be able to build and maintain name recognition in our markets of interest and our business may be adversely affected. </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:14pt 0pt 0pt 0pt;">If our trademarks and trade names are not adequately protected, then we may not be able to build and maintain name recognition in our markets of interest, and our business may be adversely affected. We currently have registered and unregistered trademarks in the United States. Our trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition among potential collaborators or customers in our markets of interest. At times, competitors may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. Further, there could be potential trade name or trademark infringement claims brought by owners of other trademarks or trade names that incorporate variations of our trademarks or trade names. In addition, we have not registered our trademarks internationally, and the laws of certain foreign countries may not protect proprietary rights to the same extent as do the laws of the United States. Over the long term, if we </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">65</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:14pt;text-align:justify;margin:0pt;">are unable to successfully register our trademarks and trade names and/or establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively and our business may be adversely affected. Our efforts to enforce or protect our proprietary rights related to trademarks, trade secrets, domain names, copyrights or other intellectual property may be ineffective and could result in substantial costs and diversion of resources and could adversely impact our financial condition or results of operations.</p><a id="_0e319d6e_9069_49a6_90ea_190ddf8ca88b"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 12pt 0pt;"> <b style="font-weight:bold;">Risks Related to Ownership of Our Common Stock </b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The trading price of the shares of our common stock has been and could continue to be highly volatile, and purchasers of our common stock may not be able to resell their shares of our common stock at or above the price at which they purchased their shares and could incur substantial losses. </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our stock price has been and is likely to continue to be volatile. The stock market in general has experienced extreme volatility that has often been unrelated to the operating performance of particular companies. As a result of this volatility, investors may not be able to sell their shares of our common stock at or above the price at which they purchased their shares. The market price for our common stock may be influenced by many factors, including:</p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the passage of legislation or other regulatory developments in the United States or foreign countries; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">actual or anticipated variations in our financial results or those of companies that are perceived to be similar to us; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in the structure of healthcare payment systems, especially in light of current or proposed reforms to the U.S. healthcare system; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to develop and commercialize additional products; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">announcements by us or our competitors of significant acquisitions, strategic collaborations, joint ventures or capital commitments; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">market conditions in medical device sectors and issuance of securities analysts&#39; research reports or recommendations; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">sales of our stock by us, our insiders and our other stockholders; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the trading volume of our common stock; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">speculation in the press or investment community; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">general economic, industry and market conditions, or other events or factors, many of which are beyond our control; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">additions or departures of key personnel; and </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">intellectual property, product liability or other litigation against us. </span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, the stock market has recently experienced significant volatility with respect to medical device and other life sciences company stocks. The volatility of medical device and other medical technology company stocks often does not relate to the operating performance of the companies represented by the stock. As we operate in a single industry, we are especially vulnerable to these factors to the extent that they affect our industry or our products, or to a lesser extent our markets.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="background:#ffffff;">Following periods of volatility in the market price of a company&#8217;s securities, securities class action litigation has often been instituted against that company, as has been the case with us. Such litigation can result in substantial costs and diversion of management attention and resources, which could significantly harm </span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">66</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">our profitability and reputation and could expose us to liability or impact negatively our business, financial condition, operating results, and prospects.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Anti-takeover provisions in our charter documents and under Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management. </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Provisions in our amended and restated certificate of incorporation and amended and restated bylaws, as well as provisions of Delaware law, may delay or prevent an acquisition of us or a change in our management. These provisions include:</p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">authorizing the issuance of &quot;blank check&quot; preferred stock, the terms of which may be established and shares of which may be issued without stockholder approval; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">limiting the removal of directors by the stockholders; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">prohibiting cumulative voting in the election of directors, which would otherwise allow for less than a majority of stockholders to elect director candidates; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">prohibiting stockholder action by written consent, thereby requiring all stockholder actions to be taken at a meeting of our stockholders; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">eliminating the ability of stockholders to call a special meeting of stockholders; and </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">establishing advance notice and compliance requirements for nominations for election to the board of directors, for soliciting proxies in support of nominations or for proposing matters that can be acted upon at stockholder meetings. </span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">These provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors, who are responsible for appointing the members of our management. In addition, because we are incorporated in Delaware, we are governed by the provisions of Section&#160;203 of the Delaware General Corporation Law, which limits the ability of stockholders owning in excess of 15% of our outstanding voting stock to merge or combine with us. These provisions would apply even if an offer rejected by our board were considered beneficial by some stockholders. Any provision of our amended and restated certificate of incorporation or our amended and restated bylaws or Delaware law that has the effect of delaying or deterring a change of control could limit the opportunity for our stockholders to receive a premium for their shares of our common stock, and could also affect the price that some investors are willing to pay for our common stock. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If securities or industry analysts do not publish research, or publish inaccurate or unfavorable research, about our business, the price of our common stock and our trading volume could decline. </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The trading market for our common stock depends in part on the research and reports that securities or industry analysts publish about us or our business. If too few securities or industry analysts commence or maintain coverage of our company, the trading price for our common stock would likely be negatively affected. If one or more of the analysts who cover us downgrade our common stock or publish inaccurate or unfavorable research about our business, the price of our common stock would likely decline. If one or more of these analysts cease coverage of our company or fail to publish reports on us regularly, demand for our common stock could decrease, which might cause the price of our shares and trading volume to decline. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Claims for indemnification by our directors and officers may reduce our available funds to satisfy successful third-party claims against us and may reduce the amount of money available to us. </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our amended and restated certificate of incorporation and amended and restated bylaws provide that we will indemnify our directors and officers, in each case to the fullest extent permitted by Delaware law. </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">67</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;margin:0pt;">In addition, as permitted by Section&#160;145 of the Delaware General Corporation Law, our amended and restated bylaws and our indemnification agreements with our directors and officers provide that we will indemnify our directors and officers for serving us in those capacities or for serving other business enterprises at our request, to the fullest extent permitted by Delaware law; Delaware law provides that a corporation may indemnify such person if such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to the best interests of the corporation and, with respect to any criminal proceeding, had no reasonable cause to believe such person&#39;s conduct was unlawful and that we are required to advance expenses, as incurred, to our directors and officers in connection with defending a proceeding, except that such directors or officers shall undertake to repay such advances if it is ultimately determined that such person is not entitled to indemnification.</p><a id="_0aa1a87f_257b_4b0f_bcb6_ab33f12c708b"></a><a id="Item1BUnresolvedStaffComments_540074"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Item 1B. &#160;Unresolved Staff Comments.</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">None</p><a id="_45266c85_16f6_4c29_8a6e_07b2d5f98c15"></a><a id="Item2Properties_393200"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item 2. &#160;Properties.</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We currently lease approximately 150,000 square feet of office space for our corporate headquarters in Minneapolis, Minnesota. The initial lease for this space of approximately 80,000 square feet commenced in September 2019 and had an initial expiration date in February 2030. Subsequently, we entered into amendments to our initial lease to include an additional approximately 70,000 square feet of office space and to extend the expiration date of the entire leased space to February 2031. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We also lease approximately 63,000 square feet of office, assembly and warehouse space at another facility in Minneapolis, Minnesota, that has an expiration date in March 2027. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;margin:0pt;">We believe that these facilities are adequate to meet our business requirements for the near term and that additional space will be available on commercially reasonable terms, if required.</p><a id="_744a4d56_b643_4977_9259_2c02a44a2ab1"></a><a id="Item3LegalProceedings_92048"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item 3. &#160;Legal Proceedings.</b></p><a id="_Hlk64882577"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;margin:0pt;">Information pertaining to certain legal proceedings in which we are involved can be found in Note 12 &#8211; &#8220;Commitments and Contingencies&#8221; to our consolidated financial statements included in Part II, Item 8 of this report and is incorporated herein by reference.</p><a id="_1b435e2a_b445_4862_b348_1065a769004f"></a><a id="Item4MineSafetyDisclosures_923755"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item 4. Mine Safety Disclosures.</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Not Applicable.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">68</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_73f41c6b_02f4_4758_8994_40f73d9584cc"></a><a id="PARTII_338450"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:center;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">PART II</b></p><a id="_4d69a469_7856_4005_88ca_c3e6eb84152e"></a><a id="Item5MarketForRegistrantsCommonEquityRel"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item 5. &#160;Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Market Information</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our common stock has been listed on The Nasdaq Stock Market LLC under the symbol &quot;TCMD&quot; since July&#160;28, 2016.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Holders</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of February 17, 2023, there were approximately 31 holders of record of our common stock. The actual number of holders of common stock is greater than this number of record holders and includes stockholders who are beneficial owners but whose shares are held in street name by brokers and nominees. The number of holders of record also does not include stockholders whose shares may be held in trust by other entities. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Recent Sales of Unregistered Securities</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">None.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Issuer Purchases of Equity Securities</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">None.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Equity Compensation Plan Information</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The information required by this Item concerning equity compensation plans is incorporated herein by reference from Part III, Item&#160;12 of this report.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">69</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:258.75pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Stock Performance Graph</b> </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The graph below compares the cumulative total stockholder return on our common stock with the cumulative total stockholder returns on the Nasdaq Composite Index, Russell 2000 Index and S&amp;P Healthcare Equipment Select Industry Index for the periods indicated. The graph assumes that $100 was invested on December 31, 2017, in our common stock and each of the indices and that all dividends, if any, were reinvested. No cash dividends have been declared on our common stock. Stockholder returns over the indicated periods should not be considered indicative of future stockholder returns.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;text-align:center;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><img src="tcmd-20221231x10k008.jpg" alt="Graphic" style="display:inline-block;height:258.75pt;width:364.52pt;" /></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-5.038124%;padding-left:0pt;padding-right:0pt;width:110.07%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:40.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:40.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Index</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">12/31/2017</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">12/31/2018</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">12/31/2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">12/31/2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">12/31/2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">12/31/2022</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:40.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Tactile Systems Technology, Inc.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 100</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 157</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 233</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 155</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 66</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 40</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:40.78%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Nasdaq Composite Index</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 100</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 96</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 130</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 187</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 227</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 152</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:40.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Russell 2000 Index</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 100</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 88</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 109</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 129</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 146</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 115</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:40.78%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">S&amp;P Healthcare Equipment Select Industry Index</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 100</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 109</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 134</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 178</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 184</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 140</span></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;font-weight:bold;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin:14pt 0pt 0pt 0pt;"><span style="font-size:1pt;font-weight:bold;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:14pt 0pt 0pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">70</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_cf31115e_b0a8_498d_90e6_81646c204cb0"></a><a id="Item6SelectedFinancialData_879996"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item 6. &#160;[Reserved</b><b style="font-weight:bold;">.]</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 0pt 18pt;"><span style="font-size:1pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><a id="_7ce6c630_6a99_43cc_b4e6_eba66e4ed0ee"></a><a id="Item7ManagementsDiscussionandAnalyisofFi"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Item 7. &#160;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</b><b style="font-weight:bold;">.</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our consolidated financial statements and the accompanying notes thereto included elsewhere in this report.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">This Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations focuses on discussion of year-over-year comparisons between 2022 and 2021. Discussion of 2020 results and year-over-year comparisons between 2021 and 2020 that are not included in this Annual Report on Form 10-K can be found in &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; in Part II, Item 7 of our Annual Report on Form 10-K for the year ended December 31, 2021, filed with the SEC on February 23, 2022.</p><a id="_16d74b54_29cb_435d_a7d2_a3312625b69e"></a><a id="_Hlk63440248"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:14pt;padding-top:2pt;text-align:justify;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Coronavirus (COVID-19)</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:14pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">The United States economy in general and our business specifically have been negatively affected by the COVID-19 pandemic. We have seen adverse impacts as it relates to the decline in the number of patients that healthcare facilities and clinics are able to treat due to enhanced safety protocols, particularly during most of 2021 and during the first quarter of 2022.&#160;We have also seen staffing challenges, both in our organization and at the clinics we serve, as another lingering consequence of the COVID-19 pandemic. While we saw some level of recovery in 2022 after the first quarter, ongoing consequences of the pandemic remain uncertain. There are no reliable estimates of how long the pandemic will last, whether any recovery will be sustained or will reverse course, the severity of any resurgence of COVID-19 or variant strains of the virus, the effectiveness of vaccines and attitudes towards receiving them, or what ultimate effects the pandemic will have. For that reason, we are unable to reasonably estimate the long-term impact of the pandemic on our business at this time. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:14pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">Since the onset of COVID-19, we have remained proactive to ensure we continue to adapt to the needs of our employees, clinicians and patients. However, we cannot assure you these changes to our processes and practices will be successful in mitigating the impact of COVID-19 on our business. We continue to evaluate and, if appropriate, will adopt other measures in the future related to the ongoing safety of our employees, clinicians and patients.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Overview</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;margin:0pt;">We are a medical technology company that develops and provides innovative medical devices for the treatment of underserved chronic diseases. Our mission is to help people suffering from chronic diseases live better and care for themselves at home. We focus our efforts on advancing the standard of care in treating underserved chronic diseases in the home setting to improve patient outcomes and quality of life and help control rising healthcare expenditures. Our areas of therapeutic focus are (1) vascular disease, with a goal of advancing the standard of care in treating lymphedema and chronic venous insufficiency, (2) oncology, where lymphedema is a common consequence among cancer survivors and (3) providing airway clearance therapy for those suffering from chronic respiratory conditions. We possess a unique, scalable platform to deliver at-home healthcare solutions throughout the United States. This evolving home care delivery model is recognized by policymakers and insurance payers as a key for controlling rising healthcare costs. Our solutions deliver cost-effective, clinically proven, long-term treatment for people with these chronic diseases.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">Our current lymphedema products are the Flexitouch and Entre systems and our airway clearance product is the AffloVest. A predecessor to our Flexitouch system received 510(k) clearance from the U.S. Food and Drug Administration (the &#8220;FDA&#8221;) in July 2002, and we introduced the system to address the many limitations of self-administered home-based manual lymphatic drainage therapy. We began selling our more advanced Flexitouch system after receiving 510(k) clearance from the FDA in October 2006. In September 2016, we received 510(k) clearance from the FDA for the Flexitouch system in treating lymphedema of the head and neck. In June 2017, we announced that we received 510(k) clearance from the FDA for the Flexitouch Plus, the third-generation version of our Flexitouch system. In December 2020, we received 510(k) clearance for two </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">71</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;">new indications for our Flexitouch Plus system: phlebolymphedema and lipedema. We introduced our Entre system in the United States in February 2013. The Entre system is sold or rented to patients who need a simple pump or who do not yet qualify for insurance reimbursement for an advanced compression device such as our Flexitouch system. Sales and rentals of our lymphedema products represented 86% and 98% of our revenue in the years ended December 31, 2022 and 2021, respectively. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">On September 8, 2021, we acquired the assets of the AffloVest airway clearance product line from IBC, a privately-held company which developed and manufactured AffloVest. AffloVest is a portable, wearable vest that provides airway clearance to&#160;treat patients with chronic respiratory conditions such as bronchiectasis or conditions resulting from neuromuscular disorders. For the years ended December 31, 2022 and 2021, sales of AffloVest represented 14% and 2% of our revenue, respectively.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;margin:0pt;">To support the growth of our business, we continue to invest in our commercial infrastructure, consisting of our direct sales force, training resources, reimbursement capabilities and clinical expertise. We market our lymphedema products in the United States using a direct-to-patient and -provider model. The AffloVest device is sold through respiratory durable medical equipment providers throughout the United States that service patients and bill third-party payers for the product. We also employ a small group of respiratory specialists, who educate DME representatives, provide product demonstrations for targeted clinicians and support technical questions related to the AffloVest. As of December 31, 2022, we employed a field staff of 287 Tactile employees, made up of sales representatives, as well as managers, who provide support throughout the United States for our lymphedema and respiratory therapies. This compares to a field staff of 262 as of December 31, 2021.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">We invest in our reimbursement function to improve operational efficiencies and enhance individual payer expertise, while continuing our strategic focus of payer development. Our payer relations function focuses on payer policy development, education, contract negotiations, and data analysis. Our reimbursement operations function is responsible for verifying patient insurance benefits, individual patient case development, prior authorization submissions, case follow-up, and appeals when necessary. Since the onset of COVID-19, our reimbursement function has been actively working with Medicare and a broad base of private payers to understand the ever-changing reimbursement criteria being introduced. While the U.S. government&#8217;s declaration of a public health emergency (PHE) related to the COVID-19 pandemic has relaxed some Medicare criteria for respiratory patients, these circumstances are ever-changing, and the extent to which these changes will remain in place and the impact on our business in the future are not determinable at this time.</p><a id="_Hlk69461730"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;margin:0pt;">We also have a clinical team, consisting of a scientific advisory board, in-house therapists and nurses, and a Chief Medical Officer, that serves as a resource to clinicians and patients and guides the development of clinical evidence in support of our products. Most clinical studies require observation and interaction with clinicians and patients to monitor results and progress. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">We rely on third-party contract manufacturers for the sourcing of parts, the assembly of our controllers and the manufacturing of the garments used with our systems. We conduct final assembly of the garments used with our products, perform quality assurance and ship our products from our facility in Minnesota. The AffloVest device continued to be manufactured and shipped by IBC on our behalf pursuant to a Transition Services Agreement through April 30, 2022. On May 1,<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"> </sup>2022, we began manufacturing and shipping the AffloVest device from our Minnesota-based facility.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">To date, our supply chain has not been materially impacted by COVID-19. We continue to receive our product on time and believe that we have enough safety stock to meet our short and mid-term demand. However, we cannot assure you that our supply chain will not be materially impacted in the future or that we will be able to meet any increased demand.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">In July 2022, we launched Kylee&#8482;, a free mobile application that allows for patients to manage their conditions by tracking treatments and symptoms, as well as having direct access to educational resources.&#160;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;"><span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">For the year ended December 31, 2022, we generated revenue of $246.8 million and had a net loss of $17.9 million, compared to revenue of $208.1&#160;million and a net loss of $11.8&#160;million for the year ended </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">72</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">December 31, 2021, and revenue of $187.1&#160;million and a net loss of $0.6&#160;million for the year ended December&#160;31, 2020. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our primary sources of capital since our initial public offering in 2016 have been from operating income and bank financing.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We operate in one segment for financial reporting purposes.</p><a id="_e7e6c98d_7816_497c_b2a6_8eccf9acd9aa"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:10pt;text-align:justify;text-indent:-10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Components of our Results of Operations </b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:10pt;text-align:justify;text-indent:-10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Revenue</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 11pt 0pt;">We derive revenue from sales and rentals of our Flexitouch and Entre systems to patients in the United States. Revenue growth has been driven by increased clinician, patient and payer awareness of lymphedema and the clinical efficacy of our Flexitouch system, and the launch of our Entre system in 2013. We have expanded our direct sales force, which helps us drive and support our revenue growth and intend to continue this expansion. However, any reversal in these recent trends could have a negative impact on our future revenue.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:11pt;text-align:justify;text-indent:36pt;margin:0pt;">We sell or rent our Flexitouch and Entre systems either directly to patients or to the Veterans Administration on behalf of patients, who are referred to us by physicians, therapists or nurses. We bill payers, such as private insurers, Medicare, or Medicaid, on behalf of our patients and bill patients directly for their cost-sharing amounts, including any portion of an unsatisfied deductible and any copayments or co-insurance. We bill the Veterans Administration directly for the purchase or lease of our product on behalf of the patient. Approximately 10% of our revenue in 2022 and 13% of our revenue in 2021 came from the Veterans Administration. Approximately 19% of our revenue in 2022 and 17% of our revenue in 2021 came from Medicare patients. Changes to the level of Medicare coverage for our products could reduce the number of Medicare patients who have access to our products. Our products currently are not subject to the competitive bidding process for supplying covered items to Medicare recipients.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt 0pt 11pt 0pt;">We derive revenue from sales of our AffloVest product to accredited DME providers. These respiratory DME providers provide a full range of solutions for these patients with complex diseases, and represent a large, developed channel. Respiratory DME partners serve the role of receiving prescriptions, verifying coverage criteria, shipping, billing and training the patient. We intend to expand and support our respiratory DME partners, in an effort to help demonstrate HFCWO as a staple among the host of treatments they bring to chronic respiratory patients, thereby allowing us to continue to grow revenue from this product offering.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our revenue has fluctuated, and we expect our revenue to continue to fluctuate, from quarter to quarter due to a variety of factors, including seasonality. See Item 7. &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations &#8211; Seasonality&#8221; for a further discussion of factors contributing to our seasonality. Further, our revenue is impacted by fluctuations in the mix of products being sold and rented during each period and changes in the mix of our payers and contract pricing.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Furthermore, we expect our revenue to continue to increase in the future as a result of increased awareness of our solutions, expansion of our direct sales force, our DME partners, enhanced marketing and customer support efforts, continued focus on developing clinical and economic outcomes data, and efforts related to expanded third-party reimbursement. However, we also anticipate pricing pressure from private insurers, which will result in continued downward pressure on our revenue growth rate.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:10pt;text-align:justify;text-indent:-10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Cost of Revenue and Gross Margin </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Cost of revenue consists primarily of component costs, direct labor, overhead costs, product warranties, provisions for slow-moving and obsolete inventory, delivery costs for items sold or rented, and amortization related to the intangible assets related to our products. Overhead costs include the cost of quality assurance, material procurement, inventory control, facilities, equipment and operations supervision and management. Cost of revenue also includes depreciation expense for product tooling and equipment as well as shipping costs. We expect overhead costs as a percentage of revenue to decrease as a result of expected </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">73</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">increases in production volume and yields. We expect cost of revenue to increase in absolute dollars primarily if, and to the extent, our revenue grows. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We provide a warranty for our products against defects in material and workmanship for a period of one to five years. We record a liability for future warranty claims at the time of sale for the warranty period offered to a customer in cost of revenue. If the assumptions used in calculating the provision were to materially change, such as incurring higher than anticipated warranty claims, an additional provision may be required.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We calculate gross margin as gross profit divided by revenue. Our gross margin has been and will continue to be affected by a variety of factors, including product and payer mix, production volumes, manufacturing costs and cost-reduction strategies. We continue to work to reduce product manufacturing costs through enhanced product design efforts as well as supply chain initiatives in an effort to offset anticipated price erosion. Our gross margin will likely fluctuate from quarter to quarter. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:10pt;text-align:justify;text-indent:-10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Sales and Marketing Expenses </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our sales and marketing expenses consist primarily of personnel-related expenses, including salaries, bonuses, commissions and benefits for employees. They also include expenses for patient training, social media and advertising, informational kits, public relations and other promotional and marketing activities, field sales travel and entertainment expenses, trade shows and conferences, stock-based compensation, as well as customer service. We expect sales and marketing expenses to continue to increase in absolute dollars as we expand our commercial infrastructure to drive and support our planned revenue growth. To the extent our revenue grows, we expect sales and marketing expenses to decrease as a percentage of revenue over time. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:10pt;text-align:justify;text-indent:-10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Research and Development Expenses </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Research and development, or R&amp;D, expenses consist primarily of personnel-related expenses, third-party product development costs, laboratory supplies, consulting fees and related costs, clinical research expenses, expenses related to clinical and regulatory affairs, patent amortization costs, stock-based compensation and patent legal fees, including defense costs, and testing costs for new product launches. Clinical research expenses include clinical trial management and monitoring, payment to clinical investigators, consulting fees, data management, stock-based compensation, travel expenses and the cost of manufacturing products for clinical trials. We have made substantial investments in R&amp;D since our inception. Our R&amp;D efforts have focused primarily on activities designed to enhance our technologies and to support development and commercialization of new and existing products. We expect R&amp;D expenses to increase for the foreseeable future as we continue to develop, enhance and commercialize new products and expand clinical trial efforts. We expect R&amp;D expenses as a percentage of our revenue to vary over time depending on the level and timing of initiating new product development efforts, as well as our clinical trial activities.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Intangible Asset Amortization and Earn-Out</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"></span><span style="font-size:10pt;">Amortization of intangible assets includes the amortization expense of our definite-lived intangible assets, consisting of patents, customer relationships, customer accounts, developed technology and defensive intangible assets. The costs of definite-lived intangibles are amortized to expense over their useful lives. Indefinite-lived intangible assets, such as goodwill and tradenames, are not amortized; we test for impairment on these assets annually. </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The fair value of the earn-out, which is payable if certain future U.S. revenues of AffloVest are met, is recorded as a liability. On a quarterly basis the earn-out is revalued to fair value. Any gain or loss related to this revaluation is recorded through the income statement.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:10pt;text-align:justify;text-indent:-10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Reimbursement, General and Administrative Expenses </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Reimbursement, general and administrative expenses consist primarily of compensation, including salaries, bonuses and benefits for employees in our patient services and advocacy, billing and collections, case management, payer relations and governmental affairs and reimbursement operations departments, as well as finance, human resources and administration, information technology, business development and general </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">74</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">management functions, and facilities costs. Reimbursement expenses also include consulting, travel to payer case manager seminars, professional development and training, and certification expenses. General and administrative expenses also include professional services such as legal, consulting and accounting services, stock-based compensation, travel expenses, insurance and acquisition costs.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:10pt;text-align:justify;text-indent:-10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Other Income (Expense), Net </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Other income (expense), net consists primarily of interest income related to investment income earned on our invested capital portfolio and interest expense related to our debt obligations.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:10pt;text-align:justify;text-indent:-10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Income Tax Expense (Benefit)</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:14pt 0pt 0pt 0pt;">Our income tax expense (benefit) consists primarily of permanent differences related to share-based compensation activity, as well as deferred income taxes resulting from temporary differences between the reporting of amounts for financial statement purposes and income tax purposes.</p><a id="_8ec4ba8d_7a49_45e2_aa59_90ae3b52ce9c"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:14pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Critical Accounting Estimates </b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our discussion and analysis of our financial condition and results of operations are based upon our financial statements, which have been prepared in accordance with generally accepted accounting principles in the United States, or GAAP. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets and liabilities, and related disclosure of contingent assets and liabilities, revenue and expenses at the date of the financial statements. Generally, we base our estimates on historical experience and on various other assumptions in accordance with GAAP that we believe to be reasonable under the circumstances. Actual results may differ from these estimates and such differences could be material to our financial position and results of operations. Critical accounting estimates are those that involve a significant level of estimation uncertainty and have had or are reasonably likely to have a material impact on our financial condition and results of operations.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">While our significant accounting policies are more fully described in Note&#160;3 to our consolidated financial statements included elsewhere in this report, we believe the following discussion addresses our most critical accounting estimates, which involve significant subjectivity and judgment, and changes to such estimates or assumptions could have a material impact on our financial condition or operating results. Therefore, we consider an understanding of the variability and judgment required in making these estimates and assumptions to be critical in fully understanding and evaluating our reported financial results. </p><a id="_c8924416_f8d4_418f_b9b5_03a1b8cfb735"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:10pt;text-align:justify;text-indent:-10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Revenue Recognition</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:14pt 0pt 0pt 0pt;">We derive revenue from the sales and rentals of our proprietary line of Flexitouch and Entre systems, and from sales of our AffloVest product. We recognize revenue when control of the product has been transferred to our customer, in the amount of the expected consideration to be received for the product. Expected consideration is estimated as follows:</p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:0pt;margin-top:14pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:normal;">Flexitouch and Entre systems. </i><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"> Expected consideration to be received is estimated based on a detailed review of historical pricing adjustments and collections. Specifically, payment history of the applicable payer, as well as historical patient collections, serve as primary sources of information in estimating expected consideration.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:14pt 0pt 0pt 0pt;">We update our assessment of collectability on a quarterly basis, with any adjustments for Flexitouch and Entre systems being reflected as sales and rental revenue and AffloVest products being reflected as bad debt expense within reimbursement, general and administrative expenses in the Consolidated Statements of Operations in the period of adjustment.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:14pt 0pt 0pt 0pt;">If in the future we determine that another method is more reasonable, or if another method for calculating these input assumptions is prescribed by authoritative guidance, the expected consideration associated with the sales and rentals of our products could change significantly. Changes in contractual pricing, </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">75</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;">payment trends and rebate structures would impact, either positively or negatively, our sales and rental revenue.</p><a id="_d6864565_eeb3_4fa7_868d_6c669062dd8f"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:10pt;text-align:justify;text-indent:-10pt;margin:14pt 0pt 12pt 0pt;"><i style="font-style:italic;">Stock-Based Compensation </i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The fair value of stock options is estimated at the date of grant, using the Black-Scholes option-pricing model, except for the valuation of certain &#8220;CEO&#8221; related stock options subject to a market condition which uses the Monte Carlo Simulation model. We recognize the fair value of each award as an expense on a straight-line basis over the requisite service period, which is generally the vesting period of the equity grant. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Monte Carlo Simulation and Black-Scholes valuation models require the input of highly subjective assumptions, including the expected term of the option, the expected volatility of the price of our common stock, the risk-free interest rate and the expected dividend yield. These estimates involve inherent uncertainties and the significant application of management&#39;s judgment. If factors change and different assumptions are used, our stock-based compensation expense could be materially different in the future. We determined weighted-average valuation assumptions as follows:</p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23.05pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:normal;">Expected term</i><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">.&#160;&#160;&#160;&#160;We use the &quot;simplified method&quot; to determine the expected term of the stock option. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:normal;">Expected volatility</i><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">.&#160;&#160;&#160;&#160;Expected volatility for grants issued in and prior to the first fiscal quarter of 2021 was estimated using the average historical volatility of public companies of similar size and industry over a similar period as the expected term assumption used for our options. Beginning in the second fiscal quarter of 2021, we had sufficient historical data to transition to utilizing our average historical volatility over a similar period as the expected term assumption used for our options as the expected volatility. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:normal;">Risk-free interest rate</i><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">.&#160;&#160;&#160;&#160;The risk-free interest rate is based on the yields of U.S. Treasury securities with maturities similar to the expected term of the options for each option group. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:normal;">Expected dividend yield</i><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">.&#160;&#160;&#160;&#160;We have never declared or paid any cash dividends on our common stock and do not presently plan to pay cash dividends on our common stock in the foreseeable future. Consequently, we use an expected dividend yield of zero. </span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If in the future we determine that another method is more reasonable, or if another method for calculating these input assumptions is prescribed by authoritative guidance, the fair value calculated for our stock options could change significantly. Higher volatility and longer expected lives would result in an increase to stock-based compensation expense determined at the date of grant. Stock-based compensation expense affects our cost of revenue, sales and marketing expenses, research and development expenses, and reimbursement, general and administrative expenses. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:14pt;text-align:justify;text-indent:36pt;margin:14pt 0pt 0pt 0pt;">We estimate our forfeiture rate based on an analysis of our actual forfeitures and will continue to evaluate the appropriateness of the forfeiture rate based on actual forfeiture experience, analysis of employee turnover behavior and other factors. Quarterly changes in the estimated forfeiture rate can have a significant effect on reported stock-based compensation expense, as the cumulative effect of adjusting the rate for all expense amortization is recognized in the period the forfeiture estimate is changed. If a revised forfeiture rate is higher than the previously estimated forfeiture rate, an adjustment is made that will result in a decrease to the stock-based compensation expense recognized in the consolidated financial statements. If a revised forfeiture rate is lower than the previously estimated forfeiture rate, an adjustment is made that will result in an increase to the stock-based compensation expense recognized in the consolidated financial statements. The effect of forfeiture adjustments was insignificant for the years ended December&#160;31, 2022, 2021 and 2020. We will continue to use significant judgment in evaluating the expected term, volatility and forfeiture rate related to our stock-based compensation. </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">76</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_25fb5546_0eac_4cf8_a6ee_aa947223d077"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Results of Operations</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Comparison of the Years Ended December 31, 2022 and 2021</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">The following table presents our results of operations for the periods indicated:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.07212067%;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:37.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:8.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:4.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:2.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:8.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:4.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:2.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:8.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:5.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:37.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:normal;width:39.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:37.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:normal;width:39.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31,</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:normal;width:19.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Change</b></p></td></tr><tr><td style="vertical-align:bottom;width:37.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">(In&#160;thousands)</p></td><td style="vertical-align:bottom;white-space:normal;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:normal;width:19.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:normal;width:19.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:10.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">%</b></p></td></tr><tr><td style="vertical-align:bottom;width:37.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Consolidated Statement</p></td><td style="vertical-align:bottom;white-space:normal;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:7.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">%&#160;of</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:7.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">%&#160;of</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:37.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">of Operations Data:</p></td><td style="vertical-align:bottom;white-space:normal;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:7.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">revenue</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">revenue</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:37.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Revenue</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:37.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Sales revenue</p></td><td style="vertical-align:bottom;white-space:normal;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:8.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 211,345</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 86</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:8.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 177,914</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 86</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 33,431</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 19</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:37.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Rental revenue</p></td><td style="vertical-align:bottom;white-space:normal;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 35,440</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 14</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 30,143</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 14</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 5,297</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 18</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:37.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Total revenue</p></td><td style="vertical-align:bottom;white-space:normal;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 246,785</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 100</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 208,057</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 100</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 38,728</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 19</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:37.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Cost of revenue</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:37.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Cost of sales revenue</p></td><td style="vertical-align:bottom;white-space:normal;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 59,619</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 24</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 50,222</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 24</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 9,397</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 19</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:37.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Cost of rental revenue</p></td><td style="vertical-align:bottom;white-space:normal;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 11,190</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 5</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 9,622</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 5</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,568</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 16</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:37.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Total cost of revenue</p></td><td style="vertical-align:bottom;white-space:normal;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 70,809</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 29</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 59,844</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 29</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 10,965</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 18</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:37.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Gross profit</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:37.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Gross profit - sales revenue</p></td><td style="vertical-align:bottom;white-space:normal;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 151,726</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 61</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 127,692</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 62</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 24,034</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 19</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:37.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Gross profit - rental revenue</p></td><td style="vertical-align:bottom;white-space:normal;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 24,250</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 10</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 20,521</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 9</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3,729</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 18</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:37.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Gross profit</p></td><td style="vertical-align:bottom;white-space:normal;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 175,976</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 71</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 148,213</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 71</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 27,763</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 19</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:37.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Operating expenses</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:37.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Sales and marketing </p></td><td style="vertical-align:bottom;white-space:normal;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 106,418</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 43</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 86,775</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 42</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 19,643</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 23</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:37.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:normal;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 7,088</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 5,659</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,429</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 25</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:37.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Reimbursement, general and administrative</p></td><td style="vertical-align:bottom;white-space:normal;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 60,796</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 25</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 56,802</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 27</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3,994</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 7</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:37.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Intangible asset amortization and earn-out</p></td><td style="vertical-align:bottom;white-space:normal;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 14,432</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 5</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 739</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 13,693</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">N.M.</p></td><td style="vertical-align:bottom;white-space:normal;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:37.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Total operating expenses</p></td><td style="vertical-align:bottom;white-space:normal;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 188,734</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 76</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 149,975</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 72</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 38,759</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 26</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:37.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Loss from operations</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (12,758)</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (5)</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (1,762)</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (1)</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (10,996)</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">N.M.</p></td><td style="vertical-align:bottom;white-space:normal;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:37.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Other expense</p></td><td style="vertical-align:bottom;white-space:normal;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (2,715)</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (1)</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (531)</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (2,184)</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">N.M.</p></td><td style="vertical-align:bottom;white-space:normal;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:37.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Loss before income taxes</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (15,473)</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (6)</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (2,293)</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (1)</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (13,180)</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">N.M.</p></td><td style="vertical-align:bottom;white-space:normal;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:37.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Income tax expense</p></td><td style="vertical-align:bottom;white-space:normal;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,393</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 9,518</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 5</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (7,125)</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (75)</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:37.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net loss</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:8.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (17,866)</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (7)</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:8.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (11,811)</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (5)</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:8.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (6,055)</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 51</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><span style="background:#ffffff;">&#8220;N.M.&#8221; Not Meaningful</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:10pt;text-align:justify;text-indent:-10pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Revenue</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Revenue increased $38.7 million, or 19%, to $246.8 million in the year ended December&#160;31,&#160;2022, compared to $208.1 million in the year ended December&#160;31,&#160;2021. The increase in revenue was attributable to an increase of approximately $29.4 million in sales of our airway clearance product line, which consists of the AffloVest product we acquired on September 8, 2021, and an increase of $9.4 million, or 5%, in sales and rentals of the lymphedema product line compared to the year ended December 31, 2021. While we saw some level of recovery in 2022 after the first quarter, revenue in 2022 from the lymphedema product line was adversely affected by the fact that first quarter 2022 revenue was negatively impacted by the prolonged recovery from COVID-19, including the resurgence due to the Omicron variant during that period, which resulted in restricted access to clinics and hospitals and disrupted the recovery in patient visits versus the pre-COVID environment. In addition, the challenging labor market continued to impact our ability to recruit and retain quality candidates for our direct sales force, particularly during the first quarter of 2022.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Revenue from the Veterans Administration represented 10% and 12% of total revenue for the years ended December 31, 2022 and 2021, respectively. Revenue from Medicare represented 19% and 17% of total revenue for the years ended December 31, 2022 and 2021, respectively. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="color:#ff0000;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">77</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">The following table summarizes our revenue by product for the years ended December&#160;31,&#160;2022 and 2021, both in dollars and percentage of total revenue: </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100.76%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:33.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:33.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:33.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:27.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Change</b></p></td></tr><tr><td style="vertical-align:bottom;width:33.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">(In&#160;thousands)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">%</b></p></td></tr><tr><td style="vertical-align:bottom;width:33.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Revenue</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:33.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Lymphedema products</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 212,266</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 202,913</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 9,353</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5%</p></td></tr><tr><td style="vertical-align:bottom;width:33.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Airway clearance products</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 34,519</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 5,144</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 29,375</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">N.M.</p></td></tr><tr><td style="vertical-align:bottom;width:33.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 246,785</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 208,057</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 38,728</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">19%</p></td></tr><tr><td style="vertical-align:bottom;width:33.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:33.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Percentage of total revenue</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:33.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Lymphedema products</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">86%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">98%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:33.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Airway clearance products</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">14%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:33.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">100%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">100%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;padding-left:10.1pt;text-align:justify;text-indent:-10.1pt;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Cost of Revenue and Gross Margin</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">Cost of revenue increased $11.0 million, or 18%, to $70.8 million during the year ended December 31, 2022, compared to $59.8 million during the year ended December 31, 2021. The increase in cost of revenue was primarily attributable to the additional cost of revenue related to AffloVest.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">Gross margin was 71% for both of the years ended December 31, 2022 and 2021. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;padding-left:10pt;text-align:justify;text-indent:-10pt;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Sales and Marketing Expenses</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-top:2pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">Sales and marketing expenses increased $19.6 million, or 23%, to $106.4 million during the year ended December 31, 2022, compared to $86.8 million during the year ended December 31, 2021. The increase was primarily attributable to a:</p><div style="margin-top:14pt;"></div><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:0pt;margin-top:14pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:57pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">$15.8 million increase in personnel-related compensation expense as a result of the increased headcount in the collective field commercial team; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:57pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">$2.6 million increase in travel and entertainment expenses;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:57pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">$1.2 million increase related to our annual national sales training meeting;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:57pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">$0.6 million increase related to sales meetings and tradeshows; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:57pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">$0.1 million increase in expenses for new product introductions.</span></td></tr></table><div style="margin-top:14pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:14pt 0pt 0pt 0pt;">These increases were partially offset by a $0.7 million decrease in professional services.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;padding-left:10pt;text-align:justify;text-indent:-10pt;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Research and Development Expenses</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">Research and development (&#8220;R&amp;D&#8221;) expenses increased $1.4 million, or 25%, to $7.1 million during the year ended December 31, 2022, compared to $5.7 million during the year ended December 31, 2021, which was primarily attributable to an increase in personnel-related expense and R&amp;D supplies.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">78</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;padding-left:10pt;text-align:justify;text-indent:-10pt;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Reimbursement, General and Administrative Expenses</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-top:2pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">Reimbursement, general and administrative expenses increased $4.0 million, or 7%, to $60.8 million during the year ended December 31, 2022, compared to $56.8 million during the year ended December 31, 2021. The increase was primarily attributable to a:</p><div style="margin-top:14pt;"></div><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:0pt;margin-top:14pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:59.25pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">$4.0 million increase in personnel-related compensation expense as a result of increased headcount in our reimbursement operations, payer relations and corporate functions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:59.25pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">$0.7 million increase in occupancy costs, depreciation expense, and legal and professional fees; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:59.25pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">$0.1 million increase in travel and entertainment.</span></td></tr></table><div style="margin-top:14pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:14pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:14pt 0pt 0pt 0pt;">These increases were partially offset by a $0.8 million decrease in acquisition costs. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;padding-left:10pt;text-align:justify;text-indent:-10pt;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Intangible Asset Amortization and Earn-out</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">Intangible asset amortization and earn-out expenses increased $13.7 million to $14.4 million during the year ended December 31, 2022, compared to $0.7 million during the year ended December 31, 2021. The increase in intangible asset amortization and earn-out expense was primarily attributable to the increase in the estimated fair value of our earn-out liability related to the AffloVest acquisition.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;padding-left:10pt;text-align:justify;text-indent:-10pt;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Other Expense, Net</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">Other expense, net was $2.7 million for the year ended December 31, 2022, compared to $0.5 million for the year ended December 31, 2021. The increase was primarily attributable to an increase in interest expense.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;padding-left:10pt;text-align:justify;text-indent:-10pt;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Income Tax Expense</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:14pt;padding-top:2pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">We recorded an income tax expense of $2.4 million and $9.5 million for the years ended December 31, 2022 and 2021, respectively. The current year tax expense was primarily driven by the change in deferred tax assets and corresponding increase in the full valuation allowance which remains in place after an assessment of existing positive and negative evidence indicated these deferred tax assets would not be realizable.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:14pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">Management assesses the available positive and negative evidence to estimate whether sufficient future taxable income will be generated to permit use of the existing deferred tax assets. Based on this evaluation, as of December 31, 2022 and 2021, a valuation allowance of $17.8 million and $12.0 million, respectively, was recorded to recognize only the residual portion of the existing deferred tax asset that are more likely than not to be realized and which comprises the assets that will not be offset by the reversal of deferred tax liabilities. The amount of the deferred tax asset considered realizable which will be offset by reversing deferred tax liabilities, however, could be adjusted in the future if estimates of taxable income during the carryforward period are reduced or increased or if objective negative evidence in the form of cumulative losses is no longer present and additional weight is given to subjective evidence such as projections for growth.</p><a id="_8d01b40c_833d_4833_9b6a_9e2cb5402398"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Seasonality</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Our business is affected by seasonality. In the first quarter of each year, when most patients have started a new insurance year and have not yet met their annual out-of-pocket payment obligations, we experience substantially reduced demand for our products. We typically experience higher revenue in the third and fourth quarters of the year when more patients have met their annual insurance deductibles, thereby reducing their out-of-pocket costs for our products, and because patients desire to exhaust their flexible spending accounts at year end. This seasonality applies only to purchases and rentals of our products by patients covered by commercial insurance and is not relevant to Medicare, Medicaid or the Veterans Administration, as those payers either do not have plans that have declining deductibles over the course of the plan year and/or do not have plans that include patient deductibles for purchases or rentals of our products. </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">79</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;margin:0pt;">Further, seasonality trends have been, and may continue to be, different than historical trends as a result of the COVID-19 pandemic and related impacts.</p><a id="_b452b642_6408_43a2_b73b_b0dca8a49f98"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Liquidity and Capital Resources</b></p><a id="_0bcb2331_e85b_4dda_835c_7701108ae24e"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Overview </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;margin:0pt;">As of December 31, 2022, we had cash and cash equivalents of $21.9 million and net accounts receivable of $77.9 million compared to cash and cash equivalents of $28.2 million and net accounts receivable of $62.3 million as of December 31, 2021. Our primary sources of capital since our initial public offering in 2016 have been from operating income and bank financing.</p><a id="_41a3cf4e_d766_4632_8fae_2c520f8295af"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Cash Flows</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">The following table summarizes our cash flows for the periods indicated:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:46.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:2.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:12.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:3.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:12.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:3.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:12.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:46.49%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:normal;width:50.78%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.49%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:normal;width:50.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:46.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">(In&#160;thousands)</p></td><td style="vertical-align:bottom;white-space:normal;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:14.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:normal;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:14.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:normal;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:14.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Net cash provided by (used in):</p></td><td style="vertical-align:bottom;white-space:normal;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.49%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Operating activities</p></td><td style="vertical-align:bottom;white-space:normal;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:12.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 5,209</span></p></td><td style="vertical-align:bottom;white-space:normal;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:12.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,631</span></p></td><td style="vertical-align:bottom;white-space:normal;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:12.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,794</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Investing activities</p></td><td style="vertical-align:bottom;white-space:normal;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (1,909)</span></p></td><td style="vertical-align:bottom;white-space:normal;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (82,184)</span></p></td><td style="vertical-align:bottom;white-space:normal;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 20,179</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.49%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Financing activities</p></td><td style="vertical-align:bottom;white-space:normal;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (9,600)</span></p></td><td style="vertical-align:bottom;white-space:normal;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 59,927</span></p></td><td style="vertical-align:bottom;white-space:normal;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:12.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,112</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Net (decrease) increase in cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:normal;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.99%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:12.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (6,300)</span></p></td><td style="vertical-align:bottom;white-space:normal;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.99%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:12.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (19,626)</span></p></td><td style="vertical-align:bottom;white-space:normal;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.99%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:12.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 25,085</span></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;padding-left:10.1pt;text-indent:-10.1pt;background:#ffffff;margin:0pt;"><span style="font-size:1pt;visibility:hidden;background:#ffff00;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:10.1pt;text-align:justify;text-indent:-10.1pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Net Cash Provided by Operating Activities</span></p><a id="_Hlk31462641"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Net cash provided by operating activities during the year ended December 31, 2022, was $5.2 million, resulting from a net loss of $17.9 million and non-cash net income adjustments of $27.7 million, which were offset by a change in net operating assets and liabilities of $4.6 million. The non-cash net income adjustments primarily consisted of $11.9 million change in fair value of earn-out liability, $9.6 million of stock-based compensation expense, and $6.3 million of depreciation and amortization expense. Changes in operating assets and liabilities were unfavorably impacted by increasing accounts receivable, net investment in leases and continued investment in inventory designed to meet future projected demand, partially offset by an increase in current liabilities.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;margin:0pt;">Net cash provided by operating activities during the year ended December 31, 2021, was $2.6 million, resulting from a net loss of $11.8 million and non-cash net income adjustments of $23.9 million, which were offset by an increase in net operating assets and liabilities of $9.5 million. The non-cash net income adjustments primarily consisted of $10.2 million of stock-based compensation expense, $10.2 million of deferred income tax expense and $3.7 million of depreciation and amortization expense. Changes in operating assets and liabilities were unfavorably impacted by increasing accounts receivable, net investment in leases and income taxes payable, partially offset by an increase in current liabilities.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Net Cash (Used in) Investing Activities</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">Net cash used in investing activities during the year ended December 31, 2022, was $1.9 million, primarily consisting of $1.8 million in purchases of property and equipment primarily related to office equipment, production tooling and tenant improvements and $0.1 million related to the acquisition of patents and other intangible assets.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">Net cash used in investing activities during the year ended December 31, 2021, was $82.2 million, primarily consisting of acquisition-related payments of $79.8 million associated with the acquisition of the AffloVest business and $2.1 million in purchases of property and equipment primarily related to office </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">80</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;">equipment, production tooling and tenant improvements and $0.3 million related to the acquisition of patents and other intangible assets.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Net Cash (Used in) Provided by Financing Activities</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">Net cash used in financing activities during the year ended December 31, 2022, was $9.6 million, primarily consisting of payments of $6.0 million on notes payable and a payment of $5.0 million on the AffloVest earn-out, partially offset by $1.4 million in proceeds from exercises of common stock options and the issuance of common stock under the ESPP. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">Net cash provided by financing activities during the year ended December 31, 2021, was $59.9 million, primarily consisting of borrowings of $54.8 million net of debt issuance costs incurred and $6.3 million in proceeds from exercises of common stock options and the issuance of common stock under the ESPP, partially offset by $1.2 million in taxes paid for the net share settlement of performance and restricted stock units. </p><a id="_dce10737_0dc9_43a8_bc9f_0210b88fab68"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Credit Agreement</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">On April 30, 2021, we entered into an Amended and Restated Credit Agreement (the &#8220;Restated Credit Agreement&#8221;) with the lenders from time to time party thereto, and Wells Fargo Bank, National Association, as Administrative Agent. The Restated Credit Agreement amended and restated in its entirety the prior credit agreement.<span style="font-size:12pt;"> </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">On September 8, 2021, we entered into a First Amendment Agreement (the &#8220;First Amendment&#8221;), which amends the Restated Credit Agreement (as amended by the First Amendment and the Second Amendment (as defined below), the &#8220;Credit Agreement&#8221;) with the lenders from time to time party thereto, and Wells Fargo Bank, National Association, as administrative agent. The First Amendment, among other things, adds a $30.0 million incremental term loan to the $25.0 million revolving credit facility provided by the Restated Credit Agreement. The term loan and the revolving credit facility mature on September 8, 2024. The Credit Agreement provides that, subject to satisfaction of certain conditions, we may increase the amount of the revolving loans available under the Credit Agreement and/or add one or more term loan facilities in an amount not to exceed $25.0 million in the aggregate, such that the total aggregate principal amount of loans available under the Credit Agreement (including under the revolving credit facility) does not exceed $80.0 million.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;text-align:justify;text-indent:27pt;background:#ffffff;margin:0pt;"><span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;background:#ffff00;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">Our obligations under the Credit Agreement are secured by a security interest in substantially all of our and our subsidiaries&#8217; assets and are also guaranteed by our subsidiaries. The Credit Agreement contains a number of restrictions and covenants, including that we maintain compliance with a maximum leverage ratio, minimum fixed charge coverage ratio and a minimum consolidated EBITDA covenant. As of December 31, 2022, we were in compliance with all financial covenants under the Credit Agreement.<span style="font-size:12pt;"> </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">On September 8, 2021, in connection with the closing of the acquisition of the AffloVest business, we borrowed the $30.0 million term loan and utilized that borrowing, together with a draw of $25.0 million under the revolving credit facility and cash on hand, to fund the purchase price.&#160;The principal of the term loan is required to be repaid in quarterly installments of $750,000 commencing&#160;January 7, 2022,&#160;through&#160;July 8, 2024,&#160;with the remaining outstanding balance due on&#160;September 8, 2024<span style="color:#ff0000;">. </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;text-align:justify;margin:0pt;"><span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">On February 22, 2022, we entered into a Second Amendment Agreement (the &#8220;Second Amendment&#8221;), which further amends the Credit Agreement. The Second Amendment modifies the maximum leverage ratio, the minimum fixed charge coverage ratio and the minimum consolidated EBITDA covenants under the Credit Agreement, and adds a minimum liquidity covenant. The Second Amendment also increases the applicable margin for LIBOR rate loans under the Credit Agreement during the period commencing on the date of the Second Amendment and ending on the last day of the fiscal quarter ending June 30, 2023.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Pursuant to the Second Amendment, on February 22, 2022, we made a mandatory principal prepayment of the term loan under the Credit Agreement of $3.0 million. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">As of December 31, 2022, we had outstanding borrowings of $49.0 million under the Credit Agreement, comprised of $24.0 million under the term loan and $25.0 million under the revolving credit facility.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">81</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:14pt;text-align:justify;text-indent:36pt;margin:0pt;">For additional information regarding the Credit Agreement, including interest rates, fees and maturities, see Note 11 &#8211; &#8220;Credit Agreement&#8221; of the consolidated financial statements contained in this report.</p><a id="_6017e503_9fd3_4ee4_9424_5be58a5609bc"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;padding-left:10.1pt;text-align:justify;text-indent:-10.1pt;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Future Cash Requirements</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">Our material estimated future cash requirements under our contractual obligations and commercial commitments as of December 31, 2022, in total and disaggregated into current (payable in 2023) and long-term (payable after 2023) obligations, are summarized as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:31.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:31.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="14" style="vertical-align:bottom;white-space:nowrap;width:66.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Payments Due By Period</b></p></td></tr><tr><td style="vertical-align:bottom;width:31.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Less&#160;Than</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">More&#160;Than</b></p></td></tr><tr><td style="vertical-align:bottom;width:31.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0.05pt 0pt 0.05pt 0pt;">(In&#160;thousands)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">1&#160;Year</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">1-3&#160;Years</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">3-5&#160;Years</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">5&#160;Years</b></p></td></tr><tr><td style="vertical-align:bottom;width:31.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Purchase commitments <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 33,478</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 33,478</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:31.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Operating lease obligations <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(2)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 27,227</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 3,427</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 6,936</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 6,782</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 10,082</span></p></td></tr><tr><td style="vertical-align:bottom;width:31.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Note payable payments <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(3)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 24,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 3,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 21,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:31.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Revolving line of credit payments <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(4)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 25,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 25,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:31.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Interest payments <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(5)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 5,778</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 3,539</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 2,239</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:31.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Earn-out obligation <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(6)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 13,050</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 13,050</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:31.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 128,533</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 56,494</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 55,175</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 6,782</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 10,082</span></p></td></tr></table><div style="margin-top:6pt;"></div><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-decoration-line:none;text-transform:none;vertical-align:baseline;white-space:nowrap;width:18pt;padding:0pt 0pt 6pt 0pt;">(1)</td><td style="padding:0pt 0pt 6pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-style:normal;font-weight:normal;">We issued purchase orders in 2022 totaling $33.5 million for goods that we expect to receive and pay for in 2023.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-decoration-line:none;text-transform:none;vertical-align:baseline;white-space:nowrap;width:18pt;padding:0pt 0pt 6pt 0pt;">(2)</td><td style="padding:0pt 0pt 6pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-style:normal;font-weight:normal;">We currently lease approximately 150,000 square feet of office space for our corporate headquarters in Minneapolis, Minnesota, under a lease that expires in February 2031 and approximately 63,000 square feet of office, assembly and warehouse space at another facility in Minneapolis, Minnesota, under a lease that expires in March 2027. We entered into a fleet vehicle program for certain members of our field sales organization in 2016. At December 31, 2022, we had two vehicles under this program with current lease commitments. Furthermore, we lease office equipment from time-to-time based on our needs and these commitments are classified as operating leases. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-decoration-line:none;text-transform:none;vertical-align:baseline;white-space:nowrap;width:18pt;padding:0pt 0pt 6pt 0pt;">(3)</td><td style="padding:0pt 0pt 6pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-style:normal;font-weight:normal;background:#ffffff;">Reflects principal </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-style:normal;font-weight:normal;">payment obligations under our term loan.</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-style:normal;font-weight:normal;background:#ffffff;"> Refer to Note 11 &#8216;&#8216;Credit Agreement&#8217;&#8217; to our consolidated financial statements included in this report for additional information regarding the maturities of debt principal. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-decoration-line:none;text-transform:none;vertical-align:baseline;white-space:nowrap;width:18pt;padding:0pt 0pt 6pt 0pt;">(4)</td><td style="padding:0pt 0pt 6pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-style:normal;font-weight:normal;background:#ffffff;">Reflects re</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-style:normal;font-weight:normal;">payment of the principal of outstanding borrowings under our revolving line of credit based on the scheduled maturity date.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-decoration-line:none;text-transform:none;vertical-align:baseline;white-space:nowrap;width:18pt;padding:0pt 0pt 6pt 0pt;">(5)</td><td style="padding:0pt 0pt 6pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-style:normal;font-weight:normal;background:#ffffff;">Interest payment amounts on long-term debt are calculated using outstanding balances and interest rates in effect on December&#160;31, 2022.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-decoration-line:none;text-transform:none;vertical-align:baseline;white-space:nowrap;width:18pt;padding:0pt;">(6)</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-style:normal;font-weight:normal;">In connection with the acquisition of AffloVest, as of December 31, 2022, we were obligated to make an earn-out payment in the amount of $5.0 million (as well as an imputed interest payment of $250,000) by May 26, 2023, and may be obligated to make an additional earn-out payment of up to $10.0 million in cash, if certain future financial results of the AffloVest business are met. </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-style:normal;font-weight:normal;background:#ffffff;">The fair value of this obligation at December 31, 2022 was $13.1 million, which is reflected on our Consolidated Balance Sheets.</span></td></tr></table><div style="margin-top:14pt;"><a id="_1ed4aa25_1222_4c2c_8f2a_a79e61a880a7"></a></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Adequacy of Resources</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">Our future cash requirements may vary significantly from those now planned and will depend on many factors, including:</p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:23.05pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 12pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 12pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the impact of the COVID-19 pandemic on our business;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:23.05pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 12pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 12pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">sales and marketing resources needed to further penetrate our market;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:23.05pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 12pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 12pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">expansion of our operations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:23.05pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 12pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 12pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">response of competitors to our solutions and applications; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:23.05pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 12pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 12pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">costs associated with clinical research activities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:23.05pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 12pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 12pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">increases in interest rates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:23.05pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 12pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 12pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">labor shortages and wage inflation;</span></td></tr></table></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">82</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:23.05pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 12pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 12pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">costs to develop and implement new products; and </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:23.05pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">use of capital for acquisitions</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">or licenses, if any.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">Historically, we have experienced increases in our expenditures consistent with the growth in our revenue, operations and personnel, and we anticipate that our expenditures will continue to increase as we expand our business.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">Although the impact of the COVID-19 pandemic and other factors such as inflation and rising interest rates are difficult to predict, we believe our cash, cash equivalents and cash flows from operations will be sufficient to meet our working capital, capital expenditure, debt repayment and related interest, and other cash requirements for at least the next twelve months.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">Inflation and changing prices did not have a material effect on our business during the year ended December 31, 2022, and we do not expect that inflation or changing prices will materially affect our business for at least the next twelve months.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Coronavirus Aid, Relief, and Economic Security (CARES) Act</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">On March 27, 2020 the CARES Act was signed into law. The CARES Act is a tax-and-spending package intended to provide economic relief to address the impact of the COVID-19 pandemic. The CARES Act includes several tax provisions that, among other things, allow businesses to carry back net operating losses (&#8220;NOLs&#8221;) arising in 2018, 2019, and 2020 to the prior five tax years. In the third quarter of 2020, we collected $2.9 million related to the carry back of our NOLs arising from these prior tax years.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:14pt;padding-top:2pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">In addition, the CARES Act provided $100 billion in relief funds to hospitals and other healthcare providers on the front lines of the COVID-19 pandemic. An initial $30 billion of the funds were released for immediate infusion and were distributed to all facilities and providers that received Medicare fee-for-service (&#8220;FFS&#8221;) reimbursements in 2019. On April 10, 2020, we received $1.2 million of the initial allotment to all facilities and providers which was determined to be our proportionate share. Within 45 days of each reporting period end, we complied with the reporting requirements confirming funds were utilized in a manner described within the terms and conditions outlined by the U.S. Department of Health &amp; Human Services. As of December 31, 2020, we recognized all of the funds received in the initial allotment as other income.</p><a id="_b90cf5c0_cb05_4e60_8724_cd0624e67b00"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Off-Balance Sheet Arrangements</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined under the applicable regulations.</p><a id="_7f86bfde_59bb_402c_81db_ec9c0c8bf538"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:10.1pt;text-align:justify;text-indent:-10.1pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Recent Accounting Pronouncements</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;margin:0pt;">Refer to Note 3 - &#8220;Summary of Significant Accounting Policies,&#8221; of our consolidated financial statements contained in this report for a description of recently issued accounting pronouncements that are applicable to our business.</p><a id="_95fc78b6_5927_4ff7_8ac2_b052ee0b47c8"></a><a id="Item3QuantitativeandQualitativeDisclosur"></a><a id="Item7AQuantitativeandQualitativeDisclosu"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item 7A. Quantitative and Qualitative Disclosures About Market Risk</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:10pt;text-align:justify;text-indent:-10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Interest Rate Risk </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">We are exposed to market risk from changes in interest rates, primarily related to our investments and our borrowings. The principal objectives of our investment activities are to preserve principal, provide liquidity and maximize income consistent with minimizing risk of material loss. The recorded carrying amounts of cash and cash equivalents approximate fair value due to their short maturities. Our interest income is sensitive to changes in the general level of interest rates in the United States, particularly since our investments are generally short-term in nature. Based on the nature of our short-term investments, an immediate 100 basis point change in interest rates would not have a material effect on the fair market value of our portfolio. <span style="background:#ffffff;">We also </span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">83</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">have exposure to variable interest rates through our credit facility, as the interest expense related to any borrowings will fluctuate with changes in LIBOR and other benchmark rates. Therefore, increases in interest rates may impact our net income or loss by increasing the cost of carrying debt.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:10pt;text-align:justify;text-indent:-10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Inflation </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Inflationary factors, such as increases in our cost of revenue, sales and marketing expenses and reimbursement expenses, may adversely affect our operating results. Although we do not believe that inflation has had a material impact on our financial condition or results of operations to date, a high rate of inflation in the future may have an adverse effect on our ability to maintain and increase our gross margin, and on our sales and marketing and reimbursement expenses as a percentage of our revenue if the prices for our products do not increase as much or more than these increased costs. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:10pt;text-align:justify;text-indent:-10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Credit Risk</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2022 and 2021, our cash and cash equivalents were maintained with one financial institution in the United States. We perform periodic evaluations of the relative credit standing of this financial institution and believe it has sufficient assets and liquidity to conduct its operations in the ordinary course of business with little or no credit risk to us. We have not experienced any losses on our cash or cash equivalents to date. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our accounts receivable primarily relate to revenue from the sale of our products to patients in the United States. As of December&#160;31, 2022 and 2021, our accounts receivable were $77.9&#160;million and $62.3&#160;million, respectively. We had accounts receivable from two insurers representing approximately 45% and 21% of accounts receivable as of December 31, 2022. We had accounts receivable from two insurers representing approximately 33% and 24% of accounts receivable as of December 31, 2021. The credit risks associated with customers which for these purposes are insurers considers aggregation for entities that are known to be under common control. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;padding-left:10pt;text-align:justify;text-indent:-10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Foreign Currency Risk </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">Our business is conducted in U.S. dollars and international transactions have been nominal. As we begin building relationships to commercialize our products internationally, our results of operations and cash flows may become increasingly subject to changes in foreign exchange rates.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">84</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_7d34b640_f98a_4750_a65d_07a8d0d3d38c"></a><a id="Item8FinancialStatementsandSupplementary"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;">Item 8.  Financial Statements and Supplementary Data.</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:93.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:93.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Index to Financial Statements</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.61%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:93.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:93.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"><a href="#Reportofindependent"><span style="font-style:normal;font-weight:normal;">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span></a> (PCAOB ID Number <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" name="dei:AuditorFirmId" id="Narr_SeHKIkKgJkGWfadMCAWisQ">248</ix:nonNumeric>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">86</p></td></tr><tr><td style="vertical-align:bottom;width:93.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a href="#Balance"><span style="font-style:normal;font-weight:normal;">Consolidated Balance Sheets</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">88</p></td></tr><tr><td style="vertical-align:top;width:93.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><a href="#Operations"><span style="font-style:normal;font-weight:normal;">Consolidated Statements of Operations</span></a> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">89</p></td></tr><tr><td style="vertical-align:top;width:93.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><a href="#Comprehensive_Loss"><span style="font-style:normal;font-weight:normal;">Consolidated Statements of Comprehensive Loss </span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">90</p></td></tr><tr><td style="vertical-align:top;width:93.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><a href="#Equity"><span style="font-style:normal;font-weight:normal;">Consolidated Statements of Stockholders&#8217; Equity</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">91</p></td></tr><tr><td style="vertical-align:top;width:93.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><a href="#Cash_Flows"><span style="font-style:normal;font-weight:normal;">Consolidated Statements of Cash Flows</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">92</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;background:#ffff00;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">85</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_c9856220_4047_45aa_8336_3e765fbbbd3e"></a><a id="Reportofindependent"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;">Board of Directors and Stockholders</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">Tactile Systems Technology, Inc.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:14.0pt;margin:0pt;"><b style="font-weight:bold;">Opinion on the financial statements</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:14.0pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We have audited the accompanying consolidated balance sheets of Tactile Systems Technology, Inc. (a Delaware corporation) and subsidiary (the &#8220;Company&#8221;) as of December 31, 2022 and 2021, the related consolidated statements of operations, comprehensive loss, stockholders&#8217; equity, and cash flows for each of the three years in the period ended December 31, 2022, and the related notes (collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the<span style="color:#0000ff;"> </span>financial statements present fairly, in all material respects, the financial position of the Company<span style="color:#0000ff;"> </span>as of December 31, 2022 and 2021, and the results of its<span style="color:#0000ff;"> </span>operations and its<span style="color:#0000ff;"> </span>cash flows for each of the three years in the period ended December 31, 2022, in conformity with accounting principles generally accepted in the United States of America. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;), the Company&#8217;s internal control over financial reporting as of December 31, 2022, based on criteria established in the 2013 <i style="font-style:italic;">Internal Control&#8212;Integrated Framework</i> issued by the Committee of Sponsoring Organizations of the Treadway Commission (&#8220;COSO&#8221;), and our report dated February 21, 2023<span style="color:#0000ff;"> </span>expressed an unqualified opinion.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:14.0pt;margin:0pt;"><b style="font-weight:bold;">Basis for opinion</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:14.0pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:14.0pt;margin:0pt;"><b style="font-weight:bold;">Critical audit matter</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:14.0pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The critical audit matter<span style="color:#0000ff;"> </span>communicated below is a matter<span style="color:#0000ff;"> </span>arising from the current period audit of the financial statements that was<span style="color:#0000ff;"> </span>communicated or required to be communicated to the audit committee and that: (1) relates<span style="color:#0000ff;"> </span>to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matter<span style="color:#0000ff;"> </span>below, providing a<span style="color:#0000ff;"> </span>separate opinion<span style="color:#0000ff;"> </span>on the critical audit matter<span style="color:#0000ff;"> </span>or on the accounts or disclosures to which it relates. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Transaction Price Adjustment &#8211; Uncollected Lymphedema Product Sales with Commercial Payers and Medicare </i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">As described further in Note 3. Summary of Significant Accounting Policies &#8211; Revenue Recognition to the consolidated financial statements, revenue is recognized upon transfer of control of the product to the patient based on a transaction price determined to be the amount of expected consideration to be received for the </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">86</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">product. In most cases, there is a contracted third-party payer, such as a commercial insurer, Medicare or the Veteran&#8217;s Administration involved with the transaction. The transaction price is impacted by multiple factors including the terms and conditions contracted by third-party payers. Thus, payments from third-party payers typically are less than the Company&#8217;s standard charge and represent an implicit price concession, resulting in variable consideration. The transaction price for commercial payers is determined based on the payment history of the payer drawn from actual write-off and collections experience over a rolling 12-month period, as well as historical patient collections by payer. The Company assesses the variable consideration for each Medicare claim as a percentage of the total invoice price based on ultimate approval and collection history. There is not variable consideration with sales to the Veterans Administration. The results of the variable consideration assessment are the primary source of information in estimating the recognition of net revenue and the net valuation of the related accounts receivable<span style="background:#ffffff;">.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We identified the transaction price adjustment, as it relates to the uncollected Lymphedema product sales to commercial payers and Medicare, as a critical audit matter. The principal considerations for our determination of this as a critical audit matter are:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">The transaction price adjustment is related to material accounts and disclosures that are important to the users of the consolidated financial statements</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Significant judgment is required to estimate the expected amount of cash consideration to be collected, which is a key input into management&#8217;s transaction price adjustment</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">As it relates to sales with Medicare, the future collection could significantly differ from those subjective estimates given the payment uncertainty due to the appeals process for claims initially denied</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">.</span></td></tr></table><div style="margin-top:8pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Our audit procedures related to the transaction price adjustment &#8211; uncollected Lymphedema product sales with commercial payers and Medicare included the following, among others:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_Hlk127203057"></a><a id="_Hlk96001420"></a><a id="_Hlk95805824"></a><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">We tested the design and operating effectiveness of management&#8217;s key controls relating to their Medicare and commercial payer transaction price assessments and commercial payer lookback analysis through reperformance, observation of the control being performed, and inspection of supporting documentation providing evidence of control performance.</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">To test management&#8217;s estimate of the commercial payer transaction price adjustment, we: (1) recomputed management&#8217;s calculation of the historical collection amount by payer based on transactions that occurred during the year for a sample of commercial payers and (2) tested the completeness and accuracy of the underlying data used in management&#8217;s calculation of the historical collection amount.</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">For sales to patients insured by commercial payers, we assessed the reasonableness of management&#8217;s year-end analysis of the transaction price adjustment recorded in the prior year compared to actual pricing adjustments experienced in the current period by recomputing the results of management&#8217;s historical lookback analysis of collection amounts by payer portfolio and total reserve.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">For sales to patients covered by Medicare, we: (1) tested management&#8217;s estimate by evaluating the determination of collection percentage assumptions, (2) recalculated the related transaction price adjustment based upon management&#8217;s assumptions and (3) tested the completeness and accuracy of the underlying data inputs for the collection percentage determination</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">.</span></td></tr></table><div style="margin-top:8pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:14.0pt;margin:0pt 0pt 14.19pt 0pt;">/s/ <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" name="dei:AuditorName" id="Narr_RDkte8rbuk6QVG05WnJ_BQ">GRANT THORNTON LLP </ix:nonNumeric></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:14.0pt;margin:0pt 0pt 14.19pt 0pt;">We have served as the Company&#8217;s auditor since 2015.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" name="dei:AuditorLocation" id="Narr_yQ2C5VLtZE6ZgXL2sGg7zg">Minneapolis, Minnesota</ix:nonNumeric></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">February 21, 2023</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">87</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_1a0df766_f2f7_490c_8ded_1cf78a9f2de2"></a><a id="Balance"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;background:#ffffff;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_be5fa61a_9cdb_4c0f_832c_2bb4b79cd175"></a><a id="Tc_59JgM_jEzkKf6eyR7dn7dQ_1_0"></a><a id="Tc_JpTTkSjEIEGkncjm7vacCA_2_0"></a><a id="Tc_7i7ASqKUfka02JB9ag4nmQ_3_2"></a><a id="Tc_gdEfQIXT6k-9q9mTdm5nRw_3_5"></a><a id="Tc_QGPCDxFQJkqcHVwXYjCH1Q_4_0"></a><a id="Tc_LWzYmIznlkif3UIvb-diYg_4_2"></a><a id="Tc_9zG101srVkSDExWQQaxXbA_4_5"></a><a id="Tc_Xl2Od9tTWEKdo5ImwQ1coA_5_0"></a><a id="Tc_8T5NwPZiyUWUV8h_5PB4aQ_6_0"></a><a id="Tc_bUDHSqkOikiDfQlG1DVEJw_7_0"></a><a id="Tc_4pXaDIxL1kCm9mtg65mrwA_7_2"></a><a id="Tc_bTJxa2FheUOIqoE3sQR5Dw_7_5"></a><a id="Tc_VTK9yDoviUSJr8a1fPEw0w_8_0"></a><a id="Tc_uY51wXQqUUiN2QmrUhnD3w_9_0"></a><a id="Tc_-FsNaQsynUSHqKV9nlkZgQ_10_0"></a><a id="Tc_dHz9jVwLlU2UjnHBRwQ5DQ_11_0"></a><a id="Tc_K2lVa42UUUSK4i2OT-vSyA_12_0"></a><a id="Tc_7Jt2sinDN029JlaKJqRwmQ_13_0"></a><a id="Tc_4irMbEuwHEaMzhDwjVIXCQ_14_0"></a><a id="Tc_epv-dAdngUeWlMiDi4mDIg_15_0"></a><a id="Tc_fh9E0AhH0kilQVy8brFpng_16_0"></a><a id="Tc_p9rYl2z1gUOqP2OQgqVZDA_17_0"></a><a id="Tc_f3tVbtEHzUWmiNVnwHNRsw_18_0"></a><a id="Tc_n8tRCE-S2EqQwcaUbSpzRA_19_0"></a><a id="Tc_0PFty6ZRHEq_HK_2fkRPuQ_20_0"></a><a id="Tc_lMZ6drmi7Umn1tnwyuq78w_21_0"></a><a id="Tc_SThnX3xSV0yb5_NJiiiT3A_21_2"></a><a id="Tc_3ub4WpyyvUGAWwL5xYdUjQ_21_5"></a><a id="Tc_okNLL85JjEa-McFQxADzLQ_22_0"></a><a id="Tc_U5o6yJZO7ku1sODBbkuy-Q_23_0"></a><a id="Tc_95gLSDaA7EeVBYKKFJLWiw_24_0"></a><a id="Tc_1VWEwoG5T0KmAV5k5prSUQ_24_2"></a><a id="Tc_lu17Wi-kLEe7be1-uLc6sw_24_5"></a><a id="Tc_Bi7-l8geiUiqsB3378W-SA_25_0"></a><a id="Tc_iE6VLMQov0SsoSzXsjydgQ_26_0"></a><a id="Tc_Tlxz08cEqkK072gNRMddkQ_27_0"></a><a id="Tc_ez0YgguVDkyOXCbJLUr-Jg_28_0"></a><a id="Tc_sDxdYOjhsU6o9tivS7xOzA_29_0"></a><a id="Tc_T2ABRrl5sk2BG5SCB-K77A_30_0"></a><a id="Tc_8lkHO7id50a6kPGFxqbNzg_31_0"></a><a id="Tc_p00X3To2p0GUTg3GQuxkWA_32_0"></a><a id="Tc_HabOqyyIqES2qblnXNaexA_33_0"></a><a id="Tc_3m860aevOkqNZMdbOWjeWQ_34_0"></a><a id="Tc_3PZaRn2GR0aDkUa6HA--qA_35_0"></a><a id="Tc_ZUbZL5wzKU-R_XTILb8P3w_36_0"></a><a id="Tc_nGZnc-tnekedKmGdW62zrA_36_3"></a><a id="Tc_28_RYmzx7EGfU2S6BQqBVw_37_0"></a><a id="Tc_WqJAdC_UUkKq3e0yMdKhCA_38_0"></a><a id="Tc_vbeEiTVW6k6QLvmN-scfNA_39_0"></a><a id="Tc_GQSn5M-cpEWXhCp2ayBVyg_40_0"></a><a id="Tc_1dGWYVNywE-XGs-okw2ujw_40_3"></a><a id="Tc_EgT-1L35UU6uUCS3W6yK3w_41_0"></a><a id="Tc_NddmqUzs7UuyJhAm3QplqQ_42_0"></a><a id="Tc_xgzMT0iv8EqYKb89OM3x9A_44_0"></a><a id="Tc_m1MHZlf5RkaHz4qyf8W4HA_46_0"></a><a id="Tc_GnObL2JcDkSbAl0GRn9cSw_47_0"></a><a id="_61cef2eb_5243_4592_a0ed_ce7b4ef4ffa2"></a><a id="_61cef2eb_5243_4592_a0ed_ce7b4ef4ffa2_2"></a><a id="_61cef2eb_5243_4592_a0ed_ce7b4ef4ffa2_3"></a><a id="Tc_28dwigVMg0ihhZcPgH-8vw_48_0"></a><a id="Tc_HfOPzQo5Tk6z7iB1GyY2Jg_49_0"></a><a id="Tc_4_f-2aOtG0W3OvnWcqMDhQ_50_0"></a><a id="Tc_A2XDQRQtCUy6W_Wz-2XdmA_51_0"></a><a id="Tc_frrWDnBgRkO4MkAyKxDedw_52_0"></a><a id="Tc_ry7tl8kysU64CfaEkk566A_52_2"></a><a id="Tc_0WmE1S8x406nZjrDRev5hQ_52_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td colspan="7" style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-size:8.5pt;font-weight:bold;">Tactile Systems Technology, Inc.</b></p></td></tr><tr><td colspan="7" style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-size:8.5pt;font-weight:bold;">Consolidated Balance Sheets</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-size:8.5pt;font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-size:8.5pt;font-weight:bold;">December 31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-size:8.5pt;font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-size:8.5pt;font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">(In&#160;thousands,&#160;except share and per share data)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-size:8.5pt;font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-size:8.5pt;font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-size:8.5pt;font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-size:8.5pt;font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;font-style:italic;font-weight:bold;">Assets</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8.5pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-size:8.5pt;font-weight:bold;">Current assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:8.5pt;">Cash and cash equivalents</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_UWVYpgtCukG3thPVKSkWYA_7_3">21,929</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_rfywgA-c5kWcjqxvFhelfw_7_6">28,229</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:69.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:8.5pt;">Accounts receivable</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="Tc_NR7xjgSD80utHkSCseq6sQ_8_3">54,826</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="Tc_VBgbD0J5l0CgH8RdkU3UfA_8_6">49,478</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:69.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:8.5pt;">Net investment in leases</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetInvestmentInLease" scale="3" id="Tc_CS3zZk_se0mPhvobiydXEQ_9_3">16,130</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetInvestmentInLease" scale="3" id="Tc_D2ZkEs2ib0OQw_w4lxJDKg_9_6">12,482</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:69.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:8.5pt;">Inventories</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="Tc__rnUk2ZsqEmMvkSo-jqcVA_10_3">23,124</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="Tc_iENYuGixaUGo-uH6iuQ0wA_10_6">19,217</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:69.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:8.5pt;">Prepaid expenses and other current assets</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="Tc_O9rtfLD9ukiNIFIqX_PxoA_11_3">3,754</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="Tc_2iauKbqLv0-ka3IP6cj6Lw_11_6">4,141</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:69.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0pt 24pt;"><span style="font-size:8.5pt;">Total current assets</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_Ha_8xg2L4UizzY3GGxGY7w_12_3">119,763</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_1k87bGRbd0ukOu2y0nhUxw_12_6">113,547</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:69.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-size:8.5pt;font-weight:bold;">Non-current assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:8.5pt;">Property and equipment, net</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_kONsIqJFOEaJhSoRpnQPLA_14_3">6,077</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_jj1D-fSUmkiArUte2HtwDw_14_6">6,750</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:69.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:8.5pt;">Right of use operating lease assets</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_TS74wyQbk0qLHmupu5WahA_15_3">21,322</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_San6iMNKOEyjEG_tdCXXsg_15_6">23,984</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:69.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:8.5pt;">Intangible assets, net</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" id="Tc_151N_jblB0e19rkyl8uI8A_16_3">50,375</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" id="Tc_amvxBBipoEKQHin9uKsLkg_16_6">54,081</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:69.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:8.5pt;">Goodwill</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="Tc_fIVOMeYoOUGLuATFaAhE2g_17_3">31,063</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="Tc_aj7IGjkMZkWp0ozNpyfuBQ_17_6">31,063</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:69.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:8.5pt;">Accounts receivable, non-current</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw" decimals="-3" format="ixt:numdotdecimal" name="tcmd:MedicareAccountsReceivableNonCurrent" scale="3" id="Tc_bwuIbyNPa0Omv9c-ZeBzkA_18_3">23,061</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q" decimals="-3" format="ixt:numdotdecimal" name="tcmd:MedicareAccountsReceivableNonCurrent" scale="3" id="Tc_0J2eQw28MU23ZtFaGuesSw_18_6">12,847</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:69.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:8.5pt;">Other non-current assets</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="Tc_IrWDnmS0-0iBlhz9beNFlQ_19_3">3,335</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="Tc_0D119ArpI0m_CHlxNGLhxw_19_6">1,998</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:69.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0pt 24pt;"><span style="font-size:8.5pt;">Total non-current assets</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsNoncurrent" scale="3" id="Tc_TKAuIdo_vk-qBDnveOdrsg_20_3">135,233</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsNoncurrent" scale="3" id="Tc_BJVChsWrbUyZDZJwP_f2yg_20_6">130,723</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:69.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0pt 36pt;"><b style="font-size:8.5pt;font-weight:bold;">Total assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="Tc_q7FPGAKQW0etKOTxAzxUWg_21_3">254,996</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="Tc_R49vGEe7ZEiNntd0aScsyQ_21_6">244,270</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:69.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;font-style:italic;font-weight:bold;">Liabilities and Stockholders&#39; Equity</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-size:8.5pt;font-weight:bold;">Current liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:8.5pt;">Accounts payable</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="Tc_e9-g5W9opkaq9Ma69K8K6Q_24_3">9,984</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="Tc_UoKkLP6h20-HAICvSnUa4A_24_6">5,023</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:69.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:8.5pt;">Note payable</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NotesPayableCurrent" scale="3" id="Tc_yYMJktZ5m0K4A9Zqpex9Xw_25_3">2,968</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NotesPayableCurrent" scale="3" id="Tc_Cljh0MDeqke6PqzmiCvI8A_25_6">2,960</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:69.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:8.5pt;">Earn-out, current</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw" decimals="-3" format="ixt:numdotdecimal" name="tcmd:EarnOutCurrent" scale="3" id="Tc_0qAjzBBmAkSDQtR6ZzNVfw_26_3">13,050</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q" decimals="-3" format="ixt:numdotdecimal" name="tcmd:EarnOutCurrent" scale="3" id="Tc_lzC_KvXwbEWZ9PwyXovIhA_26_6">3,250</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:69.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:8.5pt;">Accrued payroll and related taxes</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="Tc_mn8uGdvHw0WQphuu7qbscQ_27_3">17,100</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="Tc_qPtr2BjVcU2p4N7hkdiQjA_27_6">12,139</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:69.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:8.5pt;">Accrued expenses</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_tkQq_MtvXEOlAKbiXVsN7Q_28_3">9,240</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_m1MGxNDv-kKJ8hE5y72caQ_28_6">5,262</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:69.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:8.5pt;">Income taxes payable</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedIncomeTaxesCurrent" scale="3" id="Tc_qQyYONy9OkyrjReByXvkwg_29_3">2,336</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedIncomeTaxesCurrent" scale="3" id="Tc_R4azmm1KeU28wV4YozjSZA_29_6">16</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:69.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:8.5pt;">Operating lease liabilities</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_-dE7GqdQikKSM7afN58IDg_30_3">2,500</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_6Dw2cOYuLUCyOyQlzV6jWg_30_6">2,506</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:69.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:8.5pt;">Other current liabilities</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="Tc_EcZMc5Bpf06NwQoWr2WXWA_31_3">7,152</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="Tc_UndutZasuUOneqoxwDZUIw_31_6">3,305</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:69.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0pt 24pt;"><span style="font-size:8.5pt;">Total current liabilities</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_zmzYxK38aEGzeasqEx7C4g_32_3">64,330</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_Bt4i-ztGw0y5HHE98P7U_g_32_6">34,461</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:69.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-size:8.5pt;font-weight:bold;">Non-current liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:8.5pt;">Revolving line of credit, non-current</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LineOfCredit" scale="3" id="Tc_T24MrPVxp0S0h97C-Zrv0g_34_3">24,916</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LineOfCredit" scale="3" id="Tc_jmqFKje4306AmmTAhNq_zQ_34_6">24,857</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:69.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:8.5pt;">Note payable, non-current</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermNotesPayable" scale="3" id="Tc_kQrdJPSgzE68XGiJysgHiw_35_3">20,979</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermNotesPayable" scale="3" id="Tc__fC0GgJ-tUOQlxagjlYf8g_35_6">26,933</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:69.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:8.5pt;">Earn-out, non-current</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q" decimals="-3" format="ixt:numdotdecimal" name="tcmd:EarnOutNonCurrent" scale="3" id="Tc_vTk1cxpjZEylateX9c-9kw_36_6">2,950</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:69.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:8.5pt;">Accrued warranty reserve, non-current</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProductWarrantyAccrualNoncurrent" scale="3" id="Tc_t5NkCF-tjkOJIqTHKYoBzw_37_3">2,207</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProductWarrantyAccrualNoncurrent" scale="3" id="Tc_Us3xPqUilk6d1o-X5vb6wg_37_6">3,108</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:69.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:8.5pt;">Income taxes payable, non-current</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedIncomeTaxesNoncurrent" scale="3" id="Tc_SMkQ7DviUk-xTiTV5ZV4fw_38_3">298</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedIncomeTaxesNoncurrent" scale="3" id="Tc_B6YdfBdU9UmkPArwJHAn4A_38_6">348</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:69.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:8.5pt;">Operating lease liabilities, non-current</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_YhiF5YGo3E6ss0B1dmTOhg_39_3">20,866</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_qoO-GnmS9kWWBhe1x7vFaw_39_6">23,354</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:69.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:8.5pt;">Deferred income taxes</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="3" id="Tc_pyFjYX4wqkqPZlEZs4MY1w_40_6">32</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:69.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0pt 24pt;"><span style="font-size:8.5pt;">Total non-current liabilities</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesNoncurrent" scale="3" id="Tc_fvvkno2ktEmUuaNYrnzNGw_41_3">69,266</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesNoncurrent" scale="3" id="Tc_mze89qmn2ESH4_U67G7cNQ_41_6">81,582</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:69.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0pt 36pt;"><b style="font-size:8.5pt;font-weight:bold;">Total liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="Tc_sRftdJloDkK5NMxxggiNJQ_42_3">133,596</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="Tc_mvipkR7o3kCP7eZKl0blUQ_42_6">116,043</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:69.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:8.5pt;font-weight:bold;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-size:8.5pt;font-weight:bold;">Commitments and Contingencies</b><span style="font-size:8.5pt;"> (see Note 12)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-size:8.5pt;font-weight:bold;">Stockholders&#8217; equity:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:8.5pt;">Preferred stock, </span><span style="font-size:8.5pt;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q" contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_si2v5aTdYEip5FofHm72kA"><ix:nonFraction unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q" contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr__UVRZDxqaUmTrbopCAgTSg">0.001</ix:nonFraction></ix:nonFraction></span><span style="font-size:8.5pt;"> par value, </span><span style="font-size:8.5pt;"><ix:nonFraction unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ" contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_-HZrkhRAwUuSVaX8jrJMAw"><ix:nonFraction unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ" contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_dXmRkz9G5U2L-VYRNxG7Pw">50,000,000</ix:nonFraction></ix:nonFraction></span><span style="font-size:8.5pt;"> shares authorized; </span><span style="font-size:8.5pt;"><ix:nonFraction unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ" contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="Narr_peVh5PLZH0eXP-Zd8Ef0hQ"><ix:nonFraction unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ" contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="Narr_8SQrETTBrEWaMgJHF6VXfQ">none</ix:nonFraction></ix:nonFraction></span><span style="font-size:8.5pt;"> issued and </span><span style="font-size:8.5pt;">outstanding</span><span style="font-size:8.5pt;"> as of December 31, 2022 and December 31, 2021</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_3S7QxW9bN0-5rDK2dHG7WQ;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8.5pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_FZYePmsfUEaYRZiApBW7xw;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8.5pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td></tr><tr><td style="vertical-align:bottom;width:69.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:8.5pt;">Common stock, </span><span style="font-size:8.5pt;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q" contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_YZTCd8M9AkOsv66b-jfZ1w"><ix:nonFraction unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q" contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_ZC_wsJYK7UWQyRcjN_aS7w">0.001</ix:nonFraction></ix:nonFraction></span><span style="font-size:8.5pt;"> par value, </span><span style="font-size:8.5pt;"><ix:nonFraction unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ" contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_GNd-H-06Jk-E4CF3KKzcqw"><ix:nonFraction unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ" contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_HfvGAR_huE23O8H1DmRYaA">300,000,000</ix:nonFraction></ix:nonFraction></span><span style="font-size:8.5pt;"> shares authorized; </span><span style="font-size:8.5pt;"><ix:nonFraction unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ" contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_jKuZ0VWtk0WQoUFe5BRz5w">20,252,677</ix:nonFraction></span><span style="font-size:8.5pt;"> shares issued and </span><span style="-sec-ix-hidden:Hidden__bCQNAsLokuxTIDsHWGXFQ;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8.5pt;font-style:normal;font-weight:normal;">outstanding</span></span><span style="font-size:8.5pt;"> as of December 31, 2022; </span><span style="font-size:8.5pt;"><ix:nonFraction unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ" contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_6hr9PN7jgUC0T9Lr2DrO8w">19,877,786</ix:nonFraction></span><span style="font-size:8.5pt;"> shares issued and </span><span style="-sec-ix-hidden:Hidden_xOwJC91HdkeMBD-SeycYHA;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8.5pt;font-style:normal;font-weight:normal;">outstanding</span></span><span style="font-size:8.5pt;"> as of December 31, 2021</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="3" id="Tc_nSDdQ5Cg4Ue0PRFcLpaAsA_48_3">20</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="3" id="Tc_cNJzlgCJGEmsqQ2IwLvYLw_48_6">20</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:69.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:8.5pt;">Additional paid-in capital</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="Tc_j58URLoOGkiXP8sYAjXy2A_49_3">131,001</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="Tc_mAHEoPfQVEKG5Y0Blige_g_49_6">119,962</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:69.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:8.5pt;">(Accumulated deficit) retained earnings</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="3" id="Tc_JulqCei9IUaB5lU3xgZaQw_50_3">9,621</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="Tc_QZfMcwcFuk6kLGDRDAgfrg_50_6">8,245</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:69.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0pt 24pt;"><b style="font-size:8.5pt;font-weight:bold;">Total stockholders&#8217; equity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_g7p1N4GvpkmPH-3YyHjB5w_51_3">121,400</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_Ibxo_C4dx0SIXmEs2vuXFg_51_6">128,227</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:69.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0pt 36pt;"><b style="font-size:8.5pt;font-weight:bold;">Total liabilities and stockholders&#8217; equity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_-c_8k_yv7kKc8W5Unm6pbQ_52_3">254,996</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_5NGuqHiKb0iEP9ceLfN-Mg_52_6">244,270</ix:nonFraction></span></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:6pt;background:#ffffff;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:justify;background:#ffffff;margin:0pt;">The accompanying notes are an integral part of these consolidated financial statements.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">88</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_23884206_4737_4a94_8c02_eaa3cf3c477c"></a><a id="ConsolidatedStatementsofOp"></a><a id="Operations"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;background:#ffffff;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_cf714e49_d184_4032_b652_2e45a663f6b6"></a><a id="Tc_cTEpJXT5k0W-lKyK1Xeu_A_1_0"></a><a id="Tc__qS3UMGEqEaDMlavoLP4Lw_2_0"></a><a id="ConsolidatedStatementsofOperations_48531"></a><a id="Tc_zsIxCTzDN0CiliTtbSDVKw_5_2"></a><a id="Tc_DD5Qpn4rXkmV_h5Eh5_72A_6_2"></a><a id="Tc_nZ67llnAhEa5TgMi8zZIOA_7_0"></a><a id="Tc_XW9uisNN5E-uqNfpMY5rRw_7_2"></a><a id="Tc_i3BMSNbBTUGz_RVl3lvUsA_7_5"></a><a id="Tc_MDtls0RsrECOu0qtAcHR3A_7_8"></a><a id="Tc_OLgIMSr5UU-JcwIkHu-9dQ_8_0"></a><a id="Tc_YieIySyvokqXGQIOA6-TKw_9_0"></a><a id="Tc_-6aoddZGo0WYTKUJLWaaEQ_9_2"></a><a id="Tc_wK_dPkucwE2FOOCjtxnsCA_9_5"></a><a id="Tc_ecL2SqJJG0afycU1UHjDyg_9_8"></a><a id="Tc_KMiN7AjhekOe9OsQWkdScw_10_0"></a><a id="Tc_NoOY580lR0Gwn547jng2FQ_11_0"></a><a id="Tc_u9cYiN2_Wk-U_klPAB3BCw_12_0"></a><a id="Tc_yoSRylLXl0KZpzj1v5Ne4A_13_0"></a><a id="Tc_cKwaRA2OP0S7lJNjOjG_ug_14_0"></a><a id="Tc_G2OgocW7A0uIps9mQPxJbQ_15_0"></a><a id="Tc_WvHAHMyFGkqetobe4PjHfw_16_0"></a><a id="Tc_i2w4322gVUOiM9K5dNG-dg_17_0"></a><a id="Tc_NTeKUVJKgU-oxfF9KxVSdw_18_0"></a><a id="Tc_s6uJezBrqUevIJnjH1ADhg_19_0"></a><a id="Tc_3devVhia1UyGlcm8xNthUg_20_0"></a><a id="Tc_WRP_bZq2AkmDbrAVwty08Q_21_0"></a><a id="Tc_fPmb1zntT0Ku2PumOkQHNQ_22_0"></a><a id="Tc_PNo06rB7Ck21C9FPV9niUA_23_0"></a><a id="Tc_WBOH5Xy9YUG57xldrVqiUw_24_0"></a><a id="Tc_QGDGdOcqtk-NOYjCDOQl_A_25_0"></a><a id="Tc_Bjt0eQPrx02EMzfVucsIBg_26_0"></a><a id="Tc_W4YEI7SFpkmZbyCjhXdxIg_27_0"></a><a id="Tc_lENW973AGkCtqRfNSi3wOA_28_0"></a><a id="Tc_LhXFb7PBMkKxt7PnH4FlPQ_29_0"></a><a id="Tc_JjA0C1Wr9UumeRhBCNwrDA_30_0"></a><a id="Tc_x_jkz2OPRUK856i7ZewZ5Q_30_2"></a><a id="Tc_OwJR-6fCo06EZRq_8wj_8Q_30_5"></a><a id="Tc_oTOgbuOgP0KHtga23hw72w_30_8"></a><a id="Tc_YcNAmhnah0mhtnb85n0lpg_31_0"></a><a id="Tc_WKyaRbY2ukSA1FZN_RDOhg_32_0"></a><a id="Tc_UAdwxOISskOcQJwhjiG7QQ_32_2"></a><a id="Tc_KQ1BnW3POk67Ng5VBHw1AQ_32_5"></a><a id="Tc_ijF_abz7LE6Yk1OiAvz_9Q_32_8"></a><a id="Tc_CIIa-VXHXkmToWYTDb3ycg_33_0"></a><a id="Tc_9r5uq2b79E23hb_VT_au0Q_33_2"></a><a id="Tc_rdeZJEr-0kKSW6Bq2lwKxg_33_5"></a><a id="Tc_bFYVGRszSEWts0KXQx4htA_33_8"></a><a id="Tc_EMkjbh3S2E6tHs_xfB-bDA_34_0"></a><a id="Tc_wsM_nv4SgkSaCUT6AFlTHA_35_0"></a><a id="Tc_h9HJIjHyyUO3kvd3okNtPw_36_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:51.03%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="10" style="vertical-align:bottom;white-space:nowrap;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Tactile Systems Technology, Inc.</b></p></td></tr><tr><td colspan="10" style="vertical-align:bottom;white-space:nowrap;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Consolidated Statements of Operations</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.03%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.03%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.03%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:46.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:51.03%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:46.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">(In&#160;thousands,&#160;except&#160;share and per share data)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Revenue</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.03%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Sales revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_SP3wyCMXCU2i6drZEHq64A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_dgwKQUmqokGOHhuOarM9pg_9_3">211,345</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_hfu9P6iNKUi9O4wj8Mt1eQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_i9HAD3YX0EOBtF_smN06dA_9_6">177,914</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2020_To_12_31_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember_cRwZGotvHkm9Z1U4mHwTFw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_us4EexZoWECtCn-YN43jbw_9_9">161,497</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:51.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Rental revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_tcmd_RentalProductServiceMember_UQEeT0sALU2WyRpN4h-d1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_0-cvrlUGekiUUiz3WTTncw_10_3">35,440</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_tcmd_RentalProductServiceMember_SHuwLl4tzECMukntSz1kJw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_7OL4gP0DVU2_jAzCU_9H7Q_10_6">30,143</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2020_To_12_31_2020_srt_ProductOrServiceAxis_tcmd_RentalProductServiceMember_NFKOoDrORk2r6CW4q3szBw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_PZtzIwozkka4Qz_zrIbEFg_10_9">25,633</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:51.03%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Total revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_VQ9Nb7rUdUG9oSRh1o9nXg_11_3">246,785</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_J6vMXVxX2Uy40vTdhNFCKw_11_6">208,057</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_Mx8PoHHTcEGUEmEgMtXQEw_11_9">187,130</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:51.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Cost of revenue</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.03%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Cost of sales revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_SP3wyCMXCU2i6drZEHq64A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfRevenue" scale="3" id="Tc_5M1fb_snL0GiXEZfIXIIcQ_13_3">59,619</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_hfu9P6iNKUi9O4wj8Mt1eQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfRevenue" scale="3" id="Tc_Ij52zBzHFUOktj4tR4eOQw_13_6">50,222</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2020_To_12_31_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember_cRwZGotvHkm9Z1U4mHwTFw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfRevenue" scale="3" id="Tc_RvvmnAqpoEylwsSZF2GxqA_13_9">45,309</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:51.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Cost of rental revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_tcmd_RentalProductServiceMember_UQEeT0sALU2WyRpN4h-d1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfRevenue" scale="3" id="Tc_UqM7pOm5MUig32SsXj9FEg_14_3">11,190</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_tcmd_RentalProductServiceMember_SHuwLl4tzECMukntSz1kJw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfRevenue" scale="3" id="Tc_xlLoEarRQEOB8TeTdPBYyw_14_6">9,622</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2020_To_12_31_2020_srt_ProductOrServiceAxis_tcmd_RentalProductServiceMember_NFKOoDrORk2r6CW4q3szBw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfRevenue" scale="3" id="Tc_wKf5DeeW-kS7ubfJ29PyKQ_14_9">9,011</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:51.03%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Total cost of revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfRevenue" scale="3" id="Tc_g6KBxWLJVUGAZhEx6P-Qow_15_3">70,809</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfRevenue" scale="3" id="Tc_bJHbbRFKAkCoJykPk5IhKA_15_6">59,844</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfRevenue" scale="3" id="Tc_3pSKzBLLKEmi7REUx-jDfQ_15_9">54,320</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:51.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Gross profit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.03%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Gross profit - sales revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_SP3wyCMXCU2i6drZEHq64A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="3" id="Tc_KA_XI6H1xEC7OfoSKG9Q2w_17_3">151,726</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_hfu9P6iNKUi9O4wj8Mt1eQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="3" id="Tc_NuYr--bj_0-D5xALlFXAbw_17_6">127,692</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2020_To_12_31_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember_cRwZGotvHkm9Z1U4mHwTFw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="3" id="Tc_w4W4SaSD5kGU-jmEnER0Qg_17_9">116,188</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:51.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Gross profit - rental revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_tcmd_RentalProductServiceMember_UQEeT0sALU2WyRpN4h-d1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="3" id="Tc_egGzsEiFpUeJHvB2jZP1Fg_18_3">24,250</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_tcmd_RentalProductServiceMember_SHuwLl4tzECMukntSz1kJw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="3" id="Tc_myKB-9BouUCJXM1S3QtXng_18_6">20,521</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2020_To_12_31_2020_srt_ProductOrServiceAxis_tcmd_RentalProductServiceMember_NFKOoDrORk2r6CW4q3szBw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="3" id="Tc_9r3HPPA3O0CypBfQ58c0hQ_18_9">16,622</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:51.03%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Gross profit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="3" id="Tc_tTp1y2Eg4kqXZaXDGOqWSQ_19_3">175,976</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="3" id="Tc_fgznoyD4gEqivnoEOElFyw_19_6">148,213</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="3" id="Tc_Iv0hO1rXP0ufrRvljtkJLQ_19_9">132,810</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:51.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Operating expenses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.03%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Sales and marketing</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingAndMarketingExpense" scale="3" id="Tc_qnToGWLLCECOBajk07NCig_21_3">106,418</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingAndMarketingExpense" scale="3" id="Tc_9CwgfepvKUenpGgHcA289A_21_6">86,775</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingAndMarketingExpense" scale="3" id="Tc_-0n768rB5ESo62rsIeppUg_21_9">79,634</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:51.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_ooW63zii40maAXg4Sakq0w_22_3">7,088</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_PRUgMcYKhUaDaD6hwKQplw_22_6">5,659</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_PR3OBCFzX0CcrQNUvzAQeQ_22_9">5,264</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:51.03%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Reimbursement, general and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="Tc_xCRseyENhU6PGzG8bGbBVQ_23_3">60,796</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="Tc_5NIG258MqEWKwH7mR13vDQ_23_6">56,802</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="Tc_0Oz1ZHVc_0Kgszi_-ysL8g_23_9">51,343</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:51.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Intangible asset amortization and earn-out</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" decimals="-3" format="ixt:numdotdecimal" name="tcmd:AmortizationOfIntangibleAssetsAndEarnOuts" scale="3" id="Tc_1s4mbqLveE2rKQPVFuJiCw_24_3">14,432</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g" decimals="-3" format="ixt:numdotdecimal" name="tcmd:AmortizationOfIntangibleAssetsAndEarnOuts" scale="3" id="Tc_dXhDfnpayUimAzPAylsoQA_24_6">739</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA" decimals="-3" format="ixt:numdotdecimal" name="tcmd:AmortizationOfIntangibleAssetsAndEarnOuts" scale="3" id="Tc_B--guv3R00ub2bAuQHJs3A_24_9">197</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:51.03%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Total operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="Tc_VJ2NccjbTUqMOQluOeCtxQ_25_3">188,734</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="Tc_hqBGO6h5SU-vU1W77UY5oA_25_6">149,975</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="Tc_QRO6qzShDESyNe8OrkIIew_25_9">136,438</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:51.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Loss from operations</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_oSpbTuVgyEiS8_0i1KfrzQ_26_3">12,758</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_2pFk6SRx9kWbRyogTCCuNg_26_6">1,762</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_KmGOJs_fB0Cbj8n-0AnovA_26_9">3,628</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:51.03%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Other (expense) income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" sign="-" scale="3" id="Tc_oLeHZkrTyE-DbCfevHVoig_27_3">2,715</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" sign="-" scale="3" id="Tc_hehQjydhYUa81LguCWi3Mg_27_6">531</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="Tc_39p4x6KFwUu8jQbdS8x6FA_27_9">1,367</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:51.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Loss before income taxes</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="3" id="Tc_x-7SgZMtQEmKC7vvCefm3Q_28_3">15,473</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="3" id="Tc_2NHoRiPnMkSx9q5OulcxLg_28_6">2,293</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="3" id="Tc_5QjNpbor1kurUr2ICKdM7g_28_9">2,261</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:51.03%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Income tax expense (benefit)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="Tc_KyqixvJ1JEyUm-RWKta7ZQ_29_3">2,393</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="Tc_jcIyqLUTaki0lHCBmTs-0w_29_6">9,518</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" sign="-" scale="3" id="Tc_AXn1kRSw10Cz4YORUASobA_29_9">1,641</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:51.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="3" id="Tc_J8WHgJqN10-yXC7pJRP9ug_30_3">17,866</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="3" id="Tc_XL49vIHGIkutXf6kuaNsog_30_6">11,811</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="3" id="Tc_y84iVuj4CEyjkhjiMaDEbw_30_9">620</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:51.03%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Net loss per common share</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Basic</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">(<ix:nonFraction unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q" contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" sign="-" scale="0" id="Tc_b3J_sLUbfUmlRbI-tJkaxQ_32_3">0.89</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">(<ix:nonFraction unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q" contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g" decimals="2" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" sign="-" scale="0" id="Tc_3jSLDmqdGkOqX0S0CRIdiQ_32_6">0.60</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">(<ix:nonFraction unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q" contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" sign="-" scale="0" id="Tc_p4I30vCC-UOYFQz-v6AdPQ_32_9">0.03</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:51.03%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">(<ix:nonFraction unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q" contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" sign="-" scale="0" id="Tc_sldD6oDQAUyv_z8J6rfX0Q_33_3">0.89</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">(<ix:nonFraction unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q" contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g" decimals="2" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" sign="-" scale="0" id="Tc_yOOar1wkLEqT4hOwqAV5BA_33_6">0.60</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">(<ix:nonFraction unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q" contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" sign="-" scale="0" id="Tc_TRC0D7As2UyvbWHxo_FiAg_33_9">0.03</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:51.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Weighted-average common shares used to compute net loss per common share</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.03%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Basic</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ" contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_guiMXGLFoEOzvof7N8RNsA_35_3">20,067,969</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ" contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_2IiHsAqO5k25haexHxNf5g_35_6">19,719,485</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ" contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_DuwFfu68qUiabVELgJryEg_35_9">19,346,929</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:51.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ" contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_5QSB0xtU8kW7UCj2aeWZkA_36_3">20,067,969</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ" contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_UC6UF4pi2E2D2PfFQFtL6Q_36_6">19,719,485</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ" contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_kK_x8KJnjk64a0OsD77RBg_36_9">19,346,929</ix:nonFraction></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:6pt;background:#ffffff;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;">The accompanying notes are an integral part of these consolidated financial statements<span style="font-size:10pt;">.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">89</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Comprehensive_Loss"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_44cb6c02_90c6_4905_8aaf_83da9c210c63"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><a id="_8303b820_068d_4cec_9ebb_95bf979f8f14"></a><a id="Tc_l6mIy8PAXE2p-paK4Mk_OA_1_0"></a><a id="Tc_5-Dq5jQOS0-x9N4odAOjew_2_0"></a><a id="Tc_B5mWBOsrkkCD88bNtVk7_w_3_1"></a><a id="Tc_BPcgrfQP5k6STDPt2Ku2vg_4_1"></a><a id="Tc_0bZLxN6eM0mDKoE0kgweSw_5_0"></a><a id="Tc_Xwr6DnVIc0O_RekPC_fNxg_5_1"></a><a id="Tc_WjwpSNv2lUu7e95lNNNbBg_5_4"></a><a id="Tc__GlSe861NUaxpfxk6RSMUQ_5_7"></a><a id="Tc_W-yKBQK1QU-X4_XKiOBJuQ_6_0"></a><a id="Tc_bJgBR71YykaYRtxOFpjWWg_6_1"></a><a id="Tc_s1NHalgw1ES1FGbskBqOOQ_6_4"></a><a id="Tc_3xV_joY8pUW0cZyIDn4iiQ_6_7"></a><a id="Tc_2huMjCv_I06DAfBUZA_-kg_7_0"></a><a id="Tc_Wsczqm0mrkSpL-d9IerjLA_8_0"></a><a id="Tc_1Vd0kcCbm02sinqPJBf3qA_8_2"></a><a id="Tc_EpDlCFpLz0SqdSXEntqpng_8_5"></a><a id="Tc_czFS_njx1UWN3CH4zDIfsg_9_0"></a><a id="Tc_xmvPFq_VmEuE5Ug3It_nCw_9_2"></a><a id="Tc_1B2eU7log0GFCjdm5Ucp4A_9_5"></a><a id="Tc_gx6lmic3MkKlodeKxPNJfw_10_0"></a><a id="Tc_0nh-KXVSzkmfG3yCg1j6qA_10_2"></a><a id="Tc_xecWc5vfOkmUwq8uGmj44g_10_5"></a><a id="Tc_zVhy3UEiEEeVNWmEOJt8bw_11_0"></a><a id="Tc_uGoL07A0NUqLJTAIcBPHbw_11_1"></a><a id="Tc_lHKXQEZBZkW4LNSpykk2sA_11_4"></a><a id="Tc_1KB7ySEjykOPE73ZRf3wtQ_11_7"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:55.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td colspan="9" style="vertical-align:bottom;white-space:nowrap;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Tactile Systems Technology, Inc.</b></p></td></tr><tr><td colspan="9" style="vertical-align:bottom;white-space:nowrap;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Consolidated Statements of Comprehensive Loss</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:44.01%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:55.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:44.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:55.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">(In&#160;thousands)</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_hFwhUN-gukSNH3X_uhs9eA_6_2">17,866</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_sL9nsRSA3EC7Gu943ZTWiQ_6_5">11,811</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_sZzeYz00Hke3GgcYRvaQOA_6_8">620</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0pt 12pt;">Other comprehensive loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0pt 24pt;">Unrealized loss on marketable securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" sign="-" scale="3" id="Tc_oGLOajyU1UaXt0xK__8pbg_8_8">21</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0pt 24pt;">Income tax related to items of other comprehensive loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" scale="3" id="Tc_XFA6lM3AokCdNfhZZuoSNA_9_8">5</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0pt 12pt;">Total other comprehensive loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" sign="-" scale="3" id="Tc_8yqniDuZFESC5xniXmZPQQ_10_8">26</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">Comprehensive loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" sign="-" scale="3" id="Tc_m0g8cGgzVkuqhUEZAhLHFg_11_2">17,866</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" sign="-" scale="3" id="Tc_symwVaD2JUOgI6TeeluI9w_11_5">11,811</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" sign="-" scale="3" id="Tc_VyRcUqBoU0WrsSLNfC9IYA_11_8">646</ix:nonFraction>)</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:justify;margin:0pt;">The accompanying notes are an integral part of these consolidated financial statements.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Arial','Helvetica','sans-serif';line-height:0pt;text-align:justify;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">90</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:8%;padding-right:8%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_b470a7e5_e63a_4f4d_9383_83f55f772f02"></a><a id="ConsolidatedStatementsofSE"></a><a id="Equity"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;background:#ffffff;margin:0pt 0pt 6pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_1abda04e_aafc_4edc_94fa_74d8d70bb55a"></a><a id="Tc_eA061yUapUW0s1Tj8-D45Q_1_0"></a><a id="Tc_LSEbZmr620ix06ZdyyxZTw_2_0"></a><a id="Tc_gt_FpRRl1kS3QMXsyVB2fg_5_10"></a><a id="Tc_WnbAwsv6IE2lewf17q7hdA_5_13"></a><a id="Tc_yIkRmS6nAk6AFX9b4ocjdg_6_7"></a><a id="Tc_KWwOZpfIBEGPsM8ecWzxzw_6_10"></a><a id="Tc_QzhTK2LaiE-DW_ciL4Z10Q_6_13"></a><a id="Tc_T_h0esBFvUCZnIdXNROzFA_7_2"></a><a id="Tc_PSra7LFyfEaVQyCOEXeBvA_7_7"></a><a id="Tc_xxjIPcicmU2fIY-pLH4_mQ_7_10"></a><a id="Tc_vFt3r0iRxE2fXx7iwSMubg_7_13"></a><a id="Tc_W_9QufStwk-MBS92sJYA9g_8_0"></a><a id="Tc_eeeOhwRlykKnSzRvlB2W5w_8_2"></a><a id="Tc_d7YLFK6zYku2N9I5bYFgzg_8_4"></a><a id="Tc_MnwTbTwGckK7wzSAxUZ_-A_8_7"></a><a id="Tc_bwuZRqnK3EOUh4RTB6kLEg_8_10"></a><a id="Tc_xgnKG70OcEmupkEqno0J4g_8_13"></a><a id="Tc_VZ7dAPxY1Ue1za9Db8O4Tw_8_16"></a><a id="Tc_eisVuwLmw0qlPaYYl8AmOQ_9_0"></a><a id="Tc_jrDt7dHJ-U6BfLQ-2dd3_Q_9_4"></a><a id="Tc_iITZypf9l0KXkwkWD3w08g_9_7"></a><a id="Tc_-3y1V7iAfkKTYJh9HNFzXA_9_10"></a><a id="Tc_n-dk5fqpWUSCXqnMAzFQaQ_9_13"></a><a id="Tc_vxoplOsXZE-94-TfyTC-Qg_9_16"></a><a id="Tc_A0iW0p8lCUeNkb5Cczg7-A_10_0"></a><a id="Tc_o3jhOAN2_UCPNFvWcq0Lcg_10_2"></a><a id="Tc_oKAFdjm6Kk6cCOHtWQu3hQ_10_5"></a><a id="Tc_Th6V-3ND7EajJeXqNvVZYQ_10_11"></a><a id="Tc_UNlIlA5uhUSTXge_SBiQDg_10_14"></a><a id="Tc_Q6xInWMFbkStZKpoqBYtLw_11_0"></a><a id="Tc_4NzyOnJaSkCuC7BIWAlLzw_11_5"></a><a id="Tc_bOMRRFt_CUOtBEkMYrZxxg_11_11"></a><a id="Tc_FHdIneKcSE6I-dhAk2tZyQ_11_14"></a><a id="Tc_wSClCIwsMEeV7Ml4c_fjhQ_12_0"></a><a id="Tc_PZ9kDSi_kky5LDwX9KjIvw_12_5"></a><a id="Tc_uyD2LfkFXEuq6vaM9_2jbw_12_11"></a><a id="Tc_cGI3DvDnvUO3FIRU59NxGA_12_14"></a><a id="Tc_All3NJu4ZEGVc4IDkQt6bw_13_0"></a><a id="Tc_9ScZXGNpfEuwVgnNkilRBQ_13_5"></a><a id="Tc_GbudFVtXy0Ov-J8g4Bfidg_13_11"></a><a id="Tc_54ib7dBDkEic01-EEvhzWA_13_14"></a><a id="Tc_oEv9CDYdikqGLjmBuRmPpQ_14_0"></a><a id="Tc_0kNjwfjzA0WW2ro1zO6jCQ_14_2"></a><a id="Tc_ejRBeTuFpUirWXEVWhqmjA_14_5"></a><a id="Tc_71eRZ9cS7UCcoeov9JVOgg_14_8"></a><a id="Tc_StGA8H4CGkOOzqhpFyiObQ_15_0"></a><a id="Tc_u77evUvBykiDT2jSoQuuWA_15_4"></a><a id="Tc_vH8usFD84UC7I79KGh_4Ng_15_7"></a><a id="Tc_fgsEzBIO5UWtGS9c7pvOvw_15_10"></a><a id="Tc_EPKcwNiR9UOmmlCkNsNrJw_15_13"></a><a id="Tc_5c5ycIDeAka7TKcMkSvzTw_15_14"></a><a id="Tc_cofAFNi7EEyOnFZQTdXODA_15_16"></a><a id="Tc_k_GsjVeKXkG41jPsUDxX3A_16_0"></a><a id="Tc_XYNWJBrWVU2INTB172Ix_Q_16_2"></a><a id="Tc_iqdz-zXwLESe7kIEbOeV5g_16_5"></a><a id="Tc_L4pu1f-pWkeCPS47El-X3A_16_11"></a><a id="Tc_qQdbA9dY1EKg8CJFuBXbfg_16_14"></a><a id="Tc_i39Mg6iN_0aJNifgbcNpQA_17_0"></a><a id="Tc_XgWzJlDUdUKvGSEGxulLZA_17_11"></a><a id="Tc_nqcHtlL1K0OQ6FOg4dJ8fA_17_14"></a><a id="Tc_3k2XdWf00kKsCpnqYwbrlw_18_0"></a><a id="Tc_YvCZzLXWLkuqpGvrUDPcYw_18_5"></a><a id="Tc__Uz6VjH5HkWEcFtPBSk7Yg_18_11"></a><a id="Tc_FHhGX9SSIE-ijEMJBptX2g_18_14"></a><a id="Tc_HrOYQmjtpk61V9P6eZ2NEw_19_0"></a><a id="Tc_QHMXaOLwi0OT7DBem_pATA_19_5"></a><a id="Tc_g-Z15QS8HUW--N06VJhVAQ_19_11"></a><a id="Tc_sDUJtRr1OEamUdKDzssnng_19_14"></a><a id="Tc_JOFg8M8Kwkijlcq3mTUfng_20_0"></a><a id="Tc_4CuVAZqVvkyFjGeofccfew_20_2"></a><a id="Tc_g5EegUOu60Kdc78PbvBFoA_20_5"></a><a id="Tc_JQEQyXSthUWWbg3jOkpdwA_20_8"></a><a id="Tc_9sh0A0RkoU6f-KWLxYETgw_20_14"></a><a id="Tc_NEJFBIVMgEG0iwnprm3rgQ_21_0"></a><a id="Tc_ePwwEZIUiUOYf8dcTIF80g_21_4"></a><a id="Tc_c-JmullYi0qeu7vl59sEYA_21_7"></a><a id="Tc_73tmwkz42k-6IcdXvGWtIQ_21_10"></a><a id="Tc_y-W-2kZYEka4N5Fib9eF-w_21_13"></a><a id="Tc_-b1StammAE-40mqp-X7xVg_21_14"></a><a id="Tc_vAXwa35da0iuysTRFpSB1g_21_16"></a><a id="Tc_gkBamlDTKUi5yk7zVPcQoQ_22_0"></a><a id="Tc_rX6cqNGMGUitkxpcre9-mg_22_2"></a><a id="Tc_dAZcH4bUm0Ojq6xzRSUMig_22_5"></a><a id="Tc_XMyg5Z4Cn0eKRTz_u02aWA_22_11"></a><a id="Tc_-qOmjyRKNkiPvxe2T1bf0Q_22_14"></a><a id="Tc_gDRUlWRV60em4loB6Q3d3A_23_0"></a><a id="Tc_pdiLjuWgAUCjntVJmwrq_Q_23_5"></a><a id="Tc_fUtOiGj-mkutjhPrrnbKsw_23_11"></a><a id="Tc_0tVS5vyaeky3oF_1lUJuxA_23_14"></a><a id="Tc_KMmAOwOG1EqOJu3urg8e5Q_24_0"></a><a id="Tc_Ejz53q0qEkKz4x5rrNpy7A_24_5"></a><a id="Tc_e50_bZzTQEeF_BTgan7Fzw_24_11"></a><a id="Tc_eRO7AuDAdUOUG1k9qYp0ew_24_14"></a><a id="Tc_8atLvXZIYkCrgm3MM87Uaw_25_0"></a><a id="Tc_2NC22ZAEXEiEoW8R-p_dOQ_25_2"></a><a id="Tc_cFpAzAz_-0WpDdhkNR3UTw_25_5"></a><a id="Tc_5QlAkWpzEEeWnwn3LhrRuA_25_8"></a><a id="Tc_hYc715vu-0-Pg6aXz1u_qw_25_14"></a><a id="Tc_U8g6FnJ-c0qh09Y4CFtXiA_26_0"></a><a id="Tc_qL9QmJe_X0uEx0SdRZxA4g_26_4"></a><a id="Tc_JTGhCMqp_EewE9AK3bMyfQ_26_7"></a><a id="Tc_6pwOu7vXpEiyG17nKv2KOg_26_10"></a><a id="Tc_CdHNyxyc20i9I9Mti-FVxg_26_13"></a><a id="Tc_bRJoMEyuQkC4EGf6VJB2TQ_26_14"></a><a id="Tc_MHPMFF_pakeBiUgtFm-HLA_26_16"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:31.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td colspan="18" style="vertical-align:bottom;white-space:nowrap;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Tactile Systems Technology, Inc.</b></p></td></tr><tr><td colspan="18" style="vertical-align:bottom;white-space:nowrap;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Consolidated Statements of Stockholders&#8217; Equity</b></p></td></tr><tr><td style="vertical-align:bottom;width:31.01%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:31.01%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.87%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:31.01%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:19.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.87%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:31.01%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.87%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Additional</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Deficit)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:31.01%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:19.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Common&#160;Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.87%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Paid-In</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Retained</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Comprehensive</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:31.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">(In&#160;thousands,&#160;except share data)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Par&#160;Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Earnings</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:31.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Balances, December&#160;31, 2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_831Iwe84l0uIaFkRq3YMEA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_4rbNp7GVCEyI8FPWuwsUzA_9_2">19,152,715</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_831Iwe84l0uIaFkRq3YMEA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_NHQ_3He4dEuYr1VvePHaxw_9_5">19</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_bAXadoBqGUyVY6l0rjAY1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_yxWoePSRM060HjFQ6BbEow_9_8">91,874</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_SzV_dAN03kCUiZaHywHGxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_Umi8zJbiXE6rzJl87hDF5w_9_11">20,676</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_dwEtqEfNw0CpirbkcmdKtw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_yR0EFNSz8EqECGLA0j0WDA_9_14">26</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2019_3ga0jBjg6EKA4-znaQ36NQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_8vfWJEPSDUOqPhA4AkUl8w_9_17">112,595</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:31.01%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_dZyQCZO280GpmViirHXo1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="Tc_Iz_KpalNzUKsfmVGSkNz_A_10_8">10,689</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="Tc_axB24DiRzka4U_8iceNsKQ_10_17">10,689</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:31.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Exercise of common stock options and vesting of restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_26fO_zM0qkaf9YFqHV50Wg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_sYCd5IYZCUyzDKV8lU998w_11_2">303,709</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_dZyQCZO280GpmViirHXo1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_967iU3JV9km9OsL7FWeEEw_11_8">1,068</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_pAerDGAB00afPYqrPHjPeg_11_17">1,068</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:31.01%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Taxes paid for net share settlement of restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_26fO_zM0qkaf9YFqHV50Wg" decimals="INF" format="ixt:numdotdecimal" name="tcmd:AdjustmentsToAdditionalPaidInCapitalSharesOther" scale="0" id="Tc_jilFcF1cRUWvg2RzQHRS7Q_12_2">37,790</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_dZyQCZO280GpmViirHXo1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" sign="-" scale="3" id="Tc_vVO7A0zYYUiBDtFzfJ6rEQ_12_8">1,854</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" sign="-" scale="3" id="Tc_o3f6onOqK06RkqTCX6ArIQ_12_17">1,854</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:31.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Common shares issued for employee stock purchase plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_26fO_zM0qkaf9YFqHV50Wg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="Tc_AeRiFmfsVUSEFJMC24lf6g_13_2">74,084</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_dZyQCZO280GpmViirHXo1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="Tc_uxOUaP1ibkaK9qQ17vWMzw_13_8">2,898</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="Tc_Csa8xrIm8E-dfy_nBSBiUg_13_17">2,898</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:31.01%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Comprehensive loss for the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_CN1dmz1V3Ue1flAlam2dNQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" sign="-" scale="3" id="Tc_kcnFFHXeREOmJdhoFU19ag_14_11">620</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_aFuDPm3quE6OkMXnwfeySg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" sign="-" scale="3" id="Tc__9iEExGMm0iEzaPpEk7HBg_14_14">26</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" sign="-" scale="3" id="Tc_LrEhNmHktkOtPY9WpqWhcQ_14_17">646</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:31.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Balances, December&#160;31,&#160;2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Qp36H0EGtUGt3jcLLgZfHw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_AMqhGkJGmk-_zAAt30GbVA_15_2">19,492,718</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Qp36H0EGtUGt3jcLLgZfHw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_0FmU7cdqoU-SyWiTvCuIJA_15_5">19</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_iD4fs-NVZUqKbPMH2pu8Tg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_TAT3Us11dEqWhSrTW3gfpA_15_8">104,675</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_BPwmELKt2UWgprqGAT1saQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_ej_TK63vcUmQcMuUClbz4A_15_11">20,056</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2020_q95ww8WB7U-18mlScI3MCA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_pU2qQgkg5Uen2Vku1GAXTw_15_17">124,750</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:31.01%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Yly5bMDTYE-lx-OvMp67yw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="Tc_YXKtPSKoXkaHAI8BEZ7ZDg_16_8">10,173</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="Tc_tH27-pyWkEGpRmNl9OCTEQ_16_17">10,173</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:31.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Exercise of common stock options and vesting of performance and restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_4VmedOiWwk-TuOc3qFFccg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_-5DbVN_Z1kuiS9ZLvAEfAQ_17_2">333,763</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_4VmedOiWwk-TuOc3qFFccg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_GSsQYh460UO5W3q3E4Yg4A_17_5">1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Yly5bMDTYE-lx-OvMp67yw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_ttGooq7SWkqMulfwRIc0uQ_17_8">3,975</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_hlHw0N7rP0iXw90-oN-khw_17_17">3,976</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:31.01%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Taxes paid for net share settlement of restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_4VmedOiWwk-TuOc3qFFccg" decimals="INF" format="ixt:numdotdecimal" name="tcmd:AdjustmentsToAdditionalPaidInCapitalSharesOther" scale="0" id="Tc_DLYszDnQE06q3Thm-JcmUg_18_2">22,357</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Yly5bMDTYE-lx-OvMp67yw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" sign="-" scale="3" id="Tc_d--0JWrRoE2Ublojxttsvg_18_8">1,173</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" sign="-" scale="3" id="Tc_CpgIKMmNQEWaogYjxZODcQ_18_17">1,173</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:31.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Common shares issued for employee stock purchase plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_4VmedOiWwk-TuOc3qFFccg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="Tc_rWJN_ecekEe-8WSQZssc2g_19_2">73,662</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Yly5bMDTYE-lx-OvMp67yw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="Tc_WTDiGr26REW0nDSBopM77w_19_8">2,312</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="Tc_YKw1YU0760W_usqTmf_sNw_19_17">2,312</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:31.01%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Comprehensive loss for the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_YaY3_P_Sw02KL1vnK5w7IQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" sign="-" scale="3" id="Tc_-SvHBxbiKEukiojyYCiTxQ_20_11">11,811</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" sign="-" scale="3" id="Tc_4Ig_ZLRBqk-Uf_Gb1S53oA_20_17">11,811</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:31.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Balances, December&#160;31,&#160;2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_BMz7mX7-OUWrFBdwQYForQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_6bIGNs39IkGw8W7eqExetQ_21_2">19,877,786</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_BMz7mX7-OUWrFBdwQYForQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_rVoPEqg0p02UcN8ZHVXO7g_21_5">20</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_JAb6JFyA10K9maMFF2T0yQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_NOhWFltSAU2CsJ9IP4y-Bg_21_8">119,962</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_H3RLfzlePUicZ6gsHqIN-g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_lTOJ-EOFBEq4oK2ghFkkCQ_21_11">8,245</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_3YfdpMzU5ECqufP_hBfFSQ_21_17">128,227</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:31.01%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_AggAm3MT3EmHS5mE0Dp2Yg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="Tc_S2JiRwVu50ykLROPTY0slg_22_8">9,600</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="Tc_GdAC4VZlVki846a_UHCKZA_22_17">9,600</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:31.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Exercise of common stock options and vesting of performance and restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_TR941NiDcUCdRWACyKn3Wg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_EmvhVYa9vEucgXpCzwkr5w_23_2">225,282</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_AggAm3MT3EmHS5mE0Dp2Yg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_X53KzzEec0GiddYNgy6ZKg_23_8">153</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_WjlvYYJoTUSgYjbjSFcSAQ_23_17">153</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:31.01%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Common shares issued for employee stock purchase plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_TR941NiDcUCdRWACyKn3Wg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="Tc_1zJWCm8t30-qTq7r-JBqPg_24_2">149,609</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_AggAm3MT3EmHS5mE0Dp2Yg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="Tc_h9OqNzkV0kGi6tW3oC3uIA_24_8">1,286</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="Tc_EntakCK3qkqh7lPyhSnPxg_24_17">1,286</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:31.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Comprehensive loss for the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_WCG-z2RnpUGRHcHammTWIw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" sign="-" scale="3" id="Tc_ak1uwN1Z-kKm0ueSJoUD7w_25_11">17,866</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" sign="-" scale="3" id="Tc_JdX4OTGtnUy31dqX3rd0jg_25_17">17,866</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:31.01%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Balances, December&#160;31,&#160;2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_jyxtNFkIQECm4cCy3eQwzQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_FhRWIdIB3E6GUvQlRBm98g_26_2">20,252,677</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_jyxtNFkIQECm4cCy3eQwzQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_IPPsAZwQ8kqQ8GCdwGyC0A_26_5">20</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_dQSyY2Nl1EyEQUyJvn7F7A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_6FsApqOQ0EqrOE2q8fGolg_26_8">131,001</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_-1H3pbcbgE2pDEcuUUIOQA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_gwMED-JFT0CydZFoDki4Wg_26_11">9,621</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_dQbFm1y3WEyYBpn4npvoXw_26_17">121,400</ix:nonFraction></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:6pt;background:#ffffff;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:justify;background:#ffffff;margin:0pt;">The accompanying notes are an integral part of these consolidated financial statements.</p><p style="display:none;font-family:'Arial','Helvetica','sans-serif';line-height:0pt;background:#ffffff;margin:0pt;"><span style="font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">91</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:84%;border:0;margin:30pt 8% 30pt 8%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_96e0c4af_3bdb_4a5f_a687_488bb83b573e"></a><a id="Cash_Flows"></a><a id="ConsolidatedStatementsofCF"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;background:#ffffff;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_6340acf7_9fdf_42c5_81d0_8e8d70e903d6"></a><a id="Tc_xaJNjjAn3ESn1ASzPEGPpQ_1_0"></a><a id="Tc_0mPHe_rLhUiwz5hp4xL1dA_2_0"></a><a id="Tc_y9yrPThcMUGamLFtxNCmOA_4_2"></a><a id="Tc_Z3Opu44kNEijaL3Sp8UPoQ_5_0"></a><a id="Tc_h-_dgtEzmUW_XoKMjkBeFw_5_2"></a><a id="Tc_BS5gi5HA1UCZNCqGgUKsCA_5_5"></a><a id="Tc_muRz9J1uTk6Htd1Yz0FqVg_5_8"></a><a id="Tc_JbyoHHDM1kO7co4ia7XTgQ_6_0"></a><a id="Tc_Gn-asJ6Ny02sNUPfW_Grag_7_0"></a><a id="Tc_LL48uT4ack2oEAuhhR3xgw_7_2"></a><a id="Tc_SVN4LI1iQUCHCEHLSF079w_7_5"></a><a id="Tc_IjWiHhriTU6z6ORd0a-zKg_7_8"></a><a id="Tc_wj446ZsWn0K4cAorG51Y7g_8_0"></a><a id="Tc_5mIjrxCYg0CZ_3cTCOqryg_9_0"></a><a id="Tc_Hx30TpMGXU-2-0D62IEyKA_10_0"></a><a id="Tc_WN7aR1VJvEq2Ogkj9A2gXw_10_3"></a><a id="Tc_Wmt7Jo4Kz0u-49a4ONU8Ig_10_6"></a><a id="Tc_hwleuD8HZUeQrMGcGsJCgA_11_0"></a><a id="Tc_bPCedNv4-Eu4_fkdgY-V8Q_12_0"></a><a id="Tc_kkrBOnej4kC9tUYJslWR5Q_13_0"></a><a id="Tc_FzYlqfl6yUujSztwM5vokg_13_3"></a><a id="Tc_F_HBIdOpJ0-pcelJm-_t6A_13_6"></a><a id="Tc_po8G4Kw0OkCilZhCjKxVGA_14_0"></a><a id="Tc_5m5nhgMO7kKdh8p1LUg8PA_14_3"></a><a id="Tc_LinN5W3xMUGlCG6AkqxyGA_14_6"></a><a id="Tc_iMhoktTVWkCNdYlZ-YQ44g_15_0"></a><a id="Tc_nlX-olove0qYvd6OO-0evA_15_9"></a><a id="Tc_A4u6LtM_2kS6vWKtmuiaUw_16_0"></a><a id="Tc_l4fBeSTf8EedcETMnJj71A_16_9"></a><a id="Tc_DE9pBTdpNESXTsJL8HdDCA_17_0"></a><a id="Tc_zfENzo-4wUGYzym3CVBjBA_18_0"></a><a id="Tc_3LX3Y0ZItkGhaCyt7EpCfA_19_0"></a><a id="Tc_06iv-eyCkk6A7MNAT0BZbQ_20_0"></a><a id="Tc_QpjJqnD0tkO_ImmaSD5lRw_21_0"></a><a id="Tc_Pjtpd9Por0Gvj3T5TAGMOw_22_0"></a><a id="Tc_lrJKKrSSWEK317x7h11chw_23_0"></a><a id="Tc_ErY2rM3lRUegR9Zw-wXWGw_24_0"></a><a id="Tc_x6XvP-mo9Ui9vGIZYi6DaA_25_0"></a><a id="Tc_H5kA3czsnU6kfeubjCZxuw_26_0"></a><a id="Tc_PueZS-pYXk2UKIZB3MxDKQ_27_0"></a><a id="Tc_pLUKvodHdEyiRVCcyOJ5AQ_28_0"></a><a id="Tc_g3fkSUmu-k2NpW8TJTj_Zw_29_0"></a><a id="Tc_qlxhLiGq30idWrx3GAOXFA_30_0"></a><a id="Tc_TqKsD-lYd0-Tz1ZOUfWK_g_30_3"></a><a id="Tc_6SlIs1wJv0Km7i28oUzpVw_30_6"></a><a id="Tc_SPoVE9isC0GWQoacHBYEQQ_31_0"></a><a id="Tc_kBELoVTzjkm-8Gj9fNHxDA_31_3"></a><a id="Tc_VPuh1snhVkm6llFfsQ0PFg_31_9"></a><a id="Tc_WKs036689U2YMF1lFLnLtQ_32_0"></a><a id="Tc_ctsqRxgnE0CctGd7t4bLVQ_33_0"></a><a id="Tc_8XKkFm8wIkuXagSnOxFgxQ_33_6"></a><a id="Tc_RuyMKQBk6UKq0v7u0azk9g_33_9"></a><a id="Tc_CdKijixWsUm2dRSYnYoCaQ_34_0"></a><a id="Tc_vnpVl_gAPEG_xhwZhiC8qg_35_0"></a><a id="Tc_U0g0reLbsE6j3jPiXn0QvQ_35_3"></a><a id="Tc_1vHMPi1N1U6ko5PtfHzfHw_35_6"></a><a id="Tc_o7nWQMiPzkCl-E22Q25B9w_36_0"></a><a id="Tc_3d3KHi6CJE6e6FMnaBk9PQ_37_0"></a><a id="Tc_lIDZDGaf-kKieALNCgYTFA_38_0"></a><a id="Tc_heZnePyzpUyh8qqcaTNv4A_38_3"></a><a id="Tc_Ub9EXnHk5E2gGvSF3_hOHA_38_9"></a><a id="Tc_WAzwcfclWkC07N-J1twIJA_39_0"></a><a id="Tc_qsxZGN4NiE6rJ63AKoBC1A_39_3"></a><a id="Tc_sauGN9VDWEixa-k2_zQ-EA_39_9"></a><a id="Tc_X8URaOj6GEWvHnatyDfXDQ_40_0"></a><a id="Tc_AKcrxdpM4U6pz8f5NmM6Mw_40_6"></a><a id="Tc_WHIos3nLz0CRflz9UWComw_40_9"></a><a id="Tc_UTTyGCiJg0GVRlToKYKwNw_41_0"></a><a id="Tc_HAf1Zzgtf0aRDcP8XuauwA_41_6"></a><a id="Tc_rMM1Gb9Mikqu8a_fqDWR5w_42_0"></a><a id="Tc_oWYluVRcvEmdixRXDIhHqQ_42_9"></a><a id="Tc_TMhE_a09Uk-j9d5v4ffehQ_43_0"></a><a id="Tc_sxpgbDcbZUex12x71nLArQ_43_3"></a><a id="Tc_u5MYkzIgsUqkwxwJSF-O0g_44_0"></a><a id="Tc_4ayAnVL9wkCnTWmP9HsEmA_45_0"></a><a id="Tc_jVxByvFPSUiNRi33TeK0Rg_46_0"></a><a id="Tc__XS46O-2jU-szurqbdjbAg_47_0"></a><a id="Tc_XG2gZg-oU0SfQ4nRdJC7Gw_48_0"></a><a id="Tc_XvwunVDtt0-PsN7Yvb1fJA_49_0"></a><a id="Tc_gIKSiqzh8EWrEhijXR_ISw_49_2"></a><a id="Tc_Z7l5k3OA5EWiwf9gXg54ew_49_5"></a><a id="Tc_MirSRHIDOkSYdksPufHFEQ_49_8"></a><a id="Tc_QkH_rZQnfUCJiswm7ttCWw_51_0"></a><a id="Tc_8lVVEOB7GUupQxac5jNWRw_52_0"></a><a id="Tc_ZKpGUnJmr0unqIINzUOrYA_52_2"></a><a id="Tc_0Gmk-9zYLkuEJ0PCtDYvZQ_52_5"></a><a id="Tc_jx3tTI2xskW1IB2JYnE9Tg_52_8"></a><a id="Tc_eIn0hxvmq0a06ipY6tLyPA_52_9"></a><a id="Tc_lo_ck_Cyz0egzIZK_M4jcQ_53_0"></a><a id="Tc_pGE1JNdtOkGt6DqNP-JZZw_53_2"></a><a id="Tc_3D_T2jLEs0mq4kBAFqWKNw_53_5"></a><a id="Tc_18z8U7zg4U6fUO6GQczXwA_53_8"></a><a id="Tc_J-rk9iasfU6YLaH0Vixr0w_54_0"></a><a id="Tc_6TVWiUjJxkmkovBvksLbtg_54_2"></a><a id="Tc_VligkTXtQkO6tRQJRYPz7Q_54_5"></a><a id="Tc_WdlCbccQaEeN_1Gl31X9Xw_54_8"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td colspan="10" style="vertical-align:bottom;white-space:nowrap;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Tactile Systems Technology, Inc.</b></p></td></tr><tr><td colspan="10" style="vertical-align:bottom;white-space:nowrap;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Consolidated Statements of Cash Flows</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:59.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:37.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:37.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">(In&#160;thousands)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr style="height:12.2pt;"><td style="vertical-align:bottom;width:59.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Cash flows from operating activities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0pt 12pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_JG1FohiKBE2upYERT9pOpg_7_3">17,866</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_njfiHWOqmU62uMI4gJZcVg_7_6">11,811</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_MuT3qSWEjU-vZir5RNFFxw_7_9">620</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:59.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0pt 12pt;">Adjustments to reconcile net loss to net cash provided by operating activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#ff0000;font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0pt 24pt;">Depreciation and amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="Tc_qDYKxG4HnkCZ6FSl7s-OKw_9_3">6,268</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="Tc__e-mCB5KTEOsNdXjOIX6-w_9_6">3,681</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="Tc_QUiOgX-mJ06GXahVRcEzfw_9_9">2,794</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:59.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0pt 24pt;">Net amortization of premiums and discounts on securities available-for-sale</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA" decimals="-3" format="ixt:numdotdecimal" name="tcmd:AmortizationOfPremiumsAndDiscountsOnSecuritiesAvailableForSale" sign="-" scale="3" id="Tc_L4TKwcDrPEKlrEEJuOBAlQ_10_9">91</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:59.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0pt 24pt;">Deferred income taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" scale="3" id="Tc_md48ulbts0GUoq7FvakyIw_11_3">32</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" sign="-" scale="3" id="Tc_zbfJZDu_tUKhg3VwJoRbzw_11_6">10,230</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" scale="3" id="Tc_26OjiFIVukiq6PvtsbwOnA_11_9">1,233</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:59.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0pt 24pt;">Stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_YvdQLRWGlU2raah1ZhiqwQ_12_3">9,600</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_ZtzCEt83DUKph3W5H7zG4Q_12_6">10,173</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_-1wKsMDuaESfR9QJjYDCuA_12_9">10,689</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:59.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0pt 24pt;">Gain on other investments and maturities of marketable securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:MarketableSecuritiesGainLoss" scale="3" id="Tc_DHCTjAq1YkO-RPNQcNOB2g_13_9">11</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:59.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0pt 24pt;">Impairment losses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetImpairmentCharges" scale="3" id="Tc_O8heaOzFcEO_KvTCOvRuGA_14_9">4,025</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:59.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0pt 24pt;">Loss on disposal of property and equipment and intangibles</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GainLossOnDispositionOfAssets1" sign="-" scale="3" id="Tc_Zg9zIQyVikKkimbLesY-uQ_15_3">20</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GainLossOnDispositionOfAssets1" sign="-" scale="3" id="Tc_GsYoZ2_9AUWplTZ7VdRPNw_15_6">20</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:59.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0pt 24pt;">Change in fair value of earn-out liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesFairValueAdjustment" sign="-" scale="3" id="Tc_e1ETpTTU9ke5Tr9a8oRW4A_16_3">11,850</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesFairValueAdjustment" scale="3" id="Tc_g237Hm_Mz0ucnCT1szVJiQ_16_6">200</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:59.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0pt 24pt;">Changes in assets and liabilities, net of acquisition:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0pt 36pt;">Accounts receivable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="Tc_Q1wOdKuv80GwleZTt3VVsg_18_3">5,348</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="Tc_shL4OXkY2Um1JbfDZBSN8w_18_6">5,629</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="Tc_SMkhx5ZdqkulMptX6W2Rug_18_9">10,405</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:59.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0pt 36pt;">Net investment in leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" decimals="-3" format="ixt:numdotdecimal" name="tcmd:IncreaseDecreaseInNetInvestmentInLease" scale="3" id="Tc_I5DLvPwu0k6uq-W36QwFXQ_19_3">3,648</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g" decimals="-3" format="ixt:numdotdecimal" name="tcmd:IncreaseDecreaseInNetInvestmentInLease" scale="3" id="Tc_Uv8T5B6JXEyspJ0iv5Wf_g_19_6">1,774</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA" decimals="-3" format="ixt:numdotdecimal" name="tcmd:IncreaseDecreaseInNetInvestmentInLease" scale="3" id="Tc_6BbjUZIllku_10egDP3pLA_19_9">2,561</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:59.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0pt 36pt;">Inventories</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="Tc_avrByfSp30muTNojgKsyiQ_20_3">3,907</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" sign="-" scale="3" id="Tc_dz0NJ5RIfUS7LTOOreLFSg_20_6">972</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" sign="-" scale="3" id="Tc__68rX4U9ekq1eHzfnPPZ1A_20_9">318</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:59.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0pt 36pt;">Income taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInIncomeTaxesReceivable" sign="-" scale="3" id="Tc_t0LwfiNOl0uhGfvYBsEyDg_21_3">2,270</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInIncomeTaxesReceivable" scale="3" id="Tc_INdlyoIJ4EazVQ4ak3NGPQ_21_6">2,294</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInIncomeTaxesReceivable" sign="-" scale="3" id="Tc_bAQXCoM-KkixXqlB1t-lkw_21_9">1,972</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:59.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0pt 36pt;">Prepaid expenses and other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="Tc_kIfKyZyklE6tvxGGdGrusw_22_3">950</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="Tc_msGP0205Vkiog5HsUj8wUA_22_6">1,489</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="Tc_ADZ4gI72zEWRqRuEgKhsdQ_22_9">528</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:59.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0pt 36pt;">Right of use operating lease assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" decimals="-3" format="ixt:numdotdecimal" name="tcmd:IncreaseDecreaseInOperatingLeaseRightOfUseAsset" sign="-" scale="3" id="Tc_aIs4l1gdYUKxq8jr4Pb8BQ_23_3">168</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g" decimals="-3" format="ixt:numdotdecimal" name="tcmd:IncreaseDecreaseInOperatingLeaseRightOfUseAsset" sign="-" scale="3" id="Tc_Ww0sWC4160iCvXjOlCtS-Q_23_6">614</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA" decimals="-3" format="ixt:numdotdecimal" name="tcmd:IncreaseDecreaseInOperatingLeaseRightOfUseAsset" sign="-" scale="3" id="Tc_NjiUYa0Zq0GVtkxKdgojyg_23_9">559</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:59.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0pt 36pt;">Accounts receivable, non-current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerAsset" scale="3" id="Tc_NIVJ3b2QFU-xqAQFHrJkVQ_24_3">10,214</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerAsset" scale="3" id="Tc_ybICp83TaU-TC5THGF-T9Q_24_6">3,414</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerAsset" scale="3" id="Tc_Y3CW-RIogk2WJUZ176WiGg_24_9">5,249</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:59.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0pt 36pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="Tc_x_ia48WyPUiaHr4h9qCx7g_25_3">4,961</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="Tc_IrjclXbkQk6XB1XHrC8-1A_25_6">826</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="Tc_O1_V9f5-3UOGo_ACD2RR_w_25_9">337</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:59.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0pt 36pt;">Accrued payroll and related taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" scale="3" id="Tc_2dXII_2uYEWDGIQOjQUvwg_26_3">4,961</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" scale="3" id="Tc_DrgVLKO3UEuzHFQe1VrBNg_26_6">551</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" scale="3" id="Tc_U9Ww0FDM9ECCkPc8lvgHWQ_26_9">1,490</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:59.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0pt 36pt;">Accrued expenses and other liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" decimals="-3" format="ixt:numdotdecimal" name="tcmd:IncreaseDecreaseInOtherAccruedLiabilitiesAndIncomeTaxesPayable" scale="3" id="Tc_5fZBq9PGsEGdm2tVuAqSgg_27_3">7,076</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g" decimals="-3" format="ixt:numdotdecimal" name="tcmd:IncreaseDecreaseInOtherAccruedLiabilitiesAndIncomeTaxesPayable" scale="3" id="Tc_Jyzc-G-7M0OyUL1sMVzOwQ_27_6">2,175</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA" decimals="-3" format="ixt:numdotdecimal" name="tcmd:IncreaseDecreaseInOtherAccruedLiabilitiesAndIncomeTaxesPayable" scale="3" id="Tc_uZ8nxrxBnk6AW5FgM8iK0g_27_9">1,308</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:59.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0pt 48pt;">Net cash provided by operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="Tc_w8OztEMfRkybXJAbAYA0Pg_28_3">5,209</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="Tc_Zzw6mSCNG0i2DPS8--Aifg_28_6">2,631</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="Tc_54HXWIU7sUCt0KFqmr12JQ_28_9">2,794</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:59.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Cash flows from investing activities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0pt 12pt;">Proceeds from maturities of securities available-for-sale</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" scale="3" id="Tc_6EP1KXaLdUOGrTmaNbrH3Q_30_9">22,500</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:59.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0pt 12pt;">Payments related to acquisition</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g" decimals="-3" format="ixt:numdotdecimal" name="tcmd:PaymentsToAcquireProductiveAsset" scale="3" id="Tc_CxIRyfxvz02440NgrEjxJQ_31_6">79,829</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:59.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0pt 12pt;">Purchases of property and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="Tc_dOv5JHHBJku-eFaeOJNW0Q_32_3">1,780</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="Tc_-PmVT4LX5kSo61b1oFp9EQ_32_6">2,103</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="Tc_XH3JxhJ8UEeAJ-D2B-RXCQ_32_9">2,059</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:59.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0pt 12pt;">Proceeds from sale of property and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="3" id="Tc__dJ7EqC6qE2dRCZvAuVWWw_33_3">11</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:59.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0pt 12pt;">Intangible assets expenditures</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="3" id="Tc_cEju7Ib_vkiOSQRT3MgnjQ_34_3">140</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="3" id="Tc_t3r0t1fg00aEBh3FEqBBBQ_34_6">252</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="3" id="Tc_vTVVpO5T5UWlzS03O1NYwA_34_9">232</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:59.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0pt 12pt;">Other investments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireOtherInvestments" scale="3" id="Tc_gCvAHuvY50axm2NXHuqm9A_35_9">30</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:59.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0pt 48pt;">Net cash (used in) provided by investing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="3" id="Tc_I0RPmrR-PUqCLjnEbNqpQA_36_3">1,909</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="3" id="Tc_jP2rzymzXkW3sT4mHL7ROw_36_6">82,184</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="Tc_7IFvMprfDUyd1NF83d2eag_36_9">20,179</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:59.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Cash flows from financing activities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0pt 12pt;">Proceeds from issuance of note payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromNotesPayable" scale="3" id="Tc_iZcMGUsv1kuhlglhjxWzpQ_38_6">30,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:59.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0pt 12pt;">Proceeds from revolving line of credit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromLinesOfCredit" scale="3" id="Tc_cleFUPh-p0-cuQ2NMggTCg_39_6">25,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:59.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0pt 12pt;">Payment on earn-out</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" scale="3" id="Tc_Be7OLdBjOEymILiXoVvpEQ_40_3">5,000</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:59.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0pt 12pt;">Payments on note payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfNotesPayable" scale="3" id="Tc_Gl8J3I6JJ0GswoavXke_Hw_41_3">6,000</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0pt 12pt;">Payments of deferred debt issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="3" id="Tc_LPolhorwoEOSZDFepm79KQ_42_3">39</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="3" id="Tc_b6RKEQnCJ06fBLrDzQDUhQ_42_6">188</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:59.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0pt 12pt;">Taxes paid for net share settlement of performance and restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g" decimals="-3" format="ixt:numdotdecimal" name="tcmd:PaymentOfTaxesForNetShareSettlementOfRestrictedStockUnits" scale="3" id="Tc_Y7N6gtDlh0m7O6wuclSycw_43_6">1,173</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA" decimals="-3" format="ixt:numdotdecimal" name="tcmd:PaymentOfTaxesForNetShareSettlementOfRestrictedStockUnits" scale="3" id="Tc_XuzeaH6lJESWkCiGAdJI1g_43_9">1,854</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:59.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0pt 12pt;">Proceeds from exercise of common stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="Tc_cxwf8f2djEy6PTIfa-M4Xg_44_3">153</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="Tc_9webpGxevkKhe3G3x5iq_Q_44_6">3,976</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="Tc_NE_ZgDCByUKVY2xQZSNSEA_44_9">1,068</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:59.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0pt 12pt;">Proceeds from the issuance of common stock from the employee stock purchase plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="Tc_JiMzMfnyKEKKbj4CyoJEfg_45_3">1,286</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="Tc_hyPuksMUXkWT4cLPThyooQ_45_6">2,312</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="Tc_srspgfreF0urDqZ7UcDmow_45_9">2,898</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:59.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0pt 48pt;">Net cash (used in) provided by financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" sign="-" scale="3" id="Tc_o_CFlfe47kOZEHjg0IMXLg_46_3">9,600</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="Tc_2mofP9XQB0eUIifZQ6clxg_46_6">59,927</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="Tc_9iVeR_kCz0OVYzBKNOvL5g_46_9">2,112</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:59.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Net (decrease) increase in cash and cash equivalents</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" sign="-" scale="3" id="Tc_UxuE2L2rUka9z3e5x8tNkA_47_3">6,300</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" sign="-" scale="3" id="Tc_iTvLmTVoYUCizLmqeEIjkQ_47_6">19,626</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" scale="3" id="Tc_LSf4-Wii0UKEL5kuuxf3yA_47_9">25,085</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:59.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">Cash and cash equivalents &#8211; beginning of period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_LBElmJZ5bEqx3I4ABc4dfQ_48_3">28,229</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2020_q95ww8WB7U-18mlScI3MCA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_by7HrvoeV0eIU-NWcBbiRQ_48_6">47,855</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2019_3ga0jBjg6EKA4-znaQ36NQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_-8g2eqSAGkKxkxRyyhMsnw_48_9">22,770</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:59.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">Cash and cash equivalents &#8211; end of period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_8SrDmW9FXUqSUzLcgx0P0g_49_3">21,929</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_giTWFzW_Q0S9YWfCPJpTug_49_6">28,229</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2020_q95ww8WB7U-18mlScI3MCA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_YgrzYMn_vUeYFkYLFZmVsw_49_9">47,855</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:59.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Supplemental cash flow disclosure</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0pt 12pt;">Cash paid for interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="3" id="Tc_w0604vMankiT9aetBFT4vQ_52_3">2,186</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="3" id="Tc_JacEh5ec7EamH-P1P0rrDw_52_6">130</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:59.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0pt 12pt;">Cash paid for taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxesPaid" scale="3" id="Tc_TPmwtxCc_UqoVwqQivygwg_53_3">44</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxesPaid" scale="3" id="Tc_0tZ7AIkiLEWOL1K16LbSow_53_6">1,593</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxesPaid" scale="3" id="Tc_hLH5Uxsu2UWO3xeurCHDaw_53_9">543</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:59.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0pt 12pt;">Capital expenditures incurred but not yet paid</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1" scale="3" id="Tc_mwKKsgtRZUC-ycCUm7PcrA_54_3">38</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1" scale="3" id="Tc_JEBJz6g7q02lN0ImA5IUsg_54_6">23</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1" scale="3" id="Tc_-yf9Z14JS0GJTcWqZ_vgOA_54_9">17</ix:nonFraction></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:justify;background:#ffffff;margin:0pt;">The accompanying notes are an integral part of these consolidated financial statements.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">92</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_72fd5ecb_ece0_49b7_9b75_4ca058bf0d25"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="Notes"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Tactile Systems Technology, Inc.</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:center;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Notes to the Consolidated Financial Statements</b></p><a id="_Hlk54609759"></a><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" name="us-gaap:NatureOfOperations" id="Tb_ZvwkzDztn0uMtgJbrBwePA" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Note 1. &#160;Nature of Business and Operations</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Tactile Systems Technology, Inc. (&#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221;) manufactures and distributes medical devices for the treatment of patients with underserved chronic diseases at home. We provide our Flexitouch and Entre systems, which help control symptoms of lymphedema, a chronic progressive medical condition, through our direct sales force for use in the home and sell or rent them through vascular, wound and lymphedema clinics throughout the United States. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On September 8, 2021, we acquired the assets of the AffloVest airway clearance business (&#8220;AffloVest Acquisition&#8221;) from International Biophysics Corporation (&#8220;IBC&#8221;), a privately-held company which developed and manufactured AffloVest. AffloVest is a portable, wearable vest that treats patients with chronic respiratory conditions. We sell this device through home medical equipment and durable medical equipment (&#8220;DME&#8221;) providers throughout the United States.&#160;</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We were originally incorporated in Minnesota under the name Tactile Systems Technology, Inc. on January&#160;30, 1995. During 2006, we established a merger corporation and subsequently, on July&#160;21, 2006, merged with and into this merger corporation, resulting in us being reincorporated as a Delaware corporation. The resulting corporation assumed the name Tactile Systems Technology, Inc. In September 2013, we began doing business as &#8220;Tactile Medical.&#8221;</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On August 2, 2016, we closed the initial public offering of our common stock, which resulted in the sale of <ix:nonFraction unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ" contextRef="Duration_8_2_2016_To_8_2_2016_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_oNbQsAMXk0uBUzklZFhmAA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr__3NXhWJUP06052j8xqXqRw">4,120,000</ix:nonFraction> shares of our common stock at a public offering price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q" contextRef="As_Of_8_2_2016_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_G1Q8otm7u0SlPI0I3gLpyg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_jIiYYU17sEi4nPnjY0gWiA">10.00</ix:nonFraction> per share. We received net proceeds from the initial public offering of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_8_2_2016_To_8_2_2016_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_oNbQsAMXk0uBUzklZFhmAA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" scale="6" id="Narr_8Qvtc3QHBkO1zxhdwx5tow">35.4</ix:nonFraction> million, after deducting underwriting discounts and approximately $<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_8_2_2016_To_8_2_2016_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_oNbQsAMXk0uBUzklZFhmAA" decimals="-5" format="ixt:numdotdecimal" name="tcmd:ExpenseRelatingToInitialPublicOffering" scale="6" id="Narr_v_bnt46ba06QQYXfBPxTzA">2.9</ix:nonFraction> million of transaction expenses.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;margin:0pt;">Our business is affected by seasonality. In the first quarter of each year, when most patients have started a new insurance year and have not yet met their annual out-of-pocket payment obligations, we experience substantially reduced demand for our products. We typically experience higher revenue in the third and fourth quarters of the year when patients have met their annual insurance deductibles, thereby reducing their out-of-pocket costs for our products, and because patients desire to exhaust their flexible spending accounts at year end. This seasonality applies only to purchases and rentals of our products by patients covered by commercial insurance and is not relevant to Medicare, Medicaid or the Veterans Administration, as those payers either do not have plans that have declining deductibles over the course of the plan year and/or do not have plans that include patient deductibles for purchases or rentals of our products. Further, seasonality trends have been, and may continue to be, different than historical trends as a result of the COVID-19 pandemic and related impacts.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" id="Tb_rTPt-rczPEajIs8j39mocg" continuedAt="Tb_rTPt-rczPEajIs8j39mocg_cont1" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Note 2. &#160;Basis of Presentation</b></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="Tb_laBrlrni8US1-db0pxvaUQ" continuedAt="Tb_laBrlrni8US1-db0pxvaUQ_cont1" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) and pursuant to the rules and regulations of the SEC. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The results for the year ended December&#160;31,&#160;2022, are not necessarily indicative of results to be expected for any future year.</p></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">93</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_rTPt-rczPEajIs8j39mocg_cont1"><ix:continuation id="Tb_laBrlrni8US1-db0pxvaUQ_cont1"></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" name="us-gaap:ConsolidationPolicyTextBlock" id="Tb_EQ5gWnTHdk6dPdLW_wiXUg" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Principles of Consolidation</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our accompanying consolidated financial statements include the accounts of Tactile Systems Technology, Inc. and its wholly owned subsidiary, Swelling Solutions, Inc. All intercompany balances and transactions have been eliminated in consolidation.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" name="tcmd:UnusualRisksAndUncertaintiesPolicyTextBlock" id="Tb_P2WoV9Aq6UKvFAuyOv9OrA" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Risks and Uncertainties</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:14pt;text-align:justify;background:#ffffff;margin:2pt 0pt 0pt 0pt;"><i style="font-style:italic;">Coronavirus (COVID-19)</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:14pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">The United States economy in general and our business specifically have been negatively affected by the COVID-19 pandemic. We have seen adverse impacts as it relates to the decline in the number of patients that healthcare facilities and clinics are able to treat due to enhanced safety protocols, particularly during 2020, most of 2021 and the first quarter of 2022. We have also seen staffing challenges, both in our organization and at the clinics we serve, as another lingering consequence of the COVID-19 pandemic. While we saw some level of recovery in 2022, ongoing consequences of the pandemic remain uncertain. There are no reliable estimates of how long the pandemic will last, whether any recovery will be sustained or will reverse course, the severity of any resurgence of COVID-19 or variant strains of the virus, the effectiveness of vaccines and attitudes towards receiving them, or what ultimate effects the pandemic will have. For that reason, we are unable to reasonably estimate the long-term impact of the pandemic on our business at this time. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">Since the onset of COVID-19, we have remained proactive to adapt to the needs of our employees, clinicians and patients. We cannot assure you that these changes to our processes and practices will be successful in mitigating the impact of COVID-19 on our business. We continue to evaluate and, if appropriate, will adopt other measures in the future related to the ongoing safety of our employees, clinicians and patients.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" name="us-gaap:UseOfEstimates" id="Tb_tcSM9koTRU67277pE7Q3bQ" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:14pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Use of Estimates</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and to disclose contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="Tb_VVG6SIxM1Ey2lCBS75thtg" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Comprehensive Loss</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="color:#2b2c2b;">Comprehensive loss reflects the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. Our comprehensive loss represents net loss adjusted for unrealized gains and losses on available-for-sale marketable securities and the related taxes.</span></p></ix:nonNumeric><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="Tb_Gb7Ab0Wm5kW_wmOvtDhNKg" continuedAt="Tb_Gb7Ab0Wm5kW_wmOvtDhNKg_cont1" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Note 3. &#160;Summary of Significant Accounting Policies</b></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="Tb_Pnf9NZMVFka-DLjOCic7tA" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Cash and Cash Equivalents</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Cash and cash equivalents consist of all cash on hand and deposits. Our cash was held primarily in checking accounts as of December 31, 2022 and 2021.<b style="font-weight:bold;"> </b>At times the amount of cash on deposit may exceed the federally insured limit of the bank. Deposit accounts at each of the institutions are insured up to $250,000&#160;by the Federal Deposit Insurance Corporation (FDIC). At December 31, 2022 and 2021, the Company exceeded&#160;FDIC&#160;limits at various institutions. The Company has not experienced any losses in such accounts and believes there is little to no exposure to any significant credit risk.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" name="us-gaap:InvestmentPolicyTextBlock" id="Tb_n4oam2Qf6Eyy8TlcqZ07EQ" continuedAt="Tb_n4oam2Qf6Eyy8TlcqZ07EQ_cont1" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Equity Investments</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="color:#2b2c2b;">Equity investments (including equity securities) with readily determinable fair value are reported at fair value, with unrealized gains and losses included in the determination of net loss. For equity investments with no readily determinable fair value, we measure these investments at cost less impairment, if any, plus or minus </span></p></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">94</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_Gb7Ab0Wm5kW_wmOvtDhNKg_cont1" continuedAt="Tb_Gb7Ab0Wm5kW_wmOvtDhNKg_cont2"><ix:continuation id="Tb_n4oam2Qf6Eyy8TlcqZ07EQ_cont1"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="color:#2b2c2b;">changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. Such observable price changes may include instances where the investee issues equity securities to new investors, thus creating a new indicator of fair value, as an example. As of each of December&#160;31,&#160;2022 and 2021, the total carrying value of our equity investments, with no readily determinable fair value, was </span><span style="color:#2b2c2b;">$<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" scale="6" id="Narr_fG_laBaLj0abkLQ6iH9yYA"><ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" scale="6" id="Narr_199WeT2-mk2CnZcjc65f-A">0.3</ix:nonFraction></ix:nonFraction></span><span style="color:#2b2c2b;"> million, and are included in other non-current assets on our Consolidated Balance Sheets. On an annual basis, we perform a qualitative assessment considering impairment indicators to evaluate whether these investments are impaired and also monitor for any observable price changes. During the years ended December&#160;31,&#160;2022 and 2021, we did not have any impairment loss on these investments. </span></p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" name="us-gaap:TradeAndOtherAccountsReceivablePolicy" id="Tb_E0O_dsuCDE6mp1SuKV1tNw" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Accounts Receivable</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The majority of our accounts receivable and revenue are from commercial insurance payers and government payers, such as Medicare, the Veterans Administration and Medicaid.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Accounts receivable are recorded based on management&#8217;s assessment of the expected consideration to be received, based on a detailed review of historical pricing adjustments and collections. Management relies on the results of the assessment, which includes payment history of the applicable payer as well as historical patient collections, as a primary source of information in estimating the collectability of our accounts receivable. We update our assessment on a quarterly basis, which to date has not resulted in any material adjustments to the valuation of our accounts receivable. We believe the assessment provides reasonable estimates of our accounts receivable valuation, and therefore we believe that substantially all accounts receivable are fully collectible. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A portion of our claims to Medicare are initially denied and enter the appeals process, where many are ultimately reviewed by an Administrative Law Judge. After final adjudication of all claims, approximately <ix:nonFraction unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw" contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw" decimals="2" format="ixt:numdotdecimal" name="tcmd:PercentageOfClaimsApproved" scale="-2" id="Narr_xw5G-xnuyEuD_UD4GtcYtQ">90</ix:nonFraction>% of the claims submitted are approved (this is on a number of claims, not a dollars claimed, basis across all our products). The appeals process can be lengthy, lasting more than a year in most cases. Accordingly, we classify a portion of our Medicare accounts receivable as non-current based on our experience with Medicare collections.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" name="us-gaap:InventoryPolicyTextBlock" id="Tb_MThJAm6BSkCb6E81a0zNQA" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Inventories</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Inventories are valued at the lower of cost (first-in, first-out method) or net realizable value.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="Tb_yRTr4yTf8UKiiWylsaDDhA" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Property and Equipment</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Property and equipment are stated at cost and are depreciated using the straight-line method over their estimated useful lives of <span style="-sec-ix-hidden:Hidden_-K2S-WgBSE6sH7tBYgqsYw;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">three</span></span> to <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_VpuMgvUm10Cec1Yu-NEe1Q" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Narr_vuJOAcWzME27hs3xDAGfog">seven years</ix:nonNumeric>. Leasehold improvements are depreciated over the remaining life of the respective building lease agreement. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Major expenditures for property and equipment are capitalized. Maintenance, repairs and minor renewals are expensed as incurred. When assets are retired or otherwise disposed of, their costs and related accumulated depreciation are removed from the accumulated depreciation accounts and the resulting gains or losses are included in income. The value of demonstration equipment in the possession of our field sales representatives is capitalized and depreciated over the estimated useful life of the equipment. </p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="Tb_eBB1mIUx40mlDhVxNkuO0Q" continuedAt="Tb_eBB1mIUx40mlDhVxNkuO0Q_cont1" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Revenue Recognition</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We derive revenue from the sales and rentals of our Flexitouch and Entre systems, and from the sales of our AffloVest.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Flexitouch and Entre</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We recognize revenue when control of the product has been transferred to our customer, in the amount of the expected consideration to be received for the product. In general, revenue from the sale or rental of a product is recognized upon shipment, unless circumstances dictate that control has not yet passed to the customer. </p></ix:nonNumeric></ix:continuation></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">95</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_Gb7Ab0Wm5kW_wmOvtDhNKg_cont2" continuedAt="Tb_Gb7Ab0Wm5kW_wmOvtDhNKg_cont3"><ix:continuation id="Tb_eBB1mIUx40mlDhVxNkuO0Q_cont1" continuedAt="Tb_eBB1mIUx40mlDhVxNkuO0Q_cont2"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We provide a warranty for these products against defects in material and workmanship for a period of <span style="-sec-ix-hidden:Hidden_y-RzrDjl6U6YAkZa8g5tjg;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">one</span></span> to <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_tcmd_GarmentsMember_srt_RangeAxis_srt_MaximumMember_fiHw-QVcjESriGs85ZfH7w" format="ixt-sec:durwordsen" name="tcmd:TermOfProductWarranty" id="Narr_s8_hN_H0ckSjAOmqz8GwTA">five years</ix:nonNumeric> on garments and <span style="-sec-ix-hidden:Hidden_2vCz5hZwoEmnfJJOj_Lktg;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">one</span></span> to <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_tcmd_ControllersMember_srt_RangeAxis_srt_MaximumMember_wiN7jXmrnkGpVKBXgBLvJA" format="ixt-sec:durwordsen" name="tcmd:TermOfProductWarranty" id="Narr_fhqeQ4ytnE2D-XztUiwocQ">two years</ix:nonNumeric> on controllers. In accordance with applicable accounting guidance, we have determined these were assurance warranties and therefore not considered a performance obligation. In addition, we did not evaluate immaterial promised goods or services in the context of the contract. As a result, the sale or rental of these products represent a single performance obligation that is satisfied at a point in time and is short-term in nature. In certain cases, we receive payment from Medicare sales over a period of time that may exceed <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" format="ixt-sec:durwordsen" name="tcmd:MedicareReceivablesTimePeriod" id="Narr_U7s_A0B5t0yslLaa9hzi-g">one year</ix:nonNumeric>. Despite these extended payment terms, no significant financing component is deemed to exist as the terms are not for the benefit of the patient with whom we have the contract. Rather, the extended payment terms occur as a result of an initial claim denial, which subsequently enters the Medicare appeals process as noted below. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We commercially distribute these products directly to patients who are referred to us by physicians, therapists or nurses. In most cases, there is a third-party payer, such as a commercial insurer, Medicare or the Veterans Administration, involved with the transaction. Our contractual relationship resides with the patient when the third-party payer is either a commercial insurer or Medicare and with the Veterans Administration if the patient is covered under their services. Revenue is recognized from such sales upon transfer of control of the product to the customer at a transaction price determined by collection history. As a result, the transaction price is impacted by multiple factors, including the terms and conditions contracted by various third-party payers, and therefore payments from third-party payers typically are less than our standard charge and represent an implicit price concession, resulting in variable consideration. As most contracts are with each individual sale to a patient, we have elected the portfolio approach to determine the transaction price, and ultimately the expected consideration. The portfolios used to determine transaction price are at the payer level, with pricing for each payer assessed based on the underlying similar characteristics. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For any of our products sold to patients covered by private payers, such as commercial insurance companies, revenue is recognized upon shipment. A product is not shipped until we have received a prescription from a physician for our products and, as applicable, receipt of prior authorization from payers. At shipment, we invoice the payer for the total product price, and we recognize revenue in the amount of cash consideration anticipated to be received based on the transaction price. After the insurance payer has remitted payment, we separately invoice the patient for their portion of the payment obligation, such as copayments and deductibles. The transaction price is determined based on the payment history of the applicable payer drawn from actual write-off and collections experience from the payer over a rolling 12-month period, as well as historical patient collections. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For our products sold to Medicare patients, we recognize revenue from such sales upon shipment of our products, which can occur only after we have received a prescription from a physician and all applicable patient documentation is obtained. The transaction price for our Entre systems is determined based on the payment history using the same methodology as our private insurers. A portion of our claims for our Flexitouch system are initially denied, and enter the appeals process, which can be lengthy. We assess the variable consideration for each of these claims as a percentage of the total invoice price based on ultimate approval and collection history. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For our products sold to the Veterans Administration on behalf of the patient, our contract is with the Veterans Administration rather than the patient. We enter into individual sales contracts with the Veterans Administration on behalf of each patient. These contracts determine the amount of consideration, which is typically paid in full within <span style="-sec-ix-hidden:Hidden_29m0XALLYEGpUDkg67Logg;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">2</span></span>-<ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_VpuMgvUm10Cec1Yu-NEe1Q" format="ixt-sec:durwordsen" name="tcmd:PeriodForConsiderationPaymentAfterShipmentDate" id="Narr_8QWacby3n0WNCa9mMuLB6g">3 days</ix:nonNumeric> of shipment, and therefore there is no implicit price concession. In addition, the contracts provide for the right of control to transfer to the Veterans Administration upon delivery of the product to the patient, at which time revenue is recognized.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We incur incremental costs that directly relate to the sales of our products; however, as the <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" format="ixt:booleantrue" name="us-gaap:RevenuePracticalExpedientIncrementalCostOfObtainingContract" id="Narr_c4rhe8WJGUuFgJRVtD-xzw">amortization period would be less than one year</ix:nonNumeric>, we have elected the practical expedient to expense these costs as incurred.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We sell and rent these products either directly to patients or the Veterans Administration on behalf of patients, who are referred to us by physicians, therapists or nurses. We bill private insurers and other payers, Medicare, and the Veterans Administration directly for purchases or rentals of our product on behalf of a patient and bill patients directly for their cost-sharing amounts, including any portion of an unsatisfied deductible and any copayments or co-insurance obligation. </p></ix:continuation></ix:continuation></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">96</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_Gb7Ab0Wm5kW_wmOvtDhNKg_cont3" continuedAt="Tb_Gb7Ab0Wm5kW_wmOvtDhNKg_cont4"><ix:continuation id="Tb_eBB1mIUx40mlDhVxNkuO0Q_cont2"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A portion of our revenue is derived from patients who obtain our products under multiple-month rental arrangements. We bill these patients&#8217; insurance payers monthly over the duration of the rental term. Title to these products passes to the patients at the end of the rental period. Rental agreements are recorded as sales-type leases in accordance with Accounting Standards Update (&#8220;ASU&#8221;) No.&#160;2016-02, &#8220;Leases&#8221; (Topic 842) (&#8220;ASC 842&#8221;). Accordingly, as sales-type leases, the transaction price for the entire rental term is recognized upon transfer of control. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">AffloVest</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The AffloVest device is sold through durable medical equipment providers. Revenue is recognized when control of the promised goods or services is transferred to the distributors, in an amount that reflects the consideration we expect to be entitled to in exchange for transferring those goods or providing services. We account for a contract when it has approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance and collectability of consideration is probable. When determining whether the distributor has obtained control of the goods or services, we consider any future performance obligations. Generally, there is no post-shipment obligation on products sold other than warranty obligations in the normal and ordinary course of business. Consequently, revenue from the sale of the AffloVest product is recognized at shipment, unless circumstances dictate that control has not yet passed to the distributor.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Certain of our contracts include volume-based incentives which involve rebates that are negotiated at or prior to the time of sale with the customer and are redeemable only if the customer achieves a specified cumulative level of sales or sales increase. Under these incentive programs, at the time of sale, we determine the most likely amount of the rebate to be paid based on forecasted sales levels. These forecasts are updated at least quarterly for applicable customers, and the transaction price is reduced for the anticipated cost of the rebate. If the forecasted sales for a customer change, the accrual for rebates is adjusted to reflect the new rebates expected to be earned by the customer.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Amounts billed to customers for shipping and handling activities after the customer obtains control are treated as a promised service performance obligation and recorded in revenue in the accompanying Consolidated Statements of Operations. Shipping and handling costs incurred for the delivery of goods to customers are considered a cost to fulfill the contract and are included in cost of revenue sold in the accompanying Consolidated Statements of Operations.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We provide a warranty for the AffloVest products against defects in material and workmanship for a period of <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_tcmd_AfflovestMember_dBqlEgBFb02-NFr9MvkVnw" format="ixt-sec:durwordsen" name="tcmd:TermOfProductWarranty" id="Narr_NewFfqtXtE23njY2ors8uw">five years</ix:nonNumeric>. In accordance with applicable accounting guidance, we have determined these were assurance warranties and therefore not considered a performance obligation. In addition, we did not evaluate immaterial promised goods or services in the context of the contract. As a result, the sale of these products represents a single performance obligation that is satisfied at a point in time and is short-term in nature.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" name="us-gaap:AdvertisingCostsPolicyTextBlock" id="Tb_K4v0vDZpkE6Wc9p1xvLmug" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Advertising</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Advertising costs are charged to operations when incurred. Advertising expense was $<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AdvertisingExpense" scale="6" id="Narr_xfS7xUfYtUKs0-h5g3Bk-g"><ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AdvertisingExpense" scale="6" id="Narr_P4mYe_P4tU2k4hax4E4dpg"><ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AdvertisingExpense" scale="6" id="Narr_ZVdpjf_nRkKjgUlHhNBm3g">0.1</ix:nonFraction></ix:nonFraction></ix:nonFraction> million for each of the years ended December&#160;31,&#160;2022, 2021 and 2020.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="Tb_JW93bL1cFkCRTKdLH7PzrQ" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Research and Development Costs</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We expense research and development costs as incurred, including expenses associated with clinical research studies and development.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" name="us-gaap:CostOfSalesPolicyTextBlock" id="Tb_UQPaRhljQ0-XlGRFDVduRw" continuedAt="Tb_UQPaRhljQ0-XlGRFDVduRw_cont1" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Shipping and Handling Costs</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Amounts billed to customers for shipping and handling activities after the customer obtains control are treated as a promised service performance obligation and recorded in&#160;total revenue&#160;in the accompanying Consolidated Statements of Operations. Shipping and handling costs incurred for the delivery of goods to customers are considered a cost to fulfill the contract and are included in&#160;cost of revenue&#160;in the accompanying Consolidated Statements of Operations.</p></ix:nonNumeric></ix:continuation></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">97</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_Gb7Ab0Wm5kW_wmOvtDhNKg_cont4" continuedAt="Tb_Gb7Ab0Wm5kW_wmOvtDhNKg_cont5"><ix:continuation id="Tb_UQPaRhljQ0-XlGRFDVduRw_cont1"></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" name="us-gaap:StandardProductWarrantyPolicy" id="Tb_gxs-WtUP90mSlyxaU5A0OQ" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Product Warranty</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We provide a warranty for our products against defects in material and workmanship for a period of <span style="-sec-ix-hidden:Hidden_9oGSvawUkUuA-bl9OI56kg;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">one</span></span> to <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_tcmd_GarmentsMember_srt_RangeAxis_srt_MaximumMember_fiHw-QVcjESriGs85ZfH7w" format="ixt-sec:durwordsen" name="tcmd:TermOfProductWarranty" id="Narr_YPsSSqgu5UCN82hNxCGZZQ">five years</ix:nonNumeric>. We record a liability for future warranty claims at the time of sale for the warranty period offered to a customer. If the assumptions used in calculating the provision were to materially change, such as incurring higher than anticipated warranty claims, an additional provision may be required.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="Tb_qbrixVQDO0asFhh-hoPBkw" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Impairment of Long-Lived Assets </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We review long-lived assets, including property and equipment and patents, for impairment whenever events or changes in business circumstances indicate that the carrying amount of an asset may not be fully recoverable. We will assess long-lived assets used in operations for impairment indicators, including when undiscounted cash flows estimated to be generated by those assets are less than the assets&#8217; carrying amount (see Note 8 &#8211; &#8220;Goodwill and Intangible Assets&#8221;).</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" name="us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy" id="Tb_EbAYWm7SqUujdiy7ee6gXA" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Goodwill</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Goodwill represents the excess of the purchase price paid over the estimated fair value of the net assets acquired and liabilities assumed in the acquisition of a business. Goodwill is not amortized, but is tested for impairment at least annually or on an interim basis if an event occurs or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying value. We perform our annual assessment of goodwill for impairment as of July 1st&#160;of each fiscal year. See Note 8 &#8211; &#8220;Goodwill and Intangible Assets&#8221; for additional information.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="Tb_hnKCNZKF_06zK775mQvdwQ" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Stock-Based Compensation</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Stock options are valued using the Black-Scholes option-pricing model, except that the valuation of certain &#8220;CEO&#8221; related stock options subject to a market condition involve the use of the Monte Carlo Simulation model. The Monte Carlo Simulation and the Black-Scholes valuation models require the input of highly subjective assumptions. The assumptions include the expected term of the option, the expected volatility of the price of our common stock, expected dividend yield and the risk-free interest rate. These estimates involve inherent uncertainties and the significant application of management&#8217;s judgment. If factors change and different assumptions are used, our stock-based compensation expense could be materially different in the future. We recognize compensation expense for these options on a straight-line basis over the requisite service period (see Note 13 &#8211; &#8220;Stockholders&#8217; Equity&#8221;).</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" name="us-gaap:IncomeTaxPolicyTextBlock" id="Tb_Wle3J1FdVUuL1CGi6HParA" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Income Taxes</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Income taxes are accounted for under the liability method. Deferred income taxes are provided for temporary differences between the financial reporting and the tax basis of assets and liabilities. If we determine in the future that it is more likely than not that we will not realize all or a portion of the deferred tax assets, we will record a valuation allowance in the period the determination is made (see Note 15 &#8211; &#8220;Income Taxes&#8221;). Changes in tax rates are reflected in the tax provision as they occur.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" name="us-gaap:EarningsPerSharePolicyTextBlock" id="Tb_bJwUcl5jcEWuf0VZ9yHyJQ" continuedAt="Tb_bJwUcl5jcEWuf0VZ9yHyJQ_cont1" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Net (Loss) Income Per Common Share</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;"> </span>Basic net (loss) income per common share is computed based on the weighted average number of shares of common stock outstanding during the period. Diluted net (loss) income per common share is computed based on the weighted average number of shares of common stock plus the effect of dilutive potential stock-based awards outstanding during the period using the treasury stock method. Dilutive potential stock-based awards include outstanding common stock options, time- and performance-based restricted stock units and employee stock purchase plan shares.</p></ix:nonNumeric></ix:continuation></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">98</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_Gb7Ab0Wm5kW_wmOvtDhNKg_cont5"><ix:continuation id="Tb_bJwUcl5jcEWuf0VZ9yHyJQ_cont1"></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="Tb_FOwCtFFpLUCuyzS2_OBxXQ" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Business Segments</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We operate and report in only&#160;<ix:nonFraction unitRef="Unit_Standard_segment_zejw3MrZOkWEznPtKLNRGQ" contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" id="Narr_F6xQ6sLeAEevFFJ3PdxSSg">one</ix:nonFraction>&#160;operating and <span style="-sec-ix-hidden:Hidden_hf125MM_GkGhx3Sj6QqkPA;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">reportable</span></span> segment. Our chief operating decision maker does not use financial information below revenue to allocate resources.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" name="tcmd:NewAccountingPronouncementsNoteYetAdoptedPolicyPolicyTextBlock" id="Tb_iR8Unoe76EWS2pk1CXKT8g" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Accounting Pronouncement Not Yet Adopted</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In December 2022, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued ASU No. 2022-06, &#8220;Reference Rate Reform (Topic 848) &#8212; Facilitation of the Effect of Reference Rate Reform on Financial Reporting&#8221; (&#8220;ASU 2022-06&#8221;), which provides optional expedients and exceptions for applying GAAP to transactions affected by reference rate (e.g., LIBOR) reform if certain criteria are met, for a limited period of time to ease the potential burden in accounting for (or recognizing the effects of) reference rate reform on financial reporting. The ASU deferred the sunset date of Topic 848 from December 31, 2022 to December 31, 2024. The ASU is effective as of December 21, 2022 through December 31, 2024. We continue to evaluate transactions or contract modifications occurring as a result of reference rate reform and determine whether to apply the optional guidance on an ongoing basis. We have not elected any expedients to date and are currently evaluating any potential future impacts on the consolidated financial statements. </p></ix:nonNumeric></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" name="us-gaap:AssetAcquisitionTextBlock" id="Tb_JfSMn0aEU0GjKVcL5WeHhQ" continuedAt="Tb_JfSMn0aEU0GjKVcL5WeHhQ_cont1" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Note 4. Acquisitions</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">On&#160;September 8, 2021,&#160;we entered into an Asset Purchase Agreement (&#8220;AffloVest APA&#8221;) to acquire the AffloVest therapy business from International Biophysics Corporation (&#8220;IBC&#8221;). Under the terms of the AffloVest APA, we agreed to pay IBC a total of up to $<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_9_8_2021_To_9_8_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_BusinessAcquisitionAxis_tcmd_AfflovestPMember_cXLgD3w8o0mAJ_EMBbTfZg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationConsiderationTransferred1" scale="6" id="Narr_E6GEp5ENkUKHqP9cnlieoQ">100.0</ix:nonFraction>&#160;million for the purchase of substantially all of the assets related to its branded high frequency chest wall oscillation vest therapy business, other than specifically identified excluded assets. We acquired AffloVest to further expand our position as a leader in treating patients with underserved chronic conditions in the home. The acquired assets included inventory, tooling, intellectual property, permits and approvals, data and records, and customer and supplier information. At closing, $<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_9_8_2021_To_9_8_2021_us-gaap_BusinessAcquisitionAxis_tcmd_AfflovestPMember_9xzfRGshm0aKb9OM49UhSQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="6" id="Narr_NRdnyY5jeE--6oxrMFe80Q">80.0</ix:nonFraction>&#160;million of the purchase price was paid, of which a total of $<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_9_8_2021_To_9_8_2021_us-gaap_BusinessAcquisitionAxis_tcmd_AfflovestPMember_9xzfRGshm0aKb9OM49UhSQ" decimals="-5" format="ixt:numdotdecimal" name="tcmd:AssetAcquisitionConsiderationTransferredEscrowAccount" scale="6" id="Narr_Vlo9_6Dr70mDf9SgIIAGCg">0.5</ix:nonFraction> million was deposited into an escrow account at closing for purposes of satisfying certain post-closing purchase price adjustments and indemnification claims. Subsequent to closing, $<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_9_8_2021_To_9_8_2021_us-gaap_BusinessAcquisitionAxis_tcmd_AfflovestPMember_9xzfRGshm0aKb9OM49UhSQ" decimals="-5" format="ixt:numdotdecimal" name="tcmd:AssetAcquisitionAmountReceivedResultingFromWorkingCapitalAdjustment" scale="6" id="Narr_DzZwGh_Zz0C583iGQPjMnQ">0.2</ix:nonFraction> million was returned to us as a result of working capital adjustments.&#160;The AffloVest acquisition was funded through a combination of cash on hand and proceeds from borrowings.&#160;</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:24.5pt;margin:0pt 7.2pt 0pt 7.2pt;"><span style="color:#ff0000;font-size:12pt;">&#160;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">On November 4, 2022, we entered into an Amendment to the AffloVest APA, the &#8220;Amendment&#8221; with IBC, which modifies the terms of the earn-out arrangement under the AffloVest APA, as follows:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:27pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:45pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:normal;background:#ffffff;">Initial Earn-Out: </i><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">The AffloVest APA provided for an initial earn-out equal to </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;"><ix:nonFraction unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw" contextRef="Duration_9_8_2021_To_9_8_2021_srt_StatementScenarioAxis_tcmd_AssetAcquisitionEarnoutPaymentsRevenueTargetsFromOctoberTwoThousandTwentyOneToSeptemberTwoThousandTwentyTwoMember_us-gaap_BusinessAcquisitionAxis_tcmd_AfflovestPMember_ekMNWGfKGkOGXb6VuFuvcQ" decimals="1" format="ixt:numdotdecimal" name="tcmd:AssetAcquisitionBusinessRevenueToExceedBaseRevenueMultiplier" scale="0" id="Narr_e6M-ya5OdkmjbgWTZxSBYg">1.5</ix:nonFraction></span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;"> times the amount by which the AffloVest U.S. revenues in the period from&#160;</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">October 1, 2021&#160;</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">to&#160;</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">September 30, 2022 (the &#8220;Initial Earn-Out Period&#8221;) exceed a specified amount;</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;"> provided that in no event will the payment exceed </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_9_8_2021_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_tcmd_AssetAcquisitionEarnoutPaymentsRevenueTargetsFromOctoberTwoThousandTwentyOneToSeptemberTwoThousandTwentyTwoMember_us-gaap_BusinessAcquisitionAxis_tcmd_AfflovestPMember_u62XShicPUa52TcVaICEVA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="Narr_bvc_ObT-L0mSSyBFRF_RtA">10.0</ix:nonFraction></span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;"> million.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:81pt;"></td><td style="font-family:'Courier New';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">The Amendment provides that the calculated amount of the initial earn-out payment is </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_11_4_2022_us-gaap_BusinessAcquisitionAxis_tcmd_AfflovestPMember_mDniF7LA_kiQpOIIlQZs3g" decimals="-5" format="ixt:numdotdecimal" name="tcmd:AssetAcquisitionEarnOutLiability" scale="6" id="Narr_6zCB6spqY0KNgm0ubgzI7A">10.0</ix:nonFraction></span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;"> million, of which the Company paid </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_11_4_2022_srt_StatementScenarioAxis_tcmd_EarnOutPeriodOnOrBeforeNovember282022Member_us-gaap_BusinessAcquisitionAxis_tcmd_AfflovestPMember_YJ8bNR_NZ0CvMpF7RV_aqw" decimals="-5" format="ixt:numdotdecimal" name="tcmd:AssetAcquisitionEarnOutLiability" scale="6" id="Narr_YvpHq42Ejki_C5dUAgi8BA">5.0</ix:nonFraction></span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;"> million on or before November 28, 2022, and of which the Company will pay </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_11_4_2022_srt_StatementScenarioAxis_tcmd_EarnOutPeriodOnOrBeforeMay262023Member_us-gaap_BusinessAcquisitionAxis_tcmd_AfflovestPMember_en0im7ZgS0KUsbPg8tTm6A" decimals="-5" format="ixt:numdotdecimal" name="tcmd:AssetAcquisitionEarnOutLiability" scale="6" id="Narr_LnAGeTFanUW6FlhMrscsZQ">5.0</ix:nonFraction></span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;"> million, plus an imputed interest payment of </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_11_4_2022_srt_StatementScenarioAxis_tcmd_EarnOutPeriodOnOrBeforeMay262023Member_us-gaap_BusinessAcquisitionAxis_tcmd_AfflovestPMember_en0im7ZgS0KUsbPg8tTm6A" decimals="0" format="ixt:numdotdecimal" name="tcmd:AssetAcquisitionImputedInterestPayable" scale="0" id="Narr_WMkF29gwSkGcVHYOx43K7g">250,000</ix:nonFraction></span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">, on or before May 26, 2023.</span></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 63pt;"><span style="margin-left:0pt;visibility:hidden;background:#ffffff;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:45pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:normal;background:#ffffff;">Second Earn-Out:</i><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;"> The AffloVest APA provided for a second earn-out equal to </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;"><ix:nonFraction unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw" contextRef="Duration_9_8_2021_To_9_8_2021_srt_StatementScenarioAxis_tcmd_AssetAcquisitionEarnoutPaymentsRevenueTargetsFromOctoberTwoThousandTwentyTwoToSeptemberTwoThousandTwentyThreeMember_us-gaap_BusinessAcquisitionAxis_tcmd_AfflovestPMember_HRn8Gvyx7UuDkFsUjw2MWw" decimals="1" format="ixt:numdotdecimal" name="tcmd:AssetAcquisitionBusinessRevenueToExceedBaseRevenueMultiplier" scale="0" id="Narr_7ENHYr6LKkyo5Wz-Jf12oA">1.5</ix:nonFraction></span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;"> times the amount by which the AffloVest U.S. revenues in the period from&#160;</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">October 1, 2022&#160;</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">to&#160;</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">September 30, 2023 exceed the revenues recognized during the Initial Earn-Out Period;</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;"> provided that in no event will the payment exceed </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_9_8_2021_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_tcmd_AssetAcquisitionEarnoutPaymentsRevenueTargetsFromOctoberTwoThousandTwentyTwoToSeptemberTwoThousandTwentyThreeMember_us-gaap_BusinessAcquisitionAxis_tcmd_AfflovestPMember_o1oljgm50kqF7GpMnEHq0g" decimals="-5" format="ixt:numdotdecimal" name="tcmd:AssetAcquisitionEarnOutLiability" scale="6" id="Narr_c5xZUn3D8kGpR6kP11DYEQ">10.0</ix:nonFraction></span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;"> million.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:81pt;"></td><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">The Amendment changes the </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;"><ix:nonFraction unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw" contextRef="Duration_11_4_2022_To_11_4_2022_us-gaap_BusinessAcquisitionAxis_tcmd_AfflovestPMember_pimwAjq0t0WJdAD0aYSTWA" decimals="1" format="ixt:numdotdecimal" name="tcmd:AssetAcquisitionBusinessRevenueToExceedBaseRevenueMultiplier" scale="0" id="Narr_ySmR-8A1VUqcZ_OQxqhCRQ">1.5</ix:nonFraction></span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;"> times multiplier to </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;"><ix:nonFraction unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw" contextRef="Duration_11_4_2022_To_11_4_2022_srt_StatementScenarioAxis_tcmd_SecondEarnOutAmendmentMember_us-gaap_BusinessAcquisitionAxis_tcmd_AfflovestPMember_AEZMhjNrNkqvyABhlnwRPg" decimals="1" format="ixt:numdotdecimal" name="tcmd:AssetAcquisitionBusinessRevenueToExceedBaseRevenueMultiplier" scale="0" id="Narr_q_6PC15W0UK8djPLN7nSaA">3.0</ix:nonFraction></span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;"> times, but still provides that in no event will the second earn-out payment exceed </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_11_4_2022_srt_StatementScenarioAxis_tcmd_SecondEarnOutAmendmentMember_us-gaap_BusinessAcquisitionAxis_tcmd_AfflovestPMember_la2cedehBk-qL-iSyE1pIA" decimals="-5" format="ixt:numdotdecimal" name="tcmd:AssetAcquisitionEarnOutLiability" scale="6" id="Narr_9DUvUkE080mHy79NW1JVAg">10.0</ix:nonFraction></span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;"> million. </span></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 63pt;"><span style="color:#ff0000;font-family:'Times New Roman','Times','serif';margin-left:0pt;visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">The fair value of the earn-out as of the acquisition date was $<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_9_8_2021_8l4xBubq7Umd0Y3dMd0UnQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="Narr_oRW3Innfj06k-muNqp-2lQ">6.4</ix:nonFraction>&#160;million. The fair value of the earn-out, reflecting management&#8217;s estimate of the likelihood of achieving these targets, was determined by employing a Monte Carlo Simulation model. This amount and the current versus non-current allocation will be remeasured at the end of each reporting period until the payment requirement ends, with any adjustments reported in income from operations (see Note 17 &#8211; &#8220;Fair Value Measurements&#8221;).</p></ix:nonNumeric></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">99</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_097ab7af_67dc_4d6a_97a1_9b14b54115bc"></a><a id="Tc_J4WgCHzI8kOZG26mWRpEzQ_1_0"></a><a id="Tc__i8vDBOw_EGzg6S05zqrLg_1_2"></a><a id="Tc_dc1z5JZ2aECk5Ig9P7BRHw_2_0"></a><a id="Tc_t5ij89q1akCvydux4ixcpQ_2_2"></a><a id="Tc_Ej0mjyGLPUiqB3qWfRbtpA_3_0"></a><a id="Tc_4ZhTZ_01Gki3WK9LQ_wA9w_3_3"></a><a id="Tc_3mcLUuicKE-YGUKl3YZe9g_4_0"></a><a id="Tc_qCVhUATCUESuTswLo4kw3Q_5_0"></a><a id="Tc_puclcIHbUkCfDFU8vDTt_A_6_0"></a><a id="Tc_0m6rISIyn0yeY5JvY1l5FQ_6_2"></a><a id="_0275bdd5_93a2_4244_8570_46853fc5a586"></a><a id="Tc_kgSFLpQlCEuWAsuIgAxEVQ_2_0"></a><a id="Tc_QBDlFqLp2E2qDgQ337JFiQ_2_2"></a><a id="Tc_McHiqHsWuEC6jLVnAAGFeA_2_6"></a><a id="Tc_nx8Xj96dGUmkN_cZISu4qg_3_0"></a><a id="Tc_o0GRkRQ600mLMOCkI8Af0A_3_2"></a><a id="Tc_14llVd-k1UWMTyaKN2ODNw_4_0"></a><a id="Tc_oIvRany94ECdERX0BBY8zg_5_0"></a><a id="Tc_UOWcGqSCm0qnt7Bb3bh1_A_5_6"></a><a id="Tc_JHAfrDn5h0SKplFjLhVS9Q_6_0"></a><a id="Tc_syYda7BsFE6yhfnurOBigg_6_2"></a><a id="Tc_O3hhMMxBnE-Zu8HEKd6qQw_1_2"></a><a id="Tc_u1p5JcTQ8EGTmK59oQS0jw_2_2"></a><a id="Tc_rMtEtkmNU0KKCp1triPgKw_3_0"></a><a id="Tc_X9VOhgRDEUahM5L9UYMG8Q_3_2"></a><a id="Tc_Um-5luO2VU2RNASlMnwjHQ_3_5"></a><a id="Tc_bWTvVxH5ekCWevDnhp0WiA_4_0"></a><a id="Tc_rj3WdYxjAUyUvfBZhB8kUw_4_2"></a><a id="Tc_oZ9mC44GEEOudQfgn9AFjg_4_5"></a><a id="Tc_ADbPiMgSkEaGDAGWN6ZLRg_5_0"></a><a id="Tc_k_yveI_p5Uqq0nWiknHzxg_5_2"></a><a id="Tc_uXnGt5M5Nk-GWO4MoySKYg_5_5"></a><ix:continuation id="Tb_JfSMn0aEU0GjKVcL5WeHhQ_cont1"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">On the date of AffloVest Acquisition, we allocated the assets acquired based on an estimate of their fair values.&#160;The following table summarizes the purchase price allocation:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" name="us-gaap:AssetAcquisitionTableTextBlock" id="Tb_ApG3HSp9PkKc0RPzMIk0FQ" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:25.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0.05pt 0pt 0.05pt 0pt;">(In&#160;millions)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:29.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;">Allocated Fair Value</p></td></tr><tr><td style="vertical-align:bottom;width:66.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Inventories</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_9_8_2021_us-gaap_BusinessAcquisitionAxis_tcmd_AfflovestPMember_3FbjYCEqNkWAlMK4QIberg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="6" id="Tc__jnWRu6R40-JuuvEdae3EQ_2_3">1.6</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.78%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Property and equipment<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.03%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:66.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Intangible assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_9_8_2021_us-gaap_BusinessAcquisitionAxis_tcmd_AfflovestPMember_3FbjYCEqNkWAlMK4QIberg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="Tc_8QucS4cBPUGPPTGS_Voe8A_4_3">53.5</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.78%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Goodwill</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_9_8_2021_us-gaap_BusinessAcquisitionAxis_tcmd_AfflovestPMember_3FbjYCEqNkWAlMK4QIberg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="6" id="Tc_3DMvyV0H9UmXRY42EyG0Nw_5_3">31.1</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;">Purchase price </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_9_8_2021_us-gaap_BusinessAcquisitionAxis_tcmd_AfflovestPMember_3FbjYCEqNkWAlMK4QIberg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AssetsNet" scale="6" id="Tc_iEaEr59AGE-q7UcM08hTAQ_6_3">86.2</ix:nonFraction></p></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-decoration-line:none;text-transform:none;vertical-align:baseline;white-space:nowrap;width:18pt;padding:0pt 0pt 6pt 0pt;">(1)</td><td style="padding:0pt 0pt 6pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-style:normal;font-weight:normal;">The purchase price included less than </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-style:normal;font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_9_8_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_BusinessAcquisitionAxis_tcmd_AfflovestPMember_jLq6gqZQRUe0_w5vfb9Asg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="Narr_sc1gZls4bESwNZ2WcEN47g">0.1</ix:nonFraction></span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-style:normal;font-weight:normal;"> million of property and equipment.</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-style:normal;font-weight:normal;"> </span></td></tr></table></ix:nonNumeric><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="font-size:10pt;">The goodwill reflects expected synergies of combining the acquired products and customer information with our existing operations and is deductible for tax purposes over&#160;</span><ix:nonNumeric contextRef="Duration_9_8_2021_To_9_8_2021_JHuv2YIhr0-DMtiV3Vl0PA" format="ixt-sec:durwordsen" name="tcmd:GoodwillAmortizationPeriodForTaxPurposes" id="Narr_T3F-sjkUFUympDTkkhUXyg"><span style="font-size:10pt;">15&#160;years</span></ix:nonNumeric><span style="font-size:10pt;">.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" name="tcmd:FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfAssetAcquisitionTableTextBlock" id="Tb_dc7BVw5L3k67TnIJfLgPiQ" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt;">The following table reflects the allocation of purchase price to the acquired intangible assets and related estimated useful lives:&#160;</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:21.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:20.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">(In&#160;millions)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">Allocated Fair Value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">Estimated Useful Life</p></td></tr><tr><td style="vertical-align:bottom;width:49.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Customer relationships</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_9_8_2021_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_CustomerRelationshipsMember_W5D5EY3MR0edt8BoVhmVUQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="Tc_WJsHznx1NU2nFbJx6wkF-Q_3_3">31.0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_9_8_2021_To_9_8_2021_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_CustomerRelationshipsMember_vwfc8GlHbEG6FpxSb_48hw" format="ixt-sec:durwordsen" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="Tc_23EDBAk5GkyQdCzh2R27hA_3_6">13 years</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:49.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Developed technology</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_9_8_2021_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_1vdqkBPIV06qt_Sb8l9xvw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="Tc_U12Ayh4jDEOtwAGa0ORejg_4_3">13.0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_9_8_2021_To_9_8_2021_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_9xTBZJ8BSEyOBEAowNs5qA" format="ixt-sec:durwordsen" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="Tc_BA40rrs8KkOQMukZ66cemA_4_6">11 years</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:49.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Tradenames</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_9_8_2021_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember_cbYze6WHq0-MzNMIXQ6G8Q" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" scale="6" id="Tc_x4EyBMy5SkiP4PfEDYNF4A_5_3">9.5</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">Indefinite</p></td></tr><tr><td style="vertical-align:bottom;width:49.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total intangible assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_9_8_2021_8l4xBubq7Umd0Y3dMd0UnQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="Tc_7eTYD6n9pkm_GzikTSKXPQ_6_3">53.5</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt;">The weighted-average amortization period of the acquired intangible assets was&#160;<ix:nonNumeric contextRef="Duration_9_8_2021_To_9_8_2021_JHuv2YIhr0-DMtiV3Vl0PA" format="ixt-sec:duryear" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" id="Narr_IAuQg_69TUi3-Qsm_o64pg">12.3</ix:nonNumeric>&#160;years.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The fair market valuations associated with the assets acquired fall within Level&#160;3 of the fair value hierarchy, due to the use of significant unobservable inputs to determine fair value. The fair value measurements were calculated using unobservable inputs, primarily using the income approach, specifically the discounted cash flow method. The amount and timing of future cash flows within our analysis was based on our due diligence models, most recent operational budgets, long-range strategic plans and other estimates.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Transaction costs, such as legal and other costs, related to the acquisition aggregated approximately $<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_9_8_2021_To_9_8_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_0hChIJ5gE0K__CcmmMTvmQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" scale="6" id="Narr_9DA92pcbMky9CuBnFwr36w">0.8</ix:nonFraction>&#160;million. These costs have been expensed as incurred and are included in reimbursement, general and administrative expenses in our Consolidated Statements of Operations for the year ended December 31, 2021.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Consolidated Statements of Operations reflect the AffloVest operations beginning September 9, 2021. As the AffloVest business has been integrated with our existing operations, we are unable to determine the amount of AffloVest earnings from the acquisition date that is included in the Consolidated Statements of Operations. The following unaudited pro forma information for the years ended December&#160;31, 2021 and 2020 presents the revenue and net income assuming the acquisition of AffloVest had occurred as of January 1, 2020. This information has been prepared for comparative purposes only and is&#160;not&#160;indicative of what actual results would have been if the acquisition had taken place at the beginning of fiscal&#160;2020,&#160;or of future results.</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" name="us-gaap:BusinessAcquisitionProFormaInformationTextBlock" id="Tb_ZA2LkFpREUqBm37C3evFVA" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:41.04%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">Year Ended</p></td></tr><tr><td style="vertical-align:bottom;width:55.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:41.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">December&#160;31,&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:55.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">(In&#160;thousands)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">2020</p></td></tr><tr><td style="vertical-align:bottom;width:55.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Total revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_4_1_2021_To_12_31_2021_us-gaap_BusinessAcquisitionAxis_tcmd_AfflovestPMember_C1E4O7zjlUGPDClD_oKeEg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessAcquisitionsProFormaRevenue" scale="3" id="Tc_oOfyQ1_svEWTF6V1Nw03Xw_4_3">219,414</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_4_1_2020_To_12_31_2020_us-gaap_BusinessAcquisitionAxis_tcmd_AfflovestPMember_jQCcMt5pY0Os-LuUZm0lRA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessAcquisitionsProFormaRevenue" scale="3" id="Tc_0M5FmSlirEWq9AX68rHRUQ_4_6">203,193</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:55.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Net (loss) income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_4_1_2021_To_12_31_2021_us-gaap_BusinessAcquisitionAxis_tcmd_AfflovestPMember_C1E4O7zjlUGPDClD_oKeEg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss" sign="-" scale="3" id="Tc_96Y6yJ7zOECwK8xy2ReVOg_5_3">7,633</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_4_1_2020_To_12_31_2020_us-gaap_BusinessAcquisitionAxis_tcmd_AfflovestPMember_jQCcMt5pY0Os-LuUZm0lRA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss" scale="3" id="Tc_QPz6s7tfJkaQAeraXi0rng_5_6">11,832</ix:nonFraction></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">These pro forma results include certain adjustments, primarily due to increases in amortization expense due to fair value adjustments of intangible assets, increases in interest expense due to additional borrowings incurred to finance the acquisition and amortization of debt issuance costs incurred to finance the transaction, acquisition related costs including transaction costs such as legal, accounting, valuation and other professional services, and related tax effects.</p></ix:continuation><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;letter-spacing:-0.15pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">100</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" name="us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" id="Tb_6aZhg-BLTU2auNY5QHatJQ" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Note 5. &#160;Accounts Receivable</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="white-space:pre-wrap;"> </span>We had accounts receivable from <ix:nonFraction unitRef="Unit_Standard_item_-67QV0kzWUGc8AbcCukKig" contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" decimals="INF" format="ixt-sec:numwordsen" name="tcmd:ConcentrationRiskNumberOfInsuranceCompanies" scale="0" id="Narr_le0lZpYWqE--jUoIyqQtkA">two</ix:nonFraction> insurers representing approximately <ix:nonFraction unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw" contextRef="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_tcmd_InsuranceCompanyOneMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_N4xxMFKVj0S35nREv_ENMA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="Narr_bP67sdHaL0-bOAGxiyaweA">45</ix:nonFraction>% and <ix:nonFraction unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw" contextRef="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_tcmd_InsuranceCompanyTwoMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_xVT-UB4QW0Gw2arUgYbYcQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="Narr_YT6LMGpk-E2xEkEl6feFIw">21</ix:nonFraction>% of accounts receivable as of December 31, 2022. We had accounts receivable from <ix:nonFraction unitRef="Unit_Standard_item_-67QV0kzWUGc8AbcCukKig" contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g" decimals="INF" format="ixt-sec:numwordsen" name="tcmd:ConcentrationRiskNumberOfInsuranceCompanies" scale="0" id="Narr_6juchAUKeUuxmC5pto5Y4A">two</ix:nonFraction> insurers representing approximately <ix:nonFraction unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw" contextRef="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_tcmd_InsuranceCompanyOneMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_1-eh01sLXEOTZIQ08pcPiw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="Narr_LQ-HW6wHsk2n7fy9bHCo2w">33</ix:nonFraction>% and <ix:nonFraction unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw" contextRef="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_tcmd_InsuranceCompanyTwoMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_vLNz00UhJUufY_Zqk3iO2A" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="Narr_C-lR-9dptEqXH9brQVB5LA">24</ix:nonFraction>% of accounts receivable as of December 31, 2021. Revenue from these insurers accounted for <ix:nonFraction unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw" contextRef="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_tcmd_InsuranceCompanyOneMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_0HtNQF4hrEWyegzUln8uIA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="Narr_Kf7A2iwIC0iT1uZa2_KfRQ">19</ix:nonFraction>% and <ix:nonFraction unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw" contextRef="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_tcmd_InsuranceCompanyTwoMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_YhUWFBciaEqXEvSlvrAhSQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="Narr_L0rnULrFXEqjekFE-H_3jA">10</ix:nonFraction>% of our total revenue for the year ended December 31, 2022, and <ix:nonFraction unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw" contextRef="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_tcmd_InsuranceCompanyOneMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_qYkwWgdcNkuDHHwGOvxkhQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="Narr_bAmmkove6kqjAD9SRAMgKA">17</ix:nonFraction>% and <ix:nonFraction unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw" contextRef="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_tcmd_InsuranceCompanyTwoMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_3m0fCb_Nf0uWfI863PsLKw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="Narr_0qVAo4GO7EiHSc2CLA1JqQ">12</ix:nonFraction>% for the year ended December 31, 2021. The credit risks associated with customers which for these purposes are insurers considers aggregation for entities that are known to be under common control.</p></ix:nonNumeric><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="Tc_bXgTqIcgR0utSRtKqXRe0w_1_0"></a><a id="Tc_-nzTNhb-9ku-edqkWViTWQ_1_2"></a><a id="Tc_ICNkvKtPck2lJNHDHp2Wdw_1_5"></a><a id="Tc_3e_ZVVG4y0ea1zzbmawUwg_2_0"></a><a id="Tc_TjPkmUeaEUmc_xN8oYuYUw_2_2"></a><a id="Tc_lAADGpuKzkGlJVYag0H9_w_2_5"></a><a id="Tc_h3E4kzouJkOWXF_hN7Qb2w_3_0"></a><a id="Tc_hjyJGOGvLUKae4y4kA9_rQ_4_0"></a><a id="Tc_kXVlAf8S7E-0yXH-RoyA4w_4_2"></a><a id="Tc_3avU0xh2-Emfgnt35auFTg_4_5"></a><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" name="us-gaap:InventoryDisclosureTextBlock" id="Tb_g_opK2f7mUmyIUVRlEyFjw" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Note 6. &#160;Inventories</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Inventories consisted of the following:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="Tb_hW7Z57WPm0O_EEasxK4CoA" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:40.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:25.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:25.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:40.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0.05pt 0pt 0.05pt 0pt;">(In&#160;thousands)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:27.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">At December&#160;31,&#160;2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:27.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">At December&#160;31,&#160;2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:40.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Finished goods</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoods" scale="3" id="Tc_JULdPq7BSkG2uVOnOdkJjw_2_3">5,100</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoods" scale="3" id="Tc_q7R1R8wiOki41tfrntYIRA_2_6">8,242</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:40.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Component parts and work-in-process</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryWorkInProcess" scale="3" id="Tc_FrzmwOtYU0GnqUpMtRKBJw_3_3">18,024</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryWorkInProcess" scale="3" id="Tc_XqYzcsK1iEqWF6eFsnEalQ_3_6">10,975</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:40.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;">Total inventories</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="Tc_jP8qL9Wif0-GS4WNzvJOig_4_3">23,124</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="Tc_FwnuQ5Jh7kmZNmeS_23_6Q_4_6">19,217</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-size:1pt;font-weight:bold;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-size:1pt;font-weight:bold;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><a id="Tc_g__XMLCk5kGqsTmAvjkL7A_1_2"></a><a id="Tc_jEcxzBfdUEGoZipgo-eruQ_2_0"></a><a id="Tc_pa2xa1SQaESaQE0R0iG1Jg_2_2"></a><a id="Tc_DuoX-U4vbkW1d88sL1OMLw_2_5"></a><a id="Tc_1uvZYjGLYUiyEyNkihdlag_3_0"></a><a id="Tc_Kri_mm1un02qPCTWT9DAuQ_3_2"></a><a id="Tc_obTRajj4LkyZtJueeCTlUg_3_5"></a><a id="Tc_SYrfkr11LU-ZCAI5sF_KRw_4_0"></a><a id="Tc_TutcabK9SUmmmLBEm1BuiA_5_0"></a><a id="Tc_ka1mJjV3HEqZGDgd75bxkw_6_0"></a><a id="Tc_A4DvVyzFTkKduBbWfj-_gw_7_0"></a><a id="Tc_V_7C-SK4Ski_mIhwy1H4WQ_8_0"></a><a id="Tc_hMq7UQLsykSbeuG545y4RA_9_0"></a><a id="Tc_S7CJpL-xrUqUW7-swoScbA_10_0"></a><a id="Tc_nc1lDDQykkW5qIkwLI1Y3w_11_0"></a><a id="Tc_M5k-UT1vwkS2bAMHNyquQw_11_2"></a><a id="Tc_1OezyCjbz0WbCPEfaphZUw_11_5"></a><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="Tb_PFWa_L0ql0-XA2fXvD66DQ" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Note 7. &#160;Property and Equipment</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Property and equipment consisted of the following:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="Tb_0QkkUl5XiEuLaJr6NviawQ" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:53.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:53.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:43.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">At December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:53.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">(In&#160;thousands)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:53.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_Yh5OMODH40SC-Um87PF3UA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_PBBOTMk8N0Sc0nvZOx3hSg_3_3">8,274</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_Uf5xoWiQAkuLZI9kCZLPRA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_Vy_U9GOfOkWfl7jqyD5K8Q_3_6">8,051</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:53.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Tooling</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ToolsDiesAndMoldsMember_NTOCOwxcN0WCHhE4s7Z6xg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_LCAo-KT6AkW110r8-0o6hQ_4_3">3,390</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ToolsDiesAndMoldsMember_Pvs6l_E6h0O5TC299fq4Bg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_DbHdR8B5OEGfnZ345H2u2A_4_6">2,545</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:53.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Furniture and fixtures</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_wBBLS9cO1EGcEb4aYAZlcA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_6994_xfzA0G1dO8Oc_y9ww_5_3">2,087</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_cb8KtxnOaUusasmEVS4S6w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_LpMfFkv8-Eu6iIwOKEZngg_5_6">2,104</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:53.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_MA9Tzfj_Zkq7UAzFHCpHMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_vHVtSQbmkUC5kc6V9c0oMQ_6_3">1,493</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_MU5-dZQMLEOZnQDTmaetLQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_d6cs-r5wNES3PfEvbFHFiw_6_6">1,458</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:53.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Demonstration equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_tcmd_DemoEquipmentMember_r01Fmv-tlE2ZfmS0SxVG8g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_yKaLB1X37EquowvG8QCj3w_7_3">1,012</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_tcmd_DemoEquipmentMember_3j_rU49gBEimc7YFgpwKEw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_ARUrFTaUiUe6v81RSTWuHQ_7_6">632</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:53.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Construction in progress</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember_jGU_hCQP7EaA8kqaHpKwsg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_xMBW8TSvdEaKidnEi0rnPQ_8_3">606</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember_Ko8IgMBkWUy1Erw3_JKPQg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_NibQlt7u8EO242mbwjBdYg_8_6">1,003</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:53.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Subtotal</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.44%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_Yo4aA2S2pU6Ve18BdwcrHA_9_3">16,862</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.44%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_lUP074KAHEqu65y8KVz4NQ_9_6">15,793</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:53.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Less: accumulated depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="Tc_zM2vqMNNikuFZ83svagdUA_10_3">10,785</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="Tc_rwlMlhHsZEa7LriW3EwJtQ_10_6">9,043</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:53.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_rOwOKMKLB0udeNJOWeexTA_11_3">6,077</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_8K0NxOo2sE2XNfBuw0yyvg_11_6">6,750</ix:nonFraction></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;margin:0pt;">Depreciation expense was $<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="6" id="Narr_BUry312dmUq_U-XPmFGyYg">2.5</ix:nonFraction> million, $<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="6" id="Narr_4ipjagSN0U-lZogXkkQehA">2.3</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="6" id="Narr_ZRN15ZaOGUOR6fcVAUHezg">2.4</ix:nonFraction> million for the years ended December&#160;31,&#160;2022, 2021 and 2020, respectively.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="Tb_mdHKyW0TMkuzMN8wBcxMzw" continuedAt="Tb_mdHKyW0TMkuzMN8wBcxMzw_cont1" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Note 8. &#160;Goodwill and Intangible Assets</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;padding-left:10pt;text-align:justify;text-indent:-10pt;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Goodwill</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">In the third quarter of fiscal 2021, we completed the AffloVest Acquisition. The purchase price of the AffloVest business exceeded the net acquisition-date estimated fair value amounts of the identifiable assets acquired and the liabilities assumed by $<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_9_30_2021_us-gaap_BusinessAcquisitionAxis_tcmd_AfflovestPMember_0vr8lFFgNk-hj48fe5kJDg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="6" id="Narr_h3jzVeVJTUyP2yMVKgibkQ">31.1</ix:nonFraction> million, which was assigned to goodwill.&#160;</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">101</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_a9d9ed05_3f41_43f5_b01b_01c4600b0c0e"></a><a id="Tc_Fe6PXHGYvkKGcPJpw4m3dw_1_2"></a><a id="Tc_C8bihKhRq0ODiVolYakiZg_1_4"></a><a id="Tc_TlHSpVCMvEu9ILjzzNIYUQ_2_2"></a><a id="Tc_JoXelqj_R0eDwcozEkJOnw_2_4"></a><a id="Tc_UT_O2ZwJ-Umf0U974GDIEQ_3_2"></a><a id="Tc_wfxdASxpTEaEAugaUEki3A_3_4"></a><a id="Tc_yixCFk2zGU6q2rQ6jFGNfg_3_7"></a><a id="Tc_EH6bqsQPCUOO9Njo1Vopdg_3_10"></a><a id="Tc_dyy1k3qS9kiVn8uDueiZEA_4_0"></a><a id="Tc_hRpgJbNHrUao2hkyAXBHnA_4_2"></a><a id="Tc_3wywa0Y3cUSTQwTNc_yHOQ_4_4"></a><a id="Tc_gCtHN0AUOk6wEmkQxKG82Q_4_7"></a><a id="Tc_QPz6OOZ30UiYZ1lo0yPtmw_4_10"></a><a id="Tc_zD25yyyiwEWnZKWriHouHw_5_0"></a><a id="Tc_kxtsWss-RkCpgDudW-zEUQ_6_0"></a><a id="Tc_95KsgZkflEubliopTe1T0A_6_4"></a><a id="Tc_-mvV0A4fIkykrzE9wmi5WA_6_7"></a><a id="Tc___BQQTRH6Ei12TPWz6TxCQ_6_10"></a><a id="Tc_dbm1OZuxPk6aAVY54pBkZA_7_0"></a><a id="Tc_Zl-ICj1AnkyID0qEUqzQ3g_8_0"></a><a id="Tc_ySJVe1gjk0-cSdPerJaRtA_8_2"></a><a id="Tc_uCaf9R0EFkaGB1BYUueYwg_9_0"></a><a id="Tc_7O6Uny1VY0e9J4U0ltHHlQ_10_0"></a><a id="Tc_UMxG9RLMZ02Pr056BWa5XA_11_0"></a><a id="Tc_fSUs1-JZG0iTTPKnm0ZaYw_12_0"></a><a id="Tc_cnTdSU1BjEqNvfhAVjZJFw_13_0"></a><a id="Tc_0sf53zP11kKKmd-IUpzrWQ_13_8"></a><a id="Tc_zd8hdwi1jUqZHLq6hiaAhQ_14_0"></a><a id="Tc_fUG_-uA7PEGAjGAQHESZSg_14_8"></a><a id="Tc_-V_g865o1U6Z4CcefHmz_Q_15_0"></a><a id="Tc_MWfcqbke_Ua_dJv1deS6yA_15_4"></a><a id="Tc_pc03UJyUAUiahSaXWdNgNA_15_7"></a><a id="Tc_oBarqUkS2EOjamPGeurzgQ_15_10"></a><a id="_b8f1bac4_7d7d_4ed5_a01c_cc3a0e7d1d10"></a><a id="Tc_YNS-faekDUqS1H6bLDCLqg_1_2"></a><a id="Tc_V0PIxAaGtEKMmDjNhIwd2A_1_4"></a><a id="Tc_p8IMNNR5w0WGtHC6k2Wrlw_2_2"></a><a id="Tc_7Pi_QBRqa0aj_SNV_hEwrg_2_4"></a><a id="Tc_nyzagtSjgUeDIj73gOz0Tg_3_2"></a><a id="Tc_Evy8bgdAiEWRsHavEcc3eg_3_4"></a><a id="Tc_VG7e7EhyQEiGcbz4UUIyng_3_7"></a><a id="Tc_vNJP5I3I30Kzoe9n9sYkYQ_3_10"></a><a id="Tc_WL8w34m2XEmSJ7KA1m5K4w_4_0"></a><a id="Tc_2uEL5g2uKkyPuXZX34CVPQ_4_2"></a><a id="Tc_pk37mFi-K0Wl41i07R1eWw_4_4"></a><a id="Tc_eN5q7Pp020KUmELNSVgvoA_4_7"></a><a id="Tc_MkDsa6RUME6_LYbh4MqvAg_4_10"></a><a id="Tc_QIXnpzBXMEmHYO5rkZfLlQ_5_0"></a><a id="Tc_hGAT5Ah3fk6JJNcJBo0yBg_6_0"></a><a id="Tc_utSvPwG8bUqZu8j9n47JPg_6_4"></a><a id="Tc_u7zSh6MsgU2AyrplRR5r8A_6_7"></a><a id="Tc_oKQ4-8xTZ0yMqwWE7Lrs_Q_6_10"></a><a id="Tc_mesZrQ9W2UiKAd2a81Sx4Q_7_0"></a><a id="Tc_R7iGGjXMYEed0yvpQWOwhA_8_0"></a><a id="Tc_QNiH-ylAq0m9MWqXNgIo-w_9_0"></a><a id="Tc_IpMzwTwPYUqQkwkbwn2Hdg_10_0"></a><a id="Tc_6hsXn2toC0e5-yRJ_X9m0A_11_0"></a><a id="Tc_OJDDFR1uWkqyEa11jBnt_w_12_0"></a><a id="Tc_LHG8MajObkCqOAPX8ZDB9g_13_0"></a><a id="Tc_ZLZx4_O3CkKelptC8NDVdw_13_8"></a><a id="Tc_Uib9bgLzGkCRuRioh_8IJw_14_0"></a><a id="Tc_yAWPTQ7A3E6WGQHV_5v4-w_14_8"></a><a id="Tc_UNkqWF8vMk2MJMKSz-k_dg_15_0"></a><a id="Tc_OT8Cd8O4Ykm8HeULIjJx_Q_15_4"></a><a id="Tc_2WfTkJVFE0qHtT3rzqllvg_15_7"></a><a id="Tc_lq2sDXCqLEmn3_Qo4ZwklQ_15_10"></a><a id="Tc_wgZWf_DXVkGfqtFo1p5VIg_1_0"></a><a id="Tc_3_r-fcoocU6ciSo0ym4x3w_2_0"></a><a id="Tc_5gIrZKloAU62-QUCA5ED6g_2_2"></a><a id="Tc_Ay5OZ7ZtV06jiVPRY-PZLg_3_0"></a><a id="Tc_a5mItPi0TECi6TZ8ryXHpA_4_0"></a><a id="Tc_a4VZMbzaDkiamNbNIqqDrQ_5_0"></a><a id="Tc_-o_A_19UvEWGbezchfucMg_6_0"></a><a id="Tc_fhN86yQL6EuHTSMh0yKq1Q_7_0"></a><a id="Tc_ENuvwLRrMEiFxJncuxn3IA_8_0"></a><a id="Tc_YzXTml1oeUSMy1OVvm3v8g_8_2"></a><ix:continuation id="Tb_mdHKyW0TMkuzMN8wBcxMzw_cont1" continuedAt="Tb_mdHKyW0TMkuzMN8wBcxMzw_cont2"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;padding-left:10pt;text-align:justify;text-indent:-10pt;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Intangible Assets</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">Our patents and other intangible assets are summarized as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="Tb_8zczWr9tt0ug3M3rOt2YUA" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:30.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:48.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">At December&#160;31,&#160;2022</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortization</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Carrying</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Net</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">(In&#160;thousands)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Period</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortization</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Definite-lived intangible assets:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Patents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_PatentsMember_bHnLKkfY50SShKWlCELEaA" format="ixt-sec:durwordsen" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" id="Tc_rxx98p-dhkKI1neb8hYgpA_6_2">12 years</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_PatentsMember_EzMi2_I88kuyRc4Rc_5PoQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="Tc_2tHidTYlEEeZe48Yn04ecg_6_5">897</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_PatentsMember_EzMi2_I88kuyRc4Rc_5PoQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="Tc_H2IXQSeSe0ye1xpFAuDN3w_6_8">173</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_PatentsMember_EzMi2_I88kuyRc4Rc_5PoQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="Tc_iy5nK1kYGEeW9dfAEtrjTQ_6_11">724</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Defensive intangible assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_tcmd_DefensiveIntangibleAssetsMember_6NFOXe0OVEae4LCvhvDg5A" format="ixt-sec:durwordsen" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" id="Tc_X3NLg93nMkuuHsYSvWMCrg_7_2">2 years</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_tcmd_DefensiveIntangibleAssetsMember_LZ89k11DfEu3IXN3jY-Q_A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="Tc_z8luboGv8EqP3OyEvPKE-A_7_5">1,126</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_tcmd_DefensiveIntangibleAssetsMember_LZ89k11DfEu3IXN3jY-Q_A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="Tc_C156l0nugkShC2OC1peySw_7_8">764</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_tcmd_DefensiveIntangibleAssetsMember_LZ89k11DfEu3IXN3jY-Q_A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="Tc_ZeQWYSMKoEm9RZ7y7IJL8Q_7_11">362</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Customer accounts</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&lt; <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_CustomerContractsMember_zWlWYJGY4UyP-QjMu9VYLA" format="ixt-sec:durwordsen" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" id="Narr_05XXyhgHzUe90COwEu__3A">1 year</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_CustomerContractsMember_YzWU1KiStEOVgQlfeA7jcw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="Tc_PXkjaXnP10Ktd8II38obmA_8_5">125</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_CustomerContractsMember_YzWU1KiStEOVgQlfeA7jcw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="Tc_Pr2GPEBDHk6VNzF_IcJWpQ_8_8">114</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_CustomerContractsMember_YzWU1KiStEOVgQlfeA7jcw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="Tc_u5EKMtUCNUiy9hqIkmmEkQ_8_11">11</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Customer relationships</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_CustomerRelationshipsMember_jYH-emDiWkiQNaMDqVEM4w" format="ixt-sec:durwordsen" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" id="Tc__vq1Cfi1gUCABr8kmOMboA_9_2">12 years</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_CustomerRelationshipsMember_Y08o1mZ38kCDCzt3GAQN8A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="Tc_8SPGd0zBeUaiRV8hoanQiA_9_5">31,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_CustomerRelationshipsMember_Y08o1mZ38kCDCzt3GAQN8A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="Tc_89aCgUi3LEC55r0ot8WqKw_9_8">3,127</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_CustomerRelationshipsMember_Y08o1mZ38kCDCzt3GAQN8A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="Tc_ZMXKjSqJOE-lH16kRCd36g_9_11">27,873</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Developed technology</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_lM7vBgl8SkW3zbCRJ6akww" format="ixt-sec:durwordsen" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" id="Tc_B5SgGsW2hUyWr4pg8a12BQ_10_2">10 years</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_lL8SrIZbB0O4E4gu1p47vA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="Tc_vyRzrnTUCUSc4MN3v3XJuw_10_5">13,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_lL8SrIZbB0O4E4gu1p47vA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="Tc_R-uJQtpX5U2SvRHiIrQf0g_10_8">1,550</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_lL8SrIZbB0O4E4gu1p47vA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="Tc_XtRPbVt08kuCoHY7PQix2g_10_11">11,450</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Subtotal</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="Tc_OgUIydUpekmztORjV1rfrg_11_5">46,148</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="Tc_Int4gofLK0ebMjy5PHYeaQ_11_8">5,728</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="Tc_x5aZxzds2ku9H6nXbl2D2A_11_11">40,420</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Unamortized intangible assets:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Tradenames</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2022_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember_IyWAZ3ta8E2Ea1SMrdPPBQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="3" id="Tc_54Iku5N8SUuCzqNYJC2_mQ_13_5">9,500</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2022_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember_IyWAZ3ta8E2Ea1SMrdPPBQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="3" id="Tc_yGMY9GXppUya4XezASkK8g_13_11">9,500</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Patents pending</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2022_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_PatentsMember_LNA_h_4RnkaxxN0_I1BWbQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="3" id="Tc_62KIK5_6p0yetXo6OZ7hhQ_14_5">455</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2022_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_PatentsMember_LNA_h_4RnkaxxN0_I1BWbQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="3" id="Tc_r6mQOthDiEC2V3gnevpZHw_14_11">455</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total intangible assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" scale="3" id="Tc_X9bSjCFKqEmcdz_pnBQaJw_15_5">56,103</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="Tc_hlPmkLZzbEqy0E_G95_75A_15_8">5,728</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" id="Tc_3Nw_7eDEDUyEWNkrvu-PqQ_15_11">50,375</ix:nonFraction></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:30.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:48.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">At December&#160;31,&#160;2021</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amortization</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Carrying</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0.05pt 0pt 0.05pt 0pt;">(In&#160;thousands)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Period</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amortization</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Definite-lived intangible assets:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Patents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_PatentsMember_nZCthuPEmEK_vsD9bnMPZg" format="ixt-sec:durwordsen" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" id="Tc_nvFLNZCRXUCi7rX-CKCtrQ_6_2">12 years</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2021_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_PatentsMember_JkjaHeEoUE2DyDTDEjvMwQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="Tc_8J5A34XQSUyw3GAfzDCesQ_6_5">666</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2021_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_PatentsMember_JkjaHeEoUE2DyDTDEjvMwQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="Tc_4DIUBQ9vV0qNQlOaqw3VgA_6_8">109</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2021_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_PatentsMember_JkjaHeEoUE2DyDTDEjvMwQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="Tc_cl0Y9ssmkkWKFr1Jc7uk7Q_6_11">557</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Defensive intangible assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_tcmd_DefensiveIntangibleAssetsMember_62-asFO7iEyeD8pb1fZgLA" format="ixt-sec:durwordsen" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" id="Tc_I5zCwe7ByEWoE5s4vRjuGA_7_2">3 years</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2021_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_tcmd_DefensiveIntangibleAssetsMember_QV0b5loORke7y1IpAQUFJQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="Tc_efFkGI2Z00Wmen928NJlgQ_7_5">1,125</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2021_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_tcmd_DefensiveIntangibleAssetsMember_QV0b5loORke7y1IpAQUFJQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="Tc_tpdJiRl3o0aeg4pk0jBTfA_7_8">592</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2021_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_tcmd_DefensiveIntangibleAssetsMember_QV0b5loORke7y1IpAQUFJQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="Tc_RTbv5UZoGkSS3kddCe8Rpg_7_11">533</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Customer accounts</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_CustomerContractsMember_8VJEgmF_UkWBYfqLoC4C3A" format="ixt-sec:durwordsen" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" id="Tc_DiUMF93Oc0agQhCEPfgx8w_8_2">1 year</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2021_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_CustomerContractsMember_fTqSuCd94keomoVYMmQiIw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="Tc_zurX-bzNgEarx7kjwb386g_8_5">125</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2021_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_CustomerContractsMember_fTqSuCd94keomoVYMmQiIw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="Tc_y9id3S0qN0q5bHVGQqGUlg_8_8">89</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2021_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_CustomerContractsMember_fTqSuCd94keomoVYMmQiIw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="Tc_WGouyfFHw0GL6OmTfDTscw_8_11">36</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Customer relationships</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_CustomerRelationshipsMember_64UYdGsGlUaBziSx02KLVQ" format="ixt-sec:durwordsen" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" id="Tc_M3QN2CoxkES3QPGHVPQf6g_9_2">13 years</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2021_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_CustomerRelationshipsMember_dmnRIghXk0SjwOQAgPqgtg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="Tc_uaWzfOPWn0qthR1DNviTwg_9_5">31,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2021_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_CustomerRelationshipsMember_dmnRIghXk0SjwOQAgPqgtg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="Tc_ljM3Bbts1US_A8ZtihTzqA_9_8">742</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2021_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_CustomerRelationshipsMember_dmnRIghXk0SjwOQAgPqgtg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="Tc_paVwcPxwUUeWDJ2xvhvCuA_9_11">30,258</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Developed technology</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_TEkHdFvt00SmYBkAMY4_HQ" format="ixt-sec:durwordsen" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" id="Tc_n7qo09b-TEaUut-JtQUBBw_10_2">11 years</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2021_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_iZuKEYAKNU6aSfE3kxIqUw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="Tc_Klv-FgXNr0qPqSq5FIifrg_10_5">13,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2021_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_iZuKEYAKNU6aSfE3kxIqUw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="Tc_kKGWJ8QUpUy28e5NWop-jQ_10_8">368</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2021_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_iZuKEYAKNU6aSfE3kxIqUw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="Tc_NW8sc4J-WUSA3HXE307NUg_10_11">12,632</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;">Subtotal</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="Tc_D9RcHG0T5EeB5KM92JVWuA_11_5">45,916</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="Tc_y8cjMMBdykeH3O9j6LhsdQ_11_8">1,900</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="Tc_sb6m6QSEFU2kaoUFbTdgtg_11_11">44,016</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unamortized intangible assets:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Tradenames</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2021_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember_aBd3a_ELrEOm_yysA0S0ag" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="3" id="Tc_z7-4bbu57kecS4rCxowAeQ_13_5">9,500</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2021_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember_aBd3a_ELrEOm_yysA0S0ag" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="3" id="Tc_pluMAnyXGEuzZ-ddHk8pZQ_13_11">9,500</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Patents pending</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2021_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_PatentsMember_m8rPRrVCGkCmV2jH3V3EGA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="3" id="Tc_xYDN85b6z0aEKaPPCehkgg_14_5">565</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2021_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_PatentsMember_m8rPRrVCGkCmV2jH3V3EGA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="3" id="Tc_dkp8caztME-rF3bOGwI9-A_14_11">565</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;">Total intangible assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" scale="3" id="Tc_eWQFEp2C7k28GjaEwY7QDw_15_5">55,981</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="Tc_mgkESC9wbkq1WGcQImqzOQ_15_8">1,900</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" id="Tc_ueyS6z0HaUmYXjnMBS19Rg_15_11">54,081</ix:nonFraction></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">Amortization expense was $<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="Narr_XxWL8pQApU-7MaI2cOZDVg">3.8</ix:nonFraction> million, $<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="Narr_FpWv08aVskSbGaVd40YXww">1.4</ix:nonFraction> million, and $<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="Narr_qeRMeBM10EW23LnnT3lLMg">0.4</ix:nonFraction> million for the years ended December&#160;31,&#160;2022, 2021 and 2020, respectively. Future amortization expenses are expected as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="Tb_kDCfTB2XA0aOX-Qs3TOpqQ" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:30.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:54.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">(In&#160;thousands)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:30.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:30.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" scale="3" id="Tc_dUnzn4YgrkGBLmbCLZwZWA_2_3">3,808</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:54.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:30.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" scale="3" id="Tc_HULrzvQ9XkSkn6syZbTZxw_3_3">3,787</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:54.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:30.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" scale="3" id="Tc__nvcJxP5_EiPgyHGUqFNiA_4_3">3,697</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:54.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:30.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" scale="3" id="Tc_ncYh-A88gEumC0600CEHSw_5_3">3,633</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:54.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:30.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" scale="3" id="Tc_cuREnv3_oEWr25GZ8Cw8PQ_6_3">3,623</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:54.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:30.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" scale="3" id="Tc_zuksRQ4wT0OkQVbIpirthw_7_3">21,872</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:54.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:30.85%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="Tc_sPzycbi-G0GhHqFkdtLoag_8_3">40,420</ix:nonFraction></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;padding-bottom:14pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:2pt 0pt 0pt 0pt;"><span style="font-size:10pt;">The weighted-average remaining amortization period for these intangible assets was </span><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" id="Narr_KIZUjFPq-E2WtT6RSaRgEQ"><span style="font-size:10pt;">11.0</span></ix:nonNumeric><span style="font-size:10pt;"> years as of December&#160;31,&#160;2022.</span></p></ix:continuation></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">102</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_mdHKyW0TMkuzMN8wBcxMzw_cont2"></ix:continuation><a id="Tc_aKA3gTI0VkGNh2n_XYY4AQ_1_0"></a><a id="Tc_lHNYieUol0W8PR7li3apcg_1_2"></a><a id="Tc_xezFKBsgykmEIQdXwOoTbw_1_5"></a><a id="Tc_kNm_UFhruUa0hQQ94EOQDw_2_0"></a><a id="Tc_pg_ekALWlEWB2q8UUPwrIw_2_2"></a><a id="Tc_oYwFs3lvSUOl3BqNRlzJ_w_2_5"></a><a id="Tc_4wH794ZlyUKGbjXVrQ5G9g_3_0"></a><a id="Tc_SCXCTbjidkehJkvbI8mtQw_4_0"></a><a id="Tc_aP45HuuLBUCPnWHsQYVUXQ_5_0"></a><a id="Tc_hlcSpaieokOgw-7NxlX0Bg_6_0"></a><a id="Tc_LnjSYXUxB0CaUstP0gkwGw_7_0"></a><a id="Tc_FaxSTqlQuUG4fzUEUrVA0A_8_0"></a><a id="Tc_btbu9Z5egUSGfjBkEBumjQ_9_0"></a><a id="Tc_8DaF-oCxdk6QgwsIh_A1ng_9_2"></a><a id="Tc_aL4r0cIpEk-FnmC2huCZ-Q_9_5"></a><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" name="tcmd:AccruedExpensesDisclosureCurrentTextBlock" id="Tb_UF_tMkA2qkOn2UslyECT1w" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Note 9. &#160;Accrued Expenses</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">Accrued expenses consisted of the following:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" name="tcmd:ScheduleOfAccruedExpensesTableTextBlock" id="Tb_VTx-8tSMIkmyjmQl2naHxA" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:34.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:27.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:27.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:34.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">(In&#160;thousands)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:30.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">At December&#160;31,&#160;2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:30.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">At December&#160;31,&#160;2021</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:34.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">In-transit inventory</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw" decimals="-3" format="ixt:numdotdecimal" name="tcmd:InTransitInventoryAccruedExpense" scale="3" id="Tc_3W9U4kSqXkWE6scMjdJN0g_2_3">3,228</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q" decimals="-3" format="ixt:numdotdecimal" name="tcmd:InTransitInventoryAccruedExpense" scale="3" id="Tc_iaccneYFLkC4FWl8OeI8fw_2_6">416</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:34.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Warranty</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.87%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProductWarrantyAccrualClassifiedCurrent" scale="3" id="Tc_WREW-GQdbkG2OK6tdHCXBw_3_3">2,005</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.87%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProductWarrantyAccrualClassifiedCurrent" scale="3" id="Tc_pFkHJqQO8k-ykBpLeH3w0g_3_6">1,851</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:34.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Travel</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw" decimals="-3" format="ixt:numdotdecimal" name="tcmd:AccruedTravelAndEntertainmentCurrent" scale="3" id="Tc_3fhHz91y80aoil1mZOpliw_4_3">1,121</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q" decimals="-3" format="ixt:numdotdecimal" name="tcmd:AccruedTravelAndEntertainmentCurrent" scale="3" id="Tc_WyDORHc8A0SIOXNJgwQAXg_4_6">661</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:34.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Legal and consulting</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.87%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="Tc_1EJLd0mOMEO8oFc8d42weQ_5_3">730</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.87%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="Tc_vS99gAcnBkqkQzeKyzJ-Jg_5_6">1,371</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:34.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Clinical studies</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw" decimals="-3" format="ixt:numdotdecimal" name="tcmd:AccruedClinicalStudiesExpensesCurrent" scale="3" id="Tc_FiEpRhgYdUyCHGx1qrGgjQ_6_3">276</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q" decimals="-3" format="ixt:numdotdecimal" name="tcmd:AccruedClinicalStudiesExpensesCurrent" scale="3" id="Tc_w-W8R_2un0mD37coKH5JgQ_6_6">113</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:34.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Sales and use tax</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.87%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw" decimals="-3" format="ixt:numdotdecimal" name="tcmd:AccruedSalesAndUseTax" scale="3" id="Tc_LW7srx82bUOXAKRPENmyBg_7_3">147</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.87%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q" decimals="-3" format="ixt:numdotdecimal" name="tcmd:AccruedSalesAndUseTax" scale="3" id="Tc_VV8NtIP99k68aBzSOXXDHQ_7_6">106</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:34.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="Tc_RI7Sdm9OJ0qk6vkZx7V9fw_8_3">1,733</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="Tc_Ax3r9gy2A0qOoIUgzBcKKg_8_6">744</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:34.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_dGvdAFUPr0C13ZprVaHo2A_9_3">9,240</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_lmOCRTtegkO48hFcMPH06g_9_6">5,262</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><a id="Tc_G80Ji6dBREabXRKfIku0qA_1_1"></a><a id="Tc_lz_OTDvnxk6-tWUzZVN80A_2_1"></a><a id="Tc_RajhQn4UsU-zm9vKP8I-5g_3_0"></a><a id="Tc_YiWg7cCHQkGdDYnGm7qRdg_3_1"></a><a id="Tc_-VVYcn4YtU6Vp2VvmdjM-w_3_4"></a><a id="Tc_ThXeBHx_D0SCgRxRCcEvQg_3_8"></a><a id="Tc_4UOu7aEyc0aLgHRQfj2mkg_4_0"></a><a id="Tc_d8ZKfVnfoUCB7-R8x54Yzg_4_1"></a><a id="Tc_yHWe-LAMhECKciMyMjRbeA_4_4"></a><a id="Tc_niOIKGov10Gt2Jz9yfgU2g_4_7"></a><a id="Tc_Zv0UsOmDbEma-uP-KGpmkg_5_0"></a><a id="Tc_ALlfB0m56kiNthK5MVxWYw_6_0"></a><a id="Tc_jCUyOoB_pEKodMnggb08dw_7_0"></a><a id="Tc_m0GUz4DabkWq-Iv4E0L1gQ_7_1"></a><a id="Tc_DymFnGb1LEiORK2taXyRmg_7_4"></a><a id="Tc_91qQ6omEek-ICa2rCC13MA_7_7"></a><a id="Tc_8hmrYLlMA0-ifonu2Jzb6w_9_0"></a><a id="Tc_j2dbm70e2UaDblyKbB6VxA_9_1"></a><a id="Tc_GdnDNrMqZ02RA4kcwL9obg_9_4"></a><a id="Tc_d8DZOUSeYUawnUSAztkM7w_9_7"></a><a id="Tc_GRgIqM-ogEC5Aai_hwa9_Q_10_0"></a><a id="Tc_2o7q-EBw2UiJB4GxByM-eQ_11_0"></a><a id="Tc_MftmsqKTkkiWQ3accWhOYQ_11_1"></a><a id="Tc_JWuH-G-hrUicId5OkAlJ9g_11_4"></a><a id="Tc_MEpy6HwmTUCm7fEY4fBz0w_11_7"></a><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" name="us-gaap:ProductWarrantyDisclosureTextBlock" id="Tb_E1Dh5YELzk-L-Ea8EfQrYw" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Note&#160;10. &#160;Warranty Reserves</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The activity in the warranty reserve during and as of the end of the year presented was as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" name="us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock" id="Tb_GvvJ30-GPE6LN7uONo3XFw" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:40.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:40.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:59.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:40.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:59.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:40.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">(In&#160;thousands)</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:40.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Beginning balance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StandardProductWarrantyAccrual" scale="3" id="Tc_wQIkH1vst0mPJm70E1rSJg_4_2">4,959</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2020_q95ww8WB7U-18mlScI3MCA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StandardProductWarrantyAccrual" scale="3" id="Tc_ZkLLqXq9PkOO_ChoRiKxGw_4_5">4,841</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2019_3ga0jBjg6EKA4-znaQ36NQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StandardProductWarrantyAccrual" scale="3" id="Tc_kzSmFOhES0m5OTnraXyRcA_4_8">3,759</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:40.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Warranty provision</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.76%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StandardProductWarrantyAccrualWarrantiesIssued" scale="3" id="Tc_suR8FGTt3EiP-yGOLs6DoA_5_2">2,047</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.78%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StandardProductWarrantyAccrualWarrantiesIssued" scale="3" id="Tc_HxbopVIkYUGZIhj_-bsT6Q_5_5">2,606</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StandardProductWarrantyAccrualWarrantiesIssued" scale="3" id="Tc_MzIIknw6Ckqv-JSkYqAzqQ_5_8">2,957</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:40.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Processed warranty claims</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StandardProductWarrantyAccrualPayments" scale="3" id="Tc_F6vt4-XHLkiqnio_XTe3CQ_6_2">2,794</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StandardProductWarrantyAccrualPayments" scale="3" id="Tc_JPddDHmDQkiewmZ8ckvpoA_6_5">2,488</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StandardProductWarrantyAccrualPayments" scale="3" id="Tc_InJWNpKQK0G3tg74rx577g_6_8">1,875</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:40.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Ending balance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StandardProductWarrantyAccrual" scale="3" id="Tc_Jazkr-gwek-0O3JsmRx1NA_7_2">4,212</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StandardProductWarrantyAccrual" scale="3" id="Tc_ckzO1WaisECVio0nW_BtTQ_7_5">4,959</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2020_q95ww8WB7U-18mlScI3MCA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StandardProductWarrantyAccrual" scale="3" id="Tc_rV2FNtRetEWGgdbdIaMRjQ_7_8">4,841</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:40.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#ff0000;font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Accrued warranty reserve, current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.76%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProductWarrantyAccrualClassifiedCurrent" scale="3" id="Tc_I66_--q63km6bFPy0lA95w_9_2">2,005</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.78%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProductWarrantyAccrualClassifiedCurrent" scale="3" id="Tc_UDGyKTySGUqc-pJAsuzgHQ_9_5">1,851</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2020_q95ww8WB7U-18mlScI3MCA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProductWarrantyAccrualClassifiedCurrent" scale="3" id="Tc_hUbAQNfgtkq5f0MAQSclJA_9_8">1,606</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:40.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Accrued warranty reserve, non-current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProductWarrantyAccrualNoncurrent" scale="3" id="Tc_coh3ibhzhEi-dsdSUAqyoQ_10_2">2,207</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProductWarrantyAccrualNoncurrent" scale="3" id="Tc_4ZapMWuKkEiyJv1kY8PqOA_10_5">3,108</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2020_q95ww8WB7U-18mlScI3MCA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProductWarrantyAccrualNoncurrent" scale="3" id="Tc_yYPUxC4xZEOmCyTFw8iAvg_10_8">3,235</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:40.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total accrued warranty reserve</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProductWarrantyAccrual" scale="3" id="Tc_LaPih9EESU-6tTJ0oftl0A_11_2">4,212</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProductWarrantyAccrual" scale="3" id="Tc_2YRMjOmu-0-ZCUQUcc5NLA_11_5">4,959</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2020_q95ww8WB7U-18mlScI3MCA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProductWarrantyAccrual" scale="3" id="Tc_BbVdPmKLokSZWgsJaZCxvA_11_8">4,841</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" name="us-gaap:DebtDisclosureTextBlock" id="Tb_dY42E7MiMEiSBZCm--KMaQ" continuedAt="Tb_dY42E7MiMEiSBZCm--KMaQ_cont1" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Note&#160;11. &#160;Credit Agreement</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">On April 30, 2021, we entered into an Amended and Restated Credit Agreement (the &#8220;Restated Credit Agreement&#8221;) with the lenders from time to time party thereto, and Wells Fargo Bank, National Association, as Administrative Agent. The Restated Credit Agreement amended and restated in its entirety our prior credit agreement.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27pt;background:#ffffff;margin:0pt;">On September 8, 2021, we entered into a First Amendment Agreement (the &#8220;First Amendment&#8221;), which amends the Restated Credit Agreement (as amended by the First Amendment, the &#8220;Credit Agreement&#8221;) with the lenders from time to time party thereto and Wells Fargo Bank, National Association, as Administrative Agent. The First Amendment, among other things, adds a $<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_9_8_2021_us-gaap_CreditFacilityAxis_tcmd_TermLoanMember_oz1r9Y66CkacJQ3itM6kfg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="Narr_BzMcFWIrukebIqtsWlaaeg">30.0</ix:nonFraction> million incremental term loan to the $<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_9_8_2021_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_4ewNm1bD10K5QwII7IVr3g" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="Narr_WzvF12MxeEWLvtEjoflPSQ">25.0</ix:nonFraction> million revolving credit facility provided by the Restated Credit Agreement. The term loan is reflected as a note payable on our Consolidated Balance Sheets. The term loan and the revolving credit facility mature on September 8, 2024. The Credit Agreement provides that, subject to satisfaction of certain conditions, we may increase the amount of the revolving loans available under the Credit Agreement and/or add one or more term loan facilities in an amount not to exceed $<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_9_8_2021_To_9_8_2021_JHuv2YIhr0-DMtiV3Vl0PA" decimals="-5" format="ixt:numdotdecimal" name="tcmd:LineOfCreditThresholdContingentIncreaseInBorrowingCapacity" scale="6" id="Narr_GPmLeAYrcEms1-b_teHyMg">25.0</ix:nonFraction> million in the aggregate, such that the total aggregate principal amount of loans available under the Credit Agreement (including under the revolving credit facility) does not exceed $<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_9_8_2021_8l4xBubq7Umd0Y3dMd0UnQ" decimals="-5" format="ixt:numdotdecimal" name="tcmd:CreditAgreementTotalAggregatePrincipalAmount" scale="6" id="Narr_hVuNRnoTmUiZI5NLVDa12g">80.0</ix:nonFraction> million.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">&#160;</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27pt;background:#ffffff;margin:0pt;">On September 8, 2021, in connection with the closing of the AffloVest Acquisition, we borrowed the $<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_9_8_2021_us-gaap_CreditFacilityAxis_tcmd_TermLoanMember_oz1r9Y66CkacJQ3itM6kfg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="Narr_30fUBbh56US9cVVqA4K9SA">30.0</ix:nonFraction> million term loan and utilized that borrowing, together with a draw of $<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_9_8_2021_8l4xBubq7Umd0Y3dMd0UnQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LineOfCredit" scale="6" id="Narr_XjKzZlyiG0SrUs5GvqzYjQ">25.0</ix:nonFraction> million under the revolving credit facility and cash on hand, to fund the purchase price.&#160;As of both December 31, 2022 and 2021, there was no availability under our Credit Agreement.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;text-align:justify;text-indent:27pt;background:#ffffff;margin:0pt;"><span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">103</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_87449605_35b9_4e80_b462_3496b4a932ec"></a><a id="Tc_tDHnAxjr4EyTVFWaZnuvMw_1_0"></a><a id="Tc_DgeXDTz9f0W_ql0EUg-3_g_1_2"></a><a id="Tc_FcWlOLMnVke0QlCQw_Ge7A_2_0"></a><a id="Tc_ujImD3-we0StvArEs9H6lA_3_0"></a><a id="Tc_YBe4gXpkJ0WOajhKYJVseA_4_0"></a><a id="Tc_K25WI2hWrEan0J44zdnmHA_4_2"></a><ix:continuation id="Tb_dY42E7MiMEiSBZCm--KMaQ_cont1"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27pt;background:#ffffff;margin:0pt;">On February 22, 2022, we entered into a Second Amendment Agreement (the &#8220;Second Amendment&#8221;), which further amends the Credit Agreement.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;text-align:justify;text-indent:27pt;margin:0pt;"><span style="font-size:10pt;">The principal of the term loan is required to be repaid in </span><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_CreditFacilityAxis_tcmd_TermLoanMember_3Cnmib--SkSEPm4Zq4wPzQ" name="us-gaap:DebtInstrumentFrequencyOfPeriodicPayment" id="Narr_UZcaDkKK7USC9Xd6VPHlCQ"><span style="font-size:10pt;">quarterly</span></ix:nonNumeric><span style="font-size:10pt;"> installments of </span><span style="font-size:10pt;">$<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_CreditFacilityAxis_tcmd_TermLoanMember_3Cnmib--SkSEPm4Zq4wPzQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentPeriodicPayment" scale="0" id="Narr_R8r4cMbVU0OXSOXwwCKBZQ">750,000</ix:nonFraction></span><span style="font-size:10pt;"> commencing&#160;January 7, 2022,&#160;through&#160;July 8, 2024,&#160;with the remaining outstanding balance due on&#160;September 8, 2024. Pursuant to the Second Amendment, we made a mandatory principal prepayment of the term loan of </span><span style="font-size:10pt;">$<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_2_22_2022_To_2_22_2022_us-gaap_CreditFacilityAxis_tcmd_TermLoanMember_L6c2GMdVeE2wHtiYF_EBdA" decimals="-5" format="ixt:numdotdecimal" name="tcmd:DebtInstrumentPaymentOfMandatoryPrincipalPrepayment" scale="6" id="Narr_D0P_LUw5mUW896lmRHY1Cg">3.0</ix:nonFraction></span><span style="font-size:10pt;"> million on February 22, 2022.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;text-align:justify;text-indent:27pt;margin:0pt;"><span style="color:#ff0000;font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27pt;margin:0pt;">The term loan and amounts drawn under the revolving credit facility bear interest, at our option, at a rate equal to (a) the highest of (i) the prime rate, (ii) the federal funds rate plus <ix:nonFraction unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_VariableRateAxis_us-gaap_FederalFundsEffectiveSwapRateMember_Ox5KmpqBekOgFh1i9iNuQg" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="Narr_mCggTYTV8UG50izjW3K9IA">0.50</ix:nonFraction>% and (iii) LIBOR for an interest period of one month plus <ix:nonFraction unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_VariableRateAxis_us-gaap_BaseRateMember_bmZqSyyD0UC5KiXp5eY0wA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="Narr_hTlodoz290qvnbI9ri4yYw">1</ix:nonFraction>% (the &#8220;Base Rate&#8221;) plus an applicable margin or (b) LIBOR for an interest period of one, three or six months, at our option, plus the applicable margin. The applicable margin is <ix:nonFraction unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw" contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_VariableRateAxis_us-gaap_BaseRateMember_RkYOxE7JdkmHm__eg3-sdw" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="Narr_Luji0YDRa0ysnzSOBCtdKQ">0.75</ix:nonFraction>% to <ix:nonFraction unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw" contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_VariableRateAxis_us-gaap_BaseRateMember_cKhsiHfOCE28P3WddmWqow" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="Narr_HaTdGJPDxEmn0xZt0dc8lQ">2.25</ix:nonFraction>% on loans bearing interest at the Base Rate and <ix:nonFraction unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw" contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_VariableRateAxis_us-gaap_LondonInterbankOfferedRateLIBORMember_qtvC3cCEtUGvoYG_aiVd5w" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="Narr_i6ElFAX4NEarHf3ENNnLjg">1.75</ix:nonFraction>% to <ix:nonFraction unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw" contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_VariableRateAxis_us-gaap_LondonInterbankOfferedRateLIBORMember_5Ok3Lj-bZEKdl_78m7_07g" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="Narr_qVFrKruZvUOR3Ayiml1XTQ">3.25</ix:nonFraction>% on loans bearing interest at LIBOR, in each case depending on our consolidated total leverage ratio; except that, pursuant to the Second Amendment, during the period commencing on February 22, 2022 and ending on the last day of the fiscal quarter ending June 30, 2023, the applicable margin for LIBOR rate loans is <ix:nonFraction unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_VariableRateAxis_us-gaap_LondonInterbankOfferedRateLIBORMember_6BVYYrgoDEySTxjBn4sZ3A" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="Narr_4dL3AGIUN0enQOx6FN2BqQ">3.50</ix:nonFraction>%. At December 31, 2022,&#160;all outstanding borrowings were subject to interest at a rate calculated at LIBOR plus an applicable margin, for an interest rate of <ix:nonFraction unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_VariableRateAxis_us-gaap_LondonInterbankOfferedRateLIBORMember_27-_EKPJYUWpaRUxj1OYBQ" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="Narr_-DFbbO36eU2HFv0LtQQPeg">7.41</ix:nonFraction>%. Undrawn portions of the revolving credit facility are subject to an unused line fee at a rate per annum from <ix:nonFraction unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw" contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_i_HrmJK0qEam7JhO2g89aw" decimals="5" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" scale="-2" id="Narr_1gvWaCed9UupNFd5tV3g6g">0.300</ix:nonFraction>% to <ix:nonFraction unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw" contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_fVykz_MeNEanAhnkwaVQuw" decimals="5" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" scale="-2" id="Narr_D-q-VwK7GUC5am_CFeqxDw">0.375</ix:nonFraction>%, depending on our consolidated total leverage ratio.&#160;</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:60.5pt;margin:0pt;">&#160;</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:27.35pt;margin:0pt;">Maturities of the term loan for the next three years as of December 31, 2022, were as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="Tb_alBEJbZ75EOvZHg3uj_7ZQ" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:25.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">(In&#160;thousands)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:29.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2022_us-gaap_CreditFacilityAxis_tcmd_TermLoanMember_VIrloQlsfEmn_JzIEt95jA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" scale="3" id="Tc_BymTUb5oy0-uCHIqmwCyXQ_2_3">3,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.78%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2022_us-gaap_CreditFacilityAxis_tcmd_TermLoanMember_VIrloQlsfEmn_JzIEt95jA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" scale="3" id="Tc_AlhHlEtlukGCXd9QPbZYyA_3_3">21,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2022_us-gaap_CreditFacilityAxis_tcmd_TermLoanMember_VIrloQlsfEmn_JzIEt95jA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="3" id="Tc_64pIVkF_ZUir3eUJCWrJAQ_4_3">24,000</ix:nonFraction></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27.35pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;margin:0pt;">Our obligations under the Credit Agreement are secured by a security interest in substantially all of our and our subsidiaries&#8217; assets and are also guaranteed by our subsidiaries. The Credit Agreement contains a number of restrictions and covenants, including that we maintain compliance with a maximum leverage ratio, minimum fixed charge coverage ratio and a minimum consolidated EBITDA covenant. As of December 31, 2022, we were in compliance with all financial covenants under the Credit Agreement.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="Tb_5lNDgT0izkW_ca4IdFKK3Q" continuedAt="Tb_5lNDgT0izkW_ca4IdFKK3Q_cont1" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Note&#160;12. &#160;Commitments and Contingencies</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:10pt;text-align:justify;text-indent:-10pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Lease Obligations</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We lease property and equipment under operating leases, typically with terms greater than <ix:nonNumeric contextRef="As_Of_12_31_2022_srt_RangeAxis_srt_MinimumMember_EXKUiZxnk0qVwfOmUunwkw" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="Narr_jRgk1qfeQ0Sv3W8MmoDOeQ">12 months</ix:nonNumeric>, and determine if an arrangement contains a lease at inception. In general, an arrangement contains a lease if there is an identified asset and we have the right to direct the use of and obtain substantially all of the economic benefit from the use of the identified asset. We record an operating lease liability at the present value of lease payments over the lease term on the commencement date. The related right of use (&#8220;ROU&#8221;) operating lease asset reflects rental escalation clauses, as well as renewal options and/or termination options. The exercise of lease renewal and/or termination options are at our discretion and are included in the determination of the lease term and lease payment obligations when it is deemed reasonably certain that the option will be exercised. When available, we use the rate implicit in the lease to discount lease payments to present value; however, certain leases do not provide a readily determinable implicit rate. Therefore, we must estimate our incremental borrowing rate to discount the lease payments based on information available at lease commencement.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We classify our leases as buildings, vehicles or computer and office equipment and do not separate lease and nonlease components of contracts for any of the aforementioned classifications. In accordance with applicable guidance, we do not record leases with terms that are less than one year on the Consolidated Balance Sheets.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">None of our lease agreements contain material restrictive covenants or residual value guarantees.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Buildings</i></p></ix:nonNumeric></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">104</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_5lNDgT0izkW_ca4IdFKK3Q_cont1" continuedAt="Tb_5lNDgT0izkW_ca4IdFKK3Q_cont2"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We lease certain office and warehouse space at various locations in the United States where we provide services. These leases are typically greater than one year with fixed, escalating rents over the noncancelable terms and, therefore, ROU operating lease assets and operating lease liabilities are recorded on the Consolidated Balance Sheets, with rent expense recognized on a straight-line basis over the term of the lease. The remaining lease terms vary from approximately <span style="-sec-ix-hidden:Hidden_cPi9QUIkvEuGhENNTJkqkw;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">one</span></span> to <ix:nonNumeric contextRef="As_Of_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember_bxiv0zaNYUqU9S4A8vYbgw" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="Narr_Nj69dB6C2EmR-QQxxbHgcA">eight years</ix:nonNumeric> as of December&#160;31,&#160;2022.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We entered into a lease (&#8220;initial lease&#8221;) in October 2018, for approximately <ix:nonFraction unitRef="Unit_Standard_sqft_pFxGS_NorEW8LBFrHYvkFg" contextRef="As_Of_10_31_2018_us-gaap_PropertyPlantAndEquipmentByTypeAxis_tcmd_CorporateHeadQuarterInitialLeaseMember_iOfecFzhU0CEX9fKgtv8qA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AreaOfLand" scale="0" id="Narr_unPrKVzQaEGXd05QZac-nw">80,000</ix:nonFraction> square feet of office space for our new corporate headquarters in Minneapolis, Minnesota. In December 2018, we amended the initial lease to add approximately <ix:nonFraction unitRef="Unit_Standard_sqft_pFxGS_NorEW8LBFrHYvkFg" contextRef="As_Of_12_31_2018_us-gaap_PropertyPlantAndEquipmentByTypeAxis_tcmd_CorporateHeadQuarterSecondLeaseMember_kJI6F8P6zkKbLuYO9IJnVw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AreaOfLand" scale="0" id="Narr_nbMKMSi7e0uxPXdAMqryag">29,000</ix:nonFraction> square feet of additional office space, which is accounted for as a separate lease (&#8220;second lease&#8221;) in accordance with ASU No. 2016-02, &#8220;Leases&#8221; (Topic 842) (&#8220;ASC 842&#8221;). In December 2019, we further amended the lease which extended the expiration date of the initial lease, extended the expiration date of and added approximately <ix:nonFraction unitRef="Unit_Standard_sqft_pFxGS_NorEW8LBFrHYvkFg" contextRef="As_Of_12_31_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_tcmd_CorporateHeadQuarterSecondLeaseMember_RayR2gEiIEWjwHNeeJouhw" decimals="INF" format="ixt:numdotdecimal" name="tcmd:AdditionalOfficeSpaceAdded" scale="0" id="Narr_rlZD2aKuaUiZ9n2Mf4y5cg">4,000</ix:nonFraction> square feet to the second lease, as well as added approximately <ix:nonFraction unitRef="Unit_Standard_sqft_pFxGS_NorEW8LBFrHYvkFg" contextRef="As_Of_12_31_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_tcmd_CorporateHeadQuarterThirdLeaseMember_i4Zbs1u8B0-YqSUpBTf3Hg" decimals="INF" format="ixt:numdotdecimal" name="tcmd:AdditionalOfficeSpaceAdded" scale="0" id="Narr_JjAqB4Gvl0CIgyqKtj4DZw">37,000</ix:nonFraction> square feet of additional office space, accounted for as a separate lease (&#8220;third lease&#8221;) in accordance with ASC 842. The portion of the space covered under the initial lease was placed in service in September 2019. This portion was recognized as an operating lease and included in the ROU operating lease assets and operating lease liabilities on the Consolidated Balance Sheets. The portion of the space covered under the second lease commenced in September 2020. Finally, the portion of the space covered under the third lease commenced in September 2021.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Vehicles</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We lease vehicles for certain members of our field sales organization under a vehicle fleet program whereby the initial, noncancelable lease is for a term of <ix:nonNumeric contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_VehiclesMember_WEhReoFIrk61ZFxikX2DoA" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="Narr_gQVCZNMoE0aBfgq6jEAgQQ">367 days</ix:nonNumeric>, thus more than one year. Subsequent to the initial term, the lease becomes a month-to-month, cancelable lease. As of December&#160;31,&#160;2022, we had approximately <ix:nonFraction unitRef="Unit_Standard_item_-67QV0kzWUGc8AbcCukKig" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_VehiclesMember_2k-hdZ3H2UWc6uo6P8NZ5Q" decimals="INF" format="ixt-sec:numwordsen" name="tcmd:NumberOfVehiclesWithAgreementsWithinInitialNoncancelableLeaseTerm" scale="0" id="Narr_zhIo04f7pU-7c0p1SOPCsw">two</ix:nonFraction> vehicles with agreements within the initial, noncancelable lease term that are recorded as ROU operating lease assets and operating lease liabilities. In addition to monthly rental fees specific to the vehicle, there are fixed monthly nonlease components that have been included in the ROU operating lease assets and operating lease liabilities. The nonlease components are not significant. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Computer and Office Equipment</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We also have operating lease agreements for certain computer and office equipment. The remaining lease terms as of December 31, 2022, ranged from less than <ix:nonNumeric contextRef="As_Of_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_pmPeDzOSDEq1hwWSnhZm1A" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="Narr_13w3rbWPXEK_RyP3XB47hw">one year</ix:nonNumeric> to approximately <ix:nonNumeric contextRef="As_Of_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_CBz12HaJ3EelHnd3ISwWrQ" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="Narr_vICnHAeqTkiO3QYdFMF3xw">four years</ix:nonNumeric> with fixed monthly payments that are included in the ROU operating lease assets and operating lease liabilities. The leases provide an option to purchase the related equipment at fair market value at the end of the lease. The leases will automatically <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_lwkNBH8qPUKwpTFPfFM4eg" format="ixt:booleantrue" name="us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend" id="Narr_4NjBSxt8zUW9Bb6xd_XRZg">renew</ix:nonNumeric> as a month-to-month rental at the end of the lease if the equipment is not purchased or returned.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:continuation></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">105</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_oJ5Sart460e0Ies4j9sgRw_1_0"></a><a id="Tc_vJueoiFAsEq99NpfIysP8w_1_2"></a><a id="Tc_j17cid6WCEuOkAVFFOWwiw_1_5"></a><a id="Tc__vZv1nPACEecMqav_v2Tdg_2_2"></a><a id="Tc_zd5wYGD8T0mEfINfKdyBEg_2_5"></a><a id="Tc_XQSgtuSSu0WV1Y8Vk3fAPw_4_0"></a><a id="Tc_AaFNi-S9ikOAvODmNXhY6Q_5_2"></a><a id="Tc_8DOvJNhxM0qOUQ4JnvxjDA_5_5"></a><a id="Tc_u1D-88DoLkKJLAisuVRRLA_7_0"></a><a id="Tc_hM8gcRbcZUS5IEWvmHqChw_7_2"></a><a id="Tc_a7JrfCDb4EyWUD8WmioTnw_7_5"></a><a id="Tc_lxj0kaRPBEK44Fa4RPdDew_9_0"></a><a id="Tc_hiz_UIvY2kqB-tDfxFnkRQ_10_0"></a><a id="Tc_an5QwIEexUqIrdRnUdQpqw_10_3"></a><a id="Tc_gv9LFllbpUmmpYM1FwNS4Q_10_6"></a><a id="Tc_qGCA19DkAU2MOp6WS-dYhQ_11_0"></a><a id="Tc_g3H8z7fOekKJVDrhY2JOLw_13_2"></a><a id="Tc_YF-2avXIm0WnkfxTfFoduw_14_2"></a><a id="Tc_I5b2XFwt6EynD6yKJUAGag_14_5"></a><a id="Tc_FtQk_oxadE2HvSwxHHwRkQ_15_0"></a><a id="Tc_B8_OBh6oqU2j9kwSCSguHg_16_0"></a><a id="Tc_jStrUW4JUEuWgJc9UDbbRw_16_2"></a><a id="Tc_orsm7HxRzUazMchhxJhQEQ_16_5"></a><a id="Tc_kLjfO9L9LEOv57_VgygVaw_17_0"></a><a id="Tc_mfjCH1snHEGjvzyGY6V1kQ_17_2"></a><a id="Tc_OmXaB8O2B0W-20YPbL9GTw_17_5"></a><a id="Tc_BqreMAcafUK0LKcmnW-8jg_1_0"></a><a id="Tc_gdazW8_seECdFlMHNANbcQ_2_0"></a><a id="Tc_HnPgzMPf5kmwPQJzRz4AyQ_2_2"></a><a id="Tc_8KeJlyGUqUuUEAHC9PKrhQ_3_0"></a><a id="Tc_hxhtp8vENkOioSdLMIDKaA_4_0"></a><a id="Tc_GdiwimHOdUODPPdv5ERtOg_5_0"></a><a id="Tc__ANxExa14UKuC_U7DGP6wQ_6_0"></a><a id="Tc_AXIJEQQlhUeWbphPIyWtQQ_7_0"></a><a id="Tc__0nDiR4SmkW2TvJoyBQN0Q_8_0"></a><a id="Tc_LTBquT9LtEC5AgnoW_mIWw_9_0"></a><a id="Tc_HvvrF9dHw067zl3Uv_2N9A_10_0"></a><a id="Tc_invuhsqvKkqGzj5NfGHWiA_11_0"></a><a id="Tc__ktOmi-L1ESHfREn3jkwKg_12_0"></a><a id="Tc_xdVR3GWAsEes8XL6_GzbkQ_12_2"></a><ix:continuation id="Tb_5lNDgT0izkW_ca4IdFKK3Q_cont2" continuedAt="Tb_5lNDgT0izkW_ca4IdFKK3Q_cont3"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Lease Position, Undiscounted Cash Flow and Supplemental Information</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The table below presents information related to our ROU operating lease assets and operating lease liabilities that we have recorded:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" name="tcmd:AssetsAndLiabilitiesLesseeTableTextBlock" id="Tb_p4ja9FDTQE6Rf2kYG6jX4g" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:54.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:54.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">(In&#160;thousands)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">At December&#160;31,&#160;2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">At December&#160;31,&#160;2021</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:54.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_tKPJpXeds0SiabhmYWAMEg;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Right of use operating lease assets</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_F34676yGyUKJGOqRCcz4XA_2_3">21,322</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_L-Xj8me3p0KhYXcVnzDy8Q_2_6">23,984</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:54.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:54.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Operating lease liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:54.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="-sec-ix-hidden:Hidden_tyE6-ij7k06Rv5IRQ6iD1Q;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Current</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_nFmNc9cxa0-HysSIjaxzyQ_5_3">2,500</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_lEsNrPrjcUyj-dlwcrKmsQ_5_6">2,506</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:54.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="-sec-ix-hidden:Hidden_hRi5aCIDPEGUkAgK0iaGvw;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Non-current</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_gf2pklp_eUO7m6r93eTIDA_6_3">20,866</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_W0bZD-4EYU6a5M0kOKotww_6_6">23,354</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:54.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="Tc_2xomv-OTdE-cDuwH2e4VLw_7_3">23,366</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="Tc_O5LbvdvTSU6BGMthqvnfWA_7_6">25,860</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:54.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:54.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Operating leases: </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:54.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Weighted average remaining lease term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="Narr_jCJAHnLaY0GPh4dD4ENVGg">7.7</ix:nonNumeric> years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="Narr_KprKWDFrrEKC-Jogt6ixDQ">8.6</ix:nonNumeric> years</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:54.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Weighted average discount rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw" contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw" decimals="4" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="Tc_zZV-FRdEGkezXTFrLir48A_11_3">4.2</ix:nonFraction>%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw" contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q" decimals="4" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="Tc_gkITc5pcREWfQR2qnJtsfQ_11_6">4.2</ix:nonFraction>%</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:54.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="margin-left:0pt;vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:54.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:43.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:54.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:20.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:20.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:54.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Supplemental cash flow information for our operating leases:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:54.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Cash paid for operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="3" id="Tc_CUKslC1Hyk-1FEtFw2zmZg_16_3">3,575</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="3" id="Tc_C80mneKtp0m6R7-K8-dEEQ_16_6">3,379</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:54.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Non-cash right of use assets obtained in exchange for new operating lease obligations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="Tc_uM7gcruW30q3o1ddtw4HIw_17_3">49</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="Tc_62fh4j5XcUyHibVYimWjjQ_17_6">6,920</ix:nonFraction></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The table below reconciles the undiscounted cash flows under the operating lease liabilities recorded on the Consolidated Balance Sheets for the periods presented:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" name="us-gaap:OperatingLeaseLeaseIncomeTableTextBlock" id="Tb_CneW3X52h0qo036cWqbGFA" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:65.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:27.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:65.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">(In&#160;thousands)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="Tc_KHtCiozWPUmPoK1KGDHtmQ_2_3">3,427</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="Tc_6URCSVAGYkiSlV5ALBIJ-g_3_3">3,418</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" id="Tc_gUcuFBv0XUygyL58Se1YLg_4_3">3,517</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="3" id="Tc_cW45Wn5Xx0eV5N6iUCajKQ_5_3">3,615</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" scale="3" id="Tc_jGqxvs_NnEOHS9qsqKfsCQ_6_3">3,167</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:65.19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" scale="3" id="Tc_kissKi53pEiQRFCb5HWlUA_7_3">10,082</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:65.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Total minimum lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="Tc_eN96DebMZUiAPgD66COG1Q_8_3">27,226</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:65.19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Less: Amount of lease payments representing interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="Tc_VYistoDRDE-tMyzyLpqU3Q_9_3">3,860</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:65.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Present value of future minimum lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="Tc_EeW9W3T2F0C6YqQ6pIGT1Q_10_3">23,366</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:65.19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Less: Current obligations under operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_1Vk9_Yv0LkydbXskqSqZMw_11_3">2,500</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:65.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Non-current obligations under operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_KQFip3hKt0a8FUwCN2vutA_12_3">20,866</ix:nonFraction></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;padding-left:10.1pt;text-indent:-10.1pt;background:#ffffff;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">Operating lease costs were $<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="6" id="Narr_DhccbuYRp0GvY3zJudDPUA">3.8</ix:nonFraction> million, $<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="6" id="Narr_MMTlcCob7UGs0hAMHhz90A">3.6</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="6" id="Narr_3hBhm67K0EyzBNcC5FN4LQ">3.0</ix:nonFraction> million for the years ended December&#160;31,&#160;2022, 2021 and 2020, respectively. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Major Vendors</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">We had purchases from <ix:nonFraction unitRef="Unit_Standard_item_-67QV0kzWUGc8AbcCukKig" contextRef="As_Of_12_31_2022_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_tcmd_VendorOneMember_X8R2b_l6g02zwqRLkFf0tg" decimals="INF" format="ixt-sec:numwordsen" name="tcmd:NumberOfVendors" scale="0" id="Narr_c8gdSrOjsk2yBXbq31yXZA">one</ix:nonFraction> vendor that accounted for <ix:nonFraction unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_CostOfGoodsTotalMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_SupplierConcentrationRiskMember_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_tcmd_VendorOneMember_vviffeAE5EGD7qLxiUROxg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="Narr_qn7zx24Uyk2J5WA3npfboQ">18</ix:nonFraction>% of our total purchases for the year ended December 31, 2022 and purchases from <ix:nonFraction unitRef="Unit_Standard_item_-67QV0kzWUGc8AbcCukKig" contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q" decimals="INF" format="ixt-sec:numwordsen" name="tcmd:NumberOfVendors" scale="0" id="Narr_AocE7MUK-kuW7PPVNf57ng">two</ix:nonFraction> vendors that accounted for <ix:nonFraction unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_CostOfGoodsTotalMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_SupplierConcentrationRiskMember_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_tcmd_VendorTwoMember_ofzmjVvnsUW7aaWOzboUlQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="Narr_mUNml8ry7E23CGgthQ6svw">32</ix:nonFraction>% of total purchases for the year ended December&#160;31,&#160;2021.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:10pt;text-align:justify;text-indent:-10pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Purchase Commitment</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;margin:0pt;">We issued purchase orders in 2022 totaling $<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PurchaseObligationDueInNextTwelveMonths" scale="6" id="Narr_abmb9jrOV06bJHeSp2ACiA">33.5</ix:nonFraction> million for goods that we expect to receive within the next year.</p></ix:continuation></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">106</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_5lNDgT0izkW_ca4IdFKK3Q_cont3"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Retirement Plan</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:14pt;padding-top:2pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">We maintain a 401(k) retirement plan for our employees to which eligible employees can contribute a percentage of their pre-tax compensation. We recorded an expense related to our discretionary contributions to the 401(k) plan of $<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_RetirementPlanNameAxis_tcmd_DefinedContribution401kRetirementPlanMember_tDmbZG8x90OrgLeuanK9nw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" scale="6" id="Narr_fyRtIjoyvku8NgrZW3NeCw">1.5</ix:nonFraction> million, $<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_RetirementPlanNameAxis_tcmd_DefinedContribution401kRetirementPlanMember_zWNpuLNXTEuhSfDngvS76w" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" scale="6" id="Narr_0e2TwmsD0UGiFyjGJ-x4ag">1.2</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_RetirementPlanNameAxis_tcmd_DefinedContribution401kRetirementPlanMember_tGvCSx6Y1EuXw-i1zDT2EA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" scale="6" id="Narr_G0tChw_FTESLmRqPe1AHrA">0.3</ix:nonFraction> million for the years ended December&#160;31,&#160;2022, 2021 and 2020, respectively.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:14pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Legal Proceedings</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt;">From time to time, we are subject to various claims and legal proceedings arising in the ordinary course of business. Regardless of outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;margin:14pt 0pt 0pt 0pt;">We and certain of our present or former officers have been sued in a purported securities class action lawsuit that was filed in the United States District Court for the District of Minnesota on September 29, 2020, and that is pending under the caption<i style="font-style:italic;"> Brian Mart v. Tactile Systems Technology, Inc., et al</i>., File No. 0:20-cv-02074-NEB-BRT (the &#8220;Mart Lawsuit&#8221;).&#160;On April 19, 2021, the plaintiff filed an Amended Complaint against us and eight of our present and former officers and directors.&#160;Plaintiff seeks to represent a class consisting of investors who purchased our common stock in the market during the time period from May 7, 2018 through June 8, 2020 (&#8220;alleged class period&#8221;). The Amended Complaint alleges the following claims under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;): (1) that we and certain officer defendants made materially false or misleading public statements about our business, operational and compliance policies, and results during the alleged class period in violation of Section 10(b) of the Exchange Act; (2) that we and the individual defendants engaged in a scheme to defraud investors&#160;in order to allow the individual defendants to sell our stock in violation of Section 10(b) of the Exchange Act; (3) that the individual defendants engaged in improper insider trading of our stock in violation of Section 20A of the Exchange Act; and (4) that we and the individual defendants are liable under Section 20(a) of the Exchange Act because each defendant is a controlling person. On June 18, 2021, we and the individual defendants filed a motion to dismiss the Amended Complaint. On March 31, 2022, the court granted in part, and denied in part, the defendants&#8217; motion to dismiss. All claims against three individual defendants were dismissed, and most claims against four other individual defendants were dismissed. On November 21, 2022, the company announced that it entered a Memorandum of Understanding to settle this matter. The Company does not expect to fund any portion of cash payments made in connection with the $<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_11_21_2022_m22jugRAaEmtVeWbOHw3dw" decimals="-6" format="ixt:numdotdecimal" name="tcmd:LitigationSettlementAgreementAmount" scale="6" id="Narr_zwVttwUn4EugNv5-_pApew">5</ix:nonFraction> million settlement amount. The settlement does not constitute an admission of liability or wrongdoing by the Company. The settlement is subject to the parties reaching agreement on various non-monetary terms and court approval of the final terms will be required.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:14pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:2pt 0pt 0pt 0pt;">On May 24, 2022, a stockholder derivative lawsuit was filed in the United States District Court for the District of Minnesota, purportedly on behalf of the Company against certain of our present and former officers and directors and the Company (as a nominal defendant), captioned <i style="font-style:italic;">Jack Weaver v. Moen</i>, et al., File No. 0:22-cv-01403-NEB-BRT. This complaint generally arises out of the same subject matter as the Mart Lawsuit and alleges the following claims under the Exchange Act and common law: (1) that the director defendants made materially false or misleading public statements in proxy statements in violation of Section 14(a) of the Exchange Act; (2) that the director defendants&#8217; stock and option awards should be rescinded under Section 29(b) of the Exchange Act; (3) that the officer defendants&#8217; employment contract compensation should be rescinded under Section 29(b) of the Exchange Act; (4) that certain officer defendants are liable for contribution arising out of any liability incurred in the Mart Lawsuit, under Sections 10(b) and 21D of the Exchange Act; (5) that the individual defendants breached their fiduciary duties; and (6) that the individual defendants were unjustly enriched. The lawsuit seeks unspecified damages. In August, the matter was transferred to the United States District Court for the District of Delaware by order granting the Parties Stipulation to Transfer. On February 10, 2023, we filed a motion to dismiss the action. We are defending the action as it proceeds.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" name="us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock" id="Tb_ULz7QtaTRk2fGmIkgJ4MbA" continuedAt="Tb_ULz7QtaTRk2fGmIkgJ4MbA_cont1" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Note&#160;13. &#160;Stockholders&#39; Equity</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">We completed an initial public offering of our common stock on August 2, 2016, in which we sold <ix:nonFraction unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ" contextRef="Duration_8_2_2016_To_8_2_2016_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_oNbQsAMXk0uBUzklZFhmAA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_u7faJlJM1kyVNisuTf4SRg">4,120,000</ix:nonFraction> shares of our common stock at a public offering price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q" contextRef="As_Of_8_2_2016_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_G1Q8otm7u0SlPI0I3gLpyg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_aaptrjx_KEKSoYeuEb5S6A">10.00</ix:nonFraction> per share. Immediately prior to the completion of the initial public offering, all then-outstanding shares of our Series A and Series B preferred stock </p></ix:nonNumeric></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">107</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_9269H-5_JUOoLY_XltU4WQ_1_2"></a><a id="Tc_75dzuWNw7keNxF3hD7oZzA_2_0"></a><a id="Tc_v3SiBMS92U6rjExh7x4s8g_2_2"></a><a id="Tc_IgWRhvtmbUS4C2lr_suYZA_3_0"></a><a id="Tc_DsnIKei0ME-qgBz2JJ9QyQ_4_0"></a><a id="Tc_SsKhvHgHA0CR_wndOjGgog_5_0"></a><a id="Tc_fbgJeLw7o0qoxkdb8iI7Hw_6_0"></a><a id="Tc_7eP09E5U3kWUXfzcl_5hZw_6_2"></a><ix:continuation id="Tb_ULz7QtaTRk2fGmIkgJ4MbA_cont1" continuedAt="Tb_ULz7QtaTRk2fGmIkgJ4MbA_cont2"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;">were converted into <ix:nonFraction unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ" contextRef="Duration_8_2_2016_To_8_2_2016_jh5ft8WN0USibAdtcwGHiA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ConversionOfStockSharesConverted1" scale="0" id="Narr_cLj8DQ-_Q0u3sGxxrBBn_g">5,924,453</ix:nonFraction> shares of our common stock. Our Series A preferred stock converted to common stock at a ratio of 1-for-<ix:nonFraction unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw" contextRef="Duration_8_2_2016_To_8_2_2016_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_QQrwNskzWkG7CPUnrW9tVw" decimals="2" format="ixt:numdotdecimal" name="tcmd:PreferredStockToCommonStockConversionRatio" scale="0" id="Narr_3NtKsXzMI0iCFF8TEb-vSQ">1.03</ix:nonFraction> and our Series B preferred stock converted to common stock at a ratio of 1-for-<ix:nonFraction unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw" contextRef="Duration_8_2_2016_To_8_2_2016_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_F3xqjLu7uEyeSRqBJT0RuA" decimals="0" format="ixt:numdotdecimal" name="tcmd:PreferredStockToCommonStockConversionRatio" scale="0" id="Narr_0WNP4T7GN0yEaXxT9IUzQQ">1</ix:nonFraction>. In addition, immediately prior to the completion of the initial public offering, we issued <ix:nonFraction unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ" contextRef="Duration_8_2_2016_To_8_2_2016_jh5ft8WN0USibAdtcwGHiA" decimals="INF" format="ixt:numdotdecimal" name="tcmd:StockIssuedDuringPeriodPriorToCompletionOfInitialOfferingSharesNewIssues" scale="0" id="Narr_wquyIq56WkGeb6niwD3gTg">2,354,323</ix:nonFraction> additional shares of our common stock that our Series A and Series B preferred stockholders were entitled to receive in connection with the conversion of the preferred stock, and we issued <ix:nonFraction unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ" contextRef="Duration_8_2_2016_To_8_2_2016_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_F3xqjLu7uEyeSRqBJT0RuA" decimals="INF" format="ixt:numdotdecimal" name="tcmd:StockIssuedDuringPeriodRequiredToFundStockDividendsSharesNewIssues" scale="0" id="Narr_WA07ZZuMvkOUosVjEXRWqQ">956,842</ix:nonFraction> shares of our common stock to pay accrued dividends on our Series B preferred stock. We also paid $<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_8_2_2016_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_Y9mdYePcDUyiYIOsBHbTDA" decimals="-5" format="ixt:numdotdecimal" name="tcmd:AccruedCumulativeDividends" scale="6" id="Narr_uMVrCu1gNEOBHM6luYq4ng">8.2</ix:nonFraction> million in cumulative accrued dividends to our Series A convertible preferred stockholders in connection with the initial public offering, including $<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_8_2_2016_To_8_2_2016_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_QQrwNskzWkG7CPUnrW9tVw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfOrdinaryDividends" scale="6" id="Narr_q2WD1Y_EvEK7OubpJAI91Q">0.1</ix:nonFraction> million of dividends paid to the holders of the common restricted shares.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:10.1pt;text-align:justify;text-indent:-10.1pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Stock-Based Compensation</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Our 2016 Equity Incentive Plan (the &#8220;2016 Plan&#8221;) authorizes us to grant stock options, stock appreciation rights, restricted stock, stock units and other stock-based awards to employees, non-employee directors and certain consultants and advisors. There were up to <ix:nonFraction unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ" contextRef="As_Of_12_31_2022_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_MJZ8uZEAPEmYMAtcEg9uBg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="Narr_tTS2gKsFUk6HfdkVD9JTDg">4,800,000</ix:nonFraction> shares of our common stock initially reserved for issuance pursuant to the 2016 Plan. The 2016 Plan provides that the number of shares reserved and available for issuance under the 2016 Plan will automatically increase annually on January 1 of each calendar year, commencing in 2017 and ending on and including January 1, 2026, by an amount equal to the lesser of: (a) <ix:nonFraction unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw" contextRef="As_Of_12_31_2022_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_MJZ8uZEAPEmYMAtcEg9uBg" decimals="2" format="ixt:numdotdecimal" name="tcmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticAnnualIncreaseInSharesReservedAndAvailableForIssuancePercentage" scale="-2" id="Narr_pZ8rpbVJD0KsxNqxQZl6PQ">5</ix:nonFraction>% of the number of common shares of stock outstanding as of December 31 of the immediately preceding calendar year, or (b) <ix:nonFraction unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ" contextRef="As_Of_12_31_2022_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_MJZ8uZEAPEmYMAtcEg9uBg" decimals="INF" format="ixt:numdotdecimal" name="tcmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticAnnualIncreaseInSharesReservedAndAvailableForIssuanceNumber" scale="0" id="Narr_0ZFjnNCKLkG8hC0oqfwShw">2,500,000</ix:nonFraction> shares; provided, however, that our Board of Directors may determine that any annual increase be a lesser number. In addition, all awards granted under our 2007 Omnibus Stock Plan and our 2003 Stock Option Plan that were outstanding when the 2016 Plan became effective and that are forfeited, expire, are cancelled, are settled for cash or otherwise not issued, will become available for issuance under the 2016 Plan. Pursuant to the automatic increase feature of the 2016 Plan, <ix:nonFraction unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ" contextRef="Duration_1_1_2021_To_1_1_2021_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_GIA9oCLf2kOobzBosxqDOQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="0" id="Narr_1_N0SY5R70ClfjMIogBHoA">972,591</ix:nonFraction> shares were added as available for issuance thereunder on January 1, 2021. Our Board of Directors exercised its prerogative to forego the automatic increase on each of January 1, 2023 and 2022.<span style="font-size:12pt;"> </span>As of December&#160;31,&#160;2022, <ix:nonFraction unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ" contextRef="As_Of_12_31_2022_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_MJZ8uZEAPEmYMAtcEg9uBg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Narr_LbHRIzgqnkGYK9L8uMdW5A">5,957,683</ix:nonFraction> shares were available for future grant pursuant to the 2016 Plan.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Upon adoption and approval of the 2016 Plan, all of our previous equity incentive compensation plans were terminated. However, existing awards under those plans continue to vest in accordance with the original vesting schedules and will expire at the end of their original terms.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">In the second fiscal quarter of 2020, our Board of Directors appointed a new President and Chief Executive Officer (&#8220;CEO&#8221;), effective June 8, 2020. In conjunction with the acceptance of the written offer, our CEO received both restricted stock units and stock option awards under our 2016 Plan during the third fiscal quarter of 2020 and the stock options have a <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_Apyhw0rpjEqZ3vFtmoPsAg" format="ixt-sec:durwordsen" name="tcmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermOfPeriod" id="Narr_-XTtxw9xGEap-7kt2f_0zQ">seven year</ix:nonNumeric> term. A portion of the awards vested on June 30, 2021, with the remaining portion of the awards vesting over a period of <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_Apyhw0rpjEqZ3vFtmoPsAg" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_kylCa8U3lUO8aJd6W5Cy_Q">three years</ix:nonNumeric> from the date of grant. Further, the stock options were valued at the date of grant using the Monte Carlo Simulation model due to a market condition that required that our stock price exceed&#160;$<ix:nonFraction unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q" contextRef="As_Of_12_31_2022_srt_RangeAxis_srt_MinimumMember_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_MEZgTABuGkCMjTedZP40gQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharePrice" scale="0" id="Narr_yzWuKlVPykOxMAfjQ7KyGw">40.15</ix:nonFraction>&#160;for&#160;<span style="-sec-ix-hidden:Hidden_94egicmKoESPdhUuU5X_1w;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">20</span></span>&#160;consecutive trading days during the term of the option in order to vest. This condition was satisfied in the first quarter of 2021.&#160;The following table sets forth the estimated fair value of these stock options granted and the assumptions on which the fair value was determined:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="Group_1RVy9P0P4UCs4cF19rpDLw" continuedAt="Group_1RVy9P0P4UCs4cF19rpDLw_2" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:33.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:33.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Expected term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:33.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_pIMx6D2N4k6Y7IdL9DkQmg">4.5</ix:nonNumeric> years</p></td></tr><tr><td style="vertical-align:bottom;width:62.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:33.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw" contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Tc_7q59cLAJHEexrOt5Nl9ODA_3_2">45.39</ix:nonFraction>%</p></td></tr><tr><td style="vertical-align:bottom;width:62.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:33.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw" contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Tc_RhiTJxkyjUi03zsdqESa-Q_4_2">0.4</ix:nonFraction>%</p></td></tr><tr><td style="vertical-align:bottom;width:62.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:33.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw" contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Tc_D_hko44xRUeHi39icCsy0A_5_2">0</ix:nonFraction>%</p></td></tr><tr><td style="vertical-align:bottom;width:62.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Fair value on the date of grant</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:33.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q" contextRef="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MinimumMember_1ONqRYxs-E23uhkk4rcXew" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_bkROy5Rq2UeBlINqKAT3eg">13.60</ix:nonFraction> - $<ix:nonFraction unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q" contextRef="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MaximumMember_AgQnIK2l2UG-kwV420MM5g" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_B-ISxZ57fEaTaLbgzegYPg">14.70</ix:nonFraction></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:continuation></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">108</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_L6ROZ53F_kGJ527PrIliDw_1_1"></a><a id="Tc_H9L4weOdEkCw2BTZXHXbbQ_2_1"></a><a id="Tc_aalMrsMCxUKeLEQ4X2J-Ow_3_0"></a><a id="Tc_vyb-HolkjESpanfcPo3_og_3_1"></a><a id="Tc__RSnLrA9tUWGdHD6nMr97g_3_4"></a><a id="Tc_5bxRL78fdUqIFgWxhT-y8w_3_7"></a><a id="Tc_vLNzZbZXB0aOGp32jW97-w_4_0"></a><a id="Tc_WiFL_SLjSEqF2-GbngAtIg_4_1"></a><a id="Tc_-F82bLdb2E-MSONW4MOIBw_4_4"></a><a id="Tc_3MM5LclreUuKF9xumki0zQ_4_7"></a><a id="Tc_5i6HQw0ZK0KdFBTbav5VdQ_5_0"></a><a id="Tc_-kT6a5G3t020jHqjk9_ZxA_6_0"></a><a id="Tc_QYksRtdpV0aKOeTxJlUASA_7_0"></a><a id="Tc_m3uJBHl6mEm1uk0BqpYAcQ_8_0"></a><a id="Tc_tchFqIlSCESlyoQWlGvYpA_8_1"></a><a id="Tc_gqBI3Iwty0SNDdj1fxgZNQ_8_4"></a><a id="Tc_hzXjUmAIYEW8QeaEwwQCRg_8_7"></a><a id="_Hlk94796594"></a><a id="Tc_msb2xP6U2EOr1j_cCoBMLA_1_2"></a><a id="Tc_Hyn7ncq0sUqRTRIIVHt-Ig_1_4"></a><a id="Tc_gZzjeQ0_qEeJEl5OCx0fEw_1_6"></a><a id="Tc_Tx7vkJy-eE-LI4FOCR7eiw_2_0"></a><a id="Tc_-ho6zY12o0i3S_H6UzRNJg_2_2"></a><a id="Tc_lIWuRMisNkeiWDH-cuLGHA_2_4"></a><a id="Tc_gF0uX95GCkCUEnGbVnm1YA_2_6"></a><a id="Tc_ITRGUjjjRE6BnISzgH6VVA_3_0"></a><a id="Tc_xxZHQ91EkEKH8qUmUFYvVA_3_2"></a><a id="Tc_b548QaHiSUGF_4OKlYSmQQ_3_4"></a><a id="Tc_7aP7T4_eBU-A30LcUP4x-Q_3_6"></a><a id="Tc_gjYukXBgjk2E9eqRgB0xMA_4_0"></a><a id="Tc_-1gld7Wd_kWQqTuoG4LJkg_4_2"></a><a id="Tc_5omplgRMV0OjGYfGSloSPQ_4_4"></a><a id="Tc_pG-qrBNzjUqWrYISBo8EUQ_4_6"></a><a id="Tc_mNpAVqhuJUqMjshcaOYLUQ_5_0"></a><a id="Tc_FKSb3kYeCkm0FVZ5niy6IQ_5_6"></a><a id="Tc_DQBKdxxu_Ee8WNDvXerU5Q_6_0"></a><a id="Tc_YYLKED5Yf02fVQPaJpsq-g_6_2"></a><a id="Tc_Wi71DGwnHkyKdaWWPPh18w_6_4"></a><a id="Tc_N8h6bFM_X0Kzs3c3HQfb1w_6_6"></a><ix:continuation id="Tb_ULz7QtaTRk2fGmIkgJ4MbA_cont2" continuedAt="Tb_ULz7QtaTRk2fGmIkgJ4MbA_cont3"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">We recorded total stock-based compensation expense of $<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="Narr_7FXgdJSPRky2_iPQ_xiRlw">9.6</ix:nonFraction> million, $<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="Narr_5pTaR6luyk-VX97ph0DIaA">10.2</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="Narr_pvGmFWMHkEGOCAfRHkRNCg">10.7</ix:nonFraction> million for the years ended December&#160;31,&#160;2022, 2021 and 2020, respectively. This expense was allocated as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="Tb_kG_p8vFCsUibDMS9BZ2F6g" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:59.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:40.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:59.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:40.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">(In&#160;thousands)</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Cost of revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_1cM49KVdP0WP3FTRdFVJvA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_R1RFe4XR8ka8fVe5FPZTJw_4_2">367</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_-Mhsa97jY0mecFzNVd7m8w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_Q_L6ltVNTkKvOuWVJLLdZQ_4_5">433</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_jRQ3JtT1NE2Wt3xFenHFEw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_spwdzBxAcESo4bM3ZRwQxA_4_8">539</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:59.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Sales and marketing expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingAndMarketingExpenseMember_6DUS8nZX1k2uITtnX1jELw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_QXG0Z6YnB0qnyY8-fBEStA_5_2">4,060</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingAndMarketingExpenseMember_tE0YJWqzRkusl6_G8TxGpA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_HUAkZUlcCkiJoYpIv7D-3Q_5_5">4,069</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingAndMarketingExpenseMember_LOcVV8870UGUDxZpsZpW1A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_q1-WPksIK020NJFhwlKx0Q_5_8">5,058</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:59.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_WkeJd_L3IEm8ahIsJkn_Ww" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_wLGl0GCKlkWjzAARG1jW3Q_6_2">226</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_NHelbVJut0SpZ1MaGzM82w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_CCavWpq02E-30fkF5N7Q3g_6_5">314</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_2oRfq2ewaUy6AGWg2Xby5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_BDlZ3qur0U27QOCs2boQ9g_6_8">360</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:59.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Reimbursement, general and administrative expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_Ny2qblOYAkWwzAuljmv4Ow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_z3FjtynpmEivCYRov-KRRw_7_2">4,947</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_oF6quC9QMU-Gu_UPthtpzw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_JM77SBo1O0yAAWFEJjN1EQ_7_5">5,357</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_DbypvZkVpEePjQqYGvgkEw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_Z2vpad-A8U6oX-Vh-a0ujA_7_8">4,732</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:59.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_k_b8nPvoAkqplOlN7-ZLKg_8_2">9,600</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_RBYLXDLlWEOwHKPxaMXYew_8_5">10,173</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_1SVbpxSV902Y5jjE8Km_FQ_8_8">10,689</ix:nonFraction></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Stock Options</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;padding-top:2pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="font-size:10pt;">Stock options issued to participants other than non-employees typically vest over </span><span style="-sec-ix-hidden:Hidden_6Mhakd_sLkqC71m6G0M6Og;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">three</span></span><span style="font-size:10pt;"> or </span><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_x68hCF8ixkS5q2MJuoiIYA" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_0n_-lBqI6UCK6gT1JTa8lg"><span style="font-size:10pt;">four years</span></ix:nonNumeric><span style="font-size:10pt;"> and typically have a contractual term of </span><span style="-sec-ix-hidden:Hidden_tp1Se7X6AEitbPWWRbR6bw;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">seven</span></span><span style="font-size:10pt;"> or </span><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_x68hCF8ixkS5q2MJuoiIYA" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="Narr_lSyz3boeYUaSjAabBuwrJA"><span style="font-size:10pt;">ten years</span></ix:nonNumeric><span style="font-size:10pt;">. Stock-based compensation expense included in our Consolidated Statements of Operations for stock options was </span><span style="font-size:10pt;">$<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_6-UgFP9YHkKs37vGGIhEVw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="Narr_YmiZ_YiIZEaTxr00h-5t7A">2.5</ix:nonFraction></span><span style="font-size:10pt;"> million, </span><span style="font-size:10pt;">$<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_SKlrM8781Eet0zFbC3ewTw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="Narr_UuHTfh_PLkSgKw3GJBrCeg">4.3</ix:nonFraction></span><span style="font-size:10pt;"> million and </span><span style="font-size:10pt;">$<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_qOmCDKQT9Eyfuidf3pzRYg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="Narr_mPSnttvCjEifcJ5B8wl3iw">4.0</ix:nonFraction></span><span style="font-size:10pt;"> million for the years ended December&#160;31,&#160;2022, 2021 and 2020, respectively. The total grant date fair value of options vested during the year was </span><span style="font-size:10pt;">$<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_6-UgFP9YHkKs37vGGIhEVw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="6" id="Narr_GW3JggF9Gka17Evn73B1EQ">3.3</ix:nonFraction></span><span style="font-size:10pt;"> million, </span><span style="font-size:10pt;">$<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_SKlrM8781Eet0zFbC3ewTw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="6" id="Narr_Va2j3HuvO0-7ka01jvC9xQ">4.3</ix:nonFraction></span><span style="font-size:10pt;"> million and </span><span style="font-size:10pt;">$<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_qOmCDKQT9Eyfuidf3pzRYg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="6" id="Narr_b5f2_chNgkySWrsFyBupUQ">3.0</ix:nonFraction></span><span style="font-size:10pt;"> million for the years ended December&#160;31,&#160;2022, 2021 and 2020, respectively.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;padding-bottom:14pt;text-align:justify;text-indent:36pt;margin:14pt 0pt 0pt 0pt;"><span style="font-size:10pt;">At December&#160;31,&#160;2022, there was approximately </span><span style="font-size:10pt;">$<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_Un8xxO7K-UGnIxffkFMjsw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="6" id="Narr_VkyyfMMwTE20B7zW_urZ_w">1.6</ix:nonFraction></span><span style="font-size:10pt;"> million of total unrecognized pre-tax stock option expense under our equity compensation plans, which is expected to be recognized on a straight-line basis over a weighted-average period of</span> <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_6-UgFP9YHkKs37vGGIhEVw" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="Narr_890jM8xWqEqfqoVcKJiOyw"><span style="font-size:10pt;">1.2</span></ix:nonNumeric><span style="font-size:10pt;"> years.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">The fair value of each option grant is estimated on the date of grant using the Black-Scholes option pricing model, other than options that have a market-based vesting condition, which are valued using the Monte Carlo Simulation model. Annually, we make predictive assumptions regarding future stock price volatility, dividend yield, expected term and forfeiture rate. The dividend yield assumption is based on expected annual dividend yield on the grant date. To date, <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:DividendsCommonStock" scale="6" id="Narr_Hhlbx_I0ykmp1Esb65eRMw">no</ix:nonFraction> dividend on common stock has been paid by us. Expected volatility for grants issued in and prior to the first fiscal quarter of 2021 was estimated using the average historical volatility of public companies of similar size and industry over a similar period as the expected term assumption used for our options. Beginning in the second fiscal quarter of 2021, we had sufficient historical data to transition to utilizing our average historical volatility over a similar period as the expected term assumption used for our options as the expected volatility. The risk-free interest rate is based on the yields of U.S. Treasury securities with maturities similar to the expected term of the options for each option group. We use the &#8220;simplified method&#8221; to determine the expected term of the stock option grants. We utilize this method because we do not have sufficient public company exercise data in which to make a reasonable estimate. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">The following table sets forth the estimated fair values of our stock options granted in each of the years indicated, and the assumptions on which the fair values were determined:</p><ix:continuation id="Group_1RVy9P0P4UCs4cF19rpDLw_2" continuedAt="Group_1RVy9P0P4UCs4cF19rpDLw_2_cont1"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:35.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:35.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:35.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Expected term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_EUn6f84eb0OJm-52SjcRtw;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">4.5</span></span> years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_M9XtAoRCQE23lB3X4M3v9w;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">4.5</span></span> years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_iCRDlIEFVkGCl5KX7TVfHQ;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">4.5</span></span> years</p></td></tr><tr><td style="vertical-align:bottom;width:35.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw" contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_L2H-B4harkuWLN7SUIOPRQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Narr_ilb9DSPIK0e-sSwC7HLnvw">59.2</ix:nonFraction>%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw" contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_N_-EN94zSkyi4738ywQnkQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Narr_VjvhvHeVWUqD38PlYOrmpg">45.0</ix:nonFraction> - <ix:nonFraction unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw" contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_cTbUJaM5EEi7_dTn33kCIQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Narr_wB3sIVnoSkO6-_-Bvl-4tg">52.3</ix:nonFraction>%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw" contextRef="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_KSWzHsfkUUCC4ceQE_HELQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Narr_Wg2ADXFMgE-7lwN5s0DX0w">44.1</ix:nonFraction> - <ix:nonFraction unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw" contextRef="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_X4ApOCKa20aLE0iARpjyBw" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Narr_XZnyQUZQ90uSienv4M2iEQ">46.4</ix:nonFraction>%</p></td></tr><tr><td style="vertical-align:bottom;width:35.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw" contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_L2H-B4harkuWLN7SUIOPRQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Narr_2dIp_fcbe0WcGWI0lwDaNQ">4.3</ix:nonFraction>%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw" contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_N_-EN94zSkyi4738ywQnkQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Narr_4YyRBmO3CEO0TC7ld8zi5Q">0.6</ix:nonFraction> - <ix:nonFraction unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw" contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_cTbUJaM5EEi7_dTn33kCIQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Narr_9jeHk0xHZ0qGHlZdnqsa5w">1.1</ix:nonFraction>%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw" contextRef="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_KSWzHsfkUUCC4ceQE_HELQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Narr_-gCibK86s0KF46m4ndmULg">0.2</ix:nonFraction> - <ix:nonFraction unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw" contextRef="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_X4ApOCKa20aLE0iARpjyBw" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Narr_qnHtJ1tCNEqx2limZSXk0Q">0.9</ix:nonFraction>%</p></td></tr><tr><td style="vertical-align:bottom;width:35.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_6-UgFP9YHkKs37vGGIhEVw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Tc_6osXOSKOQkOc-hgRYjk73Q_5_2">0</ix:nonFraction>%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_SKlrM8781Eet0zFbC3ewTw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Tc_JyQ3rnUF5UiD8i89LS1Alw_5_4">0</ix:nonFraction>%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_qOmCDKQT9Eyfuidf3pzRYg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Narr_UffjQjR_gU6BWW1jYBmD6w">0</ix:nonFraction>%</p></td></tr><tr><td style="vertical-align:bottom;width:35.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Fair value on the date of grant</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;">$ <ix:nonFraction unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q" contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_L2H-B4harkuWLN7SUIOPRQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_MYt94Ayba0GhKKMIOZctFw">8.11</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q" contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_N_-EN94zSkyi4738ywQnkQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_0Decfsr-z0u3Y0a1PPaIUQ">13.04</ix:nonFraction> - $<ix:nonFraction unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q" contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_cTbUJaM5EEi7_dTn33kCIQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_Dmj34MH9aUGKVJJd6Y4x-A">22.90</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q" contextRef="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_KSWzHsfkUUCC4ceQE_HELQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_ky9n3wfW-Umf_VXuxu72Rw">13.45</ix:nonFraction> - $<ix:nonFraction unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q" contextRef="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_X4ApOCKa20aLE0iARpjyBw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_JYkj6axSr0O58Eph3y2uCQ">18.64</ix:nonFraction></p></td></tr></table></ix:continuation></ix:continuation></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">109</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_60fdbf6d_f4d4_495e_95c2_17ad2090d435"></a><a id="Tc_AcHQ4k-nSkW5USiIrpnLeQ_1_4"></a><a id="Tc_1QaWFKM_CE-YmFagE6JFYQ_1_7"></a><a id="Tc_vseH38O7X06DHrAqpQ9nUw_2_4"></a><a id="Tc_Aa6PsuoWzUSCepP7UG6kKQ_2_7"></a><a id="Tc_mpAG4jwp2EeoFBeaRDemng_2_9"></a><a id="Tc_oXyet-GmRkmOfD08Muf9WQ_3_2"></a><a id="Tc_6_i8GFwkbUydVeL_zKTZgg_3_4"></a><a id="Tc_dkiP40nR50WDc_g33ed4Ag_3_7"></a><a id="Tc_b-eWsFbAhUe2YnUx0a35MA_3_9"></a><a id="Tc_BzAkBR3r10WYho3jTn6_xQ_4_0"></a><a id="Tc_uEPFdKvoAESzS5ufRdMGfA_4_2"></a><a id="Tc_Vq8thplOPEWzLsJO8DsGAQ_4_4"></a><a id="Tc_h52DSku4E0GV-RAOxW-pVA_4_7"></a><a id="Tc_JtTfjJYTJEKnFVeqd8_OHA_4_9"></a><a id="Tc_SWwnYLu1vUuV_cqK9wHL0Q_5_0"></a><a id="Tc_Wp_DLVLgo0WWL9LmPp5qwQ_5_4"></a><a id="Tc_S8f6QrKZkEuLEeEiDijOlA_5_7"></a><a id="Tc_gH6EXBPTkU23xUO6QWNpLQ_5_9"></a><a id="Tc_L6hbhyberUOd2uczXFgQug_6_0"></a><a id="Tc_w1oKuesmbUSwsazMWcu-bA_6_4"></a><a id="Tc_-1q9vTV01U-jDncEkuZmhQ_7_0"></a><a id="Tc_WaQzwn0okku6qudt7LhMNg_7_4"></a><a id="Tc_cQmcZU9NBUClm_cbvA6suQ_7_9"></a><a id="Tc_D95oUo5bd0yKwzdiXpSw1w_8_0"></a><a id="Tc_DSoFAr0RjU6MfTvnB3HQpQ_8_4"></a><a id="Tc_iCE5SLHSSka0elotB5Rhtg_9_0"></a><a id="Tc_gognfExA_kqosEkEb7Fh1g_9_4"></a><a id="Tc_5ToXqpi9rU2t-fh7ByYOkA_10_0"></a><a id="Tc_UeosaPWVDkOX8eQcuMR5dQ_10_4"></a><a id="Tc_JAX66AKvGUu0N7v3FRVf0w_10_7"></a><a id="Tc_emtvpqZyPUa6KZf9dK7-fQ_10_9"></a><a id="Tc_6AvD1cX5HEKRdJW_45wCqg_11_0"></a><a id="Tc_MiJRsYk-Fky213ihuOr9ZA_11_4"></a><a id="Tc_QPOtzfxjNkq0SMtRy2HWNA_12_0"></a><a id="Tc_LZ1QzGRMN0-UH_SNo_DWKQ_12_4"></a><a id="Tc_VE0wrkuTgEWncdIfar4_Mg_12_9"></a><a id="Tc_xhV4DmjsaUWyB07CJ4Q6_g_13_0"></a><a id="Tc_albV6-nwBUuOzul_n-Eaxw_13_4"></a><a id="Tc_HYSPBMPDiUeH55W6eft6xg_14_0"></a><a id="Tc_gvH_vcUHc0iuN1xxnGU_-A_14_4"></a><a id="Tc_VbkaohdemEGF_FRRdXYa6Q_15_0"></a><a id="Tc_lPvZKcO1Nk-60hJtwFde9w_15_4"></a><a id="Tc_wb9W3yTJV02GVOBVFfckLQ_15_7"></a><a id="Tc_GuNAAFsqsE65NcYmcykx6Q_15_9"></a><a id="Tc_3NeFgiELw02VfhvnNKw5Ag_16_0"></a><a id="Tc_G_3asakCGU2ArR66_EEUVQ_16_4"></a><a id="Tc_RlvD6sXYP0ik0npAjuW5zQ_17_0"></a><a id="Tc_mvEsh4Z6EUuhHq8pliyZjQ_17_4"></a><a id="Tc_pjY3JQc4zUCj-MR-yzFfBg_17_9"></a><a id="Tc_DGvEz2vB_EC8v2QIW6OqsQ_18_0"></a><a id="Tc_IOOcHMmJnEGcFgZitZX2eQ_18_4"></a><a id="Tc_J7SUwRUULUuSTPgvmbhxXA_19_0"></a><a id="Tc_2cbRJ8bgAEKNXcDoujYYmw_19_4"></a><a id="Tc_qlyrdF2Gv0Gl2n2vXFrOFg_20_0"></a><a id="Tc_LS1MQabBnEWBo_JS_6fmLw_20_4"></a><a id="Tc_LIXSfmU6Mk-fENeoxt2FCA_20_7"></a><a id="Tc_A62qk2wZoE2nIzZtlmaL-w_20_9"></a><a id="Tc_uDNMV1vnhkORNraCysLmMg_22_0"></a><a id="Tc_Ocg3HDpn9UuZkSDg7iMVog_22_4"></a><a id="Tc_cEFkfnvGoEOl0LOI9Lcm2g_22_7"></a><a id="Tc_XKbidLbfbkaQc_KkSinkzg_22_9"></a><a id="_c4c5035f_a3b4_4f8d_bd17_204039472a4d"></a><a id="Tc_0XcsiH3QQUCiEsaLk_64xA_1_2"></a><a id="Tc_AvarQWzJbEC5OYHw9UtNbg_2_2"></a><a id="Tc_878Rb7Tri0a7bECjne3zBw_3_0"></a><a id="Tc_OfcKwg44BkSIcmWa9WmTfw_3_2"></a><a id="Tc_c3waM2zCyUu9SvDeKBwtwA_3_5"></a><a id="Tc_ZKXssUq-iE2crB0kHaExBw_4_0"></a><a id="Tc_GqUk9zEiY0y-ErtMBsZbvA_5_0"></a><a id="Tc_nry6aOKu10GVI61n1Dbwfw_6_0"></a><a id="_0803ef82_eb2c_425a_a6e4_8d951518a219"></a><a id="Tc_Y6ICAuyKnUOLwF7J1tALeQ_1_2"></a><a id="Tc_cQ2P2t2rx0KG4A1apiyeLg_2_2"></a><a id="Tc_LEPB2ey1I0CXk9kN4ofKgw_3_0"></a><a id="Tc_7hn5vBk_aU6ba9Trfi9y5w_3_2"></a><a id="Tc_3HfT4gssp02RQlwQLn3diQ_3_5"></a><a id="Tc_mVHmwuj4dk-CK28FFLwBXQ_4_0"></a><a id="Tc_AJ7urxs5BUuuts7HiIXSvA_4_2"></a><a id="Tc_0-X53ldlyEKeWk8ZuQDJAg_4_5"></a><a id="Tc__q1HHxX75UCde89QorxmNA_5_0"></a><a id="Tc_-dHDMZQS00667h-tpGP_6A_6_0"></a><a id="Tc_jUL8e456T0GJ19jlb6s3dw_7_0"></a><ix:continuation id="Tb_ULz7QtaTRk2fGmIkgJ4MbA_cont3" continuedAt="Tb_ULz7QtaTRk2fGmIkgJ4MbA_cont4"><ix:continuation id="Group_1RVy9P0P4UCs4cF19rpDLw_2_cont1"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-size:1pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">Our stock option activity for the three years ended December&#160;31,&#160;2022, 2021 and 2020, was as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="Tb_oMc4hoIn10aMp--Oe6y9Cg" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.11848831%;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:38.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise&#160;Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Intrinsic</b></p></td></tr><tr><td style="vertical-align:bottom;width:38.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0.05pt 0pt 0.05pt 0pt;">(In&#160;thousands except options and per share data)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Per Share </b><sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Contractual Life</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Value </b><sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(2)</sup></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Balance at December 31, 2019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ" contextRef="As_Of_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_c4XlEVcSZkGUgY9pO9GVYw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc__X4FXhVHSUSwEXypDapQfQ_5_2">866,955</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q" contextRef="As_Of_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_c4XlEVcSZkGUgY9pO9GVYw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_q_acRcogG0WhxMlGYjwrGA_5_5">28.76</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_VEK6kkacQUeh0rcfcqChxQ" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Narr_i76Z7F3mykuzs8vq0H2MTw">6.3</ix:nonNumeric> years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_c4XlEVcSZkGUgY9pO9GVYw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="Tc_6sKlh3FHg0e1ZJhtJPQ8FQ_5_10">33,957</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_qOmCDKQT9Eyfuidf3pzRYg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Tc_27FrX3Vo-0OFIpBWt9C9IA_6_2">378,695</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_qOmCDKQT9Eyfuidf3pzRYg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_rdvRUSmovU6GV84XlToNAw_6_5">44.84</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_qOmCDKQT9Eyfuidf3pzRYg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_8oBwM51T-EGal-1XVuOB-Q_7_2">147,741</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_qOmCDKQT9Eyfuidf3pzRYg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_BkdXLKNyVkqJrZUmQt_zwA_7_5">7.24</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_qOmCDKQT9Eyfuidf3pzRYg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="3" id="Tc_rORTCCGPB0yaq_xTfw8nrQ_7_10">6,540</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_qOmCDKQT9Eyfuidf3pzRYg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="Tc_qsptCN4mmEuMp39O07b_hw_8_2">54,824</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_qOmCDKQT9Eyfuidf3pzRYg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_v0p7r0yRBkOm7FvJbykwGg_8_5">50.25</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;">Cancelled/Expired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_qOmCDKQT9Eyfuidf3pzRYg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" scale="0" id="Tc_HJOWQ8K9ZUCWQmwURwbxIA_9_2">3,376</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_qOmCDKQT9Eyfuidf3pzRYg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_Na7-rCqWJU2ZTaP-9phlkg_9_5">63.61</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Balance at December 31, 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ" contextRef="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_YXF4jcKSZ0az4v_DZj-Otw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_vAkMK7sM5EutgCL52i4Srw_10_2">1,039,709</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q" contextRef="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_YXF4jcKSZ0az4v_DZj-Otw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_zE4iiK_B1US3g6uoDQ-M2A_10_5">36.43</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_qOmCDKQT9Eyfuidf3pzRYg" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Narr_oHGM55QSS0iC_QEmhaI3kQ">5.6</ix:nonNumeric> years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_YXF4jcKSZ0az4v_DZj-Otw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="3" id="Tc_Qy6SxGFKHUey37DVO-teFg_10_10">13,381</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_SKlrM8781Eet0zFbC3ewTw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Tc_PVEjYuUUnEqO8-r1knHAYg_11_2">188,748</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_SKlrM8781Eet0zFbC3ewTw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_1kuBFIIbXUaKlbyq5yEnFQ_11_5">49.33</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_SKlrM8781Eet0zFbC3ewTw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_Tf3YbeYhM0e2M8l45kj3TQ_12_2">175,516</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_SKlrM8781Eet0zFbC3ewTw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_MDEVOVg1Ukic0h7wHqhYFw_12_5">22.65</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_SKlrM8781Eet0zFbC3ewTw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="3" id="Tc_tBPchSOaZE6P6YamJR-uTw_12_10">4,901</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_SKlrM8781Eet0zFbC3ewTw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="Tc_jtjWBuZ63UqTmFJwqjSN6w_13_2">92,773</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_SKlrM8781Eet0zFbC3ewTw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_2q5ii88GGku4wgDvVqbA_w_13_5">49.77</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;">Cancelled/Expired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_SKlrM8781Eet0zFbC3ewTw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" scale="0" id="Tc_aIIWGMFyKEW2TJTqLcaR0w_14_2">44,944</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_SKlrM8781Eet0zFbC3ewTw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_AX2L-yeCRkC2pRZNG1E7ZA_14_5">57.78</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Balance at December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ" contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember___xLca8jWE2AqShfBEgmlw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_xqv6K85IT0OfcHuUp0IvcQ_15_2">915,224</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q" contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember___xLca8jWE2AqShfBEgmlw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_i7oYvwF2GEGVd9s7Mx01gg_15_5">39.33</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_SKlrM8781Eet0zFbC3ewTw" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Narr_5eWvWpYlJUOPgsdOg01tjw">5.0</ix:nonNumeric> years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember___xLca8jWE2AqShfBEgmlw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="Tc_6o_QFfLR8kyyJ3GjYGBPkw_15_10">2,068</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_6-UgFP9YHkKs37vGGIhEVw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Tc_yd6RRSCLmUehCN8Btpna8A_16_2">47,280</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_6-UgFP9YHkKs37vGGIhEVw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_m2RtcofNKUiqLnKfl6Vs9w_16_5">6.17</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_6-UgFP9YHkKs37vGGIhEVw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_GZ6eCIeZL0KjFpNIe3sXQg_17_2">90,878</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_6-UgFP9YHkKs37vGGIhEVw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="Tc__z1CNbW5g0a-2TA4GMvojw_17_5">1.68</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_6-UgFP9YHkKs37vGGIhEVw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="3" id="Tc_G4uro0VOeU6CBIxbDvNhiA_17_10">916</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_6-UgFP9YHkKs37vGGIhEVw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="Tc_m4EPz7X5PUGpvhZ5_a-eaw_18_2">92,981</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_6-UgFP9YHkKs37vGGIhEVw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_yJFjzZ9Lx0uHBJ7BRvN-xA_18_5">36.28</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;">Cancelled/Expired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_6-UgFP9YHkKs37vGGIhEVw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" scale="0" id="Tc_woFp_p-iIECMMhC4J3dfzw_19_2">163,338</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_6-UgFP9YHkKs37vGGIhEVw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_8tyLAUkrs0S_em0nv8ujGQ_19_5">37.65</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Balance at December 31, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ" contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_Un8xxO7K-UGnIxffkFMjsw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_krtGBd8x0EyJ4ssdsN0Wig_20_2">615,307</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q" contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_Un8xxO7K-UGnIxffkFMjsw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_PJLVhtBoSkmwg9nJkOwwIw_20_5">43.25</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_6-UgFP9YHkKs37vGGIhEVw" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Narr_w3cBTW0e-0ywFEbbinynpA">4.7</ix:nonNumeric> years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_Un8xxO7K-UGnIxffkFMjsw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="Tc_qHE6EVgu106ESpwcXV28mQ_20_10">164</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Options exercisable at December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ" contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_Un8xxO7K-UGnIxffkFMjsw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="Tc_OpxbOvmpRkitQlmQhZFI1Q_22_2">435,363</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q" contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_Un8xxO7K-UGnIxffkFMjsw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="Tc_gdcIV3GFUEyJVUBfipfQIg_22_5">43.83</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_6-UgFP9YHkKs37vGGIhEVw" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="Narr_UfjX9sSsIkCPUC2pjy_0qw">4.5</ix:nonNumeric> years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_Un8xxO7K-UGnIxffkFMjsw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="3" id="Tc_h9u5DiafsEOSdnqhsjjasg_22_10">84</ix:nonFraction></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;padding-bottom:6pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-size:1pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><div style="margin-top:0pt;"></div><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-decoration-line:none;text-transform:none;vertical-align:baseline;white-space:nowrap;width:18pt;padding:0pt 0pt 6pt 0pt;">(1)</td><td style="padding:0pt 0pt 6pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-style:normal;font-weight:normal;">The exercise price of each option granted during the periods shown was equal to the market price of the underlying stock on the date of grant.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-decoration-line:none;text-transform:none;vertical-align:baseline;white-space:nowrap;width:18pt;padding:0pt 0pt 12pt 0pt;">(2)</td><td style="padding:0pt 0pt 12pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-style:normal;font-weight:normal;">The aggregate intrinsic value of options exercised represents the difference between the exercise price of the option and the closing stock price of our common stock on the date of exercise. The aggregate intrinsic value of options outstanding represents the difference between the exercise price of the option and the closing stock price of our common stock on the last trading day of the period.</span></td></tr></table></ix:nonNumeric><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">Options exercisable of <ix:nonFraction unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ" contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember___xLca8jWE2AqShfBEgmlw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="Narr_2MbwZa-UskujrTu5U_6VaQ">517,316</ix:nonFraction> at December&#160;31,&#160;2021, and <ix:nonFraction unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ" contextRef="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_YXF4jcKSZ0az4v_DZj-Otw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="Narr_sqxTw10zrkOZvDZShKGa4Q">489,866</ix:nonFraction> at December&#160;31,&#160;2020 had weighted average exercise prices of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q" contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember___xLca8jWE2AqShfBEgmlw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="Narr_EFeSDap9FUSvH4-R6TsxWg">32.60</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q" contextRef="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_YXF4jcKSZ0az4v_DZj-Otw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="Narr_lUvxP6mrlkeRAvNOr4z7DA">25.39</ix:nonFraction>, respectively.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">The following summarizes additional information about our stock options:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" name="us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock" id="Tb_HEhGRMPVf0KaN-FHr4zviw" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:61.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:35.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:35.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number of:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Non-vested options, beginning of the year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ" contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember___xLca8jWE2AqShfBEgmlw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" scale="0" id="Tc_HZi0LM1MsE-1lCDy9Z8FAw_4_3">397,908</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ" contextRef="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_YXF4jcKSZ0az4v_DZj-Otw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" scale="0" id="Tc_XlMDxr7sDE6Jcst2GVRgtg_4_6">549,843</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:61.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Non-vested options, end of the year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ" contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_Un8xxO7K-UGnIxffkFMjsw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" scale="0" id="Tc_TVKd1RR_-UqewW_hhZwH6A_5_3">179,944</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ" contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember___xLca8jWE2AqShfBEgmlw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" scale="0" id="Tc_z00kxmO1BU67WtnVYZN4sw_5_6">397,908</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:61.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Vested options, end of the year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_6-UgFP9YHkKs37vGGIhEVw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" scale="0" id="Tc_TPNTe1-aF0WqLLP3w3qD8w_6_3">435,363</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_SKlrM8781Eet0zFbC3ewTw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" scale="0" id="Tc_gwGiKMrr20-h3eUY2gFEzQ_6_6">517,316</ix:nonFraction></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;"><span style="font-size:1pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:61.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:35.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:35.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted-average grant date fair value of: </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Non-vested options, beginning of the year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q" contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember___xLca8jWE2AqShfBEgmlw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="Tc_ZPgTdd-zQka393nlD7URCA_4_3">18.02</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q" contextRef="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_YXF4jcKSZ0az4v_DZj-Otw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="Tc_5CeEe91oAUepT8NqnA_2Sg_4_6">18.03</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:61.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Non-vested options, end of the year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q" contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_Un8xxO7K-UGnIxffkFMjsw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="Tc_pMxcbk5cuUaXI_gHBkQ2PQ_5_3">16.24</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q" contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember___xLca8jWE2AqShfBEgmlw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="Tc_BAyvteYzr0CDWp_19KPRNw_5_6">18.02</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:61.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Vested options, end of the year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_6-UgFP9YHkKs37vGGIhEVw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" scale="0" id="Tc_AkOPr_wkqEuNJ0Yve-HvZg_6_3">17.53</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_SKlrM8781Eet0zFbC3ewTw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" scale="0" id="Tc_WLu74SVo2EaEJMjH93yEmQ_6_6">13.27</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:61.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Forfeited options, during the year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_6-UgFP9YHkKs37vGGIhEVw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" scale="0" id="Tc_JZCly6KuYEqvpx_6L6kl5A_7_3">14.73</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_SKlrM8781Eet0zFbC3ewTw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" scale="0" id="Tc_hwsYVPZD00GlfMnAjXRttQ_7_6">19.26</ix:nonFraction></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;padding-bottom:12pt;background:#ffffff;margin:0pt;"><span style="font-size:1pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></ix:continuation></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">110</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_5de4a997_7fac_4380_adf2_4d2ba893adcd"></a><a id="Tc_-gR5MUzVPku6c10lJphH6w_1_4"></a><a id="Tc_kDyFR2r9QEq3iZXA8Gh3vA_2_4"></a><a id="Tc_JSCWTdXzXEST6-zylusl2g_2_7"></a><a id="Tc_vfjPwEYfzUO-JEXcMeCyMg_3_2"></a><a id="Tc_D6c3IOZN80qjqSXeEdWTNQ_3_4"></a><a id="Tc_T6Slo8SCYkiilYmGMj4MgA_3_7"></a><a id="Tc_Ah_CwQ0opEK6Lr1zMtUStw_4_0"></a><a id="Tc__kv8CR7EOUOQQaCt82AwMQ_4_2"></a><a id="Tc_wuxL6a2JqEKUu86QBZiSzg_4_4"></a><a id="Tc_Fq9fzbPay06E2bDaXT5F7A_4_7"></a><a id="Tc_MdZXt8cugEGi0It0lJcuHw_5_0"></a><a id="Tc_3lk-zXa5kkqpwclwPYZ-Mg_5_4"></a><a id="Tc_CT2tfYM0AEqoRRDJzVPyjw_5_7"></a><a id="Tc_RehnR6djTEqC1EPzLOGnxA_6_0"></a><a id="Tc_LE2OCfk5l0-BgQNBYr1REw_6_4"></a><a id="Tc_V8l-Ij650EmuFFcDSmFpMA_7_0"></a><a id="Tc_K7QiCb1takif_tJWWm4YyQ_7_4"></a><a id="Tc_W1yzAK-K7k6UTpKhp4qBfA_8_0"></a><a id="Tc_cS_nMt6FsE-H7qkgoqpfeQ_8_4"></a><a id="Tc_Bn8rKolf_UeEukGe-abu_Q_9_0"></a><a id="Tc_CiiqwPPkE06TPZh4s5bpwg_9_4"></a><a id="Tc_347DlugOj0qLLr_LM9UlUw_10_0"></a><a id="Tc_ms6qjKwDaEOZUq-mktcNJQ_10_4"></a><a id="Tc_ezkLxEgKN02Hp4qqvaixUg_10_7"></a><a id="Tc_pufTeJlia0aBC0WQw5rung_11_0"></a><a id="Tc_HZ81gQI0vkWl9e46HahnEg_11_4"></a><a id="Tc_V0d0MppXdEyTzM6QxFSvyQ_12_0"></a><a id="Tc_EZf8yVDxOke2WzROXe2oCA_12_4"></a><a id="Tc_kzj6PhYmZE6FUNpFNaQBXw_13_0"></a><a id="Tc_5ml8ced9B0ea_js5EQMoFw_13_4"></a><a id="Tc_XeJktRXsE0S4RiBHpJnFtg_14_0"></a><a id="Tc_vcYJT-y0jUWeNSaOu9j24A_14_4"></a><a id="Tc_uEY1dI4KyUabHSoRXS_CLw_14_7"></a><a id="Tc_LP_63EB5o0-BxGVIdYnquw_15_0"></a><a id="Tc_UIPMtiDE3kyZtxLXIvKFoA_15_4"></a><a id="Tc_GIl2ZSgA0kuF3IG3X4b5LA_16_0"></a><a id="Tc_h7VylTNDLkWWFxkjahp2bQ_16_4"></a><a id="Tc_RIrA73Ijpkam1tUcUiUsqg_17_0"></a><a id="Tc_ujNMVHeNCkaC7a5019TL5Q_17_4"></a><a id="Tc_U1ACX3KoQU25moTJCAtJbA_18_0"></a><a id="Tc_0W-kav_rV0a5Wup_LbujQw_18_4"></a><a id="Tc_ZgYUkegkkUCOnwMm_6rYMA_18_7"></a><ix:continuation id="Tb_ULz7QtaTRk2fGmIkgJ4MbA_cont4" continuedAt="Tb_ULz7QtaTRk2fGmIkgJ4MbA_cont5"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Time-Based Restricted Stock Unit</span><i style="font-style:italic;">s</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:10pt;">We have granted time-based restricted stock units to certain participants under the 2016 Plan that are stock-settled with common shares. Time-based restricted stock units granted under the 2016 Plan vest over </span><span style="-sec-ix-hidden:Hidden_fHxG8ZvlB0ieDTwHUV85QA;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">one</span></span><span style="font-size:10pt;"> to </span><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_tcmd_TimeBasedRestrictedStockUnitsRsusMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_8RJLAbFs-0aC61lHpsR90Q" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_Qr22M_rc_EaB43T6jg2MlQ"><span style="font-size:10pt;">three years</span></ix:nonNumeric><span style="font-size:10pt;">. Stock-based compensation expense included in our Consolidated Statements of Operations for time-based restricted stock units was </span><span style="font-size:10pt;">$<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_tcmd_TimeBasedRestrictedStockUnitsRsusMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_Nb-WbjXmjUKf3z1gH8kH5Q" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="Narr_1fsRwh5bAkK4ApPgwZmpig">5.8</ix:nonFraction></span><span style="font-size:10pt;"> million, </span><span style="font-size:10pt;">$<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_tcmd_TimeBasedRestrictedStockUnitsRsusMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_YpNaI4H08kWMKCFdksUPJg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="Narr_i28y2vukCkO0mCAGHORY_w">4.9</ix:nonFraction></span><span style="font-size:10pt;"> million and </span><span style="font-size:10pt;">$<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_tcmd_TimeBasedRestrictedStockUnitsRsusMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_-BKViJhhwkykuZDgY3GR5A" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="Narr_EzWBDJPYv0uatI2dpfMGMA">5.2</ix:nonFraction></span><span style="font-size:10pt;"> million for the years ended December&#160;31,&#160;2022, 2021 and 2020, respectively. As of December&#160;31,&#160;2022, there was approximately </span><span style="font-size:10pt;">$<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_tcmd_TimeBasedRestrictedStockUnitsRsusMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_qc0c3k5OY0eKiJM_sgU8nA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="6" id="Narr_lO0J0FnY1k6sxViq9KWUWw">7.8</ix:nonFraction></span><span style="font-size:10pt;"> million of total unrecognized pre-tax compensation expense related to outstanding time-based restricted stock units that is expected to be recognized over a weighted-average period of </span><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_tcmd_TimeBasedRestrictedStockUnitsRsusMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_Nb-WbjXmjUKf3z1gH8kH5Q" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="Narr_T3qRajyySU2Z68qt5AJO4g"><span style="font-size:10pt;">1.9</span></ix:nonNumeric><span style="font-size:10pt;"> years. </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our time-based restricted stock unit activity for the years ended December&#160;31,&#160;2022, 2021 and 2020 was as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_tcmd_TimeBasedRestrictedStockUnitsRsusMember_OqoDokUrok2FtqlOs8iQLQ" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" id="Tb_eh61YCkdY0WVltybATDARw" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:46.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:46.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average Grant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Units</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Date Fair Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Intrinsic</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0.05pt 0pt 0.05pt 0pt;">(In&#160;thousands except unit and per unit data)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Per Unit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-size:10pt;font-weight:bold;">Value </b><sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Balance at December 31, 2019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ" contextRef="As_Of_12_31_2019_us-gaap_AwardTypeAxis_tcmd_TimeBasedRestrictedStockUnitsRsusMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_IaK_VsGjOEiqSEoE-zGXOw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="Tc_Y0t_2DIZtEu0ZU7gQMurgg_5_2">171,687</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q" contextRef="As_Of_12_31_2019_us-gaap_AwardTypeAxis_tcmd_TimeBasedRestrictedStockUnitsRsusMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_IaK_VsGjOEiqSEoE-zGXOw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="Tc_vprmLEMik0Gu5gGJs0K8aQ_5_5">43.74</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2019_3ga0jBjg6EKA4-znaQ36NQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" scale="3" id="Tc_EuskLxFMp06-e-wF3VfNpQ_5_8">11,591</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_tcmd_TimeBasedRestrictedStockUnitsRsusMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_-BKViJhhwkykuZDgY3GR5A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="Tc_DlMXBYcxfU-OW8rocX5jXw_6_2">175,582</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_tcmd_TimeBasedRestrictedStockUnitsRsusMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_-BKViJhhwkykuZDgY3GR5A" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Tc_6nAH36d5V0uOPNK155SLDA_6_5">46.42</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;">Modification</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_tcmd_TimeBasedRestrictedStockUnitsRsusMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_-BKViJhhwkykuZDgY3GR5A" decimals="INF" format="ixt:numdotdecimal" name="tcmd:SharebasedcompensationArrangementBySharebasedpaymentAwardEquityInstrumentsOtherThanOptionsModifiedInPeriod" scale="0" id="Tc__LicHWlCCUWxxhl0PkwKew_7_2">2,288</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_tcmd_TimeBasedRestrictedStockUnitsRsusMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_-BKViJhhwkykuZDgY3GR5A" decimals="2" format="ixt:numdotdecimal" name="tcmd:SharebasedcompensationArrangementBySharebasedpaymentAwardEquityInstrumentsOtherThanOptionsModifiedWeightedAverageGrantDateFairValue" scale="0" id="Tc_hwz1Gqc57UiHUuk59T6Lvg_7_5">21.85</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;">Vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_tcmd_TimeBasedRestrictedStockUnitsRsusMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_-BKViJhhwkykuZDgY3GR5A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="Tc_IXb0KKaQDEGRDqb3KeCw8w_8_2">118,014</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_tcmd_TimeBasedRestrictedStockUnitsRsusMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_-BKViJhhwkykuZDgY3GR5A" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Tc_CMAND2AAnkeMLL-x2OuHJw_8_5">37.57</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;">Cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_tcmd_TimeBasedRestrictedStockUnitsRsusMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_-BKViJhhwkykuZDgY3GR5A" decimals="INF" format="ixt:numdotdecimal" name="tcmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod" scale="0" id="Tc_s2T1Ww2vMU2pTT4IRmbi1A_9_2">20,074</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_tcmd_TimeBasedRestrictedStockUnitsRsusMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_-BKViJhhwkykuZDgY3GR5A" decimals="2" format="ixt:numdotdecimal" name="tcmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancellationsWeightedAverageGrantDateFairValue" scale="0" id="Tc_6mx-Xv6qakW1VLXgcdv4lw_9_5">53.03</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Balance at December 31, 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ" contextRef="As_Of_12_31_2020_us-gaap_AwardTypeAxis_tcmd_TimeBasedRestrictedStockUnitsRsusMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_Rx5oCF5RME-QoxzFqBAV1g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="Tc_Vi0N21Yjoku30a8KW981dg_10_2">211,469</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q" contextRef="As_Of_12_31_2020_us-gaap_AwardTypeAxis_tcmd_TimeBasedRestrictedStockUnitsRsusMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_Rx5oCF5RME-QoxzFqBAV1g" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="Tc_SM_sgV2xEEKyouiK7gPUUg_10_5">48.29</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2020_q95ww8WB7U-18mlScI3MCA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" scale="3" id="Tc_t2iAXX00pE6Gdhn0kmrsJw_10_8">9,503</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_tcmd_TimeBasedRestrictedStockUnitsRsusMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_YpNaI4H08kWMKCFdksUPJg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="Tc_1tZFZpooF06UcOBFni0Q3g_11_2">189,762</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_tcmd_TimeBasedRestrictedStockUnitsRsusMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_YpNaI4H08kWMKCFdksUPJg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Tc_SUPm6sLOGkC_epWcvmNokw_11_5">40.31</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;">Vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_tcmd_TimeBasedRestrictedStockUnitsRsusMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_YpNaI4H08kWMKCFdksUPJg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="Tc_S37W3karLEiMNsR6hY0j5g_12_2">106,521</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_tcmd_TimeBasedRestrictedStockUnitsRsusMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_YpNaI4H08kWMKCFdksUPJg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Tc_o-AynhgikUOUeM4z0ZYyfQ_12_5">47.43</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;">Cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_tcmd_TimeBasedRestrictedStockUnitsRsusMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_YpNaI4H08kWMKCFdksUPJg" decimals="INF" format="ixt:numdotdecimal" name="tcmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod" scale="0" id="Tc_rkQxG-amXEKv4u16kytHkg_13_2">35,563</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_tcmd_TimeBasedRestrictedStockUnitsRsusMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_YpNaI4H08kWMKCFdksUPJg" decimals="2" format="ixt:numdotdecimal" name="tcmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancellationsWeightedAverageGrantDateFairValue" scale="0" id="Tc_09oy_dhQgEaze53kgbmmoA_13_5">51.76</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Balance at December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ" contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_tcmd_TimeBasedRestrictedStockUnitsRsusMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_RfN-hRdVK0WQ7dibE-9y_A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="Tc_gGJrTm-gyUWAbb1H5t9v6g_14_2">259,147</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q" contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_tcmd_TimeBasedRestrictedStockUnitsRsusMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_RfN-hRdVK0WQ7dibE-9y_A" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="Tc_Hj2icQFQ5ky8tWtImoORug_14_5">42.32</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_tcmd_TimeBasedRestrictedStockUnitsRsusMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_RfN-hRdVK0WQ7dibE-9y_A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" scale="3" id="Tc_saFk2DU2gU-JIk662fto-g_14_8">4,932</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_tcmd_TimeBasedRestrictedStockUnitsRsusMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_Nb-WbjXmjUKf3z1gH8kH5Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="Tc_-x1QC-KwKEmGHbKKM8MXmg_15_2">539,525</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_tcmd_TimeBasedRestrictedStockUnitsRsusMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_Nb-WbjXmjUKf3z1gH8kH5Q" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Tc_4toNV38ZH0i86quODrkong_15_5">15.03</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;">Vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_tcmd_TimeBasedRestrictedStockUnitsRsusMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_Nb-WbjXmjUKf3z1gH8kH5Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="Tc_o1ttkGwR30Sf0xDk0QWf4g_16_2">123,528</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_tcmd_TimeBasedRestrictedStockUnitsRsusMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_Nb-WbjXmjUKf3z1gH8kH5Q" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Tc_z_p50NJ-ckGIz8veLQZi9g_16_5">43.20</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;">Cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_tcmd_TimeBasedRestrictedStockUnitsRsusMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_Nb-WbjXmjUKf3z1gH8kH5Q" decimals="INF" format="ixt:numdotdecimal" name="tcmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod" scale="0" id="Tc_iP9-2B5xuUySSUJc-ulOSg_17_2">84,602</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_tcmd_TimeBasedRestrictedStockUnitsRsusMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_Nb-WbjXmjUKf3z1gH8kH5Q" decimals="2" format="ixt:numdotdecimal" name="tcmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancellationsWeightedAverageGrantDateFairValue" scale="0" id="Tc_27lrhMUbw0u1GVxKzW7lhQ_17_5">26.91</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Balance at December 31, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ" contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_tcmd_TimeBasedRestrictedStockUnitsRsusMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_qc0c3k5OY0eKiJM_sgU8nA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="Tc_0qCmxQRH2Ee5pzfZjFipwA_18_2">590,542</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q" contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_tcmd_TimeBasedRestrictedStockUnitsRsusMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_qc0c3k5OY0eKiJM_sgU8nA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="Tc_nKMDFaUDlE2W-Au1uBa4cg_18_5">19.42</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_tcmd_TimeBasedRestrictedStockUnitsRsusMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_qc0c3k5OY0eKiJM_sgU8nA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" scale="3" id="Tc_8xPbiNzzDEKaNASJgmBTdQ_18_8">6,779</ix:nonFraction></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;padding-bottom:6pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-size:1pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><div style="margin-top:0pt;"></div><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 6pt 0pt;">(1)</td><td style="padding:0pt 0pt 6pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-style:normal;font-weight:normal;">The aggregate intrinsic value of time-based restricted stock units outstanding was based on our closing stock price on the last trading day of the period.</span></td></tr></table></ix:nonNumeric><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Performance-Based Restricted Stock Units</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">We have granted performance-based restricted stock units (&#8220;PSUs&#8221;) to certain participants under the 2016 Plan. These PSUs have both performance-based and time-based vesting features. The PSUs granted in 2018 were earned to the extent performance goals based on revenue and adjusted EBITDA were achieved in 2019. The PSUs granted in 2019 were earned to the extent performance goals based on revenue and adjusted EBITDA were achieved in 2020. The PSUs granted in 2020 were earned to the extent performance goals based on revenue and adjusted EBITDA were achieved in 2021. The PSUs granted in 2021 will be earned if and to the extent performance goals based on revenue and adjusted EBITDA are achieved in 2022. The PSUs granted in 2022 will be earned if and to the extent performance goals based on revenue change and adjusted EBITDA margin are achieved in 2023. The number of PSUs earned will depend on the level at which the performance targets are achieved and can range from <ix:nonFraction unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw" contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_tcmd_PerformanceBasedStockSettledRestrictedStockUnitsMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_CmpNEKSSE0O0i2jPBWOaAg" decimals="2" format="ixt:numdotdecimal" name="tcmd:PercentageToEarnPerformanceBasedStockSettledRestrictedStockUnits" scale="-2" id="Narr_1ZsiGqYA6keHHUhYk3mUoQ">50</ix:nonFraction>% of target if threshold performance is achieved and up to <ix:nonFraction unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw" contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_tcmd_PerformanceBasedStockSettledRestrictedStockUnitsMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_Hlc6i7-A9EusSlzegAjTIQ" decimals="2" format="ixt:numdotdecimal" name="tcmd:PercentageToEarnPerformanceBasedStockSettledRestrictedStockUnits" scale="-2" id="Narr_TX9hoQsEQU6xs_iFcVfgbw">150</ix:nonFraction>% of target if maximum performance is achieved. <span style="-sec-ix-hidden:Hidden_sHnOWzszGUy7ZkN0NmbHuA;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">One-third</span></span> of the earned PSUs will vest on the date the Compensation and Organization Committee certifies the number of PSUs earned, and the remaining <span style="-sec-ix-hidden:Hidden_v4hPxGJ7JkKjemco7Ewk7A;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">two-thirds</span></span> of the earned PSUs will vest on the first anniversary of that certification date. All earned and vested PSUs will be settled in shares of common stock. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Stock-based compensation expense included in our Consolidated Statements of Operations for PSUs was $<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_tcmd_PerformanceBasedStockSettledRestrictedStockUnitsMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_UgLe632XY0y4wqXfkaKIqg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="Narr_fd42dJca-kS-7Yo79FgV8A">0.5</ix:nonFraction> million, $<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_tcmd_PerformanceBasedStockSettledRestrictedStockUnitsMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_7x_jPqkWGkShM1NIyefKfQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="Narr_ZHr8pHUaXEqECymr27nQnA">0.2</ix:nonFraction> million, and $<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_tcmd_PerformanceBasedStockSettledRestrictedStockUnitsMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_rm8GPwYY40y-DieCnmoBug" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="Narr_h6jyrOneyUmbXrnBssLAUw">0.5</ix:nonFraction> million for the years ended December&#160;31,&#160;2022, 2021 and 2020, respectively. The stock-based compensation expense for the year ended December 31, 2022 reflects an expense of $<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_tcmd_TwoThousandEighteenAndTwoThousandTwentyPerformanceBasedRestrictedStockUnitsMember_WZVx9pkMD0SJKZFhIdnWjQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="Narr_0P8NHPSIEUqHn4MNLiiX4A">0.6</ix:nonFraction> million related to the PSUs granted in 2022. The stock-based compensation expense for the year ended December 31, 2021 reflects a $<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_tcmd_PerformanceBasedStockSettledRestrictedStockUnitsMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_7x_jPqkWGkShM1NIyefKfQ" decimals="-5" format="ixt:numdotdecimal" name="tcmd:StockBasedCompensationExpenseMinimumTargets" scale="6" id="Narr_CzA6UtG5c0mjWcAsKvOZ1Q">0.5</ix:nonFraction>&#160;million benefit due to a change in the estimated payout associated with PSUs granted in 2020 being below the minimum performance target threshold level, as defined, </p></ix:continuation></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">111</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_fbf03683_2920_4cf8_b914_7ad43f9d6044"></a><a id="Tc_AJlELXaMMkGRhJzAy5zmTQ_1_2"></a><a id="Tc_f81zWW2sdUOuXsGYuIsApw_1_4"></a><a id="Tc_0K4H47wvz0yWe4_C7JF_aw_2_2"></a><a id="Tc_7WuCye1D8kuLIP37MczpIA_2_4"></a><a id="Tc_Lxu5njYujE2Qh7mVPBLNuA_2_7"></a><a id="Tc_X4CRsuvFqk6l7s2WZACodQ_3_2"></a><a id="Tc_Rd35snX86E-pWw1DM0EO6w_3_4"></a><a id="Tc_hpGXaHZcH0qecR6tLQh-Ow_3_7"></a><a id="Tc_0eEauw2dL0S57cPqmp8LaA_4_0"></a><a id="Tc_6z5DXu1ci0OrDaVwE0_3yw_4_2"></a><a id="Tc_eaaOmWooIUuxidkeRDbs7Q_4_4"></a><a id="Tc_ulDfp4sKWUqH7O203rXxxA_4_7"></a><a id="Tc_cjwV5yGTskKGQAVXQhvhDA_5_0"></a><a id="Tc_iA76jbaFHUacRxNRF21AgQ_5_4"></a><a id="Tc_qyrLVygbpE-KPOBl8pv4kg_5_7"></a><a id="Tc_IqL348d0XEqzxzdN_aKQ-w_6_0"></a><a id="Tc_qrU3iWE2VUufK2aHOqAj_w_6_4"></a><a id="Tc_YjzK0Yv0i0CBi-8_-7VN1A_7_0"></a><a id="Tc_84APIKfckUSI4PW4R7nLiw_7_4"></a><a id="Tc_BbY5gKobP0uE1odLvFPNlQ_8_0"></a><a id="Tc_3z_jyWn040mmDX4zWRozqA_8_4"></a><a id="Tc_aP_65H1EmUKhkkabsHroeg_9_0"></a><a id="Tc_3wp7TuYIIUynqwB8_SvbMA_9_4"></a><a id="Tc_XXxtqAm5zkaUT2CJO17ovg_9_7"></a><a id="Tc_J_7xbSIEukuObbzeKWZPFw_10_0"></a><a id="Tc_aFBoP3kfOE6tf7FdrHqu_Q_10_4"></a><a id="Tc_1KJKLySuUUmg-PcbbBbezw_11_0"></a><a id="Tc_2Y_VMqaYh0G-Zif2Bb8bPA_11_4"></a><a id="Tc_N0hi2ADQ70GndIdmi3B5zA_12_0"></a><a id="Tc_H3xH5uHvFkSTqCTL2xb0lQ_12_4"></a><a id="Tc_GNwt-Ax-xUameX-xkNjpuQ_13_0"></a><a id="Tc_KcIi40fsXUaArcTn9hXKEQ_13_4"></a><a id="Tc_bS-Sx_9p70SLLvhSrCqpCA_13_7"></a><a id="Tc_nZdFxpyMEk2_Z_BJ-uVtRQ_14_0"></a><a id="Tc_33G4iwnp1kOk_bkWbfd8mA_14_4"></a><a id="Tc_hfigaDSqyEa0VafU-50xhQ_15_0"></a><a id="Tc_JIg0PpLhq0GOuWe9Cv5poQ_15_4"></a><a id="Tc_5ZxSTusXMkKtUjgr4p56cw_16_0"></a><a id="Tc_RybY5x221EWo6GiQom47oQ_16_4"></a><a id="Tc_y92NKWXcVU6yxWCR091gyA_17_0"></a><a id="Tc_H_3VGOP9vUSMnWLX3SIncg_17_4"></a><a id="Tc_nndqctO51Ui5CFYYwtErVA_17_7"></a><ix:continuation id="Tb_ULz7QtaTRk2fGmIkgJ4MbA_cont5"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;">partially offset by an expense of $<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_tcmd_TwoThousandEighteenAndTwoThousandTwentyPerformanceBasedRestrictedStockUnitsMember_HDcRO5L1FU2oWQGAEeWYwA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="Narr_pkOcXoaj9EmYZGXi8rlBEQ">0.7</ix:nonFraction> million related to the PSUs granted in 2018 and 2021. As of December&#160;31,&#160;2022, there was approximately $<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_tcmd_PerformanceBasedStockSettledRestrictedStockUnitsMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_GskkIzSZ40CADy7RgEQqjw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" scale="6" id="Narr_8xZUkK1QzU2kyHoCcreprg">1.4</ix:nonFraction> million of total unrecognized pre-tax compensation expense related to outstanding PSUs that is expected to be recognized over a weighted average period of <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_tcmd_PerformanceBasedStockSettledRestrictedStockUnitsMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_UgLe632XY0y4wqXfkaKIqg" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="Narr_Ac73fwRicEiYnpOBIUVbfw">2.0</ix:nonNumeric> years. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">Our performance-based restricted stock unit activity at the estimated payout of <ix:nonFraction unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_tcmd_PerformanceBasedStockSettledRestrictedStockUnitsMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_rm8GPwYY40y-DieCnmoBug" decimals="2" format="ixt:numdotdecimal" name="tcmd:EstimatedPayoutPercentage" scale="-2" id="Narr_4sa-_NLQw0acmHN0EFyVTg"><ix:nonFraction unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_tcmd_PerformanceBasedStockSettledRestrictedStockUnitsMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_7x_jPqkWGkShM1NIyefKfQ" decimals="2" format="ixt:numdotdecimal" name="tcmd:EstimatedPayoutPercentage" scale="-2" id="Narr_vIk5gKa7OEKkvAZ7qOi4tA"><ix:nonFraction unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_tcmd_PerformanceBasedStockSettledRestrictedStockUnitsMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_UgLe632XY0y4wqXfkaKIqg" decimals="2" format="ixt:numdotdecimal" name="tcmd:EstimatedPayoutPercentage" scale="-2" id="Narr_uzBnPcdxkUa3C_Yx5DdS4A">100</ix:nonFraction></ix:nonFraction></ix:nonFraction>% of target for the years ended December&#160;31,&#160;2022, 2021 and 2020, was as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_tcmd_PerformanceBasedStockSettledRestrictedStockUnitsMember_jgqU-RDfJkWBTKO22fvJHw" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" id="Tb_IqGbyC2ygUqzrd-VMBKpBg" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:44.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:44.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Performance-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Based</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average Grant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Units</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Date Fair Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Intrinsic</b></p></td></tr><tr><td style="vertical-align:bottom;width:44.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0.05pt 0pt 0.05pt 0pt;">(In&#160;thousands except unit and per unit data)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Per Unit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-size:10pt;font-weight:bold;">Value </b><sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Balance at December 31, 2019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ" contextRef="As_Of_12_31_2019_us-gaap_AwardTypeAxis_tcmd_PerformanceBasedStockSettledRestrictedStockUnitsMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_vFDEcLAy5EyVpxGp-lSAGQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="Tc_V8FP6C2xkU6trC2n0bo9rw_5_2">91,151</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q" contextRef="As_Of_12_31_2019_us-gaap_AwardTypeAxis_tcmd_PerformanceBasedStockSettledRestrictedStockUnitsMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_vFDEcLAy5EyVpxGp-lSAGQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="Tc_4-ZYsbhbj0yqCmHeiiMBwA_5_5">44.63</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2019_us-gaap_AwardTypeAxis_tcmd_PerformanceBasedStockSettledRestrictedStockUnitsMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_vFDEcLAy5EyVpxGp-lSAGQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" scale="3" id="Tc_7bfs7OkuvEipd6trK2komg_5_8">6,154</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_tcmd_PerformanceBasedStockSettledRestrictedStockUnitsMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_rm8GPwYY40y-DieCnmoBug" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="Tc_PJky2I8nfE-xnsQE7DmVmQ_6_2">31,731</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_tcmd_PerformanceBasedStockSettledRestrictedStockUnitsMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_rm8GPwYY40y-DieCnmoBug" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Tc_Dai2Af-M2k2gp49RxWlN_A_6_5">50.41</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;">Vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_tcmd_PerformanceBasedStockSettledRestrictedStockUnitsMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_rm8GPwYY40y-DieCnmoBug" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="Tc_Wfqqv2BCB0GNkHMt3CJaew_7_2">26,204</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_tcmd_PerformanceBasedStockSettledRestrictedStockUnitsMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_rm8GPwYY40y-DieCnmoBug" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Tc_hjMyMqMc1Eq3O7acdqxP_w_7_5">33.58</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;">Cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_tcmd_PerformanceBasedStockSettledRestrictedStockUnitsMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_rm8GPwYY40y-DieCnmoBug" decimals="INF" format="ixt:numdotdecimal" name="tcmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod" scale="0" id="Tc_akINmGkVPUmm_RFMeq2O0A_8_2">17,375</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_tcmd_PerformanceBasedStockSettledRestrictedStockUnitsMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_rm8GPwYY40y-DieCnmoBug" decimals="2" format="ixt:numdotdecimal" name="tcmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancellationsWeightedAverageGrantDateFairValue" scale="0" id="Tc_yzJ6WBV-YE6QqbS-sxRXaQ_8_5">52.87</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Balance at December 31, 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ" contextRef="As_Of_12_31_2020_us-gaap_AwardTypeAxis_tcmd_PerformanceBasedStockSettledRestrictedStockUnitsMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_WpTm0Lj5Q0WDgY5zSwuAIg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="Tc_71fq2o4xA0qD4T-KGiScvg_9_2">79,303</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q" contextRef="As_Of_12_31_2020_us-gaap_AwardTypeAxis_tcmd_PerformanceBasedStockSettledRestrictedStockUnitsMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_WpTm0Lj5Q0WDgY5zSwuAIg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="Tc_gzX0dZQJ_E2q-A-0WCNTLA_9_5">47.83</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2020_us-gaap_AwardTypeAxis_tcmd_PerformanceBasedStockSettledRestrictedStockUnitsMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_WpTm0Lj5Q0WDgY5zSwuAIg" decimals="-3" format="ixt:numdotdecimal" name="tcmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueDeferredAndUnissued" scale="3" id="Tc_rtcm2p5B7kq9-w56sdzWgw_9_8">3,564</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_tcmd_PerformanceBasedStockSettledRestrictedStockUnitsMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_7x_jPqkWGkShM1NIyefKfQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="Tc_g1gh6e30r062l3OR1pjrsA_10_2">39,419</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_tcmd_PerformanceBasedStockSettledRestrictedStockUnitsMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_7x_jPqkWGkShM1NIyefKfQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Tc_Cwfjsk47L0-RrtRP7ZA4Ng_10_5">51.82</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;">Vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_tcmd_PerformanceBasedStockSettledRestrictedStockUnitsMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_7x_jPqkWGkShM1NIyefKfQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="Tc_QEfEuvOMjEi9G_Zu6cLgeQ_11_2">34,159</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_tcmd_PerformanceBasedStockSettledRestrictedStockUnitsMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_7x_jPqkWGkShM1NIyefKfQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Tc_UfLWeKVMp0SpECkLCRjp1A_11_5">33.98</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;">Cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_tcmd_PerformanceBasedStockSettledRestrictedStockUnitsMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_7x_jPqkWGkShM1NIyefKfQ" decimals="INF" format="ixt:numdotdecimal" name="tcmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod" scale="0" id="Tc_Ao4LHLYUGU6YXdURK4Z4zA_12_2">30,246</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_tcmd_PerformanceBasedStockSettledRestrictedStockUnitsMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_7x_jPqkWGkShM1NIyefKfQ" decimals="2" format="ixt:numdotdecimal" name="tcmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancellationsWeightedAverageGrantDateFairValue" scale="0" id="Tc_9rRkrRORXUSBfZ3IfVFbww_12_5">64.39</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Balance at December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ" contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_tcmd_PerformanceBasedStockSettledRestrictedStockUnitsMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_yXZPu2ZWyESDFq8L-JZCHg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="Tc_8zN6B0PFqkSW51cyAYL1EA_13_2">54,317</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q" contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_tcmd_PerformanceBasedStockSettledRestrictedStockUnitsMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_yXZPu2ZWyESDFq8L-JZCHg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="Tc_OOn9FIl2sEqfTPAVKu0pjA_13_5">50.22</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_tcmd_PerformanceBasedStockSettledRestrictedStockUnitsMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_yXZPu2ZWyESDFq8L-JZCHg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" scale="3" id="Tc_gut30S889EihPCa_gfywIQ_13_8">1,034</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_tcmd_PerformanceBasedStockSettledRestrictedStockUnitsMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_UgLe632XY0y4wqXfkaKIqg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="Tc_ppTdBapTikukglNg6UlUqg_14_2">131,710</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_tcmd_PerformanceBasedStockSettledRestrictedStockUnitsMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_UgLe632XY0y4wqXfkaKIqg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Tc_TYyYfPdisEq5L7MbERY5Fg_14_5">18.54</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;">Vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_tcmd_PerformanceBasedStockSettledRestrictedStockUnitsMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_UgLe632XY0y4wqXfkaKIqg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="Tc__k0z8_BTI0iE2yMv2Hy8Xg_15_2">4,407</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_tcmd_PerformanceBasedStockSettledRestrictedStockUnitsMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_UgLe632XY0y4wqXfkaKIqg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Tc_lJBvoUXdpkWN9DCWBlpD-w_15_5">12.31</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;">Cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_tcmd_PerformanceBasedStockSettledRestrictedStockUnitsMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_UgLe632XY0y4wqXfkaKIqg" decimals="INF" format="ixt:numdotdecimal" name="tcmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod" scale="0" id="Tc_FqRzDVI4zEGKdpbeMTlV5w_16_2">26,002</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_tcmd_PerformanceBasedStockSettledRestrictedStockUnitsMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_UgLe632XY0y4wqXfkaKIqg" decimals="2" format="ixt:numdotdecimal" name="tcmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancellationsWeightedAverageGrantDateFairValue" scale="0" id="Tc_3UtcLNAENUiE0ouyQDhxIg_16_5">42.53</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Balance at December 31, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ" contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_tcmd_PerformanceBasedStockSettledRestrictedStockUnitsMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_GskkIzSZ40CADy7RgEQqjw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="Tc_wkl66G4DK0mTiZm4kL7Fpg_17_2">155,618</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q" contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_tcmd_PerformanceBasedStockSettledRestrictedStockUnitsMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_GskkIzSZ40CADy7RgEQqjw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="Tc_W1dzvyNTmUuqnRleZ07mrw_17_5">25.05</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_tcmd_PerformanceBasedStockSettledRestrictedStockUnitsMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_GskkIzSZ40CADy7RgEQqjw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" scale="3" id="Tc_D4OeYbCtG02lXvoE180RYw_17_8">1,786</ix:nonFraction></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;padding-bottom:6pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-size:1pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><div style="margin-top:0pt;"></div><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 12pt 0pt;">(1)</td><td style="padding:0pt 0pt 12pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-style:normal;font-weight:normal;">The aggregate intrinsic value of performance-based restricted stock units outstanding was based on our closing stock price on the last trading day of the period</span></td></tr></table></ix:nonNumeric><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Employee Stock Purchase Plan</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">Our employee stock purchase plan (&#8220;ESPP&#8221;), which was approved by our Board of Directors on April 27, 2016, and by our stockholders on June 20, 2016, allows participating employees to purchase shares of our common stock at a discount through payroll deductions. The ESPP is available to all of our employees and employees of participating subsidiaries. Participating employees may purchase common stock, on a voluntary after-tax basis, at a price equal to <ix:nonFraction unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_EmployeeStockMember_cKXRqo7dk0-EdILU7PZBhg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="Narr_njquulaRNEmrqbckUW3zrQ">85</ix:nonFraction>% of the lower of the closing market price per share of our common stock on the first or last trading day of each stock purchase period. The ESPP provides for <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_EmployeeStockMember_cKXRqo7dk0-EdILU7PZBhg" format="ixt-sec:durwordsen" name="tcmd:EmployeeStockPurchasePlanOfferingPeriodsPeriod" id="Narr_3813uZD-FUCcvjiZ8xN33Q">six-month</ix:nonNumeric> purchase periods, beginning on May 16 and November 16 of each calendar year. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">A total of <ix:nonFraction unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ" contextRef="As_Of_4_27_2017_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_EmployeeStockMember_1JhNvac8pkCgs2t4mxK9oQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Narr_VjHHdYhgZ0CgRfwuMxQe3A">1,600,000</ix:nonFraction> shares of common stock was initially reserved for issuance under the ESPP. This share reserve will automatically be supplemented each January 1, commencing in 2017 and ending on and including January 1, 2026, by an amount equal to the least of (a) <ix:nonFraction unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_EmployeeStockMember_cKXRqo7dk0-EdILU7PZBhg" decimals="INF" format="ixt:numdotdecimal" name="tcmd:IncrementalSharesToBeIssuedPercentage" scale="-2" id="Narr_DcWkKGr9qUWZ-i2D2Y41gQ">1</ix:nonFraction>% of the shares of our common stock outstanding on the immediately preceding December 31, (b) <ix:nonFraction unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_EmployeeStockMember_cKXRqo7dk0-EdILU7PZBhg" decimals="INF" format="ixt:numdotdecimal" name="tcmd:IncrementalShareIncrease" scale="0" id="Narr_klin9hyspEGa3CDiTj4-Cg">500,000</ix:nonFraction> shares or (c) such lesser amount as our Board of Directors may determine. Pursuant to the automatic increase feature of the ESPP, <ix:nonFraction unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ" contextRef="Duration_1_1_2021_To_1_1_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_EmployeeStockMember_oauLVrUQf0Cdq6kFtZ4aEg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="0" id="Narr_YsKLxa2kOkywFwZUR-y9zg">194,518</ix:nonFraction> shares were added as available for issuance thereunder on January 1, 2021. Our Board of Directors exercised its prerogative to forego the automatic increase on each of January 1, 2023 and 2022. As of December&#160;31,&#160;2022, <ix:nonFraction unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ" contextRef="As_Of_12_31_2022_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_EmployeeStockMember_h6LWksYkZk-wYDJVCmudqg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Narr_CCqVi1zsrkepb_36f9vasA">1,559,151</ix:nonFraction> shares were available for future issuance under the ESPP. We recognized $<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_EmployeeStockMember_cKXRqo7dk0-EdILU7PZBhg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="Narr_GncSWJIWn0Kxu_DUeDEY1Q">0.8</ix:nonFraction> million, $<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_EmployeeStockMember_5xoE_s_XYkyuIAK5oWCe8Q" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="Narr_XAoehqw_wkGf7-6-9F9ijw">0.8</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_EmployeeStockMember_8hDu8hXfJECRLadm6BTlqQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="Narr_a-eUq54Yl0m94q2Ck_6Utw">0.9</ix:nonFraction> million in stock-based compensation expense related to the ESPP for the years ended December&#160;31,&#160;2022, 2021 and 2020, respectively.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">112</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_c32e8b7f_ed0b_4d28_8ed7_e65ba4ae37d4"></a><a id="Tc_nV-yJIg8HEyeEj3rfkg7OQ_1_1"></a><a id="Tc_hgjaILzNKkKyZjl2KkWdBA_2_1"></a><a id="Tc_oNf83a85_Ei6B8yvEAzsIQ_3_0"></a><a id="Tc_a8KDCizkA0ylSgEprNbojA_3_1"></a><a id="Tc_fkBgZKzV7EaAliRUoUv7zA_3_4"></a><a id="Tc_JnRO8mLr9kqChHNl84_0TQ_3_7"></a><a id="Tc_QSY7bfnVDkypOyggETyaaA_4_0"></a><a id="Tc_9ywIPKmpIEeYVj7o0nV-rw_5_0"></a><a id="Tc_MxnibXKnaEmahv2okmKm3A_5_1"></a><a id="Tc_-562YeIkck-u56ZesJLT8A_5_4"></a><a id="Tc_sROkcJmjAk-Ee-t7exoUDA_5_7"></a><a id="Tc_fR13sa_PwEunJxnOM0-ZLQ_6_0"></a><a id="Tc_OUJobFfJD0OmSpMEnhCnIw_6_8"></a><a id="Tc_gmIV4L6ON0OFApiDSyUwEA_7_0"></a><a id="Tc_LtTbqihMDkSzPyjYVCVYaA_7_1"></a><a id="Tc_UarrVdwzQ02W3NJPKbmMlg_7_4"></a><a id="Tc_-p2fA1wLdk28g2FHOEFWvg_7_7"></a><a id="Tc_1g0Wu_dzYEia0J87FWd9SA_9_0"></a><a id="Tc_7QYPIJg29kqXm6kQJ5DWbg_10_0"></a><a id="Tc_PEiX-rQGRUa0yRS7syHQzg_11_0"></a><a id="Tc_4hs--Vd0MU2jFiH0Dujffg_11_8"></a><a id="Tc_e3jnaEFkekqBFQdDBHkInw_12_0"></a><a id="Tc_ucOL0PI1Yk2u9ewTmYrurA_1_1"></a><a id="Tc_ztTe128n80SKNIMGHT599g_2_1"></a><a id="Tc_umw-bIVZQke-0fPJYH5cvQ_3_0"></a><a id="Tc_Ooe01cb3fkKmIOiL6rJ5WA_3_1"></a><a id="Tc_-dmBC26xakGgEejx1TUwFQ_3_4"></a><a id="Tc_FTxOLbaXk02OylFLXaq9Rw_3_7"></a><a id="Tc_LsgiQFJgQkiLwDMMa4gEuw_4_0"></a><a id="Tc_wYy97TgwU0O_conEdyyIDg_4_1"></a><a id="Tc_rtrzqJmT7EaXla5_PL2nag_4_4"></a><a id="Tc_uVPit-JXj0e_9VvS3zmZdQ_4_7"></a><a id="Tc_HKFYXmIMnEuRQz-5BLZpjg_5_0"></a><a id="Tc_0kp-hd6cWkyR7Cyv6J73cQ_6_0"></a><a id="Tc_LXxExv0Q1EStguBl6gjFHg_7_0"></a><a id="Tc_d1ehHHx7JUKeb4qUqQdlMg_7_8"></a><a id="Tc_jvSSAlv06kOFAn8bfxBeHA_8_0"></a><a id="Tc_hUGknelA50OJlwOrSZTNHg_8_1"></a><a id="Tc_YMaIaSrje0yGbzZ2wvIERg_8_4"></a><a id="Tc_cxgwSVJnGU-A1vmKhuNnxw_8_7"></a><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="Tb_twJ05CDow0yds3g40tQJCw" continuedAt="Tb_twJ05CDow0yds3g40tQJCw_cont1" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Note 14. &#160;Revenue</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">We derive our revenue from the sale and rental of our products to our customers in the United States. The following table presents our revenue, inclusive of sales and rental revenue, disaggregated by product:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="Tb_wglRPKvPiUqNEBLu0OJRGw" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:44.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:44.76%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:55.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:44.76%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:55.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:44.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0.05pt 0pt 0.05pt 0pt;">(In&#160;thousands)</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:44.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Revenue</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:44.76%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Lymphedema products</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_tcmd_FlexitouchSystemMember_CGH6jrZrrEuNDGgcZtJaOQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_WYs9uCCgeUGEP1f8lKKCQQ_5_2">212,266</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_tcmd_FlexitouchSystemMember_DXKUE6FvQUC574PEnBV1Ow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_q9xnLz3wpUq6NBzLXJzWDw_5_5">202,913</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2020_To_12_31_2020_srt_ProductOrServiceAxis_tcmd_FlexitouchSystemMember_H2Jxo4pTn0OGkO2d39JE6g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_UamahxSdJE-WVs2vLxYSgQ_5_8">187,130</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:44.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Airway clearance products</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_tcmd_AfflovestMember_dBqlEgBFb02-NFr9MvkVnw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_lxOGcxfrs0eLFjiFJWpBiw_6_2">34,519</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_tcmd_AfflovestMember__lGIQFNyT06Uzw8ThGA7KA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_h-MZKXJvc0O6fExPO1MZ3w_6_5">5,144</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:44.76%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_sK1LJCrR30u96rmWUmuy5g_7_2">246,785</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc__w_vYc9N_kavNC0gPgOwdA_7_5">208,057</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_AOw4xfX-B06qWi6un2JnqA_7_8">187,130</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:44.76%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Percentage of total revenue</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:44.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Lymphedema products</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw" contextRef="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_tcmd_FlexitouchSystemMember_CGH6jrZrrEuNDGgcZtJaOQ" decimals="2" format="ixt:numdotdecimal" name="tcmd:PercentageOfRevenue" scale="-2" id="Tc_ti9ARL2iq0GfeYteLM6wPw_10_2">86</ix:nonFraction>%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw" contextRef="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_tcmd_FlexitouchSystemMember_DXKUE6FvQUC574PEnBV1Ow" decimals="2" format="ixt:numdotdecimal" name="tcmd:PercentageOfRevenue" scale="-2" id="Tc_I4JKpZATME-mUjmd5N_Mdg_10_5">98</ix:nonFraction>%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw" contextRef="Duration_1_1_2020_To_12_31_2020_srt_ProductOrServiceAxis_tcmd_FlexitouchSystemMember_H2Jxo4pTn0OGkO2d39JE6g" decimals="2" format="ixt:numdotdecimal" name="tcmd:PercentageOfRevenue" scale="-2" id="Tc_X_XIbTIEBUef4fb5Uis1cw_10_8">100</ix:nonFraction>%</p></td></tr><tr><td style="vertical-align:bottom;width:44.76%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Airway clearance products</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw" contextRef="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_tcmd_AfflovestMember_dBqlEgBFb02-NFr9MvkVnw" decimals="2" format="ixt:numdotdecimal" name="tcmd:PercentageOfRevenue" scale="-2" id="Tc_BC-LHcY-BUSKmDUxOEymww_11_2">14</ix:nonFraction>%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw" contextRef="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_tcmd_AfflovestMember__lGIQFNyT06Uzw8ThGA7KA" decimals="2" format="ixt:numdotdecimal" name="tcmd:PercentageOfRevenue" scale="-2" id="Tc_EOW_oZs500y5V1lWmle3Kg_11_5">2</ix:nonFraction>%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;">N.M.</p></td></tr><tr><td style="vertical-align:bottom;width:44.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw" contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" decimals="2" format="ixt:numdotdecimal" name="tcmd:PercentageOfRevenue" scale="-2" id="Tc_NVzwUl_ZA0mssYmdjchdEA_12_2">100</ix:nonFraction>%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw" contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g" decimals="2" format="ixt:numdotdecimal" name="tcmd:PercentageOfRevenue" scale="-2" id="Tc_ZcY6vIwMxkyc-YMS56oZNw_12_5">100</ix:nonFraction>%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.93%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw" contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA" decimals="2" format="ixt:numdotdecimal" name="tcmd:PercentageOfRevenue" scale="-2" id="Tc_iSQSkJNhJ0uVSen2_LVApA_12_8">100</ix:nonFraction>%</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-size:1pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">Our revenue by channel, inclusive of sales and rental revenue, for the years ended December&#160;31,&#160;2022, 2021 and 2020 are summarized in the following table:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" name="tcmd:ScheduleOfRevenueFromThirdPartyPayersTableTextBlock" id="Tb_nlHTxFgJiEy37GjLNbC5aw" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:44.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.76%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:55.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:44.76%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:55.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:44.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0.05pt 0pt 0.05pt 0pt;">(In&#160;thousands)</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:44.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Private insurers and other payers</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_tcmd_PrivateInsurersMember_Gl5_xQhWx0SDBOy0s9jDJA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_RioCTkd3J0GlEGVYPZpHbw_4_2">139,087</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_tcmd_PrivateInsurersMember_7J0YXfLIgU2pD3Cizu1_Aw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_q7w1aoivC02rAedFmr6AOg_4_5">141,377</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2020_To_12_31_2020_srt_MajorCustomersAxis_tcmd_PrivateInsurersMember_6NttS8BSLkSGb2rID11mYQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_X9MCOxoV9U2T8-Qpd5N-GQ_4_8">132,789</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:44.76%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Veterans Administration</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_tcmd_VeteransAdministrationMember_UImO_mSEIUWRj4_3Jkesdw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_Jq1FO9QnGE26WedJD3wFZw_5_2">25,507</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_tcmd_VeteransAdministrationMember_QGri6VTOrky2n0lhb6O-wg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_vpz8j3r2D0-Wt13IhrUZhQ_5_5">25,654</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2020_To_12_31_2020_srt_MajorCustomersAxis_tcmd_VeteransAdministrationMember_nKPbjM6STkCgVrqDgy_u8Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_eGY9f2md6EmABLMDXbpbbw_5_8">24,485</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:44.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Medicare</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_tcmd_MedicareMember_K5sCGhJDSUOfkdarnEOQWg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_9vYGcNqrqEK4gP88jzGYUw_6_2">47,672</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_tcmd_MedicareMember_rK1KRWcE20Ot8cBmMKEQsA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_pGaZBmkcLE2W51bcsBHX7g_6_5">35,882</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2020_To_12_31_2020_srt_MajorCustomersAxis_tcmd_MedicareMember__J8_VCY0Ok-NPKhYcRHpiw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_pI1scNkMI0u_z6wGExagbw_6_8">29,856</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:44.76%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Durable medical equipment distributors</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_tcmd_DurableMedicalEquipmentDistributorsMember_VSaj6O2pMU2ypZXriiw1kg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_3vTAldIAe0q-8oXUMyx9gQ_7_2">34,519</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_tcmd_DurableMedicalEquipmentDistributorsMember_FRHWIP8w2UG8vVzzhUcyKg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_3SkpumlQ00-wOeQ4V1fCUA_7_5">5,144</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:44.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_wmCwb9ZXA0Sw3w6DQHqUFg_8_2">246,785</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_GB7XSCie1UqzxKKbS9RiHw_8_5">208,057</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.93%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_nefKKYRRMUGpHSQ6Uw4sKw_8_8">187,130</ix:nonFraction></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="font-size:1pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;"><span style="font-size:10pt;">Our rental revenue is derived from rent-to-purchase arrangements that typically range from </span><span style="-sec-ix-hidden:Hidden_8JEPt4Tv9EexWjz9141gSw;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">three</span></span><span style="font-size:10pt;"> to </span><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_VpuMgvUm10Cec1Yu-NEe1Q" format="ixt-sec:durwordsen" name="tcmd:RentToPurchaseArrangementsRentalPeriod" id="Narr_ChLHHKEdRkKQeKL7tOYaiw"><span style="font-size:10pt;">ten months</span></ix:nonNumeric><span style="font-size:10pt;">. As title transfers to the patient, with whom we have the contract, upon the termination of the lease term and because collectability is probable, under ASC 842, these are recognized as sales-type leases. Each rental agreement contains two components, the controller and related garments, both of which are interdependent and recognized as one lease component. </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:11pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 11pt 0pt;">The revenue and associated cost of revenue of sales-type leases are recognized on the lease commencement date and a net investment in leases is recorded on the Consolidated Balance Sheet. We bill the patients&#8217; insurance payers monthly over the duration of the rental term. We record the net investment in leases and recognize revenue upon commencement of the lease in the amount of the expected consideration to be received through the monthly payments. Similar to our sales revenue, the transaction price is impacted by multiple factors, including the terms and conditions contracted by various third party payers. As the rental contract resides with the patients, we have elected the portfolio approach, at the payer level, to determine the expected consideration, which considers the impact of early terminations. While the contract is with the patient, in certain circumstances, the third party payer elects an initial rental period with an option to extend. We assess the likelihood of extending the lease at the onset of the lease to determine if the option is reasonably certain to be exercised. As the lease is short-term in nature, we anticipate collection of substantially all of the net investment within the first year of the lease agreement. Completion of these payments represents the fair market value of the equipment, and as such, interest income is not applicable. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">113</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_jylpynQK8EGlD685ooiN6w_1_3"></a><a id="Tc_Hy2_BEGTo0OVh_xDOSkaUw_2_0"></a><a id="Tc_HmVfTOw54EyyU_VT5kU_JA_2_3"></a><a id="Tc_x4SZLDV6nUiGidFdI1Wu8g_2_6"></a><a id="Tc_Z0CtWL_l5EqB1VNwcSQBJA_2_9"></a><a id="Tc_iNFihs_sA0a3aJ2MNNt7_A_3_0"></a><a id="Tc_aZDhrqzMsUW4H9tzkctIRw_3_3"></a><a id="Tc_F4rIzrpNfEC1J4m7J2-sDg_3_6"></a><a id="Tc_q1uLnpOxsEu8wqjVNSK3SQ_3_9"></a><a id="Tc_RkvSLm8HTEC4lcYiE3dchQ_4_0"></a><a id="Tc_dMPtMbvMFUy-OVaTHvw1tQ_5_0"></a><a id="Tc_DlTR9aO0qEeTZI1ScW_MAA_5_3"></a><a id="Tc_Zrg7bhcAO0ay8oXdBTyNdg_5_6"></a><a id="Tc_T9BBZmXS2E6EMMzIKrcpeA_5_9"></a><ix:continuation id="Tb_twJ05CDow0yds3g40tQJCw_cont1"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:11pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt 0pt 11pt 0pt;">Rental revenue for the years ended December&#160;31,&#160;2022, 2021 and 2020, was primarily related to private insurers. Sales-type lease revenue and the associated cost of revenue for the years ended December&#160;31,&#160;2022, 2021 and 2020, was:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" name="us-gaap:SalesTypeLeaseLeaseIncomeTableTextBlock" id="Tb_ItQwJzjR1kas9PC6qDxAYQ" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:37.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:37.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:56.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:37.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">(In&#160;thousands)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:37.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Sales-type lease revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SalesTypeLeaseRevenue" scale="3" id="Tc_a7-w_WKc1USt_jHN2LQ-0Q_3_4">35,440</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SalesTypeLeaseRevenue" scale="3" id="Tc_nhbRP0JZZES2yNIkIbQMmg_3_7">30,143</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SalesTypeLeaseRevenue" scale="3" id="Tc_QMtji4nqSUCA4DOzoK9jyw_3_10">25,633</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:37.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Cost of sales-type lease revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsSoldSalesTypeLease" scale="3" id="Tc_MUZc1kSyTk6GZ0eTU8ZnBw_4_4">11,190</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsSoldSalesTypeLease" scale="3" id="Tc_GAyBUQexdkeJXMl5pj_Euw_4_7">9,622</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsSoldSalesTypeLease" scale="3" id="Tc_NmMvZeA6i0GR5T8q9B9v8A_4_10">9,011</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:37.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Gross profit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SalesTypeLeaseSellingProfitLoss" scale="3" id="Tc__D3kYtHDeU-LPVxljXQx6g_5_4">24,250</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SalesTypeLeaseSellingProfitLoss" scale="3" id="Tc_5qb1OfmO10inE86-TVM3pg_5_7">20,521</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SalesTypeLeaseSellingProfitLoss" scale="3" id="Tc_JUTwsCvtGUuI0HK0Kx3Aew_5_10">16,622</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-size:1pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><a id="Tc_YkdJDRipKkqqKo_rKUm4jw_1_2"></a><a id="Tc_6hXl3yQG7Ui3xZ3z5o9RVg_2_0"></a><a id="Tc_sps8nQCquUWz3urWJf8Ewg_2_2"></a><a id="Tc_C9Nd0oGkK0O5V7w6yB-YGg_2_5"></a><a id="Tc_la6txlDhzkaPmWr7HK2ZpA_2_8"></a><a id="Tc_WWNBPjbORU-9OvpNkLb8mg_3_0"></a><a id="Tc_l6WVu6iZ00KSxzcN16dx2Q_3_2"></a><a id="Tc_TJg8bnWJlUGNp5ue-ABc9w_3_5"></a><a id="Tc_xHXc6FBhckCTVskgM9R1yg_3_8"></a><a id="Tc_bbXyGW7E90CJUYGefRZUeQ_4_0"></a><a id="Tc_RsBAiDjI00-a_EF_1dKavg_7_0"></a><a id="Tc_EyYhNS0fEE-XPtHjIcK2Wg_8_0"></a><a id="Tc_nfgRr5GDk0Ka265aX82shQ_8_3"></a><a id="Tc_jTziWzH54U2pgm5OM3j-Ag_11_0"></a><a id="Tc_IUGGEb74UE-UbJMr5OC7lw_11_9"></a><a id="Tc_kL-vCuucfkyzdbUdGoa06A_12_0"></a><a id="Tc_Ap8ysClbEkmu125jdmu1Xg_12_3"></a><a id="Tc_SqZwU4WwuEymOpojuObHjQ_12_6"></a><a id="Tc_COxvEN412kCuPb5xv4ko0w_15_0"></a><a id="Tc_cUQtIxroOUq0g6-4LMvD5g_15_2"></a><a id="Tc_WsiLbHBbVEmH5N5WfoCrwg_15_5"></a><a id="Tc_XmUYrqii-kOSpvh5TDmHmw_15_8"></a><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" name="us-gaap:IncomeTaxDisclosureTextBlock" id="Tb_0phMMrbH00uQiv2IxSbcTA" continuedAt="Tb_0phMMrbH00uQiv2IxSbcTA_cont1" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Note 15. &#160;Income Taxes</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">The provision (benefit) for income tax expense consisted of the following:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="Tb_vRtuGO9D80SEA-e8AX_vPg" continuedAt="Tb_vRtuGO9D80SEA-e8AX_vPg_cont1" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:52.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:52.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:44.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:52.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0.05pt 0pt 0.05pt 0pt;">(In&#160;thousands)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:52.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Current income taxes, Federal</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="3" id="Tc_yUBBycTYj0Wy55m3LbMunA_3_3">1,838</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CurrentFederalTaxExpenseBenefit" sign="-" scale="3" id="Tc_ax7Y7h0ji0y5GDcx-RG9Dg_3_6">1,274</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CurrentFederalTaxExpenseBenefit" sign="-" scale="3" id="Tc_TsOIe8J7M0iUwlUG2S0KfQ_3_9">653</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:52.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Current income taxes, State</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="Tc_zaDQarCzgU69hdy5XHrIqg_4_3">637</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="Tc_KcPTVJ53lUqPwiPqBNNOTg_4_6">214</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="Tc_7-VtqRJFeEqCf5JTKQu0yQ_4_9">294</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:52.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" id="Tc_-jhMG7cWWEqEcrduhmPmvg_5_3">2,475</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CurrentIncomeTaxExpenseBenefit" sign="-" scale="3" id="Tc_X87I-X4re0q0P9Uv19PU4w_5_6">1,060</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CurrentIncomeTaxExpenseBenefit" sign="-" scale="3" id="Tc_eeBcwlE0vk-ZuNz780drmA_5_9">359</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:52.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Deferred income taxes, Federal</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" sign="-" scale="3" id="Tc_5FJ7l8Xss0u_t1tSXAsImQ_7_3">32</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="3" id="Tc_h102KgIQKkyrCCPcM06Uxg_7_6">7,874</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" sign="-" scale="3" id="Tc_-tcoa-sI8E-WFnU6tNR_Xw_7_9">833</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:52.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Deferred income taxes, State</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="3" id="Tc_FibORdBgbUq9bF2Gxr_gKw_8_6">2,356</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" sign="-" scale="3" id="Tc_jk8CCdc74k61GlF5zVpXBw_8_9">395</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:52.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" sign="-" scale="3" id="Tc_2gjUxBhDHkmZxt8lTW8rzw_9_3">32</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" id="Tc_i8eS4xJgDEazl2o4rfOwmw_9_6">10,230</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" sign="-" scale="3" id="Tc_s1tuYXnKFEad8WqsPWUTBQ_9_9">1,228</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:52.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Unrecognized tax benefit, Federal</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_CnxzEZbj2keHiRpKCxnEuw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" sign="-" scale="3" id="Tc_7D6DPk1quUSQRf3zBoOTdg_11_3">50</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_CdFl24OyvE-vHZl3Dyt3tg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" scale="3" id="Tc_psXUjmWTp0a2FCYhlJzQXQ_11_6">348</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:52.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Unrecognized tax benefit, State</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_IoIhyk8NdE6DGInICUHwgg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" sign="-" scale="3" id="Tc_3kbtORAqE0e-Ym1KTB525Q_12_9">54</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:52.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" sign="-" scale="3" id="Tc_fK5jdotflUyiDN1TjdcBkA_13_3">50</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" scale="3" id="Tc_QyEPSh06OkiMyeieXYFjjA_13_6">348</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" sign="-" scale="3" id="Tc_I-IrMAIDRUK_LMm6VjL3qQ_13_9">54</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:52.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;">Total provision (benefit) for income taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="Tc_3qeIJJGHo0m2O7nJ48Xiyg_15_3">2,393</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="Tc_9qSIgOrTAEu5-PcVulHIfw_15_6">9,518</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" sign="-" scale="3" id="Tc_6Lq_t0LqyUmol7EPJevWkQ_15_9">1,641</ix:nonFraction>)</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="font-size:1pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">114</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_6K6SDfrnBUS76dkbR_GFMw_1_2"></a><a id="Tc_KI1Tk9G6Z02_VmP_Bf5CZw_2_0"></a><a id="Tc__PQfvQksJUWX4l1wCiAXkA_2_2"></a><a id="Tc_lBvzR09C0UGRyT1NU4-3EQ_2_5"></a><a id="Tc_l_z567j7-0-EiMzhPE2IEw_3_0"></a><a id="Tc_bUPAbYW70E6rGV6KRF0p7w_4_0"></a><a id="Tc_FJ3ObHy5WEKl7pScjqDzQQ_4_2"></a><a id="Tc_I8JsUCkUjkyZpL1V5EsowA_4_5"></a><a id="Tc_yDz8oyAi6E2Kp3319AFWTw_5_0"></a><a id="Tc_Z878quwDJE2uj82u5p1__A_6_0"></a><a id="Tc_C2F52HqbUkWRZmfbc5KKxw_7_0"></a><a id="Tc_lJ_zeBr--EK_UXJdmOVJ0Q_8_0"></a><a id="Tc_AtjCfNP39k6XJoj15bt2bg_9_0"></a><a id="Tc_p-ocjSAqJ0qYJtkQVTN95A_10_0"></a><a id="Tc_tjyOcnx9B0SKjiLF3zVgKA_11_0"></a><a id="Tc_WRA4MfpEs0iRvCrNu6X63w_12_0"></a><a id="Tc_9TWnnuSRvECsNQZCgZ2KGw_12_6"></a><a id="Tc_SLEf-pwkZkqFQ7a5gGEiJA_13_0"></a><a id="Tc_7YCNgzJp3UODRDzNdw8L6g_14_0"></a><a id="Tc_GyihmUT-vUmKmKdgs_tzWA_16_0"></a><a id="Tc_dBVmNA2B2EKGY9mmudxKrw_17_0"></a><a id="Tc_nPi9WNveTEuwAQODHyVmpA_18_0"></a><a id="Tc_1-aKfEGzK0qJ7rJS-fjHaQ_19_0"></a><a id="Tc_F4eFbHfOV06OHQ3Y1jnszQ_20_0"></a><a id="Tc_gdo8848EUUK6bkfclzMpUg_21_0"></a><a id="Tc_p3OjPK2GyU6MPvtrKTgZLA_23_0"></a><a id="Tc_qhQBf6fatUu9sk7JxyISlQ_25_0"></a><a id="Tc_PWsfDVPAd0Cyf_UKGHJbzg_25_2"></a><a id="Tc_l-0VSsl0vkCwpEE_MmWGtw_25_3"></a><a id="Tc_eomG5N9OvkOpYlpf3AkXvA_25_5"></a><a id="Tc_evdlnniECUyK0hmldc8bgA_1_2"></a><a id="Tc_iW0qI9NDTE-b8HyrUkzfOw_2_2"></a><a id="Tc_LyP-tkMkvUSYGT7kXPQ_ZQ_2_5"></a><a id="Tc_DPmsnfkIE0SUDbYXNoe8sg_2_8"></a><a id="Tc_p92a6lY72kSmGjC6OYrrlQ_3_0"></a><a id="Tc_m_3hS7jXdEqbq2tDAWZ2Sw_3_3"></a><a id="Tc_0e4EwZpUTU28TtIBnq2PCg_3_6"></a><a id="Tc_FSiJvoiTLky6Oi8e8YAuQA_3_9"></a><a id="Tc_GiinwDjXq0GvXTeqFk5Ezw_4_0"></a><a id="Tc_HGXfhfOXCEWQFEM2i9gsMw_5_0"></a><a id="Tc_Dgu4FXF4XUW_3nbzpEiy4w_5_2"></a><a id="Tc_91TuupMXmkuHMi_qEh7Nzg_6_0"></a><a id="Tc_vpNY9zmX90iqsplblt7UNA_6_2"></a><a id="Tc_WfLNUs9O60eOiuU8yBux1Q_6_5"></a><a id="Tc_LhsPfFXWA06xlGG6AWOAxg_7_0"></a><a id="Tc_6TKR_yw5ckKlQRQowlM19Q_7_2"></a><a id="Tc_c2Z8ZZwGLUW1PZ_RZ7Cgcw_7_5"></a><a id="Tc_kCdZHlhjj0GpxmijM5kOXQ_8_0"></a><a id="Tc_7mygObrTsUeQG6-gXJKjGQ_9_0"></a><a id="Tc_t2Ww0iX-8E-Lmp2TWXQ1Nw_9_8"></a><a id="Tc_Q59KTNKdpEeiFdxjiFOlIQ_10_0"></a><a id="Tc_JjdiLDRLJkGlTn575zK_yQ_11_0"></a><a id="Tc_XzmLlyUSbUqUIc6hKQrOAQ_12_0"></a><a id="Tc_X7v1g_dK5ECcm0d-UaIZPQ_12_2"></a><a id="Tc_5_L1mhfC9EiBbMtrEmAY6A_12_8"></a><a id="Tc_04Hr4GYrrkCgPDqPchfH5A_13_0"></a><a id="Tc_WjXu_wcmiUqwcayDcfscLw_13_2"></a><a id="Tc_1YlbBY0ryEKc-dtRUWmG0g_13_5"></a><a id="Tc_k6Vy_1Zk202M-DICj4ItNw_14_0"></a><a id="Tc_vKWOpaOTlUWZZwKAKnKsFA_14_8"></a><a id="Tc_WL8rhtHxp0W106LcPKqAUA_15_0"></a><a id="Tc_z-3sZGVA10K3Fej6_kQT0w_15_2"></a><a id="Tc_IT_J9DM890mS_abw6NQCXA_15_5"></a><a id="Tc_9ZUhgAAJDEqnPptDE7dQ_Q_16_0"></a><a id="Tc_tRZSw6J2DkeNJrhHqr2tFg_17_0"></a><a id="Tc_Hlc6ztRLy0ursWsG3Aspsg_18_0"></a><a id="Tc_KSfZ16aY1ECMxo2opknnSg_18_2"></a><a id="Tc_IEwVv5gmGU-s1pCZNnsFVQ_19_0"></a><a id="Tc_GmftwNSFm0yjqzAL4vmElA_20_0"></a><a id="Tc_rBe4rAXNG0qmLwVY8d627g_20_3"></a><a id="Tc_zPFdKGkLkUSFnhtkxrcK3Q_20_6"></a><a id="Tc_m-bthQkkUEiicPMkoAa4og_20_9"></a><ix:continuation id="Tb_0phMMrbH00uQiv2IxSbcTA_cont1" continuedAt="Tb_0phMMrbH00uQiv2IxSbcTA_cont2"><ix:continuation id="Tb_vRtuGO9D80SEA-e8AX_vPg_cont1"></ix:continuation><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">The components of our deferred tax assets and liabilities were as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="Tb_KGHvySR_LkuRmM_q831dPQ" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:61.32%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:35.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">At December&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0.05pt 0pt 0.05pt 0pt;">(In&#160;thousands)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Deferred tax assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.32%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 12pt;">Operating lease liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw" decimals="-3" format="ixt:numdotdecimal" name="tcmd:DeferredTaxAssetsOperatingLeaseLiability" scale="3" id="Tc_81sF-AEoHUepG9OuR-2yAw_4_3">5,945</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q" decimals="-3" format="ixt:numdotdecimal" name="tcmd:DeferredTaxAssetsOperatingLeaseLiability" scale="3" id="Tc_tha-kHyA6UiTj31EbOaEbA_4_6">6,490</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:61.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 12pt;">Net operating loss carryforwards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" id="Tc_Hzgz7uG9rUGUVMRRytIICw_5_3">179</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" id="Tc_Med7MzgSm06EwnRcjAeiMA_5_6">671</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:61.32%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 12pt;">Accounts receivable and inventory reserves</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" scale="3" id="Tc_w1TpJCIRqUWVCdVTcqUzsw_6_3">6,013</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" scale="3" id="Tc_DBO9DjXV5kSJzAckenBLkw_6_6">4,658</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:61.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 12pt;">Stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="3" id="Tc_ZsEWjbOUM02MD8BpmC1tcQ_7_3">4,886</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="3" id="Tc_gGipb-v_mE6vKheaXP1ptw_7_6">3,777</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:61.32%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 12pt;">Accrued liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" scale="3" id="Tc_wJTrsGq770m0dHKoX8L4aA_8_3">1,914</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" scale="3" id="Tc_AlPV_vHIaUeYyNPpy0Jc8w_8_6">1,104</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:61.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 12pt;">Warranty reserves</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves" scale="3" id="Tc_HUAXHLW8FU2KIhMQ_93DZw_9_3">1,071</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves" scale="3" id="Tc_3aIAgA9gWkCC3jh01kWBBw_9_6">1,245</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:61.32%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 12pt;">Intangible assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" scale="3" id="Tc_BhGWgwThr0mNnzisDwyGtw_10_3">2,947</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" scale="3" id="Tc_jAYlKaaoAU6fUetTbI4jTg_10_6">579</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:61.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 12pt;">Business credits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw" decimals="-3" format="ixt:numdotdecimal" name="tcmd:DeferredTaxAssetsBusinessCredits" scale="3" id="Tc_zLSBgZpogU-hR-ehlasrtg_11_3">536</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q" decimals="-3" format="ixt:numdotdecimal" name="tcmd:DeferredTaxAssetsBusinessCredits" scale="3" id="Tc_0TDOHuGu-0WTULN4DkkMfA_11_6">682</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:61.32%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 12pt;">R&amp;D expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw" decimals="-3" format="ixt:numdotdecimal" name="tcmd:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsResearchAndDevelopmentExpenses" scale="3" id="Tc_lyK-H34_YkewfEAgSr2VvQ_12_3">1,103</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:61.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 12pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOther" scale="3" id="Tc_ZzKJ5PIjJ0CpUxYlE8P5FQ_13_3">183</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOther" scale="3" id="Tc_mwYVviwTZk2FCerkbplfFQ_13_6">199</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:61.32%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Total deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" id="Tc_9BNjw-UgHk-kFidaN7gILg_14_3">24,777</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" id="Tc_EV8QyW7XxU2F2OCnhoEAig_14_6">19,405</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:61.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.32%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Deferred tax liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 12pt;">Right-of-use asset</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw" decimals="-3" format="ixt:numdotdecimal" name="tcmd:DeferredTaxLiabilitiesRightOfUseAssets" scale="3" id="Tc_O83bapA7CUCTLvXmrEjxCA_17_3">5,425</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q" decimals="-3" format="ixt:numdotdecimal" name="tcmd:DeferredTaxLiabilitiesRightOfUseAssets" scale="3" id="Tc_lu5xUIl-W0WYBXJH078T2Q_17_6">6,019</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:61.32%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 12pt;">Fixed assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="3" id="Tc_R8lwB4H8M0mY0ji07dydEw_18_3">1,080</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="3" id="Tc_DSLxYuVoRUGZ3gwAy2RJEQ_18_6">914</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:61.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 12pt;">Prepaid expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilitiesPrepaidExpenses" scale="3" id="Tc_I18nLjVD3UePqF9iNCBjMg_19_3">251</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilitiesPrepaidExpenses" scale="3" id="Tc_rORmyNprz0ijH3lZ8FvImg_19_6">378</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:61.32%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 12pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilitiesOther" scale="3" id="Tc_BcDO9UBjGUespkGwI8wWKA_20_3">186</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilitiesOther" scale="3" id="Tc_GAvMaQN6bEKU3OVZV_FOtw_20_6">87</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:61.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Total deferred tax liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilities" scale="3" id="Tc_qn1t9ET3F0WrIq9cl4MuEw_21_3">6,942</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilities" scale="3" id="Tc_oDjYNwv0nkaZLR2sFsi5Lw_21_6">7,398</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:61.32%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 12pt;">Valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="Tc_IrBV4XeLKE2sIBRx8BckNQ_23_3">17,835</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="Tc_CgiX2c968kqaNmkedH5ZGA_23_6">12,039</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:61.32%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Net deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="3" id="Tc_jwClA5Y3DUa0gQ_2rU-Kzw_25_6">32</ix:nonFraction>)</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;padding-bottom:12pt;background:#ffffff;margin:0pt;"><span style="font-size:1pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">A reconciliation of income tax (benefit) expense to the statutory federal tax rate is as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="Tb_LL0u6zU1BEqG2sFY9HEHJQ" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:53.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:44.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:53.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:53.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Tax expense at statutory rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw" contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Tc_bAnu5wU4X0WOA4rtz5tvrA_3_2">21.0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw" contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Tc_4dGL9vVk30icV7rP6YF0tw_3_5">21.0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw" contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Tc_C77eMJFPGkSrq1K7fah5mA_3_8">21.0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:53.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">State income taxes, net of federal benefit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw" contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="Tc_dBLVVEfWkEWt53v6cBFOhQ_4_2">4.1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw" contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" sign="-" scale="-2" id="Tc_3jIoi4_U6UWUJR-w5DTb1g_4_5">1.1</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw" contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" sign="-" scale="-2" id="Tc_dUc_4pN0GUiDpgR1UlOEvQ_4_8">7.9</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Executive compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw" contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g" decimals="3" format="ixt:numdotdecimal" name="tcmd:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationPercent" sign="-" scale="-2" id="Tc_CCc4JsboKkG1kkODB0wWsw_5_5">14.2</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw" contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA" decimals="3" format="ixt:numdotdecimal" name="tcmd:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationPercent" sign="-" scale="-2" id="Tc_QzeUEyRauU-2GrBOlZfnHA_5_8">5.5</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Meals and entertainment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw" contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment" sign="-" scale="-2" id="Tc_nPyIs37eAkKmP4MEuX1BQg_6_8">10.6</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Incentive stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw" contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA" decimals="3" format="ixt:numdotdecimal" name="tcmd:EffectiveIncomeTaxRateReconciliationIncentiveStockOptions" sign="-" scale="-2" id="Tc_NnXG3wayvked0MW5nL59sQ_7_8">0.4</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Employee Stock Purchase Plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw" contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" decimals="3" format="ixt:numdotdecimal" name="tcmd:EffectiveIncomeTaxRateReconciliationEmployeeStockPurchasePlan" sign="-" scale="-2" id="Tc_XYl9w4ldNUK60R9gNHCKRA_8_2">1.0</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw" contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g" decimals="3" format="ixt:numdotdecimal" name="tcmd:EffectiveIncomeTaxRateReconciliationEmployeeStockPurchasePlan" sign="-" scale="-2" id="Tc_HHchc08Ab0-Z9Nm8ZHG32g_8_5">7.5</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw" contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA" decimals="3" format="ixt:numdotdecimal" name="tcmd:EffectiveIncomeTaxRateReconciliationEmployeeStockPurchasePlan" sign="-" scale="-2" id="Tc_yHChl3x-gEuLabYSeo7y8A_8_8">8.6</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Federal business credits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw" contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" decimals="3" format="ixt:numdotdecimal" name="tcmd:EffectiveIncomeTaxRateReconciliationFederalBusinessCreditPercent" scale="-2" id="Tc_kKjl8iJuE0m6UfSgBi0V5Q_9_2">1.6</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw" contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g" decimals="3" format="ixt:numdotdecimal" name="tcmd:EffectiveIncomeTaxRateReconciliationFederalBusinessCreditPercent" scale="-2" id="Tc_cNm4uOsdkk2kuqjGzLl7bA_9_5">10.9</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw" contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" sign="-" scale="-2" id="Tc_CmbkWufQAES9NO6cpWz7tA_10_2">37.4</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw" contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" sign="-" scale="-2" id="Tc_X3TcweT8ukikFs1h1DddFQ_10_5">525.0</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw" contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="Tc_DJQMKxppn0yz2td3lFy5XQ_10_8">8.0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Return to provision</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw" contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" decimals="3" format="ixt:numdotdecimal" name="tcmd:EffectiveIncomeTaxRateReconciliationReturnToProvision" sign="-" scale="-2" id="Tc_z4b8pMcsEUiRsm7Rr7PYhA_11_2">0.2</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw" contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g" decimals="3" format="ixt:numdotdecimal" name="tcmd:EffectiveIncomeTaxRateReconciliationReturnToProvision" sign="-" scale="-2" id="Tc_0CnzezVRHkK_qnKCOXxaGQ_11_5">6.5</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw" contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA" decimals="3" format="ixt:numdotdecimal" name="tcmd:EffectiveIncomeTaxRateReconciliationReturnToProvision" scale="-2" id="Tc_giK3qx435UWKmAD0kCouvg_11_8">3.6</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Research and development credits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw" contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" scale="-2" id="Tc_K1q34R2StkOLBmX-ZGiM6g_12_5">60.2</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">IRS exam</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw" contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA" decimals="3" format="ixt:numdotdecimal" name="tcmd:EffectiveIncomeTaxRateReconciliationInternalRevenueServiceExam" scale="-2" id="Tc_6oAynu9gIU6XEbbO7fhjIQ_13_8">2.5</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Deferred reprice - state</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw" contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal" scale="-2" id="Tc_y6fTrh1d9EqNDNo1D8bucQ_14_2">0.9</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw" contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal" scale="-2" id="Tc_N9UiTdeM8E23yo98l1zHpg_14_5">3.3</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Federal carryback claim deferred rate differential</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw" contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA" decimals="3" format="ixt:numdotdecimal" name="tcmd:EffectiveIncomeTaxRateReconciliationFederalCarrybackClaimPercent" scale="-2" id="Tc_UKjIdpCPM026wML8TyTQfA_15_8">38.5</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Unrecognized tax benefits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw" contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" decimals="3" format="ixt:numdotdecimal" name="tcmd:EffectiveIncomeTaxRateReconciliationUnrecognizedTaxBenefits" sign="-" scale="-2" id="Tc_jE3Zau4uckuNIiJumeKMFg_16_2">0.3</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw" contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g" decimals="3" format="ixt:numdotdecimal" name="tcmd:EffectiveIncomeTaxRateReconciliationUnrecognizedTaxBenefits" sign="-" scale="-2" id="Tc__V3yoUgQokme8okSVquScA_16_5">2.2</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw" contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA" decimals="3" format="ixt:numdotdecimal" name="tcmd:EffectiveIncomeTaxRateReconciliationUnrecognizedTaxBenefits" scale="-2" id="Tc_Nsg90IBFR0KKYY8pneUivA_16_8">2.3</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Excess benefit on non-qualified stock options and RSUs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw" contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" decimals="3" format="ixt:numdotdecimal" name="tcmd:EffectiveIncomeTaxRateReconciliationExcessTaxBenefitOnNonQualifiedStockOptionsAndRsu" sign="-" scale="-2" id="Tc_36-DuxOooUiAxUfAavAdoA_17_2">3.7</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw" contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g" decimals="3" format="ixt:numdotdecimal" name="tcmd:EffectiveIncomeTaxRateReconciliationExcessTaxBenefitOnNonQualifiedStockOptionsAndRsu" scale="-2" id="Tc_o5iK1510IEOr6aE5Mien1Q_17_5">47.2</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw" contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA" decimals="3" format="ixt:numdotdecimal" name="tcmd:EffectiveIncomeTaxRateReconciliationExcessTaxBenefitOnNonQualifiedStockOptionsAndRsu" scale="-2" id="Tc_gcJF1TrBQUmcexCa6O-rzg_17_8">28.0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Interest and penalties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw" contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g" decimals="3" format="ixt:numdotdecimal" name="tcmd:EffectiveIncomeTaxRateReconciliationInterestAndPenaltyPercent" sign="-" scale="-2" id="Tc_dHPaH3Qg2kSFK-MbbxuPFg_18_5">0.7</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw" contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA" decimals="3" format="ixt:numdotdecimal" name="tcmd:EffectiveIncomeTaxRateReconciliationInterestAndPenaltyPercent" scale="-2" id="Tc_2uNGkIWqKEeFcV7Llg6Mvg_18_8">1.9</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw" contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" sign="-" scale="-2" id="Tc_ylGm5FKCDEi_GQfsjQiR2w_19_2">0.5</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw" contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" sign="-" scale="-2" id="Tc__SpmDR2hIUiK8_xOKS4M0w_19_5">0.5</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw" contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" sign="-" scale="-2" id="Tc_7TnF8kJB2EiOTgZFi-usug_19_8">0.2</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;">Net effective rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw" contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" sign="-" scale="-2" id="Tc_5U44jjgl-0abW4M8A2zihA_20_2">15.5</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw" contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" sign="-" scale="-2" id="Tc_Zp-Mqjxuqkir5SdQWrHHAQ_20_5">415.1</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw" contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="Tc_IqoZQ_fKN0qTgFzxwqWaJw_20_8">72.6</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;">%</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;"><span style="font-size:1pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:continuation></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">115</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_odtOGRSs3UmaDiufvGiAsg_1_2"></a><a id="Tc_Qq3-gPmvi0SIXK1118R_cw_2_0"></a><a id="Tc_H1t_ZTXAB0apjsZYhs6G2A_2_2"></a><a id="Tc_qb_sZf5ni06rEDclBf_k6w_2_5"></a><a id="Tc_eMhZJsYbE0iqjMEi4ESGGA_2_8"></a><a id="Tc_mlrGurT7hUStdtutjSjGEw_3_0"></a><a id="Tc_ibD0T1YZxUKUcA5H9ra7ig_3_2"></a><a id="Tc_PDB0yZYt0EWljFZmmc7BDw_3_5"></a><a id="Tc_n25vnohKBUme0LT5pC05Tg_3_6"></a><a id="Tc_12V6zhZrXUK_Ci-SWBlwOg_3_8"></a><a id="Tc_n7-662YE1kiyEgY8hqTwEA_4_0"></a><a id="Tc_DHQe1F3YqU2wa6UTMW9Dbg_5_0"></a><a id="Tc_MpBZrg8uXEKQXlCfnMbobA_5_2"></a><a id="Tc_hKV47tUqJ0WPz7D7lgvygA_5_5"></a><a id="Tc_l867oa_U1USbBw-8815yFQ_5_8"></a><a id="Tc_vdjW2efFF0m4fnssaHw2qg_5_9"></a><ix:continuation id="Tb_0phMMrbH00uQiv2IxSbcTA_cont2"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">A reconciliation of unrecognized tax benefits (&#8220;UTB&#8221;) is as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" id="Tb_NP5PnNQ8JkqCKUVWkGazgw" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:54.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:54.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:43.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:54.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0.05pt 0pt 0.05pt 0pt;">(In&#160;thousands)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:54.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Balance beginning of the year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="Tc_BqDLtUrQd0K-M7ITJ4D1gw_3_3">522</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2019_3ga0jBjg6EKA4-znaQ36NQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="Tc_-AVPV2zIcU-0hfCqa1TplQ_3_9">54</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:54.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Gross change &#8212; tax positions in prior year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" decimals="-3" format="ixt:numdotdecimal" name="tcmd:UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions" scale="3" id="Tc_qmkM9ibNHEC7_ovHAfpbwQ_4_3">90</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g" decimals="-3" format="ixt:numdotdecimal" name="tcmd:UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions" scale="3" id="Tc_so5YEQgIzEm0jYLU8Jhufg_4_6">522</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA" decimals="-3" format="ixt:numdotdecimal" name="tcmd:UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions" sign="-" scale="3" id="Tc_2VZglRvOCEy7__fX8Y6WCA_4_9">54</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:54.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;">Balance end of the year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="Tc_4PlBU_gHh0WWlO-WbPyheg_5_3">612</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="Tc_Wu4M1jR9j0yrBwr4hk1SuA_5_6">522</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-size:1pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:14pt;padding-top:2pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">Deferred income taxes result from temporary differences between the reporting of amounts for financial statement purposes and income tax purposes. These differences relate primarily to different methods used for income tax purposes including depreciation and amortization, warranty and vacation accruals, and deductions related to allowances for doubtful accounts receivable, and inventory reserves.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:14pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">As of December 31, 2022, the Company had approximately $<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_WDmzwEjdBUiA-CU6PKMNzQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="6" id="Narr_h-0BfbmlWE23Wreme0RJaQ">179</ix:nonFraction> thousand of state net operating loss (&quot;NOL&quot;) carryforwards. The state NOL carryforward amounts expire beginning in tax years 2027 if not utilized.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:14pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">The Company is subject to income tax examinations in the U.S. federal jurisdiction as well as in various state jurisdictions. U.S. federal and state tax years prior to 2019 are closed to examination. In the event of any future tax assessments, we have elected to record the income taxes and any related interest and penalties as income tax expense on our Consolidated Statement of Operations. The Company is not under exam in any jurisdictions.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:14pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">We recognize the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. For tax positions meeting the more likely than not threshold, the amount recognized in the consolidated financial statements is the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement with the relevant tax authority. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:14pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">Management assesses the available positive and negative evidence to estimate whether sufficient future taxable income will be generated to permit use of the existing deferred tax assets. A significant piece of objective negative evidence evaluated was the cumulative loss expected to be incurred over the three-year period ended December 31, 2022. Such objective evidence limits the ability to consider other subjective evidence, such as our projections for future growth. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:14pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">On the basis of this evaluation, as of December 31, 2022, a valuation allowance of $<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="6" id="Narr_LJFbyMEq4EiSy_jHYJYR7A">17.8</ix:nonFraction> million was recorded to recognize only the portion of the deferred tax assets that is more likely than not to be realized. The amount of the deferred tax assets considered realizable, however, could be adjusted if estimates of future taxable income during the carryforward period are reduced or increased or if objective negative evidence in the form of cumulative losses is no longer present and additional weight is given to subjective evidence such as our projections for growth. <span style="background:#ffff00;"> </span></p></ix:continuation><a id="Tc_zkoeHHu1qUu2Ah8-vFbWDA_1_1"></a><a id="Tc_IHRNJlb7KEeXrbwqu9MjiQ_2_1"></a><a id="Tc_kLnChV6axUa3SQ9LPOqLjg_3_0"></a><a id="Tc_V-Zp9e2SJkyS0c8ZOeel9w_3_1"></a><a id="Tc_EuUc0TvOsUWoXim70178EQ_3_4"></a><a id="Tc_rpvVj1jJ7Uyyfrmb23iz1A_3_7"></a><a id="Tc_tXIoLsH0Q02a5UaYwarPZg_4_0"></a><a id="Tc_aRjC5Im8iUmDQ07y2ScEvw_4_1"></a><a id="Tc_qgEgRwIYokqyaJYPA-UjVw_4_4"></a><a id="Tc_1S58VnIHUEy_-Hzgvla65g_4_7"></a><a id="Tc_Q8TLvvjL1EmqAfXzSvSbow_5_0"></a><a id="Tc_iCalYVs8G0ienkXqfDmyZg_6_0"></a><a id="Tc_NdMecxpT4kWPp4piHC3jaw_7_0"></a><a id="Tc_YdXQtoLYYk6G0YZYs7VR3g_7_1"></a><a id="Tc_ZR5pIXonWkScqxLZKO4LPQ_7_4"></a><a id="Tc_NSTXkKoX0UqKnPJxORWoIg_7_7"></a><a id="Tc_hG7dUMO8I0-h0GX4-Eyciw_8_0"></a><a id="Tc_4Wp57WWSckWDGVpryKUH3w_8_1"></a><a id="Tc_IKzWOkekKkCecdFPnLwQ_g_8_4"></a><a id="Tc_hzpUHZ2OUEmqY9Anb9vCFw_8_7"></a><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" name="us-gaap:EarningsPerShareTextBlock" id="Tb_w7C4fztvxUKT4iWfvLLtaQ" continuedAt="Tb_w7C4fztvxUKT4iWfvLLtaQ_cont1" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Note 16. &#160;Net (Loss) Income Per Common Share</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">The following table sets forth the computation of our basic and diluted net loss per share:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="Tb_jPIbHC4TfkieXtZNDiYlpw" continuedAt="Tb_jPIbHC4TfkieXtZNDiYlpw_cont1" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:57.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:57.35%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:42.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.35%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:42.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">(In&#160;thousands,&#160;except&#160;share and per share data)</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:middle;width:57.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="3" id="Tc_e6Ps1FGoa0KcpHIxFrrC7g_4_2">17,866</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="3" id="Tc_Jo3rrYfMZk2RlCSw_2uRTQ_4_5">11,811</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="3" id="Tc_MLzhjLavBkun-ibeiAJNlw_4_8">620</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:57.35%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Weighted-average shares outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ" contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_AGUs1feRo0-g0_czn21yiw_5_2">20,067,969</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ" contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_Hz_DfMNfwkignq9SUCYhoQ_5_5">19,719,485</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ" contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc__8JfVz0tpkeVmn66BO2FZg_5_8">19,346,929</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:57.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Weighted-average shares used to compute diluted net loss per share</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ" contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_uOD2RG6j8kmWAqT1eRt0Xw_6_2">20,067,969</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ" contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_HezStFTjDEmNAuQ_cyK3CQ_6_5">19,719,485</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ" contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_biVB9u7BaEWBMLt9BhTbxg_6_8">19,346,929</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:57.35%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Net loss per share - Basic</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">(<ix:nonFraction unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q" contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_37xKf2qY0kyoVIt7Qhe1fw_7_2">0.89</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">(<ix:nonFraction unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q" contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_PH3JpZ63_0e-YcuufXaiNw_7_5">0.60</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">(<ix:nonFraction unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q" contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_GksFu9oJCkGZCNgWpLE6jQ_7_8">0.03</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:57.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Net loss per share - Diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">(<ix:nonFraction unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q" contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_6JeUMi-lAUGIBm9RtBvajA_8_2">0.89</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">(<ix:nonFraction unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q" contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_h6zGhVMZjEuMmOR6wQuINg_8_5">0.60</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">(<ix:nonFraction unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q" contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_fLTYT8fNLkSe4dxoS09QUQ_8_8">0.03</ix:nonFraction>)</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">116</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_87bWIhzp6kGHa2G74UP34g_1_1"></a><a id="Tc_kjAPKDr3wU-_9_eNBJnwgw_2_1"></a><a id="Tc_tEsW-IBT0U66jA2bhE3gEQ_3_1"></a><a id="Tc_zS9hapN1yk611WL3rdicOQ_3_3"></a><a id="Tc_5xhxxtpCVkuZrxXlxRsC2w_3_5"></a><a id="Tc_3-ralbTed0mmjvfCHx-isA_4_0"></a><a id="Tc_sSXPaz97Ek-YlU8CI6-ktw_5_0"></a><a id="Tc_BHWjypkyD06KE97axrAxzw_6_0"></a><a id="Tc_W9Ipc4gbYU6aQ63gtIjfow_7_0"></a><a id="Tc_g3pOeHe7KEG-GNISAdtg5A_8_0"></a><ix:continuation id="Tb_w7C4fztvxUKT4iWfvLLtaQ_cont1"><ix:continuation id="Tb_jPIbHC4TfkieXtZNDiYlpw_cont1"></ix:continuation><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">The following common stock equivalents were excluded from the computation of diluted net loss per common share for the periods presented because including them would have been anti-dilutive:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="Tb_20p9yOQAp0CEVssUIeWCEw" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:46.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:46.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:53.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:53.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_zrOdl-ZHU0eDIaMQWN19yQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_ViSy-CS_m0aZyUhkuF2nSw_4_1">590,542</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_CIZJzOcjHUyKmot1xYLGwA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_rAGN2IU9C0-ASjH4316vjQ_4_3">265,616</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_t1GQxjJoS0WeSfGLeyxUPw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_WqnUrGU6IkOdQhKeT_i_uQ_4_5">218,686</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Common stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_Qq8im1g0PUaVhc7NKNKkWg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_q1cOF1pD-E2-ffWIDxuNkg_5_1">615,307</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_ghRyW-vZS0uZBW3nKbbR-g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_1bf93K1b80aWumBTIj25hQ_5_3">915,224</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_bg4XNhQ5v0uWr2dXSfREiw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_nKlyDivgCU22S0AzgkKgPQ_5_5">1,039,709</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Performance stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_PerformanceSharesMember_2SwhGbNgwU-bMQqkqXN2dA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_UKNZ1aSe5kSFfhAmFo3uIg_6_1">155,618</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_PerformanceSharesMember_rMVulEGBZE-wAbQ2SAc66Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_O9I7o4vi7kCuXaWQzjZg5w_6_3">54,317</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_PerformanceSharesMember_c5JOwteMr0ax5Sb2--bJyg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_XZbXVBVlpEeSPiX1x-iIew_6_5">96,383</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Employee stock purchase plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_tcmd_EmployeeStockPurchasePlanMember_4b4qjiA0fk6pyDx0k4A_zw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_nLo0qYRr8EKjJ_U3_vQaHQ_7_1">100,506</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_tcmd_EmployeeStockPurchasePlanMember_f1tc7L44FUqMy8SxWvmMoQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_MTc5tl0f30GhpZCz_7illA_7_3">34,809</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_tcmd_EmployeeStockPurchasePlanMember_C8tXw8ygUkKbK1P0V6S3LQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_s_Yq2dDZoEa0VG5bxOZnHA_7_5">53,205</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ" contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_bvhnnGsrg0KaeMC63a6HsA_8_1">1,461,973</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ" contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_MiQ9LaWeakidxr3Uf3fQEg_8_3">1,269,966</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ" contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_BiV6rKXjQE6hxbg9D6Hmuw_8_5">1,407,983</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;background:#ffffff;margin:0pt;"><span style="font-size:1pt;font-weight:bold;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;"><span style="font-size:1pt;font-weight:bold;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><a id="Tc_cWhwJwddpEieorjWhB1hRg_1_0"></a><a id="Tc_5dk9FY9yoE2MWFgtFzgCzA_2_0"></a><a id="Tc_ITGGJYT_Q0y_6wAqR8wcLQ_2_2"></a><a id="Tc_YMFMcUX_zEe6z354w2Y6lw_3_0"></a><a id="Tc_3HXexdN94EialzN5PFiA7g_3_3"></a><a id="Tc_6A6knrunmkS6-tgimvnPoQ_4_0"></a><a id="Tc_PgH9deat_06NSfllarkSbQ_5_0"></a><a id="Tc_DA9IzCjR-0meAQR0vq1XMg_6_0"></a><a id="Tc_UsoViVqmh0--NafZLjBxAA_6_2"></a><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" name="us-gaap:FairValueDisclosuresTextBlock" id="Tb_Xgc1U9Isg0CUyj4vH7ypTg" continuedAt="Tb_Xgc1U9Isg0CUyj4vH7ypTg_cont1" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Note 17. &#160;Fair Value Measurements</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We determine the fair value of our assets and liabilities based on the exchange price that would be received for an asset or paid to transfer a liability (exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value maximize the use of observable inputs and minimize the use of unobservable inputs. We use a fair value hierarchy with three levels of inputs, of which the first two are considered observable and the last unobservable, to measure fair value. The fair value hierarchy gives the highest priority to quoted prices in active markets for identical assets or liabilities (Level 1). The next highest priority is based on quoted prices for similar assets or liabilities in active markets or quoted prices for identical or similar assets or liabilities in non-active markets or other observable inputs (Level 2). The lowest priority is given to unobservable inputs (Level 3). As of December 31, 2021, we no longer had any money market mutual funds. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">We have obligations to pay a $<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2022_srt_RangeAxis_srt_MaximumMember__4L7Euy5PkiEdMffnWdNng" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="Narr_P7Val_kvZk2TjrEAdOl6wQ">5.0</ix:nonFraction> million agreed-upon earn-out payment in cash and up to an additional $<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2022_srt_RangeAxis_srt_MaximumMember__4L7Euy5PkiEdMffnWdNng" decimals="-5" format="ixt:numdotdecimal" name="tcmd:BusinessCombinationAdditionalContingentConsiderationLiability" scale="6" id="Narr_AEXFRPsB8UK9oevzVzX_Xg">10.0</ix:nonFraction> million earn-out payment in cash if certain future U.S. revenues of the AffloVest are met. The earn-out liability was valued by employing a Monte Carlo Simulation model in a risk-neutral framework, which is a Level 3 input. The underlying simulated variable includes recognized revenue. The recognized revenue volatility estimate was based on a study of historical asset volatility for a set of comparable public companies. The model includes other assumptions including the market price of risk, which was calculated as the weighted average cost of capital less the long-term risk-free rate. The earn-out liability is adjusted to fair value at each reporting date until settled. Changes in fair value will be included in intangible asset amortization and earn-out expenses in our Consolidated Statements of Operations.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;text-align:justify;margin:0pt;"><span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="background:#ffffff;">Changes in the earn-out liability measured at fair value using Level 3 inputs were as follows:</span></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="Tb_rcnU2sXCwUWcKOJU80HAsA" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;background:#ffffff;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:69.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0.05pt 0pt 0.05pt 0pt;">(In&#160;thousands)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:26.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:69.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Earn-out liability at December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="3" id="Tc_JXP8fpujakW35_SsABThig_2_3">6,200</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:69.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;">Addition for acquisition</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:69.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;">Payment on earn-out</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" scale="3" id="Tc_HCdM9-jXYEy0pI-zbHlr7A_4_3">5,000</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:69.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;">Fair value adjustments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="3" id="Tc_YUwbd82MCEyWH5RjH9DLMQ_5_3">11,850</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:69.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Earn-out liability at December 31, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="3" id="Tc_-Sd23IlnHkuZls9lgW4dfA_6_3">13,050</ix:nonFraction></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;text-align:justify;margin:0pt;"><span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;background:#ffffff;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">As of December 31, 2022, the fair value of the earn-out liability accrued but not yet earned totaled $<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" scale="6" id="Narr_83JVYOf2ukyHENaDi6S-nw">8.1</ix:nonFraction> million and was classified as a current liability. The remaining $<ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" scale="6" id="Narr_J-bkn6Tqu0ikmETlfTydBA">5.0</ix:nonFraction> million of the earn-out liability had been earned and is to be paid by May 26, 2023.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">117</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_dd60709b_0caa_48c4_bea4_10348d4cc12d"></a><a id="Tc_NoAaCLOA80uvQW4KocZn-A_1_2"></a><a id="Tc_jRVloAC9KUCn86TRvn0L6g_2_2"></a><a id="Tc__UjfQyzHXkGDzStKPdEBRg_3_2"></a><a id="Tc_KWRBM7PoHUGgkhE24LPfEA_3_5"></a><a id="Tc_wWDhJh9q1U2JZzjvrQFY7g_4_2"></a><a id="Tc_TETuWzu7LUiGvESYCW1WkA_4_5"></a><a id="Tc_BX7Kd66AR0mxRq6XCXBIBw_4_8"></a><a id="Tc_UzxyIdtLKEKSgOxzHkIvnQ_5_2"></a><a id="Tc_yN_lcLq78kGkEeR-pHp6VA_5_5"></a><a id="Tc_vvFEwKjj8EGqTlufNMrzLg_5_8"></a><a id="Tc_iegzl0qnCUeOUvXZxbh-_Q_6_2"></a><a id="Tc_Np_KMDJdeUGKPvMYVAlAOA_6_5"></a><a id="Tc_130opEU7vUu0ewryG9JQQg_6_8"></a><a id="Tc_7sHEPi1hIkmYWDenb3V-oQ_7_0"></a><a id="Tc_0lTKqRa6PkC022W-da1_0Q_7_2"></a><a id="Tc_2AcyDLfjLEKZhtO3eaWsEQ_7_5"></a><a id="Tc_3PQqfUCOGEeRb5tEtuZw5g_7_8"></a><a id="Tc_JVRtzDIpeUaBIAEaoNmRug_7_11"></a><a id="Tc_-kWZ4VzWME-IslDwoy6bFQ_8_0"></a><a id="Tc_mhfi-i9IekqbVBXITO3DsA_9_0"></a><a id="Tc_4pvTtxz300O3vsZuXO4XWQ_9_2"></a><a id="Tc_uqO0BeyHq0eDMaBo89W2Ag_9_3"></a><a id="Tc_6W7M2a3wPUyMFXomskcxQw_9_6"></a><a id="Tc_8KMM5ekRMkCMNd8nKKUHcw_9_8"></a><a id="Tc_Kf3qwBwZ5kGhqydRTLImyw_9_11"></a><a id="Tc_eoM-hVzD00WHpw22WIPNZg_10_0"></a><a id="Tc_RSPBx98quU2fS7RuyrsAYw_10_2"></a><a id="Tc_VHSaQDWZc0Kay_0y2EXOPA_10_3"></a><a id="Tc_VfrAw6RuHkq8-ZyBBT2BLg_10_5"></a><a id="Tc_IAPOKjivv0O6MlEfzKmAQA_10_6"></a><a id="Tc_IqYxyQltGkqxD32jqA4VyA_10_8"></a><a id="Tc_NocuILXaQECzI6a0NKa0vA_10_11"></a><a id="_342599c7_52dd_44ae_8f17_174f7d906c25"></a><a id="Tc_ENrRED5zGkqRFE0AqSMDJw_1_2"></a><a id="Tc_RBQ-5o61c0WxKg6HH4xmtg_2_2"></a><a id="Tc_flaHDMWmn0-TXVx-Axv0Qw_3_2"></a><a id="Tc_26OAZfFvQ0y5STmZvYMRXQ_3_5"></a><a id="Tc_F4AyLVo7R0qAAUqmxmgTbw_4_2"></a><a id="Tc_2KPsPIYvSUOvN0VNYL0Zkw_4_5"></a><a id="Tc_jrfdR0CmfE2RyV_Gp13TpA_4_8"></a><a id="Tc_yc9W652230-Mp-b_KT5lyw_5_2"></a><a id="Tc_RNiHAou-f0Gb9cSm-xp3zA_5_5"></a><a id="Tc_Gt_BEjkF406PUMnRXuEZlA_5_8"></a><a id="Tc_i_l7S2_9xEyKUJ_f1HzV5g_6_2"></a><a id="Tc_UKG2yaL900uTCmVM52biQA_6_5"></a><a id="Tc_3p9xKfwSKEy2UqpbR3-BHw_6_8"></a><a id="Tc_1NNerSsoRkmaNe69JN1Cbw_7_0"></a><a id="Tc_uKgOwTXnFUmykZ2ILCuwSQ_7_2"></a><a id="Tc_AHuD8OxNtU278UuylD3gVg_7_5"></a><a id="Tc_VPIS6ZxfFUK1wNm3CeWXow_7_8"></a><a id="Tc__DXMYwlemUSYf_sPZRq1TA_7_11"></a><a id="Tc_iEhp7bQsF0SLmf6jB_ClGQ_8_0"></a><a id="Tc_g8fYJfrqJEeukPeMcN4QYw_9_0"></a><a id="Tc_BUJBz8uO9k6atO1oObK3fA_9_2"></a><a id="Tc_ZFlFJVDLHku7Ix36R4O0Zw_9_3"></a><a id="Tc_LtMIxvJ2s0mT3WPLyWk1_g_9_5"></a><a id="Tc_OjDsixSQ7E6e5rtQLEnAcg_9_6"></a><a id="Tc_48Ad03eS0EShCz5Jw3tZqw_9_8"></a><a id="Tc_rvm82oqhf0i_5u3RNLpgoA_9_11"></a><a id="Tc_3027XbSYQk-6ZKOyU6x0xQ_10_0"></a><a id="Tc_GelHsss27Ei9pQLoKv9d7g_10_2"></a><a id="Tc_xDDEGEjePUSRT4neWRem2A_10_3"></a><a id="Tc_HEo0PLxDo0WP-FUjjZRIUw_10_5"></a><a id="Tc_hAhID9oMmUafdfdb7bVmeQ_10_6"></a><a id="Tc_3ijnCIBzFE6a16d8Cun85g_10_8"></a><a id="Tc_vZbR7XZyh0OrodopsbkumA_10_11"></a><a id="_e2b66487_12a0_4917_9766_f90f9930a0ad"></a><ix:continuation id="Tb_Xgc1U9Isg0CUyj4vH7ypTg_cont1"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following provides information regarding fair value measurements for our remaining contingent earn-out liability as of December&#160;31,&#160;2022, and December 31, 2021, according to the three-level fair value hierarchy:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" id="Tb_WdJRULa-50eaB5WygLwUpQ" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:36.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:61.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">At December 31, 2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:36.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Quoted&#160;Prices</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">in&#160;Active</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Markets&#160;for</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Identical</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Observable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unobservable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">(In&#160;thousands)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;3)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:36.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Recurring Fair Value Measurements:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Earn-out liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_uLFZTWJi2k6g6WI1HfkiNA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="3" id="Tc_gCwrLKlkfk2UCayfHdjgLg_9_9">8,050</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_vevcUAPFYESbYWLi7G0kaQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="3" id="Tc_bnfW-BSXdEq1MpGYsi87gw_9_12">8,050</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:36.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_uLFZTWJi2k6g6WI1HfkiNA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="3" id="Tc_PIRKjEdrJ0e9910YCw9rSA_10_9">8,050</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_vevcUAPFYESbYWLi7G0kaQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="3" id="Tc_mCOnuFVV70qyx4vXmSeGhA_10_12">8,050</ix:nonFraction></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:36.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:61.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">At December 31, 2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:36.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Quoted&#160;Prices</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">in&#160;Active</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Markets&#160;for</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Identical</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Observable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unobservable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">(In&#160;thousands)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;3)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:36.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Recurring Fair Value Measurements:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Earn-out liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_9V6sgB50n0-ZfOQSvVu1Mw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="3" id="Tc_5XVRS0nDqUS_VbtDfy372g_9_9">6,200</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="3" id="Tc_z5AYIuHH-EWtemvF7pJxpw_9_12">6,200</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:36.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_KVbTIgc1_EmIcfBzONO5-g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="3" id="Tc_p-BFIQrD8kqj_i-C4unpwQ_10_9">6,200</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg" contextRef="As_Of_12_31_2021_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_91EX6xEDf0-UcTWUZJ8XyA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="3" id="Tc_6eLQf2V5U0-tvBkfwZzf6g_10_12">6,200</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:1pt;margin:0pt 0pt 12pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;margin:0pt;">The carrying amounts of financial instruments such as cash equivalents, accounts receivable, other assets, accounts payable, accrued expenses and other liabilities approximate their related fair values due to the short-term maturities of these items. Non-financial assets, such as equipment and leasehold improvements, and intangible assets are subject to non-recurring fair value measurements if they are deemed impaired.<span style="color:#ff0000;"> </span></p></ix:continuation><a id="Item9ChangesinandDisagreementsWithAccoun"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Item 9. &#160;Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">None.</p><a id="_9971057a_f069_4eaf_8e2a_7eb4f1167b42"></a><a id="Item4ControlsandProcedures_119285"></a><a id="Item9AControlsandProcedures_324410"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Item 9A. Controls and Procedures.</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Evaluation of Disclosure Controls and Procedures</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of December 31, 2022. The term &#8220;disclosure controls and procedures,&#8221; as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC&#8217;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company&#8217;s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of December 31, 2022, our Chief Executive Officer and Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">118</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Changes in Internal Control over Financial Reporting</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">There was no change in the company&#8217;s internal control over financial reporting, as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act, that occurred during the quarter ended December 31, 2022 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Management Report on Internal Control over Financial Reporting</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">Management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act. Internal control over financial reporting is a process designed by, or under the supervision of, a company&#8217;s principal executive and principal financial officers, or persons performing similar functions, and effected by the company&#8217;s board of directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with U.S. generally accepted accounting principles. It includes those policies and procedures that: </p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:23.05pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 12pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 12pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets of the company; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:23.05pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 12pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 12pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with U.S. generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:23.05pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">Our management conducted an assessment of the effectiveness of our internal control over financial reporting based on the criteria set forth in &#8220;Internal Control-Integrated Framework (2013)&#8221; issued by the Committee of Sponsoring Organizations of the Treadway Commission (&#8220;COSO&#8221;). Based on this assessment, management concluded that, as of December 31, 2022, our internal control over financial reporting was effective. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">Our independent registered public accounting firm has audited the effectiveness of our internal control over financial reporting as of December 31, 2022, as stated in its report which appears below.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">119</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Board of Directors and Shareholders</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">Tactile Systems Technology, Inc.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="color:#4f81bd;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;min-height:14.0pt;margin:0pt;"><b style="color:#000000;font-weight:bold;">Opinion on internal control over financial reporting</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We have audited the internal control over financial reporting of Tactile Systems Technology, Inc. (a Delaware corporation) and subsidiary (the &#8220;Company&#8221;) as of December 31, 2022, based on criteria established in the 2013 <i style="font-style:italic;">Internal Control&#8212;Integrated Framework</i> issued by the Committee of Sponsoring Organizations of the Treadway Commission (&#8220;COSO&#8221;). In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2022, based on criteria established in the 2013 <i style="font-style:italic;">Internal Control&#8212;Integrated Framework</i> issued by COSO.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;), the consolidated financial statements of the Company as of and for the year ended December 31, 2022, and our report dated February 21, 2023 expressed an unqualified opinion on those financial statements.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="color:#4f81bd;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;min-height:14.0pt;margin:0pt;"><b style="color:#000000;font-weight:bold;">Basis for opinion</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The Company&#8217;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Management Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company&#8217;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="color:#4f81bd;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;min-height:14.0pt;margin:0pt;"><b style="color:#000000;font-weight:bold;">Definition and limitations of internal control over financial reporting</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">120</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:14.0pt;margin:0pt 0pt 14.19pt 0pt;">/s/ GRANT THORNTON LLP</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Minneapolis, Minnesota</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">February 21, 2023</p><a id="Item5OtherInformation_507706"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">121</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_cf0dbc7c_8dd5_4abc_9f2b_043978aaa9ef"></a><a id="Item9BOtherInformation_904802"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Item 9B. Other Information.</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"></span>None</p><a id="_873b55e5_aff9_4ef0_b375_b977c8355593"></a><a id="ITEM9CDisclosureregarding"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Item 9C. &#160;Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"></span>Not applicable.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">122</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_2f525096_3ada_43ed_974f_9962fcb56784"></a><a id="PARTIII_933629"></a><a id="PARTIIOTHERINFORMATION_513372"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;background:#ffffff;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">PART&#160;II</b><b style="font-weight:bold;">I</b></p><a id="_d2405058_0462_460e_b03d_6f393d831386"></a><a id="Item10DirectorsExecutiveOfficersandCorpo"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item 10. &#160;Directors, Executive Officers and Corporate Governance</b><b style="font-weight:bold;">.</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Information About our Executive Officers</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Daniel Reuvers</i>, age 59, has served as our President and Chief Executive Officer, and as a member of our Board of Directors, since June 2020. Previously, he was at Integra LifeSciences Holdings Corporation, where he has served as the Executive Vice President and President, Codman Specialty Surgical, since December 2016. His responsibilities there included global sales, marketing, product development, quality and regulatory, and service and repair. He joined Integra in 2008 as Vice President of Marketing &amp; Product Development for the company&#8217;s surgical instrument business, and held a series of roles with progressively increased responsibility. Among his accomplishments there, he led the $1B acquisition and integration of the Codman business from Johnson &amp; Johnson. Previously, he served as President of Advanced Respiratory and Omni-Tract Surgical, both resulting in acquisitions by Hill-Rom and Integra, respectively. Mr. Reuvers served on the board of Respirtech, Inc. for 10 years, until their acquisition by Philips.</p><a id="_APPENDIX_A"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Kristie T. Burns</i>, age 51, has served as our Senior Vice President, Marketing &amp; Clinical Affairs since joining the company in March 2021. Prior to joining our company, Ms. Burns was the Chief Marketing Officer of Cala Health, Inc., a privately-held bioelectronic medicine company developing wearable neuromodulation therapies for chronic disease, from January 2017 until March 2021. At Cala Health, she organized the company&#8217;s commercial functions and managed the U.S. commercial introduction of its lead product. Prior to joining Cala Health, Inc., Ms. Burns served as Vice President of Solutions Marketing, ResMed Americas of ResMed Inc. (NYSE: RMD), a global leader in digital health and cloud-connected medical devices focused on sleep apnea and other chronic diseases, from December 2003 to February 2016. Ms. Burns held various marketing and leadership roles of increasing responsibility with ResMed Inc. beginning in 2003. At ResMed Inc., her responsibilities included managing marketing and legal due diligence teams and leading the collaboration between multiple teams following a significant market reorganization. Ms. Burns previously served in consulting and business development roles of increasing responsibility at a privately-held cardiology consulting practice that was subsequently acquired by GE Medical Systems, from 1994 to 1999.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Brent A. Moen</i>, age 55, has served as our Chief Financial Officer since joining the company in September 2018. Prior to joining our company, Mr.&#160;Moen served as Chief Financial Officer of Entellus Medical,&#160;Inc., a publicly held medical device company, from May&#160;2016 until the company&#8217;s acquisition by Stryker Corporation in February&#160;2018. Prior to joining Entellus Medical, Mr.&#160;Moen served as Executive Vice President and Chief Financial Officer of ABRA Auto Body&#160;&amp; Glass LP, an automotive collision repair company, from November&#160;2013 to May&#160;2015. Mr.&#160;Moen previously served as Senior Vice President and Chief Financial Officer of Regis Corporation, a publicly held owner, franchisor and operator of beauty salons, from January&#160;2011 to December&#160;2012. Mr.&#160;Moen held various financial roles of increasing responsibility with Regis Corporation, beginning in 2000. Mr.&#160;Moen holds a B.A. in Accounting from the University of North Dakota and is a Certified Public Accountant (inactive) and started his professional career with Coopers and Lybrand.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Eric Pauls</i>, age 48, has served as our Senior Vice President, Sales since joining the company in May 2021. Prior to joining our company, Mr. Pauls served in positions of increasing responsibility at Royal Philips (NYSE: PHG; AEX: PHIA), a leading health technology company. He most recently held the position of Business Sales Leader for Sleep and Respiratory Care, North America. In this position, Mr. Pauls was responsible for a sleep and respiratory business, where he led a team of 500 sales and support personnel across multiple sales channels. From July 2017 to September 2019, he served as Business Segment Leader for RespirTech, a U.S.-based provider of an in-home wearable treatment for patients with chronic respiratory conditions, which was acquired by Philips in 2017. Mr. Pauls was Vice President of Sales for Key Accounts from January 2015 to June 2017 and Director of Sales for National Accounts from July 2012 to January 2014, leading targeted sales teams within Philips&#8217; Sleep and Respiratory Care business. He joined Philips Respironics as a Technical Sales Specialist in 2002, and was subsequently promoted to multiple positions within its sales organization over the following decade. Mr. Pauls holds a M.B.A. from Baker University and a B.S. in Respiratory Care from the University of Kansas. </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">123</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Corporate Governance</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our board of directors has adopted a Code of Business Conduct and Ethics that applies to our directors, officers and employees. This code is available on the corporate governance section of our website (which is a subsection of the investor relations section of our website) at the following address: www.tactilemedical.com. We intend to disclose on our website any amendments or waivers to the Code that are required to be disclosed by SEC rules.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Other Information</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">Additional information required by this Item 10 will be contained in our definitive proxy statement for our 2023 Annual Meeting of Stockholders (the &#8220;Definitive Proxy Statement&#8221;) and is incorporated herein by reference.</p><a id="_54f9190d_a223_4483_bef8_34126f3927df"></a><a id="ITEM_11_EXECUTIVE_COMPENSATION"></a><a id="Item11ExecutiveCompensation_884168"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Item 11. Executi</b><b style="font-weight:bold;">ve Compensation.</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">The information required by this Item 11 will be contained in the Definitive Proxy Statement and is incorporated herein by reference.</p><a id="_1bbe2218_0b0e_4899_9d91_4fe4d10a5524"></a><a id="ITEM_12_SECURITY_OWNERSHIP_CERTAIN_BENEF"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Item 12. Security Ownership of Certain Beneficial Own</b><b style="font-weight:bold;">ers and Management and Related Stockholder Matters.</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">The information required by this Item 12 will be contained in the Definitive Proxy Statement and is incorporated herein by reference.</p><a id="_983df012_5cad_492d_b3a7_75670912b550"></a><a id="ITEM_13_CERTAIN_RELATIONSHIPS_RELATED_TR"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Item 13. Certain Relationships and Related</b><b style="font-weight:bold;"> Transactions, and Director Independence.</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">The information required by this Item 13 will be contained in the Definitive Proxy Statement and is incorporated herein by reference.</p><a id="_a7c52f5d_ff14_49e3_a9ce_3e6941e37da9"></a><a id="ITEM_14_PRINCIPAL_ACCOUNTING_FEES_SERVIC"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Item 14. Principal Accou</b><b style="font-weight:bold;">ntant Fees and Services.</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">The information required by this Item 14 will be contained in the Definitive Proxy Statement and is incorporated herein by reference.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">124</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_7be56f9f_de40_45c4_9d90_b312406502f0"></a><a id="PARTIV_90088"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;background:#ffffff;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">PART IV</b></p><a id="_8eb920cd_6f4d_4f7e_a31b_58f0dd93ba18"></a><a id="Item15ExhibitsFinancialStatementSchedule"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item 15. &#160;Exhibits, Financial Statement Schedules.</b></p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23.05pt;"></td><td style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">1.</td><td style="padding:0pt;"><i style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:normal;">Financial Statements</i></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 41.05pt;">The following financial statements of Tactile Systems Technology, Inc. are set forth in Part II, Item 8:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 41.05pt;">Report of Independent Registered Public Accounting Firm</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 41.05pt;">Consolidated Balance Sheets as of December 31, 2022 and 2021</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 41.05pt;">Consolidated Statements of Operations for the years ended December 31, 2022, 2021 and 2020</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 41.05pt;">Consolidated Statements of Comprehensive Loss for the years ended December 31, 2022, 2021 and 2020</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 41.05pt;">Consolidated Statements of Stockholders&#8217; Equity for the years ended December 31, 2022, 2021 and 2020</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 41.05pt;">Consolidated Statements of Cash Flows for the years ended December 31, 2022, 2021 and 2020</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 41.05pt;">Notes to Consolidated Financial Statements</p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23.05pt;"></td><td style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">2.</td><td style="padding:0pt;"><i style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:normal;">Financial Statement Schedules</i></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 41.05pt;">Not applicable.</p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:23.05pt;"></td><td style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">3.</td><td style="padding:0pt;"><i style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:normal;">Exhibits</i></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:41.05pt;margin:0pt;">A list of exhibits required to be filed as part of this report is set forth in the Exhibit Index below.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_022166ac_a13a_48dd_8c13_e28f4f41159a"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:center;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">EXHIBIT&#160;INDEX</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;background:#ffffff;margin:0pt 0pt 12pt 0pt;"><span style="font-size:1pt;visibility:hidden;background:#ffff00;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:normal;width:8.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:6.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:14.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:8.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:9.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:normal;width:32.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Incorporated&#160;by&#160;Reference</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:6.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:14.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Filed</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:8.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Description&#160;of&#160;Exhibit</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:6.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Form</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:14.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Date of Filing</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Herewith</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:6.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:14.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:25.3pt;"><td style="vertical-align:top;white-space:normal;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">2.1</p></td><td style="vertical-align:bottom;white-space:normal;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1027838/000110465921113788/tm2127128d1_ex2-1.htm"><span style="font-style:normal;font-weight:normal;background:#ffffff;">Asset Purchase Agreement, dated as of September 8, 2021, among Tactile Systems Technology, Inc., International Biophysics Corporation and H. David Shockley, Jr.</span></a></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:6.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:14.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">09/08/2021</p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">2.1</p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:normal;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">2.2</p></td><td style="vertical-align:top;white-space:normal;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1027838/000155837022016626/tcmd-20220930xex2d1.htm">Amendment to Asset Purchase Agreement,</a></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1027838/000155837022016626/tcmd-20220930xex2d1.htm">dated as of November 4, 2022, by and</a></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1027838/000155837022016626/tcmd-20220930xex2d1.htm">between Tactile Systems Technology, Inc. and</a></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1027838/000155837022016626/tcmd-20220930xex2d1.htm">Movair, Inc. (f/k/a International Biophysics</a></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1027838/000155837022016626/tcmd-20220930xex2d1.htm">Corporation)</a></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:6.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:14.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">11/07/2022</p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">2.1</p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:normal;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">3.1</p></td><td style="vertical-align:top;white-space:normal;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1027838/000110465919028209/a19-9664_1ex3d2.htm"><span style="font-style:normal;font-weight:normal;">Amended and Restated Certificate of Incorporation, as amended through May 9, 2019</span></a></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:6.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:14.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">05/09/2019</p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">3.2</p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:normal;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:6.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:14.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:normal;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">3.2</p></td><td style="vertical-align:top;white-space:normal;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="tcmd-20221231xex3d2.htm">Amended and Restated Bylaws, effective </a></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="tcmd-20221231xex3d2.htm">D</a><a style="-sec-extract:exhibit;" href="tcmd-20221231xex3d2.htm">ecember 19, 2022</a></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:6.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:14.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td style="vertical-align:top;white-space:normal;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:6.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:14.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:normal;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">4.1</p></td><td style="vertical-align:top;white-space:normal;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1027838/000155837022001758/tcmd-20211231xex4d1.htm"><span style="font-style:normal;font-weight:normal;">Description of the Registrant&#39;s securities registered pursuant to Section 12 of the Securities Exchange Act of 1934</span></a></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:6.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">10-K</p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:14.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">02/23/2022</p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">4.1</p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:normal;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:6.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:14.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:normal;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">4.2</p></td><td style="vertical-align:top;white-space:normal;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1027838/000104746916012971/a2228259zex-4_1.htm"><span style="font-style:normal;font-weight:normal;">Specimen Certificate representing shares of common stock</span></a></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:6.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">S-1</p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:14.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">05/06/2016</p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">4.1</p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:normal;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:6.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:14.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">125</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr><td style="vertical-align:top;white-space:normal;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">4.3</p></td><td style="vertical-align:top;white-space:normal;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1027838/000110465923004598/tm233510d2_ex4-3.htm"><span style="font-style:normal;font-weight:normal;">Form of Senior Indenture</span></a></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:6.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">S-3</p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:14.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">01/18/2023</p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">4.3</p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:normal;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:6.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:14.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:normal;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">4.4</p></td><td style="vertical-align:top;white-space:normal;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1027838/000110465923004598/tm233510d2_ex4-4.htm"><span style="font-style:normal;font-weight:normal;">Form of Subordinated Indenture</span></a></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:6.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">S-3</p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:14.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">01/18/2023</p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">4.4</p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:normal;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:6.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:14.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:normal;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">10.1*</p></td><td style="vertical-align:top;white-space:normal;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1027838/000104746916009839/a2227029zex-10_5.htm"><span style="font-style:normal;font-weight:normal;">2007 Omnibus Stock Plan</span></a></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:6.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">S-1</p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:14.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">01/25/2016</p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">10.5</p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:normal;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:6.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:14.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:normal;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">10.2*</p></td><td style="vertical-align:top;white-space:normal;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1027838/000104746916009839/a2227029zex-10_6.htm"><span style="font-style:normal;font-weight:normal;">Form of Incentive Stock Option Agreement under 2007 Omnibus Stock Plan</span></a></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:6.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">S-1</p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:14.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">01/25/2016</p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">10.6</p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:normal;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:6.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:14.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:normal;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">10.3*</p></td><td style="vertical-align:top;white-space:normal;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1027838/000104746916009839/a2227029zex-10_7.htm"><span style="font-style:normal;font-weight:normal;">Form of Non-Statutory Stock Option Agreement (Employee) under 2007 Omnibus Stock Plan</span></a></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:6.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">S-1</p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:14.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">01/25/2016</p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">10.7</p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:normal;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:6.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:14.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:normal;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">10.4*</p></td><td style="vertical-align:top;white-space:normal;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1027838/000104746916009839/a2227029zex-10_8.htm"><span style="font-style:normal;font-weight:normal;">Form of Non-Statutory Stock Option Agreement (Directors) under 2007 Omnibus Stock Plan</span></a></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:6.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">S-1</p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:14.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">01/25/2016</p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">10.8</p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:normal;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:6.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:14.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:normal;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">10.5*</p></td><td style="vertical-align:top;white-space:normal;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1027838/000104746916009839/a2227029zex-10_9.htm"><span style="font-style:normal;font-weight:normal;">Form of Non-Statutory Stock Option Agreement (Consultants) under 2007 Omnibus Stock Plan</span></a></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:6.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">S-1</p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:14.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">01/25/2016</p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">10.9</p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:normal;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:6.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:14.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:normal;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">10.6*</p></td><td style="vertical-align:top;white-space:normal;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1027838/000104746916009839/a2227029zex-10_10.htm"><span style="font-style:normal;font-weight:normal;">Form of Restricted Stock Agreement</span></a></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:6.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">S-1</p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:14.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">01/25/2016</p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">10.10</p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:normal;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:6.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:14.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:normal;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">10.7*</p></td><td style="vertical-align:top;white-space:normal;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1027838/000104746916013724/a2228882zex-10_11.htm"><span style="font-style:normal;font-weight:normal;">2016 Equity Incentive Plan</span></a></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:6.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">S-1</p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:14.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">06/09/2016</p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">10.11</p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:normal;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:6.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:14.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:normal;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">10.8*</p></td><td style="vertical-align:top;white-space:normal;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1027838/000104746916013724/a2228882zex-10_12.htm"><span style="font-style:normal;font-weight:normal;">Form of Non-Qualified Stock Option Agreement under 2016 Equity Incentive Plan</span></a></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:6.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">S-1</p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:14.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">06/09/2016</p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">10.12</p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:normal;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:6.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:14.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:normal;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">10.9*</p></td><td style="vertical-align:top;white-space:normal;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1027838/000155837020004980/tcmd-20200331xex10d1.htm"><span style="font-style:normal;font-weight:normal;">Form of Non-Qualified Stock Option Agreement under 2016 Equity Incentive Plan (to be used for awards beginning in 2020)</span></a></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:6.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:14.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">05/04/2020</p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:normal;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:6.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:14.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:normal;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">10.10*</p></td><td style="vertical-align:top;white-space:normal;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1027838/000104746916013724/a2228882zex-10_13.htm"><span style="font-style:normal;font-weight:normal;">Form of Incentive Stock Option Agreement under 2016 Equity Incentive Plan</span></a></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:6.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">S-1</p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:14.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">06/09/2016</p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">10.13</p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:normal;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:6.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:14.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:normal;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">10.11*</p></td><td style="vertical-align:top;white-space:normal;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1027838/000155837020004980/tcmd-20200331xex10d2.htm"><span style="font-style:normal;font-weight:normal;">Form of Incentive Stock Option Agreement under 2016 Equity Incentive Plan (to be used for awards beginning in 2020)</span></a></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:6.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:14.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">05/04/2020</p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">10.2</p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:normal;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:6.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:14.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:normal;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">10.12*</p></td><td style="vertical-align:top;white-space:normal;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1027838/000104746916013724/a2228882zex-10_14.htm"><span style="font-style:normal;font-weight:normal;">Form of Restricted Stock Agreement under 2016 Equity Incentive Plan</span></a></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:6.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">S-1</p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:14.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">06/09/2016</p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">10.14</p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:normal;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:6.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:14.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:normal;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">10.13*</p></td><td style="vertical-align:top;white-space:normal;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1027838/000104746916013724/a2228882zex-10_15.htm"><span style="font-style:normal;font-weight:normal;">Form of Restricted Stock Unit Award Agreement under 2016 Equity Incentive Plan</span></a></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:6.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">S-1</p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:14.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">06/09/2016</p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">10.15</p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:normal;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:6.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:14.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:normal;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">10.14*</p></td><td style="vertical-align:top;white-space:normal;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1027838/000155837019004072/tcmd-20190331ex10304e384.htm"><span style="font-style:normal;font-weight:normal;">Form of Restricted Stock Unit Aw</span><span style="font-style:normal;font-weight:normal;">ard</span><span style="font-style:normal;font-weight:normal;"> Agreement under 2016 Equity Incentive Plan (to be used for awards beginning in 2019)</span></a></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:6.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:14.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">05/06/2019</p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">10.3</p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:normal;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:6.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:14.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:normal;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">10.15*</p></td><td style="vertical-align:top;white-space:normal;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1027838/000155837020004980/tcmd-20200331xex10d3.htm"><span style="font-style:normal;font-weight:normal;">Form of Restricted Stock Unit Aw</span><span style="font-style:normal;font-weight:normal;">ard</span><span style="font-style:normal;font-weight:normal;"> Agreement under 2016 Equity Incentive Plan (to be used for awards beginning in 2020)</span></a></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:6.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:14.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">05/04/2020</p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">10.3</p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:normal;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:6.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:14.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:normal;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">10.16*</p></td><td style="vertical-align:top;white-space:normal;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1027838/000104746916013724/a2228882zex-10_16.htm"><span style="font-style:normal;font-weight:normal;">Form of Restricted Stock Unit Agreement under 2016 Equity Incentive Plan (Quarterly Awards)</span></a></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:6.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">S-1</p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:14.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">06/09/2016</p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">10.16</p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:normal;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:6.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:14.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">126</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr><td style="vertical-align:top;white-space:normal;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">10.17*</p></td><td style="vertical-align:top;white-space:normal;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1027838/000110465918012281/a18-6748_1ex10d1.htm"><span style="font-style:normal;font-weight:normal;">Form of Performance Stock Unit Agreement under the 2016 Equity Incentive Plan to be used for awards beginning in 2018</span></a></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:6.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:14.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">02/27/2018</p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:normal;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:6.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:14.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:normal;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">10.18*</p></td><td style="vertical-align:top;white-space:normal;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1027838/000155837019004072/tcmd-20190331ex104f5929f.htm"><span style="font-style:normal;font-weight:normal;">Form of Performance Stock Unit Award Agreement under 2016 Equity Incentive Plan (to be used for awards beginning in 2019)</span></a></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:6.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:14.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">05/06/2019</p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">10.4</p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:normal;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:6.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:14.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:normal;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">10.19*</p></td><td style="vertical-align:top;white-space:normal;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1027838/000155837020004980/tcmd-20200331xex10d4.htm"><span style="font-style:normal;font-weight:normal;">Form of Performance Stock Unit Award Agreement under 2016 Equity Incentive Plan (to be used for awards beginning in 2020)</span></a></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:6.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:14.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">05/04/2020</p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">10.4</p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:normal;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:6.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:14.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:normal;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">10.20*</p></td><td style="vertical-align:top;white-space:normal;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1027838/000104746916013724/a2228882zex-10_17.htm"><span style="font-style:normal;font-weight:normal;">Employee Stock Purchase Plan</span></a></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:6.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">S-1</p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:14.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">06/09/2016</p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">10.17</p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:normal;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:6.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:14.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:normal;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">10.21*</p></td><td style="vertical-align:top;white-space:normal;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1027838/000155837018001091/tcmd-20171231ex101865ae6.htm"><span style="font-style:normal;font-weight:normal;">First Declaration of Amendment to Employee Stock Purchase Plan</span></a></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:6.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">10-K</p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:14.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">02/26/2018</p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">10.18</p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:normal;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:6.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:14.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:normal;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">10.22*</p></td><td style="vertical-align:top;white-space:normal;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1027838/000110465917015826/a17-8127_1ex10d1.htm"><span style="font-style:normal;font-weight:normal;">Management Incentive Plan</span></a></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:6.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:14.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">03/10/2017</p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:normal;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:6.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:14.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:normal;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">10.23*</p></td><td style="vertical-align:top;white-space:normal;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1027838/000155837022001758/tcmd-20211231xex10d23.htm"><span style="font-style:normal;font-weight:normal;">Non-Employee Director Compensation Policy</span></a></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:6.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">10-K</p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:14.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">02/23/2022</p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">10.23</p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:normal;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:6.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:14.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:normal;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">10.24*</p></td><td style="vertical-align:top;white-space:normal;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1027838/000104746916012971/a2228259zex-10_19.htm"><span style="font-style:normal;font-weight:normal;">Form of Director and Officer Indemnification Agreement</span></a></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:6.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">S-1</p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:14.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">05/06/2016</p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">10.19</p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:normal;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:6.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:14.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:normal;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">10.25*</p></td><td style="vertical-align:top;white-space:normal;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1027838/000155837018008484/tcmd-20180930ex10287f7e7.htm"><span style="font-style:normal;font-weight:normal;">Tactile Systems Technology, Inc. Executive Employee Severance Plan</span></a></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:6.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:14.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">11/05/2018</p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">10.2</p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:normal;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:6.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:14.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:normal;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">10.26*</p></td><td style="vertical-align:top;white-space:normal;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1027838/000155837018008484/tcmd-20180930ex1035d3a2b.htm"><span style="font-style:normal;font-weight:normal;">Form of Confidentiality, Assignment of Intellectual Property and Restrictive Covenants Agreement</span></a></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:6.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:14.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">11/05/2018</p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">10.3</p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:normal;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:6.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:14.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:normal;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">10.27*</p></td><td style="vertical-align:top;white-space:normal;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1027838/000110465920065086/tm2020406d1_ex10-1.htm"><span style="font-style:normal;font-weight:normal;">Offer letter between Daniel L. Reuvers and Tactile Systems Technology, Inc. dated May 20, 2020</span></a></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:6.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:14.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">05/22/2020</p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:normal;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:6.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:14.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:normal;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">10.28*</p></td><td style="vertical-align:top;white-space:normal;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1027838/000110465920003227/tm201839d1_ex10-1.htm"><span style="font-style:normal;font-weight:normal;">Transition and Consulting Agreement, dated as of January 10, 2020, by and between Gerald R. Mattys and Tactile Systems Technology, Inc.</span></a></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:6.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:14.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">01/13/2020</p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:normal;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:6.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:14.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:normal;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">10.29*</p></td><td style="vertical-align:top;white-space:normal;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1027838/000155837022001758/tcmd-20211231xex10d29.htm"><span style="font-style:normal;font-weight:normal;">Offer letter between Eric Pauls and Tactile Systems Technology, Inc. dated April 19, 2021</span></a></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:6.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">10-K</p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:14.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">02/23/2022</p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">10.29</p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:normal;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:6.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:14.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:normal;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">10.30*</p></td><td style="vertical-align:top;white-space:normal;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1027838/000155837022001758/tcmd-20211231xex10d30.htm"><span style="font-style:normal;font-weight:normal;">Offer letter between Kristie Burns and Tactile Systems Technology, Inc. dated February 1, 2021</span></a></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:6.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">10-K</p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:14.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">02/23/2022</p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">10.30</p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:normal;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:6.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:14.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:normal;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">10.31</p></td><td style="vertical-align:top;white-space:normal;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1027838/000155837018006459/tcmd-20180630ex10182d3c0.htm"><span style="font-style:normal;font-weight:normal;">Credit Agreement, dated as of August 3, 2018, by and among Tactile Systems Technology, Inc., the lenders from time to time party thereto and Wells Fargo Bank, National Association</span></a></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:6.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:14.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">08/06/2018</p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:normal;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:6.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:14.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:normal;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">10.32</p></td><td style="vertical-align:top;white-space:normal;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1027838/000155837019001320/tcmd-20181231ex1033c32f7.htm"><span style="font-style:normal;font-weight:normal;">First Amendment to Credit Agreement, dated as of February 12, 2019, by and among Tactile Systems Technology, Inc., the lenders party thereto and Wells Fargo Bank, National Association</span></a></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:6.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">10-K</p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:14.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">02/28/2019</p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">10.33</p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">127</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr><td style="vertical-align:top;white-space:normal;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:6.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:14.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:normal;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">10.33</p></td><td style="vertical-align:top;white-space:normal;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1027838/000155837019004072/tcmd-20190331ex102b7e5da.htm"><span style="font-style:normal;font-weight:normal;">Waiver and Second Amendment to Credit Agreement, dated as of March 25, 2019, by and among Tactile Systems Technology, Inc., the lenders party thereto and Wells Fargo Bank, National Association</span></a></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:6.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:14.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">05/06/2019</p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">10.2</p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:normal;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:6.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:14.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:normal;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">10.34</p></td><td style="vertical-align:top;white-space:normal;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1027838/000155837019009809/ex-10d1.htm"><span style="font-style:normal;font-weight:normal;">Third Amendment to Credit Agreement, dated as of August 2, 2019, by and among Tactile Systems Technology, Inc., the lenders party thereto and Wells Fargo Bank, National Association</span></a></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:6.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:14.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">11/04/2019</p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:normal;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:6.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:14.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:normal;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">10.35</p></td><td style="vertical-align:top;white-space:normal;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1027838/000155837021005528/tcmd-20210331xex10d1.htm"><span style="font-style:normal;font-weight:normal;background:#ffffff;">Amended and Restated Credit Agreement, dated as of April 30, 2021, by and among Tactile Systems Technology, Inc., the lenders from time to time party thereto and Wells Fargo Bank, National Association, as Administrative Agent</span></a></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:6.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:14.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">05/03/2021</p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:normal;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:6.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:14.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:normal;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">10.36</p></td><td style="vertical-align:top;white-space:normal;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1027838/000110465921113788/tm2127128d1_ex10-1.htm"><span style="font-style:normal;font-weight:normal;background:#ffffff;">First Amendment Agreement, dated as of September 8, 2021, among Tactile Systems Technology, Inc., the lenders signatory thereto and Wells Fargo Bank, National Association, as administrative agent</span></a></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:6.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:14.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">09/08/2021</p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:normal;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:6.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:14.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:normal;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">10.37</p></td><td style="vertical-align:top;white-space:normal;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1027838/000155837022001758/tcmd-20211231xex10d37.htm"><span style="font-style:normal;font-weight:normal;">Second Amendment Agreement, dated as of February 22, 2022, among Tactile Systems Technology, Inc., the lenders signatory thereto and Wells Fargo Bank, National Association, as administrative agent</span></a></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:6.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">10-K</p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:14.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">02/23/2022</p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">10.37</p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:normal;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:6.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:14.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:normal;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">21.1</p></td><td style="vertical-align:top;white-space:normal;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1027838/000104746916009839/a2227029zex-21_1.htm"><span style="font-style:normal;font-weight:normal;">Subsidiaries</span></a></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:6.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">S-1</p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:14.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">01/25/2016</p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">21.1</p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:normal;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:6.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:14.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:normal;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">23.1</p></td><td style="vertical-align:top;white-space:normal;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="tcmd-20221231xex23d1.htm"><span style="font-style:normal;font-weight:normal;">Consent of Grant Thornton LLP</span></a></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:6.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:14.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td style="vertical-align:top;white-space:normal;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:6.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:14.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:normal;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">24.1</p></td><td style="vertical-align:top;white-space:normal;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a href="#SIGNATURES_745994"><span style="font-style:normal;font-weight:normal;">Power of Attorney (included in signature page)</span></a></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:6.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:14.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td style="vertical-align:top;white-space:normal;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:6.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:14.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:normal;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">31.1</p></td><td style="vertical-align:top;white-space:normal;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="tcmd-20221231xex31d1.htm"><span style="font-style:normal;font-weight:normal;">Certification of Principal Executive Officer pursuant to Rule 13a-14(a) / 15d-14(a) of the Securities Exchange Act of 1934, as amended</span></a></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:6.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:14.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td style="vertical-align:top;white-space:normal;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:6.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:14.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:normal;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">31.2</p></td><td style="vertical-align:top;white-space:normal;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="tcmd-20221231xex31d2.htm"><span style="font-style:normal;font-weight:normal;">Certification of Principal Financial Officer pursuant to Rule 13a-14(a) / 15d-14(a) of the Securities Exchange Act of 1934, as amended</span></a></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:6.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:14.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td style="vertical-align:top;white-space:normal;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:6.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:14.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:normal;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">32.1</p></td><td style="vertical-align:top;white-space:normal;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="tcmd-20221231xex32d1.htm"><span style="font-style:normal;font-weight:normal;">Certification of Principal Executive Officer pursuant to 18 U.S.C. &#167;1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</span></a></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:6.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:14.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td style="vertical-align:top;white-space:normal;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:6.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:14.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:normal;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">32.2</p></td><td style="vertical-align:top;white-space:normal;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="tcmd-20221231xex32d2.htm"><span style="font-style:normal;font-weight:normal;">Certification of Principal Financial Officer pursuant to 18 U.S.C. &#167;1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</span></a></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:6.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:14.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td style="vertical-align:top;white-space:normal;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:6.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:14.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">128</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr><td style="vertical-align:top;white-space:normal;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">101.1</p></td><td style="vertical-align:top;white-space:normal;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The following financial statements from the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2022, formatted in Inline XBRL: (i) Balance Sheets, (ii) Statements of Operations, (iii) Statements of Comprehensive Loss, (iv) Statements of Stockholders&#8217; Equity, (v) Statements of Cash Flows, and (vi) Notes to the Financial Statements</p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:6.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:14.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td style="vertical-align:top;white-space:normal;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:6.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:14.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:normal;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">104.1</p></td><td style="vertical-align:top;white-space:normal;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Cover page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101.1)</p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:6.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:14.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td style="vertical-align:top;white-space:normal;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:6.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:14.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:normal;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">*</p></td><td style="vertical-align:top;white-space:normal;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="9" style="vertical-align:top;width:89.34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Indicates management contract or compensatory plan or arrangement.</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><a id="_ed6d336d_b400_4c0b_8e5a_5b6b6a6fc5f1"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="Item16Form10KSummary_290554"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Item 16. &#160;Form 10-K Summary</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">None.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">129</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_cf42071f_51ee_4387_b7c6_72207cc433c4"></a><a id="SIGNATURES_745994"></a><a id="_56743"></a><a id="Signature"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:center;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">SIGNATURE</b><b style="font-weight:bold;">S</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:48.76%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:48.76%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Tactile Systems Technology, Inc.</b></p></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:48.76%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:48.76%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:48.76%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;background:#ffffff;margin:0pt;">Date: February 21, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.01%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:44.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;">/s/ Daniel L. Reuvers</p></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:48.76%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.01%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:44.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;">Daniel L. Reuvers</p></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:48.76%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.01%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:44.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;">Chief Executive Officer</p></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:48.76%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.01%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:44.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;">(Principal executive officer)</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:11pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="background:#ffffff;">Each of the undersigned hereby appoints Daniel L. Reuvers and Brent A. Moen, and each of them (with full power to act alone), as attorneys and agents for the undersigned, with full power of substitution, for and in the name, place and stead of the undersigned, to sign and file with the Securities and Exchange Commission under the Securities Exchange Act of 1934, as amended, any and all amendments and exhibits to this annual report on Form 10-K and any and all applications, instruments and other documents to be filed with the Securities and Exchange Commission pertaining to this annual report on Form 10-K or any amendments thereto, with full power and authority to do and perform any and all acts and things whatsoever requisite and necessary or desirable. Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities indicated on February 21, 2023.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;white-space:nowrap;width:35.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:61.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:35.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Name</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:61.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Title</b></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:35.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:61.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:35.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">/s/ Daniel L. Reuvers</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:61.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Chief Executive Officer (principal executive officer) and Director</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:35.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Daniel L. Reuvers</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:61.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:35.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:61.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:35.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">/s/ Brent A. Moen</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:61.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Chief Financial Officer (principal financial officer and principal</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:35.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Brent A. Moen</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:61.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">accounting officer)</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:35.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:61.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:35.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">/s/ William W. Burke</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:61.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Chairman of the Board of Directors</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:35.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">William W. Burke</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:61.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:35.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:61.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:35.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">/s/ Valerie L. Asbury</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:61.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Director</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:35.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Valerie L. Asbury</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:61.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:35.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:61.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:35.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">/s/ Sheri L. Dodd</p></td><td style="vertical-align:middle;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:61.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Director</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:35.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Sheri L. Dodd</p></td><td style="vertical-align:middle;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:61.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:35.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:61.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:35.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">/s/ Raymond O. Huggenberger</p></td><td style="vertical-align:middle;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:61.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Director</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:35.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Raymond O. Huggenberger</p></td><td style="vertical-align:middle;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:61.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:35.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:61.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:35.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">/s/ Deepti Jain</p></td><td style="vertical-align:middle;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:61.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Director</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:35.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Deepti Jain</p></td><td style="vertical-align:middle;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:61.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:35.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:61.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:35.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">/s/ D. Brent Shafer</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:61.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Director</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:35.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">D. Brent Shafer</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:61.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:35.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:61.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:35.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">/s/ Carmen B. Volkart</p></td><td style="vertical-align:middle;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:61.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Director</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:35.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Carmen B. Volkart</p></td><td style="vertical-align:middle;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:61.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:35.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:61.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">130</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.2
<SEQUENCE>2
<FILENAME>tcmd-20221231xex3d2.htm
<DESCRIPTION>EX-3.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 2/21/2023 01:38:15 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">TACTILE SYSTEMS TECHNOLOGY, INC.</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">AMENDED AND RESTATED BYLAWS</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Effective: December 19, 2022</b></p><div style="font-family:'Times New Roman Bold';font-size:10pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:center;text-indent:0pt;"><font style="color:#010000;display:inline-block;font-family:'Times New Roman','Times','serif';min-width:36pt;text-transform:uppercase;white-space:nowrap;">Article I</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br></b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">OFFICES</b></div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:72pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">Section 1.1</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">REGISTERED OFFICE</u><font style="white-space:pre-wrap;">.  The Corporation shall maintain a registered office and registered agent within the State of Delaware at such place within such State as may be designated from time to time by the board of directors of the Corporation.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:72pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">Section 1.2</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">OTHER OFFICES</u><font style="white-space:pre-wrap;">.  The Corporation may also have offices in such other places, either within or without the State of Delaware, as the board of directors may from time to time designate or the business of the Corporation may from time to time require.</font></div><div style="font-family:'Times New Roman Bold';font-size:10pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:center;text-indent:0pt;"><font style="color:#010000;display:inline-block;font-family:'Times New Roman','Times','serif';min-width:72pt;text-transform:uppercase;white-space:nowrap;">Article II</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br></b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">STOCKHOLDERS</b></div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:72pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">Section 2.1</font>MEETINGS OF STOCKHOLDERS.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(a)</font><i style="font-style:italic;">ANNUAL MEETINGS.</i><font style="white-space:pre-wrap;">  Annual meetings of the stockholders, at which they shall elect members of the board of directors and transact such other business as may properly come before the meeting, shall be held on such date and at such time as the board of directors may designate.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(b)</font><i style="font-style:italic;">SPECIAL MEETINGS.</i><font style="white-space:pre-wrap;">  Except as otherwise required by law, special meetings of stockholders of the Corporation for any purpose or purposes may be called only by the board of directors, the Chair of the board or the Chief Executive Officer of the Corporation. Special meetings of the stockholders may not be called by any other person or persons.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(c)</font><i style="font-style:italic;">PLACE OF MEETINGS. </i> Meetings of the stockholders shall be held at such place, either within or without the State of Delaware, or solely by means of remote communication, as the board of directors shall determine.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(d)</font><i style="font-style:italic;white-space:pre-wrap;">NOTICE OF MEETING.  </i>Notice, stating the place, if any, day and time of the meeting, and the means of remote communication, if any, shall be delivered by the Corporation not less than ten days nor more than 60 days before the date of the meeting to each stockholder of record entitled to vote at such meeting. Notice of a special meeting shall also state the purpose or purposes for which the meeting has been called. Without limiting the manner by which notice may otherwise be given, notice may be given by a form of electronic transmission that satisfies the requirements of the Delaware General Corporation Law. If mailed, such notice shall be deemed to be delivered when deposited in the United States mail with postage thereon prepaid, addressed to the stockholder at his or her address as it appears in the Corporation&#8217;s records. Meetings may be held without notice if all stockholders entitled to vote are present, or if notice is waived by those not present in accordance with Article VIII of these Bylaws. Any previously scheduled meeting of the stockholders may be postponed, and any special meeting of the stockholders may be cancelled, by resolution of the board of directors upon public notice given prior to the date previously scheduled for such meeting of stockholders. Only such business shall be conducted at a special meeting of stockholders as shall have been brought before the meeting pursuant to the Corporation&#8217;s notice of meeting (or any supplement thereto).</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(e)</font><i style="font-style:italic;">CHAIR OF STOCKHOLDERS MEETING. </i>The Chair of the board, or in the Chair&#8217;s absence, a Vice Chair, or in the absence of any Vice Chair, the Chief Executive Officer, or in the absence of the Chief Executive Officer, the Secretary, or in the absence of the Secretary, a chair chosen by a majority of the directors present, shall act as chair of the meetings of the stockholders.</div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;">1</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(f)</font><i style="font-style:italic;letter-spacing:-0.15pt;">CONDUCT OF MEETINGS</i><font style="letter-spacing:-0.15pt;">. The board of directors shall be entitled to make such rules and regulations for the conduct of meetings of stockholders as it shall deem necessary, appropriate, or convenient. Subject to such rules and regulations of the board of directors, if any, the chair of any meeting of stockholders shall have the right and authority to prescribe such rules, regulations, and procedures and to do all such acts as, in the judgment of such chair, are necessary, appropriate, or convenient for the proper conduct of the meeting, including, without limitation, establishing an agenda or order of business for the meeting, rules and procedures for maintaining order at the meeting and the safety of those present, limitations on participation in the meeting to stockholders of record of the Corporation, their duly authorized and constituted proxies, and such other persons as the chair shall permit, restrictions on entry to the meeting after the time fixed for the commencement thereof, limitations on the time allotted to questions or comments by participants, and regulation of the opening and closing of the polls for balloting and matters which are to be voted on by ballot.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:72pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">Section 2.2</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">QUORUM OF STOCKHOLDERS; ADJOURNMENT; REQUIRED VOTE; PROXIES</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(a)</font><i style="font-style:italic;">QUORUM OF STOCKHOLDERS; ADJOURNMENT. </i>Except as otherwise provided by law, by the Amended and Restated Certificate of Incorporation of the Corporation (the &#8220;<i style="font-style:italic;">Certificate of Incorporation</i>&#8221;) or by these Bylaws, the holders of a majority of the voting power of the shares of stock of the Corporation issued and outstanding and entitled to vote, present in person or represented by proxy, shall constitute a quorum at all meetings of the stockholders, except that when specified business is to be voted on by a class or series of stock voting as a class, the holders of a majority of the shares of such class or series issued and outstanding and entitled to vote shall constitute a quorum of such class or series for the transaction of such business. The chair of the meeting or a majority of the shares so represented may adjourn the meeting from time to time, whether or not there is such a quorum. No notice of the time and place of adjourned meetings need be given, except that notice of the adjourned meeting shall be required if the adjournment is for more than 30 days or if after the adjournment a new record date is fixed for the adjourned meeting. The stockholders present at a duly called meeting at which a quorum is present may continue to transact business until adjournment, notwithstanding the withdrawal of enough stockholders to leave less than a quorum.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(b)</font><i style="font-style:italic;">REQUIRED VOTE. </i> Except as is otherwise required by law, the Certificate of Incorporation or these Bylaws, each holder of record of shares of stock of the Corporation having voting powers shall be entitled, at each meeting of the stockholders, to one vote for every share of such stock standing in his or her name on the record of stockholders of the Corporation and, if a quorum is present and unless otherwise required by the Certificate of Incorporation, the affirmative vote of a majority of the shares of stock represented at the meeting and entitled to vote on the subject matter shall be the act of the stockholders, except with respect to the election of directors. Election of directors at all meetings of the stockholders at which directors are to be elected shall, subject to the rights of the holders of any series of Preferred Stock to elect directors under specified circumstances, be elected by a plurality of the votes cast.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(c)</font><i style="font-style:italic;">PROXIES</i><font style="white-space:pre-wrap;">.  Each stockholder of record entitled to vote at any meeting may do so in person or by proxy authorized by an instrument in writing or in such other manner or form, such as electronic transmission, permitted by the Delaware General Corporation Law, by such stockholder or his or her duly authorized attorney in fact. </font><font style="letter-spacing:-0.15pt;">Any stockholder directly or indirectly soliciting proxies from other stockholders must use a proxy card color other than white, which shall be reserved for the exclusive use by the board of directors.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:72pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">Section 2.3</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">LIST OF STOCKHOLDERS</u>. At least ten days before each meeting of stockholders, the Secretary or agent having charge of the stock transfer book shall make a complete list of the stockholders entitled to vote at such meeting, arranged in alphabetical order, with the address of each and the number of shares held by each. Such list shall be subject to inspection by any stockholder for a period of ten days prior to such meeting, for any purpose related to the meeting, at the principal office of the Corporation at any time during usual business hours or on a reasonably accessible electronic network.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:72pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">Section 2.4</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">NOTICE OF STOCKHOLDER BUSINESS AND NOMINATIONS</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(a)</font><i style="font-style:italic;">ANNUAL MEETINGS OF STOCKHOLDERS.</i></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;">2</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:36pt;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(1)</font>Nominations of persons for election to the board of directors of the Corporation and the proposal of business to be considered by the stockholders may be made at an annual meeting of stockholders (A) pursuant to the Corporation&#8217;s notice of meeting, (B) by or at the direction of the board of directors, or (C) by any stockholder of the Corporation who was a stockholder of record at the time of giving of notice provided for in this Section 2.4, who is entitled to vote at the meeting and who complies with the notice procedures set forth in this Section 2.4.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:36pt;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(2)</font>For nominations or other business to be properly brought before an annual meeting by a stockholder pursuant to clause (C) of paragraph (a)(1) of this Section 2.4, the stockholder must have given timely notice thereof in writing to the Secretary of the Corporation and such other business must otherwise be a proper matter for stockholder action. To be timely, a stockholder&#8217;s notice shall be delivered to the Secretary at the principal executive offices of the Corporation not later than the close of business on the 90th day nor earlier than the close of business on the 120th day prior to the first anniversary of the preceding year&#8217;s annual meeting; <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u>, <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</u>, that in the event that the date of the annual meeting is more than 30 days before or more than 60 days after such anniversary date, notice by the stockholder to be timely must be so delivered not earlier than the close of business on the 120th day prior to the date of such annual meeting and not later than the close of business on the later of the 90th day prior to the date of such annual meeting or the 10th day following the day on which public announcement of the date of such meeting is first made by the Corporation. In no event shall any adjournment or postponement of an annual meeting or the public announcement thereof commence a new time period (or extend any time period) for the giving of a stockholder&#8217;s notice as described above. Such stockholder&#8217;s notice must set forth:</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:72pt;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(A)</font>as to each person whom the stockholder proposes to nominate for election or reelection as a director, (i) all information relating to such person that is required to be disclosed in solicitations of proxies for election of directors in an election contest, or is otherwise required, in each case pursuant to Regulation 14A under the Securities Exchange Act of 1934, as amended (the &#8220;<i style="font-style:italic;">Exchange Act</i>&#8221;) (including such person&#8217;s written consent to being named in any proxy materials as a nominee and to serving as a director if elected), and (ii) information relating to any agreement, arrangement or understanding, including a voting commitment, or any relationship, including financial transactions and compensation, between such person and the stockholder or any Stockholder Associated Person (as defined in Section 2.4(c)(2) below); provided, that the Corporation may also require any proposed nominee to furnish such other information as the Corporation may reasonably require to determine the eligibility of such proposed nominee to serve as a director;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:72pt;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(B)</font>as to any business, other than the nomination of a director or directors, that the stockholder proposes to bring before the meeting, (i) a brief description of the business desired to be brought before the meeting, the reasons for conducting such business at the meeting and any material interest of such stockholder and any Stockholder Associated Person in such business, (ii) a description of all agreements, arrangements and understandings between such stockholder and any Stockholder Associated Person and any other person or persons (including their names) in connection with the proposal of such business by such stockholder, and (iii) if the proposal or business is to be included in the Corporation&#8217;s proxy statement, the text of the proposal or business (including the text of any resolutions proposed for consideration and in the event that such business includes a proposal to amend these Bylaws, the language of the proposed amendment); and</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:72pt;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(C)</font>as to the stockholder giving the notice and any Stockholder Associated Person, (i) the name and address of such stockholder, as they appear on the Corporation&#8217;s stock ledger, and the name and address, if different, of such Stockholder Associated Person, (ii) the class, series and number of all shares of stock of the Corporation which are held of record or are beneficially owned by such stockholder and by such Stockholder Associated Person, (iii) the nominee holder for, and the number of, shares owned beneficially but not of record by such stockholder and by such Stockholder Associated Person, (iv) any derivative position, including without limitation any option, warrant, convertible security, stock appreciation right, or similar </div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;">3</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:72pt;text-indent:0pt;">right with an exercise or conversion privilege or a settlement payment or mechanism at a price related to any class or series of shares of the Corporation or with a value derived in whole or in part from the value of any class or series of shares of the Corporation, directly or indirectly held or beneficially held by such stockholder and such Stockholder Associated Person, and whether and the extent to which any hedging, equity swap or other transaction or series of transactions has been entered into by or on behalf of, or any other agreement, arrangement or understanding (including any short position or interest or any borrowing or lending of shares of stock) has been made by, such stockholder or such Stockholder Associated Person with respect to any shares of stock of the Corporation, or whether such stockholder or Stockholder Associated Person has an economic interest in the Corporation not reported as record or beneficial ownership, (v) any proxy, contract, arrangement, understanding or relationship pursuant to which such stockholder or Stockholder Associated Person has a right to vote any shares of stock of the Corporation, (vi) any rights to dividends on the shares of the Corporation owned beneficially by such stockholder or Stockholder Associated Person that are separated or separable from the underlying shares of the Corporation, (vii) a representation that the stockholder is a holder of record of stock of the Corporation entitled to vote at such meeting and intends to appear in person or through a qualified representative at the meeting to propose such nomination or business, and (viii) as to any business, other than the nomination of a director or directors, a representation whether such stockholder or Stockholder Associated Person intends or is part of a group which intends (x) to deliver a proxy statement and/or form of proxy to holders of at least the percentage of the Corporation&#8217;s outstanding capital stock required to elect the nominee or to approve or adopt the proposal and/or (y) otherwise to solicit proxies from stockholders in support of such nomination or proposal, and the information called for by this paragraph (2)(C) shall be supplemented by such stockholder and Stockholder Associated Person not later than 10 days after the record date for the meeting to disclose such information as of the record date.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:72pt;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(D)</font>A stockholder who intends to solicit proxies in support of director nominees other than the Corporation&#8217;s director nominees and who has delivered a notice of nomination pursuant to this Section 2.4 shall promptly certify to the Corporation, and notify the Corporation in writing, that it has complied with or will comply with the requirements of Rule 14a-19 under the Exchange Act, and upon request of the Corporation, shall, not later than five business days prior to the date of the applicable meeting of stockholders, deliver to the Corporation reasonable evidence of such compliance.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:36pt;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(3)</font>Notwithstanding anything in the second sentence of paragraph (a)(2) of this Section 2.4 to the contrary, in the event that the number of directors to be elected to the board of directors of the Corporation is increased and there is no public announcement by the Corporation naming all of the nominees for director or specifying the size of the increased board of directors at least 100 days prior to the first anniversary of the preceding year&#8217;s annual meeting, a stockholder&#8217;s notice required by this Section 2.4 shall also be considered timely, but only with respect to nominees for any new positions created by such increase, if it shall be delivered to the Secretary at the principal executive offices of the Corporation not later than the close of business on the 10th day following the day on which such public announcement is first made by the Corporation.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(b)</font> <i style="font-style:italic;">SPECIAL MEETINGS OF STOCKHOLDERS</i>. The business to be transacted at any special meeting shall be limited to the purposes stated in the notice of such meetings. Nominations of persons for election to the board of directors may be made at a special meeting of stockholders at which directors are to be elected pursuant to the Corporation&#8217;s notice of meeting (1) by or at the direction of the board of directors or (2) provided that the board of directors has determined that directors shall be elected at such meeting, by any stockholder of the Corporation who is a stockholder of record at the time of giving of notice provided for in this Section 2.4 and is a stockholder of record at the time of the special meeting, who is entitled to vote at the meeting and who complies with the notice procedures set forth in this Section 2.4. In the event the Corporation calls a special meeting of stockholders for the purpose of electing one or more directors to the board of directors, any such stockholder may nominate a person or persons (as the case may be), for election to such position(s) as specified in the Corporation&#8217;s notice of meeting, if the stockholder&#8217;s notice required by paragraph (a)(2) of this Section 2.4 shall be delivered to the Secretary at the principal executive offices of the Corporation not earlier than the close of </div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;">4</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;">business on the 120th day prior to the date of such special meeting and not later than the close of business on the later of the 90th day prior to the date of such special meeting or the 10th day following the day on which public announcement is first made of the date of the special meeting and of the nominees proposed by the board of directors to be elected at such meeting. In no event shall any adjournment or postponement of a special meeting or the public announcement thereof commence a new time period (or extend any time period) for the giving of a stockholder&#8217;s notice as described above.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(c)</font><i style="font-style:italic;">GENERAL.</i></div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:36pt;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(1)</font>Only such persons who are nominated in accordance with the procedures set forth in this Section 2.4 shall be eligible to serve as directors and only such business shall be conducted at a meeting of stockholders as shall have been brought before the meeting in accordance with the procedures set forth in this Section 2.4. Except as otherwise provided by law, the Certificate of Incorporation or these Bylaws, the chair of the meeting shall have the power and duty to determine whether a nomination or any business proposed to be brought before the meeting was made or proposed, as the case may be, in accordance with the procedures set forth in this Section 2.4 and, if any proposed nomination or business is not in compliance with this Section 2.4, to declare that such defective nomination or proposal shall be disregarded. Notwithstanding the foregoing provisions of this Section 2.4, if the stockholder (or a qualified representative of the stockholder) does not appear at the annual or special meeting of stockholders of the Corporation to present a nomination or proposal, such nomination or proposed business shall be disregarded, notwithstanding that proxies in respect of such vote may have been received by the Corporation. Unless otherwise required by law, if any stockholder (i) provides notice pursuant to Rule 14a-19 under the Exchange Act and (ii) subsequently (A) notifies the Corporation that such stockholder no longer intends to solicit proxies in support of director nominees other than the Corporation&#8217;s director nominees in accordance with Rule 14a-19, (B) fails to comply with the requirements of Rule 14a-19, or (C) fails to provide reasonable evidence sufficient to satisfy the Corporation that such requirements have been met, then such stockholder&#8217;s nominations shall be deemed null and void and the Corporation shall disregard any proxies or votes solicited for any nominee proposed by such stockholder.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:36pt;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(2)</font>For purposes of this Bylaw, (A) &#8220;<i style="font-style:italic;">public announcement</i>&#8221; shall mean disclosure in a press release reported by the Dow Jones News Service, Associated Press or other national news service or in a document publicly filed by the Corporation with the Securities and Exchange Commission pursuant to Section 13, 14 or 15(d) of the Exchange Act; and (B) <i style="font-style:italic;">&#8220;Stockholder Associated Person&#8221;</i> of any stockholder shall mean (i) any person or entity controlling, controlled by or under common control with, directly or indirectly, or acting in concert with, such stockholder, (ii) any beneficial owner of shares of stock of the Corporation owned of record or beneficially by such stockholder, and (iii) any person or entity controlling, controlled by or under common control with a Stockholder Associated Person as defined in the foregoing clauses (B)(i) or (B)(ii).</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:36pt;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(3)</font>Notwithstanding the foregoing provisions of this Section 2.4, a stockholder shall also comply with all applicable requirements of the Exchange Act and the rules and regulations thereunder (including Rule 14a-19) with respect to the matters set forth in this Section 2.4. Nothing in this Section 2.4 shall be deemed to affect any rights (A) of stockholders to request inclusion of proposals in the Corporation&#8217;s proxy statement pursuant to Rule 14a-8 under the Exchange Act or (B) of the holders of any series of Preferred Stock to elect directors under specified circumstances.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:72pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">Section 2.5</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">INSPECTORS OF ELECTIONS</u>. The board of directors by resolution shall appoint one or more inspectors, which inspector or inspectors may include individuals who serve the Corporation in other capacities, including, without limitation, as officers, employees, agents or representatives, to act at the meetings of stockholders and make a written report thereof. One or more persons may be designated as alternate inspectors to replace any inspector who fails to act. If no inspector or alternate has been appointed to act or is able to act at a meeting of stockholders, the chair of the meeting shall appoint one or more inspectors to act at the meeting. Each inspector, before discharging his or her duties, shall take and sign an oath faithfully to execute the duties of inspector with strict impartiality and according to the best of his or her ability. The inspectors shall have the duties prescribed by law.</div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;">5</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman Bold';font-size:10pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:center;text-indent:0pt;"><font style="color:#010000;display:inline-block;font-family:'Times New Roman','Times','serif';min-width:72pt;text-transform:uppercase;white-space:nowrap;">Article III</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br></b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">BOARD OF DIRECTORS</b></div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:72pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">Section 3.1</font> <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">GENERAL POWERS</u>. The business and affairs of the Corporation shall be managed under the direction of the board of directors. In addition to the powers and authorities by these Bylaws expressly conferred upon them, the board of directors may exercise all such powers of the Corporation and do all such lawful acts and things as are not by statute or by the Certificate of Incorporation or by these Bylaws required to be exercised or done by the stockholders.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:72pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">Section 3.2</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">NUMBER</u>. Subject to the rights of the holders of any series of Preferred Stock to elect directors under specified circumstances, the number of directors of the Corporation shall be fixed, and may be increased or decreased from time to time, exclusively by the board of directors; <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u>, <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</u>, that no decrease in the number comprising the entire board of directors made pursuant to this Section 3.2 shall shorten the term of any incumbent director. The directors shall hold office until their successors are elected and qualified. At each annual meeting of the stockholders of the Corporation, the directors whose term expires at that meeting shall be elected for a term expiring at the next annual meeting of stockholders.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:72pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">Section 3.3</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">SPECIAL MEETINGS</u><font style="white-space:pre-wrap;">.  Special meetings of the board of directors may be called by the Chair of the board, the Chief Executive Officer or the board of directors. The person or persons authorized to call special meetings of the board of directors may fix the place and time of the meetings. Notice of any special meeting shall be given to each director and shall state the time and place for the special meeting.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:72pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">Section 3.4</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">NOTICE</u><font style="white-space:pre-wrap;">.  If notice of a board of directors&#8217; meeting is required to be given, notice of shall be given to each director at his or her business or residence in writing by hand delivery, first-class or overnight mail or courier service, electronic transmission (including, without limitation, via facsimile transmission or electronic mail), or orally by telephone. If mailed by first-class mail, such notice shall be deemed adequately delivered when deposited in the United States mails so addressed, with postage thereon prepaid, no later than the third business day preceding the date of such meeting. If by overnight mail or courier service, such notice shall be deemed adequately delivered when the notice is delivered to the overnight mail or courier service company at least twenty-four hours before such meeting. If by electronic transmission, such notice shall be deemed adequately delivered when the notice is transmitted at least 12 hours before such meeting. If by telephone or by hand delivery, the notice shall be given at least 12 hours prior to the time set for the meeting. Neither the business to be transacted at, nor the purpose of, any regular or special meeting of the board of directors need be specified in the notice of such meeting, except for amendments to these Bylaws, as provided under Article IX of these Bylaws. A meeting may be held at any time without notice if all the directors are present or if those not present waive notice of the meeting in accordance with Article VIII of these Bylaws.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:72pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">Section 3.5</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">QUORUM</u><font style="white-space:pre-wrap;">.  Subject to Section 3.8 of these Bylaws and except as may be otherwise specifically provided by law or the Certificate of Incorporation, a majority of the board of directors then in office shall constitute a quorum for the transaction of business, but if at any meeting of the board of directors there shall be less than a quorum present, a majority of the directors present may adjourn the meeting from time to time without further notice. The act of the majority of the directors present at a meeting at which a quorum is present shall be the act of the board of directors, except as may be otherwise specifically provided by law or the Certificate of Incorporation. The directors present at a duly organized meeting may continue to transact business until adjournment, notwithstanding the withdrawal of enough directors to leave less than a quorum.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:72pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">Section 3.6</font> <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">USE OF COMMUNICATIONS EQUIPMENT</u><font style="white-space:pre-wrap;">.  Directors may participate in a meeting of the board of directors or any committee thereof by means of conference telephone or other communications equipment by means of which all persons participating in the meeting can hear each other, and such participation in a meeting shall constitute presence in person at the meeting.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:72pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">Section 3.7</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">ACTION BY CONSENT OF THE BOARD OF DIRECTORS</u><font style="white-space:pre-wrap;">.  Any action required or permitted to be taken at any meeting of the board of directors or of any committee thereof may be taken without a meeting if all members of the board or committee, as the case may be, consent thereto in writing or by electronic transmission, and the writing or writings or electronic transmission or transmissions are filed with the minutes of proceedings of the board or committee.</font></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;">6</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:72pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">Section 3.8</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">VACANCIES</u><font style="white-space:pre-wrap;">.  Subject to applicable law and the rights of the holders of any series of Preferred Stock with respect to such series of Preferred Stock, and unless the board of directors otherwise determines, vacancies resulting from death, resignation, retirement, disqualification, removal from office or other cause, and newly created directorships resulting from any increase in the authorized number of directors, may be filled only by the affirmative vote of a majority of the remaining directors, though less than a quorum of the board of directors, or by the sole remaining director, and each director so chosen shall hold office for a term expiring at the annual meeting of stockholders at which the term of the class to which he or she has been elected expires and until such director&#8217;s successor shall have been duly elected and qualified.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:72pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">Section 3.9</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">COMMITTEES</u>.</div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The board of directors may designate one or more committees, each of which shall consist of one or more directors. The board of directors may designate one or more directors as alternate members of any committee, who may replace any absent or disqualified member at any meeting of the committee. In the absence or disqualification of any member of such committee or committees, the member or members thereof present at any meeting and not disqualified from voting, whether or not constituting a quorum, may unanimously appoint another member of the board of directors to act at the meeting in the place of any such absent or disqualified member.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Any committee shall, to the extent provided in a resolution of the board of directors and subject to the limitations contained in the Delaware General Corporation Law, have and may exercise all the powers and authority of the board of directors in the management of the business and affairs of the Corporation. Each committee shall keep such records and report to the board of directors in such manner as the board of directors may from time to time determine. Except as the board of directors may otherwise determine, any committee may make rules for the conduct of its business. Except as provided in the next sentence, and unless otherwise provided in a resolution of the board of directors or in rules adopted by the committee, each committee shall conduct its business as nearly as possible in the same manner as provided in these Bylaws for the board of directors. A majority of the members of a committee shall constitute a quorum, and the act of a majority of the members of a committee present at any meeting at which a quorum is present shall be the act of the committee.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The board of directors shall have power at any time to fill vacancies in, to change the membership of, or to dissolve any such committee. The term of office of the members of each committee shall be as fixed from time to time by the board of directors; provided, however, that any committee member who ceases to be a member of the board of directors shall automatically cease to be a committee member.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Nothing herein shall be deemed to prevent the board of directors from appointing one or more committees consisting in whole or in part of persons who are not directors of the Corporation; provided, however, that no such committee shall have or may exercise any authority of the board of directors.</p><div style="font-family:'Times New Roman Bold';font-size:10pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:center;text-indent:0pt;"><font style="color:#010000;display:inline-block;font-family:'Times New Roman','Times','serif';min-width:72pt;text-transform:uppercase;white-space:nowrap;">Article IV</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br></b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">BOOKS AND RECORDS</b></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-indent:36pt;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">The board of directors shall cause to be kept a record containing the minutes of the proceedings of the meetings of the board and of the stockholders, appropriate stock books and registers and such books of records and accounts as may be necessary for the proper conduct of the business of the Corporation. Unless otherwise required by the laws of Delaware, the books and records of the Corporation may be kept at the principal office of the Corporation, or at any other place or places inside or outside the State of Delaware.</font></p><div style="font-family:'Times New Roman Bold';font-size:10pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:center;text-indent:0pt;"><font style="color:#010000;display:inline-block;font-family:'Times New Roman','Times','serif';min-width:72pt;text-transform:uppercase;white-space:nowrap;">Article V</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br></b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">OFFICERS</b></div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:72pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">Section 5.1</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">OFFICERS; ELECTION OR APPOINTMENT</u><font style="white-space:pre-wrap;">.  The board of directors shall take such action as may be necessary from time to time to ensure that the Corporation has such officers as are necessary, under Section 6.1 of these Bylaws and the Delaware General Corporation Law as currently in effect or as the same may hereafter be amended, to enable it to sign stock certificates. In addition, the board of directors at any time and from time to time may elect (a) one or more Chair of the board and/or one or more Vice Chairs of the board, (b) one or more Chief Executive Officers, one or more Presidents and/or one or more Chief Operating Officers, (c) one or </font></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;">7</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;"><font style="white-space:pre-wrap;">more Vice Presidents, one or more Treasurers and/or one or more Secretaries and/or (d) one or more other officers, in each case if and to the extent the board of directors deems desirable. The board of directors may give any officer such further designations or alternate titles as it considers desirable. In addition, the board of directors at any time and from time to time may authorize the Chair of the board or the Chief Executive Officer of the Corporation to appoint one or more officers of the kind described in clauses (c) and (d) above. Any number of offices may be held by the same person and directors may hold any office unless the Certificate of Incorporation or these Bylaws otherwise provide.</font></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-indent:36pt;margin:0pt 0pt 8pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:72pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section 5.2</font></font><font style="font-family:'Times New Roman','Times','serif';"> </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">TERM OF OFFICE; RESIGNATION; REMOVAL; VACANCIES</u><font style="font-family:'Times New Roman','Times','serif';white-space:pre-wrap;">.  Unless otherwise provided in the resolution of the board of directors electing or authorizing the appointment of any officer, each officer shall hold office until his or her successor is elected or appointed and qualified or until his or her earlier resignation or removal. Any officer may resign at any time upon written notice to the board of directors or to such person or persons as the board of directors may designate. Such resignation shall take effect at the time specified therein or, if not so specified, upon receipt, and unless otherwise specified therein no acceptance of such resignation shall be necessary to make it effective. The board of directors may remove any officer with or without cause at any time. The Chair of the board or the Chief Executive Officer authorized by the board of directors to appoint a person to hold an office of the Corporation may also remove such person from such office with or without cause at any time, unless otherwise provided in the resolution of the board providing such authorization. Any such removal shall be without prejudice to the contractual rights of such officer, if any, with the Corporation, but the election or appointment of an officer shall not of itself create contractual rights. Any vacancy occurring in any office of the Corporation by death, resignation, removal or otherwise may be filled by the board of directors at any regular or special meeting or by the Chair of the board or the Chief Executive Officer authorized by the board of directors to appoint a person to hold such office.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-indent:36pt;margin:0pt 0pt 8pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:72pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section 5.3 </font></font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">POWERS AND DUTIES</u><font style="font-family:'Times New Roman','Times','serif';white-space:pre-wrap;">.  The officers of the Corporation shall have such powers and duties in the management of the Corporation as shall be stated in these Bylaws or in a resolution of the board of directors which is not inconsistent with these Bylaws and, to the extent not so stated, as generally pertain to their respective offices, subject to the control of the board of directors. A Secretary or such other officer appointed to do so by the board of directors shall have the duty to record the proceedings of the meetings of the stockholders, the board of directors and any committees in a book to be kept for that purpose.</font></p><div style="font-family:'Times New Roman Bold';font-size:10pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:center;text-indent:0pt;"><font style="color:#010000;display:inline-block;font-family:'Times New Roman','Times','serif';min-width:72pt;text-transform:uppercase;white-space:nowrap;">Article VI</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration-line:none;"><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br></b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">STOCK</b></div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:72pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">Section 6.1</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">STOCK CERTIFICATES</u><font style="white-space:pre-wrap;">.  The shares of the Corporation may be either in certificated or in uncertificated form. If shares are issued in uncertificated form, each stockholder shall be entitled upon written request to a stock certificate or certificates duly numbered, certifying the number and class of shares in the Corporation owned by him and otherwise as specified in this Section 6.1. Each certificate for shares of stock shall be in such form as may be prescribed by the board of directors and shall be signed in the name of the Corporation by (a) the Chair of the board, the Chief Executive Officer, the President or a Vice President, and (b) by the Secretary or an Assistant Secretary or the Treasurer or an Assistant Treasurer. Any or all of the signatures on a certificate may be a facsimile. In case any officer, transfer agent or registrar who has signed or whose facsimile signature has been placed upon a certificate shall have ceased to be such officer, transfer agent or registrar before such certificate is issued, it may be issued by the Corporation with the same effect as if he or she were such officer, transfer agent or registrar at the date of issue. Each certificate will include any legends required by law or deemed necessary or advisable by the board of directors.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:72pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">Section 6.2</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">LOST, STOLEN OR DESTROYED CERTIFICATES</u><font style="white-space:pre-wrap;">.  The Corporation may issue a new certificate of stock or uncertificated shares in place of any certificate theretofore issued by it, alleged to have been lost, stolen or destroyed, and the Corporation and/or the board of directors may require the owner of such lost, stolen or destroyed certificate, or his or her legal representatives, to make an affidavit of that fact and/or to give the Corporation a bond in such sum as it may direct as indemnity against any claim that may be made against the Corporation on account of the alleged loss, theft or destruction of any such certificate or issuance of any such new certificate or uncertificated shares. Anything herein to the contrary notwithstanding, the board of directors, in its </font></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;">8</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;"><font style="white-space:pre-wrap;">absolute discretion, may refuse to issue any such new certificate or uncertificated shares, except pursuant to legal proceedings under the laws of the State of Delaware.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:72pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">Section 6.3</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">TRANSFERS OF STOCK</u><font style="white-space:pre-wrap;">.  The shares of the stock of the Corporation shall be transferable on the books of the Corporation by the holder thereof in person or by his or her attorney upon surrender for cancellation of a certificate or certificates for at least the same number of shares, or other evidence of ownership if no certificates shall have been issued, with an assignment and power of transfer endorsed thereon or attached thereto, duly executed, and with such proof of the validity and authenticity of the signature as the Corporation or its agents may reasonably require.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:72pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">Section 6.4</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">REGISTERED STOCKHOLDERS</u><font style="white-space:pre-wrap;">.  The Corporation shall be entitled to recognize the exclusive right of a person registered on its books as the owner of shares to receive dividends, and to vote as such owner, and to hold liable for calls and assessments a person registered on its books as the owner of shares, and shall not be bound to recognize any equitable or legal claim or claims to or interest in such shares on the part of any other person, whether or not it shall have express or other notice thereof, except as otherwise provided by the laws of the State of Delaware.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:72pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">Section 6.5</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">REGULATIONS</u><font style="white-space:pre-wrap;">.  Except as otherwise provided by law, the board of directors may make such additional rules and regulations, not inconsistent with the Bylaws, as it may deem expedient concerning the issue, transfer and registration of the securities of the Corporation. The board of directors may appoint, or authorize any officer or officers to appoint, one or more transfer agents and one or more registrars and may require all certificates for shares of capital stock to bear the signature or signatures of any of them.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:72pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">Section 6.6</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">RECORD DATE</u><font style="white-space:pre-wrap;">.  For the purpose of determining stockholders entitled to notice of, or to vote at, any meeting of stockholders or any adjournment thereof, or for the purpose of determining stockholders entitled to receive payment of any dividend or other distribution or allotment of any rights, or entitlements to exercise any rights in respect of any change, conversion or exchange of stock, or for the purpose of any other lawful action, the board of directors may fix, in advance, a record date. Such date shall not be more than 60 nor less than ten days before the date of any such meeting, nor more than 60 days prior to any other action.</font></div><div style="font-family:'Times New Roman Bold';font-size:10pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:center;text-indent:0pt;"><font style="color:#010000;display:inline-block;font-family:'Times New Roman','Times','serif';min-width:72pt;text-transform:uppercase;white-space:nowrap;">Article VII</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration-line:none;"><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br></b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">DEPOSITARIES AND CHECKS</b></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Depositaries of the funds of the Corporation shall be designated by the board of directors; and all checks on such funds shall be signed by such officers or other employees of the Corporation as the board of directors from time to time may designate.</p><div style="font-family:'Times New Roman Bold';font-size:10pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:center;text-indent:0pt;"><font style="color:#010000;display:inline-block;font-family:'Times New Roman','Times','serif';min-width:72pt;text-transform:uppercase;white-space:nowrap;">Article VIII</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration-line:none;"><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br></b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">WAIVER OF NOTICE</b></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Any notice of a meeting required to be given by law, by the Certificate of Incorporation, or by these Bylaws may be waived by the person entitled thereto, either before or after the time of such meeting stated in such notice. Neither the business to be transacted at, nor the purpose of, any annual or special meeting of the stockholders or the board of directors or committee thereof need be specified in any waiver of notice of such meeting. Attendance at any meeting shall constitute waiver of notice except attendance for the express purpose of objecting, at the beginning of the meeting, to the transaction of business because the meeting is not lawfully called or convened.</p><div style="font-family:'Times New Roman Bold';font-size:10pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:center;text-indent:0pt;"><font style="color:#010000;display:inline-block;font-family:'Times New Roman','Times','serif';min-width:72pt;text-transform:uppercase;white-space:nowrap;">Article IX</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration-line:none;"><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br></b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">AMENDMENT</b></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">In furtherance and not in limitation of the powers conferred by law, the board of directors is expressly authorized to adopt, amend and repeal these Bylaws, subject to the power of the holders of capital stock of the Corporation to adopt, amend or repeal the Bylaws; provided, however, that, with respect to the power of holders of the capital stock to adopt, amend and repeal Bylaws of the Corporation, notwithstanding any other provision of these Bylaws or any provision of law which might otherwise permit a lesser vote or no vote, but in addition to any affirmative vote of the holders of any particular class or series of the capital stock of the Corporation required by </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;">9</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">law, these Bylaws or any preferred stock, the affirmative vote of the holders of at least a majority of the voting power of all of the then-outstanding shares entitled to vote generally in the election of directors, voting together as a single class, shall be required to adopt, amend or repeal any provision of these Bylaws.</p><div style="font-family:'Times New Roman Bold';font-size:10pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:center;text-indent:0pt;"><font style="color:#010000;display:inline-block;font-family:'Times New Roman','Times','serif';min-width:72pt;text-transform:uppercase;white-space:nowrap;">Article X</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration-line:none;"><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br></b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">INDEMNIFICATION AND INSURANCE</b></div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:72pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">Section 10.1</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">RIGHT TO INDEMNIFICATION</u><font style="white-space:pre-wrap;">.  Each person who was or is made a party or is threatened to be made a party to or is involved in any action, suit, claim or proceeding, whether civil, criminal, administrative or investigative (hereinafter a &#8220;</font><i style="font-style:italic;">proceeding</i>&#8221;), by reason of the fact that he or she or a person of whom he or she is the legal representative is or was a director or officer of the Corporation or is or was serving at the request of the Corporation as a director, officer, employee or agent of another corporation or of a partnership, joint venture, trust or other enterprise, including service with respect to employee benefit plans maintained or sponsored by the Corporation, whether the basis of such proceeding is alleged action in an official capacity as a director, officer, employee or agent or in any other capacity while serving as a director, officer, employee or agent, shall be indemnified and held harmless by the Corporation to the fullest extent authorized by the Delaware General Corporation Law as the same exists or may hereafter be amended (but, in the case of any such amendment, only to the extent that such amendment permits the Corporation to provide broader indemnification rights than said law permitted the Corporation to provide prior to such amendment), against all expense, liability and loss (including attorneys&#8217; fees, judgments, fines, ERISA excise taxes or penalties and amounts paid or to be paid in settlement) reasonably incurred or suffered by such person in connection therewith and such indemnification shall continue as to a person who has ceased to be a director, officer, employee or agent and shall inure to the benefit of his or her heirs, executors and administrators; provided, however, that except as provided in Section 10.4 of this Article X, the Corporation shall indemnify any such person seeking indemnification in connection with a proceeding (or part thereof) initiated by such person only if such proceeding (or part thereof) was authorized by the board of directors.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:72pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">Section 10.2</font> <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">ADVANCEMENT OF EXPENSES</u><font style="white-space:pre-wrap;">.  The right to indemnification conferred in this Article X shall be a contract right and shall include the right to be paid by the Corporation the expenses incurred in defending any such proceeding in advance of its final disposition, such advances to be paid by the Corporation after receipt by the Corporation of a written statement or statements from the claimant requesting such advance or advances; provided, however, that if the Delaware General Corporation Law requires, the payment of such expenses incurred by a director or officer in his or her capacity as a director or officer (and not in any other capacity in which service was or is rendered by such person while a director or officer, including, without limitation, service to an employee benefit plan) in advance of the final disposition of a proceeding, shall be made only upon delivery to the Corporation of an undertaking by or on behalf of such director or officer, to repay all amounts so advanced if it shall ultimately be determined that such director or officer is not entitled to be indemnified under this Article X or otherwise.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:72pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">Section 10.3</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">OBTAINING INDEMNIFICATION</u><font style="white-space:pre-wrap;">.  To obtain indemnification under this Article X, a claimant shall submit to the Corporation a written request, including therein or therewith such documentation and information as is reasonably available to the claimant and is reasonably necessary to determine whether and to what extent the claimant is entitled to indemnification. Upon written request by a claimant for indemnification pursuant to the first sentence of this Section 10.3, a determination, if required by applicable law, with respect to the claimant&#8217;s entitlement thereto shall be made as follows: (1) if requested by the claimant, by Independent Counsel (as hereinafter defined), or (2) if no request is made by the claimant for a determination by Independent Counsel, (i) by the board of directors by a majority vote of a quorum consisting of Disinterested Directors (as hereinafter defined), or (ii) if a quorum of the board of directors consisting of Disinterested Directors is not obtainable or, even if obtainable, such quorum of Disinterested Directors so directs, by Independent Counsel in a written opinion to the board of directors, a copy of which shall be delivered to the claimant, or (iii) if a quorum of Disinterested Directors so directs, by the stockholders of the Corporation. In the event the determination of entitlement to indemnification is to be made by Independent Counsel at the request of the claimant, the Independent Counsel shall be selected by the board of directors unless there shall have occurred within two years prior to the date of the commencement of the action, suit or proceeding for which indemnification is claimed a Change in Control (as defined below), in which case the Independent Counsel shall be selected by the claimant unless the claimant shall request that such selection be made by the board of directors. If it is so determined that the claimant is entitled to indemnification, payment to the claimant shall be made within 30 days after such determination. If a claimant is successful, in whole or in part, in </font></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;">10</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;"><font style="white-space:pre-wrap;">any suit brought against the Corporation to recover the unpaid amount of any written claim to indemnification, the claimant shall be entitled to be paid also the expense of prosecuting such claim.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:72pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">Section 10.4</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">RIGHT OF CLAIMANT TO BRING SUIT</u><font style="white-space:pre-wrap;">.  If a claim under Section 10.1 of this Article X is not paid in full by the Corporation within thirty days after a written claim pursuant to Section 10.3 of this Article X has been received by the Corporation, the claimant may at any time thereafter bring suit against the Corporation to recover the unpaid amount of the claim and, if successful in whole or in part, the claimant shall be entitled to be paid also the expense of prosecuting such claim. It shall be a defense to any such action (other than an action brought to enforce a claim for expenses incurred in defending any proceeding in advance of its final disposition where the required undertaking, if any is required, has been tendered to the Corporation) that the claimant has not met the standard of conduct which makes it permissible under the Delaware General Corporation Law for the Corporation to indemnify the claimant for the amount claimed, but the burden of proving such defense shall be on the Corporation. Neither the failure of the Corporation (including its board of directors, Independent Counsel or stockholders) to have made a determination prior to the commencement of such action that indemnification of the claimant is proper in the circumstances because he or she has met the applicable standard of conduct set forth in the Delaware General Corporation Law, nor an actual determination by the Corporation (including its board of directors, Independent Counsel or stockholders) that the claimant has not met such applicable standard of conduct, shall be a defense to the action or create a presumption that the claimant has not met the applicable standard of conduct.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:72pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">Section 10.5</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">CORPORATION&#8217;S OBLIGATION TO INDEMNIFY</u><font style="white-space:pre-wrap;">.  If a determination shall have been made pursuant to Section 10.3 of this Article X that the claimant is entitled to indemnification, the Corporation shall be bound by such determination in any judicial proceeding commenced pursuant to Section 10.4 of this Article X.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:72pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">Section 10.6</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">PRECLUSION FROM CHALLENGING ARTICLE X</u><font style="white-space:pre-wrap;">.  The Corporation shall be precluded from asserting in any judicial proceeding commenced pursuant to Section 10.4 of this Article X that the procedures and presumptions of this Article X are not valid, binding and enforceable and shall stipulate in such proceeding that the Corporation is bound by all the provisions of this Article X.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For purposes of this Article X:</p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(a)</font><font style="white-space:pre-wrap;"> &#8220;</font><i style="font-style:italic;">Change in Control</i>&#8221; shall be deemed to occur only if a majority of the members of the board of directors shall not be (i) individuals elected as directors of the Corporation for whose election proxies shall have been solicited by the board of directors of the Corporation or (ii) individuals elected or appointed by the board of directors of the Corporation to fill vacancies on the board of directors caused by death or resignation (but not by removal) or to fill newly created directorships.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(b)</font>&#8220;<i style="font-style:italic;">Disinterested Director</i>&#8221; means a director of the Corporation who is not and was not a party to the matter in respect of which indemnification is sought by the claimant.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(c)</font>&#8220;<i style="font-style:italic;">Independent Counsel</i>&#8221; means a law firm, a member of a law firm, or an independent practitioner, that is experienced in matters of corporation law and shall include any person who, under the applicable standards of professional conduct then prevailing, would not have a conflict of interest in representing either the Corporation or the claimant in an action to determine the claimant&#8217;s rights under this Article X.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:72pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">Section 10.7</font> <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">NON-EXCLUSIVITY OF RIGHTS</u><font style="white-space:pre-wrap;">.  The right to indemnification and the payment of expenses incurred in defending a proceeding in advance of its final disposition conferred in this Article X shall not be exclusive of any other right which any person may have or hereafter acquire under any statute, provision of the Certificate of Incorporation, Bylaws, agreement, vote of stockholders or otherwise. No repeal or modification of this Article X shall in any way diminish or adversely affect the rights of any director, officer, employee or agent of the Corporation hereunder in respect of any occurrence or matter arising prior to any such repeal or modification.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:72pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">Section 10.8</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">INSURANCE</u><font style="white-space:pre-wrap;">.  The Corporation may maintain insurance, at its expense, to protect itself and any director, officer, employee or agent of the Corporation or another Corporation, partnership, joint venture, </font></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;">11</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;"><font style="white-space:pre-wrap;">trust or other enterprise against any expense, liability or loss, whether or not the Corporation would have the power to indemnify such person against such expense, liability or loss under the Delaware General Corporation Law. To the extent that the Corporation maintains any policy or policies providing such insurance, each such director or officer, and each such agent or employee to which rights to indemnification have been granted as provided in Section 10.9 of this Article X, shall be covered by such policy or policies in accordance with its or their terms to the maximum extent of the coverage thereunder for any such director, officer, employee or agent.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:72pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">Section 10.9</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">OTHER EMPLOYEES AND AGENTS</u><font style="white-space:pre-wrap;">.  The Corporation may, to the extent authorized from time to time by the board of directors, grant rights to indemnification, and rights to be paid by the Corporation the expenses incurred in defending any proceeding in advance of its final disposition, to any employee or agent or class of employees or agents of the Corporation (including the heirs, executors, administrators or estate of each such person) to the fullest extent of the provisions of this Article X with respect to the indemnification and advancement of expenses of directors and officers of the Corporation.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:72pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">Section 10.10</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">VALIDITY OF ARTICLE X</u><font style="white-space:pre-wrap;">.  If any provision or provisions of this Article X shall be held to be invalid, illegal or unenforceable for any reason whatsoever: (a) the validity, legality and enforceability of the remaining provisions of this Article X (including, without limitation, each portion of any paragraph of this Article X containing any such provision held to be invalid, illegal or unenforceable, that is not itself held to be invalid, illegal or unenforceable) shall not in any way be affected or impaired thereby; and (b) to the fullest extent possible, the provisions of this Article X (including, without limitation, each such portion of any paragraph of this Article X containing any such provision held to be invalid, illegal or unenforceable) shall be construed so as to give effect to the intent manifested by the provision held invalid, illegal or unenforceable.</font></div><div style="font-family:'Times New Roman Bold';font-size:10pt;font-weight:bold;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:center;text-indent:0pt;"><font style="color:#010000;display:inline-block;font-family:'Times New Roman','Times','serif';min-width:72pt;text-transform:uppercase;white-space:nowrap;">Article XI</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br></b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">MISCELLANEOUS PROVISIONS</b></div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:72pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">Section 11.1</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">FISCAL YEAR</u><font style="white-space:pre-wrap;">.  The fiscal year of the Corporation shall be as fixed by the board of directors.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:72pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">Section 11.2</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">DIVIDENDS</u><font style="white-space:pre-wrap;">.  The board of directors may from time to time declare, and the Corporation may pay, dividends on its outstanding shares in the manner and upon the terms and conditions provided by law and the Certificate of Incorporation.</font></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-indent:36pt;margin:0pt 0pt 8pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:72pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section 11.3</font></font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">EXCLUSIVE FORUM FOR SECURITIES ACT CLAIMS</u><font style="font-family:'Times New Roman','Times','serif';">. Unless the Corporation consents in writing to the selection of an alternative forum, the federal district courts of the United States of America shall, to the fullest extent permitted by law, be the sole and exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act of 1933, as amended.</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;">12</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>tcmd-20221231xex23d1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 2/21/2023 01:38:14 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Exhibit&#160;23.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:18pt 0pt 0pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">We have issued our reports dated February&#160;21, 2023, with respect to the consolidated financial state&#173;ments and internal control over financial reporting included in the Annual Report of Tactile Systems Technology, Inc. on Form 10-</font><font style="font-family:'Arial','Helvetica','sans-serif';white-space:pre-wrap;">K for the year ended December 31, 2022.  We consent to the incorporation by reference of said reports in the Registration Statements of Tactile Systems Technology, Inc.</font><font style="font-family:'Arial','Helvetica','sans-serif';"> </font><font style="font-family:'Arial','Helvetica','sans-serif';">on Forms S-8 (File Nos. 333-212704, 333-216278, 333-223249, 333-236681, and 333-253449) and on Form S-3 (File No. 333-269287).&#160; </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">/s/ Grant Thornton LLP </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Minneapolis, Minnesota</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">February 21, 2023</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>tcmd-20221231xex31d1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 2/21/2023 01:38:14 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:0.07;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.3pt 0pt 0pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Exhibit 31.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.3pt 0pt 0pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-weight:bold;text-align:center;margin:3.75pt 0pt 0pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;">CERTIFICATION</b><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;letter-spacing:2.3pt;"> </b><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;">PURSUANT TO</b><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;letter-spacing:0.95pt;"> </b><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;">RULE</b><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;letter-spacing:1.8pt;"> </b><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;">13a-14(a)/15d-14(a) OF</b><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;letter-spacing:0.9pt;"> </b><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;">THE</b><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;letter-spacing:1.25pt;"> </b><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;">SECURITIES</b><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;letter-spacing:2.25pt;"> </b><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;">EXCHANGE</b><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;letter-spacing:1.8pt;"> </b><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;">ACT OF</b><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;letter-spacing:0.75pt;">&#160;</b><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;">1934,</b><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;letter-spacing:0.2pt;"> </b><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;">AS</b><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;letter-spacing:1.1pt;"> </b><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;">ADOPTED</b><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;letter-spacing:1.6pt;"> </b><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;">PURSUANT</b><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;letter-spacing:1.65pt;"> </b><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;">TO</b><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;letter-spacing:0.85pt;"> </b><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;">SECTION</b><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;letter-spacing:0.75pt;"> </b><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;">302</b><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;letter-spacing:1.15pt;"> </b><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;">OF</b><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;letter-spacing:0.55pt;"> </b><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;">THE</b><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;letter-spacing:0.9pt;"> </b><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;">SARBANES-OXLEY ACT</b><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;letter-spacing:1.3pt;">&#160;</b><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;">OF</b><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;letter-spacing:0.8pt;"> </b><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;">2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;">I,</font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;letter-spacing:-0.35pt;"> </font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;">Daniel L. Reuvers,</font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;letter-spacing:0.3pt;"> certify </font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;">that:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">1.</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">I have reviewed this Annual Report on Form 10-K of Tactile Systems Technology, Inc.;</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">2.</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">3.</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">4.</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">The registrant&#39;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">a.</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><font style="font-family:'Arial','Helvetica','sans-serif';margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">b.</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><font style="font-family:'Arial','Helvetica','sans-serif';margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">c.</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Evaluated the effectiveness of the registrant&#39;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">d.</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Disclosed in this report any change in the registrant&#39;s internal control over financial reporting that occurred during the registrant&#39;s most recent fiscal quarter (the registrant&#39;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#39;s internal control over financial reporting; and</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">5.</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">The registrant&#39;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#39;s auditors and the audit committee of the registrant&#39;s board of directors (or persons performing the equivalent functions):</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">a.</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#39;s ability to record, process, summarize and report financial information; and</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><font style="font-family:'Arial','Helvetica','sans-serif';margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">b.</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#39;s internal control over financial reporting.</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">/s/</i><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;letter-spacing:1.25pt;"> </i><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">Daniel L. Reuvers </i></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-weight:bold;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:normal;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-weight:bold;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;">Daniel L. Reuvers</b></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.1pt 0pt 0pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.1pt 0pt 0pt 0pt;"><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">Chief</i><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;letter-spacing:0.05pt;"> </i><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">Executive Officer</i></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Date: </font><font style="font-family:'Arial','Helvetica','sans-serif';">February 21, 2023</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:0.07;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:10.29%;margin-right:10.29%;margin-top:30pt;page-break-after:avoid;width:79.41%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>tcmd-20221231xex31d2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 2/21/2023 01:38:15 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:0.07;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.3pt 0pt 0pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Exhibit 31.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.34pt 0pt 0pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0.34pt 0pt 0pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">CERTIFICATION</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;letter-spacing:2.15pt;"> </b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">PURSUANT</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;letter-spacing:0.1pt;"> </b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">TO</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;letter-spacing:0.75pt;"> </b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">RULE</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;letter-spacing:2pt;"> </b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">13a-14(a)/15d-14(a)</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;letter-spacing:0.15pt;"> </b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">OF</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;letter-spacing:0.95pt;"> </b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">THE</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;letter-spacing:1.5pt;"> </b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">SECURITIES</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;letter-spacing:2.15pt;"> </b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">EXCHANGE</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;letter-spacing:2.3pt;"> </b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">ACT</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"> </b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">OF</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;letter-spacing:1.3pt;"> </b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">1934,</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;letter-spacing:0.35pt;"> </b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">AS</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;letter-spacing:0.85pt;"> </b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">ADOPTED</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;letter-spacing:2pt;"> </b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">PURSUANT</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;letter-spacing:2pt;"> </b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">TO</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;letter-spacing:0.95pt;"> </b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">SECTION</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;letter-spacing:0.85pt;"> </b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">302</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;letter-spacing:1.4pt;"> </b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">OF</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;letter-spacing:0.75pt;"> </b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">THE</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;letter-spacing:0.9pt;"> </b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">SARBANES-OXLEY</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;letter-spacing:0.4pt;"> </b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">ACT</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;letter-spacing:1.45pt;"> </b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">OF</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;letter-spacing:1pt;"> </b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.3pt 0pt 0pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;">I,</font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;letter-spacing:0.6pt;"> </font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;">Brent A. Moen,</font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;letter-spacing:1.25pt;"> </font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;">certify</font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;letter-spacing:0.45pt;"> </font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;">that:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">1.</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">I have reviewed this Annual Report on Form 10-K of Tactile Systems Technology, Inc.;</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">2.</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">3.</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">4.</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">The registrant&#39;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">a.</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><font style="font-family:'Arial','Helvetica','sans-serif';margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">b.</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><font style="font-family:'Arial','Helvetica','sans-serif';margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">c.</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Evaluated the effectiveness of the registrant&#39;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">d.</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Disclosed in this report any change in the registrant&#39;s internal control over financial reporting that occurred during the registrant&#39;s most recent fiscal quarter (the registrant&#39;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#39;s internal control over financial reporting; and</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">5.</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">The registrant&#39;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#39;s auditors and the audit committee of the registrant&#39;s board of directors (or persons performing the equivalent functions):</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">a.</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#39;s ability to record, process, summarize and report financial information; and</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><font style="font-family:'Arial','Helvetica','sans-serif';margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">b.</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#39;s internal control over financial reporting.</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">/s/ Brent A. Moen</i></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-weight:bold;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:normal;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-weight:bold;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;">Brent A. Moen</b></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.1pt 0pt 0pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.1pt 0pt 0pt 0pt;"><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">Chief Financial Officer</i></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Date: </font><font style="font-family:'Arial','Helvetica','sans-serif';">February 21, 2023</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:0.07;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:10.29%;margin-right:10.29%;margin-top:30pt;page-break-after:avoid;width:79.41%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>tcmd-20221231xex32d1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 2/21/2023 01:38:32 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:0.07;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Exhibit 32.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-weight:bold;">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-weight:bold;">AS ADOPTED PURSUANT TO</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-weight:bold;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">In connection with the Annual Report on Form 10-K of Tactile Systems Technology, Inc. (the &#8220;Company&#8221;) for the period ended December 31, 2022, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), the undersigned, Daniel L. Reuvers, Chief Executive Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to his knowledge:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><font style="font-family:'Arial','Helvetica','sans-serif';margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">/s/</i><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;letter-spacing:1.25pt;"> </i><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">Daniel L. Reuvers </i></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-weight:bold;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:normal;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-weight:bold;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;">Daniel L. Reuvers</b></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.1pt 0pt 0pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.1pt 0pt 0pt 0pt;"><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">Chief</i><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;letter-spacing:0.05pt;"> </i><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">Executive Officer</i></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Date: </font><font style="font-family:'Arial','Helvetica','sans-serif';">February 21, 2023</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:0.07;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:10.29%;margin-right:10.29%;margin-top:30pt;page-break-after:avoid;width:79.41%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>7
<FILENAME>tcmd-20221231xex32d2.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 2/21/2023 01:38:34 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:0.07;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-weight:bold;text-align:right;margin:0.6pt 0pt 0pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;">Exhibit 32.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-weight:bold;margin:0.6pt 0pt 0pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:normal;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-weight:bold;text-align:center;margin:0.6pt 0pt 0pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-weight:bold;">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-weight:bold;text-align:center;margin:0.6pt 0pt 0pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-weight:bold;">AS ADOPTED PURSUANT TO</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-weight:bold;text-align:center;margin:0.6pt 0pt 0pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-weight:bold;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-weight:bold;margin:0.6pt 0pt 0pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:normal;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">In connection with the Annual Report on Form 10-K of Tactile Systems Technology, Inc. (the &#8220;Company&#8221;) for the period ended December 31, 2022, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), the undersigned, Brent A. Moen, Chief Financial Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to his knowledge: </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><font style="font-family:'Arial','Helvetica','sans-serif';margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.1pt 0pt 0pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.1pt 0pt 0pt 0pt;"><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">/s/ Brent A. Moen</i></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.1pt 0pt 0pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.1pt 0pt 0pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Brent A. Moen</b></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.1pt 0pt 0pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.1pt 0pt 0pt 0pt;"><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">Chief Financial Officer</i></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;">Date:&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;">February 21, 2023</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:0.07;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:10.29%;margin-right:10.29%;margin-top:30pt;page-break-after:avoid;width:79.41%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>tcmd-20221231x10k005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tcmd-20221231x10k005.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $1 M\# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MD_O_ /@/_!/N'-&:^'O^&N/'O_/33_\ P&_^O1_PUQX]_P">FG_^ W_UZ/\
M4_,O[OW_ / #_B(^2?W_ /P'_@GW#FC-?#W_  UQX]_YZ:?_ . W_P!>C_AK
MCQ[_ ,]-/_\  ;_Z]'^I^9?W?O\ ^ '_ !$?)/[_ /X#_P $^X<T9KX>_P"&
MN/'O_/33_P#P&_\ KT?\-<>/?^>FG_\ @-_]>C_4_,O[OW_\ /\ B(^2?W__
M  '_ ()]PYI"WY5\/_\ #7'CW_GII_\ X#?_ %ZZ'X>_M.>-/$OCKP_I-X]B
M;2]OH;>79;X;:S '!SP:RJ\)YC1IRJ2Y;)7W[?(WH>(.38BK"C#GO)I+W>K=
MNY]@*<BEIJC"BG5\:?I@4444 %%%% !1110 4444 %%%% !1110 4444 9&J
M>+=(T77-%T>^OH[?4]9>6+3[9\[KAHXS)(%^B*6Y["M7>,=Z^>/VD?$FF>#/
MC9\!=<UN[33](M-5U83WDJMY<6_2YE7<0#C+$ >YKS+QOXOU75/B;>?#WPWK
M-[>Z%\6;S3]:T;5[25\65I"0NLI&YY3]W;1%1Q\UT?Q /M3>,XY_*@.#7PCX
MJT+7+FR\0>*(/$7B:UUL?%]?#]L]K>RHMMIL]_#;RI'']T*8Y9#NQP<$'@56
M^).J7WPSU7Q=X2AUW7]/\(Z7\0_"T<$\=Q/+<PVMW;JUVD4G+LI;<VT9P6;%
M 'VIXV\?:9X"MM)GU(3%-3U6TTB'R4W'SKB01QY]%W'DUT>\8KX"N[4^*;/7
MM&\-:QKE[\-_^%@^%8M#U,S3.\4CLAOOLTSC?Y:N4^;HK,^#Q6I\2'\7?#O3
MOBEX3\+ZKJT'A;3_ !7H"37-TUQ=-8:;=6R/>E74^:8O,P6V'*J[XQ0!]T;U
MQG^E<QX7^(NE>+?$OBW0[$3"\\,WL5A?>8F%,DEO'<+L/<;)5_'-?&PN-2T7
MX;6JGQ_)K?P[OO&]C#K%QH,=XB:3IIM9#+&LTC/(8GN%MM[*<()'' SCEY;^
M_P!$\-_%27P+JFJIX3O?B)I$-[K-[%=2LND'3(1(Y8;9C )%1-ZG(3G.WF@#
M]&-RXZ<>F*7<O^17PK8Z?K,_A'P7I=G\0;C7= U?XEV=JLGA_P"UP+96C6%P
M9[99I69VC9UW$[L#>0"".*.K:#K'@_P;\2_$.G:[XE>_\#?$*RTSP[!+?3R1
M064ES8>;'L/^M1A=3 EL\8Z;: /O?>N>G/TIP.17P;K/Q(OKO]J+0I-%74=,
MNXO'9T348KG4KN:XFM/WL;%K<IY,=L^$:,[NFT@Y)K[Q3[@^E #J^5O^"E?_
M ":]J7_85T__ -'BOJFOE;_@I7_R:]J7_85T_P#]'BNK"?[Q#U1A7_A2]#\D
M****^[/FPHHHH **** "BBB@ HHHH ***^A?V0?A#X&^*=WXSN/'KW<6DZ-9
MVLJRVLYB\MI9_*W,1U R/UK*K4C1@YR-(0<Y<J/GJBOL[X _L6:)J_Q"\::3
M\1#>+8:;KG_".:4+:4PM>7.QYS(".JB!4;_@7M7C_@?]E/7OB/X:&JZ'XAT"
M6\FMKJ\@T1KEC>-%"S!@V%VHWRYVL<\CUK!8RBVU?:WXFGL)I)V/$:*^@_"G
M[%7BWQ?H'AK4;37_  Y#<^)-,.IZ3I5Q=LMW=*$+LBICJH R>G/L:YOPW^S'
MXG\3:Q\-]-@O+""X\=VL]WI_G%L0+#NWK+@=?E/2K^L4M?>V)]E/L>045]C-
M\ _#=C^RUX/BM+KP;+XL\6ZE+"^NZI</') 1*H\N!R,*8PI$@/'WL9)%>9WO
M[&OC,ZSX1LM'U'1_$-OXFGN+>UO["9Q!"T"[IC*74%0J@G/?'TK..+I2O=V_
MX!3H36RN>"T5]2_#K]C32/$D7C!M2^)/ARY33-"DU*SN-(O"\:2*Y0O/E25B
M4KSW.01Q7GUM^R[XBO=;^'&G6VK:5<_\)V]TNEW,3.8@L#$%V.,[6QE<=B,U
M:Q5)MJ^W_#B=&:2=CQNBO<D_9&\4R>#])UT:SH2OK%S<6.F:6]PRW=]<Q7+V
M[11*1R=R$YZ $9K2UC]B;QEI5_IEK#K&AZFUSK4/A^Z:SED86%W(,J)<J,CM
ME>]/ZU1_F#V,^Q\]T5W_ ,3O@WJ/PR\8VGA>35=,\0:U.WDO;Z+,9C!/OV"!
M^!^\R1Q[UV'Q$_9/\:> /A?X8\6W&B:J7O+:\N=9MI;=5721#-LCWD'.'3YZ
MOV]-<NN^Q/LY:Z;'B%%?1/PJ^'WPXM?V<-7^)'C?1=6URXM?$J:*EOINH&VV
MQO"CANA!();Z\5ZEX0_9-^&%Q\1);Z_O=4NOAW?>"E\7V.^4Q7-LGG(CK(R_
M>"JV?_U5A/%P@VFGI^)<:,I)-=3XDHK[,^$G[%V@S_&WQYH7CF6['AG1]1@T
MG2W@F,3WLUR?,MR&'7$'S''K5WPQ^RSX+_X5-'XF/@[6/&%ZVN:K82QVNO)8
M"""VN98XV^?ACM0 XYSS4RQM*+LM=OQ*6'FU<^)J*DN&BDN)F@0QP,[&-&;)
M523M!/<@8YJ.N\Y@HHHH$%%%% !1110 4444 %>S?L:?\G2_#3_L*G_T1+7C
M->S?L:?\G2_#3_L*G_T1+6&(_@S]'^1K2_B1]3]A?BGXT;X<?#+Q/XJ6V^VM
MHNFSZ@+<MM\WRXRVW/;.*^%_^'KMR/\ F0(__ X_X5]@_M0_\FV_$W_L6[__
M -$-7X>'O7SV78:E7C)U%>QZF+K3IR2BS] O^'KUS_T(,?\ X''_  H_X>O7
M/_0@Q_\ @<?\*_/RBO7_ +/PW\OXLX?K57N?>^L_\%3KC5](OK%O <<8N8)(
M=_VTG;N4KGI[U\4_#[Q_KWPN\5:?XB\-W\FG:K9-E)4/##NCC^)3T(-<]171
M2PM*DG&$=S*=:=1IM['[0?LL?M4:%^T9X7#(8].\46:#^T-)+<@]/,C_ +T9
M/?MT->[ALU^ _@3QSKGPW\4V'B'PY?RZ=JUFX>*:(]?56'\2GH5/6OV]^"/C
M+7_'_P ,= U[Q+H+^&]9O+<23V#G[I[,!U4,/F"GD9P:^8Q^#6&ES0^%GL8:
MO[56>Z.*_; _Y)'_ -Q&W_FU?$M?;7[8'_)(_P#N(V_\VKXEK]6X-_Y%TO\
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M$'8([#!9<\$CMD8J*OHD[JY\=)<KL%=A\'?^2K>$/^PK;_\ H8KCZ[#X._\
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M%%% !1110 5W_P .OBLW@#P5\1- 73S=GQ;I2::+D3;#:%9-XD P=WTR/K7
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M63/H3PE^TGX,\">+-6GT'X5P6'A76=!FT/4M%&KRM)<K)('\SSRN5( V@ <
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M_@-X_P!(TJTDO]3OM"O+>VM8L;Y9&A8*HSW).*_(T_L@?&C/_)-];_[XC_\
MBZ_;:/[@I=H]!7R.&QD\*FHJ]SW*N'C6=VS\1_\ AD'XT?\ 1-];_P"^(_\
MXNE_X9 ^-'_1-];_ .^(_P#XNOVWP/048'H*[/[7J_RK\3#ZE#NS\0[G]DGX
MQV=O+<3?#O6HX8D,CNR1X50,DGY_05Y(OS$8YSC&.]?O[XTCW^$-<"KDFQG
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M+QMN4[E(/6NQHIIN+NMQ-)JS/F7_ (=U_ __ *%V]_\ !K<?_%4?\.Z_@?\
M]"[>_P#@UN/_ (JOIG%&*W^L5_YW]YG[*G_*CYF_X=U_ _\ Z%V]_P#!K<?_
M !5'_#NOX'_]"[>_^#6X_P#BJ^F<48H^L5_YW]X>RI_RH^9O^'=?P/\ ^A=O
M?_!K<?\ Q5'_  [K^!__ $+M[_X-;C_XJOIG%&*/K%?^=_>'LJ?\J/F;_AW7
M\#_^A=O?_!K<?_%4?\.Z_@?_ -"[>_\ @UN/_BJ^F<48H^LU_P"=_>'LJ?\
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M'_Q5'_#NOX'_ /0NWO\ X-;C_P"*KZ9Q1BCZQ7_G?WA[*G_*CYF_X=U_ _\
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M^LU_YW][#ZA@_P#GS'_P%?Y''_\ "H/!'_0J:/\ ^ :?X4?\*@\$?]"IH_\
MX!I_A7844?6:_P#._O8?4,'_ ,^8_P#@*_R./_X5!X(_Z%31_P#P#3_"I['X
M6>$-,O8+NT\-:7;74#B2*:*U161AT(('!%=312>(K-6<W][&L#A(NZI1O_A7
M^0@&*6BBN<[@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "LSQ)XFTOP?HEWK&M7\&F:7:)OGN[EPD<2Y RQ/09(_.M.HYD5
MHWW $8Y!&10!P/@[]H+X;_$'6QH_AOQKHNN:H=_^B6-XDLGR#+C:#V')]*]
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M_;)UV:P_M&(C_61W"HS/_LX!VCL:U;WX/Z->ZUXIUC7]0N[J&/7#ID965(V
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MZUYKJG[7G@>TT?PM>Z<M_KT_B/3#K%G868@AG2T!"M))]HEC52'.S;N+%@0
M<$BQI7[5GA+Q-?\ AFV\-6.L^*1KFE6^MK+I5JCK:64TS0I+,&=6QYB.K! Y
M78<@<9 +WP<^#9\ >._BEXLO([1=3\8:X+M?LBD".TBA2.%3G^,D2R-CC=(:
M]9KSCP1\<=+^('C'6-#TG1]:DM=,N[G3Y=;:W3["UU;L%FA#!RZLI.!O10V#
M@GC/H] "&O@7_@K'_P BM\./^PC>?^B4K[Z/2OA/_@J?H6IZ[X9^'::;IE[J
M31ZA>%Q96TDQ0>2F"0@./QKNP+2Q,&SFQ/\ "9^:E%;W_"O_ !5_T*^N?^"N
MX_\ B*/^%?\ BK_H5]<_\%=Q_P#$5]ISQ[GS_*^Q@UW6D?&[QIH4'@Z&PUN6
MVC\(RSS:,$1?]%:8DR]OF#9.0?6L/_A7_BK_ *%?7/\ P5W'_P 11_PK_P 5
M?]"OKG_@KN/_ (BIDZ<M)-?@4E-;&_%\=O',#:V\?B"XCEUK5H=;OI5 WRWD
M3AXY<]005& ..*WM:_:M^*'B"33GOO$KRMI^I1ZO;;;>-0ET@8++@#DX=LYZ
MYYK@O^%?^*O^A7US_P %=Q_\11_PK_Q5_P!"OKG_ (*[C_XBLW"@]6E^!2E4
M75FHGQ@\71Z5J>G1ZQ+%:ZEK*Z_<B-0K-?*^]9@1R"&YXKI/%/[4GQ-\9Z9/
MI^K^)I;NSGG@N9(?)10TL,@DC<X'W@P4D]\#/2N'_P"%?^*O^A7US_P5W'_Q
M%'_"O_%7_0KZY_X*[C_XBGR4&[V7X"3J)6U.STG]IOXD:)K7B+5;/Q')'>^(
M+A+K46:%&6:9%"I)M(PK   $>@J33OVHOB9I7B'7=;M_$THO]<>*34#)$CI.
M\:!$<H1@,%4#(&>*XC_A7_BK_H5]<_\ !7<?_$4?\*_\5?\ 0KZY_P""NX_^
M(I<E#LOP'S5.[.BE^/?CN?PI=>&Y/$$[Z3<W[:D\3*I87#3"8NK8RN9%#<=Z
MV]?_ &KOBEXGLI+34O%4UQ;R36UR\9B0!I8)5EBD.!RP=%.>^T5P7_"O_%7_
M $*^N?\ @KN/_B*/^%?^*O\ H5]<_P#!7<?_ !%')0[+\ YJG=F_I'QU\;Z%
MX\UCQC8Z[+!K^L;O[0N BE;D-C(="-I' XQVJ36_CWXY\1?\)!]OUMIEUZQA
MTV_18459;>)V>., #"@,['CUKG/^%?\ BK_H5]<_\%=Q_P#$4?\ "O\ Q5_T
M*^N?^"NX_P#B*?+1O>R_ 5ZEK:F">316]_PK_P 5?]"OKG_@KN/_ (BC_A7_
M (J_Z%?7/_!7<?\ Q%:\\>_Y$<K[&#7U+_P38_Y.AL_^P)?_ /M*OGC_ (5_
MXJ_Z%?7/_!7<?_$5]._\$Z/">NZ/^TQ9W%_H>IV%N-&OE,UU8RQ("?*P-S*!
MD^E<F+G%X>=GT-Z":J1T/M;]N/X.>)?C?\&8/#OA6W@N-335[:[*3R^6OEHL
M@8YP>?F%?!7_  [F^-/_ $"M,_\  \?_ !-?KY17S%#'5</#DA:Q[%3#0JRY
MI'Y!_P##N;XT_P#0*TS_ ,#Q_P#$T?\ #N;XT_\ 0*TS_P #Q_\ $U^OE%='
M]JU_(R^I4O,_%WXD?L5_%#X4>"]1\4^(-/L(=(T\(T[PW@=P&<(,+@9Y85Y5
MX \ :]\3O%ECX<\.6$FHZK>/MCB0?*H[NY_A4=237[)_M>>!-:^)OP \2^&/
M#UK]LU?4FMH8(BP5<_:(R68GHH ))] :I?LO?LN:!^SCX5$-N$U'Q+>*#J6K
MLF&D;^XG]V,=AWZGFNR&9M47*?Q=$8/!IU$EL0?LL?LJZ%^SGX6 54U+Q5>(
M#J&JLO)/_/./^Z@]._4U[Q28Q2U\].<JDG.;NV>I&*@K(^+_ /@H1_R$O W_
M %QO?_0H*^1*^Q_V^='U#5=1\$FRL+N]"17FXVUN\NW+0XSM!QTKY._X1'7O
M^@%JO_@!-_\ $U\!F4)/%S:7;\D>!BHMUI:?U8R:*UO^$1U[_H!:K_X 3?\
MQ-'_  B.O?\ 0"U7_P  )O\ XFO,]G+LSEY9=C)KOO#GQU\:^$]!LM'TO6#;
MZ?9[OL\?DHQBW$L=I(R.2:Y?_A$=>_Z 6J_^ $W_ ,31_P (CKW_ $ M5_\
M ";_ .)K2'M:;O"Z^\J//'X;HN2?$'Q!/I6LZ=+J<TUMK%S'=WPD.YII4(*L
M6/.00/RK5N_C3XROM?DUJ?6I9=2DT]M+:=E!/V=NJ8]_6N>_X1'7O^@%JO\
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M)KB_VDQ76G,E\I12)6*[=W3@XXR*Q/\ A'-7_P"@3J'_ ("2?_$T?\(YJ_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
9HH **** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>tcmd-20221231x10k006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tcmd-20221231x10k006.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &% T0# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BO.?BEXK\5^"X!J6E6MC?:4 !-YL3F2 ^IPP!4^N.
M.]>=V7Q[\:ZDK-::-8W*J<,8K>1L'W^>@#Z*HKY^_P"%T?$'_H7+;_P%E_\
MBZ/^%T?$'_H7+;_P%E_^+H ^@:*^?O\ A='Q!_Z%RV_\!9?_ (NC_A='Q!_Z
M%RV_\!9?_BZ /H&BOG[_ (71\0?^A<MO_ 67_P"+H_X71\0?^A<MO_ 67_XN
M@#Z!HKY^_P"%T?$'_H7+;_P%E_\ BZ/^%T?$'_H7+;_P%E_^+H ^@:*^?O\
MA='Q!_Z%RV_\!9?_ (NC_A='Q!_Z%RV_\!9?_BZ /H&BOG[_ (71\0?^A<MO
M_ 67_P"+H_X71\0?^A<MO_ 67_XN@#Z!HKY^_P"%T?$'_H7+;_P%E_\ BZ/^
M%T?$'_H7+;_P%E_^+H ^@:*^?O\ A='Q!_Z%RV_\!9?_ (NC_A='Q!_Z%RV_
M\!9?_BZ /H&BOG[_ (71\0?^A<MO_ 67_P"+H_X71\0?^A<MO_ 67_XN@#Z!
MHKY^_P"%T?$'_H7+;_P%E_\ BZ/^%T?$'_H7+;_P%E_^+H ^@:*^?O\ A='Q
M!_Z%RV_\!9?_ (NC_A='Q!_Z%RV_\!9?_BZ /H&BOG[_ (71\0?^A<MO_ 67
M_P"+H_X71\0?^A<MO_ 67_XN@#Z!HKY^_P"%T?$'_H7+;_P%E_\ BZ/^%T?$
M'_H7+;_P%E_^+H ^@:*^?O\ A='Q!_Z%RV_\!9?_ (NC_A='Q!_Z%RV_\!9?
M_BZ /H&BOG[_ (71\0?^A<MO_ 67_P"+JUH_Q]UJPUFWB\4Z3%96$W!DAB='
M3_:PS'('<=: /=Z*AM+N&^MXY[>19H9%#I(ARK ]"#6;XH?68=(FET(6LE^@
MW+%=J2D@_NY!&#[T ;%%?.7_  T#XR^WM9?V3I_VQ6*-!Y$F\,.HQOZU<_X7
M3\0?^A<MO_ 67_XN@#Z!HKY^_P"%T?$'_H7+;_P%E_\ BZ/^%T?$'_H7+;_P
M%E_^+H ^@:*^?O\ A='Q!_Z%RV_\!9?_ (NC_A='Q!_Z%RV_\!9?_BZ /H&B
MOG[_ (71\0?^A<MO_ 67_P"+H_X71\0?^A<MO_ 67_XN@#Z!HKY^_P"%T?$'
M_H7+;_P%E_\ BZ/^%T?$'_H7+;_P%E_^+H ^@:*^?O\ A='Q!_Z%RV_\!9?_
M (NC_A='Q!_Z%RV_\!9?_BZ /H&BOG[_ (71\0?^A<MO_ 67_P"+H_X71\0?
M^A<MO_ 67_XN@#Z!HKY^_P"%T?$'_H7+;_P%E_\ BZ/^%T?$'_H7+;_P%E_^
M+H ^@:*^?O\ A='Q!_Z%RV_\!9?_ (NC_A='Q!_Z%RV_\!9?_BZ /H&BOG[_
M (71\0?^A<MO_ 67_P"+H_X71\0?^A<MO_ 67_XN@#Z!HKY^_P"%T?$'_H7+
M;_P%E_\ BZ/^%T?$'_H7+;_P%E_^+H ^@:*^?O\ A='Q!_Z%RV_\!9?_ (NC
M_A='Q!_Z%RV_\!9?_BZ /H&BOG[_ (71\0?^A<MO_ 67_P"+H_X71\0?^A<M
MO_ 67_XN@#Z!HKY^_P"%T?$'_H7+;_P%E_\ BZ/^%T?$'_H7+;_P%E_^+H ^
M@:*^?O\ A='Q!_Z%RV_\!9?_ (NC_A='Q!_Z%RV_\!9?_BZ /H&BOGR7XW>/
M8(VDE\/VJ1H,LQM9< ?]]UZI\._B'8^/=*\^$B&]B %Q:DY*'U'JI]: .OHK
M(\2MJZ:3-+H8MGOU&Y([M6*/_L\$8/O7A3?'_P 9QZ@]BVD:>+Q&*-!Y$F\,
M.V-] 'T917S]_P +H^(/_0N6W_@++_\ %T?\+H^(/_0N6W_@++_\70!] T5\
M_?\ "Z/B#_T+EM_X"R__ !='_"Z/B#_T+EM_X"R__%T ?0-%?/W_  NCX@_]
M"Y;?^ LO_P 71_PNCX@_]"Y;?^ LO_Q= 'T#17S]_P +H^(/_0N6W_@++_\
M%T?\+H^(/_0N6W_@++_\70!] T5\_?\ "Z/B#_T+EM_X"R__ !='_"Z/B#_T
M+EM_X"R__%T ?0-%?/W_  NCX@_]"Y;?^ LO_P 71_PNCX@_]"Y;?^ LO_Q=
M 'T#17S]_P +H^(/_0N6W_@++_\ %T?\+H^(/_0N6W_@++_\70!] T5\_?\
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M627$[:3JRFWU2$E,2#:7(['_ &OYUUN,]JVOBQ\*(_%T)U33 +?6X1D%>/.
M['W]#7G'A+Q;)=RMI6JH;?5(3L(<8+D=C_M4 =;BC%%% !BC%%% !BC%%% !
MBC%%% !BC%%% !BC%%% !BC%%% !BC%%% !BC%%% !BC%%% !BC%%% !BC%%
M% !BC%%% !BD9592K*&4\$$=:6B@#AKZRU#X=ZRNOZ"Q%N#^_M^JX[@CNI_2
MO>O OCK3_'6D)=V;A95P)K=C\T;>GT]#7GK*'4JP#*1@@]#7#WEIJ/PYUI=>
MT%B+;/[^WZKCN"/[O\J /I^BN;\#>.=/\<Z.EY9N%E'$UNQ^:)O0_P!#724
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M+X5:WX-C+P^'M.^.<>G6-LEPP-M R.I2-LY7@'D'.<GK0!^JAU2R$#SF]M1
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MZ=+#)::3I]I)"I2)[>SBC:-2<D*54%03R0.#31X8T5<8T;31B;[0,6,7$O\
MST^[]_\ VNOO6E10!4N-(L+N^AO9["TGO(/]5<RVZ-+'_NN1N7\"*>=-LVU!
M;\VEL;Y4\H79A4S!.NT/C<%R3QG'/2K%% &>?#FD&P>Q_LG3_L,CF1[7['%Y
M+.>K%-NTM[XS5NTL[?3[9+>TMX;6W3A(;>-8T7Z*H 'X"I:* "BBB@ HHK-U
M_7[;P]8M<7!R>B1@\N?04 )X@\06WAVQ-Q.V6/$<0ZN?2JGPX^'5Y\0=37Q%
MXA5ETT',%L>!+CIQ_=_G3?AU\.[SXB:FOB'Q I72U;,%L>!+CV_N_P Z]YO+
MVTT/3GGGDCM;.W3+,<!444 )?7UGH.FR7%Q)':6=NF68\*JC_/2OG?Q7XJU'
MXOZV;2T,EIX>MGSS_%_M-ZL>P[4OBSQ9J/Q?UO['9[[3P_;OG)_C_P!IO4GL
M.U=+IFF6^D64=K:QB.)/S)]3[T &FZ;;Z19QVUM&(XD''J?<^]6J** "BBB@
M HHHH **** "O /VS?#GAOQA\.](T;7/&B^!-2N-5A;1=5FMWFA%ZO*+)M!
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M 7X8?#&Z\6WZ>)_$J%H"0]M:2# ?T8CLH[#O7O2J$4*   , "D1%10% 4#@
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M ,]I_P#P':O8?^%3^#_^A=T__OR*/^%3^#_^A=T__OR* /'O^%DZ'_SVG_\
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M'_"R=#_Y[3_^ [5[#_PJ?P?_ -"[I_\ WY%'_"I_!_\ T+NG_P#?D4 >/?\
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MQ[_A9.A_\]I__ =J/^%DZ'_SVG_\!VKV'_A4_@__ *%W3_\ OR*/^%3^#_\
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M6O?HXUB0(H"JHP .@%$:+&BHBA%48"J, #TIU !1110 4444 %%%% !1110
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MZ=J5O>7VD2K#?P1-EK=V7<JOZ$CF@#9HI,C&<C% (/0YH 6BDR,XSS1D9ZT
M+16#X[\:Z9\.?!VL^)]9DDBTK2;22\NFBC,CB-!EB%').!TK6T^^BU.QM[N
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MGA30]2U4Q>3]NO--@EG\O^YO9"VWVSBNEBC2&-8XT"(@"JJC  '0"@!]%%%
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MEL8FLUC7[J"$KL"CL,8%6?#_ (7T;P?I46F:#I5CHFFQ',=EIULEO"F3DX1
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MA;Z(@_= F*1[FQU4 X/<]:ZV;5+2WE6.6XABD9E4(\B@DMG:,$]3@X'?!KX
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MI 61_,7:P R2#GD8YKX(^)'@/Q#>:1&]Q8:K9^$8O'FJW6KB+P[_ &NOE/\
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M#'I6[X@=HM"U!T8HZV\A#*<$':>: +H SU/XYJO-?VMO=PVLES%'=3@F*%Y
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MF^(_A_X%\9Z5+/X>TJ\\1P:?K*:I83 10,\BD(\D2AR0@.8P<$[>O%>R:?\
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MM10A! Y4#..<FK^E_LS>&;4Z*=4U'6_$QTK3+G1XCK-VDOF6LP"LDFV-<X4
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M>>*Y+^XOPD;1LSWDQ=1(0P.-Q7"XS7U<2!U.*B:[A6;RC*@EV[MA89QZX]*
M/CCQ-^S;KFH?$+QG?:Q\.9?&ND>,[F*]=8/'-UI<5EF*..6WNH(W5)E4H2'5
M7+# (&!7K.C?";6]-U?XX3K800Q>*$ACTG9.I,BII45OM8]5 D1@-WU[UZ_X
M;\4Z/XPTB+5=#U.TU;392PCN[*998G()!PP.#@@C\*U,@=Z /G+PG\%/$FE>
M(_V=+RXT^V2#P5X:O].U;;.A^SW$MO9QH(P/O F&497H/K6%\,/@)XT\+^+/
MA]>ZA96\=IHVO^+;^[*7:,8X+Z1VM2H'4L&&0/N]Z^I9;J*&6.-Y$5Y.$5F
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M.ZR#$BDJH)# G(Z'-;\/@3P[;C2!'HEA'_9"-'I^VW4?9%*[2L?'R@CC [4
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M5[@H@C3><?-A%51GH !6!X1^"W@'P#K=WK'AKP7H.@ZK=AA/>:=IT4$K@G+
MLJ@X)Y('!- '@GQ^^-'BWX,_$#QCHL.HSWDOC'0+?_A!X)%7;;ZSYPLY($X^
M;FXMK@@YX67C KBOB_\ %[Q1X)U6\NO#?C#QMKD_A#5M'T#4KB:/2X=#\]_L
MJSPSQR;;FXEE69I"\0.UI%"X"FOLK7/!>@^)M2TC4-6T:QU*^T><W6G7-U;K
M)):2E=I>)B,HV.,BN?UWX$_#KQ/XFF\1ZOX&\/:GKTR(DFIW>FPR7#A""F7*
MY)4J,'J,"@#YM?Q-J?ASXA^)?[-N3;?;OC'IME< 1H_F0OI]N'3YE.,X'(P?
M0BN'^)>OZ]\1/ANOC+6_']ZD[_$FWT=/!N+9;.&*VU=(HX@NSSO."QB5GWDD
M$_*%YK[AD^'7A>6[>Z?P_IK7+ZBFKM*;9"QO$4(EP3C_ %@55 ?J !61J'P)
M^'6J^)+CQ!>>!O#UUKEP\<DVHS:9"T\CHRLC,Y7)(95(/7Y1Z4 ?,/B/XU^(
M?^%PZ#=^'/$7C*^T*]\:IX5NWOX],@T4@R^5-!!#Q=-)&3Q-@C(R?EKC_#.K
M>)?@M\%_B7K?AGQ5JU_JMUX]FT7_ (FM[;+!:+)<0H]UN:':DN&^^X*#@[:^
MSQ\"_AV/%DGB<>!_#P\1R3I=-JO]FP_:3,I!63S-N=P('S9SQ5M_A#X(DU'7
M;]_".B/>:]&(=5G:PB+7Z#^&8E?W@X'WL]* /E?4/&?QE^&_@76;77O$']FV
MU]JNEZ?9:K>ZM9ZMJ&F)<2[)I7>.WACVX(*%T.#GJ*[#X":-+H'[57Q3TV;Q
M;>^,GMM&TQ/[0U%H&N8QF0^5(T*(I89SDJ#AAFO;M#^!OP\\->&]0\/Z5X(\
M/Z?H>HC%YI]OIL207(Z8D4+A_P >E7?!?PI\&_#D2?\ "+>%M(\.^9&L3_V9
M91P;T4D@':!D D]: /G[Q%\1/%_@7XW:A=Z]KVL7.AWUS-:^';71I+*XTJ9T
M@+BTNHMOVB*?<"?,#%3D#CI69H?B7Q7<?L\:G\46^*>K7GB'4]&N+M-(/V,6
M5I,&X$,2Q"1?+Z'+'/.:^D+;X0>![/QK+XOM_".B0>*901)K,=A$+M\C!)DV
M[LD<9SFJ-I\!/AO8ZGJNHVW@/PY;W^JHR7US%ID*R7*L<L'8+D@GKZ]Z /FK
MQ[KGQ1T"^^'7@S2O%^N:_>^*;"75KS4I=2L=*N'E5$/V>VE>UD1$&XML",Y_
MO8K/U[XA_&[9\// -]?I_;VJ0ZA<75_HVO6=K<7(AD"Q1"[>U>(R!#N=4B!)
M] #7UWXM^&7A+Q[H<&C>)/#>E:[I4!4PV>HVB311%1@%58';@<<50U3X)?#_
M %KPG:>%[[P7H-WX<LVW6VE2Z=$UO WJB;<*?<4 ?/&E7_Q;U_4OA9X1\1^.
MY?#^H:E#JPU6\\.RVMW+<10O&(1YQA\M9@&&YE0<[@%&>(OA]\4/&5]XA^#V
ME:OK\FJR'Q/X@T6]O);:%9+^&U6186DPF%?"@DIMR<]N*^GM'^&WA7P]_9/]
ME^'-+TT:3')%IXM+1(A:(^-ZQ[0-H;:,XZXI+7X;>%;&[LKJW\/:;!<V5S/>
MVTL=JBM#/-GSI4./E9\G<1R<\T ?)?PI\;_$6/PS\&O'NJ?$35M;_P"$HUYM
M$U#0[NVMELC;.ERR,NR,2"5#"I\S?\V2" *;^SWXB^*/Q;\?>"O$=QK_ (X.
MC.;Z^\0"XBM+?0)8]Q6SCLL1^9(I[C.=HRQ5N#]9#X9>%[?0=-TBUT+3[*QT
MN8W.G0P6R*EE-A@)8EQA'&]\$?WCZU\Z_"K]BJ\\ ^-?"6IW&H>%8(O#5P]R
M-6T'09++6M9+1NFV_N3.RNK>9O<!?F901MH ^LZ*0# I: "BBB@ HHHH ***
M* "OFKXHZOKOB#]H.[\'Q?$Z^\!Z.GAC^U%AT_[*LTDRR,#(&F1\*H + #D=
MQ7TK7D/B_P#9U\._$+XJS^)_%>EZ/XDTIM+CL8M+U33UN/+D60OY@9\@<'&
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M#.>F>KUS]HS2_#>L^*_$2R:]JVE:?X:T[65TV,0" QSRL@,2[1)YI_B#,0<
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MO^&* /'_ (:_M6>*+CX8Q:WXQ\#7*ZS?ZQ-H^C6.EWMM(^IW N)(UB4!L1;
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M* /N '(I:P/ $]Q<^!O#TUVTCW4FGV[RM+G>7,:EBV>^<UOT %%%% !1110
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M2UN+22>U,!!=055Q&PXS@9!/K0!]\^8./?I09!Z5^=?[7%AI?AS6=;\,>&?
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MD P*6OES5?VH/'>L7MW#X2\#Z:JV/A>'Q1>+XDOY[.6!#O+V_EK$S%_D(!(
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MNSW/YT;!ZG\Z=10 SR_<_G2[/<_G3J* &A,=S^=&P9ZG\Z=10 4444 %%%%
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M4^,+OPKI/B.SU#Q!:&07-A;EF>$HV'#\84@]B03VR* .6'[/#7_@[6_#>O\
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M+!TP<XRP!.>* .VHI!R*6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MJYF79--:Q2.I[$H":U:CMX5MX(XD&$10JCV%24 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
7!1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>tcmd-20221231x10k007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tcmd-20221231x10k007.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" '  FH# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **CG5GA=4?R
MW((#XSM/KBO /''Q*^('@36&LKR2Q>)LM!<K9X29?4?-P1W':@#Z#HKYUB^)
MWQ,GB22.TM7C<95EMT((]1\]._X65\3O^?&V_P# 9/\ XN@#Z(HKYW_X65\3
MO^?&V_\  9/_ (NC_A97Q._Y\;;_ ,!D_P#BZ /HBBOG?_A97Q._Y\;;_P !
MD_\ BZ/^%E?$[_GQMO\ P&3_ .+H ^B**^=_^%E?$[_GQMO_  &3_P"+H_X6
M5\3O^?&V_P# 9/\ XN@#Z(HKYW_X65\3O^?&V_\  9/_ (NC_A97Q._Y\;;_
M ,!D_P#BZ /HBBOG?_A97Q._Y\;;_P !D_\ BZ/^%E?$[_GQMO\ P&3_ .+H
M ^B**^=_^%E?$[_GQMO_  &3_P"+H_X65\3O^?&V_P# 9/\ XN@#Z(HKYW_X
M65\3O^?&V_\  9/_ (NC_A97Q._Y\;;_ ,!D_P#BZ /HBBOG?_A97Q._Y\;;
M_P !D_\ BZ/^%E?$[_GQMO\ P&3_ .+H ^B**^=_^%E?$[_GQMO_  &3_P"+
MH_X65\3O^?&V_P# 9/\ XN@#Z(HKYW_X65\3O^?&V_\  9/_ (NC_A97Q._Y
M\;;_ ,!D_P#BZ /HBBOG?_A97Q._Y\;;_P !D_\ BZ/^%E?$[_GQMO\ P&3_
M .+H ^B**^=_^%E?$[_GQMO_  &3_P"+H_X65\3O^?&V_P# 9/\ XN@#Z(HK
MYW_X65\3O^?&V_\  9/_ (NC_A97Q._Y\;;_ ,!D_P#BZ /HBBOG?_A97Q._
MY\;;_P !D_\ BZ/^%E?$[_GQMO\ P&3_ .+H ^B**^=_^%E?$[_GQMO_  &3
M_P"+JQI'QN\3:#K-NGBJRC&GS<%HH0C)_M##$''<4 ?0%%5M/U"WU.SANK65
M9[>50R2(<A@>]5]?AU"?3)ETNYCM;[&8GFCWIGT(]* -&BOFO4_C%X_TC6)-
M+NELH;U'V>6UJ!D]B"6Q@^M7/^%D_$[_ )\;;_P&3_XN@#Z(HKYW_P"%E?$[
M_GQMO_ 9/_BZ/^%E?$[_ )\;;_P&3_XN@#Z(HKYW_P"%E?$[_GQMO_ 9/_BZ
M/^%E?$[_ )\;;_P&3_XN@#Z(HKYW_P"%E?$[_GQMO_ 9/_BZ/^%E?$[_ )\;
M;_P&3_XN@#Z(HKYW_P"%E?$[_GQMO_ 9/_BZ/^%E?$[_ )\;;_P&3_XN@#Z(
MHKYW_P"%E?$[_GQMO_ 9/_BZ/^%E?$[_ )\;;_P&3_XN@#Z(HKYW_P"%E?$[
M_GQMO_ 9/_BZ/^%E?$[_ )\;;_P&3_XN@#Z(HKYW_P"%E?$[_GQMO_ 9/_BZ
M/^%E?$[_ )\;;_P&3_XN@#Z(HKYW_P"%E?$[_GQMO_ 9/_BZ/^%E?$[_ )\;
M;_P&3_XN@#Z(HKYW_P"%E?$[_GQMO_ 9/_BZ/^%E?$[_ )\;;_P&3_XN@#Z(
MHKYW_P"%E?$[_GQMO_ 9/_BZ/^%E?$[_ )\;;_P&3_XN@#Z(HKYW_P"%E?$[
M_GQMO_ 9/_BZ/^%E?$[_ )\;;_P&3_XN@#Z(HKYW_P"%E?$[_GQMO_ 9/_BZ
M/^%E?$[_ )\;;_P&3_XN@#Z(HKYW_P"%E?$[_GQMO_ 9/_BZ/^%E?$[_ )\;
M;_P&3_XN@#Z(HKYW_P"%E?$[_GQMO_ 9/_BZ/^%E?$[_ )\;;_P&3_XN@#Z(
MHKYW_P"%E?$[_GQMO_ 9/_BZ/^%E?$[_ )\;;_P&3_XN@#Z(HKPKPI\;M7T_
M7EL/&,$=M#,!LGCBV>4>Q."05^G2O<HI4F171@Z, P93D$=B#0 ^BBB@ HHH
MH **** "BBB@!",UB>+O"6G^,M'ET[4(M\;<I(OWXF[,I[&MRB@#Y?,>I_"?
M7/['U@--I4A+6]RH^7']Y?\ V9>W\^XBD2>-9(V5XW&593D$>M>E^+O".G^,
MM'ET_4(]\;<I(O#Q-V93V/\ ^JOGQAJ?PHUPZ-K ,VER$M;W*CY2N?O+_5>W
M\P#NL48IL<B31K)&X>-AN5E.01ZBG4 &*,444 &*,444 &*,444 &*,444 &
M*,444 &*,444 &*,444 &*,444 &*,444 &*,444 &*,444 &*,444 &*,44
M4 &*IZOI%MK=D]K=)NC;H>ZGU%7** .0\&^,]1^$>LC3M1+W.@3ME6'/E_[2
M_P!5KZ,L+^VU2TBNK:99[>50Z2(<A@:\6U?2+;6[)[6Z0,C=#W4^HKG?!?C+
M4?A'K/\ 9NI%[G0)VRK 9V?[2_U6@#USXF?#2T\?::2 MOJ<(_<7./\ QUO4
M']*\=\/>(+O0M2?P_P"($:WNX6V1R2=_0$]\]C7TC8WT&J6<-S:RI-!*H=)$
M.0PKD/B9\,[/QYIV1M@U2%3Y%R!_XZWJ/Y4 <C@48KB_#WB&\T/4G\/^($:W
MNX6V)))W] 3W]C7:4 &*,444 &*,444 &*,444 &*,444 &*,444 &*,444
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MJE%?*GQ?_;N\(:7!I-G\-O$^A>)->D\06FEWMI<13,!;R.5DDB/R!\' W*6
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M@X/<5^>.K_L]>,?$7B#XA>!Y-,OX]$^&5MJVK^%Y4BD5+B:>:*:%$.,.=JD
M#)R37ZFLS.<LQ8^K')I?,<@#>V!T&3@?2@#\U;_P;XK\1_LY6WCK6M$OAXL\
M9_$BTU:\M5LY#-#;Q>9&@9=NX*/G.2,8(]:]3O'O?"W[1W[1NG7V@ZT3XNT0
M-I%Y!ITDMK,([1RV9E&U>1M ZEN*^V/-DW%O,?<>K;CD_C2"1U7:'8+G. Q
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MM[<=D'8=^I]P TC2+_QGJS>(_$3&9I"## PPN.W'9!V'?J??N,8HHH ****
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M ,,\:_\ ]#6/^^)?_BZ/^&>-?_Z&L?\ ?$O_ ,70!K;6_NG\J-K?W3^59/\
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M 'Q+_P#%T?\ #/&O_P#0UC_OB7_XN@#6VM_=/Y4;6_NG\JR?^&>-?_Z&L?\
M?$O_ ,71_P ,\:__ -#6/^^)?_BZ -;:W]T_E1M;^Z?RK)_X9XU__H:Q_P!\
M2_\ Q='_  SQK_\ T-8_[XE_^+H UMK?W3^5&UO[I_*LG_AGC7_^AK'_ 'Q+
M_P#%T?\ #/&O_P#0UC_OB7_XN@#6VM_=/Y4;6_NG\JR?^&>-?_Z&L?\ ?$O_
M ,71_P ,\:__ -#6/^^)?_BZ -;:W]T_E1M;^Z?RK)_X9XU__H:Q_P!\2_\
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MEY4<MOS75>$/V7?$.@:#\-/[0UZSU7Q'H_B-_$GB/4Y%<?VA.\;(QC^7J!L
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MO"DIV-*J%002,@$UZCX ?QG/I,Q\;6FAVFI"8^2F@W4]Q"8\#!9IHT8-G=P
M1C'-> W/[,'CL^#=8^%4&NZ"GPKU/5IKYKYXI_[8AM);LW<MFJ8\HDN603%L
MA&^X2,T =U_PU+I__":^--(_X137%T/P7),OB#Q0_D+I]BB6BW(;F022%E;&
MV-&9?E+ !A7 C]HKQ+XP^.OP7LSX=\1^ O#FNP:O?R1:S]F\K4[5;)9(';RW
M<Q.A.XQ/M9=P)SSCO+;]G:;4=!^.FA:OJ,(TWXBWL\D,EJ&,EK#+IT%I\P8
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M0:-86&L7?B'2_%MWJNEZD#+M^U[FDS;RM\S-$?EQR,A1@ _2\'(ST^M .?\
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M"R3H 64 ]<9'-7/%7CW0O!,NCQZWJ":>=7ODTVR,J.5EN&5F6/< 0I(5L;L
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M![AI&4,7\Q]J] X&3@8 /I>BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M1KG6-)T^[U*QE%['"5616:*5A"ZET)5^H)P<B@"^G[+NGVW[-4'PBMM:D@B
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MQY?_  _^$/COPSX<O8KGQ+:0Z;/JOC'0_%-WJ.FWUI+<".:Z:0EWLYRA=W"
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M>K#83QQS6E\!O!'BCX=?#/2_"WB:^TG49=(A2PL[G28)81);1H%1I%D9OWA
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M(OVQ++6-!^'UYX>\&ZQKFH>,GO[:UTV*>WC>VN+3 E25V;9L#;AY@)&%R,Y
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M)FDL)&++EV($JL<M'N&0QKZ?^#7@&[\ >%I;.^TKPGH]W/<-.]KX.THV%FO
M RI)+MQRY SP,#% '(W_ .TE<^'?B;H_AKQ'X)O="TS6M2.DZ?JDVIV<LDD^
MUWC+VL<AECCD$3[7.?X=P7-80_; (NKN]D^'^M1^$-.\3R^%M0\1-=6_E07
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M3QM\"O!6MZU=M?:I>:<K7%RX :5@2NXX[G S[UZ=0 UEW=R/H: @'_UZ=10
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M.YHBXP 1DCF@#'T;]I[QWXA\7_%:[M[BS@\*V/AVYU+PU$;1#)^XE\DSN_\
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M&IRWTFIW)G_M2UAFD#RPK"$\ISD$*Y=< \J<5IZ[^ROJ%Y\=]#\1Z?J=E;^
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M;EKS4;S2X9)[A_O2OMP6/N<9- 'HE%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#Q_]K;Q
M3KW@S]GKQIK'AN>>SU2VL\B[MES+;1%U$LR^A2,NP/;;GM7A_P 5M$^'/A[X
M;V5KX!\22ZZ9/%'A>YO%?Q#/JP ;4HO+F)DED"-)AB=N-VWIQ7V;+&DL;)(J
MNC##*PR"/0US^F?#KPGI&FMI^G^&M&LK!KA;LVMMI\,<1G5@RR[54#>" 0V,
M@@'- 'POKMYXY\??$+XDW@\4>'_#7BO0_$[6>EZAK?C>\TN72[5!$80NFI"8
M98I59B6<GS"[#(VC!\>/B<J>-_$'B#P[*VBZ[X>\5Z?I#ZAJ?C>ZBO99"]OY
MD5II S$]N4D8'?C<"[#I7W7JOP^\+ZYKMKK6I>'-(U#6+0 6^H75A%+<0@'(
MV2,I9>?0TS4/AOX3U76GUB]\,:->:LZ+&]_<:?#).RJ<JID*EB 0"!GB@#Y4
MMX=.L_%G[0_C_P 2ZKXJU&+PCJ,@L-/TS6[B!+2,Z=$9/*B1PF]MW5P0N 1@
MY)\X\%>--0TGQ-\1=*TJ_M-+TJ[^&]UKG]FZ7XUN?$#0W DC$<TDTN##-MD8
M'RR5;KG@5^@T&@Z;:O?-#I]K"U\_F731PJIN&VA<R8'SG: ,G/ Q61I'PR\'
MZ!#+%IGA71-.BFB>&1+33H8E>-R"Z$*HRK$ D'@X&>E 'R!X7BU7X:ZS\%-1
M\/:UKNHZOXN\&W=QJJ:GJT]ZM_-'IJSPOY<CE%97  ,87@X.<U6T+Q+H_A_]
MF2[\<^$O&5]K7QBU#PQ/>W8FU^XN9GN N;AFLR[)&86R !&NS: !Z_;<?AO2
M(IM.E33+))=.C,5DZVZ!K9"NTK&<?(-O&%P,<57TKP1X=T+4M0U'3=!TS3[_
M % [KRZM;..*6Y/K(ZJ"_P#P(F@#Y<_9;TC6[7Q]INH6/B;PTWAR_P!%:6]T
MRP\=7GB&YU"8[#'>;+B)?*(^8,4(!WXQP*N>+O!'A$_MTZ3J.ML;2[N/##W%
MH\VK3VXFN8[F(*$02JKX!Y0 @]2#7TGX=\ >&/"%U=W.A>'=)T6XNSNN)M.L
M8K=YCG.7**"QSZU9U;PGHFOWMA=ZGH]AJ-U82>=:3W=JDKV[_P!Z-F!*'W7!
MH ^"_!_A\^#?A?HOQ!TO6=;M_$7_  LJ>QP-5G%H+:;56BE@^S!A$4922<J3
MDYSTI;R[\<^/O'_CF_/B7P_X=\6:/XE:TL+O6O'-YILNG6RF,Q(--6$PRQR*
M2<L27+$9&*^\AX1T,6*V7]C:?]C6X^UK;_98_+$V_?Y@7&-^[YMW7/.<U6U/
MX?>%]:UVVUO4/#FD7^LVV!!J-S8127$6.FV1E++^!H ^4[:"QM?%?[0'CSQ+
MJGBC4D\*7Y6ST[3-<N(([539QF3RHU<)N;/WG!V]1CDUYAX9\:ZGI6H_$33]
M'O[?2=,NOA]-K(T[2O&ESK[P3[TV322R@&&;:QR(R0>3GBOT,@T+3;9KUH=/
MM8FOFWW12%09VQMS)@?,<<9.>*XGQ/\  SPKJO@C7_#VBZ-I7A=M5L9K(WFF
MZ9#&T2R?>("A<\@$C/) H ^3/"%IIFO:K\*]+\$^.]8UW4/&/AFX7Q-CQ'/>
M$C[("MPX,C"!XYL*"@3TYKN/V;?''B#XO_$3P]8:E?7@?X<:5+I^NJ)'5+C5
M"YA3S!GYSY2&3G/+ U]&_#GX7:#\-=#L;33-,L(M0CLK>SNM3M[&.">],4:H
M'D*C+$[<\DXJA\)?A+%\,'\473Z@=6U3Q#J\NJW=X;<0$[@%2,*">$50,]3R
M: /GCXN:9X+UG]KW4+/QKXDGT"P/@LO$D.M2:8+AUG!^9XW1FV#Y@N[&1T->
M8CQOXT\8Z%\(-"US5(+[P[J-AJ4J3>(?$]UH4>J-%.5MFDO+=&=W\KY@A(#8
MW'-??&O^ /#'BMW?6O#NDZP[JJLU_8Q3DA3N4'>IX!Y'H:FU[P9H'BG25TO6
MM#TW5],7&VRO[2.>$8Z81U*\=N* /C;1?#?B#7O$'P:\(>+/'$FM6-W-JRSR
M>%_$EQ+'<6R(3%;R7:B.278/E+<-QUKE=;\8^*--\$Z+X0@UEI_#"^/+_1+F
M;7/$5S8*;6- T%M-J"*\R*6. <Y;@$U][6?A/1-/_L_[+H]A;?V>I2S\FUC3
M[,I&"(\#Y 1QA<4RZ\&>'[W2[W3;C0]-GTZ]<RW5I+:1M%.YZLZ%<,3CJ0:
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M]88^%?@M5TM1X1T(+I7.G@:9!_H?.?W7R?N^?[N*ZF@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH *0KD]Z6B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
BBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>tcmd-20221231x10k008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tcmd-20221231x10k008.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &Q F(# 2(  A$! Q$!_\0
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ME:IIUMX*U2R"BWOI+:-EU6:=K6Y)6/+)$F<L1\NQA0![[17AVJ^)/BM!\?\
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M]\,XA!>Q:'!#XMBUL>(/^$RCM;8:V]W]M-VQ:Z\K+(S%HRA&WRCLP!C'M=%
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M &UX(\*ZGX4L;B#5/&.M^,Y99-Z7.MPV,<D(P!L46EM I'?YE)R>N.*Z2B@
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M;6G?\_\ :_\ ?Y?\:NT4 4O[:T[_ )_[7_O\O^-']M:=_P _]K_W^7_&KM%
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M=[8Z?:Z9;);V=M#:6Z?=B@C"(OT XJ?]MK]J:_\  I?I%?\ DQ?^PT.]5_\
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M%'   X 'I4M*KBN:/LJ*Y8=NK_Q/K^2Z((4;/GF[R_+T73\PHHHKA.D****
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M 5&TDG94E=VU?O5([^9\)F#6-Q,Z\ZZLVVDW)V3>BTB]CK**Y/\ X1+6Y/\
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M=,U.TUK3K:_L+F*\LKF,2PSPL&212,@@CJ*M5P<O)[MK6.N]]0HHHH ****
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M ..UF\ZRZ+M*LDS2.19E)7C1;7R_KYGM-%4M$U:'7M%L-3MU=+>]MX[F-90
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M_P#$T?VM!_SSNO\ P$E_^)JVCK*BNC!T895E.01ZBG5XYW%+^UH/^>=U_P"
MDO\ \31_:T'_ #SNO_ 27_XFKM% %+^UH/\ GG=?^ DO_P 31_:T'_/.Z_\
M 27_ .)JX2 ,G@5D:AXQT'2L_;-9L+9A_#)<H&_+.: +?]K0?\\[K_P$E_\
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MU[-]]GU[G+9X=>ZKQ_%>GEY?=V.QV?$C4>LF@:1&?[JR3R#\_EH_X0/Q-?\
M_(2\=7Q!ZII]M';8^C#)K4^'GQ)T/XG:%_:>BW#-L;R[BUF79/:R#K'(G52.
M?8]B:ZFN"=.5*3A-6:.F,E-*47='!#X,:#<'.IW.JZT>YO[]VS_WSBMC3_AK
MX6TO'V?0+ $=&DA$C#\6R:Z6BH*(K>VAM(Q'!$D*#HL:A1^0J6BB@ HHHH *
M*** &2Q)/&T<B+)&PP5<9!^HKDM5^$OA?5)?/735T^Z!RMQI[&W=3Z_+@9^H
MKL** . _X0SQ;H?.B>+7O(ATM=;B$V?K*OS?I1_PFWBG0^-<\(RW,0ZW6BRB
M<'_MF?F'XFN_HH Y#2/BOX7U>7R1JB65T#AK>^4P.I]/FP,_0UUL<B3(KQLK
MHPR&4Y!%4=7\/:9KT7EZEI]M?)C \^(.1]">GX5R4GP@TZRD,N@ZCJ7AR4G.
MVRN6,1/^TC9!'M0!WM%<!]G^(>@?ZNYTSQ1;KVF0VMP?H1\GYTH^+,>ED+XC
MT'5- />=X?/MQ_VT3K^5 '?45D:)XNT7Q&H.F:I:WA/.R.0;Q]5ZC\16O0!'
M.LCP2+"XBE*D([+N"MC@D9&?ID5B_P#")PPPQO;3O%J:,9/M[#<\C'&[>.-R
MG &W@  8Q@8WJ*XL1@L/BFG6C=K;5Z=;KL_[RLUT9M"M.GI!V_KKW7EL%%%%
M=IB%%%% !1110 4444 %%5[Z_M=+M7N;RYAM+9,;YIW"(N3@9)X') _&K% !
M1110 45YR/VA?A^Q &OY)Z 65Q_\;K6\-_%SPCXMNKBWTO6$GDMX&N9?,ADA
M5(U(!8LZJ, L._>N&GC\)5DH4ZT6WLE)._IJ>A4R_&4HN=2C));MQ:MZZ'85
M6U'4K32+*:\OKJ&RLX5W2W%Q((XT'JS'@#ZUY+JO[0#>(]1FT;X9Z+)XTU*,
M[)=0!\K3+4\<O,>&X.<+U[&DT_X"W7BV]AU7XH:Z_BR\1M\6CV^8=+MC_LQC
M!D/^TV,]P:]]83V2YL5+D\MY/Y=/G;RN>(Z_/I17-Y]/OZ_*Y%>_'75?'5U+
MIGPLT%M?=6,<GB#40T&F0'GHQ^:4@]E^HR*MZ%^S_#J6IQ:Y\0]7F\=:VAW1
MPW*[-/M3G.(K<?*?3+9SUP#7K%G96^G6L5M:016UM$NV.&% B(/0 < 5-0\9
M[-<F&CR+OO)^KZ>BLAJAS.]9\S_#[O\ .XR*)((DCC18XT 5448"@= !V%/H
MJ.6>.$9DD6,>K,!7FRDDKR9U)7T1)16=-XBTJW_UNIV<?^_<(/ZU2F\>>'H/
MO:Q:G_<DW?RS7FU<TP%#^+7A'UE%?FSHCAJ\_A@W\F;U%<H_Q0\-*=JZB96_
MNQP2-_[+2?\ "R=/D_U%CJEUZ>39L<_GBO/?$>37M'%PEZ24ORN;_P!GXOK2
MDO5-?F=917)?\)U<R_ZCPQK+?]=8!'_,UA7?B'7VUR4Z3X?DMKZ2'?<133HR
M, ,([*,;6&,#GY@,8.!CBQ7%&!H1C*FIU+M*T85&]>WNV;\KK2[5VK/:GEM:
M;:E:/K*/XZGI5%>?>'+#Q-J&FB2#5;&PBF<O)+'$TT[/T;?OP PQC&!C &!B
MM3_A7D=YSJNL:EJ>>L;S^7$?^ K_ (U>'SG&XVC&KAL%+WE>\I1C'7S]Z7_D
MGI<53"4:,W&I66G9-O\ 1?B;.H^*-(TK(N]2MH&'\#2#=_WR.:QC\2+&Z)73
M+'4-7;H&M;9MGXLV,5IZ?X,T/2L&VTNV1AT=DWL/Q;)K-\1?%3PIX5)BOM9M
MA<#Y1;6Y\Z7/8;$R1^.*NJ\U<>?$5Z="/DG)_P#@4G%?^2%TJ=&I+DH4IU)?
M=^"3?XB?VKXNU+_CUT:STQ#T>_N/,/UVITH_X1?7]0YU'Q--$IZQ:="L6/H_
M6L/_ (6/XG\1\>&/!ETL+=+[7'%K']0G+,/I2?\ " >,/$G/B3QE+:0-]ZQ\
M/Q_9U]QYI^<CZBN'ZE#$_'4K5_63IQ_\E]G%KY2._DE1_B.G2\OCE]WO-/U<
M2QK&D^!O"/[_ %^_B:<#(;4KLO(WT3//X"L^R^*$%XGE>!_!M]JZGA;E8%LK
M0^G[Q@,_E71>'_A)X3\-R":VT>&>ZSDW5YF>4GUW/G!^F*Z\# P.E>AA<GCA
MWS4*=.C_ ((IR^<FE^,7ZG/5QN'V?-5_Q.T?_ 4V_P#R9'FW]@?$;Q/SJ6OV
M/A>T;K;:1#YTV/0R/]T^ZU<TOX)>&+2Y%WJ$%QXBO^]UK,[7#'_@)^7]*[ZB
MO6CE]"_-43F^\G?[D]%\DCEEF6(MRTFH+M%<OWM:OYMD5M:PV4"0V\,<$*#"
MQQ*%5?H!4M9NI^)-)T4$W^IVEECM/.J'\B:YBY^,WA9)3#:74^JW _Y96%L\
MI/XX _6O122T1YC;;NSM);J&"2%)94C>9MD:NP!=L$X4=S@$X'8&I:^6_B=\
M6;KQ!XLT^YT^*XTZ+2'W10W(VR"8-\Q=0>.@7'L?4UZOH&L>._'6D6VI65YH
M6DV%PN4:..2>8<X((/RY!!'X4Q'IM07=];6$7F75Q%;1_P!^9PH_,UQ/_"M]
M7U'_ )"_C;5[D'[R6 2T4^V%!XJ:T^#7A.WE\V;3FU"?O+>SO*3]03C]* +.
MI?%KPCI9*RZY;2OT"VV9R3Z?(#5#_A:YO^-'\,:YJ>>DOV;R8C_P-C_2NNTW
M0-,T< 6&G6ED!_S[PJG\A5^@#@O[9^(6J?\ 'KX?TO1E/1M1O#,0/I'1_P (
MCXTU/_D(>,ELT/6'3+)5_)VYKO:* ."'P;T>[.=6O]7UT]2+^^<K^2XXK;TS
MX>>&='P;30K&-AT=H0[C_@39-=%10 U$6-0JJ%4<  8 IU%% %>_T^UU2U>U
MO;:&[MI,;X9XPZ-@Y&5/!Y /X5D?\(!X7_Z%O2/_  !B_P#B:WZ* *>F:/8:
M+ T&G65M80,V\QVL2QJ6P!G"@#. .?:KE%% !1110!Y3\0O@_=2ZU)XR\"7B
M>'_&B+^]R/\ 1=34?\L[A.A)QP_4?D1I_#'XPVGCJ6?1M3M)/#WC&Q&+[0[L
MX=<?QQ'_ ):1GJ"/4>H)]#KA/BA\)-.^),%K="XET;Q'IY\S3M<L^)[9NN/]
MI#W4^IQ@\UZ4*\*T52Q/3:75>3[Q\MUT[/DE3E3;G2^:Z/\ R?Y]>YW=%>1>
M!_BYJ6D^(X_!/Q&AATKQ*>+'4XOELM64<;HV. LGJAQR>,9 KUVN6M0G0ERS
MZ[/HUW3-J=2-17C_ ,,%%%%<YJ%%%% !1110 4444 %%%% !1110 4A (P>1
M2T4 <OK?PR\,>(&+W6CVZS$Y\^W'DR9]=R8)/UK(_P"%>:YHO/A_Q??0H.EK
MJ:BZC^@)P5'TKOZ* . /B;QOH /]J^&[?6(%^]<Z-/AL>OEOR3]*XOP?\;FU
MWXI21RO)!HE^JVUM#,0/*<?=8@$C+$D''JO]VO2?B9%K=UX0O+3P_:FZU"Z_
M<<2I'Y<9SO;+$=N.#G+ ]J^=H_@AXZBD5TT9D=3D,MY "#ZY\R@#ZSHK+\+S
M:E<>'[%]8MOLFI^4%N(MRM\XX)RI(P<9Z]ZU* "BBB@ HHHH **** /GG]KV
M'PE-9>$Y/%GB'P1I\-G<7%[!HOQ(@5]#U@K&$:)Y'(6&<"0>7)ME90TK"&4!
M@O,1_$7X?S_&/X!ZQ?W&F>"?%NKZ&8U\+:IJB1W6F1W%JGV>T2V9@(BTC"/"
M1H9&C0$$HH7ZEO+"UU!8ENK:&Y6*19HQ-&'"2*<JXST8'D'J*L4 ?G!#<^'S
MX$T^YT(V_P#PD0\/RCXQ/IX3[4K?VMI_V_\ M79R)1&-5QYGS"(7&WY17U?^
MR^OAQ5^(1\!C3A\.&\0*= .B!/[-*_8;7[3]C\O]WY7VGSL^7\OF^=WS7N%%
M 'P)X9M([SS$F0+&AWBX Y0XYSZCV]>E=/IW@S2=8U9+232;O7TA3SWTZV20
M";#+\TA3ED!*_+D#.W\?7C^RY'"LD%KXE>*T\PND<ED'<#MN8.-Q [X'T%=/
M\/O@S<> O$$6HKKXO8A"\#P&RV%D;!P&WG&&53T/0^M?FV$X7Q5"I1JK$.GR
M-RM!JZDU;F3<7K]GE5E;WKWOS?:9CG\,75K-0O&:MK_*MDU?YWWO=;;<2GQA
MU;PC81:?9^$UT2P@7;'!%I[1(@]@7 _2JI_:(OY>9)KRV'_3"P@<_K+7T?5&
M\T/3=1S]JT^UN<]?.A5_YBO=J\/NLW*6,K-_]?&O_2>5_B>+2S&%-6^KP?R_
MS;7X'A%I\96U,9-_XKE!_P"?;1X5_P#09#5T^/\ 2FYO+OQXOJ/LYC'Z9KTZ
M\^%GA*^SYOA^Q7/_ #QC\K_T'%9I^"OAJ$DV*WVF'UL[V1<?F37+_JO2^U5E
M+_%*I+\ZAU?VM2_Y\V]&E_[8>?MX_P#A_P#\ODGB63U^U++_ $-/M_B%\(@W
M^IG+]S,DW]6KO/\ A6%[:_\ 'AXT\00^@N9UG4?@0*:_A+QO;C$7B^UOU'1+
M[3$'ZJ<FA<,86+O[&BW_ 'J-W][F#S2D]+5%Z5$O_;#G+3XC_"Q<>7!9_P#;
M6)/_ &8ULVGQ.^'Z8\B33(?H]LG_ +.*272?'$'^NTGPGJJ?[*21N?KN&*J2
MC4XO^/\ ^%6GW*]Y+6:WDS_P$KFO2I97*A_"ITEZ4[?DSGEBL+4^+VG_ (&G
M_P"VHZ.W^*GA8KB'5-/ _NC4+4?IYM78OB%HTW^KN[:3/]V^MC_[5KA9;[PH
MG_(2^%EU:GO(-#BD0?\  EJL=0^#\S[+K1[.PD/\%QIKQ']%Q7H+Z]%62A^*
M_1F'_">^LU\HO]4=MXM\<+:>$=;N]/<)=P6,\L,JS0/L=8V*G&\YP0.,'Z&O
MEN/X_P#CR*221-;1'E(9V6QM@7(  )/E\\ #\*]C\4>'?A5>>$M;ETF/2#J2
MV,[6JQ3E9#*(V*;5+ D[L8&*^;8]!NX''VVUGM59<IYT93=[C/6OC,[CFM?%
MT:-%\K=_AE*WJW96T_ ^WR)Y10PE:M72DDU\<8W]$KN^I[C\(/C]>+)JZ>)&
MO-8NYVB>UM]-T^,R.V&$A(0+DX$8R?2O1;CQ9\1/$*_\27PG#HELW2YUF=6E
MQZB)2"#[&O+_ -FKQ)I?@I?$[ZW>)IXF^S>5YH.9 /-SM &3U'3U%>Q?\+AT
MZ]XT?2=9US/W7L[)A'^+-C _"O9R;#XNK@:?UBK);Z6M+XGNW=_=8\3.Z^#H
M8^HL-1B]M=X_"MHJR^^^MS&_X5EJNO\ S>+=;UW65;EK.T>&TMC[%$?)^N0:
MZOP[X3T7PFH&D>%A9,!CS46$R'ZN7+'\36;_ ,)+XZU3_CQ\*6NF(>DNJ7H;
M\T3D4?\ "->.M4_X_O%=KIB'K%I=D&_)WY%?04L%AZ,N>,+R[O5_>[O\3YVK
MC\36CR2G:/9:+[E9?@=A]OG_ .@;<_\ ?47_ ,76+JGQ$T?1<B^GCMF'5'N8
M-_\ WSYF?TK)_P"%/:=>\ZQJVLZYG[R7EZPC_!5Q@?C6UI?PY\,:-@VNA62,
M.CO$)&'_  )LFNXX#GX_C?HEXYCT[3]7U:0'&VQL_,Y^N:D?QKXPU%<Z7X(E
MB0])=2O$B(^J=?UKO418D"HH11P%48 IU 'FIM_B3JI_TF\L]%0]M.MDG8#Z
MR2=:/^%;SW_.LZKXEU3/6+[7%#$?^ *_]:]*HH X;3/AQX9TD@P^$!(PYW7)
MCF.?7YY#70R^=%IT]MI^G2V$C1LL3HD)6-B,!MHD&<'!QQ6Q10!\]O\ LW7,
MKL[ZO=.[')9K*(DG_P "*]%^&?A"_P#AYIEU822W6IVTD@EB4PQ1>4<8;_EL
MV0<+Z8P?6N_HH I?;Y_^@;=?]]1?_%T?;Y_^@;=?]]1?_%U=HH I?;Y_^@;=
M?]]1?_%T?;Y_^@;=?]]1?_%U=HH I?;Y_P#H&W7_ 'U%_P#%T?;Y_P#H&W7_
M 'U%_P#%U=HH I?;Y_\ H&W7_?47_P 71]OG_P"@;=?]]1?_ !=7:* *7V^?
M_H&W7_?47_Q='V^?_H&W7_?47_Q=7:* *7V^?_H&W7_?47_Q='V^?_H&W7_?
M47_Q=7:* *7V^?\ Z!MU_P!]1?\ Q='V^?\ Z!MU_P!]1?\ Q=7:* *7V^?_
M *!MU_WU%_\ %T?;Y_\ H&W7_?47_P 75VB@"E]OG_Z!MU_WU%_\71]OG_Z!
MMU_WU%_\75VB@#DO''A+2_B+H$VCZ]H$]Y:2<J2T0DB?LZ-ORK#U'XY&17E^
MD^//$GP%EAT?QXEWK'A*240:;XH.UI8 >%BNP&('H),\X[\[??:JZII=GK>G
M7%AJ%M%>V5PACFMYT#I(IZ@@]:[:.(Y(^RJKF@^G5>:?1_@^ISU*7,^>#M+^
MM'_7H0P:LUU!'-#8SS0R*'22.2%E92,@@A^01WI_V^?_ *!MU_WU%_\ %UXG
M<:3XA_9PO&N]$BN_$GPS8EKG20QEN]''4O 3R\0Y)4]/S:O8_"WBO2?&NAVV
ML:)?1:CIUP,I-$<CW!'4$="#R*5?#^S2J0?-![/]'V?E]UT.G5YWR25I+I^J
M[HL_;Y_^@;=?]]1?_%T?;Y_^@;=?]]1?_%U=HKC-RE]OG_Z!MU_WU%_\71]O
MG_Z!MU_WU%_\75VB@"E]OG_Z!MU_WU%_\71]OG_Z!MU_WU%_\75VB@"E]OG_
M .@;=?\ ?47_ ,71]OG_ .@;=?\ ?47_ ,75VB@"E]OG_P"@;=?]]1?_ !='
MV^?_ *!MU_WU%_\ %U=HH I?;Y_^@;=?]]1?_%T?;Y_^@;=?]]1?_%U=HH I
M?;Y_^@;=?]]1?_%T?;Y_^@;=?]]1?_%U=HH I?;Y_P#H&W7_ 'U%_P#%U/;S
MO.I+V\EN1VD*G/\ WR34U% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %,DB29"DB*ZGJK#(I]% &+>>"_#^H9^TZ)ITY/
M\3VJ$_GC-?+OBSPCK6J>(K^YTWPCJ=EI[2$00QZ?* $' .-O4XR?<U]>44 >
M)? #2+FP6_L=9\,RVDZ$3P7UWIY1B. R;V4=."!GNWI7MM%% !1110 4444
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M4LXM1AL'NX$OYHVEBM6E42NBD!F5<Y(!(R1TR/6K5>>TUN=-PHHHI#"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBJ\]_:VMS;6\US#%
M<7)98(GD"O*0I9@H/+$ $G'89H L4444 %%%% !1110 4444 %%%% !1110
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M'X>C31\.&UN(Z,=#"?V87^PVPN?L?E_N_*\T'=Y?R^;Y_P#%OKW&B@!&SM.
M">P)Q5/S=1_Y];7_ ,"6_P#C=7:* *7FZC_SZVO_ ($M_P#&Z/-U'_GUM?\
MP);_ .-U=HH I>;J/_/K:_\ @2W_ ,;H\W4?^?6U_P# EO\ XW5VB@"EYNH_
M\^MK_P"!+?\ QNCS=1_Y];7_ ,"6_P#C=7:* *7FZC_SZVO_ ($M_P#&Z/-U
M'_GUM?\ P);_ .-U=HH I>;J/_/K:_\ @2W_ ,;H\W4?^?6U_P# EO\ XW5V
MB@"EYNH_\^MK_P"!+?\ QNCS=1_Y];7_ ,"6_P#C=7:* *7FZC_SZVO_ ($M
M_P#&Z/-U'_GUM?\ P);_ .-U=HH I>;J/_/K:_\ @2W_ ,;H\W4?^?6U_P#
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M];7_ ,"6_P#C=7:* *7FZC_SZVO_ ($M_P#&Z/-U'_GUM?\ P);_ .-U=HH
MI>;J/_/K:_\ @2W_ ,;H\W4?^?6U_P# EO\ XW5VB@"EYNH_\^MK_P"!+?\
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M"2 8'XFCV6$G\%1Q_P 2T^^-_P @YZT?B@GZ/]';\SU?S=1_Y];7_P "6_\
MC=3V[3LI\^..,]A'(7S^:BOGWQ_\2_BO\#= .K^(H/#GBO1Q*L N;-)[>X#-
MG!D !15XZ],D#.2*^6/#_P"TGXTT7XFS>-)K\WUS=$)=V+L5MY8 >(@O.T+D
M[2.023SEL^IA<BKXN$JE.2:6SON^WE\SBK9E2H249)WZ^2/TOHK!\"^,+7Q_
MX0TKQ#90W%O:ZA")DBNHRDB\D$$'W!P1P1@@D$&MZOG)QE"3A)6:/5C)22DM
MF%%%%24%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M'<9XH VJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MC/\ Z#^@_P#@CF_^3*/[/\9_]!_0?_!'-_\ )E=110!R_P#9_C/_ *#^@_\
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M_P"@_H/_ ((YO_DRNHHH Y?^S_&?_0?T'_P1S?\ R91_9_C/_H/Z#_X(YO\
MY,KJ** .7_L_QG_T']!_\$<W_P F4?V?XS_Z#^@_^".;_P"3*ZBB@#E_[/\
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M6CVXQ*\ZE2K2R9QY .01][IQ734P1()6D"*)& 5G Y(&< GT&3^9H ?1110
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M5LV?AC1M/O+6[M=)L;:[M;0:?!/#;(DD-L""($8#*QY53L''RCCB@#3HHHH
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M>T:T\/6FCV]W#9Z1I%K#:6$;W+1&6?R8T \W$(4-GA7<8^8T]?@?\.4\9?\
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MQA^RCX,\<>&;?1-4EOI[6WMI+>$S1VMR$+W:7>\Q30/%(1)& %D1D*D@J>M
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%9?B?0O^$FT&\TO^T;_2?M*!/MFF3^3<Q<@Y1\':>,=.A-5%)M
M)NR$[I:&I6!9^/O#VH>+;SPO;ZO;3:_9Q+-/8*WSHI_0D<9 .1E<@9&?/?\
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M^'YM/TOPI=7.JRZQ=7<WB_5/%,ES/'8FVMT>6^A1_*D#M#/&.&MP\8)\XF,
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MQ7\&:UKEWX,U/P<^GZEJ6FI;ZI<VMQY[6EU/;,P-O*^"&@(93@!MP1I$"R,
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L4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>12
<FILENAME>tcmd-20221231.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.2.0.4 -->
<!--Based on XBRL 2.1-->
<!--Created on: 2/21/2023 1:38:41 PM-->
<!--Modified on: 2/21/2023 1:38:41 PM-->
<xsd:schema xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" targetNamespace="http://www.tactilemedical.com/20221231" elementFormDefault="qualified" attributeFormDefault="unqualified" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:tcmd="http://www.tactilemedical.com/20221231" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:currency="http://xbrl.sec.gov/currency/2022" xmlns:us-roles="http://fasb.org/us-roles/2022" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:sic="http://xbrl.sec.gov/sic/2022" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:srt-roles="http://fasb.org/srt-roles/2022" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:exch="http://xbrl.sec.gov/exch/2022" xmlns:naics="http://xbrl.sec.gov/naics/2022" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:attributeFormDefault="unqualified" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:srt="http://fasb.org/srt/2022" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:dtr="http://www.xbrl.org/2009/dtr" xmlns:cef="http://xbrl.sec.gov/cef/2022" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.tactilemedical.com/role/DisclosureStandardAndCustomAxisDomainDefaults" id="DisclosureStandardAndCustomAxisDomainDefaults">
        <link:definition>99900 - Disclosure - Standard And Custom Axis Domain Defaults</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tactilemedical.com/role/StatementConsolidatedBalanceSheets" id="StatementConsolidatedBalanceSheets">
        <link:definition>00100 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfOperations" id="StatementConsolidatedStatementsOfOperations">
        <link:definition>00200 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfComprehensiveLoss" id="StatementConsolidatedStatementsOfComprehensiveLoss">
        <link:definition>00300 - Statement - Consolidated Statements of Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfCashFlows" id="StatementConsolidatedStatementsOfCashFlows">
        <link:definition>00500 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tactilemedical.com/role/DisclosurePurchasePriceAllocationDetails" id="DisclosurePurchasePriceAllocationDetails">
        <link:definition>40402 - Disclosure - Purchase Price Allocation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tactilemedical.com/role/DisclosurePatentCostsNetDetailsCalc2" id="DisclosurePatentCostsNetDetailsCalc2">
        <link:definition>40502 - Disclosure - Patent Costs, Net (Details) (Calc 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tactilemedical.com/role/DisclosureInventoriesDetails" id="DisclosureInventoriesDetails">
        <link:definition>40601 - Disclosure - Inventories (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tactilemedical.com/role/DisclosurePropertyAndEquipmentDetails" id="DisclosurePropertyAndEquipmentDetails">
        <link:definition>40701 - Disclosure - Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tactilemedical.com/role/DisclosureGoodwillAndIntangibleAssetsDetails" id="DisclosureGoodwillAndIntangibleAssetsDetails">
        <link:definition>40801 - Disclosure - Goodwill And Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tactilemedical.com/role/DisclosureAccruedExpensesDetails" id="DisclosureAccruedExpensesDetails">
        <link:definition>40901 - Disclosure - Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tactilemedical.com/role/DisclosureWarrantyReservesDetails" id="DisclosureWarrantyReservesDetails">
        <link:definition>41001 - Disclosure - Warranty Reserves (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesUndiscountedCashFlowsDetailsCalc2" id="DisclosureCommitmentsAndContingenciesUndiscountedCashFlowsDetailsCalc2">
        <link:definition>41004 - Disclosure - Commitments and Contingencies - Undiscounted cash flows (Details) - Calc2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tactilemedical.com/role/DisclosureCreditAgreementMaturitiesOfDebtDetails" id="DisclosureCreditAgreementMaturitiesOfDebtDetails">
        <link:definition>41102 - Disclosure - Credit Agreement - Maturities of Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesLeaseRelatedAssetsAndLiabilitiesDetails" id="DisclosureCommitmentsAndContingenciesLeaseRelatedAssetsAndLiabilitiesDetails">
        <link:definition>41202 - Disclosure - Commitments and Contingencies - Lease related assets and liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesUndiscountedCashFlowsDetails" id="DisclosureCommitmentsAndContingenciesUndiscountedCashFlowsDetails">
        <link:definition>41203 - Disclosure - Commitments and Contingencies - Undiscounted cash flows (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tactilemedical.com/role/DisclosureRevenueDetails" id="DisclosureRevenueDetails">
        <link:definition>41401 - Disclosure - Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tactilemedical.com/role/DisclosureIncomeTaxesDetails" id="DisclosureIncomeTaxesDetails">
        <link:definition>41501 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tactilemedical.com/role/DisclosureDisclosureIncomeTaxesDetailsCalc2" id="DisclosureDisclosureIncomeTaxesDetailsCalc2">
        <link:definition>41601 - Disclosure - Disclosure - Income Taxes (Details) (Calc 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tactilemedical.com/role/DisclosureNetLossIncomePerCommonShareBasicAndDilutedNetLossPerShareDetails" id="DisclosureNetLossIncomePerCommonShareBasicAndDilutedNetLossPerShareDetails">
        <link:definition>41601 - Disclosure - Net (Loss) Income Per Common Share - Basic and Diluted Net Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tactilemedical.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tactilemedical.com/role/StatementConsolidatedBalanceSheetsParenthetical" id="StatementConsolidatedBalanceSheetsParenthetical">
        <link:definition>00105 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfStockholdersEquity" id="StatementConsolidatedStatementsOfStockholdersEquity">
        <link:definition>00400 - Statement - Consolidated Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tactilemedical.com/role/DisclosureNatureOfBusinessAndOperations" id="DisclosureNatureOfBusinessAndOperations">
        <link:definition>10101 - Disclosure - Nature of Business and Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tactilemedical.com/role/DisclosureBasisOfPresentation" id="DisclosureBasisOfPresentation">
        <link:definition>10201 - Disclosure - Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tactilemedical.com/role/DisclosureSummaryOfSignificantAccountingPolicies" id="DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>10301 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tactilemedical.com/role/DisclosureGoodwillAndIntangibleAssets" id="DisclosureGoodwillAndIntangibleAssets">
        <link:definition>10801 - Disclosure - Goodwill and Intangible Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tactilemedical.com/role/DisclosureAccruedExpenses" id="DisclosureAccruedExpenses">
        <link:definition>10901 - Disclosure - Accrued Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingencies" id="DisclosureCommitmentsAndContingencies">
        <link:definition>11201 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tactilemedical.com/role/DisclosureStockholdersEquity" id="DisclosureStockholdersEquity">
        <link:definition>11301 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tactilemedical.com/role/DisclosureIncomeTaxes" id="DisclosureIncomeTaxes">
        <link:definition>11501 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tactilemedical.com/role/DisclosureNetLossIncomePerCommonShare" id="DisclosureNetLossIncomePerCommonShare">
        <link:definition>11601 - Disclosure - Net (Loss) Income Per Common Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tactilemedical.com/role/DisclosureFairValueMeasurements" id="DisclosureFairValueMeasurements">
        <link:definition>11701 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tactilemedical.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>20302 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tactilemedical.com/role/DisclosureGoodwillAndIntangibleAssetsTables" id="DisclosureGoodwillAndIntangibleAssetsTables">
        <link:definition>30803 - Disclosure - Goodwill and Intangible Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tactilemedical.com/role/DisclosureAccruedExpensesTables" id="DisclosureAccruedExpensesTables">
        <link:definition>30903 - Disclosure - Accrued Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesTables" id="DisclosureCommitmentsAndContingenciesTables">
        <link:definition>31203 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tactilemedical.com/role/DisclosureStockholdersEquityTables" id="DisclosureStockholdersEquityTables">
        <link:definition>31303 - Disclosure - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tactilemedical.com/role/DisclosureIncomeTaxesTables" id="DisclosureIncomeTaxesTables">
        <link:definition>31503 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tactilemedical.com/role/DisclosureNetLossPerShareTables" id="DisclosureNetLossPerShareTables">
        <link:definition>31603 - Disclosure - Net Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tactilemedical.com/role/DisclosureFairValueMeasurementsTables" id="DisclosureFairValueMeasurementsTables">
        <link:definition>31703 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tactilemedical.com/role/DisclosureNatureOfBusinessAndOperationsDetails" id="DisclosureNatureOfBusinessAndOperationsDetails">
        <link:definition>40101 - Disclosure - Nature of Business and Operations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tactilemedical.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesDetails">
        <link:definition>40302 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tactilemedical.com/role/DisclosureAcquisitionsDetails" id="DisclosureAcquisitionsDetails">
        <link:definition>40401 - Disclosure - Acquisitions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tactilemedical.com/role/DisclosureAcquisitionsPurchasePriceAllocationDetails" id="DisclosureAcquisitionsPurchasePriceAllocationDetails">
        <link:definition>40402 - Disclosure - Acquisitions - Purchase Price Allocation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tactilemedical.com/role/DisclosureAcquisitionsAllocationOfPurchasePriceDetails" id="DisclosureAcquisitionsAllocationOfPurchasePriceDetails">
        <link:definition>40403 - Disclosure - Acquisitions - Allocation of Purchase Price (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tactilemedical.com/role/DisclosureAcquisitionsConsolidatedStatementsOfOperationsReflectAfflovestOperationsDetails" id="DisclosureAcquisitionsConsolidatedStatementsOfOperationsReflectAfflovestOperationsDetails">
        <link:definition>40404 - Disclosure - Acquisitions - Consolidated Statements of Operations Reflect AffloVest Operations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tactilemedical.com/role/DisclosureAccountsReceivableDetails" id="DisclosureAccountsReceivableDetails">
        <link:definition>40501 - Disclosure - Accounts Receivable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tactilemedical.com/role/DisclosureCreditAgreementDetails" id="DisclosureCreditAgreementDetails">
        <link:definition>41101 - Disclosure - Credit Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesLeaseObligationsDetails" id="DisclosureCommitmentsAndContingenciesLeaseObligationsDetails">
        <link:definition>41201 - Disclosure - Commitments and Contingencies - Lease Obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesMajorVendorsDetails" id="DisclosureCommitmentsAndContingenciesMajorVendorsDetails">
        <link:definition>41205 - Disclosure - Commitments and Contingencies - Major Vendors (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesRetirementPlanDetails" id="DisclosureCommitmentsAndContingenciesRetirementPlanDetails">
        <link:definition>41207 - Disclosure - Commitments and Contingencies - Retirement Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesLegalProceedingsDetails" id="DisclosureCommitmentsAndContingenciesLegalProceedingsDetails">
        <link:definition>41208 - Disclosure - Commitments and Contingencies - Legal Proceedings (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tactilemedical.com/role/DisclosureStockholdersEquitySeriesBPreferredStockDetails" id="DisclosureStockholdersEquitySeriesBPreferredStockDetails">
        <link:definition>41301 - Disclosure - Stockholders' Equity - Series A &amp; B Preferred Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockBasedCompensationDetails" id="DisclosureStockholdersEquityStockBasedCompensationDetails">
        <link:definition>41302 - Disclosure - Stockholders' Equity - Stock-Based Compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails" id="DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails">
        <link:definition>41303 - Disclosure - Stockholders' Equity - Stock Options and Restricted Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tactilemedical.com/role/DisclosureStockholdersEquityEmployeeStockPurchasePlanDetails" id="DisclosureStockholdersEquityEmployeeStockPurchasePlanDetails">
        <link:definition>41304 - Disclosure - Stockholders' Equity - Employee Stock Purchase Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tactilemedical.com/role/DisclosureNetLossIncomePerCommonShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" id="DisclosureNetLossIncomePerCommonShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails">
        <link:definition>41602 - Disclosure - Net (Loss) Income Per Common Share - Antidilutive Securities Excluded From Computation of Earnings Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tactilemedical.com/role/DisclosureFairValueMeasurementsDetails" id="DisclosureFairValueMeasurementsDetails">
        <link:definition>41701 - Disclosure - Fair Value Measurements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tactilemedical.com/role/DisclosureFairValueMeasurementsEarnOutLiabilityDetails" id="DisclosureFairValueMeasurementsEarnOutLiabilityDetails">
        <link:definition>41702 - Disclosure - Fair Value Measurements - Earn out liability (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tactilemedical.com/role/DisclosureFairValueMeasurementsFairValueHierarchyDetails" id="DisclosureFairValueMeasurementsFairValueHierarchyDetails">
        <link:definition>41703 - Disclosure - Fair Value Measurements - Fair Value Hierarchy (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tactilemedical.com/role/DisclosureAcquisitions" id="DisclosureAcquisitions">
        <link:definition>10401 - Disclosure - Acquisitions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tactilemedical.com/role/DisclosureAccountsReceivable" id="DisclosureAccountsReceivable">
        <link:definition>10501 - Disclosure - Accounts Receivable</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tactilemedical.com/role/DisclosureInventories" id="DisclosureInventories">
        <link:definition>10601 - Disclosure - Inventories</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tactilemedical.com/role/DisclosurePropertyAndEquipment" id="DisclosurePropertyAndEquipment">
        <link:definition>10701 - Disclosure - Property and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tactilemedical.com/role/DisclosureWarrantyReserves" id="DisclosureWarrantyReserves">
        <link:definition>11001 - Disclosure - Warranty Reserves</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tactilemedical.com/role/DisclosureCreditAgreement" id="DisclosureCreditAgreement">
        <link:definition>11101 - Disclosure - Credit Agreement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tactilemedical.com/role/DisclosureRevenue" id="DisclosureRevenue">
        <link:definition>11401 - Disclosure - Revenue</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tactilemedical.com/role/DisclosureAcquisitionsTables" id="DisclosureAcquisitionsTables">
        <link:definition>30403 - Disclosure - Acquisitions (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tactilemedical.com/role/DisclosureInventoriesTables" id="DisclosureInventoriesTables">
        <link:definition>30603 - Disclosure - Inventories (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tactilemedical.com/role/DisclosurePropertyAndEquipmentTables" id="DisclosurePropertyAndEquipmentTables">
        <link:definition>30703 - Disclosure - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tactilemedical.com/role/DisclosureWarrantyReservesTables" id="DisclosureWarrantyReservesTables">
        <link:definition>31003 - Disclosure - Warranty Reserves (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tactilemedical.com/role/DisclosureCreditAgreementTables" id="DisclosureCreditAgreementTables">
        <link:definition>31103 - Disclosure - Credit Agreement (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tactilemedical.com/role/DisclosureRevenueTables" id="DisclosureRevenueTables">
        <link:definition>31403 - Disclosure - Revenue (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tactilemedical.com/role/DisclosureSummaryOfSignificantAccountingPoliciesSegmentDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesSegmentDetails">
        <link:definition>40301 - Disclosure - Summary of Significant Accounting Policies - Segment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesLeaseCommitmentsAndOperatingLeaseCostDetails" id="DisclosureCommitmentsAndContingenciesLeaseCommitmentsAndOperatingLeaseCostDetails">
        <link:definition>41204 - Disclosure - Commitments and Contingencies - Lease commitments and operating lease cost (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesPurchaseCommitmentsDetails" id="DisclosureCommitmentsAndContingenciesPurchaseCommitmentsDetails">
        <link:definition>41206 - Disclosure - Commitments and Contingencies - Purchase Commitments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="tcmd-20221231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links, all" />
      <link:linkbaseRef xlink:type="simple" xlink:href="tcmd-20221231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links, all" />
      <link:linkbaseRef xlink:type="simple" xlink:href="tcmd-20221231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links, all" />
      <link:linkbaseRef xlink:type="simple" xlink:href="tcmd-20221231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links, all" />
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd" />
  <xsd:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd" />
  <xsd:element id="tcmd_EquityIncentivePlan2016Member" name="EquityIncentivePlan2016Member" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="tcmd_EmployeeStockPurchasePlanOfferingPeriodsPeriod" name="EmployeeStockPurchasePlanOfferingPeriodsPeriod" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="tcmd_MedicareAccountsReceivableNonCurrent" name="MedicareAccountsReceivableNonCurrent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="tcmd_AccruedCumulativeDividends" name="AccruedCumulativeDividends" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="tcmd_StockIssuedDuringPeriodPriorToCompletionOfInitialOfferingSharesNewIssues" name="StockIssuedDuringPeriodPriorToCompletionOfInitialOfferingSharesNewIssues" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="tcmd_StockIssuedDuringPeriodRequiredToFundStockDividendsSharesNewIssues" name="StockIssuedDuringPeriodRequiredToFundStockDividendsSharesNewIssues" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="tcmd_AccruedExpensesDisclosureCurrentTextBlock" name="AccruedExpensesDisclosureCurrentTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="tcmd_NumberOfVendors" name="NumberOfVendors" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <xsd:element id="tcmd_DefinedContribution401kRetirementPlanMember" name="DefinedContribution401kRetirementPlanMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="tcmd_IncomeTaxTable" name="IncomeTaxTable" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="tcmd_IncomeTaxLineItems" name="IncomeTaxLineItems" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="tcmd_IncrementalSharesToBeIssuedPercentage" name="IncrementalSharesToBeIssuedPercentage" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="tcmd_IncrementalShareIncrease" name="IncrementalShareIncrease" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="tcmd_PreferredStockToCommonStockConversionRatio" name="PreferredStockToCommonStockConversionRatio" nillable="true" type="xbrli:pureItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="tcmd_PercentageOfClaimsApproved" name="PercentageOfClaimsApproved" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <xsd:element id="tcmd_MedicareMember" name="MedicareMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="tcmd_InsuranceCompanyOneMember" name="InsuranceCompanyOneMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="tcmd_InsuranceCompanyTwoMember" name="InsuranceCompanyTwoMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="tcmd_ConcentrationRiskNumberOfInsuranceCompanies" name="ConcentrationRiskNumberOfInsuranceCompanies" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="tcmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticAnnualIncreaseInSharesReservedAndAvailableForIssuancePercentage" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticAnnualIncreaseInSharesReservedAndAvailableForIssuancePercentage" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <xsd:element id="tcmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticAnnualIncreaseInSharesReservedAndAvailableForIssuanceNumber" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticAnnualIncreaseInSharesReservedAndAvailableForIssuanceNumber" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <xsd:element id="tcmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="tcmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancellationsWeightedAverageGrantDateFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancellationsWeightedAverageGrantDateFairValue" nillable="true" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="tcmd_GarmentsMember" name="GarmentsMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="tcmd_TermOfProductWarranty" name="TermOfProductWarranty" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="tcmd_ControllersMember" name="ControllersMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="tcmd_PaymentOfTaxesForNetShareSettlementOfRestrictedStockUnits" name="PaymentOfTaxesForNetShareSettlementOfRestrictedStockUnits" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="tcmd_EmployeeStockPurchasePlanMember" name="EmployeeStockPurchasePlanMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="tcmd_ExpenseRelatingToInitialPublicOffering" name="ExpenseRelatingToInitialPublicOffering" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="tcmd_AccruedTravelAndEntertainmentCurrent" name="AccruedTravelAndEntertainmentCurrent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="tcmd_ScheduleOfAccruedExpensesTableTextBlock" name="ScheduleOfAccruedExpensesTableTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="tcmd_NatureOfBusinessAndOperationAbstract" name="NatureOfBusinessAndOperationAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="tcmd_DemoEquipmentMember" name="DemoEquipmentMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="tcmd_EffectiveIncomeTaxRateReconciliationUnrecognizedTaxBenefits" name="EffectiveIncomeTaxRateReconciliationUnrecognizedTaxBenefits" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="tcmd_EffectiveIncomeTaxRateReconciliationEmployeeStockPurchasePlan" name="EffectiveIncomeTaxRateReconciliationEmployeeStockPurchasePlan" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="tcmd_EffectiveIncomeTaxRateReconciliationIncentiveStockOptions" name="EffectiveIncomeTaxRateReconciliationIncentiveStockOptions" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="tcmd_EffectiveIncomeTaxRateReconciliationReturnToProvision" name="EffectiveIncomeTaxRateReconciliationReturnToProvision" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="tcmd_EffectiveIncomeTaxRateReconciliationExcessTaxBenefitOnNonQualifiedStockOptionsAndRsu" name="EffectiveIncomeTaxRateReconciliationExcessTaxBenefitOnNonQualifiedStockOptionsAndRsu" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="tcmd_IncreaseDecreaseInOtherAccruedLiabilitiesAndIncomeTaxesPayable" name="IncreaseDecreaseInOtherAccruedLiabilitiesAndIncomeTaxesPayable" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="tcmd_AdjustmentsToAdditionalPaidInCapitalSharesOther" name="AdjustmentsToAdditionalPaidInCapitalSharesOther" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="tcmd_PerformanceBasedStockSettledRestrictedStockUnitsMember" name="PerformanceBasedStockSettledRestrictedStockUnitsMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="tcmd_PercentageToEarnPerformanceBasedStockSettledRestrictedStockUnits" name="PercentageToEarnPerformanceBasedStockSettledRestrictedStockUnits" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="tcmd_DefensiveIntangibleAssetsMember" name="DefensiveIntangibleAssetsMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="tcmd_TimeBasedRestrictedStockUnitsRsusMember" name="TimeBasedRestrictedStockUnitsRsusMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="tcmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueDeferredAndUnissued" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueDeferredAndUnissued" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="tcmd_MedicareReceivablesTimePeriod" name="MedicareReceivablesTimePeriod" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="tcmd_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationPercent" name="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationPercent" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="tcmd_EffectiveIncomeTaxRateReconciliationInterestAndPenaltyPercent" name="EffectiveIncomeTaxRateReconciliationInterestAndPenaltyPercent" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="tcmd_ScheduleOfRevenueFromThirdPartyPayersTableTextBlock" name="ScheduleOfRevenueFromThirdPartyPayersTableTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="tcmd_FlexitouchSystemMember" name="FlexitouchSystemMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="tcmd_VeteransAdministrationMember" name="VeteransAdministrationMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="tcmd_PrivateInsurersMember" name="PrivateInsurersMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="tcmd_PercentageOfRevenue" name="PercentageOfRevenue" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="tcmd_PeriodForConsiderationPaymentAfterShipmentDate" name="PeriodForConsiderationPaymentAfterShipmentDate" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="tcmd_EffectiveIncomeTaxRateReconciliationInternalRevenueServiceExam" name="EffectiveIncomeTaxRateReconciliationInternalRevenueServiceExam" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="tcmd_RentalProductServiceMember" name="RentalProductServiceMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="tcmd_IncreaseDecreaseInNetInvestmentInLease" name="IncreaseDecreaseInNetInvestmentInLease" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="tcmd_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" name="IncreaseDecreaseInOperatingLeaseRightOfUseAsset" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="tcmd_NumberOfVehiclesWithAgreementsWithinInitialNoncancelableLeaseTerm" name="NumberOfVehiclesWithAgreementsWithinInitialNoncancelableLeaseTerm" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="tcmd_AssetsAndLiabilitiesLesseeTableTextBlock" name="AssetsAndLiabilitiesLesseeTableTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="tcmd_AccruedSalesAndUseTax" name="AccruedSalesAndUseTax" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="tcmd_CorporateHeadQuarterInitialLeaseMember" name="CorporateHeadQuarterInitialLeaseMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="tcmd_CorporateHeadQuarterSecondLeaseMember" name="CorporateHeadQuarterSecondLeaseMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="tcmd_AmortizationOfPremiumsAndDiscountsOnSecuritiesAvailableForSale" name="AmortizationOfPremiumsAndDiscountsOnSecuritiesAvailableForSale" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="tcmd_AccruedClinicalStudiesExpensesCurrent" name="AccruedClinicalStudiesExpensesCurrent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="tcmd_DeferredTaxAssetsOperatingLeaseLiability" name="DeferredTaxAssetsOperatingLeaseLiability" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="tcmd_DeferredTaxLiabilitiesRightOfUseAssets" name="DeferredTaxLiabilitiesRightOfUseAssets" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="tcmd_AdditionalOfficeSpaceAdded" name="AdditionalOfficeSpaceAdded" nillable="true" type="dtr-types:areaItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <xsd:element id="tcmd_CorporateHeadQuarterThirdLeaseMember" name="CorporateHeadQuarterThirdLeaseMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="tcmd_EstimatedPayoutPercentage" name="EstimatedPayoutPercentage" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="tcmd_InTransitInventoryAccruedExpense" name="InTransitInventoryAccruedExpense" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="tcmd_UnusualRisksAndUncertaintiesPolicyTextBlock" name="UnusualRisksAndUncertaintiesPolicyTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="tcmd_SharebasedcompensationArrangementBySharebasedpaymentAwardEquityInstrumentsOtherThanOptionsModifiedInPeriod" name="SharebasedcompensationArrangementBySharebasedpaymentAwardEquityInstrumentsOtherThanOptionsModifiedInPeriod" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="tcmd_SharebasedcompensationArrangementBySharebasedpaymentAwardEquityInstrumentsOtherThanOptionsModifiedWeightedAverageGrantDateFairValue" name="SharebasedcompensationArrangementBySharebasedpaymentAwardEquityInstrumentsOtherThanOptionsModifiedWeightedAverageGrantDateFairValue" nillable="true" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="tcmd_StockBasedCompensationExpenseMinimumTargets" name="StockBasedCompensationExpenseMinimumTargets" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="tcmd_NumberOfConsecutiveTradingDaysInWhichStockPriceExceedCertainPercentageOfClosingPriceOfCommonStockRequiredForAwardToBeGranted" name="NumberOfConsecutiveTradingDaysInWhichStockPriceExceedCertainPercentageOfClosingPriceOfCommonStockRequiredForAwardToBeGranted" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="tcmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermOfPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardTermOfPeriod" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="tcmd_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions" name="UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="tcmd_EffectiveIncomeTaxRateReconciliationFederalCarrybackClaimPercent" name="EffectiveIncomeTaxRateReconciliationFederalCarrybackClaimPercent" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="tcmd_TwoThousandEighteenAndTwoThousandTwentyPerformanceBasedRestrictedStockUnitsMember" name="TwoThousandEighteenAndTwoThousandTwentyPerformanceBasedRestrictedStockUnitsMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="tcmd_VendorOneMember" name="VendorOneMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="tcmd_VendorTwoMember" name="VendorTwoMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="TermLoanMember" id="tcmd_TermLoanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="LineOfCreditThresholdContingentIncreaseInBorrowingCapacity" id="tcmd_LineOfCreditThresholdContingentIncreaseInBorrowingCapacity" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="CreditAgreementTotalAggregatePrincipalAmount" id="tcmd_CreditAgreementTotalAggregatePrincipalAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="AfflovestPMember" id="tcmd_AfflovestPMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="AssetAcquisitionConsiderationTransferredEscrowAccount" id="tcmd_AssetAcquisitionConsiderationTransferredEscrowAccount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="AssetAcquisitionBusinessRevenueToExceedBaseRevenueMultiplier" id="tcmd_AssetAcquisitionBusinessRevenueToExceedBaseRevenueMultiplier" type="xbrli:pureItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="GoodwillAmortizationPeriodForTaxPurposes" id="tcmd_GoodwillAmortizationPeriodForTaxPurposes" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfAssetAcquisitionTableTextBlock" id="tcmd_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfAssetAcquisitionTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="DebtInstrumentLeverageRatioTierAxis" id="tcmd_DebtInstrumentLeverageRatioTierAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="DebtInstrumentLeverageRatioTierDomain" id="tcmd_DebtInstrumentLeverageRatioTierDomain" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="AssetAcquisitionEarnoutPaymentsRevenueTargetsFromOctoberTwoThousandTwentyTwoToSeptemberTwoThousandTwentyThreeMember" id="tcmd_AssetAcquisitionEarnoutPaymentsRevenueTargetsFromOctoberTwoThousandTwentyTwoToSeptemberTwoThousandTwentyThreeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="AssetAcquisitionEarnoutPaymentsRevenueTargetsFromOctoberTwoThousandTwentyOneToSeptemberTwoThousandTwentyTwoMember" id="tcmd_AssetAcquisitionEarnoutPaymentsRevenueTargetsFromOctoberTwoThousandTwentyOneToSeptemberTwoThousandTwentyTwoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="EarnOutNonCurrent" id="tcmd_EarnOutNonCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="PaymentsToAcquireProductiveAsset" id="tcmd_PaymentsToAcquireProductiveAsset" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="AfflovestMember" id="tcmd_AfflovestMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="DurableMedicalEquipmentDistributorsMember" id="tcmd_DurableMedicalEquipmentDistributorsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="NewAccountingPronouncementsNoteYetAdoptedPolicyPolicyTextBlock" id="tcmd_NewAccountingPronouncementsNoteYetAdoptedPolicyPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="AssetAcquisitionAmountReceivedResultingFromWorkingCapitalAdjustment" id="tcmd_AssetAcquisitionAmountReceivedResultingFromWorkingCapitalAdjustment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="EarnOutCurrent" id="tcmd_EarnOutCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="AmortizationOfIntangibleAssetsAndEarnOuts" id="tcmd_AmortizationOfIntangibleAssetsAndEarnOuts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="DeferredTaxAssetsBusinessCredits" id="tcmd_DeferredTaxAssetsBusinessCredits" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="EffectiveIncomeTaxRateReconciliationFederalBusinessCreditPercent" id="tcmd_EffectiveIncomeTaxRateReconciliationFederalBusinessCreditPercent" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="DebtInstrumentPaymentOfMandatoryPrincipalPrepayment" id="tcmd_DebtInstrumentPaymentOfMandatoryPrincipalPrepayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="RentToPurchaseArrangementsRentalPeriod" id="tcmd_RentToPurchaseArrangementsRentalPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="EarningsPerShareOtherDisclosureAbstract" id="tcmd_EarningsPerShareOtherDisclosureAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="AssetAcquisitionEarnOutLiability" id="tcmd_AssetAcquisitionEarnOutLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="EarnOutPeriodOnOrBeforeNovember282022Member" id="tcmd_EarnOutPeriodOnOrBeforeNovember282022Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="EarnOutPeriodOnOrBeforeMay262023Member" id="tcmd_EarnOutPeriodOnOrBeforeMay262023Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="AssetAcquisitionImputedInterestPayable" id="tcmd_AssetAcquisitionImputedInterestPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="SecondEarnOutAmendmentMember" id="tcmd_SecondEarnOutAmendmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsResearchAndDevelopmentExpenses" id="tcmd_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsResearchAndDevelopmentExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="BusinessCombinationAdditionalContingentConsiderationLiability" id="tcmd_BusinessCombinationAdditionalContingentConsiderationLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="LitigationSettlementAgreementAmount" id="tcmd_LitigationSettlementAgreementAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>13
<FILENAME>tcmd-20221231_cal.xml
<DESCRIPTION>EX-101.CAL
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.2.0.4 -->
<!--Based on XBRL 2.1-->
<!--Created on: 2/21/2023 1:38:41 PM-->
<!--Modified on: 2/21/2023 1:38:41 PM-->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <roleRef xlink:type="simple" xlink:href="tcmd-20221231.xsd#StatementConsolidatedBalanceSheets" roleURI="http://www.tactilemedical.com/role/StatementConsolidatedBalanceSheets" />
  <roleRef xlink:type="simple" xlink:href="tcmd-20221231.xsd#StatementConsolidatedStatementsOfOperations" roleURI="http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfOperations" />
  <roleRef xlink:type="simple" xlink:href="tcmd-20221231.xsd#StatementConsolidatedStatementsOfComprehensiveLoss" roleURI="http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfComprehensiveLoss" />
  <roleRef xlink:type="simple" xlink:href="tcmd-20221231.xsd#StatementConsolidatedStatementsOfCashFlows" roleURI="http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfCashFlows" />
  <roleRef xlink:type="simple" xlink:href="tcmd-20221231.xsd#DisclosurePurchasePriceAllocationDetails" roleURI="http://www.tactilemedical.com/role/DisclosurePurchasePriceAllocationDetails" />
  <roleRef xlink:type="simple" xlink:href="tcmd-20221231.xsd#DisclosurePatentCostsNetDetailsCalc2" roleURI="http://www.tactilemedical.com/role/DisclosurePatentCostsNetDetailsCalc2" />
  <roleRef xlink:type="simple" xlink:href="tcmd-20221231.xsd#DisclosureInventoriesDetails" roleURI="http://www.tactilemedical.com/role/DisclosureInventoriesDetails" />
  <roleRef xlink:type="simple" xlink:href="tcmd-20221231.xsd#DisclosurePropertyAndEquipmentDetails" roleURI="http://www.tactilemedical.com/role/DisclosurePropertyAndEquipmentDetails" />
  <roleRef xlink:type="simple" xlink:href="tcmd-20221231.xsd#DisclosureGoodwillAndIntangibleAssetsDetails" roleURI="http://www.tactilemedical.com/role/DisclosureGoodwillAndIntangibleAssetsDetails" />
  <roleRef xlink:type="simple" xlink:href="tcmd-20221231.xsd#DisclosureAccruedExpensesDetails" roleURI="http://www.tactilemedical.com/role/DisclosureAccruedExpensesDetails" />
  <roleRef xlink:type="simple" xlink:href="tcmd-20221231.xsd#DisclosureWarrantyReservesDetails" roleURI="http://www.tactilemedical.com/role/DisclosureWarrantyReservesDetails" />
  <roleRef xlink:type="simple" xlink:href="tcmd-20221231.xsd#DisclosureCommitmentsAndContingenciesUndiscountedCashFlowsDetailsCalc2" roleURI="http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesUndiscountedCashFlowsDetailsCalc2" />
  <roleRef xlink:type="simple" xlink:href="tcmd-20221231.xsd#DisclosureCreditAgreementMaturitiesOfDebtDetails" roleURI="http://www.tactilemedical.com/role/DisclosureCreditAgreementMaturitiesOfDebtDetails" />
  <roleRef xlink:type="simple" xlink:href="tcmd-20221231.xsd#DisclosureCommitmentsAndContingenciesLeaseRelatedAssetsAndLiabilitiesDetails" roleURI="http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesLeaseRelatedAssetsAndLiabilitiesDetails" />
  <roleRef xlink:type="simple" xlink:href="tcmd-20221231.xsd#DisclosureCommitmentsAndContingenciesUndiscountedCashFlowsDetails" roleURI="http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesUndiscountedCashFlowsDetails" />
  <roleRef xlink:type="simple" xlink:href="tcmd-20221231.xsd#DisclosureRevenueDetails" roleURI="http://www.tactilemedical.com/role/DisclosureRevenueDetails" />
  <roleRef xlink:type="simple" xlink:href="tcmd-20221231.xsd#DisclosureIncomeTaxesDetails" roleURI="http://www.tactilemedical.com/role/DisclosureIncomeTaxesDetails" />
  <roleRef xlink:type="simple" xlink:href="tcmd-20221231.xsd#DisclosureDisclosureIncomeTaxesDetailsCalc2" roleURI="http://www.tactilemedical.com/role/DisclosureDisclosureIncomeTaxesDetailsCalc2" />
  <roleRef xlink:type="simple" xlink:href="tcmd-20221231.xsd#DisclosureNetLossIncomePerCommonShareBasicAndDilutedNetLossPerShareDetails" roleURI="http://www.tactilemedical.com/role/DisclosureNetLossIncomePerCommonShareBasicAndDilutedNetLossPerShareDetails" />
  <calculationLink xlink:role="http://www.tactilemedical.com/role/StatementConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - Consolidated Balance Sheets">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_638125835182894925" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent_638125835182894925" order="1" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638125835182894925" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638125835182894925" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638125835182894925" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent_638125835182894925" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638125835182894925" xlink:to="us-gaap_AccountsReceivableNetCurrent_638125835182894925" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet_638125835182894925" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638125835182894925" xlink:to="us-gaap_InventoryNet_638125835182894925" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetInvestmentInLease" xlink:label="us-gaap_NetInvestmentInLease_638125835182894925" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638125835182894925" xlink:to="us-gaap_NetInvestmentInLease_638125835182894925" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638125835182894925" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638125835182894925" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638125835182894925" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent_638125835182904927" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsNoncurrent_638125835182904927" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_638125835182904927" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent_638125835182904927" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_638125835182904927" order="1" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638125835182904927" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent_638125835182904927" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638125835182904927" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_638125835182904927" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent_638125835182904927" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_638125835182904927" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill_638125835182904927" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent_638125835182904927" xlink:to="us-gaap_Goodwill_638125835182904927" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_MedicareAccountsReceivableNonCurrent" xlink:label="tcmd_MedicareAccountsReceivableNonCurrent_638125835182904927" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent_638125835182904927" xlink:to="tcmd_MedicareAccountsReceivableNonCurrent_638125835182904927" order="5" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent_638125835182904927" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent_638125835182904927" xlink:to="us-gaap_OtherAssetsNoncurrent_638125835182904927" order="6" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_638125835182904927" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities_638125835182904927" order="1" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_638125835182914927" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638125835182904927" xlink:to="us-gaap_LiabilitiesCurrent_638125835182914927" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_638125835182914927" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638125835182914927" xlink:to="us-gaap_AccountsPayableCurrent_638125835182914927" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent_638125835182914927" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638125835182914927" xlink:to="us-gaap_NotesPayableCurrent_638125835182914927" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_638125835182914927" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638125835182914927" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_638125835182914927" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_638125835182914927" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638125835182914927" xlink:to="us-gaap_AccruedLiabilitiesCurrent_638125835182914927" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="us-gaap_AccruedIncomeTaxesCurrent_638125835182914927" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638125835182914927" xlink:to="us-gaap_AccruedIncomeTaxesCurrent_638125835182914927" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638125835182914927" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638125835182914927" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638125835182914927" order="6" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent_638125835182924926" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638125835182914927" xlink:to="us-gaap_OtherLiabilitiesCurrent_638125835182924926" order="7" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_EarnOutCurrent" xlink:label="tcmd_EarnOutCurrent_638125835182924926" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638125835182914927" xlink:to="tcmd_EarnOutCurrent_638125835182924926" order="8" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent_638125835182924926" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638125835182904927" xlink:to="us-gaap_LiabilitiesNoncurrent_638125835182924926" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCredit" xlink:label="us-gaap_LineOfCredit_638125835182924926" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent_638125835182924926" xlink:to="us-gaap_LineOfCredit_638125835182924926" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermNotesPayable" xlink:label="us-gaap_LongTermNotesPayable_638125835182924926" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent_638125835182924926" xlink:to="us-gaap_LongTermNotesPayable_638125835182924926" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductWarrantyAccrualNoncurrent" xlink:label="us-gaap_ProductWarrantyAccrualNoncurrent_638125835182924926" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent_638125835182924926" xlink:to="us-gaap_ProductWarrantyAccrualNoncurrent_638125835182924926" order="3" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_EarnOutNonCurrent" xlink:label="tcmd_EarnOutNonCurrent_638125835182924926" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent_638125835182924926" xlink:to="tcmd_EarnOutNonCurrent_638125835182924926" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesNoncurrent" xlink:label="us-gaap_AccruedIncomeTaxesNoncurrent_638125835182934927" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent_638125835182924926" xlink:to="us-gaap_AccruedIncomeTaxesNoncurrent_638125835182934927" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638125835182934927" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent_638125835182924926" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638125835182934927" order="6" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet_638125835182934927" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent_638125835182924926" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet_638125835182934927" order="7" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638125835182934927" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity_638125835182934927" order="2" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_638125835182934927" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638125835182934927" xlink:to="us-gaap_PreferredStockValue_638125835182934927" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_638125835182934927" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638125835182934927" xlink:to="us-gaap_CommonStockValue_638125835182934927" order="2" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_638125835182934927" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638125835182934927" xlink:to="us-gaap_AdditionalPaidInCapital_638125835182934927" order="3" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638125835182944928" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638125835182934927" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638125835182944928" order="4" use="optional" weight="1" priority="3" />
  </calculationLink>
  <calculationLink xlink:role="http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfOperations" xlink:type="extended" xlink:title="00200 - Statement - Consolidated Statements of Operations">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_638125835182944928" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_IncomeTaxExpenseBenefit_638125835182944928" order="1" use="optional" weight="-1" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638125835182944928" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638125835182944928" order="2" use="optional" weight="1" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_638125835182944928" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638125835182944928" xlink:to="us-gaap_OperatingIncomeLoss_638125835182944928" order="1" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit_638125835182944928" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_638125835182944928" xlink:to="us-gaap_GrossProfit_638125835182944928" order="1" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638125835182944928" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GrossProfit_638125835182944928" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638125835182944928" order="1" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue_638125835182954927" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GrossProfit_638125835182944928" xlink:to="us-gaap_CostOfRevenue_638125835182954927" order="2" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_638125835182954927" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_638125835182944928" xlink:to="us-gaap_OperatingExpenses_638125835182954927" order="2" use="optional" weight="-1" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="us-gaap_SellingAndMarketingExpense_638125835182954927" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_638125835182954927" xlink:to="us-gaap_SellingAndMarketingExpense_638125835182954927" order="1" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_638125835182954927" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_638125835182954927" xlink:to="us-gaap_ResearchAndDevelopmentExpense_638125835182954927" order="2" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_638125835182954927" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_638125835182954927" xlink:to="us-gaap_GeneralAndAdministrativeExpense_638125835182954927" order="3" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_AmortizationOfIntangibleAssetsAndEarnOuts" xlink:label="tcmd_AmortizationOfIntangibleAssetsAndEarnOuts_638125835182954927" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_638125835182954927" xlink:to="tcmd_AmortizationOfIntangibleAssetsAndEarnOuts_638125835182954927" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense_638125835182954927" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638125835182944928" xlink:to="us-gaap_NonoperatingIncomeExpense_638125835182954927" order="2" use="optional" weight="1" priority="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfComprehensiveLoss" xlink:type="extended" xlink:title="00300 - Statement - Consolidated Statements of Comprehensive Loss">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638125835182954927" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss_638125835182954927" order="1" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_638125835182964930" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_638125835182964930" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" xlink:label="us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1_638125835182964930" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_638125835182964930" xlink:to="us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1_638125835182964930" order="1" use="optional" weight="-1" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_638125835182964930" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_638125835182964930" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_638125835182964930" order="2" use="optional" weight="1" priority="4" />
  </calculationLink>
  <calculationLink xlink:role="http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00500 - Statement - Consolidated Statements of Cash Flows">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_638125835182964930" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_638125835182964930" order="1" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_638125835182964930" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638125835182964930" xlink:to="us-gaap_ProfitLoss_638125835182964930" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:label="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_638125835182964930" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638125835182964930" xlink:to="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_638125835182964930" order="2" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges_638125835182964930" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638125835182964930" xlink:to="us-gaap_AssetImpairmentCharges_638125835182964930" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization_638125835182964930" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638125835182964930" xlink:to="us-gaap_DepreciationDepletionAndAmortization_638125835182964930" order="4" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_AmortizationOfPremiumsAndDiscountsOnSecuritiesAvailableForSale" xlink:label="tcmd_AmortizationOfPremiumsAndDiscountsOnSecuritiesAvailableForSale_638125835182964930" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638125835182964930" xlink:to="tcmd_AmortizationOfPremiumsAndDiscountsOnSecuritiesAvailableForSale_638125835182964930" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:label="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_638125835182974930" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638125835182964930" xlink:to="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_638125835182974930" order="6" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_638125835182974930" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638125835182964930" xlink:to="us-gaap_ShareBasedCompensation_638125835182974930" order="7" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueAdjustment" xlink:label="us-gaap_LiabilitiesFairValueAdjustment_638125835182974930" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638125835182964930" xlink:to="us-gaap_LiabilitiesFairValueAdjustment_638125835182974930" order="8" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_638125835182974930" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638125835182964930" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_638125835182974930" order="9" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories_638125835182974930" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638125835182964930" xlink:to="us-gaap_IncreaseDecreaseInInventories_638125835182974930" order="10" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_IncreaseDecreaseInNetInvestmentInLease" xlink:label="tcmd_IncreaseDecreaseInNetInvestmentInLease_638125835182974930" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638125835182964930" xlink:to="tcmd_IncreaseDecreaseInNetInvestmentInLease_638125835182974930" order="11" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638125835182974930" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638125835182964930" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638125835182974930" order="12" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="us-gaap_GainLossOnDispositionOfAssets1_638125835182974930" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638125835182964930" xlink:to="us-gaap_GainLossOnDispositionOfAssets1_638125835182974930" order="13" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesGainLoss" xlink:label="us-gaap_MarketableSecuritiesGainLoss_638125835182984930" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638125835182964930" xlink:to="us-gaap_MarketableSecuritiesGainLoss_638125835182984930" order="14" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:label="tcmd_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_638125835182984930" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638125835182964930" xlink:to="tcmd_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_638125835182984930" order="15" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerAsset_638125835182984930" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638125835182964930" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerAsset_638125835182984930" order="16" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_638125835182984930" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638125835182964930" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_638125835182984930" order="17" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_638125835182984930" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638125835182964930" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_638125835182984930" order="18" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_IncreaseDecreaseInOtherAccruedLiabilitiesAndIncomeTaxesPayable" xlink:label="tcmd_IncreaseDecreaseInOtherAccruedLiabilitiesAndIncomeTaxesPayable_638125835182984930" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638125835182964930" xlink:to="tcmd_IncreaseDecreaseInOtherAccruedLiabilitiesAndIncomeTaxesPayable_638125835182984930" order="19" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_638125835182984930" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_638125835182984930" order="2" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_638125835182984930" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638125835182984930" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_638125835182984930" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_PaymentsToAcquireProductiveAsset" xlink:label="tcmd_PaymentsToAcquireProductiveAsset_638125835182994930" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638125835182984930" xlink:to="tcmd_PaymentsToAcquireProductiveAsset_638125835182994930" order="2" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_638125835182994930" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638125835182984930" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_638125835182994930" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638125835182994930" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638125835182984930" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638125835182994930" order="4" use="optional" weight="-1" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_638125835182994930" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638125835182984930" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_638125835182994930" order="5" use="optional" weight="-1" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireOtherInvestments" xlink:label="us-gaap_PaymentsToAcquireOtherInvestments_638125835182994930" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638125835182984930" xlink:to="us-gaap_PaymentsToAcquireOtherInvestments_638125835182994930" order="6" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_638125835182994930" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_638125835182994930" order="3" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="us-gaap_RepaymentsOfNotesPayable_638125835182994930" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638125835182994930" xlink:to="us-gaap_RepaymentsOfNotesPayable_638125835182994930" order="1" use="optional" weight="-1" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="us-gaap_ProceedsFromNotesPayable_638125835183004929" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638125835182994930" xlink:to="us-gaap_ProceedsFromNotesPayable_638125835183004929" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:label="us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_638125835183004929" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638125835182994930" xlink:to="us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_638125835183004929" order="3" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_PaymentOfTaxesForNetShareSettlementOfRestrictedStockUnits" xlink:label="tcmd_PaymentOfTaxesForNetShareSettlementOfRestrictedStockUnits_638125835183004929" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638125835182994930" xlink:to="tcmd_PaymentOfTaxesForNetShareSettlementOfRestrictedStockUnits_638125835183004929" order="4" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="us-gaap_ProceedsFromLinesOfCredit_638125835183004929" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638125835182994930" xlink:to="us-gaap_ProceedsFromLinesOfCredit_638125835183004929" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_638125835183004929" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638125835182994930" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts_638125835183004929" order="6" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_638125835183004929" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638125835182994930" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_638125835183004929" order="7" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638125835183014925" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638125835182994930" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638125835183014925" order="8" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.tactilemedical.com/role/DisclosurePurchasePriceAllocationDetails" xlink:type="extended" xlink:title="40402 - Disclosure - Purchase Price Allocation (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNet" xlink:label="us-gaap_AssetsNet" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet_638125835183014925" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNet" xlink:to="us-gaap_InventoryNet_638125835183014925" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_638125835183014925" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_638125835183014925" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_638125835183014925" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNet" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_638125835183014925" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill_638125835183014925" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNet" xlink:to="us-gaap_Goodwill_638125835183014925" order="4" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.tactilemedical.com/role/DisclosurePatentCostsNetDetailsCalc2" xlink:type="extended" xlink:title="40502 - Disclosure - Patent Costs, Net (Details) (Calc 2)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_638125835183024924" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_638125835183024924" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_638125835183024924" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_638125835183024924" order="2" use="optional" weight="-1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.tactilemedical.com/role/DisclosureInventoriesDetails" xlink:type="extended" xlink:title="40601 - Disclosure - Inventories (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoods" xlink:label="us-gaap_InventoryFinishedGoods_638125835183024924" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryFinishedGoods_638125835183024924" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcess" xlink:label="us-gaap_InventoryWorkInProcess_638125835183024924" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryWorkInProcess_638125835183024924" order="2" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.tactilemedical.com/role/DisclosurePropertyAndEquipmentDetails" xlink:type="extended" xlink:title="40701 - Disclosure - Property and Equipment (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_638125835183024924" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_638125835183024924" order="1" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_638125835183024924" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_638125835183024924" order="2" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.tactilemedical.com/role/DisclosureGoodwillAndIntangibleAssetsDetails" xlink:type="extended" xlink:title="40801 - Disclosure - Goodwill And Intangible Assets (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_638125835183024924" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_638125835183024924" order="1" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_638125835183034925" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_638125835183034925" order="2" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_638125835183034925" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_638125835183034925" order="3" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_638125835183034925" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_638125835183034925" order="4" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_638125835183034925" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_638125835183034925" order="5" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_638125835183034925" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_638125835183034925" order="6" use="optional" weight="1" priority="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.tactilemedical.com/role/DisclosureAccruedExpensesDetails" xlink:type="extended" xlink:title="40901 - Disclosure - Accrued Expenses (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductWarrantyAccrualClassifiedCurrent" xlink:label="us-gaap_ProductWarrantyAccrualClassifiedCurrent_638125835183034925" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_ProductWarrantyAccrualClassifiedCurrent_638125835183034925" order="1" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_638125835183034925" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_638125835183034925" order="2" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_InTransitInventoryAccruedExpense" xlink:label="tcmd_InTransitInventoryAccruedExpense_638125835183034925" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="tcmd_InTransitInventoryAccruedExpense_638125835183034925" order="3" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_AccruedClinicalStudiesExpensesCurrent" xlink:label="tcmd_AccruedClinicalStudiesExpensesCurrent_638125835183044926" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="tcmd_AccruedClinicalStudiesExpensesCurrent_638125835183044926" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_AccruedTravelAndEntertainmentCurrent" xlink:label="tcmd_AccruedTravelAndEntertainmentCurrent_638125835183044926" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="tcmd_AccruedTravelAndEntertainmentCurrent_638125835183044926" order="5" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_AccruedSalesAndUseTax" xlink:label="tcmd_AccruedSalesAndUseTax_638125835183044926" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="tcmd_AccruedSalesAndUseTax_638125835183044926" order="6" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_638125835183044926" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_638125835183044926" order="7" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.tactilemedical.com/role/DisclosureWarrantyReservesDetails" xlink:type="extended" xlink:title="41001 - Disclosure - Warranty Reserves (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductWarrantyAccrual" xlink:label="us-gaap_ProductWarrantyAccrual" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductWarrantyAccrualClassifiedCurrent" xlink:label="us-gaap_ProductWarrantyAccrualClassifiedCurrent_638125835183044926" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ProductWarrantyAccrual" xlink:to="us-gaap_ProductWarrantyAccrualClassifiedCurrent_638125835183044926" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductWarrantyAccrualNoncurrent" xlink:label="us-gaap_ProductWarrantyAccrualNoncurrent_638125835183044926" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ProductWarrantyAccrual" xlink:to="us-gaap_ProductWarrantyAccrualNoncurrent_638125835183044926" order="2" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesUndiscountedCashFlowsDetailsCalc2" xlink:type="extended" xlink:title="41004 - Disclosure - Commitments and Contingencies - Undiscounted cash flows (Details) - Calc2">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_638125835183044926" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_638125835183044926" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_638125835183054925" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiability_638125835183054925" order="2" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.tactilemedical.com/role/DisclosureCreditAgreementMaturitiesOfDebtDetails" xlink:type="extended" xlink:title="41102 - Disclosure - Credit Agreement - Maturities of Debt (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_638125835183054925" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_638125835183054925" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_638125835183054925" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_638125835183054925" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesLeaseRelatedAssetsAndLiabilitiesDetails" xlink:type="extended" xlink:title="41202 - Disclosure - Commitments and Contingencies - Lease related assets and liabilities (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638125835183054925" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638125835183054925" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638125835183054925" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638125835183054925" order="2" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesUndiscountedCashFlowsDetails" xlink:type="extended" xlink:title="41203 - Disclosure - Commitments and Contingencies - Undiscounted cash flows (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_638125835183054925" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_638125835183054925" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_638125835183064931" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_638125835183064931" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_638125835183064931" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_638125835183064931" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_638125835183064931" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_638125835183064931" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638125835183064931" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638125835183064931" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638125835183064931" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638125835183064931" order="6" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.tactilemedical.com/role/DisclosureRevenueDetails" xlink:type="extended" xlink:title="41401 - Disclosure - Revenue (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesTypeLeaseSellingProfitLoss" xlink:label="us-gaap_SalesTypeLeaseSellingProfitLoss" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsSoldSalesTypeLease" xlink:label="us-gaap_CostOfGoodsSoldSalesTypeLease_638125835183064931" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_SalesTypeLeaseSellingProfitLoss" xlink:to="us-gaap_CostOfGoodsSoldSalesTypeLease_638125835183064931" order="1" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesTypeLeaseRevenue" xlink:label="us-gaap_SalesTypeLeaseRevenue_638125835183064931" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_SalesTypeLeaseSellingProfitLoss" xlink:to="us-gaap_SalesTypeLeaseRevenue_638125835183064931" order="2" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.tactilemedical.com/role/DisclosureIncomeTaxesDetails" xlink:type="extended" xlink:title="41501 - Disclosure - Income Taxes (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross_638125835183074927" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsGross_638125835183074927" order="1" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638125835183074927" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638125835183074927" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638125835183074927" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_DeferredTaxAssetsOperatingLeaseLiability" xlink:label="tcmd_DeferredTaxAssetsOperatingLeaseLiability_638125835183074927" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638125835183074927" xlink:to="tcmd_DeferredTaxAssetsOperatingLeaseLiability_638125835183074927" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_638125835183074927" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638125835183074927" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_638125835183074927" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_638125835183074927" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638125835183074927" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_638125835183074927" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_DeferredTaxAssetsBusinessCredits" xlink:label="tcmd_DeferredTaxAssetsBusinessCredits_638125835183074927" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638125835183074927" xlink:to="tcmd_DeferredTaxAssetsBusinessCredits_638125835183074927" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsResearchAndDevelopmentExpenses" xlink:label="tcmd_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsResearchAndDevelopmentExpenses_638125835183074927" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638125835183074927" xlink:to="tcmd_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsResearchAndDevelopmentExpenses_638125835183074927" order="6" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_638125835183074927" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638125835183074927" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_638125835183074927" order="7" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves_638125835183074927" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638125835183074927" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves_638125835183074927" order="8" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_638125835183074927" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638125835183074927" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_638125835183074927" order="9" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther_638125835183084931" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638125835183074927" xlink:to="us-gaap_DeferredTaxAssetsOther_638125835183084931" order="10" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_638125835183084931" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_638125835183084931" order="2" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_638125835183084931" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities_638125835183084931" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_638125835183084931" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_DeferredTaxLiabilitiesRightOfUseAssets" xlink:label="tcmd_DeferredTaxLiabilitiesRightOfUseAssets_638125835183084931" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities_638125835183084931" xlink:to="tcmd_DeferredTaxLiabilitiesRightOfUseAssets_638125835183084931" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:label="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_638125835183084931" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities_638125835183084931" xlink:to="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_638125835183084931" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="us-gaap_DeferredTaxLiabilitiesOther_638125835183084931" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities_638125835183084931" xlink:to="us-gaap_DeferredTaxLiabilitiesOther_638125835183084931" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_638125835183084931" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_638125835183084931" order="3" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638125835183094926" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638125835183094926" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment_638125835183094926" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment_638125835183094926" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_638125835183094926" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_638125835183094926" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationPercent" xlink:label="tcmd_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationPercent_638125835183094926" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="tcmd_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationPercent_638125835183094926" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_EffectiveIncomeTaxRateReconciliationExcessTaxBenefitOnNonQualifiedStockOptionsAndRsu" xlink:label="tcmd_EffectiveIncomeTaxRateReconciliationExcessTaxBenefitOnNonQualifiedStockOptionsAndRsu_638125835183094926" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="tcmd_EffectiveIncomeTaxRateReconciliationExcessTaxBenefitOnNonQualifiedStockOptionsAndRsu_638125835183094926" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_638125835183094926" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_638125835183094926" order="6" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_638125835183094926" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_638125835183094926" order="7" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_EffectiveIncomeTaxRateReconciliationEmployeeStockPurchasePlan" xlink:label="tcmd_EffectiveIncomeTaxRateReconciliationEmployeeStockPurchasePlan_638125835183104927" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="tcmd_EffectiveIncomeTaxRateReconciliationEmployeeStockPurchasePlan_638125835183104927" order="8" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_EffectiveIncomeTaxRateReconciliationFederalBusinessCreditPercent" xlink:label="tcmd_EffectiveIncomeTaxRateReconciliationFederalBusinessCreditPercent_638125835183104927" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="tcmd_EffectiveIncomeTaxRateReconciliationFederalBusinessCreditPercent_638125835183104927" order="9" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_EffectiveIncomeTaxRateReconciliationReturnToProvision" xlink:label="tcmd_EffectiveIncomeTaxRateReconciliationReturnToProvision_638125835183104927" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="tcmd_EffectiveIncomeTaxRateReconciliationReturnToProvision_638125835183104927" order="10" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_EffectiveIncomeTaxRateReconciliationFederalCarrybackClaimPercent" xlink:label="tcmd_EffectiveIncomeTaxRateReconciliationFederalCarrybackClaimPercent_638125835183104927" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="tcmd_EffectiveIncomeTaxRateReconciliationFederalCarrybackClaimPercent_638125835183104927" order="11" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_EffectiveIncomeTaxRateReconciliationInternalRevenueServiceExam" xlink:label="tcmd_EffectiveIncomeTaxRateReconciliationInternalRevenueServiceExam_638125835183104927" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="tcmd_EffectiveIncomeTaxRateReconciliationInternalRevenueServiceExam_638125835183104927" order="12" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal_638125835183104927" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal_638125835183104927" order="13" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_EffectiveIncomeTaxRateReconciliationUnrecognizedTaxBenefits" xlink:label="tcmd_EffectiveIncomeTaxRateReconciliationUnrecognizedTaxBenefits_638125835183104927" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="tcmd_EffectiveIncomeTaxRateReconciliationUnrecognizedTaxBenefits_638125835183104927" order="14" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_EffectiveIncomeTaxRateReconciliationIncentiveStockOptions" xlink:label="tcmd_EffectiveIncomeTaxRateReconciliationIncentiveStockOptions_638125835183114928" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="tcmd_EffectiveIncomeTaxRateReconciliationIncentiveStockOptions_638125835183114928" order="15" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_EffectiveIncomeTaxRateReconciliationInterestAndPenaltyPercent" xlink:label="tcmd_EffectiveIncomeTaxRateReconciliationInterestAndPenaltyPercent_638125835183114928" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="tcmd_EffectiveIncomeTaxRateReconciliationInterestAndPenaltyPercent_638125835183114928" order="16" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_638125835183114928" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_638125835183114928" order="17" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_638125835183114928" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_638125835183114928" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_638125835183124927" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit_638125835183114928" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit_638125835183124927" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_638125835183124927" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit_638125835183114928" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_638125835183124927" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_638125835183124927" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_638125835183124927" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_638125835183124927" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit_638125835183124927" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_638125835183124927" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_638125835183124927" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit_638125835183124927" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_638125835183124927" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_638125835183124927" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_638125835183124927" order="3" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.tactilemedical.com/role/DisclosureDisclosureIncomeTaxesDetailsCalc2" xlink:type="extended" xlink:title="41601 - Disclosure - Disclosure - Income Taxes (Details) (Calc 2)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross_638125835183134932" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilitiesNet_1" xlink:to="us-gaap_DeferredTaxAssetsGross_638125835183134932" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_638125835183134932" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilitiesNet_1" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_638125835183134932" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_638125835183134932" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilitiesNet_1" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_638125835183134932" order="3" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.tactilemedical.com/role/DisclosureNetLossIncomePerCommonShareBasicAndDilutedNetLossPerShareDetails" xlink:type="extended" xlink:title="41601 - Disclosure - Net (Loss) Income Per Common Share - Basic and Diluted Net Loss Per Share (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638125835183134932" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638125835183134932" order="1" use="optional" weight="1" priority="2" />
  </calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>14
<FILENAME>tcmd-20221231_def.xml
<DESCRIPTION>EX-101.DEF
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.2.0.4 -->
<!--Based on XBRL 2.1-->
<!--Created on: 2/21/2023 1:38:41 PM-->
<!--Modified on: 2/21/2023 1:38:41 PM-->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <roleRef xlink:type="simple" xlink:href="tcmd-20221231.xsd#StatementConsolidatedStatementsOfOperations" roleURI="http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfOperations" />
  <roleRef xlink:type="simple" xlink:href="tcmd-20221231.xsd#StatementConsolidatedStatementsOfStockholdersEquity" roleURI="http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfStockholdersEquity" />
  <roleRef xlink:type="simple" xlink:href="tcmd-20221231.xsd#DisclosureStockholdersEquityTables" roleURI="http://www.tactilemedical.com/role/DisclosureStockholdersEquityTables" />
  <roleRef xlink:type="simple" xlink:href="tcmd-20221231.xsd#DisclosureNatureOfBusinessAndOperationsDetails" roleURI="http://www.tactilemedical.com/role/DisclosureNatureOfBusinessAndOperationsDetails" />
  <roleRef xlink:type="simple" xlink:href="tcmd-20221231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesDetails" roleURI="http://www.tactilemedical.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" />
  <roleRef xlink:type="simple" xlink:href="tcmd-20221231.xsd#DisclosureAcquisitionsDetails" roleURI="http://www.tactilemedical.com/role/DisclosureAcquisitionsDetails" />
  <roleRef xlink:type="simple" xlink:href="tcmd-20221231.xsd#DisclosureAcquisitionsPurchasePriceAllocationDetails" roleURI="http://www.tactilemedical.com/role/DisclosureAcquisitionsPurchasePriceAllocationDetails" />
  <roleRef xlink:type="simple" xlink:href="tcmd-20221231.xsd#DisclosureAcquisitionsAllocationOfPurchasePriceDetails" roleURI="http://www.tactilemedical.com/role/DisclosureAcquisitionsAllocationOfPurchasePriceDetails" />
  <roleRef xlink:type="simple" xlink:href="tcmd-20221231.xsd#DisclosureAcquisitionsConsolidatedStatementsOfOperationsReflectAfflovestOperationsDetails" roleURI="http://www.tactilemedical.com/role/DisclosureAcquisitionsConsolidatedStatementsOfOperationsReflectAfflovestOperationsDetails" />
  <roleRef xlink:type="simple" xlink:href="tcmd-20221231.xsd#DisclosureAccountsReceivableDetails" roleURI="http://www.tactilemedical.com/role/DisclosureAccountsReceivableDetails" />
  <roleRef xlink:type="simple" xlink:href="tcmd-20221231.xsd#DisclosurePropertyAndEquipmentDetails" roleURI="http://www.tactilemedical.com/role/DisclosurePropertyAndEquipmentDetails" />
  <roleRef xlink:type="simple" xlink:href="tcmd-20221231.xsd#DisclosureGoodwillAndIntangibleAssetsDetails" roleURI="http://www.tactilemedical.com/role/DisclosureGoodwillAndIntangibleAssetsDetails" />
  <roleRef xlink:type="simple" xlink:href="tcmd-20221231.xsd#DisclosureCreditAgreementDetails" roleURI="http://www.tactilemedical.com/role/DisclosureCreditAgreementDetails" />
  <roleRef xlink:type="simple" xlink:href="tcmd-20221231.xsd#DisclosureCreditAgreementMaturitiesOfDebtDetails" roleURI="http://www.tactilemedical.com/role/DisclosureCreditAgreementMaturitiesOfDebtDetails" />
  <roleRef xlink:type="simple" xlink:href="tcmd-20221231.xsd#DisclosureCommitmentsAndContingenciesLeaseObligationsDetails" roleURI="http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesLeaseObligationsDetails" />
  <roleRef xlink:type="simple" xlink:href="tcmd-20221231.xsd#DisclosureCommitmentsAndContingenciesMajorVendorsDetails" roleURI="http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesMajorVendorsDetails" />
  <roleRef xlink:type="simple" xlink:href="tcmd-20221231.xsd#DisclosureCommitmentsAndContingenciesRetirementPlanDetails" roleURI="http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesRetirementPlanDetails" />
  <roleRef xlink:type="simple" xlink:href="tcmd-20221231.xsd#DisclosureStockholdersEquitySeriesBPreferredStockDetails" roleURI="http://www.tactilemedical.com/role/DisclosureStockholdersEquitySeriesBPreferredStockDetails" />
  <roleRef xlink:type="simple" xlink:href="tcmd-20221231.xsd#DisclosureStockholdersEquityStockBasedCompensationDetails" roleURI="http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockBasedCompensationDetails" />
  <roleRef xlink:type="simple" xlink:href="tcmd-20221231.xsd#DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails" roleURI="http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails" />
  <roleRef xlink:type="simple" xlink:href="tcmd-20221231.xsd#DisclosureStockholdersEquityEmployeeStockPurchasePlanDetails" roleURI="http://www.tactilemedical.com/role/DisclosureStockholdersEquityEmployeeStockPurchasePlanDetails" />
  <roleRef xlink:type="simple" xlink:href="tcmd-20221231.xsd#DisclosureRevenueDetails" roleURI="http://www.tactilemedical.com/role/DisclosureRevenueDetails" />
  <roleRef xlink:type="simple" xlink:href="tcmd-20221231.xsd#DisclosureIncomeTaxesDetails" roleURI="http://www.tactilemedical.com/role/DisclosureIncomeTaxesDetails" />
  <roleRef xlink:type="simple" xlink:href="tcmd-20221231.xsd#DisclosureNetLossIncomePerCommonShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" roleURI="http://www.tactilemedical.com/role/DisclosureNetLossIncomePerCommonShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" />
  <roleRef xlink:type="simple" xlink:href="tcmd-20221231.xsd#DisclosureFairValueMeasurementsDetails" roleURI="http://www.tactilemedical.com/role/DisclosureFairValueMeasurementsDetails" />
  <roleRef xlink:type="simple" xlink:href="tcmd-20221231.xsd#DisclosureFairValueMeasurementsEarnOutLiabilityDetails" roleURI="http://www.tactilemedical.com/role/DisclosureFairValueMeasurementsEarnOutLiabilityDetails" />
  <roleRef xlink:type="simple" xlink:href="tcmd-20221231.xsd#DisclosureFairValueMeasurementsFairValueHierarchyDetails" roleURI="http://www.tactilemedical.com/role/DisclosureFairValueMeasurementsFairValueHierarchyDetails" />
  <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" />
  <link:roleRef roleURI="http://www.tactilemedical.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:href="tcmd-20221231.xsd#DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="simple" />
  <link:roleRef xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd#eedm" roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended" xlink:title="Extensible Enumeration Domain Members">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_1" xlink:title="us-gaap_LiabilitiesCurrentAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_1" xlink:title="us-gaap_OperatingLeaseLiabilityCurrent_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_LiabilitiesCurrentAbstract_1" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:title="definition:us-gaap_LiabilitiesCurrentAbstract_1 To us-gaap_OperatingLeaseLiabilityCurrent_1" order="1" priority="0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract_1" xlink:title="us-gaap_AssetsAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_1" xlink:title="us-gaap_OperatingLeaseRightOfUseAsset_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AssetsAbstract_1" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:title="definition:us-gaap_AssetsAbstract_1 To us-gaap_OperatingLeaseRightOfUseAsset_1" order="1" priority="0" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.tactilemedical.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="extended" xlink:title="99900 - Disclosure - Standard And Custom Axis Domain Defaults">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_1" xlink:title="dei_LegalEntityAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_1" xlink:title="dei_EntityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="dei_LegalEntityAxis_1" xlink:to="dei_EntityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:dei_LegalEntityAxis_1 To dei_EntityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_1" xlink:title="us-gaap_StatementClassOfStockAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_1" xlink:title="us-gaap_ClassOfStockDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementClassOfStockAxis_1" xlink:to="us-gaap_ClassOfStockDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementClassOfStockAxis_1 To us-gaap_ClassOfStockDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_1" xlink:title="srt_ProductOrServiceAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_1" xlink:title="srt_ProductsAndServicesDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_ProductOrServiceAxis_1" xlink:to="srt_ProductsAndServicesDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_ProductOrServiceAxis_1 To srt_ProductsAndServicesDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_1" xlink:title="srt_StatementScenarioAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_1" xlink:title="srt_ScenarioUnspecifiedDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_StatementScenarioAxis_1" xlink:to="srt_ScenarioUnspecifiedDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_StatementScenarioAxis_1 To srt_ScenarioUnspecifiedDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_1" xlink:title="us-gaap_StatementEquityComponentsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_1" xlink:title="us-gaap_EquityComponentDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementEquityComponentsAxis_1" xlink:to="us-gaap_EquityComponentDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementEquityComponentsAxis_1 To us-gaap_EquityComponentDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_1" xlink:title="us-gaap_SubsequentEventTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_1" xlink:title="us-gaap_SubsequentEventTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_SubsequentEventTypeAxis_1" xlink:to="us-gaap_SubsequentEventTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_SubsequentEventTypeAxis_1 To us-gaap_SubsequentEventTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_1" xlink:title="us-gaap_AwardTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AwardTypeAxis_1" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AwardTypeAxis_1 To us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_1" xlink:title="us-gaap_SubsidiarySaleOfStockAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_1" xlink:title="us-gaap_SaleOfStockNameOfTransactionDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_1" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_SubsidiarySaleOfStockAxis_1 To us-gaap_SaleOfStockNameOfTransactionDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis_1" xlink:title="us-gaap_FinancialInstrumentAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" xlink:title="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FinancialInstrumentAxis_1" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FinancialInstrumentAxis_1 To us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_1" xlink:title="us-gaap_IncomeStatementLocationAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_1" xlink:title="us-gaap_IncomeStatementLocationDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeStatementLocationAxis_1" xlink:to="us-gaap_IncomeStatementLocationDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_IncomeStatementLocationAxis_1 To us-gaap_IncomeStatementLocationDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1" xlink:title="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1" xlink:title="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1 To us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_1" xlink:title="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_1" xlink:title="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_1" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_1 To us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis_1" xlink:title="us-gaap_CreditFacilityAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain_1" xlink:title="us-gaap_CreditFacilityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_CreditFacilityAxis_1" xlink:to="us-gaap_CreditFacilityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_CreditFacilityAxis_1 To us-gaap_CreditFacilityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="us-gaap_LineOfCreditFacilityAxis_1" xlink:title="us-gaap_LineOfCreditFacilityAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain_1" xlink:title="us-gaap_LineOfCreditFacilityLenderDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_LineOfCreditFacilityAxis_1" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_LineOfCreditFacilityAxis_1 To us-gaap_LineOfCreditFacilityLenderDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_1" xlink:title="srt_RangeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember_1" xlink:title="srt_RangeMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_RangeAxis_1" xlink:to="srt_RangeMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_RangeAxis_1 To srt_RangeMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis_1" xlink:title="us-gaap_VariableRateAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain_1" xlink:title="us-gaap_VariableRateDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_VariableRateAxis_1" xlink:to="us-gaap_VariableRateDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_VariableRateAxis_1 To us-gaap_VariableRateDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:title="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:title="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_PropertyPlantAndEquipmentByTypeAxis_1 To us-gaap_PropertyPlantAndEquipmentTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_1" xlink:title="us-gaap_ConcentrationRiskByBenchmarkAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_1" xlink:title="us-gaap_ConcentrationRiskBenchmarkDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis_1" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ConcentrationRiskByBenchmarkAxis_1 To us-gaap_ConcentrationRiskBenchmarkDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_1" xlink:title="us-gaap_ConcentrationRiskByTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain_1" xlink:title="us-gaap_ConcentrationRiskTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ConcentrationRiskByTypeAxis_1" xlink:to="us-gaap_ConcentrationRiskTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ConcentrationRiskByTypeAxis_1 To us-gaap_ConcentrationRiskTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_1" xlink:title="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_1" xlink:title="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_1" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_1 To us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanNameAxis" xlink:label="us-gaap_RetirementPlanNameAxis_1" xlink:title="us-gaap_RetirementPlanNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanNameDomain" xlink:label="us-gaap_RetirementPlanNameDomain_1" xlink:title="us-gaap_RetirementPlanNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_RetirementPlanNameAxis_1" xlink:to="us-gaap_RetirementPlanNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_RetirementPlanNameAxis_1 To us-gaap_RetirementPlanNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_1" xlink:title="us-gaap_PlanNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_1" xlink:title="us-gaap_PlanNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_PlanNameAxis_1" xlink:to="us-gaap_PlanNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_PlanNameAxis_1 To us-gaap_PlanNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_1" xlink:title="srt_TitleOfIndividualAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" xlink:title="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_TitleOfIndividualAxis_1" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_TitleOfIndividualAxis_1 To srt_TitleOfIndividualWithRelationshipToEntityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" xlink:title="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember_1" xlink:title="us-gaap_TypeOfAdoptionMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" xlink:to="us-gaap_TypeOfAdoptionMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1 To us-gaap_TypeOfAdoptionMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis_1" xlink:title="us-gaap_VestingAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_1" xlink:title="us-gaap_VestingDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_VestingAxis_1" xlink:to="us-gaap_VestingDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_VestingAxis_1 To us-gaap_VestingDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1 To us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis_1" xlink:title="srt_MajorCustomersAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain_1" xlink:title="srt_NameOfMajorCustomerDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_MajorCustomersAxis_1" xlink:to="srt_NameOfMajorCustomerDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_MajorCustomersAxis_1 To srt_NameOfMajorCustomerDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis_1" xlink:title="us-gaap_IncomeTaxAuthorityAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_1" xlink:title="us-gaap_IncomeTaxAuthorityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeTaxAuthorityAxis_1" xlink:to="us-gaap_IncomeTaxAuthorityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_IncomeTaxAuthorityAxis_1 To us-gaap_IncomeTaxAuthorityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis_1" xlink:title="srt_StatementGeographicalAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_1" xlink:title="srt_SegmentGeographicalDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_StatementGeographicalAxis_1" xlink:to="srt_SegmentGeographicalDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_StatementGeographicalAxis_1 To srt_SegmentGeographicalDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" xlink:title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_1" xlink:title="us-gaap_AntidilutiveSecuritiesNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1 To us-gaap_AntidilutiveSecuritiesNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_1" xlink:title="us-gaap_FairValueByMeasurementFrequencyAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_1" xlink:title="us-gaap_FairValueMeasurementFrequencyDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis_1" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FairValueByMeasurementFrequencyAxis_1 To us-gaap_FairValueMeasurementFrequencyDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" xlink:title="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" xlink:title="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FairValueByFairValueHierarchyLevelAxis_1 To us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis_1" xlink:title="us-gaap_BusinessAcquisitionAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_1" xlink:title="us-gaap_BusinessAcquisitionAcquireeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_BusinessAcquisitionAxis_1" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_BusinessAcquisitionAxis_1 To us-gaap_BusinessAcquisitionAcquireeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_1" xlink:title="us-gaap_DebtInstrumentAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_1" xlink:title="us-gaap_DebtInstrumentNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_DebtInstrumentAxis_1" xlink:to="us-gaap_DebtInstrumentNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_DebtInstrumentAxis_1 To us-gaap_DebtInstrumentNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis_1" xlink:title="srt_RestatementAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain_1" xlink:title="srt_RestatementDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_RestatementAxis_1" xlink:to="srt_RestatementDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_RestatementAxis_1 To srt_RestatementDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusAxis" xlink:label="us-gaap_LitigationStatusAxis_1" xlink:title="us-gaap_LitigationStatusAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain" xlink:label="us-gaap_LitigationStatusDomain_1" xlink:title="us-gaap_LitigationStatusDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_LitigationStatusAxis_1" xlink:to="us-gaap_LitigationStatusDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_LitigationStatusAxis_1 To us-gaap_LitigationStatusDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_1" xlink:title="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" xlink:label="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_1" xlink:title="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_1" xlink:to="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_1 To us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_1" xlink:title="us-gaap_TypeOfArrangementAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:title="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_TypeOfArrangementAxis_1" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_TypeOfArrangementAxis_1 To us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_1" xlink:title="srt_CounterpartyNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_1" xlink:title="srt_RepurchaseAgreementCounterpartyNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_CounterpartyNameAxis_1" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_CounterpartyNameAxis_1 To srt_RepurchaseAgreementCounterpartyNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:label="us-gaap_LossContingenciesByNatureOfContingencyAxis_1" xlink:title="us-gaap_LossContingenciesByNatureOfContingencyAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="us-gaap_LossContingencyNatureDomain_1" xlink:title="us-gaap_LossContingencyNatureDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_LossContingenciesByNatureOfContingencyAxis_1" xlink:to="us-gaap_LossContingencyNatureDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_LossContingenciesByNatureOfContingencyAxis_1 To us-gaap_LossContingencyNatureDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:title="us-gaap_AssetAcquisitionAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:title="us-gaap_AssetAcquisitionDomain_1" />
    <link:loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_DebtInstrumentLeverageRatioTierAxis" xlink:label="tcmd_DebtInstrumentLeverageRatioTierAxis_1" xlink:title="tcmd_DebtInstrumentLeverageRatioTierAxis_1" />
    <link:loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_DebtInstrumentLeverageRatioTierDomain" xlink:label="tcmd_DebtInstrumentLeverageRatioTierDomain_1" xlink:title="tcmd_DebtInstrumentLeverageRatioTierDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="tcmd_DebtInstrumentLeverageRatioTierAxis_1" xlink:to="tcmd_DebtInstrumentLeverageRatioTierDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:tcmd_DebtInstrumentLeverageRatioTierAxis_1 To tcmd_DebtInstrumentLeverageRatioTierDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="us-gaap_AssetAcquisitionAxis_1" xlink:title="us-gaap_AssetAcquisitionAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="us-gaap_AssetAcquisitionDomain_1" xlink:title="us-gaap_AssetAcquisitionDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AssetAcquisitionAxis_1" xlink:to="us-gaap_AssetAcquisitionDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AssetAcquisitionAxis_1 To us-gaap_AssetAcquisitionDomain_1" order="1" />
  </link:definitionLink>
  <definitionLink xlink:role="http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfOperations" xlink:type="extended" xlink:title="00200 - Statement - Consolidated Statements of Operations">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_638125835183144930" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_638125835183144930" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_RentalProductServiceMember" xlink:label="tcmd_RentalProductServiceMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ProductsAndServicesDomain" xlink:to="tcmd_RentalProductServiceMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CostOfRevenue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GrossProfit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="us-gaap_SellingAndMarketingExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_SellingAndMarketingExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_AmortizationOfIntangibleAssetsAndEarnOuts" xlink:label="tcmd_AmortizationOfIntangibleAssetsAndEarnOuts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="tcmd_AmortizationOfIntangibleAssetsAndEarnOuts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NonoperatingIncomeExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_EarningsPerShareOtherDisclosureAbstract" xlink:label="tcmd_EarningsPerShareOtherDisclosureAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_StatementLineItems" xlink:to="tcmd_EarningsPerShareOtherDisclosureAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="tcmd_EarningsPerShareOtherDisclosureAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="tcmd_EarningsPerShareOtherDisclosureAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfStockholdersEquity" xlink:type="extended" xlink:title="00400 - Statement - Consolidated Statements of Stockholders' Equity">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_638125835183184990" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_638125835183184990" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockholdersEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_SharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_AdjustmentsToAdditionalPaidInCapitalSharesOther" xlink:label="tcmd_AdjustmentsToAdditionalPaidInCapitalSharesOther" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:to="tcmd_AdjustmentsToAdditionalPaidInCapitalSharesOther" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.tactilemedical.com/role/DisclosureStockholdersEquityTables" xlink:type="extended" xlink:title="31303 - Disclosure - Stockholders' Equity (Tables)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638125835183214932" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638125835183214932" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_TimeBasedRestrictedStockUnitsRsusMember" xlink:label="tcmd_TimeBasedRestrictedStockUnitsRsusMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="tcmd_TimeBasedRestrictedStockUnitsRsusMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_PerformanceBasedStockSettledRestrictedStockUnitsMember" xlink:label="tcmd_PerformanceBasedStockSettledRestrictedStockUnitsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="tcmd_PerformanceBasedStockSettledRestrictedStockUnitsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.tactilemedical.com/role/DisclosureNatureOfBusinessAndOperationsDetails" xlink:type="extended" xlink:title="40101 - Disclosure - Nature of Business and Operations (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:label="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_638125835183324935" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_638125835183324935" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_ExpenseRelatingToInitialPublicOffering" xlink:label="tcmd_ExpenseRelatingToInitialPublicOffering" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="tcmd_ExpenseRelatingToInitialPublicOffering" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.tactilemedical.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" xlink:type="extended" xlink:title="40302 - Disclosure - Summary of Significant Accounting Policies (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_638125835183344940" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_638125835183344940" use="optional" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_GarmentsMember" xlink:label="tcmd_GarmentsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="tcmd_GarmentsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_ControllersMember" xlink:label="tcmd_ControllersMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ProductsAndServicesDomain" xlink:to="tcmd_ControllersMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_AfflovestMember" xlink:label="tcmd_AfflovestMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_ProductsAndServicesDomain" xlink:to="tcmd_AfflovestMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638125835183344940" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_638125835183344940" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValueAbstract" xlink:label="us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValueAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValueAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:label="us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValueAbstract" xlink:to="us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetAbstract" xlink:label="us-gaap_AccountsReceivableNetAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccountsReceivableNetAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_PercentageOfClaimsApproved" xlink:label="tcmd_PercentageOfClaimsApproved" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AccountsReceivableNetAbstract" xlink:to="tcmd_PercentageOfClaimsApproved" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionAbstract" xlink:label="us-gaap_RevenueRecognitionAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueRecognitionAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_MedicareReceivablesTimePeriod" xlink:label="tcmd_MedicareReceivablesTimePeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RevenueRecognitionAbstract" xlink:to="tcmd_MedicareReceivablesTimePeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_PeriodForConsiderationPaymentAfterShipmentDate" xlink:label="tcmd_PeriodForConsiderationPaymentAfterShipmentDate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RevenueRecognitionAbstract" xlink:to="tcmd_PeriodForConsiderationPaymentAfterShipmentDate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuePracticalExpedientIncrementalCostOfObtainingContract" xlink:label="us-gaap_RevenuePracticalExpedientIncrementalCostOfObtainingContract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_RevenueRecognitionAbstract" xlink:to="us-gaap_RevenuePracticalExpedientIncrementalCostOfObtainingContract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketingAndAdvertisingExpenseAbstract" xlink:label="us-gaap_MarketingAndAdvertisingExpenseAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_MarketingAndAdvertisingExpenseAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvertisingExpense" xlink:label="us-gaap_AdvertisingExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_MarketingAndAdvertisingExpenseAbstract" xlink:to="us-gaap_AdvertisingExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StandardProductWarrantyDisclosureAbstract" xlink:label="us-gaap_StandardProductWarrantyDisclosureAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StandardProductWarrantyDisclosureAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_TermOfProductWarranty" xlink:label="tcmd_TermOfProductWarranty" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StandardProductWarrantyDisclosureAbstract" xlink:to="tcmd_TermOfProductWarranty" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.tactilemedical.com/role/DisclosureAcquisitionsDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Acquisitions (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionTable" xlink:label="us-gaap_AssetAcquisitionTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_AssetAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_638125835183374937" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_638125835183374937" use="optional" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_AfflovestPMember" xlink:label="tcmd_AfflovestPMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="tcmd_AfflovestPMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_AssetAcquisitionTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638125835183374937" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_638125835183374937" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_AssetAcquisitionTable" xlink:to="srt_StatementScenarioAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_638125835183384936" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain_638125835183384936" use="optional" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_AssetAcquisitionEarnoutPaymentsRevenueTargetsFromOctoberTwoThousandTwentyTwoToSeptemberTwoThousandTwentyThreeMember" xlink:label="tcmd_AssetAcquisitionEarnoutPaymentsRevenueTargetsFromOctoberTwoThousandTwentyTwoToSeptemberTwoThousandTwentyThreeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="tcmd_AssetAcquisitionEarnoutPaymentsRevenueTargetsFromOctoberTwoThousandTwentyTwoToSeptemberTwoThousandTwentyThreeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_AssetAcquisitionEarnoutPaymentsRevenueTargetsFromOctoberTwoThousandTwentyOneToSeptemberTwoThousandTwentyTwoMember" xlink:label="tcmd_AssetAcquisitionEarnoutPaymentsRevenueTargetsFromOctoberTwoThousandTwentyOneToSeptemberTwoThousandTwentyTwoMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="tcmd_AssetAcquisitionEarnoutPaymentsRevenueTargetsFromOctoberTwoThousandTwentyOneToSeptemberTwoThousandTwentyTwoMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_EarnOutPeriodOnOrBeforeNovember282022Member" xlink:label="tcmd_EarnOutPeriodOnOrBeforeNovember282022Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="tcmd_EarnOutPeriodOnOrBeforeNovember282022Member" use="optional" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_EarnOutPeriodOnOrBeforeMay262023Member" xlink:label="tcmd_EarnOutPeriodOnOrBeforeMay262023Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="tcmd_EarnOutPeriodOnOrBeforeMay262023Member" use="optional" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_SecondEarnOutAmendmentMember" xlink:label="tcmd_SecondEarnOutAmendmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="tcmd_SecondEarnOutAmendmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_AssetAcquisitionTable" xlink:to="us-gaap_IncomeStatementLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_638125835183394936" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_638125835183394936" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionLineItems" xlink:label="us-gaap_AssetAcquisitionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_AssetAcquisitionTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_PaymentsToAcquireBusinessesGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_AssetAcquisitionConsiderationTransferredEscrowAccount" xlink:label="tcmd_AssetAcquisitionConsiderationTransferredEscrowAccount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="tcmd_AssetAcquisitionConsiderationTransferredEscrowAccount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_AssetAcquisitionAmountReceivedResultingFromWorkingCapitalAdjustment" xlink:label="tcmd_AssetAcquisitionAmountReceivedResultingFromWorkingCapitalAdjustment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="tcmd_AssetAcquisitionAmountReceivedResultingFromWorkingCapitalAdjustment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_AssetAcquisitionBusinessRevenueToExceedBaseRevenueMultiplier" xlink:label="tcmd_AssetAcquisitionBusinessRevenueToExceedBaseRevenueMultiplier" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="tcmd_AssetAcquisitionBusinessRevenueToExceedBaseRevenueMultiplier" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_AssetAcquisitionEarnOutLiability" xlink:label="tcmd_AssetAcquisitionEarnOutLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="tcmd_AssetAcquisitionEarnOutLiability" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:label="us-gaap_BusinessCombinationAcquisitionRelatedCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationAcquisitionRelatedCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_AssetAcquisitionImputedInterestPayable" xlink:label="tcmd_AssetAcquisitionImputedInterestPayable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="tcmd_AssetAcquisitionImputedInterestPayable" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.tactilemedical.com/role/DisclosureAcquisitionsPurchasePriceAllocationDetails" xlink:type="extended" xlink:title="40402 - Disclosure - Acquisitions - Purchase Price Allocation (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionTable" xlink:label="us-gaap_AssetAcquisitionTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_AssetAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_638125835183414937" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_638125835183414937" use="optional" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_AfflovestPMember" xlink:label="tcmd_AfflovestPMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="tcmd_AfflovestPMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_AssetAcquisitionTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638125835183414937" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_638125835183414937" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionLineItems" xlink:label="us-gaap_AssetAcquisitionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_AssetAcquisitionTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionConsiderationTransferredAbstract" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferredAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferredAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AssetAcquisitionConsiderationTransferredAbstract" xlink:to="us-gaap_InventoryNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AssetAcquisitionConsiderationTransferredAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AssetAcquisitionConsiderationTransferredAbstract" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_AssetAcquisitionConsiderationTransferredAbstract" xlink:to="us-gaap_Goodwill" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNet" xlink:label="us-gaap_AssetsNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_AssetAcquisitionConsiderationTransferredAbstract" xlink:to="us-gaap_AssetsNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_GoodwillAmortizationPeriodForTaxPurposes" xlink:label="tcmd_GoodwillAmortizationPeriodForTaxPurposes" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="tcmd_GoodwillAmortizationPeriodForTaxPurposes" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.tactilemedical.com/role/DisclosureAcquisitionsAllocationOfPurchasePriceDetails" xlink:type="extended" xlink:title="40403 - Disclosure - Acquisitions - Allocation of Purchase Price (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionTable" xlink:label="us-gaap_AssetAcquisitionTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_AssetAcquisitionTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_638125835183434939" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_638125835183434939" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRelationshipsMember" xlink:label="us-gaap_CustomerRelationshipsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_CustomerRelationshipsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="us-gaap_DevelopedTechnologyRightsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_DevelopedTechnologyRightsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeNamesMember" xlink:label="us-gaap_TradeNamesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_TradeNamesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_AssetAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_638125835183434939" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_638125835183434939" use="optional" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_AfflovestPMember" xlink:label="tcmd_AfflovestPMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="tcmd_AfflovestPMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionLineItems" xlink:label="us-gaap_AssetAcquisitionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_AssetAcquisitionTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsGrossExcludingGoodwill" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_IntangibleAssetsGrossExcludingGoodwill" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:label="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.tactilemedical.com/role/DisclosureAcquisitionsConsolidatedStatementsOfOperationsReflectAfflovestOperationsDetails" xlink:type="extended" xlink:title="40404 - Disclosure - Acquisitions - Consolidated Statements of Operations Reflect AffloVest Operations (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionTable" xlink:label="us-gaap_AssetAcquisitionTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_AssetAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_638125835183454933" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_638125835183454933" use="optional" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_AfflovestPMember" xlink:label="tcmd_AfflovestPMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="tcmd_AfflovestPMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionLineItems" xlink:label="us-gaap_AssetAcquisitionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_AssetAcquisitionTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:label="us-gaap_BusinessAcquisitionsProFormaRevenue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionsProFormaRevenue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:label="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.tactilemedical.com/role/DisclosureAccountsReceivableDetails" xlink:type="extended" xlink:title="40501 - Disclosure - Accounts Receivable (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTable" xlink:label="us-gaap_ConcentrationRiskTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="srt_MajorCustomersAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain_638125835183464938" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain_638125835183464938" use="optional" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_InsuranceCompanyOneMember" xlink:label="tcmd_InsuranceCompanyOneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="tcmd_InsuranceCompanyOneMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_InsuranceCompanyTwoMember" xlink:label="tcmd_InsuranceCompanyTwoMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="tcmd_InsuranceCompanyTwoMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain_638125835183464938" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain_638125835183464938" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CustomerConcentrationRiskMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_638125835183474934" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_638125835183474934" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember" xlink:label="us-gaap_AccountsReceivableMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_AccountsReceivableMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesRevenueNetMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="us-gaap_ConcentrationRiskLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetAbstract" xlink:label="us-gaap_AccountsReceivableNetAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_AccountsReceivableNetAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_ConcentrationRiskNumberOfInsuranceCompanies" xlink:label="tcmd_ConcentrationRiskNumberOfInsuranceCompanies" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AccountsReceivableNetAbstract" xlink:to="tcmd_ConcentrationRiskNumberOfInsuranceCompanies" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AccountsReceivableNetAbstract" xlink:to="us-gaap_ConcentrationRiskPercentage1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.tactilemedical.com/role/DisclosurePropertyAndEquipmentDetails" xlink:type="extended" xlink:title="40701 - Disclosure - Property and Equipment (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638125835183484933" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_638125835183484933" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_638125835183484933" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_638125835183484933" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ToolsDiesAndMoldsMember" xlink:label="us-gaap_ToolsDiesAndMoldsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ToolsDiesAndMoldsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdsAndLeaseholdImprovementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdsAndLeaseholdImprovementsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_DemoEquipmentMember" xlink:label="tcmd_DemoEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="tcmd_DemoEquipmentMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xlink:to="us-gaap_Depreciation" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.tactilemedical.com/role/DisclosureGoodwillAndIntangibleAssetsDetails" xlink:type="extended" xlink:title="40801 - Disclosure - Goodwill And Intangible Assets (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638125835183504941" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_638125835183504941" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_638125835183514934" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_638125835183514934" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PatentsMember" xlink:label="us-gaap_PatentsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_PatentsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_DefensiveIntangibleAssetsMember" xlink:label="tcmd_DefensiveIntangibleAssetsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="tcmd_DefensiveIntangibleAssetsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerContractsMember" xlink:label="us-gaap_CustomerContractsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_CustomerContractsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRelationshipsMember" xlink:label="us-gaap_CustomerRelationshipsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_CustomerRelationshipsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="us-gaap_DevelopedTechnologyRightsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_DevelopedTechnologyRightsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_638125835183514934" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_638125835183514934" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_PatentsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeNamesMember" xlink:label="us-gaap_TradeNamesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_TradeNamesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_BusinessAcquisitionAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_638125835183524940" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_638125835183524940" use="optional" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_AfflovestPMember" xlink:label="tcmd_AfflovestPMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="tcmd_AfflovestPMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_Goodwill" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:label="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsGrossExcludingGoodwill" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_IntangibleAssetsGrossExcludingGoodwill" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_AmortizationOfIntangibleAssets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:label="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.tactilemedical.com/role/DisclosureCreditAgreementDetails" xlink:type="extended" xlink:title="41101 - Disclosure - Credit Agreement (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityTable" xlink:label="us-gaap_LineOfCreditFacilityTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="us-gaap_CreditFacilityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain_638125835183574937" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain_638125835183574937" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="us-gaap_RevolvingCreditFacilityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_RevolvingCreditFacilityMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_TermLoanMember" xlink:label="tcmd_TermLoanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="tcmd_TermLoanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638125835183574937" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_638125835183574937" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="us-gaap_VariableRateAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain_638125835183584936" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain_638125835183584936" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FederalFundsEffectiveSwapRateMember" xlink:label="us-gaap_FederalFundsEffectiveSwapRateMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_VariableRateDomain" xlink:to="us-gaap_FederalFundsEffectiveSwapRateMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BaseRateMember" xlink:label="us-gaap_BaseRateMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_VariableRateDomain" xlink:to="us-gaap_BaseRateMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:label="us-gaap_LondonInterbankOfferedRateLIBORMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_VariableRateDomain" xlink:to="us-gaap_LondonInterbankOfferedRateLIBORMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLineItems" xlink:label="us-gaap_LineOfCreditFacilityLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_LineOfCreditFacilityTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:label="us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCredit" xlink:label="us-gaap_LineOfCredit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_LineOfCredit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_LineOfCreditThresholdContingentIncreaseInBorrowingCapacity" xlink:label="tcmd_LineOfCreditThresholdContingentIncreaseInBorrowingCapacity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="tcmd_LineOfCreditThresholdContingentIncreaseInBorrowingCapacity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_CreditAgreementTotalAggregatePrincipalAmount" xlink:label="tcmd_CreditAgreementTotalAggregatePrincipalAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="tcmd_CreditAgreementTotalAggregatePrincipalAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_LongTermDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="us-gaap_DebtInstrumentPeriodicPayment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_DebtInstrumentPeriodicPayment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" xlink:label="us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_DebtInstrumentPaymentOfMandatoryPrincipalPrepayment" xlink:label="tcmd_DebtInstrumentPaymentOfMandatoryPrincipalPrepayment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="tcmd_DebtInstrumentPaymentOfMandatoryPrincipalPrepayment" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.tactilemedical.com/role/DisclosureCreditAgreementMaturitiesOfDebtDetails" xlink:type="extended" xlink:title="41102 - Disclosure - Credit Agreement - Maturities of Debt (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityTable" xlink:label="us-gaap_LineOfCreditFacilityTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="us-gaap_CreditFacilityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain_638125835183604939" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain_638125835183604939" use="optional" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_TermLoanMember" xlink:label="tcmd_TermLoanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="tcmd_TermLoanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLineItems" xlink:label="us-gaap_LineOfCreditFacilityLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_LineOfCreditFacilityTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtByMaturityAbstract" xlink:label="us-gaap_LongTermDebtByMaturityAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_LongTermDebtByMaturityAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LongTermDebtByMaturityAbstract" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LongTermDebtByMaturityAbstract" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LongTermDebtByMaturityAbstract" xlink:to="us-gaap_LongTermDebt" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesLeaseObligationsDetails" xlink:type="extended" xlink:title="41201 - Disclosure - Commitments and Contingencies - Lease Obligations (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_638125835183624949" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_638125835183624949" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingMember" xlink:label="us-gaap_BuildingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_BuildingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VehiclesMember" xlink:label="us-gaap_VehiclesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_VehiclesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_CorporateHeadQuarterInitialLeaseMember" xlink:label="tcmd_CorporateHeadQuarterInitialLeaseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="tcmd_CorporateHeadQuarterInitialLeaseMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_CorporateHeadQuarterSecondLeaseMember" xlink:label="tcmd_CorporateHeadQuarterSecondLeaseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="tcmd_CorporateHeadQuarterSecondLeaseMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_CorporateHeadQuarterThirdLeaseMember" xlink:label="tcmd_CorporateHeadQuarterThirdLeaseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="tcmd_CorporateHeadQuarterThirdLeaseMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638125835183634938" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_638125835183634938" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AreaOfLand" xlink:label="us-gaap_AreaOfLand" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_AreaOfLand" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_AdditionalOfficeSpaceAdded" xlink:label="tcmd_AdditionalOfficeSpaceAdded" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="tcmd_AdditionalOfficeSpaceAdded" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_NumberOfVehiclesWithAgreementsWithinInitialNoncancelableLeaseTerm" xlink:label="tcmd_NumberOfVehiclesWithAgreementsWithinInitialNoncancelableLeaseTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="tcmd_NumberOfVehiclesWithAgreementsWithinInitialNoncancelableLeaseTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesMajorVendorsDetails" xlink:type="extended" xlink:title="41205 - Disclosure - Commitments and Contingencies - Major Vendors (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTable" xlink:label="us-gaap_ConcentrationRiskTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_638125835183644937" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_638125835183644937" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsTotalMember" xlink:label="us-gaap_CostOfGoodsTotalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_CostOfGoodsTotalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain_638125835183654942" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain_638125835183654942" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplierConcentrationRiskMember" xlink:label="us-gaap_SupplierConcentrationRiskMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_SupplierConcentrationRiskMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_638125835183654942" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_638125835183654942" use="optional" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_VendorOneMember" xlink:label="tcmd_VendorOneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:to="tcmd_VendorOneMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_VendorTwoMember" xlink:label="tcmd_VendorTwoMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:to="tcmd_VendorTwoMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="us-gaap_ConcentrationRiskLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_NumberOfVendors" xlink:label="tcmd_NumberOfVendors" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="tcmd_NumberOfVendors" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesRetirementPlanDetails" xlink:type="extended" xlink:title="41207 - Disclosure - Commitments and Contingencies - Retirement Plan (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanTable" xlink:label="us-gaap_DefinedContributionPlanTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanNameAxis" xlink:label="us-gaap_RetirementPlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_DefinedContributionPlanTable" xlink:to="us-gaap_RetirementPlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanNameDomain" xlink:label="us-gaap_RetirementPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RetirementPlanNameAxis" xlink:to="us-gaap_RetirementPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanNameDomain" xlink:label="us-gaap_RetirementPlanNameDomain_638125835183664943" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_RetirementPlanNameAxis" xlink:to="us-gaap_RetirementPlanNameDomain_638125835183664943" use="optional" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_DefinedContribution401kRetirementPlanMember" xlink:label="tcmd_DefinedContribution401kRetirementPlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RetirementPlanNameDomain" xlink:to="tcmd_DefinedContribution401kRetirementPlanMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.tactilemedical.com/role/DisclosureStockholdersEquitySeriesBPreferredStockDetails" xlink:type="extended" xlink:title="41301 - Disclosure - Stockholders' Equity - Series A &amp; B Preferred Stock (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_638125835183674942" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_638125835183674942" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_638125835183684943" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_638125835183684943" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="us-gaap_ConversionOfStockSharesConverted1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_PreferredStockToCommonStockConversionRatio" xlink:label="tcmd_PreferredStockToCommonStockConversionRatio" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="tcmd_PreferredStockToCommonStockConversionRatio" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_StockIssuedDuringPeriodPriorToCompletionOfInitialOfferingSharesNewIssues" xlink:label="tcmd_StockIssuedDuringPeriodPriorToCompletionOfInitialOfferingSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="tcmd_StockIssuedDuringPeriodPriorToCompletionOfInitialOfferingSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_StockIssuedDuringPeriodRequiredToFundStockDividendsSharesNewIssues" xlink:label="tcmd_StockIssuedDuringPeriodRequiredToFundStockDividendsSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="tcmd_StockIssuedDuringPeriodRequiredToFundStockDividendsSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_AccruedCumulativeDividends" xlink:label="tcmd_AccruedCumulativeDividends" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="tcmd_AccruedCumulativeDividends" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfOrdinaryDividends" xlink:label="us-gaap_PaymentsOfOrdinaryDividends" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="us-gaap_PaymentsOfOrdinaryDividends" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockBasedCompensationDetails" xlink:type="extended" xlink:title="41302 - Disclosure - Stockholders' Equity - Stock-Based Compensation (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_638125835183704942" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_638125835183704942" use="optional" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_EquityIncentivePlan2016Member" xlink:label="tcmd_EquityIncentivePlan2016Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="tcmd_EquityIncentivePlan2016Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_638125835183704942" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_638125835183704942" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember" xlink:label="us-gaap_CostOfSalesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_CostOfSalesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingAndMarketingExpenseMember" xlink:label="us-gaap_SellingAndMarketingExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingAndMarketingExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAbstract" xlink:label="us-gaap_ShareBasedCompensationAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensationAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticAnnualIncreaseInSharesReservedAndAvailableForIssuancePercentage" xlink:label="tcmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticAnnualIncreaseInSharesReservedAndAvailableForIssuancePercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="tcmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticAnnualIncreaseInSharesReservedAndAvailableForIssuancePercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticAnnualIncreaseInSharesReservedAndAvailableForIssuanceNumber" xlink:label="tcmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticAnnualIncreaseInSharesReservedAndAvailableForIssuanceNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="tcmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticAnnualIncreaseInSharesReservedAndAvailableForIssuanceNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails" xlink:type="extended" xlink:title="41303 - Disclosure - Stockholders' Equity - Stock Options and Restricted Stock (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_638125835183734942" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_638125835183734942" use="optional" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_EquityIncentivePlan2016Member" xlink:label="tcmd_EquityIncentivePlan2016Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="tcmd_EquityIncentivePlan2016Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_VestingAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_638125835183744943" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain_638125835183744943" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638125835183744943" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638125835183744943" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_TimeBasedRestrictedStockUnitsRsusMember" xlink:label="tcmd_TimeBasedRestrictedStockUnitsRsusMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="tcmd_TimeBasedRestrictedStockUnitsRsusMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_PerformanceBasedStockSettledRestrictedStockUnitsMember" xlink:label="tcmd_PerformanceBasedStockSettledRestrictedStockUnitsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="tcmd_PerformanceBasedStockSettledRestrictedStockUnitsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_TwoThousandEighteenAndTwoThousandTwentyPerformanceBasedRestrictedStockUnitsMember" xlink:label="tcmd_TwoThousandEighteenAndTwoThousandTwentyPerformanceBasedRestrictedStockUnitsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="tcmd_PerformanceBasedStockSettledRestrictedStockUnitsMember" xlink:to="tcmd_TwoThousandEighteenAndTwoThousandTwentyPerformanceBasedRestrictedStockUnitsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_638125835183754942" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_638125835183754942" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ChiefExecutiveOfficerMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638125835183834940" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_638125835183834940" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermOfPeriod" xlink:label="tcmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermOfPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="tcmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermOfPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="us-gaap_SharePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_StockBasedCompensationExpenseMinimumTargets" xlink:label="tcmd_StockBasedCompensationExpenseMinimumTargets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="tcmd_StockBasedCompensationExpenseMinimumTargets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_NumberOfConsecutiveTradingDaysInWhichStockPriceExceedCertainPercentageOfClosingPriceOfCommonStockRequiredForAwardToBeGranted" xlink:label="tcmd_NumberOfConsecutiveTradingDaysInWhichStockPriceExceedCertainPercentageOfClosingPriceOfCommonStockRequiredForAwardToBeGranted" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="tcmd_NumberOfConsecutiveTradingDaysInWhichStockPriceExceedCertainPercentageOfClosingPriceOfCommonStockRequiredForAwardToBeGranted" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsCommonStock" xlink:label="us-gaap_DividendsCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="us-gaap_DividendsCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_SharebasedcompensationArrangementBySharebasedpaymentAwardEquityInstrumentsOtherThanOptionsModifiedInPeriod" xlink:label="tcmd_SharebasedcompensationArrangementBySharebasedpaymentAwardEquityInstrumentsOtherThanOptionsModifiedInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="tcmd_SharebasedcompensationArrangementBySharebasedpaymentAwardEquityInstrumentsOtherThanOptionsModifiedInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod" xlink:label="tcmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="tcmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_PercentageToEarnPerformanceBasedStockSettledRestrictedStockUnits" xlink:label="tcmd_PercentageToEarnPerformanceBasedStockSettledRestrictedStockUnits" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="tcmd_PercentageToEarnPerformanceBasedStockSettledRestrictedStockUnits" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_EstimatedPayoutPercentage" xlink:label="tcmd_EstimatedPayoutPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="tcmd_EstimatedPayoutPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="21" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_SharebasedcompensationArrangementBySharebasedpaymentAwardEquityInstrumentsOtherThanOptionsModifiedWeightedAverageGrantDateFairValue" xlink:label="tcmd_SharebasedcompensationArrangementBySharebasedpaymentAwardEquityInstrumentsOtherThanOptionsModifiedWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="tcmd_SharebasedcompensationArrangementBySharebasedpaymentAwardEquityInstrumentsOtherThanOptionsModifiedWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancellationsWeightedAverageGrantDateFairValue" xlink:label="tcmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancellationsWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="tcmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancellationsWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="22" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueDeferredAndUnissued" xlink:label="tcmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueDeferredAndUnissued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract" xlink:to="tcmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueDeferredAndUnissued" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.tactilemedical.com/role/DisclosureStockholdersEquityEmployeeStockPurchasePlanDetails" xlink:type="extended" xlink:title="41304 - Disclosure - Stockholders' Equity - Employee Stock Purchase Plan (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_638125835184034944" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_638125835184034944" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_EmployeeStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_638125835184044945" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_638125835184044945" use="optional" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_EquityIncentivePlan2016Member" xlink:label="tcmd_EquityIncentivePlan2016Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="tcmd_EquityIncentivePlan2016Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_EmployeeStockPurchasePlanOfferingPeriodsPeriod" xlink:label="tcmd_EmployeeStockPurchasePlanOfferingPeriodsPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="tcmd_EmployeeStockPurchasePlanOfferingPeriodsPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_IncrementalSharesToBeIssuedPercentage" xlink:label="tcmd_IncrementalSharesToBeIssuedPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="tcmd_IncrementalSharesToBeIssuedPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_IncrementalShareIncrease" xlink:label="tcmd_IncrementalShareIncrease" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="tcmd_IncrementalShareIncrease" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.tactilemedical.com/role/DisclosureRevenueDetails" xlink:type="extended" xlink:title="41401 - Disclosure - Revenue (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_ProductOrServiceAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_638125835184054945" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_638125835184054945" use="optional" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_FlexitouchSystemMember" xlink:label="tcmd_FlexitouchSystemMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="tcmd_FlexitouchSystemMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_AfflovestMember" xlink:label="tcmd_AfflovestMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ProductsAndServicesDomain" xlink:to="tcmd_AfflovestMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_MajorCustomersAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain_638125835184064945" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain_638125835184064945" use="optional" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_PrivateInsurersMember" xlink:label="tcmd_PrivateInsurersMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="tcmd_PrivateInsurersMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_VeteransAdministrationMember" xlink:label="tcmd_VeteransAdministrationMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="tcmd_VeteransAdministrationMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_MedicareMember" xlink:label="tcmd_MedicareMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="tcmd_MedicareMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_DurableMedicalEquipmentDistributorsMember" xlink:label="tcmd_DurableMedicalEquipmentDistributorsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="tcmd_DurableMedicalEquipmentDistributorsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638125835184064945" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_638125835184064945" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_PercentageOfRevenue" xlink:label="tcmd_PercentageOfRevenue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="tcmd_PercentageOfRevenue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesTypeLeaseLeaseIncomeAbstract" xlink:label="us-gaap_SalesTypeLeaseLeaseIncomeAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_SalesTypeLeaseLeaseIncomeAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesTypeLeaseRevenue" xlink:label="us-gaap_SalesTypeLeaseRevenue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SalesTypeLeaseLeaseIncomeAbstract" xlink:to="us-gaap_SalesTypeLeaseRevenue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsSoldSalesTypeLease" xlink:label="us-gaap_CostOfGoodsSoldSalesTypeLease" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SalesTypeLeaseLeaseIncomeAbstract" xlink:to="us-gaap_CostOfGoodsSoldSalesTypeLease" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesTypeLeaseSellingProfitLoss" xlink:label="us-gaap_SalesTypeLeaseSellingProfitLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SalesTypeLeaseLeaseIncomeAbstract" xlink:to="us-gaap_SalesTypeLeaseSellingProfitLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_RentToPurchaseArrangementsRentalPeriod" xlink:label="tcmd_RentToPurchaseArrangementsRentalPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_SalesTypeLeaseLeaseIncomeAbstract" xlink:to="tcmd_RentToPurchaseArrangementsRentalPeriod" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.tactilemedical.com/role/DisclosureIncomeTaxesDetails" xlink:type="extended" xlink:title="41501 - Disclosure - Income Taxes (Details)">
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_IncomeTaxTable" xlink:label="tcmd_IncomeTaxTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="tcmd_IncomeTaxTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_638125835184084947" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_638125835184084947" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_IncomeTaxLineItems" xlink:label="tcmd_IncomeTaxLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="tcmd_IncomeTaxLineItems" xlink:to="tcmd_IncomeTaxTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="tcmd_IncomeTaxLineItems" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="tcmd_IncomeTaxLineItems" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="tcmd_IncomeTaxLineItems" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="tcmd_IncomeTaxLineItems" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="tcmd_IncomeTaxLineItems" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="tcmd_IncomeTaxLineItems" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="tcmd_IncomeTaxLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="tcmd_IncomeTaxLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="tcmd_IncomeTaxLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="tcmd_IncomeTaxLineItems" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_DeferredTaxAssetsOperatingLeaseLiability" xlink:label="tcmd_DeferredTaxAssetsOperatingLeaseLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="tcmd_DeferredTaxAssetsOperatingLeaseLiability" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_DeferredTaxAssetsBusinessCredits" xlink:label="tcmd_DeferredTaxAssetsBusinessCredits" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="tcmd_DeferredTaxAssetsBusinessCredits" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsResearchAndDevelopmentExpenses" xlink:label="tcmd_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsResearchAndDevelopmentExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="tcmd_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsResearchAndDevelopmentExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsOther" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_DeferredTaxLiabilitiesRightOfUseAssets" xlink:label="tcmd_DeferredTaxLiabilitiesRightOfUseAssets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="tcmd_DeferredTaxLiabilitiesRightOfUseAssets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:label="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="us-gaap_DeferredTaxLiabilitiesOther" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesOther" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="tcmd_IncomeTaxLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationPercent" xlink:label="tcmd_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationPercent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="tcmd_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationPercent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_EffectiveIncomeTaxRateReconciliationIncentiveStockOptions" xlink:label="tcmd_EffectiveIncomeTaxRateReconciliationIncentiveStockOptions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="tcmd_EffectiveIncomeTaxRateReconciliationIncentiveStockOptions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_EffectiveIncomeTaxRateReconciliationEmployeeStockPurchasePlan" xlink:label="tcmd_EffectiveIncomeTaxRateReconciliationEmployeeStockPurchasePlan" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="tcmd_EffectiveIncomeTaxRateReconciliationEmployeeStockPurchasePlan" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_EffectiveIncomeTaxRateReconciliationFederalBusinessCreditPercent" xlink:label="tcmd_EffectiveIncomeTaxRateReconciliationFederalBusinessCreditPercent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="tcmd_EffectiveIncomeTaxRateReconciliationFederalBusinessCreditPercent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_EffectiveIncomeTaxRateReconciliationReturnToProvision" xlink:label="tcmd_EffectiveIncomeTaxRateReconciliationReturnToProvision" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="tcmd_EffectiveIncomeTaxRateReconciliationReturnToProvision" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_EffectiveIncomeTaxRateReconciliationInternalRevenueServiceExam" xlink:label="tcmd_EffectiveIncomeTaxRateReconciliationInternalRevenueServiceExam" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="tcmd_EffectiveIncomeTaxRateReconciliationInternalRevenueServiceExam" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_EffectiveIncomeTaxRateReconciliationFederalCarrybackClaimPercent" xlink:label="tcmd_EffectiveIncomeTaxRateReconciliationFederalCarrybackClaimPercent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="tcmd_EffectiveIncomeTaxRateReconciliationFederalCarrybackClaimPercent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_EffectiveIncomeTaxRateReconciliationUnrecognizedTaxBenefits" xlink:label="tcmd_EffectiveIncomeTaxRateReconciliationUnrecognizedTaxBenefits" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="tcmd_EffectiveIncomeTaxRateReconciliationUnrecognizedTaxBenefits" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_EffectiveIncomeTaxRateReconciliationExcessTaxBenefitOnNonQualifiedStockOptionsAndRsu" xlink:label="tcmd_EffectiveIncomeTaxRateReconciliationExcessTaxBenefitOnNonQualifiedStockOptionsAndRsu" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="tcmd_EffectiveIncomeTaxRateReconciliationExcessTaxBenefitOnNonQualifiedStockOptionsAndRsu" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_EffectiveIncomeTaxRateReconciliationInterestAndPenaltyPercent" xlink:label="tcmd_EffectiveIncomeTaxRateReconciliationInterestAndPenaltyPercent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="tcmd_EffectiveIncomeTaxRateReconciliationInterestAndPenaltyPercent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:label="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="tcmd_IncomeTaxLineItems" xlink:to="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="us-gaap_UnrecognizedTaxBenefits" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions" xlink:label="tcmd_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="tcmd_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="tcmd_IncomeTaxLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.tactilemedical.com/role/DisclosureNetLossIncomePerCommonShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:type="extended" xlink:title="41602 - Disclosure - Net (Loss) Income Per Common Share - Antidilutive Securities Excluded From Computation of Earnings Per Share (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638125835184194951" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638125835184194951" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_EmployeeStockPurchasePlanMember" xlink:label="tcmd_EmployeeStockPurchasePlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="tcmd_EmployeeStockPurchasePlanMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_638125835184204952" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_638125835184204952" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_PerformanceSharesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.tactilemedical.com/role/DisclosureFairValueMeasurementsDetails" xlink:type="extended" xlink:title="41701 - Disclosure - Fair Value Measurements (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638125835184214951" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_638125835184214951" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_BusinessCombinationAdditionalContingentConsiderationLiability" xlink:label="tcmd_BusinessCombinationAdditionalContingentConsiderationLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="tcmd_BusinessCombinationAdditionalContingentConsiderationLiability" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.tactilemedical.com/role/DisclosureFairValueMeasurementsEarnOutLiabilityDetails" xlink:type="extended" xlink:title="41702 - Disclosure - Fair Value Measurements - Earn out liability (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638125835184214951" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638125835184214951" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:label="us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.tactilemedical.com/role/DisclosureFairValueMeasurementsFairValueHierarchyDetails" xlink:type="extended" xlink:title="41703 - Disclosure - Fair Value Measurements - Fair Value Hierarchy (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_638125835184234955" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_638125835184234955" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638125835184234955" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638125835184234955" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" priority="1" use="optional" />
  </definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>15
<FILENAME>tcmd-20221231_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.2.0.4 -->
<!--Based on XBRL 2.1-->
<!--Created on: 2/21/2023 1:38:41 PM-->
<!--Modified on: 2/21/2023 1:38:41 PM-->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Document and Entity Information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentInformationTable_lbl" xml:lang="en-US">Document Information [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentInformationLineItems_lbl" xml:lang="en-US">Document Information [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xml:lang="en-US">ICFR Auditor Attestation Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="dei_AuditorName" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl" xml:lang="en-US">Auditor Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US">Auditor Firm ID</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US">Auditor Location</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Consolidated Balance Sheets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Net Loss Per Share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Assets, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Accounts Receivable, Net, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Accounts receivable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetInvestmentInLease" xlink:label="us-gaap_NetInvestmentInLease" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetInvestmentInLease" xlink:to="us-gaap_NetInvestmentInLease_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetInvestmentInLease_lbl" xml:lang="en-US">Net Investment in Lease</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetInvestmentInLease_lbl" xml:lang="en-US">Net investment in leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Inventory, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Inventories</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Total inventories</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Inventories</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid Expense and Other Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses and other current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsMiscellaneousAbstract" xlink:label="us-gaap_OtherAssetsMiscellaneousAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsMiscellaneousAbstract" xlink:to="us-gaap_OtherAssetsMiscellaneousAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsMiscellaneousAbstract_lbl" xml:lang="en-US">Other Assets, Miscellaneous [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsMiscellaneousAbstract_lbl" xml:lang="en-US">Non-current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property, Plant and Equipment, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property, plant and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating Lease, Right-of-Use Asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Right of use operating lease assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xml:lang="en-US">Total intangible assets (Net)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xml:lang="en-US">Intangible assets, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xml:lang="en-US">Intangible assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Goodwill" xlink:to="us-gaap_Goodwill_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Goodwill_lbl" xml:lang="en-US">Goodwill</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Goodwill_lbl" xml:lang="en-US">Goodwill</label>
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_MedicareAccountsReceivableNonCurrent" xlink:label="tcmd_MedicareAccountsReceivableNonCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcmd_MedicareAccountsReceivableNonCurrent" xlink:to="tcmd_MedicareAccountsReceivableNonCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tcmd_MedicareAccountsReceivableNonCurrent_lbl" xml:lang="en-US">Amount of non-current accounts receivable on account of medicare.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tcmd_MedicareAccountsReceivableNonCurrent_lbl" xml:lang="en-US">Medicare Accounts Receivable Non Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="tcmd_MedicareAccountsReceivableNonCurrent_lbl" xml:lang="en-US">Accounts receivable, non-current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US">Other Assets, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US">Other non-current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrent_lbl" xml:lang="en-US">Assets, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsNoncurrent_lbl" xml:lang="en-US">Total non-current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities and Stockholders' Equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Liabilities, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableCurrent" xlink:to="us-gaap_NotesPayableCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayableCurrent_lbl" xml:lang="en-US">Notes Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NotesPayableCurrent_lbl" xml:lang="en-US">Note payable</label>
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_EarnOutCurrent" xlink:label="tcmd_EarnOutCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcmd_EarnOutCurrent" xlink:to="tcmd_EarnOutCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tcmd_EarnOutCurrent_lbl" xml:lang="en-US">Carrying value as of the balance sheet date of earn-out liability (due within one year or beyond the operating cycle, if longer).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tcmd_EarnOutCurrent_lbl" xml:lang="en-US">Earn-out, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tcmd_EarnOutCurrent_lbl" xml:lang="en-US">Earn-out, current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US">Employee-related Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued payroll and related taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Total</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="us-gaap_AccruedIncomeTaxesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedIncomeTaxesCurrent" xlink:to="us-gaap_AccruedIncomeTaxesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedIncomeTaxesCurrent_lbl" xml:lang="en-US">Accrued Income Taxes, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedIncomeTaxesCurrent_lbl" xml:lang="en-US">Income taxes payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating Lease, Liability, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Less: Current obligations under operating lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating lease liabilities, Current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US">Other Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US">Other current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US">Non-current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCredit" xlink:label="us-gaap_LineOfCredit" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCredit" xlink:to="us-gaap_LineOfCredit_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCredit_lbl" xml:lang="en-US">Long-term Line of Credit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LineOfCredit_lbl" xml:lang="en-US">Revolving line of credit, non-current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LineOfCredit_lbl" xml:lang="en-US">Credit facility outstanding amount</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermNotesPayable" xlink:label="us-gaap_LongTermNotesPayable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermNotesPayable" xlink:to="us-gaap_LongTermNotesPayable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermNotesPayable_lbl" xml:lang="en-US">Notes Payable, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermNotesPayable_lbl" xml:lang="en-US">Note payable, non-current</label>
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_EarnOutNonCurrent" xlink:label="tcmd_EarnOutNonCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcmd_EarnOutNonCurrent" xlink:to="tcmd_EarnOutNonCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tcmd_EarnOutNonCurrent_lbl" xml:lang="en-US">Carrying value as of the balance sheet date of earn-out liability (due after one year or beyond the operating cycle, if longer).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tcmd_EarnOutNonCurrent_lbl" xml:lang="en-US">Earn-out, Non-current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tcmd_EarnOutNonCurrent_lbl" xml:lang="en-US">Earn-out, non-current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductWarrantyAccrualNoncurrent" xlink:label="us-gaap_ProductWarrantyAccrualNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductWarrantyAccrualNoncurrent" xlink:to="us-gaap_ProductWarrantyAccrualNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProductWarrantyAccrualNoncurrent_lbl" xml:lang="en-US">Product Warranty Accrual, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProductWarrantyAccrualNoncurrent_lbl" xml:lang="en-US">Accrued warranty reserve, non-current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesNoncurrent" xlink:label="us-gaap_AccruedIncomeTaxesNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedIncomeTaxesNoncurrent" xlink:to="us-gaap_AccruedIncomeTaxesNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedIncomeTaxesNoncurrent_lbl" xml:lang="en-US">Accrued Income Taxes, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccruedIncomeTaxesNoncurrent_lbl" xml:lang="en-US">Income taxes payable, non-current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating Lease, Liability, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating lease liabilities, non-current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Non-current obligations under operating lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet_lbl" xml:lang="en-US">Deferred Income Tax Liabilities, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet_lbl" xml:lang="en-US">Net deferred tax liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet_lbl" xml:lang="en-US">Deferred income taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xml:lang="en-US">Total long-term liabilities, net of current portion</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xml:lang="en-US">Total non-current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitment and Contingencies</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and Contingencies (see Note 12)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders' equity:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred stock, $0.001 par value, 50,000,000 shares authorized; none issued and outstanding as of December 31, 2022 and December 31, 2021</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, $0.001 par value, 300,000,000 shares authorized; 20,252,677 shares issued and outstanding as of December 31, 2022; 19,877,786 shares issued and outstanding as of December 31, 2021</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional Paid in Capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">(Accumulated deficit) retained earnings</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Balances at the end</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Balances at the beginning</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Liabilities and Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities and stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock, shares issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred Stock, Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, shares outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common shares authorized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common Stock, Shares, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares, issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares, outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Consolidated Statements of Operations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductOrServiceAxis_lbl" xml:lang="en-US">Products and Services [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductsAndServicesDomain_lbl" xml:lang="en-US">Products and Services [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductMember" xlink:to="us-gaap_ProductMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProductMember_lbl" xml:lang="en-US">Sales revenue</label>
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_RentalProductServiceMember" xlink:label="tcmd_RentalProductServiceMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcmd_RentalProductServiceMember" xlink:to="tcmd_RentalProductServiceMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tcmd_RentalProductServiceMember_lbl" xml:lang="en-US">Information relating to rental product services which generate revenue for the company.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tcmd_RentalProductServiceMember_lbl" xml:lang="en-US">Rental revenue</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US">Total revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US">Revenue</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfRevenue" xlink:to="us-gaap_CostOfRevenue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfRevenue_lbl" xml:lang="en-US">Cost of Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostOfRevenue_lbl" xml:lang="en-US">Total cost of revenue</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrossProfit_lbl" xml:lang="en-US">Gross Profit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_GrossProfit_lbl" xml:lang="en-US">Gross profit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating Expenses [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="us-gaap_SellingAndMarketingExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingAndMarketingExpense" xlink:to="us-gaap_SellingAndMarketingExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingAndMarketingExpense_lbl" xml:lang="en-US">Selling and Marketing Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SellingAndMarketingExpense_lbl" xml:lang="en-US">Sales and marketing</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and Development Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Reimbursement, general and administrative</label>
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_AmortizationOfIntangibleAssetsAndEarnOuts" xlink:label="tcmd_AmortizationOfIntangibleAssetsAndEarnOuts" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcmd_AmortizationOfIntangibleAssetsAndEarnOuts" xlink:to="tcmd_AmortizationOfIntangibleAssetsAndEarnOuts_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tcmd_AmortizationOfIntangibleAssetsAndEarnOuts_lbl" xml:lang="en-US">Amount of impairment of intangible asset and earn outs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tcmd_AmortizationOfIntangibleAssetsAndEarnOuts_lbl" xml:lang="en-US">Amortization of Intangible Assets and Earn outs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tcmd_AmortizationOfIntangibleAssetsAndEarnOuts_lbl" xml:lang="en-US">Intangible asset amortization and earn-out</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Operating Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Operating Income (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Loss from operations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Nonoperating Income (Expense)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Other (expense) income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">Loss before income taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income tax expense (benefit)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US">Net loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US">Net (Loss) Income Per Common Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US">Net loss per common share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:to="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_lbl" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Basic Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_lbl" xml:lang="en-US">Basic (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:to="us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_lbl" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Diluted Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_lbl" xml:lang="en-US">Diluted (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_EarningsPerShareOtherDisclosureAbstract" xlink:label="tcmd_EarningsPerShareOtherDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcmd_EarningsPerShareOtherDisclosureAbstract" xlink:to="tcmd_EarningsPerShareOtherDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tcmd_EarningsPerShareOtherDisclosureAbstract_lbl" xml:lang="en-US">n/a</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tcmd_EarningsPerShareOtherDisclosureAbstract_lbl" xml:lang="en-US">Earnings Per Share Other Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="tcmd_EarningsPerShareOtherDisclosureAbstract_lbl" xml:lang="en-US">Weighted-average common shares used to compute net loss per common share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Basic (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted-average shares outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Diluted (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted-average shares used to compute diluted net loss per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" xml:lang="en-US">Consolidated Statements of Comprehensive Loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl" xml:lang="en-US">Other comprehensive loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xml:lang="en-US">Other Comprehensive Income (Loss), Unrealized Holding Gain (Loss) on Securities Arising During Period, Net of Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xml:lang="en-US">Unrealized loss on marketable securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" xlink:label="us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" xlink:to="us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1_lbl" xml:lang="en-US">Other Comprehensive Income (Loss), Tax, Portion Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1_lbl" xml:lang="en-US">Income tax related to items of other comprehensive loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_lbl" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_lbl" xml:lang="en-US">Total other comprehensive loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US">Comprehensive loss for the period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US">Comprehensive loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US">Consolidated Statements of Stockholders' Equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-In Capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">(Accumulated Deficit) Retained Earnings</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US">Accumulated Other Comprehensive Loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balances at the end (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balances at the beginning (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" xml:lang="en-US">Adjustments to Additional Paid in Capital, Share-based Compensation, Stock Options, Requisite Service Period Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" xml:lang="en-US">Stock-based compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US">Exercise of common stock options and vesting of performance and restricted stock units</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Exercise of common stock options and vesting of performance and restricted stock units (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_lbl" xml:lang="en-US">Adjustment to Additional Paid in Capital, Income Tax Effect from Share-based Compensation, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_lbl" xml:lang="en-US">Taxes paid for net share settlement of performance and restricted stock units</label>
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_AdjustmentsToAdditionalPaidInCapitalSharesOther" xlink:label="tcmd_AdjustmentsToAdditionalPaidInCapitalSharesOther" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcmd_AdjustmentsToAdditionalPaidInCapitalSharesOther" xlink:to="tcmd_AdjustmentsToAdditionalPaidInCapitalSharesOther_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tcmd_AdjustmentsToAdditionalPaidInCapitalSharesOther_lbl" xml:lang="en-US">Number of share issued related to tax settlement of restricted stock units</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tcmd_AdjustmentsToAdditionalPaidInCapitalSharesOther_lbl" xml:lang="en-US">Adjustments To Additional Paid In Capital Shares Other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="tcmd_AdjustmentsToAdditionalPaidInCapitalSharesOther_lbl" xml:lang="en-US">Taxes paid for net share settlement of performance and restricted stock units (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xml:lang="en-US">Common shares issued for employee stock purchase plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xml:lang="en-US">Common shares issued for employee stock purchase plan (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Consolidated Statements of Cash Flows</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInContinuingOperationsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInContinuingOperationsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInContinuingOperationsAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Continuing Operations [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInContinuingOperationsAbstract_lbl" xml:lang="en-US">Cash flows from operating activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">Net loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash provided by operating activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US">Depreciation, Depletion and Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization</label>
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_AmortizationOfPremiumsAndDiscountsOnSecuritiesAvailableForSale" xlink:label="tcmd_AmortizationOfPremiumsAndDiscountsOnSecuritiesAvailableForSale" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcmd_AmortizationOfPremiumsAndDiscountsOnSecuritiesAvailableForSale" xlink:to="tcmd_AmortizationOfPremiumsAndDiscountsOnSecuritiesAvailableForSale_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tcmd_AmortizationOfPremiumsAndDiscountsOnSecuritiesAvailableForSale_lbl" xml:lang="en-US">The amount of net amortization of premiums and discounts on securities available-for-sale.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tcmd_AmortizationOfPremiumsAndDiscountsOnSecuritiesAvailableForSale_lbl" xml:lang="en-US">Amortization Of Premiums And Discounts On Securities Available For Sale</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tcmd_AmortizationOfPremiumsAndDiscountsOnSecuritiesAvailableForSale_lbl" xml:lang="en-US">Net amortization of premiums and discounts on securities available-for-sale</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:label="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:to="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_lbl" xml:lang="en-US">Increase (Decrease) in Deferred Income Taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_lbl" xml:lang="en-US">Deferred income taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Share-based Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesGainLoss" xlink:label="us-gaap_MarketableSecuritiesGainLoss" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesGainLoss" xlink:to="us-gaap_MarketableSecuritiesGainLoss_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesGainLoss_lbl" xml:lang="en-US">Marketable Securities, Gain (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_MarketableSecuritiesGainLoss_lbl" xml:lang="en-US">Gain on other investments and maturities of marketable securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetImpairmentCharges" xlink:to="us-gaap_AssetImpairmentCharges_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetImpairmentCharges_lbl" xml:lang="en-US">Asset Impairment Charges</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetImpairmentCharges_lbl" xml:lang="en-US">Impairment losses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="us-gaap_GainLossOnDispositionOfAssets1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnDispositionOfAssets1" xlink:to="us-gaap_GainLossOnDispositionOfAssets1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnDispositionOfAssets1_lbl" xml:lang="en-US">Gain (Loss) on Disposition of Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainLossOnDispositionOfAssets1_lbl" xml:lang="en-US">Loss on disposal of property and equipment and intangibles</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueAdjustment" xlink:label="us-gaap_LiabilitiesFairValueAdjustment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueAdjustment" xlink:to="us-gaap_LiabilitiesFairValueAdjustment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesFairValueAdjustment_lbl" xml:lang="en-US">Liabilities, Fair Value Adjustment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LiabilitiesFairValueAdjustment_lbl" xml:lang="en-US">Change in fair value of earn-out liability</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in assets and liabilities, net of acquisition:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Accounts receivable</label>
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_IncreaseDecreaseInNetInvestmentInLease" xlink:label="tcmd_IncreaseDecreaseInNetInvestmentInLease" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcmd_IncreaseDecreaseInNetInvestmentInLease" xlink:to="tcmd_IncreaseDecreaseInNetInvestmentInLease_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tcmd_IncreaseDecreaseInNetInvestmentInLease_lbl" xml:lang="en-US">Represents the increase (decrease) in net investment in leases.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tcmd_IncreaseDecreaseInNetInvestmentInLease_lbl" xml:lang="en-US">Increase (Decrease) In Net Investment in Lease</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="tcmd_IncreaseDecreaseInNetInvestmentInLease_lbl" xml:lang="en-US">Net investment in leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US">Increase (Decrease) in Inventories</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US">Inventories</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:label="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:to="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_lbl" xml:lang="en-US">Increase (Decrease) in Income Taxes Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_lbl" xml:lang="en-US">Income taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid expenses and other assets</label>
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:label="tcmd_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcmd_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:to="tcmd_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tcmd_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Represents the increase (decrease) in right of use operating lease assets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tcmd_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Increase (Decrease) In Operating Lease Right Of Use Asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="tcmd_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Right of use operating lease assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerAsset" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerAsset_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerAsset_lbl" xml:lang="en-US">Increase (Decrease) in Contract Receivables, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerAsset_lbl" xml:lang="en-US">Accounts receivable, non-current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl" xml:lang="en-US">Increase (Decrease) in Employee Related Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl" xml:lang="en-US">Accrued payroll and related taxes</label>
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_IncreaseDecreaseInOtherAccruedLiabilitiesAndIncomeTaxesPayable" xlink:label="tcmd_IncreaseDecreaseInOtherAccruedLiabilitiesAndIncomeTaxesPayable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcmd_IncreaseDecreaseInOtherAccruedLiabilitiesAndIncomeTaxesPayable" xlink:to="tcmd_IncreaseDecreaseInOtherAccruedLiabilitiesAndIncomeTaxesPayable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tcmd_IncreaseDecreaseInOtherAccruedLiabilitiesAndIncomeTaxesPayable_lbl" xml:lang="en-US">The increase (decrease) during the reporting period in other expenses (excluding accrued payroll and related taxes) and income taxes payable incurred but not yet paid.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tcmd_IncreaseDecreaseInOtherAccruedLiabilitiesAndIncomeTaxesPayable_lbl" xml:lang="en-US">Increase Decrease In Other Accrued Liabilities And Income Taxes Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tcmd_IncreaseDecreaseInOtherAccruedLiabilitiesAndIncomeTaxesPayable_lbl" xml:lang="en-US">Accrued expenses and other liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash provided by operating activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US">Cash flows from investing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_lbl" xml:lang="en-US">Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_lbl" xml:lang="en-US">Proceeds from maturities of securities available-for-sale</label>
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_PaymentsToAcquireProductiveAsset" xlink:label="tcmd_PaymentsToAcquireProductiveAsset" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcmd_PaymentsToAcquireProductiveAsset" xlink:to="tcmd_PaymentsToAcquireProductiveAsset_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tcmd_PaymentsToAcquireProductiveAsset_lbl" xml:lang="en-US">The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible asset.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tcmd_PaymentsToAcquireProductiveAsset_lbl" xml:lang="en-US">Payments to Acquire Productive Asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="tcmd_PaymentsToAcquireProductiveAsset_lbl" xml:lang="en-US">Payments related to acquisition</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchases of property and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xml:lang="en-US">Proceeds from Sale of Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xml:lang="en-US">Proceeds from sale of property and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xml:lang="en-US">Payments to Acquire Intangible Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xml:lang="en-US">Intangible assets expenditures</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireOtherInvestments" xlink:label="us-gaap_PaymentsToAcquireOtherInvestments" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireOtherInvestments" xlink:to="us-gaap_PaymentsToAcquireOtherInvestments_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireOtherInvestments_lbl" xml:lang="en-US">Payments to Acquire Other Investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireOtherInvestments_lbl" xml:lang="en-US">Other investments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash (used in) provided by investing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US">Cash flows from financing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="us-gaap_ProceedsFromNotesPayable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromNotesPayable" xlink:to="us-gaap_ProceedsFromNotesPayable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromNotesPayable_lbl" xml:lang="en-US">Proceeds from Notes Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromNotesPayable_lbl" xml:lang="en-US">Proceeds from issuance of note payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="us-gaap_ProceedsFromLinesOfCredit" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromLinesOfCredit" xlink:to="us-gaap_ProceedsFromLinesOfCredit_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromLinesOfCredit_lbl" xml:lang="en-US">Proceeds from Lines of Credit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromLinesOfCredit_lbl" xml:lang="en-US">Proceeds from revolving line of credit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:label="us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:to="us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_lbl" xml:lang="en-US">Payment for Contingent Consideration Liability, Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_lbl" xml:lang="en-US">Payment on earn-out</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="us-gaap_RepaymentsOfNotesPayable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfNotesPayable" xlink:to="us-gaap_RepaymentsOfNotesPayable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfNotesPayable_lbl" xml:lang="en-US">Repayments of Notes Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfNotesPayable_lbl" xml:lang="en-US">Payments on note payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" xml:lang="en-US">Payments of Debt Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" xml:lang="en-US">Payments of deferred debt issuance costs</label>
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_PaymentOfTaxesForNetShareSettlementOfRestrictedStockUnits" xlink:label="tcmd_PaymentOfTaxesForNetShareSettlementOfRestrictedStockUnits" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcmd_PaymentOfTaxesForNetShareSettlementOfRestrictedStockUnits" xlink:to="tcmd_PaymentOfTaxesForNetShareSettlementOfRestrictedStockUnits_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tcmd_PaymentOfTaxesForNetShareSettlementOfRestrictedStockUnits_lbl" xml:lang="en-US">Amount of cash outflow for taxes paid for net share settlement of restricted stock units.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tcmd_PaymentOfTaxesForNetShareSettlementOfRestrictedStockUnits_lbl" xml:lang="en-US">Payment of Taxes for the Net Share Settlement of Restricted Stock Units</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="tcmd_PaymentOfTaxesForNetShareSettlementOfRestrictedStockUnits_lbl" xml:lang="en-US">Taxes paid for net share settlement of performance and restricted stock units</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Proceeds from Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Proceeds from exercise of common stock options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from Issuance of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from the issuance of common stock from the employee stock purchase plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash (used in) provided by financing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xml:lang="en-US">Net (decrease) increase in cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash and cash equivalents - end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash and cash equivalents - beginning of period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental cash flow disclosure</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Interest Paid, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Cash paid for interest</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaid" xlink:label="us-gaap_IncomeTaxesPaid" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaid" xlink:to="us-gaap_IncomeTaxesPaid_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaid_lbl" xml:lang="en-US">Income Taxes Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxesPaid_lbl" xml:lang="en-US">Cash paid for taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1" xlink:to="us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1_lbl" xml:lang="en-US">Noncash or Part Noncash Acquisition, Value of Assets Acquired</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1_lbl" xml:lang="en-US">Capital expenditures incurred but not yet paid</label>
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_NatureOfBusinessAndOperationAbstract" xlink:label="tcmd_NatureOfBusinessAndOperationAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcmd_NatureOfBusinessAndOperationAbstract" xlink:to="tcmd_NatureOfBusinessAndOperationAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tcmd_NatureOfBusinessAndOperationAbstract_lbl" xml:lang="en-US">n/a</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tcmd_NatureOfBusinessAndOperationAbstract_lbl" xml:lang="en-US">Nature of Business and Operations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NatureOfOperations_lbl" xml:lang="en-US">Nature of Operations [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NatureOfOperations_lbl" xml:lang="en-US">Nature of Business and Operations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Basis of Presentation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Basis of Presentation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Summary of Significant Accounting Policies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Summary of Significant Accounting Policies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAbstract" xlink:label="us-gaap_AssetAcquisitionAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionAbstract" xlink:to="us-gaap_AssetAcquisitionAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetAcquisitionAbstract_lbl" xml:lang="en-US">Acquisitions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionTextBlock" xlink:label="us-gaap_AssetAcquisitionTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionTextBlock" xlink:to="us-gaap_AssetAcquisitionTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetAcquisitionTextBlock_lbl" xml:lang="en-US">Asset Acquisition [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetAcquisitionTextBlock_lbl" xml:lang="en-US">Acquisitions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesAbstract" xlink:label="us-gaap_ReceivablesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="us-gaap_ReceivablesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReceivablesAbstract_lbl" xml:lang="en-US">Accounts Receivable.</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:to="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_lbl" xml:lang="en-US">Loans, Notes, Trade and Other Receivables Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_lbl" xml:lang="en-US">Accounts Receivable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureAbstract_lbl" xml:lang="en-US">Inventories</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureTextBlock" xlink:to="us-gaap_InventoryDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xml:lang="en-US">Inventory Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xml:lang="en-US">Inventories</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US">Property and Equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">Property and Equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xml:lang="en-US">Goodwill and Intangible Assets.</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl" xml:lang="en-US">Goodwill and Intangible Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Accrued Expenses</label>
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_AccruedExpensesDisclosureCurrentTextBlock" xlink:label="tcmd_AccruedExpensesDisclosureCurrentTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcmd_AccruedExpensesDisclosureCurrentTextBlock" xlink:to="tcmd_AccruedExpensesDisclosureCurrentTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tcmd_AccruedExpensesDisclosureCurrentTextBlock_lbl" xml:lang="en-US">The entire disclosure for accrued expenses that are classified as current at the end of the reporting period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tcmd_AccruedExpensesDisclosureCurrentTextBlock_lbl" xml:lang="en-US">Accrued Expenses Disclosure, Current [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tcmd_AccruedExpensesDisclosureCurrentTextBlock_lbl" xml:lang="en-US">Accrued Expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StandardProductWarrantyDisclosureAbstract" xlink:label="us-gaap_StandardProductWarrantyDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StandardProductWarrantyDisclosureAbstract" xlink:to="us-gaap_StandardProductWarrantyDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StandardProductWarrantyDisclosureAbstract_lbl" xml:lang="en-US">Warranty Reserves</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StandardProductWarrantyDisclosureAbstract_lbl" xml:lang="en-US">Product Warranty</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductWarrantyDisclosureTextBlock" xlink:label="us-gaap_ProductWarrantyDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductWarrantyDisclosureTextBlock" xlink:to="us-gaap_ProductWarrantyDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProductWarrantyDisclosureTextBlock_lbl" xml:lang="en-US">Product Warranty Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProductWarrantyDisclosureTextBlock_lbl" xml:lang="en-US">Warranty Reserves</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US">Credit Agreement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">Debt Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">Credit Agreement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xml:lang="en-US">Stockholders' Equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:to="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">Shareholders' Equity and Share-based Payments [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">Stockholders' Equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract_lbl" xml:lang="en-US">Revenue.</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl" xml:lang="en-US">Revenue</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_IncomeTaxTable" xlink:label="tcmd_IncomeTaxTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcmd_IncomeTaxTable" xlink:to="tcmd_IncomeTaxTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tcmd_IncomeTaxTable_lbl" xml:lang="en-US">Disclosures pertaining to Income Taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tcmd_IncomeTaxTable_lbl" xml:lang="en-US">Income Tax Table</label>
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_IncomeTaxLineItems" xlink:label="tcmd_IncomeTaxLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcmd_IncomeTaxLineItems" xlink:to="tcmd_IncomeTaxLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tcmd_IncomeTaxLineItems_lbl" xml:lang="en-US">Line items represent financial concepts included in a table</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tcmd_IncomeTaxLineItems_lbl" xml:lang="en-US">Income Tax Line Items</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tcmd_IncomeTaxLineItems_lbl" xml:lang="en-US">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US">Earnings Per Share [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US">Net (Loss) Income Per Common Share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US">Fair Value Measurements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US">Fair Value Disclosures [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US">Fair Value Measurements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of Presentation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US">Principles of Consolidation</label>
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_UnusualRisksAndUncertaintiesPolicyTextBlock" xlink:label="tcmd_UnusualRisksAndUncertaintiesPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcmd_UnusualRisksAndUncertaintiesPolicyTextBlock" xlink:to="tcmd_UnusualRisksAndUncertaintiesPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tcmd_UnusualRisksAndUncertaintiesPolicyTextBlock_lbl" xml:lang="en-US">Disclosure of accounting policy for the nature of the unusual risk or uncertainty, such as the threat of expropriation of its assets by a foreign government, rapid technological obsolescence in the industry, risk of natural disaster from earthquake or weather events, and disease pandemic.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tcmd_UnusualRisksAndUncertaintiesPolicyTextBlock_lbl" xml:lang="en-US">Unusual Risks and Uncertainties [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tcmd_UnusualRisksAndUncertaintiesPolicyTextBlock_lbl" xml:lang="en-US">Risks and Uncertainties</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xml:lang="en-US">Comprehensive Loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and Cash Equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="us-gaap_InvestmentPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentPolicyTextBlock" xlink:to="us-gaap_InvestmentPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentPolicyTextBlock_lbl" xml:lang="en-US">Investment, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentPolicyTextBlock_lbl" xml:lang="en-US">Equity Investments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" xml:lang="en-US">Trade and Other Accounts Receivable, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" xml:lang="en-US">Accounts Receivable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xml:lang="en-US">Inventory, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xml:lang="en-US">Inventories</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property and Equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xml:lang="en-US">Revenue Recognition, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xml:lang="en-US">Revenue Recognition</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvertisingCostsPolicyTextBlock" xlink:label="us-gaap_AdvertisingCostsPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdvertisingCostsPolicyTextBlock" xlink:to="us-gaap_AdvertisingCostsPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdvertisingCostsPolicyTextBlock_lbl" xml:lang="en-US">Advertising Costs, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdvertisingCostsPolicyTextBlock_lbl" xml:lang="en-US">Advertising</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development Costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesPolicyTextBlock" xlink:label="us-gaap_CostOfSalesPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfSalesPolicyTextBlock" xlink:to="us-gaap_CostOfSalesPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfSalesPolicyTextBlock_lbl" xml:lang="en-US">Cost of Sales, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostOfSalesPolicyTextBlock_lbl" xml:lang="en-US">Shipping and Handling Costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StandardProductWarrantyPolicy" xlink:label="us-gaap_StandardProductWarrantyPolicy" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StandardProductWarrantyPolicy" xlink:to="us-gaap_StandardProductWarrantyPolicy_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StandardProductWarrantyPolicy_lbl" xml:lang="en-US">Standard Product Warranty, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StandardProductWarrantyPolicy_lbl" xml:lang="en-US">Product Warranty</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US">Impairment of Long-Lived Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:to="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_lbl" xml:lang="en-US">Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_lbl" xml:lang="en-US">Goodwill</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Stock-Based Compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Net (Loss) Income Per Common Share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Business Segments</label>
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_NewAccountingPronouncementsNoteYetAdoptedPolicyPolicyTextBlock" xlink:label="tcmd_NewAccountingPronouncementsNoteYetAdoptedPolicyPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcmd_NewAccountingPronouncementsNoteYetAdoptedPolicyPolicyTextBlock" xlink:to="tcmd_NewAccountingPronouncementsNoteYetAdoptedPolicyPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tcmd_NewAccountingPronouncementsNoteYetAdoptedPolicyPolicyTextBlock_lbl" xml:lang="en-US">Disclosure of accounting policy pertaining to new accounting pronouncements not yet adopted.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tcmd_NewAccountingPronouncementsNoteYetAdoptedPolicyPolicyTextBlock_lbl" xml:lang="en-US">New Accounting Pronouncements, Note Yet Adopted Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tcmd_NewAccountingPronouncementsNoteYetAdoptedPolicyPolicyTextBlock_lbl" xml:lang="en-US">Accounting Pronouncement Not Yet Adopted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionTableTextBlock" xlink:label="us-gaap_AssetAcquisitionTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionTableTextBlock" xlink:to="us-gaap_AssetAcquisitionTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetAcquisitionTableTextBlock_lbl" xml:lang="en-US">Asset Acquisition [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetAcquisitionTableTextBlock_lbl" xml:lang="en-US">Summary of purchase price allocation</label>
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfAssetAcquisitionTableTextBlock" xlink:label="tcmd_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfAssetAcquisitionTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcmd_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfAssetAcquisitionTableTextBlock" xlink:to="tcmd_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfAssetAcquisitionTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tcmd_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfAssetAcquisitionTableTextBlock_lbl" xml:lang="en-US">Tabular disclosure of finite-lived and indefinite-lived intangible assets acquired as part of a asset acquisition agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tcmd_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfAssetAcquisitionTableTextBlock_lbl" xml:lang="en-US">Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Asset Acquisition [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tcmd_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfAssetAcquisitionTableTextBlock_lbl" xml:lang="en-US">Schedule of allocation of the purchase price</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:label="us-gaap_BusinessAcquisitionProFormaInformationTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:to="us-gaap_BusinessAcquisitionProFormaInformationTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionProFormaInformationTextBlock_lbl" xml:lang="en-US">Business Acquisition, Pro Forma Information [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessAcquisitionProFormaInformationTextBlock_lbl" xml:lang="en-US">Schedule of condensed consolidated statements of operations reflect AffoVest operations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xml:lang="en-US">Schedule of inventories</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Schedule of components of property and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xml:lang="en-US">Schedule of finite lived intangible assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xml:lang="en-US">Finite-lived Intangible Assets Amortization Expense [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xml:lang="en-US">Schedule of future amortization expense</label>
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_ScheduleOfAccruedExpensesTableTextBlock" xlink:label="tcmd_ScheduleOfAccruedExpensesTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcmd_ScheduleOfAccruedExpensesTableTextBlock" xlink:to="tcmd_ScheduleOfAccruedExpensesTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tcmd_ScheduleOfAccruedExpensesTableTextBlock_lbl" xml:lang="en-US">Tabular disclosure of the carrying value as of the balance sheet date of accrued expenses excluding accounts payable. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tcmd_ScheduleOfAccruedExpensesTableTextBlock_lbl" xml:lang="en-US">Schedule of Accrued Expenses [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tcmd_ScheduleOfAccruedExpensesTableTextBlock_lbl" xml:lang="en-US">Schedule of Accrued Expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock" xlink:label="us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock" xlink:to="us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock_lbl" xml:lang="en-US">Schedule of Product Warranty Liability [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock_lbl" xml:lang="en-US">Schedule of warranty reserves</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl" xml:lang="en-US">Schedule of Maturities of Long-term Debt [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl" xml:lang="en-US">Schedule of maturities of the term note payable</label>
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:label="tcmd_AssetsAndLiabilitiesLesseeTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcmd_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:to="tcmd_AssetsAndLiabilitiesLesseeTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tcmd_AssetsAndLiabilitiesLesseeTableTextBlock_lbl" xml:lang="en-US">The tabular disclosure of lease-related assets and liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tcmd_AssetsAndLiabilitiesLesseeTableTextBlock_lbl" xml:lang="en-US">Assets and Liabilities, Lessee [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tcmd_AssetsAndLiabilitiesLesseeTableTextBlock_lbl" xml:lang="en-US">Summary of lease-related assets and liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLeaseIncomeTableTextBlock" xlink:label="us-gaap_OperatingLeaseLeaseIncomeTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLeaseIncomeTableTextBlock" xlink:to="us-gaap_OperatingLeaseLeaseIncomeTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLeaseIncomeTableTextBlock_lbl" xml:lang="en-US">Operating Lease, Lease Income [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLeaseIncomeTableTextBlock_lbl" xml:lang="en-US">Summary of undiscounted cash flows</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US">Equity Award [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US">Restricted Stock Units</label>
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_TimeBasedRestrictedStockUnitsRsusMember" xlink:label="tcmd_TimeBasedRestrictedStockUnitsRsusMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcmd_TimeBasedRestrictedStockUnitsRsusMember" xlink:to="tcmd_TimeBasedRestrictedStockUnitsRsusMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tcmd_TimeBasedRestrictedStockUnitsRsusMember_lbl" xml:lang="en-US">Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tcmd_TimeBasedRestrictedStockUnitsRsusMember_lbl" xml:lang="en-US">Time-Based Restricted Stock Units</label>
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_PerformanceBasedStockSettledRestrictedStockUnitsMember" xlink:label="tcmd_PerformanceBasedStockSettledRestrictedStockUnitsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcmd_PerformanceBasedStockSettledRestrictedStockUnitsMember" xlink:to="tcmd_PerformanceBasedStockSettledRestrictedStockUnitsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tcmd_PerformanceBasedStockSettledRestrictedStockUnitsMember_lbl" xml:lang="en-US">This member stands for performance-based stock-settled restricted stock units plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tcmd_PerformanceBasedStockSettledRestrictedStockUnitsMember_lbl" xml:lang="en-US">Performance-based stock-settled restricted stock units</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US">Schedule of allocation of total stock-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of estimated fair values and assumptions for stock options granted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of stock option activity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of Nonvested Share Activity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of Share-based Compensation, Restricted Stock Units Award Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of stock-settled restricted stock unit activity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xml:lang="en-US">Summary of revenue disaggregated by product</label>
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_ScheduleOfRevenueFromThirdPartyPayersTableTextBlock" xlink:label="tcmd_ScheduleOfRevenueFromThirdPartyPayersTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcmd_ScheduleOfRevenueFromThirdPartyPayersTableTextBlock" xlink:to="tcmd_ScheduleOfRevenueFromThirdPartyPayersTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tcmd_ScheduleOfRevenueFromThirdPartyPayersTableTextBlock_lbl" xml:lang="en-US">Tabular disclosure of disaggregation of revenue revenues from third-party payers.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tcmd_ScheduleOfRevenueFromThirdPartyPayersTableTextBlock_lbl" xml:lang="en-US">Schedule Of Revenue From Third Party Payers [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tcmd_ScheduleOfRevenueFromThirdPartyPayersTableTextBlock_lbl" xml:lang="en-US">Summary of revenue by channel</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesTypeLeaseLeaseIncomeTableTextBlock" xlink:label="us-gaap_SalesTypeLeaseLeaseIncomeTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesTypeLeaseLeaseIncomeTableTextBlock" xlink:to="us-gaap_SalesTypeLeaseLeaseIncomeTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalesTypeLeaseLeaseIncomeTableTextBlock_lbl" xml:lang="en-US">Sales-type Lease, Lease Income [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SalesTypeLeaseLeaseIncomeTableTextBlock_lbl" xml:lang="en-US">Sales-type lease revenue and the associated cost of goods sold</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US">Schedule of provision (benefit) for income tax expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of components of the Company's deferred tax assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">Schedule of reconciliation of income tax expense (benefit)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xml:lang="en-US">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xml:lang="en-US">Schedule of unrecognized tax benefits ("UTB")</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US">Schedule of computation of the basic and diluted net loss per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">Schedule of potentially dilutive securities outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xml:lang="en-US">Schedule of changes in the earn-out liability</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xml:lang="en-US">Schedule of fair value measurements for our earn-out liability, cash equivalents and marketable securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:label="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable_lbl" xml:lang="en-US">Schedule of Subsidiary or Equity Method Investee [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US">Sale of Stock [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IPOMember_lbl" xml:lang="en-US">IPO</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xml:lang="en-US">Subsidiary, Sale of Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Number of shares of common stock sold</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US">Shares Issued, Price Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US">Share price (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US">IPO price per share (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US">Proceeds from Issuance Initial Public Offering</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US">Proceeds from IPO</label>
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_ExpenseRelatingToInitialPublicOffering" xlink:label="tcmd_ExpenseRelatingToInitialPublicOffering" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcmd_ExpenseRelatingToInitialPublicOffering" xlink:to="tcmd_ExpenseRelatingToInitialPublicOffering_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tcmd_ExpenseRelatingToInitialPublicOffering_lbl" xml:lang="en-US">Amount of expenses relating to the initial public offering during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tcmd_ExpenseRelatingToInitialPublicOffering_lbl" xml:lang="en-US">Expense Relating To Initial Public Offering</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tcmd_ExpenseRelatingToInitialPublicOffering_lbl" xml:lang="en-US">Expense Relating To Initial Public Offering</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US">Number of Operating Segments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US">Number of operating segment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfReportableSegments" xlink:to="us-gaap_NumberOfReportableSegments_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xml:lang="en-US">Number of Reportable Segments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xml:lang="en-US">Number of reportable segment</label>
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_GarmentsMember" xlink:label="tcmd_GarmentsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcmd_GarmentsMember" xlink:to="tcmd_GarmentsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tcmd_GarmentsMember_lbl" xml:lang="en-US">Represents information pertaining to garments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tcmd_GarmentsMember_lbl" xml:lang="en-US">Garments</label>
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_ControllersMember" xlink:label="tcmd_ControllersMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcmd_ControllersMember" xlink:to="tcmd_ControllersMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tcmd_ControllersMember_lbl" xml:lang="en-US">Represents information pertaining to controllers.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tcmd_ControllersMember_lbl" xml:lang="en-US">Controllers</label>
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_AfflovestMember" xlink:label="tcmd_AfflovestMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcmd_AfflovestMember" xlink:to="tcmd_AfflovestMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tcmd_AfflovestMember_lbl" xml:lang="en-US">Represents information pertaining to AffloVest.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tcmd_AfflovestMember_lbl" xml:lang="en-US">AffloVest</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Range [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US">Range [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValueAbstract" xlink:label="us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValueAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValueAbstract" xlink:to="us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValueAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValueAbstract_lbl" xml:lang="en-US">Equity Securities, FV-NI and without Readily Determinable Fair Value [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValueAbstract_lbl" xml:lang="en-US">Equity Securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:label="us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:to="us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_lbl" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_lbl" xml:lang="en-US">Equity security without readily determinable fair value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetAbstract" xlink:label="us-gaap_AccountsReceivableNetAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetAbstract" xlink:to="us-gaap_AccountsReceivableNetAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetAbstract_lbl" xml:lang="en-US">Accounts Receivable, Net [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableNetAbstract_lbl" xml:lang="en-US">Accounts Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccountsReceivableNetAbstract_lbl" xml:lang="en-US">Accounts Receivable</label>
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_PercentageOfClaimsApproved" xlink:label="tcmd_PercentageOfClaimsApproved" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcmd_PercentageOfClaimsApproved" xlink:to="tcmd_PercentageOfClaimsApproved_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tcmd_PercentageOfClaimsApproved_lbl" xml:lang="en-US">Represents information pertaining to approved claims based on number of claims.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tcmd_PercentageOfClaimsApproved_lbl" xml:lang="en-US">Percentage Of Claims Approved</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tcmd_PercentageOfClaimsApproved_lbl" xml:lang="en-US">Percentage of claims</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_lbl" xml:lang="en-US">Property, Plant and Equipment, Net, by Type [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_lbl" xml:lang="en-US">Property and Equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Property, Plant and Equipment, Useful Life</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Useful life</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionAbstract" xlink:label="us-gaap_RevenueRecognitionAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionAbstract" xlink:to="us-gaap_RevenueRecognitionAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionAbstract_lbl" xml:lang="en-US">Revenue Recognition</label>
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_MedicareReceivablesTimePeriod" xlink:label="tcmd_MedicareReceivablesTimePeriod" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcmd_MedicareReceivablesTimePeriod" xlink:to="tcmd_MedicareReceivablesTimePeriod_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tcmd_MedicareReceivablesTimePeriod_lbl" xml:lang="en-US">Period of term over which the payment from Medicare sales are receivable, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tcmd_MedicareReceivablesTimePeriod_lbl" xml:lang="en-US">Medicare Receivables, Time Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tcmd_MedicareReceivablesTimePeriod_lbl" xml:lang="en-US">Medicare receivables period of time</label>
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_PeriodForConsiderationPaymentAfterShipmentDate" xlink:label="tcmd_PeriodForConsiderationPaymentAfterShipmentDate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcmd_PeriodForConsiderationPaymentAfterShipmentDate" xlink:to="tcmd_PeriodForConsiderationPaymentAfterShipmentDate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tcmd_PeriodForConsiderationPaymentAfterShipmentDate_lbl" xml:lang="en-US">Represents the period for consideration payment after shipment date.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tcmd_PeriodForConsiderationPaymentAfterShipmentDate_lbl" xml:lang="en-US">Period for Consideration Payment After Shipment Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tcmd_PeriodForConsiderationPaymentAfterShipmentDate_lbl" xml:lang="en-US">Period for consideration payment after shipment date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuePracticalExpedientIncrementalCostOfObtainingContract" xlink:label="us-gaap_RevenuePracticalExpedientIncrementalCostOfObtainingContract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuePracticalExpedientIncrementalCostOfObtainingContract" xlink:to="us-gaap_RevenuePracticalExpedientIncrementalCostOfObtainingContract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenuePracticalExpedientIncrementalCostOfObtainingContract_lbl" xml:lang="en-US">Revenue, Practical Expedient, Incremental Cost of Obtaining Contract [true false]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RevenuePracticalExpedientIncrementalCostOfObtainingContract_lbl" xml:lang="en-US">Revenue for practical expedient</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketingAndAdvertisingExpenseAbstract" xlink:label="us-gaap_MarketingAndAdvertisingExpenseAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketingAndAdvertisingExpenseAbstract" xlink:to="us-gaap_MarketingAndAdvertisingExpenseAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketingAndAdvertisingExpenseAbstract_lbl" xml:lang="en-US">Marketing and Advertising Expense [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_MarketingAndAdvertisingExpenseAbstract_lbl" xml:lang="en-US">Advertising</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvertisingExpense" xlink:label="us-gaap_AdvertisingExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdvertisingExpense" xlink:to="us-gaap_AdvertisingExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdvertisingExpense_lbl" xml:lang="en-US">Advertising Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdvertisingExpense_lbl" xml:lang="en-US">Advertising Expense</label>
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_TermOfProductWarranty" xlink:label="tcmd_TermOfProductWarranty" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcmd_TermOfProductWarranty" xlink:to="tcmd_TermOfProductWarranty_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tcmd_TermOfProductWarranty_lbl" xml:lang="en-US">Represents the term of product warranty.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tcmd_TermOfProductWarranty_lbl" xml:lang="en-US">Term Of Product Warranty</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tcmd_TermOfProductWarranty_lbl" xml:lang="en-US">Product Warranty</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionTable" xlink:label="us-gaap_AssetAcquisitionTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionTable" xlink:to="us-gaap_AssetAcquisitionTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetAcquisitionTable_lbl" xml:lang="en-US">Asset Acquisition [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xml:lang="en-US">Business Acquisition [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</label>
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_AfflovestPMember" xlink:label="tcmd_AfflovestPMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcmd_AfflovestPMember" xlink:to="tcmd_AfflovestPMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tcmd_AfflovestPMember_lbl" xml:lang="en-US">Represent information pertaining to AffloVest APA.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tcmd_AfflovestPMember_lbl" xml:lang="en-US">AffloVest APA</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementScenarioAxis_lbl" xml:lang="en-US">Scenario [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xml:lang="en-US">Scenario, Unspecified [Domain]</label>
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_AssetAcquisitionEarnoutPaymentsRevenueTargetsFromOctoberTwoThousandTwentyOneToSeptemberTwoThousandTwentyTwoMember" xlink:label="tcmd_AssetAcquisitionEarnoutPaymentsRevenueTargetsFromOctoberTwoThousandTwentyOneToSeptemberTwoThousandTwentyTwoMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcmd_AssetAcquisitionEarnoutPaymentsRevenueTargetsFromOctoberTwoThousandTwentyOneToSeptemberTwoThousandTwentyTwoMember" xlink:to="tcmd_AssetAcquisitionEarnoutPaymentsRevenueTargetsFromOctoberTwoThousandTwentyOneToSeptemberTwoThousandTwentyTwoMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tcmd_AssetAcquisitionEarnoutPaymentsRevenueTargetsFromOctoberTwoThousandTwentyOneToSeptemberTwoThousandTwentyTwoMember_lbl" xml:lang="en-US">Represents the achievement of revenue targets from October 1, 2021 to September 30, 2022 which triggers earnout payments under asset acquisition.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tcmd_AssetAcquisitionEarnoutPaymentsRevenueTargetsFromOctoberTwoThousandTwentyOneToSeptemberTwoThousandTwentyTwoMember_lbl" xml:lang="en-US">Earn-out period exceed Base Revenues from October 1, 2021 to September 30, 2022</label>
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_AssetAcquisitionEarnoutPaymentsRevenueTargetsFromOctoberTwoThousandTwentyTwoToSeptemberTwoThousandTwentyThreeMember" xlink:label="tcmd_AssetAcquisitionEarnoutPaymentsRevenueTargetsFromOctoberTwoThousandTwentyTwoToSeptemberTwoThousandTwentyThreeMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcmd_AssetAcquisitionEarnoutPaymentsRevenueTargetsFromOctoberTwoThousandTwentyTwoToSeptemberTwoThousandTwentyThreeMember" xlink:to="tcmd_AssetAcquisitionEarnoutPaymentsRevenueTargetsFromOctoberTwoThousandTwentyTwoToSeptemberTwoThousandTwentyThreeMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tcmd_AssetAcquisitionEarnoutPaymentsRevenueTargetsFromOctoberTwoThousandTwentyTwoToSeptemberTwoThousandTwentyThreeMember_lbl" xml:lang="en-US">Represents the achievement of revenue targets from October 1, 2022 to September 30, 2023 which triggers earnout payments under asset acquisition.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tcmd_AssetAcquisitionEarnoutPaymentsRevenueTargetsFromOctoberTwoThousandTwentyTwoToSeptemberTwoThousandTwentyThreeMember_lbl" xml:lang="en-US">Earn-out period exceed Base Revenues from October 1, 2022 to September 30, 2023</label>
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_EarnOutPeriodOnOrBeforeNovember282022Member" xlink:label="tcmd_EarnOutPeriodOnOrBeforeNovember282022Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcmd_EarnOutPeriodOnOrBeforeNovember282022Member" xlink:to="tcmd_EarnOutPeriodOnOrBeforeNovember282022Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tcmd_EarnOutPeriodOnOrBeforeNovember282022Member_lbl" xml:lang="en-US">Represents the information pertaining to earnout period on or before November 28, 2022.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tcmd_EarnOutPeriodOnOrBeforeNovember282022Member_lbl" xml:lang="en-US">Earn-out period on or before November 28,2022</label>
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_EarnOutPeriodOnOrBeforeMay262023Member" xlink:label="tcmd_EarnOutPeriodOnOrBeforeMay262023Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcmd_EarnOutPeriodOnOrBeforeMay262023Member" xlink:to="tcmd_EarnOutPeriodOnOrBeforeMay262023Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tcmd_EarnOutPeriodOnOrBeforeMay262023Member_lbl" xml:lang="en-US">Represents the information pertaining to earnout period on or before may 26, 2023.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tcmd_EarnOutPeriodOnOrBeforeMay262023Member_lbl" xml:lang="en-US">Earn-out period on or before May 26, 2023</label>
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_SecondEarnOutAmendmentMember" xlink:label="tcmd_SecondEarnOutAmendmentMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcmd_SecondEarnOutAmendmentMember" xlink:to="tcmd_SecondEarnOutAmendmentMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tcmd_SecondEarnOutAmendmentMember_lbl" xml:lang="en-US">Represents the information pertaining to second earnout amendment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tcmd_SecondEarnOutAmendmentMember_lbl" xml:lang="en-US">Second earn-out amendment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Income Statement Location [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US">Income Statement Location [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">Reimbursement, general and administrative expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionLineItems" xlink:label="us-gaap_AssetAcquisitionLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_AssetAcquisitionLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetAcquisitionLineItems_lbl" xml:lang="en-US">Asset Acquisition [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetAcquisitionLineItems_lbl" xml:lang="en-US">Acquisitions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" xml:lang="en-US">Asset Acquisition, Consideration Transferred</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" xml:lang="en-US">Total consideration transferred</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="us-gaap_PaymentsToAcquireBusinessesGross_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross_lbl" xml:lang="en-US">Payments to Acquire Productive Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross_lbl" xml:lang="en-US">Purchase price</label>
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_AssetAcquisitionConsiderationTransferredEscrowAccount" xlink:label="tcmd_AssetAcquisitionConsiderationTransferredEscrowAccount" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcmd_AssetAcquisitionConsiderationTransferredEscrowAccount" xlink:to="tcmd_AssetAcquisitionConsiderationTransferredEscrowAccount_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tcmd_AssetAcquisitionConsiderationTransferredEscrowAccount_lbl" xml:lang="en-US">Amount in escrow account recognized as part of consideration transferred in asset acquisition.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tcmd_AssetAcquisitionConsiderationTransferredEscrowAccount_lbl" xml:lang="en-US">Asset Acquisition, Consideration Transferred, Escrow Account</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tcmd_AssetAcquisitionConsiderationTransferredEscrowAccount_lbl" xml:lang="en-US">Escrow account</label>
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_AssetAcquisitionAmountReceivedResultingFromWorkingCapitalAdjustment" xlink:label="tcmd_AssetAcquisitionAmountReceivedResultingFromWorkingCapitalAdjustment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcmd_AssetAcquisitionAmountReceivedResultingFromWorkingCapitalAdjustment" xlink:to="tcmd_AssetAcquisitionAmountReceivedResultingFromWorkingCapitalAdjustment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tcmd_AssetAcquisitionAmountReceivedResultingFromWorkingCapitalAdjustment_lbl" xml:lang="en-US">Amount received for assets acquisition from working capital adjustment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tcmd_AssetAcquisitionAmountReceivedResultingFromWorkingCapitalAdjustment_lbl" xml:lang="en-US">Asset Acquisition, Amount Received Resulting From Working Capital Adjustment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tcmd_AssetAcquisitionAmountReceivedResultingFromWorkingCapitalAdjustment_lbl" xml:lang="en-US">Working capital adjustments</label>
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_AssetAcquisitionBusinessRevenueToExceedBaseRevenueMultiplier" xlink:label="tcmd_AssetAcquisitionBusinessRevenueToExceedBaseRevenueMultiplier" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcmd_AssetAcquisitionBusinessRevenueToExceedBaseRevenueMultiplier" xlink:to="tcmd_AssetAcquisitionBusinessRevenueToExceedBaseRevenueMultiplier_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tcmd_AssetAcquisitionBusinessRevenueToExceedBaseRevenueMultiplier_lbl" xml:lang="en-US">The multiplier applied to the amount by which the Business's Revenue in the initial earnout period exceed Base Revenues.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tcmd_AssetAcquisitionBusinessRevenueToExceedBaseRevenueMultiplier_lbl" xml:lang="en-US">Asset Acquisition, Business Revenue To Exceed Base Revenue, Multiplier</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tcmd_AssetAcquisitionBusinessRevenueToExceedBaseRevenueMultiplier_lbl" xml:lang="en-US">Business revenue to exceed base revenue, Multiplier</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability_lbl" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability_lbl" xml:lang="en-US">Earn-out liability, ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability_lbl" xml:lang="en-US">Earn-out liability, beginning balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability_lbl" xml:lang="en-US">Earn-out liability</label>
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_AssetAcquisitionEarnOutLiability" xlink:label="tcmd_AssetAcquisitionEarnOutLiability" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcmd_AssetAcquisitionEarnOutLiability" xlink:to="tcmd_AssetAcquisitionEarnOutLiability_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tcmd_AssetAcquisitionEarnOutLiability_lbl" xml:lang="en-US">The amount of earn out liability recognized in asset acquisition.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tcmd_AssetAcquisitionEarnOutLiability_lbl" xml:lang="en-US">Asset Acquisition, Earn Out Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tcmd_AssetAcquisitionEarnOutLiability_lbl" xml:lang="en-US">Earn-out liability, asset acquisition</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:label="us-gaap_BusinessCombinationAcquisitionRelatedCosts" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:to="us-gaap_BusinessCombinationAcquisitionRelatedCosts_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationAcquisitionRelatedCosts_lbl" xml:lang="en-US">Business Combination, Acquisition Related Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationAcquisitionRelatedCosts_lbl" xml:lang="en-US">Transaction costs</label>
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_AssetAcquisitionImputedInterestPayable" xlink:label="tcmd_AssetAcquisitionImputedInterestPayable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcmd_AssetAcquisitionImputedInterestPayable" xlink:to="tcmd_AssetAcquisitionImputedInterestPayable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tcmd_AssetAcquisitionImputedInterestPayable_lbl" xml:lang="en-US">The amount of imputed interest payable as at the date of asset acquisition.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tcmd_AssetAcquisitionImputedInterestPayable_lbl" xml:lang="en-US">Asset Acquisition, Imputed Interest Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tcmd_AssetAcquisitionImputedInterestPayable_lbl" xml:lang="en-US">Imputed interest payment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionConsiderationTransferredAbstract" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferredAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionConsiderationTransferredAbstract" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferredAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferredAbstract_lbl" xml:lang="en-US">Asset Acquisition, Consideration Transferred [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferredAbstract_lbl" xml:lang="en-US">Purchase price allocation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNet" xlink:label="us-gaap_AssetsNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNet" xlink:to="us-gaap_AssetsNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNet_lbl" xml:lang="en-US">Net Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsNet_lbl" xml:lang="en-US">Purchase price</label>
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_GoodwillAmortizationPeriodForTaxPurposes" xlink:label="tcmd_GoodwillAmortizationPeriodForTaxPurposes" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcmd_GoodwillAmortizationPeriodForTaxPurposes" xlink:to="tcmd_GoodwillAmortizationPeriodForTaxPurposes_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tcmd_GoodwillAmortizationPeriodForTaxPurposes_lbl" xml:lang="en-US">Period over which goodwill is deductible for tax purposes.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tcmd_GoodwillAmortizationPeriodForTaxPurposes_lbl" xml:lang="en-US">Goodwill, Amortization Period For Tax Purposes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tcmd_GoodwillAmortizationPeriodForTaxPurposes_lbl" xml:lang="en-US">Amortization period for tax purposes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRelationshipsMember" xlink:label="us-gaap_CustomerRelationshipsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerRelationshipsMember" xlink:to="us-gaap_CustomerRelationshipsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CustomerRelationshipsMember_lbl" xml:lang="en-US">Customer relationships</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="us-gaap_DevelopedTechnologyRightsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DevelopedTechnologyRightsMember" xlink:to="us-gaap_DevelopedTechnologyRightsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DevelopedTechnologyRightsMember_lbl" xml:lang="en-US">Developed technology</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeNamesMember" xlink:label="us-gaap_TradeNamesMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TradeNamesMember" xlink:to="us-gaap_TradeNamesMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TradeNamesMember_lbl" xml:lang="en-US">Tradenames</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US">Finite lived intangible assets, Allocated Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US">Total</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsGrossExcludingGoodwill" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsGrossExcludingGoodwill_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsGrossExcludingGoodwill_lbl" xml:lang="en-US">Intangible Assets, Gross (Excluding Goodwill)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IntangibleAssetsGrossExcludingGoodwill_lbl" xml:lang="en-US">Indefinite lived intangible assets excluding goodwill, Allocated fair value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IntangibleAssetsGrossExcludingGoodwill_lbl" xml:lang="en-US">Total intangible assets (Gross)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xml:lang="en-US">Estimated Useful Life</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:label="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:to="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_lbl" xml:lang="en-US">Acquired Finite-lived Intangible Assets, Weighted Average Useful Life</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_lbl" xml:lang="en-US">Weighted average amortization period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:label="us-gaap_BusinessAcquisitionsProFormaRevenue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:to="us-gaap_BusinessAcquisitionsProFormaRevenue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionsProFormaRevenue_lbl" xml:lang="en-US">Business Acquisition, Pro Forma Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessAcquisitionsProFormaRevenue_lbl" xml:lang="en-US">Total revenue</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:label="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:to="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_lbl" xml:lang="en-US">Business Acquisition, Pro Forma Net Income (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_lbl" xml:lang="en-US">Net (loss) income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTable" xlink:label="us-gaap_ConcentrationRiskTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskTable_lbl" xml:lang="en-US">Concentration Risk [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_MajorCustomersAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MajorCustomersAxis_lbl" xml:lang="en-US">Customer [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="srt_NameOfMajorCustomerDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_NameOfMajorCustomerDomain_lbl" xml:lang="en-US">Customer [Domain]</label>
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_InsuranceCompanyOneMember" xlink:label="tcmd_InsuranceCompanyOneMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcmd_InsuranceCompanyOneMember" xlink:to="tcmd_InsuranceCompanyOneMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tcmd_InsuranceCompanyOneMember_lbl" xml:lang="en-US">Represents one of the customer for the entity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tcmd_InsuranceCompanyOneMember_lbl" xml:lang="en-US">Insurer One</label>
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_InsuranceCompanyTwoMember" xlink:label="tcmd_InsuranceCompanyTwoMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcmd_InsuranceCompanyTwoMember" xlink:to="tcmd_InsuranceCompanyTwoMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tcmd_InsuranceCompanyTwoMember_lbl" xml:lang="en-US">Represents Information pertaining to customer two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tcmd_InsuranceCompanyTwoMember_lbl" xml:lang="en-US">Insurer Two</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xml:lang="en-US">Concentration Risk Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_ConcentrationRiskTypeDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskTypeDomain_lbl" xml:lang="en-US">Concentration Risk Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerConcentrationRiskMember" xlink:to="us-gaap_CustomerConcentrationRiskMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl" xml:lang="en-US">Customer Concentration Risk</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xml:lang="en-US">Concentration Risk Benchmark [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xml:lang="en-US">Concentration Risk Benchmark [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember" xlink:label="us-gaap_AccountsReceivableMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableMember" xlink:to="us-gaap_AccountsReceivableMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableMember_lbl" xml:lang="en-US">Accounts Receivable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNetMember" xlink:to="us-gaap_SalesRevenueNetMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalesRevenueNetMember_lbl" xml:lang="en-US">Revenue</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="us-gaap_ConcentrationRiskLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskLineItems_lbl" xml:lang="en-US">Concentration Risk [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ConcentrationRiskLineItems_lbl" xml:lang="en-US">Commitments and Contingencies</label>
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_ConcentrationRiskNumberOfInsuranceCompanies" xlink:label="tcmd_ConcentrationRiskNumberOfInsuranceCompanies" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcmd_ConcentrationRiskNumberOfInsuranceCompanies" xlink:to="tcmd_ConcentrationRiskNumberOfInsuranceCompanies_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tcmd_ConcentrationRiskNumberOfInsuranceCompanies_lbl" xml:lang="en-US">Represents information pertaining to number of insurance companies.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tcmd_ConcentrationRiskNumberOfInsuranceCompanies_lbl" xml:lang="en-US">Concentration Risk, Number Of Insurance Companies</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tcmd_ConcentrationRiskNumberOfInsuranceCompanies_lbl" xml:lang="en-US">Number of insurers</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xml:lang="en-US">Concentration Risk, Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xml:lang="en-US">Total purchases (in percentage)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xml:lang="en-US">Percentage of concentration</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNetAbstract" xlink:label="us-gaap_InventoryNetAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNetAbstract" xlink:to="us-gaap_InventoryNetAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNetAbstract_lbl" xml:lang="en-US">Inventory, Net [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InventoryNetAbstract_lbl" xml:lang="en-US">Inventories</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoods" xlink:label="us-gaap_InventoryFinishedGoods" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoods" xlink:to="us-gaap_InventoryFinishedGoods_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryFinishedGoods_lbl" xml:lang="en-US">Inventory, Finished Goods, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryFinishedGoods_lbl" xml:lang="en-US">Finished goods</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcess" xlink:label="us-gaap_InventoryWorkInProcess" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWorkInProcess" xlink:to="us-gaap_InventoryWorkInProcess_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryWorkInProcess_lbl" xml:lang="en-US">Inventory, Work in Process, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryWorkInProcess_lbl" xml:lang="en-US">Component parts and work-in-process</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquipmentMember_lbl" xml:lang="en-US">Equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ToolsDiesAndMoldsMember" xlink:label="us-gaap_ToolsDiesAndMoldsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ToolsDiesAndMoldsMember" xlink:to="us-gaap_ToolsDiesAndMoldsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ToolsDiesAndMoldsMember_lbl" xml:lang="en-US">Tooling</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US">Furniture and Fixtures</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdsAndLeaseholdImprovementsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdsAndLeaseholdImprovementsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdsAndLeaseholdImprovementsMember_lbl" xml:lang="en-US">Leasehold improvements</label>
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_DemoEquipmentMember" xlink:label="tcmd_DemoEquipmentMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcmd_DemoEquipmentMember" xlink:to="tcmd_DemoEquipmentMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tcmd_DemoEquipmentMember_lbl" xml:lang="en-US">This member stands for demo equipment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tcmd_DemoEquipmentMember_lbl" xml:lang="en-US">Demonstration equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionInProgressMember" xlink:to="us-gaap_ConstructionInProgressMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xml:lang="en-US">Construction in progress</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Property, Plant and Equipment [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Property and Equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Property, Plant and Equipment, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Subtotal</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Less: accumulated depreciation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PatentsMember" xlink:label="us-gaap_PatentsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PatentsMember" xlink:to="us-gaap_PatentsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PatentsMember_lbl" xml:lang="en-US">Patents</label>
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_DefensiveIntangibleAssetsMember" xlink:label="tcmd_DefensiveIntangibleAssetsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcmd_DefensiveIntangibleAssetsMember" xlink:to="tcmd_DefensiveIntangibleAssetsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tcmd_DefensiveIntangibleAssetsMember_lbl" xml:lang="en-US">This member stands for defensive intangible assets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tcmd_DefensiveIntangibleAssetsMember_lbl" xml:lang="en-US">Defensive intangible assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerContractsMember" xlink:label="us-gaap_CustomerContractsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerContractsMember" xlink:to="us-gaap_CustomerContractsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CustomerContractsMember_lbl" xml:lang="en-US">Customer accounts</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xml:lang="en-US">Patents and Intangibles</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNetAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNetAbstract_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Net [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNetAbstract_lbl" xml:lang="en-US">Definite-lived intangible assets:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:label="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:to="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Remaining Amortization Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_lbl" xml:lang="en-US">Weighted Average Amortization Period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xml:lang="en-US">Gross Carrying Amount</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xml:lang="en-US">Accumulated Amortization</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_lbl" xml:lang="en-US">Indefinite-lived Intangible Assets (Excluding Goodwill) [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_lbl" xml:lang="en-US">Unamortized intangible assets:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_lbl" xml:lang="en-US">Indefinite-lived Intangible Assets (Excluding Goodwill)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_lbl" xml:lang="en-US">Gross Carrying Amount, Indefinite</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US">Amortization of Intangible Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US">Amortization expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:label="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_lbl" xml:lang="en-US">Future Amortization</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xml:lang="en-US">2023</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xml:lang="en-US">2024</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Three</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xml:lang="en-US">2025</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Four</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xml:lang="en-US">2026</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Five</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xml:lang="en-US">2027</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, after Year Five</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl" xml:lang="en-US">Thereafter</label>
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_InTransitInventoryAccruedExpense" xlink:label="tcmd_InTransitInventoryAccruedExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcmd_InTransitInventoryAccruedExpense" xlink:to="tcmd_InTransitInventoryAccruedExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tcmd_InTransitInventoryAccruedExpense_lbl" xml:lang="en-US">In-transit inventory accrued expense.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tcmd_InTransitInventoryAccruedExpense_lbl" xml:lang="en-US">In-transit inventory accrued expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tcmd_InTransitInventoryAccruedExpense_lbl" xml:lang="en-US">In-transit inventory</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductWarrantyAccrualClassifiedCurrent" xlink:label="us-gaap_ProductWarrantyAccrualClassifiedCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductWarrantyAccrualClassifiedCurrent" xlink:to="us-gaap_ProductWarrantyAccrualClassifiedCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProductWarrantyAccrualClassifiedCurrent_lbl" xml:lang="en-US">Product Warranty Accrual, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProductWarrantyAccrualClassifiedCurrent_lbl" xml:lang="en-US">Warranty</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProductWarrantyAccrualClassifiedCurrent_lbl" xml:lang="en-US">Accrued warranty reserve, current</label>
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_AccruedTravelAndEntertainmentCurrent" xlink:label="tcmd_AccruedTravelAndEntertainmentCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcmd_AccruedTravelAndEntertainmentCurrent" xlink:to="tcmd_AccruedTravelAndEntertainmentCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tcmd_AccruedTravelAndEntertainmentCurrent_lbl" xml:lang="en-US">Carrying value as of the balance sheet date of obligations incurred through that date and payable for travel and entertainment expenses. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tcmd_AccruedTravelAndEntertainmentCurrent_lbl" xml:lang="en-US">Accrued Travel And Entertainment Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tcmd_AccruedTravelAndEntertainmentCurrent_lbl" xml:lang="en-US">Travel</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US">Accrued Professional Fees, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US">Legal and consulting</label>
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_AccruedClinicalStudiesExpensesCurrent" xlink:label="tcmd_AccruedClinicalStudiesExpensesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcmd_AccruedClinicalStudiesExpensesCurrent" xlink:to="tcmd_AccruedClinicalStudiesExpensesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tcmd_AccruedClinicalStudiesExpensesCurrent_lbl" xml:lang="en-US">The carrying amount as of the balance sheet date of accrued clinical studies.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tcmd_AccruedClinicalStudiesExpensesCurrent_lbl" xml:lang="en-US">Accrued Clinical Studies Expenses, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tcmd_AccruedClinicalStudiesExpensesCurrent_lbl" xml:lang="en-US">Clinical studies</label>
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_AccruedSalesAndUseTax" xlink:label="tcmd_AccruedSalesAndUseTax" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcmd_AccruedSalesAndUseTax" xlink:to="tcmd_AccruedSalesAndUseTax_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tcmd_AccruedSalesAndUseTax_lbl" xml:lang="en-US">Carrying value as of the balance sheet date of obligations relating to sales and use tax.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tcmd_AccruedSalesAndUseTax_lbl" xml:lang="en-US">Accrued Sales And Use Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tcmd_AccruedSalesAndUseTax_lbl" xml:lang="en-US">Sales and use tax</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Other Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Other</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MovementInStandardProductWarrantyAccrualRollForward" xlink:label="us-gaap_MovementInStandardProductWarrantyAccrualRollForward" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MovementInStandardProductWarrantyAccrualRollForward" xlink:to="us-gaap_MovementInStandardProductWarrantyAccrualRollForward_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MovementInStandardProductWarrantyAccrualRollForward_lbl" xml:lang="en-US">Movement in Standard Product Warranty Accrual [Roll Forward]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StandardProductWarrantyAccrual" xlink:label="us-gaap_StandardProductWarrantyAccrual" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StandardProductWarrantyAccrual" xlink:to="us-gaap_StandardProductWarrantyAccrual_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StandardProductWarrantyAccrual_lbl" xml:lang="en-US">Standard Product Warranty Accrual</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StandardProductWarrantyAccrual_lbl" xml:lang="en-US">Ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StandardProductWarrantyAccrual_lbl" xml:lang="en-US">Beginning balance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StandardProductWarrantyAccrualWarrantiesIssued" xlink:label="us-gaap_StandardProductWarrantyAccrualWarrantiesIssued" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StandardProductWarrantyAccrualWarrantiesIssued" xlink:to="us-gaap_StandardProductWarrantyAccrualWarrantiesIssued_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StandardProductWarrantyAccrualWarrantiesIssued_lbl" xml:lang="en-US">Standard Product Warranty Accrual, Increase for Warranties Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StandardProductWarrantyAccrualWarrantiesIssued_lbl" xml:lang="en-US">Warranty provision</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StandardProductWarrantyAccrualPayments" xlink:label="us-gaap_StandardProductWarrantyAccrualPayments" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StandardProductWarrantyAccrualPayments" xlink:to="us-gaap_StandardProductWarrantyAccrualPayments_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StandardProductWarrantyAccrualPayments_lbl" xml:lang="en-US">Standard Product Warranty Accrual, Decrease for Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StandardProductWarrantyAccrualPayments_lbl" xml:lang="en-US">Processed warranty claims</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductWarrantyAccrual" xlink:label="us-gaap_ProductWarrantyAccrual" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductWarrantyAccrual" xlink:to="us-gaap_ProductWarrantyAccrual_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProductWarrantyAccrual_lbl" xml:lang="en-US">Standard and Extended Product Warranty Accrual</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ProductWarrantyAccrual_lbl" xml:lang="en-US">Total accrued warranty reserve</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityTable" xlink:label="us-gaap_LineOfCreditFacilityTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="us-gaap_LineOfCreditFacilityTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityTable_lbl" xml:lang="en-US">Line of Credit Facility [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CreditFacilityAxis_lbl" xml:lang="en-US">Credit Facility [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_CreditFacilityDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CreditFacilityDomain_lbl" xml:lang="en-US">Credit Facility [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="us-gaap_RevolvingCreditFacilityMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevolvingCreditFacilityMember" xlink:to="us-gaap_RevolvingCreditFacilityMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevolvingCreditFacilityMember_lbl" xml:lang="en-US">Revolving credit facility</label>
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_TermLoanMember" xlink:label="tcmd_TermLoanMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcmd_TermLoanMember" xlink:to="tcmd_TermLoanMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tcmd_TermLoanMember_lbl" xml:lang="en-US">Represents information pertaining to term loan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tcmd_TermLoanMember_lbl" xml:lang="en-US">Term Loan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VariableRateAxis_lbl" xml:lang="en-US">Variable Rate [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableRateDomain" xlink:to="us-gaap_VariableRateDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VariableRateDomain_lbl" xml:lang="en-US">Variable Rate [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FederalFundsEffectiveSwapRateMember" xlink:label="us-gaap_FederalFundsEffectiveSwapRateMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FederalFundsEffectiveSwapRateMember" xlink:to="us-gaap_FederalFundsEffectiveSwapRateMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FederalFundsEffectiveSwapRateMember_lbl" xml:lang="en-US">Federal Funds</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BaseRateMember" xlink:label="us-gaap_BaseRateMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BaseRateMember" xlink:to="us-gaap_BaseRateMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BaseRateMember_lbl" xml:lang="en-US">Base Rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:label="us-gaap_LondonInterbankOfferedRateLIBORMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:to="us-gaap_LondonInterbankOfferedRateLIBORMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LondonInterbankOfferedRateLIBORMember_lbl" xml:lang="en-US">LIBOR</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLineItems" xlink:label="us-gaap_LineOfCreditFacilityLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_LineOfCreditFacilityLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityLineItems_lbl" xml:lang="en-US">Line of Credit Facility [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LineOfCreditFacilityLineItems_lbl" xml:lang="en-US">Credit Agreement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xml:lang="en-US">Line of credit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xml:lang="en-US">Basis spread (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:label="us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:to="us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_lbl" xml:lang="en-US">Line of Credit Facility, Unused Capacity, Commitment Fee Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_lbl" xml:lang="en-US">Unused line fee (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US">Debt Instrument, Face Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US">Debt instrument face amount</label>
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_LineOfCreditThresholdContingentIncreaseInBorrowingCapacity" xlink:label="tcmd_LineOfCreditThresholdContingentIncreaseInBorrowingCapacity" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcmd_LineOfCreditThresholdContingentIncreaseInBorrowingCapacity" xlink:to="tcmd_LineOfCreditThresholdContingentIncreaseInBorrowingCapacity_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tcmd_LineOfCreditThresholdContingentIncreaseInBorrowingCapacity_lbl" xml:lang="en-US">Line Of Credit, Threshold Contingent Increase In Borrowing Capacity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tcmd_LineOfCreditThresholdContingentIncreaseInBorrowingCapacity_lbl" xml:lang="en-US">Line Of Credit, Threshold Contingent Increase In Borrowing Capacity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tcmd_LineOfCreditThresholdContingentIncreaseInBorrowingCapacity_lbl" xml:lang="en-US">Line of credit, threshold contingent increase in borrowing capacity</label>
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_CreditAgreementTotalAggregatePrincipalAmount" xlink:label="tcmd_CreditAgreementTotalAggregatePrincipalAmount" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcmd_CreditAgreementTotalAggregatePrincipalAmount" xlink:to="tcmd_CreditAgreementTotalAggregatePrincipalAmount_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tcmd_CreditAgreementTotalAggregatePrincipalAmount_lbl" xml:lang="en-US">The total aggregate principal amount under the credit agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tcmd_CreditAgreementTotalAggregatePrincipalAmount_lbl" xml:lang="en-US">Credit Agreement, Total Aggregate Principal Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tcmd_CreditAgreementTotalAggregatePrincipalAmount_lbl" xml:lang="en-US">Credit agreement, total aggregate principal amount</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebt_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebt_lbl" xml:lang="en-US">Long-term Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebt_lbl" xml:lang="en-US">Long-term debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LongTermDebt_lbl" xml:lang="en-US">Total</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="us-gaap_DebtInstrumentPeriodicPayment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentPeriodicPayment" xlink:to="us-gaap_DebtInstrumentPeriodicPayment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentPeriodicPayment_lbl" xml:lang="en-US">Debt Instrument, Periodic Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentPeriodicPayment_lbl" xml:lang="en-US">Debt instrument periodic payment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" xlink:label="us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" xlink:to="us-gaap_DebtInstrumentFrequencyOfPeriodicPayment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFrequencyOfPeriodicPayment_lbl" xml:lang="en-US">Debt Instrument, Frequency of Periodic Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentFrequencyOfPeriodicPayment_lbl" xml:lang="en-US">Debt instrument frequency of periodic payment</label>
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_DebtInstrumentPaymentOfMandatoryPrincipalPrepayment" xlink:label="tcmd_DebtInstrumentPaymentOfMandatoryPrincipalPrepayment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcmd_DebtInstrumentPaymentOfMandatoryPrincipalPrepayment" xlink:to="tcmd_DebtInstrumentPaymentOfMandatoryPrincipalPrepayment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tcmd_DebtInstrumentPaymentOfMandatoryPrincipalPrepayment_lbl" xml:lang="en-US">The amount of mandatory principal prepayment paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tcmd_DebtInstrumentPaymentOfMandatoryPrincipalPrepayment_lbl" xml:lang="en-US">Debt Instrument, Payment of Mandatory Principal Prepayment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tcmd_DebtInstrumentPaymentOfMandatoryPrincipalPrepayment_lbl" xml:lang="en-US">Principal prepayment of term loan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtByMaturityAbstract" xlink:label="us-gaap_LongTermDebtByMaturityAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtByMaturityAbstract" xlink:to="us-gaap_LongTermDebtByMaturityAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtByMaturityAbstract_lbl" xml:lang="en-US">Long-term Debt, Fiscal Year Maturity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtByMaturityAbstract_lbl" xml:lang="en-US">Maturities of notes payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl" xml:lang="en-US">Long-Term Debt, Maturity, Year Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl" xml:lang="en-US">2023</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl" xml:lang="en-US">Long-Term Debt, Maturity, Year Three</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl" xml:lang="en-US">2024</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xml:lang="en-US">Lessee, Lease, Description [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingMember" xlink:label="us-gaap_BuildingMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BuildingMember" xlink:to="us-gaap_BuildingMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BuildingMember_lbl" xml:lang="en-US">Building</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VehiclesMember" xlink:label="us-gaap_VehiclesMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VehiclesMember" xlink:to="us-gaap_VehiclesMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VehiclesMember_lbl" xml:lang="en-US">Vehicles</label>
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_CorporateHeadQuarterInitialLeaseMember" xlink:label="tcmd_CorporateHeadQuarterInitialLeaseMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcmd_CorporateHeadQuarterInitialLeaseMember" xlink:to="tcmd_CorporateHeadQuarterInitialLeaseMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tcmd_CorporateHeadQuarterInitialLeaseMember_lbl" xml:lang="en-US">Represents member for initial lease for corporate head quarter.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tcmd_CorporateHeadQuarterInitialLeaseMember_lbl" xml:lang="en-US">Initial lease</label>
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_CorporateHeadQuarterSecondLeaseMember" xlink:label="tcmd_CorporateHeadQuarterSecondLeaseMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcmd_CorporateHeadQuarterSecondLeaseMember" xlink:to="tcmd_CorporateHeadQuarterSecondLeaseMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tcmd_CorporateHeadQuarterSecondLeaseMember_lbl" xml:lang="en-US">Represents member for second lease corporate head quarter.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tcmd_CorporateHeadQuarterSecondLeaseMember_lbl" xml:lang="en-US">Second lease</label>
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_CorporateHeadQuarterThirdLeaseMember" xlink:label="tcmd_CorporateHeadQuarterThirdLeaseMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcmd_CorporateHeadQuarterThirdLeaseMember" xlink:to="tcmd_CorporateHeadQuarterThirdLeaseMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tcmd_CorporateHeadQuarterThirdLeaseMember_lbl" xml:lang="en-US">Represents member for third lease corporate head quarter.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tcmd_CorporateHeadQuarterThirdLeaseMember_lbl" xml:lang="en-US">Third lease</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xml:lang="en-US">Lessee, Lease, Description [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xml:lang="en-US">Commitments and Contingencies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xml:lang="en-US">Remaining lease terms</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AreaOfLand" xlink:label="us-gaap_AreaOfLand" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AreaOfLand" xlink:to="us-gaap_AreaOfLand_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AreaOfLand_lbl" xml:lang="en-US">Area of Land</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AreaOfLand_lbl" xml:lang="en-US">Area of office space</label>
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_AdditionalOfficeSpaceAdded" xlink:label="tcmd_AdditionalOfficeSpaceAdded" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcmd_AdditionalOfficeSpaceAdded" xlink:to="tcmd_AdditionalOfficeSpaceAdded_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tcmd_AdditionalOfficeSpaceAdded_lbl" xml:lang="en-US">Additional office space added to the lease.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tcmd_AdditionalOfficeSpaceAdded_lbl" xml:lang="en-US">Additional office space added</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tcmd_AdditionalOfficeSpaceAdded_lbl" xml:lang="en-US">Additional office space added to the lease</label>
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_NumberOfVehiclesWithAgreementsWithinInitialNoncancelableLeaseTerm" xlink:label="tcmd_NumberOfVehiclesWithAgreementsWithinInitialNoncancelableLeaseTerm" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcmd_NumberOfVehiclesWithAgreementsWithinInitialNoncancelableLeaseTerm" xlink:to="tcmd_NumberOfVehiclesWithAgreementsWithinInitialNoncancelableLeaseTerm_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tcmd_NumberOfVehiclesWithAgreementsWithinInitialNoncancelableLeaseTerm_lbl" xml:lang="en-US">Represents the number of vehicles with agreements within the initial, noncancelable lease term.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tcmd_NumberOfVehiclesWithAgreementsWithinInitialNoncancelableLeaseTerm_lbl" xml:lang="en-US">Number of Vehicles with Agreements Within Initial, Noncancelable Lease Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tcmd_NumberOfVehiclesWithAgreementsWithinInitialNoncancelableLeaseTerm_lbl" xml:lang="en-US">Number of vehicles with agreements within the initial, noncancelable lease term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" xml:lang="en-US">Lessee, Operating Lease, Existence of Option to Extend [true false]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" xml:lang="en-US">Option to renew</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:label="us-gaap_AssetsAndLiabilitiesLesseeAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:to="us-gaap_AssetsAndLiabilitiesLesseeAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAndLiabilitiesLesseeAbstract_lbl" xml:lang="en-US">Assets and Liabilities, Lessee [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAndLiabilitiesLesseeAbstract_lbl" xml:lang="en-US">Lease-related assets and liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_lbl" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_lbl" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_lbl" xml:lang="en-US">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Operating Lease, Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Present value of future minimum lease payments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Weighted average remaining lease term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Weighted average discount rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US">Operating Lease, Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US">Cash paid for operating lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US">Non-cash right of use assets obtained in exchange for new operating lease obligations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xml:lang="en-US">Operating Lease Liabilities, Payments Due [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xml:lang="en-US">Undiscounted cash flows</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">2023</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">2024</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Three</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US">2025</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Four</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US">2026</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Five</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xml:lang="en-US">2027</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due after Year Five</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xml:lang="en-US">Thereafter</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total minimum lease payments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Less: Amount of lease payments representing interest</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Amortization Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xml:lang="en-US">Operating lease cost</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsTotalMember" xlink:label="us-gaap_CostOfGoodsTotalMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsTotalMember" xlink:to="us-gaap_CostOfGoodsTotalMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfGoodsTotalMember_lbl" xml:lang="en-US">Purchases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplierConcentrationRiskMember" xlink:label="us-gaap_SupplierConcentrationRiskMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplierConcentrationRiskMember" xlink:to="us-gaap_SupplierConcentrationRiskMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplierConcentrationRiskMember_lbl" xml:lang="en-US">Vendor</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_lbl" xml:lang="en-US">Supplier [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_lbl" xml:lang="en-US">Supplier [Domain]</label>
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_VendorOneMember" xlink:label="tcmd_VendorOneMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcmd_VendorOneMember" xlink:to="tcmd_VendorOneMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tcmd_VendorOneMember_lbl" xml:lang="en-US">Represents the information pertaining to vendor one.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tcmd_VendorOneMember_lbl" xml:lang="en-US">Vendor One</label>
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_VendorTwoMember" xlink:label="tcmd_VendorTwoMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcmd_VendorTwoMember" xlink:to="tcmd_VendorTwoMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tcmd_VendorTwoMember_lbl" xml:lang="en-US">Represents the information pertaining to vendor two.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tcmd_VendorTwoMember_lbl" xml:lang="en-US">Vendor Two</label>
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_NumberOfVendors" xlink:label="tcmd_NumberOfVendors" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcmd_NumberOfVendors" xlink:to="tcmd_NumberOfVendors_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tcmd_NumberOfVendors_lbl" xml:lang="en-US">Represents the number of vendors.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tcmd_NumberOfVendors_lbl" xml:lang="en-US">Number Of Vendors</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tcmd_NumberOfVendors_lbl" xml:lang="en-US">Number of vendors</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseObligationFiscalYearMaturityAbstract" xlink:label="us-gaap_PurchaseObligationFiscalYearMaturityAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PurchaseObligationFiscalYearMaturityAbstract" xlink:to="us-gaap_PurchaseObligationFiscalYearMaturityAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PurchaseObligationFiscalYearMaturityAbstract_lbl" xml:lang="en-US">Purchase Obligation, Fiscal Year Maturity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PurchaseObligationFiscalYearMaturityAbstract_lbl" xml:lang="en-US">Purchase commitments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:label="us-gaap_PurchaseObligationDueInNextTwelveMonths" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:to="us-gaap_PurchaseObligationDueInNextTwelveMonths_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PurchaseObligationDueInNextTwelveMonths_lbl" xml:lang="en-US">Purchase Obligation, Due in Next Twelve Months</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PurchaseObligationDueInNextTwelveMonths_lbl" xml:lang="en-US">Purchase orders issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanTable" xlink:label="us-gaap_DefinedContributionPlanTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanTable" xlink:to="us-gaap_DefinedContributionPlanTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanTable_lbl" xml:lang="en-US">Defined Contribution Plan [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanNameAxis" xlink:label="us-gaap_RetirementPlanNameAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetirementPlanNameAxis" xlink:to="us-gaap_RetirementPlanNameAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetirementPlanNameAxis_lbl" xml:lang="en-US">Retirement Plan Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanNameDomain" xlink:label="us-gaap_RetirementPlanNameDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetirementPlanNameDomain" xlink:to="us-gaap_RetirementPlanNameDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetirementPlanNameDomain_lbl" xml:lang="en-US">Defined Contribution Plan Name [Domain] (Deprecated 2017-01-31)</label>
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_DefinedContribution401kRetirementPlanMember" xlink:label="tcmd_DefinedContribution401kRetirementPlanMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcmd_DefinedContribution401kRetirementPlanMember" xlink:to="tcmd_DefinedContribution401kRetirementPlanMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tcmd_DefinedContribution401kRetirementPlanMember_lbl" xml:lang="en-US">Represent information pertaining to Defined Contribution 401K Retirement Plan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tcmd_DefinedContribution401kRetirementPlanMember_lbl" xml:lang="en-US">401(k)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanDisclosureLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems_lbl" xml:lang="en-US">Defined Contribution Plan Disclosure [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems_lbl" xml:lang="en-US">Retirement Plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xml:lang="en-US">Defined Contribution Plan, Employer Discretionary Contribution Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xml:lang="en-US">Discretionary contributions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingenciesTable_lbl" xml:lang="en-US">Loss Contingencies [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingenciesLineItems_lbl" xml:lang="en-US">Loss Contingencies [Line Items]</label>
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_LitigationSettlementAgreementAmount" xlink:label="tcmd_LitigationSettlementAgreementAmount" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcmd_LitigationSettlementAgreementAmount" xlink:to="tcmd_LitigationSettlementAgreementAmount_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tcmd_LitigationSettlementAgreementAmount_lbl" xml:lang="en-US">Amount of settlement amount of litigation under settlement agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tcmd_LitigationSettlementAgreementAmount_lbl" xml:lang="en-US">Litigation Settlement Agreement, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tcmd_LitigationSettlementAgreementAmount_lbl" xml:lang="en-US">Settlement amount</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xml:lang="en-US">Schedule of Stock by Class [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US">Class of Stock [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesBPreferredStockMember" xlink:to="us-gaap_SeriesBPreferredStockMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl" xml:lang="en-US">Series B Preferred Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xml:lang="en-US">Series A Preferred Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US">Class of Stock [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US">Stockholders' Equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl" xml:lang="en-US">Preferred Stock, Number of Shares, Par Value and Other Disclosures [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl" xml:lang="en-US">Preferred stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xml:lang="en-US">Conversion of Stock, Shares Converted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xml:lang="en-US">Conversion of preferred stock to common stock (in shares)</label>
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_PreferredStockToCommonStockConversionRatio" xlink:label="tcmd_PreferredStockToCommonStockConversionRatio" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcmd_PreferredStockToCommonStockConversionRatio" xlink:to="tcmd_PreferredStockToCommonStockConversionRatio_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tcmd_PreferredStockToCommonStockConversionRatio_lbl" xml:lang="en-US">Represent the conversion ratio of preferred stock to common stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tcmd_PreferredStockToCommonStockConversionRatio_lbl" xml:lang="en-US">Preferred Stock To Common Stock Conversion Ratio</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tcmd_PreferredStockToCommonStockConversionRatio_lbl" xml:lang="en-US">Preferred stock to common stock conversion ratio</label>
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_StockIssuedDuringPeriodPriorToCompletionOfInitialOfferingSharesNewIssues" xlink:label="tcmd_StockIssuedDuringPeriodPriorToCompletionOfInitialOfferingSharesNewIssues" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcmd_StockIssuedDuringPeriodPriorToCompletionOfInitialOfferingSharesNewIssues" xlink:to="tcmd_StockIssuedDuringPeriodPriorToCompletionOfInitialOfferingSharesNewIssues_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tcmd_StockIssuedDuringPeriodPriorToCompletionOfInitialOfferingSharesNewIssues_lbl" xml:lang="en-US">Number of new stock issued relating to the IPO that Series A and Series B preferred stockholders are entitled to receive.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tcmd_StockIssuedDuringPeriodPriorToCompletionOfInitialOfferingSharesNewIssues_lbl" xml:lang="en-US">Stock Issued During Period Prior To Completion Of Initial Offering Shares New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tcmd_StockIssuedDuringPeriodPriorToCompletionOfInitialOfferingSharesNewIssues_lbl" xml:lang="en-US">Number of new stock issued relating to the IPO that Series A and Series B preferred stockholders are entitled to receive</label>
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_StockIssuedDuringPeriodRequiredToFundStockDividendsSharesNewIssues" xlink:label="tcmd_StockIssuedDuringPeriodRequiredToFundStockDividendsSharesNewIssues" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcmd_StockIssuedDuringPeriodRequiredToFundStockDividendsSharesNewIssues" xlink:to="tcmd_StockIssuedDuringPeriodRequiredToFundStockDividendsSharesNewIssues_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tcmd_StockIssuedDuringPeriodRequiredToFundStockDividendsSharesNewIssues_lbl" xml:lang="en-US">Number of new stock issued to pay accrued stock dividends relating to initial offering price.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tcmd_StockIssuedDuringPeriodRequiredToFundStockDividendsSharesNewIssues_lbl" xml:lang="en-US">Stock Issued During Period Required To Fund Stock Dividends Shares New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tcmd_StockIssuedDuringPeriodRequiredToFundStockDividendsSharesNewIssues_lbl" xml:lang="en-US">Number of new stock issued to pay accrued stock dividends relating to initial offering price</label>
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_AccruedCumulativeDividends" xlink:label="tcmd_AccruedCumulativeDividends" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcmd_AccruedCumulativeDividends" xlink:to="tcmd_AccruedCumulativeDividends_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tcmd_AccruedCumulativeDividends_lbl" xml:lang="en-US">Amount of cumulative cash dividends accrued as of the end of the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tcmd_AccruedCumulativeDividends_lbl" xml:lang="en-US">Accrued Cumulative Dividends</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfOrdinaryDividends" xlink:label="us-gaap_PaymentsOfOrdinaryDividends" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfOrdinaryDividends" xlink:to="us-gaap_PaymentsOfOrdinaryDividends_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfOrdinaryDividends_lbl" xml:lang="en-US">Payments of Ordinary Dividends</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsOfOrdinaryDividends_lbl" xml:lang="en-US">Payment of dividends</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US">Plan Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_EquityIncentivePlan2016Member" xlink:label="tcmd_EquityIncentivePlan2016Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcmd_EquityIncentivePlan2016Member" xlink:to="tcmd_EquityIncentivePlan2016Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tcmd_EquityIncentivePlan2016Member_lbl" xml:lang="en-US">Represents information pertaining to the 2016 Equity Incentive Plan (the "2016 Plan").</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tcmd_EquityIncentivePlan2016Member_lbl" xml:lang="en-US">2016 Plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember" xlink:label="us-gaap_CostOfSalesMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfSalesMember" xlink:to="us-gaap_CostOfSalesMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfSalesMember_lbl" xml:lang="en-US">Cost of revenue.</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingAndMarketingExpenseMember" xlink:label="us-gaap_SellingAndMarketingExpenseMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingAndMarketingExpenseMember" xlink:to="us-gaap_SellingAndMarketingExpenseMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingAndMarketingExpenseMember_lbl" xml:lang="en-US">Sales and marketing expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and development expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAbstract" xlink:label="us-gaap_ShareBasedCompensationAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="us-gaap_ShareBasedCompensationAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationAbstract_lbl" xml:lang="en-US">Share-based Compensation [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationAbstract_lbl" xml:lang="en-US">Stock-based compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US">Number of shares authorized</label>
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticAnnualIncreaseInSharesReservedAndAvailableForIssuancePercentage" xlink:label="tcmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticAnnualIncreaseInSharesReservedAndAvailableForIssuancePercentage" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticAnnualIncreaseInSharesReservedAndAvailableForIssuancePercentage" xlink:to="tcmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticAnnualIncreaseInSharesReservedAndAvailableForIssuancePercentage_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tcmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticAnnualIncreaseInSharesReservedAndAvailableForIssuancePercentage_lbl" xml:lang="en-US">Represents information pertaining to the automatic annual increase in shares reserved and available for issuance as a percentage to outstanding number of shares. The automatic increases occur on the first day of the year beginning January 1, 2017.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tcmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticAnnualIncreaseInSharesReservedAndAvailableForIssuancePercentage_lbl" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award, Automatic Annual Increase In Shares Reserved And Available For Issuance, Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tcmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticAnnualIncreaseInSharesReservedAndAvailableForIssuancePercentage_lbl" xml:lang="en-US">Automatic annual increase to the number of shares reserved and available for issuance as a percentage of outstanding common stock (as a percent)</label>
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticAnnualIncreaseInSharesReservedAndAvailableForIssuanceNumber" xlink:label="tcmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticAnnualIncreaseInSharesReservedAndAvailableForIssuanceNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticAnnualIncreaseInSharesReservedAndAvailableForIssuanceNumber" xlink:to="tcmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticAnnualIncreaseInSharesReservedAndAvailableForIssuanceNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tcmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticAnnualIncreaseInSharesReservedAndAvailableForIssuanceNumber_lbl" xml:lang="en-US">Represents information pertaining to the automatic annual increase in shares reserved and available for issuance. The automatic increases occur on the first day of the year beginning January 1, 2017.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tcmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticAnnualIncreaseInSharesReservedAndAvailableForIssuanceNumber_lbl" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award, Automatic Annual Increase In Shares Reserved And Available For Issuance, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tcmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticAnnualIncreaseInSharesReservedAndAvailableForIssuanceNumber_lbl" xml:lang="en-US">Automatic annual increase to the number of shares reserved and available for issuance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Shares reserved</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Shares available for future issuance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Allocated Share-based Compensation Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Compensation expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Stock-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract_lbl" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract_lbl" xml:lang="en-US">Unrecognized stock-based compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US">Unrecognized stock-based compensation expense, period for recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US">Weighted-average period over which unrecognized compensation cost is expected to be recognized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VestingAxis_lbl" xml:lang="en-US">Vesting [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_VestingDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VestingDomain_lbl" xml:lang="en-US">Vesting [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xml:lang="en-US">Tranche one</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xml:lang="en-US">Tranche two</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Common stock options</label>
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_TwoThousandEighteenAndTwoThousandTwentyPerformanceBasedRestrictedStockUnitsMember" xlink:label="tcmd_TwoThousandEighteenAndTwoThousandTwentyPerformanceBasedRestrictedStockUnitsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcmd_TwoThousandEighteenAndTwoThousandTwentyPerformanceBasedRestrictedStockUnitsMember" xlink:to="tcmd_TwoThousandEighteenAndTwoThousandTwentyPerformanceBasedRestrictedStockUnitsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tcmd_TwoThousandEighteenAndTwoThousandTwentyPerformanceBasedRestrictedStockUnitsMember_lbl" xml:lang="en-US">Represents information pertaining to 2018 and 2021 Performance Based Restricted Stock Units Member.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tcmd_TwoThousandEighteenAndTwoThousandTwentyPerformanceBasedRestrictedStockUnitsMember_lbl" xml:lang="en-US">2018 and 2021 PSUs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title of Individual [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xml:lang="en-US">Relationship to Entity [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefExecutiveOfficerMember" xlink:to="srt_ChiefExecutiveOfficerMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ChiefExecutiveOfficerMember_lbl" xml:lang="en-US">Chief Executive Officer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Stockholders' Equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Additional General Disclosures [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_lbl" xml:lang="en-US">Stock-based compensation, general disclosures.</label>
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermOfPeriod" xlink:label="tcmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermOfPeriod" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermOfPeriod" xlink:to="tcmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermOfPeriod_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tcmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermOfPeriod_lbl" xml:lang="en-US">Period of awards in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tcmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermOfPeriod_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Term of Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tcmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermOfPeriod_lbl" xml:lang="en-US">Share-based payment award, term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US">Vesting period (in years)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Share Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Stock price</label>
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_StockBasedCompensationExpenseMinimumTargets" xlink:label="tcmd_StockBasedCompensationExpenseMinimumTargets" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcmd_StockBasedCompensationExpenseMinimumTargets" xlink:to="tcmd_StockBasedCompensationExpenseMinimumTargets_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tcmd_StockBasedCompensationExpenseMinimumTargets_lbl" xml:lang="en-US">The amount estimated payout to reflect an estimated failure to achieve the minimum targets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tcmd_StockBasedCompensationExpenseMinimumTargets_lbl" xml:lang="en-US">Stock Based Compensation Expense Minimum Targets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tcmd_StockBasedCompensationExpenseMinimumTargets_lbl" xml:lang="en-US">Estimated payout</label>
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_NumberOfConsecutiveTradingDaysInWhichStockPriceExceedCertainPercentageOfClosingPriceOfCommonStockRequiredForAwardToBeGranted" xlink:label="tcmd_NumberOfConsecutiveTradingDaysInWhichStockPriceExceedCertainPercentageOfClosingPriceOfCommonStockRequiredForAwardToBeGranted" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcmd_NumberOfConsecutiveTradingDaysInWhichStockPriceExceedCertainPercentageOfClosingPriceOfCommonStockRequiredForAwardToBeGranted" xlink:to="tcmd_NumberOfConsecutiveTradingDaysInWhichStockPriceExceedCertainPercentageOfClosingPriceOfCommonStockRequiredForAwardToBeGranted_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tcmd_NumberOfConsecutiveTradingDaysInWhichStockPriceExceedCertainPercentageOfClosingPriceOfCommonStockRequiredForAwardToBeGranted_lbl" xml:lang="en-US">Number of consecutive trading days in which the stock price exceed a certain percentage of closing price of common stock required for the award to be granted.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tcmd_NumberOfConsecutiveTradingDaysInWhichStockPriceExceedCertainPercentageOfClosingPriceOfCommonStockRequiredForAwardToBeGranted_lbl" xml:lang="en-US">Number of consecutive trading days in which the stock price exceed a certain percentage of closing price of common stock required for the award to be granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tcmd_NumberOfConsecutiveTradingDaysInWhichStockPriceExceedCertainPercentageOfClosingPriceOfCommonStockRequiredForAwardToBeGranted_lbl" xml:lang="en-US">Number of consecutive trading days</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US">Term (in years)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US">Total unrecognized pre-tax compensation expense related to nonvested stock option awards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xml:lang="en-US">Total unrecognized pre-tax compensation expense related to awards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xml:lang="en-US">Compensation arrangement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xml:lang="en-US">Total grant date fair value of options vested during the period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsCommonStock" xlink:label="us-gaap_DividendsCommonStock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsCommonStock" xlink:to="us-gaap_DividendsCommonStock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DividendsCommonStock_lbl" xml:lang="en-US">Dividends, Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DividendsCommonStock_lbl" xml:lang="en-US">Dividends paid to date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xml:lang="en-US">Estimated fair values and assumptions for stock options granted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Expected volatility (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk-free interest rate (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Expected dividend yield (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Fair value per share of options on the date of grant (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US">Options Outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Outstanding at end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Outstanding at beginning of period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Granted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Forfeited</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xml:lang="en-US">Cancelled/Expired</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US">Weighted Average Exercise Price Per Share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Outstanding at end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Outstanding at beginning of period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Granted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Exercised</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Forfeited</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Cancelled</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Cancelled/Expired</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xml:lang="en-US">Other information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Options exercisable number of shares exercisable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Options exercisable, weighted-average exercise price</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted average remaining contractual life (in years)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Options exercisable, weighted-average remaining contractual life</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Options outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Exercised</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Options exercisable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_lbl" xml:lang="en-US">Number of:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xml:lang="en-US">Non-vested options end of the year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xml:lang="en-US">Non vested options beginning of the year</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xml:lang="en-US">Vested options end of the year</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_lbl" xml:lang="en-US">Weighted-average grant date fair value of:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Non-vested options end of the year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Non-vested options beginning of the year</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Vested options end of the year</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Forfeited options during the year</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xml:lang="en-US">Units Outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Restricted stock unit awards outstanding at the end of the period (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Restricted stock unit awards outstanding at the beginning of the period (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US">Share-based awards granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US">Granted (in shares)</label>
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_SharebasedcompensationArrangementBySharebasedpaymentAwardEquityInstrumentsOtherThanOptionsModifiedInPeriod" xlink:label="tcmd_SharebasedcompensationArrangementBySharebasedpaymentAwardEquityInstrumentsOtherThanOptionsModifiedInPeriod" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcmd_SharebasedcompensationArrangementBySharebasedpaymentAwardEquityInstrumentsOtherThanOptionsModifiedInPeriod" xlink:to="tcmd_SharebasedcompensationArrangementBySharebasedpaymentAwardEquityInstrumentsOtherThanOptionsModifiedInPeriod_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tcmd_SharebasedcompensationArrangementBySharebasedpaymentAwardEquityInstrumentsOtherThanOptionsModifiedInPeriod_lbl" xml:lang="en-US">The number of equity-based payment instruments, excluding stock (or unit) options, that were modified during the reporting period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tcmd_SharebasedcompensationArrangementBySharebasedpaymentAwardEquityInstrumentsOtherThanOptionsModifiedInPeriod_lbl" xml:lang="en-US">Share Based Compensation Arrangement By ShareBasedPayment Award Equity Instruments Other Than Options Modified In Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tcmd_SharebasedcompensationArrangementBySharebasedpaymentAwardEquityInstrumentsOtherThanOptionsModifiedInPeriod_lbl" xml:lang="en-US">Modification (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US">Vested (in shares)</label>
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod" xlink:label="tcmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod" xlink:to="tcmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tcmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod_lbl" xml:lang="en-US">The number of equity-based payment instruments, excluding stock (or unit) options, that were cancelled during the reporting period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tcmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Cancelled in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="tcmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod_lbl" xml:lang="en-US">Cancelled (in shares)</label>
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_PercentageToEarnPerformanceBasedStockSettledRestrictedStockUnits" xlink:label="tcmd_PercentageToEarnPerformanceBasedStockSettledRestrictedStockUnits" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcmd_PercentageToEarnPerformanceBasedStockSettledRestrictedStockUnits" xlink:to="tcmd_PercentageToEarnPerformanceBasedStockSettledRestrictedStockUnits_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tcmd_PercentageToEarnPerformanceBasedStockSettledRestrictedStockUnits_lbl" xml:lang="en-US">Percentage to earn or vest the performance-based stock-settled restricted stock units.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tcmd_PercentageToEarnPerformanceBasedStockSettledRestrictedStockUnits_lbl" xml:lang="en-US">Percentage to earn the performance-based stock-settled restricted stock units</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tcmd_PercentageToEarnPerformanceBasedStockSettledRestrictedStockUnits_lbl" xml:lang="en-US">Percentage to earn or vest the performance-based stock-settled restricted stock units</label>
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_EstimatedPayoutPercentage" xlink:label="tcmd_EstimatedPayoutPercentage" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcmd_EstimatedPayoutPercentage" xlink:to="tcmd_EstimatedPayoutPercentage_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tcmd_EstimatedPayoutPercentage_lbl" xml:lang="en-US">Percentage of estimated payout.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tcmd_EstimatedPayoutPercentage_lbl" xml:lang="en-US">Estimated Payout Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tcmd_EstimatedPayoutPercentage_lbl" xml:lang="en-US">Payout percentage</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xml:lang="en-US">Weighted Average Grant Date Fair Value Per Unit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Restricted stock unit awards outstanding at the end of the period (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Restricted stock unit awards outstanding at the beginning of the period (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Granted (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_SharebasedcompensationArrangementBySharebasedpaymentAwardEquityInstrumentsOtherThanOptionsModifiedWeightedAverageGrantDateFairValue" xlink:label="tcmd_SharebasedcompensationArrangementBySharebasedpaymentAwardEquityInstrumentsOtherThanOptionsModifiedWeightedAverageGrantDateFairValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcmd_SharebasedcompensationArrangementBySharebasedpaymentAwardEquityInstrumentsOtherThanOptionsModifiedWeightedAverageGrantDateFairValue" xlink:to="tcmd_SharebasedcompensationArrangementBySharebasedpaymentAwardEquityInstrumentsOtherThanOptionsModifiedWeightedAverageGrantDateFairValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tcmd_SharebasedcompensationArrangementBySharebasedpaymentAwardEquityInstrumentsOtherThanOptionsModifiedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were modified during the reporting period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tcmd_SharebasedcompensationArrangementBySharebasedpaymentAwardEquityInstrumentsOtherThanOptionsModifiedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Share Based Compensation Arrangement By ShareBasedPayment Award Equity Instruments Other Than Options Modified Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tcmd_SharebasedcompensationArrangementBySharebasedpaymentAwardEquityInstrumentsOtherThanOptionsModifiedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Modification (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Vested (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancellationsWeightedAverageGrantDateFairValue" xlink:label="tcmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancellationsWeightedAverageGrantDateFairValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancellationsWeightedAverageGrantDateFairValue" xlink:to="tcmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancellationsWeightedAverageGrantDateFairValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tcmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancellationsWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were cancelled during the reporting period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tcmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancellationsWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Cancellations, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tcmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancellationsWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Cancelled (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_lbl" xml:lang="en-US">Aggregate Intrinsic Value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl" xml:lang="en-US">Restricted stock unit awards, Average Intrinsic Value</label>
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueDeferredAndUnissued" xlink:label="tcmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueDeferredAndUnissued" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueDeferredAndUnissued" xlink:to="tcmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueDeferredAndUnissued_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tcmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueDeferredAndUnissued_lbl" xml:lang="en-US">Intrinsic value of equity-based compensation awards deferred and Unissued, Excludes stock and unit options.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tcmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueDeferredAndUnissued_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Deferred and Unissued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tcmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueDeferredAndUnissued_lbl" xml:lang="en-US">Restricted stock unit awards deferred and unissued, Average Intrinsic Value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockMember" xlink:to="us-gaap_EmployeeStockMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockMember_lbl" xml:lang="en-US">Employee Stock Purchase Plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xml:lang="en-US">Purchase price of common stock under plan (as a percent)</label>
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_EmployeeStockPurchasePlanOfferingPeriodsPeriod" xlink:label="tcmd_EmployeeStockPurchasePlanOfferingPeriodsPeriod" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcmd_EmployeeStockPurchasePlanOfferingPeriodsPeriod" xlink:to="tcmd_EmployeeStockPurchasePlanOfferingPeriodsPeriod_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tcmd_EmployeeStockPurchasePlanOfferingPeriodsPeriod_lbl" xml:lang="en-US">Period which an employee's right to purchase shares of stock at a discount, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tcmd_EmployeeStockPurchasePlanOfferingPeriodsPeriod_lbl" xml:lang="en-US">Employee Stock Purchase Plan, Offering Periods, Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tcmd_EmployeeStockPurchasePlanOfferingPeriodsPeriod_lbl" xml:lang="en-US">Offering period (in months)</label>
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_IncrementalSharesToBeIssuedPercentage" xlink:label="tcmd_IncrementalSharesToBeIssuedPercentage" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcmd_IncrementalSharesToBeIssuedPercentage" xlink:to="tcmd_IncrementalSharesToBeIssuedPercentage_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tcmd_IncrementalSharesToBeIssuedPercentage_lbl" xml:lang="en-US">Represents the incremental annual share percentage increase minimum.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tcmd_IncrementalSharesToBeIssuedPercentage_lbl" xml:lang="en-US">Incremental Shares To Be Issued Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tcmd_IncrementalSharesToBeIssuedPercentage_lbl" xml:lang="en-US">Incremental share increase (as a percent)</label>
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_IncrementalShareIncrease" xlink:label="tcmd_IncrementalShareIncrease" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcmd_IncrementalShareIncrease" xlink:to="tcmd_IncrementalShareIncrease_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tcmd_IncrementalShareIncrease_lbl" xml:lang="en-US">Represents the minimum increase in shares on an annual basis.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tcmd_IncrementalShareIncrease_lbl" xml:lang="en-US">Incremental Share Increase</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tcmd_IncrementalShareIncrease_lbl" xml:lang="en-US">Incremental share increase (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xml:lang="en-US">Increase in number of shares reserved and available for issuance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_DisaggregationOfRevenueTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisaggregationOfRevenueTable_lbl" xml:lang="en-US">Disaggregation of Revenue [Table]</label>
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_FlexitouchSystemMember" xlink:label="tcmd_FlexitouchSystemMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcmd_FlexitouchSystemMember" xlink:to="tcmd_FlexitouchSystemMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tcmd_FlexitouchSystemMember_lbl" xml:lang="en-US">Represents information pertaining to Flexitouch system.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tcmd_FlexitouchSystemMember_lbl" xml:lang="en-US">Flexitouch system</label>
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_PrivateInsurersMember" xlink:label="tcmd_PrivateInsurersMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcmd_PrivateInsurersMember" xlink:to="tcmd_PrivateInsurersMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tcmd_PrivateInsurersMember_lbl" xml:lang="en-US">Represents information pertaining to private insurers and other payers.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tcmd_PrivateInsurersMember_lbl" xml:lang="en-US">Private insurers and other payers</label>
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_VeteransAdministrationMember" xlink:label="tcmd_VeteransAdministrationMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcmd_VeteransAdministrationMember" xlink:to="tcmd_VeteransAdministrationMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tcmd_VeteransAdministrationMember_lbl" xml:lang="en-US">Represents information pertaining to veterans administration.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tcmd_VeteransAdministrationMember_lbl" xml:lang="en-US">Veterans Administration</label>
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_MedicareMember" xlink:label="tcmd_MedicareMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcmd_MedicareMember" xlink:to="tcmd_MedicareMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tcmd_MedicareMember_lbl" xml:lang="en-US">Represents information pertaining to government payer medicare.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tcmd_MedicareMember_lbl" xml:lang="en-US">Medicare</label>
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_DurableMedicalEquipmentDistributorsMember" xlink:label="tcmd_DurableMedicalEquipmentDistributorsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcmd_DurableMedicalEquipmentDistributorsMember" xlink:to="tcmd_DurableMedicalEquipmentDistributorsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tcmd_DurableMedicalEquipmentDistributorsMember_lbl" xml:lang="en-US">Represents information pertaining to Durable medical equipment distributors.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tcmd_DurableMedicalEquipmentDistributorsMember_lbl" xml:lang="en-US">Durable medical equipment distributors</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisaggregationOfRevenueLineItems_lbl" xml:lang="en-US">Disaggregation of Revenue [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisaggregationOfRevenueLineItems_lbl" xml:lang="en-US">Revenue</label>
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_PercentageOfRevenue" xlink:label="tcmd_PercentageOfRevenue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcmd_PercentageOfRevenue" xlink:to="tcmd_PercentageOfRevenue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tcmd_PercentageOfRevenue_lbl" xml:lang="en-US">Percentage of revenue disaggregated by products.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tcmd_PercentageOfRevenue_lbl" xml:lang="en-US">Percentage Of Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tcmd_PercentageOfRevenue_lbl" xml:lang="en-US">Percentage of total revenue (in percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesTypeLeaseLeaseIncomeAbstract" xlink:label="us-gaap_SalesTypeLeaseLeaseIncomeAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesTypeLeaseLeaseIncomeAbstract" xlink:to="us-gaap_SalesTypeLeaseLeaseIncomeAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalesTypeLeaseLeaseIncomeAbstract_lbl" xml:lang="en-US">Sales-type Lease, Lease Income [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SalesTypeLeaseLeaseIncomeAbstract_lbl" xml:lang="en-US">Revenue from sale type lease</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesTypeLeaseRevenue" xlink:label="us-gaap_SalesTypeLeaseRevenue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesTypeLeaseRevenue" xlink:to="us-gaap_SalesTypeLeaseRevenue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalesTypeLeaseRevenue_lbl" xml:lang="en-US">Sales-type Lease, Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SalesTypeLeaseRevenue_lbl" xml:lang="en-US">Sales-type lease revenue</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsSoldSalesTypeLease" xlink:label="us-gaap_CostOfGoodsSoldSalesTypeLease" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsSoldSalesTypeLease" xlink:to="us-gaap_CostOfGoodsSoldSalesTypeLease_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfGoodsSoldSalesTypeLease_lbl" xml:lang="en-US">Cost of Goods Sold, Sales-type Lease</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostOfGoodsSoldSalesTypeLease_lbl" xml:lang="en-US">Cost of sales-type lease revenue</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesTypeLeaseSellingProfitLoss" xlink:label="us-gaap_SalesTypeLeaseSellingProfitLoss" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesTypeLeaseSellingProfitLoss" xlink:to="us-gaap_SalesTypeLeaseSellingProfitLoss_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalesTypeLeaseSellingProfitLoss_lbl" xml:lang="en-US">Sales-type Lease, Selling Profit (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_SalesTypeLeaseSellingProfitLoss_lbl" xml:lang="en-US">Gross profit</label>
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_RentToPurchaseArrangementsRentalPeriod" xlink:label="tcmd_RentToPurchaseArrangementsRentalPeriod" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcmd_RentToPurchaseArrangementsRentalPeriod" xlink:to="tcmd_RentToPurchaseArrangementsRentalPeriod_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tcmd_RentToPurchaseArrangementsRentalPeriod_lbl" xml:lang="en-US">Rental period of rent-to-purchase arrangements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tcmd_RentToPurchaseArrangementsRentalPeriod_lbl" xml:lang="en-US">Rent-to-purchase arrangements, Rental Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tcmd_RentToPurchaseArrangementsRentalPeriod_lbl" xml:lang="en-US">Rental period of rent-to-purchase arrangements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US">Income Tax Authority [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xml:lang="en-US">Income Tax Authority [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DomesticCountryMember_lbl" xml:lang="en-US">U.S. federal</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xml:lang="en-US">State</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xml:lang="en-US">Current Federal Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xml:lang="en-US">Current income taxes, Federal</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xml:lang="en-US">Current income taxes, State</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Current Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Current income taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Deferred income taxes, Federal</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Deferred income taxes, State</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Deferred income taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl" xml:lang="en-US">Unrecognized tax benefit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">Net effective rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" xml:lang="en-US">Components of Deferred Tax Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" xml:lang="en-US">Components of Deferred Tax Assets</label>
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_DeferredTaxAssetsOperatingLeaseLiability" xlink:label="tcmd_DeferredTaxAssetsOperatingLeaseLiability" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcmd_DeferredTaxAssetsOperatingLeaseLiability" xlink:to="tcmd_DeferredTaxAssetsOperatingLeaseLiability_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tcmd_DeferredTaxAssetsOperatingLeaseLiability_lbl" xml:lang="en-US">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from Operating Lease Liability.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tcmd_DeferredTaxAssetsOperatingLeaseLiability_lbl" xml:lang="en-US">Deferred Tax Assets, Operating Lease Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tcmd_DeferredTaxAssetsOperatingLeaseLiability_lbl" xml:lang="en-US">Operating lease liability</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss carryforwards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_lbl" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Allowance for Doubtful Accounts</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_lbl" xml:lang="en-US">Accounts receivable and inventory reserves</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US">Stock-based compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl" xml:lang="en-US">Accrued liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves_lbl" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Warranty Reserves</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves_lbl" xml:lang="en-US">Warranty reserves</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xml:lang="en-US">Deferred Tax Assets, Goodwill and Intangible Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xml:lang="en-US">Intangible assets</label>
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_DeferredTaxAssetsBusinessCredits" xlink:label="tcmd_DeferredTaxAssetsBusinessCredits" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcmd_DeferredTaxAssetsBusinessCredits" xlink:to="tcmd_DeferredTaxAssetsBusinessCredits_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tcmd_DeferredTaxAssetsBusinessCredits_lbl" xml:lang="en-US">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from business credits..</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tcmd_DeferredTaxAssetsBusinessCredits_lbl" xml:lang="en-US">Deferred Tax Assets, Business Credits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tcmd_DeferredTaxAssetsBusinessCredits_lbl" xml:lang="en-US">Business credits</label>
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsResearchAndDevelopmentExpenses" xlink:label="tcmd_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsResearchAndDevelopmentExpenses" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcmd_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsResearchAndDevelopmentExpenses" xlink:to="tcmd_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsResearchAndDevelopmentExpenses_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tcmd_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsResearchAndDevelopmentExpenses_lbl" xml:lang="en-US">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from research and development expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tcmd_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsResearchAndDevelopmentExpenses_lbl" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Research and Development Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tcmd_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsResearchAndDevelopmentExpenses_lbl" xml:lang="en-US">R&amp;D expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xml:lang="en-US">Deferred Tax Assets, Other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xml:lang="en-US">Other</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US">Deferred Tax Assets, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US">Total deferred tax assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_lbl" xml:lang="en-US">Components of Deferred Tax Liabilities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_lbl" xml:lang="en-US">Deferred tax liabilities:</label>
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_DeferredTaxLiabilitiesRightOfUseAssets" xlink:label="tcmd_DeferredTaxLiabilitiesRightOfUseAssets" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcmd_DeferredTaxLiabilitiesRightOfUseAssets" xlink:to="tcmd_DeferredTaxLiabilitiesRightOfUseAssets_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tcmd_DeferredTaxLiabilitiesRightOfUseAssets_lbl" xml:lang="en-US">Amount of deferred tax consequences attributable to taxable temporary differences derived from right-of-use assets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tcmd_DeferredTaxLiabilitiesRightOfUseAssets_lbl" xml:lang="en-US">Deferred Tax Liabilities, Right-of-use Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="tcmd_DeferredTaxLiabilitiesRightOfUseAssets_lbl" xml:lang="en-US">Right-of-use asset</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xml:lang="en-US">Deferred Tax Liabilities, Property, Plant and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xml:lang="en-US">Fixed assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:label="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:to="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_lbl" xml:lang="en-US">Deferred Tax Liabilities, Prepaid Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_lbl" xml:lang="en-US">Prepaid expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="us-gaap_DeferredTaxLiabilitiesOther" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesOther" xlink:to="us-gaap_DeferredTaxLiabilitiesOther_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesOther_lbl" xml:lang="en-US">Deferred Tax Liabilities, Other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesOther_lbl" xml:lang="en-US">Other</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xml:lang="en-US">Deferred Tax Liabilities, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xml:lang="en-US">Total deferred tax liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Net deferred tax assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Valuation allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Valuation allowance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Tax expense at statutory rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">State income taxes, net of federal benefit</label>
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationPercent" xlink:label="tcmd_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationPercent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcmd_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationPercent" xlink:to="tcmd_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationPercent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tcmd_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationPercent_lbl" xml:lang="en-US">Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to executive compensation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tcmd_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationPercent_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Executive Compensation , Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tcmd_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationPercent_lbl" xml:lang="en-US">Executive compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Meals and Entertainment, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment_lbl" xml:lang="en-US">Meals and entertainment</label>
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_EffectiveIncomeTaxRateReconciliationIncentiveStockOptions" xlink:label="tcmd_EffectiveIncomeTaxRateReconciliationIncentiveStockOptions" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcmd_EffectiveIncomeTaxRateReconciliationIncentiveStockOptions" xlink:to="tcmd_EffectiveIncomeTaxRateReconciliationIncentiveStockOptions_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tcmd_EffectiveIncomeTaxRateReconciliationIncentiveStockOptions_lbl" xml:lang="en-US">Percentage of Effective Income Tax Rate Reconciliation, Incentive stock options.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tcmd_EffectiveIncomeTaxRateReconciliationIncentiveStockOptions_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Incentive Stock Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tcmd_EffectiveIncomeTaxRateReconciliationIncentiveStockOptions_lbl" xml:lang="en-US">Incentive stock options</label>
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_EffectiveIncomeTaxRateReconciliationEmployeeStockPurchasePlan" xlink:label="tcmd_EffectiveIncomeTaxRateReconciliationEmployeeStockPurchasePlan" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcmd_EffectiveIncomeTaxRateReconciliationEmployeeStockPurchasePlan" xlink:to="tcmd_EffectiveIncomeTaxRateReconciliationEmployeeStockPurchasePlan_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tcmd_EffectiveIncomeTaxRateReconciliationEmployeeStockPurchasePlan_lbl" xml:lang="en-US">Percentage of effective income tax rate reconciliation, employee stock purchase plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tcmd_EffectiveIncomeTaxRateReconciliationEmployeeStockPurchasePlan_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Employee Stock Purchase Plan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tcmd_EffectiveIncomeTaxRateReconciliationEmployeeStockPurchasePlan_lbl" xml:lang="en-US">Employee Stock Purchase Plan</label>
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_EffectiveIncomeTaxRateReconciliationFederalBusinessCreditPercent" xlink:label="tcmd_EffectiveIncomeTaxRateReconciliationFederalBusinessCreditPercent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcmd_EffectiveIncomeTaxRateReconciliationFederalBusinessCreditPercent" xlink:to="tcmd_EffectiveIncomeTaxRateReconciliationFederalBusinessCreditPercent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tcmd_EffectiveIncomeTaxRateReconciliationFederalBusinessCreditPercent_lbl" xml:lang="en-US">Percentage of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from federal business credits.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tcmd_EffectiveIncomeTaxRateReconciliationFederalBusinessCreditPercent_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Federal Business Credit Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tcmd_EffectiveIncomeTaxRateReconciliationFederalBusinessCreditPercent_lbl" xml:lang="en-US">Federal business credits</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Valuation allowance</label>
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_EffectiveIncomeTaxRateReconciliationReturnToProvision" xlink:label="tcmd_EffectiveIncomeTaxRateReconciliationReturnToProvision" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcmd_EffectiveIncomeTaxRateReconciliationReturnToProvision" xlink:to="tcmd_EffectiveIncomeTaxRateReconciliationReturnToProvision_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tcmd_EffectiveIncomeTaxRateReconciliationReturnToProvision_lbl" xml:lang="en-US">Percentage of effective income tax rate reconciliation, return to provision.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tcmd_EffectiveIncomeTaxRateReconciliationReturnToProvision_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Return to Provision</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tcmd_EffectiveIncomeTaxRateReconciliationReturnToProvision_lbl" xml:lang="en-US">Return to provision</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_lbl" xml:lang="en-US">Research and development credits</label>
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_EffectiveIncomeTaxRateReconciliationInternalRevenueServiceExam" xlink:label="tcmd_EffectiveIncomeTaxRateReconciliationInternalRevenueServiceExam" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcmd_EffectiveIncomeTaxRateReconciliationInternalRevenueServiceExam" xlink:to="tcmd_EffectiveIncomeTaxRateReconciliationInternalRevenueServiceExam_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tcmd_EffectiveIncomeTaxRateReconciliationInternalRevenueServiceExam_lbl" xml:lang="en-US">Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to IRS exam</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tcmd_EffectiveIncomeTaxRateReconciliationInternalRevenueServiceExam_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Internal Revenue Service, Exam</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tcmd_EffectiveIncomeTaxRateReconciliationInternalRevenueServiceExam_lbl" xml:lang="en-US">IRS exam</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Settlement, State and Local, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal_lbl" xml:lang="en-US">Deferred reprice - state</label>
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_EffectiveIncomeTaxRateReconciliationFederalCarrybackClaimPercent" xlink:label="tcmd_EffectiveIncomeTaxRateReconciliationFederalCarrybackClaimPercent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcmd_EffectiveIncomeTaxRateReconciliationFederalCarrybackClaimPercent" xlink:to="tcmd_EffectiveIncomeTaxRateReconciliationFederalCarrybackClaimPercent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tcmd_EffectiveIncomeTaxRateReconciliationFederalCarrybackClaimPercent_lbl" xml:lang="en-US">Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to federal carryback claim.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tcmd_EffectiveIncomeTaxRateReconciliationFederalCarrybackClaimPercent_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Federal Carryback Claim, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tcmd_EffectiveIncomeTaxRateReconciliationFederalCarrybackClaimPercent_lbl" xml:lang="en-US">Federal carryback claim deferred rate differential</label>
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_EffectiveIncomeTaxRateReconciliationUnrecognizedTaxBenefits" xlink:label="tcmd_EffectiveIncomeTaxRateReconciliationUnrecognizedTaxBenefits" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcmd_EffectiveIncomeTaxRateReconciliationUnrecognizedTaxBenefits" xlink:to="tcmd_EffectiveIncomeTaxRateReconciliationUnrecognizedTaxBenefits_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tcmd_EffectiveIncomeTaxRateReconciliationUnrecognizedTaxBenefits_lbl" xml:lang="en-US">Percentage of effective income tax rate reconciliation, unrecognized tax benefits.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tcmd_EffectiveIncomeTaxRateReconciliationUnrecognizedTaxBenefits_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Unrecognized Tax Benefits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tcmd_EffectiveIncomeTaxRateReconciliationUnrecognizedTaxBenefits_lbl" xml:lang="en-US">Unrecognized tax benefits</label>
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_EffectiveIncomeTaxRateReconciliationExcessTaxBenefitOnNonQualifiedStockOptionsAndRsu" xlink:label="tcmd_EffectiveIncomeTaxRateReconciliationExcessTaxBenefitOnNonQualifiedStockOptionsAndRsu" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcmd_EffectiveIncomeTaxRateReconciliationExcessTaxBenefitOnNonQualifiedStockOptionsAndRsu" xlink:to="tcmd_EffectiveIncomeTaxRateReconciliationExcessTaxBenefitOnNonQualifiedStockOptionsAndRsu_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tcmd_EffectiveIncomeTaxRateReconciliationExcessTaxBenefitOnNonQualifiedStockOptionsAndRsu_lbl" xml:lang="en-US">Percentage of effective income tax rate reconciliation, excess tax benefit on non-qualified stock options and RSU.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tcmd_EffectiveIncomeTaxRateReconciliationExcessTaxBenefitOnNonQualifiedStockOptionsAndRsu_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation Excess Tax Benefit On Non-qualified Stock Options and RSU</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tcmd_EffectiveIncomeTaxRateReconciliationExcessTaxBenefitOnNonQualifiedStockOptionsAndRsu_lbl" xml:lang="en-US">Excess benefit on non-qualified stock options and RSUs</label>
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_EffectiveIncomeTaxRateReconciliationInterestAndPenaltyPercent" xlink:label="tcmd_EffectiveIncomeTaxRateReconciliationInterestAndPenaltyPercent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcmd_EffectiveIncomeTaxRateReconciliationInterestAndPenaltyPercent" xlink:to="tcmd_EffectiveIncomeTaxRateReconciliationInterestAndPenaltyPercent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tcmd_EffectiveIncomeTaxRateReconciliationInterestAndPenaltyPercent_lbl" xml:lang="en-US">Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to interest and penalties.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tcmd_EffectiveIncomeTaxRateReconciliationInterestAndPenaltyPercent_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Interest And Penalty, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tcmd_EffectiveIncomeTaxRateReconciliationInterestAndPenaltyPercent_lbl" xml:lang="en-US">Interest and penalties</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xml:lang="en-US">Other</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:label="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_lbl" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_lbl" xml:lang="en-US">Reconciliation of unrecognized tax benefits</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US">Unrecognized Tax Benefits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US">Balance end of the year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US">Balance beginning of the year</label>
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions" xlink:label="tcmd_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcmd_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions" xlink:to="tcmd_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tcmd_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions_lbl" xml:lang="en-US">Amount of increase (decrease) in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tcmd_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions_lbl" xml:lang="en-US">Unrecognized Tax Benefits, Increase (Decrease) Resulting from Prior Period Tax Positions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tcmd_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions_lbl" xml:lang="en-US">Gross change - tax positions in prior year</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Earnings Per Share, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Net loss per share - Basic</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Earnings Per Share, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Net loss per share - Diluted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</label>
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_EmployeeStockPurchasePlanMember" xlink:label="tcmd_EmployeeStockPurchasePlanMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcmd_EmployeeStockPurchasePlanMember" xlink:to="tcmd_EmployeeStockPurchasePlanMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tcmd_EmployeeStockPurchasePlanMember_lbl" xml:lang="en-US">Represents the information pertaining to Employee stock purchase plan shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tcmd_EmployeeStockPurchasePlanMember_lbl" xml:lang="en-US">Employee stock purchase plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US">Antidilutive Securities [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US">Antidilutive Securities, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PerformanceSharesMember" xlink:to="us-gaap_PerformanceSharesMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PerformanceSharesMember_lbl" xml:lang="en-US">Performance stock units</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US">Net Loss Per Share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Antidilutive securities excluded from computation of earnings per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US">Fair Value Measurements</label>
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_BusinessCombinationAdditionalContingentConsiderationLiability" xlink:label="tcmd_BusinessCombinationAdditionalContingentConsiderationLiability" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcmd_BusinessCombinationAdditionalContingentConsiderationLiability" xlink:to="tcmd_BusinessCombinationAdditionalContingentConsiderationLiability_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tcmd_BusinessCombinationAdditionalContingentConsiderationLiability_lbl" xml:lang="en-US">Business Combination Additional Contingent Consideration Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tcmd_BusinessCombinationAdditionalContingentConsiderationLiability_lbl" xml:lang="en-US">Business Combination Additional Contingent Consideration Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tcmd_BusinessCombinationAdditionalContingentConsiderationLiability_lbl" xml:lang="en-US">Additional earn out payment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US">Fair Value, Hierarchy [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US">Fair Value Hierarchy [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US">Significant Unobservable Inputs (Level 3)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_lbl" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_lbl" xml:lang="en-US">Fair value adjustments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_lbl" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_lbl" xml:lang="en-US">Fair value measure, earn out liability current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xml:lang="en-US">Measurement Frequency [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xml:lang="en-US">Fair Value, Measurement Frequency [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xml:lang="en-US">Recurring</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xml:lang="en-US">Available-for-sale Securities, Debt Securities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xml:lang="en-US">Available for sale debt securities</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>16
<FILENAME>tcmd-20221231_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.2.0.4 -->
<!--Based on XBRL 2.1-->
<!--Created on: 2/21/2023 1:38:41 PM-->
<!--Modified on: 2/21/2023 1:38:41 PM-->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <roleRef xlink:type="simple" xlink:href="tcmd-20221231.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.tactilemedical.com/role/DocumentDocumentAndEntityInformation" />
  <roleRef xlink:type="simple" xlink:href="tcmd-20221231.xsd#StatementConsolidatedBalanceSheets" roleURI="http://www.tactilemedical.com/role/StatementConsolidatedBalanceSheets" />
  <roleRef xlink:type="simple" xlink:href="tcmd-20221231.xsd#StatementConsolidatedBalanceSheetsParenthetical" roleURI="http://www.tactilemedical.com/role/StatementConsolidatedBalanceSheetsParenthetical" />
  <roleRef xlink:type="simple" xlink:href="tcmd-20221231.xsd#StatementConsolidatedStatementsOfOperations" roleURI="http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfOperations" />
  <roleRef xlink:type="simple" xlink:href="tcmd-20221231.xsd#StatementConsolidatedStatementsOfComprehensiveLoss" roleURI="http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfComprehensiveLoss" />
  <roleRef xlink:type="simple" xlink:href="tcmd-20221231.xsd#StatementConsolidatedStatementsOfStockholdersEquity" roleURI="http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfStockholdersEquity" />
  <roleRef xlink:type="simple" xlink:href="tcmd-20221231.xsd#StatementConsolidatedStatementsOfCashFlows" roleURI="http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfCashFlows" />
  <roleRef xlink:type="simple" xlink:href="tcmd-20221231.xsd#DisclosureNatureOfBusinessAndOperations" roleURI="http://www.tactilemedical.com/role/DisclosureNatureOfBusinessAndOperations" />
  <roleRef xlink:type="simple" xlink:href="tcmd-20221231.xsd#DisclosureBasisOfPresentation" roleURI="http://www.tactilemedical.com/role/DisclosureBasisOfPresentation" />
  <roleRef xlink:type="simple" xlink:href="tcmd-20221231.xsd#DisclosureSummaryOfSignificantAccountingPolicies" roleURI="http://www.tactilemedical.com/role/DisclosureSummaryOfSignificantAccountingPolicies" />
  <roleRef xlink:type="simple" xlink:href="tcmd-20221231.xsd#DisclosureAcquisitions" roleURI="http://www.tactilemedical.com/role/DisclosureAcquisitions" />
  <roleRef xlink:type="simple" xlink:href="tcmd-20221231.xsd#DisclosureAccountsReceivable" roleURI="http://www.tactilemedical.com/role/DisclosureAccountsReceivable" />
  <roleRef xlink:type="simple" xlink:href="tcmd-20221231.xsd#DisclosureInventories" roleURI="http://www.tactilemedical.com/role/DisclosureInventories" />
  <roleRef xlink:type="simple" xlink:href="tcmd-20221231.xsd#DisclosurePropertyAndEquipment" roleURI="http://www.tactilemedical.com/role/DisclosurePropertyAndEquipment" />
  <roleRef xlink:type="simple" xlink:href="tcmd-20221231.xsd#DisclosureGoodwillAndIntangibleAssets" roleURI="http://www.tactilemedical.com/role/DisclosureGoodwillAndIntangibleAssets" />
  <roleRef xlink:type="simple" xlink:href="tcmd-20221231.xsd#DisclosureAccruedExpenses" roleURI="http://www.tactilemedical.com/role/DisclosureAccruedExpenses" />
  <roleRef xlink:type="simple" xlink:href="tcmd-20221231.xsd#DisclosureWarrantyReserves" roleURI="http://www.tactilemedical.com/role/DisclosureWarrantyReserves" />
  <roleRef xlink:type="simple" xlink:href="tcmd-20221231.xsd#DisclosureCreditAgreement" roleURI="http://www.tactilemedical.com/role/DisclosureCreditAgreement" />
  <roleRef xlink:type="simple" xlink:href="tcmd-20221231.xsd#DisclosureCommitmentsAndContingencies" roleURI="http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingencies" />
  <roleRef xlink:type="simple" xlink:href="tcmd-20221231.xsd#DisclosureStockholdersEquity" roleURI="http://www.tactilemedical.com/role/DisclosureStockholdersEquity" />
  <roleRef xlink:type="simple" xlink:href="tcmd-20221231.xsd#DisclosureRevenue" roleURI="http://www.tactilemedical.com/role/DisclosureRevenue" />
  <roleRef xlink:type="simple" xlink:href="tcmd-20221231.xsd#DisclosureIncomeTaxes" roleURI="http://www.tactilemedical.com/role/DisclosureIncomeTaxes" />
  <roleRef xlink:type="simple" xlink:href="tcmd-20221231.xsd#DisclosureNetLossIncomePerCommonShare" roleURI="http://www.tactilemedical.com/role/DisclosureNetLossIncomePerCommonShare" />
  <roleRef xlink:type="simple" xlink:href="tcmd-20221231.xsd#DisclosureFairValueMeasurements" roleURI="http://www.tactilemedical.com/role/DisclosureFairValueMeasurements" />
  <roleRef xlink:type="simple" xlink:href="tcmd-20221231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.tactilemedical.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" />
  <roleRef xlink:type="simple" xlink:href="tcmd-20221231.xsd#DisclosureAcquisitionsTables" roleURI="http://www.tactilemedical.com/role/DisclosureAcquisitionsTables" />
  <roleRef xlink:type="simple" xlink:href="tcmd-20221231.xsd#DisclosureInventoriesTables" roleURI="http://www.tactilemedical.com/role/DisclosureInventoriesTables" />
  <roleRef xlink:type="simple" xlink:href="tcmd-20221231.xsd#DisclosurePropertyAndEquipmentTables" roleURI="http://www.tactilemedical.com/role/DisclosurePropertyAndEquipmentTables" />
  <roleRef xlink:type="simple" xlink:href="tcmd-20221231.xsd#DisclosureGoodwillAndIntangibleAssetsTables" roleURI="http://www.tactilemedical.com/role/DisclosureGoodwillAndIntangibleAssetsTables" />
  <roleRef xlink:type="simple" xlink:href="tcmd-20221231.xsd#DisclosureAccruedExpensesTables" roleURI="http://www.tactilemedical.com/role/DisclosureAccruedExpensesTables" />
  <roleRef xlink:type="simple" xlink:href="tcmd-20221231.xsd#DisclosureWarrantyReservesTables" roleURI="http://www.tactilemedical.com/role/DisclosureWarrantyReservesTables" />
  <roleRef xlink:type="simple" xlink:href="tcmd-20221231.xsd#DisclosureCreditAgreementTables" roleURI="http://www.tactilemedical.com/role/DisclosureCreditAgreementTables" />
  <roleRef xlink:type="simple" xlink:href="tcmd-20221231.xsd#DisclosureCommitmentsAndContingenciesTables" roleURI="http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesTables" />
  <roleRef xlink:type="simple" xlink:href="tcmd-20221231.xsd#DisclosureStockholdersEquityTables" roleURI="http://www.tactilemedical.com/role/DisclosureStockholdersEquityTables" />
  <roleRef xlink:type="simple" xlink:href="tcmd-20221231.xsd#DisclosureRevenueTables" roleURI="http://www.tactilemedical.com/role/DisclosureRevenueTables" />
  <roleRef xlink:type="simple" xlink:href="tcmd-20221231.xsd#DisclosureIncomeTaxesTables" roleURI="http://www.tactilemedical.com/role/DisclosureIncomeTaxesTables" />
  <roleRef xlink:type="simple" xlink:href="tcmd-20221231.xsd#DisclosureNetLossPerShareTables" roleURI="http://www.tactilemedical.com/role/DisclosureNetLossPerShareTables" />
  <roleRef xlink:type="simple" xlink:href="tcmd-20221231.xsd#DisclosureFairValueMeasurementsTables" roleURI="http://www.tactilemedical.com/role/DisclosureFairValueMeasurementsTables" />
  <roleRef xlink:type="simple" xlink:href="tcmd-20221231.xsd#DisclosureNatureOfBusinessAndOperationsDetails" roleURI="http://www.tactilemedical.com/role/DisclosureNatureOfBusinessAndOperationsDetails" />
  <roleRef xlink:type="simple" xlink:href="tcmd-20221231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesSegmentDetails" roleURI="http://www.tactilemedical.com/role/DisclosureSummaryOfSignificantAccountingPoliciesSegmentDetails" />
  <roleRef xlink:type="simple" xlink:href="tcmd-20221231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesDetails" roleURI="http://www.tactilemedical.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" />
  <roleRef xlink:type="simple" xlink:href="tcmd-20221231.xsd#DisclosureAcquisitionsDetails" roleURI="http://www.tactilemedical.com/role/DisclosureAcquisitionsDetails" />
  <roleRef xlink:type="simple" xlink:href="tcmd-20221231.xsd#DisclosureAcquisitionsPurchasePriceAllocationDetails" roleURI="http://www.tactilemedical.com/role/DisclosureAcquisitionsPurchasePriceAllocationDetails" />
  <roleRef xlink:type="simple" xlink:href="tcmd-20221231.xsd#DisclosureAcquisitionsAllocationOfPurchasePriceDetails" roleURI="http://www.tactilemedical.com/role/DisclosureAcquisitionsAllocationOfPurchasePriceDetails" />
  <roleRef xlink:type="simple" xlink:href="tcmd-20221231.xsd#DisclosureAcquisitionsConsolidatedStatementsOfOperationsReflectAfflovestOperationsDetails" roleURI="http://www.tactilemedical.com/role/DisclosureAcquisitionsConsolidatedStatementsOfOperationsReflectAfflovestOperationsDetails" />
  <roleRef xlink:type="simple" xlink:href="tcmd-20221231.xsd#DisclosureAccountsReceivableDetails" roleURI="http://www.tactilemedical.com/role/DisclosureAccountsReceivableDetails" />
  <roleRef xlink:type="simple" xlink:href="tcmd-20221231.xsd#DisclosureInventoriesDetails" roleURI="http://www.tactilemedical.com/role/DisclosureInventoriesDetails" />
  <roleRef xlink:type="simple" xlink:href="tcmd-20221231.xsd#DisclosurePropertyAndEquipmentDetails" roleURI="http://www.tactilemedical.com/role/DisclosurePropertyAndEquipmentDetails" />
  <roleRef xlink:type="simple" xlink:href="tcmd-20221231.xsd#DisclosureGoodwillAndIntangibleAssetsDetails" roleURI="http://www.tactilemedical.com/role/DisclosureGoodwillAndIntangibleAssetsDetails" />
  <roleRef xlink:type="simple" xlink:href="tcmd-20221231.xsd#DisclosureAccruedExpensesDetails" roleURI="http://www.tactilemedical.com/role/DisclosureAccruedExpensesDetails" />
  <roleRef xlink:type="simple" xlink:href="tcmd-20221231.xsd#DisclosureWarrantyReservesDetails" roleURI="http://www.tactilemedical.com/role/DisclosureWarrantyReservesDetails" />
  <roleRef xlink:type="simple" xlink:href="tcmd-20221231.xsd#DisclosureCreditAgreementDetails" roleURI="http://www.tactilemedical.com/role/DisclosureCreditAgreementDetails" />
  <roleRef xlink:type="simple" xlink:href="tcmd-20221231.xsd#DisclosureCreditAgreementMaturitiesOfDebtDetails" roleURI="http://www.tactilemedical.com/role/DisclosureCreditAgreementMaturitiesOfDebtDetails" />
  <roleRef xlink:type="simple" xlink:href="tcmd-20221231.xsd#DisclosureCommitmentsAndContingenciesLeaseObligationsDetails" roleURI="http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesLeaseObligationsDetails" />
  <roleRef xlink:type="simple" xlink:href="tcmd-20221231.xsd#DisclosureCommitmentsAndContingenciesLeaseRelatedAssetsAndLiabilitiesDetails" roleURI="http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesLeaseRelatedAssetsAndLiabilitiesDetails" />
  <roleRef xlink:type="simple" xlink:href="tcmd-20221231.xsd#DisclosureCommitmentsAndContingenciesUndiscountedCashFlowsDetails" roleURI="http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesUndiscountedCashFlowsDetails" />
  <roleRef xlink:type="simple" xlink:href="tcmd-20221231.xsd#DisclosureCommitmentsAndContingenciesLeaseCommitmentsAndOperatingLeaseCostDetails" roleURI="http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesLeaseCommitmentsAndOperatingLeaseCostDetails" />
  <roleRef xlink:type="simple" xlink:href="tcmd-20221231.xsd#DisclosureCommitmentsAndContingenciesMajorVendorsDetails" roleURI="http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesMajorVendorsDetails" />
  <roleRef xlink:type="simple" xlink:href="tcmd-20221231.xsd#DisclosureCommitmentsAndContingenciesPurchaseCommitmentsDetails" roleURI="http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesPurchaseCommitmentsDetails" />
  <roleRef xlink:type="simple" xlink:href="tcmd-20221231.xsd#DisclosureCommitmentsAndContingenciesRetirementPlanDetails" roleURI="http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesRetirementPlanDetails" />
  <roleRef xlink:type="simple" xlink:href="tcmd-20221231.xsd#DisclosureCommitmentsAndContingenciesLegalProceedingsDetails" roleURI="http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesLegalProceedingsDetails" />
  <roleRef xlink:type="simple" xlink:href="tcmd-20221231.xsd#DisclosureStockholdersEquitySeriesBPreferredStockDetails" roleURI="http://www.tactilemedical.com/role/DisclosureStockholdersEquitySeriesBPreferredStockDetails" />
  <roleRef xlink:type="simple" xlink:href="tcmd-20221231.xsd#DisclosureStockholdersEquityStockBasedCompensationDetails" roleURI="http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockBasedCompensationDetails" />
  <roleRef xlink:type="simple" xlink:href="tcmd-20221231.xsd#DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails" roleURI="http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails" />
  <roleRef xlink:type="simple" xlink:href="tcmd-20221231.xsd#DisclosureStockholdersEquityEmployeeStockPurchasePlanDetails" roleURI="http://www.tactilemedical.com/role/DisclosureStockholdersEquityEmployeeStockPurchasePlanDetails" />
  <roleRef xlink:type="simple" xlink:href="tcmd-20221231.xsd#DisclosureRevenueDetails" roleURI="http://www.tactilemedical.com/role/DisclosureRevenueDetails" />
  <roleRef xlink:type="simple" xlink:href="tcmd-20221231.xsd#DisclosureIncomeTaxesDetails" roleURI="http://www.tactilemedical.com/role/DisclosureIncomeTaxesDetails" />
  <roleRef xlink:type="simple" xlink:href="tcmd-20221231.xsd#DisclosureNetLossIncomePerCommonShareBasicAndDilutedNetLossPerShareDetails" roleURI="http://www.tactilemedical.com/role/DisclosureNetLossIncomePerCommonShareBasicAndDilutedNetLossPerShareDetails" />
  <roleRef xlink:type="simple" xlink:href="tcmd-20221231.xsd#DisclosureNetLossIncomePerCommonShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" roleURI="http://www.tactilemedical.com/role/DisclosureNetLossIncomePerCommonShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" />
  <roleRef xlink:type="simple" xlink:href="tcmd-20221231.xsd#DisclosureFairValueMeasurementsDetails" roleURI="http://www.tactilemedical.com/role/DisclosureFairValueMeasurementsDetails" />
  <roleRef xlink:type="simple" xlink:href="tcmd-20221231.xsd#DisclosureFairValueMeasurementsEarnOutLiabilityDetails" roleURI="http://www.tactilemedical.com/role/DisclosureFairValueMeasurementsEarnOutLiabilityDetails" />
  <roleRef xlink:type="simple" xlink:href="tcmd-20221231.xsd#DisclosureFairValueMeasurementsFairValueHierarchyDetails" roleURI="http://www.tactilemedical.com/role/DisclosureFairValueMeasurementsFairValueHierarchyDetails" />
  <presentationLink xlink:role="http://www.tactilemedical.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType_638125835184244967" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType_638125835184244967" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport_638125835184244967" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentAnnualReport_638125835184244967" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_638125835184244967" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate_638125835184244967" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport_638125835184244967" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport_638125835184244967" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_638125835184254954" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber_638125835184254954" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_638125835184254954" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName_638125835184254954" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_638125835184254954" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_638125835184254954" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_638125835184254954" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber_638125835184254954" order="8" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_638125835184254954" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1_638125835184254954" order="9" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_638125835184254954" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown_638125835184254954" order="10" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_638125835184254954" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince_638125835184254954" order="11" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_638125835184254954" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode_638125835184254954" order="12" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_638125835184254954" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode_638125835184254954" order="13" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_638125835184254954" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber_638125835184254954" order="14" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_638125835184254954" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle_638125835184254954" order="15" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_638125835184254954" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol_638125835184254954" order="16" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_638125835184264953" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName_638125835184264953" order="17" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus_638125835184264953" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus_638125835184264953" order="18" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent_638125835184264953" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent_638125835184264953" order="19" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory_638125835184264953" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory_638125835184264953" order="20" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness_638125835184264953" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness_638125835184264953" order="21" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_638125835184264953" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany_638125835184264953" order="22" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag_638125835184264953" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag_638125835184264953" order="23" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany_638125835184264953" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany_638125835184264953" order="24" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding_638125835184264953" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding_638125835184264953" order="25" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="dei_AuditorName_638125835184264953" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorName_638125835184264953" order="26" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId_638125835184274955" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorFirmId_638125835184274955" order="27" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation_638125835184274955" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorLocation_638125835184274955" order="28" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_638125835184274955" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey_638125835184274955" order="29" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate_638125835184274955" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate_638125835184274955" order="30" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus_638125835184274955" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus_638125835184274955" order="31" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus_638125835184274955" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus_638125835184274955" order="32" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_638125835184274955" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag_638125835184274955" order="33" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer_638125835184284952" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer_638125835184284952" order="34" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers_638125835184284952" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers_638125835184284952" order="35" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat_638125835184284952" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat_638125835184284952" order="36" use="optional" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tactilemedical.com/role/StatementConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - Consolidated Balance Sheets">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract_638125835184284952" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract_638125835184284952" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract_638125835184284952" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638125835184284952" xlink:to="us-gaap_AssetsCurrentAbstract_638125835184284952" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638125835184284952" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638125835184284952" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638125835184284952" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent_638125835184284952" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638125835184284952" xlink:to="us-gaap_AccountsReceivableNetCurrent_638125835184284952" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetInvestmentInLease" xlink:label="us-gaap_NetInvestmentInLease_638125835184294952" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638125835184284952" xlink:to="us-gaap_NetInvestmentInLease_638125835184294952" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet_638125835184294952" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638125835184284952" xlink:to="us-gaap_InventoryNet_638125835184294952" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638125835184294952" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638125835184284952" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638125835184294952" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_638125835184294952" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638125835184284952" xlink:to="us-gaap_AssetsCurrent_638125835184294952" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsMiscellaneousAbstract" xlink:label="us-gaap_OtherAssetsMiscellaneousAbstract_638125835184294952" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638125835184284952" xlink:to="us-gaap_OtherAssetsMiscellaneousAbstract_638125835184294952" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_638125835184294952" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherAssetsMiscellaneousAbstract_638125835184294952" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_638125835184294952" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638125835184294952" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherAssetsMiscellaneousAbstract_638125835184294952" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638125835184294952" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_638125835184294952" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherAssetsMiscellaneousAbstract_638125835184294952" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_638125835184294952" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill_638125835184294952" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherAssetsMiscellaneousAbstract_638125835184294952" xlink:to="us-gaap_Goodwill_638125835184294952" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_MedicareAccountsReceivableNonCurrent" xlink:label="tcmd_MedicareAccountsReceivableNonCurrent_638125835184294952" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherAssetsMiscellaneousAbstract_638125835184294952" xlink:to="tcmd_MedicareAccountsReceivableNonCurrent_638125835184294952" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent_638125835184294952" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherAssetsMiscellaneousAbstract_638125835184294952" xlink:to="us-gaap_OtherAssetsNoncurrent_638125835184294952" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent_638125835184294952" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherAssetsMiscellaneousAbstract_638125835184294952" xlink:to="us-gaap_AssetsNoncurrent_638125835184294952" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets_638125835184304954" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638125835184284952" xlink:to="us-gaap_Assets_638125835184304954" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638125835184304954" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638125835184304954" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_638125835184304954" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638125835184304954" xlink:to="us-gaap_LiabilitiesCurrentAbstract_638125835184304954" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_638125835184304954" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638125835184304954" xlink:to="us-gaap_AccountsPayableCurrent_638125835184304954" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent_638125835184304954" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638125835184304954" xlink:to="us-gaap_NotesPayableCurrent_638125835184304954" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_EarnOutCurrent" xlink:label="tcmd_EarnOutCurrent_638125835184304954" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638125835184304954" xlink:to="tcmd_EarnOutCurrent_638125835184304954" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_638125835184304954" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638125835184304954" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_638125835184304954" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_638125835184304954" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638125835184304954" xlink:to="us-gaap_AccruedLiabilitiesCurrent_638125835184304954" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="us-gaap_AccruedIncomeTaxesCurrent_638125835184304954" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638125835184304954" xlink:to="us-gaap_AccruedIncomeTaxesCurrent_638125835184304954" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638125835184314953" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638125835184304954" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638125835184314953" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent_638125835184314953" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638125835184304954" xlink:to="us-gaap_OtherLiabilitiesCurrent_638125835184314953" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_638125835184314953" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638125835184304954" xlink:to="us-gaap_LiabilitiesCurrent_638125835184314953" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_638125835184314953" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638125835184304954" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_638125835184314953" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCredit" xlink:label="us-gaap_LineOfCredit_638125835184314953" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract_638125835184314953" xlink:to="us-gaap_LineOfCredit_638125835184314953" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermNotesPayable" xlink:label="us-gaap_LongTermNotesPayable_638125835184314953" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract_638125835184314953" xlink:to="us-gaap_LongTermNotesPayable_638125835184314953" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_EarnOutNonCurrent" xlink:label="tcmd_EarnOutNonCurrent_638125835184314953" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract_638125835184314953" xlink:to="tcmd_EarnOutNonCurrent_638125835184314953" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductWarrantyAccrualNoncurrent" xlink:label="us-gaap_ProductWarrantyAccrualNoncurrent_638125835184314953" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract_638125835184314953" xlink:to="us-gaap_ProductWarrantyAccrualNoncurrent_638125835184314953" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesNoncurrent" xlink:label="us-gaap_AccruedIncomeTaxesNoncurrent_638125835184324953" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract_638125835184314953" xlink:to="us-gaap_AccruedIncomeTaxesNoncurrent_638125835184324953" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638125835184324953" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract_638125835184314953" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638125835184324953" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet_638125835184324953" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract_638125835184314953" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet_638125835184324953" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent_638125835184324953" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract_638125835184314953" xlink:to="us-gaap_LiabilitiesNoncurrent_638125835184324953" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_638125835184324953" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract_638125835184314953" xlink:to="us-gaap_Liabilities_638125835184324953" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_638125835184324953" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638125835184304954" xlink:to="us-gaap_CommitmentsAndContingencies_638125835184324953" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract_638125835184324953" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638125835184304954" xlink:to="us-gaap_StockholdersEquityAbstract_638125835184324953" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_638125835184334954" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638125835184324953" xlink:to="us-gaap_PreferredStockValue_638125835184334954" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_638125835184334954" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638125835184324953" xlink:to="us-gaap_CommonStockValue_638125835184334954" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_638125835184334954" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638125835184324953" xlink:to="us-gaap_AdditionalPaidInCapital_638125835184334954" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638125835184334954" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638125835184324953" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638125835184334954" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638125835184334954" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638125835184324953" xlink:to="us-gaap_StockholdersEquity_638125835184334954" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_638125835184334954" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638125835184324953" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_638125835184334954" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tactilemedical.com/role/StatementConsolidatedBalanceSheetsParenthetical" xlink:type="extended" xlink:title="00105 - Statement - Consolidated Balance Sheets (Parenthetical)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_638125835184344961" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_638125835184344961" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized_638125835184344961" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized_638125835184344961" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued_638125835184344961" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued_638125835184344961" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding_638125835184344961" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding_638125835184344961" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_638125835184344961" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_638125835184344961" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_638125835184344961" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized_638125835184344961" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_638125835184344961" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued_638125835184344961" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_638125835184344961" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding_638125835184344961" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfOperations" xlink:type="extended" xlink:title="00200 - Statement - Consolidated Statements of Operations">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638125835184354953" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_StatementTable_638125835184354953" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_638125835184354953" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638125835184354953" xlink:to="srt_ProductOrServiceAxis_638125835184354953" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_638125835184354953" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_638125835184354953" xlink:to="srt_ProductsAndServicesDomain_638125835184354953" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember_638125835184354953" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638125835184354953" xlink:to="us-gaap_ProductMember_638125835184354953" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_RentalProductServiceMember" xlink:label="tcmd_RentalProductServiceMember_638125835184354953" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638125835184354953" xlink:to="tcmd_RentalProductServiceMember_638125835184354953" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638125835184354953" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638125835184354953" xlink:to="us-gaap_StatementLineItems_638125835184354953" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638125835184354953" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638125835184354953" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638125835184354953" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue_638125835184354953" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638125835184354953" xlink:to="us-gaap_CostOfRevenue_638125835184354953" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit_638125835184354953" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638125835184354953" xlink:to="us-gaap_GrossProfit_638125835184354953" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract_638125835184354953" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638125835184354953" xlink:to="us-gaap_OperatingExpensesAbstract_638125835184354953" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="us-gaap_SellingAndMarketingExpense_638125835184354953" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638125835184354953" xlink:to="us-gaap_SellingAndMarketingExpense_638125835184354953" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_638125835184354953" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638125835184354953" xlink:to="us-gaap_ResearchAndDevelopmentExpense_638125835184354953" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_638125835184364954" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638125835184354953" xlink:to="us-gaap_GeneralAndAdministrativeExpense_638125835184364954" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_AmortizationOfIntangibleAssetsAndEarnOuts" xlink:label="tcmd_AmortizationOfIntangibleAssetsAndEarnOuts_638125835184404954" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638125835184354953" xlink:to="tcmd_AmortizationOfIntangibleAssetsAndEarnOuts_638125835184404954" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_638125835184404954" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638125835184354953" xlink:to="us-gaap_OperatingExpenses_638125835184404954" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_638125835184414958" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638125835184354953" xlink:to="us-gaap_OperatingIncomeLoss_638125835184414958" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense_638125835184414958" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638125835184354953" xlink:to="us-gaap_NonoperatingIncomeExpense_638125835184414958" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638125835184414958" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638125835184354953" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638125835184414958" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_638125835184414958" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638125835184354953" xlink:to="us-gaap_IncomeTaxExpenseBenefit_638125835184414958" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_638125835184414958" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638125835184354953" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_638125835184414958" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract_638125835184414958" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638125835184354953" xlink:to="us-gaap_EarningsPerShareAbstract_638125835184414958" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_638125835184414958" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_638125835184414958" xlink:to="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_638125835184414958" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_638125835184414958" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_638125835184414958" xlink:to="us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_638125835184414958" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_EarningsPerShareOtherDisclosureAbstract" xlink:label="tcmd_EarningsPerShareOtherDisclosureAbstract_638125835184414958" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638125835184354953" xlink:to="tcmd_EarningsPerShareOtherDisclosureAbstract_638125835184414958" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638125835184424956" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcmd_EarningsPerShareOtherDisclosureAbstract_638125835184414958" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638125835184424956" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638125835184424956" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcmd_EarningsPerShareOtherDisclosureAbstract_638125835184414958" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638125835184424956" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfComprehensiveLoss" xlink:type="extended" xlink:title="00300 - Statement - Consolidated Statements of Comprehensive Loss">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_636234564670211119" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638125835184424956" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_636234564670211119" xlink:to="us-gaap_NetIncomeLoss_638125835184424956" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_638125835184424956" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_636234564670211119" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_638125835184424956" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_638125835184424956" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_638125835184424956" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_638125835184424956" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" xlink:label="us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1_638125835184424956" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_638125835184424956" xlink:to="us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1_638125835184424956" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_638125835184424956" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_638125835184424956" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_638125835184424956" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_638125835184424956" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_638125835184424956" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_638125835184424956" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfStockholdersEquity" xlink:type="extended" xlink:title="00400 - Statement - Consolidated Statements of Stockholders' Equity">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638125835184434955" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable_638125835184434955" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_638125835184434955" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638125835184434955" xlink:to="us-gaap_StatementEquityComponentsAxis_638125835184434955" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_638125835184434955" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638125835184434955" xlink:to="us-gaap_CommonStockMember_638125835184434955" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember_638125835184434955" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638125835184434955" xlink:to="us-gaap_AdditionalPaidInCapitalMember_638125835184434955" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember_638125835184434955" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638125835184434955" xlink:to="us-gaap_RetainedEarningsMember_638125835184434955" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_638125835184434955" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638125835184434955" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_638125835184434955" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_638125835184434955" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638125835184434955" xlink:to="us-gaap_EquityComponentDomain_638125835184434955" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638125835184434955" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638125835184434955" xlink:to="us-gaap_StatementLineItems_638125835184434955" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638125835184434955" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638125835184434955" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638125835184434955" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638125835184434955" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638125835184434955" xlink:to="us-gaap_StockholdersEquity_638125835184434955" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_638125835184434955" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638125835184434955" xlink:to="us-gaap_SharesOutstanding_638125835184434955" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_638125835184434955" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638125835184434955" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_638125835184434955" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_638125835184434955" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638125835184434955" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_638125835184434955" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638125835184444956" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638125835184434955" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638125835184444956" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_638125835184444956" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638125835184434955" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_638125835184444956" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_AdjustmentsToAdditionalPaidInCapitalSharesOther" xlink:label="tcmd_AdjustmentsToAdditionalPaidInCapitalSharesOther_638125835184444956" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_638125835184444956" xlink:to="tcmd_AdjustmentsToAdditionalPaidInCapitalSharesOther_638125835184444956" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_638125835184444956" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638125835184434955" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_638125835184444956" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_638125835184444956" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_638125835184444956" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_638125835184444956" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_638125835184444956" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638125835184434955" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_638125835184444956" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638125835184444956" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638125835184434955" xlink:to="us-gaap_StockholdersEquity_638125835184444956" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_638125835184444956" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638125835184434955" xlink:to="us-gaap_SharesOutstanding_638125835184444956" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00500 - Statement - Consolidated Statements of Cash Flows">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInContinuingOperationsAbstract_638125835184454955" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInContinuingOperationsAbstract_638125835184454955" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_638125835184454955" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInContinuingOperationsAbstract_638125835184454955" xlink:to="us-gaap_ProfitLoss_638125835184454955" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638125835184454955" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInContinuingOperationsAbstract_638125835184454955" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638125835184454955" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization_638125835184454955" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638125835184454955" xlink:to="us-gaap_DepreciationDepletionAndAmortization_638125835184454955" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_AmortizationOfPremiumsAndDiscountsOnSecuritiesAvailableForSale" xlink:label="tcmd_AmortizationOfPremiumsAndDiscountsOnSecuritiesAvailableForSale_638125835184454955" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638125835184454955" xlink:to="tcmd_AmortizationOfPremiumsAndDiscountsOnSecuritiesAvailableForSale_638125835184454955" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:label="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_638125835184454955" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638125835184454955" xlink:to="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_638125835184454955" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_638125835184454955" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638125835184454955" xlink:to="us-gaap_ShareBasedCompensation_638125835184454955" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesGainLoss" xlink:label="us-gaap_MarketableSecuritiesGainLoss_638125835184454955" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638125835184454955" xlink:to="us-gaap_MarketableSecuritiesGainLoss_638125835184454955" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges_638125835184454955" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638125835184454955" xlink:to="us-gaap_AssetImpairmentCharges_638125835184454955" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="us-gaap_GainLossOnDispositionOfAssets1_638125835184454955" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638125835184454955" xlink:to="us-gaap_GainLossOnDispositionOfAssets1_638125835184454955" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueAdjustment" xlink:label="us-gaap_LiabilitiesFairValueAdjustment_638125835184454955" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638125835184454955" xlink:to="us-gaap_LiabilitiesFairValueAdjustment_638125835184454955" order="8" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638125835184454955" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638125835184454955" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638125835184454955" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_638125835184454955" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638125835184454955" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_638125835184454955" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_IncreaseDecreaseInNetInvestmentInLease" xlink:label="tcmd_IncreaseDecreaseInNetInvestmentInLease_638125835184464956" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638125835184454955" xlink:to="tcmd_IncreaseDecreaseInNetInvestmentInLease_638125835184464956" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories_638125835184464956" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638125835184454955" xlink:to="us-gaap_IncreaseDecreaseInInventories_638125835184464956" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:label="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_638125835184464956" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638125835184454955" xlink:to="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_638125835184464956" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638125835184464956" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638125835184454955" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638125835184464956" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:label="tcmd_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_638125835184464956" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638125835184454955" xlink:to="tcmd_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_638125835184464956" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerAsset_638125835184464956" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638125835184454955" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerAsset_638125835184464956" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_638125835184464956" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638125835184454955" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_638125835184464956" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_638125835184464956" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638125835184454955" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_638125835184464956" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_IncreaseDecreaseInOtherAccruedLiabilitiesAndIncomeTaxesPayable" xlink:label="tcmd_IncreaseDecreaseInOtherAccruedLiabilitiesAndIncomeTaxesPayable_638125835184464956" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638125835184454955" xlink:to="tcmd_IncreaseDecreaseInOtherAccruedLiabilitiesAndIncomeTaxesPayable_638125835184464956" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_638125835184464956" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInContinuingOperationsAbstract_638125835184454955" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_638125835184464956" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_638125835184474960" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_638125835184474960" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_638125835184474960" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_638125835184474960" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_638125835184474960" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_PaymentsToAcquireProductiveAsset" xlink:label="tcmd_PaymentsToAcquireProductiveAsset_638125835184474960" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_638125835184474960" xlink:to="tcmd_PaymentsToAcquireProductiveAsset_638125835184474960" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638125835184474960" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_638125835184474960" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638125835184474960" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_638125835184474960" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_638125835184474960" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_638125835184474960" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_638125835184474960" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_638125835184474960" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_638125835184474960" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireOtherInvestments" xlink:label="us-gaap_PaymentsToAcquireOtherInvestments_638125835184474960" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_638125835184474960" xlink:to="us-gaap_PaymentsToAcquireOtherInvestments_638125835184474960" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_638125835184474960" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_638125835184474960" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_638125835184474960" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_638125835184484957" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_638125835184484957" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="us-gaap_ProceedsFromNotesPayable_638125835184484957" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_638125835184484957" xlink:to="us-gaap_ProceedsFromNotesPayable_638125835184484957" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="us-gaap_ProceedsFromLinesOfCredit_638125835184484957" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_638125835184484957" xlink:to="us-gaap_ProceedsFromLinesOfCredit_638125835184484957" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:label="us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_638125835184484957" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_638125835184484957" xlink:to="us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_638125835184484957" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="us-gaap_RepaymentsOfNotesPayable_638125835184484957" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_638125835184484957" xlink:to="us-gaap_RepaymentsOfNotesPayable_638125835184484957" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_638125835184484957" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_638125835184484957" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts_638125835184484957" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_PaymentOfTaxesForNetShareSettlementOfRestrictedStockUnits" xlink:label="tcmd_PaymentOfTaxesForNetShareSettlementOfRestrictedStockUnits_638125835184484957" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_638125835184484957" xlink:to="tcmd_PaymentOfTaxesForNetShareSettlementOfRestrictedStockUnits_638125835184484957" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_638125835184484957" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_638125835184484957" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_638125835184484957" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638125835184494954" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_638125835184484957" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638125835184494954" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_638125835184494954" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_638125835184484957" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_638125835184494954" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_638125835184494954" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_638125835184494954" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638125835184494954" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638125835184494954" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6381258351844949541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6381258351844949541" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_638125835184494954" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_638125835184494954" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet_638125835184504958" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_638125835184494954" xlink:to="us-gaap_InterestPaidNet_638125835184504958" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaid" xlink:label="us-gaap_IncomeTaxesPaid_638125835184504958" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_638125835184494954" xlink:to="us-gaap_IncomeTaxesPaid_638125835184504958" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1_638125835184504958" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_638125835184494954" xlink:to="us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1_638125835184504958" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="7" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tactilemedical.com/role/DisclosureNatureOfBusinessAndOperations" xlink:type="extended" xlink:title="10101 - Disclosure - Nature of Business and Operations">
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_NatureOfBusinessAndOperationAbstract" xlink:label="tcmd_NatureOfBusinessAndOperationAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations_638125835184504958" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcmd_NatureOfBusinessAndOperationAbstract" xlink:to="us-gaap_NatureOfOperations_638125835184504958" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tactilemedical.com/role/DisclosureBasisOfPresentation" xlink:type="extended" xlink:title="10201 - Disclosure - Basis of Presentation">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_638125835184504958" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_638125835184504958" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tactilemedical.com/role/DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="extended" xlink:title="10301 - Disclosure - Summary of Significant Accounting Policies">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_638125835184514959" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_638125835184514959" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tactilemedical.com/role/DisclosureAcquisitions" xlink:type="extended" xlink:title="10401 - Disclosure - Acquisitions">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAbstract" xlink:label="us-gaap_AssetAcquisitionAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionTextBlock" xlink:label="us-gaap_AssetAcquisitionTextBlock_638125835184514959" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionAbstract" xlink:to="us-gaap_AssetAcquisitionTextBlock_638125835184514959" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tactilemedical.com/role/DisclosureAccountsReceivable" xlink:type="extended" xlink:title="10501 - Disclosure - Accounts Receivable">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesAbstract" xlink:label="us-gaap_ReceivablesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_638125835184514959" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_638125835184514959" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tactilemedical.com/role/DisclosureInventories" xlink:type="extended" xlink:title="10601 - Disclosure - Inventories">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock_638125835184524958" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureTextBlock_638125835184524958" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tactilemedical.com/role/DisclosurePropertyAndEquipment" xlink:type="extended" xlink:title="10701 - Disclosure - Property and Equipment">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_638125835184524958" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_638125835184524958" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tactilemedical.com/role/DisclosureGoodwillAndIntangibleAssets" xlink:type="extended" xlink:title="10801 - Disclosure - Goodwill and Intangible Assets">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_638125835184524958" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_638125835184524958" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tactilemedical.com/role/DisclosureAccruedExpenses" xlink:type="extended" xlink:title="10901 - Disclosure - Accrued Expenses">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_AccruedExpensesDisclosureCurrentTextBlock" xlink:label="tcmd_AccruedExpensesDisclosureCurrentTextBlock_638125835184524958" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="tcmd_AccruedExpensesDisclosureCurrentTextBlock_638125835184524958" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tactilemedical.com/role/DisclosureWarrantyReserves" xlink:type="extended" xlink:title="11001 - Disclosure - Warranty Reserves">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StandardProductWarrantyDisclosureAbstract" xlink:label="us-gaap_StandardProductWarrantyDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductWarrantyDisclosureTextBlock" xlink:label="us-gaap_ProductWarrantyDisclosureTextBlock_638125835184524958" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StandardProductWarrantyDisclosureAbstract" xlink:to="us-gaap_ProductWarrantyDisclosureTextBlock_638125835184524958" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tactilemedical.com/role/DisclosureCreditAgreement" xlink:type="extended" xlink:title="11101 - Disclosure - Credit Agreement">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock_638125835184534955" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock_638125835184534955" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingencies" xlink:type="extended" xlink:title="11201 - Disclosure - Commitments and Contingencies">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_638125835184534955" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_638125835184534955" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tactilemedical.com/role/DisclosureStockholdersEquity" xlink:type="extended" xlink:title="11301 - Disclosure - Stockholders' Equity">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_638125835184534955" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_638125835184534955" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tactilemedical.com/role/DisclosureRevenue" xlink:type="extended" xlink:title="11401 - Disclosure - Revenue">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock_638125835184534955" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock_638125835184534955" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tactilemedical.com/role/DisclosureIncomeTaxes" xlink:type="extended" xlink:title="11501 - Disclosure - Income Taxes">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_638125835184544953" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_638125835184544953" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tactilemedical.com/role/DisclosureNetLossIncomePerCommonShare" xlink:type="extended" xlink:title="11601 - Disclosure - Net (Loss) Income Per Common Share">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock_638125835184544953" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock_638125835184544953" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tactilemedical.com/role/DisclosureFairValueMeasurements" xlink:type="extended" xlink:title="11701 - Disclosure - Fair Value Measurements">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock_638125835184544953" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock_638125835184544953" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tactilemedical.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" xlink:title="20302 - Disclosure - Summary of Significant Accounting Policies (Policies)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_638125835184544953" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_638125835184544953" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock_638125835184544953" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_ConsolidationPolicyTextBlock_638125835184544953" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_UnusualRisksAndUncertaintiesPolicyTextBlock" xlink:label="tcmd_UnusualRisksAndUncertaintiesPolicyTextBlock_638125835184544953" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="tcmd_UnusualRisksAndUncertaintiesPolicyTextBlock_638125835184544953" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates_638125835184544953" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_UseOfEstimates_638125835184544953" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_638125835184554955" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_638125835184554955" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_638125835184554955" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_638125835184554955" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="us-gaap_InvestmentPolicyTextBlock_638125835184554955" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_InvestmentPolicyTextBlock_638125835184554955" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_638125835184554955" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy_638125835184554955" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock_638125835184554955" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_InventoryPolicyTextBlock_638125835184554955" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_638125835184554955" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_638125835184554955" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_638125835184554955" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_638125835184554955" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvertisingCostsPolicyTextBlock" xlink:label="us-gaap_AdvertisingCostsPolicyTextBlock_638125835184554955" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_AdvertisingCostsPolicyTextBlock_638125835184554955" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_638125835184554955" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_638125835184554955" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesPolicyTextBlock" xlink:label="us-gaap_CostOfSalesPolicyTextBlock_638125835184554955" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_CostOfSalesPolicyTextBlock_638125835184554955" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StandardProductWarrantyPolicy" xlink:label="us-gaap_StandardProductWarrantyPolicy_638125835184554955" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_StandardProductWarrantyPolicy_638125835184554955" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_638125835184554955" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_638125835184554955" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_638125835184564954" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_638125835184564954" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_638125835184564954" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_638125835184564954" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_638125835184564954" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_638125835184564954" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_638125835184564954" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_638125835184564954" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_638125835184564954" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_638125835184564954" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_NewAccountingPronouncementsNoteYetAdoptedPolicyPolicyTextBlock" xlink:label="tcmd_NewAccountingPronouncementsNoteYetAdoptedPolicyPolicyTextBlock_638125835184564954" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="tcmd_NewAccountingPronouncementsNoteYetAdoptedPolicyPolicyTextBlock_638125835184564954" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tactilemedical.com/role/DisclosureAcquisitionsTables" xlink:type="extended" xlink:title="30403 - Disclosure - Acquisitions (Tables)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAbstract" xlink:label="us-gaap_AssetAcquisitionAbstract_4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionTableTextBlock" xlink:label="us-gaap_AssetAcquisitionTableTextBlock_638125835184564954" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionAbstract_4" xlink:to="us-gaap_AssetAcquisitionTableTextBlock_638125835184564954" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfAssetAcquisitionTableTextBlock" xlink:label="tcmd_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfAssetAcquisitionTableTextBlock_638125835184574959" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionAbstract_4" xlink:to="tcmd_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfAssetAcquisitionTableTextBlock_638125835184574959" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:label="us-gaap_BusinessAcquisitionProFormaInformationTextBlock_638125835184574959" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionAbstract_4" xlink:to="us-gaap_BusinessAcquisitionProFormaInformationTextBlock_638125835184574959" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tactilemedical.com/role/DisclosureInventoriesTables" xlink:type="extended" xlink:title="30603 - Disclosure - Inventories (Tables)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_638125835184574959" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_638125835184574959" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tactilemedical.com/role/DisclosurePropertyAndEquipmentTables" xlink:type="extended" xlink:title="30703 - Disclosure - Property and Equipment (Tables)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_638125835184574959" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_638125835184574959" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="7" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tactilemedical.com/role/DisclosureGoodwillAndIntangibleAssetsTables" xlink:type="extended" xlink:title="30803 - Disclosure - Goodwill and Intangible Assets (Tables)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_638125835184574959" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_638125835184574959" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_638125835184574959" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_638125835184574959" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tactilemedical.com/role/DisclosureAccruedExpensesTables" xlink:type="extended" xlink:title="30903 - Disclosure - Accrued Expenses (Tables)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_ScheduleOfAccruedExpensesTableTextBlock" xlink:label="tcmd_ScheduleOfAccruedExpensesTableTextBlock_638125835184584956" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="tcmd_ScheduleOfAccruedExpensesTableTextBlock_638125835184584956" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tactilemedical.com/role/DisclosureWarrantyReservesTables" xlink:type="extended" xlink:title="31003 - Disclosure - Warranty Reserves (Tables)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StandardProductWarrantyDisclosureAbstract" xlink:label="us-gaap_StandardProductWarrantyDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock" xlink:label="us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock_638125835184584956" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StandardProductWarrantyDisclosureAbstract" xlink:to="us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock_638125835184584956" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tactilemedical.com/role/DisclosureCreditAgreementTables" xlink:type="extended" xlink:title="31103 - Disclosure - Credit Agreement (Tables)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_638125835184584956" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract_1" xlink:to="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_638125835184584956" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesTables" xlink:type="extended" xlink:title="31203 - Disclosure - Commitments and Contingencies (Tables)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:label="tcmd_AssetsAndLiabilitiesLesseeTableTextBlock_638125835184594978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="tcmd_AssetsAndLiabilitiesLesseeTableTextBlock_638125835184594978" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLeaseIncomeTableTextBlock" xlink:label="us-gaap_OperatingLeaseLeaseIncomeTableTextBlock_638125835184594978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseLeaseIncomeTableTextBlock_638125835184594978" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tactilemedical.com/role/DisclosureStockholdersEquityTables" xlink:type="extended" xlink:title="31303 - Disclosure - Stockholders' Equity (Tables)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract_636068659397303643" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638125835184594978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract_636068659397303643" xlink:to="us-gaap_StatementTable_638125835184594978" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638125835184594978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638125835184594978" xlink:to="us-gaap_AwardTypeAxis_638125835184594978" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638125835184594978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638125835184594978" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638125835184594978" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_638125835184594978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638125835184594978" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_638125835184594978" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_TimeBasedRestrictedStockUnitsRsusMember" xlink:label="tcmd_TimeBasedRestrictedStockUnitsRsusMember_638125835184594978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedStockUnitsRSUMember_638125835184594978" xlink:to="tcmd_TimeBasedRestrictedStockUnitsRsusMember_638125835184594978" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_PerformanceBasedStockSettledRestrictedStockUnitsMember" xlink:label="tcmd_PerformanceBasedStockSettledRestrictedStockUnitsMember_638125835184594978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedStockUnitsRSUMember_638125835184594978" xlink:to="tcmd_PerformanceBasedStockSettledRestrictedStockUnitsMember_638125835184594978" order="2" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638125835184594978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638125835184594978" xlink:to="us-gaap_StatementLineItems_638125835184594978" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_638125835184594978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638125835184594978" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_638125835184594978" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_638125835184594978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638125835184594978" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_638125835184594978" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_638125835184594978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638125835184594978" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_638125835184594978" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_638125835184604955" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638125835184594978" xlink:to="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_638125835184604955" order="4" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_638125835184604955" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638125835184594978" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_638125835184604955" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tactilemedical.com/role/DisclosureRevenueTables" xlink:type="extended" xlink:title="31403 - Disclosure - Revenue (Tables)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_638125835184604955" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock_638125835184604955" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_ScheduleOfRevenueFromThirdPartyPayersTableTextBlock" xlink:label="tcmd_ScheduleOfRevenueFromThirdPartyPayersTableTextBlock_638125835184604955" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="tcmd_ScheduleOfRevenueFromThirdPartyPayersTableTextBlock_638125835184604955" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesTypeLeaseLeaseIncomeTableTextBlock" xlink:label="us-gaap_SalesTypeLeaseLeaseIncomeTableTextBlock_638125835184604955" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_SalesTypeLeaseLeaseIncomeTableTextBlock_638125835184604955" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tactilemedical.com/role/DisclosureIncomeTaxesTables" xlink:type="extended" xlink:title="31503 - Disclosure - Income Taxes (Tables)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_638125835184604955" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_638125835184604955" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_638125835184604955" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_638125835184604955" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_638125835184604955" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_638125835184604955" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_638125835184614957" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_638125835184614957" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tactilemedical.com/role/DisclosureNetLossPerShareTables" xlink:type="extended" xlink:title="31603 - Disclosure - Net Loss Per Share (Tables)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_638125835184614957" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_638125835184614957" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_638125835184614957" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_638125835184614957" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tactilemedical.com/role/DisclosureFairValueMeasurementsTables" xlink:type="extended" xlink:title="31703 - Disclosure - Fair Value Measurements (Tables)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract_636232962865744867" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_638125835184614957" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract_636232962865744867" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_638125835184614957" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_638125835184614957" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract_636232962865744867" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_638125835184614957" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tactilemedical.com/role/DisclosureNatureOfBusinessAndOperationsDetails" xlink:type="extended" xlink:title="40101 - Disclosure - Nature of Business and Operations (Details)">
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_NatureOfBusinessAndOperationAbstract" xlink:label="tcmd_NatureOfBusinessAndOperationAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:label="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable_638125835184614957" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcmd_NatureOfBusinessAndOperationAbstract" xlink:to="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable_638125835184614957" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_638125835184614957" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable_638125835184614957" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_638125835184614957" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_638125835184624955" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638125835184614957" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_638125835184624955" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember_638125835184624955" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638125835184624955" xlink:to="us-gaap_IPOMember_638125835184624955" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_638125835184624955" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable_638125835184614957" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_638125835184624955" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638125835184624955" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638125835184624955" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638125835184624955" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare_638125835184624955" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638125835184624955" xlink:to="us-gaap_SharesIssuedPricePerShare_638125835184624955" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_638125835184624955" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638125835184624955" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_638125835184624955" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_ExpenseRelatingToInitialPublicOffering" xlink:label="tcmd_ExpenseRelatingToInitialPublicOffering_638125835184624955" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638125835184624955" xlink:to="tcmd_ExpenseRelatingToInitialPublicOffering_638125835184624955" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tactilemedical.com/role/DisclosureSummaryOfSignificantAccountingPoliciesSegmentDetails" xlink:type="extended" xlink:title="40301 - Disclosure - Summary of Significant Accounting Policies - Segment (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments_638125835184624955" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NumberOfOperatingSegments_638125835184624955" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments_638125835184624955" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NumberOfReportableSegments_638125835184624955" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tactilemedical.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" xlink:type="extended" xlink:title="40302 - Disclosure - Summary of Significant Accounting Policies (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_636517049941958246" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638125835184634955" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_636517049941958246" xlink:to="us-gaap_StatementTable_638125835184634955" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_638125835184634955" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638125835184634955" xlink:to="srt_ProductOrServiceAxis_638125835184634955" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_638125835184634955" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_638125835184634955" xlink:to="srt_ProductsAndServicesDomain_638125835184634955" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_GarmentsMember" xlink:label="tcmd_GarmentsMember_638125835184634955" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638125835184634955" xlink:to="tcmd_GarmentsMember_638125835184634955" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_ControllersMember" xlink:label="tcmd_ControllersMember_638125835184634955" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638125835184634955" xlink:to="tcmd_ControllersMember_638125835184634955" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_AfflovestMember" xlink:label="tcmd_AfflovestMember_638125835184634955" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638125835184634955" xlink:to="tcmd_AfflovestMember_638125835184634955" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638125835184634955" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638125835184634955" xlink:to="srt_RangeAxis_638125835184634955" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638125835184634955" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638125835184634955" xlink:to="srt_RangeMember_638125835184634955" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638125835184634955" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638125835184634955" xlink:to="srt_MinimumMember_638125835184634955" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638125835184634955" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638125835184634955" xlink:to="srt_MaximumMember_638125835184634955" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638125835184634955" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638125835184634955" xlink:to="us-gaap_StatementLineItems_638125835184634955" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValueAbstract" xlink:label="us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValueAbstract_638125835184634955" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638125835184634955" xlink:to="us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValueAbstract_638125835184634955" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:label="us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_638125835184644955" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValueAbstract_638125835184634955" xlink:to="us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_638125835184644955" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetAbstract" xlink:label="us-gaap_AccountsReceivableNetAbstract_638125835184644955" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638125835184634955" xlink:to="us-gaap_AccountsReceivableNetAbstract_638125835184644955" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_PercentageOfClaimsApproved" xlink:label="tcmd_PercentageOfClaimsApproved_638125835184644955" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsReceivableNetAbstract_638125835184644955" xlink:to="tcmd_PercentageOfClaimsApproved_638125835184644955" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_638125835184644955" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638125835184634955" xlink:to="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_638125835184644955" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_638125835184644955" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_638125835184644955" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_638125835184644955" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionAbstract" xlink:label="us-gaap_RevenueRecognitionAbstract_638125835184644955" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638125835184634955" xlink:to="us-gaap_RevenueRecognitionAbstract_638125835184644955" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="4" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_MedicareReceivablesTimePeriod" xlink:label="tcmd_MedicareReceivablesTimePeriod_638125835184644955" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionAbstract_638125835184644955" xlink:to="tcmd_MedicareReceivablesTimePeriod_638125835184644955" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_PeriodForConsiderationPaymentAfterShipmentDate" xlink:label="tcmd_PeriodForConsiderationPaymentAfterShipmentDate_638125835184644955" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionAbstract_638125835184644955" xlink:to="tcmd_PeriodForConsiderationPaymentAfterShipmentDate_638125835184644955" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuePracticalExpedientIncrementalCostOfObtainingContract" xlink:label="us-gaap_RevenuePracticalExpedientIncrementalCostOfObtainingContract_638125835184644955" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionAbstract_638125835184644955" xlink:to="us-gaap_RevenuePracticalExpedientIncrementalCostOfObtainingContract_638125835184644955" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketingAndAdvertisingExpenseAbstract" xlink:label="us-gaap_MarketingAndAdvertisingExpenseAbstract_638125835184644955" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638125835184634955" xlink:to="us-gaap_MarketingAndAdvertisingExpenseAbstract_638125835184644955" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvertisingExpense" xlink:label="us-gaap_AdvertisingExpense_638125835184644955" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketingAndAdvertisingExpenseAbstract_638125835184644955" xlink:to="us-gaap_AdvertisingExpense_638125835184644955" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StandardProductWarrantyDisclosureAbstract" xlink:label="us-gaap_StandardProductWarrantyDisclosureAbstract_638125835184654960" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638125835184634955" xlink:to="us-gaap_StandardProductWarrantyDisclosureAbstract_638125835184654960" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_TermOfProductWarranty" xlink:label="tcmd_TermOfProductWarranty_638125835184654960" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StandardProductWarrantyDisclosureAbstract_638125835184654960" xlink:to="tcmd_TermOfProductWarranty_638125835184654960" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tactilemedical.com/role/DisclosureAcquisitionsDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Acquisitions (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAbstract" xlink:label="us-gaap_AssetAcquisitionAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionTable" xlink:label="us-gaap_AssetAcquisitionTable_638125835184654960" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionAbstract_1" xlink:to="us-gaap_AssetAcquisitionTable_638125835184654960" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis_638125835184654960" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionTable_638125835184654960" xlink:to="us-gaap_BusinessAcquisitionAxis_638125835184654960" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_638125835184654960" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis_638125835184654960" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_638125835184654960" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_AfflovestPMember" xlink:label="tcmd_AfflovestPMember_638125835184654960" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain_638125835184654960" xlink:to="tcmd_AfflovestPMember_638125835184654960" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638125835184654960" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionTable_638125835184654960" xlink:to="srt_RangeAxis_638125835184654960" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638125835184654960" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638125835184654960" xlink:to="srt_RangeMember_638125835184654960" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638125835184654960" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638125835184654960" xlink:to="srt_MaximumMember_638125835184654960" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_638125835184664956" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionTable_638125835184654960" xlink:to="srt_StatementScenarioAxis_638125835184664956" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_638125835184664956" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_638125835184664956" xlink:to="srt_ScenarioUnspecifiedDomain_638125835184664956" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_AssetAcquisitionEarnoutPaymentsRevenueTargetsFromOctoberTwoThousandTwentyOneToSeptemberTwoThousandTwentyTwoMember" xlink:label="tcmd_AssetAcquisitionEarnoutPaymentsRevenueTargetsFromOctoberTwoThousandTwentyOneToSeptemberTwoThousandTwentyTwoMember_638125835184664956" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638125835184664956" xlink:to="tcmd_AssetAcquisitionEarnoutPaymentsRevenueTargetsFromOctoberTwoThousandTwentyOneToSeptemberTwoThousandTwentyTwoMember_638125835184664956" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_AssetAcquisitionEarnoutPaymentsRevenueTargetsFromOctoberTwoThousandTwentyTwoToSeptemberTwoThousandTwentyThreeMember" xlink:label="tcmd_AssetAcquisitionEarnoutPaymentsRevenueTargetsFromOctoberTwoThousandTwentyTwoToSeptemberTwoThousandTwentyThreeMember_638125835184664956" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638125835184664956" xlink:to="tcmd_AssetAcquisitionEarnoutPaymentsRevenueTargetsFromOctoberTwoThousandTwentyTwoToSeptemberTwoThousandTwentyThreeMember_638125835184664956" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_EarnOutPeriodOnOrBeforeNovember282022Member" xlink:label="tcmd_EarnOutPeriodOnOrBeforeNovember282022Member_638125835184664956" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638125835184664956" xlink:to="tcmd_EarnOutPeriodOnOrBeforeNovember282022Member_638125835184664956" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_EarnOutPeriodOnOrBeforeMay262023Member" xlink:label="tcmd_EarnOutPeriodOnOrBeforeMay262023Member_638125835184664956" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638125835184664956" xlink:to="tcmd_EarnOutPeriodOnOrBeforeMay262023Member_638125835184664956" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_SecondEarnOutAmendmentMember" xlink:label="tcmd_SecondEarnOutAmendmentMember_638125835184664956" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638125835184664956" xlink:to="tcmd_SecondEarnOutAmendmentMember_638125835184664956" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_638125835184664956" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionTable_638125835184654960" xlink:to="us-gaap_IncomeStatementLocationAxis_638125835184664956" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_638125835184664956" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_638125835184664956" xlink:to="us-gaap_IncomeStatementLocationDomain_638125835184664956" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_638125835184664956" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638125835184664956" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_638125835184664956" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionLineItems" xlink:label="us-gaap_AssetAcquisitionLineItems_638125835184664956" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionTable_638125835184654960" xlink:to="us-gaap_AssetAcquisitionLineItems_638125835184664956" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_638125835184674961" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems_638125835184664956" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1_638125835184674961" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross_638125835184674961" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems_638125835184664956" xlink:to="us-gaap_PaymentsToAcquireBusinessesGross_638125835184674961" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_AssetAcquisitionConsiderationTransferredEscrowAccount" xlink:label="tcmd_AssetAcquisitionConsiderationTransferredEscrowAccount_638125835184674961" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems_638125835184664956" xlink:to="tcmd_AssetAcquisitionConsiderationTransferredEscrowAccount_638125835184674961" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_AssetAcquisitionAmountReceivedResultingFromWorkingCapitalAdjustment" xlink:label="tcmd_AssetAcquisitionAmountReceivedResultingFromWorkingCapitalAdjustment_638125835184674961" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems_638125835184664956" xlink:to="tcmd_AssetAcquisitionAmountReceivedResultingFromWorkingCapitalAdjustment_638125835184674961" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_AssetAcquisitionBusinessRevenueToExceedBaseRevenueMultiplier" xlink:label="tcmd_AssetAcquisitionBusinessRevenueToExceedBaseRevenueMultiplier_638125835184674961" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems_638125835184664956" xlink:to="tcmd_AssetAcquisitionBusinessRevenueToExceedBaseRevenueMultiplier_638125835184674961" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability_638125835184674961" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems_638125835184664956" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability_638125835184674961" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_AssetAcquisitionEarnOutLiability" xlink:label="tcmd_AssetAcquisitionEarnOutLiability_638125835184674961" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems_638125835184664956" xlink:to="tcmd_AssetAcquisitionEarnOutLiability_638125835184674961" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:label="us-gaap_BusinessCombinationAcquisitionRelatedCosts_638125835184674961" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems_638125835184664956" xlink:to="us-gaap_BusinessCombinationAcquisitionRelatedCosts_638125835184674961" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_AssetAcquisitionImputedInterestPayable" xlink:label="tcmd_AssetAcquisitionImputedInterestPayable_638125835184674961" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems_638125835184664956" xlink:to="tcmd_AssetAcquisitionImputedInterestPayable_638125835184674961" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tactilemedical.com/role/DisclosureAcquisitionsPurchasePriceAllocationDetails" xlink:type="extended" xlink:title="40402 - Disclosure - Acquisitions - Purchase Price Allocation (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAbstract" xlink:label="us-gaap_AssetAcquisitionAbstract_5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionTable" xlink:label="us-gaap_AssetAcquisitionTable_638125835184684956" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionAbstract_5" xlink:to="us-gaap_AssetAcquisitionTable_638125835184684956" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis_638125835184684956" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionTable_638125835184684956" xlink:to="us-gaap_BusinessAcquisitionAxis_638125835184684956" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_638125835184684956" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis_638125835184684956" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_638125835184684956" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_AfflovestPMember" xlink:label="tcmd_AfflovestPMember_638125835184684956" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain_638125835184684956" xlink:to="tcmd_AfflovestPMember_638125835184684956" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638125835184684956" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionTable_638125835184684956" xlink:to="srt_RangeAxis_638125835184684956" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638125835184684956" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638125835184684956" xlink:to="srt_RangeMember_638125835184684956" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638125835184684956" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638125835184684956" xlink:to="srt_MaximumMember_638125835184684956" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionLineItems" xlink:label="us-gaap_AssetAcquisitionLineItems_638125835184684956" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionTable_638125835184684956" xlink:to="us-gaap_AssetAcquisitionLineItems_638125835184684956" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionConsiderationTransferredAbstract" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferredAbstract_638125835184684956" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems_638125835184684956" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferredAbstract_638125835184684956" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet_638125835184684956" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionConsiderationTransferredAbstract_638125835184684956" xlink:to="us-gaap_InventoryNet_638125835184684956" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_638125835184684956" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionConsiderationTransferredAbstract_638125835184684956" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_638125835184684956" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_638125835184694957" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionConsiderationTransferredAbstract_638125835184684956" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_638125835184694957" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill_638125835184694957" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionConsiderationTransferredAbstract_638125835184684956" xlink:to="us-gaap_Goodwill_638125835184694957" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNet" xlink:label="us-gaap_AssetsNet_638125835184694957" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionConsiderationTransferredAbstract_638125835184684956" xlink:to="us-gaap_AssetsNet_638125835184694957" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_GoodwillAmortizationPeriodForTaxPurposes" xlink:label="tcmd_GoodwillAmortizationPeriodForTaxPurposes_638125835184694957" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems_638125835184684956" xlink:to="tcmd_GoodwillAmortizationPeriodForTaxPurposes_638125835184694957" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tactilemedical.com/role/DisclosureAcquisitionsAllocationOfPurchasePriceDetails" xlink:type="extended" xlink:title="40403 - Disclosure - Acquisitions - Allocation of Purchase Price (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAbstract" xlink:label="us-gaap_AssetAcquisitionAbstract_3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionTable" xlink:label="us-gaap_AssetAcquisitionTable_638125835184694957" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionAbstract_3" xlink:to="us-gaap_AssetAcquisitionTable_638125835184694957" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_638125835184694957" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionTable_638125835184694957" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_638125835184694957" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_638125835184694957" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_638125835184694957" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_638125835184694957" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRelationshipsMember" xlink:label="us-gaap_CustomerRelationshipsMember_638125835184694957" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_638125835184694957" xlink:to="us-gaap_CustomerRelationshipsMember_638125835184694957" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="us-gaap_DevelopedTechnologyRightsMember_638125835184694957" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_638125835184694957" xlink:to="us-gaap_DevelopedTechnologyRightsMember_638125835184694957" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeNamesMember" xlink:label="us-gaap_TradeNamesMember_638125835184694957" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_638125835184694957" xlink:to="us-gaap_TradeNamesMember_638125835184694957" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis_638125835184704961" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionTable_638125835184694957" xlink:to="us-gaap_BusinessAcquisitionAxis_638125835184704961" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_638125835184704961" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis_638125835184704961" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_638125835184704961" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_AfflovestPMember" xlink:label="tcmd_AfflovestPMember_638125835184704961" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain_638125835184704961" xlink:to="tcmd_AfflovestPMember_638125835184704961" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionLineItems" xlink:label="us-gaap_AssetAcquisitionLineItems_638125835184704961" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionTable_638125835184694957" xlink:to="us-gaap_AssetAcquisitionLineItems_638125835184704961" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_638125835184704961" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems_638125835184704961" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_638125835184704961" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsGrossExcludingGoodwill_638125835184704961" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems_638125835184704961" xlink:to="us-gaap_IntangibleAssetsGrossExcludingGoodwill_638125835184704961" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_638125835184704961" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems_638125835184704961" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_638125835184704961" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/netLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_638125835184704961" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems_638125835184704961" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_638125835184704961" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:label="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_638125835184704961" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems_638125835184704961" xlink:to="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_638125835184704961" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tactilemedical.com/role/DisclosureAcquisitionsConsolidatedStatementsOfOperationsReflectAfflovestOperationsDetails" xlink:type="extended" xlink:title="40404 - Disclosure - Acquisitions - Consolidated Statements of Operations Reflect AffloVest Operations (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAbstract" xlink:label="us-gaap_AssetAcquisitionAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionTable" xlink:label="us-gaap_AssetAcquisitionTable_638125835184714960" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionAbstract_2" xlink:to="us-gaap_AssetAcquisitionTable_638125835184714960" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis_638125835184714960" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionTable_638125835184714960" xlink:to="us-gaap_BusinessAcquisitionAxis_638125835184714960" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_638125835184714960" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis_638125835184714960" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_638125835184714960" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_AfflovestPMember" xlink:label="tcmd_AfflovestPMember_638125835184714960" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain_638125835184714960" xlink:to="tcmd_AfflovestPMember_638125835184714960" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionLineItems" xlink:label="us-gaap_AssetAcquisitionLineItems_638125835184714960" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionTable_638125835184714960" xlink:to="us-gaap_AssetAcquisitionLineItems_638125835184714960" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:label="us-gaap_BusinessAcquisitionsProFormaRevenue_638125835184714960" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems_638125835184714960" xlink:to="us-gaap_BusinessAcquisitionsProFormaRevenue_638125835184714960" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:label="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_638125835184714960" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems_638125835184714960" xlink:to="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_638125835184714960" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tactilemedical.com/role/DisclosureAccountsReceivableDetails" xlink:type="extended" xlink:title="40501 - Disclosure - Accounts Receivable (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesAbstract" xlink:label="us-gaap_ReceivablesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTable" xlink:label="us-gaap_ConcentrationRiskTable_638125835184714960" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="us-gaap_ConcentrationRiskTable_638125835184714960" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis_638125835184714960" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable_638125835184714960" xlink:to="srt_MajorCustomersAxis_638125835184714960" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain_638125835184714960" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis_638125835184714960" xlink:to="srt_NameOfMajorCustomerDomain_638125835184714960" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_InsuranceCompanyOneMember" xlink:label="tcmd_InsuranceCompanyOneMember_638125835184714960" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain_638125835184714960" xlink:to="tcmd_InsuranceCompanyOneMember_638125835184714960" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_InsuranceCompanyTwoMember" xlink:label="tcmd_InsuranceCompanyTwoMember_638125835184724961" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain_638125835184714960" xlink:to="tcmd_InsuranceCompanyTwoMember_638125835184724961" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_638125835184724961" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable_638125835184714960" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_638125835184724961" order="2" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain_638125835184724961" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis_638125835184724961" xlink:to="us-gaap_ConcentrationRiskTypeDomain_638125835184724961" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember_638125835184724961" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTypeDomain_638125835184724961" xlink:to="us-gaap_CustomerConcentrationRiskMember_638125835184724961" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_638125835184724961" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable_638125835184714960" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_638125835184724961" order="3" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_638125835184724961" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis_638125835184724961" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_638125835184724961" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember" xlink:label="us-gaap_AccountsReceivableMember_638125835184724961" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain_638125835184724961" xlink:to="us-gaap_AccountsReceivableMember_638125835184724961" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember_638125835184724961" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain_638125835184724961" xlink:to="us-gaap_SalesRevenueNetMember_638125835184724961" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="us-gaap_ConcentrationRiskLineItems_638125835184724961" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable_638125835184714960" xlink:to="us-gaap_ConcentrationRiskLineItems_638125835184724961" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetAbstract" xlink:label="us-gaap_AccountsReceivableNetAbstract_638125835184724961" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskLineItems_638125835184724961" xlink:to="us-gaap_AccountsReceivableNetAbstract_638125835184724961" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_ConcentrationRiskNumberOfInsuranceCompanies" xlink:label="tcmd_ConcentrationRiskNumberOfInsuranceCompanies_638125835184724961" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsReceivableNetAbstract_638125835184724961" xlink:to="tcmd_ConcentrationRiskNumberOfInsuranceCompanies_638125835184724961" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1_638125835184724961" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsReceivableNetAbstract_638125835184724961" xlink:to="us-gaap_ConcentrationRiskPercentage1_638125835184724961" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="7" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tactilemedical.com/role/DisclosureInventoriesDetails" xlink:type="extended" xlink:title="40601 - Disclosure - Inventories (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNetAbstract" xlink:label="us-gaap_InventoryNetAbstract_638125835184734962" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryNetAbstract_638125835184734962" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoods" xlink:label="us-gaap_InventoryFinishedGoods_638125835184734962" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryNetAbstract_638125835184734962" xlink:to="us-gaap_InventoryFinishedGoods_638125835184734962" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcess" xlink:label="us-gaap_InventoryWorkInProcess_638125835184734962" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryNetAbstract_638125835184734962" xlink:to="us-gaap_InventoryWorkInProcess_638125835184734962" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet_638125835184734962" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryNetAbstract_638125835184734962" xlink:to="us-gaap_InventoryNet_638125835184734962" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="8" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tactilemedical.com/role/DisclosurePropertyAndEquipmentDetails" xlink:type="extended" xlink:title="40701 - Disclosure - Property and Equipment (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638125835184734962" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638125835184734962" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638125835184734962" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638125835184734962" xlink:to="srt_RangeAxis_638125835184734962" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638125835184734962" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638125835184734962" xlink:to="srt_RangeMember_638125835184734962" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638125835184734962" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638125835184734962" xlink:to="srt_MaximumMember_638125835184734962" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638125835184734962" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638125835184734962" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638125835184734962" order="2" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_638125835184734962" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638125835184734962" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_638125835184734962" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember_638125835184744961" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638125835184734962" xlink:to="us-gaap_EquipmentMember_638125835184744961" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ToolsDiesAndMoldsMember" xlink:label="us-gaap_ToolsDiesAndMoldsMember_638125835184744961" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638125835184734962" xlink:to="us-gaap_ToolsDiesAndMoldsMember_638125835184744961" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember_638125835184744961" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638125835184734962" xlink:to="us-gaap_FurnitureAndFixturesMember_638125835184744961" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdsAndLeaseholdImprovementsMember_638125835184744961" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638125835184734962" xlink:to="us-gaap_LeaseholdsAndLeaseholdImprovementsMember_638125835184744961" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_DemoEquipmentMember" xlink:label="tcmd_DemoEquipmentMember_638125835184744961" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638125835184734962" xlink:to="tcmd_DemoEquipmentMember_638125835184744961" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember_638125835184744961" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638125835184734962" xlink:to="us-gaap_ConstructionInProgressMember_638125835184744961" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_638125835184744961" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638125835184734962" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_638125835184744961" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_638125835184744961" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638125835184744961" xlink:to="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_638125835184744961" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_638125835184744961" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_638125835184744961" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_638125835184744961" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_638125835184744961" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_638125835184744961" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_638125835184744961" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_638125835184744961" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_638125835184744961" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_638125835184744961" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_638125835184744961" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_638125835184744961" xlink:to="us-gaap_Depreciation_638125835184744961" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tactilemedical.com/role/DisclosureGoodwillAndIntangibleAssetsDetails" xlink:type="extended" xlink:title="40801 - Disclosure - Goodwill And Intangible Assets (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_638125835184754961" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_638125835184754961" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis_638125835184754961" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_638125835184754961" xlink:to="us-gaap_BusinessAcquisitionAxis_638125835184754961" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_638125835184754961" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis_638125835184754961" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_638125835184754961" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_AfflovestPMember" xlink:label="tcmd_AfflovestPMember_638125835184754961" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain_638125835184754961" xlink:to="tcmd_AfflovestPMember_638125835184754961" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638125835184754961" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_638125835184754961" xlink:to="srt_RangeAxis_638125835184754961" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638125835184754961" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638125835184754961" xlink:to="srt_RangeMember_638125835184754961" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638125835184754961" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638125835184754961" xlink:to="srt_MaximumMember_638125835184754961" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_638125835184754961" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_638125835184754961" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_638125835184754961" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_638125835184754961" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_638125835184754961" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_638125835184754961" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PatentsMember" xlink:label="us-gaap_PatentsMember_638125835184754961" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_638125835184754961" xlink:to="us-gaap_PatentsMember_638125835184754961" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_DefensiveIntangibleAssetsMember" xlink:label="tcmd_DefensiveIntangibleAssetsMember_638125835184764968" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_638125835184754961" xlink:to="tcmd_DefensiveIntangibleAssetsMember_638125835184764968" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerContractsMember" xlink:label="us-gaap_CustomerContractsMember_638125835184764968" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_638125835184754961" xlink:to="us-gaap_CustomerContractsMember_638125835184764968" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRelationshipsMember" xlink:label="us-gaap_CustomerRelationshipsMember_638125835184764968" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_638125835184754961" xlink:to="us-gaap_CustomerRelationshipsMember_638125835184764968" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="us-gaap_DevelopedTechnologyRightsMember_638125835184764968" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_638125835184754961" xlink:to="us-gaap_DevelopedTechnologyRightsMember_638125835184764968" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_638125835184764968" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_638125835184754961" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_638125835184764968" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_638125835184764968" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_638125835184764968" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_638125835184764968" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeNamesMember" xlink:label="us-gaap_TradeNamesMember_638125835184764968" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_638125835184764968" xlink:to="us-gaap_TradeNamesMember_638125835184764968" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PatentsMember" xlink:label="us-gaap_PatentsMember_638125835184764968" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_638125835184764968" xlink:to="us-gaap_PatentsMember_638125835184764968" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_638125835184764968" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_638125835184754961" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems_638125835184764968" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill_638125835184764968" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems_638125835184764968" xlink:to="us-gaap_Goodwill_638125835184764968" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNetAbstract_638125835184764968" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems_638125835184764968" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNetAbstract_638125835184764968" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:label="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_638125835184774964" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAbstract_638125835184764968" xlink:to="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_638125835184774964" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_638125835184774964" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAbstract_638125835184764968" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_638125835184774964" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_638125835184774964" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAbstract_638125835184764968" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_638125835184774964" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_638125835184774964" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAbstract_638125835184764968" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_638125835184774964" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_638125835184774964" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems_638125835184764968" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_638125835184774964" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_638125835184774964" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_638125835184774964" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_638125835184774964" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsGrossExcludingGoodwill_638125835184774964" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems_638125835184764968" xlink:to="us-gaap_IntangibleAssetsGrossExcludingGoodwill_638125835184774964" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_638125835184774964" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems_638125835184764968" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_638125835184774964" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/netLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets_638125835184774964" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems_638125835184764968" xlink:to="us-gaap_AmortizationOfIntangibleAssets_638125835184774964" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:label="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_638125835184784962" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems_638125835184764968" xlink:to="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_638125835184784962" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_638125835184784962" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_638125835184784962" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_638125835184784962" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_638125835184784962" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_638125835184784962" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_638125835184784962" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_638125835184784962" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_638125835184784962" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_638125835184784962" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_638125835184784962" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_638125835184784962" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_638125835184784962" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_638125835184784962" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_638125835184784962" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_638125835184784962" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_638125835184784962" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_638125835184784962" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_638125835184784962" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_638125835184794964" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_638125835184784962" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_638125835184794964" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tactilemedical.com/role/DisclosureAccruedExpensesDetails" xlink:type="extended" xlink:title="40901 - Disclosure - Accrued Expenses (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_InTransitInventoryAccruedExpense" xlink:label="tcmd_InTransitInventoryAccruedExpense_638125835184794964" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="tcmd_InTransitInventoryAccruedExpense_638125835184794964" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductWarrantyAccrualClassifiedCurrent" xlink:label="us-gaap_ProductWarrantyAccrualClassifiedCurrent_638125835184794964" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_ProductWarrantyAccrualClassifiedCurrent_638125835184794964" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_AccruedTravelAndEntertainmentCurrent" xlink:label="tcmd_AccruedTravelAndEntertainmentCurrent_638125835184794964" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="tcmd_AccruedTravelAndEntertainmentCurrent_638125835184794964" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_638125835184794964" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_638125835184794964" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_AccruedClinicalStudiesExpensesCurrent" xlink:label="tcmd_AccruedClinicalStudiesExpensesCurrent_638125835184794964" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="tcmd_AccruedClinicalStudiesExpensesCurrent_638125835184794964" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_AccruedSalesAndUseTax" xlink:label="tcmd_AccruedSalesAndUseTax_638125835184794964" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="tcmd_AccruedSalesAndUseTax_638125835184794964" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_638125835184794964" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_638125835184794964" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_638125835184794964" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent_638125835184794964" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tactilemedical.com/role/DisclosureWarrantyReservesDetails" xlink:type="extended" xlink:title="41001 - Disclosure - Warranty Reserves (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StandardProductWarrantyDisclosureAbstract" xlink:label="us-gaap_StandardProductWarrantyDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MovementInStandardProductWarrantyAccrualRollForward" xlink:label="us-gaap_MovementInStandardProductWarrantyAccrualRollForward_638125835184804962" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StandardProductWarrantyDisclosureAbstract" xlink:to="us-gaap_MovementInStandardProductWarrantyAccrualRollForward_638125835184804962" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StandardProductWarrantyAccrual" xlink:label="us-gaap_StandardProductWarrantyAccrual_638125835184804962" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MovementInStandardProductWarrantyAccrualRollForward_638125835184804962" xlink:to="us-gaap_StandardProductWarrantyAccrual_638125835184804962" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StandardProductWarrantyAccrualWarrantiesIssued" xlink:label="us-gaap_StandardProductWarrantyAccrualWarrantiesIssued_638125835184804962" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MovementInStandardProductWarrantyAccrualRollForward_638125835184804962" xlink:to="us-gaap_StandardProductWarrantyAccrualWarrantiesIssued_638125835184804962" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StandardProductWarrantyAccrualPayments" xlink:label="us-gaap_StandardProductWarrantyAccrualPayments_638125835184804962" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MovementInStandardProductWarrantyAccrualRollForward_638125835184804962" xlink:to="us-gaap_StandardProductWarrantyAccrualPayments_638125835184804962" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StandardProductWarrantyAccrual" xlink:label="us-gaap_StandardProductWarrantyAccrual_6381258351848049621" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MovementInStandardProductWarrantyAccrualRollForward_638125835184804962" xlink:to="us-gaap_StandardProductWarrantyAccrual_6381258351848049621" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductWarrantyAccrualClassifiedCurrent" xlink:label="us-gaap_ProductWarrantyAccrualClassifiedCurrent_638125835184804962" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MovementInStandardProductWarrantyAccrualRollForward_638125835184804962" xlink:to="us-gaap_ProductWarrantyAccrualClassifiedCurrent_638125835184804962" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductWarrantyAccrualNoncurrent" xlink:label="us-gaap_ProductWarrantyAccrualNoncurrent_638125835184804962" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MovementInStandardProductWarrantyAccrualRollForward_638125835184804962" xlink:to="us-gaap_ProductWarrantyAccrualNoncurrent_638125835184804962" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductWarrantyAccrual" xlink:label="us-gaap_ProductWarrantyAccrual_638125835184804962" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MovementInStandardProductWarrantyAccrualRollForward_638125835184804962" xlink:to="us-gaap_ProductWarrantyAccrual_638125835184804962" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tactilemedical.com/role/DisclosureCreditAgreementDetails" xlink:type="extended" xlink:title="41101 - Disclosure - Credit Agreement (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityTable" xlink:label="us-gaap_LineOfCreditFacilityTable_638125835184804962" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_LineOfCreditFacilityTable_638125835184804962" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis_638125835184814963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityTable_638125835184804962" xlink:to="us-gaap_CreditFacilityAxis_638125835184814963" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain_638125835184814963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis_638125835184814963" xlink:to="us-gaap_CreditFacilityDomain_638125835184814963" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="us-gaap_RevolvingCreditFacilityMember_638125835184814963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain_638125835184814963" xlink:to="us-gaap_RevolvingCreditFacilityMember_638125835184814963" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_TermLoanMember" xlink:label="tcmd_TermLoanMember_638125835184814963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain_638125835184814963" xlink:to="tcmd_TermLoanMember_638125835184814963" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638125835184814963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityTable_638125835184804962" xlink:to="srt_RangeAxis_638125835184814963" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638125835184814963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638125835184814963" xlink:to="srt_RangeMember_638125835184814963" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638125835184814963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638125835184814963" xlink:to="srt_MaximumMember_638125835184814963" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638125835184814963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638125835184814963" xlink:to="srt_MinimumMember_638125835184814963" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis_638125835184814963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityTable_638125835184804962" xlink:to="us-gaap_VariableRateAxis_638125835184814963" order="3" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain_638125835184814963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateAxis_638125835184814963" xlink:to="us-gaap_VariableRateDomain_638125835184814963" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FederalFundsEffectiveSwapRateMember" xlink:label="us-gaap_FederalFundsEffectiveSwapRateMember_638125835184814963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateDomain_638125835184814963" xlink:to="us-gaap_FederalFundsEffectiveSwapRateMember_638125835184814963" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BaseRateMember" xlink:label="us-gaap_BaseRateMember_638125835184814963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateDomain_638125835184814963" xlink:to="us-gaap_BaseRateMember_638125835184814963" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:label="us-gaap_LondonInterbankOfferedRateLIBORMember_638125835184814963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateDomain_638125835184814963" xlink:to="us-gaap_LondonInterbankOfferedRateLIBORMember_638125835184814963" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLineItems" xlink:label="us-gaap_LineOfCreditFacilityLineItems_638125835184824962" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityTable_638125835184804962" xlink:to="us-gaap_LineOfCreditFacilityLineItems_638125835184824962" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_638125835184824962" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems_638125835184824962" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_638125835184824962" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_638125835184824962" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems_638125835184824962" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_638125835184824962" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:label="us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_638125835184824962" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems_638125835184824962" xlink:to="us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_638125835184824962" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCredit" xlink:label="us-gaap_LineOfCredit_638125835184824962" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems_638125835184824962" xlink:to="us-gaap_LineOfCredit_638125835184824962" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount_638125835184824962" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems_638125835184824962" xlink:to="us-gaap_DebtInstrumentFaceAmount_638125835184824962" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_LineOfCreditThresholdContingentIncreaseInBorrowingCapacity" xlink:label="tcmd_LineOfCreditThresholdContingentIncreaseInBorrowingCapacity_638125835184864965" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems_638125835184824962" xlink:to="tcmd_LineOfCreditThresholdContingentIncreaseInBorrowingCapacity_638125835184864965" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_CreditAgreementTotalAggregatePrincipalAmount" xlink:label="tcmd_CreditAgreementTotalAggregatePrincipalAmount_638125835184864965" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems_638125835184824962" xlink:to="tcmd_CreditAgreementTotalAggregatePrincipalAmount_638125835184864965" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt_638125835184864965" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems_638125835184824962" xlink:to="us-gaap_LongTermDebt_638125835184864965" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="us-gaap_DebtInstrumentPeriodicPayment_638125835184864965" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems_638125835184824962" xlink:to="us-gaap_DebtInstrumentPeriodicPayment_638125835184864965" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" xlink:label="us-gaap_DebtInstrumentFrequencyOfPeriodicPayment_638125835184864965" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems_638125835184824962" xlink:to="us-gaap_DebtInstrumentFrequencyOfPeriodicPayment_638125835184864965" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_DebtInstrumentPaymentOfMandatoryPrincipalPrepayment" xlink:label="tcmd_DebtInstrumentPaymentOfMandatoryPrincipalPrepayment_638125835184874964" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems_638125835184824962" xlink:to="tcmd_DebtInstrumentPaymentOfMandatoryPrincipalPrepayment_638125835184874964" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tactilemedical.com/role/DisclosureCreditAgreementMaturitiesOfDebtDetails" xlink:type="extended" xlink:title="41102 - Disclosure - Credit Agreement - Maturities of Debt (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract_3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityTable" xlink:label="us-gaap_LineOfCreditFacilityTable_638125835184874964" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract_3" xlink:to="us-gaap_LineOfCreditFacilityTable_638125835184874964" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis_638125835184874964" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityTable_638125835184874964" xlink:to="us-gaap_CreditFacilityAxis_638125835184874964" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain_638125835184874964" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis_638125835184874964" xlink:to="us-gaap_CreditFacilityDomain_638125835184874964" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_TermLoanMember" xlink:label="tcmd_TermLoanMember_638125835184874964" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain_638125835184874964" xlink:to="tcmd_TermLoanMember_638125835184874964" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLineItems" xlink:label="us-gaap_LineOfCreditFacilityLineItems_638125835184874964" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityTable_638125835184874964" xlink:to="us-gaap_LineOfCreditFacilityLineItems_638125835184874964" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtByMaturityAbstract" xlink:label="us-gaap_LongTermDebtByMaturityAbstract_638125835184874964" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems_638125835184874964" xlink:to="us-gaap_LongTermDebtByMaturityAbstract_638125835184874964" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_638125835184874964" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermDebtByMaturityAbstract_638125835184874964" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_638125835184874964" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_638125835184874964" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermDebtByMaturityAbstract_638125835184874964" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_638125835184874964" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt_638125835184874964" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermDebtByMaturityAbstract_638125835184874964" xlink:to="us-gaap_LongTermDebt_638125835184874964" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesLeaseObligationsDetails" xlink:type="extended" xlink:title="41201 - Disclosure - Commitments and Contingencies - Lease Obligations (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable_638125835184884990" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeLeaseDescriptionTable_638125835184884990" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638125835184884990" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable_638125835184884990" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638125835184884990" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_638125835184884990" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638125835184884990" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_638125835184884990" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingMember" xlink:label="us-gaap_BuildingMember_638125835184884990" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638125835184884990" xlink:to="us-gaap_BuildingMember_638125835184884990" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VehiclesMember" xlink:label="us-gaap_VehiclesMember_638125835184884990" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638125835184884990" xlink:to="us-gaap_VehiclesMember_638125835184884990" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember_638125835184884990" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638125835184884990" xlink:to="us-gaap_EquipmentMember_638125835184884990" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_CorporateHeadQuarterInitialLeaseMember" xlink:label="tcmd_CorporateHeadQuarterInitialLeaseMember_638125835184884990" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638125835184884990" xlink:to="tcmd_CorporateHeadQuarterInitialLeaseMember_638125835184884990" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_CorporateHeadQuarterSecondLeaseMember" xlink:label="tcmd_CorporateHeadQuarterSecondLeaseMember_638125835184884990" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638125835184884990" xlink:to="tcmd_CorporateHeadQuarterSecondLeaseMember_638125835184884990" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_CorporateHeadQuarterThirdLeaseMember" xlink:label="tcmd_CorporateHeadQuarterThirdLeaseMember_638125835184884990" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638125835184884990" xlink:to="tcmd_CorporateHeadQuarterThirdLeaseMember_638125835184884990" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638125835184884990" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable_638125835184884990" xlink:to="srt_RangeAxis_638125835184884990" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638125835184884990" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638125835184884990" xlink:to="srt_RangeMember_638125835184884990" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638125835184894965" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638125835184884990" xlink:to="srt_MinimumMember_638125835184894965" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638125835184894965" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638125835184884990" xlink:to="srt_MaximumMember_638125835184894965" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_638125835184894965" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable_638125835184884990" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_638125835184894965" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_638125835184894965" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638125835184894965" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_638125835184894965" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AreaOfLand" xlink:label="us-gaap_AreaOfLand_638125835184894965" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638125835184894965" xlink:to="us-gaap_AreaOfLand_638125835184894965" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_AdditionalOfficeSpaceAdded" xlink:label="tcmd_AdditionalOfficeSpaceAdded_638125835184894965" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638125835184894965" xlink:to="tcmd_AdditionalOfficeSpaceAdded_638125835184894965" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_NumberOfVehiclesWithAgreementsWithinInitialNoncancelableLeaseTerm" xlink:label="tcmd_NumberOfVehiclesWithAgreementsWithinInitialNoncancelableLeaseTerm_638125835184894965" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638125835184894965" xlink:to="tcmd_NumberOfVehiclesWithAgreementsWithinInitialNoncancelableLeaseTerm_638125835184894965" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_638125835184894965" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638125835184894965" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_638125835184894965" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesLeaseRelatedAssetsAndLiabilitiesDetails" xlink:type="extended" xlink:title="41202 - Disclosure - Commitments and Contingencies - Lease related assets and liabilities (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:label="us-gaap_AssetsAndLiabilitiesLesseeAbstract_638125835184904965" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_AssetsAndLiabilitiesLesseeAbstract_638125835184904965" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_638125835184904965" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAndLiabilitiesLesseeAbstract_638125835184904965" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_638125835184904965" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638125835184904965" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAndLiabilitiesLesseeAbstract_638125835184904965" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638125835184904965" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_638125835184904965" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAndLiabilitiesLesseeAbstract_638125835184904965" xlink:to="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_638125835184904965" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638125835184904965" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAndLiabilitiesLesseeAbstract_638125835184904965" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638125835184904965" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_638125835184904965" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAndLiabilitiesLesseeAbstract_638125835184904965" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_638125835184904965" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638125835184904965" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAndLiabilitiesLesseeAbstract_638125835184904965" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638125835184904965" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_638125835184904965" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAndLiabilitiesLesseeAbstract_638125835184904965" xlink:to="us-gaap_OperatingLeaseLiability_638125835184904965" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_638125835184904965" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAndLiabilitiesLesseeAbstract_638125835184904965" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_638125835184904965" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_638125835184904965" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAndLiabilitiesLesseeAbstract_638125835184904965" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_638125835184904965" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments_638125835184904965" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAndLiabilitiesLesseeAbstract_638125835184904965" xlink:to="us-gaap_OperatingLeasePayments_638125835184904965" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_638125835184904965" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAndLiabilitiesLesseeAbstract_638125835184904965" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_638125835184904965" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesUndiscountedCashFlowsDetails" xlink:type="extended" xlink:title="41203 - Disclosure - Commitments and Contingencies - Undiscounted cash flows (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638125835184914966" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638125835184914966" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638125835184914966" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638125835184914966" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638125835184914966" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638125835184914966" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638125835184914966" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638125835184914966" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_638125835184914966" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638125835184914966" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_638125835184914966" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_638125835184914966" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638125835184914966" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_638125835184914966" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_638125835184914966" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638125835184914966" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_638125835184914966" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_638125835184914966" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638125835184914966" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_638125835184914966" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_638125835184914966" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638125835184914966" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_638125835184914966" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_638125835184914966" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638125835184914966" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_638125835184914966" order="8" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_638125835184914966" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638125835184914966" xlink:to="us-gaap_OperatingLeaseLiability_638125835184914966" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638125835184914966" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638125835184914966" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638125835184914966" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638125835184914966" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638125835184914966" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638125835184914966" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="9" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesLeaseCommitmentsAndOperatingLeaseCostDetails" xlink:type="extended" xlink:title="41204 - Disclosure - Commitments and Contingencies - Lease commitments and operating lease cost (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_638125835184924964" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_638125835184924964" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesMajorVendorsDetails" xlink:type="extended" xlink:title="41205 - Disclosure - Commitments and Contingencies - Major Vendors (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTable" xlink:label="us-gaap_ConcentrationRiskTable_638125835184924964" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_ConcentrationRiskTable_638125835184924964" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_638125835184924964" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable_638125835184924964" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_638125835184924964" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_638125835184924964" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis_638125835184924964" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_638125835184924964" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsTotalMember" xlink:label="us-gaap_CostOfGoodsTotalMember_638125835184924964" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain_638125835184924964" xlink:to="us-gaap_CostOfGoodsTotalMember_638125835184924964" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_638125835184924964" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable_638125835184924964" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_638125835184924964" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain_638125835184934966" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis_638125835184924964" xlink:to="us-gaap_ConcentrationRiskTypeDomain_638125835184934966" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplierConcentrationRiskMember" xlink:label="us-gaap_SupplierConcentrationRiskMember_638125835184934966" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTypeDomain_638125835184934966" xlink:to="us-gaap_SupplierConcentrationRiskMember_638125835184934966" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_638125835184934966" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable_638125835184924964" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_638125835184934966" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_638125835184934966" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_638125835184934966" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_638125835184934966" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_VendorOneMember" xlink:label="tcmd_VendorOneMember_638125835184934966" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_638125835184934966" xlink:to="tcmd_VendorOneMember_638125835184934966" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_VendorTwoMember" xlink:label="tcmd_VendorTwoMember_638125835184934966" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_638125835184934966" xlink:to="tcmd_VendorTwoMember_638125835184934966" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="us-gaap_ConcentrationRiskLineItems_638125835184934966" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable_638125835184924964" xlink:to="us-gaap_ConcentrationRiskLineItems_638125835184934966" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_NumberOfVendors" xlink:label="tcmd_NumberOfVendors_638125835184934966" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskLineItems_638125835184934966" xlink:to="tcmd_NumberOfVendors_638125835184934966" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1_638125835184934966" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskLineItems_638125835184934966" xlink:to="us-gaap_ConcentrationRiskPercentage1_638125835184934966" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesPurchaseCommitmentsDetails" xlink:type="extended" xlink:title="41206 - Disclosure - Commitments and Contingencies - Purchase Commitments (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseObligationFiscalYearMaturityAbstract" xlink:label="us-gaap_PurchaseObligationFiscalYearMaturityAbstract_638125835184944965" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_PurchaseObligationFiscalYearMaturityAbstract_638125835184944965" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:label="us-gaap_PurchaseObligationDueInNextTwelveMonths_638125835184944965" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PurchaseObligationFiscalYearMaturityAbstract_638125835184944965" xlink:to="us-gaap_PurchaseObligationDueInNextTwelveMonths_638125835184944965" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesRetirementPlanDetails" xlink:type="extended" xlink:title="41207 - Disclosure - Commitments and Contingencies - Retirement Plan (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanTable" xlink:label="us-gaap_DefinedContributionPlanTable_638125835184944965" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanTable_638125835184944965" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanNameAxis" xlink:label="us-gaap_RetirementPlanNameAxis_638125835184944965" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanTable_638125835184944965" xlink:to="us-gaap_RetirementPlanNameAxis_638125835184944965" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanNameDomain" xlink:label="us-gaap_RetirementPlanNameDomain_638125835184944965" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RetirementPlanNameAxis_638125835184944965" xlink:to="us-gaap_RetirementPlanNameDomain_638125835184944965" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_DefinedContribution401kRetirementPlanMember" xlink:label="tcmd_DefinedContribution401kRetirementPlanMember_638125835184944965" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RetirementPlanNameDomain_638125835184944965" xlink:to="tcmd_DefinedContribution401kRetirementPlanMember_638125835184944965" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems_638125835184944965" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanTable_638125835184944965" xlink:to="us-gaap_DefinedContributionPlanDisclosureLineItems_638125835184944965" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_638125835184944965" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems_638125835184944965" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_638125835184944965" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesLegalProceedingsDetails" xlink:type="extended" xlink:title="41208 - Disclosure - Commitments and Contingencies - Legal Proceedings (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_637496182701913724" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_LitigationSettlementAgreementAmount" xlink:label="tcmd_LitigationSettlementAgreementAmount_638125835184944965" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_637496182701913724" xlink:to="tcmd_LitigationSettlementAgreementAmount_638125835184944965" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tactilemedical.com/role/DisclosureStockholdersEquitySeriesBPreferredStockDetails" xlink:type="extended" xlink:title="41301 - Disclosure - Stockholders' Equity - Series A &amp; B Preferred Stock (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract_636068670329323643" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable_638125835184954965" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract_636068670329323643" xlink:to="us-gaap_ScheduleOfStockByClassTable_638125835184954965" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_638125835184954965" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_638125835184954965" xlink:to="us-gaap_StatementClassOfStockAxis_638125835184954965" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_638125835184954965" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638125835184954965" xlink:to="us-gaap_ClassOfStockDomain_638125835184954965" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember_638125835184954965" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638125835184954965" xlink:to="us-gaap_SeriesBPreferredStockMember_638125835184954965" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember_638125835184954965" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638125835184954965" xlink:to="us-gaap_SeriesAPreferredStockMember_638125835184954965" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_638125835184954965" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_638125835184954965" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_638125835184954965" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_638125835184954965" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638125835184954965" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_638125835184954965" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember_638125835184954965" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638125835184954965" xlink:to="us-gaap_IPOMember_638125835184954965" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems_638125835184954965" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_638125835184954965" xlink:to="us-gaap_ClassOfStockLineItems_638125835184954965" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_638125835184954965" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638125835184954965" xlink:to="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_638125835184954965" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638125835184954965" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_638125835184954965" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638125835184954965" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare_638125835184964965" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_638125835184954965" xlink:to="us-gaap_SharesIssuedPricePerShare_638125835184964965" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1_638125835184964965" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_638125835184954965" xlink:to="us-gaap_ConversionOfStockSharesConverted1_638125835184964965" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_PreferredStockToCommonStockConversionRatio" xlink:label="tcmd_PreferredStockToCommonStockConversionRatio_638125835184964965" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_638125835184954965" xlink:to="tcmd_PreferredStockToCommonStockConversionRatio_638125835184964965" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_StockIssuedDuringPeriodPriorToCompletionOfInitialOfferingSharesNewIssues" xlink:label="tcmd_StockIssuedDuringPeriodPriorToCompletionOfInitialOfferingSharesNewIssues_638125835184964965" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_638125835184954965" xlink:to="tcmd_StockIssuedDuringPeriodPriorToCompletionOfInitialOfferingSharesNewIssues_638125835184964965" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_StockIssuedDuringPeriodRequiredToFundStockDividendsSharesNewIssues" xlink:label="tcmd_StockIssuedDuringPeriodRequiredToFundStockDividendsSharesNewIssues_638125835184964965" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_638125835184954965" xlink:to="tcmd_StockIssuedDuringPeriodRequiredToFundStockDividendsSharesNewIssues_638125835184964965" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_AccruedCumulativeDividends" xlink:label="tcmd_AccruedCumulativeDividends_638125835184964965" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_638125835184954965" xlink:to="tcmd_AccruedCumulativeDividends_638125835184964965" order="7" use="optional" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfOrdinaryDividends" xlink:label="us-gaap_PaymentsOfOrdinaryDividends_638125835184964965" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_638125835184954965" xlink:to="us-gaap_PaymentsOfOrdinaryDividends_638125835184964965" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockBasedCompensationDetails" xlink:type="extended" xlink:title="41302 - Disclosure - Stockholders' Equity - Stock-Based Compensation (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract_636068732490018874" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638125835184964965" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract_636068732490018874" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638125835184964965" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_638125835184974964" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638125835184964965" xlink:to="us-gaap_PlanNameAxis_638125835184974964" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_638125835184974964" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_638125835184974964" xlink:to="us-gaap_PlanNameDomain_638125835184974964" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_EquityIncentivePlan2016Member" xlink:label="tcmd_EquityIncentivePlan2016Member_638125835184974964" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638125835184974964" xlink:to="tcmd_EquityIncentivePlan2016Member_638125835184974964" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_638125835184974964" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638125835184964965" xlink:to="us-gaap_IncomeStatementLocationAxis_638125835184974964" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_638125835184974964" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_638125835184974964" xlink:to="us-gaap_IncomeStatementLocationDomain_638125835184974964" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember" xlink:label="us-gaap_CostOfSalesMember_638125835184974964" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638125835184974964" xlink:to="us-gaap_CostOfSalesMember_638125835184974964" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingAndMarketingExpenseMember" xlink:label="us-gaap_SellingAndMarketingExpenseMember_638125835184974964" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638125835184974964" xlink:to="us-gaap_SellingAndMarketingExpenseMember_638125835184974964" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_638125835184974964" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638125835184974964" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_638125835184974964" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_638125835184974964" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638125835184974964" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_638125835184974964" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638125835184974964" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638125835184964965" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638125835184974964" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAbstract" xlink:label="us-gaap_ShareBasedCompensationAbstract_638125835184974964" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638125835184974964" xlink:to="us-gaap_ShareBasedCompensationAbstract_638125835184974964" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_638125835184974964" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationAbstract_638125835184974964" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_638125835184974964" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticAnnualIncreaseInSharesReservedAndAvailableForIssuancePercentage" xlink:label="tcmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticAnnualIncreaseInSharesReservedAndAvailableForIssuancePercentage_638125835184974964" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationAbstract_638125835184974964" xlink:to="tcmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticAnnualIncreaseInSharesReservedAndAvailableForIssuancePercentage_638125835184974964" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticAnnualIncreaseInSharesReservedAndAvailableForIssuanceNumber" xlink:label="tcmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticAnnualIncreaseInSharesReservedAndAvailableForIssuanceNumber_638125835184984966" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationAbstract_638125835184974964" xlink:to="tcmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticAnnualIncreaseInSharesReservedAndAvailableForIssuanceNumber_638125835184984966" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638125835184984966" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationAbstract_638125835184974964" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638125835184984966" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_638125835184984966" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationAbstract_638125835184974964" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_638125835184984966" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_638125835184984966" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationAbstract_638125835184974964" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_638125835184984966" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract_638125835184984966" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638125835184974964" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract_638125835184984966" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_638125835184984966" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract_638125835184984966" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_638125835184984966" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails" xlink:type="extended" xlink:title="41303 - Disclosure - Stockholders' Equity - Stock Options and Restricted Stock (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract_636068748695208874" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638125835184984966" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract_636068748695208874" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638125835184984966" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_638125835184994967" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638125835184984966" xlink:to="us-gaap_PlanNameAxis_638125835184994967" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_638125835184994967" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_638125835184994967" xlink:to="us-gaap_PlanNameDomain_638125835184994967" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_EquityIncentivePlan2016Member" xlink:label="tcmd_EquityIncentivePlan2016Member_638125835184994967" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638125835184994967" xlink:to="tcmd_EquityIncentivePlan2016Member_638125835184994967" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis_638125835184994967" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638125835184984966" xlink:to="us-gaap_VestingAxis_638125835184994967" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_638125835184994967" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis_638125835184994967" xlink:to="us-gaap_VestingDomain_638125835184994967" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_638125835184994967" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_638125835184994967" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember_638125835184994967" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_638125835184994967" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_638125835184994967" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_638125835184994967" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638125835184994967" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638125835184984966" xlink:to="us-gaap_AwardTypeAxis_638125835184994967" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638125835184994967" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638125835184994967" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638125835184994967" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638125835184994967" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638125835184994967" xlink:to="us-gaap_EmployeeStockOptionMember_638125835184994967" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_638125835184994967" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638125835184994967" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_638125835184994967" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_TimeBasedRestrictedStockUnitsRsusMember" xlink:label="tcmd_TimeBasedRestrictedStockUnitsRsusMember_638125835184994967" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedStockUnitsRSUMember_638125835184994967" xlink:to="tcmd_TimeBasedRestrictedStockUnitsRsusMember_638125835184994967" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_PerformanceBasedStockSettledRestrictedStockUnitsMember" xlink:label="tcmd_PerformanceBasedStockSettledRestrictedStockUnitsMember_638125835184994967" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedStockUnitsRSUMember_638125835184994967" xlink:to="tcmd_PerformanceBasedStockSettledRestrictedStockUnitsMember_638125835184994967" order="2" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_TwoThousandEighteenAndTwoThousandTwentyPerformanceBasedRestrictedStockUnitsMember" xlink:label="tcmd_TwoThousandEighteenAndTwoThousandTwentyPerformanceBasedRestrictedStockUnitsMember_638125835185004967" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcmd_PerformanceBasedStockSettledRestrictedStockUnitsMember_638125835184994967" xlink:to="tcmd_TwoThousandEighteenAndTwoThousandTwentyPerformanceBasedRestrictedStockUnitsMember_638125835185004967" order="1" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_638125835185004967" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638125835184984966" xlink:to="srt_TitleOfIndividualAxis_638125835185004967" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_638125835185004967" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis_638125835185004967" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_638125835185004967" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember_638125835185004967" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638125835185004967" xlink:to="srt_ChiefExecutiveOfficerMember_638125835185004967" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638125835185004967" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638125835184984966" xlink:to="srt_RangeAxis_638125835185004967" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638125835185004967" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638125835185004967" xlink:to="srt_RangeMember_638125835185004967" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638125835185004967" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638125835185004967" xlink:to="srt_MinimumMember_638125835185004967" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638125835185004967" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638125835185004967" xlink:to="srt_MaximumMember_638125835185004967" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638125835185004967" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638125835184984966" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638125835185004967" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_638125835185004967" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638125835185004967" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_638125835185004967" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermOfPeriod" xlink:label="tcmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermOfPeriod_638125835185014966" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_638125835185004967" xlink:to="tcmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermOfPeriod_638125835185014966" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638125835185014966" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_638125835185004967" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638125835185014966" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice_638125835185014966" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_638125835185004967" xlink:to="us-gaap_SharePrice_638125835185014966" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_StockBasedCompensationExpenseMinimumTargets" xlink:label="tcmd_StockBasedCompensationExpenseMinimumTargets_638125835185014966" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_638125835185004967" xlink:to="tcmd_StockBasedCompensationExpenseMinimumTargets_638125835185014966" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_NumberOfConsecutiveTradingDaysInWhichStockPriceExceedCertainPercentageOfClosingPriceOfCommonStockRequiredForAwardToBeGranted" xlink:label="tcmd_NumberOfConsecutiveTradingDaysInWhichStockPriceExceedCertainPercentageOfClosingPriceOfCommonStockRequiredForAwardToBeGranted_638125835185014966" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_638125835185004967" xlink:to="tcmd_NumberOfConsecutiveTradingDaysInWhichStockPriceExceedCertainPercentageOfClosingPriceOfCommonStockRequiredForAwardToBeGranted_638125835185014966" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_638125835185014966" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_638125835185004967" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_638125835185014966" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_638125835185014966" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_638125835185004967" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_638125835185014966" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_638125835185014966" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_638125835185004967" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_638125835185014966" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_638125835185024967" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_638125835185004967" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_638125835185024967" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_638125835185024967" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_638125835185004967" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_638125835185024967" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_638125835185024967" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_638125835185004967" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_638125835185024967" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_638125835185024967" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_638125835185004967" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_638125835185024967" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsCommonStock" xlink:label="us-gaap_DividendsCommonStock_638125835185024967" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_638125835185004967" xlink:to="us-gaap_DividendsCommonStock_638125835185024967" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_638125835185024967" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_638125835185004967" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_638125835185024967" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_638125835185024967" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_638125835185024967" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_638125835185024967" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_638125835185024967" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_638125835185024967" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_638125835185024967" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_638125835185034967" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_638125835185024967" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_638125835185034967" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_638125835185034967" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_638125835185024967" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_638125835185034967" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638125835185034967" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_638125835185024967" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638125835185034967" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638125835185034967" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_638125835185004967" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638125835185034967" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638125835185034967" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638125835185034967" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638125835185034967" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638125835185034967" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638125835185034967" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638125835185034967" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638125835185044968" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638125835185034967" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638125835185044968" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_638125835185044968" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638125835185034967" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_638125835185044968" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_638125835185044968" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638125835185034967" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_638125835185044968" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638125835185044968" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638125835185034967" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638125835185044968" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638125835185044968" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_638125835185004967" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638125835185044968" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_638125835185044968" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638125835185044968" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_638125835185044968" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_638125835185054968" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638125835185044968" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_638125835185054968" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_638125835185054968" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638125835185044968" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_638125835185054968" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_638125835185054968" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638125835185044968" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_638125835185054968" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_638125835185054968" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638125835185044968" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_638125835185054968" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_638125835185054968" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638125835185044968" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_638125835185054968" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638125835185054968" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_638125835185004967" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638125835185054968" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_638125835185064968" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638125835185054968" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_638125835185064968" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_638125835185064968" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638125835185054968" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_638125835185064968" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_638125835185064968" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638125835185054968" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_638125835185064968" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_638125835185064968" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638125835185054968" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_638125835185064968" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_638125835185064968" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638125835185054968" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_638125835185064968" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_638125835185074977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638125835185054968" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_638125835185074977" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_638125835185074977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638125835185054968" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_638125835185074977" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638125835185074977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638125835185054968" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638125835185074977" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_638125835185074977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_638125835185004967" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_638125835185074977" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_638125835185074977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_638125835185074977" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_638125835185074977" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_638125835185084968" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_638125835185074977" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_638125835185084968" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_638125835185084968" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_638125835185074977" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_638125835185084968" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_638125835185084968" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_638125835185004967" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_638125835185084968" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_638125835185084968" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_638125835185084968" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_638125835185084968" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_6381258351850849681" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_638125835185084968" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_6381258351850849681" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_638125835185094968" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_638125835185084968" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_638125835185094968" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_638125835185094968" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_638125835185084968" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_638125835185094968" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638125835185094968" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_638125835185004967" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638125835185094968" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_638125835185094968" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638125835185094968" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_638125835185094968" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_638125835185104968" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638125835185094968" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_638125835185104968" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_SharebasedcompensationArrangementBySharebasedpaymentAwardEquityInstrumentsOtherThanOptionsModifiedInPeriod" xlink:label="tcmd_SharebasedcompensationArrangementBySharebasedpaymentAwardEquityInstrumentsOtherThanOptionsModifiedInPeriod_638125835185104968" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638125835185094968" xlink:to="tcmd_SharebasedcompensationArrangementBySharebasedpaymentAwardEquityInstrumentsOtherThanOptionsModifiedInPeriod_638125835185104968" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_638125835185104968" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638125835185094968" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_638125835185104968" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod" xlink:label="tcmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod_638125835185104968" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638125835185094968" xlink:to="tcmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod_638125835185104968" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_638125835185104968" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638125835185094968" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_638125835185104968" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_PercentageToEarnPerformanceBasedStockSettledRestrictedStockUnits" xlink:label="tcmd_PercentageToEarnPerformanceBasedStockSettledRestrictedStockUnits_638125835185114968" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638125835185094968" xlink:to="tcmd_PercentageToEarnPerformanceBasedStockSettledRestrictedStockUnits_638125835185114968" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_EstimatedPayoutPercentage" xlink:label="tcmd_EstimatedPayoutPercentage_638125835185114968" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638125835185094968" xlink:to="tcmd_EstimatedPayoutPercentage_638125835185114968" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_638125835185114968" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_638125835185004967" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_638125835185114968" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_638125835185114968" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_638125835185114968" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_638125835185114968" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638125835185124968" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_638125835185114968" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638125835185124968" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_SharebasedcompensationArrangementBySharebasedpaymentAwardEquityInstrumentsOtherThanOptionsModifiedWeightedAverageGrantDateFairValue" xlink:label="tcmd_SharebasedcompensationArrangementBySharebasedpaymentAwardEquityInstrumentsOtherThanOptionsModifiedWeightedAverageGrantDateFairValue_638125835185124968" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_638125835185114968" xlink:to="tcmd_SharebasedcompensationArrangementBySharebasedpaymentAwardEquityInstrumentsOtherThanOptionsModifiedWeightedAverageGrantDateFairValue_638125835185124968" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_638125835185124968" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_638125835185114968" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_638125835185124968" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancellationsWeightedAverageGrantDateFairValue" xlink:label="tcmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancellationsWeightedAverageGrantDateFairValue_638125835185124968" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_638125835185114968" xlink:to="tcmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancellationsWeightedAverageGrantDateFairValue_638125835185124968" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_638125835185134969" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_638125835185114968" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_638125835185134969" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_638125835185134969" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_638125835185004967" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_638125835185134969" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_638125835185134969" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_638125835185134969" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_638125835185134969" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueDeferredAndUnissued" xlink:label="tcmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueDeferredAndUnissued_638125835185134969" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_638125835185134969" xlink:to="tcmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueDeferredAndUnissued_638125835185134969" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tactilemedical.com/role/DisclosureStockholdersEquityEmployeeStockPurchasePlanDetails" xlink:type="extended" xlink:title="41304 - Disclosure - Stockholders' Equity - Employee Stock Purchase Plan (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract_636068770131448656" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable_638125835185144969" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract_636068770131448656" xlink:to="us-gaap_ScheduleOfStockByClassTable_638125835185144969" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_638125835185144969" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_638125835185144969" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_638125835185144969" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_638125835185144969" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638125835185144969" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_638125835185144969" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember_638125835185144969" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638125835185144969" xlink:to="us-gaap_EmployeeStockMember_638125835185144969" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_638125835185144969" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_638125835185144969" xlink:to="us-gaap_PlanNameAxis_638125835185144969" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_638125835185154969" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_638125835185144969" xlink:to="us-gaap_PlanNameDomain_638125835185154969" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_EquityIncentivePlan2016Member" xlink:label="tcmd_EquityIncentivePlan2016Member_638125835185154969" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638125835185154969" xlink:to="tcmd_EquityIncentivePlan2016Member_638125835185154969" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems_638125835185154969" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_638125835185144969" xlink:to="us-gaap_ClassOfStockLineItems_638125835185154969" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_638125835185154969" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638125835185154969" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_638125835185154969" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_EmployeeStockPurchasePlanOfferingPeriodsPeriod" xlink:label="tcmd_EmployeeStockPurchasePlanOfferingPeriodsPeriod_638125835185154969" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638125835185154969" xlink:to="tcmd_EmployeeStockPurchasePlanOfferingPeriodsPeriod_638125835185154969" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_638125835185154969" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638125835185154969" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_638125835185154969" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_IncrementalSharesToBeIssuedPercentage" xlink:label="tcmd_IncrementalSharesToBeIssuedPercentage_638125835185154969" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638125835185154969" xlink:to="tcmd_IncrementalSharesToBeIssuedPercentage_638125835185154969" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_IncrementalShareIncrease" xlink:label="tcmd_IncrementalShareIncrease_638125835185154969" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638125835185154969" xlink:to="tcmd_IncrementalShareIncrease_638125835185154969" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_638125835185154969" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638125835185154969" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_638125835185154969" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_638125835185154969" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638125835185154969" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_638125835185154969" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tactilemedical.com/role/DisclosureRevenueDetails" xlink:type="extended" xlink:title="41401 - Disclosure - Revenue (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable_638125835185164970" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_DisaggregationOfRevenueTable_638125835185164970" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_638125835185164970" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable_638125835185164970" xlink:to="srt_ProductOrServiceAxis_638125835185164970" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_638125835185164970" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_638125835185164970" xlink:to="srt_ProductsAndServicesDomain_638125835185164970" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_FlexitouchSystemMember" xlink:label="tcmd_FlexitouchSystemMember_638125835185164970" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638125835185164970" xlink:to="tcmd_FlexitouchSystemMember_638125835185164970" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_AfflovestMember" xlink:label="tcmd_AfflovestMember_638125835185164970" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638125835185164970" xlink:to="tcmd_AfflovestMember_638125835185164970" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis_638125835185164970" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable_638125835185164970" xlink:to="srt_MajorCustomersAxis_638125835185164970" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain_638125835185164970" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis_638125835185164970" xlink:to="srt_NameOfMajorCustomerDomain_638125835185164970" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_PrivateInsurersMember" xlink:label="tcmd_PrivateInsurersMember_638125835185164970" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain_638125835185164970" xlink:to="tcmd_PrivateInsurersMember_638125835185164970" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_VeteransAdministrationMember" xlink:label="tcmd_VeteransAdministrationMember_638125835185164970" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain_638125835185164970" xlink:to="tcmd_VeteransAdministrationMember_638125835185164970" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_MedicareMember" xlink:label="tcmd_MedicareMember_638125835185164970" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain_638125835185164970" xlink:to="tcmd_MedicareMember_638125835185164970" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_DurableMedicalEquipmentDistributorsMember" xlink:label="tcmd_DurableMedicalEquipmentDistributorsMember_638125835185164970" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain_638125835185164970" xlink:to="tcmd_DurableMedicalEquipmentDistributorsMember_638125835185164970" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638125835185164970" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable_638125835185164970" xlink:to="srt_RangeAxis_638125835185164970" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638125835185164970" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638125835185164970" xlink:to="srt_RangeMember_638125835185164970" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638125835185174978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638125835185164970" xlink:to="srt_MinimumMember_638125835185174978" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638125835185174978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638125835185164970" xlink:to="srt_MaximumMember_638125835185174978" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems_638125835185174978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable_638125835185164970" xlink:to="us-gaap_DisaggregationOfRevenueLineItems_638125835185174978" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638125835185174978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems_638125835185174978" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638125835185174978" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_PercentageOfRevenue" xlink:label="tcmd_PercentageOfRevenue_638125835185174978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems_638125835185174978" xlink:to="tcmd_PercentageOfRevenue_638125835185174978" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesTypeLeaseLeaseIncomeAbstract" xlink:label="us-gaap_SalesTypeLeaseLeaseIncomeAbstract_638125835185174978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems_638125835185174978" xlink:to="us-gaap_SalesTypeLeaseLeaseIncomeAbstract_638125835185174978" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesTypeLeaseRevenue" xlink:label="us-gaap_SalesTypeLeaseRevenue_638125835185174978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SalesTypeLeaseLeaseIncomeAbstract_638125835185174978" xlink:to="us-gaap_SalesTypeLeaseRevenue_638125835185174978" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsSoldSalesTypeLease" xlink:label="us-gaap_CostOfGoodsSoldSalesTypeLease_638125835185174978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SalesTypeLeaseLeaseIncomeAbstract_638125835185174978" xlink:to="us-gaap_CostOfGoodsSoldSalesTypeLease_638125835185174978" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesTypeLeaseSellingProfitLoss" xlink:label="us-gaap_SalesTypeLeaseSellingProfitLoss_638125835185174978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SalesTypeLeaseLeaseIncomeAbstract_638125835185174978" xlink:to="us-gaap_SalesTypeLeaseSellingProfitLoss_638125835185174978" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_RentToPurchaseArrangementsRentalPeriod" xlink:label="tcmd_RentToPurchaseArrangementsRentalPeriod_638125835185174978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SalesTypeLeaseLeaseIncomeAbstract_638125835185174978" xlink:to="tcmd_RentToPurchaseArrangementsRentalPeriod_638125835185174978" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tactilemedical.com/role/DisclosureIncomeTaxesDetails" xlink:type="extended" xlink:title="41501 - Disclosure - Income Taxes (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_636154942059491163" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_IncomeTaxTable" xlink:label="tcmd_IncomeTaxTable_638125835185184978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_636154942059491163" xlink:to="tcmd_IncomeTaxTable_638125835185184978" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis_638125835185184978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcmd_IncomeTaxTable_638125835185184978" xlink:to="us-gaap_IncomeTaxAuthorityAxis_638125835185184978" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_638125835185184978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis_638125835185184978" xlink:to="us-gaap_IncomeTaxAuthorityDomain_638125835185184978" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember_638125835185184978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain_638125835185184978" xlink:to="us-gaap_DomesticCountryMember_638125835185184978" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember_638125835185184978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain_638125835185184978" xlink:to="us-gaap_StateAndLocalJurisdictionMember_638125835185184978" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_IncomeTaxLineItems" xlink:label="tcmd_IncomeTaxLineItems_638125835185184978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcmd_IncomeTaxTable_638125835185184978" xlink:to="tcmd_IncomeTaxLineItems_638125835185184978" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_638125835185184978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcmd_IncomeTaxLineItems_638125835185184978" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit_638125835185184978" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_638125835185184978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcmd_IncomeTaxLineItems_638125835185184978" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_638125835185184978" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_638125835185184978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcmd_IncomeTaxLineItems_638125835185184978" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_638125835185184978" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_638125835185184978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcmd_IncomeTaxLineItems_638125835185184978" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_638125835185184978" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_638125835185194970" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcmd_IncomeTaxLineItems_638125835185184978" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_638125835185194970" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_638125835185194970" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcmd_IncomeTaxLineItems_638125835185184978" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_638125835185194970" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_638125835185194970" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcmd_IncomeTaxLineItems_638125835185184978" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_638125835185194970" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_638125835185194970" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcmd_IncomeTaxLineItems_638125835185184978" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_638125835185194970" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_638125835185194970" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcmd_IncomeTaxLineItems_638125835185184978" xlink:to="us-gaap_IncomeTaxExpenseBenefit_638125835185194970" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_638125835185194970" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcmd_IncomeTaxLineItems_638125835185184978" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_638125835185194970" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_DeferredTaxAssetsOperatingLeaseLiability" xlink:label="tcmd_DeferredTaxAssetsOperatingLeaseLiability_638125835185194970" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_638125835185194970" xlink:to="tcmd_DeferredTaxAssetsOperatingLeaseLiability_638125835185194970" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638125835185194970" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_638125835185194970" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638125835185194970" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_638125835185194970" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_638125835185194970" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_638125835185194970" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_638125835185194970" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_638125835185194970" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_638125835185194970" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_638125835185194970" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_638125835185194970" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_638125835185194970" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves_638125835185204975" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_638125835185194970" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves_638125835185204975" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_638125835185204975" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_638125835185194970" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_638125835185204975" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_DeferredTaxAssetsBusinessCredits" xlink:label="tcmd_DeferredTaxAssetsBusinessCredits_638125835185204975" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_638125835185194970" xlink:to="tcmd_DeferredTaxAssetsBusinessCredits_638125835185204975" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsResearchAndDevelopmentExpenses" xlink:label="tcmd_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsResearchAndDevelopmentExpenses_638125835185204975" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_638125835185194970" xlink:to="tcmd_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsResearchAndDevelopmentExpenses_638125835185204975" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther_638125835185204975" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_638125835185194970" xlink:to="us-gaap_DeferredTaxAssetsOther_638125835185204975" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross_638125835185204975" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_638125835185194970" xlink:to="us-gaap_DeferredTaxAssetsGross_638125835185204975" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_638125835185204975" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_638125835185194970" xlink:to="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_638125835185204975" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_DeferredTaxLiabilitiesRightOfUseAssets" xlink:label="tcmd_DeferredTaxLiabilitiesRightOfUseAssets_638125835185204975" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_638125835185204975" xlink:to="tcmd_DeferredTaxLiabilitiesRightOfUseAssets_638125835185204975" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_638125835185204975" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_638125835185204975" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_638125835185204975" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:label="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_638125835185214970" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_638125835185204975" xlink:to="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_638125835185214970" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="us-gaap_DeferredTaxLiabilitiesOther_638125835185214970" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_638125835185204975" xlink:to="us-gaap_DeferredTaxLiabilitiesOther_638125835185214970" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_638125835185214970" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_638125835185204975" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_638125835185214970" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet_638125835185214970" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_638125835185204975" xlink:to="us-gaap_DeferredTaxAssetsNet_638125835185214970" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet_638125835185214970" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_638125835185204975" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet_638125835185214970" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_638125835185214970" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_638125835185194970" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_638125835185214970" order="13" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_638125835185214970" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcmd_IncomeTaxLineItems_638125835185184978" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_638125835185214970" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638125835185224971" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_638125835185214970" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638125835185224971" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_638125835185224971" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_638125835185214970" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_638125835185224971" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationPercent" xlink:label="tcmd_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationPercent_638125835185224971" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_638125835185214970" xlink:to="tcmd_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationPercent_638125835185224971" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment_638125835185224971" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_638125835185214970" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment_638125835185224971" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_EffectiveIncomeTaxRateReconciliationIncentiveStockOptions" xlink:label="tcmd_EffectiveIncomeTaxRateReconciliationIncentiveStockOptions_638125835185224971" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_638125835185214970" xlink:to="tcmd_EffectiveIncomeTaxRateReconciliationIncentiveStockOptions_638125835185224971" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_EffectiveIncomeTaxRateReconciliationEmployeeStockPurchasePlan" xlink:label="tcmd_EffectiveIncomeTaxRateReconciliationEmployeeStockPurchasePlan_638125835185224971" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_638125835185214970" xlink:to="tcmd_EffectiveIncomeTaxRateReconciliationEmployeeStockPurchasePlan_638125835185224971" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_EffectiveIncomeTaxRateReconciliationFederalBusinessCreditPercent" xlink:label="tcmd_EffectiveIncomeTaxRateReconciliationFederalBusinessCreditPercent_638125835185224971" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_638125835185214970" xlink:to="tcmd_EffectiveIncomeTaxRateReconciliationFederalBusinessCreditPercent_638125835185224971" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_638125835185234971" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_638125835185214970" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_638125835185234971" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_EffectiveIncomeTaxRateReconciliationReturnToProvision" xlink:label="tcmd_EffectiveIncomeTaxRateReconciliationReturnToProvision_638125835185234971" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_638125835185214970" xlink:to="tcmd_EffectiveIncomeTaxRateReconciliationReturnToProvision_638125835185234971" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_638125835185234971" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_638125835185214970" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_638125835185234971" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_EffectiveIncomeTaxRateReconciliationInternalRevenueServiceExam" xlink:label="tcmd_EffectiveIncomeTaxRateReconciliationInternalRevenueServiceExam_638125835185234971" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_638125835185214970" xlink:to="tcmd_EffectiveIncomeTaxRateReconciliationInternalRevenueServiceExam_638125835185234971" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal_638125835185234971" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_638125835185214970" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal_638125835185234971" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_EffectiveIncomeTaxRateReconciliationFederalCarrybackClaimPercent" xlink:label="tcmd_EffectiveIncomeTaxRateReconciliationFederalCarrybackClaimPercent_638125835185234971" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_638125835185214970" xlink:to="tcmd_EffectiveIncomeTaxRateReconciliationFederalCarrybackClaimPercent_638125835185234971" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_EffectiveIncomeTaxRateReconciliationUnrecognizedTaxBenefits" xlink:label="tcmd_EffectiveIncomeTaxRateReconciliationUnrecognizedTaxBenefits_638125835185244972" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_638125835185214970" xlink:to="tcmd_EffectiveIncomeTaxRateReconciliationUnrecognizedTaxBenefits_638125835185244972" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_EffectiveIncomeTaxRateReconciliationExcessTaxBenefitOnNonQualifiedStockOptionsAndRsu" xlink:label="tcmd_EffectiveIncomeTaxRateReconciliationExcessTaxBenefitOnNonQualifiedStockOptionsAndRsu_638125835185244972" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_638125835185214970" xlink:to="tcmd_EffectiveIncomeTaxRateReconciliationExcessTaxBenefitOnNonQualifiedStockOptionsAndRsu_638125835185244972" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_EffectiveIncomeTaxRateReconciliationInterestAndPenaltyPercent" xlink:label="tcmd_EffectiveIncomeTaxRateReconciliationInterestAndPenaltyPercent_638125835185244972" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_638125835185214970" xlink:to="tcmd_EffectiveIncomeTaxRateReconciliationInterestAndPenaltyPercent_638125835185244972" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_638125835185244972" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_638125835185214970" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_638125835185244972" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:label="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_638125835185244972" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcmd_IncomeTaxLineItems_638125835185184978" xlink:to="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_638125835185244972" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits_638125835185244972" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_638125835185244972" xlink:to="us-gaap_UnrecognizedTaxBenefits_638125835185244972" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions" xlink:label="tcmd_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions_638125835185254971" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_638125835185244972" xlink:to="tcmd_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions_638125835185254971" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits_638125835185254971" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_638125835185244972" xlink:to="us-gaap_UnrecognizedTaxBenefits_638125835185254971" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_638125835185254971" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcmd_IncomeTaxLineItems_638125835185184978" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_638125835185254971" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tactilemedical.com/role/DisclosureNetLossIncomePerCommonShareBasicAndDilutedNetLossPerShareDetails" xlink:type="extended" xlink:title="41601 - Disclosure - Net (Loss) Income Per Common Share - Basic and Diluted Net Loss Per Share (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_638125835185264972" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_638125835185264972" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638125835185264972" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638125835185264972" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638125835185264972" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638125835185264972" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_638125835185264972" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasic_638125835185264972" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_638125835185264972" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareDiluted_638125835185264972" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tactilemedical.com/role/DisclosureNetLossIncomePerCommonShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:type="extended" xlink:title="41602 - Disclosure - Net (Loss) Income Per Common Share - Antidilutive Securities Excluded From Computation of Earnings Per Share (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638125835185264972" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638125835185264972" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638125835185264972" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638125835185264972" xlink:to="us-gaap_AwardTypeAxis_638125835185264972" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638125835185264972" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638125835185264972" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638125835185264972" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_638125835185264972" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638125835185264972" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_638125835185264972" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_EmployeeStockPurchasePlanMember" xlink:label="tcmd_EmployeeStockPurchasePlanMember_638125835185264972" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638125835185264972" xlink:to="tcmd_EmployeeStockPurchasePlanMember_638125835185264972" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638125835185264972" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638125835185264972" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638125835185264972" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_638125835185274974" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638125835185264972" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_638125835185274974" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638125835185274974" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638125835185274974" xlink:to="us-gaap_EmployeeStockOptionMember_638125835185274974" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember_638125835185274974" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638125835185274974" xlink:to="us-gaap_PerformanceSharesMember_638125835185274974" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638125835185274974" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638125835185264972" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638125835185274974" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_638125835185274974" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638125835185274974" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_638125835185274974" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tactilemedical.com/role/DisclosureFairValueMeasurementsDetails" xlink:type="extended" xlink:title="41701 - Disclosure - Fair Value Measurements (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract_636232959102466343" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638125835185274974" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract_636232959102466343" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638125835185274974" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638125835185274974" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638125835185274974" xlink:to="srt_RangeAxis_638125835185274974" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638125835185274974" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638125835185274974" xlink:to="srt_RangeMember_638125835185274974" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638125835185274974" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638125835185274974" xlink:to="srt_MaximumMember_638125835185274974" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638125835185274974" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638125835185274974" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638125835185274974" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability_638125835185284976" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638125835185274974" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability_638125835185284976" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tcmd-20221231.xsd#tcmd_BusinessCombinationAdditionalContingentConsiderationLiability" xlink:label="tcmd_BusinessCombinationAdditionalContingentConsiderationLiability_638125835185284976" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638125835185274974" xlink:to="tcmd_BusinessCombinationAdditionalContingentConsiderationLiability_638125835185284976" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tactilemedical.com/role/DisclosureFairValueMeasurementsEarnOutLiabilityDetails" xlink:type="extended" xlink:title="41702 - Disclosure - Fair Value Measurements - Earn out liability (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638125835185284976" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract_1" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638125835185284976" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_638125835185284976" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638125835185284976" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_638125835185284976" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638125835185284976" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_638125835185284976" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638125835185284976" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member_638125835185284976" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638125835185284976" xlink:to="us-gaap_FairValueInputsLevel3Member_638125835185284976" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638125835185284976" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638125835185284976" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638125835185284976" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability_638125835185284976" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638125835185284976" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability_638125835185284976" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:label="us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_638125835185284976" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638125835185284976" xlink:to="us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_638125835185284976" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_638125835185284976" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638125835185284976" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_638125835185284976" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability_6381258351852849761" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638125835185284976" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability_6381258351852849761" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_638125835185294971" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638125835185284976" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_638125835185294971" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tactilemedical.com/role/DisclosureFairValueMeasurementsFairValueHierarchyDetails" xlink:type="extended" xlink:title="41703 - Disclosure - Fair Value Measurements - Fair Value Hierarchy (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract_636232959102466343_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638125835185294971" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract_636232959102466343_1" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638125835185294971" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_638125835185294971" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638125835185294971" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_638125835185294971" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_638125835185294971" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis_638125835185294971" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_638125835185294971" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_638125835185294971" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain_638125835185294971" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_638125835185294971" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_638125835185294971" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638125835185294971" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_638125835185294971" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638125835185294971" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_638125835185294971" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638125835185294971" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member_638125835185294971" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638125835185294971" xlink:to="us-gaap_FairValueInputsLevel3Member_638125835185294971" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638125835185294971" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638125835185294971" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638125835185294971" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability_638125835185294971" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638125835185294971" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability_638125835185294971" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_638125835185304971" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638125835185294971" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_638125835185304971" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139814958466272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Feb. 17, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Document and Entity Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37799<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Tactile Systems Technology, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">41-1801204<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">3701 Wayzata Blvd, Suite 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Minneapolis<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">55416<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">612<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">355-5100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, Par Value $0.001 Per Share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">TCMD<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,250,951<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">GRANT THORNTON LLP <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">248<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Minneapolis, Minnesota<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001027838<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 146,541,485<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139814959406976">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 21,929<span></span>
</td>
<td class="nump">$ 28,229<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">54,826<span></span>
</td>
<td class="nump">49,478<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetInvestmentInLease', window );">Net investment in leases</a></td>
<td class="nump">16,130<span></span>
</td>
<td class="nump">12,482<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">23,124<span></span>
</td>
<td class="nump">19,217<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">3,754<span></span>
</td>
<td class="nump">4,141<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">119,763<span></span>
</td>
<td class="nump">113,547<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsMiscellaneousAbstract', window );"><strong>Non-current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">6,077<span></span>
</td>
<td class="nump">6,750<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right of use operating lease assets</a></td>
<td class="nump">21,322<span></span>
</td>
<td class="nump">23,984<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">50,375<span></span>
</td>
<td class="nump">54,081<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">31,063<span></span>
</td>
<td class="nump">31,063<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcmd_MedicareAccountsReceivableNonCurrent', window );">Accounts receivable, non-current</a></td>
<td class="nump">23,061<span></span>
</td>
<td class="nump">12,847<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non-current assets</a></td>
<td class="nump">3,335<span></span>
</td>
<td class="nump">1,998<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total non-current assets</a></td>
<td class="nump">135,233<span></span>
</td>
<td class="nump">130,723<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">254,996<span></span>
</td>
<td class="nump">244,270<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">9,984<span></span>
</td>
<td class="nump">5,023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Note payable</a></td>
<td class="nump">2,968<span></span>
</td>
<td class="nump">2,960<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcmd_EarnOutCurrent', window );">Earn-out, current</a></td>
<td class="nump">13,050<span></span>
</td>
<td class="nump">3,250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued payroll and related taxes</a></td>
<td class="nump">17,100<span></span>
</td>
<td class="nump">12,139<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">9,240<span></span>
</td>
<td class="nump">5,262<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesCurrent', window );">Income taxes payable</a></td>
<td class="nump">2,336<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">2,500<span></span>
</td>
<td class="nump">2,506<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">7,152<span></span>
</td>
<td class="nump">3,305<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">64,330<span></span>
</td>
<td class="nump">34,461<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Non-current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Revolving line of credit, non-current</a></td>
<td class="nump">24,916<span></span>
</td>
<td class="nump">24,857<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Note payable, non-current</a></td>
<td class="nump">20,979<span></span>
</td>
<td class="nump">26,933<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcmd_EarnOutNonCurrent', window );">Earn-out, non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,950<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductWarrantyAccrualNoncurrent', window );">Accrued warranty reserve, non-current</a></td>
<td class="nump">2,207<span></span>
</td>
<td class="nump">3,108<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesNoncurrent', window );">Income taxes payable, non-current</a></td>
<td class="nump">298<span></span>
</td>
<td class="nump">348<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, non-current</a></td>
<td class="nump">20,866<span></span>
</td>
<td class="nump">23,354<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total non-current liabilities</a></td>
<td class="nump">69,266<span></span>
</td>
<td class="nump">81,582<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">133,596<span></span>
</td>
<td class="nump">116,043<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies (see Note 12)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value, 50,000,000 shares authorized; none issued and outstanding as of December 31, 2022 and December 31, 2021</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value, 300,000,000 shares authorized; 20,252,677 shares issued and outstanding as of December 31, 2022; 19,877,786 shares issued and outstanding as of December 31, 2021</a></td>
<td class="nump">20<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">131,001<span></span>
</td>
<td class="nump">119,962<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">(Accumulated deficit) retained earnings</a></td>
<td class="num">(9,621)<span></span>
</td>
<td class="nump">8,245<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">121,400<span></span>
</td>
<td class="nump">128,227<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 254,996<span></span>
</td>
<td class="nump">$ 244,270<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcmd_EarnOutCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of earn-out liability (due within one year or beyond the operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcmd_EarnOutCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcmd_EarnOutNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of earn-out liability (due after one year or beyond the operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcmd_EarnOutNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcmd_MedicareAccountsReceivableNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of non-current accounts receivable on account of medicare.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcmd_MedicareAccountsReceivableNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetInvestmentInLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of net investment in sales-type and direct financing leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7A<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=SL6953401-111524<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919253-210447<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123420820&amp;loc=SL77919306-209978<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetInvestmentInLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsMiscellaneousAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsMiscellaneousAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductWarrantyAccrualNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and due after one year (or beyond the operating cycle if longer) for estimated claims under standard and extended warranty protection rights granted to customers.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductWarrantyAccrualNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139814958437472">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Consolidated Balance Sheets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">50,000,000<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common shares authorized</a></td>
<td class="nump">300,000,000<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares, issued</a></td>
<td class="nump">20,252,677<span></span>
</td>
<td class="nump">19,877,786<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares, outstanding</a></td>
<td class="nump">20,252,677<span></span>
</td>
<td class="nump">19,877,786<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139814958623984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 246,785<span></span>
</td>
<td class="nump">$ 208,057<span></span>
</td>
<td class="nump">$ 187,130<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Total cost of revenue</a></td>
<td class="nump">70,809<span></span>
</td>
<td class="nump">59,844<span></span>
</td>
<td class="nump">54,320<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">175,976<span></span>
</td>
<td class="nump">148,213<span></span>
</td>
<td class="nump">132,810<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Sales and marketing</a></td>
<td class="nump">106,418<span></span>
</td>
<td class="nump">86,775<span></span>
</td>
<td class="nump">79,634<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">7,088<span></span>
</td>
<td class="nump">5,659<span></span>
</td>
<td class="nump">5,264<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Reimbursement, general and administrative</a></td>
<td class="nump">60,796<span></span>
</td>
<td class="nump">56,802<span></span>
</td>
<td class="nump">51,343<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcmd_AmortizationOfIntangibleAssetsAndEarnOuts', window );">Intangible asset amortization and earn-out</a></td>
<td class="nump">14,432<span></span>
</td>
<td class="nump">739<span></span>
</td>
<td class="nump">197<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">188,734<span></span>
</td>
<td class="nump">149,975<span></span>
</td>
<td class="nump">136,438<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(12,758)<span></span>
</td>
<td class="num">(1,762)<span></span>
</td>
<td class="num">(3,628)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other (expense) income</a></td>
<td class="num">(2,715)<span></span>
</td>
<td class="num">(531)<span></span>
</td>
<td class="nump">1,367<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(15,473)<span></span>
</td>
<td class="num">(2,293)<span></span>
</td>
<td class="num">(2,261)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense (benefit)</a></td>
<td class="nump">2,393<span></span>
</td>
<td class="nump">9,518<span></span>
</td>
<td class="num">(1,641)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss</a></td>
<td class="num">$ (17,866)<span></span>
</td>
<td class="num">$ (11,811)<span></span>
</td>
<td class="num">$ (620)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net loss per common share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare', window );">Basic (in dollars per share)</a></td>
<td class="num">$ (0.89)<span></span>
</td>
<td class="num">$ (0.60)<span></span>
</td>
<td class="num">$ (0.03)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare', window );">Diluted (in dollars per share)</a></td>
<td class="num">$ (0.89)<span></span>
</td>
<td class="num">$ (0.60)<span></span>
</td>
<td class="num">$ (0.03)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcmd_EarningsPerShareOtherDisclosureAbstract', window );"><strong>Weighted-average common shares used to compute net loss per common share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">20,067,969<span></span>
</td>
<td class="nump">19,719,485<span></span>
</td>
<td class="nump">19,346,929<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">20,067,969<span></span>
</td>
<td class="nump">19,719,485<span></span>
</td>
<td class="nump">19,346,929<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Sales revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 211,345<span></span>
</td>
<td class="nump">$ 177,914<span></span>
</td>
<td class="nump">$ 161,497<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Total cost of revenue</a></td>
<td class="nump">59,619<span></span>
</td>
<td class="nump">50,222<span></span>
</td>
<td class="nump">45,309<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">151,726<span></span>
</td>
<td class="nump">127,692<span></span>
</td>
<td class="nump">116,188<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=tcmd_RentalProductServiceMember', window );">Rental revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">35,440<span></span>
</td>
<td class="nump">30,143<span></span>
</td>
<td class="nump">25,633<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Total cost of revenue</a></td>
<td class="nump">11,190<span></span>
</td>
<td class="nump">9,622<span></span>
</td>
<td class="nump">9,011<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">$ 24,250<span></span>
</td>
<td class="nump">$ 20,521<span></span>
</td>
<td class="nump">$ 16,622<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcmd_AmortizationOfIntangibleAssetsAndEarnOuts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment of intangible asset and earn outs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcmd_AmortizationOfIntangibleAssetsAndEarnOuts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcmd_EarningsPerShareOtherDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>n/a</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcmd_EarningsPerShareOtherDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 18: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868656-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868656-224227<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total amount of expenses directly related to the marketing or selling of products or services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=tcmd_RentalProductServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=tcmd_RentalProductServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139814958442416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Consolidated Statements of Comprehensive Loss</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (17,866)<span></span>
</td>
<td class="num">$ (11,811)<span></span>
</td>
<td class="num">$ (620)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive loss</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized loss on marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1', window );">Income tax related to items of other comprehensive loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Total other comprehensive loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(26)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (17,866)<span></span>
</td>
<td class="num">$ (11,811)<span></span>
</td>
<td class="num">$ (646)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) allocated to other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139814959011152">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>(Accumulated Deficit) Retained Earnings</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balances at the beginning at Dec. 31, 2019</a></td>
<td class="nump">$ 19<span></span>
</td>
<td class="nump">$ 91,874<span></span>
</td>
<td class="nump">$ 20,676<span></span>
</td>
<td class="nump">$ 26<span></span>
</td>
<td class="nump">$ 112,595<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balances at the beginning (in shares) at Dec. 31, 2019</a></td>
<td class="nump">19,152,715<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,689<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,689<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of common stock options and vesting of performance and restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,068<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,068<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of common stock options and vesting of performance and restricted stock units (in shares)</a></td>
<td class="nump">303,709<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther', window );">Taxes paid for net share settlement of performance and restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,854)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,854)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcmd_AdjustmentsToAdditionalPaidInCapitalSharesOther', window );">Taxes paid for net share settlement of performance and restricted stock units (in shares)</a></td>
<td class="num">(37,790)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Common shares issued for employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,898<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,898<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Common shares issued for employee stock purchase plan (in shares)</a></td>
<td class="nump">74,084<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss for the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(620)<span></span>
</td>
<td class="num">$ (26)<span></span>
</td>
<td class="num">(646)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balances at the end at Dec. 31, 2020</a></td>
<td class="nump">$ 19<span></span>
</td>
<td class="nump">104,675<span></span>
</td>
<td class="nump">20,056<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">124,750<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balances at the end (in shares) at Dec. 31, 2020</a></td>
<td class="nump">19,492,718<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,173<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,173<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of common stock options and vesting of performance and restricted stock units</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">3,975<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,976<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of common stock options and vesting of performance and restricted stock units (in shares)</a></td>
<td class="nump">333,763<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther', window );">Taxes paid for net share settlement of performance and restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,173)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,173)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcmd_AdjustmentsToAdditionalPaidInCapitalSharesOther', window );">Taxes paid for net share settlement of performance and restricted stock units (in shares)</a></td>
<td class="num">(22,357)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Common shares issued for employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,312<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,312<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Common shares issued for employee stock purchase plan (in shares)</a></td>
<td class="nump">73,662<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss for the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,811)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,811)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balances at the end at Dec. 31, 2021</a></td>
<td class="nump">$ 20<span></span>
</td>
<td class="nump">119,962<span></span>
</td>
<td class="nump">8,245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">128,227<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balances at the end (in shares) at Dec. 31, 2021</a></td>
<td class="nump">19,877,786<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of common stock options and vesting of performance and restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">153<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">153<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of common stock options and vesting of performance and restricted stock units (in shares)</a></td>
<td class="nump">225,282<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Common shares issued for employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,286<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,286<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Common shares issued for employee stock purchase plan (in shares)</a></td>
<td class="nump">149,609<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss for the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(17,866)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(17,866)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balances at the end at Dec. 31, 2022</a></td>
<td class="nump">$ 20<span></span>
</td>
<td class="nump">$ 131,001<span></span>
</td>
<td class="num">$ (9,621)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 121,400<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balances at the end (in shares) at Dec. 31, 2022</a></td>
<td class="nump">20,252,677<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcmd_AdjustmentsToAdditionalPaidInCapitalSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share issued related to tax settlement of restricted stock units</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcmd_AdjustmentsToAdditionalPaidInCapitalSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other increase (decrease) in additional paid in capital (APIC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139814959495680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInContinuingOperationsAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (17,866)<span></span>
</td>
<td class="num">$ (11,811)<span></span>
</td>
<td class="num">$ (620)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">6,268<span></span>
</td>
<td class="nump">3,681<span></span>
</td>
<td class="nump">2,794<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcmd_AmortizationOfPremiumsAndDiscountsOnSecuritiesAvailableForSale', window );">Net amortization of premiums and discounts on securities available-for-sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(91)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes', window );">Deferred income taxes</a></td>
<td class="num">(32)<span></span>
</td>
<td class="nump">10,230<span></span>
</td>
<td class="num">(1,233)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">9,600<span></span>
</td>
<td class="nump">10,173<span></span>
</td>
<td class="nump">10,689<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesGainLoss', window );">Gain on other investments and maturities of marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Loss on disposal of property and equipment and intangibles</a></td>
<td class="nump">20<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueAdjustment', window );">Change in fair value of earn-out liability</a></td>
<td class="nump">11,850<span></span>
</td>
<td class="num">(200)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities, net of acquisition:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(5,348)<span></span>
</td>
<td class="num">(5,629)<span></span>
</td>
<td class="num">(10,405)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcmd_IncreaseDecreaseInNetInvestmentInLease', window );">Net investment in leases</a></td>
<td class="num">(3,648)<span></span>
</td>
<td class="num">(1,774)<span></span>
</td>
<td class="num">(2,561)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="num">(3,907)<span></span>
</td>
<td class="nump">972<span></span>
</td>
<td class="nump">318<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable', window );">Income taxes</a></td>
<td class="nump">2,270<span></span>
</td>
<td class="num">(2,294)<span></span>
</td>
<td class="nump">1,972<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="num">(950)<span></span>
</td>
<td class="num">(1,489)<span></span>
</td>
<td class="num">(528)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcmd_IncreaseDecreaseInOperatingLeaseRightOfUseAsset', window );">Right of use operating lease assets</a></td>
<td class="nump">168<span></span>
</td>
<td class="nump">614<span></span>
</td>
<td class="nump">559<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerAsset', window );">Accounts receivable, non-current</a></td>
<td class="num">(10,214)<span></span>
</td>
<td class="num">(3,414)<span></span>
</td>
<td class="num">(5,249)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">4,961<span></span>
</td>
<td class="nump">826<span></span>
</td>
<td class="nump">337<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Accrued payroll and related taxes</a></td>
<td class="nump">4,961<span></span>
</td>
<td class="nump">551<span></span>
</td>
<td class="nump">1,490<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcmd_IncreaseDecreaseInOtherAccruedLiabilitiesAndIncomeTaxesPayable', window );">Accrued expenses and other liabilities</a></td>
<td class="nump">7,076<span></span>
</td>
<td class="nump">2,175<span></span>
</td>
<td class="nump">1,308<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="nump">5,209<span></span>
</td>
<td class="nump">2,631<span></span>
</td>
<td class="nump">2,794<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities', window );">Proceeds from maturities of securities available-for-sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcmd_PaymentsToAcquireProductiveAsset', window );">Payments related to acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(79,829)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(1,780)<span></span>
</td>
<td class="num">(2,103)<span></span>
</td>
<td class="num">(2,059)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from sale of property and equipment</a></td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Intangible assets expenditures</a></td>
<td class="num">(140)<span></span>
</td>
<td class="num">(252)<span></span>
</td>
<td class="num">(232)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireOtherInvestments', window );">Other investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(30)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash (used in) provided by investing activities</a></td>
<td class="num">(1,909)<span></span>
</td>
<td class="num">(82,184)<span></span>
</td>
<td class="nump">20,179<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from issuance of note payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Proceeds from revolving line of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities', window );">Payment on earn-out</a></td>
<td class="num">(5,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Payments on note payable</a></td>
<td class="num">(6,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payments of deferred debt issuance costs</a></td>
<td class="num">(39)<span></span>
</td>
<td class="num">(188)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcmd_PaymentOfTaxesForNetShareSettlementOfRestrictedStockUnits', window );">Taxes paid for net share settlement of performance and restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,173)<span></span>
</td>
<td class="num">(1,854)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of common stock options</a></td>
<td class="nump">153<span></span>
</td>
<td class="nump">3,976<span></span>
</td>
<td class="nump">1,068<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the issuance of common stock from the employee stock purchase plan</a></td>
<td class="nump">1,286<span></span>
</td>
<td class="nump">2,312<span></span>
</td>
<td class="nump">2,898<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash (used in) provided by financing activities</a></td>
<td class="num">(9,600)<span></span>
</td>
<td class="nump">59,927<span></span>
</td>
<td class="nump">2,112<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net (decrease) increase in cash and cash equivalents</a></td>
<td class="num">(6,300)<span></span>
</td>
<td class="num">(19,626)<span></span>
</td>
<td class="nump">25,085<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents - beginning of period</a></td>
<td class="nump">28,229<span></span>
</td>
<td class="nump">47,855<span></span>
</td>
<td class="nump">22,770<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents - end of period</a></td>
<td class="nump">21,929<span></span>
</td>
<td class="nump">28,229<span></span>
</td>
<td class="nump">47,855<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental cash flow disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">2,186<span></span>
</td>
<td class="nump">130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Cash paid for taxes</a></td>
<td class="nump">44<span></span>
</td>
<td class="nump">1,593<span></span>
</td>
<td class="nump">543<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1', window );">Capital expenditures incurred but not yet paid</a></td>
<td class="nump">$ 38<span></span>
</td>
<td class="nump">$ 23<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcmd_AmortizationOfPremiumsAndDiscountsOnSecuritiesAvailableForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net amortization of premiums and discounts on securities available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcmd_AmortizationOfPremiumsAndDiscountsOnSecuritiesAvailableForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcmd_IncreaseDecreaseInNetInvestmentInLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the increase (decrease) in net investment in leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcmd_IncreaseDecreaseInNetInvestmentInLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcmd_IncreaseDecreaseInOperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the increase (decrease) in right of use operating lease assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcmd_IncreaseDecreaseInOperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcmd_IncreaseDecreaseInOtherAccruedLiabilitiesAndIncomeTaxesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other expenses (excluding accrued payroll and related taxes) and income taxes payable incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcmd_IncreaseDecreaseInOtherAccruedLiabilitiesAndIncomeTaxesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcmd_PaymentOfTaxesForNetShareSettlementOfRestrictedStockUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for taxes paid for net share settlement of restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcmd_PaymentOfTaxesForNetShareSettlementOfRestrictedStockUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcmd_PaymentsToAcquireProductiveAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcmd_PaymentsToAcquireProductiveAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in income taxes receivable, which represents the amount due from tax authorities for refunds of overpayments or recoveries of income taxes paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInIncomeTaxesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of addition (reduction) to the amount at which a liability could be incurred (settled) in a current transaction between willing parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized and realized gain (loss) on investment in marketable security, including other-than-temporary impairment (OTTI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of an asset or business acquired in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireOtherInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireOtherInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3151-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139814964354208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Business and Operations<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcmd_NatureOfBusinessAndOperationAbstract', window );"><strong>Nature of Business and Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Nature of Business and Operations</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Note 1. &#160;Nature of Business and Operations</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Tactile Systems Technology, Inc. (&#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221;) manufactures and distributes medical devices for the treatment of patients with underserved chronic diseases at home. We provide our Flexitouch and Entre systems, which help control symptoms of lymphedema, a chronic progressive medical condition, through our direct sales force for use in the home and sell or rent them through vascular, wound and lymphedema clinics throughout the United States. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On September 8, 2021, we acquired the assets of the AffloVest airway clearance business (&#8220;AffloVest Acquisition&#8221;) from International Biophysics Corporation (&#8220;IBC&#8221;), a privately-held company which developed and manufactured AffloVest. AffloVest is a portable, wearable vest that treats patients with chronic respiratory conditions. We sell this device through home medical equipment and durable medical equipment (&#8220;DME&#8221;) providers throughout the United States.&#160;</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We were originally incorporated in Minnesota under the name Tactile Systems Technology, Inc. on January&#160;30, 1995. During 2006, we established a merger corporation and subsequently, on July&#160;21, 2006, merged with and into this merger corporation, resulting in us being reincorporated as a Delaware corporation. The resulting corporation assumed the name Tactile Systems Technology, Inc. In September 2013, we began doing business as &#8220;Tactile Medical.&#8221;</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On August 2, 2016, we closed the initial public offering of our common stock, which resulted in the sale of 4,120,000 shares of our common stock at a public offering price of $10.00 per share. We received net proceeds from the initial public offering of approximately $35.4 million, after deducting underwriting discounts and approximately $2.9 million of transaction expenses.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;margin:0pt;">Our business is affected by seasonality. In the first quarter of each year, when most patients have started a new insurance year and have not yet met their annual out-of-pocket payment obligations, we experience substantially reduced demand for our products. We typically experience higher revenue in the third and fourth quarters of the year when patients have met their annual insurance deductibles, thereby reducing their out-of-pocket costs for our products, and because patients desire to exhaust their flexible spending accounts at year end. This seasonality applies only to purchases and rentals of our products by patients covered by commercial insurance and is not relevant to Medicare, Medicaid or the Veterans Administration, as those payers either do not have plans that have declining deductibles over the course of the plan year and/or do not have plans that include patient deductibles for purchases or rentals of our products. Further, seasonality trends have been, and may continue to be, different than historical trends as a result of the COVID-19 pandemic and related impacts.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcmd_NatureOfBusinessAndOperationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>n/a</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcmd_NatureOfBusinessAndOperationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139815041672944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Basis of Presentation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Note 2. &#160;Basis of Presentation</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) and pursuant to the rules and regulations of the SEC. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The results for the year ended December&#160;31,&#160;2022, are not necessarily indicative of results to be expected for any future year.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Principles of Consolidation</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our accompanying consolidated financial statements include the accounts of Tactile Systems Technology, Inc. and its wholly owned subsidiary, Swelling Solutions, Inc. All intercompany balances and transactions have been eliminated in consolidation.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Risks and Uncertainties</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:14pt;text-align:justify;background:#ffffff;margin:2pt 0pt 0pt 0pt;"><i style="font-style:italic;">Coronavirus (COVID-19)</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:14pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">The United States economy in general and our business specifically have been negatively affected by the COVID-19 pandemic. We have seen adverse impacts as it relates to the decline in the number of patients that healthcare facilities and clinics are able to treat due to enhanced safety protocols, particularly during 2020, most of 2021 and the first quarter of 2022. We have also seen staffing challenges, both in our organization and at the clinics we serve, as another lingering consequence of the COVID-19 pandemic. While we saw some level of recovery in 2022, ongoing consequences of the pandemic remain uncertain. There are no reliable estimates of how long the pandemic will last, whether any recovery will be sustained or will reverse course, the severity of any resurgence of COVID-19 or variant strains of the virus, the effectiveness of vaccines and attitudes towards receiving them, or what ultimate effects the pandemic will have. For that reason, we are unable to reasonably estimate the long-term impact of the pandemic on our business at this time. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">Since the onset of COVID-19, we have remained proactive to adapt to the needs of our employees, clinicians and patients. We cannot assure you that these changes to our processes and practices will be successful in mitigating the impact of COVID-19 on our business. We continue to evaluate and, if appropriate, will adopt other measures in the future related to the ongoing safety of our employees, clinicians and patients.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:14pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Use of Estimates</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and to disclose contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Comprehensive Loss</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="color:#2b2c2b;">Comprehensive loss reflects the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. Our comprehensive loss represents net loss adjusted for unrealized gains and losses on available-for-sale marketable securities and the related taxes.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139815041602896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Note 3. &#160;Summary of Significant Accounting Policies</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Cash and Cash Equivalents</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Cash and cash equivalents consist of all cash on hand and deposits. Our cash was held primarily in checking accounts as of December 31, 2022 and 2021.<b style="font-weight:bold;"> </b>At times the amount of cash on deposit may exceed the federally insured limit of the bank. Deposit accounts at each of the institutions are insured up to $250,000&#160;by the Federal Deposit Insurance Corporation (FDIC). At December 31, 2022 and 2021, the Company exceeded&#160;FDIC&#160;limits at various institutions. The Company has not experienced any losses in such accounts and believes there is little to no exposure to any significant credit risk.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Equity Investments</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="color:#2b2c2b;">Equity investments (including equity securities) with readily determinable fair value are reported at fair value, with unrealized gains and losses included in the determination of net loss. For equity investments with no readily determinable fair value, we measure these investments at cost less impairment, if any, plus or minus </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="color:#2b2c2b;">changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. Such observable price changes may include instances where the investee issues equity securities to new investors, thus creating a new indicator of fair value, as an example. As of each of December&#160;31,&#160;2022 and 2021, the total carrying value of our equity investments, with no readily determinable fair value, was </span><span style="color:#2b2c2b;">$0.3</span><span style="color:#2b2c2b;"> million, and are included in other non-current assets on our Consolidated Balance Sheets. On an annual basis, we perform a qualitative assessment considering impairment indicators to evaluate whether these investments are impaired and also monitor for any observable price changes. During the years ended December&#160;31,&#160;2022 and 2021, we did not have any impairment loss on these investments. </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Accounts Receivable</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The majority of our accounts receivable and revenue are from commercial insurance payers and government payers, such as Medicare, the Veterans Administration and Medicaid.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Accounts receivable are recorded based on management&#8217;s assessment of the expected consideration to be received, based on a detailed review of historical pricing adjustments and collections. Management relies on the results of the assessment, which includes payment history of the applicable payer as well as historical patient collections, as a primary source of information in estimating the collectability of our accounts receivable. We update our assessment on a quarterly basis, which to date has not resulted in any material adjustments to the valuation of our accounts receivable. We believe the assessment provides reasonable estimates of our accounts receivable valuation, and therefore we believe that substantially all accounts receivable are fully collectible. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A portion of our claims to Medicare are initially denied and enter the appeals process, where many are ultimately reviewed by an Administrative Law Judge. After final adjudication of all claims, approximately 90% of the claims submitted are approved (this is on a number of claims, not a dollars claimed, basis across all our products). The appeals process can be lengthy, lasting more than a year in most cases. Accordingly, we classify a portion of our Medicare accounts receivable as non-current based on our experience with Medicare collections.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Inventories</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Inventories are valued at the lower of cost (first-in, first-out method) or net realizable value.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Property and Equipment</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Property and equipment are stated at cost and are depreciated using the straight-line method over their estimated useful lives of <span style="-sec-ix-hidden:Hidden_-K2S-WgBSE6sH7tBYgqsYw;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">three</span></span> to seven years. Leasehold improvements are depreciated over the remaining life of the respective building lease agreement. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Major expenditures for property and equipment are capitalized. Maintenance, repairs and minor renewals are expensed as incurred. When assets are retired or otherwise disposed of, their costs and related accumulated depreciation are removed from the accumulated depreciation accounts and the resulting gains or losses are included in income. The value of demonstration equipment in the possession of our field sales representatives is capitalized and depreciated over the estimated useful life of the equipment. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Revenue Recognition</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We derive revenue from the sales and rentals of our Flexitouch and Entre systems, and from the sales of our AffloVest.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Flexitouch and Entre</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We recognize revenue when control of the product has been transferred to our customer, in the amount of the expected consideration to be received for the product. In general, revenue from the sale or rental of a product is recognized upon shipment, unless circumstances dictate that control has not yet passed to the customer. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We provide a warranty for these products against defects in material and workmanship for a period of <span style="-sec-ix-hidden:Hidden_y-RzrDjl6U6YAkZa8g5tjg;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">one</span></span> to five years on garments and <span style="-sec-ix-hidden:Hidden_2vCz5hZwoEmnfJJOj_Lktg;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">one</span></span> to two years on controllers. In accordance with applicable accounting guidance, we have determined these were assurance warranties and therefore not considered a performance obligation. In addition, we did not evaluate immaterial promised goods or services in the context of the contract. As a result, the sale or rental of these products represent a single performance obligation that is satisfied at a point in time and is short-term in nature. In certain cases, we receive payment from Medicare sales over a period of time that may exceed one year. Despite these extended payment terms, no significant financing component is deemed to exist as the terms are not for the benefit of the patient with whom we have the contract. Rather, the extended payment terms occur as a result of an initial claim denial, which subsequently enters the Medicare appeals process as noted below. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We commercially distribute these products directly to patients who are referred to us by physicians, therapists or nurses. In most cases, there is a third-party payer, such as a commercial insurer, Medicare or the Veterans Administration, involved with the transaction. Our contractual relationship resides with the patient when the third-party payer is either a commercial insurer or Medicare and with the Veterans Administration if the patient is covered under their services. Revenue is recognized from such sales upon transfer of control of the product to the customer at a transaction price determined by collection history. As a result, the transaction price is impacted by multiple factors, including the terms and conditions contracted by various third-party payers, and therefore payments from third-party payers typically are less than our standard charge and represent an implicit price concession, resulting in variable consideration. As most contracts are with each individual sale to a patient, we have elected the portfolio approach to determine the transaction price, and ultimately the expected consideration. The portfolios used to determine transaction price are at the payer level, with pricing for each payer assessed based on the underlying similar characteristics. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For any of our products sold to patients covered by private payers, such as commercial insurance companies, revenue is recognized upon shipment. A product is not shipped until we have received a prescription from a physician for our products and, as applicable, receipt of prior authorization from payers. At shipment, we invoice the payer for the total product price, and we recognize revenue in the amount of cash consideration anticipated to be received based on the transaction price. After the insurance payer has remitted payment, we separately invoice the patient for their portion of the payment obligation, such as copayments and deductibles. The transaction price is determined based on the payment history of the applicable payer drawn from actual write-off and collections experience from the payer over a rolling 12-month period, as well as historical patient collections. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For our products sold to Medicare patients, we recognize revenue from such sales upon shipment of our products, which can occur only after we have received a prescription from a physician and all applicable patient documentation is obtained. The transaction price for our Entre systems is determined based on the payment history using the same methodology as our private insurers. A portion of our claims for our Flexitouch system are initially denied, and enter the appeals process, which can be lengthy. We assess the variable consideration for each of these claims as a percentage of the total invoice price based on ultimate approval and collection history. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For our products sold to the Veterans Administration on behalf of the patient, our contract is with the Veterans Administration rather than the patient. We enter into individual sales contracts with the Veterans Administration on behalf of each patient. These contracts determine the amount of consideration, which is typically paid in full within <span style="-sec-ix-hidden:Hidden_29m0XALLYEGpUDkg67Logg;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">2</span></span>-3 days of shipment, and therefore there is no implicit price concession. In addition, the contracts provide for the right of control to transfer to the Veterans Administration upon delivery of the product to the patient, at which time revenue is recognized.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We incur incremental costs that directly relate to the sales of our products; however, as the amortization period would be less than one year, we have elected the practical expedient to expense these costs as incurred.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We sell and rent these products either directly to patients or the Veterans Administration on behalf of patients, who are referred to us by physicians, therapists or nurses. We bill private insurers and other payers, Medicare, and the Veterans Administration directly for purchases or rentals of our product on behalf of a patient and bill patients directly for their cost-sharing amounts, including any portion of an unsatisfied deductible and any copayments or co-insurance obligation. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A portion of our revenue is derived from patients who obtain our products under multiple-month rental arrangements. We bill these patients&#8217; insurance payers monthly over the duration of the rental term. Title to these products passes to the patients at the end of the rental period. Rental agreements are recorded as sales-type leases in accordance with Accounting Standards Update (&#8220;ASU&#8221;) No.&#160;2016-02, &#8220;Leases&#8221; (Topic 842) (&#8220;ASC 842&#8221;). Accordingly, as sales-type leases, the transaction price for the entire rental term is recognized upon transfer of control. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">AffloVest</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The AffloVest device is sold through durable medical equipment providers. Revenue is recognized when control of the promised goods or services is transferred to the distributors, in an amount that reflects the consideration we expect to be entitled to in exchange for transferring those goods or providing services. We account for a contract when it has approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance and collectability of consideration is probable. When determining whether the distributor has obtained control of the goods or services, we consider any future performance obligations. Generally, there is no post-shipment obligation on products sold other than warranty obligations in the normal and ordinary course of business. Consequently, revenue from the sale of the AffloVest product is recognized at shipment, unless circumstances dictate that control has not yet passed to the distributor.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Certain of our contracts include volume-based incentives which involve rebates that are negotiated at or prior to the time of sale with the customer and are redeemable only if the customer achieves a specified cumulative level of sales or sales increase. Under these incentive programs, at the time of sale, we determine the most likely amount of the rebate to be paid based on forecasted sales levels. These forecasts are updated at least quarterly for applicable customers, and the transaction price is reduced for the anticipated cost of the rebate. If the forecasted sales for a customer change, the accrual for rebates is adjusted to reflect the new rebates expected to be earned by the customer.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Amounts billed to customers for shipping and handling activities after the customer obtains control are treated as a promised service performance obligation and recorded in revenue in the accompanying Consolidated Statements of Operations. Shipping and handling costs incurred for the delivery of goods to customers are considered a cost to fulfill the contract and are included in cost of revenue sold in the accompanying Consolidated Statements of Operations.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We provide a warranty for the AffloVest products against defects in material and workmanship for a period of five years. In accordance with applicable accounting guidance, we have determined these were assurance warranties and therefore not considered a performance obligation. In addition, we did not evaluate immaterial promised goods or services in the context of the contract. As a result, the sale of these products represents a single performance obligation that is satisfied at a point in time and is short-term in nature.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Advertising</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Advertising costs are charged to operations when incurred. Advertising expense was $0.1 million for each of the years ended December&#160;31,&#160;2022, 2021 and 2020.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Research and Development Costs</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We expense research and development costs as incurred, including expenses associated with clinical research studies and development.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Shipping and Handling Costs</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Amounts billed to customers for shipping and handling activities after the customer obtains control are treated as a promised service performance obligation and recorded in&#160;total revenue&#160;in the accompanying Consolidated Statements of Operations. Shipping and handling costs incurred for the delivery of goods to customers are considered a cost to fulfill the contract and are included in&#160;cost of revenue&#160;in the accompanying Consolidated Statements of Operations.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Product Warranty</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We provide a warranty for our products against defects in material and workmanship for a period of <span style="-sec-ix-hidden:Hidden_9oGSvawUkUuA-bl9OI56kg;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">one</span></span> to five years. We record a liability for future warranty claims at the time of sale for the warranty period offered to a customer. If the assumptions used in calculating the provision were to materially change, such as incurring higher than anticipated warranty claims, an additional provision may be required.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Impairment of Long-Lived Assets </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We review long-lived assets, including property and equipment and patents, for impairment whenever events or changes in business circumstances indicate that the carrying amount of an asset may not be fully recoverable. We will assess long-lived assets used in operations for impairment indicators, including when undiscounted cash flows estimated to be generated by those assets are less than the assets&#8217; carrying amount (see Note 8 &#8211; &#8220;Goodwill and Intangible Assets&#8221;).</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Goodwill</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Goodwill represents the excess of the purchase price paid over the estimated fair value of the net assets acquired and liabilities assumed in the acquisition of a business. Goodwill is not amortized, but is tested for impairment at least annually or on an interim basis if an event occurs or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying value. We perform our annual assessment of goodwill for impairment as of July 1st&#160;of each fiscal year. See Note 8 &#8211; &#8220;Goodwill and Intangible Assets&#8221; for additional information.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Stock-Based Compensation</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Stock options are valued using the Black-Scholes option-pricing model, except that the valuation of certain &#8220;CEO&#8221; related stock options subject to a market condition involve the use of the Monte Carlo Simulation model. The Monte Carlo Simulation and the Black-Scholes valuation models require the input of highly subjective assumptions. The assumptions include the expected term of the option, the expected volatility of the price of our common stock, expected dividend yield and the risk-free interest rate. These estimates involve inherent uncertainties and the significant application of management&#8217;s judgment. If factors change and different assumptions are used, our stock-based compensation expense could be materially different in the future. We recognize compensation expense for these options on a straight-line basis over the requisite service period (see Note 13 &#8211; &#8220;Stockholders&#8217; Equity&#8221;).</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Income Taxes</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Income taxes are accounted for under the liability method. Deferred income taxes are provided for temporary differences between the financial reporting and the tax basis of assets and liabilities. If we determine in the future that it is more likely than not that we will not realize all or a portion of the deferred tax assets, we will record a valuation allowance in the period the determination is made (see Note 15 &#8211; &#8220;Income Taxes&#8221;). Changes in tax rates are reflected in the tax provision as they occur.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Net (Loss) Income Per Common Share</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;"> </span>Basic net (loss) income per common share is computed based on the weighted average number of shares of common stock outstanding during the period. Diluted net (loss) income per common share is computed based on the weighted average number of shares of common stock plus the effect of dilutive potential stock-based awards outstanding during the period using the treasury stock method. Dilutive potential stock-based awards include outstanding common stock options, time- and performance-based restricted stock units and employee stock purchase plan shares.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Business Segments</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We operate and report in only&#160;one&#160;operating and <span style="-sec-ix-hidden:Hidden_hf125MM_GkGhx3Sj6QqkPA;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">reportable</span></span> segment. Our chief operating decision maker does not use financial information below revenue to allocate resources.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Accounting Pronouncement Not Yet Adopted</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In December 2022, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued ASU No. 2022-06, &#8220;Reference Rate Reform (Topic 848) &#8212; Facilitation of the Effect of Reference Rate Reform on Financial Reporting&#8221; (&#8220;ASU 2022-06&#8221;), which provides optional expedients and exceptions for applying GAAP to transactions affected by reference rate (e.g., LIBOR) reform if certain criteria are met, for a limited period of time to ease the potential burden in accounting for (or recognizing the effects of) reference rate reform on financial reporting. The ASU deferred the sunset date of Topic 848 from December 31, 2022 to December 31, 2024. The ASU is effective as of December 21, 2022 through December 31, 2024. We continue to evaluate transactions or contract modifications occurring as a result of reference rate reform and determine whether to apply the optional guidance on an ongoing basis. We have not elected any expedients to date and are currently evaluating any potential future impacts on the consolidated financial statements. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139814960259712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAbstract', window );"><strong>Acquisitions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionTextBlock', window );">Acquisitions</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Note 4. Acquisitions</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">On&#160;September 8, 2021,&#160;we entered into an Asset Purchase Agreement (&#8220;AffloVest APA&#8221;) to acquire the AffloVest therapy business from International Biophysics Corporation (&#8220;IBC&#8221;). Under the terms of the AffloVest APA, we agreed to pay IBC a total of up to $100.0&#160;million for the purchase of substantially all of the assets related to its branded high frequency chest wall oscillation vest therapy business, other than specifically identified excluded assets. We acquired AffloVest to further expand our position as a leader in treating patients with underserved chronic conditions in the home. The acquired assets included inventory, tooling, intellectual property, permits and approvals, data and records, and customer and supplier information. At closing, $80.0&#160;million of the purchase price was paid, of which a total of $0.5 million was deposited into an escrow account at closing for purposes of satisfying certain post-closing purchase price adjustments and indemnification claims. Subsequent to closing, $0.2 million was returned to us as a result of working capital adjustments.&#160;The AffloVest acquisition was funded through a combination of cash on hand and proceeds from borrowings.&#160;</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:24.5pt;margin:0pt 7.2pt 0pt 7.2pt;"><span style="color:#ff0000;font-size:12pt;">&#160;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">On November 4, 2022, we entered into an Amendment to the AffloVest APA, the &#8220;Amendment&#8221; with IBC, which modifies the terms of the earn-out arrangement under the AffloVest APA, as follows:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:27pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:45pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:normal;background:#ffffff;">Initial Earn-Out: </i><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">The AffloVest APA provided for an initial earn-out equal to </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">1.5</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;"> times the amount by which the AffloVest U.S. revenues in the period from&#160;</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">October 1, 2021&#160;</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">to&#160;</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">September 30, 2022 (the &#8220;Initial Earn-Out Period&#8221;) exceed a specified amount;</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;"> provided that in no event will the payment exceed </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">$10.0</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;"> million.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:81pt;"/><td style="font-family:'Courier New';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">The Amendment provides that the calculated amount of the initial earn-out payment is </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">$10.0</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;"> million, of which the Company paid </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">$5.0</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;"> million on or before November 28, 2022, and of which the Company will pay </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">$5.0</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;"> million, plus an imputed interest payment of </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">$250,000</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">, on or before May 26, 2023.</span></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 63pt;"><span style="margin-left:0pt;visibility:hidden;background:#ffffff;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:45pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:normal;background:#ffffff;">Second Earn-Out:</i><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;"> The AffloVest APA provided for a second earn-out equal to </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">1.5</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;"> times the amount by which the AffloVest U.S. revenues in the period from&#160;</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">October 1, 2022&#160;</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">to&#160;</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">September 30, 2023 exceed the revenues recognized during the Initial Earn-Out Period;</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;"> provided that in no event will the payment exceed </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">$10.0</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;"> million.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:81pt;"/><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">The Amendment changes the </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">1.5</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;"> times multiplier to </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">3.0</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;"> times, but still provides that in no event will the second earn-out payment exceed </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">$10.0</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;"> million. </span></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 63pt;"><span style="color:#ff0000;font-family:'Times New Roman','Times','serif';margin-left:0pt;visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">The fair value of the earn-out as of the acquisition date was $6.4&#160;million. The fair value of the earn-out, reflecting management&#8217;s estimate of the likelihood of achieving these targets, was determined by employing a Monte Carlo Simulation model. This amount and the current versus non-current allocation will be remeasured at the end of each reporting period until the payment requirement ends, with any adjustments reported in income from operations (see Note 17 &#8211; &#8220;Fair Value Measurements&#8221;).</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">On the date of AffloVest Acquisition, we allocated the assets acquired based on an estimate of their fair values.&#160;The following table summarizes the purchase price allocation:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:25.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0.05pt 0pt 0.05pt 0pt;">(In&#160;millions)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:29.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;">Allocated Fair Value</p></td></tr><tr><td style="vertical-align:bottom;width:66.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Inventories</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 1.6</p></td></tr><tr><td style="vertical-align:bottom;width:66.78%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Property and equipment<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.03%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:66.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Intangible assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 53.5</p></td></tr><tr><td style="vertical-align:bottom;width:66.78%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Goodwill</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 31.1</p></td></tr><tr><td style="vertical-align:bottom;width:66.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;">Purchase price </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 86.2</p></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-decoration-line:none;text-transform:none;vertical-align:baseline;white-space:nowrap;width:18pt;padding:0pt 0pt 6pt 0pt;">(1)</td><td style="padding:0pt 0pt 6pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-style:normal;font-weight:normal;">The purchase price included less than </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-style:normal;font-weight:normal;">$0.1</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-style:normal;font-weight:normal;"> million of property and equipment.</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-style:normal;font-weight:normal;"> </span></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="font-size:10pt;">The goodwill reflects expected synergies of combining the acquired products and customer information with our existing operations and is deductible for tax purposes over&#160;</span><span style="font-size:10pt;">15&#160;years</span><span style="font-size:10pt;">.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt;">The following table reflects the allocation of purchase price to the acquired intangible assets and related estimated useful lives:&#160;</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:21.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:20.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">(In&#160;millions)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">Allocated Fair Value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">Estimated Useful Life</p></td></tr><tr><td style="vertical-align:bottom;width:49.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Customer relationships</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 31.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">13 years</p></td></tr><tr><td style="vertical-align:bottom;width:49.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Developed technology</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">11 years</p></td></tr><tr><td style="vertical-align:bottom;width:49.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Tradenames</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">Indefinite</p></td></tr><tr><td style="vertical-align:bottom;width:49.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total intangible assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 53.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt;">The weighted-average amortization period of the acquired intangible assets was&#160;12.3&#160;years.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The fair market valuations associated with the assets acquired fall within Level&#160;3 of the fair value hierarchy, due to the use of significant unobservable inputs to determine fair value. The fair value measurements were calculated using unobservable inputs, primarily using the income approach, specifically the discounted cash flow method. The amount and timing of future cash flows within our analysis was based on our due diligence models, most recent operational budgets, long-range strategic plans and other estimates.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Transaction costs, such as legal and other costs, related to the acquisition aggregated approximately $0.8&#160;million. These costs have been expensed as incurred and are included in reimbursement, general and administrative expenses in our Consolidated Statements of Operations for the year ended December 31, 2021.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Consolidated Statements of Operations reflect the AffloVest operations beginning September 9, 2021. As the AffloVest business has been integrated with our existing operations, we are unable to determine the amount of AffloVest earnings from the acquisition date that is included in the Consolidated Statements of Operations. The following unaudited pro forma information for the years ended December&#160;31, 2021 and 2020 presents the revenue and net income assuming the acquisition of AffloVest had occurred as of January 1, 2020. This information has been prepared for comparative purposes only and is&#160;not&#160;indicative of what actual results would have been if the acquisition had taken place at the beginning of fiscal&#160;2020,&#160;or of future results.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:41.04%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">Year Ended</p></td></tr><tr><td style="vertical-align:bottom;width:55.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:41.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">December&#160;31,&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:55.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">(In&#160;thousands)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">2020</p></td></tr><tr><td style="vertical-align:bottom;width:55.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Total revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 219,414</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 203,193</p></td></tr><tr><td style="vertical-align:bottom;width:55.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Net (loss) income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (7,633)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,832</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">These pro forma results include certain adjustments, primarily due to increases in amortization expense due to fair value adjustments of intangible assets, increases in interest expense due to additional borrowings incurred to finance the acquisition and amortization of debt issuance costs incurred to finance the transaction, acquisition related costs including transaction costs such as legal, accounting, valuation and other professional services, and related tax effects.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 15<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=6911878&amp;loc=d3e8732-128492<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139814960422832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Receivable<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesAbstract', window );"><strong>Accounts Receivable.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock', window );">Accounts Receivable</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Note 5. &#160;Accounts Receivable</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="white-space:pre-wrap;"> </span>We had accounts receivable from two insurers representing approximately 45% and 21% of accounts receivable as of December 31, 2022. We had accounts receivable from two insurers representing approximately 33% and 24% of accounts receivable as of December 31, 2021. Revenue from these insurers accounted for 19% and 10% of our total revenue for the year ended December 31, 2022, and 17% and 12% for the year ended December 31, 2021. The credit risks associated with customers which for these purposes are insurers considers aggregation for entities that are known to be under common control.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for claims held for amounts due a entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -URI https://asc.fasb.org/subtopic&amp;trid=2196772<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139814963736608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventories</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventories</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Note 6. &#160;Inventories</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Inventories consisted of the following:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:40.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:25.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:25.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:40.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0.05pt 0pt 0.05pt 0pt;">(In&#160;thousands)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:27.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">At December&#160;31,&#160;2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:27.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">At December&#160;31,&#160;2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:40.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Finished goods</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 5,100</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 8,242</p></td></tr><tr><td style="vertical-align:bottom;width:40.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Component parts and work-in-process</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 18,024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 10,975</p></td></tr><tr><td style="vertical-align:bottom;width:40.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;">Total inventories</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 23,124</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 19,217</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-size:1pt;font-weight:bold;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI https://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139814960305616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Note 7. &#160;Property and Equipment</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Property and equipment consisted of the following:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:53.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:53.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:43.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">At December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:53.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">(In&#160;thousands)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:53.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,274</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,051</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:53.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Tooling</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,390</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,545</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:53.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Furniture and fixtures</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,087</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,104</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:53.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,493</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,458</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:53.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Demonstration equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,012</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 632</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:53.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Construction in progress</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 606</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,003</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:53.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Subtotal</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.44%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 16,862</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.44%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,793</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:53.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Less: accumulated depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (10,785)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (9,043)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:53.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,077</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,750</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;margin:0pt;">Depreciation expense was $2.5 million, $2.3 million and $2.4 million for the years ended December&#160;31,&#160;2022, 2021 and 2020, respectively.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI https://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139814960273232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Goodwill and Intangible Assets</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Note 8. &#160;Goodwill and Intangible Assets</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;padding-left:10pt;text-align:justify;text-indent:-10pt;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Goodwill</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">In the third quarter of fiscal 2021, we completed the AffloVest Acquisition. The purchase price of the AffloVest business exceeded the net acquisition-date estimated fair value amounts of the identifiable assets acquired and the liabilities assumed by $31.1 million, which was assigned to goodwill.&#160;</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;padding-left:10pt;text-align:justify;text-indent:-10pt;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Intangible Assets</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">Our patents and other intangible assets are summarized as follows:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:30.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:48.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">At December&#160;31,&#160;2022</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortization</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Carrying</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Net</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">(In&#160;thousands)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Period</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortization</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Definite-lived intangible assets:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Patents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">12 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 897</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 173</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 724</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Defensive intangible assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,126</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 764</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 362</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Customer accounts</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&lt; 1 year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 125</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 114</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Customer relationships</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">12 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 31,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,127</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 27,873</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Developed technology</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">10 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,550</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,450</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Subtotal</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 46,148</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,728</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 40,420</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Unamortized intangible assets:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Tradenames</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,500</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Patents pending</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 455</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 455</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total intangible assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 56,103</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,728</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 50,375</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:30.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:48.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">At December&#160;31,&#160;2021</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amortization</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Carrying</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0.05pt 0pt 0.05pt 0pt;">(In&#160;thousands)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Period</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amortization</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Definite-lived intangible assets:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Patents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;">12 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 666</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 109</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 557</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Defensive intangible assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;">3 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 1,125</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 592</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 533</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Customer accounts</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;">1 year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 125</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 89</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 36</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Customer relationships</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;">13 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 31,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 742</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 30,258</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Developed technology</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;">11 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 13,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 368</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 12,632</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;">Subtotal</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 45,916</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 1,900</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 44,016</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unamortized intangible assets:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Tradenames</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 9,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 9,500</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Patents pending</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 565</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 565</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;">Total intangible assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 55,981</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 1,900</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 54,081</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">Amortization expense was $3.8 million, $1.4 million, and $0.4 million for the years ended December&#160;31,&#160;2022, 2021 and 2020, respectively. Future amortization expenses are expected as follows:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:30.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:54.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">(In&#160;thousands)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:30.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:30.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,808</p></td></tr><tr><td style="vertical-align:bottom;width:54.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:30.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,787</p></td></tr><tr><td style="vertical-align:bottom;width:54.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:30.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,697</p></td></tr><tr><td style="vertical-align:bottom;width:54.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:30.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,633</p></td></tr><tr><td style="vertical-align:bottom;width:54.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:30.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,623</p></td></tr><tr><td style="vertical-align:bottom;width:54.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:30.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21,872</p></td></tr><tr><td style="vertical-align:bottom;width:54.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:30.85%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 40,420</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;padding-bottom:14pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:2pt 0pt 0pt 0pt;"><span style="font-size:10pt;">The weighted-average remaining amortization period for these intangible assets was </span><span style="font-size:10pt;">11.0</span><span style="font-size:10pt;"> years as of December&#160;31,&#160;2022.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI https://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139814960214480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcmd_AccruedExpensesDisclosureCurrentTextBlock', window );">Accrued Expenses</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Note 9. &#160;Accrued Expenses</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">Accrued expenses consisted of the following:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:34.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:27.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:27.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:34.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">(In&#160;thousands)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:30.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">At December&#160;31,&#160;2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:30.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">At December&#160;31,&#160;2021</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:34.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">In-transit inventory</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,228</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 416</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:34.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Warranty</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.87%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,005</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.87%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,851</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:34.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Travel</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,121</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 661</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:34.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Legal and consulting</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.87%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 730</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.87%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,371</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:34.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Clinical studies</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 276</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 113</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:34.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Sales and use tax</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.87%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 147</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.87%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 106</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:34.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,733</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 744</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:34.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,240</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,262</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcmd_AccruedExpensesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accrued expenses that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcmd_AccruedExpensesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139814964503312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warranty Reserves<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StandardProductWarrantyDisclosureAbstract', window );"><strong>Warranty Reserves</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductWarrantyDisclosureTextBlock', window );">Warranty Reserves</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Note&#160;10. &#160;Warranty Reserves</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The activity in the warranty reserve during and as of the end of the year presented was as follows:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:40.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:40.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:59.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:40.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:59.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:40.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">(In&#160;thousands)</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:40.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Beginning balance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,959</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,841</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,759</p></td></tr><tr><td style="vertical-align:bottom;width:40.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Warranty provision</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.76%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,047</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.78%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,606</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,957</p></td></tr><tr><td style="vertical-align:bottom;width:40.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Processed warranty claims</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (2,794)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (2,488)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (1,875)</p></td></tr><tr><td style="vertical-align:bottom;width:40.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Ending balance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,212</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,959</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,841</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:40.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#ff0000;font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Accrued warranty reserve, current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.76%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,005</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.78%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,851</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,606</p></td></tr><tr><td style="vertical-align:bottom;width:40.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Accrued warranty reserve, non-current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,207</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,108</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,235</p></td></tr><tr><td style="vertical-align:bottom;width:40.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total accrued warranty reserve</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,212</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,959</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,841</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductWarrantyDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for standard and extended product warranties and other product guarantee contracts, including a tabular reconciliation of the changes in the guarantor's aggregate product warranty liability for the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -URI https://asc.fasb.org/topic&amp;trid=2155896<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductWarrantyDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StandardProductWarrantyDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StandardProductWarrantyDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139814960295024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Credit Agreement<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Credit Agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Credit Agreement</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Note&#160;11. &#160;Credit Agreement</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">On April 30, 2021, we entered into an Amended and Restated Credit Agreement (the &#8220;Restated Credit Agreement&#8221;) with the lenders from time to time party thereto, and Wells Fargo Bank, National Association, as Administrative Agent. The Restated Credit Agreement amended and restated in its entirety our prior credit agreement.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27pt;background:#ffffff;margin:0pt;">On September 8, 2021, we entered into a First Amendment Agreement (the &#8220;First Amendment&#8221;), which amends the Restated Credit Agreement (as amended by the First Amendment, the &#8220;Credit Agreement&#8221;) with the lenders from time to time party thereto and Wells Fargo Bank, National Association, as Administrative Agent. The First Amendment, among other things, adds a $30.0 million incremental term loan to the $25.0 million revolving credit facility provided by the Restated Credit Agreement. The term loan is reflected as a note payable on our Consolidated Balance Sheets. The term loan and the revolving credit facility mature on September 8, 2024. The Credit Agreement provides that, subject to satisfaction of certain conditions, we may increase the amount of the revolving loans available under the Credit Agreement and/or add one or more term loan facilities in an amount not to exceed $25.0 million in the aggregate, such that the total aggregate principal amount of loans available under the Credit Agreement (including under the revolving credit facility) does not exceed $80.0 million.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">&#160;</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27pt;background:#ffffff;margin:0pt;">On September 8, 2021, in connection with the closing of the AffloVest Acquisition, we borrowed the $30.0 million term loan and utilized that borrowing, together with a draw of $25.0 million under the revolving credit facility and cash on hand, to fund the purchase price.&#160;As of both December 31, 2022 and 2021, there was no availability under our Credit Agreement.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;text-align:justify;text-indent:27pt;background:#ffffff;margin:0pt;"><span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27pt;background:#ffffff;margin:0pt;">On February 22, 2022, we entered into a Second Amendment Agreement (the &#8220;Second Amendment&#8221;), which further amends the Credit Agreement.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;text-align:justify;text-indent:27pt;margin:0pt;"><span style="font-size:10pt;">The principal of the term loan is required to be repaid in </span><span style="font-size:10pt;">quarterly</span><span style="font-size:10pt;"> installments of </span><span style="font-size:10pt;">$750,000</span><span style="font-size:10pt;"> commencing&#160;January 7, 2022,&#160;through&#160;July 8, 2024,&#160;with the remaining outstanding balance due on&#160;September 8, 2024. Pursuant to the Second Amendment, we made a mandatory principal prepayment of the term loan of </span><span style="font-size:10pt;">$3.0</span><span style="font-size:10pt;"> million on February 22, 2022.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;text-align:justify;text-indent:27pt;margin:0pt;"><span style="color:#ff0000;font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27pt;margin:0pt;">The term loan and amounts drawn under the revolving credit facility bear interest, at our option, at a rate equal to (a) the highest of (i) the prime rate, (ii) the federal funds rate plus 0.50% and (iii) LIBOR for an interest period of one month plus 1% (the &#8220;Base Rate&#8221;) plus an applicable margin or (b) LIBOR for an interest period of one, three or six months, at our option, plus the applicable margin. The applicable margin is 0.75% to 2.25% on loans bearing interest at the Base Rate and 1.75% to 3.25% on loans bearing interest at LIBOR, in each case depending on our consolidated total leverage ratio; except that, pursuant to the Second Amendment, during the period commencing on February 22, 2022 and ending on the last day of the fiscal quarter ending June 30, 2023, the applicable margin for LIBOR rate loans is 3.50%. At December 31, 2022,&#160;all outstanding borrowings were subject to interest at a rate calculated at LIBOR plus an applicable margin, for an interest rate of 7.41%. Undrawn portions of the revolving credit facility are subject to an unused line fee at a rate per annum from 0.300% to 0.375%, depending on our consolidated total leverage ratio.&#160;</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:60.5pt;margin:0pt;">&#160;</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:27.35pt;margin:0pt;">Maturities of the term loan for the next three years as of December 31, 2022, were as follows:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:25.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">(In&#160;thousands)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:29.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,000</p></td></tr><tr><td style="vertical-align:bottom;width:66.78%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21,000</p></td></tr><tr><td style="vertical-align:bottom;width:66.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 24,000</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27.35pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;margin:0pt;">Our obligations under the Credit Agreement are secured by a security interest in substantially all of our and our subsidiaries&#8217; assets and are also guaranteed by our subsidiaries. The Credit Agreement contains a number of restrictions and covenants, including that we maintain compliance with a maximum leverage ratio, minimum fixed charge coverage ratio and a minimum consolidated EBITDA covenant. As of December 31, 2022, we were in compliance with all financial covenants under the Credit Agreement.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI https://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139814960369872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Note&#160;12. &#160;Commitments and Contingencies</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:10pt;text-align:justify;text-indent:-10pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Lease Obligations</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We lease property and equipment under operating leases, typically with terms greater than 12 months, and determine if an arrangement contains a lease at inception. In general, an arrangement contains a lease if there is an identified asset and we have the right to direct the use of and obtain substantially all of the economic benefit from the use of the identified asset. We record an operating lease liability at the present value of lease payments over the lease term on the commencement date. The related right of use (&#8220;ROU&#8221;) operating lease asset reflects rental escalation clauses, as well as renewal options and/or termination options. The exercise of lease renewal and/or termination options are at our discretion and are included in the determination of the lease term and lease payment obligations when it is deemed reasonably certain that the option will be exercised. When available, we use the rate implicit in the lease to discount lease payments to present value; however, certain leases do not provide a readily determinable implicit rate. Therefore, we must estimate our incremental borrowing rate to discount the lease payments based on information available at lease commencement.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We classify our leases as buildings, vehicles or computer and office equipment and do not separate lease and nonlease components of contracts for any of the aforementioned classifications. In accordance with applicable guidance, we do not record leases with terms that are less than one year on the Consolidated Balance Sheets.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">None of our lease agreements contain material restrictive covenants or residual value guarantees.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Buildings</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We lease certain office and warehouse space at various locations in the United States where we provide services. These leases are typically greater than one year with fixed, escalating rents over the noncancelable terms and, therefore, ROU operating lease assets and operating lease liabilities are recorded on the Consolidated Balance Sheets, with rent expense recognized on a straight-line basis over the term of the lease. The remaining lease terms vary from approximately <span style="-sec-ix-hidden:Hidden_cPi9QUIkvEuGhENNTJkqkw;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">one</span></span> to eight years as of December&#160;31,&#160;2022.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We entered into a lease (&#8220;initial lease&#8221;) in October 2018, for approximately 80,000 square feet of office space for our new corporate headquarters in Minneapolis, Minnesota. In December 2018, we amended the initial lease to add approximately 29,000 square feet of additional office space, which is accounted for as a separate lease (&#8220;second lease&#8221;) in accordance with ASU No. 2016-02, &#8220;Leases&#8221; (Topic 842) (&#8220;ASC 842&#8221;). In December 2019, we further amended the lease which extended the expiration date of the initial lease, extended the expiration date of and added approximately 4,000 square feet to the second lease, as well as added approximately 37,000 square feet of additional office space, accounted for as a separate lease (&#8220;third lease&#8221;) in accordance with ASC 842. The portion of the space covered under the initial lease was placed in service in September 2019. This portion was recognized as an operating lease and included in the ROU operating lease assets and operating lease liabilities on the Consolidated Balance Sheets. The portion of the space covered under the second lease commenced in September 2020. Finally, the portion of the space covered under the third lease commenced in September 2021.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Vehicles</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We lease vehicles for certain members of our field sales organization under a vehicle fleet program whereby the initial, noncancelable lease is for a term of 367 days, thus more than one year. Subsequent to the initial term, the lease becomes a month-to-month, cancelable lease. As of December&#160;31,&#160;2022, we had approximately two vehicles with agreements within the initial, noncancelable lease term that are recorded as ROU operating lease assets and operating lease liabilities. In addition to monthly rental fees specific to the vehicle, there are fixed monthly nonlease components that have been included in the ROU operating lease assets and operating lease liabilities. The nonlease components are not significant. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Computer and Office Equipment</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We also have operating lease agreements for certain computer and office equipment. The remaining lease terms as of December 31, 2022, ranged from less than one year to approximately four years with fixed monthly payments that are included in the ROU operating lease assets and operating lease liabilities. The leases provide an option to purchase the related equipment at fair market value at the end of the lease. The leases will automatically renew as a month-to-month rental at the end of the lease if the equipment is not purchased or returned.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Lease Position, Undiscounted Cash Flow and Supplemental Information</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The table below presents information related to our ROU operating lease assets and operating lease liabilities that we have recorded:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:54.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:54.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">(In&#160;thousands)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">At December&#160;31,&#160;2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">At December&#160;31,&#160;2021</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:54.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_tKPJpXeds0SiabhmYWAMEg;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Right of use operating lease assets</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21,322</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 23,984</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:54.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:54.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Operating lease liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:54.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="-sec-ix-hidden:Hidden_tyE6-ij7k06Rv5IRQ6iD1Q;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Current</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,506</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:54.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="-sec-ix-hidden:Hidden_hRi5aCIDPEGUkAgK0iaGvw;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Non-current</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20,866</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 23,354</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:54.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 23,366</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 25,860</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:54.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:54.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Operating leases: </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:54.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Weighted average remaining lease term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">7.7 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">8.6 years</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:54.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Weighted average discount rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">4.2%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">4.2%</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:54.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="margin-left:0pt;vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:54.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:43.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:54.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:20.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:20.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:54.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Supplemental cash flow information for our operating leases:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:54.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Cash paid for operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,575</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,379</p></td></tr><tr><td style="vertical-align:bottom;width:54.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Non-cash right of use assets obtained in exchange for new operating lease obligations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 49</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,920</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The table below reconciles the undiscounted cash flows under the operating lease liabilities recorded on the Consolidated Balance Sheets for the periods presented:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:65.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:27.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:65.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">(In&#160;thousands)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,427</p></td></tr><tr><td style="vertical-align:bottom;width:65.19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,418</p></td></tr><tr><td style="vertical-align:bottom;width:65.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,517</p></td></tr><tr><td style="vertical-align:bottom;width:65.19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,615</p></td></tr><tr><td style="vertical-align:bottom;width:65.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,167</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:65.19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,082</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:65.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Total minimum lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 27,226</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:65.19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Less: Amount of lease payments representing interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (3,860)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:65.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Present value of future minimum lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 23,366</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:65.19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Less: Current obligations under operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (2,500)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:65.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Non-current obligations under operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20,866</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;padding-left:10.1pt;text-indent:-10.1pt;background:#ffffff;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">Operating lease costs were $3.8 million, $3.6 million and $3.0 million for the years ended December&#160;31,&#160;2022, 2021 and 2020, respectively. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Major Vendors</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">We had purchases from one vendor that accounted for 18% of our total purchases for the year ended December 31, 2022 and purchases from two vendors that accounted for 32% of total purchases for the year ended December&#160;31,&#160;2021.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:10pt;text-align:justify;text-indent:-10pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Purchase Commitment</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;margin:0pt;">We issued purchase orders in 2022 totaling $33.5 million for goods that we expect to receive within the next year.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Retirement Plan</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:14pt;padding-top:2pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">We maintain a 401(k) retirement plan for our employees to which eligible employees can contribute a percentage of their pre-tax compensation. We recorded an expense related to our discretionary contributions to the 401(k) plan of $1.5 million, $1.2 million and $0.3 million for the years ended December&#160;31,&#160;2022, 2021 and 2020, respectively.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:14pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Legal Proceedings</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt;">From time to time, we are subject to various claims and legal proceedings arising in the ordinary course of business. Regardless of outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;margin:14pt 0pt 0pt 0pt;">We and certain of our present or former officers have been sued in a purported securities class action lawsuit that was filed in the United States District Court for the District of Minnesota on September 29, 2020, and that is pending under the caption<i style="font-style:italic;"> Brian Mart v. Tactile Systems Technology, Inc., et al</i>., File No. 0:20-cv-02074-NEB-BRT (the &#8220;Mart Lawsuit&#8221;).&#160;On April 19, 2021, the plaintiff filed an Amended Complaint against us and eight of our present and former officers and directors.&#160;Plaintiff seeks to represent a class consisting of investors who purchased our common stock in the market during the time period from May 7, 2018 through June 8, 2020 (&#8220;alleged class period&#8221;). The Amended Complaint alleges the following claims under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;): (1) that we and certain officer defendants made materially false or misleading public statements about our business, operational and compliance policies, and results during the alleged class period in violation of Section 10(b) of the Exchange Act; (2) that we and the individual defendants engaged in a scheme to defraud investors&#160;in order to allow the individual defendants to sell our stock in violation of Section 10(b) of the Exchange Act; (3) that the individual defendants engaged in improper insider trading of our stock in violation of Section 20A of the Exchange Act; and (4) that we and the individual defendants are liable under Section 20(a) of the Exchange Act because each defendant is a controlling person. On June 18, 2021, we and the individual defendants filed a motion to dismiss the Amended Complaint. On March 31, 2022, the court granted in part, and denied in part, the defendants&#8217; motion to dismiss. All claims against three individual defendants were dismissed, and most claims against four other individual defendants were dismissed. On November 21, 2022, the company announced that it entered a Memorandum of Understanding to settle this matter. The Company does not expect to fund any portion of cash payments made in connection with the $5 million settlement amount. The settlement does not constitute an admission of liability or wrongdoing by the Company. The settlement is subject to the parties reaching agreement on various non-monetary terms and court approval of the final terms will be required.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:14pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:2pt 0pt 0pt 0pt;">On May 24, 2022, a stockholder derivative lawsuit was filed in the United States District Court for the District of Minnesota, purportedly on behalf of the Company against certain of our present and former officers and directors and the Company (as a nominal defendant), captioned <i style="font-style:italic;">Jack Weaver v. Moen</i>, et al., File No. 0:22-cv-01403-NEB-BRT. This complaint generally arises out of the same subject matter as the Mart Lawsuit and alleges the following claims under the Exchange Act and common law: (1) that the director defendants made materially false or misleading public statements in proxy statements in violation of Section 14(a) of the Exchange Act; (2) that the director defendants&#8217; stock and option awards should be rescinded under Section 29(b) of the Exchange Act; (3) that the officer defendants&#8217; employment contract compensation should be rescinded under Section 29(b) of the Exchange Act; (4) that certain officer defendants are liable for contribution arising out of any liability incurred in the Mart Lawsuit, under Sections 10(b) and 21D of the Exchange Act; (5) that the individual defendants breached their fiduciary duties; and (6) that the individual defendants were unjustly enriched. The lawsuit seeks unspecified damages. In August, the matter was transferred to the United States District Court for the District of Delaware by order granting the Parties Stipulation to Transfer. On February 10, 2023, we filed a motion to dismiss the action. We are defending the action as it proceeds.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139814960305616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock', window );">Stockholders' Equity</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Note&#160;13. &#160;Stockholders' Equity</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">We completed an initial public offering of our common stock on August 2, 2016, in which we sold 4,120,000 shares of our common stock at a public offering price of $10.00 per share. Immediately prior to the completion of the initial public offering, all then-outstanding shares of our Series A and Series B preferred stock </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;">were converted into 5,924,453 shares of our common stock. Our Series A preferred stock converted to common stock at a ratio of 1-for-1.03 and our Series B preferred stock converted to common stock at a ratio of 1-for-1. In addition, immediately prior to the completion of the initial public offering, we issued 2,354,323 additional shares of our common stock that our Series A and Series B preferred stockholders were entitled to receive in connection with the conversion of the preferred stock, and we issued 956,842 shares of our common stock to pay accrued dividends on our Series B preferred stock. We also paid $8.2 million in cumulative accrued dividends to our Series A convertible preferred stockholders in connection with the initial public offering, including $0.1 million of dividends paid to the holders of the common restricted shares.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:10.1pt;text-align:justify;text-indent:-10.1pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Stock-Based Compensation</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Our 2016 Equity Incentive Plan (the &#8220;2016 Plan&#8221;) authorizes us to grant stock options, stock appreciation rights, restricted stock, stock units and other stock-based awards to employees, non-employee directors and certain consultants and advisors. There were up to 4,800,000 shares of our common stock initially reserved for issuance pursuant to the 2016 Plan. The 2016 Plan provides that the number of shares reserved and available for issuance under the 2016 Plan will automatically increase annually on January 1 of each calendar year, commencing in 2017 and ending on and including January 1, 2026, by an amount equal to the lesser of: (a) 5% of the number of common shares of stock outstanding as of December 31 of the immediately preceding calendar year, or (b) 2,500,000 shares; provided, however, that our Board of Directors may determine that any annual increase be a lesser number. In addition, all awards granted under our 2007 Omnibus Stock Plan and our 2003 Stock Option Plan that were outstanding when the 2016 Plan became effective and that are forfeited, expire, are cancelled, are settled for cash or otherwise not issued, will become available for issuance under the 2016 Plan. Pursuant to the automatic increase feature of the 2016 Plan, 972,591 shares were added as available for issuance thereunder on January 1, 2021. Our Board of Directors exercised its prerogative to forego the automatic increase on each of January 1, 2023 and 2022.<span style="font-size:12pt;"> </span>As of December&#160;31,&#160;2022, 5,957,683 shares were available for future grant pursuant to the 2016 Plan.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Upon adoption and approval of the 2016 Plan, all of our previous equity incentive compensation plans were terminated. However, existing awards under those plans continue to vest in accordance with the original vesting schedules and will expire at the end of their original terms.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">In the second fiscal quarter of 2020, our Board of Directors appointed a new President and Chief Executive Officer (&#8220;CEO&#8221;), effective June 8, 2020. In conjunction with the acceptance of the written offer, our CEO received both restricted stock units and stock option awards under our 2016 Plan during the third fiscal quarter of 2020 and the stock options have a seven year term. A portion of the awards vested on June 30, 2021, with the remaining portion of the awards vesting over a period of three years from the date of grant. Further, the stock options were valued at the date of grant using the Monte Carlo Simulation model due to a market condition that required that our stock price exceed&#160;$40.15&#160;for&#160;<span style="-sec-ix-hidden:Hidden_94egicmKoESPdhUuU5X_1w;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">20</span></span>&#160;consecutive trading days during the term of the option in order to vest. This condition was satisfied in the first quarter of 2021.&#160;The following table sets forth the estimated fair value of these stock options granted and the assumptions on which the fair value was determined:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:33.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:33.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Expected term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:33.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">4.5 years</p></td></tr><tr><td style="vertical-align:bottom;width:62.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:33.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">45.39%</p></td></tr><tr><td style="vertical-align:bottom;width:62.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:33.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">0.4%</p></td></tr><tr><td style="vertical-align:bottom;width:62.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:33.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">0%</p></td></tr><tr><td style="vertical-align:bottom;width:62.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Fair value on the date of grant</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:33.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">$13.60 - $14.70</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">We recorded total stock-based compensation expense of $9.6 million, $10.2 million and $10.7 million for the years ended December&#160;31,&#160;2022, 2021 and 2020, respectively. This expense was allocated as follows:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:59.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:40.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:59.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:40.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">(In&#160;thousands)</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Cost of revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 367</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 433</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 539</p></td></tr><tr><td style="vertical-align:bottom;width:59.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Sales and marketing expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,060</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,069</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,058</p></td></tr><tr><td style="vertical-align:bottom;width:59.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 226</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 314</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 360</p></td></tr><tr><td style="vertical-align:bottom;width:59.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Reimbursement, general and administrative expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,947</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,357</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,732</p></td></tr><tr><td style="vertical-align:bottom;width:59.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,600</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,173</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,689</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Stock Options</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;padding-top:2pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="font-size:10pt;">Stock options issued to participants other than non-employees typically vest over </span><span style="-sec-ix-hidden:Hidden_6Mhakd_sLkqC71m6G0M6Og;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">three</span></span><span style="font-size:10pt;"> or </span><span style="font-size:10pt;">four years</span><span style="font-size:10pt;"> and typically have a contractual term of </span><span style="-sec-ix-hidden:Hidden_tp1Se7X6AEitbPWWRbR6bw;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">seven</span></span><span style="font-size:10pt;"> or </span><span style="font-size:10pt;">ten years</span><span style="font-size:10pt;">. Stock-based compensation expense included in our Consolidated Statements of Operations for stock options was </span><span style="font-size:10pt;">$2.5</span><span style="font-size:10pt;"> million, </span><span style="font-size:10pt;">$4.3</span><span style="font-size:10pt;"> million and </span><span style="font-size:10pt;">$4.0</span><span style="font-size:10pt;"> million for the years ended December&#160;31,&#160;2022, 2021 and 2020, respectively. The total grant date fair value of options vested during the year was </span><span style="font-size:10pt;">$3.3</span><span style="font-size:10pt;"> million, </span><span style="font-size:10pt;">$4.3</span><span style="font-size:10pt;"> million and </span><span style="font-size:10pt;">$3.0</span><span style="font-size:10pt;"> million for the years ended December&#160;31,&#160;2022, 2021 and 2020, respectively.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;padding-bottom:14pt;text-align:justify;text-indent:36pt;margin:14pt 0pt 0pt 0pt;"><span style="font-size:10pt;">At December&#160;31,&#160;2022, there was approximately </span><span style="font-size:10pt;">$1.6</span><span style="font-size:10pt;"> million of total unrecognized pre-tax stock option expense under our equity compensation plans, which is expected to be recognized on a straight-line basis over a weighted-average period of</span> <span style="font-size:10pt;">1.2</span><span style="font-size:10pt;"> years.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">The fair value of each option grant is estimated on the date of grant using the Black-Scholes option pricing model, other than options that have a market-based vesting condition, which are valued using the Monte Carlo Simulation model. Annually, we make predictive assumptions regarding future stock price volatility, dividend yield, expected term and forfeiture rate. The dividend yield assumption is based on expected annual dividend yield on the grant date. To date, no dividend on common stock has been paid by us. Expected volatility for grants issued in and prior to the first fiscal quarter of 2021 was estimated using the average historical volatility of public companies of similar size and industry over a similar period as the expected term assumption used for our options. Beginning in the second fiscal quarter of 2021, we had sufficient historical data to transition to utilizing our average historical volatility over a similar period as the expected term assumption used for our options as the expected volatility. The risk-free interest rate is based on the yields of U.S. Treasury securities with maturities similar to the expected term of the options for each option group. We use the &#8220;simplified method&#8221; to determine the expected term of the stock option grants. We utilize this method because we do not have sufficient public company exercise data in which to make a reasonable estimate. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">The following table sets forth the estimated fair values of our stock options granted in each of the years indicated, and the assumptions on which the fair values were determined:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:35.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:35.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:35.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Expected term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_EUn6f84eb0OJm-52SjcRtw;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">4.5</span></span> years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_M9XtAoRCQE23lB3X4M3v9w;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">4.5</span></span> years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_iCRDlIEFVkGCl5KX7TVfHQ;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">4.5</span></span> years</p></td></tr><tr><td style="vertical-align:bottom;width:35.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;">59.2%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;">45.0 - 52.3%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;">44.1 - 46.4%</p></td></tr><tr><td style="vertical-align:bottom;width:35.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;">4.3%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;">0.6 - 1.1%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;">0.2 - 0.9%</p></td></tr><tr><td style="vertical-align:bottom;width:35.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;">0%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;">0%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;">0%</p></td></tr><tr><td style="vertical-align:bottom;width:35.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Fair value on the date of grant</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;">$ 8.11</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;">$13.04 - $22.90</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;">$13.45 - $18.64</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-size:1pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">Our stock option activity for the three years ended December&#160;31,&#160;2022, 2021 and 2020, was as follows:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.11848831%;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:38.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise&#160;Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Intrinsic</b></p></td></tr><tr><td style="vertical-align:bottom;width:38.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0.05pt 0pt 0.05pt 0pt;">(In&#160;thousands except options and per share data)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Per Share </b><sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Contractual Life</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Value </b><sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(2)</sup></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Balance at December 31, 2019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 866,955</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 28.76</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;">6.3 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 33,957</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 378,695</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 44.84</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (147,741)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 7.24</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 6,540</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (54,824)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 50.25</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;">Cancelled/Expired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (3,376)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 63.61</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Balance at December 31, 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 1,039,709</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 36.43</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;">5.6 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 13,381</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 188,748</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 49.33</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (175,516)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 22.65</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 4,901</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (92,773)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 49.77</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;">Cancelled/Expired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (44,944)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 57.78</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Balance at December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 915,224</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 39.33</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;">5.0 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 2,068</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 47,280</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 6.17</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (90,878)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 1.68</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 916</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (92,981)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 36.28</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;">Cancelled/Expired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (163,338)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 37.65</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Balance at December 31, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 615,307</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 43.25</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;">4.7 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 164</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Options exercisable at December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 435,363</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 43.83</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;">4.5 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 84</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;padding-bottom:6pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-size:1pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><div style="margin-top:0pt;"/><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-decoration-line:none;text-transform:none;vertical-align:baseline;white-space:nowrap;width:18pt;padding:0pt 0pt 6pt 0pt;">(1)</td><td style="padding:0pt 0pt 6pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-style:normal;font-weight:normal;">The exercise price of each option granted during the periods shown was equal to the market price of the underlying stock on the date of grant.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-decoration-line:none;text-transform:none;vertical-align:baseline;white-space:nowrap;width:18pt;padding:0pt 0pt 12pt 0pt;">(2)</td><td style="padding:0pt 0pt 12pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-style:normal;font-weight:normal;">The aggregate intrinsic value of options exercised represents the difference between the exercise price of the option and the closing stock price of our common stock on the date of exercise. The aggregate intrinsic value of options outstanding represents the difference between the exercise price of the option and the closing stock price of our common stock on the last trading day of the period.</span></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">Options exercisable of 517,316 at December&#160;31,&#160;2021, and 489,866 at December&#160;31,&#160;2020 had weighted average exercise prices of $32.60 and $25.39, respectively.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">The following summarizes additional information about our stock options:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:61.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:35.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:35.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number of:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Non-vested options, beginning of the year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 397,908</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 549,843</p></td></tr><tr><td style="vertical-align:bottom;width:61.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Non-vested options, end of the year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 179,944</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 397,908</p></td></tr><tr><td style="vertical-align:bottom;width:61.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Vested options, end of the year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 435,363</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 517,316</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;"><span style="font-size:1pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:61.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:35.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:35.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted-average grant date fair value of: </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Non-vested options, beginning of the year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 18.02</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 18.03</p></td></tr><tr><td style="vertical-align:bottom;width:61.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Non-vested options, end of the year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 16.24</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 18.02</p></td></tr><tr><td style="vertical-align:bottom;width:61.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Vested options, end of the year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 17.53</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 13.27</p></td></tr><tr><td style="vertical-align:bottom;width:61.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Forfeited options, during the year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 14.73</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 19.26</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;padding-bottom:12pt;background:#ffffff;margin:0pt;"><span style="font-size:1pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Time-Based Restricted Stock Unit</span><i style="font-style:italic;">s</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:10pt;">We have granted time-based restricted stock units to certain participants under the 2016 Plan that are stock-settled with common shares. Time-based restricted stock units granted under the 2016 Plan vest over </span><span style="-sec-ix-hidden:Hidden_fHxG8ZvlB0ieDTwHUV85QA;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">one</span></span><span style="font-size:10pt;"> to </span><span style="font-size:10pt;">three years</span><span style="font-size:10pt;">. Stock-based compensation expense included in our Consolidated Statements of Operations for time-based restricted stock units was </span><span style="font-size:10pt;">$5.8</span><span style="font-size:10pt;"> million, </span><span style="font-size:10pt;">$4.9</span><span style="font-size:10pt;"> million and </span><span style="font-size:10pt;">$5.2</span><span style="font-size:10pt;"> million for the years ended December&#160;31,&#160;2022, 2021 and 2020, respectively. As of December&#160;31,&#160;2022, there was approximately </span><span style="font-size:10pt;">$7.8</span><span style="font-size:10pt;"> million of total unrecognized pre-tax compensation expense related to outstanding time-based restricted stock units that is expected to be recognized over a weighted-average period of </span><span style="font-size:10pt;">1.9</span><span style="font-size:10pt;"> years. </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our time-based restricted stock unit activity for the years ended December&#160;31,&#160;2022, 2021 and 2020 was as follows:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:46.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:46.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average Grant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Units</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Date Fair Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Intrinsic</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0.05pt 0pt 0.05pt 0pt;">(In&#160;thousands except unit and per unit data)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Per Unit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-size:10pt;font-weight:bold;">Value </b><sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Balance at December 31, 2019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 171,687</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 43.74</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 11,591</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 175,582</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 46.42</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;">Modification</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 2,288</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 21.85</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;">Vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (118,014)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 37.57</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;">Cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (20,074)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 53.03</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Balance at December 31, 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 211,469</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 48.29</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 9,503</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 189,762</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 40.31</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;">Vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (106,521)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 47.43</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;">Cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (35,563)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 51.76</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Balance at December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 259,147</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 42.32</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 4,932</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 539,525</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 15.03</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;">Vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (123,528)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 43.20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;">Cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (84,602)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 26.91</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Balance at December 31, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 590,542</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 19.42</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 6,779</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;padding-bottom:6pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-size:1pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><div style="margin-top:0pt;"/><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 6pt 0pt;">(1)</td><td style="padding:0pt 0pt 6pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-style:normal;font-weight:normal;">The aggregate intrinsic value of time-based restricted stock units outstanding was based on our closing stock price on the last trading day of the period.</span></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Performance-Based Restricted Stock Units</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">We have granted performance-based restricted stock units (&#8220;PSUs&#8221;) to certain participants under the 2016 Plan. These PSUs have both performance-based and time-based vesting features. The PSUs granted in 2018 were earned to the extent performance goals based on revenue and adjusted EBITDA were achieved in 2019. The PSUs granted in 2019 were earned to the extent performance goals based on revenue and adjusted EBITDA were achieved in 2020. The PSUs granted in 2020 were earned to the extent performance goals based on revenue and adjusted EBITDA were achieved in 2021. The PSUs granted in 2021 will be earned if and to the extent performance goals based on revenue and adjusted EBITDA are achieved in 2022. The PSUs granted in 2022 will be earned if and to the extent performance goals based on revenue change and adjusted EBITDA margin are achieved in 2023. The number of PSUs earned will depend on the level at which the performance targets are achieved and can range from 50% of target if threshold performance is achieved and up to 150% of target if maximum performance is achieved. <span style="-sec-ix-hidden:Hidden_sHnOWzszGUy7ZkN0NmbHuA;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">One-third</span></span> of the earned PSUs will vest on the date the Compensation and Organization Committee certifies the number of PSUs earned, and the remaining <span style="-sec-ix-hidden:Hidden_v4hPxGJ7JkKjemco7Ewk7A;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">two-thirds</span></span> of the earned PSUs will vest on the first anniversary of that certification date. All earned and vested PSUs will be settled in shares of common stock. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Stock-based compensation expense included in our Consolidated Statements of Operations for PSUs was $0.5 million, $0.2 million, and $0.5 million for the years ended December&#160;31,&#160;2022, 2021 and 2020, respectively. The stock-based compensation expense for the year ended December 31, 2022 reflects an expense of $0.6 million related to the PSUs granted in 2022. The stock-based compensation expense for the year ended December 31, 2021 reflects a $0.5&#160;million benefit due to a change in the estimated payout associated with PSUs granted in 2020 being below the minimum performance target threshold level, as defined, </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;">partially offset by an expense of $0.7 million related to the PSUs granted in 2018 and 2021. As of December&#160;31,&#160;2022, there was approximately $1.4 million of total unrecognized pre-tax compensation expense related to outstanding PSUs that is expected to be recognized over a weighted average period of 2.0 years. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">Our performance-based restricted stock unit activity at the estimated payout of 100% of target for the years ended December&#160;31,&#160;2022, 2021 and 2020, was as follows:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:44.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:44.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Performance-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Based</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average Grant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Units</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Date Fair Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Intrinsic</b></p></td></tr><tr><td style="vertical-align:bottom;width:44.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0.05pt 0pt 0.05pt 0pt;">(In&#160;thousands except unit and per unit data)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Per Unit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-size:10pt;font-weight:bold;">Value </b><sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Balance at December 31, 2019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 91,151</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 44.63</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 6,154</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 31,731</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 50.41</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;">Vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (26,204)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 33.58</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;">Cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (17,375)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 52.87</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Balance at December 31, 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 79,303</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 47.83</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 3,564</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 39,419</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 51.82</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;">Vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (34,159)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 33.98</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;">Cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (30,246)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 64.39</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Balance at December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 54,317</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 50.22</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 1,034</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 131,710</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 18.54</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;">Vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (4,407)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 12.31</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;">Cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (26,002)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 42.53</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Balance at December 31, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 155,618</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 25.05</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 1,786</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;padding-bottom:6pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-size:1pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><div style="margin-top:0pt;"/><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 12pt 0pt;">(1)</td><td style="padding:0pt 0pt 12pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-style:normal;font-weight:normal;">The aggregate intrinsic value of performance-based restricted stock units outstanding was based on our closing stock price on the last trading day of the period</span></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Employee Stock Purchase Plan</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">Our employee stock purchase plan (&#8220;ESPP&#8221;), which was approved by our Board of Directors on April 27, 2016, and by our stockholders on June 20, 2016, allows participating employees to purchase shares of our common stock at a discount through payroll deductions. The ESPP is available to all of our employees and employees of participating subsidiaries. Participating employees may purchase common stock, on a voluntary after-tax basis, at a price equal to 85% of the lower of the closing market price per share of our common stock on the first or last trading day of each stock purchase period. The ESPP provides for six-month purchase periods, beginning on May 16 and November 16 of each calendar year. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">A total of 1,600,000 shares of common stock was initially reserved for issuance under the ESPP. This share reserve will automatically be supplemented each January 1, commencing in 2017 and ending on and including January 1, 2026, by an amount equal to the least of (a) 1% of the shares of our common stock outstanding on the immediately preceding December 31, (b) 500,000 shares or (c) such lesser amount as our Board of Directors may determine. Pursuant to the automatic increase feature of the ESPP, 194,518 shares were added as available for issuance thereunder on January 1, 2021. Our Board of Directors exercised its prerogative to forego the automatic increase on each of January 1, 2023 and 2022. As of December&#160;31,&#160;2022, 1,559,151 shares were available for future issuance under the ESPP. We recognized $0.8 million, $0.8 million and $0.9 million in stock-based compensation expense related to the ESPP for the years ended December&#160;31,&#160;2022, 2021 and 2020, respectively.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139814960214480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenue</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Note 14. &#160;Revenue</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">We derive our revenue from the sale and rental of our products to our customers in the United States. The following table presents our revenue, inclusive of sales and rental revenue, disaggregated by product:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:44.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:44.76%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:55.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:44.76%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:55.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:44.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0.05pt 0pt 0.05pt 0pt;">(In&#160;thousands)</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:44.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Revenue</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:44.76%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Lymphedema products</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 212,266</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 202,913</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 187,130</p></td></tr><tr><td style="vertical-align:bottom;width:44.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Airway clearance products</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 34,519</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 5,144</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:44.76%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 246,785</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 208,057</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 187,130</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:44.76%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Percentage of total revenue</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:44.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Lymphedema products</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;">86%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;">98%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;">100%</p></td></tr><tr><td style="vertical-align:bottom;width:44.76%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Airway clearance products</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;">14%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;">2%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;">N.M.</p></td></tr><tr><td style="vertical-align:bottom;width:44.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;">100%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;">100%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.93%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;">100%</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-size:1pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">Our revenue by channel, inclusive of sales and rental revenue, for the years ended December&#160;31,&#160;2022, 2021 and 2020 are summarized in the following table:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:44.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.76%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:55.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:44.76%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:55.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:44.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0.05pt 0pt 0.05pt 0pt;">(In&#160;thousands)</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:44.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Private insurers and other payers</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 139,087</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 141,377</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 132,789</p></td></tr><tr><td style="vertical-align:bottom;width:44.76%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Veterans Administration</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 25,507</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 25,654</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 24,485</p></td></tr><tr><td style="vertical-align:bottom;width:44.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Medicare</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 47,672</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 35,882</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 29,856</p></td></tr><tr><td style="vertical-align:bottom;width:44.76%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Durable medical equipment distributors</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 34,519</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 5,144</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:44.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 246,785</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 208,057</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.93%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 187,130</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="font-size:1pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;"><span style="font-size:10pt;">Our rental revenue is derived from rent-to-purchase arrangements that typically range from </span><span style="-sec-ix-hidden:Hidden_8JEPt4Tv9EexWjz9141gSw;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">three</span></span><span style="font-size:10pt;"> to </span><span style="font-size:10pt;">ten months</span><span style="font-size:10pt;">. As title transfers to the patient, with whom we have the contract, upon the termination of the lease term and because collectability is probable, under ASC 842, these are recognized as sales-type leases. Each rental agreement contains two components, the controller and related garments, both of which are interdependent and recognized as one lease component. </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:11pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 11pt 0pt;">The revenue and associated cost of revenue of sales-type leases are recognized on the lease commencement date and a net investment in leases is recorded on the Consolidated Balance Sheet. We bill the patients&#8217; insurance payers monthly over the duration of the rental term. We record the net investment in leases and recognize revenue upon commencement of the lease in the amount of the expected consideration to be received through the monthly payments. Similar to our sales revenue, the transaction price is impacted by multiple factors, including the terms and conditions contracted by various third party payers. As the rental contract resides with the patients, we have elected the portfolio approach, at the payer level, to determine the expected consideration, which considers the impact of early terminations. While the contract is with the patient, in certain circumstances, the third party payer elects an initial rental period with an option to extend. We assess the likelihood of extending the lease at the onset of the lease to determine if the option is reasonably certain to be exercised. As the lease is short-term in nature, we anticipate collection of substantially all of the net investment within the first year of the lease agreement. Completion of these payments represents the fair market value of the equipment, and as such, interest income is not applicable. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:11pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt 0pt 11pt 0pt;">Rental revenue for the years ended December&#160;31,&#160;2022, 2021 and 2020, was primarily related to private insurers. Sales-type lease revenue and the associated cost of revenue for the years ended December&#160;31,&#160;2022, 2021 and 2020, was:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:37.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:37.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:56.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:37.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">(In&#160;thousands)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:37.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Sales-type lease revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 35,440</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 30,143</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 25,633</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:37.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Cost of sales-type lease revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,190</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,622</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,011</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:37.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Gross profit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 24,250</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20,521</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 16,622</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI https://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139814960305616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Note 15. &#160;Income Taxes</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">The provision (benefit) for income tax expense consisted of the following:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:52.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:52.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:44.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:52.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0.05pt 0pt 0.05pt 0pt;">(In&#160;thousands)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:52.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Current income taxes, Federal</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 1,838</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (1,274)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (653)</p></td></tr><tr><td style="vertical-align:bottom;width:52.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Current income taxes, State</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 637</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 214</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 294</p></td></tr><tr><td style="vertical-align:bottom;width:52.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 2,475</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (1,060)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (359)</p></td></tr><tr><td style="vertical-align:bottom;width:52.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Deferred income taxes, Federal</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (32)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 7,874</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (833)</p></td></tr><tr><td style="vertical-align:bottom;width:52.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Deferred income taxes, State</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 2,356</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (395)</p></td></tr><tr><td style="vertical-align:bottom;width:52.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (32)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 10,230</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (1,228)</p></td></tr><tr><td style="vertical-align:bottom;width:52.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Unrecognized tax benefit, Federal</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (50)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 348</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:52.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Unrecognized tax benefit, State</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (54)</p></td></tr><tr><td style="vertical-align:bottom;width:52.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (50)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 348</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (54)</p></td></tr><tr><td style="vertical-align:bottom;width:52.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;">Total provision (benefit) for income taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 2,393</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 9,518</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (1,641)</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="font-size:1pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">The components of our deferred tax assets and liabilities were as follows:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:61.32%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:35.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">At December&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0.05pt 0pt 0.05pt 0pt;">(In&#160;thousands)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Deferred tax assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.32%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 12pt;">Operating lease liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 5,945</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 6,490</p></td></tr><tr><td style="vertical-align:bottom;width:61.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 12pt;">Net operating loss carryforwards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 179</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 671</p></td></tr><tr><td style="vertical-align:bottom;width:61.32%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 12pt;">Accounts receivable and inventory reserves</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 6,013</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 4,658</p></td></tr><tr><td style="vertical-align:bottom;width:61.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 12pt;">Stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 4,886</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 3,777</p></td></tr><tr><td style="vertical-align:bottom;width:61.32%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 12pt;">Accrued liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 1,914</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 1,104</p></td></tr><tr><td style="vertical-align:bottom;width:61.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 12pt;">Warranty reserves</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 1,071</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 1,245</p></td></tr><tr><td style="vertical-align:bottom;width:61.32%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 12pt;">Intangible assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 2,947</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 579</p></td></tr><tr><td style="vertical-align:bottom;width:61.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 12pt;">Business credits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 536</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 682</p></td></tr><tr><td style="vertical-align:bottom;width:61.32%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 12pt;">R&amp;D expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 1,103</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:61.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 12pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 183</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 199</p></td></tr><tr><td style="vertical-align:bottom;width:61.32%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Total deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 24,777</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 19,405</p></td></tr><tr><td style="vertical-align:bottom;width:61.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.32%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Deferred tax liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 12pt;">Right-of-use asset</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (5,425)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (6,019)</p></td></tr><tr><td style="vertical-align:bottom;width:61.32%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 12pt;">Fixed assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (1,080)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (914)</p></td></tr><tr><td style="vertical-align:bottom;width:61.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 12pt;">Prepaid expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (251)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (378)</p></td></tr><tr><td style="vertical-align:bottom;width:61.32%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 12pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (186)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (87)</p></td></tr><tr><td style="vertical-align:bottom;width:61.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Total deferred tax liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (6,942)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (7,398)</p></td></tr><tr><td style="vertical-align:bottom;width:61.32%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 12pt;">Valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (17,835)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (12,039)</p></td></tr><tr><td style="vertical-align:bottom;width:61.32%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Net deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (32)</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;padding-bottom:12pt;background:#ffffff;margin:0pt;"><span style="font-size:1pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">A reconciliation of income tax (benefit) expense to the statutory federal tax rate is as follows:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:53.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:44.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:53.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:53.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Tax expense at statutory rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:53.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">State income taxes, net of federal benefit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 4.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (1.1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (7.9)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Executive compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (14.2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (5.5)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Meals and entertainment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (10.6)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Incentive stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (0.4)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Employee Stock Purchase Plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (1.0)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (7.5)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (8.6)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Federal business credits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 1.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 10.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (37.4)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (525.0)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 8.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Return to provision</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (0.2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (6.5)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 3.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Research and development credits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 60.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">IRS exam</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 2.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Deferred reprice - state</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 0.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 3.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Federal carryback claim deferred rate differential</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 38.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Unrecognized tax benefits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (0.3)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (2.2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 2.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Excess benefit on non-qualified stock options and RSUs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (3.7)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 47.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 28.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Interest and penalties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (0.7)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 1.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (0.5)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (0.5)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (0.2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;">Net effective rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (15.5)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (415.1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 72.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;">%</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;"><span style="font-size:1pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">A reconciliation of unrecognized tax benefits (&#8220;UTB&#8221;) is as follows:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:54.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:54.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:43.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:54.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0.05pt 0pt 0.05pt 0pt;">(In&#160;thousands)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:54.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Balance beginning of the year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 522</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 54</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:54.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Gross change &#8212; tax positions in prior year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 90</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 522</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (54)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:54.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;">Balance end of the year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 612</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 522</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-size:1pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:14pt;padding-top:2pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">Deferred income taxes result from temporary differences between the reporting of amounts for financial statement purposes and income tax purposes. These differences relate primarily to different methods used for income tax purposes including depreciation and amortization, warranty and vacation accruals, and deductions related to allowances for doubtful accounts receivable, and inventory reserves.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:14pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">As of December 31, 2022, the Company had approximately $179 thousand of state net operating loss ("NOL") carryforwards. The state NOL carryforward amounts expire beginning in tax years 2027 if not utilized.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:14pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">The Company is subject to income tax examinations in the U.S. federal jurisdiction as well as in various state jurisdictions. U.S. federal and state tax years prior to 2019 are closed to examination. In the event of any future tax assessments, we have elected to record the income taxes and any related interest and penalties as income tax expense on our Consolidated Statement of Operations. The Company is not under exam in any jurisdictions.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:14pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">We recognize the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. For tax positions meeting the more likely than not threshold, the amount recognized in the consolidated financial statements is the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement with the relevant tax authority. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:14pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">Management assesses the available positive and negative evidence to estimate whether sufficient future taxable income will be generated to permit use of the existing deferred tax assets. A significant piece of objective negative evidence evaluated was the cumulative loss expected to be incurred over the three-year period ended December 31, 2022. Such objective evidence limits the ability to consider other subjective evidence, such as our projections for future growth. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:14pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">On the basis of this evaluation, as of December 31, 2022, a valuation allowance of $17.8 million was recorded to recognize only the portion of the deferred tax assets that is more likely than not to be realized. The amount of the deferred tax assets considered realizable, however, could be adjusted if estimates of future taxable income during the carryforward period are reduced or increased or if objective negative evidence in the form of cumulative losses is no longer present and additional weight is given to subjective evidence such as our projections for growth. <span style="background:#ffff00;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139814960333216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net (Loss) Income Per Common Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net (Loss) Income Per Common Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net (Loss) Income Per Common Share</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Note 16. &#160;Net (Loss) Income Per Common Share</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">The following table sets forth the computation of our basic and diluted net loss per share:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:57.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:57.35%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:42.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.35%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:42.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">(In&#160;thousands,&#160;except&#160;share and per share data)</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:middle;width:57.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (17,866)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (11,811)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (620)</p></td></tr><tr><td style="vertical-align:bottom;width:57.35%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Weighted-average shares outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20,067,969</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19,719,485</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19,346,929</p></td></tr><tr><td style="vertical-align:bottom;width:57.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Weighted-average shares used to compute diluted net loss per share</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20,067,969</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19,719,485</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19,346,929</p></td></tr><tr><td style="vertical-align:bottom;width:57.35%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Net loss per share - Basic</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">(0.89)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">(0.60)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">(0.03)</p></td></tr><tr><td style="vertical-align:bottom;width:57.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Net loss per share - Diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">(0.89)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">(0.60)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">(0.03)</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">The following common stock equivalents were excluded from the computation of diluted net loss per common share for the periods presented because including them would have been anti-dilutive:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:46.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:46.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:53.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:53.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 590,542</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 265,616</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 218,686</p></td></tr><tr><td style="vertical-align:bottom;width:46.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Common stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 615,307</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 915,224</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 1,039,709</p></td></tr><tr><td style="vertical-align:bottom;width:46.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Performance stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 155,618</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 54,317</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 96,383</p></td></tr><tr><td style="vertical-align:bottom;width:46.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Employee stock purchase plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 100,506</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 34,809</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 53,205</p></td></tr><tr><td style="vertical-align:bottom;width:46.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 1,461,973</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 1,269,966</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 1,407,983</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;background:#ffffff;margin:0pt;"><span style="font-size:1pt;font-weight:bold;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139814960240112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Note 17. &#160;Fair Value Measurements</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We determine the fair value of our assets and liabilities based on the exchange price that would be received for an asset or paid to transfer a liability (exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value maximize the use of observable inputs and minimize the use of unobservable inputs. We use a fair value hierarchy with three levels of inputs, of which the first two are considered observable and the last unobservable, to measure fair value. The fair value hierarchy gives the highest priority to quoted prices in active markets for identical assets or liabilities (Level 1). The next highest priority is based on quoted prices for similar assets or liabilities in active markets or quoted prices for identical or similar assets or liabilities in non-active markets or other observable inputs (Level 2). The lowest priority is given to unobservable inputs (Level 3). As of December 31, 2021, we no longer had any money market mutual funds. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">We have obligations to pay a $5.0 million agreed-upon earn-out payment in cash and up to an additional $10.0 million earn-out payment in cash if certain future U.S. revenues of the AffloVest are met. The earn-out liability was valued by employing a Monte Carlo Simulation model in a risk-neutral framework, which is a Level 3 input. The underlying simulated variable includes recognized revenue. The recognized revenue volatility estimate was based on a study of historical asset volatility for a set of comparable public companies. The model includes other assumptions including the market price of risk, which was calculated as the weighted average cost of capital less the long-term risk-free rate. The earn-out liability is adjusted to fair value at each reporting date until settled. Changes in fair value will be included in intangible asset amortization and earn-out expenses in our Consolidated Statements of Operations.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;text-align:justify;margin:0pt;"><span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="background:#ffffff;">Changes in the earn-out liability measured at fair value using Level 3 inputs were as follows:</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;background:#ffffff;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:69.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0.05pt 0pt 0.05pt 0pt;">(In&#160;thousands)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:26.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:69.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Earn-out liability at December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 6,200</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:69.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;">Addition for acquisition</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:69.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;">Payment on earn-out</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (5,000)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:69.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;">Fair value adjustments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 11,850</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:69.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Earn-out liability at December 31, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 13,050</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;text-align:justify;margin:0pt;"><span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">As of December 31, 2022, the fair value of the earn-out liability accrued but not yet earned totaled $8.1 million and was classified as a current liability. The remaining $5.0 million of the earn-out liability had been earned and is to be paid by May 26, 2023.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following provides information regarding fair value measurements for our remaining contingent earn-out liability as of December&#160;31,&#160;2022, and December 31, 2021, according to the three-level fair value hierarchy:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:36.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:61.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">At December 31, 2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:36.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Quoted&#160;Prices</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">in&#160;Active</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Markets&#160;for</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Identical</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Observable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unobservable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">(In&#160;thousands)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;3)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:36.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Recurring Fair Value Measurements:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Earn-out liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,050</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,050</p></td></tr><tr><td style="vertical-align:bottom;width:36.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,050</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,050</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:36.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:61.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">At December 31, 2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:36.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Quoted&#160;Prices</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">in&#160;Active</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Markets&#160;for</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Identical</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Observable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unobservable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">(In&#160;thousands)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;3)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:36.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Recurring Fair Value Measurements:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Earn-out liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,200</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,200</p></td></tr><tr><td style="vertical-align:bottom;width:36.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,200</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,200</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:1pt;margin:0pt 0pt 12pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;margin:0pt;">The carrying amounts of financial instruments such as cash equivalents, accounts receivable, other assets, accounts payable, accrued expenses and other liabilities approximate their related fair values due to the short-term maturities of these items. Non-financial assets, such as equipment and leasehold improvements, and intangible assets are subject to non-recurring fair value measurements if they are deemed impaired.<span style="color:#ff0000;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139814958428160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) and pursuant to the rules and regulations of the SEC. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The results for the year ended December&#160;31,&#160;2022, are not necessarily indicative of results to be expected for any future year.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Principles of Consolidation</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our accompanying consolidated financial statements include the accounts of Tactile Systems Technology, Inc. and its wholly owned subsidiary, Swelling Solutions, Inc. All intercompany balances and transactions have been eliminated in consolidation.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcmd_UnusualRisksAndUncertaintiesPolicyTextBlock', window );">Risks and Uncertainties</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Risks and Uncertainties</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:14pt;text-align:justify;background:#ffffff;margin:2pt 0pt 0pt 0pt;"><i style="font-style:italic;">Coronavirus (COVID-19)</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:14pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">The United States economy in general and our business specifically have been negatively affected by the COVID-19 pandemic. We have seen adverse impacts as it relates to the decline in the number of patients that healthcare facilities and clinics are able to treat due to enhanced safety protocols, particularly during 2020, most of 2021 and the first quarter of 2022. We have also seen staffing challenges, both in our organization and at the clinics we serve, as another lingering consequence of the COVID-19 pandemic. While we saw some level of recovery in 2022, ongoing consequences of the pandemic remain uncertain. There are no reliable estimates of how long the pandemic will last, whether any recovery will be sustained or will reverse course, the severity of any resurgence of COVID-19 or variant strains of the virus, the effectiveness of vaccines and attitudes towards receiving them, or what ultimate effects the pandemic will have. For that reason, we are unable to reasonably estimate the long-term impact of the pandemic on our business at this time. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">Since the onset of COVID-19, we have remained proactive to adapt to the needs of our employees, clinicians and patients. We cannot assure you that these changes to our processes and practices will be successful in mitigating the impact of COVID-19 on our business. We continue to evaluate and, if appropriate, will adopt other measures in the future related to the ongoing safety of our employees, clinicians and patients.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:14pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Use of Estimates</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and to disclose contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Comprehensive Loss</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="color:#2b2c2b;">Comprehensive loss reflects the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. Our comprehensive loss represents net loss adjusted for unrealized gains and losses on available-for-sale marketable securities and the related taxes.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Cash and Cash Equivalents</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Cash and cash equivalents consist of all cash on hand and deposits. Our cash was held primarily in checking accounts as of December 31, 2022 and 2021.<b style="font-weight:bold;"> </b>At times the amount of cash on deposit may exceed the federally insured limit of the bank. Deposit accounts at each of the institutions are insured up to $250,000&#160;by the Federal Deposit Insurance Corporation (FDIC). At December 31, 2022 and 2021, the Company exceeded&#160;FDIC&#160;limits at various institutions. The Company has not experienced any losses in such accounts and believes there is little to no exposure to any significant credit risk.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Equity Investments</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Equity Investments</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="color:#2b2c2b;">Equity investments (including equity securities) with readily determinable fair value are reported at fair value, with unrealized gains and losses included in the determination of net loss. For equity investments with no readily determinable fair value, we measure these investments at cost less impairment, if any, plus or minus </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="color:#2b2c2b;">changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. Such observable price changes may include instances where the investee issues equity securities to new investors, thus creating a new indicator of fair value, as an example. As of each of December&#160;31,&#160;2022 and 2021, the total carrying value of our equity investments, with no readily determinable fair value, was </span><span style="color:#2b2c2b;">$0.3</span><span style="color:#2b2c2b;"> million, and are included in other non-current assets on our Consolidated Balance Sheets. On an annual basis, we perform a qualitative assessment considering impairment indicators to evaluate whether these investments are impaired and also monitor for any observable price changes. During the years ended December&#160;31,&#160;2022 and 2021, we did not have any impairment loss on these investments. </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Accounts Receivable</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Accounts Receivable</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The majority of our accounts receivable and revenue are from commercial insurance payers and government payers, such as Medicare, the Veterans Administration and Medicaid.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Accounts receivable are recorded based on management&#8217;s assessment of the expected consideration to be received, based on a detailed review of historical pricing adjustments and collections. Management relies on the results of the assessment, which includes payment history of the applicable payer as well as historical patient collections, as a primary source of information in estimating the collectability of our accounts receivable. We update our assessment on a quarterly basis, which to date has not resulted in any material adjustments to the valuation of our accounts receivable. We believe the assessment provides reasonable estimates of our accounts receivable valuation, and therefore we believe that substantially all accounts receivable are fully collectible. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A portion of our claims to Medicare are initially denied and enter the appeals process, where many are ultimately reviewed by an Administrative Law Judge. After final adjudication of all claims, approximately 90% of the claims submitted are approved (this is on a number of claims, not a dollars claimed, basis across all our products). The appeals process can be lengthy, lasting more than a year in most cases. Accordingly, we classify a portion of our Medicare accounts receivable as non-current based on our experience with Medicare collections.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventories</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Inventories</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Inventories are valued at the lower of cost (first-in, first-out method) or net realizable value.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Property and Equipment</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Property and equipment are stated at cost and are depreciated using the straight-line method over their estimated useful lives of <span style="-sec-ix-hidden:Hidden_-K2S-WgBSE6sH7tBYgqsYw;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">three</span></span> to seven years. Leasehold improvements are depreciated over the remaining life of the respective building lease agreement. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Major expenditures for property and equipment are capitalized. Maintenance, repairs and minor renewals are expensed as incurred. When assets are retired or otherwise disposed of, their costs and related accumulated depreciation are removed from the accumulated depreciation accounts and the resulting gains or losses are included in income. The value of demonstration equipment in the possession of our field sales representatives is capitalized and depreciated over the estimated useful life of the equipment. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Revenue Recognition</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We derive revenue from the sales and rentals of our Flexitouch and Entre systems, and from the sales of our AffloVest.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Flexitouch and Entre</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We recognize revenue when control of the product has been transferred to our customer, in the amount of the expected consideration to be received for the product. In general, revenue from the sale or rental of a product is recognized upon shipment, unless circumstances dictate that control has not yet passed to the customer. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We provide a warranty for these products against defects in material and workmanship for a period of <span style="-sec-ix-hidden:Hidden_y-RzrDjl6U6YAkZa8g5tjg;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">one</span></span> to five years on garments and <span style="-sec-ix-hidden:Hidden_2vCz5hZwoEmnfJJOj_Lktg;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">one</span></span> to two years on controllers. In accordance with applicable accounting guidance, we have determined these were assurance warranties and therefore not considered a performance obligation. In addition, we did not evaluate immaterial promised goods or services in the context of the contract. As a result, the sale or rental of these products represent a single performance obligation that is satisfied at a point in time and is short-term in nature. In certain cases, we receive payment from Medicare sales over a period of time that may exceed one year. Despite these extended payment terms, no significant financing component is deemed to exist as the terms are not for the benefit of the patient with whom we have the contract. Rather, the extended payment terms occur as a result of an initial claim denial, which subsequently enters the Medicare appeals process as noted below. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We commercially distribute these products directly to patients who are referred to us by physicians, therapists or nurses. In most cases, there is a third-party payer, such as a commercial insurer, Medicare or the Veterans Administration, involved with the transaction. Our contractual relationship resides with the patient when the third-party payer is either a commercial insurer or Medicare and with the Veterans Administration if the patient is covered under their services. Revenue is recognized from such sales upon transfer of control of the product to the customer at a transaction price determined by collection history. As a result, the transaction price is impacted by multiple factors, including the terms and conditions contracted by various third-party payers, and therefore payments from third-party payers typically are less than our standard charge and represent an implicit price concession, resulting in variable consideration. As most contracts are with each individual sale to a patient, we have elected the portfolio approach to determine the transaction price, and ultimately the expected consideration. The portfolios used to determine transaction price are at the payer level, with pricing for each payer assessed based on the underlying similar characteristics. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For any of our products sold to patients covered by private payers, such as commercial insurance companies, revenue is recognized upon shipment. A product is not shipped until we have received a prescription from a physician for our products and, as applicable, receipt of prior authorization from payers. At shipment, we invoice the payer for the total product price, and we recognize revenue in the amount of cash consideration anticipated to be received based on the transaction price. After the insurance payer has remitted payment, we separately invoice the patient for their portion of the payment obligation, such as copayments and deductibles. The transaction price is determined based on the payment history of the applicable payer drawn from actual write-off and collections experience from the payer over a rolling 12-month period, as well as historical patient collections. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For our products sold to Medicare patients, we recognize revenue from such sales upon shipment of our products, which can occur only after we have received a prescription from a physician and all applicable patient documentation is obtained. The transaction price for our Entre systems is determined based on the payment history using the same methodology as our private insurers. A portion of our claims for our Flexitouch system are initially denied, and enter the appeals process, which can be lengthy. We assess the variable consideration for each of these claims as a percentage of the total invoice price based on ultimate approval and collection history. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For our products sold to the Veterans Administration on behalf of the patient, our contract is with the Veterans Administration rather than the patient. We enter into individual sales contracts with the Veterans Administration on behalf of each patient. These contracts determine the amount of consideration, which is typically paid in full within <span style="-sec-ix-hidden:Hidden_29m0XALLYEGpUDkg67Logg;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">2</span></span>-3 days of shipment, and therefore there is no implicit price concession. In addition, the contracts provide for the right of control to transfer to the Veterans Administration upon delivery of the product to the patient, at which time revenue is recognized.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We incur incremental costs that directly relate to the sales of our products; however, as the amortization period would be less than one year, we have elected the practical expedient to expense these costs as incurred.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We sell and rent these products either directly to patients or the Veterans Administration on behalf of patients, who are referred to us by physicians, therapists or nurses. We bill private insurers and other payers, Medicare, and the Veterans Administration directly for purchases or rentals of our product on behalf of a patient and bill patients directly for their cost-sharing amounts, including any portion of an unsatisfied deductible and any copayments or co-insurance obligation. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A portion of our revenue is derived from patients who obtain our products under multiple-month rental arrangements. We bill these patients&#8217; insurance payers monthly over the duration of the rental term. Title to these products passes to the patients at the end of the rental period. Rental agreements are recorded as sales-type leases in accordance with Accounting Standards Update (&#8220;ASU&#8221;) No.&#160;2016-02, &#8220;Leases&#8221; (Topic 842) (&#8220;ASC 842&#8221;). Accordingly, as sales-type leases, the transaction price for the entire rental term is recognized upon transfer of control. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">AffloVest</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The AffloVest device is sold through durable medical equipment providers. Revenue is recognized when control of the promised goods or services is transferred to the distributors, in an amount that reflects the consideration we expect to be entitled to in exchange for transferring those goods or providing services. We account for a contract when it has approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance and collectability of consideration is probable. When determining whether the distributor has obtained control of the goods or services, we consider any future performance obligations. Generally, there is no post-shipment obligation on products sold other than warranty obligations in the normal and ordinary course of business. Consequently, revenue from the sale of the AffloVest product is recognized at shipment, unless circumstances dictate that control has not yet passed to the distributor.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Certain of our contracts include volume-based incentives which involve rebates that are negotiated at or prior to the time of sale with the customer and are redeemable only if the customer achieves a specified cumulative level of sales or sales increase. Under these incentive programs, at the time of sale, we determine the most likely amount of the rebate to be paid based on forecasted sales levels. These forecasts are updated at least quarterly for applicable customers, and the transaction price is reduced for the anticipated cost of the rebate. If the forecasted sales for a customer change, the accrual for rebates is adjusted to reflect the new rebates expected to be earned by the customer.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Amounts billed to customers for shipping and handling activities after the customer obtains control are treated as a promised service performance obligation and recorded in revenue in the accompanying Consolidated Statements of Operations. Shipping and handling costs incurred for the delivery of goods to customers are considered a cost to fulfill the contract and are included in cost of revenue sold in the accompanying Consolidated Statements of Operations.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We provide a warranty for the AffloVest products against defects in material and workmanship for a period of five years. In accordance with applicable accounting guidance, we have determined these were assurance warranties and therefore not considered a performance obligation. In addition, we did not evaluate immaterial promised goods or services in the context of the contract. As a result, the sale of these products represents a single performance obligation that is satisfied at a point in time and is short-term in nature.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvertisingCostsPolicyTextBlock', window );">Advertising</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Advertising</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Advertising costs are charged to operations when incurred. Advertising expense was $0.1 million for each of the years ended December&#160;31,&#160;2022, 2021 and 2020.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Research and Development Costs</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We expense research and development costs as incurred, including expenses associated with clinical research studies and development.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfSalesPolicyTextBlock', window );">Shipping and Handling Costs</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Shipping and Handling Costs</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Amounts billed to customers for shipping and handling activities after the customer obtains control are treated as a promised service performance obligation and recorded in&#160;total revenue&#160;in the accompanying Consolidated Statements of Operations. Shipping and handling costs incurred for the delivery of goods to customers are considered a cost to fulfill the contract and are included in&#160;cost of revenue&#160;in the accompanying Consolidated Statements of Operations.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StandardProductWarrantyPolicy', window );">Product Warranty</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Product Warranty</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We provide a warranty for our products against defects in material and workmanship for a period of <span style="-sec-ix-hidden:Hidden_9oGSvawUkUuA-bl9OI56kg;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">one</span></span> to five years. We record a liability for future warranty claims at the time of sale for the warranty period offered to a customer. If the assumptions used in calculating the provision were to materially change, such as incurring higher than anticipated warranty claims, an additional provision may be required.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Impairment of Long-Lived Assets </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We review long-lived assets, including property and equipment and patents, for impairment whenever events or changes in business circumstances indicate that the carrying amount of an asset may not be fully recoverable. We will assess long-lived assets used in operations for impairment indicators, including when undiscounted cash flows estimated to be generated by those assets are less than the assets&#8217; carrying amount (see Note 8 &#8211; &#8220;Goodwill and Intangible Assets&#8221;).</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy', window );">Goodwill</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Goodwill</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Goodwill represents the excess of the purchase price paid over the estimated fair value of the net assets acquired and liabilities assumed in the acquisition of a business. Goodwill is not amortized, but is tested for impairment at least annually or on an interim basis if an event occurs or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying value. We perform our annual assessment of goodwill for impairment as of July 1st&#160;of each fiscal year. See Note 8 &#8211; &#8220;Goodwill and Intangible Assets&#8221; for additional information.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Stock-Based Compensation</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Stock options are valued using the Black-Scholes option-pricing model, except that the valuation of certain &#8220;CEO&#8221; related stock options subject to a market condition involve the use of the Monte Carlo Simulation model. The Monte Carlo Simulation and the Black-Scholes valuation models require the input of highly subjective assumptions. The assumptions include the expected term of the option, the expected volatility of the price of our common stock, expected dividend yield and the risk-free interest rate. These estimates involve inherent uncertainties and the significant application of management&#8217;s judgment. If factors change and different assumptions are used, our stock-based compensation expense could be materially different in the future. We recognize compensation expense for these options on a straight-line basis over the requisite service period (see Note 13 &#8211; &#8220;Stockholders&#8217; Equity&#8221;).</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Income Taxes</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Income taxes are accounted for under the liability method. Deferred income taxes are provided for temporary differences between the financial reporting and the tax basis of assets and liabilities. If we determine in the future that it is more likely than not that we will not realize all or a portion of the deferred tax assets, we will record a valuation allowance in the period the determination is made (see Note 15 &#8211; &#8220;Income Taxes&#8221;). Changes in tax rates are reflected in the tax provision as they occur.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net (Loss) Income Per Common Share</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Net (Loss) Income Per Common Share</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;"> </span>Basic net (loss) income per common share is computed based on the weighted average number of shares of common stock outstanding during the period. Diluted net (loss) income per common share is computed based on the weighted average number of shares of common stock plus the effect of dilutive potential stock-based awards outstanding during the period using the treasury stock method. Dilutive potential stock-based awards include outstanding common stock options, time- and performance-based restricted stock units and employee stock purchase plan shares.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Business Segments</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Business Segments</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We operate and report in only&#160;one&#160;operating and <span style="-sec-ix-hidden:Hidden_hf125MM_GkGhx3Sj6QqkPA;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">reportable</span></span> segment. Our chief operating decision maker does not use financial information below revenue to allocate resources.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcmd_NewAccountingPronouncementsNoteYetAdoptedPolicyPolicyTextBlock', window );">Accounting Pronouncement Not Yet Adopted</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Accounting Pronouncement Not Yet Adopted</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In December 2022, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued ASU No. 2022-06, &#8220;Reference Rate Reform (Topic 848) &#8212; Facilitation of the Effect of Reference Rate Reform on Financial Reporting&#8221; (&#8220;ASU 2022-06&#8221;), which provides optional expedients and exceptions for applying GAAP to transactions affected by reference rate (e.g., LIBOR) reform if certain criteria are met, for a limited period of time to ease the potential burden in accounting for (or recognizing the effects of) reference rate reform on financial reporting. The ASU deferred the sunset date of Topic 848 from December 31, 2022 to December 31, 2024. The ASU is effective as of December 21, 2022 through December 31, 2024. We continue to evaluate transactions or contract modifications occurring as a result of reference rate reform and determine whether to apply the optional guidance on an ongoing basis. We have not elected any expedients to date and are currently evaluating any potential future impacts on the consolidated financial statements. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcmd_NewAccountingPronouncementsNoteYetAdoptedPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements not yet adopted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcmd_NewAccountingPronouncementsNoteYetAdoptedPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcmd_UnusualRisksAndUncertaintiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the nature of the unusual risk or uncertainty, such as the threat of expropriation of its assets by a foreign government, rapid technological obsolescence in the industry, risk of natural disaster from earthquake or weather events, and disease pandemic.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcmd_UnusualRisksAndUncertaintiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for advertising cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfSalesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cost of product sold and service rendered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 705<br> -URI https://asc.fasb.org/topic&amp;trid=2122478<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfSalesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=2144439<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI https://asc.fasb.org/topic&amp;trid=2126998<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 330<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6471895&amp;loc=d3e55923-109411<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126900757&amp;loc=d3e543-108305<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI https://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -URI https://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StandardProductWarrantyPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for standard warranties including the methodology for measuring the liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126907703&amp;loc=d3e12565-110249<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StandardProductWarrantyPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e4975-111524<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5212-111524<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=SL6953423-111524<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5093-111524<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5033-111524<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139814961411664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAbstract', window );"><strong>Acquisitions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionTableTextBlock', window );">Summary of purchase price allocation</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:25.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0.05pt 0pt 0.05pt 0pt;">(In&#160;millions)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:29.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;">Allocated Fair Value</p></td></tr><tr><td style="vertical-align:bottom;width:66.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Inventories</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 1.6</p></td></tr><tr><td style="vertical-align:bottom;width:66.78%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Property and equipment<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.03%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:66.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Intangible assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 53.5</p></td></tr><tr><td style="vertical-align:bottom;width:66.78%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Goodwill</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 31.1</p></td></tr><tr><td style="vertical-align:bottom;width:66.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;">Purchase price </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 86.2</p></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-decoration-line:none;text-transform:none;vertical-align:baseline;white-space:nowrap;width:18pt;padding:0pt 0pt 6pt 0pt;">(1)</td><td style="padding:0pt 0pt 6pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-style:normal;font-weight:normal;">The purchase price included less than </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-style:normal;font-weight:normal;">$0.1</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-style:normal;font-weight:normal;"> million of property and equipment.</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-style:normal;font-weight:normal;"> </span></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcmd_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfAssetAcquisitionTableTextBlock', window );">Schedule of allocation of the purchase price</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt;">The following table reflects the allocation of purchase price to the acquired intangible assets and related estimated useful lives:&#160;</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:21.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:20.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">(In&#160;millions)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">Allocated Fair Value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">Estimated Useful Life</p></td></tr><tr><td style="vertical-align:bottom;width:49.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Customer relationships</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 31.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">13 years</p></td></tr><tr><td style="vertical-align:bottom;width:49.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Developed technology</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">11 years</p></td></tr><tr><td style="vertical-align:bottom;width:49.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Tradenames</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">Indefinite</p></td></tr><tr><td style="vertical-align:bottom;width:49.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total intangible assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 53.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionProFormaInformationTextBlock', window );">Schedule of condensed consolidated statements of operations reflect AffoVest operations</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:41.04%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">Year Ended</p></td></tr><tr><td style="vertical-align:bottom;width:55.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:41.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">December&#160;31,&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:55.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">(In&#160;thousands)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">2020</p></td></tr><tr><td style="vertical-align:bottom;width:55.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Total revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 219,414</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 203,193</p></td></tr><tr><td style="vertical-align:bottom;width:55.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Net (loss) income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (7,633)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,832</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcmd_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfAssetAcquisitionTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of finite-lived and indefinite-lived intangible assets acquired as part of a asset acquisition agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcmd_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfAssetAcquisitionTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 15<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=6911878&amp;loc=d3e8732-128492<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionProFormaInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionProFormaInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139814960299504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventories</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of inventories</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:40.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:25.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:25.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:40.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0.05pt 0pt 0.05pt 0pt;">(In&#160;thousands)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:27.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">At December&#160;31,&#160;2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:27.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">At December&#160;31,&#160;2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:40.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Finished goods</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 5,100</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 8,242</p></td></tr><tr><td style="vertical-align:bottom;width:40.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Component parts and work-in-process</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 18,024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 10,975</p></td></tr><tr><td style="vertical-align:bottom;width:40.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;">Total inventories</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 23,124</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 19,217</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139814960243344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of components of property and equipment</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:53.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:53.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:43.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">At December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:53.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">(In&#160;thousands)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:53.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,274</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,051</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:53.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Tooling</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,390</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,545</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:53.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Furniture and fixtures</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,087</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,104</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:53.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,493</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,458</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:53.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Demonstration equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,012</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 632</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:53.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Construction in progress</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 606</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,003</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:53.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Subtotal</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.44%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 16,862</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.44%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,793</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:53.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Less: accumulated depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (10,785)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (9,043)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:53.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,077</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,750</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139814960275824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of finite lived intangible assets</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:30.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:48.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">At December&#160;31,&#160;2022</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortization</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Carrying</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Net</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">(In&#160;thousands)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Period</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortization</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Definite-lived intangible assets:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Patents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">12 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 897</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 173</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 724</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Defensive intangible assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,126</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 764</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 362</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Customer accounts</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&lt; 1 year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 125</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 114</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Customer relationships</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">12 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 31,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,127</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 27,873</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Developed technology</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">10 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,550</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,450</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Subtotal</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 46,148</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,728</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 40,420</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Unamortized intangible assets:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Tradenames</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,500</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Patents pending</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 455</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 455</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total intangible assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 56,103</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,728</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 50,375</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:30.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:48.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">At December&#160;31,&#160;2021</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amortization</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Carrying</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0.05pt 0pt 0.05pt 0pt;">(In&#160;thousands)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Period</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amortization</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Definite-lived intangible assets:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Patents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;">12 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 666</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 109</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 557</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Defensive intangible assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;">3 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 1,125</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 592</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 533</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Customer accounts</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;">1 year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 125</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 89</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 36</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Customer relationships</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;">13 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 31,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 742</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 30,258</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Developed technology</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;">11 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 13,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 368</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 12,632</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;">Subtotal</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 45,916</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 1,900</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 44,016</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unamortized intangible assets:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Tradenames</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 9,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 9,500</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Patents pending</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 565</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 565</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;">Total intangible assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 55,981</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 1,900</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 54,081</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of future amortization expense</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:30.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:54.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">(In&#160;thousands)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:30.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:30.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,808</p></td></tr><tr><td style="vertical-align:bottom;width:54.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:30.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,787</p></td></tr><tr><td style="vertical-align:bottom;width:54.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:30.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,697</p></td></tr><tr><td style="vertical-align:bottom;width:54.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:30.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,633</p></td></tr><tr><td style="vertical-align:bottom;width:54.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:30.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,623</p></td></tr><tr><td style="vertical-align:bottom;width:54.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:30.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21,872</p></td></tr><tr><td style="vertical-align:bottom;width:54.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:30.85%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 40,420</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139814960312912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcmd_ScheduleOfAccruedExpensesTableTextBlock', window );">Schedule of Accrued Expenses</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:34.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:27.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:27.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:34.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">(In&#160;thousands)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:30.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">At December&#160;31,&#160;2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:30.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">At December&#160;31,&#160;2021</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:34.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">In-transit inventory</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,228</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 416</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:34.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Warranty</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.87%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,005</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.87%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,851</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:34.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Travel</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,121</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 661</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:34.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Legal and consulting</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.87%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 730</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.87%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,371</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:34.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Clinical studies</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 276</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 113</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:34.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Sales and use tax</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.87%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 147</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.87%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 106</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:34.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,733</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 744</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:34.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,240</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,262</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcmd_ScheduleOfAccruedExpensesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying value as of the balance sheet date of accrued expenses excluding accounts payable. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcmd_ScheduleOfAccruedExpensesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139814960369872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warranty Reserves (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StandardProductWarrantyDisclosureAbstract', window );"><strong>Warranty Reserves</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock', window );">Schedule of warranty reserves</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:40.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:40.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:59.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:40.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:59.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:40.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">(In&#160;thousands)</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:40.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Beginning balance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,959</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,841</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,759</p></td></tr><tr><td style="vertical-align:bottom;width:40.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Warranty provision</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.76%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,047</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.78%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,606</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,957</p></td></tr><tr><td style="vertical-align:bottom;width:40.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Processed warranty claims</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (2,794)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (2,488)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (1,875)</p></td></tr><tr><td style="vertical-align:bottom;width:40.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Ending balance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,212</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,959</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,841</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:40.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#ff0000;font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Accrued warranty reserve, current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.76%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,005</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.78%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,851</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,606</p></td></tr><tr><td style="vertical-align:bottom;width:40.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Accrued warranty reserve, non-current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,207</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,108</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,235</p></td></tr><tr><td style="vertical-align:bottom;width:40.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total accrued warranty reserve</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,212</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,959</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,841</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in the guarantor's aggregate product warranty liability, including the beginning balance of the aggregate product warranty liability, the aggregate reductions in that liability for payments made (in cash or in kind) under the warranty, the aggregate changes in the liability for accruals related to product warranties issued during the reporting period, the aggregate changes in the liability for accruals related to preexisting warranties (including adjustments related to changes in estimates), and the ending balance of the aggregate product warranty liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126907703&amp;loc=d3e12565-110249<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StandardProductWarrantyDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StandardProductWarrantyDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139814960184944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Credit Agreement (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Credit Agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of maturities of the term note payable</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:25.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">(In&#160;thousands)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:29.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,000</p></td></tr><tr><td style="vertical-align:bottom;width:66.78%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21,000</p></td></tr><tr><td style="vertical-align:bottom;width:66.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 24,000</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27.35pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139814960192096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcmd_AssetsAndLiabilitiesLesseeTableTextBlock', window );">Summary of lease-related assets and liabilities</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:54.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:54.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">(In&#160;thousands)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">At December&#160;31,&#160;2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">At December&#160;31,&#160;2021</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:54.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_tKPJpXeds0SiabhmYWAMEg;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Right of use operating lease assets</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21,322</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 23,984</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:54.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:54.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Operating lease liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:54.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="-sec-ix-hidden:Hidden_tyE6-ij7k06Rv5IRQ6iD1Q;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Current</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,506</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:54.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="-sec-ix-hidden:Hidden_hRi5aCIDPEGUkAgK0iaGvw;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Non-current</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20,866</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 23,354</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:54.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 23,366</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 25,860</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:54.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:54.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Operating leases: </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:54.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Weighted average remaining lease term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">7.7 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">8.6 years</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:54.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Weighted average discount rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">4.2%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">4.2%</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:54.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="margin-left:0pt;vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:54.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:43.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:54.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:20.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:20.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:54.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Supplemental cash flow information for our operating leases:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:54.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Cash paid for operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,575</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,379</p></td></tr><tr><td style="vertical-align:bottom;width:54.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Non-cash right of use assets obtained in exchange for new operating lease obligations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 49</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,920</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLeaseIncomeTableTextBlock', window );">Summary of undiscounted cash flows</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:65.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:27.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:65.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">(In&#160;thousands)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,427</p></td></tr><tr><td style="vertical-align:bottom;width:65.19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,418</p></td></tr><tr><td style="vertical-align:bottom;width:65.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,517</p></td></tr><tr><td style="vertical-align:bottom;width:65.19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,615</p></td></tr><tr><td style="vertical-align:bottom;width:65.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,167</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:65.19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,082</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:65.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Total minimum lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 27,226</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:65.19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Less: Amount of lease payments representing interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (3,860)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:65.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Present value of future minimum lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 23,366</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:65.19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Less: Current obligations under operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (2,500)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:65.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Non-current obligations under operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20,866</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;padding-left:10.1pt;text-indent:-10.1pt;background:#ffffff;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcmd_AssetsAndLiabilitiesLesseeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The tabular disclosure of lease-related assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcmd_AssetsAndLiabilitiesLesseeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLeaseIncomeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of components of income from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919372-209981<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6A<br> -URI https://asc.fasb.org/extlink&amp;oid=126900988&amp;loc=SL77927221-108306<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLeaseIncomeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139814959508640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of allocation of total stock-based compensation expense</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:59.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:40.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:59.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:40.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">(In&#160;thousands)</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Cost of revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 367</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 433</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 539</p></td></tr><tr><td style="vertical-align:bottom;width:59.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Sales and marketing expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,060</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,069</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,058</p></td></tr><tr><td style="vertical-align:bottom;width:59.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 226</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 314</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 360</p></td></tr><tr><td style="vertical-align:bottom;width:59.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Reimbursement, general and administrative expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,947</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,357</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,732</p></td></tr><tr><td style="vertical-align:bottom;width:59.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,600</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,173</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,689</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of estimated fair values and assumptions for stock options granted</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:33.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:33.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Expected term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:33.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">4.5 years</p></td></tr><tr><td style="vertical-align:bottom;width:62.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:33.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">45.39%</p></td></tr><tr><td style="vertical-align:bottom;width:62.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:33.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">0.4%</p></td></tr><tr><td style="vertical-align:bottom;width:62.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:33.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">0%</p></td></tr><tr><td style="vertical-align:bottom;width:62.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Fair value on the date of grant</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:33.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">$13.60 - $14.70</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:35.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:35.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:35.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Expected term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_EUn6f84eb0OJm-52SjcRtw;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">4.5</span></span> years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_M9XtAoRCQE23lB3X4M3v9w;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">4.5</span></span> years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_iCRDlIEFVkGCl5KX7TVfHQ;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">4.5</span></span> years</p></td></tr><tr><td style="vertical-align:bottom;width:35.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;">59.2%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;">45.0 - 52.3%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;">44.1 - 46.4%</p></td></tr><tr><td style="vertical-align:bottom;width:35.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;">4.3%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;">0.6 - 1.1%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;">0.2 - 0.9%</p></td></tr><tr><td style="vertical-align:bottom;width:35.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;">0%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;">0%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;">0%</p></td></tr><tr><td style="vertical-align:bottom;width:35.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Fair value on the date of grant</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;">$ 8.11</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;">$13.04 - $22.90</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;">$13.45 - $18.64</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-size:1pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of stock option activity</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.11848831%;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:38.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise&#160;Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Intrinsic</b></p></td></tr><tr><td style="vertical-align:bottom;width:38.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0.05pt 0pt 0.05pt 0pt;">(In&#160;thousands except options and per share data)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Per Share </b><sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Contractual Life</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Value </b><sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(2)</sup></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Balance at December 31, 2019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 866,955</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 28.76</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;">6.3 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 33,957</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 378,695</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 44.84</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (147,741)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 7.24</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 6,540</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (54,824)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 50.25</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;">Cancelled/Expired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (3,376)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 63.61</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Balance at December 31, 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 1,039,709</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 36.43</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;">5.6 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 13,381</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 188,748</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 49.33</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (175,516)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 22.65</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 4,901</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (92,773)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 49.77</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;">Cancelled/Expired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (44,944)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 57.78</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Balance at December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 915,224</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 39.33</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;">5.0 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 2,068</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 47,280</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 6.17</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (90,878)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 1.68</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 916</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (92,981)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 36.28</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;">Cancelled/Expired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (163,338)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 37.65</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Balance at December 31, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 615,307</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 43.25</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;">4.7 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 164</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Options exercisable at December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 435,363</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 43.83</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;">4.5 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 84</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;padding-bottom:6pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-size:1pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><div style="margin-top:0pt;"/><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-decoration-line:none;text-transform:none;vertical-align:baseline;white-space:nowrap;width:18pt;padding:0pt 0pt 6pt 0pt;">(1)</td><td style="padding:0pt 0pt 6pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-style:normal;font-weight:normal;">The exercise price of each option granted during the periods shown was equal to the market price of the underlying stock on the date of grant.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-decoration-line:none;text-transform:none;vertical-align:baseline;white-space:nowrap;width:18pt;padding:0pt 0pt 12pt 0pt;">(2)</td><td style="padding:0pt 0pt 12pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-style:normal;font-weight:normal;">The aggregate intrinsic value of options exercised represents the difference between the exercise price of the option and the closing stock price of our common stock on the date of exercise. The aggregate intrinsic value of options outstanding represents the difference between the exercise price of the option and the closing stock price of our common stock on the last trading day of the period.</span></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock', window );">Schedule of Nonvested Share Activity</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:61.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:35.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:35.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number of:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Non-vested options, beginning of the year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 397,908</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 549,843</p></td></tr><tr><td style="vertical-align:bottom;width:61.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Non-vested options, end of the year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 179,944</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 397,908</p></td></tr><tr><td style="vertical-align:bottom;width:61.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Vested options, end of the year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 435,363</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 517,316</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;"><span style="font-size:1pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:61.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:35.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:35.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted-average grant date fair value of: </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Non-vested options, beginning of the year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 18.02</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 18.03</p></td></tr><tr><td style="vertical-align:bottom;width:61.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Non-vested options, end of the year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 16.24</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 18.02</p></td></tr><tr><td style="vertical-align:bottom;width:61.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Vested options, end of the year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 17.53</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 13.27</p></td></tr><tr><td style="vertical-align:bottom;width:61.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Forfeited options, during the year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 14.73</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 19.26</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;padding-bottom:12pt;background:#ffffff;margin:0pt;"><span style="font-size:1pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=tcmd_TimeBasedRestrictedStockUnitsRsusMember', window );">Time-Based Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Schedule of stock-settled restricted stock unit activity</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:46.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:46.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average Grant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Units</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Date Fair Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Intrinsic</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0.05pt 0pt 0.05pt 0pt;">(In&#160;thousands except unit and per unit data)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Per Unit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-size:10pt;font-weight:bold;">Value </b><sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Balance at December 31, 2019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 171,687</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 43.74</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 11,591</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 175,582</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 46.42</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;">Modification</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 2,288</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 21.85</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;">Vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (118,014)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 37.57</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;">Cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (20,074)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 53.03</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Balance at December 31, 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 211,469</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 48.29</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 9,503</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 189,762</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 40.31</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;">Vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (106,521)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 47.43</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;">Cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (35,563)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 51.76</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Balance at December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 259,147</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 42.32</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 4,932</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 539,525</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 15.03</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;">Vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (123,528)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 43.20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;">Cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (84,602)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 26.91</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Balance at December 31, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 590,542</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 19.42</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 6,779</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;padding-bottom:6pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-size:1pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><div style="margin-top:0pt;"/><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 6pt 0pt;">(1)</td><td style="padding:0pt 0pt 6pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-style:normal;font-weight:normal;">The aggregate intrinsic value of time-based restricted stock units outstanding was based on our closing stock price on the last trading day of the period.</span></td></tr></table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=tcmd_PerformanceBasedStockSettledRestrictedStockUnitsMember', window );">Performance-based stock-settled restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Schedule of stock-settled restricted stock unit activity</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:44.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:44.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Performance-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Based</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average Grant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Units</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Date Fair Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Intrinsic</b></p></td></tr><tr><td style="vertical-align:bottom;width:44.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0.05pt 0pt 0.05pt 0pt;">(In&#160;thousands except unit and per unit data)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Per Unit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-size:10pt;font-weight:bold;">Value </b><sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Balance at December 31, 2019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 91,151</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 44.63</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 6,154</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 31,731</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 50.41</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;">Vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (26,204)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 33.58</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;">Cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (17,375)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 52.87</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Balance at December 31, 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 79,303</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 47.83</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 3,564</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 39,419</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 51.82</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;">Vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (34,159)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 33.98</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;">Cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (30,246)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 64.39</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Balance at December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 54,317</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 50.22</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 1,034</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 131,710</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 18.54</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;">Vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (4,407)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 12.31</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;">Cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (26,002)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 42.53</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Balance at December 31, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 155,618</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 25.05</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 1,786</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;padding-bottom:6pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-size:1pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><div style="margin-top:0pt;"/><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 12pt 0pt;">(1)</td><td style="padding:0pt 0pt 12pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-style:normal;font-weight:normal;">The aggregate intrinsic value of performance-based restricted stock units outstanding was based on our closing stock price on the last trading day of the period</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=tcmd_TimeBasedRestrictedStockUnitsRsusMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=tcmd_TimeBasedRestrictedStockUnitsRsusMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=tcmd_PerformanceBasedStockSettledRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=tcmd_PerformanceBasedStockSettledRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139814958463456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Summary of revenue disaggregated by product</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:44.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:44.76%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:55.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:44.76%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:55.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:44.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0.05pt 0pt 0.05pt 0pt;">(In&#160;thousands)</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:44.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Revenue</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:44.76%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Lymphedema products</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 212,266</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 202,913</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 187,130</p></td></tr><tr><td style="vertical-align:bottom;width:44.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Airway clearance products</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 34,519</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 5,144</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:44.76%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 246,785</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 208,057</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 187,130</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:44.76%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Percentage of total revenue</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:44.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Lymphedema products</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;">86%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;">98%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;">100%</p></td></tr><tr><td style="vertical-align:bottom;width:44.76%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Airway clearance products</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;">14%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;">2%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;">N.M.</p></td></tr><tr><td style="vertical-align:bottom;width:44.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;">100%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;">100%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.93%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;">100%</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-size:1pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcmd_ScheduleOfRevenueFromThirdPartyPayersTableTextBlock', window );">Summary of revenue by channel</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:44.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.76%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:55.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:44.76%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:55.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:44.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0.05pt 0pt 0.05pt 0pt;">(In&#160;thousands)</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:44.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Private insurers and other payers</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 139,087</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 141,377</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 132,789</p></td></tr><tr><td style="vertical-align:bottom;width:44.76%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Veterans Administration</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 25,507</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 25,654</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 24,485</p></td></tr><tr><td style="vertical-align:bottom;width:44.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Medicare</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 47,672</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 35,882</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 29,856</p></td></tr><tr><td style="vertical-align:bottom;width:44.76%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Durable medical equipment distributors</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 34,519</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 5,144</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:44.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 246,785</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 208,057</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.93%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 187,130</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="font-size:1pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalesTypeLeaseLeaseIncomeTableTextBlock', window );">Sales-type lease revenue and the associated cost of goods sold</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:37.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:37.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:56.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:37.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">(In&#160;thousands)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:37.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Sales-type lease revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 35,440</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 30,143</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 25,633</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:37.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Cost of sales-type lease revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,190</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,622</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,011</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:37.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Gross profit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 24,250</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20,521</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 16,622</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcmd_ScheduleOfRevenueFromThirdPartyPayersTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue revenues from third-party payers.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcmd_ScheduleOfRevenueFromThirdPartyPayersTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesTypeLeaseLeaseIncomeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of components of income from sales-type lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6A<br> -URI https://asc.fasb.org/extlink&amp;oid=126900988&amp;loc=SL77927221-108306<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919372-209981<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesTypeLeaseLeaseIncomeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139814961322128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of provision (benefit) for income tax expense</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:52.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:52.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:44.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:52.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0.05pt 0pt 0.05pt 0pt;">(In&#160;thousands)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:52.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Current income taxes, Federal</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 1,838</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (1,274)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (653)</p></td></tr><tr><td style="vertical-align:bottom;width:52.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Current income taxes, State</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 637</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 214</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 294</p></td></tr><tr><td style="vertical-align:bottom;width:52.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 2,475</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (1,060)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (359)</p></td></tr><tr><td style="vertical-align:bottom;width:52.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Deferred income taxes, Federal</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (32)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 7,874</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (833)</p></td></tr><tr><td style="vertical-align:bottom;width:52.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Deferred income taxes, State</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 2,356</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (395)</p></td></tr><tr><td style="vertical-align:bottom;width:52.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (32)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 10,230</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (1,228)</p></td></tr><tr><td style="vertical-align:bottom;width:52.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Unrecognized tax benefit, Federal</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (50)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 348</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:52.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Unrecognized tax benefit, State</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (54)</p></td></tr><tr><td style="vertical-align:bottom;width:52.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (50)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 348</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (54)</p></td></tr><tr><td style="vertical-align:bottom;width:52.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;">Total provision (benefit) for income taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 2,393</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 9,518</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (1,641)</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="font-size:1pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of components of the Company's deferred tax assets</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:61.32%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:35.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">At December&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0.05pt 0pt 0.05pt 0pt;">(In&#160;thousands)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Deferred tax assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.32%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 12pt;">Operating lease liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 5,945</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 6,490</p></td></tr><tr><td style="vertical-align:bottom;width:61.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 12pt;">Net operating loss carryforwards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 179</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 671</p></td></tr><tr><td style="vertical-align:bottom;width:61.32%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 12pt;">Accounts receivable and inventory reserves</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 6,013</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 4,658</p></td></tr><tr><td style="vertical-align:bottom;width:61.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 12pt;">Stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 4,886</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 3,777</p></td></tr><tr><td style="vertical-align:bottom;width:61.32%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 12pt;">Accrued liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 1,914</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 1,104</p></td></tr><tr><td style="vertical-align:bottom;width:61.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 12pt;">Warranty reserves</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 1,071</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 1,245</p></td></tr><tr><td style="vertical-align:bottom;width:61.32%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 12pt;">Intangible assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 2,947</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 579</p></td></tr><tr><td style="vertical-align:bottom;width:61.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 12pt;">Business credits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 536</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 682</p></td></tr><tr><td style="vertical-align:bottom;width:61.32%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 12pt;">R&amp;D expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 1,103</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:61.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 12pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 183</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 199</p></td></tr><tr><td style="vertical-align:bottom;width:61.32%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Total deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 24,777</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 19,405</p></td></tr><tr><td style="vertical-align:bottom;width:61.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.32%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Deferred tax liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 12pt;">Right-of-use asset</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (5,425)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (6,019)</p></td></tr><tr><td style="vertical-align:bottom;width:61.32%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 12pt;">Fixed assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (1,080)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (914)</p></td></tr><tr><td style="vertical-align:bottom;width:61.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 12pt;">Prepaid expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (251)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (378)</p></td></tr><tr><td style="vertical-align:bottom;width:61.32%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 12pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (186)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (87)</p></td></tr><tr><td style="vertical-align:bottom;width:61.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Total deferred tax liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (6,942)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (7,398)</p></td></tr><tr><td style="vertical-align:bottom;width:61.32%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 12pt;">Valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (17,835)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (12,039)</p></td></tr><tr><td style="vertical-align:bottom;width:61.32%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Net deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (32)</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;padding-bottom:12pt;background:#ffffff;margin:0pt;"><span style="font-size:1pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of reconciliation of income tax expense (benefit)</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:53.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:44.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:53.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:53.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Tax expense at statutory rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:53.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">State income taxes, net of federal benefit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 4.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (1.1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (7.9)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Executive compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (14.2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (5.5)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Meals and entertainment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (10.6)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Incentive stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (0.4)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Employee Stock Purchase Plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (1.0)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (7.5)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (8.6)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Federal business credits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 1.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 10.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (37.4)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (525.0)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 8.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Return to provision</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (0.2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (6.5)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 3.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Research and development credits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 60.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">IRS exam</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 2.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Deferred reprice - state</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 0.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 3.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Federal carryback claim deferred rate differential</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 38.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Unrecognized tax benefits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (0.3)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (2.2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 2.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Excess benefit on non-qualified stock options and RSUs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (3.7)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 47.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 28.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Interest and penalties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (0.7)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 1.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (0.5)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (0.5)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (0.2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;">Net effective rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (15.5)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (415.1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 72.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;">%</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;"><span style="font-size:1pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Schedule of unrecognized tax benefits ("UTB")</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:54.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:54.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:43.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:54.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0.05pt 0pt 0.05pt 0pt;">(In&#160;thousands)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:54.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Balance beginning of the year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 522</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 54</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:54.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Gross change &#8212; tax positions in prior year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 90</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 522</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (54)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:54.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;">Balance end of the year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 612</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 522</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-size:1pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 55<br> -Paragraph 217<br> -URI https://asc.fasb.org/extlink&amp;oid=126976462&amp;loc=d3e36027-109320<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139814963740784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net (Loss) Income Per Common Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of computation of the basic and diluted net loss per share</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:57.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:57.35%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:42.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.35%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:42.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">(In&#160;thousands,&#160;except&#160;share and per share data)</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:middle;width:57.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (17,866)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (11,811)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (620)</p></td></tr><tr><td style="vertical-align:bottom;width:57.35%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Weighted-average shares outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20,067,969</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19,719,485</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19,346,929</p></td></tr><tr><td style="vertical-align:bottom;width:57.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Weighted-average shares used to compute diluted net loss per share</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20,067,969</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19,719,485</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19,346,929</p></td></tr><tr><td style="vertical-align:bottom;width:57.35%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Net loss per share - Basic</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">(0.89)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">(0.60)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">(0.03)</p></td></tr><tr><td style="vertical-align:bottom;width:57.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Net loss per share - Diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">(0.89)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">(0.60)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">(0.03)</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of potentially dilutive securities outstanding</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:46.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:46.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:53.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:53.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 590,542</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 265,616</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 218,686</p></td></tr><tr><td style="vertical-align:bottom;width:46.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Common stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 615,307</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 915,224</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 1,039,709</p></td></tr><tr><td style="vertical-align:bottom;width:46.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Performance stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 155,618</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 54,317</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 96,383</p></td></tr><tr><td style="vertical-align:bottom;width:46.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Employee stock purchase plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 100,506</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 34,809</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 53,205</p></td></tr><tr><td style="vertical-align:bottom;width:46.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 1,461,973</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 1,269,966</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 1,407,983</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139814958588912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of changes in the earn-out liability</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;background:#ffffff;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:69.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0.05pt 0pt 0.05pt 0pt;">(In&#160;thousands)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:26.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:69.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Earn-out liability at December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 6,200</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:69.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;">Addition for acquisition</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:69.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;">Payment on earn-out</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (5,000)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:69.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;">Fair value adjustments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 11,850</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:69.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Earn-out liability at December 31, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 13,050</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;text-align:justify;margin:0pt;"><span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;background:#ffffff;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Schedule of fair value measurements for our earn-out liability, cash equivalents and marketable securities</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:36.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:61.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">At December 31, 2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:36.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Quoted&#160;Prices</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">in&#160;Active</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Markets&#160;for</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Identical</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Observable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unobservable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">(In&#160;thousands)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;3)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:36.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Recurring Fair Value Measurements:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Earn-out liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,050</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,050</p></td></tr><tr><td style="vertical-align:bottom;width:36.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,050</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,050</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:36.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:61.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">At December 31, 2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:36.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Quoted&#160;Prices</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">in&#160;Active</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Markets&#160;for</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Identical</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Observable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unobservable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">(In&#160;thousands)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;3)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:36.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Recurring Fair Value Measurements:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Earn-out liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,200</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,200</p></td></tr><tr><td style="vertical-align:bottom;width:36.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,200</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,200</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139814961862896">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Nature of Business and Operations (Details) - IPO<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th">
<div>Aug. 02, 2016 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares of common stock sold | shares</a></td>
<td class="nump">4,120,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">IPO price per share (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 10.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from IPO</a></td>
<td class="nump">$ 35.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcmd_ExpenseRelatingToInitialPublicOffering', window );">Expense Relating To Initial Public Offering</a></td>
<td class="nump">$ 2.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcmd_ExpenseRelatingToInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses relating to the initial public offering during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcmd_ExpenseRelatingToInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139814960253664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Segment (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segment</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segment</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139814954422128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValueAbstract', window );"><strong>Equity Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount', window );">Equity security without readily determinable fair value</a></td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetAbstract', window );"><strong>Accounts Receivable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcmd_PercentageOfClaimsApproved', window );">Percentage of claims</a></td>
<td class="nump">90.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionAbstract', window );"><strong>Revenue Recognition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcmd_MedicareReceivablesTimePeriod', window );">Medicare receivables period of time</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuePracticalExpedientIncrementalCostOfObtainingContract', window );">Revenue for practical expedient</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketingAndAdvertisingExpenseAbstract', window );"><strong>Advertising</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvertisingExpense', window );">Advertising Expense</a></td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract', window );"><strong>Property and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionAbstract', window );"><strong>Revenue Recognition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcmd_PeriodForConsiderationPaymentAfterShipmentDate', window );">Period for consideration payment after shipment date</a></td>
<td class="text">2 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract', window );"><strong>Property and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionAbstract', window );"><strong>Revenue Recognition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcmd_PeriodForConsiderationPaymentAfterShipmentDate', window );">Period for consideration payment after shipment date</a></td>
<td class="text">3 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=tcmd_GarmentsMember', window );">Garments | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StandardProductWarrantyDisclosureAbstract', window );"><strong>Product Warranty</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcmd_TermOfProductWarranty', window );">Product Warranty</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=tcmd_GarmentsMember', window );">Garments | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StandardProductWarrantyDisclosureAbstract', window );"><strong>Product Warranty</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcmd_TermOfProductWarranty', window );">Product Warranty</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=tcmd_ControllersMember', window );">Controllers | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StandardProductWarrantyDisclosureAbstract', window );"><strong>Product Warranty</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcmd_TermOfProductWarranty', window );">Product Warranty</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=tcmd_ControllersMember', window );">Controllers | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StandardProductWarrantyDisclosureAbstract', window );"><strong>Product Warranty</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcmd_TermOfProductWarranty', window );">Product Warranty</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=tcmd_AfflovestMember', window );">AffloVest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StandardProductWarrantyDisclosureAbstract', window );"><strong>Product Warranty</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcmd_TermOfProductWarranty', window );">Product Warranty</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcmd_MedicareReceivablesTimePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of term over which the payment from Medicare sales are receivable, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcmd_MedicareReceivablesTimePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcmd_PercentageOfClaimsApproved">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents information pertaining to approved claims based on number of claims.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcmd_PercentageOfClaimsApproved</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcmd_PeriodForConsiderationPaymentAfterShipmentDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the period for consideration payment after shipment date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcmd_PeriodForConsiderationPaymentAfterShipmentDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcmd_TermOfProductWarranty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the term of product warranty.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcmd_TermOfProductWarranty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980263&amp;loc=SL75117539-209714<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketingAndAdvertisingExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketingAndAdvertisingExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuePracticalExpedientIncrementalCostOfObtainingContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether practical expedient was elected to recognize incremental cost of obtaining contract as expense when incurred if amortization period would have been one year or less.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 40<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126905575&amp;loc=SL51790836-203054<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130569-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuePracticalExpedientIncrementalCostOfObtainingContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StandardProductWarrantyDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StandardProductWarrantyDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=tcmd_GarmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=tcmd_GarmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=tcmd_ControllersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=tcmd_ControllersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=tcmd_AfflovestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=tcmd_AfflovestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139814961807280">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Acquisitions (Details)<br></strong></div></th>
<th class="th">
<div>Nov. 04, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 08, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Acquisitions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Earn-out liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,400,000<span></span>
</td>
<td class="nump">$ 13,050,000<span></span>
</td>
<td class="nump">$ 6,200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">Reimbursement, general and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Acquisitions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts', window );">Transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Acquisitions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Earn-out liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=tcmd_AfflovestPMember', window );">AffloVest APA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Acquisitions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcmd_AssetAcquisitionConsiderationTransferredEscrowAccount', window );">Escrow account</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcmd_AssetAcquisitionAmountReceivedResultingFromWorkingCapitalAdjustment', window );">Working capital adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcmd_AssetAcquisitionBusinessRevenueToExceedBaseRevenueMultiplier', window );">Business revenue to exceed base revenue, Multiplier</a></td>
<td class="nump">1.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcmd_AssetAcquisitionEarnOutLiability', window );">Earn-out liability, asset acquisition</a></td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=tcmd_AfflovestPMember', window );">AffloVest APA | Earn-out period exceed Base Revenues from October 1, 2021 to September 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Acquisitions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcmd_AssetAcquisitionBusinessRevenueToExceedBaseRevenueMultiplier', window );">Business revenue to exceed base revenue, Multiplier</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=tcmd_AfflovestPMember', window );">AffloVest APA | Earn-out period exceed Base Revenues from October 1, 2022 to September 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Acquisitions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcmd_AssetAcquisitionBusinessRevenueToExceedBaseRevenueMultiplier', window );">Business revenue to exceed base revenue, Multiplier</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=tcmd_AfflovestPMember', window );">AffloVest APA | Earn-out period on or before November 28,2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Acquisitions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcmd_AssetAcquisitionEarnOutLiability', window );">Earn-out liability, asset acquisition</a></td>
<td class="nump">5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=tcmd_AfflovestPMember', window );">AffloVest APA | Earn-out period on or before May 26, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Acquisitions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcmd_AssetAcquisitionEarnOutLiability', window );">Earn-out liability, asset acquisition</a></td>
<td class="nump">5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcmd_AssetAcquisitionImputedInterestPayable', window );">Imputed interest payment</a></td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=tcmd_AfflovestPMember', window );">AffloVest APA | Second earn-out amendment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Acquisitions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcmd_AssetAcquisitionBusinessRevenueToExceedBaseRevenueMultiplier', window );">Business revenue to exceed base revenue, Multiplier</a></td>
<td class="nump">3.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcmd_AssetAcquisitionEarnOutLiability', window );">Earn-out liability, asset acquisition</a></td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=tcmd_AfflovestPMember', window );">AffloVest APA | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Acquisitions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Total consideration transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=tcmd_AfflovestPMember', window );">AffloVest APA | Maximum | Earn-out period exceed Base Revenues from October 1, 2021 to September 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Acquisitions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Earn-out liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=tcmd_AfflovestPMember', window );">AffloVest APA | Maximum | Earn-out period exceed Base Revenues from October 1, 2022 to September 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Acquisitions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcmd_AssetAcquisitionEarnOutLiability', window );">Earn-out liability, asset acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcmd_AssetAcquisitionAmountReceivedResultingFromWorkingCapitalAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount received for assets acquisition from working capital adjustment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcmd_AssetAcquisitionAmountReceivedResultingFromWorkingCapitalAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcmd_AssetAcquisitionBusinessRevenueToExceedBaseRevenueMultiplier">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The multiplier applied to the amount by which the Business's Revenue in the initial earnout period exceed Base Revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcmd_AssetAcquisitionBusinessRevenueToExceedBaseRevenueMultiplier</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcmd_AssetAcquisitionConsiderationTransferredEscrowAccount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount in escrow account recognized as part of consideration transferred in asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcmd_AssetAcquisitionConsiderationTransferredEscrowAccount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcmd_AssetAcquisitionEarnOutLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of earn out liability recognized in asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcmd_AssetAcquisitionEarnOutLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcmd_AssetAcquisitionImputedInterestPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of imputed interest payable as at the date of asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcmd_AssetAcquisitionImputedInterestPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 25<br> -Paragraph 23<br> -URI https://asc.fasb.org/extlink&amp;oid=123586518&amp;loc=d3e1043-128460<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAcquisitionRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=tcmd_AfflovestPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=tcmd_AfflovestPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=tcmd_AssetAcquisitionEarnoutPaymentsRevenueTargetsFromOctoberTwoThousandTwentyOneToSeptemberTwoThousandTwentyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=tcmd_AssetAcquisitionEarnoutPaymentsRevenueTargetsFromOctoberTwoThousandTwentyOneToSeptemberTwoThousandTwentyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=tcmd_AssetAcquisitionEarnoutPaymentsRevenueTargetsFromOctoberTwoThousandTwentyTwoToSeptemberTwoThousandTwentyThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=tcmd_AssetAcquisitionEarnoutPaymentsRevenueTargetsFromOctoberTwoThousandTwentyTwoToSeptemberTwoThousandTwentyThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=tcmd_EarnOutPeriodOnOrBeforeNovember282022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=tcmd_EarnOutPeriodOnOrBeforeNovember282022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=tcmd_EarnOutPeriodOnOrBeforeMay262023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=tcmd_EarnOutPeriodOnOrBeforeMay262023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=tcmd_SecondEarnOutAmendmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=tcmd_SecondEarnOutAmendmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139814954427440">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Acquisitions - Purchase Price Allocation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 08, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferredAbstract', window );"><strong>Purchase price allocation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,124<span></span>
</td>
<td class="nump">$ 19,217<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,077<span></span>
</td>
<td class="nump">6,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets</a></td>
<td class="nump">$ 53,500<span></span>
</td>
<td class="nump">50,375<span></span>
</td>
<td class="nump">54,081<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,063<span></span>
</td>
<td class="nump">$ 31,063<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcmd_GoodwillAmortizationPeriodForTaxPurposes', window );">Amortization period for tax purposes</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=tcmd_AfflovestPMember', window );">AffloVest APA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferredAbstract', window );"><strong>Purchase price allocation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets</a></td>
<td class="nump">53,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">31,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,100<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNet', window );">Purchase price</a></td>
<td class="nump">86,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=tcmd_AfflovestPMember', window );">AffloVest APA | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferredAbstract', window );"><strong>Purchase price allocation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcmd_GoodwillAmortizationPeriodForTaxPurposes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which goodwill is deductible for tax purposes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcmd_GoodwillAmortizationPeriodForTaxPurposes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionConsiderationTransferredAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionConsiderationTransferredAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of net assets (liabilities).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=77885760&amp;loc=SL35686385-199418<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 205<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=118262037&amp;loc=d3e9915-115836<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -URI https://asc.fasb.org/extlink&amp;oid=120401555&amp;loc=SL114874367-224272<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e604008-122996<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120401555&amp;loc=SL114874367-224272<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=tcmd_AfflovestPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=tcmd_AfflovestPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139814954342560">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Acquisitions - Allocation of Purchase Price (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 08, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Acquisitions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite lived intangible assets, Allocated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,420<span></span>
</td>
<td class="nump">$ 44,016<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Indefinite lived intangible assets excluding goodwill, Allocated fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,103<span></span>
</td>
<td class="nump">55,981<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Total intangible assets (Net)</a></td>
<td class="nump">$ 53,500<span></span>
</td>
<td class="nump">50,375<span></span>
</td>
<td class="nump">54,081<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted average amortization period</a></td>
<td class="text">12 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=tcmd_AfflovestPMember', window );">AffloVest APA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Acquisitions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Total intangible assets (Net)</a></td>
<td class="nump">$ 53,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Customer relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Acquisitions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite lived intangible assets, Allocated Fair Value</a></td>
<td class="nump">$ 31,000<span></span>
</td>
<td class="nump">27,873<span></span>
</td>
<td class="nump">30,258<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated Useful Life</a></td>
<td class="text">13 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Acquisitions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite lived intangible assets, Allocated Fair Value</a></td>
<td class="nump">$ 13,000<span></span>
</td>
<td class="nump">$ 11,450<span></span>
</td>
<td class="nump">$ 12,632<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated Useful Life</a></td>
<td class="text">11 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember', window );">Tradenames</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Acquisitions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Indefinite lived intangible assets excluding goodwill, Allocated fair value</a></td>
<td class="nump">$ 9,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of intangible assets, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsGrossExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=tcmd_AfflovestPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=tcmd_AfflovestPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139814959529680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions - Consolidated Statements of Operations Reflect AffloVest Operations (Details) - AffloVest APA - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaRevenue', window );">Total revenue</a></td>
<td class="nump">$ 219,414<span></span>
</td>
<td class="nump">$ 203,193<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss', window );">Net (loss) income</a></td>
<td class="num">$ (7,633)<span></span>
</td>
<td class="nump">$ 11,832<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionsProFormaRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionsProFormaRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=tcmd_AfflovestPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=tcmd_AfflovestPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139814954183552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Receivable (Details) - item<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetAbstract', window );"><strong>Accounts Receivable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcmd_ConcentrationRiskNumberOfInsuranceCompanies', window );">Number of insurers</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=tcmd_InsuranceCompanyOneMember', window );">Insurer One | Customer Concentration Risk | Accounts Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetAbstract', window );"><strong>Accounts Receivable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of concentration</a></td>
<td class="nump">45.00%<span></span>
</td>
<td class="nump">33.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=tcmd_InsuranceCompanyOneMember', window );">Insurer One | Customer Concentration Risk | Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetAbstract', window );"><strong>Accounts Receivable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of concentration</a></td>
<td class="nump">19.00%<span></span>
</td>
<td class="nump">17.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=tcmd_InsuranceCompanyTwoMember', window );">Insurer Two | Customer Concentration Risk | Accounts Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetAbstract', window );"><strong>Accounts Receivable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of concentration</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">24.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=tcmd_InsuranceCompanyTwoMember', window );">Insurer Two | Customer Concentration Risk | Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetAbstract', window );"><strong>Accounts Receivable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of concentration</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcmd_ConcentrationRiskNumberOfInsuranceCompanies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents information pertaining to number of insurance companies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcmd_ConcentrationRiskNumberOfInsuranceCompanies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=tcmd_InsuranceCompanyOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=tcmd_InsuranceCompanyOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=tcmd_InsuranceCompanyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=tcmd_InsuranceCompanyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139814958299152">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventories (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNetAbstract', window );"><strong>Inventories</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="nump">$ 5,100<span></span>
</td>
<td class="nump">$ 8,242<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Component parts and work-in-process</a></td>
<td class="nump">18,024<span></span>
</td>
<td class="nump">10,975<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventories</a></td>
<td class="nump">$ 23,124<span></span>
</td>
<td class="nump">$ 19,217<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139814956157760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract', window );"><strong>Property and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Subtotal</a></td>
<td class="nump">$ 16,862<span></span>
</td>
<td class="nump">$ 15,793<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="num">(10,785)<span></span>
</td>
<td class="num">(9,043)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">6,077<span></span>
</td>
<td class="nump">6,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">2,500<span></span>
</td>
<td class="nump">2,300<span></span>
</td>
<td class="nump">$ 2,400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract', window );"><strong>Property and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Subtotal</a></td>
<td class="nump">8,274<span></span>
</td>
<td class="nump">8,051<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ToolsDiesAndMoldsMember', window );">Tooling</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract', window );"><strong>Property and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Subtotal</a></td>
<td class="nump">3,390<span></span>
</td>
<td class="nump">2,545<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract', window );"><strong>Property and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Subtotal</a></td>
<td class="nump">2,087<span></span>
</td>
<td class="nump">2,104<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdsAndLeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract', window );"><strong>Property and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Subtotal</a></td>
<td class="nump">1,493<span></span>
</td>
<td class="nump">1,458<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=tcmd_DemoEquipmentMember', window );">Demonstration equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract', window );"><strong>Property and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Subtotal</a></td>
<td class="nump">1,012<span></span>
</td>
<td class="nump">632<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract', window );"><strong>Property and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Subtotal</a></td>
<td class="nump">$ 606<span></span>
</td>
<td class="nump">$ 1,003<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ToolsDiesAndMoldsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ToolsDiesAndMoldsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdsAndLeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdsAndLeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=tcmd_DemoEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=tcmd_DemoEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139814955425520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill And Intangible Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 08, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Patents and Intangibles</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 31,063<span></span>
</td>
<td class="nump">$ 31,063<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Definite-lived intangible assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Weighted Average Amortization Period</a></td>
<td class="text">11 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 46,148<span></span>
</td>
<td class="nump">45,916<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">5,728<span></span>
</td>
<td class="nump">1,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">40,420<span></span>
</td>
<td class="nump">44,016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Unamortized intangible assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Total intangible assets (Gross)</a></td>
<td class="nump">56,103<span></span>
</td>
<td class="nump">55,981<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Total intangible assets (Net)</a></td>
<td class="nump">50,375<span></span>
</td>
<td class="nump">54,081<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 53,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="nump">3,800<span></span>
</td>
<td class="nump">1,400<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract', window );"><strong>Future Amortization</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2023</a></td>
<td class="nump">3,808<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2024</a></td>
<td class="nump">3,787<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2025</a></td>
<td class="nump">3,697<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2026</a></td>
<td class="nump">3,633<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2027</a></td>
<td class="nump">3,623<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive', window );">Thereafter</a></td>
<td class="nump">21,872<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">40,420<span></span>
</td>
<td class="nump">44,016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember', window );">Tradenames</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Unamortized intangible assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Gross Carrying Amount, Indefinite</a></td>
<td class="nump">9,500<span></span>
</td>
<td class="nump">9,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember', window );">Patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Unamortized intangible assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Gross Carrying Amount, Indefinite</a></td>
<td class="nump">$ 455<span></span>
</td>
<td class="nump">$ 565<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember', window );">Patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Definite-lived intangible assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Weighted Average Amortization Period</a></td>
<td class="text">12 years<span></span>
</td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 897<span></span>
</td>
<td class="nump">$ 666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">173<span></span>
</td>
<td class="nump">109<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">724<span></span>
</td>
<td class="nump">557<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract', window );"><strong>Future Amortization</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">$ 724<span></span>
</td>
<td class="nump">$ 557<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=tcmd_DefensiveIntangibleAssetsMember', window );">Defensive intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Definite-lived intangible assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Weighted Average Amortization Period</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 1,126<span></span>
</td>
<td class="nump">$ 1,125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">764<span></span>
</td>
<td class="nump">592<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">362<span></span>
</td>
<td class="nump">533<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract', window );"><strong>Future Amortization</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">362<span></span>
</td>
<td class="nump">$ 533<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerContractsMember', window );">Customer accounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Definite-lived intangible assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Weighted Average Amortization Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">125<span></span>
</td>
<td class="nump">$ 125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">114<span></span>
</td>
<td class="nump">89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract', window );"><strong>Future Amortization</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">$ 11<span></span>
</td>
<td class="nump">$ 36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Customer relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Definite-lived intangible assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Weighted Average Amortization Period</a></td>
<td class="text">12 years<span></span>
</td>
<td class="text">13 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 31,000<span></span>
</td>
<td class="nump">$ 31,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">3,127<span></span>
</td>
<td class="nump">742<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">27,873<span></span>
</td>
<td class="nump">30,258<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract', window );"><strong>Future Amortization</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">$ 27,873<span></span>
</td>
<td class="nump">$ 30,258<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Definite-lived intangible assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Weighted Average Amortization Period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">11 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 13,000<span></span>
</td>
<td class="nump">$ 13,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">1,550<span></span>
</td>
<td class="nump">368<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">11,450<span></span>
</td>
<td class="nump">12,632<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract', window );"><strong>Future Amortization</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">$ 11,450<span></span>
</td>
<td class="nump">$ 12,632<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Customer accounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Definite-lived intangible assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Weighted Average Amortization Period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=tcmd_AfflovestPMember', window );">AffloVest APA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Patents and Intangibles</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,100<span></span>
</td>
<td class="nump">31,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Unamortized intangible assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Total intangible assets (Net)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 53,500<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of intangible assets, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsGrossExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=tcmd_DefensiveIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=tcmd_DefensiveIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerContractsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerContractsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=tcmd_AfflovestPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=tcmd_AfflovestPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139814961836288">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcmd_InTransitInventoryAccruedExpense', window );">In-transit inventory</a></td>
<td class="nump">$ 3,228<span></span>
</td>
<td class="nump">$ 416<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductWarrantyAccrualClassifiedCurrent', window );">Warranty</a></td>
<td class="nump">2,005<span></span>
</td>
<td class="nump">1,851<span></span>
</td>
<td class="nump">$ 1,606<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcmd_AccruedTravelAndEntertainmentCurrent', window );">Travel</a></td>
<td class="nump">1,121<span></span>
</td>
<td class="nump">661<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Legal and consulting</a></td>
<td class="nump">730<span></span>
</td>
<td class="nump">1,371<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcmd_AccruedClinicalStudiesExpensesCurrent', window );">Clinical studies</a></td>
<td class="nump">276<span></span>
</td>
<td class="nump">113<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcmd_AccruedSalesAndUseTax', window );">Sales and use tax</a></td>
<td class="nump">147<span></span>
</td>
<td class="nump">106<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">1,733<span></span>
</td>
<td class="nump">744<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">$ 9,240<span></span>
</td>
<td class="nump">$ 5,262<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcmd_AccruedClinicalStudiesExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying amount as of the balance sheet date of accrued clinical studies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcmd_AccruedClinicalStudiesExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcmd_AccruedSalesAndUseTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations relating to sales and use tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcmd_AccruedSalesAndUseTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcmd_AccruedTravelAndEntertainmentCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for travel and entertainment expenses. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcmd_AccruedTravelAndEntertainmentCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcmd_InTransitInventoryAccruedExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>In-transit inventory accrued expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcmd_InTransitInventoryAccruedExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductWarrantyAccrualClassifiedCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for estimated claims under standard and extended warranty protection rights granted to customers. For classified balance sheets, represents the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126907703&amp;loc=d3e12524-110249<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 25<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126907644&amp;loc=d3e11281-110244<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductWarrantyAccrualClassifiedCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139814958279936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warranty Reserves (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MovementInStandardProductWarrantyAccrualRollForward', window );"><strong>Movement in Standard Product Warranty Accrual [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StandardProductWarrantyAccrual', window );">Beginning balance</a></td>
<td class="nump">$ 4,959<span></span>
</td>
<td class="nump">$ 4,841<span></span>
</td>
<td class="nump">$ 3,759<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StandardProductWarrantyAccrualWarrantiesIssued', window );">Warranty provision</a></td>
<td class="nump">2,047<span></span>
</td>
<td class="nump">2,606<span></span>
</td>
<td class="nump">2,957<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StandardProductWarrantyAccrualPayments', window );">Processed warranty claims</a></td>
<td class="num">(2,794)<span></span>
</td>
<td class="num">(2,488)<span></span>
</td>
<td class="num">(1,875)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StandardProductWarrantyAccrual', window );">Ending balance</a></td>
<td class="nump">4,212<span></span>
</td>
<td class="nump">4,959<span></span>
</td>
<td class="nump">4,841<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductWarrantyAccrualClassifiedCurrent', window );">Accrued warranty reserve, current</a></td>
<td class="nump">2,005<span></span>
</td>
<td class="nump">1,851<span></span>
</td>
<td class="nump">1,606<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductWarrantyAccrualNoncurrent', window );">Accrued warranty reserve, non-current</a></td>
<td class="nump">2,207<span></span>
</td>
<td class="nump">3,108<span></span>
</td>
<td class="nump">3,235<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductWarrantyAccrual', window );">Total accrued warranty reserve</a></td>
<td class="nump">$ 4,212<span></span>
</td>
<td class="nump">$ 4,959<span></span>
</td>
<td class="nump">$ 4,841<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MovementInStandardProductWarrantyAccrualRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MovementInStandardProductWarrantyAccrualRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductWarrantyAccrual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for estimated claims under standard and extended warranty protection rights granted to customers.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126907703&amp;loc=d3e12565-110249<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (c)(5)<br> -URI https://asc.fasb.org/extlink&amp;oid=126907703&amp;loc=d3e12565-110249<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductWarrantyAccrual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductWarrantyAccrualClassifiedCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for estimated claims under standard and extended warranty protection rights granted to customers. For classified balance sheets, represents the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126907703&amp;loc=d3e12524-110249<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 25<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126907644&amp;loc=d3e11281-110244<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductWarrantyAccrualClassifiedCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductWarrantyAccrualNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and due after one year (or beyond the operating cycle if longer) for estimated claims under standard and extended warranty protection rights granted to customers.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductWarrantyAccrualNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StandardProductWarrantyAccrual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount as of the balance sheet date of the aggregate standard product warranty liability. Does not include the balance for the extended product warranty liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (c)(1),(c)(5)<br> -URI https://asc.fasb.org/extlink&amp;oid=126907703&amp;loc=d3e12565-110249<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StandardProductWarrantyAccrual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StandardProductWarrantyAccrualPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in the standard product warranty accrual from payments made in cash or in kind to satisfy claims under the terms of the standard product warranty. Excludes extended product warranties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph ((c)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126907703&amp;loc=d3e12565-110249<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StandardProductWarrantyAccrualPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StandardProductWarrantyAccrualWarrantiesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in the standard product warranty accrual from warranties issued. Excludes extended product warranties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph ((c)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126907703&amp;loc=d3e12565-110249<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StandardProductWarrantyAccrualWarrantiesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139814955216768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Credit Agreement (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 22, 2022</div></th>
<th class="th"><div>Sep. 08, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Credit Agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Credit facility outstanding amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000.0<span></span>
</td>
<td class="nump">$ 24,916,000<span></span>
</td>
<td class="nump">$ 24,857,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcmd_LineOfCreditThresholdContingentIncreaseInBorrowingCapacity', window );">Line of credit, threshold contingent increase in borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcmd_CreditAgreementTotalAggregatePrincipalAmount', window );">Credit agreement, total aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember', window );">LIBOR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Credit Agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving credit facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Credit Agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving credit facility | Federal Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Credit Agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving credit facility | Base Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Credit Agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving credit facility | LIBOR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Credit Agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.41%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving credit facility | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Credit Agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage', window );">Unused line fee (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving credit facility | Maximum | Base Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Credit Agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving credit facility | Maximum | LIBOR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Credit Agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving credit facility | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Credit Agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage', window );">Unused line fee (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving credit facility | Minimum | Base Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Credit Agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving credit facility | Minimum | LIBOR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Credit Agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=tcmd_TermLoanMember', window );">Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Credit Agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000.0<span></span>
</td>
<td class="nump">$ 24,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPayment', window );">Debt instrument periodic payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFrequencyOfPeriodicPayment', window );">Debt instrument frequency of periodic payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">quarterly<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcmd_DebtInstrumentPaymentOfMandatoryPrincipalPrepayment', window );">Principal prepayment of term loan</a></td>
<td class="nump">$ 3,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcmd_CreditAgreementTotalAggregatePrincipalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total aggregate principal amount under the credit agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcmd_CreditAgreementTotalAggregatePrincipalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcmd_DebtInstrumentPaymentOfMandatoryPrincipalPrepayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of mandatory principal prepayment paid</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcmd_DebtInstrumentPaymentOfMandatoryPrincipalPrepayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcmd_LineOfCreditThresholdContingentIncreaseInBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line Of Credit, Threshold Contingent Increase In Borrowing Capacity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcmd_LineOfCreditThresholdContingentIncreaseInBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFrequencyOfPeriodicPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the frequency of periodic payments (monthly, quarterly, annual).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFrequencyOfPeriodicPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the required periodic payments including both interest and principal payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_FederalFundsEffectiveSwapRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_FederalFundsEffectiveSwapRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_BaseRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_BaseRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=tcmd_TermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=tcmd_TermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139814954168608">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Credit Agreement - Maturities of Debt (Details) - Term Loan - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Sep. 08, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtByMaturityAbstract', window );"><strong>Maturities of notes payable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2023</a></td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2024</a></td>
<td class="nump">21,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="nump">$ 24,000<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtByMaturityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtByMaturityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=tcmd_TermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=tcmd_TermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139814954145792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Lease Obligations (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>item</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Oct. 31, 2018 </div>
<div>ft&#178;</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Remaining lease terms</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Building | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Remaining lease terms</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Building | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Remaining lease terms</a></td>
<td class="text">8 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember', window );">Vehicles</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Remaining lease terms</a></td>
<td class="text">367 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcmd_NumberOfVehiclesWithAgreementsWithinInitialNoncancelableLeaseTerm', window );">Number of vehicles with agreements within the initial, noncancelable lease term | item</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend', window );">Option to renew</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Equipment | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Remaining lease terms</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Equipment | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Remaining lease terms</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=tcmd_CorporateHeadQuarterInitialLeaseMember', window );">Initial lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfLand', window );">Area of office space</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=tcmd_CorporateHeadQuarterSecondLeaseMember', window );">Second lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfLand', window );">Area of office space</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcmd_AdditionalOfficeSpaceAdded', window );">Additional office space added to the lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=tcmd_CorporateHeadQuarterThirdLeaseMember', window );">Third lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcmd_AdditionalOfficeSpaceAdded', window );">Additional office space added to the lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcmd_AdditionalOfficeSpaceAdded">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional office space added to the lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcmd_AdditionalOfficeSpaceAdded</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcmd_NumberOfVehiclesWithAgreementsWithinInitialNoncancelableLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of vehicles with agreements within the initial, noncancelable lease term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcmd_NumberOfVehiclesWithAgreementsWithinInitialNoncancelableLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfLand">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of land held.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfLand</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether lessee has option to extend operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=tcmd_CorporateHeadQuarterInitialLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=tcmd_CorporateHeadQuarterInitialLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=tcmd_CorporateHeadQuarterSecondLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=tcmd_CorporateHeadQuarterSecondLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=tcmd_CorporateHeadQuarterThirdLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=tcmd_CorporateHeadQuarterThirdLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139814954481808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Lease related assets and liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAndLiabilitiesLesseeAbstract', window );"><strong>Lease-related assets and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]</a></td>
<td class="text">Right of use operating lease assets<span></span>
</td>
<td class="text">Right of use operating lease assets<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right of use operating lease assets</a></td>
<td class="nump">$ 21,322<span></span>
</td>
<td class="nump">$ 23,984<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]</a></td>
<td class="text">Operating lease liabilities, Current<span></span>
</td>
<td class="text">Operating lease liabilities, Current<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, Current</a></td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="nump">$ 2,506<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]</a></td>
<td class="text">Operating lease liabilities, non-current<span></span>
</td>
<td class="text">Operating lease liabilities, non-current<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, non-current</a></td>
<td class="nump">$ 20,866<span></span>
</td>
<td class="nump">$ 23,354<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of future minimum lease payments</a></td>
<td class="nump">$ 23,366<span></span>
</td>
<td class="nump">$ 25,860<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term</a></td>
<td class="text">7 years 8 months 12 days<span></span>
</td>
<td class="text">8 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate</a></td>
<td class="nump">4.20%<span></span>
</td>
<td class="nump">4.20%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for operating lease liabilities</a></td>
<td class="nump">$ 3,575<span></span>
</td>
<td class="nump">$ 3,379<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Non-cash right of use assets obtained in exchange for new operating lease obligations</a></td>
<td class="nump">$ 49<span></span>
</td>
<td class="nump">$ 6,920<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAndLiabilitiesLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAndLiabilitiesLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes noncurrent operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes operating lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139814958380240">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Undiscounted cash flows (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Undiscounted cash flows</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 3,427<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">3,418<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">3,517<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2026</a></td>
<td class="nump">3,615<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2027</a></td>
<td class="nump">3,167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">10,082<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total minimum lease payments</a></td>
<td class="nump">27,226<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Amount of lease payments representing interest</a></td>
<td class="num">(3,860)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of future minimum lease payments</a></td>
<td class="nump">23,366<span></span>
</td>
<td class="nump">$ 25,860<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less: Current obligations under operating lease liabilities</a></td>
<td class="num">(2,500)<span></span>
</td>
<td class="num">(2,506)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Non-current obligations under operating lease liabilities</a></td>
<td class="nump">$ 20,866<span></span>
</td>
<td class="nump">$ 23,354<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139814960351104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Lease commitments and operating lease cost (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Operating lease cost</a></td>
<td class="nump">$ 3.8<span></span>
</td>
<td class="nump">$ 3.6<span></span>
</td>
<td class="nump">$ 3.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139814959028944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Major Vendors (Details) - item<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcmd_NumberOfVendors', window );">Number of vendors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=tcmd_VendorOneMember', window );">Vendor One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcmd_NumberOfVendors', window );">Number of vendors</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_CostOfGoodsTotalMember', window );">Purchases | Vendor | Vendor One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Total purchases (in percentage)</a></td>
<td class="nump">18.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_CostOfGoodsTotalMember', window );">Purchases | Vendor | Vendor Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Total purchases (in percentage)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcmd_NumberOfVendors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of vendors.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcmd_NumberOfVendors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=tcmd_VendorOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=tcmd_VendorOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_CostOfGoodsTotalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_CostOfGoodsTotalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_SupplierConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_SupplierConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=tcmd_VendorTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=tcmd_VendorTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139815041640832">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Purchase Commitments (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseObligationFiscalYearMaturityAbstract', window );"><strong>Purchase commitments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseObligationDueInNextTwelveMonths', window );">Purchase orders issued</a></td>
<td class="nump">$ 33.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligationDueInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of purchase arrangement to be paid in next fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligationDueInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligationFiscalYearMaturityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligationFiscalYearMaturityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139814959607632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Retirement Plan (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanNameAxis=tcmd_DefinedContribution401kRetirementPlanMember', window );">401(k)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanDisclosureLineItems', window );"><strong>Retirement Plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Discretionary contributions</a></td>
<td class="nump">$ 1.5<span></span>
</td>
<td class="nump">$ 1.2<span></span>
</td>
<td class="nump">$ 0.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanNameAxis=tcmd_DefinedContribution401kRetirementPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanNameAxis=tcmd_DefinedContribution401kRetirementPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139814963734096">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Legal Proceedings (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Nov. 21, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcmd_LitigationSettlementAgreementAmount', window );">Settlement amount</a></td>
<td class="nump">$ 5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcmd_LitigationSettlementAgreementAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of settlement amount of litigation under settlement agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcmd_LitigationSettlementAgreementAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139814954471968">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' Equity - Series A &amp; B Preferred Stock (Details)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th">
<div>Aug. 02, 2016 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Preferred stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Conversion of preferred stock to common stock (in shares)</a></td>
<td class="nump">5,924,453<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcmd_StockIssuedDuringPeriodPriorToCompletionOfInitialOfferingSharesNewIssues', window );">Number of new stock issued relating to the IPO that Series A and Series B preferred stockholders are entitled to receive</a></td>
<td class="nump">2,354,323<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Preferred stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares of common stock sold</a></td>
<td class="nump">4,120,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 10.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Preferred stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcmd_PreferredStockToCommonStockConversionRatio', window );">Preferred stock to common stock conversion ratio</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcmd_StockIssuedDuringPeriodRequiredToFundStockDividendsSharesNewIssues', window );">Number of new stock issued to pay accrued stock dividends relating to initial offering price</a></td>
<td class="nump">956,842<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Preferred stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcmd_PreferredStockToCommonStockConversionRatio', window );">Preferred stock to common stock conversion ratio</a></td>
<td class="nump">1.03<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcmd_AccruedCumulativeDividends', window );">Accrued Cumulative Dividends | $</a></td>
<td class="nump">$ 8.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfOrdinaryDividends', window );">Payment of dividends | $</a></td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcmd_AccruedCumulativeDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cumulative cash dividends accrued as of the end of the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcmd_AccruedCumulativeDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcmd_PreferredStockToCommonStockConversionRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent the conversion ratio of preferred stock to common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcmd_PreferredStockToCommonStockConversionRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcmd_StockIssuedDuringPeriodPriorToCompletionOfInitialOfferingSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued relating to the IPO that Series A and Series B preferred stockholders are entitled to receive.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcmd_StockIssuedDuringPeriodPriorToCompletionOfInitialOfferingSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcmd_StockIssuedDuringPeriodRequiredToFundStockDividendsSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued to pay accrued stock dividends relating to initial offering price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcmd_StockIssuedDuringPeriodRequiredToFundStockDividendsSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfOrdinaryDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash outflow in the form of ordinary dividends to common shareholders, preferred shareholders and noncontrolling interests, generally out of earnings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfOrdinaryDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139814954162496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Stock-Based Compensation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAbstract', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation expense</a></td>
<td class="nump">$ 9,600<span></span>
</td>
<td class="nump">$ 10,173<span></span>
</td>
<td class="nump">$ 10,689<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of revenue.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAbstract', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation expense</a></td>
<td class="nump">367<span></span>
</td>
<td class="nump">433<span></span>
</td>
<td class="nump">539<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember', window );">Sales and marketing expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAbstract', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation expense</a></td>
<td class="nump">4,060<span></span>
</td>
<td class="nump">4,069<span></span>
</td>
<td class="nump">5,058<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAbstract', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation expense</a></td>
<td class="nump">226<span></span>
</td>
<td class="nump">314<span></span>
</td>
<td class="nump">360<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">Reimbursement, general and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAbstract', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation expense</a></td>
<td class="nump">$ 4,947<span></span>
</td>
<td class="nump">$ 5,357<span></span>
</td>
<td class="nump">$ 4,732<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=tcmd_EquityIncentivePlan2016Member', window );">2016 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAbstract', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized</a></td>
<td class="nump">4,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticAnnualIncreaseInSharesReservedAndAvailableForIssuancePercentage', window );">Automatic annual increase to the number of shares reserved and available for issuance as a percentage of outstanding common stock (as a percent)</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticAnnualIncreaseInSharesReservedAndAvailableForIssuanceNumber', window );">Automatic annual increase to the number of shares reserved and available for issuance</a></td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares available for future issuance</a></td>
<td class="nump">5,957,683<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticAnnualIncreaseInSharesReservedAndAvailableForIssuanceNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents information pertaining to the automatic annual increase in shares reserved and available for issuance. The automatic increases occur on the first day of the year beginning January 1, 2017.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticAnnualIncreaseInSharesReservedAndAvailableForIssuanceNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticAnnualIncreaseInSharesReservedAndAvailableForIssuancePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents information pertaining to the automatic annual increase in shares reserved and available for issuance as a percentage to outstanding number of shares. The automatic increases occur on the first day of the year beginning January 1, 2017.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticAnnualIncreaseInSharesReservedAndAvailableForIssuancePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=tcmd_EquityIncentivePlan2016Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=tcmd_EquityIncentivePlan2016Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139814951517072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Stock Options and Restricted Stock (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract', window );"><strong>Stock-based compensation, general disclosures.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 9,600<span></span>
</td>
<td class="nump">$ 10,173<span></span>
</td>
<td class="nump">$ 10,689<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsCommonStock', window );">Dividends paid to date</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Estimated fair values and assumptions for stock options granted</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45.39%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Restricted stock unit awards, Average Intrinsic Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,503<span></span>
</td>
<td class="nump">$ 11,591<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Estimated fair values and assumptions for stock options granted</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Fair value per share of options on the date of grant (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Other information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Fair value per share of options on the date of grant (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Estimated fair values and assumptions for stock options granted</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Fair value per share of options on the date of grant (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Other information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Fair value per share of options on the date of grant (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Common stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract', window );"><strong>Stock-based compensation, general disclosures.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">2,500<span></span>
</td>
<td class="nump">4,300<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Total unrecognized pre-tax compensation expense related to nonvested stock option awards</a></td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average period over which unrecognized compensation cost is expected to be recognized</a></td>
<td class="text">1 year 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Total grant date fair value of options vested during the period</a></td>
<td class="nump">$ 3,300<span></span>
</td>
<td class="nump">$ 4,300<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Estimated fair values and assumptions for stock options granted</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">4 years 6 months<span></span>
</td>
<td class="text">4 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield (as a percent)</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Options Outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at beginning of period</a></td>
<td class="nump">915,224<span></span>
</td>
<td class="nump">1,039,709<span></span>
</td>
<td class="nump">866,955<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted</a></td>
<td class="nump">47,280<span></span>
</td>
<td class="nump">188,748<span></span>
</td>
<td class="nump">378,695<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised</a></td>
<td class="num">(90,878)<span></span>
</td>
<td class="num">(175,516)<span></span>
</td>
<td class="num">(147,741)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited</a></td>
<td class="num">(92,981)<span></span>
</td>
<td class="num">(92,773)<span></span>
</td>
<td class="num">(54,824)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Cancelled/Expired</a></td>
<td class="num">(163,338)<span></span>
</td>
<td class="num">(44,944)<span></span>
</td>
<td class="num">(3,376)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at end of period</a></td>
<td class="nump">615,307<span></span>
</td>
<td class="nump">915,224<span></span>
</td>
<td class="nump">1,039,709<span></span>
</td>
<td class="nump">866,955<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at beginning of period</a></td>
<td class="nump">$ 39.33<span></span>
</td>
<td class="nump">$ 36.43<span></span>
</td>
<td class="nump">$ 28.76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted</a></td>
<td class="nump">6.17<span></span>
</td>
<td class="nump">49.33<span></span>
</td>
<td class="nump">44.84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised</a></td>
<td class="nump">1.68<span></span>
</td>
<td class="nump">22.65<span></span>
</td>
<td class="nump">7.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited</a></td>
<td class="nump">36.28<span></span>
</td>
<td class="nump">49.77<span></span>
</td>
<td class="nump">50.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Cancelled/Expired</a></td>
<td class="nump">37.65<span></span>
</td>
<td class="nump">57.78<span></span>
</td>
<td class="nump">63.61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at end of period</a></td>
<td class="nump">$ 43.25<span></span>
</td>
<td class="nump">$ 39.33<span></span>
</td>
<td class="nump">$ 36.43<span></span>
</td>
<td class="nump">$ 28.76<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Other information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options exercisable number of shares exercisable</a></td>
<td class="nump">435,363<span></span>
</td>
<td class="nump">517,316<span></span>
</td>
<td class="nump">489,866<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options exercisable, weighted-average exercise price</a></td>
<td class="nump">$ 43.83<span></span>
</td>
<td class="nump">$ 32.60<span></span>
</td>
<td class="nump">$ 25.39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life (in years)</a></td>
<td class="text">4 years 8 months 12 days<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years 7 months 6 days<span></span>
</td>
<td class="text">6 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Options exercisable, weighted-average remaining contractual life</a></td>
<td class="text">4 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Options outstanding</a></td>
<td class="nump">$ 164<span></span>
</td>
<td class="nump">$ 2,068<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33,957<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate Intrinsic Value, Exercised</a></td>
<td class="nump">916<span></span>
</td>
<td class="nump">$ 4,901<span></span>
</td>
<td class="nump">$ 6,540<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Options exercisable</a></td>
<td class="nump">$ 84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,381<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward', window );"><strong>Number of:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Non vested options beginning of the year</a></td>
<td class="nump">397,908<span></span>
</td>
<td class="nump">549,843<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Non-vested options end of the year</a></td>
<td class="nump">179,944<span></span>
</td>
<td class="nump">397,908<span></span>
</td>
<td class="nump">549,843<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Vested options end of the year</a></td>
<td class="nump">435,363<span></span>
</td>
<td class="nump">517,316<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract', window );"><strong>Weighted-average grant date fair value of:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Non-vested options beginning of the year</a></td>
<td class="nump">$ 18.02<span></span>
</td>
<td class="nump">$ 18.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Non-vested options end of the year</a></td>
<td class="nump">16.24<span></span>
</td>
<td class="nump">18.02<span></span>
</td>
<td class="nump">$ 18.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue', window );">Vested options end of the year</a></td>
<td class="nump">17.53<span></span>
</td>
<td class="nump">13.27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue', window );">Forfeited options during the year</a></td>
<td class="nump">$ 14.73<span></span>
</td>
<td class="nump">$ 19.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Common stock options | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract', window );"><strong>Stock-based compensation, general disclosures.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period (in years)</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Term (in years)</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Estimated fair values and assumptions for stock options granted</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility (as a percent)</a></td>
<td class="nump">59.20%<span></span>
</td>
<td class="nump">45.00%<span></span>
</td>
<td class="nump">44.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate (as a percent)</a></td>
<td class="nump">4.30%<span></span>
</td>
<td class="nump">0.60%<span></span>
</td>
<td class="nump">0.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Fair value per share of options on the date of grant (in dollars per share)</a></td>
<td class="nump">$ 8.11<span></span>
</td>
<td class="nump">$ 13.04<span></span>
</td>
<td class="nump">$ 13.45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Other information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Fair value per share of options on the date of grant (in dollars per share)</a></td>
<td class="nump">$ 8.11<span></span>
</td>
<td class="nump">$ 13.04<span></span>
</td>
<td class="nump">$ 13.45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Common stock options | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract', window );"><strong>Stock-based compensation, general disclosures.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period (in years)</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Term (in years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Estimated fair values and assumptions for stock options granted</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52.30%<span></span>
</td>
<td class="nump">46.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.10%<span></span>
</td>
<td class="nump">0.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Fair value per share of options on the date of grant (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22.90<span></span>
</td>
<td class="nump">$ 18.64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Other information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Fair value per share of options on the date of grant (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22.90<span></span>
</td>
<td class="nump">$ 18.64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Common stock options | Chief Executive Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract', window );"><strong>Stock-based compensation, general disclosures.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermOfPeriod', window );">Share-based payment award, term</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period (in years)</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcmd_NumberOfConsecutiveTradingDaysInWhichStockPriceExceedCertainPercentageOfClosingPriceOfCommonStockRequiredForAwardToBeGranted', window );">Number of consecutive trading days</a></td>
<td class="text">20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Common stock options | Chief Executive Officer | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract', window );"><strong>Stock-based compensation, general disclosures.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Stock price</a></td>
<td class="nump">$ 40.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=tcmd_TwoThousandEighteenAndTwoThousandTwentyPerformanceBasedRestrictedStockUnitsMember', window );">2018 and 2021 PSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract', window );"><strong>Stock-based compensation, general disclosures.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 600<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=tcmd_EquityIncentivePlan2016Member', window );">2016 Plan | Time-Based Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract', window );"><strong>Stock-based compensation, general disclosures.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">5,800<span></span>
</td>
<td class="nump">$ 4,900<span></span>
</td>
<td class="nump">$ 5,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Total unrecognized pre-tax compensation expense related to nonvested stock option awards</a></td>
<td class="nump">$ 7,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average period over which unrecognized compensation cost is expected to be recognized</a></td>
<td class="text">1 year 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Units Outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Restricted stock unit awards outstanding at the beginning of the period (in shares)</a></td>
<td class="nump">259,147<span></span>
</td>
<td class="nump">211,469<span></span>
</td>
<td class="nump">171,687<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">539,525<span></span>
</td>
<td class="nump">189,762<span></span>
</td>
<td class="nump">175,582<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcmd_SharebasedcompensationArrangementBySharebasedpaymentAwardEquityInstrumentsOtherThanOptionsModifiedInPeriod', window );">Modification (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,288<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="num">(123,528)<span></span>
</td>
<td class="num">(106,521)<span></span>
</td>
<td class="num">(118,014)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod', window );">Cancelled (in shares)</a></td>
<td class="num">(84,602)<span></span>
</td>
<td class="num">(35,563)<span></span>
</td>
<td class="num">(20,074)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Restricted stock unit awards outstanding at the end of the period (in shares)</a></td>
<td class="nump">590,542<span></span>
</td>
<td class="nump">259,147<span></span>
</td>
<td class="nump">211,469<span></span>
</td>
<td class="nump">171,687<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant Date Fair Value Per Unit</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Restricted stock unit awards outstanding at the beginning of the period (in dollars per share)</a></td>
<td class="nump">$ 42.32<span></span>
</td>
<td class="nump">$ 48.29<span></span>
</td>
<td class="nump">$ 43.74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="nump">15.03<span></span>
</td>
<td class="nump">40.31<span></span>
</td>
<td class="nump">46.42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcmd_SharebasedcompensationArrangementBySharebasedpaymentAwardEquityInstrumentsOtherThanOptionsModifiedWeightedAverageGrantDateFairValue', window );">Modification (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share)</a></td>
<td class="nump">43.20<span></span>
</td>
<td class="nump">47.43<span></span>
</td>
<td class="nump">37.57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancellationsWeightedAverageGrantDateFairValue', window );">Cancelled (in dollars per share)</a></td>
<td class="nump">26.91<span></span>
</td>
<td class="nump">51.76<span></span>
</td>
<td class="nump">53.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Restricted stock unit awards outstanding at the end of the period (in dollars per share)</a></td>
<td class="nump">$ 19.42<span></span>
</td>
<td class="nump">$ 42.32<span></span>
</td>
<td class="nump">$ 48.29<span></span>
</td>
<td class="nump">$ 43.74<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Restricted stock unit awards, Average Intrinsic Value</a></td>
<td class="nump">$ 6,779<span></span>
</td>
<td class="nump">$ 4,932<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=tcmd_EquityIncentivePlan2016Member', window );">2016 Plan | Time-Based Restricted Stock Units | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract', window );"><strong>Stock-based compensation, general disclosures.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period (in years)</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=tcmd_EquityIncentivePlan2016Member', window );">2016 Plan | Time-Based Restricted Stock Units | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract', window );"><strong>Stock-based compensation, general disclosures.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period (in years)</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=tcmd_EquityIncentivePlan2016Member', window );">2016 Plan | Performance-based stock-settled restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract', window );"><strong>Stock-based compensation, general disclosures.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcmd_StockBasedCompensationExpenseMinimumTargets', window );">Estimated payout</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 500<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Total unrecognized pre-tax compensation expense related to awards</a></td>
<td class="nump">$ 1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average period over which unrecognized compensation cost is expected to be recognized</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Units Outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Restricted stock unit awards outstanding at the beginning of the period (in shares)</a></td>
<td class="nump">54,317<span></span>
</td>
<td class="nump">79,303<span></span>
</td>
<td class="nump">91,151<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">131,710<span></span>
</td>
<td class="nump">39,419<span></span>
</td>
<td class="nump">31,731<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="num">(4,407)<span></span>
</td>
<td class="num">(34,159)<span></span>
</td>
<td class="num">(26,204)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod', window );">Cancelled (in shares)</a></td>
<td class="num">(26,002)<span></span>
</td>
<td class="num">(30,246)<span></span>
</td>
<td class="num">(17,375)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Restricted stock unit awards outstanding at the end of the period (in shares)</a></td>
<td class="nump">155,618<span></span>
</td>
<td class="nump">54,317<span></span>
</td>
<td class="nump">79,303<span></span>
</td>
<td class="nump">91,151<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcmd_EstimatedPayoutPercentage', window );">Payout percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant Date Fair Value Per Unit</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Restricted stock unit awards outstanding at the beginning of the period (in dollars per share)</a></td>
<td class="nump">$ 50.22<span></span>
</td>
<td class="nump">$ 47.83<span></span>
</td>
<td class="nump">$ 44.63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="nump">18.54<span></span>
</td>
<td class="nump">51.82<span></span>
</td>
<td class="nump">50.41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share)</a></td>
<td class="nump">12.31<span></span>
</td>
<td class="nump">33.98<span></span>
</td>
<td class="nump">33.58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancellationsWeightedAverageGrantDateFairValue', window );">Cancelled (in dollars per share)</a></td>
<td class="nump">42.53<span></span>
</td>
<td class="nump">64.39<span></span>
</td>
<td class="nump">52.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Restricted stock unit awards outstanding at the end of the period (in dollars per share)</a></td>
<td class="nump">$ 25.05<span></span>
</td>
<td class="nump">$ 50.22<span></span>
</td>
<td class="nump">$ 47.83<span></span>
</td>
<td class="nump">$ 44.63<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Restricted stock unit awards, Average Intrinsic Value</a></td>
<td class="nump">$ 1,786<span></span>
</td>
<td class="nump">$ 1,034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,154<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueDeferredAndUnissued', window );">Restricted stock unit awards deferred and unissued, Average Intrinsic Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,564<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=tcmd_EquityIncentivePlan2016Member', window );">2016 Plan | Performance-based stock-settled restricted stock units | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Units Outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcmd_PercentageToEarnPerformanceBasedStockSettledRestrictedStockUnits', window );">Percentage to earn or vest the performance-based stock-settled restricted stock units</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=tcmd_EquityIncentivePlan2016Member', window );">2016 Plan | Performance-based stock-settled restricted stock units | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Units Outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcmd_PercentageToEarnPerformanceBasedStockSettledRestrictedStockUnits', window );">Percentage to earn or vest the performance-based stock-settled restricted stock units</a></td>
<td class="nump">150.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=tcmd_EquityIncentivePlan2016Member', window );">2016 Plan | Tranche one | Performance-based stock-settled restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract', window );"><strong>Stock-based compensation, general disclosures.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Compensation arrangement</a></td>
<td class="nump">33.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=tcmd_EquityIncentivePlan2016Member', window );">2016 Plan | Tranche two | Performance-based stock-settled restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract', window );"><strong>Stock-based compensation, general disclosures.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Compensation arrangement</a></td>
<td class="nump">66.67%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcmd_EstimatedPayoutPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of estimated payout.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcmd_EstimatedPayoutPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcmd_NumberOfConsecutiveTradingDaysInWhichStockPriceExceedCertainPercentageOfClosingPriceOfCommonStockRequiredForAwardToBeGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of consecutive trading days in which the stock price exceed a certain percentage of closing price of common stock required for the award to be granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcmd_NumberOfConsecutiveTradingDaysInWhichStockPriceExceedCertainPercentageOfClosingPriceOfCommonStockRequiredForAwardToBeGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcmd_PercentageToEarnPerformanceBasedStockSettledRestrictedStockUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage to earn or vest the performance-based stock-settled restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcmd_PercentageToEarnPerformanceBasedStockSettledRestrictedStockUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueDeferredAndUnissued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of equity-based compensation awards deferred and Unissued, Excludes stock and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueDeferredAndUnissued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancellationsWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were cancelled during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancellationsWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were cancelled during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermOfPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of awards in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermOfPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcmd_SharebasedcompensationArrangementBySharebasedpaymentAwardEquityInstrumentsOtherThanOptionsModifiedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were modified during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcmd_SharebasedcompensationArrangementBySharebasedpaymentAwardEquityInstrumentsOtherThanOptionsModifiedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcmd_SharebasedcompensationArrangementBySharebasedpaymentAwardEquityInstrumentsOtherThanOptionsModifiedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were modified during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcmd_SharebasedcompensationArrangementBySharebasedpaymentAwardEquityInstrumentsOtherThanOptionsModifiedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcmd_StockBasedCompensationExpenseMinimumTargets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount estimated payout to reflect an estimated failure to achieve the minimum targets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcmd_StockBasedCompensationExpenseMinimumTargets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid common stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=tcmd_TwoThousandEighteenAndTwoThousandTwentyPerformanceBasedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=tcmd_TwoThousandEighteenAndTwoThousandTwentyPerformanceBasedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=tcmd_EquityIncentivePlan2016Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=tcmd_EquityIncentivePlan2016Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=tcmd_TimeBasedRestrictedStockUnitsRsusMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=tcmd_TimeBasedRestrictedStockUnitsRsusMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=tcmd_PerformanceBasedStockSettledRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=tcmd_PerformanceBasedStockSettledRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139814961032608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Employee Stock Purchase Plan (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Apr. 27, 2017</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,600<span></span>
</td>
<td class="nump">$ 10,173<span></span>
</td>
<td class="nump">$ 10,689<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=tcmd_EquityIncentivePlan2016Member', window );">2016 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,957,683<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Increase in number of shares reserved and available for issuance</a></td>
<td class="nump">972,591<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember', window );">Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Purchase price of common stock under plan (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcmd_EmployeeStockPurchasePlanOfferingPeriodsPeriod', window );">Offering period (in months)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,559,151<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,600,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcmd_IncrementalSharesToBeIssuedPercentage', window );">Incremental share increase (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcmd_IncrementalShareIncrease', window );">Incremental share increase (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Increase in number of shares reserved and available for issuance</a></td>
<td class="nump">194,518<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcmd_EmployeeStockPurchasePlanOfferingPeriodsPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period which an employee's right to purchase shares of stock at a discount, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcmd_EmployeeStockPurchasePlanOfferingPeriodsPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcmd_IncrementalShareIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the minimum increase in shares on an annual basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcmd_IncrementalShareIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcmd_IncrementalSharesToBeIssuedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the incremental annual share percentage increase minimum.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcmd_IncrementalSharesToBeIssuedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=tcmd_EquityIncentivePlan2016Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=tcmd_EquityIncentivePlan2016Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139814956089408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 246,785<span></span>
</td>
<td class="nump">$ 208,057<span></span>
</td>
<td class="nump">$ 187,130<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcmd_PercentageOfRevenue', window );">Percentage of total revenue (in percent)</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalesTypeLeaseLeaseIncomeAbstract', window );"><strong>Revenue from sale type lease</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalesTypeLeaseRevenue', window );">Sales-type lease revenue</a></td>
<td class="nump">$ 35,440<span></span>
</td>
<td class="nump">$ 30,143<span></span>
</td>
<td class="nump">$ 25,633<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsSoldSalesTypeLease', window );">Cost of sales-type lease revenue</a></td>
<td class="nump">11,190<span></span>
</td>
<td class="nump">9,622<span></span>
</td>
<td class="nump">9,011<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalesTypeLeaseSellingProfitLoss', window );">Gross profit</a></td>
<td class="nump">$ 24,250<span></span>
</td>
<td class="nump">20,521<span></span>
</td>
<td class="nump">16,622<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalesTypeLeaseLeaseIncomeAbstract', window );"><strong>Revenue from sale type lease</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcmd_RentToPurchaseArrangementsRentalPeriod', window );">Rental period of rent-to-purchase arrangements</a></td>
<td class="text">3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalesTypeLeaseLeaseIncomeAbstract', window );"><strong>Revenue from sale type lease</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcmd_RentToPurchaseArrangementsRentalPeriod', window );">Rental period of rent-to-purchase arrangements</a></td>
<td class="text">10 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=tcmd_PrivateInsurersMember', window );">Private insurers and other payers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 139,087<span></span>
</td>
<td class="nump">141,377<span></span>
</td>
<td class="nump">132,789<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=tcmd_VeteransAdministrationMember', window );">Veterans Administration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">25,507<span></span>
</td>
<td class="nump">25,654<span></span>
</td>
<td class="nump">24,485<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=tcmd_MedicareMember', window );">Medicare</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">47,672<span></span>
</td>
<td class="nump">35,882<span></span>
</td>
<td class="nump">29,856<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=tcmd_DurableMedicalEquipmentDistributorsMember', window );">Durable medical equipment distributors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">34,519<span></span>
</td>
<td class="nump">5,144<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=tcmd_FlexitouchSystemMember', window );">Flexitouch system</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 212,266<span></span>
</td>
<td class="nump">$ 202,913<span></span>
</td>
<td class="nump">$ 187,130<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcmd_PercentageOfRevenue', window );">Percentage of total revenue (in percent)</a></td>
<td class="nump">86.00%<span></span>
</td>
<td class="nump">98.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=tcmd_AfflovestMember', window );">AffloVest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 34,519<span></span>
</td>
<td class="nump">$ 5,144<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcmd_PercentageOfRevenue', window );">Percentage of total revenue (in percent)</a></td>
<td class="nump">14.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcmd_PercentageOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of revenue disaggregated by products.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcmd_PercentageOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcmd_RentToPurchaseArrangementsRentalPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Rental period of rent-to-purchase arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcmd_RentToPurchaseArrangementsRentalPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsSoldSalesTypeLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cost of goods sold for sales-type financing lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919372-209981<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6A<br> -URI https://asc.fasb.org/extlink&amp;oid=126900988&amp;loc=SL77927221-108306<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsSoldSalesTypeLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesTypeLeaseLeaseIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesTypeLeaseLeaseIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesTypeLeaseRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of sales-type lease revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919372-209981<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6A<br> -URI https://asc.fasb.org/extlink&amp;oid=126900988&amp;loc=SL77927221-108306<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesTypeLeaseRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesTypeLeaseSellingProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of profit (loss) recognized at commencement from sales-type lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919372-209981<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6A<br> -URI https://asc.fasb.org/extlink&amp;oid=126900988&amp;loc=SL77927221-108306<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesTypeLeaseSellingProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=tcmd_PrivateInsurersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=tcmd_PrivateInsurersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=tcmd_VeteransAdministrationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=tcmd_VeteransAdministrationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=tcmd_MedicareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=tcmd_MedicareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=tcmd_DurableMedicalEquipmentDistributorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=tcmd_DurableMedicalEquipmentDistributorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=tcmd_FlexitouchSystemMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=tcmd_FlexitouchSystemMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=tcmd_AfflovestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=tcmd_AfflovestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139814961710448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcmd_IncomeTaxLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Current income taxes, Federal</a></td>
<td class="nump">$ 1,838<span></span>
</td>
<td class="num">$ (1,274)<span></span>
</td>
<td class="num">$ (653)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">Current income taxes, State</a></td>
<td class="nump">637<span></span>
</td>
<td class="nump">214<span></span>
</td>
<td class="nump">294<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Current income taxes</a></td>
<td class="nump">2,475<span></span>
</td>
<td class="num">(1,060)<span></span>
</td>
<td class="num">(359)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Deferred income taxes, Federal</a></td>
<td class="num">(32)<span></span>
</td>
<td class="nump">7,874<span></span>
</td>
<td class="num">(833)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">Deferred income taxes, State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,356<span></span>
</td>
<td class="num">(395)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income taxes</a></td>
<td class="num">(32)<span></span>
</td>
<td class="nump">10,230<span></span>
</td>
<td class="num">(1,228)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense', window );">Unrecognized tax benefit</a></td>
<td class="num">$ (50)<span></span>
</td>
<td class="nump">$ 348<span></span>
</td>
<td class="num">$ (54)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Net effective rate</a></td>
<td class="num">(15.50%)<span></span>
</td>
<td class="num">(415.10%)<span></span>
</td>
<td class="nump">72.60%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense (benefit)</a></td>
<td class="nump">$ 2,393<span></span>
</td>
<td class="nump">$ 9,518<span></span>
</td>
<td class="num">$ (1,641)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract', window );"><strong>Components of Deferred Tax Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcmd_DeferredTaxAssetsOperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="nump">5,945<span></span>
</td>
<td class="nump">6,490<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">179<span></span>
</td>
<td class="nump">671<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts', window );">Accounts receivable and inventory reserves</a></td>
<td class="nump">6,013<span></span>
</td>
<td class="nump">4,658<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">4,886<span></span>
</td>
<td class="nump">3,777<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities', window );">Accrued liabilities</a></td>
<td class="nump">1,914<span></span>
</td>
<td class="nump">1,104<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves', window );">Warranty reserves</a></td>
<td class="nump">1,071<span></span>
</td>
<td class="nump">1,245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Intangible assets</a></td>
<td class="nump">2,947<span></span>
</td>
<td class="nump">579<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcmd_DeferredTaxAssetsBusinessCredits', window );">Business credits</a></td>
<td class="nump">536<span></span>
</td>
<td class="nump">682<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcmd_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsResearchAndDevelopmentExpenses', window );">R&amp;D expenses</a></td>
<td class="nump">1,103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">183<span></span>
</td>
<td class="nump">199<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">24,777<span></span>
</td>
<td class="nump">19,405<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcmd_DeferredTaxLiabilitiesRightOfUseAssets', window );">Right-of-use asset</a></td>
<td class="num">(5,425)<span></span>
</td>
<td class="num">(6,019)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Fixed assets</a></td>
<td class="num">(1,080)<span></span>
</td>
<td class="num">(914)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses', window );">Prepaid expenses</a></td>
<td class="num">(251)<span></span>
</td>
<td class="num">(378)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesOther', window );">Other</a></td>
<td class="num">(186)<span></span>
</td>
<td class="num">(87)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">(6,942)<span></span>
</td>
<td class="num">(7,398)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Net deferred tax liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(32)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">$ (17,835)<span></span>
</td>
<td class="num">$ (12,039)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Effective Income Tax Rate Reconciliation, Percent</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Tax expense at statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State income taxes, net of federal benefit</a></td>
<td class="nump">4.10%<span></span>
</td>
<td class="num">(1.10%)<span></span>
</td>
<td class="num">(7.90%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcmd_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationPercent', window );">Executive compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14.20%)<span></span>
</td>
<td class="num">(5.50%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment', window );">Meals and entertainment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10.60%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcmd_EffectiveIncomeTaxRateReconciliationIncentiveStockOptions', window );">Incentive stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.40%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcmd_EffectiveIncomeTaxRateReconciliationEmployeeStockPurchasePlan', window );">Employee Stock Purchase Plan</a></td>
<td class="num">(1.00%)<span></span>
</td>
<td class="num">(7.50%)<span></span>
</td>
<td class="num">(8.60%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcmd_EffectiveIncomeTaxRateReconciliationFederalBusinessCreditPercent', window );">Federal business credits</a></td>
<td class="nump">1.60%<span></span>
</td>
<td class="nump">10.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(37.40%)<span></span>
</td>
<td class="num">(525.00%)<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcmd_EffectiveIncomeTaxRateReconciliationReturnToProvision', window );">Return to provision</a></td>
<td class="num">(0.20%)<span></span>
</td>
<td class="num">(6.50%)<span></span>
</td>
<td class="nump">3.60%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment', window );">Research and development credits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcmd_EffectiveIncomeTaxRateReconciliationInternalRevenueServiceExam', window );">IRS exam</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal', window );">Deferred reprice - state</a></td>
<td class="nump">0.90%<span></span>
</td>
<td class="nump">3.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcmd_EffectiveIncomeTaxRateReconciliationFederalCarrybackClaimPercent', window );">Federal carryback claim deferred rate differential</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcmd_EffectiveIncomeTaxRateReconciliationUnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="num">(0.30%)<span></span>
</td>
<td class="num">(2.20%)<span></span>
</td>
<td class="nump">2.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcmd_EffectiveIncomeTaxRateReconciliationExcessTaxBenefitOnNonQualifiedStockOptionsAndRsu', window );">Excess benefit on non-qualified stock options and RSUs</a></td>
<td class="num">(3.70%)<span></span>
</td>
<td class="nump">47.20%<span></span>
</td>
<td class="nump">28.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcmd_EffectiveIncomeTaxRateReconciliationInterestAndPenaltyPercent', window );">Interest and penalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.70%)<span></span>
</td>
<td class="nump">1.90%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="num">(0.50%)<span></span>
</td>
<td class="num">(0.50%)<span></span>
</td>
<td class="num">(0.20%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Reconciliation of unrecognized tax benefits</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance beginning of the year</a></td>
<td class="nump">$ 522<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 54<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcmd_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions', window );">Gross change - tax positions in prior year</a></td>
<td class="nump">90<span></span>
</td>
<td class="nump">$ 522<span></span>
</td>
<td class="num">(54)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance end of the year</a></td>
<td class="nump">612<span></span>
</td>
<td class="nump">522<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="nump">17,835<span></span>
</td>
<td class="nump">12,039<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">U.S. federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcmd_IncomeTaxLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense', window );">Unrecognized tax benefit</a></td>
<td class="num">(50)<span></span>
</td>
<td class="nump">$ 348<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcmd_IncomeTaxLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense', window );">Unrecognized tax benefit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (54)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract', window );"><strong>Components of Deferred Tax Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 179,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcmd_DeferredTaxAssetsBusinessCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from business credits..</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcmd_DeferredTaxAssetsBusinessCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcmd_DeferredTaxAssetsOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from Operating Lease Liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcmd_DeferredTaxAssetsOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcmd_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from research and development expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcmd_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcmd_DeferredTaxLiabilitiesRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax consequences attributable to taxable temporary differences derived from right-of-use assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcmd_DeferredTaxLiabilitiesRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcmd_EffectiveIncomeTaxRateReconciliationEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of effective income tax rate reconciliation, employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcmd_EffectiveIncomeTaxRateReconciliationEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcmd_EffectiveIncomeTaxRateReconciliationExcessTaxBenefitOnNonQualifiedStockOptionsAndRsu">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of effective income tax rate reconciliation, excess tax benefit on non-qualified stock options and RSU.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcmd_EffectiveIncomeTaxRateReconciliationExcessTaxBenefitOnNonQualifiedStockOptionsAndRsu</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcmd_EffectiveIncomeTaxRateReconciliationFederalBusinessCreditPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from federal business credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcmd_EffectiveIncomeTaxRateReconciliationFederalBusinessCreditPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcmd_EffectiveIncomeTaxRateReconciliationFederalCarrybackClaimPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to federal carryback claim.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcmd_EffectiveIncomeTaxRateReconciliationFederalCarrybackClaimPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcmd_EffectiveIncomeTaxRateReconciliationIncentiveStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of Effective Income Tax Rate Reconciliation, Incentive stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcmd_EffectiveIncomeTaxRateReconciliationIncentiveStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcmd_EffectiveIncomeTaxRateReconciliationInterestAndPenaltyPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to interest and penalties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcmd_EffectiveIncomeTaxRateReconciliationInterestAndPenaltyPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcmd_EffectiveIncomeTaxRateReconciliationInternalRevenueServiceExam">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to IRS exam</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcmd_EffectiveIncomeTaxRateReconciliationInternalRevenueServiceExam</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcmd_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to executive compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcmd_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcmd_EffectiveIncomeTaxRateReconciliationReturnToProvision">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of effective income tax rate reconciliation, return to provision.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcmd_EffectiveIncomeTaxRateReconciliationReturnToProvision</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcmd_EffectiveIncomeTaxRateReconciliationUnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of effective income tax rate reconciliation, unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcmd_EffectiveIncomeTaxRateReconciliationUnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcmd_IncomeTaxLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcmd_IncomeTaxLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcmd_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcmd_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from warranty reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax consequences attributable to taxable temporary differences derived from prepaid expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPrepaidExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to meals and entertainment expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research and development expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139814961274976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net (Loss) Income Per Common Share - Basic and Diluted Net Loss Per Share (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net (Loss) Income Per Common Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss</a></td>
<td class="num">$ (17,866)<span></span>
</td>
<td class="num">$ (11,811)<span></span>
</td>
<td class="num">$ (620)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares outstanding</a></td>
<td class="nump">20,067,969<span></span>
</td>
<td class="nump">19,719,485<span></span>
</td>
<td class="nump">19,346,929<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares used to compute diluted net loss per share</a></td>
<td class="nump">20,067,969<span></span>
</td>
<td class="nump">19,719,485<span></span>
</td>
<td class="nump">19,346,929<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share - Basic</a></td>
<td class="num">$ (0.89)<span></span>
</td>
<td class="num">$ (0.60)<span></span>
</td>
<td class="num">$ (0.03)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share - Diluted</a></td>
<td class="num">$ (0.89)<span></span>
</td>
<td class="num">$ (0.60)<span></span>
</td>
<td class="num">$ (0.03)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139814964016064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net (Loss) Income Per Common Share - Antidilutive Securities Excluded From Computation of Earnings Per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Net Loss Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share</a></td>
<td class="nump">1,461,973<span></span>
</td>
<td class="nump">1,269,966<span></span>
</td>
<td class="nump">1,407,983<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Common stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Net Loss Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share</a></td>
<td class="nump">615,307<span></span>
</td>
<td class="nump">915,224<span></span>
</td>
<td class="nump">1,039,709<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_PerformanceSharesMember', window );">Performance stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Net Loss Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share</a></td>
<td class="nump">155,618<span></span>
</td>
<td class="nump">54,317<span></span>
</td>
<td class="nump">96,383<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Net Loss Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share</a></td>
<td class="nump">590,542<span></span>
</td>
<td class="nump">265,616<span></span>
</td>
<td class="nump">218,686<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=tcmd_EmployeeStockPurchasePlanMember', window );">Employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Net Loss Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share</a></td>
<td class="nump">100,506<span></span>
</td>
<td class="nump">34,809<span></span>
</td>
<td class="nump">53,205<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=tcmd_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=tcmd_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139814961889696">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 08, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Earn-out liability</a></td>
<td class="nump">$ 13,050<span></span>
</td>
<td class="nump">$ 6,200<span></span>
</td>
<td class="nump">$ 6,400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Earn-out liability</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcmd_BusinessCombinationAdditionalContingentConsiderationLiability', window );">Additional earn out payment</a></td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcmd_BusinessCombinationAdditionalContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination Additional Contingent Consideration Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcmd_BusinessCombinationAdditionalContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139814961138592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Earn out liability (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Earn-out liability, beginning balance</a></td>
<td class="nump">$ 6,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities', window );">Payment on earn-out</a></td>
<td class="num">(5,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Fair value adjustments</a></td>
<td class="nump">11,850<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Earn-out liability, ending balance</a></td>
<td class="nump">13,050<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Fair value measure, earn out liability current</a></td>
<td class="nump">8,100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Earn-out liability, beginning balance</a></td>
<td class="nump">$ 6,200<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139814958634944">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Fair Value Hierarchy (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 08, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Earn-out liability</a></td>
<td class="nump">$ 13,050<span></span>
</td>
<td class="nump">$ 6,200<span></span>
</td>
<td class="nump">$ 6,400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Earn-out liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Earn-out liability</a></td>
<td class="nump">8,050<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Available for sale debt securities</a></td>
<td class="nump">8,050<span></span>
</td>
<td class="nump">6,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Significant Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Earn-out liability</a></td>
<td class="nump">8,050<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Available for sale debt securities</a></td>
<td class="nump">$ 8,050<span></span>
</td>
<td class="nump">$ 6,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>tcmd-20221231x10k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:tcmd="http://www.tactilemedical.com/20221231"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="tcmd-20221231.xsd" xlink:type="simple"/>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_CnxzEZbj2keHiRpKCxnEuw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_CdFl24OyvE-vHZl3Dyt3tg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_IoIhyk8NdE6DGInICUHwgg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_TR941NiDcUCdRWACyKn3Wg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_-1H3pbcbgE2pDEcuUUIOQA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_dQSyY2Nl1EyEQUyJvn7F7A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_H3RLfzlePUicZ6gsHqIN-g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_JAb6JFyA10K9maMFF2T0yQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_BPwmELKt2UWgprqGAT1saQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_iD4fs-NVZUqKbPMH2pu8Tg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_SzV_dAN03kCUiZaHywHGxw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_bAXadoBqGUyVY6l0rjAY1g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_dwEtqEfNw0CpirbkcmdKtw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_jyxtNFkIQECm4cCy3eQwzQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_BMz7mX7-OUWrFBdwQYForQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Qp36H0EGtUGt3jcLLgZfHw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_831Iwe84l0uIaFkRq3YMEA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_8_2_2016_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_G1Q8otm7u0SlPI0I3gLpyg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-08-02</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_RangeAxis_srt_MinimumMember_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_MEZgTABuGkCMjTedZP40gQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_VEK6kkacQUeh0rcfcqChxQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_c4XlEVcSZkGUgY9pO9GVYw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MinimumMember_1ONqRYxs-E23uhkk4rcXew">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MaximumMember_AgQnIK2l2UG-kwV420MM5g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember___xLca8jWE2AqShfBEgmlw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_YXF4jcKSZ0az4v_DZj-Otw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_1_1_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_EmployeeStockMember_oauLVrUQf0Cdq6kFtZ4aEg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_1_1_2021_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_GIA9oCLf2kOobzBosxqDOQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tcmd:EquityIncentivePlan2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_N_-EN94zSkyi4738ywQnkQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_cTbUJaM5EEi7_dTn33kCIQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_X4ApOCKa20aLE0iARpjyBw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_KSWzHsfkUUCC4ceQE_HELQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_AwardTypeAxis_tcmd_TimeBasedRestrictedStockUnitsRsusMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_Rx5oCF5RME-QoxzFqBAV1g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tcmd:TimeBasedRestrictedStockUnitsRsusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tcmd:EquityIncentivePlan2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_AwardTypeAxis_tcmd_TimeBasedRestrictedStockUnitsRsusMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_IaK_VsGjOEiqSEoE-zGXOw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tcmd:TimeBasedRestrictedStockUnitsRsusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tcmd:EquityIncentivePlan2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_AwardTypeAxis_tcmd_TimeBasedRestrictedStockUnitsRsusMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_RfN-hRdVK0WQ7dibE-9y_A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tcmd:TimeBasedRestrictedStockUnitsRsusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tcmd:EquityIncentivePlan2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_AwardTypeAxis_tcmd_PerformanceBasedStockSettledRestrictedStockUnitsMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_yXZPu2ZWyESDFq8L-JZCHg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tcmd:PerformanceBasedStockSettledRestrictedStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tcmd:EquityIncentivePlan2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_AwardTypeAxis_tcmd_PerformanceBasedStockSettledRestrictedStockUnitsMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_vFDEcLAy5EyVpxGp-lSAGQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tcmd:PerformanceBasedStockSettledRestrictedStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tcmd:EquityIncentivePlan2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_tcmd_PerformanceBasedStockSettledRestrictedStockUnitsMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_9JG89pH7v0yNuwlry2fC6A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tcmd:PerformanceBasedStockSettledRestrictedStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tcmd:EquityIncentivePlan2016Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_tcmd_PerformanceBasedStockSettledRestrictedStockUnitsMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_-dmVAO8GPEe-d87xbGyf8Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tcmd:PerformanceBasedStockSettledRestrictedStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tcmd:EquityIncentivePlan2016Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_tcmd_TimeBasedRestrictedStockUnitsRsusMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_UQNyJOFH5UKq1kC0uw2-mQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tcmd:TimeBasedRestrictedStockUnitsRsusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tcmd:EquityIncentivePlan2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_tcmd_TimeBasedRestrictedStockUnitsRsusMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_8RJLAbFs-0aC61lHpsR90Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tcmd:TimeBasedRestrictedStockUnitsRsusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tcmd:EquityIncentivePlan2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_L2H-B4harkuWLN7SUIOPRQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_x68hCF8ixkS5q2MJuoiIYA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_tcmd_TimeBasedRestrictedStockUnitsRsusMember_OqoDokUrok2FtqlOs8iQLQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tcmd:TimeBasedRestrictedStockUnitsRsusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_tcmd_PerformanceBasedStockSettledRestrictedStockUnitsMember_jgqU-RDfJkWBTKO22fvJHw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tcmd:PerformanceBasedStockSettledRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_tcmd_VeteransAdministrationMember_UImO_mSEIUWRj4_3Jkesdw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">tcmd:VeteransAdministrationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_tcmd_PrivateInsurersMember_Gl5_xQhWx0SDBOy0s9jDJA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">tcmd:PrivateInsurersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_tcmd_MedicareMember_K5sCGhJDSUOfkdarnEOQWg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">tcmd:MedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_tcmd_DurableMedicalEquipmentDistributorsMember_VSaj6O2pMU2ypZXriiw1kg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">tcmd:DurableMedicalEquipmentDistributorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_tcmd_VeteransAdministrationMember_QGri6VTOrky2n0lhb6O-wg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">tcmd:VeteransAdministrationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_tcmd_PrivateInsurersMember_7J0YXfLIgU2pD3Cizu1_Aw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">tcmd:PrivateInsurersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_tcmd_MedicareMember_rK1KRWcE20Ot8cBmMKEQsA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">tcmd:MedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_tcmd_DurableMedicalEquipmentDistributorsMember_FRHWIP8w2UG8vVzzhUcyKg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">tcmd:DurableMedicalEquipmentDistributorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_srt_MajorCustomersAxis_tcmd_VeteransAdministrationMember_nKPbjM6STkCgVrqDgy_u8Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">tcmd:VeteransAdministrationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_srt_MajorCustomersAxis_tcmd_PrivateInsurersMember_6NttS8BSLkSGb2rID11mYQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">tcmd:PrivateInsurersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_srt_MajorCustomersAxis_tcmd_MedicareMember__J8_VCY0Ok-NPKhYcRHpiw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">tcmd:MedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_9_8_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_BusinessAcquisitionAxis_tcmd_AfflovestPMember_jLq6gqZQRUe0_w5vfb9Asg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tcmd:AfflovestPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-08</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ToolsDiesAndMoldsMember_NTOCOwxcN0WCHhE4s7Z6xg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ToolsDiesAndMoldsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_MA9Tzfj_Zkq7UAzFHCpHMQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdsAndLeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_wBBLS9cO1EGcEb4aYAZlcA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_Yh5OMODH40SC-Um87PF3UA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember_jGU_hCQP7EaA8kqaHpKwsg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_tcmd_DemoEquipmentMember_r01Fmv-tlE2ZfmS0SxVG8g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">tcmd:DemoEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ToolsDiesAndMoldsMember_Pvs6l_E6h0O5TC299fq4Bg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ToolsDiesAndMoldsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_MU5-dZQMLEOZnQDTmaetLQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdsAndLeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_cb8KtxnOaUusasmEVS4S6w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_Uf5xoWiQAkuLZI9kCZLPRA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember_Ko8IgMBkWUy1Erw3_JKPQg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_tcmd_DemoEquipmentMember_3j_rU49gBEimc7YFgpwKEw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">tcmd:DemoEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_CreditFacilityAxis_tcmd_TermLoanMember_VIrloQlsfEmn_JzIEt95jA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">tcmd:TermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_i_HrmJK0qEam7JhO2g89aw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_fVykz_MeNEanAhnkwaVQuw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_9_8_2021_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_4ewNm1bD10K5QwII7IVr3g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-08</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_pmPeDzOSDEq1hwWSnhZm1A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember_lOgwHc6a7keMQ5U8kHbmZA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_CBz12HaJ3EelHnd3ISwWrQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember_bxiv0zaNYUqU9S4A8vYbgw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_VehiclesMember_WEhReoFIrk61ZFxikX2DoA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_RangeAxis_srt_MinimumMember_EXKUiZxnk0qVwfOmUunwkw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_lwkNBH8qPUKwpTFPfFM4eg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_9_8_2021_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember_cbYze6WHq0-MzNMIXQ6G8Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-08</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember_IyWAZ3ta8E2Ea1SMrdPPBQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_PatentsMember_LNA_h_4RnkaxxN0_I1BWbQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember_aBd3a_ELrEOm_yysA0S0ag">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_PatentsMember_m8rPRrVCGkCmV2jH3V3EGA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_BusinessAcquisitionAxis_tcmd_AfflovestPMember_0vr8lFFgNk-hj48fe5kJDg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tcmd:AfflovestPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="Duration_9_8_2021_To_9_8_2021_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_9xTBZJ8BSEyOBEAowNs5qA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-08</startDate>
            <endDate>2021-09-08</endDate>
        </period>
    </context>
    <context id="Duration_9_8_2021_To_9_8_2021_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_CustomerRelationshipsMember_vwfc8GlHbEG6FpxSb_48hw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-08</startDate>
            <endDate>2021-09-08</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_CustomerContractsMember_zWlWYJGY4UyP-QjMu9VYLA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_PatentsMember_bHnLKkfY50SShKWlCELEaA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_lM7vBgl8SkW3zbCRJ6akww">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_CustomerRelationshipsMember_jYH-emDiWkiQNaMDqVEM4w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_tcmd_DefensiveIntangibleAssetsMember_6NFOXe0OVEae4LCvhvDg5A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">tcmd:DefensiveIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_PatentsMember_nZCthuPEmEK_vsD9bnMPZg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_TEkHdFvt00SmYBkAMY4_HQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_CustomerRelationshipsMember_64UYdGsGlUaBziSx02KLVQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_CustomerContractsMember_8VJEgmF_UkWBYfqLoC4C3A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_tcmd_DefensiveIntangibleAssetsMember_62-asFO7iEyeD8pb1fZgLA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">tcmd:DefensiveIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_9_8_2021_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_1vdqkBPIV06qt_Sb8l9xvw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-08</instant>
        </period>
    </context>
    <context id="As_Of_9_8_2021_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_CustomerRelationshipsMember_W5D5EY3MR0edt8BoVhmVUQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-08</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_PatentsMember_EzMi2_I88kuyRc4Rc_5PoQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_lL8SrIZbB0O4E4gu1p47vA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_CustomerRelationshipsMember_Y08o1mZ38kCDCzt3GAQN8A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_CustomerContractsMember_YzWU1KiStEOVgQlfeA7jcw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_tcmd_DefensiveIntangibleAssetsMember_LZ89k11DfEu3IXN3jY-Q_A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">tcmd:DefensiveIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_PatentsMember_JkjaHeEoUE2DyDTDEjvMwQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_iZuKEYAKNU6aSfE3kxIqUw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_CustomerRelationshipsMember_dmnRIghXk0SjwOQAgPqgtg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_CustomerContractsMember_fTqSuCd94keomoVYMmQiIw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_tcmd_DefensiveIntangibleAssetsMember_QV0b5loORke7y1IpAQUFJQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">tcmd:DefensiveIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_AwardTypeAxis_tcmd_TimeBasedRestrictedStockUnitsRsusMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_qc0c3k5OY0eKiJM_sgU8nA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tcmd:TimeBasedRestrictedStockUnitsRsusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tcmd:EquityIncentivePlan2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_Un8xxO7K-UGnIxffkFMjsw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_AwardTypeAxis_tcmd_PerformanceBasedStockSettledRestrictedStockUnitsMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_GskkIzSZ40CADy7RgEQqjw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tcmd:PerformanceBasedStockSettledRestrictedStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tcmd:EquityIncentivePlan2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_RetirementPlanNameAxis_tcmd_DefinedContribution401kRetirementPlanMember_tDmbZG8x90OrgLeuanK9nw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">tcmd:DefinedContribution401kRetirementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_RetirementPlanNameAxis_tcmd_DefinedContribution401kRetirementPlanMember_zWNpuLNXTEuhSfDngvS76w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">tcmd:DefinedContribution401kRetirementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_RetirementPlanNameAxis_tcmd_DefinedContribution401kRetirementPlanMember_tGvCSx6Y1EuXw-i1zDT2EA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">tcmd:DefinedContribution401kRetirementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_WDmzwEjdBUiA-CU6PKMNzQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_CreditFacilityAxis_tcmd_TermLoanMember_3Cnmib--SkSEPm4Zq4wPzQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">tcmd:TermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_9_8_2021_us-gaap_CreditFacilityAxis_tcmd_TermLoanMember_oz1r9Y66CkacJQ3itM6kfg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">tcmd:TermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-08</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_VariableRateAxis_us-gaap_LondonInterbankOfferedRateLIBORMember_qtvC3cCEtUGvoYG_aiVd5w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_VariableRateAxis_us-gaap_BaseRateMember_RkYOxE7JdkmHm__eg3-sdw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_VariableRateAxis_us-gaap_LondonInterbankOfferedRateLIBORMember_5Ok3Lj-bZEKdl_78m7_07g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_VariableRateAxis_us-gaap_BaseRateMember_cKhsiHfOCE28P3WddmWqow">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_VariableRateAxis_us-gaap_LondonInterbankOfferedRateLIBORMember_27-_EKPJYUWpaRUxj1OYBQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_VariableRateAxis_us-gaap_FederalFundsEffectiveSwapRateMember_Ox5KmpqBekOgFh1i9iNuQg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:FederalFundsEffectiveSwapRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_VariableRateAxis_us-gaap_BaseRateMember_bmZqSyyD0UC5KiXp5eY0wA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_VariableRateAxis_us-gaap_LondonInterbankOfferedRateLIBORMember_6BVYYrgoDEySTxjBn4sZ3A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_SP3wyCMXCU2i6drZEHq64A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_tcmd_RentalProductServiceMember_UQEeT0sALU2WyRpN4h-d1g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tcmd:RentalProductServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_hfu9P6iNKUi9O4wj8Mt1eQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_tcmd_RentalProductServiceMember_SHuwLl4tzECMukntSz1kJw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tcmd:RentalProductServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember_cRwZGotvHkm9Z1U4mHwTFw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_srt_ProductOrServiceAxis_tcmd_RentalProductServiceMember_NFKOoDrORk2r6CW4q3szBw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tcmd:RentalProductServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_CostOfGoodsTotalMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_SupplierConcentrationRiskMember_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_tcmd_VendorOneMember_vviffeAE5EGD7qLxiUROxg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfGoodsTotalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">tcmd:VendorOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_tcmd_InsuranceCompanyTwoMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_YhUWFBciaEqXEvSlvrAhSQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">tcmd:InsuranceCompanyTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_tcmd_InsuranceCompanyTwoMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_xVT-UB4QW0Gw2arUgYbYcQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">tcmd:InsuranceCompanyTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_tcmd_InsuranceCompanyOneMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_0HtNQF4hrEWyegzUln8uIA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">tcmd:InsuranceCompanyOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_tcmd_InsuranceCompanyOneMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_N4xxMFKVj0S35nREv_ENMA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">tcmd:InsuranceCompanyOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_CostOfGoodsTotalMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_SupplierConcentrationRiskMember_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_tcmd_VendorTwoMember_ofzmjVvnsUW7aaWOzboUlQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfGoodsTotalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">tcmd:VendorTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_tcmd_InsuranceCompanyTwoMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_3m0fCb_Nf0uWfI863PsLKw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">tcmd:InsuranceCompanyTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_tcmd_InsuranceCompanyTwoMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_vLNz00UhJUufY_Zqk3iO2A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">tcmd:InsuranceCompanyTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_tcmd_InsuranceCompanyOneMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_qYkwWgdcNkuDHHwGOvxkhQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">tcmd:InsuranceCompanyOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_tcmd_InsuranceCompanyOneMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_1-eh01sLXEOTZIQ08pcPiw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">tcmd:InsuranceCompanyOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_WCG-z2RnpUGRHcHammTWIw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_YaY3_P_Sw02KL1vnK5w7IQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_CN1dmz1V3Ue1flAlam2dNQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_aFuDPm3quE6OkMXnwfeySg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_EmployeeStockMember_h6LWksYkZk-wYDJVCmudqg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_4_27_2017_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_EmployeeStockMember_1JhNvac8pkCgs2t4mxK9oQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-04-27</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_q95ww8WB7U-18mlScI3MCA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_3ga0jBjg6EKA4-znaQ36NQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_9V6sgB50n0-ZfOQSvVu1Mw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_9_8_2021_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_tcmd_AssetAcquisitionEarnoutPaymentsRevenueTargetsFromOctoberTwoThousandTwentyOneToSeptemberTwoThousandTwentyTwoMember_us-gaap_BusinessAcquisitionAxis_tcmd_AfflovestPMember_u62XShicPUa52TcVaICEVA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">tcmd:AssetAcquisitionEarnoutPaymentsRevenueTargetsFromOctoberTwoThousandTwentyOneToSeptemberTwoThousandTwentyTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tcmd:AfflovestPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-08</instant>
        </period>
    </context>
    <context id="Duration_9_8_2021_To_9_8_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_BusinessAcquisitionAxis_tcmd_AfflovestPMember_cXLgD3w8o0mAJ_EMBbTfZg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tcmd:AfflovestPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-08</startDate>
            <endDate>2021-09-08</endDate>
        </period>
    </context>
    <context id="Duration_9_8_2021_To_9_8_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_0hChIJ5gE0K__CcmmMTvmQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-08</startDate>
            <endDate>2021-09-08</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2021_To_12_31_2021_us-gaap_BusinessAcquisitionAxis_tcmd_AfflovestPMember_C1E4O7zjlUGPDClD_oKeEg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tcmd:AfflovestPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2020_To_12_31_2020_us-gaap_BusinessAcquisitionAxis_tcmd_AfflovestPMember_jQCcMt5pY0Os-LuUZm0lRA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tcmd:AfflovestPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_uLFZTWJi2k6g6WI1HfkiNA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_vevcUAPFYESbYWLi7G0kaQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_KVbTIgc1_EmIcfBzONO5-g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_91EX6xEDf0-UcTWUZJ8XyA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_9_8_2021_us-gaap_BusinessAcquisitionAxis_tcmd_AfflovestPMember_3FbjYCEqNkWAlMK4QIberg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tcmd:AfflovestPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-08</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2018_us-gaap_PropertyPlantAndEquipmentByTypeAxis_tcmd_CorporateHeadQuarterSecondLeaseMember_kJI6F8P6zkKbLuYO9IJnVw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">tcmd:CorporateHeadQuarterSecondLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="As_Of_10_31_2018_us-gaap_PropertyPlantAndEquipmentByTypeAxis_tcmd_CorporateHeadQuarterInitialLeaseMember_iOfecFzhU0CEX9fKgtv8qA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">tcmd:CorporateHeadQuarterInitialLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_zrOdl-ZHU0eDIaMQWN19yQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_PerformanceSharesMember_2SwhGbNgwU-bMQqkqXN2dA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_Qq8im1g0PUaVhc7NKNKkWg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_tcmd_EmployeeStockPurchasePlanMember_4b4qjiA0fk6pyDx0k4A_zw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tcmd:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_CIZJzOcjHUyKmot1xYLGwA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_PerformanceSharesMember_rMVulEGBZE-wAbQ2SAc66Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_ghRyW-vZS0uZBW3nKbbR-g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_tcmd_EmployeeStockPurchasePlanMember_f1tc7L44FUqMy8SxWvmMoQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tcmd:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_t1GQxjJoS0WeSfGLeyxUPw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_PerformanceSharesMember_c5JOwteMr0ax5Sb2--bJyg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_bg4XNhQ5v0uWr2dXSfREiw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_tcmd_EmployeeStockPurchasePlanMember_C8tXw8ygUkKbK1P0V6S3LQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tcmd:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingAndMarketingExpenseMember_6DUS8nZX1k2uITtnX1jELw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_WkeJd_L3IEm8ahIsJkn_Ww">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_Ny2qblOYAkWwzAuljmv4Ow">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_6-UgFP9YHkKs37vGGIhEVw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_1cM49KVdP0WP3FTRdFVJvA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_tcmd_TwoThousandEighteenAndTwoThousandTwentyPerformanceBasedRestrictedStockUnitsMember_WZVx9pkMD0SJKZFhIdnWjQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tcmd:TwoThousandEighteenAndTwoThousandTwentyPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingAndMarketingExpenseMember_tE0YJWqzRkusl6_G8TxGpA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_NHelbVJut0SpZ1MaGzM82w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_oF6quC9QMU-Gu_UPthtpzw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_SKlrM8781Eet0zFbC3ewTw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_EmployeeStockMember_5xoE_s_XYkyuIAK5oWCe8Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_-Mhsa97jY0mecFzNVd7m8w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_tcmd_TwoThousandEighteenAndTwoThousandTwentyPerformanceBasedRestrictedStockUnitsMember_HDcRO5L1FU2oWQGAEeWYwA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tcmd:TwoThousandEighteenAndTwoThousandTwentyPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingAndMarketingExpenseMember_LOcVV8870UGUDxZpsZpW1A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_2oRfq2ewaUy6AGWg2Xby5A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_DbypvZkVpEePjQqYGvgkEw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_qOmCDKQT9Eyfuidf3pzRYg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_EmployeeStockMember_8hDu8hXfJECRLadm6BTlqQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_jRQ3JtT1NE2Wt3xFenHFEw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_AggAm3MT3EmHS5mE0Dp2Yg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Yly5bMDTYE-lx-OvMp67yw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_dZyQCZO280GpmViirHXo1g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_tcmd_GarmentsMember_srt_RangeAxis_srt_MinimumMember_k8qNoq95Rky9-_sJro6IyA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tcmd:GarmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_tcmd_GarmentsMember_srt_RangeAxis_srt_MaximumMember_fiHw-QVcjESriGs85ZfH7w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tcmd:GarmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_tcmd_ControllersMember_srt_RangeAxis_srt_MinimumMember_QvX9jbOWVkiQmu6BazrG2Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tcmd:ControllersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_tcmd_ControllersMember_srt_RangeAxis_srt_MaximumMember_wiN7jXmrnkGpVKBXgBLvJA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tcmd:ControllersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_8_2_2016_To_8_2_2016_jh5ft8WN0USibAdtcwGHiA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
        </entity>
        <period>
            <startDate>2016-08-02</startDate>
            <endDate>2016-08-02</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_tcmd_TimeBasedRestrictedStockUnitsRsusMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_Nb-WbjXmjUKf3z1gH8kH5Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tcmd:TimeBasedRestrictedStockUnitsRsusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tcmd:EquityIncentivePlan2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_tcmd_TimeBasedRestrictedStockUnitsRsusMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_YpNaI4H08kWMKCFdksUPJg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tcmd:TimeBasedRestrictedStockUnitsRsusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tcmd:EquityIncentivePlan2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_tcmd_TimeBasedRestrictedStockUnitsRsusMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_-BKViJhhwkykuZDgY3GR5A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tcmd:TimeBasedRestrictedStockUnitsRsusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tcmd:EquityIncentivePlan2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_AwardTypeAxis_tcmd_PerformanceBasedStockSettledRestrictedStockUnitsMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_WpTm0Lj5Q0WDgY5zSwuAIg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tcmd:PerformanceBasedStockSettledRestrictedStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tcmd:EquityIncentivePlan2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_MJZ8uZEAPEmYMAtcEg9uBg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tcmd:EquityIncentivePlan2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="Duration_8_2_2016_To_8_2_2016_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_F3xqjLu7uEyeSRqBJT0RuA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-08-02</startDate>
            <endDate>2016-08-02</endDate>
        </period>
    </context>
    <context id="Duration_8_2_2016_To_8_2_2016_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_QQrwNskzWkG7CPUnrW9tVw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-08-02</startDate>
            <endDate>2016-08-02</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_nUg2v2mfW0uAzRdSMTamQQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_VpuMgvUm10Cec1Yu-NEe1Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_tcmd_PerformanceBasedStockSettledRestrictedStockUnitsMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_CmpNEKSSE0O0i2jPBWOaAg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tcmd:PerformanceBasedStockSettledRestrictedStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tcmd:EquityIncentivePlan2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_tcmd_PerformanceBasedStockSettledRestrictedStockUnitsMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_Hlc6i7-A9EusSlzegAjTIQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tcmd:PerformanceBasedStockSettledRestrictedStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tcmd:EquityIncentivePlan2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_tcmd_FlexitouchSystemMember_CGH6jrZrrEuNDGgcZtJaOQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tcmd:FlexitouchSystemMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_tcmd_AfflovestMember_dBqlEgBFb02-NFr9MvkVnw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tcmd:AfflovestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_tcmd_FlexitouchSystemMember_DXKUE6FvQUC574PEnBV1Ow">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tcmd:FlexitouchSystemMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_tcmd_AfflovestMember__lGIQFNyT06Uzw8ThGA7KA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tcmd:AfflovestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_srt_ProductOrServiceAxis_tcmd_FlexitouchSystemMember_H2Jxo4pTn0OGkO2d39JE6g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tcmd:FlexitouchSystemMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_tcmd_VendorOneMember_X8R2b_l6g02zwqRLkFf0tg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">tcmd:VendorOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_VehiclesMember_2k-hdZ3H2UWc6uo6P8NZ5Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_Apyhw0rpjEqZ3vFtmoPsAg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_11_21_2022_m22jugRAaEmtVeWbOHw3dw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
        </entity>
        <period>
            <instant>2022-11-21</instant>
        </period>
    </context>
    <context id="Duration_9_8_2021_To_9_8_2021_JHuv2YIhr0-DMtiV3Vl0PA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
        </entity>
        <period>
            <startDate>2021-09-08</startDate>
            <endDate>2021-09-08</endDate>
        </period>
    </context>
    <context id="Duration_8_2_2016_To_8_2_2016_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_oNbQsAMXk0uBUzklZFhmAA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-08-02</startDate>
            <endDate>2016-08-02</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_tcmd_PerformanceBasedStockSettledRestrictedStockUnitsMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_UgLe632XY0y4wqXfkaKIqg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tcmd:PerformanceBasedStockSettledRestrictedStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tcmd:EquityIncentivePlan2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_tcmd_PerformanceBasedStockSettledRestrictedStockUnitsMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_7x_jPqkWGkShM1NIyefKfQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tcmd:PerformanceBasedStockSettledRestrictedStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tcmd:EquityIncentivePlan2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_tcmd_PerformanceBasedStockSettledRestrictedStockUnitsMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_rm8GPwYY40y-DieCnmoBug">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tcmd:PerformanceBasedStockSettledRestrictedStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tcmd:EquityIncentivePlan2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_EmployeeStockMember_cKXRqo7dk0-EdILU7PZBhg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_2_22_2022_To_2_22_2022_us-gaap_CreditFacilityAxis_tcmd_TermLoanMember_L6c2GMdVeE2wHtiYF_EBdA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">tcmd:TermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-22</startDate>
            <endDate>2022-02-22</endDate>
        </period>
    </context>
    <context id="As_Of_9_8_2021_8l4xBubq7Umd0Y3dMd0UnQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
        </entity>
        <period>
            <instant>2021-09-08</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_RangeAxis_srt_MaximumMember__4L7Euy5PkiEdMffnWdNng">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_11_4_2022_srt_StatementScenarioAxis_tcmd_SecondEarnOutAmendmentMember_us-gaap_BusinessAcquisitionAxis_tcmd_AfflovestPMember_la2cedehBk-qL-iSyE1pIA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">tcmd:SecondEarnOutAmendmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tcmd:AfflovestPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-04</instant>
        </period>
    </context>
    <context id="As_Of_11_4_2022_srt_StatementScenarioAxis_tcmd_EarnOutPeriodOnOrBeforeNovember282022Member_us-gaap_BusinessAcquisitionAxis_tcmd_AfflovestPMember_YJ8bNR_NZ0CvMpF7RV_aqw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">tcmd:EarnOutPeriodOnOrBeforeNovember282022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tcmd:AfflovestPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-04</instant>
        </period>
    </context>
    <context id="As_Of_11_4_2022_srt_StatementScenarioAxis_tcmd_EarnOutPeriodOnOrBeforeMay262023Member_us-gaap_BusinessAcquisitionAxis_tcmd_AfflovestPMember_en0im7ZgS0KUsbPg8tTm6A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">tcmd:EarnOutPeriodOnOrBeforeMay262023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tcmd:AfflovestPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-04</instant>
        </period>
    </context>
    <context id="As_Of_11_4_2022_us-gaap_BusinessAcquisitionAxis_tcmd_AfflovestPMember_mDniF7LA_kiQpOIIlQZs3g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tcmd:AfflovestPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-04</instant>
        </period>
    </context>
    <context id="As_Of_9_8_2021_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_tcmd_AssetAcquisitionEarnoutPaymentsRevenueTargetsFromOctoberTwoThousandTwentyTwoToSeptemberTwoThousandTwentyThreeMember_us-gaap_BusinessAcquisitionAxis_tcmd_AfflovestPMember_o1oljgm50kqF7GpMnEHq0g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">tcmd:AssetAcquisitionEarnoutPaymentsRevenueTargetsFromOctoberTwoThousandTwentyTwoToSeptemberTwoThousandTwentyThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tcmd:AfflovestPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-08</instant>
        </period>
    </context>
    <context id="Duration_11_4_2022_To_11_4_2022_srt_StatementScenarioAxis_tcmd_SecondEarnOutAmendmentMember_us-gaap_BusinessAcquisitionAxis_tcmd_AfflovestPMember_AEZMhjNrNkqvyABhlnwRPg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">tcmd:SecondEarnOutAmendmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tcmd:AfflovestPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-04</startDate>
            <endDate>2022-11-04</endDate>
        </period>
    </context>
    <context id="Duration_11_4_2022_To_11_4_2022_us-gaap_BusinessAcquisitionAxis_tcmd_AfflovestPMember_pimwAjq0t0WJdAD0aYSTWA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tcmd:AfflovestPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-04</startDate>
            <endDate>2022-11-04</endDate>
        </period>
    </context>
    <context id="Duration_9_8_2021_To_9_8_2021_srt_StatementScenarioAxis_tcmd_AssetAcquisitionEarnoutPaymentsRevenueTargetsFromOctoberTwoThousandTwentyTwoToSeptemberTwoThousandTwentyThreeMember_us-gaap_BusinessAcquisitionAxis_tcmd_AfflovestPMember_HRn8Gvyx7UuDkFsUjw2MWw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">tcmd:AssetAcquisitionEarnoutPaymentsRevenueTargetsFromOctoberTwoThousandTwentyTwoToSeptemberTwoThousandTwentyThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tcmd:AfflovestPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-08</startDate>
            <endDate>2021-09-08</endDate>
        </period>
    </context>
    <context id="Duration_9_8_2021_To_9_8_2021_srt_StatementScenarioAxis_tcmd_AssetAcquisitionEarnoutPaymentsRevenueTargetsFromOctoberTwoThousandTwentyOneToSeptemberTwoThousandTwentyTwoMember_us-gaap_BusinessAcquisitionAxis_tcmd_AfflovestPMember_ekMNWGfKGkOGXb6VuFuvcQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">tcmd:AssetAcquisitionEarnoutPaymentsRevenueTargetsFromOctoberTwoThousandTwentyOneToSeptemberTwoThousandTwentyTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tcmd:AfflovestPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-08</startDate>
            <endDate>2021-09-08</endDate>
        </period>
    </context>
    <context id="Duration_9_8_2021_To_9_8_2021_us-gaap_BusinessAcquisitionAxis_tcmd_AfflovestPMember_9xzfRGshm0aKb9OM49UhSQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tcmd:AfflovestPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-08</startDate>
            <endDate>2021-09-08</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_4VmedOiWwk-TuOc3qFFccg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_26fO_zM0qkaf9YFqHV50Wg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_tcmd_CorporateHeadQuarterThirdLeaseMember_i4Zbs1u8B0-YqSUpBTf3Hg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">tcmd:CorporateHeadQuarterThirdLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_tcmd_CorporateHeadQuarterSecondLeaseMember_RayR2gEiIEWjwHNeeJouhw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">tcmd:CorporateHeadQuarterSecondLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_8_2_2016_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_Y9mdYePcDUyiYIOsBHbTDA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-08-02</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_JtERcFin0ki2oKH5VRLp_g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_2_17_2023_bjzkG-0zVU2f6CDXzJQEcA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
        </entity>
        <period>
            <instant>2023-02-17</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <unit id="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_Standard_sqft_pFxGS_NorEW8LBFrHYvkFg">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_Standard_item_-67QV0kzWUGc8AbcCukKig">
        <measure>tcmd:item</measure>
    </unit>
    <unit id="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Unit_Standard_segment_zejw3MrZOkWEznPtKLNRGQ">
        <measure>tcmd:segment</measure>
    </unit>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw"
      id="Hidden_aRe_ITIiPkGRhMbMyQyrwA"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q"
      id="Hidden_9qaF8uEvyEKyjx097znuhA"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg"
      xsi:nil="true"/>
    <us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw"
      id="Hidden_2RBFup1GF0aYmRp6sPf_WA">http://fasb.org/us-gaap/2022#OperatingLeaseRightOfUseAsset</us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw"
      id="Hidden_AJFhMV1JPUOJ0hFVR48KjQ">http://fasb.org/us-gaap/2022#OperatingLeaseLiabilityCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
      contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw"
      id="Hidden_Ez5Qhbo3AU2e7FSsdfdH2g">http://fasb.org/us-gaap/2022#OperatingLeaseLiabilityNoncurrent</us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q"
      decimals="INF"
      id="Hidden_SRrXC5R_mkC7J8odlogKhQ"
      unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw"
      decimals="INF"
      id="Hidden_Z0qGnwbWkUSwt3t7s-ACpQ"
      unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ">0</us-gaap:PreferredStockSharesOutstanding>
    <dei:EntityCentralIndexKey
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      id="Tc_luXDnhlF3kmZqciYOqfRYg_5_1">0001027838</dei:EntityCentralIndexKey>
    <dei:DocumentFiscalYearFocus
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      id="Tc_1AtDzqSotkqOz95i38e_og_7_1">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      id="Tc_n2c0akmvl0i_ROFdpuXG-Q_8_1">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityFilerCategory
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      id="Hidden_WgadwSncGUeeRkl-6pghrg">Accelerated Filer</dei:EntityFilerCategory>
    <us-gaap:PreferredStockValue
      contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw"
      id="Hidden_3S7QxW9bN0-5rDK2dHG7WQ"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q"
      id="Hidden_FZYePmsfUEaYRZiApBW7xw"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg"
      xsi:nil="true"/>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw"
      decimals="INF"
      id="Hidden__bCQNAsLokuxTIDsHWGXFQ"
      unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ">20252677</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q"
      decimals="INF"
      id="Hidden_xOwJC91HdkeMBD-SeycYHA"
      unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ">19877786</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_nUg2v2mfW0uAzRdSMTamQQ"
      id="Hidden_-K2S-WgBSE6sH7tBYgqsYw">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <tcmd:TermOfProductWarranty
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_tcmd_GarmentsMember_srt_RangeAxis_srt_MinimumMember_k8qNoq95Rky9-_sJro6IyA"
      id="Hidden_y-RzrDjl6U6YAkZa8g5tjg">P1Y</tcmd:TermOfProductWarranty>
    <tcmd:TermOfProductWarranty
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_tcmd_ControllersMember_srt_RangeAxis_srt_MinimumMember_QvX9jbOWVkiQmu6BazrG2Q"
      id="Hidden_2vCz5hZwoEmnfJJOj_Lktg">P1Y</tcmd:TermOfProductWarranty>
    <tcmd:PeriodForConsiderationPaymentAfterShipmentDate
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_nUg2v2mfW0uAzRdSMTamQQ"
      id="Hidden_29m0XALLYEGpUDkg67Logg">P2D</tcmd:PeriodForConsiderationPaymentAfterShipmentDate>
    <tcmd:TermOfProductWarranty
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_tcmd_GarmentsMember_srt_RangeAxis_srt_MinimumMember_k8qNoq95Rky9-_sJro6IyA"
      id="Hidden_9oGSvawUkUuA-bl9OI56kg">P1Y</tcmd:TermOfProductWarranty>
    <us-gaap:NumberOfReportableSegments
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      decimals="INF"
      id="Hidden_hf125MM_GkGhx3Sj6QqkPA"
      unitRef="Unit_Standard_segment_zejw3MrZOkWEznPtKLNRGQ">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="As_Of_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember_lOgwHc6a7keMQ5U8kHbmZA"
      id="Hidden_cPi9QUIkvEuGhENNTJkqkw">P1Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q"
      id="Hidden_tKPJpXeds0SiabhmYWAMEg">http://fasb.org/us-gaap/2022#OperatingLeaseRightOfUseAsset</us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q"
      id="Hidden_tyE6-ij7k06Rv5IRQ6iD1Q">http://fasb.org/us-gaap/2022#OperatingLeaseLiabilityCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
      contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q"
      id="Hidden_hRi5aCIDPEGUkAgK0iaGvw">http://fasb.org/us-gaap/2022#OperatingLeaseLiabilityNoncurrent</us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <tcmd:NumberOfConsecutiveTradingDaysInWhichStockPriceExceedCertainPercentageOfClosingPriceOfCommonStockRequiredForAwardToBeGranted
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_Apyhw0rpjEqZ3vFtmoPsAg"
      id="Hidden_94egicmKoESPdhUuU5X_1w">P20D</tcmd:NumberOfConsecutiveTradingDaysInWhichStockPriceExceedCertainPercentageOfClosingPriceOfCommonStockRequiredForAwardToBeGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_L2H-B4harkuWLN7SUIOPRQ"
      id="Hidden_6Mhakd_sLkqC71m6G0M6Og">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_L2H-B4harkuWLN7SUIOPRQ"
      id="Hidden_tp1Se7X6AEitbPWWRbR6bw">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_6-UgFP9YHkKs37vGGIhEVw"
      id="Hidden_EUn6f84eb0OJm-52SjcRtw">P4Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_SKlrM8781Eet0zFbC3ewTw"
      id="Hidden_M9XtAoRCQE23lB3X4M3v9w">P4Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_KSWzHsfkUUCC4ceQE_HELQ"
      id="Hidden_iCRDlIEFVkGCl5KX7TVfHQ">P4Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_tcmd_TimeBasedRestrictedStockUnitsRsusMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_UQNyJOFH5UKq1kC0uw2-mQ"
      id="Hidden_fHxG8ZvlB0ieDTwHUV85QA">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_tcmd_PerformanceBasedStockSettledRestrictedStockUnitsMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_-dmVAO8GPEe-d87xbGyf8Q"
      decimals="4"
      id="Hidden_sHnOWzszGUy7ZkN0NmbHuA"
      unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw">0.3333</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_tcmd_PerformanceBasedStockSettledRestrictedStockUnitsMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_9JG89pH7v0yNuwlry2fC6A"
      decimals="4"
      id="Hidden_v4hPxGJ7JkKjemco7Ewk7A"
      unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw">0.6667</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <tcmd:RentToPurchaseArrangementsRentalPeriod
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_nUg2v2mfW0uAzRdSMTamQQ"
      id="Hidden_8JEPt4Tv9EexWjz9141gSw">P3M</tcmd:RentToPurchaseArrangementsRentalPeriod>
    <dei:AmendmentFlag
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      id="Narr_P_FZjDXiJE6os7CzioOzvg">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      id="Narr__7E1bFZR7UOxQE8r3H_TYg">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      id="Narr_hIv00jI6VEWI16Kfvrpu4w">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      id="Narr_cnvhmtJwOUyEUM6FEIfMEg">2022-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      id="Narr_Ztz7VCzIZkuRojT1-ls1qg">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      id="Narr_ztRMj6qtRECsLNvcNhe8Xw">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      id="Narr_gWKz5doJ8U2tjLI7bpmPkQ">001-37799</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      id="Narr__2MCmtYy-ke_SrPh6ryM7w">Tactile Systems Technology, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      id="Narr_2rD9p0g7GU6jYXBSUwmlcg">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      id="Narr_1MEtQ8s2cEue92ldbY1WQQ">3701 Wayzata Blvd, Suite 300</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      id="Narr_q4jMHmRRQUujxCJz-sVu1Q">Minneapolis</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      id="Narr_q8TnKHhDjUSoiDHoCsdwHQ">MN</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      id="Narr_p3hPBP1_W0WyVyUfIEJAdg">55416</dei:EntityAddressPostalZipCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      id="Narr_t8jtNcMvG06b9xFfrpFLuA">41-1801204</dei:EntityTaxIdentificationNumber>
    <dei:CityAreaCode
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      id="Narr_Y_a8vsaeEkCQcVUOEaQVRA">612</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      id="Narr_mt1MRhdWgk2lWfGkf7M8SQ">355-5100</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      id="Tc_0cFJOkfnk0GejTYGQTUOKw_2_0">Common Stock, Par Value $0.001 Per Share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      id="Tc_TN2IvGZJJUKSjoQKhzCgfA_2_1">TCMD</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      id="Tc_YLnAstMN9Eyq2hgvdUypeg_2_2">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      id="Narr_gRFd10SMPkmdLqNi1EkhmA">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      id="Narr_PnG9uN-hzUSpt_6ESFNIHA">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      id="Narr_54mZyRDF0UmHnBDvxH7kFQ">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      id="Narr_6UVDu1YrGUOmDPkJ0zgpKw">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntitySmallBusiness
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      id="Tc_Xa3Hbi4Pq0CueH6i2SloFw_5_6">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      id="Tc_V8S6WXcMSUWtTpc_lqlM3w_7_1">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      id="Narr_t2O1KDtGfEufwvD4fe4R2A">true</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      id="Narr_-nmHNvf9tkCxV96amA5x-Q">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="As_Of_6_30_2022_JtERcFin0ki2oKH5VRLp_g"
      decimals="0"
      id="Narr_8OC5AcAmIE6VAwQQ6emUQA"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">146541485</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="As_Of_2_17_2023_bjzkG-0zVU2f6CDXzJQEcA"
      decimals="INF"
      id="Narr_lncCeyF52Umn_If-YmdgmA"
      unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ">20250951</dei:EntityCommonStockSharesOutstanding>
    <dei:AuditorFirmId
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      id="Narr_SeHKIkKgJkGWfadMCAWisQ">248</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      id="Narr_RDkte8rbuk6QVG05WnJ_BQ">GRANT THORNTON LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      id="Narr_yQ2C5VLtZE6ZgXL2sGg7zg">Minneapolis, Minnesota</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw"
      decimals="-3"
      id="Tc_UWVYpgtCukG3thPVKSkWYA_7_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">21929000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q"
      decimals="-3"
      id="Tc_rfywgA-c5kWcjqxvFhelfw_7_6"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">28229000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw"
      decimals="-3"
      id="Tc_NR7xjgSD80utHkSCseq6sQ_8_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">54826000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q"
      decimals="-3"
      id="Tc_VBgbD0J5l0CgH8RdkU3UfA_8_6"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">49478000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:NetInvestmentInLease
      contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw"
      decimals="-3"
      id="Tc_CS3zZk_se0mPhvobiydXEQ_9_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">16130000</us-gaap:NetInvestmentInLease>
    <us-gaap:NetInvestmentInLease
      contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q"
      decimals="-3"
      id="Tc_D2ZkEs2ib0OQw_w4lxJDKg_9_6"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">12482000</us-gaap:NetInvestmentInLease>
    <us-gaap:InventoryNet
      contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw"
      decimals="-3"
      id="Tc__rnUk2ZsqEmMvkSo-jqcVA_10_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">23124000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q"
      decimals="-3"
      id="Tc_iENYuGixaUGo-uH6iuQ0wA_10_6"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">19217000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw"
      decimals="-3"
      id="Tc_O9rtfLD9ukiNIFIqX_PxoA_11_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">3754000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q"
      decimals="-3"
      id="Tc_2iauKbqLv0-ka3IP6cj6Lw_11_6"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">4141000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw"
      decimals="-3"
      id="Tc_Ha_8xg2L4UizzY3GGxGY7w_12_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">119763000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q"
      decimals="-3"
      id="Tc_1k87bGRbd0ukOu2y0nhUxw_12_6"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">113547000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw"
      decimals="-3"
      id="Tc_kONsIqJFOEaJhSoRpnQPLA_14_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">6077000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q"
      decimals="-3"
      id="Tc_jj1D-fSUmkiArUte2HtwDw_14_6"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">6750000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw"
      decimals="-3"
      id="Tc_TS74wyQbk0qLHmupu5WahA_15_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">21322000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q"
      decimals="-3"
      id="Tc_San6iMNKOEyjEG_tdCXXsg_15_6"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">23984000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw"
      decimals="-3"
      id="Tc_151N_jblB0e19rkyl8uI8A_16_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">50375000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q"
      decimals="-3"
      id="Tc_amvxBBipoEKQHin9uKsLkg_16_6"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">54081000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw"
      decimals="-3"
      id="Tc_fIVOMeYoOUGLuATFaAhE2g_17_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">31063000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q"
      decimals="-3"
      id="Tc_aj7IGjkMZkWp0ozNpyfuBQ_17_6"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">31063000</us-gaap:Goodwill>
    <tcmd:MedicareAccountsReceivableNonCurrent
      contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw"
      decimals="-3"
      id="Tc_bwuIbyNPa0Omv9c-ZeBzkA_18_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">23061000</tcmd:MedicareAccountsReceivableNonCurrent>
    <tcmd:MedicareAccountsReceivableNonCurrent
      contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q"
      decimals="-3"
      id="Tc_0J2eQw28MU23ZtFaGuesSw_18_6"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">12847000</tcmd:MedicareAccountsReceivableNonCurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw"
      decimals="-3"
      id="Tc_IrWDnmS0-0iBlhz9beNFlQ_19_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">3335000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q"
      decimals="-3"
      id="Tc_0D119ArpI0m_CHlxNGLhxw_19_6"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">1998000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw"
      decimals="-3"
      id="Tc_TKAuIdo_vk-qBDnveOdrsg_20_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">135233000</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q"
      decimals="-3"
      id="Tc_BJVChsWrbUyZDZJwP_f2yg_20_6"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">130723000</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw"
      decimals="-3"
      id="Tc_q7FPGAKQW0etKOTxAzxUWg_21_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">254996000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q"
      decimals="-3"
      id="Tc_R49vGEe7ZEiNntd0aScsyQ_21_6"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">244270000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw"
      decimals="-3"
      id="Tc_e9-g5W9opkaq9Ma69K8K6Q_24_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">9984000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q"
      decimals="-3"
      id="Tc_UoKkLP6h20-HAICvSnUa4A_24_6"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">5023000</us-gaap:AccountsPayableCurrent>
    <us-gaap:NotesPayableCurrent
      contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw"
      decimals="-3"
      id="Tc_yYMJktZ5m0K4A9Zqpex9Xw_25_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">2968000</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent
      contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q"
      decimals="-3"
      id="Tc_Cljh0MDeqke6PqzmiCvI8A_25_6"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">2960000</us-gaap:NotesPayableCurrent>
    <tcmd:EarnOutCurrent
      contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw"
      decimals="-3"
      id="Tc_0qAjzBBmAkSDQtR6ZzNVfw_26_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">13050000</tcmd:EarnOutCurrent>
    <tcmd:EarnOutCurrent
      contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q"
      decimals="-3"
      id="Tc_lzC_KvXwbEWZ9PwyXovIhA_26_6"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">3250000</tcmd:EarnOutCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw"
      decimals="-3"
      id="Tc_mn8uGdvHw0WQphuu7qbscQ_27_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">17100000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q"
      decimals="-3"
      id="Tc_qPtr2BjVcU2p4N7hkdiQjA_27_6"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">12139000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw"
      decimals="-3"
      id="Tc_tkQq_MtvXEOlAKbiXVsN7Q_28_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">9240000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q"
      decimals="-3"
      id="Tc_m1MGxNDv-kKJ8hE5y72caQ_28_6"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">5262000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw"
      decimals="-3"
      id="Tc_qQyYONy9OkyrjReByXvkwg_29_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">2336000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q"
      decimals="-3"
      id="Tc_R4azmm1KeU28wV4YozjSZA_29_6"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">16000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw"
      decimals="-3"
      id="Tc_-dE7GqdQikKSM7afN58IDg_30_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">2500000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q"
      decimals="-3"
      id="Tc_6Dw2cOYuLUCyOyQlzV6jWg_30_6"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">2506000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw"
      decimals="-3"
      id="Tc_EcZMc5Bpf06NwQoWr2WXWA_31_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">7152000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q"
      decimals="-3"
      id="Tc_UndutZasuUOneqoxwDZUIw_31_6"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">3305000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw"
      decimals="-3"
      id="Tc_zmzYxK38aEGzeasqEx7C4g_32_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">64330000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q"
      decimals="-3"
      id="Tc_Bt4i-ztGw0y5HHE98P7U_g_32_6"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">34461000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LineOfCredit
      contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw"
      decimals="-3"
      id="Tc_T24MrPVxp0S0h97C-Zrv0g_34_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">24916000</us-gaap:LineOfCredit>
    <us-gaap:LineOfCredit
      contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q"
      decimals="-3"
      id="Tc_jmqFKje4306AmmTAhNq_zQ_34_6"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">24857000</us-gaap:LineOfCredit>
    <us-gaap:LongTermNotesPayable
      contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw"
      decimals="-3"
      id="Tc_kQrdJPSgzE68XGiJysgHiw_35_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">20979000</us-gaap:LongTermNotesPayable>
    <us-gaap:LongTermNotesPayable
      contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q"
      decimals="-3"
      id="Tc__fC0GgJ-tUOQlxagjlYf8g_35_6"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">26933000</us-gaap:LongTermNotesPayable>
    <tcmd:EarnOutNonCurrent
      contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q"
      decimals="-3"
      id="Tc_vTk1cxpjZEylateX9c-9kw_36_6"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">2950000</tcmd:EarnOutNonCurrent>
    <us-gaap:ProductWarrantyAccrualNoncurrent
      contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw"
      decimals="-3"
      id="Tc_t5NkCF-tjkOJIqTHKYoBzw_37_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">2207000</us-gaap:ProductWarrantyAccrualNoncurrent>
    <us-gaap:ProductWarrantyAccrualNoncurrent
      contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q"
      decimals="-3"
      id="Tc_Us3xPqUilk6d1o-X5vb6wg_37_6"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">3108000</us-gaap:ProductWarrantyAccrualNoncurrent>
    <us-gaap:AccruedIncomeTaxesNoncurrent
      contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw"
      decimals="-3"
      id="Tc_SMkQ7DviUk-xTiTV5ZV4fw_38_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">298000</us-gaap:AccruedIncomeTaxesNoncurrent>
    <us-gaap:AccruedIncomeTaxesNoncurrent
      contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q"
      decimals="-3"
      id="Tc_B6YdfBdU9UmkPArwJHAn4A_38_6"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">348000</us-gaap:AccruedIncomeTaxesNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw"
      decimals="-3"
      id="Tc_YhiF5YGo3E6ss0B1dmTOhg_39_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">20866000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q"
      decimals="-3"
      id="Tc_qoO-GnmS9kWWBhe1x7vFaw_39_6"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">23354000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q"
      decimals="-3"
      id="Tc_pyFjYX4wqkqPZlEZs4MY1w_40_6"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">32000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw"
      decimals="-3"
      id="Tc_fvvkno2ktEmUuaNYrnzNGw_41_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">69266000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q"
      decimals="-3"
      id="Tc_mze89qmn2ESH4_U67G7cNQ_41_6"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">81582000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw"
      decimals="-3"
      id="Tc_sRftdJloDkK5NMxxggiNJQ_42_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">133596000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q"
      decimals="-3"
      id="Tc_mvipkR7o3kCP7eZKl0blUQ_42_6"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">116043000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q"
      decimals="INF"
      id="Narr_si2v5aTdYEip5FofHm72kA"
      unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw"
      decimals="INF"
      id="Narr__UVRZDxqaUmTrbopCAgTSg"
      unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q"
      decimals="INF"
      id="Narr_-HZrkhRAwUuSVaX8jrJMAw"
      unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ">50000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw"
      decimals="INF"
      id="Narr_dXmRkz9G5U2L-VYRNxG7Pw"
      unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ">50000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q"
      decimals="INF"
      id="Narr_peVh5PLZH0eXP-Zd8Ef0hQ"
      unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw"
      decimals="INF"
      id="Narr_8SQrETTBrEWaMgJHF6VXfQ"
      unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q"
      decimals="INF"
      id="Narr_YZTCd8M9AkOsv66b-jfZ1w"
      unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw"
      decimals="INF"
      id="Narr_ZC_wsJYK7UWQyRcjN_aS7w"
      unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q"
      decimals="INF"
      id="Narr_GNd-H-06Jk-E4CF3KKzcqw"
      unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw"
      decimals="INF"
      id="Narr_HfvGAR_huE23O8H1DmRYaA"
      unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw"
      decimals="INF"
      id="Narr_jKuZ0VWtk0WQoUFe5BRz5w"
      unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ">20252677</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q"
      decimals="INF"
      id="Narr_6hr9PN7jgUC0T9Lr2DrO8w"
      unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ">19877786</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw"
      decimals="-3"
      id="Tc_nSDdQ5Cg4Ue0PRFcLpaAsA_48_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">20000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q"
      decimals="-3"
      id="Tc_cNJzlgCJGEmsqQ2IwLvYLw_48_6"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">20000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw"
      decimals="-3"
      id="Tc_j58URLoOGkiXP8sYAjXy2A_49_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">131001000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q"
      decimals="-3"
      id="Tc_mAHEoPfQVEKG5Y0Blige_g_49_6"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">119962000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw"
      decimals="-3"
      id="Tc_JulqCei9IUaB5lU3xgZaQw_50_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">-9621000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q"
      decimals="-3"
      id="Tc_QZfMcwcFuk6kLGDRDAgfrg_50_6"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">8245000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw"
      decimals="-3"
      id="Tc_g7p1N4GvpkmPH-3YyHjB5w_51_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">121400000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q"
      decimals="-3"
      id="Tc_Ibxo_C4dx0SIXmEs2vuXFg_51_6"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">128227000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw"
      decimals="-3"
      id="Tc_-c_8k_yv7kKc8W5Unm6pbQ_52_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">254996000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q"
      decimals="-3"
      id="Tc_5NGuqHiKb0iEP9ceLfN-Mg_52_6"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">244270000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_SP3wyCMXCU2i6drZEHq64A"
      decimals="-3"
      id="Tc_dgwKQUmqokGOHhuOarM9pg_9_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">211345000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_hfu9P6iNKUi9O4wj8Mt1eQ"
      decimals="-3"
      id="Tc_i9HAD3YX0EOBtF_smN06dA_9_6"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">177914000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember_cRwZGotvHkm9Z1U4mHwTFw"
      decimals="-3"
      id="Tc_us4EexZoWECtCn-YN43jbw_9_9"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">161497000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_tcmd_RentalProductServiceMember_UQEeT0sALU2WyRpN4h-d1g"
      decimals="-3"
      id="Tc_0-cvrlUGekiUUiz3WTTncw_10_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">35440000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_tcmd_RentalProductServiceMember_SHuwLl4tzECMukntSz1kJw"
      decimals="-3"
      id="Tc_7OL4gP0DVU2_jAzCU_9H7Q_10_6"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">30143000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_ProductOrServiceAxis_tcmd_RentalProductServiceMember_NFKOoDrORk2r6CW4q3szBw"
      decimals="-3"
      id="Tc_PZtzIwozkka4Qz_zrIbEFg_10_9"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">25633000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      decimals="-3"
      id="Tc_VQ9Nb7rUdUG9oSRh1o9nXg_11_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">246785000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g"
      decimals="-3"
      id="Tc_J6vMXVxX2Uy40vTdhNFCKw_11_6"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">208057000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA"
      decimals="-3"
      id="Tc_Mx8PoHHTcEGUEmEgMtXQEw_11_9"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">187130000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfRevenue
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_SP3wyCMXCU2i6drZEHq64A"
      decimals="-3"
      id="Tc_5M1fb_snL0GiXEZfIXIIcQ_13_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">59619000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_hfu9P6iNKUi9O4wj8Mt1eQ"
      decimals="-3"
      id="Tc_Ij52zBzHFUOktj4tR4eOQw_13_6"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">50222000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember_cRwZGotvHkm9Z1U4mHwTFw"
      decimals="-3"
      id="Tc_RvvmnAqpoEylwsSZF2GxqA_13_9"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">45309000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_tcmd_RentalProductServiceMember_UQEeT0sALU2WyRpN4h-d1g"
      decimals="-3"
      id="Tc_UqM7pOm5MUig32SsXj9FEg_14_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">11190000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_tcmd_RentalProductServiceMember_SHuwLl4tzECMukntSz1kJw"
      decimals="-3"
      id="Tc_xlLoEarRQEOB8TeTdPBYyw_14_6"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">9622000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_ProductOrServiceAxis_tcmd_RentalProductServiceMember_NFKOoDrORk2r6CW4q3szBw"
      decimals="-3"
      id="Tc_wKf5DeeW-kS7ubfJ29PyKQ_14_9"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">9011000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      decimals="-3"
      id="Tc_g6KBxWLJVUGAZhEx6P-Qow_15_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">70809000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g"
      decimals="-3"
      id="Tc_bJHbbRFKAkCoJykPk5IhKA_15_6"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">59844000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA"
      decimals="-3"
      id="Tc_3pSKzBLLKEmi7REUx-jDfQ_15_9"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">54320000</us-gaap:CostOfRevenue>
    <us-gaap:GrossProfit
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_SP3wyCMXCU2i6drZEHq64A"
      decimals="-3"
      id="Tc_KA_XI6H1xEC7OfoSKG9Q2w_17_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">151726000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_hfu9P6iNKUi9O4wj8Mt1eQ"
      decimals="-3"
      id="Tc_NuYr--bj_0-D5xALlFXAbw_17_6"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">127692000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember_cRwZGotvHkm9Z1U4mHwTFw"
      decimals="-3"
      id="Tc_w4W4SaSD5kGU-jmEnER0Qg_17_9"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">116188000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_tcmd_RentalProductServiceMember_UQEeT0sALU2WyRpN4h-d1g"
      decimals="-3"
      id="Tc_egGzsEiFpUeJHvB2jZP1Fg_18_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">24250000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_tcmd_RentalProductServiceMember_SHuwLl4tzECMukntSz1kJw"
      decimals="-3"
      id="Tc_myKB-9BouUCJXM1S3QtXng_18_6"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">20521000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_ProductOrServiceAxis_tcmd_RentalProductServiceMember_NFKOoDrORk2r6CW4q3szBw"
      decimals="-3"
      id="Tc_9r3HPPA3O0CypBfQ58c0hQ_18_9"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">16622000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      decimals="-3"
      id="Tc_tTp1y2Eg4kqXZaXDGOqWSQ_19_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">175976000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g"
      decimals="-3"
      id="Tc_fgznoyD4gEqivnoEOElFyw_19_6"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">148213000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA"
      decimals="-3"
      id="Tc_Iv0hO1rXP0ufrRvljtkJLQ_19_9"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">132810000</us-gaap:GrossProfit>
    <us-gaap:SellingAndMarketingExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      decimals="-3"
      id="Tc_qnToGWLLCECOBajk07NCig_21_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">106418000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g"
      decimals="-3"
      id="Tc_9CwgfepvKUenpGgHcA289A_21_6"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">86775000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA"
      decimals="-3"
      id="Tc_-0n768rB5ESo62rsIeppUg_21_9"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">79634000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      decimals="-3"
      id="Tc_ooW63zii40maAXg4Sakq0w_22_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">7088000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g"
      decimals="-3"
      id="Tc_PRUgMcYKhUaDaD6hwKQplw_22_6"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">5659000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA"
      decimals="-3"
      id="Tc_PR3OBCFzX0CcrQNUvzAQeQ_22_9"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">5264000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      decimals="-3"
      id="Tc_xCRseyENhU6PGzG8bGbBVQ_23_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">60796000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g"
      decimals="-3"
      id="Tc_5NIG258MqEWKwH7mR13vDQ_23_6"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">56802000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA"
      decimals="-3"
      id="Tc_0Oz1ZHVc_0Kgszi_-ysL8g_23_9"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">51343000</us-gaap:GeneralAndAdministrativeExpense>
    <tcmd:AmortizationOfIntangibleAssetsAndEarnOuts
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      decimals="-3"
      id="Tc_1s4mbqLveE2rKQPVFuJiCw_24_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">14432000</tcmd:AmortizationOfIntangibleAssetsAndEarnOuts>
    <tcmd:AmortizationOfIntangibleAssetsAndEarnOuts
      contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g"
      decimals="-3"
      id="Tc_dXhDfnpayUimAzPAylsoQA_24_6"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">739000</tcmd:AmortizationOfIntangibleAssetsAndEarnOuts>
    <tcmd:AmortizationOfIntangibleAssetsAndEarnOuts
      contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA"
      decimals="-3"
      id="Tc_B--guv3R00ub2bAuQHJs3A_24_9"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">197000</tcmd:AmortizationOfIntangibleAssetsAndEarnOuts>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      decimals="-3"
      id="Tc_VJ2NccjbTUqMOQluOeCtxQ_25_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">188734000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g"
      decimals="-3"
      id="Tc_hqBGO6h5SU-vU1W77UY5oA_25_6"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">149975000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA"
      decimals="-3"
      id="Tc_QRO6qzShDESyNe8OrkIIew_25_9"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">136438000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      decimals="-3"
      id="Tc_oSpbTuVgyEiS8_0i1KfrzQ_26_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">-12758000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g"
      decimals="-3"
      id="Tc_2pFk6SRx9kWbRyogTCCuNg_26_6"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">-1762000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA"
      decimals="-3"
      id="Tc_KmGOJs_fB0Cbj8n-0AnovA_26_9"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">-3628000</us-gaap:OperatingIncomeLoss>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      decimals="-3"
      id="Tc_oLeHZkrTyE-DbCfevHVoig_27_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">-2715000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g"
      decimals="-3"
      id="Tc_hehQjydhYUa81LguCWi3Mg_27_6"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">-531000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA"
      decimals="-3"
      id="Tc_39p4x6KFwUu8jQbdS8x6FA_27_9"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">1367000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      decimals="-3"
      id="Tc_x-7SgZMtQEmKC7vvCefm3Q_28_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">-15473000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g"
      decimals="-3"
      id="Tc_2NHoRiPnMkSx9q5OulcxLg_28_6"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">-2293000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA"
      decimals="-3"
      id="Tc_5QjNpbor1kurUr2ICKdM7g_28_9"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">-2261000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      decimals="-3"
      id="Tc_KyqixvJ1JEyUm-RWKta7ZQ_29_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">2393000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g"
      decimals="-3"
      id="Tc_jcIyqLUTaki0lHCBmTs-0w_29_6"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">9518000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA"
      decimals="-3"
      id="Tc_AXn1kRSw10Cz4YORUASobA_29_9"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">-1641000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      decimals="-3"
      id="Tc_J8WHgJqN10-yXC7pJRP9ug_30_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">-17866000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g"
      decimals="-3"
      id="Tc_XL49vIHGIkutXf6kuaNsog_30_6"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">-11811000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA"
      decimals="-3"
      id="Tc_y84iVuj4CEyjkhjiMaDEbw_30_9"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">-620000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      decimals="2"
      id="Tc_b3J_sLUbfUmlRbI-tJkaxQ_32_3"
      unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q">-0.89</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g"
      decimals="2"
      id="Tc_3jSLDmqdGkOqX0S0CRIdiQ_32_6"
      unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q">-0.60</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA"
      decimals="2"
      id="Tc_p4I30vCC-UOYFQz-v6AdPQ_32_9"
      unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q">-0.03</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      decimals="2"
      id="Tc_sldD6oDQAUyv_z8J6rfX0Q_33_3"
      unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q">-0.89</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g"
      decimals="2"
      id="Tc_yOOar1wkLEqT4hOwqAV5BA_33_6"
      unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q">-0.60</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA"
      decimals="2"
      id="Tc_TRC0D7As2UyvbWHxo_FiAg_33_9"
      unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q">-0.03</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      decimals="0"
      id="Tc_guiMXGLFoEOzvof7N8RNsA_35_3"
      unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ">20067969</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g"
      decimals="0"
      id="Tc_2IiHsAqO5k25haexHxNf5g_35_6"
      unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ">19719485</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA"
      decimals="0"
      id="Tc_DuwFfu68qUiabVELgJryEg_35_9"
      unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ">19346929</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      decimals="0"
      id="Tc_5QSB0xtU8kW7UCj2aeWZkA_36_3"
      unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ">20067969</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g"
      decimals="0"
      id="Tc_UC6UF4pi2E2D2PfFQFtL6Q_36_6"
      unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ">19719485</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA"
      decimals="0"
      id="Tc_kK_x8KJnjk64a0OsD77RBg_36_9"
      unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ">19346929</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      decimals="-3"
      id="Tc_hFwhUN-gukSNH3X_uhs9eA_6_2"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">-17866000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g"
      decimals="-3"
      id="Tc_sL9nsRSA3EC7Gu943ZTWiQ_6_5"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">-11811000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA"
      decimals="-3"
      id="Tc_sZzeYz00Hke3GgcYRvaQOA_6_8"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">-620000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA"
      decimals="-3"
      id="Tc_oGLOajyU1UaXt0xK__8pbg_8_8"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">-21000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
      contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA"
      decimals="-3"
      id="Tc_XFA6lM3AokCdNfhZZuoSNA_9_8"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">5000</us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA"
      decimals="-3"
      id="Tc_8yqniDuZFESC5xniXmZPQQ_10_8"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">-26000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      decimals="-3"
      id="Tc_m0g8cGgzVkuqhUEZAhLHFg_11_2"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">-17866000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g"
      decimals="-3"
      id="Tc_symwVaD2JUOgI6TeeluI9w_11_5"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">-11811000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA"
      decimals="-3"
      id="Tc_VyRcUqBoU0WrsSLNfC9IYA_11_8"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">-646000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_831Iwe84l0uIaFkRq3YMEA"
      decimals="INF"
      id="Tc_4rbNp7GVCEyI8FPWuwsUzA_9_2"
      unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ">19152715</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_831Iwe84l0uIaFkRq3YMEA"
      decimals="-3"
      id="Tc_NHQ_3He4dEuYr1VvePHaxw_9_5"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">19000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_bAXadoBqGUyVY6l0rjAY1g"
      decimals="-3"
      id="Tc_yxWoePSRM060HjFQ6BbEow_9_8"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">91874000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_SzV_dAN03kCUiZaHywHGxw"
      decimals="-3"
      id="Tc_Umi8zJbiXE6rzJl87hDF5w_9_11"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">20676000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_dwEtqEfNw0CpirbkcmdKtw"
      decimals="-3"
      id="Tc_yR0EFNSz8EqECGLA0j0WDA_9_14"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">26000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_3ga0jBjg6EKA4-znaQ36NQ"
      decimals="-3"
      id="Tc_8vfWJEPSDUOqPhA4AkUl8w_9_17"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">112595000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_dZyQCZO280GpmViirHXo1g"
      decimals="-3"
      id="Tc_Iz_KpalNzUKsfmVGSkNz_A_10_8"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">10689000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA"
      decimals="-3"
      id="Tc_axB24DiRzka4U_8iceNsKQ_10_17"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">10689000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_26fO_zM0qkaf9YFqHV50Wg"
      decimals="INF"
      id="Tc_sYCd5IYZCUyzDKV8lU998w_11_2"
      unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ">303709</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_dZyQCZO280GpmViirHXo1g"
      decimals="-3"
      id="Tc_967iU3JV9km9OsL7FWeEEw_11_8"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">1068000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA"
      decimals="-3"
      id="Tc_pAerDGAB00afPYqrPHjPeg_11_17"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">1068000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <tcmd:AdjustmentsToAdditionalPaidInCapitalSharesOther
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_26fO_zM0qkaf9YFqHV50Wg"
      decimals="INF"
      id="Tc_jilFcF1cRUWvg2RzQHRS7Q_12_2"
      unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ">37790</tcmd:AdjustmentsToAdditionalPaidInCapitalSharesOther>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_dZyQCZO280GpmViirHXo1g"
      decimals="-3"
      id="Tc_vVO7A0zYYUiBDtFzfJ6rEQ_12_8"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">-1854000</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA"
      decimals="-3"
      id="Tc_o3f6onOqK06RkqTCX6ArIQ_12_17"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">-1854000</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_26fO_zM0qkaf9YFqHV50Wg"
      decimals="INF"
      id="Tc_AeRiFmfsVUSEFJMC24lf6g_13_2"
      unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ">74084</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_dZyQCZO280GpmViirHXo1g"
      decimals="-3"
      id="Tc_uxOUaP1ibkaK9qQ17vWMzw_13_8"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">2898000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA"
      decimals="-3"
      id="Tc_Csa8xrIm8E-dfy_nBSBiUg_13_17"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">2898000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_CN1dmz1V3Ue1flAlam2dNQ"
      decimals="-3"
      id="Tc_kcnFFHXeREOmJdhoFU19ag_14_11"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">-620000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_aFuDPm3quE6OkMXnwfeySg"
      decimals="-3"
      id="Tc__9iEExGMm0iEzaPpEk7HBg_14_14"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">-26000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA"
      decimals="-3"
      id="Tc_LrEhNmHktkOtPY9WpqWhcQ_14_17"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">-646000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Qp36H0EGtUGt3jcLLgZfHw"
      decimals="INF"
      id="Tc_AMqhGkJGmk-_zAAt30GbVA_15_2"
      unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ">19492718</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Qp36H0EGtUGt3jcLLgZfHw"
      decimals="-3"
      id="Tc_0FmU7cdqoU-SyWiTvCuIJA_15_5"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">19000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_iD4fs-NVZUqKbPMH2pu8Tg"
      decimals="-3"
      id="Tc_TAT3Us11dEqWhSrTW3gfpA_15_8"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">104675000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_BPwmELKt2UWgprqGAT1saQ"
      decimals="-3"
      id="Tc_ej_TK63vcUmQcMuUClbz4A_15_11"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">20056000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_q95ww8WB7U-18mlScI3MCA"
      decimals="-3"
      id="Tc_pU2qQgkg5Uen2Vku1GAXTw_15_17"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">124750000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Yly5bMDTYE-lx-OvMp67yw"
      decimals="-3"
      id="Tc_YXKtPSKoXkaHAI8BEZ7ZDg_16_8"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">10173000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g"
      decimals="-3"
      id="Tc_tH27-pyWkEGpRmNl9OCTEQ_16_17"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">10173000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_4VmedOiWwk-TuOc3qFFccg"
      decimals="INF"
      id="Tc_-5DbVN_Z1kuiS9ZLvAEfAQ_17_2"
      unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ">333763</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_4VmedOiWwk-TuOc3qFFccg"
      decimals="-3"
      id="Tc_GSsQYh460UO5W3q3E4Yg4A_17_5"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Yly5bMDTYE-lx-OvMp67yw"
      decimals="-3"
      id="Tc_ttGooq7SWkqMulfwRIc0uQ_17_8"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">3975000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g"
      decimals="-3"
      id="Tc_hlHw0N7rP0iXw90-oN-khw_17_17"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">3976000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <tcmd:AdjustmentsToAdditionalPaidInCapitalSharesOther
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_4VmedOiWwk-TuOc3qFFccg"
      decimals="INF"
      id="Tc_DLYszDnQE06q3Thm-JcmUg_18_2"
      unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ">22357</tcmd:AdjustmentsToAdditionalPaidInCapitalSharesOther>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Yly5bMDTYE-lx-OvMp67yw"
      decimals="-3"
      id="Tc_d--0JWrRoE2Ublojxttsvg_18_8"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">-1173000</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g"
      decimals="-3"
      id="Tc_CpgIKMmNQEWaogYjxZODcQ_18_17"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">-1173000</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_4VmedOiWwk-TuOc3qFFccg"
      decimals="INF"
      id="Tc_rWJN_ecekEe-8WSQZssc2g_19_2"
      unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ">73662</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Yly5bMDTYE-lx-OvMp67yw"
      decimals="-3"
      id="Tc_WTDiGr26REW0nDSBopM77w_19_8"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">2312000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g"
      decimals="-3"
      id="Tc_YKw1YU0760W_usqTmf_sNw_19_17"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">2312000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_YaY3_P_Sw02KL1vnK5w7IQ"
      decimals="-3"
      id="Tc_-SvHBxbiKEukiojyYCiTxQ_20_11"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">-11811000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g"
      decimals="-3"
      id="Tc_4Ig_ZLRBqk-Uf_Gb1S53oA_20_17"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">-11811000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_BMz7mX7-OUWrFBdwQYForQ"
      decimals="INF"
      id="Tc_6bIGNs39IkGw8W7eqExetQ_21_2"
      unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ">19877786</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_BMz7mX7-OUWrFBdwQYForQ"
      decimals="-3"
      id="Tc_rVoPEqg0p02UcN8ZHVXO7g_21_5"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">20000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_JAb6JFyA10K9maMFF2T0yQ"
      decimals="-3"
      id="Tc_NOhWFltSAU2CsJ9IP4y-Bg_21_8"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">119962000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_H3RLfzlePUicZ6gsHqIN-g"
      decimals="-3"
      id="Tc_lTOJ-EOFBEq4oK2ghFkkCQ_21_11"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">8245000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q"
      decimals="-3"
      id="Tc_3YfdpMzU5ECqufP_hBfFSQ_21_17"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">128227000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_AggAm3MT3EmHS5mE0Dp2Yg"
      decimals="-3"
      id="Tc_S2JiRwVu50ykLROPTY0slg_22_8"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">9600000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      decimals="-3"
      id="Tc_GdAC4VZlVki846a_UHCKZA_22_17"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">9600000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_TR941NiDcUCdRWACyKn3Wg"
      decimals="INF"
      id="Tc_EmvhVYa9vEucgXpCzwkr5w_23_2"
      unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ">225282</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_AggAm3MT3EmHS5mE0Dp2Yg"
      decimals="-3"
      id="Tc_X53KzzEec0GiddYNgy6ZKg_23_8"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">153000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      decimals="-3"
      id="Tc_WjlvYYJoTUSgYjbjSFcSAQ_23_17"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">153000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_TR941NiDcUCdRWACyKn3Wg"
      decimals="INF"
      id="Tc_1zJWCm8t30-qTq7r-JBqPg_24_2"
      unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ">149609</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_AggAm3MT3EmHS5mE0Dp2Yg"
      decimals="-3"
      id="Tc_h9OqNzkV0kGi6tW3oC3uIA_24_8"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">1286000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      decimals="-3"
      id="Tc_EntakCK3qkqh7lPyhSnPxg_24_17"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">1286000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_WCG-z2RnpUGRHcHammTWIw"
      decimals="-3"
      id="Tc_ak1uwN1Z-kKm0ueSJoUD7w_25_11"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">-17866000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      decimals="-3"
      id="Tc_JdX4OTGtnUy31dqX3rd0jg_25_17"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">-17866000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_jyxtNFkIQECm4cCy3eQwzQ"
      decimals="INF"
      id="Tc_FhRWIdIB3E6GUvQlRBm98g_26_2"
      unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ">20252677</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_jyxtNFkIQECm4cCy3eQwzQ"
      decimals="-3"
      id="Tc_IPPsAZwQ8kqQ8GCdwGyC0A_26_5"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">20000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_dQSyY2Nl1EyEQUyJvn7F7A"
      decimals="-3"
      id="Tc_6FsApqOQ0EqrOE2q8fGolg_26_8"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">131001000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_-1H3pbcbgE2pDEcuUUIOQA"
      decimals="-3"
      id="Tc_gwMED-JFT0CydZFoDki4Wg_26_11"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">-9621000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw"
      decimals="-3"
      id="Tc_dQbFm1y3WEyYBpn4npvoXw_26_17"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">121400000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      decimals="-3"
      id="Tc_JG1FohiKBE2upYERT9pOpg_7_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">-17866000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g"
      decimals="-3"
      id="Tc_njfiHWOqmU62uMI4gJZcVg_7_6"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">-11811000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA"
      decimals="-3"
      id="Tc_MuT3qSWEjU-vZir5RNFFxw_7_9"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">-620000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      decimals="-3"
      id="Tc_qDYKxG4HnkCZ6FSl7s-OKw_9_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">6268000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g"
      decimals="-3"
      id="Tc__e-mCB5KTEOsNdXjOIX6-w_9_6"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">3681000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA"
      decimals="-3"
      id="Tc_QUiOgX-mJ06GXahVRcEzfw_9_9"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">2794000</us-gaap:DepreciationDepletionAndAmortization>
    <tcmd:AmortizationOfPremiumsAndDiscountsOnSecuritiesAvailableForSale
      contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA"
      decimals="-3"
      id="Tc_L4TKwcDrPEKlrEEJuOBAlQ_10_9"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">-91000</tcmd:AmortizationOfPremiumsAndDiscountsOnSecuritiesAvailableForSale>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      decimals="-3"
      id="Tc_md48ulbts0GUoq7FvakyIw_11_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">32000</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g"
      decimals="-3"
      id="Tc_zbfJZDu_tUKhg3VwJoRbzw_11_6"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">-10230000</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA"
      decimals="-3"
      id="Tc_26OjiFIVukiq6PvtsbwOnA_11_9"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">1233000</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      decimals="-3"
      id="Tc_YvdQLRWGlU2raah1ZhiqwQ_12_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">9600000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g"
      decimals="-3"
      id="Tc_ZtzCEt83DUKph3W5H7zG4Q_12_6"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">10173000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA"
      decimals="-3"
      id="Tc_-1wKsMDuaESfR9QJjYDCuA_12_9"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">10689000</us-gaap:ShareBasedCompensation>
    <us-gaap:MarketableSecuritiesGainLoss
      contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA"
      decimals="-3"
      id="Tc_DHCTjAq1YkO-RPNQcNOB2g_13_9"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">11000</us-gaap:MarketableSecuritiesGainLoss>
    <us-gaap:AssetImpairmentCharges
      contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA"
      decimals="-3"
      id="Tc_O8heaOzFcEO_KvTCOvRuGA_14_9"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">4025000</us-gaap:AssetImpairmentCharges>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      decimals="-3"
      id="Tc_Zg9zIQyVikKkimbLesY-uQ_15_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">-20000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g"
      decimals="-3"
      id="Tc_GsYoZ2_9AUWplTZ7VdRPNw_15_6"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">-20000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:LiabilitiesFairValueAdjustment
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      decimals="-3"
      id="Tc_e1ETpTTU9ke5Tr9a8oRW4A_16_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">-11850000</us-gaap:LiabilitiesFairValueAdjustment>
    <us-gaap:LiabilitiesFairValueAdjustment
      contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g"
      decimals="-3"
      id="Tc_g237Hm_Mz0ucnCT1szVJiQ_16_6"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">200000</us-gaap:LiabilitiesFairValueAdjustment>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      decimals="-3"
      id="Tc_Q1wOdKuv80GwleZTt3VVsg_18_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">5348000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g"
      decimals="-3"
      id="Tc_shL4OXkY2Um1JbfDZBSN8w_18_6"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">5629000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA"
      decimals="-3"
      id="Tc_SMkhx5ZdqkulMptX6W2Rug_18_9"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">10405000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <tcmd:IncreaseDecreaseInNetInvestmentInLease
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      decimals="-3"
      id="Tc_I5DLvPwu0k6uq-W36QwFXQ_19_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">3648000</tcmd:IncreaseDecreaseInNetInvestmentInLease>
    <tcmd:IncreaseDecreaseInNetInvestmentInLease
      contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g"
      decimals="-3"
      id="Tc_Uv8T5B6JXEyspJ0iv5Wf_g_19_6"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">1774000</tcmd:IncreaseDecreaseInNetInvestmentInLease>
    <tcmd:IncreaseDecreaseInNetInvestmentInLease
      contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA"
      decimals="-3"
      id="Tc_6BbjUZIllku_10egDP3pLA_19_9"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">2561000</tcmd:IncreaseDecreaseInNetInvestmentInLease>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      decimals="-3"
      id="Tc_avrByfSp30muTNojgKsyiQ_20_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">3907000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g"
      decimals="-3"
      id="Tc_dz0NJ5RIfUS7LTOOreLFSg_20_6"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">-972000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA"
      decimals="-3"
      id="Tc__68rX4U9ekq1eHzfnPPZ1A_20_9"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">-318000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInIncomeTaxesReceivable
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      decimals="-3"
      id="Tc_t0LwfiNOl0uhGfvYBsEyDg_21_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">-2270000</us-gaap:IncreaseDecreaseInIncomeTaxesReceivable>
    <us-gaap:IncreaseDecreaseInIncomeTaxesReceivable
      contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g"
      decimals="-3"
      id="Tc_INdlyoIJ4EazVQ4ak3NGPQ_21_6"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">2294000</us-gaap:IncreaseDecreaseInIncomeTaxesReceivable>
    <us-gaap:IncreaseDecreaseInIncomeTaxesReceivable
      contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA"
      decimals="-3"
      id="Tc_bAQXCoM-KkixXqlB1t-lkw_21_9"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">-1972000</us-gaap:IncreaseDecreaseInIncomeTaxesReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      decimals="-3"
      id="Tc_kIfKyZyklE6tvxGGdGrusw_22_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">950000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g"
      decimals="-3"
      id="Tc_msGP0205Vkiog5HsUj8wUA_22_6"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">1489000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA"
      decimals="-3"
      id="Tc_ADZ4gI72zEWRqRuEgKhsdQ_22_9"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">528000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <tcmd:IncreaseDecreaseInOperatingLeaseRightOfUseAsset
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      decimals="-3"
      id="Tc_aIs4l1gdYUKxq8jr4Pb8BQ_23_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">-168000</tcmd:IncreaseDecreaseInOperatingLeaseRightOfUseAsset>
    <tcmd:IncreaseDecreaseInOperatingLeaseRightOfUseAsset
      contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g"
      decimals="-3"
      id="Tc_Ww0sWC4160iCvXjOlCtS-Q_23_6"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">-614000</tcmd:IncreaseDecreaseInOperatingLeaseRightOfUseAsset>
    <tcmd:IncreaseDecreaseInOperatingLeaseRightOfUseAsset
      contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA"
      decimals="-3"
      id="Tc_NjiUYa0Zq0GVtkxKdgojyg_23_9"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">-559000</tcmd:IncreaseDecreaseInOperatingLeaseRightOfUseAsset>
    <us-gaap:IncreaseDecreaseInContractWithCustomerAsset
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      decimals="-3"
      id="Tc_NIVJ3b2QFU-xqAQFHrJkVQ_24_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">10214000</us-gaap:IncreaseDecreaseInContractWithCustomerAsset>
    <us-gaap:IncreaseDecreaseInContractWithCustomerAsset
      contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g"
      decimals="-3"
      id="Tc_ybICp83TaU-TC5THGF-T9Q_24_6"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">3414000</us-gaap:IncreaseDecreaseInContractWithCustomerAsset>
    <us-gaap:IncreaseDecreaseInContractWithCustomerAsset
      contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA"
      decimals="-3"
      id="Tc_Y3CW-RIogk2WJUZ176WiGg_24_9"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">5249000</us-gaap:IncreaseDecreaseInContractWithCustomerAsset>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      decimals="-3"
      id="Tc_x_ia48WyPUiaHr4h9qCx7g_25_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">4961000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g"
      decimals="-3"
      id="Tc_IrjclXbkQk6XB1XHrC8-1A_25_6"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">826000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA"
      decimals="-3"
      id="Tc_O1_V9f5-3UOGo_ACD2RR_w_25_9"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">337000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      decimals="-3"
      id="Tc_2dXII_2uYEWDGIQOjQUvwg_26_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">4961000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g"
      decimals="-3"
      id="Tc_DrgVLKO3UEuzHFQe1VrBNg_26_6"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">551000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA"
      decimals="-3"
      id="Tc_U9Ww0FDM9ECCkPc8lvgHWQ_26_9"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">1490000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <tcmd:IncreaseDecreaseInOtherAccruedLiabilitiesAndIncomeTaxesPayable
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      decimals="-3"
      id="Tc_5fZBq9PGsEGdm2tVuAqSgg_27_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">7076000</tcmd:IncreaseDecreaseInOtherAccruedLiabilitiesAndIncomeTaxesPayable>
    <tcmd:IncreaseDecreaseInOtherAccruedLiabilitiesAndIncomeTaxesPayable
      contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g"
      decimals="-3"
      id="Tc_Jyzc-G-7M0OyUL1sMVzOwQ_27_6"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">2175000</tcmd:IncreaseDecreaseInOtherAccruedLiabilitiesAndIncomeTaxesPayable>
    <tcmd:IncreaseDecreaseInOtherAccruedLiabilitiesAndIncomeTaxesPayable
      contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA"
      decimals="-3"
      id="Tc_uZ8nxrxBnk6AW5FgM8iK0g_27_9"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">1308000</tcmd:IncreaseDecreaseInOtherAccruedLiabilitiesAndIncomeTaxesPayable>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      decimals="-3"
      id="Tc_w8OztEMfRkybXJAbAYA0Pg_28_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">5209000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g"
      decimals="-3"
      id="Tc_Zzw6mSCNG0i2DPS8--Aifg_28_6"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">2631000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA"
      decimals="-3"
      id="Tc_54HXWIU7sUCt0KFqmr12JQ_28_9"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">2794000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA"
      decimals="-3"
      id="Tc_6EP1KXaLdUOGrTmaNbrH3Q_30_9"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">22500000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <tcmd:PaymentsToAcquireProductiveAsset
      contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g"
      decimals="-3"
      id="Tc_CxIRyfxvz02440NgrEjxJQ_31_6"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">79829000</tcmd:PaymentsToAcquireProductiveAsset>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      decimals="-3"
      id="Tc_dOv5JHHBJku-eFaeOJNW0Q_32_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">1780000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g"
      decimals="-3"
      id="Tc_-PmVT4LX5kSo61b1oFp9EQ_32_6"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">2103000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA"
      decimals="-3"
      id="Tc_XH3JxhJ8UEeAJ-D2B-RXCQ_32_9"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">2059000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      decimals="-3"
      id="Tc__dJ7EqC6qE2dRCZvAuVWWw_33_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">11000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      decimals="-3"
      id="Tc_cEju7Ib_vkiOSQRT3MgnjQ_34_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">140000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g"
      decimals="-3"
      id="Tc_t3r0t1fg00aEBh3FEqBBBQ_34_6"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">252000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA"
      decimals="-3"
      id="Tc_vTVVpO5T5UWlzS03O1NYwA_34_9"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">232000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireOtherInvestments
      contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA"
      decimals="-3"
      id="Tc_gCvAHuvY50axm2NXHuqm9A_35_9"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">30000</us-gaap:PaymentsToAcquireOtherInvestments>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      decimals="-3"
      id="Tc_I0RPmrR-PUqCLjnEbNqpQA_36_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">-1909000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g"
      decimals="-3"
      id="Tc_jP2rzymzXkW3sT4mHL7ROw_36_6"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">-82184000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA"
      decimals="-3"
      id="Tc_7IFvMprfDUyd1NF83d2eag_36_9"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">20179000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g"
      decimals="-3"
      id="Tc_iZcMGUsv1kuhlglhjxWzpQ_38_6"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">30000000</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g"
      decimals="-3"
      id="Tc_cleFUPh-p0-cuQ2NMggTCg_39_6"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">25000000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      decimals="-3"
      id="Tc_Be7OLdBjOEymILiXoVvpEQ_40_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">5000000</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      decimals="-3"
      id="Tc_Gl8J3I6JJ0GswoavXke_Hw_41_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">6000000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      decimals="-3"
      id="Tc_LPolhorwoEOSZDFepm79KQ_42_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">39000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g"
      decimals="-3"
      id="Tc_b6RKEQnCJ06fBLrDzQDUhQ_42_6"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">188000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <tcmd:PaymentOfTaxesForNetShareSettlementOfRestrictedStockUnits
      contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g"
      decimals="-3"
      id="Tc_Y7N6gtDlh0m7O6wuclSycw_43_6"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">1173000</tcmd:PaymentOfTaxesForNetShareSettlementOfRestrictedStockUnits>
    <tcmd:PaymentOfTaxesForNetShareSettlementOfRestrictedStockUnits
      contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA"
      decimals="-3"
      id="Tc_XuzeaH6lJESWkCiGAdJI1g_43_9"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">1854000</tcmd:PaymentOfTaxesForNetShareSettlementOfRestrictedStockUnits>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      decimals="-3"
      id="Tc_cxwf8f2djEy6PTIfa-M4Xg_44_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">153000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g"
      decimals="-3"
      id="Tc_9webpGxevkKhe3G3x5iq_Q_44_6"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">3976000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA"
      decimals="-3"
      id="Tc_NE_ZgDCByUKVY2xQZSNSEA_44_9"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">1068000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      decimals="-3"
      id="Tc_JiMzMfnyKEKKbj4CyoJEfg_45_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">1286000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g"
      decimals="-3"
      id="Tc_hyPuksMUXkWT4cLPThyooQ_45_6"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">2312000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA"
      decimals="-3"
      id="Tc_srspgfreF0urDqZ7UcDmow_45_9"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">2898000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      decimals="-3"
      id="Tc_o_CFlfe47kOZEHjg0IMXLg_46_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">-9600000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g"
      decimals="-3"
      id="Tc_2mofP9XQB0eUIifZQ6clxg_46_6"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">59927000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA"
      decimals="-3"
      id="Tc_9iVeR_kCz0OVYzBKNOvL5g_46_9"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">2112000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      decimals="-3"
      id="Tc_UxuE2L2rUka9z3e5x8tNkA_47_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">-6300000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g"
      decimals="-3"
      id="Tc_iTvLmTVoYUCizLmqeEIjkQ_47_6"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">-19626000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA"
      decimals="-3"
      id="Tc_LSf4-Wii0UKEL5kuuxf3yA_47_9"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">25085000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q"
      decimals="-3"
      id="Tc_LBElmJZ5bEqx3I4ABc4dfQ_48_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">28229000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2020_q95ww8WB7U-18mlScI3MCA"
      decimals="-3"
      id="Tc_by7HrvoeV0eIU-NWcBbiRQ_48_6"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">47855000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2019_3ga0jBjg6EKA4-znaQ36NQ"
      decimals="-3"
      id="Tc_-8g2eqSAGkKxkxRyyhMsnw_48_9"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">22770000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw"
      decimals="-3"
      id="Tc_8SrDmW9FXUqSUzLcgx0P0g_49_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">21929000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q"
      decimals="-3"
      id="Tc_giTWFzW_Q0S9YWfCPJpTug_49_6"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">28229000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2020_q95ww8WB7U-18mlScI3MCA"
      decimals="-3"
      id="Tc_YgrzYMn_vUeYFkYLFZmVsw_49_9"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">47855000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      decimals="-3"
      id="Tc_w0604vMankiT9aetBFT4vQ_52_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">2186000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g"
      decimals="-3"
      id="Tc_JacEh5ec7EamH-P1P0rrDw_52_6"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">130000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaid
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      decimals="-3"
      id="Tc_TPmwtxCc_UqoVwqQivygwg_53_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">44000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g"
      decimals="-3"
      id="Tc_0tZ7AIkiLEWOL1K16LbSow_53_6"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">1593000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA"
      decimals="-3"
      id="Tc_hLH5Uxsu2UWO3xeurCHDaw_53_9"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">543000</us-gaap:IncomeTaxesPaid>
    <us-gaap:NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      decimals="-3"
      id="Tc_mwKKsgtRZUC-ycCUm7PcrA_54_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">38000</us-gaap:NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1>
    <us-gaap:NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1
      contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g"
      decimals="-3"
      id="Tc_JEBJz6g7q02lN0ImA5IUsg_54_6"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">23000</us-gaap:NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1>
    <us-gaap:NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1
      contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA"
      decimals="-3"
      id="Tc_-yf9Z14JS0GJTcWqZ_vgOA_54_9"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">17000</us-gaap:NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1>
    <us-gaap:NatureOfOperations
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      id="Tb_ZvwkzDztn0uMtgJbrBwePA">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Note 1. &#160;Nature of Business and Operations&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Tactile Systems Technology, Inc. (&#x201c;we,&#x201d; &#x201c;us,&#x201d; and &#x201c;our&#x201d;) manufactures and distributes medical devices for the treatment of patients with underserved chronic diseases at home. We provide our Flexitouch and Entre systems, which help control symptoms of lymphedema, a chronic progressive medical condition, through our direct sales force for use in the home and sell or rent them through vascular, wound and lymphedema clinics throughout the United States. &lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On September 8, 2021, we acquired the assets of the AffloVest airway clearance business (&#x201c;AffloVest Acquisition&#x201d;) from International Biophysics Corporation (&#x201c;IBC&#x201d;), a privately-held company which developed and manufactured AffloVest. AffloVest is a portable, wearable vest that treats patients with chronic respiratory conditions. We sell this device through home medical equipment and durable medical equipment (&#x201c;DME&#x201d;) providers throughout the United States.&#160;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;We were originally incorporated in Minnesota under the name Tactile Systems Technology, Inc. on January&#160;30, 1995. During 2006, we established a merger corporation and subsequently, on July&#160;21, 2006, merged with and into this merger corporation, resulting in us being reincorporated as a Delaware corporation. The resulting corporation assumed the name Tactile Systems Technology, Inc. In September 2013, we began doing business as &#x201c;Tactile Medical.&#x201d;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On August 2, 2016, we closed the initial public offering of our common stock, which resulted in the sale of 4,120,000 shares of our common stock at a public offering price of $10.00 per share. We received net proceeds from the initial public offering of approximately $35.4 million, after deducting underwriting discounts and approximately $2.9 million of transaction expenses.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;Our business is affected by seasonality. In the first quarter of each year, when most patients have started a new insurance year and have not yet met their annual out-of-pocket payment obligations, we experience substantially reduced demand for our products. We typically experience higher revenue in the third and fourth quarters of the year when patients have met their annual insurance deductibles, thereby reducing their out-of-pocket costs for our products, and because patients desire to exhaust their flexible spending accounts at year end. This seasonality applies only to purchases and rentals of our products by patients covered by commercial insurance and is not relevant to Medicare, Medicaid or the Veterans Administration, as those payers either do not have plans that have declining deductibles over the course of the plan year and/or do not have plans that include patient deductibles for purchases or rentals of our products. Further, seasonality trends have been, and may continue to be, different than historical trends as a result of the COVID-19 pandemic and related impacts.&lt;/p&gt;</us-gaap:NatureOfOperations>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_8_2_2016_To_8_2_2016_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_oNbQsAMXk0uBUzklZFhmAA"
      decimals="INF"
      id="Narr__3NXhWJUP06052j8xqXqRw"
      unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ">4120000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_8_2_2016_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_G1Q8otm7u0SlPI0I3gLpyg"
      decimals="2"
      id="Narr_jIiYYU17sEi4nPnjY0gWiA"
      unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q">10.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="Duration_8_2_2016_To_8_2_2016_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_oNbQsAMXk0uBUzklZFhmAA"
      decimals="-5"
      id="Narr_8Qvtc3QHBkO1zxhdwx5tow"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">35400000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <tcmd:ExpenseRelatingToInitialPublicOffering
      contextRef="Duration_8_2_2016_To_8_2_2016_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_oNbQsAMXk0uBUzklZFhmAA"
      decimals="-5"
      id="Narr_v_bnt46ba06QQYXfBPxTzA"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">2900000</tcmd:ExpenseRelatingToInitialPublicOffering>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      id="Tb_rTPt-rczPEajIs8j39mocg">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Note 2. &#160;Basis of Presentation&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Our accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;) and pursuant to the rules and regulations of the SEC. &lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The results for the year ended December&#160;31,&#160;2022, are not necessarily indicative of results to be expected for any future year.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Principles of Consolidation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Our accompanying consolidated financial statements include the accounts of Tactile Systems Technology, Inc. and its wholly owned subsidiary, Swelling Solutions, Inc. All intercompany balances and transactions have been eliminated in consolidation.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Risks and Uncertainties&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:14pt;text-align:justify;background:#ffffff;margin:2pt 0pt 0pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Coronavirus (COVID-19)&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:14pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"&gt;The United States economy in general and our business specifically have been negatively affected by the COVID-19 pandemic. We have seen adverse impacts as it relates to the decline in the number of patients that healthcare facilities and clinics are able to treat due to enhanced safety protocols, particularly during 2020, most of 2021 and the first quarter of 2022. We have also seen staffing challenges, both in our organization and at the clinics we serve, as another lingering consequence of the COVID-19 pandemic. While we saw some level of recovery in 2022, ongoing consequences of the pandemic remain uncertain. There are no reliable estimates of how long the pandemic will last, whether any recovery will be sustained or will reverse course, the severity of any resurgence of COVID-19 or variant strains of the virus, the effectiveness of vaccines and attitudes towards receiving them, or what ultimate effects the pandemic will have. For that reason, we are unable to reasonably estimate the long-term impact of the pandemic on our business at this time. &lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"&gt;Since the onset of COVID-19, we have remained proactive to adapt to the needs of our employees, clinicians and patients. We cannot assure you that these changes to our processes and practices will be successful in mitigating the impact of COVID-19 on our business. We continue to evaluate and, if appropriate, will adopt other measures in the future related to the ongoing safety of our employees, clinicians and patients.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:14pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and to disclose contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Comprehensive Loss&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="color:#2b2c2b;"&gt;Comprehensive loss reflects the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. Our comprehensive loss represents net loss adjusted for unrealized gains and losses on available-for-sale marketable securities and the related taxes.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      id="Tb_laBrlrni8US1-db0pxvaUQ">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Our accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;) and pursuant to the rules and regulations of the SEC. &lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The results for the year ended December&#160;31,&#160;2022, are not necessarily indicative of results to be expected for any future year.&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      id="Tb_EQ5gWnTHdk6dPdLW_wiXUg">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Principles of Consolidation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Our accompanying consolidated financial statements include the accounts of Tactile Systems Technology, Inc. and its wholly owned subsidiary, Swelling Solutions, Inc. All intercompany balances and transactions have been eliminated in consolidation.&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <tcmd:UnusualRisksAndUncertaintiesPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      id="Tb_P2WoV9Aq6UKvFAuyOv9OrA">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Risks and Uncertainties&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:14pt;text-align:justify;background:#ffffff;margin:2pt 0pt 0pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Coronavirus (COVID-19)&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:14pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"&gt;The United States economy in general and our business specifically have been negatively affected by the COVID-19 pandemic. We have seen adverse impacts as it relates to the decline in the number of patients that healthcare facilities and clinics are able to treat due to enhanced safety protocols, particularly during 2020, most of 2021 and the first quarter of 2022. We have also seen staffing challenges, both in our organization and at the clinics we serve, as another lingering consequence of the COVID-19 pandemic. While we saw some level of recovery in 2022, ongoing consequences of the pandemic remain uncertain. There are no reliable estimates of how long the pandemic will last, whether any recovery will be sustained or will reverse course, the severity of any resurgence of COVID-19 or variant strains of the virus, the effectiveness of vaccines and attitudes towards receiving them, or what ultimate effects the pandemic will have. For that reason, we are unable to reasonably estimate the long-term impact of the pandemic on our business at this time. &lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"&gt;Since the onset of COVID-19, we have remained proactive to adapt to the needs of our employees, clinicians and patients. We cannot assure you that these changes to our processes and practices will be successful in mitigating the impact of COVID-19 on our business. We continue to evaluate and, if appropriate, will adopt other measures in the future related to the ongoing safety of our employees, clinicians and patients.&lt;/p&gt;</tcmd:UnusualRisksAndUncertaintiesPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      id="Tb_tcSM9koTRU67277pE7Q3bQ">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:14pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and to disclose contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      id="Tb_VVG6SIxM1Ey2lCBS75thtg">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Comprehensive Loss&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="color:#2b2c2b;"&gt;Comprehensive loss reflects the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. Our comprehensive loss represents net loss adjusted for unrealized gains and losses on available-for-sale marketable securities and the related taxes.&lt;/span&gt;&lt;/p&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      id="Tb_Gb7Ab0Wm5kW_wmOvtDhNKg">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Note 3. &#160;Summary of Significant Accounting Policies&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Cash and cash equivalents consist of all cash on hand and deposits. Our cash was held primarily in checking accounts as of December 31, 2022 and 2021.&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;At times the amount of cash on deposit may exceed the federally insured limit of the bank. Deposit accounts at each of the institutions are insured up to $250,000&#160;by the Federal Deposit Insurance Corporation (FDIC). At December 31, 2022 and 2021, the Company exceeded&#160;FDIC&#160;limits at various institutions. The Company has not experienced any losses in such accounts and believes there is little to no exposure to any significant credit risk.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Equity Investments&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="color:#2b2c2b;"&gt;Equity investments (including equity securities) with readily determinable fair value are reported at fair value, with unrealized gains and losses included in the determination of net loss. For equity investments with no readily determinable fair value, we measure these investments at cost less impairment, if any, plus or minus &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="color:#2b2c2b;"&gt;changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. Such observable price changes may include instances where the investee issues equity securities to new investors, thus creating a new indicator of fair value, as an example. As of each of December&#160;31,&#160;2022 and 2021, the total carrying value of our equity investments, with no readily determinable fair value, was &lt;/span&gt;&lt;span style="color:#2b2c2b;"&gt;$0.3&lt;/span&gt;&lt;span style="color:#2b2c2b;"&gt; million, and are included in other non-current assets on our Consolidated Balance Sheets. On an annual basis, we perform a qualitative assessment considering impairment indicators to evaluate whether these investments are impaired and also monitor for any observable price changes. During the years ended December&#160;31,&#160;2022 and 2021, we did not have any impairment loss on these investments. &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Accounts Receivable&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The majority of our accounts receivable and revenue are from commercial insurance payers and government payers, such as Medicare, the Veterans Administration and Medicaid.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Accounts receivable are recorded based on management&#x2019;s assessment of the expected consideration to be received, based on a detailed review of historical pricing adjustments and collections. Management relies on the results of the assessment, which includes payment history of the applicable payer as well as historical patient collections, as a primary source of information in estimating the collectability of our accounts receivable. We update our assessment on a quarterly basis, which to date has not resulted in any material adjustments to the valuation of our accounts receivable. We believe the assessment provides reasonable estimates of our accounts receivable valuation, and therefore we believe that substantially all accounts receivable are fully collectible. &lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;A portion of our claims to Medicare are initially denied and enter the appeals process, where many are ultimately reviewed by an Administrative Law Judge. After final adjudication of all claims, approximately 90% of the claims submitted are approved (this is on a number of claims, not a dollars claimed, basis across all our products). The appeals process can be lengthy, lasting more than a year in most cases. Accordingly, we classify a portion of our Medicare accounts receivable as non-current based on our experience with Medicare collections.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Inventories&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Inventories are valued at the lower of cost (first-in, first-out method) or net realizable value.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Property and Equipment&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Property and equipment are stated at cost and are depreciated using the straight-line method over their estimated useful lives of &lt;span style="-sec-ix-hidden:Hidden_-K2S-WgBSE6sH7tBYgqsYw;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;three&lt;/span&gt;&lt;/span&gt; to seven years. Leasehold improvements are depreciated over the remaining life of the respective building lease agreement. &lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Major expenditures for property and equipment are capitalized. Maintenance, repairs and minor renewals are expensed as incurred. When assets are retired or otherwise disposed of, their costs and related accumulated depreciation are removed from the accumulated depreciation accounts and the resulting gains or losses are included in income. The value of demonstration equipment in the possession of our field sales representatives is capitalized and depreciated over the estimated useful life of the equipment. &lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Revenue Recognition&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;We derive revenue from the sales and rentals of our Flexitouch and Entre systems, and from the sales of our AffloVest.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Flexitouch and Entre&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;We recognize revenue when control of the product has been transferred to our customer, in the amount of the expected consideration to be received for the product. In general, revenue from the sale or rental of a product is recognized upon shipment, unless circumstances dictate that control has not yet passed to the customer. &lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;We provide a warranty for these products against defects in material and workmanship for a period of &lt;span style="-sec-ix-hidden:Hidden_y-RzrDjl6U6YAkZa8g5tjg;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;one&lt;/span&gt;&lt;/span&gt; to five years on garments and &lt;span style="-sec-ix-hidden:Hidden_2vCz5hZwoEmnfJJOj_Lktg;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;one&lt;/span&gt;&lt;/span&gt; to two years on controllers. In accordance with applicable accounting guidance, we have determined these were assurance warranties and therefore not considered a performance obligation. In addition, we did not evaluate immaterial promised goods or services in the context of the contract. As a result, the sale or rental of these products represent a single performance obligation that is satisfied at a point in time and is short-term in nature. In certain cases, we receive payment from Medicare sales over a period of time that may exceed one year. Despite these extended payment terms, no significant financing component is deemed to exist as the terms are not for the benefit of the patient with whom we have the contract. Rather, the extended payment terms occur as a result of an initial claim denial, which subsequently enters the Medicare appeals process as noted below. &lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;We commercially distribute these products directly to patients who are referred to us by physicians, therapists or nurses. In most cases, there is a third-party payer, such as a commercial insurer, Medicare or the Veterans Administration, involved with the transaction. Our contractual relationship resides with the patient when the third-party payer is either a commercial insurer or Medicare and with the Veterans Administration if the patient is covered under their services. Revenue is recognized from such sales upon transfer of control of the product to the customer at a transaction price determined by collection history. As a result, the transaction price is impacted by multiple factors, including the terms and conditions contracted by various third-party payers, and therefore payments from third-party payers typically are less than our standard charge and represent an implicit price concession, resulting in variable consideration. As most contracts are with each individual sale to a patient, we have elected the portfolio approach to determine the transaction price, and ultimately the expected consideration. The portfolios used to determine transaction price are at the payer level, with pricing for each payer assessed based on the underlying similar characteristics. &lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;For any of our products sold to patients covered by private payers, such as commercial insurance companies, revenue is recognized upon shipment. A product is not shipped until we have received a prescription from a physician for our products and, as applicable, receipt of prior authorization from payers. At shipment, we invoice the payer for the total product price, and we recognize revenue in the amount of cash consideration anticipated to be received based on the transaction price. After the insurance payer has remitted payment, we separately invoice the patient for their portion of the payment obligation, such as copayments and deductibles. The transaction price is determined based on the payment history of the applicable payer drawn from actual write-off and collections experience from the payer over a rolling 12-month period, as well as historical patient collections. &lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;For our products sold to Medicare patients, we recognize revenue from such sales upon shipment of our products, which can occur only after we have received a prescription from a physician and all applicable patient documentation is obtained. The transaction price for our Entre systems is determined based on the payment history using the same methodology as our private insurers. A portion of our claims for our Flexitouch system are initially denied, and enter the appeals process, which can be lengthy. We assess the variable consideration for each of these claims as a percentage of the total invoice price based on ultimate approval and collection history. &lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;For our products sold to the Veterans Administration on behalf of the patient, our contract is with the Veterans Administration rather than the patient. We enter into individual sales contracts with the Veterans Administration on behalf of each patient. These contracts determine the amount of consideration, which is typically paid in full within &lt;span style="-sec-ix-hidden:Hidden_29m0XALLYEGpUDkg67Logg;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;2&lt;/span&gt;&lt;/span&gt;-3 days of shipment, and therefore there is no implicit price concession. In addition, the contracts provide for the right of control to transfer to the Veterans Administration upon delivery of the product to the patient, at which time revenue is recognized.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;We incur incremental costs that directly relate to the sales of our products; however, as the amortization period would be less than one year, we have elected the practical expedient to expense these costs as incurred.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;We sell and rent these products either directly to patients or the Veterans Administration on behalf of patients, who are referred to us by physicians, therapists or nurses. We bill private insurers and other payers, Medicare, and the Veterans Administration directly for purchases or rentals of our product on behalf of a patient and bill patients directly for their cost-sharing amounts, including any portion of an unsatisfied deductible and any copayments or co-insurance obligation. &lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;A portion of our revenue is derived from patients who obtain our products under multiple-month rental arrangements. We bill these patients&#x2019; insurance payers monthly over the duration of the rental term. Title to these products passes to the patients at the end of the rental period. Rental agreements are recorded as sales-type leases in accordance with Accounting Standards Update (&#x201c;ASU&#x201d;) No.&#160;2016-02, &#x201c;Leases&#x201d; (Topic 842) (&#x201c;ASC 842&#x201d;). Accordingly, as sales-type leases, the transaction price for the entire rental term is recognized upon transfer of control. &lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;AffloVest&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The AffloVest device is sold through durable medical equipment providers. Revenue is recognized when control of the promised goods or services is transferred to the distributors, in an amount that reflects the consideration we expect to be entitled to in exchange for transferring those goods or providing services. We account for a contract when it has approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance and collectability of consideration is probable. When determining whether the distributor has obtained control of the goods or services, we consider any future performance obligations. Generally, there is no post-shipment obligation on products sold other than warranty obligations in the normal and ordinary course of business. Consequently, revenue from the sale of the AffloVest product is recognized at shipment, unless circumstances dictate that control has not yet passed to the distributor.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Certain of our contracts include volume-based incentives which involve rebates that are negotiated at or prior to the time of sale with the customer and are redeemable only if the customer achieves a specified cumulative level of sales or sales increase. Under these incentive programs, at the time of sale, we determine the most likely amount of the rebate to be paid based on forecasted sales levels. These forecasts are updated at least quarterly for applicable customers, and the transaction price is reduced for the anticipated cost of the rebate. If the forecasted sales for a customer change, the accrual for rebates is adjusted to reflect the new rebates expected to be earned by the customer.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Amounts billed to customers for shipping and handling activities after the customer obtains control are treated as a promised service performance obligation and recorded in revenue in the accompanying Consolidated Statements of Operations. Shipping and handling costs incurred for the delivery of goods to customers are considered a cost to fulfill the contract and are included in cost of revenue sold in the accompanying Consolidated Statements of Operations.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;We provide a warranty for the AffloVest products against defects in material and workmanship for a period of five years. In accordance with applicable accounting guidance, we have determined these were assurance warranties and therefore not considered a performance obligation. In addition, we did not evaluate immaterial promised goods or services in the context of the contract. As a result, the sale of these products represents a single performance obligation that is satisfied at a point in time and is short-term in nature.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Advertising&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Advertising costs are charged to operations when incurred. Advertising expense was $0.1 million for each of the years ended December&#160;31,&#160;2022, 2021 and 2020.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Research and Development Costs&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;We expense research and development costs as incurred, including expenses associated with clinical research studies and development.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Shipping and Handling Costs&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Amounts billed to customers for shipping and handling activities after the customer obtains control are treated as a promised service performance obligation and recorded in&#160;total revenue&#160;in the accompanying Consolidated Statements of Operations. Shipping and handling costs incurred for the delivery of goods to customers are considered a cost to fulfill the contract and are included in&#160;cost of revenue&#160;in the accompanying Consolidated Statements of Operations.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Product Warranty&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;We provide a warranty for our products against defects in material and workmanship for a period of &lt;span style="-sec-ix-hidden:Hidden_9oGSvawUkUuA-bl9OI56kg;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;one&lt;/span&gt;&lt;/span&gt; to five years. We record a liability for future warranty claims at the time of sale for the warranty period offered to a customer. If the assumptions used in calculating the provision were to materially change, such as incurring higher than anticipated warranty claims, an additional provision may be required.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Impairment of Long-Lived Assets &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;We review long-lived assets, including property and equipment and patents, for impairment whenever events or changes in business circumstances indicate that the carrying amount of an asset may not be fully recoverable. We will assess long-lived assets used in operations for impairment indicators, including when undiscounted cash flows estimated to be generated by those assets are less than the assets&#x2019; carrying amount (see Note 8 &#x2013; &#x201c;Goodwill and Intangible Assets&#x201d;).&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Goodwill&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Goodwill represents the excess of the purchase price paid over the estimated fair value of the net assets acquired and liabilities assumed in the acquisition of a business. Goodwill is not amortized, but is tested for impairment at least annually or on an interim basis if an event occurs or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying value. We perform our annual assessment of goodwill for impairment as of July 1st&#160;of each fiscal year. See Note 8 &#x2013; &#x201c;Goodwill and Intangible Assets&#x201d; for additional information.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Stock options are valued using the Black-Scholes option-pricing model, except that the valuation of certain &#x201c;CEO&#x201d; related stock options subject to a market condition involve the use of the Monte Carlo Simulation model. The Monte Carlo Simulation and the Black-Scholes valuation models require the input of highly subjective assumptions. The assumptions include the expected term of the option, the expected volatility of the price of our common stock, expected dividend yield and the risk-free interest rate. These estimates involve inherent uncertainties and the significant application of management&#x2019;s judgment. If factors change and different assumptions are used, our stock-based compensation expense could be materially different in the future. We recognize compensation expense for these options on a straight-line basis over the requisite service period (see Note 13 &#x2013; &#x201c;Stockholders&#x2019; Equity&#x201d;).&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Income taxes are accounted for under the liability method. Deferred income taxes are provided for temporary differences between the financial reporting and the tax basis of assets and liabilities. If we determine in the future that it is more likely than not that we will not realize all or a portion of the deferred tax assets, we will record a valuation allowance in the period the determination is made (see Note 15 &#x2013; &#x201c;Income Taxes&#x201d;). Changes in tax rates are reflected in the tax provision as they occur.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Net (Loss) Income Per Common Share&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt; &lt;/span&gt;Basic net (loss) income per common share is computed based on the weighted average number of shares of common stock outstanding during the period. Diluted net (loss) income per common share is computed based on the weighted average number of shares of common stock plus the effect of dilutive potential stock-based awards outstanding during the period using the treasury stock method. Dilutive potential stock-based awards include outstanding common stock options, time- and performance-based restricted stock units and employee stock purchase plan shares.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Business Segments&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;We operate and report in only&#160;one&#160;operating and &lt;span style="-sec-ix-hidden:Hidden_hf125MM_GkGhx3Sj6QqkPA;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;reportable&lt;/span&gt;&lt;/span&gt; segment. Our chief operating decision maker does not use financial information below revenue to allocate resources.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Accounting Pronouncement Not Yet Adopted&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In December 2022, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued ASU No. 2022-06, &#x201c;Reference Rate Reform (Topic 848) &#x2014; Facilitation of the Effect of Reference Rate Reform on Financial Reporting&#x201d; (&#x201c;ASU 2022-06&#x201d;), which provides optional expedients and exceptions for applying GAAP to transactions affected by reference rate (e.g., LIBOR) reform if certain criteria are met, for a limited period of time to ease the potential burden in accounting for (or recognizing the effects of) reference rate reform on financial reporting. The ASU deferred the sunset date of Topic 848 from December 31, 2022 to December 31, 2024. The ASU is effective as of December 21, 2022 through December 31, 2024. We continue to evaluate transactions or contract modifications occurring as a result of reference rate reform and determine whether to apply the optional guidance on an ongoing basis. We have not elected any expedients to date and are currently evaluating any potential future impacts on the consolidated financial statements. &lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      id="Tb_Pnf9NZMVFka-DLjOCic7tA">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Cash and cash equivalents consist of all cash on hand and deposits. Our cash was held primarily in checking accounts as of December 31, 2022 and 2021.&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;At times the amount of cash on deposit may exceed the federally insured limit of the bank. Deposit accounts at each of the institutions are insured up to $250,000&#160;by the Federal Deposit Insurance Corporation (FDIC). At December 31, 2022 and 2021, the Company exceeded&#160;FDIC&#160;limits at various institutions. The Company has not experienced any losses in such accounts and believes there is little to no exposure to any significant credit risk.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:InvestmentPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      id="Tb_n4oam2Qf6Eyy8TlcqZ07EQ">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Equity Investments&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="color:#2b2c2b;"&gt;Equity investments (including equity securities) with readily determinable fair value are reported at fair value, with unrealized gains and losses included in the determination of net loss. For equity investments with no readily determinable fair value, we measure these investments at cost less impairment, if any, plus or minus &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="color:#2b2c2b;"&gt;changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. Such observable price changes may include instances where the investee issues equity securities to new investors, thus creating a new indicator of fair value, as an example. As of each of December&#160;31,&#160;2022 and 2021, the total carrying value of our equity investments, with no readily determinable fair value, was &lt;/span&gt;&lt;span style="color:#2b2c2b;"&gt;$0.3&lt;/span&gt;&lt;span style="color:#2b2c2b;"&gt; million, and are included in other non-current assets on our Consolidated Balance Sheets. On an annual basis, we perform a qualitative assessment considering impairment indicators to evaluate whether these investments are impaired and also monitor for any observable price changes. During the years ended December&#160;31,&#160;2022 and 2021, we did not have any impairment loss on these investments. &lt;/span&gt;&lt;/p&gt;</us-gaap:InvestmentPolicyTextBlock>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
      contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q"
      decimals="-5"
      id="Narr_fG_laBaLj0abkLQ6iH9yYA"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">300000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
      contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw"
      decimals="-5"
      id="Narr_199WeT2-mk2CnZcjc65f-A"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">300000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      id="Tb_E0O_dsuCDE6mp1SuKV1tNw">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Accounts Receivable&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The majority of our accounts receivable and revenue are from commercial insurance payers and government payers, such as Medicare, the Veterans Administration and Medicaid.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Accounts receivable are recorded based on management&#x2019;s assessment of the expected consideration to be received, based on a detailed review of historical pricing adjustments and collections. Management relies on the results of the assessment, which includes payment history of the applicable payer as well as historical patient collections, as a primary source of information in estimating the collectability of our accounts receivable. We update our assessment on a quarterly basis, which to date has not resulted in any material adjustments to the valuation of our accounts receivable. We believe the assessment provides reasonable estimates of our accounts receivable valuation, and therefore we believe that substantially all accounts receivable are fully collectible. &lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;A portion of our claims to Medicare are initially denied and enter the appeals process, where many are ultimately reviewed by an Administrative Law Judge. After final adjudication of all claims, approximately 90% of the claims submitted are approved (this is on a number of claims, not a dollars claimed, basis across all our products). The appeals process can be lengthy, lasting more than a year in most cases. Accordingly, we classify a portion of our Medicare accounts receivable as non-current based on our experience with Medicare collections.&lt;/p&gt;</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <tcmd:PercentageOfClaimsApproved
      contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw"
      decimals="2"
      id="Narr_xw5G-xnuyEuD_UD4GtcYtQ"
      unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw">0.90</tcmd:PercentageOfClaimsApproved>
    <us-gaap:InventoryPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      id="Tb_MThJAm6BSkCb6E81a0zNQA">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Inventories&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Inventories are valued at the lower of cost (first-in, first-out method) or net realizable value.&lt;/p&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      id="Tb_yRTr4yTf8UKiiWylsaDDhA">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Property and Equipment&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Property and equipment are stated at cost and are depreciated using the straight-line method over their estimated useful lives of &lt;span style="-sec-ix-hidden:Hidden_-K2S-WgBSE6sH7tBYgqsYw;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;three&lt;/span&gt;&lt;/span&gt; to seven years. Leasehold improvements are depreciated over the remaining life of the respective building lease agreement. &lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Major expenditures for property and equipment are capitalized. Maintenance, repairs and minor renewals are expensed as incurred. When assets are retired or otherwise disposed of, their costs and related accumulated depreciation are removed from the accumulated depreciation accounts and the resulting gains or losses are included in income. The value of demonstration equipment in the possession of our field sales representatives is capitalized and depreciated over the estimated useful life of the equipment. &lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_VpuMgvUm10Cec1Yu-NEe1Q"
      id="Narr_vuJOAcWzME27hs3xDAGfog">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      id="Tb_eBB1mIUx40mlDhVxNkuO0Q">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Revenue Recognition&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;We derive revenue from the sales and rentals of our Flexitouch and Entre systems, and from the sales of our AffloVest.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Flexitouch and Entre&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;We recognize revenue when control of the product has been transferred to our customer, in the amount of the expected consideration to be received for the product. In general, revenue from the sale or rental of a product is recognized upon shipment, unless circumstances dictate that control has not yet passed to the customer. &lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;We provide a warranty for these products against defects in material and workmanship for a period of &lt;span style="-sec-ix-hidden:Hidden_y-RzrDjl6U6YAkZa8g5tjg;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;one&lt;/span&gt;&lt;/span&gt; to five years on garments and &lt;span style="-sec-ix-hidden:Hidden_2vCz5hZwoEmnfJJOj_Lktg;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;one&lt;/span&gt;&lt;/span&gt; to two years on controllers. In accordance with applicable accounting guidance, we have determined these were assurance warranties and therefore not considered a performance obligation. In addition, we did not evaluate immaterial promised goods or services in the context of the contract. As a result, the sale or rental of these products represent a single performance obligation that is satisfied at a point in time and is short-term in nature. In certain cases, we receive payment from Medicare sales over a period of time that may exceed one year. Despite these extended payment terms, no significant financing component is deemed to exist as the terms are not for the benefit of the patient with whom we have the contract. Rather, the extended payment terms occur as a result of an initial claim denial, which subsequently enters the Medicare appeals process as noted below. &lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;We commercially distribute these products directly to patients who are referred to us by physicians, therapists or nurses. In most cases, there is a third-party payer, such as a commercial insurer, Medicare or the Veterans Administration, involved with the transaction. Our contractual relationship resides with the patient when the third-party payer is either a commercial insurer or Medicare and with the Veterans Administration if the patient is covered under their services. Revenue is recognized from such sales upon transfer of control of the product to the customer at a transaction price determined by collection history. As a result, the transaction price is impacted by multiple factors, including the terms and conditions contracted by various third-party payers, and therefore payments from third-party payers typically are less than our standard charge and represent an implicit price concession, resulting in variable consideration. As most contracts are with each individual sale to a patient, we have elected the portfolio approach to determine the transaction price, and ultimately the expected consideration. The portfolios used to determine transaction price are at the payer level, with pricing for each payer assessed based on the underlying similar characteristics. &lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;For any of our products sold to patients covered by private payers, such as commercial insurance companies, revenue is recognized upon shipment. A product is not shipped until we have received a prescription from a physician for our products and, as applicable, receipt of prior authorization from payers. At shipment, we invoice the payer for the total product price, and we recognize revenue in the amount of cash consideration anticipated to be received based on the transaction price. After the insurance payer has remitted payment, we separately invoice the patient for their portion of the payment obligation, such as copayments and deductibles. The transaction price is determined based on the payment history of the applicable payer drawn from actual write-off and collections experience from the payer over a rolling 12-month period, as well as historical patient collections. &lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;For our products sold to Medicare patients, we recognize revenue from such sales upon shipment of our products, which can occur only after we have received a prescription from a physician and all applicable patient documentation is obtained. The transaction price for our Entre systems is determined based on the payment history using the same methodology as our private insurers. A portion of our claims for our Flexitouch system are initially denied, and enter the appeals process, which can be lengthy. We assess the variable consideration for each of these claims as a percentage of the total invoice price based on ultimate approval and collection history. &lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;For our products sold to the Veterans Administration on behalf of the patient, our contract is with the Veterans Administration rather than the patient. We enter into individual sales contracts with the Veterans Administration on behalf of each patient. These contracts determine the amount of consideration, which is typically paid in full within &lt;span style="-sec-ix-hidden:Hidden_29m0XALLYEGpUDkg67Logg;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;2&lt;/span&gt;&lt;/span&gt;-3 days of shipment, and therefore there is no implicit price concession. In addition, the contracts provide for the right of control to transfer to the Veterans Administration upon delivery of the product to the patient, at which time revenue is recognized.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;We incur incremental costs that directly relate to the sales of our products; however, as the amortization period would be less than one year, we have elected the practical expedient to expense these costs as incurred.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;We sell and rent these products either directly to patients or the Veterans Administration on behalf of patients, who are referred to us by physicians, therapists or nurses. We bill private insurers and other payers, Medicare, and the Veterans Administration directly for purchases or rentals of our product on behalf of a patient and bill patients directly for their cost-sharing amounts, including any portion of an unsatisfied deductible and any copayments or co-insurance obligation. &lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;A portion of our revenue is derived from patients who obtain our products under multiple-month rental arrangements. We bill these patients&#x2019; insurance payers monthly over the duration of the rental term. Title to these products passes to the patients at the end of the rental period. Rental agreements are recorded as sales-type leases in accordance with Accounting Standards Update (&#x201c;ASU&#x201d;) No.&#160;2016-02, &#x201c;Leases&#x201d; (Topic 842) (&#x201c;ASC 842&#x201d;). Accordingly, as sales-type leases, the transaction price for the entire rental term is recognized upon transfer of control. &lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;AffloVest&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The AffloVest device is sold through durable medical equipment providers. Revenue is recognized when control of the promised goods or services is transferred to the distributors, in an amount that reflects the consideration we expect to be entitled to in exchange for transferring those goods or providing services. We account for a contract when it has approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance and collectability of consideration is probable. When determining whether the distributor has obtained control of the goods or services, we consider any future performance obligations. Generally, there is no post-shipment obligation on products sold other than warranty obligations in the normal and ordinary course of business. Consequently, revenue from the sale of the AffloVest product is recognized at shipment, unless circumstances dictate that control has not yet passed to the distributor.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Certain of our contracts include volume-based incentives which involve rebates that are negotiated at or prior to the time of sale with the customer and are redeemable only if the customer achieves a specified cumulative level of sales or sales increase. Under these incentive programs, at the time of sale, we determine the most likely amount of the rebate to be paid based on forecasted sales levels. These forecasts are updated at least quarterly for applicable customers, and the transaction price is reduced for the anticipated cost of the rebate. If the forecasted sales for a customer change, the accrual for rebates is adjusted to reflect the new rebates expected to be earned by the customer.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Amounts billed to customers for shipping and handling activities after the customer obtains control are treated as a promised service performance obligation and recorded in revenue in the accompanying Consolidated Statements of Operations. Shipping and handling costs incurred for the delivery of goods to customers are considered a cost to fulfill the contract and are included in cost of revenue sold in the accompanying Consolidated Statements of Operations.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;We provide a warranty for the AffloVest products against defects in material and workmanship for a period of five years. In accordance with applicable accounting guidance, we have determined these were assurance warranties and therefore not considered a performance obligation. In addition, we did not evaluate immaterial promised goods or services in the context of the contract. As a result, the sale of these products represents a single performance obligation that is satisfied at a point in time and is short-term in nature.&lt;/p&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <tcmd:TermOfProductWarranty
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_tcmd_GarmentsMember_srt_RangeAxis_srt_MaximumMember_fiHw-QVcjESriGs85ZfH7w"
      id="Narr_s8_hN_H0ckSjAOmqz8GwTA">P5Y</tcmd:TermOfProductWarranty>
    <tcmd:TermOfProductWarranty
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_tcmd_ControllersMember_srt_RangeAxis_srt_MaximumMember_wiN7jXmrnkGpVKBXgBLvJA"
      id="Narr_fhqeQ4ytnE2D-XztUiwocQ">P2Y</tcmd:TermOfProductWarranty>
    <tcmd:MedicareReceivablesTimePeriod
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      id="Narr_U7s_A0B5t0yslLaa9hzi-g">P1Y</tcmd:MedicareReceivablesTimePeriod>
    <tcmd:PeriodForConsiderationPaymentAfterShipmentDate
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_VpuMgvUm10Cec1Yu-NEe1Q"
      id="Narr_8QWacby3n0WNCa9mMuLB6g">P3D</tcmd:PeriodForConsiderationPaymentAfterShipmentDate>
    <us-gaap:RevenuePracticalExpedientIncrementalCostOfObtainingContract
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      id="Narr_c4rhe8WJGUuFgJRVtD-xzw">true</us-gaap:RevenuePracticalExpedientIncrementalCostOfObtainingContract>
    <tcmd:TermOfProductWarranty
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_tcmd_AfflovestMember_dBqlEgBFb02-NFr9MvkVnw"
      id="Narr_NewFfqtXtE23njY2ors8uw">P5Y</tcmd:TermOfProductWarranty>
    <us-gaap:AdvertisingCostsPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      id="Tb_K4v0vDZpkE6Wc9p1xvLmug">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Advertising&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Advertising costs are charged to operations when incurred. Advertising expense was $0.1 million for each of the years ended December&#160;31,&#160;2022, 2021 and 2020.&lt;/p&gt;</us-gaap:AdvertisingCostsPolicyTextBlock>
    <us-gaap:AdvertisingExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA"
      decimals="-5"
      id="Narr_xfS7xUfYtUKs0-h5g3Bk-g"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">100000</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g"
      decimals="-5"
      id="Narr_P4mYe_P4tU2k4hax4E4dpg"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">100000</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      decimals="-5"
      id="Narr_ZVdpjf_nRkKjgUlHhNBm3g"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">100000</us-gaap:AdvertisingExpense>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      id="Tb_JW93bL1cFkCRTKdLH7PzrQ">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Research and Development Costs&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;We expense research and development costs as incurred, including expenses associated with clinical research studies and development.&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:CostOfSalesPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      id="Tb_UQPaRhljQ0-XlGRFDVduRw">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Shipping and Handling Costs&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Amounts billed to customers for shipping and handling activities after the customer obtains control are treated as a promised service performance obligation and recorded in&#160;total revenue&#160;in the accompanying Consolidated Statements of Operations. Shipping and handling costs incurred for the delivery of goods to customers are considered a cost to fulfill the contract and are included in&#160;cost of revenue&#160;in the accompanying Consolidated Statements of Operations.&lt;/p&gt;</us-gaap:CostOfSalesPolicyTextBlock>
    <us-gaap:StandardProductWarrantyPolicy
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      id="Tb_gxs-WtUP90mSlyxaU5A0OQ">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Product Warranty&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;We provide a warranty for our products against defects in material and workmanship for a period of &lt;span style="-sec-ix-hidden:Hidden_9oGSvawUkUuA-bl9OI56kg;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;one&lt;/span&gt;&lt;/span&gt; to five years. We record a liability for future warranty claims at the time of sale for the warranty period offered to a customer. If the assumptions used in calculating the provision were to materially change, such as incurring higher than anticipated warranty claims, an additional provision may be required.&lt;/p&gt;</us-gaap:StandardProductWarrantyPolicy>
    <tcmd:TermOfProductWarranty
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_tcmd_GarmentsMember_srt_RangeAxis_srt_MaximumMember_fiHw-QVcjESriGs85ZfH7w"
      id="Narr_YPsSSqgu5UCN82hNxCGZZQ">P5Y</tcmd:TermOfProductWarranty>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      id="Tb_qbrixVQDO0asFhh-hoPBkw">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Impairment of Long-Lived Assets &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;We review long-lived assets, including property and equipment and patents, for impairment whenever events or changes in business circumstances indicate that the carrying amount of an asset may not be fully recoverable. We will assess long-lived assets used in operations for impairment indicators, including when undiscounted cash flows estimated to be generated by those assets are less than the assets&#x2019; carrying amount (see Note 8 &#x2013; &#x201c;Goodwill and Intangible Assets&#x201d;).&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      id="Tb_EbAYWm7SqUujdiy7ee6gXA">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Goodwill&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Goodwill represents the excess of the purchase price paid over the estimated fair value of the net assets acquired and liabilities assumed in the acquisition of a business. Goodwill is not amortized, but is tested for impairment at least annually or on an interim basis if an event occurs or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying value. We perform our annual assessment of goodwill for impairment as of July 1st&#160;of each fiscal year. See Note 8 &#x2013; &#x201c;Goodwill and Intangible Assets&#x201d; for additional information.&lt;/p&gt;</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      id="Tb_hnKCNZKF_06zK775mQvdwQ">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Stock options are valued using the Black-Scholes option-pricing model, except that the valuation of certain &#x201c;CEO&#x201d; related stock options subject to a market condition involve the use of the Monte Carlo Simulation model. The Monte Carlo Simulation and the Black-Scholes valuation models require the input of highly subjective assumptions. The assumptions include the expected term of the option, the expected volatility of the price of our common stock, expected dividend yield and the risk-free interest rate. These estimates involve inherent uncertainties and the significant application of management&#x2019;s judgment. If factors change and different assumptions are used, our stock-based compensation expense could be materially different in the future. We recognize compensation expense for these options on a straight-line basis over the requisite service period (see Note 13 &#x2013; &#x201c;Stockholders&#x2019; Equity&#x201d;).&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      id="Tb_Wle3J1FdVUuL1CGi6HParA">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Income taxes are accounted for under the liability method. Deferred income taxes are provided for temporary differences between the financial reporting and the tax basis of assets and liabilities. If we determine in the future that it is more likely than not that we will not realize all or a portion of the deferred tax assets, we will record a valuation allowance in the period the determination is made (see Note 15 &#x2013; &#x201c;Income Taxes&#x201d;). Changes in tax rates are reflected in the tax provision as they occur.&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      id="Tb_bJwUcl5jcEWuf0VZ9yHyJQ">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Net (Loss) Income Per Common Share&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt; &lt;/span&gt;Basic net (loss) income per common share is computed based on the weighted average number of shares of common stock outstanding during the period. Diluted net (loss) income per common share is computed based on the weighted average number of shares of common stock plus the effect of dilutive potential stock-based awards outstanding during the period using the treasury stock method. Dilutive potential stock-based awards include outstanding common stock options, time- and performance-based restricted stock units and employee stock purchase plan shares.&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      id="Tb_FOwCtFFpLUCuyzS2_OBxXQ">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Business Segments&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;We operate and report in only&#160;one&#160;operating and &lt;span style="-sec-ix-hidden:Hidden_hf125MM_GkGhx3Sj6QqkPA;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;reportable&lt;/span&gt;&lt;/span&gt; segment. Our chief operating decision maker does not use financial information below revenue to allocate resources.&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      decimals="INF"
      id="Narr_F6xQ6sLeAEevFFJ3PdxSSg"
      unitRef="Unit_Standard_segment_zejw3MrZOkWEznPtKLNRGQ">1</us-gaap:NumberOfOperatingSegments>
    <tcmd:NewAccountingPronouncementsNoteYetAdoptedPolicyPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      id="Tb_iR8Unoe76EWS2pk1CXKT8g">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Accounting Pronouncement Not Yet Adopted&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In December 2022, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued ASU No. 2022-06, &#x201c;Reference Rate Reform (Topic 848) &#x2014; Facilitation of the Effect of Reference Rate Reform on Financial Reporting&#x201d; (&#x201c;ASU 2022-06&#x201d;), which provides optional expedients and exceptions for applying GAAP to transactions affected by reference rate (e.g., LIBOR) reform if certain criteria are met, for a limited period of time to ease the potential burden in accounting for (or recognizing the effects of) reference rate reform on financial reporting. The ASU deferred the sunset date of Topic 848 from December 31, 2022 to December 31, 2024. The ASU is effective as of December 21, 2022 through December 31, 2024. We continue to evaluate transactions or contract modifications occurring as a result of reference rate reform and determine whether to apply the optional guidance on an ongoing basis. We have not elected any expedients to date and are currently evaluating any potential future impacts on the consolidated financial statements. &lt;/p&gt;</tcmd:NewAccountingPronouncementsNoteYetAdoptedPolicyPolicyTextBlock>
    <us-gaap:AssetAcquisitionTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      id="Tb_JfSMn0aEU0GjKVcL5WeHhQ">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Note 4. Acquisitions&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;On&#160;September 8, 2021,&#160;we entered into an Asset Purchase Agreement (&#x201c;AffloVest APA&#x201d;) to acquire the AffloVest therapy business from International Biophysics Corporation (&#x201c;IBC&#x201d;). Under the terms of the AffloVest APA, we agreed to pay IBC a total of up to $100.0&#160;million for the purchase of substantially all of the assets related to its branded high frequency chest wall oscillation vest therapy business, other than specifically identified excluded assets. We acquired AffloVest to further expand our position as a leader in treating patients with underserved chronic conditions in the home. The acquired assets included inventory, tooling, intellectual property, permits and approvals, data and records, and customer and supplier information. At closing, $80.0&#160;million of the purchase price was paid, of which a total of $0.5 million was deposited into an escrow account at closing for purposes of satisfying certain post-closing purchase price adjustments and indemnification claims. Subsequent to closing, $0.2 million was returned to us as a result of working capital adjustments.&#160;The AffloVest acquisition was funded through a combination of cash on hand and proceeds from borrowings.&#160;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:24.5pt;margin:0pt 7.2pt 0pt 7.2pt;"&gt;&lt;span style="color:#ff0000;font-size:12pt;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;On November 4, 2022, we entered into an Amendment to the AffloVest APA, the &#x201c;Amendment&#x201d; with IBC, which modifies the terms of the earn-out arrangement under the AffloVest APA, as follows:&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:27pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:45pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;i style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:normal;background:#ffffff;"&gt;Initial Earn-Out: &lt;/i&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;"&gt;The AffloVest APA provided for an initial earn-out equal to &lt;/span&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;"&gt;1.5&lt;/span&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;"&gt; times the amount by which the AffloVest U.S. revenues in the period from&#160;&lt;/span&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;October 1, 2021&#160;&lt;/span&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;"&gt;to&#160;&lt;/span&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;September 30, 2022 (the &#x201c;Initial Earn-Out Period&#x201d;) exceed a specified amount;&lt;/span&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;"&gt; provided that in no event will the payment exceed &lt;/span&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;"&gt;$10.0&lt;/span&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;"&gt; million.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:81pt;"/&gt;&lt;td style="font-family:'Courier New';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;o&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;"&gt;The Amendment provides that the calculated amount of the initial earn-out payment is &lt;/span&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;"&gt;$10.0&lt;/span&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;"&gt; million, of which the Company paid &lt;/span&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;"&gt;$5.0&lt;/span&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;"&gt; million on or before November 28, 2022, and of which the Company will pay &lt;/span&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;"&gt;$5.0&lt;/span&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;"&gt; million, plus an imputed interest payment of &lt;/span&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;"&gt;$250,000&lt;/span&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;"&gt;, on or before May 26, 2023.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 63pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;background:#ffffff;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:45pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;i style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:normal;background:#ffffff;"&gt;Second Earn-Out:&lt;/i&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;"&gt; The AffloVest APA provided for a second earn-out equal to &lt;/span&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;"&gt;1.5&lt;/span&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;"&gt; times the amount by which the AffloVest U.S. revenues in the period from&#160;&lt;/span&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;October 1, 2022&#160;&lt;/span&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;"&gt;to&#160;&lt;/span&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;September 30, 2023 exceed the revenues recognized during the Initial Earn-Out Period;&lt;/span&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;"&gt; provided that in no event will the payment exceed &lt;/span&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;"&gt;$10.0&lt;/span&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;"&gt; million.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:81pt;"/&gt;&lt;td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;o&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;"&gt;The Amendment changes the &lt;/span&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;"&gt;1.5&lt;/span&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;"&gt; times multiplier to &lt;/span&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;"&gt;3.0&lt;/span&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;"&gt; times, but still provides that in no event will the second earn-out payment exceed &lt;/span&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;"&gt;$10.0&lt;/span&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;"&gt; million. &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 63pt;"&gt;&lt;span style="color:#ff0000;font-family:'Times New Roman','Times','serif';margin-left:0pt;visibility:hidden;background:#ffffff;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"&gt;The fair value of the earn-out as of the acquisition date was $6.4&#160;million. The fair value of the earn-out, reflecting management&#x2019;s estimate of the likelihood of achieving these targets, was determined by employing a Monte Carlo Simulation model. This amount and the current versus non-current allocation will be remeasured at the end of each reporting period until the payment requirement ends, with any adjustments reported in income from operations (see Note 17 &#x2013; &#x201c;Fair Value Measurements&#x201d;).&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"&gt;On the date of AffloVest Acquisition, we allocated the assets acquired based on an estimate of their fair values.&#160;The following table summarizes the purchase price allocation:&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:66.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;(In&#160;millions)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:29.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Allocated Fair Value&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Inventories&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 1.6&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Property and equipment&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Intangible assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 53.5&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Goodwill&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 31.1&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;"&gt;Purchase price &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 86.2&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"&gt;&lt;tr&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-decoration-line:none;text-transform:none;vertical-align:baseline;white-space:nowrap;width:18pt;padding:0pt 0pt 6pt 0pt;"&gt;(1)&lt;/td&gt;&lt;td style="padding:0pt 0pt 6pt 0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-style:normal;font-weight:normal;"&gt;The purchase price included less than &lt;/span&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-style:normal;font-weight:normal;"&gt;$0.1&lt;/span&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-style:normal;font-weight:normal;"&gt; million of property and equipment.&lt;/span&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-style:normal;font-weight:normal;"&gt; &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"&gt;&lt;span style="font-size:10pt;"&gt;The goodwill reflects expected synergies of combining the acquired products and customer information with our existing operations and is deductible for tax purposes over&#160;&lt;/span&gt;&lt;span style="font-size:10pt;"&gt;15&#160;years&lt;/span&gt;&lt;span style="font-size:10pt;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt;"&gt;The following table reflects the allocation of purchase price to the acquired intangible assets and related estimated useful lives:&#160;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:49.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:21.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:20.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;(In&#160;millions)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;Allocated Fair Value&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;Estimated Useful Life&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Customer relationships&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 31.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;13 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Developed technology&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;11 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Tradenames&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;Indefinite&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total intangible assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 53.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The weighted-average amortization period of the acquired intangible assets was&#160;12.3&#160;years.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The fair market valuations associated with the assets acquired fall within Level&#160;3 of the fair value hierarchy, due to the use of significant unobservable inputs to determine fair value. The fair value measurements were calculated using unobservable inputs, primarily using the income approach, specifically the discounted cash flow method. The amount and timing of future cash flows within our analysis was based on our due diligence models, most recent operational budgets, long-range strategic plans and other estimates.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;Transaction costs, such as legal and other costs, related to the acquisition aggregated approximately $0.8&#160;million. These costs have been expensed as incurred and are included in reimbursement, general and administrative expenses in our Consolidated Statements of Operations for the year ended December 31, 2021.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The Consolidated Statements of Operations reflect the AffloVest operations beginning September 9, 2021. As the AffloVest business has been integrated with our existing operations, we are unable to determine the amount of AffloVest earnings from the acquisition date that is included in the Consolidated Statements of Operations. The following unaudited pro forma information for the years ended December&#160;31, 2021 and 2020 presents the revenue and net income assuming the acquisition of AffloVest had occurred as of January 1, 2020. This information has been prepared for comparative purposes only and is&#160;not&#160;indicative of what actual results would have been if the acquisition had taken place at the beginning of fiscal&#160;2020,&#160;or of future results.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:55.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:55.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:41.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;Year Ended&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:41.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;December&#160;31,&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;(In&#160;thousands)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;2020&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Total revenue&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 219,414&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 203,193&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Net (loss) income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (7,633)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,832&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;These pro forma results include certain adjustments, primarily due to increases in amortization expense due to fair value adjustments of intangible assets, increases in interest expense due to additional borrowings incurred to finance the acquisition and amortization of debt issuance costs incurred to finance the transaction, acquisition related costs including transaction costs such as legal, accounting, valuation and other professional services, and related tax effects.&lt;/p&gt;</us-gaap:AssetAcquisitionTextBlock>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="Duration_9_8_2021_To_9_8_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_BusinessAcquisitionAxis_tcmd_AfflovestPMember_cXLgD3w8o0mAJ_EMBbTfZg"
      decimals="-5"
      id="Narr_E6GEp5ENkUKHqP9cnlieoQ"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">100000000.0</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="Duration_9_8_2021_To_9_8_2021_us-gaap_BusinessAcquisitionAxis_tcmd_AfflovestPMember_9xzfRGshm0aKb9OM49UhSQ"
      decimals="-5"
      id="Narr_NRdnyY5jeE--6oxrMFe80Q"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">80000000.0</us-gaap:PaymentsToAcquireBusinessesGross>
    <tcmd:AssetAcquisitionConsiderationTransferredEscrowAccount
      contextRef="Duration_9_8_2021_To_9_8_2021_us-gaap_BusinessAcquisitionAxis_tcmd_AfflovestPMember_9xzfRGshm0aKb9OM49UhSQ"
      decimals="-5"
      id="Narr_Vlo9_6Dr70mDf9SgIIAGCg"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">500000</tcmd:AssetAcquisitionConsiderationTransferredEscrowAccount>
    <tcmd:AssetAcquisitionAmountReceivedResultingFromWorkingCapitalAdjustment
      contextRef="Duration_9_8_2021_To_9_8_2021_us-gaap_BusinessAcquisitionAxis_tcmd_AfflovestPMember_9xzfRGshm0aKb9OM49UhSQ"
      decimals="-5"
      id="Narr_DzZwGh_Zz0C583iGQPjMnQ"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">200000</tcmd:AssetAcquisitionAmountReceivedResultingFromWorkingCapitalAdjustment>
    <tcmd:AssetAcquisitionBusinessRevenueToExceedBaseRevenueMultiplier
      contextRef="Duration_9_8_2021_To_9_8_2021_srt_StatementScenarioAxis_tcmd_AssetAcquisitionEarnoutPaymentsRevenueTargetsFromOctoberTwoThousandTwentyOneToSeptemberTwoThousandTwentyTwoMember_us-gaap_BusinessAcquisitionAxis_tcmd_AfflovestPMember_ekMNWGfKGkOGXb6VuFuvcQ"
      decimals="1"
      id="Narr_e6M-ya5OdkmjbgWTZxSBYg"
      unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw">1.5</tcmd:AssetAcquisitionBusinessRevenueToExceedBaseRevenueMultiplier>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="As_Of_9_8_2021_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_tcmd_AssetAcquisitionEarnoutPaymentsRevenueTargetsFromOctoberTwoThousandTwentyOneToSeptemberTwoThousandTwentyTwoMember_us-gaap_BusinessAcquisitionAxis_tcmd_AfflovestPMember_u62XShicPUa52TcVaICEVA"
      decimals="-5"
      id="Narr_bvc_ObT-L0mSSyBFRF_RtA"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">10000000.0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <tcmd:AssetAcquisitionEarnOutLiability
      contextRef="As_Of_11_4_2022_us-gaap_BusinessAcquisitionAxis_tcmd_AfflovestPMember_mDniF7LA_kiQpOIIlQZs3g"
      decimals="-5"
      id="Narr_6zCB6spqY0KNgm0ubgzI7A"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">10000000.0</tcmd:AssetAcquisitionEarnOutLiability>
    <tcmd:AssetAcquisitionEarnOutLiability
      contextRef="As_Of_11_4_2022_srt_StatementScenarioAxis_tcmd_EarnOutPeriodOnOrBeforeNovember282022Member_us-gaap_BusinessAcquisitionAxis_tcmd_AfflovestPMember_YJ8bNR_NZ0CvMpF7RV_aqw"
      decimals="-5"
      id="Narr_YvpHq42Ejki_C5dUAgi8BA"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">5000000.0</tcmd:AssetAcquisitionEarnOutLiability>
    <tcmd:AssetAcquisitionEarnOutLiability
      contextRef="As_Of_11_4_2022_srt_StatementScenarioAxis_tcmd_EarnOutPeriodOnOrBeforeMay262023Member_us-gaap_BusinessAcquisitionAxis_tcmd_AfflovestPMember_en0im7ZgS0KUsbPg8tTm6A"
      decimals="-5"
      id="Narr_LnAGeTFanUW6FlhMrscsZQ"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">5000000.0</tcmd:AssetAcquisitionEarnOutLiability>
    <tcmd:AssetAcquisitionImputedInterestPayable
      contextRef="As_Of_11_4_2022_srt_StatementScenarioAxis_tcmd_EarnOutPeriodOnOrBeforeMay262023Member_us-gaap_BusinessAcquisitionAxis_tcmd_AfflovestPMember_en0im7ZgS0KUsbPg8tTm6A"
      decimals="0"
      id="Narr_WMkF29gwSkGcVHYOx43K7g"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">250000</tcmd:AssetAcquisitionImputedInterestPayable>
    <tcmd:AssetAcquisitionBusinessRevenueToExceedBaseRevenueMultiplier
      contextRef="Duration_9_8_2021_To_9_8_2021_srt_StatementScenarioAxis_tcmd_AssetAcquisitionEarnoutPaymentsRevenueTargetsFromOctoberTwoThousandTwentyTwoToSeptemberTwoThousandTwentyThreeMember_us-gaap_BusinessAcquisitionAxis_tcmd_AfflovestPMember_HRn8Gvyx7UuDkFsUjw2MWw"
      decimals="1"
      id="Narr_7ENHYr6LKkyo5Wz-Jf12oA"
      unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw">1.5</tcmd:AssetAcquisitionBusinessRevenueToExceedBaseRevenueMultiplier>
    <tcmd:AssetAcquisitionEarnOutLiability
      contextRef="As_Of_9_8_2021_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_tcmd_AssetAcquisitionEarnoutPaymentsRevenueTargetsFromOctoberTwoThousandTwentyTwoToSeptemberTwoThousandTwentyThreeMember_us-gaap_BusinessAcquisitionAxis_tcmd_AfflovestPMember_o1oljgm50kqF7GpMnEHq0g"
      decimals="-5"
      id="Narr_c5xZUn3D8kGpR6kP11DYEQ"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">10000000.0</tcmd:AssetAcquisitionEarnOutLiability>
    <tcmd:AssetAcquisitionBusinessRevenueToExceedBaseRevenueMultiplier
      contextRef="Duration_11_4_2022_To_11_4_2022_us-gaap_BusinessAcquisitionAxis_tcmd_AfflovestPMember_pimwAjq0t0WJdAD0aYSTWA"
      decimals="1"
      id="Narr_ySmR-8A1VUqcZ_OQxqhCRQ"
      unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw">1.5</tcmd:AssetAcquisitionBusinessRevenueToExceedBaseRevenueMultiplier>
    <tcmd:AssetAcquisitionBusinessRevenueToExceedBaseRevenueMultiplier
      contextRef="Duration_11_4_2022_To_11_4_2022_srt_StatementScenarioAxis_tcmd_SecondEarnOutAmendmentMember_us-gaap_BusinessAcquisitionAxis_tcmd_AfflovestPMember_AEZMhjNrNkqvyABhlnwRPg"
      decimals="1"
      id="Narr_q_6PC15W0UK8djPLN7nSaA"
      unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw">3.0</tcmd:AssetAcquisitionBusinessRevenueToExceedBaseRevenueMultiplier>
    <tcmd:AssetAcquisitionEarnOutLiability
      contextRef="As_Of_11_4_2022_srt_StatementScenarioAxis_tcmd_SecondEarnOutAmendmentMember_us-gaap_BusinessAcquisitionAxis_tcmd_AfflovestPMember_la2cedehBk-qL-iSyE1pIA"
      decimals="-5"
      id="Narr_9DUvUkE080mHy79NW1JVAg"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">10000000.0</tcmd:AssetAcquisitionEarnOutLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="As_Of_9_8_2021_8l4xBubq7Umd0Y3dMd0UnQ"
      decimals="-5"
      id="Narr_oRW3Innfj06k-muNqp-2lQ"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">6400000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:AssetAcquisitionTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      id="Tb_ApG3HSp9PkKc0RPzMIk0FQ">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:66.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;(In&#160;millions)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:29.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Allocated Fair Value&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Inventories&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 1.6&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Property and equipment&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Intangible assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 53.5&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Goodwill&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 31.1&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;"&gt;Purchase price &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 86.2&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"&gt;&lt;tr&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-decoration-line:none;text-transform:none;vertical-align:baseline;white-space:nowrap;width:18pt;padding:0pt 0pt 6pt 0pt;"&gt;(1)&lt;/td&gt;&lt;td style="padding:0pt 0pt 6pt 0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-style:normal;font-weight:normal;"&gt;The purchase price included less than &lt;/span&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-style:normal;font-weight:normal;"&gt;$0.1&lt;/span&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-style:normal;font-weight:normal;"&gt; million of property and equipment.&lt;/span&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-style:normal;font-weight:normal;"&gt; &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:AssetAcquisitionTableTextBlock>
    <us-gaap:InventoryNet
      contextRef="As_Of_9_8_2021_us-gaap_BusinessAcquisitionAxis_tcmd_AfflovestPMember_3FbjYCEqNkWAlMK4QIberg"
      decimals="-5"
      id="Tc__jnWRu6R40-JuuvEdae3EQ_2_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">1600000</us-gaap:InventoryNet>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="As_Of_9_8_2021_us-gaap_BusinessAcquisitionAxis_tcmd_AfflovestPMember_3FbjYCEqNkWAlMK4QIberg"
      decimals="-5"
      id="Tc_8QucS4cBPUGPPTGS_Voe8A_4_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">53500000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="As_Of_9_8_2021_us-gaap_BusinessAcquisitionAxis_tcmd_AfflovestPMember_3FbjYCEqNkWAlMK4QIberg"
      decimals="-5"
      id="Tc_3DMvyV0H9UmXRY42EyG0Nw_5_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">31100000</us-gaap:Goodwill>
    <us-gaap:AssetsNet
      contextRef="As_Of_9_8_2021_us-gaap_BusinessAcquisitionAxis_tcmd_AfflovestPMember_3FbjYCEqNkWAlMK4QIberg"
      decimals="-5"
      id="Tc_iEaEr59AGE-q7UcM08hTAQ_6_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">86200000</us-gaap:AssetsNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_9_8_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_BusinessAcquisitionAxis_tcmd_AfflovestPMember_jLq6gqZQRUe0_w5vfb9Asg"
      decimals="-5"
      id="Narr_sc1gZls4bESwNZ2WcEN47g"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">100000</us-gaap:PropertyPlantAndEquipmentNet>
    <tcmd:GoodwillAmortizationPeriodForTaxPurposes
      contextRef="Duration_9_8_2021_To_9_8_2021_JHuv2YIhr0-DMtiV3Vl0PA"
      id="Narr_T3F-sjkUFUympDTkkhUXyg">P15Y</tcmd:GoodwillAmortizationPeriodForTaxPurposes>
    <tcmd:FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfAssetAcquisitionTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      id="Tb_dc7BVw5L3k67TnIJfLgPiQ">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt;"&gt;The following table reflects the allocation of purchase price to the acquired intangible assets and related estimated useful lives:&#160;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:49.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:21.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:20.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;(In&#160;millions)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;Allocated Fair Value&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;Estimated Useful Life&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Customer relationships&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 31.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;13 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Developed technology&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;11 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Tradenames&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;Indefinite&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total intangible assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 53.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</tcmd:FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfAssetAcquisitionTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="As_Of_9_8_2021_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_CustomerRelationshipsMember_W5D5EY3MR0edt8BoVhmVUQ"
      decimals="-5"
      id="Tc_WJsHznx1NU2nFbJx6wkF-Q_3_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">31000000.0</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="Duration_9_8_2021_To_9_8_2021_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_CustomerRelationshipsMember_vwfc8GlHbEG6FpxSb_48hw"
      id="Tc_23EDBAk5GkyQdCzh2R27hA_3_6">P13Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="As_Of_9_8_2021_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_1vdqkBPIV06qt_Sb8l9xvw"
      decimals="-5"
      id="Tc_U12Ayh4jDEOtwAGa0ORejg_4_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">13000000.0</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="Duration_9_8_2021_To_9_8_2021_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_9xTBZJ8BSEyOBEAowNs5qA"
      id="Tc_BA40rrs8KkOQMukZ66cemA_4_6">P11Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="As_Of_9_8_2021_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember_cbYze6WHq0-MzNMIXQ6G8Q"
      decimals="-5"
      id="Tc_x4EyBMy5SkiP4PfEDYNF4A_5_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">9500000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="As_Of_9_8_2021_8l4xBubq7Umd0Y3dMd0UnQ"
      decimals="-5"
      id="Tc_7eTYD6n9pkm_GzikTSKXPQ_6_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">53500000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="Duration_9_8_2021_To_9_8_2021_JHuv2YIhr0-DMtiV3Vl0PA"
      id="Narr_IAuQg_69TUi3-Qsm_o64pg">P12Y3M18D</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts
      contextRef="Duration_9_8_2021_To_9_8_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_0hChIJ5gE0K__CcmmMTvmQ"
      decimals="-5"
      id="Narr_9DA92pcbMky9CuBnFwr36w"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">800000</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <us-gaap:BusinessAcquisitionProFormaInformationTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      id="Tb_ZA2LkFpREUqBm37C3evFVA">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:55.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:55.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:41.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;Year Ended&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:41.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;December&#160;31,&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;(In&#160;thousands)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;2020&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Total revenue&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 219,414&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 203,193&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Net (loss) income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (7,633)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,832&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:BusinessAcquisitionProFormaInformationTextBlock>
    <us-gaap:BusinessAcquisitionsProFormaRevenue
      contextRef="Duration_4_1_2021_To_12_31_2021_us-gaap_BusinessAcquisitionAxis_tcmd_AfflovestPMember_C1E4O7zjlUGPDClD_oKeEg"
      decimals="-3"
      id="Tc_oOfyQ1_svEWTF6V1Nw03Xw_4_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">219414000</us-gaap:BusinessAcquisitionsProFormaRevenue>
    <us-gaap:BusinessAcquisitionsProFormaRevenue
      contextRef="Duration_4_1_2020_To_12_31_2020_us-gaap_BusinessAcquisitionAxis_tcmd_AfflovestPMember_jQCcMt5pY0Os-LuUZm0lRA"
      decimals="-3"
      id="Tc_0M5FmSlirEWq9AX68rHRUQ_4_6"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">203193000</us-gaap:BusinessAcquisitionsProFormaRevenue>
    <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss
      contextRef="Duration_4_1_2021_To_12_31_2021_us-gaap_BusinessAcquisitionAxis_tcmd_AfflovestPMember_C1E4O7zjlUGPDClD_oKeEg"
      decimals="-3"
      id="Tc_96Y6yJ7zOECwK8xy2ReVOg_5_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">-7633000</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
    <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss
      contextRef="Duration_4_1_2020_To_12_31_2020_us-gaap_BusinessAcquisitionAxis_tcmd_AfflovestPMember_jQCcMt5pY0Os-LuUZm0lRA"
      decimals="-3"
      id="Tc_QPz6s7tfJkaQAeraXi0rng_5_6"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">11832000</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
    <us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      id="Tb_6aZhg-BLTU2auNY5QHatJQ">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Note 5. &#160;Accounts Receivable&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt; &lt;/span&gt;We had accounts receivable from two insurers representing approximately 45% and 21% of accounts receivable as of December 31, 2022. We had accounts receivable from two insurers representing approximately 33% and 24% of accounts receivable as of December 31, 2021. Revenue from these insurers accounted for 19% and 10% of our total revenue for the year ended December 31, 2022, and 17% and 12% for the year ended December 31, 2021. The credit risks associated with customers which for these purposes are insurers considers aggregation for entities that are known to be under common control.&lt;/p&gt;</us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock>
    <tcmd:ConcentrationRiskNumberOfInsuranceCompanies
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      decimals="INF"
      id="Narr_le0lZpYWqE--jUoIyqQtkA"
      unitRef="Unit_Standard_item_-67QV0kzWUGc8AbcCukKig">2</tcmd:ConcentrationRiskNumberOfInsuranceCompanies>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_tcmd_InsuranceCompanyOneMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_N4xxMFKVj0S35nREv_ENMA"
      decimals="2"
      id="Narr_bP67sdHaL0-bOAGxiyaweA"
      unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw">0.45</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_tcmd_InsuranceCompanyTwoMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_xVT-UB4QW0Gw2arUgYbYcQ"
      decimals="2"
      id="Narr_YT6LMGpk-E2xEkEl6feFIw"
      unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw">0.21</us-gaap:ConcentrationRiskPercentage1>
    <tcmd:ConcentrationRiskNumberOfInsuranceCompanies
      contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g"
      decimals="INF"
      id="Narr_6juchAUKeUuxmC5pto5Y4A"
      unitRef="Unit_Standard_item_-67QV0kzWUGc8AbcCukKig">2</tcmd:ConcentrationRiskNumberOfInsuranceCompanies>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_tcmd_InsuranceCompanyOneMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_1-eh01sLXEOTZIQ08pcPiw"
      decimals="2"
      id="Narr_LQ-HW6wHsk2n7fy9bHCo2w"
      unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw">0.33</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_tcmd_InsuranceCompanyTwoMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_vLNz00UhJUufY_Zqk3iO2A"
      decimals="2"
      id="Narr_C-lR-9dptEqXH9brQVB5LA"
      unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw">0.24</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_tcmd_InsuranceCompanyOneMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_0HtNQF4hrEWyegzUln8uIA"
      decimals="2"
      id="Narr_Kf7A2iwIC0iT1uZa2_KfRQ"
      unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw">0.19</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_tcmd_InsuranceCompanyTwoMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_YhUWFBciaEqXEvSlvrAhSQ"
      decimals="2"
      id="Narr_L0rnULrFXEqjekFE-H_3jA"
      unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_tcmd_InsuranceCompanyOneMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_qYkwWgdcNkuDHHwGOvxkhQ"
      decimals="2"
      id="Narr_bAmmkove6kqjAD9SRAMgKA"
      unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw">0.17</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_tcmd_InsuranceCompanyTwoMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_3m0fCb_Nf0uWfI863PsLKw"
      decimals="2"
      id="Narr_0qVAo4GO7EiHSc2CLA1JqQ"
      unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw">0.12</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      id="Tb_g_opK2f7mUmyIUVRlEyFjw">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Note 6. &#160;Inventories&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Inventories consisted of the following:&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:40.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;(In&#160;thousands)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:27.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;At December&#160;31,&#160;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:27.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;At December&#160;31,&#160;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Finished goods&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 5,100&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 8,242&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Component parts and work-in-process&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 18,024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 10,975&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;"&gt;Total inventories&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 23,124&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 19,217&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;&lt;span style="font-size:1pt;font-weight:bold;margin-bottom:5pt;margin-top:5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      id="Tb_hW7Z57WPm0O_EEasxK4CoA">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:40.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;(In&#160;thousands)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:27.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;At December&#160;31,&#160;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:27.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;At December&#160;31,&#160;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Finished goods&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 5,100&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 8,242&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Component parts and work-in-process&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 18,024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 10,975&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;"&gt;Total inventories&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 23,124&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 19,217&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryFinishedGoods
      contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw"
      decimals="-3"
      id="Tc_JULdPq7BSkG2uVOnOdkJjw_2_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">5100000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods
      contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q"
      decimals="-3"
      id="Tc_q7R1R8wiOki41tfrntYIRA_2_6"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">8242000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryWorkInProcess
      contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw"
      decimals="-3"
      id="Tc_FrzmwOtYU0GnqUpMtRKBJw_3_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">18024000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryWorkInProcess
      contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q"
      decimals="-3"
      id="Tc_XqYzcsK1iEqWF6eFsnEalQ_3_6"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">10975000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryNet
      contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw"
      decimals="-3"
      id="Tc_jP8qL9Wif0-GS4WNzvJOig_4_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">23124000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q"
      decimals="-3"
      id="Tc_FwnuQ5Jh7kmZNmeS_23_6Q_4_6"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">19217000</us-gaap:InventoryNet>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      id="Tb_PFWa_L0ql0-XA2fXvD66DQ">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Note 7. &#160;Property and Equipment&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Property and equipment consisted of the following:&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:53.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:53.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:43.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;At December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:53.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;(In&#160;thousands)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:53.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,274&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,051&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:53.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Tooling&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,390&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,545&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:53.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Furniture and fixtures&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,087&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,104&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:53.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,493&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,458&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:53.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Demonstration equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,012&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 632&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:53.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Construction in progress&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 606&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,003&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:53.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Subtotal&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.56%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.44%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 16,862&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.56%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.44%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 15,793&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:53.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Less: accumulated depreciation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (10,785)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (9,043)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:53.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Property and equipment, net&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,077&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,750&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;Depreciation expense was $2.5 million, $2.3 million and $2.4 million for the years ended December&#160;31,&#160;2022, 2021 and 2020, respectively.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      id="Tb_0QkkUl5XiEuLaJr6NviawQ">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:53.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:53.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:43.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;At December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:53.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;(In&#160;thousands)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:53.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,274&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,051&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:53.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Tooling&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,390&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,545&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:53.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Furniture and fixtures&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,087&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,104&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:53.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,493&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,458&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:53.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Demonstration equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,012&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 632&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:53.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Construction in progress&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 606&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,003&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:53.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Subtotal&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.56%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.44%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 16,862&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.56%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.44%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 15,793&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:53.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Less: accumulated depreciation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (10,785)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (9,043)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:53.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Property and equipment, net&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,077&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,750&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_Yh5OMODH40SC-Um87PF3UA"
      decimals="-3"
      id="Tc_PBBOTMk8N0Sc0nvZOx3hSg_3_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">8274000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_Uf5xoWiQAkuLZI9kCZLPRA"
      decimals="-3"
      id="Tc_Vy_U9GOfOkWfl7jqyD5K8Q_3_6"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">8051000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ToolsDiesAndMoldsMember_NTOCOwxcN0WCHhE4s7Z6xg"
      decimals="-3"
      id="Tc_LCAo-KT6AkW110r8-0o6hQ_4_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">3390000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ToolsDiesAndMoldsMember_Pvs6l_E6h0O5TC299fq4Bg"
      decimals="-3"
      id="Tc_DbHdR8B5OEGfnZ345H2u2A_4_6"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">2545000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_wBBLS9cO1EGcEb4aYAZlcA"
      decimals="-3"
      id="Tc_6994_xfzA0G1dO8Oc_y9ww_5_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">2087000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_cb8KtxnOaUusasmEVS4S6w"
      decimals="-3"
      id="Tc_LpMfFkv8-Eu6iIwOKEZngg_5_6"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">2104000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_MA9Tzfj_Zkq7UAzFHCpHMQ"
      decimals="-3"
      id="Tc_vHVtSQbmkUC5kc6V9c0oMQ_6_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">1493000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_MU5-dZQMLEOZnQDTmaetLQ"
      decimals="-3"
      id="Tc_d6cs-r5wNES3PfEvbFHFiw_6_6"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">1458000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_tcmd_DemoEquipmentMember_r01Fmv-tlE2ZfmS0SxVG8g"
      decimals="-3"
      id="Tc_yKaLB1X37EquowvG8QCj3w_7_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">1012000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_tcmd_DemoEquipmentMember_3j_rU49gBEimc7YFgpwKEw"
      decimals="-3"
      id="Tc_ARUrFTaUiUe6v81RSTWuHQ_7_6"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">632000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember_jGU_hCQP7EaA8kqaHpKwsg"
      decimals="-3"
      id="Tc_xMBW8TSvdEaKidnEi0rnPQ_8_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">606000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember_Ko8IgMBkWUy1Erw3_JKPQg"
      decimals="-3"
      id="Tc_NibQlt7u8EO242mbwjBdYg_8_6"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">1003000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw"
      decimals="-3"
      id="Tc_Yo4aA2S2pU6Ve18BdwcrHA_9_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">16862000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q"
      decimals="-3"
      id="Tc_lUP074KAHEqu65y8KVz4NQ_9_6"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">15793000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw"
      decimals="-3"
      id="Tc_zM2vqMNNikuFZ83svagdUA_10_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">10785000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q"
      decimals="-3"
      id="Tc_rwlMlhHsZEa7LriW3EwJtQ_10_6"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">9043000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw"
      decimals="-3"
      id="Tc_rOwOKMKLB0udeNJOWeexTA_11_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">6077000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q"
      decimals="-3"
      id="Tc_8K0NxOo2sE2XNfBuw0yyvg_11_6"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">6750000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      decimals="-5"
      id="Narr_BUry312dmUq_U-XPmFGyYg"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">2500000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g"
      decimals="-5"
      id="Narr_4ipjagSN0U-lZogXkkQehA"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">2300000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA"
      decimals="-5"
      id="Narr_ZRN15ZaOGUOR6fcVAUHezg"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">2400000</us-gaap:Depreciation>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      id="Tb_mdHKyW0TMkuzMN8wBcxMzw">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Note 8. &#160;Goodwill and Intangible Assets&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;padding-left:10pt;text-align:justify;text-indent:-10pt;background:#ffffff;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Goodwill&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;"&gt;In the third quarter of fiscal 2021, we completed the AffloVest Acquisition. The purchase price of the AffloVest business exceeded the net acquisition-date estimated fair value amounts of the identifiable assets acquired and the liabilities assumed by $31.1 million, which was assigned to goodwill.&#160;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;padding-left:10pt;text-align:justify;text-indent:-10pt;background:#ffffff;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Intangible Assets&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;"&gt;Our patents and other intangible assets are summarized as follows:&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:30.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:30.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted-&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:48.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;At December&#160;31,&#160;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:30.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gross&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:30.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amortization&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Carrying&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Accumulated&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Net&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:30.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;(In&#160;thousands)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Period&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amount&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amortization&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amount&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:30.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Definite-lived intangible assets:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:30.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Patents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;12 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 897&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 173&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 724&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:30.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Defensive intangible assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;2 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,126&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 764&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 362&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:30.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Customer accounts&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&amp;lt; 1 year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 125&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 114&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:30.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Customer relationships&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;12 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 31,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,127&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 27,873&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:30.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Developed technology&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;10 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,550&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,450&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:30.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Subtotal&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 46,148&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,728&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 40,420&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:30.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unamortized intangible assets:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:30.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Tradenames&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,500&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,500&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:30.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Patents pending&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 455&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 455&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:30.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total intangible assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 56,103&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,728&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 50,375&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:30.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:30.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted-&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:48.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;At December&#160;31,&#160;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:30.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gross&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:30.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amortization&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Carrying&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Accumulated&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Net&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:30.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;(In&#160;thousands)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Period&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amount&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amortization&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amount&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:30.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Definite-lived intangible assets:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:30.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Patents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt;12 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 666&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 109&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 557&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:30.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Defensive intangible assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt;3 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 1,125&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 592&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 533&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:30.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Customer accounts&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt;1 year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 125&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 89&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 36&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:30.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Customer relationships&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt;13 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 31,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 742&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 30,258&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:30.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Developed technology&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt;11 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 13,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 368&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 12,632&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:30.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;"&gt;Subtotal&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 45,916&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 1,900&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 44,016&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:30.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unamortized intangible assets:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:30.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Tradenames&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 9,500&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 9,500&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:30.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Patents pending&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 565&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 565&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:30.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;"&gt;Total intangible assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 55,981&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 1,900&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 54,081&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;"&gt;Amortization expense was $3.8 million, $1.4 million, and $0.4 million for the years ended December&#160;31,&#160;2022, 2021 and 2020, respectively. Future amortization expenses are expected as follows:&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:54.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:30.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;(In&#160;thousands)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:30.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:30.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,808&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:30.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,787&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:30.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,697&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:30.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,633&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:30.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,623&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:30.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 21,872&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:30.85%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 40,420&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;padding-bottom:14pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:2pt 0pt 0pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt;The weighted-average remaining amortization period for these intangible assets was &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;11.0&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; years as of December&#160;31,&#160;2022.&lt;/span&gt;&lt;/p&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:Goodwill
      contextRef="As_Of_9_30_2021_us-gaap_BusinessAcquisitionAxis_tcmd_AfflovestPMember_0vr8lFFgNk-hj48fe5kJDg"
      decimals="-5"
      id="Narr_h3jzVeVJTUyP2yMVKgibkQ"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">31100000</us-gaap:Goodwill>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      id="Tb_8zczWr9tt0ug3M3rOt2YUA">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:30.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:30.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted-&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:48.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;At December&#160;31,&#160;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:30.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gross&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:30.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amortization&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Carrying&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Accumulated&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Net&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:30.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;(In&#160;thousands)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Period&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amount&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amortization&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amount&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:30.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Definite-lived intangible assets:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:30.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Patents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;12 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 897&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 173&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 724&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:30.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Defensive intangible assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;2 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,126&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 764&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 362&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:30.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Customer accounts&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&amp;lt; 1 year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 125&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 114&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:30.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Customer relationships&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;12 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 31,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,127&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 27,873&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:30.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Developed technology&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;10 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,550&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,450&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:30.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Subtotal&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 46,148&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,728&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 40,420&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:30.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unamortized intangible assets:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:30.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Tradenames&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,500&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,500&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:30.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Patents pending&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 455&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 455&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:30.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total intangible assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 56,103&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,728&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 50,375&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:30.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:30.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted-&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:48.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;At December&#160;31,&#160;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:30.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gross&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:30.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amortization&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Carrying&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Accumulated&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Net&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:30.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;(In&#160;thousands)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Period&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amount&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amortization&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amount&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:30.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Definite-lived intangible assets:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:30.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Patents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt;12 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 666&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 109&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 557&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:30.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Defensive intangible assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt;3 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 1,125&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 592&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 533&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:30.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Customer accounts&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt;1 year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 125&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 89&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 36&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:30.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Customer relationships&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt;13 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 31,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 742&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 30,258&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:30.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Developed technology&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt;11 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 13,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 368&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 12,632&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:30.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;"&gt;Subtotal&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 45,916&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 1,900&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 44,016&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:30.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unamortized intangible assets:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:30.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Tradenames&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 9,500&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 9,500&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:30.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Patents pending&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 565&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 565&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:30.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;"&gt;Total intangible assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 55,981&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 1,900&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 54,081&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_PatentsMember_bHnLKkfY50SShKWlCELEaA"
      id="Tc_rxx98p-dhkKI1neb8hYgpA_6_2">P12Y</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="As_Of_12_31_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_PatentsMember_EzMi2_I88kuyRc4Rc_5PoQ"
      decimals="-3"
      id="Tc_2tHidTYlEEeZe48Yn04ecg_6_5"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">897000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="As_Of_12_31_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_PatentsMember_EzMi2_I88kuyRc4Rc_5PoQ"
      decimals="-3"
      id="Tc_H2IXQSeSe0ye1xpFAuDN3w_6_8"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">173000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="As_Of_12_31_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_PatentsMember_EzMi2_I88kuyRc4Rc_5PoQ"
      decimals="-3"
      id="Tc_iy5nK1kYGEeW9dfAEtrjTQ_6_11"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">724000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_tcmd_DefensiveIntangibleAssetsMember_6NFOXe0OVEae4LCvhvDg5A"
      id="Tc_X3NLg93nMkuuHsYSvWMCrg_7_2">P2Y</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="As_Of_12_31_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_tcmd_DefensiveIntangibleAssetsMember_LZ89k11DfEu3IXN3jY-Q_A"
      decimals="-3"
      id="Tc_z8luboGv8EqP3OyEvPKE-A_7_5"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">1126000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="As_Of_12_31_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_tcmd_DefensiveIntangibleAssetsMember_LZ89k11DfEu3IXN3jY-Q_A"
      decimals="-3"
      id="Tc_C156l0nugkShC2OC1peySw_7_8"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">764000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="As_Of_12_31_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_tcmd_DefensiveIntangibleAssetsMember_LZ89k11DfEu3IXN3jY-Q_A"
      decimals="-3"
      id="Tc_ZeQWYSMKoEm9RZ7y7IJL8Q_7_11"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">362000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_CustomerContractsMember_zWlWYJGY4UyP-QjMu9VYLA"
      id="Narr_05XXyhgHzUe90COwEu__3A">P1Y</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="As_Of_12_31_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_CustomerContractsMember_YzWU1KiStEOVgQlfeA7jcw"
      decimals="-3"
      id="Tc_PXkjaXnP10Ktd8II38obmA_8_5"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">125000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="As_Of_12_31_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_CustomerContractsMember_YzWU1KiStEOVgQlfeA7jcw"
      decimals="-3"
      id="Tc_Pr2GPEBDHk6VNzF_IcJWpQ_8_8"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">114000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="As_Of_12_31_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_CustomerContractsMember_YzWU1KiStEOVgQlfeA7jcw"
      decimals="-3"
      id="Tc_u5EKMtUCNUiy9hqIkmmEkQ_8_11"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">11000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_CustomerRelationshipsMember_jYH-emDiWkiQNaMDqVEM4w"
      id="Tc__vq1Cfi1gUCABr8kmOMboA_9_2">P12Y</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="As_Of_12_31_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_CustomerRelationshipsMember_Y08o1mZ38kCDCzt3GAQN8A"
      decimals="-3"
      id="Tc_8SPGd0zBeUaiRV8hoanQiA_9_5"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">31000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="As_Of_12_31_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_CustomerRelationshipsMember_Y08o1mZ38kCDCzt3GAQN8A"
      decimals="-3"
      id="Tc_89aCgUi3LEC55r0ot8WqKw_9_8"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">3127000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="As_Of_12_31_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_CustomerRelationshipsMember_Y08o1mZ38kCDCzt3GAQN8A"
      decimals="-3"
      id="Tc_ZMXKjSqJOE-lH16kRCd36g_9_11"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">27873000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_lM7vBgl8SkW3zbCRJ6akww"
      id="Tc_B5SgGsW2hUyWr4pg8a12BQ_10_2">P10Y</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="As_Of_12_31_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_lL8SrIZbB0O4E4gu1p47vA"
      decimals="-3"
      id="Tc_vyRzrnTUCUSc4MN3v3XJuw_10_5"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">13000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="As_Of_12_31_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_lL8SrIZbB0O4E4gu1p47vA"
      decimals="-3"
      id="Tc_R-uJQtpX5U2SvRHiIrQf0g_10_8"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">1550000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="As_Of_12_31_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_lL8SrIZbB0O4E4gu1p47vA"
      decimals="-3"
      id="Tc_XtRPbVt08kuCoHY7PQix2g_10_11"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">11450000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw"
      decimals="-3"
      id="Tc_OgUIydUpekmztORjV1rfrg_11_5"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">46148000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw"
      decimals="-3"
      id="Tc_Int4gofLK0ebMjy5PHYeaQ_11_8"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">5728000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw"
      decimals="-3"
      id="Tc_x5aZxzds2ku9H6nXbl2D2A_11_11"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">40420000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="As_Of_12_31_2022_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember_IyWAZ3ta8E2Ea1SMrdPPBQ"
      decimals="-3"
      id="Tc_54Iku5N8SUuCzqNYJC2_mQ_13_5"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">9500000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="As_Of_12_31_2022_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember_IyWAZ3ta8E2Ea1SMrdPPBQ"
      decimals="-3"
      id="Tc_yGMY9GXppUya4XezASkK8g_13_11"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">9500000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="As_Of_12_31_2022_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_PatentsMember_LNA_h_4RnkaxxN0_I1BWbQ"
      decimals="-3"
      id="Tc_62KIK5_6p0yetXo6OZ7hhQ_14_5"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">455000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="As_Of_12_31_2022_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_PatentsMember_LNA_h_4RnkaxxN0_I1BWbQ"
      decimals="-3"
      id="Tc_r6mQOthDiEC2V3gnevpZHw_14_11"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">455000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw"
      decimals="-3"
      id="Tc_X9bSjCFKqEmcdz_pnBQaJw_15_5"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">56103000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw"
      decimals="-3"
      id="Tc_hlPmkLZzbEqy0E_G95_75A_15_8"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">5728000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw"
      decimals="-3"
      id="Tc_3Nw_7eDEDUyEWNkrvu-PqQ_15_11"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">50375000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_PatentsMember_nZCthuPEmEK_vsD9bnMPZg"
      id="Tc_nvFLNZCRXUCi7rX-CKCtrQ_6_2">P12Y</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="As_Of_12_31_2021_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_PatentsMember_JkjaHeEoUE2DyDTDEjvMwQ"
      decimals="-3"
      id="Tc_8J5A34XQSUyw3GAfzDCesQ_6_5"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">666000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="As_Of_12_31_2021_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_PatentsMember_JkjaHeEoUE2DyDTDEjvMwQ"
      decimals="-3"
      id="Tc_4DIUBQ9vV0qNQlOaqw3VgA_6_8"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">109000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="As_Of_12_31_2021_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_PatentsMember_JkjaHeEoUE2DyDTDEjvMwQ"
      decimals="-3"
      id="Tc_cl0Y9ssmkkWKFr1Jc7uk7Q_6_11"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">557000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_tcmd_DefensiveIntangibleAssetsMember_62-asFO7iEyeD8pb1fZgLA"
      id="Tc_I5zCwe7ByEWoE5s4vRjuGA_7_2">P3Y</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="As_Of_12_31_2021_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_tcmd_DefensiveIntangibleAssetsMember_QV0b5loORke7y1IpAQUFJQ"
      decimals="-3"
      id="Tc_efFkGI2Z00Wmen928NJlgQ_7_5"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">1125000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="As_Of_12_31_2021_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_tcmd_DefensiveIntangibleAssetsMember_QV0b5loORke7y1IpAQUFJQ"
      decimals="-3"
      id="Tc_tpdJiRl3o0aeg4pk0jBTfA_7_8"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">592000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="As_Of_12_31_2021_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_tcmd_DefensiveIntangibleAssetsMember_QV0b5loORke7y1IpAQUFJQ"
      decimals="-3"
      id="Tc_RTbv5UZoGkSS3kddCe8Rpg_7_11"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">533000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_CustomerContractsMember_8VJEgmF_UkWBYfqLoC4C3A"
      id="Tc_DiUMF93Oc0agQhCEPfgx8w_8_2">P1Y</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="As_Of_12_31_2021_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_CustomerContractsMember_fTqSuCd94keomoVYMmQiIw"
      decimals="-3"
      id="Tc_zurX-bzNgEarx7kjwb386g_8_5"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">125000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="As_Of_12_31_2021_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_CustomerContractsMember_fTqSuCd94keomoVYMmQiIw"
      decimals="-3"
      id="Tc_y9id3S0qN0q5bHVGQqGUlg_8_8"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">89000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="As_Of_12_31_2021_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_CustomerContractsMember_fTqSuCd94keomoVYMmQiIw"
      decimals="-3"
      id="Tc_WGouyfFHw0GL6OmTfDTscw_8_11"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">36000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_CustomerRelationshipsMember_64UYdGsGlUaBziSx02KLVQ"
      id="Tc_M3QN2CoxkES3QPGHVPQf6g_9_2">P13Y</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="As_Of_12_31_2021_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_CustomerRelationshipsMember_dmnRIghXk0SjwOQAgPqgtg"
      decimals="-3"
      id="Tc_uaWzfOPWn0qthR1DNviTwg_9_5"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">31000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="As_Of_12_31_2021_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_CustomerRelationshipsMember_dmnRIghXk0SjwOQAgPqgtg"
      decimals="-3"
      id="Tc_ljM3Bbts1US_A8ZtihTzqA_9_8"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">742000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="As_Of_12_31_2021_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_CustomerRelationshipsMember_dmnRIghXk0SjwOQAgPqgtg"
      decimals="-3"
      id="Tc_paVwcPxwUUeWDJ2xvhvCuA_9_11"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">30258000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_TEkHdFvt00SmYBkAMY4_HQ"
      id="Tc_n7qo09b-TEaUut-JtQUBBw_10_2">P11Y</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="As_Of_12_31_2021_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_iZuKEYAKNU6aSfE3kxIqUw"
      decimals="-3"
      id="Tc_Klv-FgXNr0qPqSq5FIifrg_10_5"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">13000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="As_Of_12_31_2021_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_iZuKEYAKNU6aSfE3kxIqUw"
      decimals="-3"
      id="Tc_kKGWJ8QUpUy28e5NWop-jQ_10_8"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">368000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="As_Of_12_31_2021_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_iZuKEYAKNU6aSfE3kxIqUw"
      decimals="-3"
      id="Tc_NW8sc4J-WUSA3HXE307NUg_10_11"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">12632000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q"
      decimals="-3"
      id="Tc_D9RcHG0T5EeB5KM92JVWuA_11_5"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">45916000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q"
      decimals="-3"
      id="Tc_y8cjMMBdykeH3O9j6LhsdQ_11_8"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">1900000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q"
      decimals="-3"
      id="Tc_sb6m6QSEFU2kaoUFbTdgtg_11_11"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">44016000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="As_Of_12_31_2021_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember_aBd3a_ELrEOm_yysA0S0ag"
      decimals="-3"
      id="Tc_z7-4bbu57kecS4rCxowAeQ_13_5"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">9500000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="As_Of_12_31_2021_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember_aBd3a_ELrEOm_yysA0S0ag"
      decimals="-3"
      id="Tc_pluMAnyXGEuzZ-ddHk8pZQ_13_11"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">9500000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="As_Of_12_31_2021_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_PatentsMember_m8rPRrVCGkCmV2jH3V3EGA"
      decimals="-3"
      id="Tc_xYDN85b6z0aEKaPPCehkgg_14_5"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">565000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="As_Of_12_31_2021_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_PatentsMember_m8rPRrVCGkCmV2jH3V3EGA"
      decimals="-3"
      id="Tc_dkp8caztME-rF3bOGwI9-A_14_11"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">565000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q"
      decimals="-3"
      id="Tc_eWQFEp2C7k28GjaEwY7QDw_15_5"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">55981000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q"
      decimals="-3"
      id="Tc_mgkESC9wbkq1WGcQImqzOQ_15_8"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">1900000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q"
      decimals="-3"
      id="Tc_ueyS6z0HaUmYXjnMBS19Rg_15_11"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">54081000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      decimals="-5"
      id="Narr_XxWL8pQApU-7MaI2cOZDVg"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">3800000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g"
      decimals="-5"
      id="Narr_FpWv08aVskSbGaVd40YXww"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">1400000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA"
      decimals="-5"
      id="Narr_qeRMeBM10EW23LnnT3lLMg"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">400000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      id="Tb_kDCfTB2XA0aOX-Qs3TOpqQ">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:54.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:30.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;(In&#160;thousands)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:30.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:30.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,808&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:30.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,787&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:30.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,697&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:30.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,633&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:30.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,623&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:30.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 21,872&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:30.85%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 40,420&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw"
      decimals="-3"
      id="Tc_dUnzn4YgrkGBLmbCLZwZWA_2_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">3808000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw"
      decimals="-3"
      id="Tc_HULrzvQ9XkSkn6syZbTZxw_3_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">3787000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw"
      decimals="-3"
      id="Tc__nvcJxP5_EiPgyHGUqFNiA_4_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">3697000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw"
      decimals="-3"
      id="Tc_ncYh-A88gEumC0600CEHSw_5_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">3633000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw"
      decimals="-3"
      id="Tc_cuREnv3_oEWr25GZ8Cw8PQ_6_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">3623000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
      contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw"
      decimals="-3"
      id="Tc_zuksRQ4wT0OkQVbIpirthw_7_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">21872000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw"
      decimals="-3"
      id="Tc_sPzycbi-G0GhHqFkdtLoag_8_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">40420000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      id="Narr_KIZUjFPq-E2WtT6RSaRgEQ">P11Y</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <tcmd:AccruedExpensesDisclosureCurrentTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      id="Tb_UF_tMkA2qkOn2UslyECT1w">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Note 9. &#160;Accrued Expenses&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;"&gt;Accrued expenses consisted of the following:&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:34.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:34.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;(In&#160;thousands)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:30.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;At December&#160;31,&#160;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:30.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;At December&#160;31,&#160;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:34.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;In-transit inventory&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,228&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 416&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:34.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Warranty&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,005&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,851&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:34.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Travel&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,121&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 661&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:34.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Legal and consulting&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 730&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,371&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:34.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Clinical studies&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 276&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 113&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:34.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Sales and use tax&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 147&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 106&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:34.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,733&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 744&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:34.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,240&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,262&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</tcmd:AccruedExpensesDisclosureCurrentTextBlock>
    <tcmd:ScheduleOfAccruedExpensesTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      id="Tb_VTx-8tSMIkmyjmQl2naHxA">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:34.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:34.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;(In&#160;thousands)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:30.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;At December&#160;31,&#160;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:30.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;At December&#160;31,&#160;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:34.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;In-transit inventory&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,228&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 416&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:34.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Warranty&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,005&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,851&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:34.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Travel&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,121&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 661&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:34.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Legal and consulting&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 730&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,371&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:34.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Clinical studies&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 276&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 113&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:34.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Sales and use tax&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 147&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 106&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:34.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,733&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 744&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:34.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,240&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,262&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</tcmd:ScheduleOfAccruedExpensesTableTextBlock>
    <tcmd:InTransitInventoryAccruedExpense
      contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw"
      decimals="-3"
      id="Tc_3W9U4kSqXkWE6scMjdJN0g_2_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">3228000</tcmd:InTransitInventoryAccruedExpense>
    <tcmd:InTransitInventoryAccruedExpense
      contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q"
      decimals="-3"
      id="Tc_iaccneYFLkC4FWl8OeI8fw_2_6"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">416000</tcmd:InTransitInventoryAccruedExpense>
    <us-gaap:ProductWarrantyAccrualClassifiedCurrent
      contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw"
      decimals="-3"
      id="Tc_WREW-GQdbkG2OK6tdHCXBw_3_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">2005000</us-gaap:ProductWarrantyAccrualClassifiedCurrent>
    <us-gaap:ProductWarrantyAccrualClassifiedCurrent
      contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q"
      decimals="-3"
      id="Tc_pFkHJqQO8k-ykBpLeH3w0g_3_6"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">1851000</us-gaap:ProductWarrantyAccrualClassifiedCurrent>
    <tcmd:AccruedTravelAndEntertainmentCurrent
      contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw"
      decimals="-3"
      id="Tc_3fhHz91y80aoil1mZOpliw_4_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">1121000</tcmd:AccruedTravelAndEntertainmentCurrent>
    <tcmd:AccruedTravelAndEntertainmentCurrent
      contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q"
      decimals="-3"
      id="Tc_WyDORHc8A0SIOXNJgwQAXg_4_6"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">661000</tcmd:AccruedTravelAndEntertainmentCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw"
      decimals="-3"
      id="Tc_1EJLd0mOMEO8oFc8d42weQ_5_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">730000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q"
      decimals="-3"
      id="Tc_vS99gAcnBkqkQzeKyzJ-Jg_5_6"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">1371000</us-gaap:AccruedProfessionalFeesCurrent>
    <tcmd:AccruedClinicalStudiesExpensesCurrent
      contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw"
      decimals="-3"
      id="Tc_FiEpRhgYdUyCHGx1qrGgjQ_6_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">276000</tcmd:AccruedClinicalStudiesExpensesCurrent>
    <tcmd:AccruedClinicalStudiesExpensesCurrent
      contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q"
      decimals="-3"
      id="Tc_w-W8R_2un0mD37coKH5JgQ_6_6"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">113000</tcmd:AccruedClinicalStudiesExpensesCurrent>
    <tcmd:AccruedSalesAndUseTax
      contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw"
      decimals="-3"
      id="Tc_LW7srx82bUOXAKRPENmyBg_7_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">147000</tcmd:AccruedSalesAndUseTax>
    <tcmd:AccruedSalesAndUseTax
      contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q"
      decimals="-3"
      id="Tc_VV8NtIP99k68aBzSOXXDHQ_7_6"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">106000</tcmd:AccruedSalesAndUseTax>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw"
      decimals="-3"
      id="Tc_RI7Sdm9OJ0qk6vkZx7V9fw_8_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">1733000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q"
      decimals="-3"
      id="Tc_Ax3r9gy2A0qOoIUgzBcKKg_8_6"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">744000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw"
      decimals="-3"
      id="Tc_dGvdAFUPr0C13ZprVaHo2A_9_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">9240000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q"
      decimals="-3"
      id="Tc_lmOCRTtegkO48hFcMPH06g_9_6"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">5262000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:ProductWarrantyDisclosureTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      id="Tb_E1Dh5YELzk-L-Ea8EfQrYw">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Note&#160;10. &#160;Warranty Reserves&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The activity in the warranty reserve during and as of the end of the year presented was as follows:&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:40.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:59.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:59.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;(In&#160;thousands)&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Beginning balance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,959&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,841&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,759&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Warranty provision&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,047&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,606&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,957&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Processed warranty claims&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,794)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,488)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,875)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Ending balance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,212&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,959&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,841&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:40.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#ff0000;font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Accrued warranty reserve, current&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,005&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,851&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,606&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Accrued warranty reserve, non-current&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,207&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,108&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,235&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total accrued warranty reserve&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,212&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,959&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,841&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ProductWarrantyDisclosureTextBlock>
    <us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      id="Tb_GvvJ30-GPE6LN7uONo3XFw">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:40.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:59.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:59.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;(In&#160;thousands)&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Beginning balance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,959&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,841&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,759&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Warranty provision&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,047&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,606&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,957&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Processed warranty claims&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,794)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,488)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,875)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Ending balance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,212&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,959&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,841&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:40.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#ff0000;font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Accrued warranty reserve, current&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,005&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,851&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,606&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Accrued warranty reserve, non-current&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,207&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,108&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,235&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total accrued warranty reserve&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,212&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,959&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,841&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock>
    <us-gaap:StandardProductWarrantyAccrual
      contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q"
      decimals="-3"
      id="Tc_wQIkH1vst0mPJm70E1rSJg_4_2"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">4959000</us-gaap:StandardProductWarrantyAccrual>
    <us-gaap:StandardProductWarrantyAccrual
      contextRef="As_Of_12_31_2020_q95ww8WB7U-18mlScI3MCA"
      decimals="-3"
      id="Tc_ZkLLqXq9PkOO_ChoRiKxGw_4_5"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">4841000</us-gaap:StandardProductWarrantyAccrual>
    <us-gaap:StandardProductWarrantyAccrual
      contextRef="As_Of_12_31_2019_3ga0jBjg6EKA4-znaQ36NQ"
      decimals="-3"
      id="Tc_kzSmFOhES0m5OTnraXyRcA_4_8"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">3759000</us-gaap:StandardProductWarrantyAccrual>
    <us-gaap:StandardProductWarrantyAccrualWarrantiesIssued
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      decimals="-3"
      id="Tc_suR8FGTt3EiP-yGOLs6DoA_5_2"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">2047000</us-gaap:StandardProductWarrantyAccrualWarrantiesIssued>
    <us-gaap:StandardProductWarrantyAccrualWarrantiesIssued
      contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g"
      decimals="-3"
      id="Tc_HxbopVIkYUGZIhj_-bsT6Q_5_5"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">2606000</us-gaap:StandardProductWarrantyAccrualWarrantiesIssued>
    <us-gaap:StandardProductWarrantyAccrualWarrantiesIssued
      contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA"
      decimals="-3"
      id="Tc_MzIIknw6Ckqv-JSkYqAzqQ_5_8"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">2957000</us-gaap:StandardProductWarrantyAccrualWarrantiesIssued>
    <us-gaap:StandardProductWarrantyAccrualPayments
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      decimals="-3"
      id="Tc_F6vt4-XHLkiqnio_XTe3CQ_6_2"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">2794000</us-gaap:StandardProductWarrantyAccrualPayments>
    <us-gaap:StandardProductWarrantyAccrualPayments
      contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g"
      decimals="-3"
      id="Tc_JPddDHmDQkiewmZ8ckvpoA_6_5"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">2488000</us-gaap:StandardProductWarrantyAccrualPayments>
    <us-gaap:StandardProductWarrantyAccrualPayments
      contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA"
      decimals="-3"
      id="Tc_InJWNpKQK0G3tg74rx577g_6_8"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">1875000</us-gaap:StandardProductWarrantyAccrualPayments>
    <us-gaap:StandardProductWarrantyAccrual
      contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw"
      decimals="-3"
      id="Tc_Jazkr-gwek-0O3JsmRx1NA_7_2"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">4212000</us-gaap:StandardProductWarrantyAccrual>
    <us-gaap:StandardProductWarrantyAccrual
      contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q"
      decimals="-3"
      id="Tc_ckzO1WaisECVio0nW_BtTQ_7_5"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">4959000</us-gaap:StandardProductWarrantyAccrual>
    <us-gaap:StandardProductWarrantyAccrual
      contextRef="As_Of_12_31_2020_q95ww8WB7U-18mlScI3MCA"
      decimals="-3"
      id="Tc_rV2FNtRetEWGgdbdIaMRjQ_7_8"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">4841000</us-gaap:StandardProductWarrantyAccrual>
    <us-gaap:ProductWarrantyAccrualClassifiedCurrent
      contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw"
      decimals="-3"
      id="Tc_I66_--q63km6bFPy0lA95w_9_2"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">2005000</us-gaap:ProductWarrantyAccrualClassifiedCurrent>
    <us-gaap:ProductWarrantyAccrualClassifiedCurrent
      contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q"
      decimals="-3"
      id="Tc_UDGyKTySGUqc-pJAsuzgHQ_9_5"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">1851000</us-gaap:ProductWarrantyAccrualClassifiedCurrent>
    <us-gaap:ProductWarrantyAccrualClassifiedCurrent
      contextRef="As_Of_12_31_2020_q95ww8WB7U-18mlScI3MCA"
      decimals="-3"
      id="Tc_hUbAQNfgtkq5f0MAQSclJA_9_8"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">1606000</us-gaap:ProductWarrantyAccrualClassifiedCurrent>
    <us-gaap:ProductWarrantyAccrualNoncurrent
      contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw"
      decimals="-3"
      id="Tc_coh3ibhzhEi-dsdSUAqyoQ_10_2"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">2207000</us-gaap:ProductWarrantyAccrualNoncurrent>
    <us-gaap:ProductWarrantyAccrualNoncurrent
      contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q"
      decimals="-3"
      id="Tc_4ZapMWuKkEiyJv1kY8PqOA_10_5"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">3108000</us-gaap:ProductWarrantyAccrualNoncurrent>
    <us-gaap:ProductWarrantyAccrualNoncurrent
      contextRef="As_Of_12_31_2020_q95ww8WB7U-18mlScI3MCA"
      decimals="-3"
      id="Tc_yYPUxC4xZEOmCyTFw8iAvg_10_8"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">3235000</us-gaap:ProductWarrantyAccrualNoncurrent>
    <us-gaap:ProductWarrantyAccrual
      contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw"
      decimals="-3"
      id="Tc_LaPih9EESU-6tTJ0oftl0A_11_2"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">4212000</us-gaap:ProductWarrantyAccrual>
    <us-gaap:ProductWarrantyAccrual
      contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q"
      decimals="-3"
      id="Tc_2YRMjOmu-0-ZCUQUcc5NLA_11_5"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">4959000</us-gaap:ProductWarrantyAccrual>
    <us-gaap:ProductWarrantyAccrual
      contextRef="As_Of_12_31_2020_q95ww8WB7U-18mlScI3MCA"
      decimals="-3"
      id="Tc_BbVdPmKLokSZWgsJaZCxvA_11_8"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">4841000</us-gaap:ProductWarrantyAccrual>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      id="Tb_dY42E7MiMEiSBZCm--KMaQ">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Note&#160;11. &#160;Credit Agreement&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"&gt;On April 30, 2021, we entered into an Amended and Restated Credit Agreement (the &#x201c;Restated Credit Agreement&#x201d;) with the lenders from time to time party thereto, and Wells Fargo Bank, National Association, as Administrative Agent. The Restated Credit Agreement amended and restated in its entirety our prior credit agreement.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27pt;background:#ffffff;margin:0pt;"&gt;On September 8, 2021, we entered into a First Amendment Agreement (the &#x201c;First Amendment&#x201d;), which amends the Restated Credit Agreement (as amended by the First Amendment, the &#x201c;Credit Agreement&#x201d;) with the lenders from time to time party thereto and Wells Fargo Bank, National Association, as Administrative Agent. The First Amendment, among other things, adds a $30.0 million incremental term loan to the $25.0 million revolving credit facility provided by the Restated Credit Agreement. The term loan is reflected as a note payable on our Consolidated Balance Sheets. The term loan and the revolving credit facility mature on September 8, 2024. The Credit Agreement provides that, subject to satisfaction of certain conditions, we may increase the amount of the revolving loans available under the Credit Agreement and/or add one or more term loan facilities in an amount not to exceed $25.0 million in the aggregate, such that the total aggregate principal amount of loans available under the Credit Agreement (including under the revolving credit facility) does not exceed $80.0 million.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27pt;background:#ffffff;margin:0pt;"&gt;On September 8, 2021, in connection with the closing of the AffloVest Acquisition, we borrowed the $30.0 million term loan and utilized that borrowing, together with a draw of $25.0 million under the revolving credit facility and cash on hand, to fund the purchase price.&#160;As of both December 31, 2022 and 2021, there was no availability under our Credit Agreement.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;text-align:justify;text-indent:27pt;background:#ffffff;margin:0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27pt;background:#ffffff;margin:0pt;"&gt;On February 22, 2022, we entered into a Second Amendment Agreement (the &#x201c;Second Amendment&#x201d;), which further amends the Credit Agreement.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;text-align:justify;text-indent:27pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;"&gt;The principal of the term loan is required to be repaid in &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;quarterly&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; installments of &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;$750,000&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; commencing&#160;January 7, 2022,&#160;through&#160;July 8, 2024,&#160;with the remaining outstanding balance due on&#160;September 8, 2024. Pursuant to the Second Amendment, we made a mandatory principal prepayment of the term loan of &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;$3.0&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; million on February 22, 2022.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;text-align:justify;text-indent:27pt;margin:0pt;"&gt;&lt;span style="color:#ff0000;font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27pt;margin:0pt;"&gt;The term loan and amounts drawn under the revolving credit facility bear interest, at our option, at a rate equal to (a) the highest of (i) the prime rate, (ii) the federal funds rate plus 0.50% and (iii) LIBOR for an interest period of one month plus 1% (the &#x201c;Base Rate&#x201d;) plus an applicable margin or (b) LIBOR for an interest period of one, three or six months, at our option, plus the applicable margin. The applicable margin is 0.75% to 2.25% on loans bearing interest at the Base Rate and 1.75% to 3.25% on loans bearing interest at LIBOR, in each case depending on our consolidated total leverage ratio; except that, pursuant to the Second Amendment, during the period commencing on February 22, 2022 and ending on the last day of the fiscal quarter ending June 30, 2023, the applicable margin for LIBOR rate loans is 3.50%. At December 31, 2022,&#160;all outstanding borrowings were subject to interest at a rate calculated at LIBOR plus an applicable margin, for an interest rate of 7.41%. Undrawn portions of the revolving credit facility are subject to an unused line fee at a rate per annum from 0.300% to 0.375%, depending on our consolidated total leverage ratio.&#160;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:60.5pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:27.35pt;margin:0pt;"&gt;Maturities of the term loan for the next three years as of December 31, 2022, were as follows:&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:66.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;(In&#160;thousands)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:29.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amount&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 21,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 24,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27.35pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;Our obligations under the Credit Agreement are secured by a security interest in substantially all of our and our subsidiaries&#x2019; assets and are also guaranteed by our subsidiaries. The Credit Agreement contains a number of restrictions and covenants, including that we maintain compliance with a maximum leverage ratio, minimum fixed charge coverage ratio and a minimum consolidated EBITDA covenant. As of December 31, 2022, we were in compliance with all financial covenants under the Credit Agreement.&lt;/p&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_9_8_2021_us-gaap_CreditFacilityAxis_tcmd_TermLoanMember_oz1r9Y66CkacJQ3itM6kfg"
      decimals="-5"
      id="Narr_BzMcFWIrukebIqtsWlaaeg"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">30000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="As_Of_9_8_2021_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_4ewNm1bD10K5QwII7IVr3g"
      decimals="-5"
      id="Narr_WzvF12MxeEWLvtEjoflPSQ"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">25000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <tcmd:LineOfCreditThresholdContingentIncreaseInBorrowingCapacity
      contextRef="Duration_9_8_2021_To_9_8_2021_JHuv2YIhr0-DMtiV3Vl0PA"
      decimals="-5"
      id="Narr_GPmLeAYrcEms1-b_teHyMg"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">25000000.0</tcmd:LineOfCreditThresholdContingentIncreaseInBorrowingCapacity>
    <tcmd:CreditAgreementTotalAggregatePrincipalAmount
      contextRef="As_Of_9_8_2021_8l4xBubq7Umd0Y3dMd0UnQ"
      decimals="-5"
      id="Narr_hVuNRnoTmUiZI5NLVDa12g"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">80000000.0</tcmd:CreditAgreementTotalAggregatePrincipalAmount>
    <us-gaap:LongTermDebt
      contextRef="As_Of_9_8_2021_us-gaap_CreditFacilityAxis_tcmd_TermLoanMember_oz1r9Y66CkacJQ3itM6kfg"
      decimals="-5"
      id="Narr_30fUBbh56US9cVVqA4K9SA"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">30000000.0</us-gaap:LongTermDebt>
    <us-gaap:LineOfCredit
      contextRef="As_Of_9_8_2021_8l4xBubq7Umd0Y3dMd0UnQ"
      decimals="-5"
      id="Narr_XjKzZlyiG0SrUs5GvqzYjQ"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">25000000.0</us-gaap:LineOfCredit>
    <us-gaap:DebtInstrumentFrequencyOfPeriodicPayment
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_CreditFacilityAxis_tcmd_TermLoanMember_3Cnmib--SkSEPm4Zq4wPzQ"
      id="Narr_UZcaDkKK7USC9Xd6VPHlCQ">quarterly</us-gaap:DebtInstrumentFrequencyOfPeriodicPayment>
    <us-gaap:DebtInstrumentPeriodicPayment
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_CreditFacilityAxis_tcmd_TermLoanMember_3Cnmib--SkSEPm4Zq4wPzQ"
      decimals="0"
      id="Narr_R8r4cMbVU0OXSOXwwCKBZQ"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">750000</us-gaap:DebtInstrumentPeriodicPayment>
    <tcmd:DebtInstrumentPaymentOfMandatoryPrincipalPrepayment
      contextRef="Duration_2_22_2022_To_2_22_2022_us-gaap_CreditFacilityAxis_tcmd_TermLoanMember_L6c2GMdVeE2wHtiYF_EBdA"
      decimals="-5"
      id="Narr_D0P_LUw5mUW896lmRHY1Cg"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">3000000.0</tcmd:DebtInstrumentPaymentOfMandatoryPrincipalPrepayment>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_VariableRateAxis_us-gaap_FederalFundsEffectiveSwapRateMember_Ox5KmpqBekOgFh1i9iNuQg"
      decimals="4"
      id="Narr_mCggTYTV8UG50izjW3K9IA"
      unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw">0.0050</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_VariableRateAxis_us-gaap_BaseRateMember_bmZqSyyD0UC5KiXp5eY0wA"
      decimals="2"
      id="Narr_hTlodoz290qvnbI9ri4yYw"
      unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw">0.01</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_VariableRateAxis_us-gaap_BaseRateMember_RkYOxE7JdkmHm__eg3-sdw"
      decimals="4"
      id="Narr_Luji0YDRa0ysnzSOBCtdKQ"
      unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw">0.0075</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_VariableRateAxis_us-gaap_BaseRateMember_cKhsiHfOCE28P3WddmWqow"
      decimals="4"
      id="Narr_HaTdGJPDxEmn0xZt0dc8lQ"
      unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw">0.0225</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_VariableRateAxis_us-gaap_LondonInterbankOfferedRateLIBORMember_qtvC3cCEtUGvoYG_aiVd5w"
      decimals="4"
      id="Narr_i6ElFAX4NEarHf3ENNnLjg"
      unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw">0.0175</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_VariableRateAxis_us-gaap_LondonInterbankOfferedRateLIBORMember_5Ok3Lj-bZEKdl_78m7_07g"
      decimals="4"
      id="Narr_qVFrKruZvUOR3Ayiml1XTQ"
      unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw">0.0325</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_VariableRateAxis_us-gaap_LondonInterbankOfferedRateLIBORMember_6BVYYrgoDEySTxjBn4sZ3A"
      decimals="4"
      id="Narr_4dL3AGIUN0enQOx6FN2BqQ"
      unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw">0.0350</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_us-gaap_VariableRateAxis_us-gaap_LondonInterbankOfferedRateLIBORMember_27-_EKPJYUWpaRUxj1OYBQ"
      decimals="4"
      id="Narr_-DFbbO36eU2HFv0LtQQPeg"
      unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw">0.0741</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_i_HrmJK0qEam7JhO2g89aw"
      decimals="5"
      id="Narr_1gvWaCed9UupNFd5tV3g6g"
      unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw">0.00300</us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage>
    <us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember_fVykz_MeNEanAhnkwaVQuw"
      decimals="5"
      id="Narr_D-q-VwK7GUC5am_CFeqxDw"
      unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw">0.00375</us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      id="Tb_alBEJbZ75EOvZHg3uj_7ZQ">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:66.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;(In&#160;thousands)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:29.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amount&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 21,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 24,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:27.35pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="As_Of_12_31_2022_us-gaap_CreditFacilityAxis_tcmd_TermLoanMember_VIrloQlsfEmn_JzIEt95jA"
      decimals="-3"
      id="Tc_BymTUb5oy0-uCHIqmwCyXQ_2_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">3000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="As_Of_12_31_2022_us-gaap_CreditFacilityAxis_tcmd_TermLoanMember_VIrloQlsfEmn_JzIEt95jA"
      decimals="-3"
      id="Tc_AlhHlEtlukGCXd9QPbZYyA_3_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">21000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebt
      contextRef="As_Of_12_31_2022_us-gaap_CreditFacilityAxis_tcmd_TermLoanMember_VIrloQlsfEmn_JzIEt95jA"
      decimals="-3"
      id="Tc_64pIVkF_ZUir3eUJCWrJAQ_4_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">24000000</us-gaap:LongTermDebt>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      id="Tb_5lNDgT0izkW_ca4IdFKK3Q">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Note&#160;12. &#160;Commitments and Contingencies&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:10pt;text-align:justify;text-indent:-10pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Lease Obligations&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;We lease property and equipment under operating leases, typically with terms greater than 12 months, and determine if an arrangement contains a lease at inception. In general, an arrangement contains a lease if there is an identified asset and we have the right to direct the use of and obtain substantially all of the economic benefit from the use of the identified asset. We record an operating lease liability at the present value of lease payments over the lease term on the commencement date. The related right of use (&#x201c;ROU&#x201d;) operating lease asset reflects rental escalation clauses, as well as renewal options and/or termination options. The exercise of lease renewal and/or termination options are at our discretion and are included in the determination of the lease term and lease payment obligations when it is deemed reasonably certain that the option will be exercised. When available, we use the rate implicit in the lease to discount lease payments to present value; however, certain leases do not provide a readily determinable implicit rate. Therefore, we must estimate our incremental borrowing rate to discount the lease payments based on information available at lease commencement.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;We classify our leases as buildings, vehicles or computer and office equipment and do not separate lease and nonlease components of contracts for any of the aforementioned classifications. In accordance with applicable guidance, we do not record leases with terms that are less than one year on the Consolidated Balance Sheets.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;None of our lease agreements contain material restrictive covenants or residual value guarantees.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Buildings&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;We lease certain office and warehouse space at various locations in the United States where we provide services. These leases are typically greater than one year with fixed, escalating rents over the noncancelable terms and, therefore, ROU operating lease assets and operating lease liabilities are recorded on the Consolidated Balance Sheets, with rent expense recognized on a straight-line basis over the term of the lease. The remaining lease terms vary from approximately &lt;span style="-sec-ix-hidden:Hidden_cPi9QUIkvEuGhENNTJkqkw;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;one&lt;/span&gt;&lt;/span&gt; to eight years as of December&#160;31,&#160;2022.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;We entered into a lease (&#x201c;initial lease&#x201d;) in October 2018, for approximately 80,000 square feet of office space for our new corporate headquarters in Minneapolis, Minnesota. In December 2018, we amended the initial lease to add approximately 29,000 square feet of additional office space, which is accounted for as a separate lease (&#x201c;second lease&#x201d;) in accordance with ASU No. 2016-02, &#x201c;Leases&#x201d; (Topic 842) (&#x201c;ASC 842&#x201d;). In December 2019, we further amended the lease which extended the expiration date of the initial lease, extended the expiration date of and added approximately 4,000 square feet to the second lease, as well as added approximately 37,000 square feet of additional office space, accounted for as a separate lease (&#x201c;third lease&#x201d;) in accordance with ASC 842. The portion of the space covered under the initial lease was placed in service in September 2019. This portion was recognized as an operating lease and included in the ROU operating lease assets and operating lease liabilities on the Consolidated Balance Sheets. The portion of the space covered under the second lease commenced in September 2020. Finally, the portion of the space covered under the third lease commenced in September 2021.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Vehicles&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;We lease vehicles for certain members of our field sales organization under a vehicle fleet program whereby the initial, noncancelable lease is for a term of 367 days, thus more than one year. Subsequent to the initial term, the lease becomes a month-to-month, cancelable lease. As of December&#160;31,&#160;2022, we had approximately two vehicles with agreements within the initial, noncancelable lease term that are recorded as ROU operating lease assets and operating lease liabilities. In addition to monthly rental fees specific to the vehicle, there are fixed monthly nonlease components that have been included in the ROU operating lease assets and operating lease liabilities. The nonlease components are not significant. &lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Computer and Office Equipment&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;We also have operating lease agreements for certain computer and office equipment. The remaining lease terms as of December 31, 2022, ranged from less than one year to approximately four years with fixed monthly payments that are included in the ROU operating lease assets and operating lease liabilities. The leases provide an option to purchase the related equipment at fair market value at the end of the lease. The leases will automatically renew as a month-to-month rental at the end of the lease if the equipment is not purchased or returned.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Lease Position, Undiscounted Cash Flow and Supplemental Information&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The table below presents information related to our ROU operating lease assets and operating lease liabilities that we have recorded:&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:54.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:54.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;(In&#160;thousands)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;At December&#160;31,&#160;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;At December&#160;31,&#160;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:54.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_tKPJpXeds0SiabhmYWAMEg;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Right of use operating lease assets&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 21,322&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 23,984&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:54.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:54.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Operating lease liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:54.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_tyE6-ij7k06Rv5IRQ6iD1Q;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Current&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,500&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,506&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:54.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_hRi5aCIDPEGUkAgK0iaGvw;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Non-current&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 20,866&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 23,354&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:54.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 23,366&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 25,860&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:54.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:54.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Operating leases: &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:54.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Weighted average remaining lease term&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;7.7 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;8.6 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:54.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Weighted average discount rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;4.2%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;4.2%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:54.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;&lt;span style="margin-left:0pt;vertical-align:top;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:54.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:43.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:54.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:20.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:20.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:54.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Supplemental cash flow information for our operating leases:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:54.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Cash paid for operating lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,575&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,379&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Non-cash right of use assets obtained in exchange for new operating lease obligations&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 49&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,920&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The table below reconciles the undiscounted cash flows under the operating lease liabilities recorded on the Consolidated Balance Sheets for the periods presented:&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:65.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:65.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;(In&#160;thousands)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,427&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,418&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,517&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,615&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,167&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:65.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,082&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:65.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Total minimum lease payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 27,226&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:65.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Less: Amount of lease payments representing interest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,860)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:65.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Present value of future minimum lease payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 23,366&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:65.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Less: Current obligations under operating lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,500)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:65.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Non-current obligations under operating lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 20,866&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;padding-left:10.1pt;text-indent:-10.1pt;background:#ffffff;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"&gt;Operating lease costs were $3.8 million, $3.6 million and $3.0 million for the years ended December&#160;31,&#160;2022, 2021 and 2020, respectively. &lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Major Vendors&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"&gt;We had purchases from one vendor that accounted for 18% of our total purchases for the year ended December 31, 2022 and purchases from two vendors that accounted for 32% of total purchases for the year ended December&#160;31,&#160;2021.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:10pt;text-align:justify;text-indent:-10pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Purchase Commitment&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;We issued purchase orders in 2022 totaling $33.5 million for goods that we expect to receive within the next year.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Retirement Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:14pt;padding-top:2pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"&gt;We maintain a 401(k) retirement plan for our employees to which eligible employees can contribute a percentage of their pre-tax compensation. We recorded an expense related to our discretionary contributions to the 401(k) plan of $1.5 million, $1.2 million and $0.3 million for the years ended December&#160;31,&#160;2022, 2021 and 2020, respectively.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:14pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Legal Proceedings&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt;"&gt;From time to time, we are subject to various claims and legal proceedings arising in the ordinary course of business. Regardless of outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;margin:14pt 0pt 0pt 0pt;"&gt;We and certain of our present or former officers have been sued in a purported securities class action lawsuit that was filed in the United States District Court for the District of Minnesota on September 29, 2020, and that is pending under the caption&lt;i style="font-style:italic;"&gt; Brian Mart v. Tactile Systems Technology, Inc., et al&lt;/i&gt;., File No. 0:20-cv-02074-NEB-BRT (the &#x201c;Mart Lawsuit&#x201d;).&#160;On April 19, 2021, the plaintiff filed an Amended Complaint against us and eight of our present and former officers and directors.&#160;Plaintiff seeks to represent a class consisting of investors who purchased our common stock in the market during the time period from May 7, 2018 through June 8, 2020 (&#x201c;alleged class period&#x201d;). The Amended Complaint alleges the following claims under the Securities Exchange Act of 1934, as amended (the &#x201c;Exchange Act&#x201d;): (1) that we and certain officer defendants made materially false or misleading public statements about our business, operational and compliance policies, and results during the alleged class period in violation of Section 10(b) of the Exchange Act; (2) that we and the individual defendants engaged in a scheme to defraud investors&#160;in order to allow the individual defendants to sell our stock in violation of Section 10(b) of the Exchange Act; (3) that the individual defendants engaged in improper insider trading of our stock in violation of Section 20A of the Exchange Act; and (4) that we and the individual defendants are liable under Section 20(a) of the Exchange Act because each defendant is a controlling person. On June 18, 2021, we and the individual defendants filed a motion to dismiss the Amended Complaint. On March 31, 2022, the court granted in part, and denied in part, the defendants&#x2019; motion to dismiss. All claims against three individual defendants were dismissed, and most claims against four other individual defendants were dismissed. On November 21, 2022, the company announced that it entered a Memorandum of Understanding to settle this matter. The Company does not expect to fund any portion of cash payments made in connection with the $5 million settlement amount. The settlement does not constitute an admission of liability or wrongdoing by the Company. The settlement is subject to the parties reaching agreement on various non-monetary terms and court approval of the final terms will be required.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:14pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:2pt 0pt 0pt 0pt;"&gt;On May 24, 2022, a stockholder derivative lawsuit was filed in the United States District Court for the District of Minnesota, purportedly on behalf of the Company against certain of our present and former officers and directors and the Company (as a nominal defendant), captioned &lt;i style="font-style:italic;"&gt;Jack Weaver v. Moen&lt;/i&gt;, et al., File No. 0:22-cv-01403-NEB-BRT. This complaint generally arises out of the same subject matter as the Mart Lawsuit and alleges the following claims under the Exchange Act and common law: (1) that the director defendants made materially false or misleading public statements in proxy statements in violation of Section 14(a) of the Exchange Act; (2) that the director defendants&#x2019; stock and option awards should be rescinded under Section 29(b) of the Exchange Act; (3) that the officer defendants&#x2019; employment contract compensation should be rescinded under Section 29(b) of the Exchange Act; (4) that certain officer defendants are liable for contribution arising out of any liability incurred in the Mart Lawsuit, under Sections 10(b) and 21D of the Exchange Act; (5) that the individual defendants breached their fiduciary duties; and (6) that the individual defendants were unjustly enriched. The lawsuit seeks unspecified damages. In August, the matter was transferred to the United States District Court for the District of Delaware by order granting the Parties Stipulation to Transfer. On February 10, 2023, we filed a motion to dismiss the action. We are defending the action as it proceeds.&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="As_Of_12_31_2022_srt_RangeAxis_srt_MinimumMember_EXKUiZxnk0qVwfOmUunwkw"
      id="Narr_jRgk1qfeQ0Sv3W8MmoDOeQ">P12M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="As_Of_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember_bxiv0zaNYUqU9S4A8vYbgw"
      id="Narr_Nj69dB6C2EmR-QQxxbHgcA">P8Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:AreaOfLand
      contextRef="As_Of_10_31_2018_us-gaap_PropertyPlantAndEquipmentByTypeAxis_tcmd_CorporateHeadQuarterInitialLeaseMember_iOfecFzhU0CEX9fKgtv8qA"
      decimals="INF"
      id="Narr_unPrKVzQaEGXd05QZac-nw"
      unitRef="Unit_Standard_sqft_pFxGS_NorEW8LBFrHYvkFg">80000</us-gaap:AreaOfLand>
    <us-gaap:AreaOfLand
      contextRef="As_Of_12_31_2018_us-gaap_PropertyPlantAndEquipmentByTypeAxis_tcmd_CorporateHeadQuarterSecondLeaseMember_kJI6F8P6zkKbLuYO9IJnVw"
      decimals="INF"
      id="Narr_nbMKMSi7e0uxPXdAMqryag"
      unitRef="Unit_Standard_sqft_pFxGS_NorEW8LBFrHYvkFg">29000</us-gaap:AreaOfLand>
    <tcmd:AdditionalOfficeSpaceAdded
      contextRef="As_Of_12_31_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_tcmd_CorporateHeadQuarterSecondLeaseMember_RayR2gEiIEWjwHNeeJouhw"
      decimals="INF"
      id="Narr_rlZD2aKuaUiZ9n2Mf4y5cg"
      unitRef="Unit_Standard_sqft_pFxGS_NorEW8LBFrHYvkFg">4000</tcmd:AdditionalOfficeSpaceAdded>
    <tcmd:AdditionalOfficeSpaceAdded
      contextRef="As_Of_12_31_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_tcmd_CorporateHeadQuarterThirdLeaseMember_i4Zbs1u8B0-YqSUpBTf3Hg"
      decimals="INF"
      id="Narr_JjAqB4Gvl0CIgyqKtj4DZw"
      unitRef="Unit_Standard_sqft_pFxGS_NorEW8LBFrHYvkFg">37000</tcmd:AdditionalOfficeSpaceAdded>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_VehiclesMember_WEhReoFIrk61ZFxikX2DoA"
      id="Narr_gQVCZNMoE0aBfgq6jEAgQQ">P367D</us-gaap:LesseeOperatingLeaseTermOfContract>
    <tcmd:NumberOfVehiclesWithAgreementsWithinInitialNoncancelableLeaseTerm
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_VehiclesMember_2k-hdZ3H2UWc6uo6P8NZ5Q"
      decimals="INF"
      id="Narr_zhIo04f7pU-7c0p1SOPCsw"
      unitRef="Unit_Standard_item_-67QV0kzWUGc8AbcCukKig">2</tcmd:NumberOfVehiclesWithAgreementsWithinInitialNoncancelableLeaseTerm>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="As_Of_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_pmPeDzOSDEq1hwWSnhZm1A"
      id="Narr_13w3rbWPXEK_RyP3XB47hw">P1Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="As_Of_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_CBz12HaJ3EelHnd3ISwWrQ"
      id="Narr_vICnHAeqTkiO3QYdFMF3xw">P4Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_lwkNBH8qPUKwpTFPfFM4eg"
      id="Narr_4NjBSxt8zUW9Bb6xd_XRZg">true</us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend>
    <tcmd:AssetsAndLiabilitiesLesseeTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      id="Tb_p4ja9FDTQE6Rf2kYG6jX4g">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:54.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:54.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;(In&#160;thousands)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;At December&#160;31,&#160;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;At December&#160;31,&#160;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:54.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_tKPJpXeds0SiabhmYWAMEg;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Right of use operating lease assets&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 21,322&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 23,984&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:54.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:54.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Operating lease liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:54.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_tyE6-ij7k06Rv5IRQ6iD1Q;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Current&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,500&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,506&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:54.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_hRi5aCIDPEGUkAgK0iaGvw;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Non-current&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 20,866&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 23,354&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:54.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 23,366&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 25,860&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:54.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:54.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Operating leases: &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:54.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Weighted average remaining lease term&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;7.7 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;8.6 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:54.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Weighted average discount rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;4.2%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;4.2%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:54.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;&lt;span style="margin-left:0pt;vertical-align:top;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:54.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:43.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:54.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:20.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:20.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:54.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Supplemental cash flow information for our operating leases:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:54.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Cash paid for operating lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,575&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,379&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Non-cash right of use assets obtained in exchange for new operating lease obligations&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 49&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,920&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</tcmd:AssetsAndLiabilitiesLesseeTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw"
      decimals="-3"
      id="Tc_F34676yGyUKJGOqRCcz4XA_2_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">21322000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q"
      decimals="-3"
      id="Tc_L-Xj8me3p0KhYXcVnzDy8Q_2_6"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">23984000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw"
      decimals="-3"
      id="Tc_nFmNc9cxa0-HysSIjaxzyQ_5_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">2500000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q"
      decimals="-3"
      id="Tc_lEsNrPrjcUyj-dlwcrKmsQ_5_6"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">2506000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw"
      decimals="-3"
      id="Tc_gf2pklp_eUO7m6r93eTIDA_6_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">20866000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q"
      decimals="-3"
      id="Tc_W0bZD-4EYU6a5M0kOKotww_6_6"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">23354000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw"
      decimals="-3"
      id="Tc_2xomv-OTdE-cDuwH2e4VLw_7_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">23366000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q"
      decimals="-3"
      id="Tc_O5LbvdvTSU6BGMthqvnfWA_7_6"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">25860000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw"
      id="Narr_jCJAHnLaY0GPh4dD4ENVGg">P7Y8M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q"
      id="Narr_KprKWDFrrEKC-Jogt6ixDQ">P8Y7M6D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw"
      decimals="4"
      id="Tc_zZV-FRdEGkezXTFrLir48A_11_3"
      unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw">0.042</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q"
      decimals="4"
      id="Tc_gkITc5pcREWfQR2qnJtsfQ_11_6"
      unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw">0.042</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeasePayments
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      decimals="-3"
      id="Tc_CUKslC1Hyk-1FEtFw2zmZg_16_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">3575000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g"
      decimals="-3"
      id="Tc_C80mneKtp0m6R7-K8-dEEQ_16_6"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">3379000</us-gaap:OperatingLeasePayments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      decimals="-3"
      id="Tc_uM7gcruW30q3o1ddtw4HIw_17_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">49000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g"
      decimals="-3"
      id="Tc_62fh4j5XcUyHibVYimWjjQ_17_6"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">6920000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:OperatingLeaseLeaseIncomeTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      id="Tb_CneW3X52h0qo036cWqbGFA">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:65.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:65.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;(In&#160;thousands)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,427&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,418&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,517&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,615&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,167&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:65.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,082&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:65.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Total minimum lease payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 27,226&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:65.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Less: Amount of lease payments representing interest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,860)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:65.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Present value of future minimum lease payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 23,366&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:65.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Less: Current obligations under operating lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,500)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:65.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Non-current obligations under operating lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 20,866&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;padding-left:10.1pt;text-indent:-10.1pt;background:#ffffff;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:OperatingLeaseLeaseIncomeTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw"
      decimals="-3"
      id="Tc_KHtCiozWPUmPoK1KGDHtmQ_2_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">3427000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw"
      decimals="-3"
      id="Tc_6URCSVAGYkiSlV5ALBIJ-g_3_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">3418000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw"
      decimals="-3"
      id="Tc_gUcuFBv0XUygyL58Se1YLg_4_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">3517000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw"
      decimals="-3"
      id="Tc_cW45Wn5Xx0eV5N6iUCajKQ_5_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">3615000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw"
      decimals="-3"
      id="Tc_jGqxvs_NnEOHS9qsqKfsCQ_6_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">3167000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw"
      decimals="-3"
      id="Tc_kissKi53pEiQRFCb5HWlUA_7_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">10082000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw"
      decimals="-3"
      id="Tc_eN96DebMZUiAPgD66COG1Q_8_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">27226000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw"
      decimals="-3"
      id="Tc_VYistoDRDE-tMyzyLpqU3Q_9_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">3860000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw"
      decimals="-3"
      id="Tc_EeW9W3T2F0C6YqQ6pIGT1Q_10_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">23366000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw"
      decimals="-3"
      id="Tc_1Vk9_Yv0LkydbXskqSqZMw_11_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">2500000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw"
      decimals="-3"
      id="Tc_KQFip3hKt0a8FUwCN2vutA_12_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">20866000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      decimals="-5"
      id="Narr_DhccbuYRp0GvY3zJudDPUA"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">3800000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g"
      decimals="-5"
      id="Narr_MMTlcCob7UGs0hAMHhz90A"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">3600000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA"
      decimals="-5"
      id="Narr_3hBhm67K0EyzBNcC5FN4LQ"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">3000000.0</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <tcmd:NumberOfVendors
      contextRef="As_Of_12_31_2022_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_tcmd_VendorOneMember_X8R2b_l6g02zwqRLkFf0tg"
      decimals="INF"
      id="Narr_c8gdSrOjsk2yBXbq31yXZA"
      unitRef="Unit_Standard_item_-67QV0kzWUGc8AbcCukKig">1</tcmd:NumberOfVendors>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_CostOfGoodsTotalMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_SupplierConcentrationRiskMember_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_tcmd_VendorOneMember_vviffeAE5EGD7qLxiUROxg"
      decimals="2"
      id="Narr_qn7zx24Uyk2J5WA3npfboQ"
      unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw">0.18</us-gaap:ConcentrationRiskPercentage1>
    <tcmd:NumberOfVendors
      contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q"
      decimals="INF"
      id="Narr_AocE7MUK-kuW7PPVNf57ng"
      unitRef="Unit_Standard_item_-67QV0kzWUGc8AbcCukKig">2</tcmd:NumberOfVendors>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_CostOfGoodsTotalMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_SupplierConcentrationRiskMember_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_tcmd_VendorTwoMember_ofzmjVvnsUW7aaWOzboUlQ"
      decimals="2"
      id="Narr_mUNml8ry7E23CGgthQ6svw"
      unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw">0.32</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:PurchaseObligationDueInNextTwelveMonths
      contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw"
      decimals="-5"
      id="Narr_abmb9jrOV06bJHeSp2ACiA"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">33500000</us-gaap:PurchaseObligationDueInNextTwelveMonths>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_RetirementPlanNameAxis_tcmd_DefinedContribution401kRetirementPlanMember_tDmbZG8x90OrgLeuanK9nw"
      decimals="-5"
      id="Narr_fyRtIjoyvku8NgrZW3NeCw"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">1500000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_RetirementPlanNameAxis_tcmd_DefinedContribution401kRetirementPlanMember_zWNpuLNXTEuhSfDngvS76w"
      decimals="-5"
      id="Narr_0e2TwmsD0UGiFyjGJ-x4ag"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">1200000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_RetirementPlanNameAxis_tcmd_DefinedContribution401kRetirementPlanMember_tGvCSx6Y1EuXw-i1zDT2EA"
      decimals="-5"
      id="Narr_G0tChw_FTESLmRqPe1AHrA"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">300000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <tcmd:LitigationSettlementAgreementAmount
      contextRef="As_Of_11_21_2022_m22jugRAaEmtVeWbOHw3dw"
      decimals="-6"
      id="Narr_zwVttwUn4EugNv5-_pApew"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">5000000</tcmd:LitigationSettlementAgreementAmount>
    <us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      id="Tb_ULz7QtaTRk2fGmIkgJ4MbA">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Note&#160;13. &#160;Stockholders' Equity&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"&gt;We completed an initial public offering of our common stock on August 2, 2016, in which we sold 4,120,000 shares of our common stock at a public offering price of $10.00 per share. Immediately prior to the completion of the initial public offering, all then-outstanding shares of our Series A and Series B preferred stock &lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;were converted into 5,924,453 shares of our common stock. Our Series A preferred stock converted to common stock at a ratio of 1-for-1.03 and our Series B preferred stock converted to common stock at a ratio of 1-for-1. In addition, immediately prior to the completion of the initial public offering, we issued 2,354,323 additional shares of our common stock that our Series A and Series B preferred stockholders were entitled to receive in connection with the conversion of the preferred stock, and we issued 956,842 shares of our common stock to pay accrued dividends on our Series B preferred stock. We also paid $8.2 million in cumulative accrued dividends to our Series A convertible preferred stockholders in connection with the initial public offering, including $0.1 million of dividends paid to the holders of the common restricted shares.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:10.1pt;text-align:justify;text-indent:-10.1pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;Our 2016 Equity Incentive Plan (the &#x201c;2016 Plan&#x201d;) authorizes us to grant stock options, stock appreciation rights, restricted stock, stock units and other stock-based awards to employees, non-employee directors and certain consultants and advisors. There were up to 4,800,000 shares of our common stock initially reserved for issuance pursuant to the 2016 Plan. The 2016 Plan provides that the number of shares reserved and available for issuance under the 2016 Plan will automatically increase annually on January 1 of each calendar year, commencing in 2017 and ending on and including January 1, 2026, by an amount equal to the lesser of: (a) 5% of the number of common shares of stock outstanding as of December 31 of the immediately preceding calendar year, or (b) 2,500,000 shares; provided, however, that our Board of Directors may determine that any annual increase be a lesser number. In addition, all awards granted under our 2007 Omnibus Stock Plan and our 2003 Stock Option Plan that were outstanding when the 2016 Plan became effective and that are forfeited, expire, are cancelled, are settled for cash or otherwise not issued, will become available for issuance under the 2016 Plan. Pursuant to the automatic increase feature of the 2016 Plan, 972,591 shares were added as available for issuance thereunder on January 1, 2021. Our Board of Directors exercised its prerogative to forego the automatic increase on each of January 1, 2023 and 2022.&lt;span style="font-size:12pt;"&gt; &lt;/span&gt;As of December&#160;31,&#160;2022, 5,957,683 shares were available for future grant pursuant to the 2016 Plan.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;Upon adoption and approval of the 2016 Plan, all of our previous equity incentive compensation plans were terminated. However, existing awards under those plans continue to vest in accordance with the original vesting schedules and will expire at the end of their original terms.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;"&gt;In the second fiscal quarter of 2020, our Board of Directors appointed a new President and Chief Executive Officer (&#x201c;CEO&#x201d;), effective June 8, 2020. In conjunction with the acceptance of the written offer, our CEO received both restricted stock units and stock option awards under our 2016 Plan during the third fiscal quarter of 2020 and the stock options have a seven year term. A portion of the awards vested on June 30, 2021, with the remaining portion of the awards vesting over a period of three years from the date of grant. Further, the stock options were valued at the date of grant using the Monte Carlo Simulation model due to a market condition that required that our stock price exceed&#160;$40.15&#160;for&#160;&lt;span style="-sec-ix-hidden:Hidden_94egicmKoESPdhUuU5X_1w;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;20&lt;/span&gt;&lt;/span&gt;&#160;consecutive trading days during the term of the option in order to vest. This condition was satisfied in the first quarter of 2021.&#160;The following table sets forth the estimated fair value of these stock options granted and the assumptions on which the fair value was determined:&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:62.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:33.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:33.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Expected term&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:33.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;4.5 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:33.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;45.39%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:33.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;0.4%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:33.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;0%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Fair value on the date of grant&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:33.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;$13.60 - $14.70&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;"&gt;We recorded total stock-based compensation expense of $9.6 million, $10.2 million and $10.7 million for the years ended December&#160;31,&#160;2022, 2021 and 2020, respectively. This expense was allocated as follows:&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:59.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:40.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:40.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;(In&#160;thousands)&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Cost of revenue&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 367&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 433&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 539&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Sales and marketing expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,060&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,069&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,058&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Research and development expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 226&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 314&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 360&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Reimbursement, general and administrative expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,947&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,357&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,732&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total stock-based compensation expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,600&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,173&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,689&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Stock Options&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;padding-top:2pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"&gt;&lt;span style="font-size:10pt;"&gt;Stock options issued to participants other than non-employees typically vest over &lt;/span&gt;&lt;span style="-sec-ix-hidden:Hidden_6Mhakd_sLkqC71m6G0M6Og;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;three&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; or &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;four years&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; and typically have a contractual term of &lt;/span&gt;&lt;span style="-sec-ix-hidden:Hidden_tp1Se7X6AEitbPWWRbR6bw;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;seven&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; or &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;ten years&lt;/span&gt;&lt;span style="font-size:10pt;"&gt;. Stock-based compensation expense included in our Consolidated Statements of Operations for stock options was &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;$2.5&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; million, &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;$4.3&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; million and &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;$4.0&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; million for the years ended December&#160;31,&#160;2022, 2021 and 2020, respectively. The total grant date fair value of options vested during the year was &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;$3.3&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; million, &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;$4.3&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; million and &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;$3.0&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; million for the years ended December&#160;31,&#160;2022, 2021 and 2020, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;padding-bottom:14pt;text-align:justify;text-indent:36pt;margin:14pt 0pt 0pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt;At December&#160;31,&#160;2022, there was approximately &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;$1.6&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; million of total unrecognized pre-tax stock option expense under our equity compensation plans, which is expected to be recognized on a straight-line basis over a weighted-average period of&lt;/span&gt; &lt;span style="font-size:10pt;"&gt;1.2&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; years.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"&gt;The fair value of each option grant is estimated on the date of grant using the Black-Scholes option pricing model, other than options that have a market-based vesting condition, which are valued using the Monte Carlo Simulation model. Annually, we make predictive assumptions regarding future stock price volatility, dividend yield, expected term and forfeiture rate. The dividend yield assumption is based on expected annual dividend yield on the grant date. To date, no dividend on common stock has been paid by us. Expected volatility for grants issued in and prior to the first fiscal quarter of 2021 was estimated using the average historical volatility of public companies of similar size and industry over a similar period as the expected term assumption used for our options. Beginning in the second fiscal quarter of 2021, we had sufficient historical data to transition to utilizing our average historical volatility over a similar period as the expected term assumption used for our options as the expected volatility. The risk-free interest rate is based on the yields of U.S. Treasury securities with maturities similar to the expected term of the options for each option group. We use the &#x201c;simplified method&#x201d; to determine the expected term of the stock option grants. We utilize this method because we do not have sufficient public company exercise data in which to make a reasonable estimate. &lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;"&gt;The following table sets forth the estimated fair values of our stock options granted in each of the years indicated, and the assumptions on which the fair values were determined:&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:35.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:35.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:35.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Expected term&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_EUn6f84eb0OJm-52SjcRtw;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;4.5&lt;/span&gt;&lt;/span&gt; years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_M9XtAoRCQE23lB3X4M3v9w;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;4.5&lt;/span&gt;&lt;/span&gt; years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_iCRDlIEFVkGCl5KX7TVfHQ;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;4.5&lt;/span&gt;&lt;/span&gt; years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:35.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt;59.2%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt;45.0 - 52.3%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt;44.1 - 46.4%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:35.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt;4.3%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt;0.6 - 1.1%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt;0.2 - 0.9%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:35.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt;0%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt;0%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt;0%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:35.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Fair value on the date of grant&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt;$ 8.11&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt;$13.04 - $22.90&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt;$13.45 - $18.64&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;"&gt;Our stock option activity for the three years ended December&#160;31,&#160;2022, 2021 and 2020, was as follows:&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.11848831%;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted-&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted-&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Aggregate&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Options&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&#160;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Intrinsic&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;(In&#160;thousands except options and per share data)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Outstanding&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Per Share &lt;/b&gt;&lt;sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Contractual Life&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Value &lt;/b&gt;&lt;sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;"&gt;(2)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Balance at December 31, 2019&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 866,955&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 28.76&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt;6.3 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 33,957&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 378,695&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 44.84&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (147,741)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 7.24&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 6,540&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (54,824)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 50.25&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;"&gt;Cancelled/Expired&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (3,376)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 63.61&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Balance at December 31, 2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 1,039,709&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 36.43&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt;5.6 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 13,381&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 188,748&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 49.33&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (175,516)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 22.65&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 4,901&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (92,773)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 49.77&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;"&gt;Cancelled/Expired&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (44,944)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 57.78&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Balance at December 31, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 915,224&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 39.33&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt;5.0 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 2,068&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 47,280&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 6.17&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (90,878)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 1.68&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 916&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (92,981)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 36.28&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;"&gt;Cancelled/Expired&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (163,338)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 37.65&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Balance at December 31, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 615,307&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 43.25&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt;4.7 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 164&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Options exercisable at December&#160;31,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 435,363&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 43.83&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt;4.5 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 84&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;padding-bottom:6pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;div style="margin-top:0pt;"/&gt;&lt;table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"&gt;&lt;tr&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-decoration-line:none;text-transform:none;vertical-align:baseline;white-space:nowrap;width:18pt;padding:0pt 0pt 6pt 0pt;"&gt;(1)&lt;/td&gt;&lt;td style="padding:0pt 0pt 6pt 0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-style:normal;font-weight:normal;"&gt;The exercise price of each option granted during the periods shown was equal to the market price of the underlying stock on the date of grant.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"&gt;&lt;tr&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-decoration-line:none;text-transform:none;vertical-align:baseline;white-space:nowrap;width:18pt;padding:0pt 0pt 12pt 0pt;"&gt;(2)&lt;/td&gt;&lt;td style="padding:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-style:normal;font-weight:normal;"&gt;The aggregate intrinsic value of options exercised represents the difference between the exercise price of the option and the closing stock price of our common stock on the date of exercise. The aggregate intrinsic value of options outstanding represents the difference between the exercise price of the option and the closing stock price of our common stock on the last trading day of the period.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"&gt;Options exercisable of 517,316 at December&#160;31,&#160;2021, and 489,866 at December&#160;31,&#160;2020 had weighted average exercise prices of $32.60 and $25.39, respectively.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;"&gt;The following summarizes additional information about our stock options:&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:61.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:35.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:35.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number of:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Non-vested options, beginning of the year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 397,908&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 549,843&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Non-vested options, end of the year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 179,944&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 397,908&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Vested options, end of the year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 435,363&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 517,316&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:61.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:35.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:35.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted-average grant date fair value of: &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Non-vested options, beginning of the year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 18.02&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 18.03&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Non-vested options, end of the year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 16.24&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 18.02&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Vested options, end of the year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 17.53&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 13.27&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Forfeited options, during the year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 14.73&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 19.26&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;padding-bottom:12pt;background:#ffffff;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Time-Based Restricted Stock Unit&lt;/span&gt;&lt;i style="font-style:italic;"&gt;s&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt;We have granted time-based restricted stock units to certain participants under the 2016 Plan that are stock-settled with common shares. Time-based restricted stock units granted under the 2016 Plan vest over &lt;/span&gt;&lt;span style="-sec-ix-hidden:Hidden_fHxG8ZvlB0ieDTwHUV85QA;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;one&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; to &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;three years&lt;/span&gt;&lt;span style="font-size:10pt;"&gt;. Stock-based compensation expense included in our Consolidated Statements of Operations for time-based restricted stock units was &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;$5.8&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; million, &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;$4.9&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; million and &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;$5.2&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; million for the years ended December&#160;31,&#160;2022, 2021 and 2020, respectively. As of December&#160;31,&#160;2022, there was approximately &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;$7.8&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; million of total unrecognized pre-tax compensation expense related to outstanding time-based restricted stock units that is expected to be recognized over a weighted-average period of &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;1.9&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; years. &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Our time-based restricted stock unit activity for the years ended December&#160;31,&#160;2022, 2021 and 2020 was as follows:&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:46.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted-&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:46.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average Grant&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Aggregate&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:46.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Units&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Date Fair Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Intrinsic&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;(In&#160;thousands except unit and per unit data)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Outstanding&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Per Unit&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-size:10pt;font-weight:bold;"&gt;Value &lt;/b&gt;&lt;sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:46.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Balance at December 31, 2019&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 171,687&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 43.74&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 11,591&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:46.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 175,582&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 46.42&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:46.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;"&gt;Modification&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 2,288&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 21.85&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:46.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;"&gt;Vested&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (118,014)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 37.57&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:46.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;"&gt;Cancelled&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (20,074)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 53.03&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:46.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Balance at December 31, 2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 211,469&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 48.29&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 9,503&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:46.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 189,762&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 40.31&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:46.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;"&gt;Vested&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (106,521)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 47.43&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:46.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;"&gt;Cancelled&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (35,563)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 51.76&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:46.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Balance at December 31, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 259,147&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 42.32&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 4,932&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:46.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 539,525&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 15.03&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:46.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;"&gt;Vested&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (123,528)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 43.20&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:46.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;"&gt;Cancelled&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (84,602)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 26.91&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:46.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Balance at December 31, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 590,542&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 19.42&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 6,779&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;padding-bottom:6pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;div style="margin-top:0pt;"/&gt;&lt;table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"&gt;&lt;tr&gt;&lt;td style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 6pt 0pt;"&gt;(1)&lt;/td&gt;&lt;td style="padding:0pt 0pt 6pt 0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-style:normal;font-weight:normal;"&gt;The aggregate intrinsic value of time-based restricted stock units outstanding was based on our closing stock price on the last trading day of the period.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Performance-Based Restricted Stock Units&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;"&gt;We have granted performance-based restricted stock units (&#x201c;PSUs&#x201d;) to certain participants under the 2016 Plan. These PSUs have both performance-based and time-based vesting features. The PSUs granted in 2018 were earned to the extent performance goals based on revenue and adjusted EBITDA were achieved in 2019. The PSUs granted in 2019 were earned to the extent performance goals based on revenue and adjusted EBITDA were achieved in 2020. The PSUs granted in 2020 were earned to the extent performance goals based on revenue and adjusted EBITDA were achieved in 2021. The PSUs granted in 2021 will be earned if and to the extent performance goals based on revenue and adjusted EBITDA are achieved in 2022. The PSUs granted in 2022 will be earned if and to the extent performance goals based on revenue change and adjusted EBITDA margin are achieved in 2023. The number of PSUs earned will depend on the level at which the performance targets are achieved and can range from 50% of target if threshold performance is achieved and up to 150% of target if maximum performance is achieved. &lt;span style="-sec-ix-hidden:Hidden_sHnOWzszGUy7ZkN0NmbHuA;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;One-third&lt;/span&gt;&lt;/span&gt; of the earned PSUs will vest on the date the Compensation and Organization Committee certifies the number of PSUs earned, and the remaining &lt;span style="-sec-ix-hidden:Hidden_v4hPxGJ7JkKjemco7Ewk7A;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;two-thirds&lt;/span&gt;&lt;/span&gt; of the earned PSUs will vest on the first anniversary of that certification date. All earned and vested PSUs will be settled in shares of common stock. &lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;Stock-based compensation expense included in our Consolidated Statements of Operations for PSUs was $0.5 million, $0.2 million, and $0.5 million for the years ended December&#160;31,&#160;2022, 2021 and 2020, respectively. The stock-based compensation expense for the year ended December 31, 2022 reflects an expense of $0.6 million related to the PSUs granted in 2022. The stock-based compensation expense for the year ended December 31, 2021 reflects a $0.5&#160;million benefit due to a change in the estimated payout associated with PSUs granted in 2020 being below the minimum performance target threshold level, as defined, &lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;partially offset by an expense of $0.7 million related to the PSUs granted in 2018 and 2021. As of December&#160;31,&#160;2022, there was approximately $1.4 million of total unrecognized pre-tax compensation expense related to outstanding PSUs that is expected to be recognized over a weighted average period of 2.0 years. &lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;"&gt;Our performance-based restricted stock unit activity at the estimated payout of 100% of target for the years ended December&#160;31,&#160;2022, 2021 and 2020, was as follows:&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:44.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Performance-&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted-&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:44.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Based&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average Grant&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Aggregate&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:44.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Units&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Date Fair Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Intrinsic&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;(In&#160;thousands except unit and per unit data)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Outstanding&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Per Unit&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-size:10pt;font-weight:bold;"&gt;Value &lt;/b&gt;&lt;sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:44.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Balance at December 31, 2019&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 91,151&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 44.63&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 6,154&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:44.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 31,731&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 50.41&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:44.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;"&gt;Vested&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (26,204)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 33.58&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:44.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;"&gt;Cancelled&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (17,375)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 52.87&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:44.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Balance at December 31, 2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 79,303&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 47.83&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 3,564&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:44.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 39,419&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 51.82&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:44.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;"&gt;Vested&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (34,159)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 33.98&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:44.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;"&gt;Cancelled&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (30,246)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 64.39&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:44.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Balance at December 31, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 54,317&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 50.22&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 1,034&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:44.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 131,710&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 18.54&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:44.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;"&gt;Vested&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (4,407)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 12.31&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:44.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;"&gt;Cancelled&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (26,002)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 42.53&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:44.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Balance at December 31, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 155,618&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 25.05&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 1,786&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;padding-bottom:6pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;div style="margin-top:0pt;"/&gt;&lt;table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"&gt;&lt;tr&gt;&lt;td style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 12pt 0pt;"&gt;(1)&lt;/td&gt;&lt;td style="padding:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-style:normal;font-weight:normal;"&gt;The aggregate intrinsic value of performance-based restricted stock units outstanding was based on our closing stock price on the last trading day of the period&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;"&gt;Our employee stock purchase plan (&#x201c;ESPP&#x201d;), which was approved by our Board of Directors on April 27, 2016, and by our stockholders on June 20, 2016, allows participating employees to purchase shares of our common stock at a discount through payroll deductions. The ESPP is available to all of our employees and employees of participating subsidiaries. Participating employees may purchase common stock, on a voluntary after-tax basis, at a price equal to 85% of the lower of the closing market price per share of our common stock on the first or last trading day of each stock purchase period. The ESPP provides for six-month purchase periods, beginning on May 16 and November 16 of each calendar year. &lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;A total of 1,600,000 shares of common stock was initially reserved for issuance under the ESPP. This share reserve will automatically be supplemented each January 1, commencing in 2017 and ending on and including January 1, 2026, by an amount equal to the least of (a) 1% of the shares of our common stock outstanding on the immediately preceding December 31, (b) 500,000 shares or (c) such lesser amount as our Board of Directors may determine. Pursuant to the automatic increase feature of the ESPP, 194,518 shares were added as available for issuance thereunder on January 1, 2021. Our Board of Directors exercised its prerogative to forego the automatic increase on each of January 1, 2023 and 2022. As of December&#160;31,&#160;2022, 1,559,151 shares were available for future issuance under the ESPP. We recognized $0.8 million, $0.8 million and $0.9 million in stock-based compensation expense related to the ESPP for the years ended December&#160;31,&#160;2022, 2021 and 2020, respectively.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_8_2_2016_To_8_2_2016_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_oNbQsAMXk0uBUzklZFhmAA"
      decimals="INF"
      id="Narr_u7faJlJM1kyVNisuTf4SRg"
      unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ">4120000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_8_2_2016_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_G1Q8otm7u0SlPI0I3gLpyg"
      decimals="2"
      id="Narr_aaptrjx_KEKSoYeuEb5S6A"
      unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q">10.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="Duration_8_2_2016_To_8_2_2016_jh5ft8WN0USibAdtcwGHiA"
      decimals="INF"
      id="Narr_cLj8DQ-_Q0u3sGxxrBBn_g"
      unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ">5924453</us-gaap:ConversionOfStockSharesConverted1>
    <tcmd:PreferredStockToCommonStockConversionRatio
      contextRef="Duration_8_2_2016_To_8_2_2016_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_QQrwNskzWkG7CPUnrW9tVw"
      decimals="2"
      id="Narr_3NtKsXzMI0iCFF8TEb-vSQ"
      unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw">1.03</tcmd:PreferredStockToCommonStockConversionRatio>
    <tcmd:PreferredStockToCommonStockConversionRatio
      contextRef="Duration_8_2_2016_To_8_2_2016_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_F3xqjLu7uEyeSRqBJT0RuA"
      decimals="0"
      id="Narr_0WNP4T7GN0yEaXxT9IUzQQ"
      unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw">1</tcmd:PreferredStockToCommonStockConversionRatio>
    <tcmd:StockIssuedDuringPeriodPriorToCompletionOfInitialOfferingSharesNewIssues
      contextRef="Duration_8_2_2016_To_8_2_2016_jh5ft8WN0USibAdtcwGHiA"
      decimals="INF"
      id="Narr_wquyIq56WkGeb6niwD3gTg"
      unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ">2354323</tcmd:StockIssuedDuringPeriodPriorToCompletionOfInitialOfferingSharesNewIssues>
    <tcmd:StockIssuedDuringPeriodRequiredToFundStockDividendsSharesNewIssues
      contextRef="Duration_8_2_2016_To_8_2_2016_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_F3xqjLu7uEyeSRqBJT0RuA"
      decimals="INF"
      id="Narr_WA07ZZuMvkOUosVjEXRWqQ"
      unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ">956842</tcmd:StockIssuedDuringPeriodRequiredToFundStockDividendsSharesNewIssues>
    <tcmd:AccruedCumulativeDividends
      contextRef="As_Of_8_2_2016_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_Y9mdYePcDUyiYIOsBHbTDA"
      decimals="-5"
      id="Narr_uMVrCu1gNEOBHM6luYq4ng"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">8200000</tcmd:AccruedCumulativeDividends>
    <us-gaap:PaymentsOfOrdinaryDividends
      contextRef="Duration_8_2_2016_To_8_2_2016_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_QQrwNskzWkG7CPUnrW9tVw"
      decimals="-5"
      id="Narr_q2WD1Y_EvEK7OubpJAI91Q"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">100000</us-gaap:PaymentsOfOrdinaryDividends>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="As_Of_12_31_2022_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_MJZ8uZEAPEmYMAtcEg9uBg"
      decimals="INF"
      id="Narr_tTS2gKsFUk6HfdkVD9JTDg"
      unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ">4800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <tcmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticAnnualIncreaseInSharesReservedAndAvailableForIssuancePercentage
      contextRef="As_Of_12_31_2022_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_MJZ8uZEAPEmYMAtcEg9uBg"
      decimals="2"
      id="Narr_pZ8rpbVJD0KsxNqxQZl6PQ"
      unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw">0.05</tcmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticAnnualIncreaseInSharesReservedAndAvailableForIssuancePercentage>
    <tcmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticAnnualIncreaseInSharesReservedAndAvailableForIssuanceNumber
      contextRef="As_Of_12_31_2022_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_MJZ8uZEAPEmYMAtcEg9uBg"
      decimals="INF"
      id="Narr_0ZFjnNCKLkG8hC0oqfwShw"
      unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ">2500000</tcmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticAnnualIncreaseInSharesReservedAndAvailableForIssuanceNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="Duration_1_1_2021_To_1_1_2021_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_GIA9oCLf2kOobzBosxqDOQ"
      decimals="INF"
      id="Narr_1_N0SY5R70ClfjMIogBHoA"
      unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ">972591</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_12_31_2022_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_MJZ8uZEAPEmYMAtcEg9uBg"
      decimals="INF"
      id="Narr_LbHRIzgqnkGYK9L8uMdW5A"
      unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ">5957683</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <tcmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermOfPeriod
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_Apyhw0rpjEqZ3vFtmoPsAg"
      id="Narr_-XTtxw9xGEap-7kt2f_0zQ">P7Y</tcmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermOfPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_Apyhw0rpjEqZ3vFtmoPsAg"
      id="Narr_kylCa8U3lUO8aJd6W5Cy_Q">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharePrice
      contextRef="As_Of_12_31_2022_srt_RangeAxis_srt_MinimumMember_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_MEZgTABuGkCMjTedZP40gQ"
      decimals="2"
      id="Narr_yzWuKlVPykOxMAfjQ7KyGw"
      unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q">40.15</us-gaap:SharePrice>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      id="Group_1RVy9P0P4UCs4cF19rpDLw">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:62.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:33.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:33.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Expected term&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:33.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;4.5 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:33.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;45.39%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:33.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;0.4%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:33.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;0%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Fair value on the date of grant&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:33.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;$13.60 - $14.70&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:35.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:35.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:35.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Expected term&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_EUn6f84eb0OJm-52SjcRtw;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;4.5&lt;/span&gt;&lt;/span&gt; years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_M9XtAoRCQE23lB3X4M3v9w;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;4.5&lt;/span&gt;&lt;/span&gt; years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_iCRDlIEFVkGCl5KX7TVfHQ;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;4.5&lt;/span&gt;&lt;/span&gt; years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:35.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt;59.2%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt;45.0 - 52.3%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt;44.1 - 46.4%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:35.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt;4.3%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt;0.6 - 1.1%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt;0.2 - 0.9%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:35.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt;0%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt;0%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt;0%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:35.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Fair value on the date of grant&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt;$ 8.11&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt;$13.04 - $22.90&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt;$13.45 - $18.64&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA"
      id="Narr_pIMx6D2N4k6Y7IdL9DkQmg">P4Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA"
      decimals="4"
      id="Tc_7q59cLAJHEexrOt5Nl9ODA_3_2"
      unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw">0.4539</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA"
      decimals="3"
      id="Tc_RhiTJxkyjUi03zsdqESa-Q_4_2"
      unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw">0.004</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA"
      decimals="2"
      id="Tc_D_hko44xRUeHi39icCsy0A_5_2"
      unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MinimumMember_1ONqRYxs-E23uhkk4rcXew"
      decimals="2"
      id="Narr_bkROy5Rq2UeBlINqKAT3eg"
      unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q">13.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MaximumMember_AgQnIK2l2UG-kwV420MM5g"
      decimals="2"
      id="Narr_B-ISxZ57fEaTaLbgzegYPg"
      unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q">14.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      decimals="-5"
      id="Narr_7FXgdJSPRky2_iPQ_xiRlw"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">9600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g"
      decimals="-5"
      id="Narr_5pTaR6luyk-VX97ph0DIaA"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">10200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA"
      decimals="-5"
      id="Narr_pvGmFWMHkEGOCAfRHkRNCg"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">10700000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      id="Tb_kG_p8vFCsUibDMS9BZ2F6g">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:59.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:40.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:40.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;(In&#160;thousands)&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Cost of revenue&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 367&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 433&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 539&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Sales and marketing expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,060&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,069&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,058&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Research and development expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 226&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 314&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 360&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Reimbursement, general and administrative expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,947&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,357&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,732&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total stock-based compensation expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,600&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,173&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,689&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_1cM49KVdP0WP3FTRdFVJvA"
      decimals="-3"
      id="Tc_R1RFe4XR8ka8fVe5FPZTJw_4_2"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">367000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_-Mhsa97jY0mecFzNVd7m8w"
      decimals="-3"
      id="Tc_Q_L6ltVNTkKvOuWVJLLdZQ_4_5"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">433000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_jRQ3JtT1NE2Wt3xFenHFEw"
      decimals="-3"
      id="Tc_spwdzBxAcESo4bM3ZRwQxA_4_8"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">539000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingAndMarketingExpenseMember_6DUS8nZX1k2uITtnX1jELw"
      decimals="-3"
      id="Tc_QXG0Z6YnB0qnyY8-fBEStA_5_2"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">4060000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingAndMarketingExpenseMember_tE0YJWqzRkusl6_G8TxGpA"
      decimals="-3"
      id="Tc_HUAkZUlcCkiJoYpIv7D-3Q_5_5"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">4069000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingAndMarketingExpenseMember_LOcVV8870UGUDxZpsZpW1A"
      decimals="-3"
      id="Tc_q1-WPksIK020NJFhwlKx0Q_5_8"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">5058000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_WkeJd_L3IEm8ahIsJkn_Ww"
      decimals="-3"
      id="Tc_wLGl0GCKlkWjzAARG1jW3Q_6_2"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">226000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_NHelbVJut0SpZ1MaGzM82w"
      decimals="-3"
      id="Tc_CCavWpq02E-30fkF5N7Q3g_6_5"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">314000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_2oRfq2ewaUy6AGWg2Xby5A"
      decimals="-3"
      id="Tc_BDlZ3qur0U27QOCs2boQ9g_6_8"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">360000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_Ny2qblOYAkWwzAuljmv4Ow"
      decimals="-3"
      id="Tc_z3FjtynpmEivCYRov-KRRw_7_2"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">4947000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_oF6quC9QMU-Gu_UPthtpzw"
      decimals="-3"
      id="Tc_JM77SBo1O0yAAWFEJjN1EQ_7_5"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">5357000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_DbypvZkVpEePjQqYGvgkEw"
      decimals="-3"
      id="Tc_Z2vpad-A8U6oX-Vh-a0ujA_7_8"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">4732000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      decimals="-3"
      id="Tc_k_b8nPvoAkqplOlN7-ZLKg_8_2"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">9600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g"
      decimals="-3"
      id="Tc_RBYLXDLlWEOwHKPxaMXYew_8_5"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">10173000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA"
      decimals="-3"
      id="Tc_1SVbpxSV902Y5jjE8Km_FQ_8_8"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">10689000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_x68hCF8ixkS5q2MJuoiIYA"
      id="Narr_0n_-lBqI6UCK6gT1JTa8lg">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_x68hCF8ixkS5q2MJuoiIYA"
      id="Narr_lSyz3boeYUaSjAabBuwrJA">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_6-UgFP9YHkKs37vGGIhEVw"
      decimals="-5"
      id="Narr_YmiZ_YiIZEaTxr00h-5t7A"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">2500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_SKlrM8781Eet0zFbC3ewTw"
      decimals="-5"
      id="Narr_UuHTfh_PLkSgKw3GJBrCeg"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">4300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_qOmCDKQT9Eyfuidf3pzRYg"
      decimals="-5"
      id="Narr_mPSnttvCjEifcJ5B8wl3iw"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">4000000.0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_6-UgFP9YHkKs37vGGIhEVw"
      decimals="-5"
      id="Narr_GW3JggF9Gka17Evn73B1EQ"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">3300000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_SKlrM8781Eet0zFbC3ewTw"
      decimals="-5"
      id="Narr_Va2j3HuvO0-7ka01jvC9xQ"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">4300000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_qOmCDKQT9Eyfuidf3pzRYg"
      decimals="-5"
      id="Narr_b5f2_chNgkySWrsFyBupUQ"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">3000000.0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_Un8xxO7K-UGnIxffkFMjsw"
      decimals="-5"
      id="Narr_VkyyfMMwTE20B7zW_urZ_w"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">1600000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_6-UgFP9YHkKs37vGGIhEVw"
      id="Narr_890jM8xWqEqfqoVcKJiOyw">P1Y2M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:DividendsCommonStock
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      decimals="-5"
      id="Narr_Hhlbx_I0ykmp1Esb65eRMw"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">0</us-gaap:DividendsCommonStock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_L2H-B4harkuWLN7SUIOPRQ"
      decimals="3"
      id="Narr_ilb9DSPIK0e-sSwC7HLnvw"
      unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw">0.592</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_N_-EN94zSkyi4738ywQnkQ"
      decimals="3"
      id="Narr_VjvhvHeVWUqD38PlYOrmpg"
      unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw">0.450</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_cTbUJaM5EEi7_dTn33kCIQ"
      decimals="3"
      id="Narr_wB3sIVnoSkO6-_-Bvl-4tg"
      unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw">0.523</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_KSWzHsfkUUCC4ceQE_HELQ"
      decimals="3"
      id="Narr_Wg2ADXFMgE-7lwN5s0DX0w"
      unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw">0.441</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_X4ApOCKa20aLE0iARpjyBw"
      decimals="3"
      id="Narr_XZnyQUZQ90uSienv4M2iEQ"
      unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw">0.464</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_L2H-B4harkuWLN7SUIOPRQ"
      decimals="3"
      id="Narr_2dIp_fcbe0WcGWI0lwDaNQ"
      unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw">0.043</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_N_-EN94zSkyi4738ywQnkQ"
      decimals="3"
      id="Narr_4YyRBmO3CEO0TC7ld8zi5Q"
      unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw">0.006</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_cTbUJaM5EEi7_dTn33kCIQ"
      decimals="3"
      id="Narr_9jeHk0xHZ0qGHlZdnqsa5w"
      unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw">0.011</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_KSWzHsfkUUCC4ceQE_HELQ"
      decimals="3"
      id="Narr_-gCibK86s0KF46m4ndmULg"
      unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw">0.002</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_X4ApOCKa20aLE0iARpjyBw"
      decimals="3"
      id="Narr_qnHtJ1tCNEqx2limZSXk0Q"
      unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw">0.009</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_6-UgFP9YHkKs37vGGIhEVw"
      decimals="2"
      id="Tc_6osXOSKOQkOc-hgRYjk73Q_5_2"
      unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_SKlrM8781Eet0zFbC3ewTw"
      decimals="2"
      id="Tc_JyQ3rnUF5UiD8i89LS1Alw_5_4"
      unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_qOmCDKQT9Eyfuidf3pzRYg"
      decimals="2"
      id="Narr_UffjQjR_gU6BWW1jYBmD6w"
      unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_L2H-B4harkuWLN7SUIOPRQ"
      decimals="2"
      id="Narr_MYt94Ayba0GhKKMIOZctFw"
      unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q">8.11</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_N_-EN94zSkyi4738ywQnkQ"
      decimals="2"
      id="Narr_0Decfsr-z0u3Y0a1PPaIUQ"
      unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q">13.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_cTbUJaM5EEi7_dTn33kCIQ"
      decimals="2"
      id="Narr_Dmj34MH9aUGKVJJd6Y4x-A"
      unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q">22.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_KSWzHsfkUUCC4ceQE_HELQ"
      decimals="2"
      id="Narr_ky9n3wfW-Umf_VXuxu72Rw"
      unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q">13.45</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_X4ApOCKa20aLE0iARpjyBw"
      decimals="2"
      id="Narr_JYkj6axSr0O58Eph3y2uCQ"
      unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q">18.64</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      id="Tb_oMc4hoIn10aMp--Oe6y9Cg">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.11848831%;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted-&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted-&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Aggregate&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Options&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&#160;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Intrinsic&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;(In&#160;thousands except options and per share data)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Outstanding&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Per Share &lt;/b&gt;&lt;sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Contractual Life&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Value &lt;/b&gt;&lt;sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;"&gt;(2)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Balance at December 31, 2019&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 866,955&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 28.76&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt;6.3 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 33,957&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 378,695&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 44.84&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (147,741)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 7.24&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 6,540&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (54,824)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 50.25&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;"&gt;Cancelled/Expired&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (3,376)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 63.61&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Balance at December 31, 2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 1,039,709&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 36.43&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt;5.6 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 13,381&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 188,748&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 49.33&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (175,516)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 22.65&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 4,901&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (92,773)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 49.77&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;"&gt;Cancelled/Expired&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (44,944)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 57.78&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Balance at December 31, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 915,224&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 39.33&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt;5.0 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 2,068&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 47,280&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 6.17&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (90,878)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 1.68&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 916&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (92,981)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 36.28&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;"&gt;Cancelled/Expired&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (163,338)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 37.65&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Balance at December 31, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 615,307&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 43.25&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt;4.7 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 164&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Options exercisable at December&#160;31,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 435,363&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 43.83&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt;4.5 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 84&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;padding-bottom:6pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;div style="margin-top:0pt;"/&gt;&lt;table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"&gt;&lt;tr&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-decoration-line:none;text-transform:none;vertical-align:baseline;white-space:nowrap;width:18pt;padding:0pt 0pt 6pt 0pt;"&gt;(1)&lt;/td&gt;&lt;td style="padding:0pt 0pt 6pt 0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-style:normal;font-weight:normal;"&gt;The exercise price of each option granted during the periods shown was equal to the market price of the underlying stock on the date of grant.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"&gt;&lt;tr&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-decoration-line:none;text-transform:none;vertical-align:baseline;white-space:nowrap;width:18pt;padding:0pt 0pt 12pt 0pt;"&gt;(2)&lt;/td&gt;&lt;td style="padding:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-style:normal;font-weight:normal;"&gt;The aggregate intrinsic value of options exercised represents the difference between the exercise price of the option and the closing stock price of our common stock on the date of exercise. The aggregate intrinsic value of options outstanding represents the difference between the exercise price of the option and the closing stock price of our common stock on the last trading day of the period.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_c4XlEVcSZkGUgY9pO9GVYw"
      decimals="INF"
      id="Tc__X4FXhVHSUSwEXypDapQfQ_5_2"
      unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ">866955</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_c4XlEVcSZkGUgY9pO9GVYw"
      decimals="2"
      id="Tc_q_acRcogG0WhxMlGYjwrGA_5_5"
      unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q">28.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_VEK6kkacQUeh0rcfcqChxQ"
      id="Narr_i76Z7F3mykuzs8vq0H2MTw">P6Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="As_Of_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_c4XlEVcSZkGUgY9pO9GVYw"
      decimals="-3"
      id="Tc_6sKlh3FHg0e1ZJhtJPQ8FQ_5_10"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">33957000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_qOmCDKQT9Eyfuidf3pzRYg"
      decimals="INF"
      id="Tc_27FrX3Vo-0OFIpBWt9C9IA_6_2"
      unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ">378695</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_qOmCDKQT9Eyfuidf3pzRYg"
      decimals="2"
      id="Tc_rdvRUSmovU6GV84XlToNAw_6_5"
      unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q">44.84</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_qOmCDKQT9Eyfuidf3pzRYg"
      decimals="INF"
      id="Tc_8oBwM51T-EGal-1XVuOB-Q_7_2"
      unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ">147741</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_qOmCDKQT9Eyfuidf3pzRYg"
      decimals="2"
      id="Tc_BkdXLKNyVkqJrZUmQt_zwA_7_5"
      unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q">7.24</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_qOmCDKQT9Eyfuidf3pzRYg"
      decimals="-3"
      id="Tc_rORTCCGPB0yaq_xTfw8nrQ_7_10"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">6540000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_qOmCDKQT9Eyfuidf3pzRYg"
      decimals="INF"
      id="Tc_qsptCN4mmEuMp39O07b_hw_8_2"
      unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ">54824</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_qOmCDKQT9Eyfuidf3pzRYg"
      decimals="2"
      id="Tc_v0p7r0yRBkOm7FvJbykwGg_8_5"
      unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q">50.25</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_qOmCDKQT9Eyfuidf3pzRYg"
      decimals="INF"
      id="Tc_HJOWQ8K9ZUCWQmwURwbxIA_9_2"
      unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ">3376</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_qOmCDKQT9Eyfuidf3pzRYg"
      decimals="2"
      id="Tc_Na7-rCqWJU2ZTaP-9phlkg_9_5"
      unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q">63.61</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_YXF4jcKSZ0az4v_DZj-Otw"
      decimals="INF"
      id="Tc_vAkMK7sM5EutgCL52i4Srw_10_2"
      unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ">1039709</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_YXF4jcKSZ0az4v_DZj-Otw"
      decimals="2"
      id="Tc_zE4iiK_B1US3g6uoDQ-M2A_10_5"
      unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q">36.43</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_qOmCDKQT9Eyfuidf3pzRYg"
      id="Narr_oHGM55QSS0iC_QEmhaI3kQ">P5Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_YXF4jcKSZ0az4v_DZj-Otw"
      decimals="-3"
      id="Tc_Qy6SxGFKHUey37DVO-teFg_10_10"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">13381000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_SKlrM8781Eet0zFbC3ewTw"
      decimals="INF"
      id="Tc_PVEjYuUUnEqO8-r1knHAYg_11_2"
      unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ">188748</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_SKlrM8781Eet0zFbC3ewTw"
      decimals="2"
      id="Tc_1kuBFIIbXUaKlbyq5yEnFQ_11_5"
      unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q">49.33</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_SKlrM8781Eet0zFbC3ewTw"
      decimals="INF"
      id="Tc_Tf3YbeYhM0e2M8l45kj3TQ_12_2"
      unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ">175516</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_SKlrM8781Eet0zFbC3ewTw"
      decimals="2"
      id="Tc_MDEVOVg1Ukic0h7wHqhYFw_12_5"
      unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q">22.65</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_SKlrM8781Eet0zFbC3ewTw"
      decimals="-3"
      id="Tc_tBPchSOaZE6P6YamJR-uTw_12_10"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">4901000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_SKlrM8781Eet0zFbC3ewTw"
      decimals="INF"
      id="Tc_jtjWBuZ63UqTmFJwqjSN6w_13_2"
      unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ">92773</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_SKlrM8781Eet0zFbC3ewTw"
      decimals="2"
      id="Tc_2q5ii88GGku4wgDvVqbA_w_13_5"
      unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q">49.77</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_SKlrM8781Eet0zFbC3ewTw"
      decimals="INF"
      id="Tc_aIIWGMFyKEW2TJTqLcaR0w_14_2"
      unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ">44944</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_SKlrM8781Eet0zFbC3ewTw"
      decimals="2"
      id="Tc_AX2L-yeCRkC2pRZNG1E7ZA_14_5"
      unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q">57.78</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember___xLca8jWE2AqShfBEgmlw"
      decimals="INF"
      id="Tc_xqv6K85IT0OfcHuUp0IvcQ_15_2"
      unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ">915224</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember___xLca8jWE2AqShfBEgmlw"
      decimals="2"
      id="Tc_i7oYvwF2GEGVd9s7Mx01gg_15_5"
      unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q">39.33</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_SKlrM8781Eet0zFbC3ewTw"
      id="Narr_5eWvWpYlJUOPgsdOg01tjw">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember___xLca8jWE2AqShfBEgmlw"
      decimals="-3"
      id="Tc_6o_QFfLR8kyyJ3GjYGBPkw_15_10"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">2068000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_6-UgFP9YHkKs37vGGIhEVw"
      decimals="INF"
      id="Tc_yd6RRSCLmUehCN8Btpna8A_16_2"
      unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ">47280</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_6-UgFP9YHkKs37vGGIhEVw"
      decimals="2"
      id="Tc_m2RtcofNKUiqLnKfl6Vs9w_16_5"
      unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q">6.17</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_6-UgFP9YHkKs37vGGIhEVw"
      decimals="INF"
      id="Tc_GZ6eCIeZL0KjFpNIe3sXQg_17_2"
      unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ">90878</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_6-UgFP9YHkKs37vGGIhEVw"
      decimals="2"
      id="Tc__z1CNbW5g0a-2TA4GMvojw_17_5"
      unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q">1.68</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_6-UgFP9YHkKs37vGGIhEVw"
      decimals="-3"
      id="Tc_G4uro0VOeU6CBIxbDvNhiA_17_10"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">916000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_6-UgFP9YHkKs37vGGIhEVw"
      decimals="INF"
      id="Tc_m4EPz7X5PUGpvhZ5_a-eaw_18_2"
      unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ">92981</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_6-UgFP9YHkKs37vGGIhEVw"
      decimals="2"
      id="Tc_yJFjzZ9Lx0uHBJ7BRvN-xA_18_5"
      unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q">36.28</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_6-UgFP9YHkKs37vGGIhEVw"
      decimals="INF"
      id="Tc_woFp_p-iIECMMhC4J3dfzw_19_2"
      unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ">163338</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_6-UgFP9YHkKs37vGGIhEVw"
      decimals="2"
      id="Tc_8tyLAUkrs0S_em0nv8ujGQ_19_5"
      unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q">37.65</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_Un8xxO7K-UGnIxffkFMjsw"
      decimals="INF"
      id="Tc_krtGBd8x0EyJ4ssdsN0Wig_20_2"
      unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ">615307</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_Un8xxO7K-UGnIxffkFMjsw"
      decimals="2"
      id="Tc_PJLVhtBoSkmwg9nJkOwwIw_20_5"
      unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q">43.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_6-UgFP9YHkKs37vGGIhEVw"
      id="Narr_w3cBTW0e-0ywFEbbinynpA">P4Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_Un8xxO7K-UGnIxffkFMjsw"
      decimals="-3"
      id="Tc_qHE6EVgu106ESpwcXV28mQ_20_10"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">164000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_Un8xxO7K-UGnIxffkFMjsw"
      decimals="INF"
      id="Tc_OpxbOvmpRkitQlmQhZFI1Q_22_2"
      unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ">435363</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_Un8xxO7K-UGnIxffkFMjsw"
      decimals="2"
      id="Tc_gdcIV3GFUEyJVUBfipfQIg_22_5"
      unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q">43.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_6-UgFP9YHkKs37vGGIhEVw"
      id="Narr_UfjX9sSsIkCPUC2pjy_0qw">P4Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_Un8xxO7K-UGnIxffkFMjsw"
      decimals="-3"
      id="Tc_h9u5DiafsEOSdnqhsjjasg_22_10"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">84000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember___xLca8jWE2AqShfBEgmlw"
      decimals="INF"
      id="Narr_2MbwZa-UskujrTu5U_6VaQ"
      unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ">517316</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_YXF4jcKSZ0az4v_DZj-Otw"
      decimals="INF"
      id="Narr_sqxTw10zrkOZvDZShKGa4Q"
      unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ">489866</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember___xLca8jWE2AqShfBEgmlw"
      decimals="2"
      id="Narr_EFeSDap9FUSvH4-R6TsxWg"
      unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q">32.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_YXF4jcKSZ0az4v_DZj-Otw"
      decimals="2"
      id="Narr_lUvxP6mrlkeRAvNOr4z7DA"
      unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q">25.39</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      id="Tb_HEhGRMPVf0KaN-FHr4zviw">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:61.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:35.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:35.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number of:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Non-vested options, beginning of the year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 397,908&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 549,843&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Non-vested options, end of the year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 179,944&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 397,908&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Vested options, end of the year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 435,363&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 517,316&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:61.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:35.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:35.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted-average grant date fair value of: &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Non-vested options, beginning of the year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 18.02&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 18.03&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Non-vested options, end of the year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 16.24&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 18.02&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Vested options, end of the year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 17.53&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 13.27&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Forfeited options, during the year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 14.73&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 19.26&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;padding-bottom:12pt;background:#ffffff;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember___xLca8jWE2AqShfBEgmlw"
      decimals="INF"
      id="Tc_HZi0LM1MsE-1lCDy9Z8FAw_4_3"
      unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ">397908</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_YXF4jcKSZ0az4v_DZj-Otw"
      decimals="INF"
      id="Tc_XlMDxr7sDE6Jcst2GVRgtg_4_6"
      unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ">549843</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_Un8xxO7K-UGnIxffkFMjsw"
      decimals="INF"
      id="Tc_TVKd1RR_-UqewW_hhZwH6A_5_3"
      unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ">179944</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember___xLca8jWE2AqShfBEgmlw"
      decimals="INF"
      id="Tc_z00kxmO1BU67WtnVYZN4sw_5_6"
      unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ">397908</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_6-UgFP9YHkKs37vGGIhEVw"
      decimals="INF"
      id="Tc_TPNTe1-aF0WqLLP3w3qD8w_6_3"
      unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ">435363</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_SKlrM8781Eet0zFbC3ewTw"
      decimals="INF"
      id="Tc_gwGiKMrr20-h3eUY2gFEzQ_6_6"
      unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ">517316</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember___xLca8jWE2AqShfBEgmlw"
      decimals="2"
      id="Tc_ZPgTdd-zQka393nlD7URCA_4_3"
      unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q">18.02</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_YXF4jcKSZ0az4v_DZj-Otw"
      decimals="2"
      id="Tc_5CeEe91oAUepT8NqnA_2Sg_4_6"
      unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q">18.03</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_Un8xxO7K-UGnIxffkFMjsw"
      decimals="2"
      id="Tc_pMxcbk5cuUaXI_gHBkQ2PQ_5_3"
      unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q">16.24</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember___xLca8jWE2AqShfBEgmlw"
      decimals="2"
      id="Tc_BAyvteYzr0CDWp_19KPRNw_5_6"
      unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q">18.02</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_6-UgFP9YHkKs37vGGIhEVw"
      decimals="2"
      id="Tc_AkOPr_wkqEuNJ0Yve-HvZg_6_3"
      unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q">17.53</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_SKlrM8781Eet0zFbC3ewTw"
      decimals="2"
      id="Tc_WLu74SVo2EaEJMjH93yEmQ_6_6"
      unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q">13.27</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_6-UgFP9YHkKs37vGGIhEVw"
      decimals="2"
      id="Tc_JZCly6KuYEqvpx_6L6kl5A_7_3"
      unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q">14.73</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_SKlrM8781Eet0zFbC3ewTw"
      decimals="2"
      id="Tc_hwsYVPZD00GlfMnAjXRttQ_7_6"
      unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q">19.26</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_tcmd_TimeBasedRestrictedStockUnitsRsusMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_8RJLAbFs-0aC61lHpsR90Q"
      id="Narr_Qr22M_rc_EaB43T6jg2MlQ">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_tcmd_TimeBasedRestrictedStockUnitsRsusMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_Nb-WbjXmjUKf3z1gH8kH5Q"
      decimals="-5"
      id="Narr_1fsRwh5bAkK4ApPgwZmpig"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">5800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_tcmd_TimeBasedRestrictedStockUnitsRsusMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_YpNaI4H08kWMKCFdksUPJg"
      decimals="-5"
      id="Narr_i28y2vukCkO0mCAGHORY_w"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">4900000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_tcmd_TimeBasedRestrictedStockUnitsRsusMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_-BKViJhhwkykuZDgY3GR5A"
      decimals="-5"
      id="Narr_EzWBDJPYv0uatI2dpfMGMA"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">5200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_tcmd_TimeBasedRestrictedStockUnitsRsusMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_qc0c3k5OY0eKiJM_sgU8nA"
      decimals="-5"
      id="Narr_lO0J0FnY1k6sxViq9KWUWw"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">7800000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_tcmd_TimeBasedRestrictedStockUnitsRsusMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_Nb-WbjXmjUKf3z1gH8kH5Q"
      id="Narr_T3qRajyySU2Z68qt5AJO4g">P1Y10M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_tcmd_TimeBasedRestrictedStockUnitsRsusMember_OqoDokUrok2FtqlOs8iQLQ"
      id="Tb_eh61YCkdY0WVltybATDARw">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:46.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted-&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:46.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average Grant&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Aggregate&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:46.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Units&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Date Fair Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Intrinsic&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;(In&#160;thousands except unit and per unit data)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Outstanding&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Per Unit&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-size:10pt;font-weight:bold;"&gt;Value &lt;/b&gt;&lt;sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:46.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Balance at December 31, 2019&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 171,687&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 43.74&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 11,591&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:46.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 175,582&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 46.42&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:46.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;"&gt;Modification&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 2,288&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 21.85&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:46.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;"&gt;Vested&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (118,014)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 37.57&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:46.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;"&gt;Cancelled&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (20,074)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 53.03&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:46.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Balance at December 31, 2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 211,469&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 48.29&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 9,503&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:46.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 189,762&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 40.31&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:46.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;"&gt;Vested&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (106,521)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 47.43&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:46.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;"&gt;Cancelled&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (35,563)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 51.76&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:46.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Balance at December 31, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 259,147&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 42.32&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 4,932&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:46.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 539,525&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 15.03&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:46.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;"&gt;Vested&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (123,528)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 43.20&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:46.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;"&gt;Cancelled&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (84,602)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 26.91&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:46.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Balance at December 31, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 590,542&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 19.42&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 6,779&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;padding-bottom:6pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;div style="margin-top:0pt;"/&gt;&lt;table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"&gt;&lt;tr&gt;&lt;td style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 6pt 0pt;"&gt;(1)&lt;/td&gt;&lt;td style="padding:0pt 0pt 6pt 0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-style:normal;font-weight:normal;"&gt;The aggregate intrinsic value of time-based restricted stock units outstanding was based on our closing stock price on the last trading day of the period.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="As_Of_12_31_2019_us-gaap_AwardTypeAxis_tcmd_TimeBasedRestrictedStockUnitsRsusMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_IaK_VsGjOEiqSEoE-zGXOw"
      decimals="INF"
      id="Tc_Y0t_2DIZtEu0ZU7gQMurgg_5_2"
      unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ">171687</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="As_Of_12_31_2019_us-gaap_AwardTypeAxis_tcmd_TimeBasedRestrictedStockUnitsRsusMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_IaK_VsGjOEiqSEoE-zGXOw"
      decimals="2"
      id="Tc_vprmLEMik0Gu5gGJs0K8aQ_5_5"
      unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q">43.74</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="As_Of_12_31_2019_3ga0jBjg6EKA4-znaQ36NQ"
      decimals="-3"
      id="Tc_EuskLxFMp06-e-wF3VfNpQ_5_8"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">11591000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_tcmd_TimeBasedRestrictedStockUnitsRsusMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_-BKViJhhwkykuZDgY3GR5A"
      decimals="INF"
      id="Tc_DlMXBYcxfU-OW8rocX5jXw_6_2"
      unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ">175582</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_tcmd_TimeBasedRestrictedStockUnitsRsusMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_-BKViJhhwkykuZDgY3GR5A"
      decimals="2"
      id="Tc_6nAH36d5V0uOPNK155SLDA_6_5"
      unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q">46.42</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <tcmd:SharebasedcompensationArrangementBySharebasedpaymentAwardEquityInstrumentsOtherThanOptionsModifiedInPeriod
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_tcmd_TimeBasedRestrictedStockUnitsRsusMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_-BKViJhhwkykuZDgY3GR5A"
      decimals="INF"
      id="Tc__LicHWlCCUWxxhl0PkwKew_7_2"
      unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ">2288</tcmd:SharebasedcompensationArrangementBySharebasedpaymentAwardEquityInstrumentsOtherThanOptionsModifiedInPeriod>
    <tcmd:SharebasedcompensationArrangementBySharebasedpaymentAwardEquityInstrumentsOtherThanOptionsModifiedWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_tcmd_TimeBasedRestrictedStockUnitsRsusMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_-BKViJhhwkykuZDgY3GR5A"
      decimals="2"
      id="Tc_hwz1Gqc57UiHUuk59T6Lvg_7_5"
      unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q">21.85</tcmd:SharebasedcompensationArrangementBySharebasedpaymentAwardEquityInstrumentsOtherThanOptionsModifiedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_tcmd_TimeBasedRestrictedStockUnitsRsusMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_-BKViJhhwkykuZDgY3GR5A"
      decimals="INF"
      id="Tc_IXb0KKaQDEGRDqb3KeCw8w_8_2"
      unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ">118014</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_tcmd_TimeBasedRestrictedStockUnitsRsusMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_-BKViJhhwkykuZDgY3GR5A"
      decimals="2"
      id="Tc_CMAND2AAnkeMLL-x2OuHJw_8_5"
      unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q">37.57</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <tcmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_tcmd_TimeBasedRestrictedStockUnitsRsusMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_-BKViJhhwkykuZDgY3GR5A"
      decimals="INF"
      id="Tc_s2T1Ww2vMU2pTT4IRmbi1A_9_2"
      unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ">20074</tcmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod>
    <tcmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancellationsWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_tcmd_TimeBasedRestrictedStockUnitsRsusMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_-BKViJhhwkykuZDgY3GR5A"
      decimals="2"
      id="Tc_6mx-Xv6qakW1VLXgcdv4lw_9_5"
      unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q">53.03</tcmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancellationsWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="As_Of_12_31_2020_us-gaap_AwardTypeAxis_tcmd_TimeBasedRestrictedStockUnitsRsusMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_Rx5oCF5RME-QoxzFqBAV1g"
      decimals="INF"
      id="Tc_Vi0N21Yjoku30a8KW981dg_10_2"
      unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ">211469</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="As_Of_12_31_2020_us-gaap_AwardTypeAxis_tcmd_TimeBasedRestrictedStockUnitsRsusMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_Rx5oCF5RME-QoxzFqBAV1g"
      decimals="2"
      id="Tc_SM_sgV2xEEKyouiK7gPUUg_10_5"
      unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q">48.29</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="As_Of_12_31_2020_q95ww8WB7U-18mlScI3MCA"
      decimals="-3"
      id="Tc_t2iAXX00pE6Gdhn0kmrsJw_10_8"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">9503000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_tcmd_TimeBasedRestrictedStockUnitsRsusMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_YpNaI4H08kWMKCFdksUPJg"
      decimals="INF"
      id="Tc_1tZFZpooF06UcOBFni0Q3g_11_2"
      unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ">189762</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_tcmd_TimeBasedRestrictedStockUnitsRsusMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_YpNaI4H08kWMKCFdksUPJg"
      decimals="2"
      id="Tc_SUPm6sLOGkC_epWcvmNokw_11_5"
      unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q">40.31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_tcmd_TimeBasedRestrictedStockUnitsRsusMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_YpNaI4H08kWMKCFdksUPJg"
      decimals="INF"
      id="Tc_S37W3karLEiMNsR6hY0j5g_12_2"
      unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ">106521</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_tcmd_TimeBasedRestrictedStockUnitsRsusMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_YpNaI4H08kWMKCFdksUPJg"
      decimals="2"
      id="Tc_o-AynhgikUOUeM4z0ZYyfQ_12_5"
      unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q">47.43</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <tcmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_tcmd_TimeBasedRestrictedStockUnitsRsusMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_YpNaI4H08kWMKCFdksUPJg"
      decimals="INF"
      id="Tc_rkQxG-amXEKv4u16kytHkg_13_2"
      unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ">35563</tcmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod>
    <tcmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancellationsWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_tcmd_TimeBasedRestrictedStockUnitsRsusMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_YpNaI4H08kWMKCFdksUPJg"
      decimals="2"
      id="Tc_09oy_dhQgEaze53kgbmmoA_13_5"
      unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q">51.76</tcmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancellationsWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_tcmd_TimeBasedRestrictedStockUnitsRsusMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_RfN-hRdVK0WQ7dibE-9y_A"
      decimals="INF"
      id="Tc_gGJrTm-gyUWAbb1H5t9v6g_14_2"
      unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ">259147</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_tcmd_TimeBasedRestrictedStockUnitsRsusMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_RfN-hRdVK0WQ7dibE-9y_A"
      decimals="2"
      id="Tc_Hj2icQFQ5ky8tWtImoORug_14_5"
      unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q">42.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_tcmd_TimeBasedRestrictedStockUnitsRsusMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_RfN-hRdVK0WQ7dibE-9y_A"
      decimals="-3"
      id="Tc_saFk2DU2gU-JIk662fto-g_14_8"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">4932000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_tcmd_TimeBasedRestrictedStockUnitsRsusMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_Nb-WbjXmjUKf3z1gH8kH5Q"
      decimals="INF"
      id="Tc_-x1QC-KwKEmGHbKKM8MXmg_15_2"
      unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ">539525</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_tcmd_TimeBasedRestrictedStockUnitsRsusMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_Nb-WbjXmjUKf3z1gH8kH5Q"
      decimals="2"
      id="Tc_4toNV38ZH0i86quODrkong_15_5"
      unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q">15.03</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_tcmd_TimeBasedRestrictedStockUnitsRsusMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_Nb-WbjXmjUKf3z1gH8kH5Q"
      decimals="INF"
      id="Tc_o1ttkGwR30Sf0xDk0QWf4g_16_2"
      unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ">123528</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_tcmd_TimeBasedRestrictedStockUnitsRsusMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_Nb-WbjXmjUKf3z1gH8kH5Q"
      decimals="2"
      id="Tc_z_p50NJ-ckGIz8veLQZi9g_16_5"
      unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q">43.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <tcmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_tcmd_TimeBasedRestrictedStockUnitsRsusMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_Nb-WbjXmjUKf3z1gH8kH5Q"
      decimals="INF"
      id="Tc_iP9-2B5xuUySSUJc-ulOSg_17_2"
      unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ">84602</tcmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod>
    <tcmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancellationsWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_tcmd_TimeBasedRestrictedStockUnitsRsusMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_Nb-WbjXmjUKf3z1gH8kH5Q"
      decimals="2"
      id="Tc_27lrhMUbw0u1GVxKzW7lhQ_17_5"
      unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q">26.91</tcmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancellationsWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_tcmd_TimeBasedRestrictedStockUnitsRsusMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_qc0c3k5OY0eKiJM_sgU8nA"
      decimals="INF"
      id="Tc_0qCmxQRH2Ee5pzfZjFipwA_18_2"
      unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ">590542</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_tcmd_TimeBasedRestrictedStockUnitsRsusMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_qc0c3k5OY0eKiJM_sgU8nA"
      decimals="2"
      id="Tc_nKMDFaUDlE2W-Au1uBa4cg_18_5"
      unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q">19.42</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_tcmd_TimeBasedRestrictedStockUnitsRsusMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_qc0c3k5OY0eKiJM_sgU8nA"
      decimals="-3"
      id="Tc_8xPbiNzzDEKaNASJgmBTdQ_18_8"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">6779000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <tcmd:PercentageToEarnPerformanceBasedStockSettledRestrictedStockUnits
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_tcmd_PerformanceBasedStockSettledRestrictedStockUnitsMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_CmpNEKSSE0O0i2jPBWOaAg"
      decimals="2"
      id="Narr_1ZsiGqYA6keHHUhYk3mUoQ"
      unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw">0.50</tcmd:PercentageToEarnPerformanceBasedStockSettledRestrictedStockUnits>
    <tcmd:PercentageToEarnPerformanceBasedStockSettledRestrictedStockUnits
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_tcmd_PerformanceBasedStockSettledRestrictedStockUnitsMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_Hlc6i7-A9EusSlzegAjTIQ"
      decimals="2"
      id="Narr_TX9hoQsEQU6xs_iFcVfgbw"
      unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw">1.50</tcmd:PercentageToEarnPerformanceBasedStockSettledRestrictedStockUnits>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_tcmd_PerformanceBasedStockSettledRestrictedStockUnitsMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_UgLe632XY0y4wqXfkaKIqg"
      decimals="-5"
      id="Narr_fd42dJca-kS-7Yo79FgV8A"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_tcmd_PerformanceBasedStockSettledRestrictedStockUnitsMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_7x_jPqkWGkShM1NIyefKfQ"
      decimals="-5"
      id="Narr_ZHr8pHUaXEqECymr27nQnA"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_tcmd_PerformanceBasedStockSettledRestrictedStockUnitsMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_rm8GPwYY40y-DieCnmoBug"
      decimals="-5"
      id="Narr_h6jyrOneyUmbXrnBssLAUw"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_tcmd_TwoThousandEighteenAndTwoThousandTwentyPerformanceBasedRestrictedStockUnitsMember_WZVx9pkMD0SJKZFhIdnWjQ"
      decimals="-5"
      id="Narr_0P8NHPSIEUqHn4MNLiiX4A"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <tcmd:StockBasedCompensationExpenseMinimumTargets
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_tcmd_PerformanceBasedStockSettledRestrictedStockUnitsMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_7x_jPqkWGkShM1NIyefKfQ"
      decimals="-5"
      id="Narr_CzA6UtG5c0mjWcAsKvOZ1Q"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">500000</tcmd:StockBasedCompensationExpenseMinimumTargets>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_tcmd_TwoThousandEighteenAndTwoThousandTwentyPerformanceBasedRestrictedStockUnitsMember_HDcRO5L1FU2oWQGAEeWYwA"
      decimals="-5"
      id="Narr_pkOcXoaj9EmYZGXi8rlBEQ"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">700000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_tcmd_PerformanceBasedStockSettledRestrictedStockUnitsMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_GskkIzSZ40CADy7RgEQqjw"
      decimals="-5"
      id="Narr_8xZUkK1QzU2kyHoCcreprg"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">1400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_tcmd_PerformanceBasedStockSettledRestrictedStockUnitsMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_UgLe632XY0y4wqXfkaKIqg"
      id="Narr_Ac73fwRicEiYnpOBIUVbfw">P2Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <tcmd:EstimatedPayoutPercentage
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_tcmd_PerformanceBasedStockSettledRestrictedStockUnitsMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_rm8GPwYY40y-DieCnmoBug"
      decimals="2"
      id="Narr_4sa-_NLQw0acmHN0EFyVTg"
      unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw">1</tcmd:EstimatedPayoutPercentage>
    <tcmd:EstimatedPayoutPercentage
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_tcmd_PerformanceBasedStockSettledRestrictedStockUnitsMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_7x_jPqkWGkShM1NIyefKfQ"
      decimals="2"
      id="Narr_vIk5gKa7OEKkvAZ7qOi4tA"
      unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw">1</tcmd:EstimatedPayoutPercentage>
    <tcmd:EstimatedPayoutPercentage
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_tcmd_PerformanceBasedStockSettledRestrictedStockUnitsMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_UgLe632XY0y4wqXfkaKIqg"
      decimals="2"
      id="Narr_uzBnPcdxkUa3C_Yx5DdS4A"
      unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw">1</tcmd:EstimatedPayoutPercentage>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_tcmd_PerformanceBasedStockSettledRestrictedStockUnitsMember_jgqU-RDfJkWBTKO22fvJHw"
      id="Tb_IqGbyC2ygUqzrd-VMBKpBg">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:44.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Performance-&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted-&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:44.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Based&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average Grant&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Aggregate&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:44.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Units&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Date Fair Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Intrinsic&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;(In&#160;thousands except unit and per unit data)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Outstanding&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Per Unit&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-size:10pt;font-weight:bold;"&gt;Value &lt;/b&gt;&lt;sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:44.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Balance at December 31, 2019&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 91,151&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 44.63&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 6,154&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:44.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 31,731&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 50.41&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:44.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;"&gt;Vested&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (26,204)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 33.58&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:44.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;"&gt;Cancelled&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (17,375)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 52.87&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:44.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Balance at December 31, 2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 79,303&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 47.83&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 3,564&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:44.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 39,419&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 51.82&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:44.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;"&gt;Vested&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (34,159)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 33.98&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:44.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;"&gt;Cancelled&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (30,246)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 64.39&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:44.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Balance at December 31, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 54,317&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 50.22&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 1,034&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:44.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 131,710&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 18.54&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:44.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;"&gt;Vested&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (4,407)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 12.31&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:44.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;"&gt;Cancelled&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (26,002)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 42.53&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:44.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Balance at December 31, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 155,618&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 25.05&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 1,786&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;padding-bottom:6pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;div style="margin-top:0pt;"/&gt;&lt;table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"&gt;&lt;tr&gt;&lt;td style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 12pt 0pt;"&gt;(1)&lt;/td&gt;&lt;td style="padding:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-style:normal;font-weight:normal;"&gt;The aggregate intrinsic value of performance-based restricted stock units outstanding was based on our closing stock price on the last trading day of the period&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="As_Of_12_31_2019_us-gaap_AwardTypeAxis_tcmd_PerformanceBasedStockSettledRestrictedStockUnitsMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_vFDEcLAy5EyVpxGp-lSAGQ"
      decimals="INF"
      id="Tc_V8FP6C2xkU6trC2n0bo9rw_5_2"
      unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ">91151</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="As_Of_12_31_2019_us-gaap_AwardTypeAxis_tcmd_PerformanceBasedStockSettledRestrictedStockUnitsMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_vFDEcLAy5EyVpxGp-lSAGQ"
      decimals="2"
      id="Tc_4-ZYsbhbj0yqCmHeiiMBwA_5_5"
      unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q">44.63</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="As_Of_12_31_2019_us-gaap_AwardTypeAxis_tcmd_PerformanceBasedStockSettledRestrictedStockUnitsMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_vFDEcLAy5EyVpxGp-lSAGQ"
      decimals="-3"
      id="Tc_7bfs7OkuvEipd6trK2komg_5_8"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">6154000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_tcmd_PerformanceBasedStockSettledRestrictedStockUnitsMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_rm8GPwYY40y-DieCnmoBug"
      decimals="INF"
      id="Tc_PJky2I8nfE-xnsQE7DmVmQ_6_2"
      unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ">31731</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_tcmd_PerformanceBasedStockSettledRestrictedStockUnitsMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_rm8GPwYY40y-DieCnmoBug"
      decimals="2"
      id="Tc_Dai2Af-M2k2gp49RxWlN_A_6_5"
      unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q">50.41</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_tcmd_PerformanceBasedStockSettledRestrictedStockUnitsMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_rm8GPwYY40y-DieCnmoBug"
      decimals="INF"
      id="Tc_Wfqqv2BCB0GNkHMt3CJaew_7_2"
      unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ">26204</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_tcmd_PerformanceBasedStockSettledRestrictedStockUnitsMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_rm8GPwYY40y-DieCnmoBug"
      decimals="2"
      id="Tc_hjMyMqMc1Eq3O7acdqxP_w_7_5"
      unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q">33.58</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <tcmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_tcmd_PerformanceBasedStockSettledRestrictedStockUnitsMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_rm8GPwYY40y-DieCnmoBug"
      decimals="INF"
      id="Tc_akINmGkVPUmm_RFMeq2O0A_8_2"
      unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ">17375</tcmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod>
    <tcmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancellationsWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_tcmd_PerformanceBasedStockSettledRestrictedStockUnitsMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_rm8GPwYY40y-DieCnmoBug"
      decimals="2"
      id="Tc_yzJ6WBV-YE6QqbS-sxRXaQ_8_5"
      unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q">52.87</tcmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancellationsWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="As_Of_12_31_2020_us-gaap_AwardTypeAxis_tcmd_PerformanceBasedStockSettledRestrictedStockUnitsMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_WpTm0Lj5Q0WDgY5zSwuAIg"
      decimals="INF"
      id="Tc_71fq2o4xA0qD4T-KGiScvg_9_2"
      unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ">79303</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="As_Of_12_31_2020_us-gaap_AwardTypeAxis_tcmd_PerformanceBasedStockSettledRestrictedStockUnitsMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_WpTm0Lj5Q0WDgY5zSwuAIg"
      decimals="2"
      id="Tc_gzX0dZQJ_E2q-A-0WCNTLA_9_5"
      unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q">47.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <tcmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueDeferredAndUnissued
      contextRef="As_Of_12_31_2020_us-gaap_AwardTypeAxis_tcmd_PerformanceBasedStockSettledRestrictedStockUnitsMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_WpTm0Lj5Q0WDgY5zSwuAIg"
      decimals="-3"
      id="Tc_rtcm2p5B7kq9-w56sdzWgw_9_8"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">3564000</tcmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueDeferredAndUnissued>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_tcmd_PerformanceBasedStockSettledRestrictedStockUnitsMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_7x_jPqkWGkShM1NIyefKfQ"
      decimals="INF"
      id="Tc_g1gh6e30r062l3OR1pjrsA_10_2"
      unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ">39419</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_tcmd_PerformanceBasedStockSettledRestrictedStockUnitsMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_7x_jPqkWGkShM1NIyefKfQ"
      decimals="2"
      id="Tc_Cwfjsk47L0-RrtRP7ZA4Ng_10_5"
      unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q">51.82</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_tcmd_PerformanceBasedStockSettledRestrictedStockUnitsMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_7x_jPqkWGkShM1NIyefKfQ"
      decimals="INF"
      id="Tc_QEfEuvOMjEi9G_Zu6cLgeQ_11_2"
      unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ">34159</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_tcmd_PerformanceBasedStockSettledRestrictedStockUnitsMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_7x_jPqkWGkShM1NIyefKfQ"
      decimals="2"
      id="Tc_UfLWeKVMp0SpECkLCRjp1A_11_5"
      unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q">33.98</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <tcmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_tcmd_PerformanceBasedStockSettledRestrictedStockUnitsMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_7x_jPqkWGkShM1NIyefKfQ"
      decimals="INF"
      id="Tc_Ao4LHLYUGU6YXdURK4Z4zA_12_2"
      unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ">30246</tcmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod>
    <tcmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancellationsWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_tcmd_PerformanceBasedStockSettledRestrictedStockUnitsMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_7x_jPqkWGkShM1NIyefKfQ"
      decimals="2"
      id="Tc_9rRkrRORXUSBfZ3IfVFbww_12_5"
      unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q">64.39</tcmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancellationsWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_tcmd_PerformanceBasedStockSettledRestrictedStockUnitsMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_yXZPu2ZWyESDFq8L-JZCHg"
      decimals="INF"
      id="Tc_8zN6B0PFqkSW51cyAYL1EA_13_2"
      unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ">54317</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_tcmd_PerformanceBasedStockSettledRestrictedStockUnitsMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_yXZPu2ZWyESDFq8L-JZCHg"
      decimals="2"
      id="Tc_OOn9FIl2sEqfTPAVKu0pjA_13_5"
      unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q">50.22</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_tcmd_PerformanceBasedStockSettledRestrictedStockUnitsMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_yXZPu2ZWyESDFq8L-JZCHg"
      decimals="-3"
      id="Tc_gut30S889EihPCa_gfywIQ_13_8"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">1034000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_tcmd_PerformanceBasedStockSettledRestrictedStockUnitsMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_UgLe632XY0y4wqXfkaKIqg"
      decimals="INF"
      id="Tc_ppTdBapTikukglNg6UlUqg_14_2"
      unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ">131710</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_tcmd_PerformanceBasedStockSettledRestrictedStockUnitsMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_UgLe632XY0y4wqXfkaKIqg"
      decimals="2"
      id="Tc_TYyYfPdisEq5L7MbERY5Fg_14_5"
      unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q">18.54</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_tcmd_PerformanceBasedStockSettledRestrictedStockUnitsMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_UgLe632XY0y4wqXfkaKIqg"
      decimals="INF"
      id="Tc__k0z8_BTI0iE2yMv2Hy8Xg_15_2"
      unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ">4407</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_tcmd_PerformanceBasedStockSettledRestrictedStockUnitsMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_UgLe632XY0y4wqXfkaKIqg"
      decimals="2"
      id="Tc_lJBvoUXdpkWN9DCWBlpD-w_15_5"
      unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q">12.31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <tcmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_tcmd_PerformanceBasedStockSettledRestrictedStockUnitsMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_UgLe632XY0y4wqXfkaKIqg"
      decimals="INF"
      id="Tc_FqRzDVI4zEGKdpbeMTlV5w_16_2"
      unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ">26002</tcmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod>
    <tcmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancellationsWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_tcmd_PerformanceBasedStockSettledRestrictedStockUnitsMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_UgLe632XY0y4wqXfkaKIqg"
      decimals="2"
      id="Tc_3UtcLNAENUiE0ouyQDhxIg_16_5"
      unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q">42.53</tcmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancellationsWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_tcmd_PerformanceBasedStockSettledRestrictedStockUnitsMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_GskkIzSZ40CADy7RgEQqjw"
      decimals="INF"
      id="Tc_wkl66G4DK0mTiZm4kL7Fpg_17_2"
      unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ">155618</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_tcmd_PerformanceBasedStockSettledRestrictedStockUnitsMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_GskkIzSZ40CADy7RgEQqjw"
      decimals="2"
      id="Tc_W1dzvyNTmUuqnRleZ07mrw_17_5"
      unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q">25.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_tcmd_PerformanceBasedStockSettledRestrictedStockUnitsMember_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_GskkIzSZ40CADy7RgEQqjw"
      decimals="-3"
      id="Tc_D4OeYbCtG02lXvoE180RYw_17_8"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">1786000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_EmployeeStockMember_cKXRqo7dk0-EdILU7PZBhg"
      decimals="INF"
      id="Narr_njquulaRNEmrqbckUW3zrQ"
      unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <tcmd:EmployeeStockPurchasePlanOfferingPeriodsPeriod
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_EmployeeStockMember_cKXRqo7dk0-EdILU7PZBhg"
      id="Narr_3813uZD-FUCcvjiZ8xN33Q">P6M</tcmd:EmployeeStockPurchasePlanOfferingPeriodsPeriod>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_4_27_2017_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_EmployeeStockMember_1JhNvac8pkCgs2t4mxK9oQ"
      decimals="INF"
      id="Narr_VjHHdYhgZ0CgRfwuMxQe3A"
      unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ">1600000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <tcmd:IncrementalSharesToBeIssuedPercentage
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_EmployeeStockMember_cKXRqo7dk0-EdILU7PZBhg"
      decimals="INF"
      id="Narr_DcWkKGr9qUWZ-i2D2Y41gQ"
      unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw">0.01</tcmd:IncrementalSharesToBeIssuedPercentage>
    <tcmd:IncrementalShareIncrease
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_EmployeeStockMember_cKXRqo7dk0-EdILU7PZBhg"
      decimals="INF"
      id="Narr_klin9hyspEGa3CDiTj4-Cg"
      unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ">500000</tcmd:IncrementalShareIncrease>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="Duration_1_1_2021_To_1_1_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_EmployeeStockMember_oauLVrUQf0Cdq6kFtZ4aEg"
      decimals="INF"
      id="Narr_YsKLxa2kOkywFwZUR-y9zg"
      unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ">194518</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_12_31_2022_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_EmployeeStockMember_h6LWksYkZk-wYDJVCmudqg"
      decimals="INF"
      id="Narr_CCqVi1zsrkepb_36f9vasA"
      unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ">1559151</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_EmployeeStockMember_cKXRqo7dk0-EdILU7PZBhg"
      decimals="-5"
      id="Narr_GncSWJIWn0Kxu_DUeDEY1Q"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_EmployeeStockMember_5xoE_s_XYkyuIAK5oWCe8Q"
      decimals="-5"
      id="Narr_XAoehqw_wkGf7-6-9F9ijw"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_EmployeeStockMember_8hDu8hXfJECRLadm6BTlqQ"
      decimals="-5"
      id="Narr_a-eUq54Yl0m94q2Ck_6Utw"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">900000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      id="Tb_twJ05CDow0yds3g40tQJCw">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Note 14. &#160;Revenue&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;"&gt;We derive our revenue from the sale and rental of our products to our customers in the United States. The following table presents our revenue, inclusive of sales and rental revenue, disaggregated by product:&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:44.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:55.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:55.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;(In&#160;thousands)&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Revenue&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Lymphedema products&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 212,266&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 202,913&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 187,130&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Airway clearance products&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 34,519&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 5,144&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 246,785&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 208,057&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 187,130&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:44.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Percentage of total revenue&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Lymphedema products&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt;86%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt;98%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt;100%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Airway clearance products&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt;14%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt;2%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt;N.M.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt;100%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt;100%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.93%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt;100%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;"&gt;Our revenue by channel, inclusive of sales and rental revenue, for the years ended December&#160;31,&#160;2022, 2021 and 2020 are summarized in the following table:&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:44.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:44.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:55.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:55.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;(In&#160;thousands)&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Private insurers and other payers&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 139,087&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 141,377&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 132,789&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Veterans Administration&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 25,507&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 25,654&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 24,485&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Medicare&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 47,672&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 35,882&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 29,856&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Durable medical equipment distributors&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 34,519&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 5,144&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 246,785&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 208,057&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.93%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 187,130&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt;Our rental revenue is derived from rent-to-purchase arrangements that typically range from &lt;/span&gt;&lt;span style="-sec-ix-hidden:Hidden_8JEPt4Tv9EexWjz9141gSw;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;three&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; to &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;ten months&lt;/span&gt;&lt;span style="font-size:10pt;"&gt;. As title transfers to the patient, with whom we have the contract, upon the termination of the lease term and because collectability is probable, under ASC 842, these are recognized as sales-type leases. Each rental agreement contains two components, the controller and related garments, both of which are interdependent and recognized as one lease component. &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:11pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 11pt 0pt;"&gt;The revenue and associated cost of revenue of sales-type leases are recognized on the lease commencement date and a net investment in leases is recorded on the Consolidated Balance Sheet. We bill the patients&#x2019; insurance payers monthly over the duration of the rental term. We record the net investment in leases and recognize revenue upon commencement of the lease in the amount of the expected consideration to be received through the monthly payments. Similar to our sales revenue, the transaction price is impacted by multiple factors, including the terms and conditions contracted by various third party payers. As the rental contract resides with the patients, we have elected the portfolio approach, at the payer level, to determine the expected consideration, which considers the impact of early terminations. While the contract is with the patient, in certain circumstances, the third party payer elects an initial rental period with an option to extend. We assess the likelihood of extending the lease at the onset of the lease to determine if the option is reasonably certain to be exercised. As the lease is short-term in nature, we anticipate collection of substantially all of the net investment within the first year of the lease agreement. Completion of these payments represents the fair market value of the equipment, and as such, interest income is not applicable. &lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:11pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt 0pt 11pt 0pt;"&gt;Rental revenue for the years ended December&#160;31,&#160;2022, 2021 and 2020, was primarily related to private insurers. Sales-type lease revenue and the associated cost of revenue for the years ended December&#160;31,&#160;2022, 2021 and 2020, was:&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:37.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:37.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:56.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:37.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;(In&#160;thousands)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:37.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Sales-type lease revenue&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 35,440&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 30,143&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 25,633&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:37.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Cost of sales-type lease revenue&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,190&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,622&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,011&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:37.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Gross profit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 24,250&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 20,521&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 16,622&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      id="Tb_wglRPKvPiUqNEBLu0OJRGw">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:44.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:55.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:55.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;(In&#160;thousands)&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Revenue&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Lymphedema products&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 212,266&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 202,913&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 187,130&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Airway clearance products&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 34,519&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 5,144&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 246,785&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 208,057&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 187,130&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:44.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Percentage of total revenue&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Lymphedema products&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt;86%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt;98%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt;100%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Airway clearance products&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt;14%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt;2%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt;N.M.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt;100%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt;100%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.93%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt;100%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_tcmd_FlexitouchSystemMember_CGH6jrZrrEuNDGgcZtJaOQ"
      decimals="-3"
      id="Tc_WYs9uCCgeUGEP1f8lKKCQQ_5_2"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">212266000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_tcmd_FlexitouchSystemMember_DXKUE6FvQUC574PEnBV1Ow"
      decimals="-3"
      id="Tc_q9xnLz3wpUq6NBzLXJzWDw_5_5"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">202913000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_ProductOrServiceAxis_tcmd_FlexitouchSystemMember_H2Jxo4pTn0OGkO2d39JE6g"
      decimals="-3"
      id="Tc_UamahxSdJE-WVs2vLxYSgQ_5_8"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">187130000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_tcmd_AfflovestMember_dBqlEgBFb02-NFr9MvkVnw"
      decimals="-3"
      id="Tc_lxOGcxfrs0eLFjiFJWpBiw_6_2"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">34519000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_tcmd_AfflovestMember__lGIQFNyT06Uzw8ThGA7KA"
      decimals="-3"
      id="Tc_h-MZKXJvc0O6fExPO1MZ3w_6_5"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">5144000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      decimals="-3"
      id="Tc_sK1LJCrR30u96rmWUmuy5g_7_2"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">246785000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g"
      decimals="-3"
      id="Tc__w_vYc9N_kavNC0gPgOwdA_7_5"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">208057000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA"
      decimals="-3"
      id="Tc_AOw4xfX-B06qWi6un2JnqA_7_8"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">187130000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <tcmd:PercentageOfRevenue
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_tcmd_FlexitouchSystemMember_CGH6jrZrrEuNDGgcZtJaOQ"
      decimals="2"
      id="Tc_ti9ARL2iq0GfeYteLM6wPw_10_2"
      unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw">0.86</tcmd:PercentageOfRevenue>
    <tcmd:PercentageOfRevenue
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_tcmd_FlexitouchSystemMember_DXKUE6FvQUC574PEnBV1Ow"
      decimals="2"
      id="Tc_I4JKpZATME-mUjmd5N_Mdg_10_5"
      unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw">0.98</tcmd:PercentageOfRevenue>
    <tcmd:PercentageOfRevenue
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_ProductOrServiceAxis_tcmd_FlexitouchSystemMember_H2Jxo4pTn0OGkO2d39JE6g"
      decimals="2"
      id="Tc_X_XIbTIEBUef4fb5Uis1cw_10_8"
      unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw">1</tcmd:PercentageOfRevenue>
    <tcmd:PercentageOfRevenue
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_tcmd_AfflovestMember_dBqlEgBFb02-NFr9MvkVnw"
      decimals="2"
      id="Tc_BC-LHcY-BUSKmDUxOEymww_11_2"
      unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw">0.14</tcmd:PercentageOfRevenue>
    <tcmd:PercentageOfRevenue
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_tcmd_AfflovestMember__lGIQFNyT06Uzw8ThGA7KA"
      decimals="2"
      id="Tc_EOW_oZs500y5V1lWmle3Kg_11_5"
      unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw">0.02</tcmd:PercentageOfRevenue>
    <tcmd:PercentageOfRevenue
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      decimals="2"
      id="Tc_NVzwUl_ZA0mssYmdjchdEA_12_2"
      unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw">1</tcmd:PercentageOfRevenue>
    <tcmd:PercentageOfRevenue
      contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g"
      decimals="2"
      id="Tc_ZcY6vIwMxkyc-YMS56oZNw_12_5"
      unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw">1</tcmd:PercentageOfRevenue>
    <tcmd:PercentageOfRevenue
      contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA"
      decimals="2"
      id="Tc_iSQSkJNhJ0uVSen2_LVApA_12_8"
      unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw">1</tcmd:PercentageOfRevenue>
    <tcmd:ScheduleOfRevenueFromThirdPartyPayersTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      id="Tb_nlHTxFgJiEy37GjLNbC5aw">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:44.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:44.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:55.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:55.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;(In&#160;thousands)&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Private insurers and other payers&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 139,087&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 141,377&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 132,789&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Veterans Administration&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 25,507&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 25,654&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 24,485&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Medicare&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 47,672&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 35,882&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 29,856&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Durable medical equipment distributors&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 34,519&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 5,144&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 246,785&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 208,057&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.93%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 187,130&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</tcmd:ScheduleOfRevenueFromThirdPartyPayersTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_tcmd_PrivateInsurersMember_Gl5_xQhWx0SDBOy0s9jDJA"
      decimals="-3"
      id="Tc_RioCTkd3J0GlEGVYPZpHbw_4_2"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">139087000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_tcmd_PrivateInsurersMember_7J0YXfLIgU2pD3Cizu1_Aw"
      decimals="-3"
      id="Tc_q7w1aoivC02rAedFmr6AOg_4_5"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">141377000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_MajorCustomersAxis_tcmd_PrivateInsurersMember_6NttS8BSLkSGb2rID11mYQ"
      decimals="-3"
      id="Tc_X9MCOxoV9U2T8-Qpd5N-GQ_4_8"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">132789000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_tcmd_VeteransAdministrationMember_UImO_mSEIUWRj4_3Jkesdw"
      decimals="-3"
      id="Tc_Jq1FO9QnGE26WedJD3wFZw_5_2"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">25507000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_tcmd_VeteransAdministrationMember_QGri6VTOrky2n0lhb6O-wg"
      decimals="-3"
      id="Tc_vpz8j3r2D0-Wt13IhrUZhQ_5_5"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">25654000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_MajorCustomersAxis_tcmd_VeteransAdministrationMember_nKPbjM6STkCgVrqDgy_u8Q"
      decimals="-3"
      id="Tc_eGY9f2md6EmABLMDXbpbbw_5_8"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">24485000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_tcmd_MedicareMember_K5sCGhJDSUOfkdarnEOQWg"
      decimals="-3"
      id="Tc_9vYGcNqrqEK4gP88jzGYUw_6_2"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">47672000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_tcmd_MedicareMember_rK1KRWcE20Ot8cBmMKEQsA"
      decimals="-3"
      id="Tc_pGaZBmkcLE2W51bcsBHX7g_6_5"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">35882000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_MajorCustomersAxis_tcmd_MedicareMember__J8_VCY0Ok-NPKhYcRHpiw"
      decimals="-3"
      id="Tc_pI1scNkMI0u_z6wGExagbw_6_8"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">29856000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_tcmd_DurableMedicalEquipmentDistributorsMember_VSaj6O2pMU2ypZXriiw1kg"
      decimals="-3"
      id="Tc_3vTAldIAe0q-8oXUMyx9gQ_7_2"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">34519000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_tcmd_DurableMedicalEquipmentDistributorsMember_FRHWIP8w2UG8vVzzhUcyKg"
      decimals="-3"
      id="Tc_3SkpumlQ00-wOeQ4V1fCUA_7_5"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">5144000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      decimals="-3"
      id="Tc_wmCwb9ZXA0Sw3w6DQHqUFg_8_2"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">246785000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g"
      decimals="-3"
      id="Tc_GB7XSCie1UqzxKKbS9RiHw_8_5"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">208057000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA"
      decimals="-3"
      id="Tc_nefKKYRRMUGpHSQ6Uw4sKw_8_8"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">187130000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <tcmd:RentToPurchaseArrangementsRentalPeriod
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_VpuMgvUm10Cec1Yu-NEe1Q"
      id="Narr_ChLHHKEdRkKQeKL7tOYaiw">P10M</tcmd:RentToPurchaseArrangementsRentalPeriod>
    <us-gaap:SalesTypeLeaseLeaseIncomeTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      id="Tb_ItQwJzjR1kas9PC6qDxAYQ">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:37.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:37.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:56.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:37.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;(In&#160;thousands)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:37.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Sales-type lease revenue&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 35,440&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 30,143&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 25,633&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:37.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Cost of sales-type lease revenue&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,190&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,622&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,011&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:37.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Gross profit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 24,250&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 20,521&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 16,622&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:SalesTypeLeaseLeaseIncomeTableTextBlock>
    <us-gaap:SalesTypeLeaseRevenue
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      decimals="-3"
      id="Tc_a7-w_WKc1USt_jHN2LQ-0Q_3_4"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">35440000</us-gaap:SalesTypeLeaseRevenue>
    <us-gaap:SalesTypeLeaseRevenue
      contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g"
      decimals="-3"
      id="Tc_nhbRP0JZZES2yNIkIbQMmg_3_7"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">30143000</us-gaap:SalesTypeLeaseRevenue>
    <us-gaap:SalesTypeLeaseRevenue
      contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA"
      decimals="-3"
      id="Tc_QMtji4nqSUCA4DOzoK9jyw_3_10"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">25633000</us-gaap:SalesTypeLeaseRevenue>
    <us-gaap:CostOfGoodsSoldSalesTypeLease
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      decimals="-3"
      id="Tc_MUZc1kSyTk6GZ0eTU8ZnBw_4_4"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">11190000</us-gaap:CostOfGoodsSoldSalesTypeLease>
    <us-gaap:CostOfGoodsSoldSalesTypeLease
      contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g"
      decimals="-3"
      id="Tc_GAyBUQexdkeJXMl5pj_Euw_4_7"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">9622000</us-gaap:CostOfGoodsSoldSalesTypeLease>
    <us-gaap:CostOfGoodsSoldSalesTypeLease
      contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA"
      decimals="-3"
      id="Tc_NmMvZeA6i0GR5T8q9B9v8A_4_10"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">9011000</us-gaap:CostOfGoodsSoldSalesTypeLease>
    <us-gaap:SalesTypeLeaseSellingProfitLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      decimals="-3"
      id="Tc__D3kYtHDeU-LPVxljXQx6g_5_4"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">24250000</us-gaap:SalesTypeLeaseSellingProfitLoss>
    <us-gaap:SalesTypeLeaseSellingProfitLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g"
      decimals="-3"
      id="Tc_5qb1OfmO10inE86-TVM3pg_5_7"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">20521000</us-gaap:SalesTypeLeaseSellingProfitLoss>
    <us-gaap:SalesTypeLeaseSellingProfitLoss
      contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA"
      decimals="-3"
      id="Tc_JUTwsCvtGUuI0HK0Kx3Aew_5_10"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">16622000</us-gaap:SalesTypeLeaseSellingProfitLoss>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      id="Tb_0phMMrbH00uQiv2IxSbcTA">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Note 15. &#160;Income Taxes&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;"&gt;The provision (benefit) for income tax expense consisted of the following:&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:52.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:44.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;(In&#160;thousands)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Current income taxes, Federal&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 1,838&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (1,274)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (653)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Current income taxes, State&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 637&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 214&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 294&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 2,475&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (1,060)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (359)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Deferred income taxes, Federal&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (32)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 7,874&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (833)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Deferred income taxes, State&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 2,356&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (395)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (32)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 10,230&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (1,228)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Unrecognized tax benefit, Federal&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (50)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 348&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Unrecognized tax benefit, State&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (54)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (50)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 348&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (54)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;"&gt;Total provision (benefit) for income taxes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 2,393&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 9,518&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (1,641)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;"&gt;The components of our deferred tax assets and liabilities were as follows:&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:61.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:35.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;At December&#160;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;(In&#160;thousands)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Deferred tax assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 12pt;"&gt;Operating lease liability&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 5,945&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 6,490&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 12pt;"&gt;Net operating loss carryforwards&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 179&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 671&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 12pt;"&gt;Accounts receivable and inventory reserves&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 6,013&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 4,658&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 12pt;"&gt;Stock-based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 4,886&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 3,777&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 12pt;"&gt;Accrued liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 1,914&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 1,104&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 12pt;"&gt;Warranty reserves&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 1,071&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 1,245&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 12pt;"&gt;Intangible assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 2,947&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 579&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 12pt;"&gt;Business credits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 536&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 682&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 12pt;"&gt;R&amp;amp;D expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 1,103&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 12pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 183&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 199&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Total deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 24,777&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 19,405&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Deferred tax liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 12pt;"&gt;Right-of-use asset&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (5,425)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (6,019)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 12pt;"&gt;Fixed assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (1,080)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (914)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 12pt;"&gt;Prepaid expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (251)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (378)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 12pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (186)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (87)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Total deferred tax liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (6,942)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (7,398)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 12pt;"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (17,835)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (12,039)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Net deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (32)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;padding-bottom:12pt;background:#ffffff;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;"&gt;A reconciliation of income tax (benefit) expense to the statutory federal tax rate is as follows:&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:53.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:44.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Tax expense at statutory rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 21.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 21.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 21.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;State income taxes, net of federal benefit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 4.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (1.1)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (7.9)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Executive compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (14.2)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (5.5)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Meals and entertainment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (10.6)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Incentive stock options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (0.4)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Employee Stock Purchase Plan&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (1.0)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (7.5)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (8.6)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Federal business credits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 1.6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 10.9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (37.4)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (525.0)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 8.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Return to provision&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (0.2)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (6.5)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 3.6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Research and development credits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 60.2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;IRS exam&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 2.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Deferred reprice - state&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 0.9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 3.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Federal carryback claim deferred rate differential&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 38.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Unrecognized tax benefits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (0.3)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (2.2)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 2.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Excess benefit on non-qualified stock options and RSUs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (3.7)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 47.2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 28.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Interest and penalties&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (0.7)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 1.9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (0.5)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (0.5)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (0.2)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;"&gt;Net effective rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (15.5)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (415.1)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 72.6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;"&gt;A reconciliation of unrecognized tax benefits (&#x201c;UTB&#x201d;) is as follows:&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:54.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:54.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:43.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:54.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;(In&#160;thousands)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:54.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Balance beginning of the year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 522&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 54&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:54.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Gross change &#x2014; tax positions in prior year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 90&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 522&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (54)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:54.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;"&gt;Balance end of the year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 612&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 522&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:14pt;padding-top:2pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"&gt;Deferred income taxes result from temporary differences between the reporting of amounts for financial statement purposes and income tax purposes. These differences relate primarily to different methods used for income tax purposes including depreciation and amortization, warranty and vacation accruals, and deductions related to allowances for doubtful accounts receivable, and inventory reserves.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:14pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"&gt;As of December 31, 2022, the Company had approximately $179 thousand of state net operating loss ("NOL") carryforwards. The state NOL carryforward amounts expire beginning in tax years 2027 if not utilized.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:14pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"&gt;The Company is subject to income tax examinations in the U.S. federal jurisdiction as well as in various state jurisdictions. U.S. federal and state tax years prior to 2019 are closed to examination. In the event of any future tax assessments, we have elected to record the income taxes and any related interest and penalties as income tax expense on our Consolidated Statement of Operations. The Company is not under exam in any jurisdictions.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:14pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"&gt;We recognize the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. For tax positions meeting the more likely than not threshold, the amount recognized in the consolidated financial statements is the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement with the relevant tax authority. &lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:14pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"&gt;Management assesses the available positive and negative evidence to estimate whether sufficient future taxable income will be generated to permit use of the existing deferred tax assets. A significant piece of objective negative evidence evaluated was the cumulative loss expected to be incurred over the three-year period ended December 31, 2022. Such objective evidence limits the ability to consider other subjective evidence, such as our projections for future growth. &lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:14pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"&gt;On the basis of this evaluation, as of December 31, 2022, a valuation allowance of $17.8 million was recorded to recognize only the portion of the deferred tax assets that is more likely than not to be realized. The amount of the deferred tax assets considered realizable, however, could be adjusted if estimates of future taxable income during the carryforward period are reduced or increased or if objective negative evidence in the form of cumulative losses is no longer present and additional weight is given to subjective evidence such as our projections for growth. &lt;span style="background:#ffff00;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      id="Tb_vRtuGO9D80SEA-e8AX_vPg">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:52.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:44.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;(In&#160;thousands)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Current income taxes, Federal&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 1,838&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (1,274)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (653)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Current income taxes, State&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 637&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 214&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 294&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 2,475&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (1,060)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (359)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Deferred income taxes, Federal&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (32)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 7,874&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (833)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Deferred income taxes, State&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 2,356&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (395)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (32)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 10,230&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (1,228)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Unrecognized tax benefit, Federal&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (50)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 348&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Unrecognized tax benefit, State&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (54)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (50)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 348&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (54)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;"&gt;Total provision (benefit) for income taxes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 2,393&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 9,518&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (1,641)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      decimals="-3"
      id="Tc_yUBBycTYj0Wy55m3LbMunA_3_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">1838000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g"
      decimals="-3"
      id="Tc_ax7Y7h0ji0y5GDcx-RG9Dg_3_6"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">-1274000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA"
      decimals="-3"
      id="Tc_TsOIe8J7M0iUwlUG2S0KfQ_3_9"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">-653000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      decimals="-3"
      id="Tc_zaDQarCzgU69hdy5XHrIqg_4_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">637000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g"
      decimals="-3"
      id="Tc_KcPTVJ53lUqPwiPqBNNOTg_4_6"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">214000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA"
      decimals="-3"
      id="Tc_7-VtqRJFeEqCf5JTKQu0yQ_4_9"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">294000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      decimals="-3"
      id="Tc_-jhMG7cWWEqEcrduhmPmvg_5_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">2475000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g"
      decimals="-3"
      id="Tc_X87I-X4re0q0P9Uv19PU4w_5_6"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">-1060000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA"
      decimals="-3"
      id="Tc_eeBcwlE0vk-ZuNz780drmA_5_9"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">-359000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      decimals="-3"
      id="Tc_5FJ7l8Xss0u_t1tSXAsImQ_7_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">-32000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g"
      decimals="-3"
      id="Tc_h102KgIQKkyrCCPcM06Uxg_7_6"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">7874000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA"
      decimals="-3"
      id="Tc_-tcoa-sI8E-WFnU6tNR_Xw_7_9"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">-833000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g"
      decimals="-3"
      id="Tc_FibORdBgbUq9bF2Gxr_gKw_8_6"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">2356000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA"
      decimals="-3"
      id="Tc_jk8CCdc74k61GlF5zVpXBw_8_9"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">-395000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      decimals="-3"
      id="Tc_2gjUxBhDHkmZxt8lTW8rzw_9_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">-32000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g"
      decimals="-3"
      id="Tc_i8eS4xJgDEazl2o4rfOwmw_9_6"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">10230000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA"
      decimals="-3"
      id="Tc_s1tuYXnKFEad8WqsPWUTBQ_9_9"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">-1228000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_CnxzEZbj2keHiRpKCxnEuw"
      decimals="-3"
      id="Tc_7D6DPk1quUSQRf3zBoOTdg_11_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">-50000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_CdFl24OyvE-vHZl3Dyt3tg"
      decimals="-3"
      id="Tc_psXUjmWTp0a2FCYhlJzQXQ_11_6"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">348000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_IoIhyk8NdE6DGInICUHwgg"
      decimals="-3"
      id="Tc_3kbtORAqE0e-Ym1KTB525Q_12_9"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">-54000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      decimals="-3"
      id="Tc_fK5jdotflUyiDN1TjdcBkA_13_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">-50000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g"
      decimals="-3"
      id="Tc_QyEPSh06OkiMyeieXYFjjA_13_6"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">348000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA"
      decimals="-3"
      id="Tc_I-IrMAIDRUK_LMm6VjL3qQ_13_9"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">-54000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      decimals="-3"
      id="Tc_3qeIJJGHo0m2O7nJ48Xiyg_15_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">2393000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g"
      decimals="-3"
      id="Tc_9qSIgOrTAEu5-PcVulHIfw_15_6"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">9518000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA"
      decimals="-3"
      id="Tc_6Lq_t0LqyUmol7EPJevWkQ_15_9"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">-1641000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      id="Tb_KGHvySR_LkuRmM_q831dPQ">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:61.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:35.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;At December&#160;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;(In&#160;thousands)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Deferred tax assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 12pt;"&gt;Operating lease liability&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 5,945&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 6,490&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 12pt;"&gt;Net operating loss carryforwards&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 179&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 671&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 12pt;"&gt;Accounts receivable and inventory reserves&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 6,013&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 4,658&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 12pt;"&gt;Stock-based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 4,886&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 3,777&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 12pt;"&gt;Accrued liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 1,914&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 1,104&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 12pt;"&gt;Warranty reserves&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 1,071&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 1,245&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 12pt;"&gt;Intangible assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 2,947&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 579&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 12pt;"&gt;Business credits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 536&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 682&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 12pt;"&gt;R&amp;amp;D expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 1,103&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 12pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 183&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 199&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Total deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 24,777&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 19,405&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Deferred tax liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 12pt;"&gt;Right-of-use asset&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (5,425)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (6,019)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 12pt;"&gt;Fixed assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (1,080)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (914)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 12pt;"&gt;Prepaid expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (251)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (378)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 12pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (186)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (87)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Total deferred tax liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (6,942)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (7,398)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 12pt;"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (17,835)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (12,039)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Net deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (32)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;padding-bottom:12pt;background:#ffffff;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <tcmd:DeferredTaxAssetsOperatingLeaseLiability
      contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw"
      decimals="-3"
      id="Tc_81sF-AEoHUepG9OuR-2yAw_4_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">5945000</tcmd:DeferredTaxAssetsOperatingLeaseLiability>
    <tcmd:DeferredTaxAssetsOperatingLeaseLiability
      contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q"
      decimals="-3"
      id="Tc_tha-kHyA6UiTj31EbOaEbA_4_6"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">6490000</tcmd:DeferredTaxAssetsOperatingLeaseLiability>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw"
      decimals="-3"
      id="Tc_Hzgz7uG9rUGUVMRRytIICw_5_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">179000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q"
      decimals="-3"
      id="Tc_Med7MzgSm06EwnRcjAeiMA_5_6"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">671000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts
      contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw"
      decimals="-3"
      id="Tc_w1TpJCIRqUWVCdVTcqUzsw_6_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">6013000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts
      contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q"
      decimals="-3"
      id="Tc_DBO9DjXV5kSJzAckenBLkw_6_6"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">4658000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw"
      decimals="-3"
      id="Tc_ZsEWjbOUM02MD8BpmC1tcQ_7_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">4886000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q"
      decimals="-3"
      id="Tc_gGipb-v_mE6vKheaXP1ptw_7_6"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">3777000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw"
      decimals="-3"
      id="Tc_wJTrsGq770m0dHKoX8L4aA_8_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">1914000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q"
      decimals="-3"
      id="Tc_AlPV_vHIaUeYyNPpy0Jc8w_8_6"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">1104000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves
      contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw"
      decimals="-3"
      id="Tc_HUAXHLW8FU2KIhMQ_93DZw_9_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">1071000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves
      contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q"
      decimals="-3"
      id="Tc_3aIAgA9gWkCC3jh01kWBBw_9_6"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">1245000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw"
      decimals="-3"
      id="Tc_BhGWgwThr0mNnzisDwyGtw_10_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">2947000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q"
      decimals="-3"
      id="Tc_jAYlKaaoAU6fUetTbI4jTg_10_6"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">579000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <tcmd:DeferredTaxAssetsBusinessCredits
      contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw"
      decimals="-3"
      id="Tc_zLSBgZpogU-hR-ehlasrtg_11_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">536000</tcmd:DeferredTaxAssetsBusinessCredits>
    <tcmd:DeferredTaxAssetsBusinessCredits
      contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q"
      decimals="-3"
      id="Tc_0TDOHuGu-0WTULN4DkkMfA_11_6"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">682000</tcmd:DeferredTaxAssetsBusinessCredits>
    <tcmd:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsResearchAndDevelopmentExpenses
      contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw"
      decimals="-3"
      id="Tc_lyK-H34_YkewfEAgSr2VvQ_12_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">1103000</tcmd:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsResearchAndDevelopmentExpenses>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw"
      decimals="-3"
      id="Tc_ZzKJ5PIjJ0CpUxYlE8P5FQ_13_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">183000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q"
      decimals="-3"
      id="Tc_mwYVviwTZk2FCerkbplfFQ_13_6"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">199000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw"
      decimals="-3"
      id="Tc_9BNjw-UgHk-kFidaN7gILg_14_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">24777000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q"
      decimals="-3"
      id="Tc_EV8QyW7XxU2F2OCnhoEAig_14_6"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">19405000</us-gaap:DeferredTaxAssetsGross>
    <tcmd:DeferredTaxLiabilitiesRightOfUseAssets
      contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw"
      decimals="-3"
      id="Tc_O83bapA7CUCTLvXmrEjxCA_17_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">5425000</tcmd:DeferredTaxLiabilitiesRightOfUseAssets>
    <tcmd:DeferredTaxLiabilitiesRightOfUseAssets
      contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q"
      decimals="-3"
      id="Tc_lu5xUIl-W0WYBXJH078T2Q_17_6"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">6019000</tcmd:DeferredTaxLiabilitiesRightOfUseAssets>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw"
      decimals="-3"
      id="Tc_R8lwB4H8M0mY0ji07dydEw_18_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">1080000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q"
      decimals="-3"
      id="Tc_DSLxYuVoRUGZ3gwAy2RJEQ_18_6"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">914000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPrepaidExpenses
      contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw"
      decimals="-3"
      id="Tc_I18nLjVD3UePqF9iNCBjMg_19_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">251000</us-gaap:DeferredTaxLiabilitiesPrepaidExpenses>
    <us-gaap:DeferredTaxLiabilitiesPrepaidExpenses
      contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q"
      decimals="-3"
      id="Tc_rORmyNprz0ijH3lZ8FvImg_19_6"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">378000</us-gaap:DeferredTaxLiabilitiesPrepaidExpenses>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw"
      decimals="-3"
      id="Tc_BcDO9UBjGUespkGwI8wWKA_20_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">186000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q"
      decimals="-3"
      id="Tc_GAvMaQN6bEKU3OVZV_FOtw_20_6"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">87000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw"
      decimals="-3"
      id="Tc_qn1t9ET3F0WrIq9cl4MuEw_21_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">6942000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q"
      decimals="-3"
      id="Tc_oDjYNwv0nkaZLR2sFsi5Lw_21_6"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">7398000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw"
      decimals="-3"
      id="Tc_IrBV4XeLKE2sIBRx8BckNQ_23_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">17835000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q"
      decimals="-3"
      id="Tc_CgiX2c968kqaNmkedH5ZGA_23_6"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">12039000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q"
      decimals="-3"
      id="Tc_jwClA5Y3DUa0gQ_2rU-Kzw_25_6"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">32000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      id="Tb_LL0u6zU1BEqG2sFY9HEHJQ">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:53.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:44.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Tax expense at statutory rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 21.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 21.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 21.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;State income taxes, net of federal benefit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 4.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (1.1)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (7.9)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Executive compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (14.2)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (5.5)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Meals and entertainment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (10.6)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Incentive stock options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (0.4)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Employee Stock Purchase Plan&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (1.0)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (7.5)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (8.6)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Federal business credits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 1.6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 10.9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (37.4)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (525.0)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 8.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Return to provision&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (0.2)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (6.5)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 3.6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Research and development credits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 60.2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;IRS exam&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 2.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Deferred reprice - state&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 0.9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 3.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Federal carryback claim deferred rate differential&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 38.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Unrecognized tax benefits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (0.3)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (2.2)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 2.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Excess benefit on non-qualified stock options and RSUs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (3.7)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 47.2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 28.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Interest and penalties&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (0.7)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 1.9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (0.5)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (0.5)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (0.2)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;"&gt;Net effective rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (15.5)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (415.1)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 72.6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      decimals="3"
      id="Tc_bAnu5wU4X0WOA4rtz5tvrA_3_2"
      unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g"
      decimals="3"
      id="Tc_4dGL9vVk30icV7rP6YF0tw_3_5"
      unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA"
      decimals="3"
      id="Tc_C77eMJFPGkSrq1K7fah5mA_3_8"
      unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      decimals="3"
      id="Tc_dBLVVEfWkEWt53v6cBFOhQ_4_2"
      unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw">0.041</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g"
      decimals="3"
      id="Tc_3jIoi4_U6UWUJR-w5DTb1g_4_5"
      unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw">-0.011</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA"
      decimals="3"
      id="Tc_dUc_4pN0GUiDpgR1UlOEvQ_4_8"
      unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw">-0.079</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <tcmd:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationPercent
      contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g"
      decimals="3"
      id="Tc_CCc4JsboKkG1kkODB0wWsw_5_5"
      unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw">-0.142</tcmd:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationPercent>
    <tcmd:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationPercent
      contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA"
      decimals="3"
      id="Tc_QzeUEyRauU-2GrBOlZfnHA_5_8"
      unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw">-0.055</tcmd:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment
      contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA"
      decimals="3"
      id="Tc_nPyIs37eAkKmP4MEuX1BQg_6_8"
      unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw">-0.106</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment>
    <tcmd:EffectiveIncomeTaxRateReconciliationIncentiveStockOptions
      contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA"
      decimals="3"
      id="Tc_NnXG3wayvked0MW5nL59sQ_7_8"
      unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw">-0.004</tcmd:EffectiveIncomeTaxRateReconciliationIncentiveStockOptions>
    <tcmd:EffectiveIncomeTaxRateReconciliationEmployeeStockPurchasePlan
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      decimals="3"
      id="Tc_XYl9w4ldNUK60R9gNHCKRA_8_2"
      unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw">-0.010</tcmd:EffectiveIncomeTaxRateReconciliationEmployeeStockPurchasePlan>
    <tcmd:EffectiveIncomeTaxRateReconciliationEmployeeStockPurchasePlan
      contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g"
      decimals="3"
      id="Tc_HHchc08Ab0-Z9Nm8ZHG32g_8_5"
      unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw">-0.075</tcmd:EffectiveIncomeTaxRateReconciliationEmployeeStockPurchasePlan>
    <tcmd:EffectiveIncomeTaxRateReconciliationEmployeeStockPurchasePlan
      contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA"
      decimals="3"
      id="Tc_yHChl3x-gEuLabYSeo7y8A_8_8"
      unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw">-0.086</tcmd:EffectiveIncomeTaxRateReconciliationEmployeeStockPurchasePlan>
    <tcmd:EffectiveIncomeTaxRateReconciliationFederalBusinessCreditPercent
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      decimals="3"
      id="Tc_kKjl8iJuE0m6UfSgBi0V5Q_9_2"
      unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw">0.016</tcmd:EffectiveIncomeTaxRateReconciliationFederalBusinessCreditPercent>
    <tcmd:EffectiveIncomeTaxRateReconciliationFederalBusinessCreditPercent
      contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g"
      decimals="3"
      id="Tc_cNm4uOsdkk2kuqjGzLl7bA_9_5"
      unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw">0.109</tcmd:EffectiveIncomeTaxRateReconciliationFederalBusinessCreditPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      decimals="3"
      id="Tc_CmbkWufQAES9NO6cpWz7tA_10_2"
      unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw">-0.374</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g"
      decimals="3"
      id="Tc_X3TcweT8ukikFs1h1DddFQ_10_5"
      unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw">-5.250</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA"
      decimals="3"
      id="Tc_DJQMKxppn0yz2td3lFy5XQ_10_8"
      unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw">0.080</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <tcmd:EffectiveIncomeTaxRateReconciliationReturnToProvision
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      decimals="3"
      id="Tc_z4b8pMcsEUiRsm7Rr7PYhA_11_2"
      unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw">-0.002</tcmd:EffectiveIncomeTaxRateReconciliationReturnToProvision>
    <tcmd:EffectiveIncomeTaxRateReconciliationReturnToProvision
      contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g"
      decimals="3"
      id="Tc_0CnzezVRHkK_qnKCOXxaGQ_11_5"
      unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw">-0.065</tcmd:EffectiveIncomeTaxRateReconciliationReturnToProvision>
    <tcmd:EffectiveIncomeTaxRateReconciliationReturnToProvision
      contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA"
      decimals="3"
      id="Tc_giK3qx435UWKmAD0kCouvg_11_8"
      unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw">0.036</tcmd:EffectiveIncomeTaxRateReconciliationReturnToProvision>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
      contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g"
      decimals="3"
      id="Tc_K1q34R2StkOLBmX-ZGiM6g_12_5"
      unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw">0.602</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment>
    <tcmd:EffectiveIncomeTaxRateReconciliationInternalRevenueServiceExam
      contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA"
      decimals="3"
      id="Tc_6oAynu9gIU6XEbbO7fhjIQ_13_8"
      unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw">0.025</tcmd:EffectiveIncomeTaxRateReconciliationInternalRevenueServiceExam>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      decimals="3"
      id="Tc_y6fTrh1d9EqNDNo1D8bucQ_14_2"
      unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw">0.009</us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal
      contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g"
      decimals="3"
      id="Tc_N9UiTdeM8E23yo98l1zHpg_14_5"
      unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw">0.033</us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal>
    <tcmd:EffectiveIncomeTaxRateReconciliationFederalCarrybackClaimPercent
      contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA"
      decimals="3"
      id="Tc_UKjIdpCPM026wML8TyTQfA_15_8"
      unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw">0.385</tcmd:EffectiveIncomeTaxRateReconciliationFederalCarrybackClaimPercent>
    <tcmd:EffectiveIncomeTaxRateReconciliationUnrecognizedTaxBenefits
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      decimals="3"
      id="Tc_jE3Zau4uckuNIiJumeKMFg_16_2"
      unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw">-0.003</tcmd:EffectiveIncomeTaxRateReconciliationUnrecognizedTaxBenefits>
    <tcmd:EffectiveIncomeTaxRateReconciliationUnrecognizedTaxBenefits
      contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g"
      decimals="3"
      id="Tc__V3yoUgQokme8okSVquScA_16_5"
      unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw">-0.022</tcmd:EffectiveIncomeTaxRateReconciliationUnrecognizedTaxBenefits>
    <tcmd:EffectiveIncomeTaxRateReconciliationUnrecognizedTaxBenefits
      contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA"
      decimals="3"
      id="Tc_Nsg90IBFR0KKYY8pneUivA_16_8"
      unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw">0.023</tcmd:EffectiveIncomeTaxRateReconciliationUnrecognizedTaxBenefits>
    <tcmd:EffectiveIncomeTaxRateReconciliationExcessTaxBenefitOnNonQualifiedStockOptionsAndRsu
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      decimals="3"
      id="Tc_36-DuxOooUiAxUfAavAdoA_17_2"
      unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw">-0.037</tcmd:EffectiveIncomeTaxRateReconciliationExcessTaxBenefitOnNonQualifiedStockOptionsAndRsu>
    <tcmd:EffectiveIncomeTaxRateReconciliationExcessTaxBenefitOnNonQualifiedStockOptionsAndRsu
      contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g"
      decimals="3"
      id="Tc_o5iK1510IEOr6aE5Mien1Q_17_5"
      unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw">0.472</tcmd:EffectiveIncomeTaxRateReconciliationExcessTaxBenefitOnNonQualifiedStockOptionsAndRsu>
    <tcmd:EffectiveIncomeTaxRateReconciliationExcessTaxBenefitOnNonQualifiedStockOptionsAndRsu
      contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA"
      decimals="3"
      id="Tc_gcJF1TrBQUmcexCa6O-rzg_17_8"
      unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw">0.280</tcmd:EffectiveIncomeTaxRateReconciliationExcessTaxBenefitOnNonQualifiedStockOptionsAndRsu>
    <tcmd:EffectiveIncomeTaxRateReconciliationInterestAndPenaltyPercent
      contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g"
      decimals="3"
      id="Tc_dHPaH3Qg2kSFK-MbbxuPFg_18_5"
      unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw">-0.007</tcmd:EffectiveIncomeTaxRateReconciliationInterestAndPenaltyPercent>
    <tcmd:EffectiveIncomeTaxRateReconciliationInterestAndPenaltyPercent
      contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA"
      decimals="3"
      id="Tc_2uNGkIWqKEeFcV7Llg6Mvg_18_8"
      unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw">0.019</tcmd:EffectiveIncomeTaxRateReconciliationInterestAndPenaltyPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      decimals="3"
      id="Tc_ylGm5FKCDEi_GQfsjQiR2w_19_2"
      unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw">-0.005</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g"
      decimals="3"
      id="Tc__SpmDR2hIUiK8_xOKS4M0w_19_5"
      unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw">-0.005</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA"
      decimals="3"
      id="Tc_7TnF8kJB2EiOTgZFi-usug_19_8"
      unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw">-0.002</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      decimals="3"
      id="Tc_5U44jjgl-0abW4M8A2zihA_20_2"
      unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw">-0.155</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g"
      decimals="3"
      id="Tc_Zp-Mqjxuqkir5SdQWrHHAQ_20_5"
      unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw">-4.151</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA"
      decimals="3"
      id="Tc_IqoZQ_fKN0qTgFzxwqWaJw_20_8"
      unitRef="Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw">0.726</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      id="Tb_NP5PnNQ8JkqCKUVWkGazgw">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:54.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:54.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:43.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:54.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;(In&#160;thousands)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:54.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Balance beginning of the year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 522&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 54&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:54.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Gross change &#x2014; tax positions in prior year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 90&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 522&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (54)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:54.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;"&gt;Balance end of the year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 612&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 522&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q"
      decimals="-3"
      id="Tc_BqDLtUrQd0K-M7ITJ4D1gw_3_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">522000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_12_31_2019_3ga0jBjg6EKA4-znaQ36NQ"
      decimals="-3"
      id="Tc_-AVPV2zIcU-0hfCqa1TplQ_3_9"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">54000</us-gaap:UnrecognizedTaxBenefits>
    <tcmd:UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      decimals="-3"
      id="Tc_qmkM9ibNHEC7_ovHAfpbwQ_4_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">90000</tcmd:UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions>
    <tcmd:UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions
      contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g"
      decimals="-3"
      id="Tc_so5YEQgIzEm0jYLU8Jhufg_4_6"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">522000</tcmd:UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions>
    <tcmd:UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions
      contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA"
      decimals="-3"
      id="Tc_2VZglRvOCEy7__fX8Y6WCA_4_9"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">-54000</tcmd:UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw"
      decimals="-3"
      id="Tc_4PlBU_gHh0WWlO-WbPyheg_5_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">612000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q"
      decimals="-3"
      id="Tc_Wu4M1jR9j0yrBwr4hk1SuA_5_6"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">522000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_WDmzwEjdBUiA-CU6PKMNzQ"
      decimals="-5"
      id="Narr_h-0BfbmlWE23Wreme0RJaQ"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">179000000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw"
      decimals="-5"
      id="Narr_LJFbyMEq4EiSy_jHYJYR7A"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">17800000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      id="Tb_w7C4fztvxUKT4iWfvLLtaQ">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Note 16. &#160;Net (Loss) Income Per Common Share&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;"&gt;The following table sets forth the computation of our basic and diluted net loss per share:&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:57.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:42.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:42.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;(In&#160;thousands,&#160;except&#160;share and per share data)&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:57.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (17,866)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (11,811)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (620)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Weighted-average shares outstanding&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 20,067,969&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 19,719,485&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 19,346,929&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Weighted-average shares used to compute diluted net loss per share&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 20,067,969&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 19,719,485&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 19,346,929&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Net loss per share - Basic&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;(0.89)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;(0.60)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;(0.03)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Net loss per share - Diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;(0.89)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;(0.60)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;(0.03)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;"&gt;The following common stock equivalents were excluded from the computation of diluted net loss per common share for the periods presented because including them would have been anti-dilutive:&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:46.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:53.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:53.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Restricted stock units&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 590,542&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 265,616&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 218,686&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Common stock options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 615,307&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 915,224&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 1,039,709&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Performance stock units&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 155,618&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 54,317&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 96,383&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Employee stock purchase plan&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 100,506&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 34,809&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 53,205&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 1,461,973&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 1,269,966&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 1,407,983&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;background:#ffffff;margin:0pt;"&gt;&lt;span style="font-size:1pt;font-weight:bold;margin-bottom:5pt;margin-top:5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      id="Tb_jPIbHC4TfkieXtZNDiYlpw">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:57.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:42.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:42.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;(In&#160;thousands,&#160;except&#160;share and per share data)&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:57.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (17,866)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (11,811)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (620)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Weighted-average shares outstanding&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 20,067,969&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 19,719,485&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 19,346,929&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Weighted-average shares used to compute diluted net loss per share&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 20,067,969&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 19,719,485&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 19,346,929&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Net loss per share - Basic&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;(0.89)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;(0.60)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;(0.03)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Net loss per share - Diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;(0.89)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;(0.60)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;(0.03)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      decimals="-3"
      id="Tc_e6Ps1FGoa0KcpHIxFrrC7g_4_2"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">-17866000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g"
      decimals="-3"
      id="Tc_Jo3rrYfMZk2RlCSw_2uRTQ_4_5"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">-11811000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA"
      decimals="-3"
      id="Tc_MLzhjLavBkun-ibeiAJNlw_4_8"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">-620000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      decimals="0"
      id="Tc_AGUs1feRo0-g0_czn21yiw_5_2"
      unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ">20067969</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g"
      decimals="0"
      id="Tc_Hz_DfMNfwkignq9SUCYhoQ_5_5"
      unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ">19719485</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA"
      decimals="0"
      id="Tc__8JfVz0tpkeVmn66BO2FZg_5_8"
      unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ">19346929</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      decimals="0"
      id="Tc_uOD2RG6j8kmWAqT1eRt0Xw_6_2"
      unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ">20067969</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g"
      decimals="0"
      id="Tc_HezStFTjDEmNAuQ_cyK3CQ_6_5"
      unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ">19719485</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA"
      decimals="0"
      id="Tc_biVB9u7BaEWBMLt9BhTbxg_6_8"
      unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ">19346929</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      decimals="2"
      id="Tc_37xKf2qY0kyoVIt7Qhe1fw_7_2"
      unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q">-0.89</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g"
      decimals="2"
      id="Tc_PH3JpZ63_0e-YcuufXaiNw_7_5"
      unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q">-0.60</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA"
      decimals="2"
      id="Tc_GksFu9oJCkGZCNgWpLE6jQ_7_8"
      unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q">-0.03</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      decimals="2"
      id="Tc_6JeUMi-lAUGIBm9RtBvajA_8_2"
      unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q">-0.89</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g"
      decimals="2"
      id="Tc_h6zGhVMZjEuMmOR6wQuINg_8_5"
      unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q">-0.60</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA"
      decimals="2"
      id="Tc_fLTYT8fNLkSe4dxoS09QUQ_8_8"
      unitRef="Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q">-0.03</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      id="Tb_20p9yOQAp0CEVssUIeWCEw">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:46.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:53.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:53.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Restricted stock units&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 590,542&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 265,616&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 218,686&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Common stock options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 615,307&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 915,224&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 1,039,709&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Performance stock units&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 155,618&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 54,317&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 96,383&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Employee stock purchase plan&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 100,506&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 34,809&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 53,205&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 1,461,973&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 1,269,966&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 1,407,983&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_zrOdl-ZHU0eDIaMQWN19yQ"
      decimals="INF"
      id="Tc_ViSy-CS_m0aZyUhkuF2nSw_4_1"
      unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ">590542</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_CIZJzOcjHUyKmot1xYLGwA"
      decimals="INF"
      id="Tc_rAGN2IU9C0-ASjH4316vjQ_4_3"
      unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ">265616</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_t1GQxjJoS0WeSfGLeyxUPw"
      decimals="INF"
      id="Tc_WqnUrGU6IkOdQhKeT_i_uQ_4_5"
      unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ">218686</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_Qq8im1g0PUaVhc7NKNKkWg"
      decimals="INF"
      id="Tc_q1cOF1pD-E2-ffWIDxuNkg_5_1"
      unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ">615307</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_ghRyW-vZS0uZBW3nKbbR-g"
      decimals="INF"
      id="Tc_1bf93K1b80aWumBTIj25hQ_5_3"
      unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ">915224</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_bg4XNhQ5v0uWr2dXSfREiw"
      decimals="INF"
      id="Tc_nKlyDivgCU22S0AzgkKgPQ_5_5"
      unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ">1039709</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_PerformanceSharesMember_2SwhGbNgwU-bMQqkqXN2dA"
      decimals="INF"
      id="Tc_UKNZ1aSe5kSFfhAmFo3uIg_6_1"
      unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ">155618</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_PerformanceSharesMember_rMVulEGBZE-wAbQ2SAc66Q"
      decimals="INF"
      id="Tc_O9I7o4vi7kCuXaWQzjZg5w_6_3"
      unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ">54317</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_PerformanceSharesMember_c5JOwteMr0ax5Sb2--bJyg"
      decimals="INF"
      id="Tc_XZbXVBVlpEeSPiX1x-iIew_6_5"
      unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ">96383</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_tcmd_EmployeeStockPurchasePlanMember_4b4qjiA0fk6pyDx0k4A_zw"
      decimals="INF"
      id="Tc_nLo0qYRr8EKjJ_U3_vQaHQ_7_1"
      unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ">100506</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_tcmd_EmployeeStockPurchasePlanMember_f1tc7L44FUqMy8SxWvmMoQ"
      decimals="INF"
      id="Tc_MTc5tl0f30GhpZCz_7illA_7_3"
      unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ">34809</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_tcmd_EmployeeStockPurchasePlanMember_C8tXw8ygUkKbK1P0V6S3LQ"
      decimals="INF"
      id="Tc_s_Yq2dDZoEa0VG5bxOZnHA_7_5"
      unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ">53205</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      decimals="INF"
      id="Tc_bvhnnGsrg0KaeMC63a6HsA_8_1"
      unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ">1461973</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2021_To_12_31_2021_OKU-kLCon0-WS0JzrRoz5g"
      decimals="INF"
      id="Tc_MiQ9LaWeakidxr3Uf3fQEg_8_3"
      unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ">1269966</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2020_To_12_31_2020_7bM7TnCKjEehVMbmr8WlZA"
      decimals="INF"
      id="Tc_BiV6rKXjQE6hxbg9D6Hmuw_8_5"
      unitRef="Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ">1407983</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      id="Tb_Xgc1U9Isg0CUyj4vH7ypTg">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Note 17. &#160;Fair Value Measurements&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;We determine the fair value of our assets and liabilities based on the exchange price that would be received for an asset or paid to transfer a liability (exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value maximize the use of observable inputs and minimize the use of unobservable inputs. We use a fair value hierarchy with three levels of inputs, of which the first two are considered observable and the last unobservable, to measure fair value. The fair value hierarchy gives the highest priority to quoted prices in active markets for identical assets or liabilities (Level 1). The next highest priority is based on quoted prices for similar assets or liabilities in active markets or quoted prices for identical or similar assets or liabilities in non-active markets or other observable inputs (Level 2). The lowest priority is given to unobservable inputs (Level 3). As of December 31, 2021, we no longer had any money market mutual funds. &lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;We have obligations to pay a $5.0 million agreed-upon earn-out payment in cash and up to an additional $10.0 million earn-out payment in cash if certain future U.S. revenues of the AffloVest are met. The earn-out liability was valued by employing a Monte Carlo Simulation model in a risk-neutral framework, which is a Level 3 input. The underlying simulated variable includes recognized revenue. The recognized revenue volatility estimate was based on a study of historical asset volatility for a set of comparable public companies. The model includes other assumptions including the market price of risk, which was calculated as the weighted average cost of capital less the long-term risk-free rate. The earn-out liability is adjusted to fair value at each reporting date until settled. Changes in fair value will be included in intangible asset amortization and earn-out expenses in our Consolidated Statements of Operations.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;background:#ffffff;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="background:#ffffff;"&gt;Changes in the earn-out liability measured at fair value using Level 3 inputs were as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;background:#ffffff;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:69.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;(In&#160;thousands)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:26.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:69.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Earn-out liability at December 31, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 6,200&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:69.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;"&gt;Addition for acquisition&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:69.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;"&gt;Payment on earn-out&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (5,000)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:69.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;"&gt;Fair value adjustments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 11,850&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:69.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Earn-out liability at December 31, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 13,050&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;background:#ffffff;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;As of December 31, 2022, the fair value of the earn-out liability accrued but not yet earned totaled $8.1 million and was classified as a current liability. The remaining $5.0 million of the earn-out liability had been earned and is to be paid by May 26, 2023.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The following provides information regarding fair value measurements for our remaining contingent earn-out liability as of December&#160;31,&#160;2022, and December 31, 2021, according to the three-level fair value hierarchy:&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:36.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:61.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;At December 31, 2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Quoted&#160;Prices&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;in&#160;Active&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Markets&#160;for&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Other&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Identical&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Observable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unobservable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;(In&#160;thousands)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;1)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;2)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;3)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Recurring Fair Value Measurements:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Earn-out liability&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,050&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,050&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,050&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,050&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:36.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:61.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;At December 31, 2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Quoted&#160;Prices&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;in&#160;Active&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Markets&#160;for&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Other&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Identical&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Observable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unobservable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;(In&#160;thousands)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;1)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;2)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;3)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Recurring Fair Value Measurements:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Earn-out liability&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,200&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,200&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,200&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,200&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:1pt;margin:0pt 0pt 12pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The carrying amounts of financial instruments such as cash equivalents, accounts receivable, other assets, accounts payable, accrued expenses and other liabilities approximate their related fair values due to the short-term maturities of these items. Non-financial assets, such as equipment and leasehold improvements, and intangible assets are subject to non-recurring fair value measurements if they are deemed impaired.&lt;span style="color:#ff0000;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="As_Of_12_31_2022_srt_RangeAxis_srt_MaximumMember__4L7Euy5PkiEdMffnWdNng"
      decimals="-5"
      id="Narr_P7Val_kvZk2TjrEAdOl6wQ"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">5000000.0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <tcmd:BusinessCombinationAdditionalContingentConsiderationLiability
      contextRef="As_Of_12_31_2022_srt_RangeAxis_srt_MaximumMember__4L7Euy5PkiEdMffnWdNng"
      decimals="-5"
      id="Narr_AEXFRPsB8UK9oevzVzX_Xg"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">10000000.0</tcmd:BusinessCombinationAdditionalContingentConsiderationLiability>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      id="Tb_rcnU2sXCwUWcKOJU80HAsA">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;background:#ffffff;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:69.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;(In&#160;thousands)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:26.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:69.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Earn-out liability at December 31, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 6,200&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:69.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;"&gt;Addition for acquisition&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:69.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;"&gt;Payment on earn-out&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (5,000)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:69.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 6pt;"&gt;Fair value adjustments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 11,850&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:69.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Earn-out liability at December 31, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 13,050&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;background:#ffffff;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q"
      decimals="-3"
      id="Tc_JXP8fpujakW35_SsABThig_2_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">6200000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      decimals="-3"
      id="Tc_HCdM9-jXYEy0pI-zbHlr7A_4_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">5000000</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      decimals="-3"
      id="Tc_YUwbd82MCEyWH5RjH9DLMQ_5_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">11850000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw"
      decimals="-3"
      id="Tc_-Sd23IlnHkuZls9lgW4dfA_6_3"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">13050000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw"
      decimals="-5"
      id="Narr_83JVYOf2ukyHENaDi6S-nw"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">8100000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      decimals="-5"
      id="Narr_J-bkn6Tqu0ikmETlfTydBA"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">5000000.0</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg"
      id="Tb_WdJRULa-50eaB5WygLwUpQ">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:36.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:61.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;At December 31, 2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Quoted&#160;Prices&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;in&#160;Active&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Markets&#160;for&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Other&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Identical&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Observable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unobservable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;(In&#160;thousands)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;1)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;2)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;3)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Recurring Fair Value Measurements:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Earn-out liability&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,050&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,050&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,050&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,050&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:36.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:61.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;At December 31, 2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Quoted&#160;Prices&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;in&#160;Active&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Markets&#160;for&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Other&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Identical&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Observable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unobservable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;(In&#160;thousands)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;1)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;2)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;3)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Recurring Fair Value Measurements:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Earn-out liability&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,200&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,200&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,200&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,200&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_uLFZTWJi2k6g6WI1HfkiNA"
      decimals="-3"
      id="Tc_gCwrLKlkfk2UCayfHdjgLg_9_9"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">8050000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="As_Of_12_31_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_vevcUAPFYESbYWLi7G0kaQ"
      decimals="-3"
      id="Tc_bnfW-BSXdEq1MpGYsi87gw_9_12"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">8050000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_uLFZTWJi2k6g6WI1HfkiNA"
      decimals="-3"
      id="Tc_PIRKjEdrJ0e9910YCw9rSA_10_9"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">8050000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="As_Of_12_31_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_vevcUAPFYESbYWLi7G0kaQ"
      decimals="-3"
      id="Tc_mCOnuFVV70qyx4vXmSeGhA_10_12"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">8050000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_9V6sgB50n0-ZfOQSvVu1Mw"
      decimals="-3"
      id="Tc_5XVRS0nDqUS_VbtDfy372g_9_9"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">6200000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q"
      decimals="-3"
      id="Tc_z5AYIuHH-EWtemvF7pJxpw_9_12"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">6200000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_KVbTIgc1_EmIcfBzONO5-g"
      decimals="-3"
      id="Tc_p-BFIQrD8kqj_i-C4unpwQ_10_9"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">6200000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="As_Of_12_31_2021_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_91EX6xEDf0-UcTWUZJ8XyA"
      decimals="-3"
      id="Tc_6eLQf2V5U0-tvBkfwZzf6g_10_12"
      unitRef="Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg">6200000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>90
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M(-Y?4LH/._("Z?\X]/\#4$L#!!0    ( /A)55;7PEHS;@<  "LD   8
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MY?I6/OXA.D)![6\I<]7\HL<6&](96NZ4ED5G#"THLK*]\J<N$'L&F$T8D,Z
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M.V<#5%:576DY,7+A^K1':;#K<\,<&WE0U@#?SZ0T+Q.[0?77(/X+4$L#!!0
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M3)6/*=B?.[RNQ[H:C..,&DTR?DLA9QG7'05C'S$B6A@E)P*N05O-AP;?ZT9
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MPT$!BNR5# 56222\)NU1:*@4C/Y:-1!N<8/,!6_NP+CJNH%8H#1K/%O?5CL
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MZ(%H#+(G*7ZEPQ:Z6HR+*EBZ,HUF20 YTD(; W_E> +5LJ]6OP[)/I"L;!/
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M,I&I03>Y93]'*4#NOH9GP@3'=>&/ ET02.N!H&D3H#IZ)D9SSY_M3MJ-=QE
M :U[8TH ZI910CPZ&2(*_@,C5 B8ZO-V<=8F+L/P(5%L+#6KH3A@84%UB<B7
M=1,A!EGO>DT)D18G\^E\/A?3\?;O(6UQRCLO9WOY=Z,(Q_^%]!,NK/B_)M_B
M8/(MVU2@Q9TPZ@N;2O^!^UEC";GH\7=2\W^0>$!J($)P0N^2$FBJ0U>"*4L(
MX/M3]'POG.>PCS+VH":[OG]8LS;6I-]::BO001NUCV$=K WQ&WTV],!'I[/C
M7N;#LJ8TB_%0!;>7LI(!&DF1Y-FY0TN$U20XKBOT5U7HW!@N!YGF6MW&B*';
M>6DW8 _3V%\)@36U*>24*NO"<,.4/&6@@J0MD".Z;"*S GJK@A1&%<=DI+)C
M)&BL);?=@M2@L"I3/6UO@669V$;9ZRO*K%))US"="4BB0ODJ*(RG(*N!,H7T
MQ49ZG#?$ ;4-30)+R2#J-%3OPU8>)'%U$V$"G0FE0(1(!J+UV"G"$YB;/./P
M)LEY"[Z_4%2^<%3>!WU9;$^;VW3X&*HMBW$8%'L?_D"?@R]B@44JUU$[FG<S
M@AJF.J.X0I$^1R)+"!V0@RM7A8J3/LK4'2)??1B&+?/AW\=759NG[HFX[)0?
M..8JTD]JZNVR1ZC24W$=>2?G",6K#A-/\N3@?LF"6C>F@HTF8Z)O=M\\6:+^
M_X+LYE3:?;I,9DD_906[>Z7.3L'2:/M/^][IZ'1!TQ1/"2!UR9#0U@?M":'8
MM!K%8G4T&> 7 MVV4G:C RT-;*U%T"[P$)TU:>2>'?$><.V0WC1FJ'OMN#8&
M.<R,E>J9A+#W>.B2]P-*?$O(?R*VP!4G=H!L)X\Z&UC'OGK)!V.O14+8V:'W
MXA?&BD 1VI1&03NU;@I@%6:U'\_&__3W![)Y=\F[3N7/0>5?]1K V$:(+2-Q
MN:Z'Z8\\G._)2I;1^V_1@@J$#R"@TKPRA=EL#[Q]2$0217RR&"\K60Z*[CD*
M8_?]*_#G-7$Q)3[QF+4?H%YI+JT_\R'ERQV?O:GLJ412H1]1+P!>_Q&R)&+V
ML/\=3@UJ0<EB%KURH+<"S+XJSY#7)KIS)M4<#RZ(0R"ZIO, >@K,_Y4\+9:M
M,H,NB[9H)7(94W'6=(G<Q.,)O0FS'X\@9D5C.E>&KD 6';W=]<Z!T+U67@Z:
M!KQF1X2YX3GT@/@I%1<!>;&-+P5&S>V+QW8TR>GX$(.[CW8\%M.! DV!Z$%W
M4,'G)HM'"(.6K4O&D#4&2DRJJE_A6M\1V(!N%%NG0ZRZ[D1/R&F9+O1&5< !
M)@90O,2(36R1^7.+3TB[59,%VE&8:O.4YSLP-#Q6&YV"BLL(8N&,IL6)84Y@
MC9/A9#G%)A#E&CH^< #L#8W0W>KX>'"$M,O#Y&9CL8BG%G+G/>\&+P+QST:\
M#.G XC!.WRH0%U4QKE>.SV$H)L1QPJ MK1H>RD !7:X:ZSC\4P%'P1]!49G!
M^YH=  1L13)I)]^^0:J;0F>LX8W'3\@@1.MC#_KMN1I5#W$@O/L6G@]L/@Z8
MXZ+Z,;D1_7>FBT&W62%H%?>P?GQXWNYWZ786=B>4.:40>9 FK8WMB_@[72WP
M)3BUJ;@X1D4W&(=&?(M8,YUN!)IWD("'46!T@!;GQ1_PSB[Q@FY-QD=4R"/!
M[7K4MH=!<M^+$N<$_I@+/O6N8N>-XQ<_K93O$,"!YXT81+1NY(A<HA[2-CW9
MBK_)JI%V&^>_>>3Q0VV[$$&/6MHXGZ8T2,=4[?E$56Q;WE$94B[CL[);%:9P
M24=7?/P8CKT (:8ILD$AZ?T!B93V\BLI4$BBK"$+^X0CO +*02I9,*61O(>P
MN-'LO\X;_DX5QE]<]AZ-8DG\ FC;./@%!(-#V[[(X0T]N(UKWWD7R?/I<7(\
MO#-?3I/G2_$!<7]<& =Q,?S].X^?34^7RR>#.TDR/5LNAC7/3*U-S#82,?.[
M@]'!Q#3L/;$OXFV+/A;@:=3I(VZU+PX:WW &0X#V>O]T++4[>]F1*+-P'$X=
MI#NX[%&7]M25I :T!_%5-M856F1J187O&EX1</U[LGS?;Z8CP6U;Z9;#DUR,
MNPUJW)^F[9DU'Q=WC&;0MA"F-6 R6$N, /PZGL1WK0R$7JW71,UGA[Z''0V^
M2X*=;OCKJQ.\;_A$V=WM/O!>AN^:_>OAZ_![B9&E(N776#J?/3N9"!N^N(8+
M;VK^RKDR'E28_\SYDP>]@.=K@Y$Z7M &W6?OBW\"4$L#!!0    ( /A)5591
M/TF;]0$  +H$   9    >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;(V476^;
M,!2&_XKE2;N:8N(DW98!4M)NVBXZ1:G:73MP *O^8+83NG\_VQ"6233J3?"Q
MS_N<]P0?TDZ;9]L ./0BA;(9;IQKUX38H@')[$RWH/Q)I8UDSH>F)K8UP,HH
MDH+0)+DADG&%\S3N[4R>ZJ,37,'.('N4DID_6Q"ZR_ <GS?VO&Y<V"!YVK(:
M'L ]MCOC(S)22BY!6:X5,E!E>#-?;Y<A/R8\<>CLQ1J%3@Y:/X?@1YGA)!@"
M 84+!.8?)[@%(0+(V_@],/%8,@@OUV?ZM]B[[^7 +-QJ\8N7KLGP)XQ*J-A1
MN+WNOL/0SRKP"BUL_$5=GTM]Q>)HG9:#V,>2J_[)7H;_X5+P^14!'00T^NX+
M19=WS+$\-;I#)F1[6EC$5J/:F^,JO)0'9_PI]SJ7;XI"'Y6S: \%\!,["$B)
M\^!P3(H!LNTA]!7(G*)[K5QCT5=50OD_@'A'HRUZMK6E5XEW4,S08OX!T832
M*[S%V.8B\A9O;W,VU6=/64Y3PH"L;<L*R+"?  OF!#A__VY^DWRYXG$Y>EQ>
MH[_U55R%3%O\J1V@U0Q-5$!3QLG%?9)@ZC@U%D5Q?[7&W7$P-_U]_)?>3_4]
M,S57%@FHO#29?5QA9/I)Z0.GVW@[#]KYNQZ7C?^X@ D)_KS2WOP0A +CYRK_
M"U!+ P04    " #X2556(>*_470"  #1!0  &0   'AL+W=O<FMS:&5E=',O
M<VAE970Q,RYX;6R=5&U/VS 0_BNG#*%-"DWBM%!*6XG"T/C A& OG]WDDE@D
MOLQV*?OWLY,T#1)T$E]BW_F>YYZS<S??DGK2!:*!EZJ4>N$5QM2S(-!)@177
M(ZI1VI.,5,6--54>Z%HA3QM0508L#$^#B@OI+>>-[UXMY[0QI9!XKT!OJHJK
MORLL:;OP(F_G>!!Y89PC6,YKGN,CFI_UO;)6T+.DHD*I!4E0F"V\RVBV&KOX
M)N"7P*T>[,%5LB9Z<L9MNO!")PA+3(QCX'9YQBLL2T=D9?SI.+T^I0,.]SOV
MFZ9V6\N::[RB\K=(3;'PIAZDF/%-:1YH^PV[>B:.+Z%2-U_8MK%1[$&RT8:J
M#FP55$*V*W_I[F$ F(;O %@'8(WN-E&C\IH;OIPKVH)RT9;-;9I2&[05)Z1[
ME$>C[*FP.+.\E<\H#2F!>AX82^C<0=*!5RV8O0..&-R1-(6&KS+%]#5!8)7T
M<MA.SHH=9+S&9 1QY ,+&3O %_?EQ0U?_+'R6O#X;;#KAYFN>8(+S_[P&M4S
M>LOC3]%I>'% VKB7-C[$_C]IA\'?R2"<CF! \FJ?D&T;;3 %RL 4"!F5MO^$
MS&=P_&G*POCBP^OG6VDI::.Y3/47N#1@7PVK-:K^Y=YR1G CI+!_:@HY4:I[
MOB.8^%$8#NRIS\8,KJBJ2=J2H.;*:+#IFA8_$?*D5I2@WG-$4S]DX[T9^N=G
M$_A!AI<@!O>RS\%B/QH@CB Z]UETMG.\]<#!H,TJ5'DS3-Q=;Z1I.Z[W]O/J
MLFW3?7@[[.ZXRH744&)FH>'H;.*!:@=(:QBJFZ9=D[$CH-D6=N:B<@'V/"/[
M!W2&2]!/\>4_4$L#!!0    ( /A)5598#KZ<, ,  ,@'   9    >&PO=V]R
M:W-H965T<R]S:&5E=#$T+GAM;*U5;6_;. S^*X(W#"M@Q/);G&9)@+YLV(!M
M*-:[VV?%9F)ALN1)<M/^^U%RXCBW-L#A]L46*?+A0TDD%SNE?Y@:P)+'1DBS
M#&IKVWD4F;*&AIF):D'BSD;IAED4]38RK096>:=&1 FETZAA7 :KA=?=Z=5"
M=59P"7>:F*YIF'ZZ!J%VRR .#HIO?%M;IXA6BY9MX1[LW^V=1BD:4"K>@#1<
M2:)ALPRNXOEUYNR]P3\<=F:T)BZ3M5(_G/"I6@;4$0(!I74(#'\/< -".""D
M\7./&0PAG>-X?4#_X'/'7-;,P(T2WWEEZV4P"T@%&]8)^TWM/L(^G]SAE4H8
M_R6[WC9) U)VQJIF[XP,&B[[/WO<G\/(849?<$CV#HGGW0?R+&^99:N%5CNB
MG36BN85/U7LC.2[=I=Q;C;L<_>SJ3N/]:OM$F*S(^Y\=;_'$[2*RB.TLHG*/
M<]WC)"_@Q GYHJ2M#7DO*ZA. 2(D-3!+#LRND[.(MU!.2!J')*%)<@8O'3)-
M/5[ZOS/M<;+G<5R5S$W+2E@&6 8&] ,$JS>OXBE]=X9E-K#,SJ'_!Y;G<;XJ
M"Z28D.?Q3M4PJ$N%U68L5$1MB*V!;)3 LN5R.R=O7LT2FK[[8_\K2_"*H5F#
M]M?\]I/$D*HS2,E<^%MWGWC$^N#ZFLS"I,A.9)K'Y"^E\!RV@SX-TTLZ2$F8
M9SGYT&G);:?!I[[ACVYM1D9T5HRDF&;D,V#9UTI4A#>M5@_@R!Q=XC"[3,=2
M/L/,&CQ*JYEO/?!;!D=KBI7S;^TT3<B-]^_ZWL4EP<!;)&I^-Z;3YV!I2NZ[
MM566B:-Z&LZFQW!Q'A;(_#.BSK$]EEW3">8NOP)\V27OR1^LW\8T+&;YQ5%Q
M&=(LO7CA+85$POC&IB$MBA.YR(]W<SN."(\X<@R0'3/D=3+)L>\)@1NAD]*#
MY,.A(AL4.*+\HWT"I@T!UX=.GYA[4V'_J)PS+FB(D\6TX&>#>)H\5\'1J+LV
MH+=^AABLE4[:OM$.VF%,7?7=^6C>S[@O3&^Y-$3 !EWII,@#HONYT0M6M;Y7
MKY7%SN^7-8Y:T,X ]S<*ZWHON ##\%[] E!+ P04    " #X2556<)&;-6(%
M  #U$P  &0   'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6SM6-MNVS@0_17"
M&Q2[@&KK;CE-##C)MMN'=H->GVEI9!.E1)6DXJ1?OT-*EI7(=MH V]V'/B06
MA\,S,YSAX>5L(^07M0;0Y+;@I3H?K;6N3B<3E:ZAH&HL*BBQ)Q>RH!J;<C51
ME02:V4$%G_BN&T\*RLK1_,S*KN7\3-2:LQ*N)5%U45!Y=P%<;,Y'WF@K>,=6
M:VT$D_E915?P'O3'ZEIB:]*A9*R 4C%1$@GY^6CAG5Z$1M\J?&*P4;UO8B)9
M"O'%-%YGYR/7. 0<4FT0*/[<P"5P;H#0C:\MYJ@S:0;VO[?H+VWL&,N2*K@4
M_#/+]/I\E(Q(!CFMN7XG-G]!&T]D\%+!E?U/-HUNX(](6BLMBG8P>E"PLOFE
MM^T\] 8D[H$!?CO MWXWAJR75U33^9D4&R*--J*9#QNJ'8W.L=(DY;V6V,MP
MG)Z_$B+;,,X)+3/RNM2T7+$E![)0"K0ZFVBT830G:8MWT>#Y!_ \G[P1I5XK
M\F>9078?8(+.=1[Z6P\O_*.(5Y".2> YQ'=]_PA>T$4<6+S@21&/]X7< (;[
M <VR.5453>%\A.M"@;R!T?S9;U[LOCCB;MBY&QY#?T*"CN.]%1I(,B;'<7?=
MKTNBUX!_3&;D:TVE!DE$3G*F4LI-4C U&R"I*"H.&C*KOLAS+CZ!TF21?JV9
M8F8)CLD'[*IJF:YQ'9%*LA0,U/T!RUJARTH1N$T!LA:P1'ZB.ZCG&<4P4)WA
MPD25G#));BBO@=!"U"5&T *S#$K-<D9-<+0)S@))'&9B-TH<NQE'9%!&IRZP
M;WE'3@)O[.&JXQQ-8I1KEJ[)AEH=MBJ-:X*LVID:DV>_);X;O-@SFW_7DE3H
MJ/'+V!1H5!*VT]LZ)J&E1_;-N*=(+CCRICKMP'_V[V?+:Y ][R0+37!-0K'$
M$+;K<C!L<0,22;UKOY("4_JCQA>%D)I]HY; M\)+*N4=*U<[K32MBYK;0MC*
MWF*]_&YK5]0*IUS]0:Y!,I'UL;%.CIMJ=:X@9R73\)SC#I(-\_;O9>>Z+9IM
M&^GU#JC<"4Y(,IOV6MXTZ+6F?FB<-WOH#>RIMZWF0]3.G./Y\4 ZC<.!+(A]
M<FFW*ZP*FJ;-&NRTN$8P:V1HPX^&,F]HP?-V!B1PFRBU9M61R>F<\QS7=8=B
MC&XZD/I3)\%)O((;/+%49HU#NBX%%ZN[G27WT(0%>RUY3A3MD7I.B.+W]5(+
MC5SZ6#&$L>.%R4 <.5-_* U=)_1=\K&D36'_W+K]("GR+BW@\34_<Z(],V9^
M/?^0]G99X-$TZS/!P9F+AC5VR(+1_6#S<7B]//P](1'FQNTOO?M9P;;K!-/]
M7OQO:-S[1>/_&8W'<=QK>>ZL7SO1]+MH/#A"X\/2BV;#;3L*@B,T_H#!^Z#)
MSM\@?I2H#SEZ@*BGX=#3P'7\*'F$IKT?H^D@'O*HYSMQX/\ 24?.S!ONF9XS
MVV,P#!T7E7^1M*V]^/M)VN@^@:0Q-XG7$]S/"BI@/GH*]\@$;C$0O+:8\_])
M,$YV]X(3;QSN6N9\?^+N)'B$E_:2T90BF&OQ\ #=\J\9C!^N@RM'56"?+/C=
MF+RL=2WMW6;@4'-K,(U4/_'.\(!A#ZFA8P%.4N D;F(:>TZ!SC29FJZH)XIG
M5A3W14@S*)KV18B-UT,)-#<WS,ZFAZ<QO\WU+E'MZ::K9)S>S7:'H^V>)<$\
M2IG*NS=M5;-_M%E1^_C4I-CSQMM#'K67R4'*QOMN]Y/>4PP2X,H^."EBB;1Y
ME>FDW9O6HGG*V:DW#V)OJ%RQ4A$..0YUQ]-H1&3SR-0TM*CLP\Y2:&1;^[D&
M7-+2*&!_+O"NWS:,@>ZE;_X/4$L#!!0    ( /A)55:Q68^\P0(  -8&   9
M    >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;*65;6_:,!#'O\HIFZI-8DWB
MA$ I($';:976K6J[];5)#A(UL9GM /WV.R>09H6B:7M#?.>[G__GAV.XENI)
MIX@&-D4N],A)C5D.7%?'*19<G\HE"IJ92U5P0Z9:N'JID"=54I&[S/,BM^"9
M<,;#RG>KQD-9FCP3>*M ET7!U?,4<[D>.;ZS<]QEB]18ASL>+OD"[]'\6-XJ
MLMR&DF0%"IU) 0KG(V?B#Z:AC:\"?F:XUJTQV$IF4CY9XSH9.9X5A#G&QA(X
M?59X@7EN023CUY;I-$O:Q/9X1_]<U4ZUS+C&"YD_9HE)1T[?@03GO,S-G5Q_
MP6T]7<N+9:ZK7UC7L7[/@;C41A;;9%)09*+^\LUV'UH)?>^-!+9-8)7N>J%*
MY24W?#Q4<@W*1A/-#JI2JVP2EPE[*/=&T6Q&>68\B6-58@)7&SIFC7KH&J+:
M.3?>$J8U@;U!\!G<2&%2#5<BP>1/@$MR&DULIVG*CA(O,3Z%P.\ \Q@[P@N:
M&H.*%_Q'C34A/$RP+V.@ESS&D4-77Z-:H3,^>>='WOD1?6&C+SQ&_RM]QPG?
MI$$X.X77I,:!.T<LZ3UI0RXY!Y,BS&5.#S,3BP&<O.LS+SC_Y^^':T%(66HN
M$OT1)@;H)+&8H6I.\Y#3AVOQR2A.P@QD8H7"2/7<4-]#T&&LW[)#/X)'KBC#
M/.^)8!W/Z^YY_4Z_Z\.#XBO,#TSZ).*U-XI\^(H+G@.54^T;/73:I[W 7N =
M0 8]'R[HG+*8"-J424:[OR>V%^VG^@'<\YRB[;JE1C!\LQ\5]O9]7@3?Z4Q5
M2T8O"%Z$AB$\2,/SUEZ>=5CHM>QNAT5L9Q^ZVVZKUQ2H%E5'M?>J%*9N.XVW
M:=J3NE>]A-<=_X:K128TY#BG5.^TUW5 U5VT-HQ<5IUK)@WUP6J8TA\/*AM
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M29ZE5IAFE@%S4.R!L2+@(2R+KP)WZD[97+N>J(G"PRN!"H:-:2Q,Z7*K0FJ
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MEM5F6XA69(R7+"_S-N<%V^X61;YDU6HEZKR\@0M6[6I\=P.VTV!7#"[>[6Y
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M,&<\:_F]G4EH^?:IA,HHAWFDH\J9RGLN5>UL(=V^&@2YP=!(L5)PAO577!B
M)BJ^W]%2@,C.0$%K?B.,@.^#YR>&28G9 I(IM:192A')@-1APU4"<BC"7Q0<
MU/MZN:[0%ZIN,$3C"Q3G'=,"M3903%>F))VG,A&=M'3)@.8-[Y..X_(+D+/"
M\U00W/"O5)3*<H7AP%ML%#4 .B!CPDY7.P)(9J;1IP'.7FAW#&FA"T!]4V@0
M.\'40#)\+R/HAT96RWDKA5G* CFAX[U62A"]H4'?%5U@L:=_NRKMJLP:-'HA
MP"-1F6SQ .QS1Y,<-"WJO7.EN31 JPR[RFMPEJ.IKT_6TZM.+R>MDI ? 'Y
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MPH3O<.'!Z=I_^\+ XW3I?^8D0=-\ /L;K5WWP!?T'T.O_@M02P,$%     @
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M#YA9&X+063EYU%=?C(;D7])T5BMH#%B[ E6T%HI;A^,E(!6'YGB/>O.<=2]
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MW<+^EGB9 VD4<'XEL"ML!\;!<#V<_PU02P,$%     @ ^$E55M_DKO'F!P
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M_L/3M6:O#SK/T!:+1V D%E1^Y@2&XV F9SA''>2P2H(G!!2O6*-,B3G/:98
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M*:9A+'+'R-B2S^JLY/>Q3R?$FT)V>B+N%T_\JN"(:%A>U91VRZN/BJ4FW^H
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M0"PRYVO7F^Z,3PN$7P5\,'XEB!@M&-XQR 0VI+SJ<CPAY5\ !"0%4]N.TW5
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MWU,P3(#H$)<2TF)H:UG;.M02<484+C?!/]H5E#41;,$\)0",R4_L9VOX/S[
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MUH%WG1ZAJ&FE@&]P&5-EBU%,XL+8D'[!ZF;/G^[:R2\[AUI!T;G@D ^$[K0
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MI%'INI=1EWK(;DG3^#YN^T2+VA]]O9:*J)>K6/P7+0K'$'S!@39K)K9QLB[
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M2WH[HG8&-%\H9;<=MT#W&IW]#U!+ P04    " #X2556>KM (6@"  "B!0
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MM0]PYTLBNS5\@GXL9W\ 4$L#!!0    ( /A)55:] N.%\0(  ! '   9
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M<?%9(:3._N9&'7;.<R[E?58N]U%)4A55SI%EZ_L#Q?+M94GT2E0*5X]Z1ZY
M9B+M8E>E'BZUC;F IIOOCW3S]%^;_2L<5*GW$X=;]AZXW#M>DW@4=2P:>1TK
M8GY-OA;H6^CS;B,?H[;E;,K"GC<*_9[/"QDY-UJ(JX(G23UO';Q<(Y@ITJ_!
M@KZ/]BM0NB\@(3>-4JML/3 Y+3EJNZ[;=^/HHIZ717:,DW@!M_AWN,9V:TA6
MI<C%\GY?R3TV8=[!2M0.@@->:OOHOJ[F6FB>/[D8_-"F?MQS!W;$^E[?M7WF
MDJ\E;Q;VSUVW-Y*G@*7AZ3T_LH,#,U9?*3L6O=L6^-Z3=I7@Z,P%_35VK$(=
M>V/Z<7R_/+Z^)@'VQNUNO8==0=NUO>@PB_^-C--?,OZ?R7@8AAV+NJ/NV@FB
M9\FX-R#C_:47C/I_VX'G#<CX(P7O@L9[OE[XI% ?(WI$J"._S]1S;1;$3\@T
M?9E,>V%?1RFS0X^]0*0#>T3[_YG4'ATHZ/NVB\&_1-JLO?#Y(EW'_H!(8V]B
MVG$\[ H&8#_V 0,G@J ]$03//Q%4NI+(LJM0<(>SH^#0<6 8^+D]?B2>Q\)0
M_#T<OV?';EP;!U[P["B.ZD=!QQ6.C"OLNE!!T!5U78A]LP()?*%A+Q^,XHL6
MV[9QWX/MB\M #YS.61I%9FF^&"ABQ*HY5K?>]J/$K#F+[\.;+QJ?N5QFI2(Y
M+##5/8EPUF7SE: QM%B;D_E<:%0T<[L"W#:R#L#G"R'TSJ@+M)]JIO\ 4$L#
M!!0    ( /A)558Q37%!M (  )T&   9    >&PO=V]R:W-H965T<R]S:&5E
M=#,P+GAM;)U586_:,!#]*Z=LJEJ)-8D3 FTA$K2=5FG5JM*MGTURD*B)S6P'
MZ+_?.8&4#8JJ?8E]YWO/[\ZZRV EU8O.$ VLRT+HH9,9L[AT79UD6')]+A<H
MZ&0F5<D-F6KNZH5"GM:@LG"9YT5NR7/AQ(/:]Z#B@:Q,D0M\4*"KLN3J=8R%
M7 T=W]DZ'O-Y9JS#C0<+/L<)FI^+!T66V[*D>8E"YU* PMG0&?F7X]#&UP&_
M<ESIG3W83*92OECC+ATZGA6$!2;&,G!:EGB-16&)2,;O#:?37FF!N_LM^]<Z
M=\IERC5>R^(Y3TTV=/H.I#CC56$>Y>H;;O+I6KY$%KK^PJJ)91<.))4VLMR
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ME8;&6;W-Z/^!R@;0^4Q*LS7L!>T?*?X#4$L#!!0    ( /A)55;0^R9GS (
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M7T3,=I/:&6B:,!U+@S1K85O3XP;6 RB^,G3BO>$+#,]E\1M02P,$%     @
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M!VD4<'TIA-Y,C(/NG\#\7U!+ P04    " #X2556ETYTO%X)  !Y)@  &0
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M:N^4LNG*,?%(3U7=&O9:!28B0'>R!$,6:R,Y!FW2? O;7O5E,^;U9+B4]]M
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MS%!1?>=4/:A\:[XMNL^5RC?F=BVC6!:Z _R_S'.U?] 3-%^;W?P74$L#!!0
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MX0!I-N#Z2@B]GQ@#W5^8^=]02P,$%     @ ^$E55G %-_C[!@  U!D  !D
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M=\!Y1%_50^2V'@*":@^=<[+&=#'N%"=, EL#D@%V/G1)SS!/+2?R;,_F)5O
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M'/#[6F"9#@.38+R4+?\&4$L#!!0    ( /A)559@$&"?:P,   ,.   9
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M<VAE971S+W-H965T-#4N>&ULK57;3MM $/V5E8LJD J^)>'2Q%(N144J;42
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MTPQ_&"!- )ZG0NC-PKR@_05%?P%02P,$%     @ ^$E55LYYY5)' P  6Q
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M;%QQ-BC.]BJ^1\.$K8.]5R?;V2J:Q#OZ=K/B<QI/WN@+M^K9]=(?3"VYU$3
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MV-9?8FE%2E&(?:\7?H(N=Z)7=&CRAM(8BN:*WH7OT)^^VZ;DGQ+T4P9?!-
M#J4Q%,W]8JV+X!0<P2DT@D-I,93&4#37F2Z"4U $?X%S>G[07SA8?&@"1]%<
M\;L$3OT)W&E3IV<)_93!%P,TC$-I#$5S_>C". 6'<0H-XU!:#*4Q%,UUI@OC
M%!3&7^!,3L\4^BL'JP_-XBB:JWZ7Q:D_B[\_I.N#]KVJ(Q/M$DJ+H32&HKE.
M=&F;GH,[%#2!0VDQE,90-->9+H%3;XY<7)>"V]DJM5K)1)#Z4+V&0(,WE!9#
M::RA'<^KS<;FIYU;<Y7N$C7UY^$[D2CSUC_=C)!)=@FEQ5 :0]%<([J432_
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MU#@5N1MX7N06F#(G'IEG,Q&/>*ERRLA,(%D6!1;;"<GY9NSXSO.#;W29*?W
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MDB&;$;M9:+%S4^I&:#/SNLO2O): M!O,\T((_;BP@V_WHI/^!%!+ P04
M" #X25566@EC.&L"  "V!@  &0   'AL+W=O<FMS:&5E=',O<VAE970U-RYX
M;6RM56MOTS 4_2M6F- F09U'5\9((ZT-""0FIE6#SUYRVUAS[&"[[?CW7#MI
M:*=TFM"^-'Z<<WS/=7J2;I5^,!6 )8^UD&8:5-8VEY2:HH*:F9%J0.+.4NF:
M69SJ%36-!E9Z4BUH'(836C,N@RSU:S<Z2]7:"B[A1A.SKFNF_\Q J.TTB(+=
MPBU?5=8MT"QMV H68.^:&XTSVJN4O 9IN))$PW(:7$67^=CA/> GAZW9&Q/G
MY%ZI!S?Y5DZ#T!4$ @KK%!@^-C '(9P0EO&[TPSZ(QUQ?[Q3_^*]HY=[9F"N
MQ"]>VFH:7 2DA"5;"WNKME^A\W/N] HEC/\EVPX;!J18&ZOJCHP5U%RV3_;8
M]6&/$$V.$.*.$#\EC(\0DHZ0O)0P[@B^U;2UXON0,\NR5*LMT0Z-:F[@F^G9
M:)]+=^T+JW&7(\]F<U77W.(]6D.8+,E<2<OE"F3!P9#WY#M@4TGQ!(5OG68.
M1T2W;RPYS<$R+LP9TNX6.3D].2,GA$MRS87 .S8IM5BQ.Y<6776SMKKX2'51
M3*ZQH,J0S[*$\E" HM7>;[SS.XN?5<RA&)$D>D?B,(X'"IJ_G!X-T/.7T\-G
MW"3][25>+_F?VQMJ=RLW'I9S$7-I&E; -, ,,: W$&1OWT23\--0JUY3+'\E
ML8,VCOLVCI]3SWX,O,Y#W6M5/GH5EZ>;+!E=I'2SWY0AS.00D[>8R3ZF1[0&
MZ-X_N@:]\LEHL+"UM.W+WJ_VX7OE,^?)^@Q#N<W0?S)MHE\SO>+2H.4E2H:C
M#^<!T6U*MA.K&I\;]\IB"OEAA1\6T Z ^TNE[&[B#N@_5=E?4$L#!!0    (
M /A)55;? Q7=% ,  !@.   9    >&PO=V]R:W-H965T<R]S:&5E=#4X+GAM
M;*V76V_:,!3'OXJ525,G;>1"N;2#2(5NVAZZH;;KGDUR(%X3.[,-=-(^_&PG
M&,)"-%A>B"\Y?Y^??8+/&6T8?Q8)@$0O64K%V$FDS*]=5T0)9%AT6 Y4S2P8
MS[!47;YT1<X!Q\8H2]W \_INA@EUPI$9F_%PQ%8R)11F'(E5EF'^:P(IVXP=
MW]D.W)-E(O6 &XYRO(0'D-_R&5<]UZK$) ,J"*.(PV+LW/C74[^K#<P;3P0V
M8J^--,J<L6?=^1R/'4][!"E$4DM@]5C#%-)4*RD_?I:BCEU3&^ZWM^H?#;R"
MF6,!4Y9^)[%,QL[003$L\"J5]VSS"4J@GM:+6"K,+]H4[_:[#HI60K*L-%8>
M9(063_Q2;L2>@=\_8A"4!L&AP>41@VYI8';.+3PS6+=8XG#$V09Q_;92TPVS
M-\9:T1"JC_%!<C5+E)T,IRS+B%3G(@7"-$931B6A2Z 1 8'>H3O\@W'T!#1F
M7*"+6Y"8I.*-FB$2LI$KE0]:R8W*]2;%>L&1]?P W:DE$H$^T!CBJH"KG+<$
MP99@$C0JWD+405W_+0J\(*AQ:/KOYGZ#.UV[H5VCUSUG0^OVJY"[K)?37_&U
MR'$$8T=]I@+X&ISP]2N_[[VO8VU)K$)^:<DOF]3#+ZML#ARQ!5H7X5)'VRAQ
M*FTAUC-B^O]J':H 6-<@]"Q"KQ&AB'/TE4*=[XVVI_K>DE@%LV\Q^^W&:+]-
M\I;$*N0#2S[X_Q@=_!56O@VK J%QD3,1AA9AV(@P6_$H41>70+_+_^5=XTC@
M-@J>>GPMB578KRS[5;N!>]4F>4MB%7+?VUW47N.Y/S*)4Y3;T[\@%.7 ([49
M*M]Z4WL5%XKZ84/9Z_C#@VAN7OA<L+T,Q#\[H!\WK!:L4?'4<VU+K<H?[/B#
M=H.ZU&N+OB6U*OTN7?(;<Y*SPKK5E*E4._A(NH>9A+N78V? EZ;T$"AB*RJ+
M9-6.VO+FQB3U!^,37?:8W'TG4]1,=Y@O"14HA862]#H#=07QH@PI.I+E)I.?
M,ZGJ M-,5.D&7+^@YA>,R6U'+V"+P? /4$L#!!0    ( /A)55:-<(K<!0(
M #,$   9    >&PO=V]R:W-H965T<R]S:&5E=#4Y+GAM;'U476^;,!3]*Y97
M3:VTQ0269LL :4DT;0^5HD;=GAVX!*O^8+8)W;^?;0AE4M(7\+7O.?<<<R]I
MI_2SJ0$L>A%<F@S7UC8K0DQ1@Z!FIAJ0[J126E#K0GTDIM% RP 2G,11=$\$
M91+G:=C;Z3Q5K>5,PDXCTPI!]=\U<-5E>([/&X_L6%N_0?*TH4?8@WUJ=MI%
M9&0IF0!IF))(0Y7A;_/5.O'Y(>$7@\Y,UL@[.2CU[(.?988C+P@X%-8S4/<Z
MP08X]T1.QI^!$X\E/7"Z/K-_#]Z=EP,UL%'\-RMMG>'/&)50T9;;1]7]@,'/
MPO,5BIOP1%V?NUQB5+3&*C& G0+!9/^F+\,]3 !Q? 40#X XZ.X+!95;:FF>
M:M4A[;,=FU\$JP'MQ#'I/\K>:G?*',[F&R4$L^Z6K4%4EFBCI&7R"+)@8-!'
MM&MU43O7:)IXNP5+&3=WZ 8QB1X8Y^Z&34JL4^1Y23%47_?5XRO5MU#,4#+_
M@.(HCM'3?HMN;^[^IR'.T.@J'EW%@3>YPCNJ+EY57U+7LWRZS.+G864:6D"&
M7<,;T"? ^?MW\_OHZQL:DU%C\A;[JT:E2] &,6-:*"^I['F^!!X_9*<\26:+
ME)RFU<FD!_PX/5!]9-(@#I6#1;/E B/=MV@?6-6$MC@HZYHL+&LWU:!]@CNO
ME++GP'?:^)_(_P%02P,$%     @ ^$E55LG?C]6) @  Q@<  !D   !X;"]W
M;W)K<VAE971S+W-H965T-C N>&ULK55=;]HP%/TK5E9-K;213[JM"Y$*V;0]
M5$)%W9Y-<B%6'3NS#;3_?M=.R* #Q ,OB3_N.;[G.+DWW4CUK"L 0UYJ+O3(
MJXQI[GQ?%Q745 ]D P)W%E+5U.!4+7W=**"E ]7<CX+@UJ\I$UZ6NK6IRE*Y
M,IP)F"JB5W5-U>L8N-R,O-#;+CRR967L@I^E#5W"#,Q3,U4X\WN6DM4@-)."
M*%B,O/OP+A_:>!?PB\%&[XR)53*7\ME.?I8C+[ ) 8?"6 :*KS5,@'-+A&G\
MZ3B]_D@+W!UOV;\[[:AE3C5,)/_-2E.-O,\>*6%!5]P\RLT/Z/2X! O)M7N2
M31<;>*18:2/K#HP9U$RT;_K2^; #"&^/ *(.$+T%)$< <0>(SP4D'2!QSK12
MG \Y-31+E=P09:.1S0Z<F0Z-\IFPUSXS"G<9XDPVD77-#-ZCT82*DDRD,$PL
M010,-/E('L$P!7:?3#D5Y#H'0QG7-[CW-,O)]=4-N2),D ?&.5ZD3GV#:5ER
MO^A2&+<I1$=2""/R@*=6FGP3)93[!#[JZ45%6U'CZ"1C#L6 Q.$'$@51=""A
MR?GP\  \/Q\>G% 3]U<4.[[D"%\2A-?/-X=\/8FS!>-.-[2 D8<508-:@Y>]
M?Q?>!E\/>7))LOQ"9'M^);U?B6./C_CUYI,]9%QR2>,N299?B&S/N&%OW/#D
MAY8S72BPY1@; "GPGU1LOC+'_NJ6[(LCL]UEG86#8>JO=[TY%!/MQ^3_QP2#
MN(]IE?@[%:X&M72=0F..*V':NM"O]LWHWM7@-^MC;%)M3_E'TW:X!ZJ63&C"
M88&4P> 3YJ7:KM%.C&Q<'9U+@U79#2MLM*!L .XOI#3;B3V@;]W97U!+ P04
M    " #X2556;,5<)@0"   Q!   &0   'AL+W=O<FMS:&5E=',O<VAE970V
M,2YX;6R=5.]KVS 0_5>$5D8+6YPH33HRV[ DC W6$1JZ?5;LBRVJ'YYTB=O_
M?I+LF S2?M@76R?=>_>>?.>T-?;)U0!(GI74+J,U8K-($E?4H+@;F0:T/]D;
MJSCZT%:):RSP,H*43-AX/$\4%YKF:=S;V#PU!Y1"P\82=U"*VY<E2--F=$)/
M&P^BJC%L)'G:\ JV@(_-QOHH&5A*H4 [832QL,_HE\EB.0WY,>&7@-:=K4EP
MLC/F*03?RXR.@R"04&!@X/YUA!5(&8B\C#\])QU*!N#Y^L3^-7KW7G;<P<K(
MWZ+$.J.?*"EASP\2'TS[#7H_L\!7&.GBD[1=[MTM)<7!H5$]V"M00G=O_MS?
MPQF L5< K >PJ+LK%%6N.?(\M:8E-F1[MK"(5B/:BQ,Z?)0M6G\J/ [SE5%*
MH+]E=(3KDJR,1J$KT(4 1SZ2'U!Q23;6% "E/W#D>@W(A70WY(H(3>Z%E/YZ
M79J@EQ-(DZ(OO>Q*LU=*_S3'$6&3#X2-&2./VS6YOKKYER;Q;@9+;+#$(N_T
M?RQ=DMG1W5ZF"U.Q< TO(*.^[1W8(]#\_;O)?/SY#;'30>ST+?;<=SU*"&()
M5^:@\9+ CF(>*<*4'?-9FAS/JR9G'1"&Z9[;2FA').P]9CRZFU%BNP;M C1-
M;(J=0=]B<5G[F08;$OSYWA@\!:'/AK]$_A=02P,$%     @ ^$E55HK7B@/$
M P  9PT  !D   !X;"]W;W)K<VAE971S+W-H965T-C(N>&ULM9=M<YLX$,>_
MBH9VVF2F9Q#&3ZG-3)STYOJBK:>>7%\KL+8U$8A*PFYF[L/?"C#8,::=I/4+
M(P&[^_M+*ZV8[J1ZT!L 0WXD(M4S9V-,=N6Z.MI PG1/9I#BDY54"3/856M7
M9PI87!@EPO4];^@FC*=.."WN+50XE;D1/(6%(CI/$J8>YR#D;N909W_C*U]O
MC+WAAM.,K6$)YBY;*.RYM9>8)Y!J+E.B8#5SKNG5G(ZL0?'&OQQV^J!-K)1[
M*1]LYV,\<SQ+! (B8UTPO&SA!H2PGI#C>^74J6-:P\/VWOO?A7@4<\\TW$CQ
MC<=F,W/&#HEAQ7)AOLK=/U )&EA_D12Z^">[ZEW/(5&NC4PJ8R1(>%I>V8]J
M( X,@G,&?F7@%]QEH(+READ63I7<$67?1F^V44@MK!&.IW96ED;A4XYV)EP:
M&3ULI(A!Z;?DP_><FT?R%UF"XJ#)-7G#DNP]F9,%#A8H!3$I+,C%+1C&A;XD
MKXE+](8I?)VGY"[E1K_#F]C^Q(7 D==3UR"IC>=&%=6\I/+/4%WGZQ[Q_'?$
M]^B0W"UOR<7KHTCEY=BQB])K_7ZMWR\B]<]$:G1IJZL-M700M#NPJ^9*9RR"
MF8/+0H/:@A.^>46'WOL.O'Z-U^_R'M[(=(LS8_-7KDAV#$N,))%,$GQ8]B]P
MT,N1N6P34H8:%*'L:MV&@XD?!(/^U-VV, 8U8]#)^#E/[D%9OA0784G"M<X1
M4X%@AJ=K2VHV0#XNON"5F2:_6!KO._.G^JJT)"B(0&JX$?@$/2F( )=RF\3@
M1*+?'P1]_XS$02UQT"D1N=NB=1H],S.&-=+PI8D[_ -XHQIO](M)4:U8;!WE
MJL;);8,>G<Q@0+'$>%[[#(YKGG$GS])28(+Q"(IE$DLA&.96AI %X27Y[V"#
M:2,K PP/R.@9J$D-->F&VB?^D]VU+7JGIV=.)O6:*N&]--LJ#[^9\*".T<ZQ
M7/QD;XR:G53AGB1;)="3Y*/M,TR;^D([ZT/7[HB(&7O$@TFD\IH[YEL>0QKK
MH\V38UGE3* ;%&GO%9G<JL$_T3 9#,>!?T9(4XEH=RFJM^Q?2-9N5\_-A:8@
MT>#%V=I9TYY+V-03VEU0?DNVEB%H<)BN/>],J:--8:&=A2&\KO+Q)D]RFX%;
M(+=U4N(FV<I2NIP<H(Q[='+T.\/55!3:75(6[!$_!XQ=2O%/>48G/%[OZ5IV
M#X[-]A/D$U-KGFHB8(567F^$ ZS*4WW9,3(K3M+WTN"YO&AN\$L(E'T!GZ^D
M-/N./9S7WU;A_U!+ P04    " #X2556+6_Q8N $  #,&P  &0   'AL+W=O
M<FMS:&5E=',O<VAE970V,RYX;6RU65%SHS80_BL:>M->9BX!A,%V:GLF"==I
M'ZZ3B7OMLPQKPP203Q)VKK^^$A PF*CQC"X/,>#=#^VG_:1=:W&D[)DG  *]
MY%G!EU8BQ/[6MGF40$[X#=U#(;_94I83(6_9SN9[!B2NG/+,QHX3V#E)"VNU
MJ)X]LM6"EB)+"WADB)=Y3MCW>\CH<6FYUNN#IW27"/7 7BWV9 =K$%_WCTS>
MV2U*G.90\)06B,%V:=VYMR'&RJ&R^#N%(S^Y1BJ4#:7/ZN:/>&DY:D200204
M!)$?!WB +%-(<AS?&E"K?:=R/+U^1?^M"EX&LR$<'FCV3QJ+9&G-+!3#EI29
M>*+'WZ$)R%=X$<UX]1\=&UO'0E')!<T;9SF"/"WJ3_+2$''BX 9O..#& 0\=
M)F\X>(V#]UZ'2>,PJ9BI0ZEX"(D@JP6C1\24M413%Q69E;<,/RW4O*\%D]^F
MTD^LUH)&SPG-8F#\%_3Y6YF*[^@:58^O[R6A,7J@N<PR3JIY^AB"(&G&KZ31
MUW6(/GZX0A]06J"_$EIR4L1\80LY+H5N1\T8[NLQX#?&X&+TA18BX>AS$4/<
M![!E0&U4^#6J>ZQ%#"&Z09[["6$'XY$!/;S?W1UQ#]_O[FBB\=HY\BH\3S='
MUYMJ,J*3R1ACND::C".I1>26[TD$2TNN$AS8 :S5SS^Y@?/K&$LFP4)#8#T&
M)RV#$QWZJI?"\**N88R]&B6H4-2*>5C- T=.X>&4E7,CUW&G7M\J'+,*9O/6
MJA>'W\;A_T\<7""ZE0ON 8H2;L9BT")<F@$FP4)#8#WF@I:YP)B& I,,F@0+
M#8'U&)RV#$Z-:*A&\4\2WPNF PF=VTR\H8#.;7SO#?G,VA!FVA#6) ..Y"8E
M=U#V#"(M=J^1C&Y;6K1+$\$D6&@(K,?BO&5Q;DQ*<Y,,F@0+#8'U&'2=KNIR
MC(BI@>DIQ0F&.]*XU7P@J!$KW_%GXY)R3PI(5QO*DZ2'L"BI=!7+C2FC>]D8
M"*VR])B7)H91M- 46I]/W/&)C<FK@3)%HTFTT!1:G\:N9G:U!>7[%>:=J0+C
M8"BP<R//G0SU-6)T(M5^'%WEZNI+UR=(\TW)."A-?4([*("1K!(;B65#F'+!
MB.J=]7K3ON3B1#&)%II"ZQ/<E=2N;TYO1HMKHVBA*;0^C5U][6J+S_?K+3AK
MC";SR;! '+'R/7\Z5-P(UM3#;TBN*W1=?:6+'3= CQD93P&M[\4I8!(M-(76
MYZVKKMV9.249K:V-HH6FT/HT=N6UJZT]5W^6^0:8:O-Y0IAJ6$J14);^._QI
MK&%R?E[\S1SU-]24T?K9%%K_][VN@,;Z OJN%#27V17)G; HY8:8%A$#F7I(
M4"020,60Q684<;UU'DB:D4T&:$L92CDO21$!(I)LM <6R;V6[$!YTU)P(5U4
MKRB3.I>K&U=YCCZ>&E^-S4P3@JJ[VZEQ;AQ_,"_Z2"^=%U-H_7GIN@&L[P9^
MR+R,DNN>UVW^6-KK!WPQO3^B.<!=<X"U5?-JW:P(/9JVI2@9Z-G"Y[W?W)\&
M,V_(EM$>P!1:S99]<LR1 ]M5QT5<JK(L1'TVT#YMCZ3NJH.8P?-[]S:L#Y8Z
MF/J<ZPMAN[3@*(.MA'1NII(Q5A\=U3>"[JO#E T5,M&KRP1(#$P9R.^WE(K7
M&_6"]@!O]1]02P,$%     @ ^$E55L;B?ED,%P  8^,  !D   !X;"]W;W)K
M<VAE971S+W-H965T-C0N>&ULQ5UMD]LVDOXKK+FMNZ3*YA!\I\^>JEA$]O9#
M-JXXV?U,2YP95B1QEN1X[*O[\0=*E/#6:KZXY<V'>#QN/@2>!AMX@ ;P]J5N
M_FP?R[)SONRV^_;=S6/7/;VYO6W7C^6N:-WZJ=R+?[FOFUW1B;\V#[?M4U,6
MF\-#N^VM[WGQ[:ZH]C=W;P^_^]#<O:V?NVVU+S\T3ON\VQ7-U_?EMGYY=\-N
M3K_XK7IX[/I?W-Z]?2H>RH]E]\?3AT;\[?:,LJEVY;ZMZKW3E/?O;GYB;SB+
MHOZ)@\D_JO*E57YV^KI\JNL_^[_\;?/NQNN+5&[+===C%.*/S^6JW&Y[*%&0
M?PVH-^>7]@^J/Y_0?S[47M3F4]&6JWK[SVK3/;Z[26^<37E?/&^[W^J7_RF'
M&AT*N*ZW[>'_SLM@Z]TXZ^>VJW?#PZ($NVI__+/X,C"A/.!'%Q[PAP=\XP&6
M7'@@&!X(S#>$%QX(AP?"J46*A@<.5;\]UOU 7%YTQ=W;IGYQFMY:H/4_'-@_
M/"WXJO9]2_G8->)?*_%<=_>QJ]=_/M;;3=FT_^7P?SU7W5?GM7/XM?/K4^_,
MUBGV&^>WLNV::MV5F^$??\C+KJBV[8_"_(^/N?/#7WYT_N+<.NUCT92M4^V=
M/_95U[X2OQ0___Y8/[<"IWU[VXEB]R^_70]%?'\LHG^AB,QW?JGWW6/K\/VF
MW.@ MZ*^YTK[ITJ_]U'$O%R[3L!>.;[G^T"!5M,?9\#C^?3'/>!Q/OEQEB%D
M!.<6$!SP JP%O.X_MHVSKG<B!+5%[_97SD.Y+YMBZVRJ=KVMVV?A5A=RWQ$_
MA/'[4/>F?2K6Y;L;$<O:LOE<WMS]YW^PV/MOB'I*L)P2C!.!:4X*STX*,?2+
M3G+*+_W/)>26(V)\0.P[C,]W6>R)!O=9I=LV8AY+ MTJAZSB--.M.%J%A01%
M9X(BE*"\^EQM2A%?G*>BVCA=[6R*#J3EB!,I=3$Y0=\TMPE2@G$B,(WA^,QP
MC,8)WG:5Z)A% [POJL;Y7&R?RV/74+1BG#%T%6+LXK2'_J$>?O/0%/O.#-M'
M5\24@8,2+*<$XT1@FM>2L]<2]+O@(CX<.NVN;':0#]#'Y_J $BS'*Q8Z7\NB
M:9W8V1T&!Q#Q1,71B$_/Q*?3B/]<;T6HWO;CJA\*\<$X3V6S+O?=CY W4,RY
MWJ $RX]@S%?CIAM&@=D)$+U4XSP[<YZAG/]6M7^^OF_*4HPX17L7(U:G$1%K
M N\H[ES>*<'R#.+=\T*#=J)W:K0S3XH(;UICWPS=L/.U*K>;"<3CP'.9)T7+
M![3^CTMC!4[U1IUX1;TQM%/^Z>&A*1_Z-OZWO9!G0L"OG7_T/3/(-2/EFA(M
M)T7C5&BZ5WSI%1^/0U(K'\="ST().\5+T6R$'O[ILU!5#],\AKYGML<HT?(!
M3=,7D1>8WX=MQ5B4L;.93K$4K0R56W>_5/MJ]PR.:/ G9Y-&*DA)T3@5FNX#
MJ4E9^+T5 2/2D(/O*-%R4C1.A:;[3LIEANOEG\\>Z[OGXZ2=4]^??53OG>ZQ
M/(CH_M<'ESD_5'MG4V^W_;C[_!3<K5/*WA4I6CZ@I6I("MS8#%S7T-I,BFV&
MJ^U?!?N-&,8>UP*$2T"6204T*5I.BL:IT'1O2!'-<+%Y[:^%5(23HN4#&@M'
M/I=K:&TFQ3;#U?8OQ9>+PP%234V*EI.B<2HTW0=2?+/LNP\'2'4Y*5I.BL:I
MT/3U,"G@?5S 7SG X6^?ZT=2M'Q TP-<Z"9&@*-ZJ>X@*?1]7.A/&@_XI *?
M%"TG1>-4:+HWI,#W<8%_[<^%5/:3HN4#6CKRM1"]4_>/G!WP\=F!5;W;"1]H
M_0Q(-.E4 2E:3HK&J=!TA\BI A^?*OCV) .?=&: %"TG1>-4:+JKY,R C\\,
M+$DU\.U%=3^R<@T JS PK?+!2ITQ##W3BN.56$J2E.<^*CCO?J\[T6:?]TVY
MKA_VU?\*KL1[7G?%%Y SIRFWAY%Q5SO[>O^Y;.7<\#$\#;/#(+FQ/85J)W+@
M!9[=HDG5.Q6:[BRIWGU<O?_SD"U8;EX7P\R[Z'VK>N/4XJ_.RV.U?M0]J7EP
M7;>=4[4'3ZX'%W[J'7HR!UV&%X@=UJX=?UBZ=I@OA@I?(>>O<*39;J5$XU1H
MNENEYO=QS7_\!H]CJ\-(2\I.=2PV?&R;YZ;:/QR&94?W@WY+K4\ML"+4"K""
MXAB !<2Q:VAV7VIV_[MK=I]4LY.BY:1HG I-3]N4FCV8N.A^*;5GY/D)&32K
M;X?(<8C929C7D.&!E.$!*BR_(=%A ,:2"583;/()-AROQ%*2I#H.?'RN8@@2
MOSYW;2=BB8B[(".D*I<4+2=%XU1HNC^4!&]<#2M^<(I.C%X>JOV^_XOH)2_W
MA0.H.EK/6.3[H=EH;3OF!5GB96;+M0W3.,ZBR&R]UY"J@92J :JO[OYZN6L;
MGM0$3.*GUF=LF[$T3<+4),2V"Y)4,&(2<@U!&$A!&.""D'\18:UJ+U!B:[K7
MF9<FJ<D)8,>2*&*Q20ID&"9)R$Q6KJ$  ZD  UP!_EPW]V5UJ:'$ "M^EC*3
M%= NL?+O(;LH3,UOD>-E7LJ)%%H!KFM6Q7Y=;K?EYE;TDU5S@9L$<' <!('5
M9 ##,,S"T"0'L N"Q%RAQ,N^E!NI5@)<K1A!N!\ZX.$WM6H5LRCP$I,EVPX*
MTSE@!X9I#A@:85IG0&J- -<:)QE^3H [!1;G0U.MQ?^%&O_8SXF#=)"J"E*T
MG!2-4Z'I^XRDJ@CQ(?VRP<( JJX*!)D;&'%L!9G%;FAM-[+-_-2UOFB\)DN9
MDEH@Q+4 ,E 8GM36%&.7F=\N9!;:M.6@7>BF9OC'"[R4$#GN#_%5,72@,#RK
M+[.ZL1GT(3/?=^/(I 2P2URK0\1+O)01.?(.\9$W.D@8GM6J(+X&WZ($L!.M
M)$E,2@"[R'-]<SB)EWDI)\I.1GQ\/6F0,&#HW"16,UA!=E'BFL//'+*+ S<V
M!Y5XV9=R(X?:(3[4GCM(".U4QC"P/+X"S(#HG$-F=G3F@)D>G?7*RQ%U2)#R
M&)*F/)*BY:1HG I-]X8<RX?X6/XTB5,>@WKQ:5LZ^^?=)^$BT22'3?[*/X+.
MLD?F81 %L34LL.TBE@26-H3PTDR,3LT6>HVA?BB'^N'(4-^F[I7S8BY"E:?1
M[U,_^@7I2Z&O.[78L\T"WTS0S $K/W*M[7MXU992)S5"B._@.VN$$TM-V1]W
MTL?#=;WOFF+=/1=;9UO=EX=\FL/T,SC?.O*BT\QU.F$-;@0J.D*!$6'2DTYR
M*D1\J0Q\!"D>D()S=5( 2M]9+R5!-"())K7GRYZ"W#/RRBEK$SC$['WZI,L4
M5&BZQZ0TB7!I<G%;X*OSF2XU/CD_O$!/.C"G?@$CWS.']#E>UMG,VN\,@BQ*
MX-%'),5+A(L7A#)4UPRP^OQ+;!)E[X(+,X^91-E6<12:BSMX/98V+2EI(ES2
M3&A:(Z."X05J-4TEN\(+,?O;MM_(@L"<C>54+]69E<(HPG/D_GX:7;T!62/-
M?R-%RTG1.!6:[@;E(!E<@_V]WI]R1D[9#MHD6)]!TG=.H)/LQ8L@2S+/E/2
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MV)1-;R#^_;ZNN]-?^A>\U,V?AV+?_3]02P,$%     @ ^$E55CQ-W0'>!
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ML-QSJ +R_992\7:C*NC.\S?_ %!+ P04    " #X2556X2E=Y/L%   -*
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M&'EP3RM/NI02:TI_<B8$V'"VRJ0I_,30^Z!@&'XRB@QY 1K6Z-@*AKM9:@E
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M=FB7[#;6XO%<&"=>/)@R7T&#A/<ACH93:Y,=1E&<[!&XO42'=HU^3R55G8X
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MPVV^&J &G"F%)C;&9;@J@T)1K0.7@CEE-YCD4E(^<[L^"BZKA0%15,&7*T,
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M4 ,  *X5   -    >&PO<W1Y;&5S+GAM;-U876_:,!3]*U&Z3JTT-82,0%9
MVI J3=JF2NW#WBI#'+#D.)EC.NBOGZ\=PD=]&>W#"@.UL>_Q.??8ODG<]BNU
MY/1N1JGR%CD7U<"?*55^"H)J,J,YJ:Z*D@J-9(7,B=)=.0VJ4E*25D#*>=!N
MM>(@)TSXP[Z8YS>YJKQ),1=JX/>:D&<O7].!'\8??<_*C8J4#OR'B_>_YH6Z
M?N?9Z]F'L[/6P^7U;OS" )=^X!3M'"!ZU6KAP@!BXO%AXONT,>GN0=)[E#'A
MWK:P&7VN=2SO'*,E#IK)_Y=\W9:3N)$2.A@Y=).WV34]J*MLV,\*L2ZVR+<!
MK4]RZCT2/O!'A+.Q9,#*2,[XTH;;$)@4O)">TE6N$X80J9XL'-H>W "U3LY$
M(4UNF\'^'M?#=X!5#PPRSAN#;=\&AOV2*$6EN-$=,]@$GT%>W;Y?EMKA5))E
MV.[X:X*YZ"3C0J94-FE"?Q4:]CG-P(YDTQE<55$& "I5Y+J1,C(M!#$>5HRZ
MH64GE/,[>#K\S+:T%]G&SIE-%TU3&ZJ;5L9V0']3S6IORG9>I>N5[+%07^9Z
M.L+TX;Z@MY)F;&'ZBZPQ@*F'N#HI2[[\S-E4Y-1._N"$PSY9\;Q9(=F3S@:E
M,M$!*GWOD4K%)IN1WY*4]W2A5N6TR'#/[1/T_&_7>4H%E81OFM:U?\RK_&K'
M4?>M+)NGRJYAI\?ZE7_L)CNG8#(^!9,G49.]4S"9G(#)[IL]-5]B,CQ^D]%Q
M[G90']<VSH1;)\(FZL')>^#_@),\7R?UQG/&%1-U;\;2E(IG!T,MK\A8_S&Z
MI:_'IS0C<Z[N&W#@K]O?:<KF>=*,NH6%J$>MV]]@>F'<'/MU+B92NJ#IJ.[*
MZ=@T/=W06>L/$':1&_-Q(QC'8FX$,"P/Y@#C6!:6YW^:3P^=C\4P;STGTD,Y
M/91C62YD9+Y8'C<GT1_W3),DBN(86]'1R.E@A*U;',./6PWS!@PL#V1ZV5KC
MNXU7R/XZP/9T7X5@,\4K$9LIOM: N-<-&$GBWFTL#S"P7<!J!_*[\T!-N3E1
M!+N*></N8!Q)$@R!6G37:!PCJQ/#U[T_V%T214GB1@!S.X@B#(&[$4<P!^ !
M0Z+(O =WWD?!ZCT5K/]#._P#4$L#!!0    ( /A)55:7BKL<P    !,"   +
M    7W)E;',O+G)E;'.=DKENPS ,0'_%T)XP!] AB#-E\18$^0%6H@_8$@6*
M19V_K]JE<9 +&7D]/!+<'FE [3BDMHNI&/T04FE:U;@!2+8ECVG.D4*NU"P>
M-8?20$3;8T.P6BP^0"X99K>]9!:G<Z17B%S7G:4]VR]/06^ KSI,<4)I2$LS
M#O#-TG\R]_,,-47E2B.56QIXT^7^=N!)T:$B6!::1<G3HAVE?QW']I#3Z:]C
M(K1Z6^CY<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ ^$E55CGFN5EC
M!0  1R\   \   !X;"]W;W)K8F]O:RYX;6S%FMM/XS@4A_\5JR_+/+!M<RN#
M*%*YS&RE&:@H8A^125QJD=A=.^$R?_V>I'0YZ82C?3GM$R1QDR].XN_GR\F+
M=4\/UCZ)UR(W?MQ;EN7JN-_WZ5(5TO]I5\K D85UA2QATSWV_<HIF?FE4F61
M]X/!(.D74IO>Z<GF7#/7QQNV5&FIK8&=]8X[K5[\Q_%Z4SQKKQ]TKLNW<:_Y
M/U<]46BC"_U+9>/>H"?\TK[\99W^94TI\WGJ;)Z/>\/U@3OE2IW^MGM>0][*
M!]_L*>7#C020<2\9P D7VOFR*=&<7P+CLX+"ZZVJM-]T7BIW(4OUW=EJI<UC
M?1JXBSZZC:8>-G_7E7CL_D\UVL5"I^K"IE6A3+FN1Z?R&M#XI5[YGC"R4./>
MIHB0)A.7IH1*$E.S/A64K>\4+CW-UG== BZJ0W>LX8";9@TX'^0Y;-M<9W#U
M3)S)7)I4B:9R/0(,",!@;X#B8"819$A ACN$G-<0]0^\L MQO5(.048$9+0W
MR'-;K!!D3$#&>X.<ES9%D D!F>RO)J5?(L@1 3GBA;R29>54S716>6V4]TU#
M5+^/=6$$>41 'O%"GDFOFWJ;.>6AZ';+^)5 ^\J+-J^*0KJWYLW3CT;#SR0T
MYI,TM14TYKCY'E#M]X 7<Y+^4\%%F_V8B70*LU3>Z\B+&Y4J_2R;JW^@4389
M,NMD:IZA ,01U:HMRAU#9GE T()O$L)!DQ/@::[J'V Z2AI#9FM\MS9[T7G>
MT$WA"S6/-8&8>-_."$/*&D-F;< ;YRIHC"]?X22^_6PI40R93?&W= Y:C3?X
M$KQRSVTP2@Y#9CN<.Y5I:,T>G5+;KQOE@R&S$"")%+I<Z[1^XT"U)01X9=*M
M+Y8RPY!;#9!$GI8VSY3S?S2?;/F&TS+E@X#9!S<*&K@*M[<!I8* 6053D]I"
MB5OYVGI\ =FC8'; %9SWX(?U_HMXQYLI5V?@PAKH6F!,R@L!LQ>^2>W$G<PK
M)7XJZ2',-9\%QJ/$$#"+@<Q']P'&I,P0L)OA(Q^)@]LZB_@O&([20\"L!Y1&
M.MDH0P3,ANB.)9V8E# "9F'0^41@3$H9 ;,RM@-*5SV&E#="9F_\EE0Z"2F5
MA-Q#55N1I1.0\DK(/E1%9!=Q@#')L2IFKW2EE\ZZI.P2,MOE/<9T<E$Z"9EU
M@O-,)QREDY!9)W6PJ7--DV?F2^FZZX^R2LALE4]"S8838U)6"9FM0@Z>M<)-
M2%DEW.<8U7V(QYTIMT3,;J$Q(XQ)"29B'[;"4?%"E5+GK2\GHNP2,=NE17<H
M9I5+E])#W\7![\4$8U)VB9CMLH4YR7.;-J6:4=X*8Y)S(<Q^V<+<'M''F)1N
M(OYQK>V1U.XWD]).M,M>3!<<)9QH3]V8=TZ,20DGVE4W9M+1C6D))Z*$$^V\
M&]/QO&/*-?'N^S%=B)1GXIUW9+H(*=?$W#V9;<)#\;-.1-!>0H7BN<.8<DW,
M/NU.=;@.,2;EFIA]XIW ;'W;,3GSSC[U3F'B,!E3MHG9)]\I3!PF8\H[,?<$
M"XD98TS*._$^YUON$XQ)>2=F]@Z-.<++0BCY),SRH3&/,"8EH(190)TC0(=B
MKIH(A[L2"66AA-E"GV'6NP_/<$9/* LE^QA/>\<4UWA=54)9*.&>K^G&O"Q6
MN7U3>,(PH2R4,%OHOX&_CDR4D&N^V'LY>.2OBX[23<*]VHN:TVQEC(323<(]
MKD9BXHR14+I)F'7SZ2CE^K'C!7Z4;D;,NOD,$[YJZ0R>^QI1NADQZ^9SS.8(
MQJ1T,VITTV\*^].33"VT4=D57,+#_E3FZ<R)^L]ZD5D4UVM$%E6>G\.^:_/#
MRFRS#GRSAOWT7U!+ P04    " #X2556K&U05SP"  "O*@  &@   'AL+U]R
M96QS+W=O<FMB;V]K+GAM;"YR96QSS=K-:J-0&,;Q6PE>0,UYOVR'IJO9=%MZ
M Y*>?- DBL>A[=U/2!?)([.83?%9R5%\_8/P0]3'EWQHQWUW*KM]7Q:?Q\.I
MK*K=./:_ZKJL=_G8EKNNSZ?SD4TW'-OQO!RV==^NW]MMKF6YC'JXG5$]/=[.
M7+Q^]?E_)G:;S7Z=?W?K/\=\&O\QN/[HAO>RRWFL%J_ML,WCJJH_#]?=I;YL
MTMUY<K5X?EM5P_-;JNJY@P2"9/X@A2"=/\@@R.8/<@CR^8,"@F+^H :"FOF#
M[B'H?OZ@!PAZF#\H+5'&)4'2!&L"K1-RG0B\3@AV(A [(=F)P.R$:"<"M1.R
MG0C<3@AW(I [(=V)P.Z$>"<"O07U%@*]!?46 KUE\K!-H+>@WD*@MZ#>0J"W
MH-Y"H+>@WD*@MZ#>0J"WH-Y"H+>@WD*@MZ+>2J"WHMY*H+>BWDJ@MTY>EA#H
MK:BW$NBMJ+<2Z*VHMQ+HK:BW$NBMJ+<2Z*VHMQ+H;:BW$>AMJ+<1Z&VHMQ'H
M;:BW$>AMDY?=!'H;ZFT$>AOJ;01Z&^IM!'H;ZFT$>AOJ;01Z.^KM!'H[ZNT$
M>COJ[01Z.^KM!'H[ZNT$>OOD8R6!WHYZ.X'>CGH[@=Z.>CN!WHYZ.X'>@7H'
M@=Z!>@>!WH%Z!X'>@7H'@=Z!>@>!WH%Z!X'>,?G9A$#O0+V#0.] O8- [T"]
M@T#O!O5N"/1N4.^&0.\&]6Y^4N\R?AURN?9\K_'Z/TGU>#XW7R]_67[OG-R7
M"\[U;45Y^@M02P,$%     @ ^$E55D!K%[H  @  QBD  !,   !;0V]N=&5N
M=%]4>7!E<UTN>&ULS=I-3L,P$ 7@JU39HL;U;P%1-L 66' !DTS;J$ELV0;*
M[7%20 )!!2H2;].HM3UOXI&^5<_NGCW%R;9K^[@HUBGY4\9BM:;.QM)YZO/*
MTH7.IOPUK)BWU<:NB(G9S+#*]8GZ-$U#C>+\[)*6]J%-DZMM_CDVKE\4@=I8
M3"YV&X>L16&];YO*IKS.'OOZ4\KT-:',)\<]<=WX>)0W%.S+A&'E^X#7<S>/
M%$)3T^36AG1MN[R+;5L6TW-+L=Q?XHL>W7+95%2[ZJ'+1\KH ]DZKHE2UY:[
MHD?[DU.^8=I]\H/SQS+[ O/.V^!\S!,+]/NXMY$,IZ<^%Z*0FOVO^)Z82Q_\
M?C1,NZ;ZA]GY>I]<V(SSB&Q\''[''V?\7O^7?0B0/B1('PJD#PW2AP'I8P[2
MQS%('R<@?? 92B,HHG(44CF*J1P%58ZB*D=AE:.XRE%@Y2BR"A19!8JL D56
M@2*K0)%5H,@J4&05*+(*%%D%BJP215:)(JM$D56BR"I19)4HLDH4626*K!)%
M5HDBJT*15:'(JE!D52BR*A19%8JL"D56A2*K0I%5H<BJ4635*+)J%%DUBJP:
M15:-(JM&D56CR*I19-4HLAH460V*K 9%5H,BJT&1U:#(:E!D-2BR&A19#8JL
M<Q19YRBRSO]3UGOG-G\</S[+SC;]6SX;_[YY_@)02P$"% ,4    " #X2556
M!T%-8H$   "Q    $               @ $     9&]C4')O<',O87!P+GAM
M;%!+ 0(4 Q0    ( /A)558>>>F\[P   "L"   1              "  :\
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M2P$"% ,4    " #X2556*&'$,-,"  #["0  &               @(%8%P
M>&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @ ^$E55HQQ3Z9-
M!@  AQT  !@              ("!81H  'AL+W=O<FMS:&5E=',O<VAE970T
M+GAM;%!+ 0(4 Q0    ( /A)5588>+!8%@,  "8,   8              "
M@>0@  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4    " #X2556
M\X-BW8L'  !$/@  &               @($P)   >&PO=V]R:W-H965T<R]S
M:&5E=#8N>&UL4$L! A0#%     @ ^$E55C3H<WWZ"0  YS0  !@
M     ("!\2L  'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    (
M /A)55::594'% <  $80   8              " @2$V  !X;"]W;W)K<VAE
M971S+W-H965T."YX;6Q02P$"% ,4    " #X25569<CG' H'   H$   &
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M970Q,RYX;6Q02P$"% ,4    " #X25566 Z^G# #  #(!P  &0
M    @(&K;   >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    (
M /A)559PD9LU8@4  /43   9              " @1)P  !X;"]W;W)K<VAE
M971S+W-H965T,34N>&UL4$L! A0#%     @ ^$E55K%9C[S! @  U@8  !D
M             ("!JW4  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"
M% ,4    " #X2556:0_+(_$"  "_!P  &0              @(&C>   >&PO
M=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( /A)55:%C+)'P <
M #45   9              " @<M[  !X;"]W;W)K<VAE971S+W-H965T,3@N
M>&UL4$L! A0#%     @ ^$E55M-FB"L*#0  ;28  !D              ("!
MPH,  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4    " #X2556
MG!O=]W@5  "%3P  &0              @($#D0  >&PO=V]R:W-H965T<R]S
M:&5E=#(P+GAM;%!+ 0(4 Q0    ( /A)559')+I_;0<  !@5   9
M      " @;*F  !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%
M  @ ^$E55C(H92CK"@  $B,  !D              ("!5JX  'AL+W=O<FMS
M:&5E=',O<VAE970R,BYX;6Q02P$"% ,4    " #X2556A->HS^8#   J"@
M&0              @(%XN0  >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+
M 0(4 Q0    ( /A)55;?Y*[QY@<  #H9   9              " @96]  !X
M;"]W;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @ ^$E55KC!T_#&
M'   LUL  !D              ("!LL4  'AL+W=O<FMS:&5E=',O<VAE970R
M-2YX;6Q02P$"% ,4    " #X25562/Q%QLT#  "9"@  &0
M@(&OX@  >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( /A)
M559ZNT A: (  *(%   9              " @;/F  !X;"]W;W)K<VAE971S
M+W-H965T,C<N>&UL4$L! A0#%     @ ^$E55KT"XX7Q @  $ <  !D
M         ("!4ND  'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"% ,4
M    " #X2556;!;6?$L$  "V$0  &0              @(%Z[   >&PO=V]R
M:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( /A)558Q37%!M (  )T&
M   9              " @?SP  !X;"]W;W)K<VAE971S+W-H965T,S N>&UL
M4$L! A0#%     @ ^$E55M#[)F?, @  30<  !D              ("!Y_,
M 'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"% ,4    " #X25568\H>
MT40"   Z!0  &0              @('J]@  >&PO=V]R:W-H965T<R]S:&5E
M=#,R+GAM;%!+ 0(4 Q0    ( /A)559G&J\][@,  !4,   9
M  " @67Y  !X;"]W;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#%     @
M^$E55I=.=+Q>"0  >28  !D              ("!BOT  'AL+W=O<FMS:&5E
M=',O<VAE970S-"YX;6Q02P$"% ,4    " #X2556SF9@%NL#  #.#   &0
M            @($?!P$ >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4
M Q0    ( /A)559P!3?X^P8  -09   9              " @4$+ 0!X;"]W
M;W)K<VAE971S+W-H965T,S8N>&UL4$L! A0#%     @ ^$E55K7- (&H P
MH D  !D              ("!<Q(! 'AL+W=O<FMS:&5E=',O<VAE970S-RYX
M;6Q02P$"% ,4    " #X25568!!@GVL#   ##@  &0              @(%2
M%@$ >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    ( /A)55;B
M%-T"I@(  !4&   9              " @?09 0!X;"]W;W)K<VAE971S+W-H
M965T,SDN>&UL4$L! A0#%     @ ^$E55EB['M8T @  2P4  !D
M     ("!T1P! 'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( /A)55;*=DJ\I0(  (X&   9              "
M@94U 0!X;"]W;W)K<VAE971S+W-H965T-#4N>&UL4$L! A0#%     @ ^$E5
M5LYYY5)' P  6Q   !D              ("!<3@! 'AL+W=O<FMS:&5E=',O
M<VAE970T-BYX;6Q02P$"% ,4    " #X2556G+[A[UD"   P!@  &0
M        @('O.P$ >&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+ 0(4 Q0
M   ( /A)55:X7?Z$J00  -<=   9              " @7\^ 0!X;"]W;W)K
M<VAE971S+W-H965T-#@N>&UL4$L! A0#%     @ ^$E55J@&<(R/"P  0($
M !D              ("!7T,! 'AL+W=O<FMS:&5E=',O<VAE970T.2YX;6Q0
M2P$"% ,4    " #X2556>1%@WR4#   1#   &0              @($E3P$
M>&PO=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+ 0(4 Q0    ( /A)558\\4:U
M90,  '$+   9              " @8%2 0!X;"]W;W)K<VAE971S+W-H965T
M-3$N>&UL4$L! A0#%     @ ^$E55MT^ICA0!P  JD<  !D
M ("!'58! 'AL+W=O<FMS:&5E=',O<VAE970U,BYX;6Q02P$"% ,4    " #X
M2556PX8*,5H"  " !@  &0              @(&D70$ >&PO=V]R:W-H965T
M<R]S:&5E=#4S+GAM;%!+ 0(4 Q0    ( /A)559;>IKGNP4  !TV   9
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M970U."YX;6Q02P$"% ,4    " #X2556C7"*W 4"   S!   &0
M    @($,= $ >&PO=V]R:W-H965T<R]S:&5E=#4Y+GAM;%!+ 0(4 Q0    (
M /A)55;)WX_5B0(  ,8'   9              " @4AV 0!X;"]W;W)K<VAE
M971S+W-H965T-C N>&UL4$L! A0#%     @ ^$E55FS%7"8$ @  ,00  !D
M             ("!"'D! 'AL+W=O<FMS:&5E=',O<VAE970V,2YX;6Q02P$"
M% ,4    " #X2556BM>* \0#  !G#0  &0              @(%#>P$ >&PO
M=V]R:W-H965T<R]S:&5E=#8R+GAM;%!+ 0(4 Q0    ( /A)558M;_%BX 0
M ,P;   9              " @3Y_ 0!X;"]W;W)K<VAE971S+W-H965T-C,N
M>&UL4$L! A0#%     @ ^$E55L;B?ED,%P  8^,  !D              ("!
M580! 'AL+W=O<FMS:&5E=',O<VAE970V-"YX;6Q02P$"% ,4    " #X2556
M/$W= =X$  #;'P  &0              @(&8FP$ >&PO=V]R:W-H965T<R]S
M:&5E=#8U+GAM;%!+ 0(4 Q0    ( /A)55;A*5WD^P4   TH   9
M      " @:V@ 0!X;"]W;W)K<VAE971S+W-H965T-C8N>&UL4$L! A0#%
M  @ ^$E55N'_*1:("@  ]$(  !D              ("!WZ8! 'AL+W=O<FMS
M:&5E=',O<VAE970V-RYX;6Q02P$"% ,4    " #X25567@-W6BH#  !,"@
M&0              @(&>L0$ >&PO=V]R:W-H965T<R]S:&5E=#8X+GAM;%!+
M 0(4 Q0    ( /A)55;K9EVG P0  !$5   9              " @?^T 0!X
M;"]W;W)K<VAE971S+W-H965T-CDN>&UL4$L! A0#%     @ ^$E55FX:X .D
M @  @0H  !D              ("!.;D! 'AL+W=O<FMS:&5E=',O<VAE970W
M,"YX;6Q02P$"% ,4    " #X2556Y6QK8AD#  !E"0  &0
M@($4O $ >&PO=V]R:W-H965T<R]S:&5E=#<Q+GAM;%!+ 0(4 Q0    ( /A)
M559Z<!1<80,  .H2   9              " @62_ 0!X;"]W;W)K<VAE971S
M+W-H965T-S(N>&UL4$L! A0#%     @ ^$E55H=D;_]0 P  KA4   T
M         ( !_,(! 'AL+W-T>6QE<RYX;6Q02P$"% ,4    " #X2556EXJ[
M',     3 @  "P              @ %WQ@$ 7W)E;',O+G)E;'-02P$"% ,4
M    " #X2556.>:Y66,%  !'+P  #P              @ %@QP$ >&PO=V]R
M:V)O;VLN>&UL4$L! A0#%     @ ^$E55JQM4%<\ @  KRH  !H
M     ( !\,P! 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%
M  @ ^$E55D!K%[H  @  QBD  !,              ( !9,\! %M#;VYT96YT
A7U1Y<&5S72YX;6Q02P4&     %  4 #G%0  E=$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>253</ContextCount>
  <ElementCount>443</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>80</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="tcmd-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tactilemedical.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="tcmd-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00100 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tactilemedical.com/role/StatementConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="tcmd-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00105 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tactilemedical.com/role/StatementConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="tcmd-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00200 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="tcmd-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00300 - Statement - Consolidated Statements of Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="tcmd-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00400 - Statement - Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="tcmd-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00500 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="tcmd-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>10101 - Disclosure - Nature of Business and Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tactilemedical.com/role/DisclosureNatureOfBusinessAndOperations</Role>
      <ShortName>Nature of Business and Operations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="tcmd-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>10201 - Disclosure - Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tactilemedical.com/role/DisclosureBasisOfPresentation</Role>
      <ShortName>Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="tcmd-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>10301 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tactilemedical.com/role/DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="tcmd-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>10401 - Disclosure - Acquisitions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tactilemedical.com/role/DisclosureAcquisitions</Role>
      <ShortName>Acquisitions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="tcmd-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>10501 - Disclosure - Accounts Receivable</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tactilemedical.com/role/DisclosureAccountsReceivable</Role>
      <ShortName>Accounts Receivable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="tcmd-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>10601 - Disclosure - Inventories</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tactilemedical.com/role/DisclosureInventories</Role>
      <ShortName>Inventories</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="tcmd-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>10701 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tactilemedical.com/role/DisclosurePropertyAndEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="tcmd-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>10801 - Disclosure - Goodwill and Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tactilemedical.com/role/DisclosureGoodwillAndIntangibleAssets</Role>
      <ShortName>Goodwill and Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="tcmd-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>10901 - Disclosure - Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tactilemedical.com/role/DisclosureAccruedExpenses</Role>
      <ShortName>Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="tcmd-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>11001 - Disclosure - Warranty Reserves</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tactilemedical.com/role/DisclosureWarrantyReserves</Role>
      <ShortName>Warranty Reserves</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="tcmd-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>11101 - Disclosure - Credit Agreement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tactilemedical.com/role/DisclosureCreditAgreement</Role>
      <ShortName>Credit Agreement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="tcmd-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>11201 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="tcmd-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>11301 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tactilemedical.com/role/DisclosureStockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="tcmd-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>11401 - Disclosure - Revenue</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tactilemedical.com/role/DisclosureRevenue</Role>
      <ShortName>Revenue</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="tcmd-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>11501 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tactilemedical.com/role/DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="tcmd-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>11601 - Disclosure - Net (Loss) Income Per Common Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tactilemedical.com/role/DisclosureNetLossIncomePerCommonShare</Role>
      <ShortName>Net (Loss) Income Per Common Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="tcmd-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>11701 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tactilemedical.com/role/DisclosureFairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="tcmd-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>20302 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tactilemedical.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.tactilemedical.com/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="tcmd-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>30403 - Disclosure - Acquisitions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tactilemedical.com/role/DisclosureAcquisitionsTables</Role>
      <ShortName>Acquisitions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.tactilemedical.com/role/DisclosureAcquisitions</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="tcmd-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>30603 - Disclosure - Inventories (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tactilemedical.com/role/DisclosureInventoriesTables</Role>
      <ShortName>Inventories (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.tactilemedical.com/role/DisclosureInventories</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="tcmd-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>30703 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tactilemedical.com/role/DisclosurePropertyAndEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.tactilemedical.com/role/DisclosurePropertyAndEquipment</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="tcmd-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>30803 - Disclosure - Goodwill and Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tactilemedical.com/role/DisclosureGoodwillAndIntangibleAssetsTables</Role>
      <ShortName>Goodwill and Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.tactilemedical.com/role/DisclosureGoodwillAndIntangibleAssets</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="tcmd-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>30903 - Disclosure - Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tactilemedical.com/role/DisclosureAccruedExpensesTables</Role>
      <ShortName>Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.tactilemedical.com/role/DisclosureAccruedExpenses</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="tcmd-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>31003 - Disclosure - Warranty Reserves (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tactilemedical.com/role/DisclosureWarrantyReservesTables</Role>
      <ShortName>Warranty Reserves (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.tactilemedical.com/role/DisclosureWarrantyReserves</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="tcmd-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>31103 - Disclosure - Credit Agreement (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tactilemedical.com/role/DisclosureCreditAgreementTables</Role>
      <ShortName>Credit Agreement (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.tactilemedical.com/role/DisclosureCreditAgreement</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="tcmd-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>31203 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingencies</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="tcmd-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>31303 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tactilemedical.com/role/DisclosureStockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.tactilemedical.com/role/DisclosureStockholdersEquity</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="tcmd-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>31403 - Disclosure - Revenue (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tactilemedical.com/role/DisclosureRevenueTables</Role>
      <ShortName>Revenue (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.tactilemedical.com/role/DisclosureRevenue</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="tcmd-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>31503 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tactilemedical.com/role/DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.tactilemedical.com/role/DisclosureIncomeTaxes</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="tcmd-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>31603 - Disclosure - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tactilemedical.com/role/DisclosureNetLossPerShareTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="tcmd-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>31703 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tactilemedical.com/role/DisclosureFairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.tactilemedical.com/role/DisclosureFairValueMeasurements</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="tcmd-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>40101 - Disclosure - Nature of Business and Operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tactilemedical.com/role/DisclosureNatureOfBusinessAndOperationsDetails</Role>
      <ShortName>Nature of Business and Operations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.tactilemedical.com/role/DisclosureNatureOfBusinessAndOperations</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="tcmd-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>40301 - Disclosure - Summary of Significant Accounting Policies - Segment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tactilemedical.com/role/DisclosureSummaryOfSignificantAccountingPoliciesSegmentDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Segment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.tactilemedical.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="tcmd-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>40302 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tactilemedical.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.tactilemedical.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="tcmd-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>40401 - Disclosure - Acquisitions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tactilemedical.com/role/DisclosureAcquisitionsDetails</Role>
      <ShortName>Acquisitions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.tactilemedical.com/role/DisclosureAcquisitionsTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="tcmd-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>40402 - Disclosure - Acquisitions - Purchase Price Allocation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tactilemedical.com/role/DisclosureAcquisitionsPurchasePriceAllocationDetails</Role>
      <ShortName>Acquisitions - Purchase Price Allocation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="tcmd-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>40403 - Disclosure - Acquisitions - Allocation of Purchase Price (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tactilemedical.com/role/DisclosureAcquisitionsAllocationOfPurchasePriceDetails</Role>
      <ShortName>Acquisitions - Allocation of Purchase Price (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="tcmd-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>40404 - Disclosure - Acquisitions - Consolidated Statements of Operations Reflect AffloVest Operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tactilemedical.com/role/DisclosureAcquisitionsConsolidatedStatementsOfOperationsReflectAfflovestOperationsDetails</Role>
      <ShortName>Acquisitions - Consolidated Statements of Operations Reflect AffloVest Operations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="tcmd-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>40501 - Disclosure - Accounts Receivable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tactilemedical.com/role/DisclosureAccountsReceivableDetails</Role>
      <ShortName>Accounts Receivable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.tactilemedical.com/role/DisclosureAccountsReceivable</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="tcmd-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>40601 - Disclosure - Inventories (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tactilemedical.com/role/DisclosureInventoriesDetails</Role>
      <ShortName>Inventories (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.tactilemedical.com/role/DisclosureInventoriesTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="tcmd-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>40701 - Disclosure - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tactilemedical.com/role/DisclosurePropertyAndEquipmentDetails</Role>
      <ShortName>Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.tactilemedical.com/role/DisclosurePropertyAndEquipmentTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="tcmd-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>40801 - Disclosure - Goodwill And Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tactilemedical.com/role/DisclosureGoodwillAndIntangibleAssetsDetails</Role>
      <ShortName>Goodwill And Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="tcmd-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>40901 - Disclosure - Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tactilemedical.com/role/DisclosureAccruedExpensesDetails</Role>
      <ShortName>Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.tactilemedical.com/role/DisclosureAccruedExpensesTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="tcmd-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>41001 - Disclosure - Warranty Reserves (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tactilemedical.com/role/DisclosureWarrantyReservesDetails</Role>
      <ShortName>Warranty Reserves (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.tactilemedical.com/role/DisclosureWarrantyReservesTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="tcmd-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>41101 - Disclosure - Credit Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tactilemedical.com/role/DisclosureCreditAgreementDetails</Role>
      <ShortName>Credit Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.tactilemedical.com/role/DisclosureCreditAgreementTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="tcmd-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>41102 - Disclosure - Credit Agreement - Maturities of Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tactilemedical.com/role/DisclosureCreditAgreementMaturitiesOfDebtDetails</Role>
      <ShortName>Credit Agreement - Maturities of Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="tcmd-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>41201 - Disclosure - Commitments and Contingencies - Lease Obligations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesLeaseObligationsDetails</Role>
      <ShortName>Commitments and Contingencies - Lease Obligations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="tcmd-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>41202 - Disclosure - Commitments and Contingencies - Lease related assets and liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesLeaseRelatedAssetsAndLiabilitiesDetails</Role>
      <ShortName>Commitments and Contingencies - Lease related assets and liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="tcmd-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>41203 - Disclosure - Commitments and Contingencies - Undiscounted cash flows (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesUndiscountedCashFlowsDetails</Role>
      <ShortName>Commitments and Contingencies - Undiscounted cash flows (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="tcmd-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>41204 - Disclosure - Commitments and Contingencies - Lease commitments and operating lease cost (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesLeaseCommitmentsAndOperatingLeaseCostDetails</Role>
      <ShortName>Commitments and Contingencies - Lease commitments and operating lease cost (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="tcmd-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>41205 - Disclosure - Commitments and Contingencies - Major Vendors (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesMajorVendorsDetails</Role>
      <ShortName>Commitments and Contingencies - Major Vendors (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="tcmd-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>41206 - Disclosure - Commitments and Contingencies - Purchase Commitments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesPurchaseCommitmentsDetails</Role>
      <ShortName>Commitments and Contingencies - Purchase Commitments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="tcmd-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>41207 - Disclosure - Commitments and Contingencies - Retirement Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesRetirementPlanDetails</Role>
      <ShortName>Commitments and Contingencies - Retirement Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="tcmd-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>41208 - Disclosure - Commitments and Contingencies - Legal Proceedings (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesLegalProceedingsDetails</Role>
      <ShortName>Commitments and Contingencies - Legal Proceedings (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="tcmd-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>41301 - Disclosure - Stockholders' Equity - Series A &amp; B Preferred Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tactilemedical.com/role/DisclosureStockholdersEquitySeriesBPreferredStockDetails</Role>
      <ShortName>Stockholders' Equity - Series A &amp; B Preferred Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="tcmd-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>41302 - Disclosure - Stockholders' Equity - Stock-Based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockBasedCompensationDetails</Role>
      <ShortName>Stockholders' Equity - Stock-Based Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="tcmd-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>41303 - Disclosure - Stockholders' Equity - Stock Options and Restricted Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails</Role>
      <ShortName>Stockholders' Equity - Stock Options and Restricted Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="tcmd-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>41304 - Disclosure - Stockholders' Equity - Employee Stock Purchase Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tactilemedical.com/role/DisclosureStockholdersEquityEmployeeStockPurchasePlanDetails</Role>
      <ShortName>Stockholders' Equity - Employee Stock Purchase Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="tcmd-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>41401 - Disclosure - Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tactilemedical.com/role/DisclosureRevenueDetails</Role>
      <ShortName>Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.tactilemedical.com/role/DisclosureRevenueTables</ParentRole>
      <Position>66</Position>
    </Report>
    <Report instance="tcmd-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>41501 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tactilemedical.com/role/DisclosureIncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.tactilemedical.com/role/DisclosureIncomeTaxesTables</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="tcmd-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>41601 - Disclosure - Net (Loss) Income Per Common Share - Basic and Diluted Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tactilemedical.com/role/DisclosureNetLossIncomePerCommonShareBasicAndDilutedNetLossPerShareDetails</Role>
      <ShortName>Net (Loss) Income Per Common Share - Basic and Diluted Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.tactilemedical.com/role/DisclosureNetLossPerShareTables</ParentRole>
      <Position>68</Position>
    </Report>
    <Report instance="tcmd-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>41602 - Disclosure - Net (Loss) Income Per Common Share - Antidilutive Securities Excluded From Computation of Earnings Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tactilemedical.com/role/DisclosureNetLossIncomePerCommonShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails</Role>
      <ShortName>Net (Loss) Income Per Common Share - Antidilutive Securities Excluded From Computation of Earnings Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.tactilemedical.com/role/DisclosureNetLossPerShareTables</ParentRole>
      <Position>69</Position>
    </Report>
    <Report instance="tcmd-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>41701 - Disclosure - Fair Value Measurements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tactilemedical.com/role/DisclosureFairValueMeasurementsDetails</Role>
      <ShortName>Fair Value Measurements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.tactilemedical.com/role/DisclosureFairValueMeasurementsTables</ParentRole>
      <Position>70</Position>
    </Report>
    <Report instance="tcmd-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>41702 - Disclosure - Fair Value Measurements - Earn out liability (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tactilemedical.com/role/DisclosureFairValueMeasurementsEarnOutLiabilityDetails</Role>
      <ShortName>Fair Value Measurements - Earn out liability (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="tcmd-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>41703 - Disclosure - Fair Value Measurements - Fair Value Hierarchy (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tactilemedical.com/role/DisclosureFairValueMeasurementsFairValueHierarchyDetails</Role>
      <ShortName>Fair Value Measurements - Fair Value Hierarchy (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 22 fact(s) appearing in ix:hidden were eligible for transformation: dei:EntityFilerCategory, tcmd:NumberOfConsecutiveTradingDaysInWhichStockPriceExceedCertainPercentageOfClosingPriceOfCommonStockRequiredForAwardToBeGranted, tcmd:PeriodForConsiderationPaymentAfterShipmentDate, tcmd:RentToPurchaseArrangementsRentalPeriod, tcmd:TermOfProductWarranty, us-gaap:CommonStockSharesOutstanding, us-gaap:LesseeOperatingLeaseTermOfContract, us-gaap:NumberOfReportableSegments, us-gaap:PreferredStockSharesOutstanding, us-gaap:PropertyPlantAndEquipmentUsefulLife, us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1, us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage, us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod, us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 -  tcmd-20221231x10k.htm 9</Log>
    <Log type="Warning">[ix-0514-Hidden-Fact-Not-Referenced] WARN: 5 fact(s) appearing in ix:hidden were not referenced by any -sec-ix-hidden style property: us-gaap:CommitmentsAndContingencies, us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList, us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList, us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList -  tcmd-20221231x10k.htm 9</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-K" original="tcmd-20221231x10k.htm">tcmd-20221231x10k.htm</File>
    <File>tcmd-20221231.xsd</File>
    <File>tcmd-20221231_cal.xml</File>
    <File>tcmd-20221231_def.xml</File>
    <File>tcmd-20221231_lab.xml</File>
    <File>tcmd-20221231_pre.xml</File>
    <File>tcmd-20221231xex23d1.htm</File>
    <File>tcmd-20221231xex31d1.htm</File>
    <File>tcmd-20221231xex31d2.htm</File>
    <File>tcmd-20221231xex32d1.htm</File>
    <File>tcmd-20221231xex32d2.htm</File>
    <File>tcmd-20221231xex3d2.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>tcmd-20221231x10k005.jpg</File>
    <File>tcmd-20221231x10k006.jpg</File>
    <File>tcmd-20221231x10k007.jpg</File>
    <File>tcmd-20221231x10k008.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="962">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="36">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>96
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "tcmd-20221231x10k.htm": {
   "axisCustom": 0,
   "axisStandard": 26,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 962,
    "http://xbrl.sec.gov/dei/2022": 36
   },
   "contextCount": 253,
   "dts": {
    "calculationLink": {
     "local": [
      "tcmd-20221231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "tcmd-20221231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "tcmd-20221231x10k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "tcmd-20221231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "tcmd-20221231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "tcmd-20221231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 678,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 25,
    "http://www.tactilemedical.com/20221231": 6,
    "http://xbrl.sec.gov/dei/2022": 5,
    "total": 36
   },
   "keyCustom": 78,
   "keyStandard": 365,
   "memberCustom": 31,
   "memberStandard": 46,
   "nsprefix": "tcmd",
   "nsuri": "http://www.tactilemedical.com/20221231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcmd-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00090 - Document - Document and Entity Information",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.tactilemedical.com/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcmd-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcmd-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10301 - Disclosure - Summary of Significant Accounting Policies",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://www.tactilemedical.com/role/DisclosureSummaryOfSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcmd-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcmd-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetAcquisitionTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10401 - Disclosure - Acquisitions",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.tactilemedical.com/role/DisclosureAcquisitions",
     "shortName": "Acquisitions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcmd-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetAcquisitionTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcmd-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10501 - Disclosure - Accounts Receivable",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.tactilemedical.com/role/DisclosureAccountsReceivable",
     "shortName": "Accounts Receivable",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcmd-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcmd-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10601 - Disclosure - Inventories",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://www.tactilemedical.com/role/DisclosureInventories",
     "shortName": "Inventories",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcmd-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcmd-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10701 - Disclosure - Property and Equipment",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://www.tactilemedical.com/role/DisclosurePropertyAndEquipment",
     "shortName": "Property and Equipment",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcmd-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcmd-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10801 - Disclosure - Goodwill and Intangible Assets",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://www.tactilemedical.com/role/DisclosureGoodwillAndIntangibleAssets",
     "shortName": "Goodwill and Intangible Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcmd-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcmd-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "tcmd:AccruedExpensesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10901 - Disclosure - Accrued Expenses",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://www.tactilemedical.com/role/DisclosureAccruedExpenses",
     "shortName": "Accrued Expenses",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcmd-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "tcmd:AccruedExpensesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcmd-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProductWarrantyDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11001 - Disclosure - Warranty Reserves",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://www.tactilemedical.com/role/DisclosureWarrantyReserves",
     "shortName": "Warranty Reserves",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcmd-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProductWarrantyDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcmd-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11101 - Disclosure - Credit Agreement",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://www.tactilemedical.com/role/DisclosureCreditAgreement",
     "shortName": "Credit Agreement",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcmd-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcmd-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11201 - Disclosure - Commitments and Contingencies",
     "menuCat": "Notes",
     "order": "19",
     "role": "http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcmd-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcmd-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00100 - Statement - Consolidated Balance Sheets",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://www.tactilemedical.com/role/StatementConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcmd-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcmd-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11301 - Disclosure - Stockholders' Equity",
     "menuCat": "Notes",
     "order": "20",
     "role": "http://www.tactilemedical.com/role/DisclosureStockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcmd-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcmd-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11401 - Disclosure - Revenue",
     "menuCat": "Notes",
     "order": "21",
     "role": "http://www.tactilemedical.com/role/DisclosureRevenue",
     "shortName": "Revenue",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcmd-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcmd-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11501 - Disclosure - Income Taxes",
     "menuCat": "Notes",
     "order": "22",
     "role": "http://www.tactilemedical.com/role/DisclosureIncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcmd-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcmd-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11601 - Disclosure - Net (Loss) Income Per Common Share",
     "menuCat": "Notes",
     "order": "23",
     "role": "http://www.tactilemedical.com/role/DisclosureNetLossIncomePerCommonShare",
     "shortName": "Net (Loss) Income Per Common Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcmd-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcmd-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11701 - Disclosure - Fair Value Measurements",
     "menuCat": "Notes",
     "order": "24",
     "role": "http://www.tactilemedical.com/role/DisclosureFairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcmd-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcmd-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "20302 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "menuCat": "Policies",
     "order": "25",
     "role": "http://www.tactilemedical.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcmd-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcmd-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetAcquisitionTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30403 - Disclosure - Acquisitions (Tables)",
     "menuCat": "Tables",
     "order": "26",
     "role": "http://www.tactilemedical.com/role/DisclosureAcquisitionsTables",
     "shortName": "Acquisitions (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcmd-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetAcquisitionTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcmd-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30603 - Disclosure - Inventories (Tables)",
     "menuCat": "Tables",
     "order": "27",
     "role": "http://www.tactilemedical.com/role/DisclosureInventoriesTables",
     "shortName": "Inventories (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcmd-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcmd-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30703 - Disclosure - Property and Equipment (Tables)",
     "menuCat": "Tables",
     "order": "28",
     "role": "http://www.tactilemedical.com/role/DisclosurePropertyAndEquipmentTables",
     "shortName": "Property and Equipment (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcmd-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcmd-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30803 - Disclosure - Goodwill and Intangible Assets (Tables)",
     "menuCat": "Tables",
     "order": "29",
     "role": "http://www.tactilemedical.com/role/DisclosureGoodwillAndIntangibleAssetsTables",
     "shortName": "Goodwill and Intangible Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcmd-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcmd-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00105 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://www.tactilemedical.com/role/StatementConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcmd-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "tcmd:AccruedExpensesDisclosureCurrentTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcmd-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "tcmd:ScheduleOfAccruedExpensesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30903 - Disclosure - Accrued Expenses (Tables)",
     "menuCat": "Tables",
     "order": "30",
     "role": "http://www.tactilemedical.com/role/DisclosureAccruedExpensesTables",
     "shortName": "Accrued Expenses (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "tcmd:AccruedExpensesDisclosureCurrentTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcmd-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "tcmd:ScheduleOfAccruedExpensesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ProductWarrantyDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcmd-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "31003 - Disclosure - Warranty Reserves (Tables)",
     "menuCat": "Tables",
     "order": "31",
     "role": "http://www.tactilemedical.com/role/DisclosureWarrantyReservesTables",
     "shortName": "Warranty Reserves (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ProductWarrantyDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcmd-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcmd-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "31103 - Disclosure - Credit Agreement (Tables)",
     "menuCat": "Tables",
     "order": "32",
     "role": "http://www.tactilemedical.com/role/DisclosureCreditAgreementTables",
     "shortName": "Credit Agreement (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcmd-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcmd-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "tcmd:AssetsAndLiabilitiesLesseeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "31203 - Disclosure - Commitments and Contingencies (Tables)",
     "menuCat": "Tables",
     "order": "33",
     "role": "http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesTables",
     "shortName": "Commitments and Contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcmd-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "tcmd:AssetsAndLiabilitiesLesseeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcmd-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "31303 - Disclosure - Stockholders' Equity (Tables)",
     "menuCat": "Tables",
     "order": "34",
     "role": "http://www.tactilemedical.com/role/DisclosureStockholdersEquityTables",
     "shortName": "Stockholders' Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcmd-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcmd-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "31403 - Disclosure - Revenue (Tables)",
     "menuCat": "Tables",
     "order": "35",
     "role": "http://www.tactilemedical.com/role/DisclosureRevenueTables",
     "shortName": "Revenue (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcmd-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcmd-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "31503 - Disclosure - Income Taxes (Tables)",
     "menuCat": "Tables",
     "order": "36",
     "role": "http://www.tactilemedical.com/role/DisclosureIncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcmd-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcmd-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "31603 - Disclosure - Net Loss Per Share (Tables)",
     "menuCat": "Tables",
     "order": "37",
     "role": "http://www.tactilemedical.com/role/DisclosureNetLossPerShareTables",
     "shortName": "Net Loss Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcmd-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcmd-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "31703 - Disclosure - Fair Value Measurements (Tables)",
     "menuCat": "Tables",
     "order": "38",
     "role": "http://www.tactilemedical.com/role/DisclosureFairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcmd-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:NatureOfOperations",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcmd-20221231x10k.htm",
      "contextRef": "Duration_8_2_2016_To_8_2_2016_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_oNbQsAMXk0uBUzklZFhmAA",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40101 - Disclosure - Nature of Business and Operations (Details)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://www.tactilemedical.com/role/DisclosureNatureOfBusinessAndOperationsDetails",
     "shortName": "Nature of Business and Operations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:NatureOfOperations",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcmd-20221231x10k.htm",
      "contextRef": "Duration_8_2_2016_To_8_2_2016_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_oNbQsAMXk0uBUzklZFhmAA",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:ProceedsFromIssuanceInitialPublicOffering",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcmd-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00200 - Statement - Consolidated Statements of Operations",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfOperations",
     "shortName": "Consolidated Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcmd-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:CostOfRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcmd-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_segment_zejw3MrZOkWEznPtKLNRGQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40301 - Disclosure - Summary of Significant Accounting Policies - Segment (Details)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://www.tactilemedical.com/role/DisclosureSummaryOfSignificantAccountingPoliciesSegmentDetails",
     "shortName": "Summary of Significant Accounting Policies - Segment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcmd-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_segment_zejw3MrZOkWEznPtKLNRGQ",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount",
       "span",
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcmd-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40302 - Disclosure - Summary of Significant Accounting Policies (Details)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://www.tactilemedical.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails",
     "shortName": "Summary of Significant Accounting Policies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount",
       "span",
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcmd-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:AssetAcquisitionTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcmd-20221231x10k.htm",
      "contextRef": "As_Of_9_8_2021_8l4xBubq7Umd0Y3dMd0UnQ",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40401 - Disclosure - Acquisitions (Details)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://www.tactilemedical.com/role/DisclosureAcquisitionsDetails",
     "shortName": "Acquisitions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcmd-20221231x10k.htm",
      "contextRef": "Duration_9_8_2021_To_9_8_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_0hChIJ5gE0K__CcmmMTvmQ",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:BusinessCombinationAcquisitionRelatedCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcmd-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryNet",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40402 - Disclosure - Acquisitions - Purchase Price Allocation (Details)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://www.tactilemedical.com/role/DisclosureAcquisitionsPurchasePriceAllocationDetails",
     "shortName": "Acquisitions - Purchase Price Allocation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcmd-20221231x10k.htm",
      "contextRef": "Duration_9_8_2021_To_9_8_2021_JHuv2YIhr0-DMtiV3Vl0PA",
      "decimals": null,
      "lang": "en-US",
      "name": "tcmd:GoodwillAmortizationPeriodForTaxPurposes",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcmd-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsNet",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40403 - Disclosure - Acquisitions - Allocation of Purchase Price (Details)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://www.tactilemedical.com/role/DisclosureAcquisitionsAllocationOfPurchasePriceDetails",
     "shortName": "Acquisitions - Allocation of Purchase Price (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcmd-20221231x10k.htm",
      "contextRef": "Duration_9_8_2021_To_9_8_2021_JHuv2YIhr0-DMtiV3Vl0PA",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:BusinessAcquisitionProFormaInformationTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcmd-20221231x10k.htm",
      "contextRef": "Duration_4_1_2021_To_12_31_2021_us-gaap_BusinessAcquisitionAxis_tcmd_AfflovestPMember_C1E4O7zjlUGPDClD_oKeEg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:BusinessAcquisitionsProFormaRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40404 - Disclosure - Acquisitions - Consolidated Statements of Operations Reflect AffloVest Operations (Details)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://www.tactilemedical.com/role/DisclosureAcquisitionsConsolidatedStatementsOfOperationsReflectAfflovestOperationsDetails",
     "shortName": "Acquisitions - Consolidated Statements of Operations Reflect AffloVest Operations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:BusinessAcquisitionProFormaInformationTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcmd-20221231x10k.htm",
      "contextRef": "Duration_4_1_2021_To_12_31_2021_us-gaap_BusinessAcquisitionAxis_tcmd_AfflovestPMember_C1E4O7zjlUGPDClD_oKeEg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:BusinessAcquisitionsProFormaRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcmd-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "tcmd:ConcentrationRiskNumberOfInsuranceCompanies",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_item_-67QV0kzWUGc8AbcCukKig",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40501 - Disclosure - Accounts Receivable (Details)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://www.tactilemedical.com/role/DisclosureAccountsReceivableDetails",
     "shortName": "Accounts Receivable (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcmd-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "tcmd:ConcentrationRiskNumberOfInsuranceCompanies",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_item_-67QV0kzWUGc8AbcCukKig",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcmd-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryFinishedGoods",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40601 - Disclosure - Inventories (Details)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://www.tactilemedical.com/role/DisclosureInventoriesDetails",
     "shortName": "Inventories (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcmd-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryFinishedGoods",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcmd-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40701 - Disclosure - Property and Equipment (Details)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://www.tactilemedical.com/role/DisclosurePropertyAndEquipmentDetails",
     "shortName": "Property and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcmd-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcmd-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40801 - Disclosure - Goodwill And Intangible Assets (Details)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://www.tactilemedical.com/role/DisclosureGoodwillAndIntangibleAssetsDetails",
     "shortName": "Goodwill And Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcmd-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcmd-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00300 - Statement - Consolidated Statements of Comprehensive Loss",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfComprehensiveLoss",
     "shortName": "Consolidated Statements of Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcmd-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "tcmd:ScheduleOfAccruedExpensesTableTextBlock",
       "tcmd:AccruedExpensesDisclosureCurrentTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcmd-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "tcmd:InTransitInventoryAccruedExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40901 - Disclosure - Accrued Expenses (Details)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://www.tactilemedical.com/role/DisclosureAccruedExpensesDetails",
     "shortName": "Accrued Expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "tcmd:ScheduleOfAccruedExpensesTableTextBlock",
       "tcmd:AccruedExpensesDisclosureCurrentTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcmd-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "tcmd:InTransitInventoryAccruedExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock",
       "us-gaap:ProductWarrantyDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcmd-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StandardProductWarrantyAccrual",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41001 - Disclosure - Warranty Reserves (Details)",
     "menuCat": "Details",
     "order": "51",
     "role": "http://www.tactilemedical.com/role/DisclosureWarrantyReservesDetails",
     "shortName": "Warranty Reserves (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock",
       "us-gaap:ProductWarrantyDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcmd-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2019_3ga0jBjg6EKA4-znaQ36NQ",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:StandardProductWarrantyAccrual",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcmd-20221231x10k.htm",
      "contextRef": "As_Of_9_8_2021_8l4xBubq7Umd0Y3dMd0UnQ",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:LineOfCredit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41101 - Disclosure - Credit Agreement (Details)",
     "menuCat": "Details",
     "order": "52",
     "role": "http://www.tactilemedical.com/role/DisclosureCreditAgreementDetails",
     "shortName": "Credit Agreement (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcmd-20221231x10k.htm",
      "contextRef": "As_Of_9_8_2021_8l4xBubq7Umd0Y3dMd0UnQ",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:LineOfCredit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcmd-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_us-gaap_CreditFacilityAxis_tcmd_TermLoanMember_VIrloQlsfEmn_JzIEt95jA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41102 - Disclosure - Credit Agreement - Maturities of Debt (Details)",
     "menuCat": "Details",
     "order": "53",
     "role": "http://www.tactilemedical.com/role/DisclosureCreditAgreementMaturitiesOfDebtDetails",
     "shortName": "Credit Agreement - Maturities of Debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcmd-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_us-gaap_CreditFacilityAxis_tcmd_TermLoanMember_VIrloQlsfEmn_JzIEt95jA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcmd-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_srt_RangeAxis_srt_MinimumMember_EXKUiZxnk0qVwfOmUunwkw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseTermOfContract",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41201 - Disclosure - Commitments and Contingencies - Lease Obligations (Details)",
     "menuCat": "Details",
     "order": "54",
     "role": "http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesLeaseObligationsDetails",
     "shortName": "Commitments and Contingencies - Lease Obligations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcmd-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_srt_RangeAxis_srt_MinimumMember_EXKUiZxnk0qVwfOmUunwkw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseTermOfContract",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcmd-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41202 - Disclosure - Commitments and Contingencies - Lease related assets and liabilities (Details)",
     "menuCat": "Details",
     "order": "55",
     "role": "http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesLeaseRelatedAssetsAndLiabilitiesDetails",
     "shortName": "Commitments and Contingencies - Lease related assets and liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "tcmd:AssetsAndLiabilitiesLesseeTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcmd-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:OperatingLeaseLeaseIncomeTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcmd-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41203 - Disclosure - Commitments and Contingencies - Undiscounted cash flows (Details)",
     "menuCat": "Details",
     "order": "56",
     "role": "http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesUndiscountedCashFlowsDetails",
     "shortName": "Commitments and Contingencies - Undiscounted cash flows (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:OperatingLeaseLeaseIncomeTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcmd-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcmd-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41204 - Disclosure - Commitments and Contingencies - Lease commitments and operating lease cost (Details)",
     "menuCat": "Details",
     "order": "57",
     "role": "http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesLeaseCommitmentsAndOperatingLeaseCostDetails",
     "shortName": "Commitments and Contingencies - Lease commitments and operating lease cost (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcmd-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcmd-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "tcmd:NumberOfVendors",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_item_-67QV0kzWUGc8AbcCukKig",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41205 - Disclosure - Commitments and Contingencies - Major Vendors (Details)",
     "menuCat": "Details",
     "order": "58",
     "role": "http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesMajorVendorsDetails",
     "shortName": "Commitments and Contingencies - Major Vendors (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcmd-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "tcmd:NumberOfVendors",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_item_-67QV0kzWUGc8AbcCukKig",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcmd-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:PurchaseObligationDueInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41206 - Disclosure - Commitments and Contingencies - Purchase Commitments (Details)",
     "menuCat": "Details",
     "order": "59",
     "role": "http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesPurchaseCommitmentsDetails",
     "shortName": "Commitments and Contingencies - Purchase Commitments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcmd-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:PurchaseObligationDueInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcmd-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_831Iwe84l0uIaFkRq3YMEA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00400 - Statement - Consolidated Statements of Stockholders' Equity",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfStockholdersEquity",
     "shortName": "Consolidated Statements of Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcmd-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_831Iwe84l0uIaFkRq3YMEA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcmd-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_us-gaap_RetirementPlanNameAxis_tcmd_DefinedContribution401kRetirementPlanMember_tDmbZG8x90OrgLeuanK9nw",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41207 - Disclosure - Commitments and Contingencies - Retirement Plan (Details)",
     "menuCat": "Details",
     "order": "60",
     "role": "http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesRetirementPlanDetails",
     "shortName": "Commitments and Contingencies - Retirement Plan (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcmd-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_us-gaap_RetirementPlanNameAxis_tcmd_DefinedContribution401kRetirementPlanMember_tDmbZG8x90OrgLeuanK9nw",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcmd-20221231x10k.htm",
      "contextRef": "As_Of_11_21_2022_m22jugRAaEmtVeWbOHw3dw",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "tcmd:LitigationSettlementAgreementAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41208 - Disclosure - Commitments and Contingencies - Legal Proceedings (Details)",
     "menuCat": "Details",
     "order": "61",
     "role": "http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesLegalProceedingsDetails",
     "shortName": "Commitments and Contingencies - Legal Proceedings (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcmd-20221231x10k.htm",
      "contextRef": "As_Of_11_21_2022_m22jugRAaEmtVeWbOHw3dw",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "tcmd:LitigationSettlementAgreementAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcmd-20221231x10k.htm",
      "contextRef": "Duration_8_2_2016_To_8_2_2016_jh5ft8WN0USibAdtcwGHiA",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ConversionOfStockSharesConverted1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41301 - Disclosure - Stockholders' Equity - Series A & B Preferred Stock (Details)",
     "menuCat": "Details",
     "order": "62",
     "role": "http://www.tactilemedical.com/role/DisclosureStockholdersEquitySeriesBPreferredStockDetails",
     "shortName": "Stockholders' Equity - Series A & B Preferred Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcmd-20221231x10k.htm",
      "contextRef": "Duration_8_2_2016_To_8_2_2016_jh5ft8WN0USibAdtcwGHiA",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ConversionOfStockSharesConverted1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcmd-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41302 - Disclosure - Stockholders' Equity - Stock-Based Compensation (Details)",
     "menuCat": "Details",
     "order": "63",
     "role": "http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockBasedCompensationDetails",
     "shortName": "Stockholders' Equity - Stock-Based Compensation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcmd-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_1cM49KVdP0WP3FTRdFVJvA",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcmd-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41303 - Disclosure - Stockholders' Equity - Stock Options and Restricted Stock (Details)",
     "menuCat": "Details",
     "order": "64",
     "role": "http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails",
     "shortName": "Stockholders' Equity - Stock Options and Restricted Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcmd-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:DividendsCommonStock",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcmd-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41304 - Disclosure - Stockholders' Equity - Employee Stock Purchase Plan (Details)",
     "menuCat": "Details",
     "order": "65",
     "role": "http://www.tactilemedical.com/role/DisclosureStockholdersEquityEmployeeStockPurchasePlanDetails",
     "shortName": "Stockholders' Equity - Employee Stock Purchase Plan (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcmd-20221231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_1_1_2021_us-gaap_PlanNameAxis_tcmd_EquityIncentivePlan2016Member_GIA9oCLf2kOobzBosxqDOQ",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcmd-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41401 - Disclosure - Revenue (Details)",
     "menuCat": "Details",
     "order": "66",
     "role": "http://www.tactilemedical.com/role/DisclosureRevenueDetails",
     "shortName": "Revenue (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcmd-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg",
      "decimals": "2",
      "lang": null,
      "name": "tcmd:PercentageOfRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_oNeMqrQtP0WajHDJ-lFSqw",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcmd-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41501 - Disclosure - Income Taxes (Details)",
     "menuCat": "Details",
     "order": "67",
     "role": "http://www.tactilemedical.com/role/DisclosureIncomeTaxesDetails",
     "shortName": "Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcmd-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcmd-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41601 - Disclosure - Net (Loss) Income Per Common Share - Basic and Diluted Net Loss Per Share (Details)",
     "menuCat": "Details",
     "order": "68",
     "role": "http://www.tactilemedical.com/role/DisclosureNetLossIncomePerCommonShareBasicAndDilutedNetLossPerShareDetails",
     "shortName": "Net (Loss) Income Per Common Share - Basic and Diluted Net Loss Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcmd-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg",
      "decimals": "2",
      "lang": null,
      "name": "us-gaap:EarningsPerShareBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Divide_USD_shares_qmHir-1xUkGsoGgXSFcU-Q",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcmd-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41602 - Disclosure - Net (Loss) Income Per Common Share - Antidilutive Securities Excluded From Computation of Earnings Per Share (Details)",
     "menuCat": "Details",
     "order": "69",
     "role": "http://www.tactilemedical.com/role/DisclosureNetLossIncomePerCommonShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails",
     "shortName": "Net (Loss) Income Per Common Share - Antidilutive Securities Excluded From Computation of Earnings Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcmd-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_YmP4fcr0rEW8HpYwSX86hQ",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcmd-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00500 - Statement - Consolidated Statements of Cash Flows",
     "menuCat": "Statements",
     "order": "7",
     "role": "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcmd-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcmd-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41701 - Disclosure - Fair Value Measurements (Details)",
     "menuCat": "Details",
     "order": "70",
     "role": "http://www.tactilemedical.com/role/DisclosureFairValueMeasurementsDetails",
     "shortName": "Fair Value Measurements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcmd-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_srt_RangeAxis_srt_MaximumMember__4L7Euy5PkiEdMffnWdNng",
      "decimals": "-5",
      "lang": null,
      "name": "tcmd:BusinessCombinationAdditionalContingentConsiderationLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcmd-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2021_kScLnQWKCkyBDnIm6otr7Q",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41702 - Disclosure - Fair Value Measurements - Earn out liability (Details)",
     "menuCat": "Details",
     "order": "71",
     "role": "http://www.tactilemedical.com/role/DisclosureFairValueMeasurementsEarnOutLiabilityDetails",
     "shortName": "Fair Value Measurements - Earn out liability (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcmd-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcmd-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_heWuJYE2ykin3oJ9w23ULw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41703 - Disclosure - Fair Value Measurements - Fair Value Hierarchy (Details)",
     "menuCat": "Details",
     "order": "72",
     "role": "http://www.tactilemedical.com/role/DisclosureFairValueMeasurementsFairValueHierarchyDetails",
     "shortName": "Fair Value Measurements - Fair Value Hierarchy (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcmd-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_vevcUAPFYESbYWLi7G0kaQ",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_ese8R86OQEiLE4IhMOwclg",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcmd-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10101 - Disclosure - Nature of Business and Operations",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://www.tactilemedical.com/role/DisclosureNatureOfBusinessAndOperations",
     "shortName": "Nature of Business and Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcmd-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcmd-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10201 - Disclosure - Basis of Presentation",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://www.tactilemedical.com/role/DisclosureBasisOfPresentation",
     "shortName": "Basis of Presentation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tcmd-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_l5ofLfmrk02MQvkAl6HfVg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 80,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r601",
      "r602",
      "r603"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r601",
      "r602",
      "r603"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r601",
      "r602",
      "r603"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Document and Entity Information"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r601",
      "r602",
      "r603"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r604"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r599"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r599"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r599"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r605"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r599"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r599"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r599"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r599"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r606"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r601",
      "r602",
      "r603"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r598"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r600"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_ChiefExecutiveOfficerMember": {
     "auth_ref": [
      "r632"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chief Executive Officer"
       }
      }
     },
     "localname": "ChiefExecutiveOfficerMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r308",
      "r577",
      "r646",
      "r763"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureAccountsReceivableDetails",
      "http://www.tactilemedical.com/role/DisclosureRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r338",
      "r339",
      "r340",
      "r341",
      "r407",
      "r535",
      "r548",
      "r560",
      "r561",
      "r574",
      "r587",
      "r597",
      "r644",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureAcquisitionsDetails",
      "http://www.tactilemedical.com/role/DisclosureAcquisitionsPurchasePriceAllocationDetails",
      "http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesLeaseObligationsDetails",
      "http://www.tactilemedical.com/role/DisclosureCreditAgreementDetails",
      "http://www.tactilemedical.com/role/DisclosureFairValueMeasurementsDetails",
      "http://www.tactilemedical.com/role/DisclosureGoodwillAndIntangibleAssetsDetails",
      "http://www.tactilemedical.com/role/DisclosurePropertyAndEquipmentDetails",
      "http://www.tactilemedical.com/role/DisclosureRevenueDetails",
      "http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails",
      "http://www.tactilemedical.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r338",
      "r339",
      "r340",
      "r341",
      "r407",
      "r535",
      "r548",
      "r560",
      "r561",
      "r574",
      "r587",
      "r597",
      "r644",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesLeaseObligationsDetails",
      "http://www.tactilemedical.com/role/DisclosureCreditAgreementDetails",
      "http://www.tactilemedical.com/role/DisclosureRevenueDetails",
      "http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails",
      "http://www.tactilemedical.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r308",
      "r577",
      "r646",
      "r763"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureAccountsReceivableDetails",
      "http://www.tactilemedical.com/role/DisclosureRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r306",
      "r537",
      "r575",
      "r596",
      "r639",
      "r640",
      "r646",
      "r762"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Products and Services [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureRevenueDetails",
      "http://www.tactilemedical.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails",
      "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r306",
      "r537",
      "r575",
      "r596",
      "r639",
      "r640",
      "r646",
      "r762"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Products and Services [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureRevenueDetails",
      "http://www.tactilemedical.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails",
      "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r338",
      "r339",
      "r340",
      "r341",
      "r396",
      "r407",
      "r440",
      "r441",
      "r442",
      "r534",
      "r535",
      "r548",
      "r560",
      "r561",
      "r574",
      "r587",
      "r597",
      "r638",
      "r644",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureAcquisitionsDetails",
      "http://www.tactilemedical.com/role/DisclosureAcquisitionsPurchasePriceAllocationDetails",
      "http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesLeaseObligationsDetails",
      "http://www.tactilemedical.com/role/DisclosureCreditAgreementDetails",
      "http://www.tactilemedical.com/role/DisclosureFairValueMeasurementsDetails",
      "http://www.tactilemedical.com/role/DisclosureGoodwillAndIntangibleAssetsDetails",
      "http://www.tactilemedical.com/role/DisclosurePropertyAndEquipmentDetails",
      "http://www.tactilemedical.com/role/DisclosureRevenueDetails",
      "http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails",
      "http://www.tactilemedical.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r338",
      "r339",
      "r340",
      "r341",
      "r396",
      "r407",
      "r440",
      "r441",
      "r442",
      "r534",
      "r535",
      "r548",
      "r560",
      "r561",
      "r574",
      "r587",
      "r597",
      "r638",
      "r644",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureAcquisitionsDetails",
      "http://www.tactilemedical.com/role/DisclosureAcquisitionsPurchasePriceAllocationDetails",
      "http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesLeaseObligationsDetails",
      "http://www.tactilemedical.com/role/DisclosureCreditAgreementDetails",
      "http://www.tactilemedical.com/role/DisclosureFairValueMeasurementsDetails",
      "http://www.tactilemedical.com/role/DisclosureGoodwillAndIntangibleAssetsDetails",
      "http://www.tactilemedical.com/role/DisclosurePropertyAndEquipmentDetails",
      "http://www.tactilemedical.com/role/DisclosureRevenueDetails",
      "http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails",
      "http://www.tactilemedical.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r260",
      "r412",
      "r608",
      "r627"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario, Unspecified [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureAcquisitionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r260",
      "r412",
      "r608",
      "r609",
      "r627"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureAcquisitionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r632",
      "r751"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Relationship to Entity [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tcmd_AccruedClinicalStudiesExpensesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.tactilemedical.com/role/DisclosureAccruedExpensesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying amount as of the balance sheet date of accrued clinical studies.",
        "label": "Accrued Clinical Studies Expenses, Current",
        "terseLabel": "Clinical studies"
       }
      }
     },
     "localname": "AccruedClinicalStudiesExpensesCurrent",
     "nsuri": "http://www.tactilemedical.com/20221231",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tcmd_AccruedCumulativeDividends": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cumulative cash dividends accrued as of the end of the period.",
        "label": "Accrued Cumulative Dividends"
       }
      }
     },
     "localname": "AccruedCumulativeDividends",
     "nsuri": "http://www.tactilemedical.com/20221231",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureStockholdersEquitySeriesBPreferredStockDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tcmd_AccruedExpensesDisclosureCurrentTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accrued expenses that are classified as current at the end of the reporting period.",
        "label": "Accrued Expenses Disclosure, Current [Text Block]",
        "terseLabel": "Accrued Expenses"
       }
      }
     },
     "localname": "AccruedExpensesDisclosureCurrentTextBlock",
     "nsuri": "http://www.tactilemedical.com/20221231",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureAccruedExpenses"
     ],
     "xbrltype": "textBlockItemType"
    },
    "tcmd_AccruedSalesAndUseTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.tactilemedical.com/role/DisclosureAccruedExpensesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations relating to sales and use tax.",
        "label": "Accrued Sales And Use Tax",
        "terseLabel": "Sales and use tax"
       }
      }
     },
     "localname": "AccruedSalesAndUseTax",
     "nsuri": "http://www.tactilemedical.com/20221231",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tcmd_AccruedTravelAndEntertainmentCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.tactilemedical.com/role/DisclosureAccruedExpensesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for travel and entertainment expenses. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Travel And Entertainment Current",
        "terseLabel": "Travel"
       }
      }
     },
     "localname": "AccruedTravelAndEntertainmentCurrent",
     "nsuri": "http://www.tactilemedical.com/20221231",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tcmd_AdditionalOfficeSpaceAdded": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional office space added to the lease.",
        "label": "Additional office space added",
        "terseLabel": "Additional office space added to the lease"
       }
      }
     },
     "localname": "AdditionalOfficeSpaceAdded",
     "nsuri": "http://www.tactilemedical.com/20221231",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesLeaseObligationsDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "tcmd_AdjustmentsToAdditionalPaidInCapitalSharesOther": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share issued related to tax settlement of restricted stock units",
        "label": "Adjustments To Additional Paid In Capital Shares Other",
        "negatedLabel": "Taxes paid for net share settlement of performance and restricted stock units (in shares)"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharesOther",
     "nsuri": "http://www.tactilemedical.com/20221231",
     "presentation": [
      "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "tcmd_AfflovestMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to AffloVest.",
        "label": "AffloVest"
       }
      }
     },
     "localname": "AfflovestMember",
     "nsuri": "http://www.tactilemedical.com/20221231",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureRevenueDetails",
      "http://www.tactilemedical.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tcmd_AfflovestPMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represent information pertaining to AffloVest APA.",
        "label": "AffloVest APA"
       }
      }
     },
     "localname": "AfflovestPMember",
     "nsuri": "http://www.tactilemedical.com/20221231",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureAcquisitionsAllocationOfPurchasePriceDetails",
      "http://www.tactilemedical.com/role/DisclosureAcquisitionsConsolidatedStatementsOfOperationsReflectAfflovestOperationsDetails",
      "http://www.tactilemedical.com/role/DisclosureAcquisitionsDetails",
      "http://www.tactilemedical.com/role/DisclosureAcquisitionsPurchasePriceAllocationDetails",
      "http://www.tactilemedical.com/role/DisclosureGoodwillAndIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tcmd_AmortizationOfIntangibleAssetsAndEarnOuts": {
     "auth_ref": [],
     "calculation": {
      "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfOperations": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of impairment of intangible asset and earn outs.",
        "label": "Amortization of Intangible Assets and Earn outs",
        "terseLabel": "Intangible asset amortization and earn-out"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssetsAndEarnOuts",
     "nsuri": "http://www.tactilemedical.com/20221231",
     "presentation": [
      "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tcmd_AmortizationOfPremiumsAndDiscountsOnSecuritiesAvailableForSale": {
     "auth_ref": [],
     "calculation": {
      "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net amortization of premiums and discounts on securities available-for-sale.",
        "label": "Amortization Of Premiums And Discounts On Securities Available For Sale",
        "terseLabel": "Net amortization of premiums and discounts on securities available-for-sale"
       }
      }
     },
     "localname": "AmortizationOfPremiumsAndDiscountsOnSecuritiesAvailableForSale",
     "nsuri": "http://www.tactilemedical.com/20221231",
     "presentation": [
      "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tcmd_AssetAcquisitionAmountReceivedResultingFromWorkingCapitalAdjustment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount received for assets acquisition from working capital adjustment.",
        "label": "Asset Acquisition, Amount Received Resulting From Working Capital Adjustment",
        "terseLabel": "Working capital adjustments"
       }
      }
     },
     "localname": "AssetAcquisitionAmountReceivedResultingFromWorkingCapitalAdjustment",
     "nsuri": "http://www.tactilemedical.com/20221231",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureAcquisitionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tcmd_AssetAcquisitionBusinessRevenueToExceedBaseRevenueMultiplier": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The multiplier applied to the amount by which the Business's Revenue in the initial earnout period exceed Base Revenues.",
        "label": "Asset Acquisition, Business Revenue To Exceed Base Revenue, Multiplier",
        "terseLabel": "Business revenue to exceed base revenue, Multiplier"
       }
      }
     },
     "localname": "AssetAcquisitionBusinessRevenueToExceedBaseRevenueMultiplier",
     "nsuri": "http://www.tactilemedical.com/20221231",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureAcquisitionsDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "tcmd_AssetAcquisitionConsiderationTransferredEscrowAccount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount in escrow account recognized as part of consideration transferred in asset acquisition.",
        "label": "Asset Acquisition, Consideration Transferred, Escrow Account",
        "terseLabel": "Escrow account"
       }
      }
     },
     "localname": "AssetAcquisitionConsiderationTransferredEscrowAccount",
     "nsuri": "http://www.tactilemedical.com/20221231",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureAcquisitionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tcmd_AssetAcquisitionEarnOutLiability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of earn out liability recognized in asset acquisition.",
        "label": "Asset Acquisition, Earn Out Liability",
        "terseLabel": "Earn-out liability, asset acquisition"
       }
      }
     },
     "localname": "AssetAcquisitionEarnOutLiability",
     "nsuri": "http://www.tactilemedical.com/20221231",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureAcquisitionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tcmd_AssetAcquisitionEarnoutPaymentsRevenueTargetsFromOctoberTwoThousandTwentyOneToSeptemberTwoThousandTwentyTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the achievement of revenue targets from October 1, 2021 to September 30, 2022 which triggers earnout payments under asset acquisition.",
        "label": "Earn-out period exceed Base Revenues from October 1, 2021 to September 30, 2022"
       }
      }
     },
     "localname": "AssetAcquisitionEarnoutPaymentsRevenueTargetsFromOctoberTwoThousandTwentyOneToSeptemberTwoThousandTwentyTwoMember",
     "nsuri": "http://www.tactilemedical.com/20221231",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureAcquisitionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tcmd_AssetAcquisitionEarnoutPaymentsRevenueTargetsFromOctoberTwoThousandTwentyTwoToSeptemberTwoThousandTwentyThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the achievement of revenue targets from October 1, 2022 to September 30, 2023 which triggers earnout payments under asset acquisition.",
        "label": "Earn-out period exceed Base Revenues from October 1, 2022 to September 30, 2023"
       }
      }
     },
     "localname": "AssetAcquisitionEarnoutPaymentsRevenueTargetsFromOctoberTwoThousandTwentyTwoToSeptemberTwoThousandTwentyThreeMember",
     "nsuri": "http://www.tactilemedical.com/20221231",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureAcquisitionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tcmd_AssetAcquisitionImputedInterestPayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of imputed interest payable as at the date of asset acquisition.",
        "label": "Asset Acquisition, Imputed Interest Payable",
        "terseLabel": "Imputed interest payment"
       }
      }
     },
     "localname": "AssetAcquisitionImputedInterestPayable",
     "nsuri": "http://www.tactilemedical.com/20221231",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureAcquisitionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tcmd_AssetsAndLiabilitiesLesseeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The tabular disclosure of lease-related assets and liabilities.",
        "label": "Assets and Liabilities, Lessee [Table Text Block]",
        "terseLabel": "Summary of lease-related assets and liabilities"
       }
      }
     },
     "localname": "AssetsAndLiabilitiesLesseeTableTextBlock",
     "nsuri": "http://www.tactilemedical.com/20221231",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "tcmd_BusinessCombinationAdditionalContingentConsiderationLiability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination Additional Contingent Consideration Liability",
        "label": "Business Combination Additional Contingent Consideration Liability",
        "terseLabel": "Additional earn out payment"
       }
      }
     },
     "localname": "BusinessCombinationAdditionalContingentConsiderationLiability",
     "nsuri": "http://www.tactilemedical.com/20221231",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tcmd_ConcentrationRiskNumberOfInsuranceCompanies": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to number of insurance companies.",
        "label": "Concentration Risk, Number Of Insurance Companies",
        "terseLabel": "Number of insurers"
       }
      }
     },
     "localname": "ConcentrationRiskNumberOfInsuranceCompanies",
     "nsuri": "http://www.tactilemedical.com/20221231",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureAccountsReceivableDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "tcmd_ControllersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to controllers.",
        "label": "Controllers"
       }
      }
     },
     "localname": "ControllersMember",
     "nsuri": "http://www.tactilemedical.com/20221231",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tcmd_CorporateHeadQuarterInitialLeaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents member for initial lease for corporate head quarter.",
        "label": "Initial lease"
       }
      }
     },
     "localname": "CorporateHeadQuarterInitialLeaseMember",
     "nsuri": "http://www.tactilemedical.com/20221231",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesLeaseObligationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tcmd_CorporateHeadQuarterSecondLeaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents member for second lease corporate head quarter.",
        "label": "Second lease"
       }
      }
     },
     "localname": "CorporateHeadQuarterSecondLeaseMember",
     "nsuri": "http://www.tactilemedical.com/20221231",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesLeaseObligationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tcmd_CorporateHeadQuarterThirdLeaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents member for third lease corporate head quarter.",
        "label": "Third lease"
       }
      }
     },
     "localname": "CorporateHeadQuarterThirdLeaseMember",
     "nsuri": "http://www.tactilemedical.com/20221231",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesLeaseObligationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tcmd_CreditAgreementTotalAggregatePrincipalAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total aggregate principal amount under the credit agreement.",
        "label": "Credit Agreement, Total Aggregate Principal Amount",
        "terseLabel": "Credit agreement, total aggregate principal amount"
       }
      }
     },
     "localname": "CreditAgreementTotalAggregatePrincipalAmount",
     "nsuri": "http://www.tactilemedical.com/20221231",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureCreditAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tcmd_DebtInstrumentPaymentOfMandatoryPrincipalPrepayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of mandatory principal prepayment paid",
        "label": "Debt Instrument, Payment of Mandatory Principal Prepayment",
        "terseLabel": "Principal prepayment of term loan"
       }
      }
     },
     "localname": "DebtInstrumentPaymentOfMandatoryPrincipalPrepayment",
     "nsuri": "http://www.tactilemedical.com/20221231",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureCreditAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tcmd_DefensiveIntangibleAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for defensive intangible assets.",
        "label": "Defensive intangible assets"
       }
      }
     },
     "localname": "DefensiveIntangibleAssetsMember",
     "nsuri": "http://www.tactilemedical.com/20221231",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureGoodwillAndIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tcmd_DeferredTaxAssetsBusinessCredits": {
     "auth_ref": [],
     "calculation": {
      "http://www.tactilemedical.com/role/DisclosureIncomeTaxesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from business credits..",
        "label": "Deferred Tax Assets, Business Credits",
        "terseLabel": "Business credits"
       }
      }
     },
     "localname": "DeferredTaxAssetsBusinessCredits",
     "nsuri": "http://www.tactilemedical.com/20221231",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tcmd_DeferredTaxAssetsOperatingLeaseLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.tactilemedical.com/role/DisclosureIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from Operating Lease Liability.",
        "label": "Deferred Tax Assets, Operating Lease Liability",
        "terseLabel": "Operating lease liability"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLeaseLiability",
     "nsuri": "http://www.tactilemedical.com/20221231",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tcmd_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsResearchAndDevelopmentExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.tactilemedical.com/role/DisclosureIncomeTaxesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from research and development expenses.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Research and Development Expenses",
        "terseLabel": "R&amp;D expenses"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsResearchAndDevelopmentExpenses",
     "nsuri": "http://www.tactilemedical.com/20221231",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tcmd_DeferredTaxLiabilitiesRightOfUseAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.tactilemedical.com/role/DisclosureIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax consequences attributable to taxable temporary differences derived from right-of-use assets.",
        "label": "Deferred Tax Liabilities, Right-of-use Assets",
        "negatedLabel": "Right-of-use asset"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesRightOfUseAssets",
     "nsuri": "http://www.tactilemedical.com/20221231",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tcmd_DefinedContribution401kRetirementPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represent information pertaining to Defined Contribution 401K Retirement Plan",
        "label": "401(k)"
       }
      }
     },
     "localname": "DefinedContribution401kRetirementPlanMember",
     "nsuri": "http://www.tactilemedical.com/20221231",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesRetirementPlanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tcmd_DemoEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for demo equipment.",
        "label": "Demonstration equipment"
       }
      }
     },
     "localname": "DemoEquipmentMember",
     "nsuri": "http://www.tactilemedical.com/20221231",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosurePropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tcmd_DurableMedicalEquipmentDistributorsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Durable medical equipment distributors.",
        "label": "Durable medical equipment distributors"
       }
      }
     },
     "localname": "DurableMedicalEquipmentDistributorsMember",
     "nsuri": "http://www.tactilemedical.com/20221231",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tcmd_EarnOutCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.tactilemedical.com/role/StatementConsolidatedBalanceSheets": {
       "order": 8.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of earn-out liability (due within one year or beyond the operating cycle, if longer).",
        "label": "Earn-out, Current",
        "terseLabel": "Earn-out, current"
       }
      }
     },
     "localname": "EarnOutCurrent",
     "nsuri": "http://www.tactilemedical.com/20221231",
     "presentation": [
      "http://www.tactilemedical.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tcmd_EarnOutNonCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.tactilemedical.com/role/StatementConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of earn-out liability (due after one year or beyond the operating cycle, if longer).",
        "label": "Earn-out, Non-current",
        "terseLabel": "Earn-out, non-current"
       }
      }
     },
     "localname": "EarnOutNonCurrent",
     "nsuri": "http://www.tactilemedical.com/20221231",
     "presentation": [
      "http://www.tactilemedical.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tcmd_EarnOutPeriodOnOrBeforeMay262023Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to earnout period on or before may 26, 2023.",
        "label": "Earn-out period on or before May 26, 2023"
       }
      }
     },
     "localname": "EarnOutPeriodOnOrBeforeMay262023Member",
     "nsuri": "http://www.tactilemedical.com/20221231",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureAcquisitionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tcmd_EarnOutPeriodOnOrBeforeNovember282022Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to earnout period on or before November 28, 2022.",
        "label": "Earn-out period on or before November 28,2022"
       }
      }
     },
     "localname": "EarnOutPeriodOnOrBeforeNovember282022Member",
     "nsuri": "http://www.tactilemedical.com/20221231",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureAcquisitionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tcmd_EarningsPerShareOtherDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "n/a",
        "label": "Earnings Per Share Other Disclosure [Abstract]",
        "verboseLabel": "Weighted-average common shares used to compute net loss per common share"
       }
      }
     },
     "localname": "EarningsPerShareOtherDisclosureAbstract",
     "nsuri": "http://www.tactilemedical.com/20221231",
     "presentation": [
      "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "tcmd_EffectiveIncomeTaxRateReconciliationEmployeeStockPurchasePlan": {
     "auth_ref": [],
     "calculation": {
      "http://www.tactilemedical.com/role/DisclosureIncomeTaxesDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of effective income tax rate reconciliation, employee stock purchase plan.",
        "label": "Effective Income Tax Rate Reconciliation, Employee Stock Purchase Plan",
        "terseLabel": "Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationEmployeeStockPurchasePlan",
     "nsuri": "http://www.tactilemedical.com/20221231",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureIncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "tcmd_EffectiveIncomeTaxRateReconciliationExcessTaxBenefitOnNonQualifiedStockOptionsAndRsu": {
     "auth_ref": [],
     "calculation": {
      "http://www.tactilemedical.com/role/DisclosureIncomeTaxesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of effective income tax rate reconciliation, excess tax benefit on non-qualified stock options and RSU.",
        "label": "Effective Income Tax Rate Reconciliation Excess Tax Benefit On Non-qualified Stock Options and RSU",
        "terseLabel": "Excess benefit on non-qualified stock options and RSUs"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationExcessTaxBenefitOnNonQualifiedStockOptionsAndRsu",
     "nsuri": "http://www.tactilemedical.com/20221231",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureIncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "tcmd_EffectiveIncomeTaxRateReconciliationFederalBusinessCreditPercent": {
     "auth_ref": [],
     "calculation": {
      "http://www.tactilemedical.com/role/DisclosureIncomeTaxesDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from federal business credits.",
        "label": "Effective Income Tax Rate Reconciliation, Federal Business Credit Percent",
        "terseLabel": "Federal business credits"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationFederalBusinessCreditPercent",
     "nsuri": "http://www.tactilemedical.com/20221231",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureIncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "tcmd_EffectiveIncomeTaxRateReconciliationFederalCarrybackClaimPercent": {
     "auth_ref": [],
     "calculation": {
      "http://www.tactilemedical.com/role/DisclosureIncomeTaxesDetails": {
       "order": 11.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to federal carryback claim.",
        "label": "Effective Income Tax Rate Reconciliation, Federal Carryback Claim, Percent",
        "terseLabel": "Federal carryback claim deferred rate differential"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationFederalCarrybackClaimPercent",
     "nsuri": "http://www.tactilemedical.com/20221231",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureIncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "tcmd_EffectiveIncomeTaxRateReconciliationIncentiveStockOptions": {
     "auth_ref": [],
     "calculation": {
      "http://www.tactilemedical.com/role/DisclosureIncomeTaxesDetails": {
       "order": 15.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of Effective Income Tax Rate Reconciliation, Incentive stock options.",
        "label": "Effective Income Tax Rate Reconciliation, Incentive Stock Options",
        "terseLabel": "Incentive stock options"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationIncentiveStockOptions",
     "nsuri": "http://www.tactilemedical.com/20221231",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureIncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "tcmd_EffectiveIncomeTaxRateReconciliationInterestAndPenaltyPercent": {
     "auth_ref": [],
     "calculation": {
      "http://www.tactilemedical.com/role/DisclosureIncomeTaxesDetails": {
       "order": 16.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to interest and penalties.",
        "label": "Effective Income Tax Rate Reconciliation, Interest And Penalty, Percent",
        "terseLabel": "Interest and penalties"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationInterestAndPenaltyPercent",
     "nsuri": "http://www.tactilemedical.com/20221231",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureIncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "tcmd_EffectiveIncomeTaxRateReconciliationInternalRevenueServiceExam": {
     "auth_ref": [],
     "calculation": {
      "http://www.tactilemedical.com/role/DisclosureIncomeTaxesDetails": {
       "order": 12.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to IRS exam",
        "label": "Effective Income Tax Rate Reconciliation, Internal Revenue Service, Exam",
        "terseLabel": "IRS exam"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationInternalRevenueServiceExam",
     "nsuri": "http://www.tactilemedical.com/20221231",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureIncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "tcmd_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationPercent": {
     "auth_ref": [],
     "calculation": {
      "http://www.tactilemedical.com/role/DisclosureIncomeTaxesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to executive compensation.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Executive Compensation , Percent",
        "terseLabel": "Executive compensation"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationPercent",
     "nsuri": "http://www.tactilemedical.com/20221231",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureIncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "tcmd_EffectiveIncomeTaxRateReconciliationReturnToProvision": {
     "auth_ref": [],
     "calculation": {
      "http://www.tactilemedical.com/role/DisclosureIncomeTaxesDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of effective income tax rate reconciliation, return to provision.",
        "label": "Effective Income Tax Rate Reconciliation, Return to Provision",
        "terseLabel": "Return to provision"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationReturnToProvision",
     "nsuri": "http://www.tactilemedical.com/20221231",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureIncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "tcmd_EffectiveIncomeTaxRateReconciliationUnrecognizedTaxBenefits": {
     "auth_ref": [],
     "calculation": {
      "http://www.tactilemedical.com/role/DisclosureIncomeTaxesDetails": {
       "order": 14.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of effective income tax rate reconciliation, unrecognized tax benefits.",
        "label": "Effective Income Tax Rate Reconciliation, Unrecognized Tax Benefits",
        "terseLabel": "Unrecognized tax benefits"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationUnrecognizedTaxBenefits",
     "nsuri": "http://www.tactilemedical.com/20221231",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureIncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "tcmd_EmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Employee stock purchase plan shares.",
        "label": "Employee stock purchase plan"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanMember",
     "nsuri": "http://www.tactilemedical.com/20221231",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureNetLossIncomePerCommonShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tcmd_EmployeeStockPurchasePlanOfferingPeriodsPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period which an employee's right to purchase shares of stock at a discount, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Employee Stock Purchase Plan, Offering Periods, Period",
        "terseLabel": "Offering period (in months)"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanOfferingPeriodsPeriod",
     "nsuri": "http://www.tactilemedical.com/20221231",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureStockholdersEquityEmployeeStockPurchasePlanDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "tcmd_EquityIncentivePlan2016Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to the 2016 Equity Incentive Plan (the \"2016 Plan\").",
        "label": "2016 Plan"
       }
      }
     },
     "localname": "EquityIncentivePlan2016Member",
     "nsuri": "http://www.tactilemedical.com/20221231",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureStockholdersEquityEmployeeStockPurchasePlanDetails",
      "http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockBasedCompensationDetails",
      "http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tcmd_EstimatedPayoutPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of estimated payout.",
        "label": "Estimated Payout Percentage",
        "terseLabel": "Payout percentage"
       }
      }
     },
     "localname": "EstimatedPayoutPercentage",
     "nsuri": "http://www.tactilemedical.com/20221231",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "tcmd_ExpenseRelatingToInitialPublicOffering": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses relating to the initial public offering during the period.",
        "label": "Expense Relating To Initial Public Offering",
        "terseLabel": "Expense Relating To Initial Public Offering"
       }
      }
     },
     "localname": "ExpenseRelatingToInitialPublicOffering",
     "nsuri": "http://www.tactilemedical.com/20221231",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureNatureOfBusinessAndOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tcmd_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfAssetAcquisitionTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of finite-lived and indefinite-lived intangible assets acquired as part of a asset acquisition agreement.",
        "label": "Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Asset Acquisition [Table Text Block]",
        "terseLabel": "Schedule of allocation of the purchase price"
       }
      }
     },
     "localname": "FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfAssetAcquisitionTableTextBlock",
     "nsuri": "http://www.tactilemedical.com/20221231",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureAcquisitionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "tcmd_FlexitouchSystemMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Flexitouch system.",
        "label": "Flexitouch system"
       }
      }
     },
     "localname": "FlexitouchSystemMember",
     "nsuri": "http://www.tactilemedical.com/20221231",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tcmd_GarmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to garments.",
        "label": "Garments"
       }
      }
     },
     "localname": "GarmentsMember",
     "nsuri": "http://www.tactilemedical.com/20221231",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tcmd_GoodwillAmortizationPeriodForTaxPurposes": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which goodwill is deductible for tax purposes.",
        "label": "Goodwill, Amortization Period For Tax Purposes",
        "terseLabel": "Amortization period for tax purposes"
       }
      }
     },
     "localname": "GoodwillAmortizationPeriodForTaxPurposes",
     "nsuri": "http://www.tactilemedical.com/20221231",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureAcquisitionsPurchasePriceAllocationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "tcmd_InTransitInventoryAccruedExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.tactilemedical.com/role/DisclosureAccruedExpensesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In-transit inventory accrued expense.",
        "label": "In-transit inventory accrued expense",
        "terseLabel": "In-transit inventory"
       }
      }
     },
     "localname": "InTransitInventoryAccruedExpense",
     "nsuri": "http://www.tactilemedical.com/20221231",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tcmd_IncomeTaxLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table",
        "label": "Income Tax Line Items",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxLineItems",
     "nsuri": "http://www.tactilemedical.com/20221231",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "tcmd_IncomeTaxTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosures pertaining to Income Taxes",
        "label": "Income Tax Table"
       }
      }
     },
     "localname": "IncomeTaxTable",
     "nsuri": "http://www.tactilemedical.com/20221231",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "tcmd_IncreaseDecreaseInNetInvestmentInLease": {
     "auth_ref": [],
     "calculation": {
      "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the increase (decrease) in net investment in leases.",
        "label": "Increase (Decrease) In Net Investment in Lease",
        "negatedLabel": "Net investment in leases"
       }
      }
     },
     "localname": "IncreaseDecreaseInNetInvestmentInLease",
     "nsuri": "http://www.tactilemedical.com/20221231",
     "presentation": [
      "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tcmd_IncreaseDecreaseInOperatingLeaseRightOfUseAsset": {
     "auth_ref": [],
     "calculation": {
      "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the increase (decrease) in right of use operating lease assets.",
        "label": "Increase (Decrease) In Operating Lease Right Of Use Asset",
        "negatedLabel": "Right of use operating lease assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseRightOfUseAsset",
     "nsuri": "http://www.tactilemedical.com/20221231",
     "presentation": [
      "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tcmd_IncreaseDecreaseInOtherAccruedLiabilitiesAndIncomeTaxesPayable": {
     "auth_ref": [],
     "calculation": {
      "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 19.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in other expenses (excluding accrued payroll and related taxes) and income taxes payable incurred but not yet paid.",
        "label": "Increase Decrease In Other Accrued Liabilities And Income Taxes Payable",
        "terseLabel": "Accrued expenses and other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherAccruedLiabilitiesAndIncomeTaxesPayable",
     "nsuri": "http://www.tactilemedical.com/20221231",
     "presentation": [
      "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tcmd_IncrementalShareIncrease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the minimum increase in shares on an annual basis.",
        "label": "Incremental Share Increase",
        "terseLabel": "Incremental share increase (in shares)"
       }
      }
     },
     "localname": "IncrementalShareIncrease",
     "nsuri": "http://www.tactilemedical.com/20221231",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureStockholdersEquityEmployeeStockPurchasePlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "tcmd_IncrementalSharesToBeIssuedPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the incremental annual share percentage increase minimum.",
        "label": "Incremental Shares To Be Issued Percentage",
        "terseLabel": "Incremental share increase (as a percent)"
       }
      }
     },
     "localname": "IncrementalSharesToBeIssuedPercentage",
     "nsuri": "http://www.tactilemedical.com/20221231",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureStockholdersEquityEmployeeStockPurchasePlanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "tcmd_InsuranceCompanyOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents one of the customer for the entity.",
        "label": "Insurer One"
       }
      }
     },
     "localname": "InsuranceCompanyOneMember",
     "nsuri": "http://www.tactilemedical.com/20221231",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureAccountsReceivableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tcmd_InsuranceCompanyTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents Information pertaining to customer two",
        "label": "Insurer Two"
       }
      }
     },
     "localname": "InsuranceCompanyTwoMember",
     "nsuri": "http://www.tactilemedical.com/20221231",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureAccountsReceivableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tcmd_LineOfCreditThresholdContingentIncreaseInBorrowingCapacity": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line Of Credit, Threshold Contingent Increase In Borrowing Capacity",
        "label": "Line Of Credit, Threshold Contingent Increase In Borrowing Capacity",
        "terseLabel": "Line of credit, threshold contingent increase in borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditThresholdContingentIncreaseInBorrowingCapacity",
     "nsuri": "http://www.tactilemedical.com/20221231",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureCreditAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tcmd_LitigationSettlementAgreementAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of settlement amount of litigation under settlement agreement.",
        "label": "Litigation Settlement Agreement, Amount",
        "terseLabel": "Settlement amount"
       }
      }
     },
     "localname": "LitigationSettlementAgreementAmount",
     "nsuri": "http://www.tactilemedical.com/20221231",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesLegalProceedingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tcmd_MedicareAccountsReceivableNonCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.tactilemedical.com/role/StatementConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of non-current accounts receivable on account of medicare.",
        "label": "Medicare Accounts Receivable Non Current",
        "verboseLabel": "Accounts receivable, non-current"
       }
      }
     },
     "localname": "MedicareAccountsReceivableNonCurrent",
     "nsuri": "http://www.tactilemedical.com/20221231",
     "presentation": [
      "http://www.tactilemedical.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tcmd_MedicareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to government payer medicare.",
        "label": "Medicare"
       }
      }
     },
     "localname": "MedicareMember",
     "nsuri": "http://www.tactilemedical.com/20221231",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tcmd_MedicareReceivablesTimePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of term over which the payment from Medicare sales are receivable, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Medicare Receivables, Time Period",
        "terseLabel": "Medicare receivables period of time"
       }
      }
     },
     "localname": "MedicareReceivablesTimePeriod",
     "nsuri": "http://www.tactilemedical.com/20221231",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "tcmd_NatureOfBusinessAndOperationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "n/a",
        "label": "Nature of Business and Operations"
       }
      }
     },
     "localname": "NatureOfBusinessAndOperationAbstract",
     "nsuri": "http://www.tactilemedical.com/20221231",
     "xbrltype": "stringItemType"
    },
    "tcmd_NewAccountingPronouncementsNoteYetAdoptedPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements not yet adopted.",
        "label": "New Accounting Pronouncements, Note Yet Adopted Policy [Policy Text Block]",
        "terseLabel": "Accounting Pronouncement Not Yet Adopted"
       }
      }
     },
     "localname": "NewAccountingPronouncementsNoteYetAdoptedPolicyPolicyTextBlock",
     "nsuri": "http://www.tactilemedical.com/20221231",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "tcmd_NumberOfConsecutiveTradingDaysInWhichStockPriceExceedCertainPercentageOfClosingPriceOfCommonStockRequiredForAwardToBeGranted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of consecutive trading days in which the stock price exceed a certain percentage of closing price of common stock required for the award to be granted.",
        "label": "Number of consecutive trading days in which the stock price exceed a certain percentage of closing price of common stock required for the award to be granted",
        "terseLabel": "Number of consecutive trading days"
       }
      }
     },
     "localname": "NumberOfConsecutiveTradingDaysInWhichStockPriceExceedCertainPercentageOfClosingPriceOfCommonStockRequiredForAwardToBeGranted",
     "nsuri": "http://www.tactilemedical.com/20221231",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "tcmd_NumberOfVehiclesWithAgreementsWithinInitialNoncancelableLeaseTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of vehicles with agreements within the initial, noncancelable lease term.",
        "label": "Number of Vehicles with Agreements Within Initial, Noncancelable Lease Term",
        "terseLabel": "Number of vehicles with agreements within the initial, noncancelable lease term"
       }
      }
     },
     "localname": "NumberOfVehiclesWithAgreementsWithinInitialNoncancelableLeaseTerm",
     "nsuri": "http://www.tactilemedical.com/20221231",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesLeaseObligationsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "tcmd_NumberOfVendors": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of vendors.",
        "label": "Number Of Vendors",
        "terseLabel": "Number of vendors"
       }
      }
     },
     "localname": "NumberOfVendors",
     "nsuri": "http://www.tactilemedical.com/20221231",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesMajorVendorsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "tcmd_PaymentOfTaxesForNetShareSettlementOfRestrictedStockUnits": {
     "auth_ref": [],
     "calculation": {
      "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for taxes paid for net share settlement of restricted stock units.",
        "label": "Payment of Taxes for the Net Share Settlement of Restricted Stock Units",
        "negatedLabel": "Taxes paid for net share settlement of performance and restricted stock units"
       }
      }
     },
     "localname": "PaymentOfTaxesForNetShareSettlementOfRestrictedStockUnits",
     "nsuri": "http://www.tactilemedical.com/20221231",
     "presentation": [
      "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tcmd_PaymentsToAcquireProductiveAsset": {
     "auth_ref": [],
     "calculation": {
      "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible asset.",
        "label": "Payments to Acquire Productive Asset",
        "negatedLabel": "Payments related to acquisition"
       }
      }
     },
     "localname": "PaymentsToAcquireProductiveAsset",
     "nsuri": "http://www.tactilemedical.com/20221231",
     "presentation": [
      "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tcmd_PercentageOfClaimsApproved": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to approved claims based on number of claims.",
        "label": "Percentage Of Claims Approved",
        "terseLabel": "Percentage of claims"
       }
      }
     },
     "localname": "PercentageOfClaimsApproved",
     "nsuri": "http://www.tactilemedical.com/20221231",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "tcmd_PercentageOfRevenue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of revenue disaggregated by products.",
        "label": "Percentage Of Revenue",
        "terseLabel": "Percentage of total revenue (in percent)"
       }
      }
     },
     "localname": "PercentageOfRevenue",
     "nsuri": "http://www.tactilemedical.com/20221231",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureRevenueDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "tcmd_PercentageToEarnPerformanceBasedStockSettledRestrictedStockUnits": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage to earn or vest the performance-based stock-settled restricted stock units.",
        "label": "Percentage to earn the performance-based stock-settled restricted stock units",
        "terseLabel": "Percentage to earn or vest the performance-based stock-settled restricted stock units"
       }
      }
     },
     "localname": "PercentageToEarnPerformanceBasedStockSettledRestrictedStockUnits",
     "nsuri": "http://www.tactilemedical.com/20221231",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "tcmd_PerformanceBasedStockSettledRestrictedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for performance-based stock-settled restricted stock units plan.",
        "label": "Performance-based stock-settled restricted stock units"
       }
      }
     },
     "localname": "PerformanceBasedStockSettledRestrictedStockUnitsMember",
     "nsuri": "http://www.tactilemedical.com/20221231",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails",
      "http://www.tactilemedical.com/role/DisclosureStockholdersEquityTables"
     ],
     "xbrltype": "domainItemType"
    },
    "tcmd_PeriodForConsiderationPaymentAfterShipmentDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the period for consideration payment after shipment date.",
        "label": "Period for Consideration Payment After Shipment Date",
        "terseLabel": "Period for consideration payment after shipment date"
       }
      }
     },
     "localname": "PeriodForConsiderationPaymentAfterShipmentDate",
     "nsuri": "http://www.tactilemedical.com/20221231",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "tcmd_PreferredStockToCommonStockConversionRatio": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represent the conversion ratio of preferred stock to common stock.",
        "label": "Preferred Stock To Common Stock Conversion Ratio",
        "terseLabel": "Preferred stock to common stock conversion ratio"
       }
      }
     },
     "localname": "PreferredStockToCommonStockConversionRatio",
     "nsuri": "http://www.tactilemedical.com/20221231",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureStockholdersEquitySeriesBPreferredStockDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "tcmd_PrivateInsurersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to private insurers and other payers.",
        "label": "Private insurers and other payers"
       }
      }
     },
     "localname": "PrivateInsurersMember",
     "nsuri": "http://www.tactilemedical.com/20221231",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tcmd_RentToPurchaseArrangementsRentalPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rental period of rent-to-purchase arrangements.",
        "label": "Rent-to-purchase arrangements, Rental Period",
        "terseLabel": "Rental period of rent-to-purchase arrangements"
       }
      }
     },
     "localname": "RentToPurchaseArrangementsRentalPeriod",
     "nsuri": "http://www.tactilemedical.com/20221231",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureRevenueDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "tcmd_RentalProductServiceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information relating to rental product services which generate revenue for the company.",
        "label": "Rental revenue"
       }
      }
     },
     "localname": "RentalProductServiceMember",
     "nsuri": "http://www.tactilemedical.com/20221231",
     "presentation": [
      "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "tcmd_ScheduleOfAccruedExpensesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying value as of the balance sheet date of accrued expenses excluding accounts payable. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Schedule of Accrued Expenses [Table Text Block]",
        "terseLabel": "Schedule of Accrued Expenses"
       }
      }
     },
     "localname": "ScheduleOfAccruedExpensesTableTextBlock",
     "nsuri": "http://www.tactilemedical.com/20221231",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureAccruedExpensesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "tcmd_ScheduleOfRevenueFromThirdPartyPayersTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue revenues from third-party payers.",
        "label": "Schedule Of Revenue From Third Party Payers [Table Text Block]",
        "terseLabel": "Summary of revenue by channel"
       }
      }
     },
     "localname": "ScheduleOfRevenueFromThirdPartyPayersTableTextBlock",
     "nsuri": "http://www.tactilemedical.com/20221231",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureRevenueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "tcmd_SecondEarnOutAmendmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to second earnout amendment.",
        "label": "Second earn-out amendment"
       }
      }
     },
     "localname": "SecondEarnOutAmendmentMember",
     "nsuri": "http://www.tactilemedical.com/20221231",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureAcquisitionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tcmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticAnnualIncreaseInSharesReservedAndAvailableForIssuanceNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to the automatic annual increase in shares reserved and available for issuance. The automatic increases occur on the first day of the year beginning January 1, 2017.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award, Automatic Annual Increase In Shares Reserved And Available For Issuance, Number",
        "terseLabel": "Automatic annual increase to the number of shares reserved and available for issuance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticAnnualIncreaseInSharesReservedAndAvailableForIssuanceNumber",
     "nsuri": "http://www.tactilemedical.com/20221231",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockBasedCompensationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "tcmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticAnnualIncreaseInSharesReservedAndAvailableForIssuancePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to the automatic annual increase in shares reserved and available for issuance as a percentage to outstanding number of shares. The automatic increases occur on the first day of the year beginning January 1, 2017.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award, Automatic Annual Increase In Shares Reserved And Available For Issuance, Percentage",
        "terseLabel": "Automatic annual increase to the number of shares reserved and available for issuance as a percentage of outstanding common stock (as a percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticAnnualIncreaseInSharesReservedAndAvailableForIssuancePercentage",
     "nsuri": "http://www.tactilemedical.com/20221231",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockBasedCompensationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "tcmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueDeferredAndUnissued": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intrinsic value of equity-based compensation awards deferred and Unissued, Excludes stock and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Deferred and Unissued",
        "terseLabel": "Restricted stock unit awards deferred and unissued, Average Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueDeferredAndUnissued",
     "nsuri": "http://www.tactilemedical.com/20221231",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tcmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancellationsWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were cancelled during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Cancellations, Weighted Average Grant Date Fair Value",
        "terseLabel": "Cancelled (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancellationsWeightedAverageGrantDateFairValue",
     "nsuri": "http://www.tactilemedical.com/20221231",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "tcmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were cancelled during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Cancelled in Period",
        "negatedLabel": "Cancelled (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod",
     "nsuri": "http://www.tactilemedical.com/20221231",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "tcmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermOfPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of awards in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Term of Period",
        "terseLabel": "Share-based payment award, term"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardTermOfPeriod",
     "nsuri": "http://www.tactilemedical.com/20221231",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "tcmd_SharebasedcompensationArrangementBySharebasedpaymentAwardEquityInstrumentsOtherThanOptionsModifiedInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were modified during the reporting period.",
        "label": "Share Based Compensation Arrangement By ShareBasedPayment Award Equity Instruments Other Than Options Modified In Period",
        "terseLabel": "Modification (in shares)"
       }
      }
     },
     "localname": "SharebasedcompensationArrangementBySharebasedpaymentAwardEquityInstrumentsOtherThanOptionsModifiedInPeriod",
     "nsuri": "http://www.tactilemedical.com/20221231",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "tcmd_SharebasedcompensationArrangementBySharebasedpaymentAwardEquityInstrumentsOtherThanOptionsModifiedWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were modified during the reporting period.",
        "label": "Share Based Compensation Arrangement By ShareBasedPayment Award Equity Instruments Other Than Options Modified Weighted Average Grant Date Fair Value",
        "terseLabel": "Modification (in dollars per share)"
       }
      }
     },
     "localname": "SharebasedcompensationArrangementBySharebasedpaymentAwardEquityInstrumentsOtherThanOptionsModifiedWeightedAverageGrantDateFairValue",
     "nsuri": "http://www.tactilemedical.com/20221231",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "tcmd_StockBasedCompensationExpenseMinimumTargets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount estimated payout to reflect an estimated failure to achieve the minimum targets",
        "label": "Stock Based Compensation Expense Minimum Targets",
        "terseLabel": "Estimated payout"
       }
      }
     },
     "localname": "StockBasedCompensationExpenseMinimumTargets",
     "nsuri": "http://www.tactilemedical.com/20221231",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tcmd_StockIssuedDuringPeriodPriorToCompletionOfInitialOfferingSharesNewIssues": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued relating to the IPO that Series A and Series B preferred stockholders are entitled to receive.",
        "label": "Stock Issued During Period Prior To Completion Of Initial Offering Shares New Issues",
        "terseLabel": "Number of new stock issued relating to the IPO that Series A and Series B preferred stockholders are entitled to receive"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodPriorToCompletionOfInitialOfferingSharesNewIssues",
     "nsuri": "http://www.tactilemedical.com/20221231",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureStockholdersEquitySeriesBPreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "tcmd_StockIssuedDuringPeriodRequiredToFundStockDividendsSharesNewIssues": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued to pay accrued stock dividends relating to initial offering price.",
        "label": "Stock Issued During Period Required To Fund Stock Dividends Shares New Issues",
        "terseLabel": "Number of new stock issued to pay accrued stock dividends relating to initial offering price"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodRequiredToFundStockDividendsSharesNewIssues",
     "nsuri": "http://www.tactilemedical.com/20221231",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureStockholdersEquitySeriesBPreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "tcmd_TermLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to term loan.",
        "label": "Term Loan"
       }
      }
     },
     "localname": "TermLoanMember",
     "nsuri": "http://www.tactilemedical.com/20221231",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureCreditAgreementDetails",
      "http://www.tactilemedical.com/role/DisclosureCreditAgreementMaturitiesOfDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tcmd_TermOfProductWarranty": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the term of product warranty.",
        "label": "Term Of Product Warranty",
        "terseLabel": "Product Warranty"
       }
      }
     },
     "localname": "TermOfProductWarranty",
     "nsuri": "http://www.tactilemedical.com/20221231",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "tcmd_TimeBasedRestrictedStockUnitsRsusMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time.",
        "label": "Time-Based Restricted Stock Units"
       }
      }
     },
     "localname": "TimeBasedRestrictedStockUnitsRsusMember",
     "nsuri": "http://www.tactilemedical.com/20221231",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails",
      "http://www.tactilemedical.com/role/DisclosureStockholdersEquityTables"
     ],
     "xbrltype": "domainItemType"
    },
    "tcmd_TwoThousandEighteenAndTwoThousandTwentyPerformanceBasedRestrictedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to 2018 and 2021 Performance Based Restricted Stock Units Member.",
        "label": "2018 and 2021 PSUs"
       }
      }
     },
     "localname": "TwoThousandEighteenAndTwoThousandTwentyPerformanceBasedRestrictedStockUnitsMember",
     "nsuri": "http://www.tactilemedical.com/20221231",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tcmd_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Increase (Decrease) Resulting from Prior Period Tax Positions",
        "terseLabel": "Gross change - tax positions in prior year"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://www.tactilemedical.com/20221231",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tcmd_UnusualRisksAndUncertaintiesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the nature of the unusual risk or uncertainty, such as the threat of expropriation of its assets by a foreign government, rapid technological obsolescence in the industry, risk of natural disaster from earthquake or weather events, and disease pandemic.",
        "label": "Unusual Risks and Uncertainties [Policy Text Block]",
        "terseLabel": "Risks and Uncertainties"
       }
      }
     },
     "localname": "UnusualRisksAndUncertaintiesPolicyTextBlock",
     "nsuri": "http://www.tactilemedical.com/20221231",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "tcmd_VendorOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to vendor one.",
        "label": "Vendor One"
       }
      }
     },
     "localname": "VendorOneMember",
     "nsuri": "http://www.tactilemedical.com/20221231",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesMajorVendorsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tcmd_VendorTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to vendor two.",
        "label": "Vendor Two"
       }
      }
     },
     "localname": "VendorTwoMember",
     "nsuri": "http://www.tactilemedical.com/20221231",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesMajorVendorsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tcmd_VeteransAdministrationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to veterans administration.",
        "label": "Veterans Administration"
       }
      }
     },
     "localname": "VeteransAdministrationMember",
     "nsuri": "http://www.tactilemedical.com/20221231",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r21",
      "r595"
     ],
     "calculation": {
      "http://www.tactilemedical.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [
      "r555"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureAccountsReceivableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable, Net [Abstract]",
        "terseLabel": "Accounts Receivable",
        "verboseLabel": "Accounts Receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureAccountsReceivableDetails",
      "http://www.tactilemedical.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r309",
      "r310"
     ],
     "calculation": {
      "http://www.tactilemedical.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, Net, Current",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedIncomeTaxesCurrent": {
     "auth_ref": [
      "r5",
      "r170",
      "r185"
     ],
     "calculation": {
      "http://www.tactilemedical.com/role/StatementConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.",
        "label": "Accrued Income Taxes, Current",
        "terseLabel": "Income taxes payable"
       }
      }
     },
     "localname": "AccruedIncomeTaxesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedIncomeTaxesNoncurrent": {
     "auth_ref": [
      "r8",
      "r170",
      "r185"
     ],
     "calculation": {
      "http://www.tactilemedical.com/role/StatementConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent.",
        "label": "Accrued Income Taxes, Noncurrent",
        "verboseLabel": "Income taxes payable, non-current"
       }
      }
     },
     "localname": "AccruedIncomeTaxesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r25"
     ],
     "calculation": {
      "http://www.tactilemedical.com/role/DisclosureAccruedExpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.tactilemedical.com/role/StatementConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureAccruedExpensesDetails",
      "http://www.tactilemedical.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r25"
     ],
     "calculation": {
      "http://www.tactilemedical.com/role/DisclosureAccruedExpensesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Legal and consulting"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r96",
      "r210"
     ],
     "calculation": {
      "http://www.tactilemedical.com/role/DisclosurePropertyAndEquipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less: accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosurePropertyAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r32",
      "r33",
      "r159",
      "r530",
      "r549",
      "r550",
      "r615",
      "r616",
      "r617",
      "r624",
      "r625",
      "r626"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "Accumulated Other Comprehensive Loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": {
     "auth_ref": [
      "r83"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Acquired Finite-lived Intangible Assets, Weighted Average Useful Life",
        "terseLabel": "Weighted average amortization period"
       }
      }
     },
     "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureAcquisitionsAllocationOfPurchasePriceDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r13",
      "r595"
     ],
     "calculation": {
      "http://www.tactilemedical.com/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r446",
      "r447",
      "r448",
      "r624",
      "r625",
      "r626",
      "r748"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash provided by operating activities:"
       }
      }
     },
     "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalOther": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other increase (decrease) in additional paid in capital (APIC).",
        "label": "Adjustment to Additional Paid in Capital, Income Tax Effect from Share-based Compensation, Net",
        "terseLabel": "Taxes paid for net share settlement of performance and restricted stock units"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.",
        "label": "Adjustments to Additional Paid in Capital, Share-based Compensation, Stock Options, Requisite Service Period Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdvertisingCostsPolicyTextBlock": {
     "auth_ref": [
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for advertising cost.",
        "label": "Advertising Costs, Policy [Policy Text Block]",
        "terseLabel": "Advertising"
       }
      }
     },
     "localname": "AdvertisingCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AdvertisingExpense": {
     "auth_ref": [
      "r452"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.",
        "label": "Advertising Expense",
        "terseLabel": "Advertising Expense"
       }
      }
     },
     "localname": "AdvertisingExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r444"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Allocated Share-based Compensation Expense",
        "terseLabel": "Compensation expense",
        "verboseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureStockholdersEquityEmployeeStockPurchasePlanDetails",
      "http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockBasedCompensationDetails",
      "http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r57",
      "r81",
      "r88"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization expense"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureGoodwillAndIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities excluded from computation of earnings per share"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureNetLossIncomePerCommonShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r67"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureNetLossIncomePerCommonShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureNetLossIncomePerCommonShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r67"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureNetLossIncomePerCommonShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AreaOfLand": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area of land held.",
        "label": "Area of Land",
        "terseLabel": "Area of office space"
       }
      }
     },
     "localname": "AreaOfLand",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesLeaseObligationsDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "us-gaap_AssetAcquisitionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Acquisitions"
       }
      }
     },
     "localname": "AssetAcquisitionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetAcquisitionConsiderationTransferredAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition, Consideration Transferred [Abstract]",
        "terseLabel": "Purchase price allocation"
       }
      }
     },
     "localname": "AssetAcquisitionConsiderationTransferredAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureAcquisitionsPurchasePriceAllocationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Asset Acquisition [Line Items]",
        "terseLabel": "Acquisitions"
       }
      }
     },
     "localname": "AssetAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureAcquisitionsAllocationOfPurchasePriceDetails",
      "http://www.tactilemedical.com/role/DisclosureAcquisitionsConsolidatedStatementsOfOperationsReflectAfflovestOperationsDetails",
      "http://www.tactilemedical.com/role/DisclosureAcquisitionsDetails",
      "http://www.tactilemedical.com/role/DisclosureAcquisitionsPurchasePriceAllocationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetAcquisitionTable": {
     "auth_ref": [
      "r746"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset acquisition.",
        "label": "Asset Acquisition [Table]"
       }
      }
     },
     "localname": "AssetAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureAcquisitionsAllocationOfPurchasePriceDetails",
      "http://www.tactilemedical.com/role/DisclosureAcquisitionsConsolidatedStatementsOfOperationsReflectAfflovestOperationsDetails",
      "http://www.tactilemedical.com/role/DisclosureAcquisitionsDetails",
      "http://www.tactilemedical.com/role/DisclosureAcquisitionsPurchasePriceAllocationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetAcquisitionTableTextBlock": {
     "auth_ref": [
      "r746"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of asset acquisition.",
        "label": "Asset Acquisition [Table Text Block]",
        "terseLabel": "Summary of purchase price allocation"
       }
      }
     },
     "localname": "AssetAcquisitionTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureAcquisitionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AssetAcquisitionTextBlock": {
     "auth_ref": [
      "r746"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for asset acquisition.",
        "label": "Asset Acquisition [Text Block]",
        "terseLabel": "Acquisitions"
       }
      }
     },
     "localname": "AssetAcquisitionTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureAcquisitions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AssetImpairmentCharges": {
     "auth_ref": [
      "r57",
      "r93"
     ],
     "calculation": {
      "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.",
        "label": "Asset Impairment Charges",
        "terseLabel": "Impairment losses"
       }
      }
     },
     "localname": "AssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r169",
      "r184",
      "r214",
      "r243",
      "r291",
      "r300",
      "r304",
      "r317",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r492",
      "r496",
      "r508",
      "r595",
      "r642",
      "r643",
      "r752"
     ],
     "calculation": {
      "http://www.tactilemedical.com/role/StatementConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsAndLiabilitiesLesseeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets and Liabilities, Lessee [Abstract]",
        "terseLabel": "Lease-related assets and liabilities"
       }
      }
     },
     "localname": "AssetsAndLiabilitiesLesseeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesLeaseRelatedAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r205",
      "r220",
      "r243",
      "r317",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r492",
      "r496",
      "r508",
      "r595",
      "r642",
      "r643",
      "r752"
     ],
     "calculation": {
      "http://www.tactilemedical.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsNet": {
     "auth_ref": [
      "r0",
      "r195",
      "r196",
      "r197",
      "r198"
     ],
     "calculation": {
      "http://www.tactilemedical.com/role/DisclosurePurchasePriceAllocationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of net assets (liabilities).",
        "label": "Net Assets",
        "totalLabel": "Purchase price"
       }
      }
     },
     "localname": "AssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureAcquisitionsPurchasePriceAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsNoncurrent": {
     "auth_ref": [
      "r243",
      "r317",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r492",
      "r496",
      "r508",
      "r642",
      "r643",
      "r752"
     ],
     "calculation": {
      "http://www.tactilemedical.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.",
        "label": "Assets, Noncurrent",
        "totalLabel": "Total non-current assets"
       }
      }
     },
     "localname": "AssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r79",
      "r320"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Available-for-sale Securities, Debt Securities, Current",
        "verboseLabel": "Available for sale debt securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureFairValueMeasurementsFairValueHierarchyDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r415",
      "r416",
      "r417",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureNetLossIncomePerCommonShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails",
      "http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails",
      "http://www.tactilemedical.com/role/DisclosureStockholdersEquityTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BaseRateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum rate investor will accept.",
        "label": "Base Rate"
       }
      }
     },
     "localname": "BaseRateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureCreditAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r66"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.",
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "verboseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureBasisOfPresentation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BuildingMember": {
     "auth_ref": [
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities.",
        "label": "Building"
       }
      }
     },
     "localname": "BuildingMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesLeaseObligationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r487",
      "r585",
      "r586"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureAcquisitionsAllocationOfPurchasePriceDetails",
      "http://www.tactilemedical.com/role/DisclosureAcquisitionsConsolidatedStatementsOfOperationsReflectAfflovestOperationsDetails",
      "http://www.tactilemedical.com/role/DisclosureAcquisitionsDetails",
      "http://www.tactilemedical.com/role/DisclosureAcquisitionsPurchasePriceAllocationDetails",
      "http://www.tactilemedical.com/role/DisclosureGoodwillAndIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r144",
      "r145",
      "r487",
      "r585",
      "r586"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureAcquisitionsAllocationOfPurchasePriceDetails",
      "http://www.tactilemedical.com/role/DisclosureAcquisitionsConsolidatedStatementsOfOperationsReflectAfflovestOperationsDetails",
      "http://www.tactilemedical.com/role/DisclosureAcquisitionsDetails",
      "http://www.tactilemedical.com/role/DisclosureAcquisitionsPurchasePriceAllocationDetails",
      "http://www.tactilemedical.com/role/DisclosureGoodwillAndIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionProFormaInformationTextBlock": {
     "auth_ref": [
      "r744",
      "r745"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.",
        "label": "Business Acquisition, Pro Forma Information [Table Text Block]",
        "terseLabel": "Schedule of condensed consolidated statements of operations reflect AffoVest operations"
       }
      }
     },
     "localname": "BusinessAcquisitionProFormaInformationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureAcquisitionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss": {
     "auth_ref": [
      "r485",
      "r486"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.",
        "label": "Business Acquisition, Pro Forma Net Income (Loss)",
        "verboseLabel": "Net (loss) income"
       }
      }
     },
     "localname": "BusinessAcquisitionsProFormaNetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureAcquisitionsConsolidatedStatementsOfOperationsReflectAfflovestOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessAcquisitionsProFormaRevenue": {
     "auth_ref": [
      "r485",
      "r486"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.",
        "label": "Business Acquisition, Pro Forma Revenue",
        "terseLabel": "Total revenue"
       }
      }
     },
     "localname": "BusinessAcquisitionsProFormaRevenue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureAcquisitionsConsolidatedStatementsOfOperationsReflectAfflovestOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationAcquisitionRelatedCosts": {
     "auth_ref": [
      "r143"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.",
        "label": "Business Combination, Acquisition Related Costs",
        "terseLabel": "Transaction costs"
       }
      }
     },
     "localname": "BusinessCombinationAcquisitionRelatedCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureAcquisitionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "auth_ref": [
      "r150",
      "r151",
      "r154"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.",
        "label": "Asset Acquisition, Consideration Transferred",
        "terseLabel": "Total consideration transferred"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferred1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureAcquisitionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": {
     "auth_ref": [
      "r490",
      "r618"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.",
        "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability",
        "terseLabel": "Fair value adjustments"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureFairValueMeasurementsEarnOutLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r149",
      "r152",
      "r489"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "periodEndLabel": "Earn-out liability, ending balance",
        "periodStartLabel": "Earn-out liability, beginning balance",
        "terseLabel": "Earn-out liability"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureAcquisitionsDetails",
      "http://www.tactilemedical.com/role/DisclosureFairValueMeasurementsDetails",
      "http://www.tactilemedical.com/role/DisclosureFairValueMeasurementsEarnOutLiabilityDetails",
      "http://www.tactilemedical.com/role/DisclosureFairValueMeasurementsFairValueHierarchyDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": {
     "auth_ref": [
      "r149",
      "r153"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Current",
        "verboseLabel": "Fair value measure, earn out liability current"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureFairValueMeasurementsEarnOutLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r59",
      "r208",
      "r563"
     ],
     "calculation": {
      "http://www.tactilemedical.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r60"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r53",
      "r59",
      "r65"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents - end of period",
        "periodStartLabel": "Cash and cash equivalents - beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "auth_ref": [
      "r53",
      "r165"
     ],
     "calculation": {
      "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect",
        "totalLabel": "Net (decrease) increase in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r215",
      "r216",
      "r217",
      "r243",
      "r264",
      "r265",
      "r268",
      "r270",
      "r279",
      "r280",
      "r317",
      "r342",
      "r344",
      "r345",
      "r346",
      "r349",
      "r350",
      "r367",
      "r368",
      "r370",
      "r371",
      "r373",
      "r508",
      "r562",
      "r607",
      "r620",
      "r628"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureStockholdersEquitySeriesBPreferredStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "verboseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureStockholdersEquityEmployeeStockPurchasePlanDetails",
      "http://www.tactilemedical.com/role/DisclosureStockholdersEquitySeriesBPreferredStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r29",
      "r175",
      "r190"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitment and Contingencies",
        "verboseLabel": "Commitments and Contingencies (see Note 12)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r100",
      "r336",
      "r337",
      "r556",
      "r641"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r30"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Shares reserved",
        "verboseLabel": "Shares available for future issuance"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureStockholdersEquityEmployeeStockPurchasePlanDetails",
      "http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockBasedCompensationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r624",
      "r625",
      "r748"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares, issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r12",
      "r116"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares, outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r12",
      "r595"
     ],
     "calculation": {
      "http://www.tactilemedical.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.001 par value, 300,000,000 shares authorized; 20,252,677 shares issued and outstanding as of December 31, 2022; 19,877,786 shares issued and outstanding as of December 31, 2021"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Assets [Abstract]",
        "terseLabel": "Components of Deferred Tax Assets"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxAssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Liabilities [Abstract]",
        "terseLabel": "Deferred tax liabilities:"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r34",
      "r225",
      "r227",
      "r232",
      "r541",
      "r545"
     ],
     "calculation": {
      "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "terseLabel": "Comprehensive loss for the period",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfComprehensiveLoss",
      "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Comprehensive Loss"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r71",
      "r72",
      "r162",
      "r163",
      "r308",
      "r555"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureAccountsReceivableDetails",
      "http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesMajorVendorsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r71",
      "r72",
      "r162",
      "r163",
      "r308",
      "r554",
      "r555"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureAccountsReceivableDetails",
      "http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesMajorVendorsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r71",
      "r72",
      "r162",
      "r163",
      "r308",
      "r555",
      "r764"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureAccountsReceivableDetails",
      "http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesMajorVendorsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Concentration Risk [Line Items]",
        "verboseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "ConcentrationRiskLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureAccountsReceivableDetails",
      "http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesMajorVendorsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r71",
      "r72",
      "r162",
      "r163",
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Total purchases (in percentage)",
        "verboseLabel": "Percentage of concentration"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureAccountsReceivableDetails",
      "http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesMajorVendorsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTable": {
     "auth_ref": [
      "r69",
      "r71",
      "r72",
      "r73",
      "r162",
      "r164",
      "r555"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Concentration Risk [Table]"
       }
      }
     },
     "localname": "ConcentrationRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureAccountsReceivableDetails",
      "http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesMajorVendorsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r71",
      "r72",
      "r162",
      "r163",
      "r308",
      "r555"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureAccountsReceivableDetails",
      "http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesMajorVendorsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r157",
      "r565"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in progress"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosurePropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConversionOfStockSharesConverted1": {
     "auth_ref": [
      "r62",
      "r63",
      "r64"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Conversion of Stock, Shares Converted",
        "verboseLabel": "Conversion of preferred stock to common stock (in shares)"
       }
      }
     },
     "localname": "ConversionOfStockSharesConverted1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureStockholdersEquitySeriesBPreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CostOfGoodsSoldSalesTypeLease": {
     "auth_ref": [
      "r277",
      "r528"
     ],
     "calculation": {
      "http://www.tactilemedical.com/role/DisclosureRevenueDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_SalesTypeLeaseSellingProfitLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost of goods sold for sales-type financing lease.",
        "label": "Cost of Goods Sold, Sales-type Lease",
        "terseLabel": "Cost of sales-type lease revenue"
       }
      }
     },
     "localname": "CostOfGoodsSoldSalesTypeLease",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfGoodsTotalMember": {
     "auth_ref": [
      "r630"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost of product sold and service rendered, when it serves as benchmark in concentration of risk calculation.",
        "label": "Purchases"
       }
      }
     },
     "localname": "CostOfGoodsTotalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesMajorVendorsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfRevenue": {
     "auth_ref": [
      "r40",
      "r243",
      "r317",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r508",
      "r642"
     ],
     "calculation": {
      "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.",
        "label": "Cost of Revenue",
        "terseLabel": "Total cost of revenue"
       }
      }
     },
     "localname": "CostOfRevenue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing cost of sales.",
        "label": "Cost of revenue."
       }
      }
     },
     "localname": "CostOfSalesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfSalesPolicyTextBlock": {
     "auth_ref": [
      "r647"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cost of product sold and service rendered.",
        "label": "Cost of Sales, Policy [Policy Text Block]",
        "terseLabel": "Shipping and Handling Costs"
       }
      }
     },
     "localname": "CostOfSalesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureCreditAgreementDetails",
      "http://www.tactilemedical.com/role/DisclosureCreditAgreementMaturitiesOfDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureCreditAgreementDetails",
      "http://www.tactilemedical.com/role/DisclosureCreditAgreementMaturitiesOfDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "auth_ref": [
      "r623",
      "r740",
      "r742"
     ],
     "calculation": {
      "http://www.tactilemedical.com/role/DisclosureIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Current Federal Tax Expense (Benefit)",
        "terseLabel": "Current income taxes, Federal"
       }
      }
     },
     "localname": "CurrentFederalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r142",
      "r470",
      "r478",
      "r623"
     ],
     "calculation": {
      "http://www.tactilemedical.com/role/DisclosureIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense (Benefit)",
        "totalLabel": "Current income taxes"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r623",
      "r740",
      "r742"
     ],
     "calculation": {
      "http://www.tactilemedical.com/role/DisclosureIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Current State and Local Tax Expense (Benefit)",
        "terseLabel": "Current income taxes, State"
       }
      }
     },
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r70",
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureAccountsReceivableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CustomerContractsMember": {
     "auth_ref": [
      "r147"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity's established relationships with its customers through contracts.",
        "label": "Customer accounts"
       }
      }
     },
     "localname": "CustomerContractsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureGoodwillAndIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CustomerRelationshipsMember": {
     "auth_ref": [
      "r147"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships.",
        "label": "Customer relationships"
       }
      }
     },
     "localname": "CustomerRelationshipsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureAcquisitionsAllocationOfPurchasePriceDetails",
      "http://www.tactilemedical.com/role/DisclosureGoodwillAndIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Credit Agreement"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r112",
      "r242",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r361",
      "r363",
      "r364",
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "verboseLabel": "Credit Agreement"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureCreditAgreement"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "verboseLabel": "Basis spread (as a percent)"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureCreditAgreementDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r166",
      "r167",
      "r351",
      "r515",
      "r572",
      "r573"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Debt instrument face amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureCreditAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFrequencyOfPeriodicPayment": {
     "auth_ref": [
      "r27",
      "r181"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the frequency of periodic payments (monthly, quarterly, annual).",
        "label": "Debt Instrument, Frequency of Periodic Payment",
        "terseLabel": "Debt instrument frequency of periodic payment"
       }
      }
     },
     "localname": "DebtInstrumentFrequencyOfPeriodicPayment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureCreditAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentPeriodicPayment": {
     "auth_ref": [
      "r27",
      "r181"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the required periodic payments including both interest and principal payments.",
        "label": "Debt Instrument, Periodic Payment",
        "terseLabel": "Debt instrument periodic payment"
       }
      }
     },
     "localname": "DebtInstrumentPeriodicPayment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureCreditAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r623",
      "r741",
      "r742"
     ],
     "calculation": {
      "http://www.tactilemedical.com/role/DisclosureIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "terseLabel": "Deferred income taxes, Federal"
       }
      }
     },
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r57",
      "r142",
      "r471",
      "r477",
      "r478",
      "r623"
     ],
     "calculation": {
      "http://www.tactilemedical.com/role/DisclosureIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "totalLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r9",
      "r10",
      "r171",
      "r182",
      "r465"
     ],
     "calculation": {
      "http://www.tactilemedical.com/role/DisclosureDisclosureIncomeTaxesDetailsCalc2": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilitiesNet",
       "weight": 1.0
      },
      "http://www.tactilemedical.com/role/DisclosureIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Liabilities, Gross",
        "negatedTotalLabel": "Total deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r456",
      "r457"
     ],
     "calculation": {
      "http://www.tactilemedical.com/role/DisclosureDisclosureIncomeTaxesDetailsCalc2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.tactilemedical.com/role/StatementConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "negatedTotalLabel": "Net deferred tax liabilities",
        "terseLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureIncomeTaxesDetails",
      "http://www.tactilemedical.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r623",
      "r741",
      "r742"
     ],
     "calculation": {
      "http://www.tactilemedical.com/role/DisclosureIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "terseLabel": "Deferred income taxes, State"
       }
      }
     },
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.tactilemedical.com/role/DisclosureIncomeTaxesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.",
        "label": "Deferred Tax Assets, Goodwill and Intangible Assets",
        "terseLabel": "Intangible assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r466"
     ],
     "calculation": {
      "http://www.tactilemedical.com/role/DisclosureDisclosureIncomeTaxesDetailsCalc2": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilitiesNet",
       "weight": -1.0
      },
      "http://www.tactilemedical.com/role/DisclosureIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r738"
     ],
     "calculation": {
      "http://www.tactilemedical.com/role/DisclosureIncomeTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Net deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r140",
      "r739"
     ],
     "calculation": {
      "http://www.tactilemedical.com/role/DisclosureIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r140",
      "r739"
     ],
     "calculation": {
      "http://www.tactilemedical.com/role/DisclosureIncomeTaxesDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r140",
      "r739"
     ],
     "calculation": {
      "http://www.tactilemedical.com/role/DisclosureIncomeTaxesDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities": {
     "auth_ref": [
      "r140",
      "r739"
     ],
     "calculation": {
      "http://www.tactilemedical.com/role/DisclosureIncomeTaxesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities",
        "terseLabel": "Accrued liabilities"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts": {
     "auth_ref": [
      "r140",
      "r739"
     ],
     "calculation": {
      "http://www.tactilemedical.com/role/DisclosureIncomeTaxesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from allowance for credit loss on accounts receivable.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Allowance for Doubtful Accounts",
        "terseLabel": "Accounts receivable and inventory reserves"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves": {
     "auth_ref": [
      "r140",
      "r739"
     ],
     "calculation": {
      "http://www.tactilemedical.com/role/DisclosureIncomeTaxesDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from warranty reserves.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Warranty Reserves",
        "terseLabel": "Warranty reserves"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r467"
     ],
     "calculation": {
      "http://www.tactilemedical.com/role/DisclosureDisclosureIncomeTaxesDetailsCalc2": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilitiesNet",
       "weight": 1.0
      },
      "http://www.tactilemedical.com/role/DisclosureIncomeTaxesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Valuation allowance",
        "terseLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesOther": {
     "auth_ref": [
      "r140",
      "r739"
     ],
     "calculation": {
      "http://www.tactilemedical.com/role/DisclosureIncomeTaxesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other.",
        "label": "Deferred Tax Liabilities, Other",
        "negatedLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesPrepaidExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.tactilemedical.com/role/DisclosureIncomeTaxesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax consequences attributable to taxable temporary differences derived from prepaid expenses.",
        "label": "Deferred Tax Liabilities, Prepaid Expenses",
        "negatedLabel": "Prepaid expenses"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesPrepaidExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "auth_ref": [
      "r140",
      "r739"
     ],
     "calculation": {
      "http://www.tactilemedical.com/role/DisclosureIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "negatedLabel": "Fixed assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Defined Contribution Plan Disclosure [Line Items]",
        "verboseLabel": "Retirement Plan"
       }
      }
     },
     "localname": "DefinedContributionPlanDisclosureLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesRetirementPlanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan.",
        "label": "Defined Contribution Plan, Employer Discretionary Contribution Amount",
        "terseLabel": "Discretionary contributions"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesRetirementPlanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanTable": {
     "auth_ref": [
      "r403"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about defined contribution pension plans or defined contribution other postretirement plans, separately for pension plans and other postretirement benefit plans.",
        "label": "Defined Contribution Plan [Table]"
       }
      }
     },
     "localname": "DefinedContributionPlanTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesRetirementPlanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r57",
      "r94"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosurePropertyAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r57",
      "r289"
     ],
     "calculation": {
      "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DevelopedTechnologyRightsMember": {
     "auth_ref": [
      "r148"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property.",
        "label": "Developed technology"
       }
      }
     },
     "localname": "DevelopedTechnologyRightsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureAcquisitionsAllocationOfPurchasePriceDetails",
      "http://www.tactilemedical.com/role/DisclosureGoodwillAndIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r393",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r646"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Summary of revenue disaggregated by product"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureRevenueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DividendsCommonStock": {
     "auth_ref": [
      "r123",
      "r180"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).",
        "label": "Dividends, Common Stock",
        "terseLabel": "Dividends paid to date"
       }
      }
     },
     "localname": "DividendsCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "U.S. federal"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureIncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net (Loss) Income Per Common Share",
        "terseLabel": "Net loss per common share"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r233",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r261",
      "r264",
      "r268",
      "r269",
      "r270",
      "r274",
      "r499",
      "r500",
      "r542",
      "r546",
      "r568"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per share - Basic"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureNetLossIncomePerCommonShareBasicAndDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r233",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r264",
      "r268",
      "r269",
      "r270",
      "r274",
      "r499",
      "r500",
      "r542",
      "r546",
      "r568"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per share - Diluted"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureNetLossIncomePerCommonShareBasicAndDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r67",
      "r68"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net (Loss) Income Per Common Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r271",
      "r272",
      "r273",
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "verboseLabel": "Net (Loss) Income Per Common Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureNetLossIncomePerCommonShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r459"
     ],
     "calculation": {
      "http://www.tactilemedical.com/role/DisclosureIncomeTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "terseLabel": "Net effective rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureIncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Percent [Abstract]",
        "terseLabel": "Effective Income Tax Rate Reconciliation, Percent"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r244",
      "r459",
      "r479"
     ],
     "calculation": {
      "http://www.tactilemedical.com/role/DisclosureIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Tax expense at statutory rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureIncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r736",
      "r743"
     ],
     "calculation": {
      "http://www.tactilemedical.com/role/DisclosureIncomeTaxesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "Valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureIncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment": {
     "auth_ref": [
      "r736",
      "r743"
     ],
     "calculation": {
      "http://www.tactilemedical.com/role/DisclosureIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to meals and entertainment expense.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Meals and Entertainment, Percent",
        "terseLabel": "Meals and entertainment"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureIncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment": {
     "auth_ref": [
      "r736",
      "r743"
     ],
     "calculation": {
      "http://www.tactilemedical.com/role/DisclosureIncomeTaxesDetails": {
       "order": 17.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research and development expense.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent",
        "terseLabel": "Research and development credits"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureIncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "auth_ref": [
      "r736",
      "r743"
     ],
     "calculation": {
      "http://www.tactilemedical.com/role/DisclosureIncomeTaxesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureIncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r736",
      "r743"
     ],
     "calculation": {
      "http://www.tactilemedical.com/role/DisclosureIncomeTaxesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "terseLabel": "State income taxes, net of federal benefit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureIncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal": {
     "auth_ref": [
      "r736",
      "r743"
     ],
     "calculation": {
      "http://www.tactilemedical.com/role/DisclosureIncomeTaxesDetails": {
       "order": 13.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax settlement.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Settlement, State and Local, Percent",
        "verboseLabel": "Deferred reprice - state"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureIncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r25"
     ],
     "calculation": {
      "http://www.tactilemedical.com/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued payroll and related taxes"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized [Abstract]",
        "terseLabel": "Unrecognized stock-based compensation"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Unrecognized stock-based compensation expense, period for recognition",
        "verboseLabel": "Weighted-average period over which unrecognized compensation cost is expected to be recognized"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockBasedCompensationDetails",
      "http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "auth_ref": [
      "r735"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options",
        "terseLabel": "Total unrecognized pre-tax compensation expense related to awards"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r735"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options",
        "terseLabel": "Total unrecognized pre-tax compensation expense related to nonvested stock option awards"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureStockholdersEquityEmployeeStockPurchasePlanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Common stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureNetLossIncomePerCommonShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails",
      "http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services.",
        "label": "Equipment"
       }
      }
     },
     "localname": "EquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesLeaseObligationsDetails",
      "http://www.tactilemedical.com/role/DisclosurePropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r116",
      "r203",
      "r229",
      "r230",
      "r231",
      "r247",
      "r248",
      "r249",
      "r251",
      "r257",
      "r259",
      "r278",
      "r318",
      "r374",
      "r446",
      "r447",
      "r448",
      "r473",
      "r474",
      "r498",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r530",
      "r549",
      "r550",
      "r551"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Securities, FV-NI and without Readily Determinable Fair Value [Abstract]",
        "terseLabel": "Equity Securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount": {
     "auth_ref": [
      "r315"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security without readily determinable fair value.",
        "label": "Equity Securities without Readily Determinable Fair Value, Amount",
        "terseLabel": "Equity security without readily determinable fair value"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureFairValueMeasurementsDetails",
      "http://www.tactilemedical.com/role/DisclosureFairValueMeasurementsEarnOutLiabilityDetails",
      "http://www.tactilemedical.com/role/DisclosureFairValueMeasurementsFairValueHierarchyDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r501",
      "r502",
      "r506"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value Measurements, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureFairValueMeasurementsDetails",
      "http://www.tactilemedical.com/role/DisclosureFairValueMeasurementsEarnOutLiabilityDetails",
      "http://www.tactilemedical.com/role/DisclosureFairValueMeasurementsFairValueHierarchyDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r160",
      "r161"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of fair value measurements for our earn-out liability, cash equivalents and marketable securities"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureFairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r360",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r502",
      "r531",
      "r532",
      "r533",
      "r572",
      "r573",
      "r582",
      "r583",
      "r584"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value, Hierarchy [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureFairValueMeasurementsEarnOutLiabilityDetails",
      "http://www.tactilemedical.com/role/DisclosureFairValueMeasurementsFairValueHierarchyDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r501",
      "r502",
      "r503",
      "r504",
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureFairValueMeasurementsFairValueHierarchyDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureFairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r360",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r502",
      "r533",
      "r572",
      "r573",
      "r582",
      "r583",
      "r584"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Significant Unobservable Inputs (Level 3)"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureFairValueMeasurementsEarnOutLiabilityDetails",
      "http://www.tactilemedical.com/role/DisclosureFairValueMeasurementsFairValueHierarchyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Fair Value, Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureFairValueMeasurementsFairValueHierarchyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r360",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r531",
      "r532",
      "r533",
      "r572",
      "r573",
      "r582",
      "r583",
      "r584"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureFairValueMeasurementsEarnOutLiabilityDetails",
      "http://www.tactilemedical.com/role/DisclosureFairValueMeasurementsFairValueHierarchyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r505",
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureFairValueMeasurementsFairValueHierarchyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FederalFundsEffectiveSwapRateMember": {
     "auth_ref": [
      "r747"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fixed rate on U.S. dollar, constant-notional interest rate swap having its variable-rate leg referenced to Federal Funds effective rate with no additional spread over Federal Funds effective rate on that variable-rate leg.",
        "label": "Federal Funds"
       }
      }
     },
     "localname": "FederalFundsEffectiveSwapRateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureCreditAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "terseLabel": "Estimated Useful Life"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureAcquisitionsAllocationOfPurchasePriceDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r212",
      "r331"
     ],
     "calculation": {
      "http://www.tactilemedical.com/role/DisclosurePatentCostsNetDetailsCalc2": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "terseLabel": "Accumulated Amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureGoodwillAndIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": {
     "auth_ref": [],
     "calculation": {
      "http://www.tactilemedical.com/role/DisclosureGoodwillAndIntangibleAssetsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureGoodwillAndIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.tactilemedical.com/role/DisclosureGoodwillAndIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureGoodwillAndIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.tactilemedical.com/role/DisclosureGoodwillAndIntangibleAssetsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Five",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureGoodwillAndIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.tactilemedical.com/role/DisclosureGoodwillAndIntangibleAssetsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureGoodwillAndIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.tactilemedical.com/role/DisclosureGoodwillAndIntangibleAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureGoodwillAndIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.tactilemedical.com/role/DisclosureGoodwillAndIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureGoodwillAndIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r328",
      "r330",
      "r331",
      "r333",
      "r538",
      "r539"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureAcquisitionsAllocationOfPurchasePriceDetails",
      "http://www.tactilemedical.com/role/DisclosureGoodwillAndIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Future Amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureGoodwillAndIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r87",
      "r539"
     ],
     "calculation": {
      "http://www.tactilemedical.com/role/DisclosurePatentCostsNetDetailsCalc2": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Gross Carrying Amount"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureGoodwillAndIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "verboseLabel": "Patents and Intangibles"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureGoodwillAndIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r82",
      "r86"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureAcquisitionsAllocationOfPurchasePriceDetails",
      "http://www.tactilemedical.com/role/DisclosureGoodwillAndIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r87",
      "r538"
     ],
     "calculation": {
      "http://www.tactilemedical.com/role/DisclosureGoodwillAndIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.tactilemedical.com/role/DisclosurePatentCostsNetDetailsCalc2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "terseLabel": "Finite lived intangible assets, Allocated Fair Value",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureAcquisitionsAllocationOfPurchasePriceDetails",
      "http://www.tactilemedical.com/role/DisclosureGoodwillAndIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Net [Abstract]",
        "terseLabel": "Definite-lived intangible assets:"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureGoodwillAndIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1": {
     "auth_ref": [
      "r538"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Assets, Remaining Amortization Period",
        "verboseLabel": "Weighted Average Amortization Period"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureGoodwillAndIntangibleAssetsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosurePropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnDispositionOfAssets1": {
     "auth_ref": [
      "r619"
     ],
     "calculation": {
      "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.",
        "label": "Gain (Loss) on Disposition of Assets",
        "negatedLabel": "Loss on disposal of property and equipment and intangibles"
       }
      }
     },
     "localname": "GainLossOnDispositionOfAssets1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "Reimbursement, general and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r38"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "Reimbursement, general and administrative expenses"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureAcquisitionsDetails",
      "http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r211",
      "r325",
      "r540",
      "r571",
      "r595",
      "r636",
      "r637"
     ],
     "calculation": {
      "http://www.tactilemedical.com/role/DisclosurePurchasePriceAllocationDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsNet",
       "weight": 1.0
      },
      "http://www.tactilemedical.com/role/StatementConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureAcquisitionsPurchasePriceAllocationDetails",
      "http://www.tactilemedical.com/role/DisclosureGoodwillAndIntangibleAssetsDetails",
      "http://www.tactilemedical.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets."
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Goodwill and Intangible Assets"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureGoodwillAndIntangibleAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": {
     "auth_ref": [
      "r326",
      "r327",
      "r571"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.",
        "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GrossProfit": {
     "auth_ref": [
      "r39",
      "r243",
      "r291",
      "r299",
      "r303",
      "r305",
      "r317",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r508",
      "r570",
      "r642"
     ],
     "calculation": {
      "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.",
        "label": "Gross Profit",
        "totalLabel": "Gross profit"
       }
      }
     },
     "localname": "GrossProfit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IPOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First sale of stock by a private company to the public.",
        "label": "IPO"
       }
      }
     },
     "localname": "IPOMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureNatureOfBusinessAndOperationsDetails",
      "http://www.tactilemedical.com/role/DisclosureStockholdersEquitySeriesBPreferredStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r92",
      "r98"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment of Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r36",
      "r168",
      "r177",
      "r194",
      "r291",
      "r299",
      "r303",
      "r305",
      "r543",
      "r570"
     ],
     "calculation": {
      "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerBasicShare": {
     "auth_ref": [
      "r35",
      "r176",
      "r178",
      "r191",
      "r233",
      "r250",
      "r252",
      "r253",
      "r254",
      "r255",
      "r264",
      "r268",
      "r269",
      "r500",
      "r542"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.",
        "label": "Income (Loss) from Continuing Operations, Per Basic Share",
        "terseLabel": "Basic (in dollars per share)"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsPerBasicShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare": {
     "auth_ref": [
      "r35",
      "r191",
      "r193",
      "r233",
      "r250",
      "r252",
      "r253",
      "r254",
      "r255",
      "r264",
      "r268",
      "r269",
      "r270",
      "r500",
      "r542",
      "r546"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Income (Loss) from Continuing Operations, Per Diluted Share",
        "terseLabel": "Diluted (in dollars per share)"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsPerDilutedShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Statements of Operations"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r334",
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureAcquisitionsDetails",
      "http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureAcquisitionsDetails",
      "http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r138"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureIncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r244",
      "r460",
      "r463",
      "r469",
      "r475",
      "r480",
      "r482",
      "r483",
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureIncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r245",
      "r258",
      "r259",
      "r290",
      "r458",
      "r476",
      "r481",
      "r547"
     ],
     "calculation": {
      "http://www.tactilemedical.com/role/DisclosureIncomeTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Income tax expense (benefit)"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureIncomeTaxesDetails",
      "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r228",
      "r454",
      "r455",
      "r463",
      "r464",
      "r468",
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxesPaid": {
     "auth_ref": [
      "r54",
      "r61"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.",
        "label": "Income Taxes Paid",
        "terseLabel": "Cash paid for taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerAsset": {
     "auth_ref": [
      "r618"
     ],
     "calculation": {
      "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.",
        "label": "Increase (Decrease) in Contract Receivables, Net",
        "negatedLabel": "Accounts receivable, non-current"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredIncomeTaxes": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.",
        "label": "Increase (Decrease) in Deferred Income Taxes",
        "negatedLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 18.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Increase (Decrease) in Employee Related Liabilities",
        "terseLabel": "Accrued payroll and related taxes"
       }
      }
     },
     "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInIncomeTaxesReceivable": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in income taxes receivable, which represents the amount due from tax authorities for refunds of overpayments or recoveries of income taxes paid.",
        "label": "Increase (Decrease) in Income Taxes Receivable",
        "negatedLabel": "Income taxes"
       }
      }
     },
     "localname": "IncreaseDecreaseInIncomeTaxesReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in assets and liabilities, net of acquisition:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r329",
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-lived Intangible Assets [Axis]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureGoodwillAndIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r90"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-lived Intangible Assets (Excluding Goodwill)",
        "terseLabel": "Gross Carrying Amount, Indefinite"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureGoodwillAndIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Indefinite-lived Intangible Assets (Excluding Goodwill) [Abstract]",
        "terseLabel": "Unamortized intangible assets:"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureGoodwillAndIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r84",
      "r90"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.",
        "label": "Indefinite-lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureGoodwillAndIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IntangibleAssetsGrossExcludingGoodwill": {
     "auth_ref": [
      "r211"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill.",
        "label": "Intangible Assets, Gross (Excluding Goodwill)",
        "terseLabel": "Indefinite lived intangible assets excluding goodwill, Allocated fair value",
        "verboseLabel": "Total intangible assets (Gross)"
       }
      }
     },
     "localname": "IntangibleAssetsGrossExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureAcquisitionsAllocationOfPurchasePriceDetails",
      "http://www.tactilemedical.com/role/DisclosureGoodwillAndIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r80",
      "r85"
     ],
     "calculation": {
      "http://www.tactilemedical.com/role/DisclosurePurchasePriceAllocationDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsNet",
       "weight": 1.0
      },
      "http://www.tactilemedical.com/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "netLabel": "Total intangible assets (Net)",
        "terseLabel": "Intangible assets, net",
        "verboseLabel": "Intangible assets"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureAcquisitionsAllocationOfPurchasePriceDetails",
      "http://www.tactilemedical.com/role/DisclosureAcquisitionsPurchasePriceAllocationDetails",
      "http://www.tactilemedical.com/role/DisclosureGoodwillAndIntangibleAssetsDetails",
      "http://www.tactilemedical.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r236",
      "r239",
      "r240"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Net",
        "terseLabel": "Cash paid for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventories"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureInventories"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoods": {
     "auth_ref": [
      "r612"
     ],
     "calculation": {
      "http://www.tactilemedical.com/role/DisclosureInventoriesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.",
        "label": "Inventory, Finished Goods, Gross",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoods",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r219",
      "r564",
      "r595"
     ],
     "calculation": {
      "http://www.tactilemedical.com/role/DisclosureInventoriesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.tactilemedical.com/role/DisclosurePurchasePriceAllocationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsNet",
       "weight": 1.0
      },
      "http://www.tactilemedical.com/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventories",
        "totalLabel": "Total inventories",
        "verboseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureAcquisitionsPurchasePriceAllocationDetails",
      "http://www.tactilemedical.com/role/DisclosureInventoriesDetails",
      "http://www.tactilemedical.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Net [Abstract]",
        "verboseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureInventoriesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r207",
      "r218",
      "r276",
      "r321",
      "r322",
      "r323",
      "r536",
      "r566"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryWorkInProcess": {
     "auth_ref": [
      "r613"
     ],
     "calculation": {
      "http://www.tactilemedical.com/role/DisclosureInventoriesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.",
        "label": "Inventory, Work in Process, Gross",
        "terseLabel": "Component parts and work-in-process"
       }
      }
     },
     "localname": "InventoryWorkInProcess",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "auth_ref": [
      "r316",
      "r761"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment in financial asset.",
        "label": "Investment, Policy [Policy Text Block]",
        "terseLabel": "Equity Investments"
       }
      }
     },
     "localname": "InvestmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdsAndLeaseholdImprovementsMember": {
     "auth_ref": [
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset held by lessee under finance lease and addition or improvement to asset held under lease arrangement.",
        "label": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdsAndLeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosurePropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "verboseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesLeaseObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesLeaseObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend": {
     "auth_ref": [
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates (true false) whether lessee has option to extend operating lease.",
        "label": "Lessee, Operating Lease, Existence of Option to Extend [true false]",
        "terseLabel": "Option to renew"
       }
      }
     },
     "localname": "LesseeOperatingLeaseExistenceOfOptionToExtend",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesLeaseObligationsDetails"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r526"
     ],
     "calculation": {
      "http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesUndiscountedCashFlowsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesUndiscountedCashFlowsDetailsCalc2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due",
        "totalLabel": "Total minimum lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesUndiscountedCashFlowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r526"
     ],
     "calculation": {
      "http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesUndiscountedCashFlowsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, Payments, Due after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesUndiscountedCashFlowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r526"
     ],
     "calculation": {
      "http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesUndiscountedCashFlowsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesUndiscountedCashFlowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r526"
     ],
     "calculation": {
      "http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesUndiscountedCashFlowsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Five",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesUndiscountedCashFlowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r526"
     ],
     "calculation": {
      "http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesUndiscountedCashFlowsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesUndiscountedCashFlowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r526"
     ],
     "calculation": {
      "http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesUndiscountedCashFlowsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesUndiscountedCashFlowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r526"
     ],
     "calculation": {
      "http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesUndiscountedCashFlowsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesUndiscountedCashFlowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r526"
     ],
     "calculation": {
      "http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesUndiscountedCashFlowsDetailsCalc2": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: Amount of lease payments representing interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesUndiscountedCashFlowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r750"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Remaining lease terms"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesLeaseObligationsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r24",
      "r243",
      "r317",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r493",
      "r496",
      "r497",
      "r508",
      "r569",
      "r642",
      "r752",
      "r753"
     ],
     "calculation": {
      "http://www.tactilemedical.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r17",
      "r173",
      "r188",
      "r595",
      "r622",
      "r634",
      "r749"
     ],
     "calculation": {
      "http://www.tactilemedical.com/role/StatementConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Stockholders' Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r26",
      "r206",
      "r243",
      "r317",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r493",
      "r496",
      "r497",
      "r508",
      "r595",
      "r642",
      "r752",
      "r753"
     ],
     "calculation": {
      "http://www.tactilemedical.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueAdjustment": {
     "auth_ref": [],
     "calculation": {
      "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of addition (reduction) to the amount at which a liability could be incurred (settled) in a current transaction between willing parties.",
        "label": "Liabilities, Fair Value Adjustment",
        "negatedLabel": "Change in fair value of earn-out liability"
       }
      }
     },
     "localname": "LiabilitiesFairValueAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "auth_ref": [
      "r2",
      "r3",
      "r4",
      "r6",
      "r7",
      "r243",
      "r317",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r493",
      "r496",
      "r497",
      "r508",
      "r642",
      "r752",
      "r753"
     ],
     "calculation": {
      "http://www.tactilemedical.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.",
        "label": "Total long-term liabilities, net of current portion",
        "totalLabel": "Total non-current liabilities"
       }
      }
     },
     "localname": "LiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Noncurrent [Abstract]",
        "terseLabel": "Non-current liabilities"
       }
      }
     },
     "localname": "LiabilitiesNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCredit": {
     "auth_ref": [
      "r6",
      "r172",
      "r183"
     ],
     "calculation": {
      "http://www.tactilemedical.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.",
        "label": "Long-term Line of Credit",
        "terseLabel": "Revolving line of credit, non-current",
        "verboseLabel": "Credit facility outstanding amount"
       }
      }
     },
     "localname": "LineOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureCreditAgreementDetails",
      "http://www.tactilemedical.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Line of Credit Facility [Line Items]",
        "verboseLabel": "Credit Agreement"
       }
      }
     },
     "localname": "LineOfCreditFacilityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureCreditAgreementDetails",
      "http://www.tactilemedical.com/role/DisclosureCreditAgreementMaturitiesOfDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r22"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "verboseLabel": "Line of credit"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureCreditAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityTable": {
     "auth_ref": [
      "r22",
      "r621"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.",
        "label": "Line of Credit Facility [Table]"
       }
      }
     },
     "localname": "LineOfCreditFacilityTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureCreditAgreementDetails",
      "http://www.tactilemedical.com/role/DisclosureCreditAgreementMaturitiesOfDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility.",
        "label": "Line of Credit Facility, Unused Capacity, Commitment Fee Percentage",
        "terseLabel": "Unused line fee (as a percent)"
       }
      }
     },
     "localname": "LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureCreditAgreementDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock": {
     "auth_ref": [
      "r633"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for claims held for amounts due a entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses.",
        "label": "Loans, Notes, Trade and Other Receivables Disclosure [Text Block]",
        "terseLabel": "Accounts Receivable"
       }
      }
     },
     "localname": "LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureAccountsReceivable"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LondonInterbankOfferedRateLIBORMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.",
        "label": "LIBOR"
       }
      }
     },
     "localname": "LondonInterbankOfferedRateLIBORMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureCreditAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r6",
      "r172",
      "r186",
      "r359",
      "r366",
      "r572",
      "r573"
     ],
     "calculation": {
      "http://www.tactilemedical.com/role/DisclosureCreditAgreementMaturitiesOfDebtDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.",
        "label": "Long-term Debt",
        "terseLabel": "Long-term debt",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureCreditAgreementDetails",
      "http://www.tactilemedical.com/role/DisclosureCreditAgreementMaturitiesOfDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtByMaturityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-term Debt, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Maturities of notes payable"
       }
      }
     },
     "localname": "LongTermDebtByMaturityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureCreditAgreementMaturitiesOfDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "auth_ref": [
      "r111",
      "r246",
      "r362"
     ],
     "calculation": {
      "http://www.tactilemedical.com/role/DisclosureCreditAgreementMaturitiesOfDebtDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureCreditAgreementMaturitiesOfDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "auth_ref": [
      "r111",
      "r246",
      "r362"
     ],
     "calculation": {
      "http://www.tactilemedical.com/role/DisclosureCreditAgreementMaturitiesOfDebtDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureCreditAgreementMaturitiesOfDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermNotesPayable": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://www.tactilemedical.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.",
        "label": "Notes Payable, Noncurrent",
        "terseLabel": "Note payable, non-current"
       }
      }
     },
     "localname": "LongTermNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesGainLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized and realized gain (loss) on investment in marketable security, including other-than-temporary impairment (OTTI).",
        "label": "Marketable Securities, Gain (Loss)",
        "negatedLabel": "Gain on other investments and maturities of marketable securities"
       }
      }
     },
     "localname": "MarketableSecuritiesGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketingAndAdvertisingExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketing and Advertising Expense [Abstract]",
        "verboseLabel": "Advertising"
       }
      }
     },
     "localname": "MarketingAndAdvertisingExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MovementInStandardProductWarrantyAccrualRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Movement in Standard Product Warranty Accrual [Roll Forward]"
       }
      }
     },
     "localname": "MovementInStandardProductWarrantyAccrualRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureWarrantyReservesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r281",
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "Nature of Operations [Text Block]",
        "verboseLabel": "Nature of Business and Operations"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureNatureOfBusinessAndOperations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Continuing Operations [Abstract]",
        "terseLabel": "Cash flows from operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r238"
     ],
     "calculation": {
      "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash (used in) provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]",
        "terseLabel": "Cash flows from financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r238"
     ],
     "calculation": {
      "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash (used in) provided by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]",
        "terseLabel": "Cash flows from investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r53",
      "r55",
      "r58"
     ],
     "calculation": {
      "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r37",
      "r58",
      "r179",
      "r192",
      "r204",
      "r223",
      "r226",
      "r231",
      "r243",
      "r250",
      "r252",
      "r253",
      "r254",
      "r255",
      "r258",
      "r259",
      "r266",
      "r291",
      "r299",
      "r303",
      "r305",
      "r317",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r500",
      "r508",
      "r570",
      "r642"
     ],
     "calculation": {
      "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r252",
      "r253",
      "r254",
      "r255",
      "r261",
      "r262",
      "r267",
      "r270",
      "r291",
      "r299",
      "r303",
      "r305",
      "r570"
     ],
     "calculation": {
      "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureNetLossIncomePerCommonShareBasicAndDilutedNetLossPerShareDetails",
      "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetInvestmentInLease": {
     "auth_ref": [
      "r313",
      "r319",
      "r527",
      "r635"
     ],
     "calculation": {
      "http://www.tactilemedical.com/role/StatementConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allowance for credit loss, of net investment in sales-type and direct financing leases.",
        "label": "Net Investment in Lease",
        "terseLabel": "Net investment in leases"
       }
      }
     },
     "localname": "NetInvestmentInLease",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1": {
     "auth_ref": [
      "r62",
      "r63",
      "r64"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of an asset or business acquired in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Noncash or Part Noncash Acquisition, Value of Assets Acquired",
        "terseLabel": "Capital expenditures incurred but not yet paid"
       }
      }
     },
     "localname": "NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "verboseLabel": "Other (expense) income"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesPayableCurrent": {
     "auth_ref": [
      "r23"
     ],
     "calculation": {
      "http://www.tactilemedical.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.",
        "label": "Notes Payable, Current",
        "terseLabel": "Note payable"
       }
      }
     },
     "localname": "NotesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r631"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segment"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureSummaryOfSignificantAccountingPoliciesSegmentDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NumberOfReportableSegments": {
     "auth_ref": [
      "r631"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.",
        "label": "Number of Reportable Segments",
        "terseLabel": "Number of reportable segment"
       }
      }
     },
     "localname": "NumberOfReportableSegments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureSummaryOfSignificantAccountingPoliciesSegmentDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r291",
      "r299",
      "r303",
      "r305",
      "r570"
     ],
     "calculation": {
      "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLeaseIncomeTableTextBlock": {
     "auth_ref": [
      "r277",
      "r529"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of components of income from operating lease.",
        "label": "Operating Lease, Lease Income [Table Text Block]",
        "terseLabel": "Summary of undiscounted cash flows"
       }
      }
     },
     "localname": "OperatingLeaseLeaseIncomeTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease Liabilities, Payments Due [Abstract]",
        "terseLabel": "Undiscounted cash flows"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesUndiscountedCashFlowsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r517"
     ],
     "calculation": {
      "http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesLeaseRelatedAssetsAndLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesUndiscountedCashFlowsDetailsCalc2": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "totalLabel": "Present value of future minimum lease payments"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesLeaseRelatedAssetsAndLiabilitiesDetails",
      "http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesUndiscountedCashFlowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r517"
     ],
     "calculation": {
      "http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesLeaseRelatedAssetsAndLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      },
      "http://www.tactilemedical.com/role/StatementConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "negatedLabel": "Less: Current obligations under operating lease liabilities",
        "terseLabel": "Operating lease liabilities",
        "verboseLabel": "Operating lease liabilities, Current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesLeaseRelatedAssetsAndLiabilitiesDetails",
      "http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesUndiscountedCashFlowsDetails",
      "http://www.tactilemedical.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r518"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes current operating lease liability.",
        "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesLeaseRelatedAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r517"
     ],
     "calculation": {
      "http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesLeaseRelatedAssetsAndLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      },
      "http://www.tactilemedical.com/role/StatementConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities, non-current",
        "verboseLabel": "Non-current obligations under operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesLeaseRelatedAssetsAndLiabilitiesDetails",
      "http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesUndiscountedCashFlowsDetails",
      "http://www.tactilemedical.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r518"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes noncurrent operating lease liability.",
        "label": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesLeaseRelatedAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r519",
      "r522"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Cash paid for operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesLeaseRelatedAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r516"
     ],
     "calculation": {
      "http://www.tactilemedical.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "verboseLabel": "Right of use operating lease assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesLeaseRelatedAssetsAndLiabilitiesDetails",
      "http://www.tactilemedical.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "auth_ref": [
      "r619"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for right-of-use asset from operating lease.",
        "label": "Operating Lease, Right-of-Use Asset, Amortization Expense",
        "terseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesLeaseCommitmentsAndOperatingLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r518"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes operating lease right-of-use asset.",
        "label": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesLeaseRelatedAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r525",
      "r594"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesLeaseRelatedAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r524",
      "r594"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average remaining lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesLeaseRelatedAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Presentation"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r25"
     ],
     "calculation": {
      "http://www.tactilemedical.com/role/DisclosureAccruedExpensesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsMiscellaneousAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Assets, Miscellaneous [Abstract]",
        "terseLabel": "Non-current assets"
       }
      }
     },
     "localname": "OtherAssetsMiscellaneousAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r213"
     ],
     "calculation": {
      "http://www.tactilemedical.com/role/StatementConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other non-current assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r155",
      "r156",
      "r158",
      "r224",
      "r227"
     ],
     "calculation": {
      "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "totalLabel": "Total other comprehensive loss"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "terseLabel": "Other comprehensive loss"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1": {
     "auth_ref": [
      "r155",
      "r156",
      "r158"
     ],
     "calculation": {
      "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Tax, Portion Attributable to Parent",
        "negatedLabel": "Income tax related to items of other comprehensive loss"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossTaxPortionAttributableToParent1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r221",
      "r222"
     ],
     "calculation": {
      "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "Other Comprehensive Income (Loss), Unrealized Holding Gain (Loss) on Securities Arising During Period, Net of Tax",
        "terseLabel": "Unrealized loss on marketable securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r25",
      "r595"
     ],
     "calculation": {
      "http://www.tactilemedical.com/role/StatementConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PatentsMember": {
     "auth_ref": [
      "r148"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.",
        "label": "Patents"
       }
      }
     },
     "localname": "PatentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureGoodwillAndIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities": {
     "auth_ref": [
      "r52"
     ],
     "calculation": {
      "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.",
        "label": "Payment for Contingent Consideration Liability, Financing Activities",
        "negatedLabel": "Payment on earn-out"
       }
      }
     },
     "localname": "PaymentForContingentConsiderationLiabilityFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureFairValueMeasurementsEarnOutLiabilityDetails",
      "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.",
        "label": "Payments of Debt Issuance Costs",
        "negatedLabel": "Payments of deferred debt issuance costs"
       }
      }
     },
     "localname": "PaymentsOfDebtIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfOrdinaryDividends": {
     "auth_ref": [
      "r49"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash outflow in the form of ordinary dividends to common shareholders, preferred shareholders and noncontrolling interests, generally out of earnings.",
        "label": "Payments of Ordinary Dividends",
        "terseLabel": "Payment of dividends"
       }
      }
     },
     "localname": "PaymentsOfOrdinaryDividends",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureStockholdersEquitySeriesBPreferredStockDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "auth_ref": [
      "r44",
      "r488"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.",
        "label": "Payments to Acquire Productive Assets",
        "terseLabel": "Purchase price"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureAcquisitionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.",
        "label": "Payments to Acquire Intangible Assets",
        "negatedLabel": "Intangible assets expenditures"
       }
      }
     },
     "localname": "PaymentsToAcquireIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireOtherInvestments": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investments classified as other.",
        "label": "Payments to Acquire Other Investments",
        "negatedLabel": "Other investments"
       }
      }
     },
     "localname": "PaymentsToAcquireOtherInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PerformanceSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement awarded for meeting performance target.",
        "label": "Performance stock units"
       }
      }
     },
     "localname": "PerformanceSharesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureNetLossIncomePerCommonShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureStockholdersEquityEmployeeStockPurchasePlanDetails",
      "http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockBasedCompensationDetails",
      "http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureStockholdersEquityEmployeeStockPurchasePlanDetails",
      "http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockBasedCompensationDetails",
      "http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Number of Shares, Par Value and Other Disclosures [Abstract]",
        "terseLabel": "Preferred stock"
       }
      }
     },
     "localname": "PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureStockholdersEquitySeriesBPreferredStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r11",
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r11",
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred stock, shares issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r11",
      "r595"
     ],
     "calculation": {
      "http://www.tactilemedical.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "verboseLabel": "Preferred stock, $0.001 par value, 50,000,000 shares authorized; none issued and outstanding as of December 31, 2022 and December 31, 2021"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r614"
     ],
     "calculation": {
      "http://www.tactilemedical.com/role/StatementConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "auth_ref": [
      "r47"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.",
        "label": "Proceeds from Issuance Initial Public Offering",
        "verboseLabel": "Proceeds from IPO"
       }
      }
     },
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureNatureOfBusinessAndOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from the issuance of common stock from the employee stock purchase plan"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromLinesOfCredit": {
     "auth_ref": [
      "r48",
      "r621"
     ],
     "calculation": {
      "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.",
        "label": "Proceeds from Lines of Credit",
        "terseLabel": "Proceeds from revolving line of credit"
       }
      }
     },
     "localname": "ProceedsFromLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r78",
      "r234",
      "r235"
     ],
     "calculation": {
      "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale",
        "terseLabel": "Proceeds from maturities of securities available-for-sale"
       }
      }
     },
     "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromNotesPayable": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a borrowing supported by a written promise to pay an obligation.",
        "label": "Proceeds from Notes Payable",
        "terseLabel": "Proceeds from issuance of note payable"
       }
      }
     },
     "localname": "ProceedsFromNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.",
        "label": "Proceeds from Sale of Property, Plant, and Equipment",
        "terseLabel": "Proceeds from sale of property and equipment"
       }
      }
     },
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r47",
      "r133"
     ],
     "calculation": {
      "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from exercise of common stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r575"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Sales revenue"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProductWarrantyAccrual": {
     "auth_ref": [
      "r106",
      "r108",
      "r174"
     ],
     "calculation": {
      "http://www.tactilemedical.com/role/DisclosureWarrantyReservesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for estimated claims under standard and extended warranty protection rights granted to customers.",
        "label": "Standard and Extended Product Warranty Accrual",
        "totalLabel": "Total accrued warranty reserve"
       }
      }
     },
     "localname": "ProductWarrantyAccrual",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureWarrantyReservesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductWarrantyAccrualClassifiedCurrent": {
     "auth_ref": [
      "r25",
      "r101",
      "r102"
     ],
     "calculation": {
      "http://www.tactilemedical.com/role/DisclosureAccruedExpensesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.tactilemedical.com/role/DisclosureWarrantyReservesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_ProductWarrantyAccrual",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for estimated claims under standard and extended warranty protection rights granted to customers. For classified balance sheets, represents the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Product Warranty Accrual, Current",
        "terseLabel": "Warranty",
        "verboseLabel": "Accrued warranty reserve, current"
       }
      }
     },
     "localname": "ProductWarrantyAccrualClassifiedCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureAccruedExpensesDetails",
      "http://www.tactilemedical.com/role/DisclosureWarrantyReservesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductWarrantyAccrualNoncurrent": {
     "auth_ref": [
      "r28"
     ],
     "calculation": {
      "http://www.tactilemedical.com/role/DisclosureWarrantyReservesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_ProductWarrantyAccrual",
       "weight": 1.0
      },
      "http://www.tactilemedical.com/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and due after one year (or beyond the operating cycle if longer) for estimated claims under standard and extended warranty protection rights granted to customers.",
        "label": "Product Warranty Accrual, Noncurrent",
        "terseLabel": "Accrued warranty reserve, non-current"
       }
      }
     },
     "localname": "ProductWarrantyAccrualNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureWarrantyReservesDetails",
      "http://www.tactilemedical.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductWarrantyDisclosureTextBlock": {
     "auth_ref": [
      "r110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for standard and extended product warranties and other product guarantee contracts, including a tabular reconciliation of the changes in the guarantor's aggregate product warranty liability for the reporting period.",
        "label": "Product Warranty Disclosure [Text Block]",
        "terseLabel": "Warranty Reserves"
       }
      }
     },
     "localname": "ProductWarrantyDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureWarrantyReserves"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r204",
      "r223",
      "r226",
      "r237",
      "r243",
      "r250",
      "r258",
      "r259",
      "r291",
      "r299",
      "r303",
      "r305",
      "r317",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r491",
      "r494",
      "r495",
      "r500",
      "r508",
      "r543",
      "r570",
      "r592",
      "r593",
      "r617",
      "r642"
     ],
     "calculation": {
      "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r97"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesLeaseObligationsDetails",
      "http://www.tactilemedical.com/role/DisclosurePropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r99",
      "r557",
      "r558",
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosurePropertyAndEquipment"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r95",
      "r209"
     ],
     "calculation": {
      "http://www.tactilemedical.com/role/DisclosurePropertyAndEquipmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Subtotal"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosurePropertyAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosurePropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r97",
      "r189",
      "r544",
      "r595"
     ],
     "calculation": {
      "http://www.tactilemedical.com/role/DisclosurePropertyAndEquipmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.tactilemedical.com/role/DisclosurePurchasePriceAllocationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsNet",
       "weight": 1.0
      },
      "http://www.tactilemedical.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net",
        "verboseLabel": "Property, plant and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureAcquisitionsPurchasePriceAllocationDetails",
      "http://www.tactilemedical.com/role/DisclosurePropertyAndEquipmentDetails",
      "http://www.tactilemedical.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Net, by Type [Abstract]",
        "verboseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNetByTypeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosurePropertyAndEquipmentDetails",
      "http://www.tactilemedical.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r97",
      "r557",
      "r558"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r97"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of components of property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosurePropertyAndEquipmentTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesLeaseObligationsDetails",
      "http://www.tactilemedical.com/role/DisclosurePropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Useful life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_PurchaseObligationDueInNextTwelveMonths": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of purchase arrangement to be paid in next fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Purchase Obligation, Due in Next Twelve Months",
        "verboseLabel": "Purchase orders issued"
       }
      }
     },
     "localname": "PurchaseObligationDueInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesPurchaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PurchaseObligationFiscalYearMaturityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase Obligation, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Purchase commitments"
       }
      }
     },
     "localname": "PurchaseObligationFiscalYearMaturityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesPurchaseCommitmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReceivablesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable."
       }
      }
     },
     "localname": "ReceivablesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]",
        "terseLabel": "Reconciliation of unrecognized tax benefits"
       }
      }
     },
     "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RepaymentsOfNotesPayable": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation.",
        "label": "Repayments of Notes Payable",
        "negatedLabel": "Payments on note payable"
       }
      }
     },
     "localname": "RepaymentsOfNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r136",
      "r199",
      "r760"
     ],
     "calculation": {
      "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r136"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Costs"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureNetLossIncomePerCommonShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails",
      "http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails",
      "http://www.tactilemedical.com/role/DisclosureStockholdersEquityTables"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r14",
      "r123",
      "r187",
      "r552",
      "r553",
      "r595"
     ],
     "calculation": {
      "http://www.tactilemedical.com/role/StatementConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "(Accumulated deficit) retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r203",
      "r247",
      "r248",
      "r249",
      "r251",
      "r257",
      "r259",
      "r318",
      "r446",
      "r447",
      "r448",
      "r473",
      "r474",
      "r498",
      "r549",
      "r551"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "(Accumulated Deficit) Retained Earnings"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetirementPlanNameAxis": {
     "auth_ref": [
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r587",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of plan designed to provide retirement benefits. Includes, but is not limited to, legal name of defined benefit and defined contribution plans.",
        "label": "Retirement Plan Name [Axis]"
       }
      }
     },
     "localname": "RetirementPlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesRetirementPlanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetirementPlanNameDomain": {
     "auth_ref": [
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r587",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of plan designed to provide retirement benefits. Includes, but is not limited to, legal name of defined benefit and defined contribution plans.",
        "label": "Defined Contribution Plan Name [Domain] (Deprecated 2017-01-31)"
       }
      }
     },
     "localname": "RetirementPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesRetirementPlanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue."
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r287",
      "r288",
      "r298",
      "r301",
      "r302",
      "r306",
      "r307",
      "r308",
      "r392",
      "r393",
      "r537"
     ],
     "calculation": {
      "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Total revenue",
        "verboseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureRevenueDetails",
      "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r395",
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue Recognition, Policy [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r394",
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureRevenue"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenuePracticalExpedientIncrementalCostOfObtainingContract": {
     "auth_ref": [
      "r324",
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates (true false) whether practical expedient was elected to recognize incremental cost of obtaining contract as expense when incurred if amortization period would have been one year or less.",
        "label": "Revenue, Practical Expedient, Incremental Cost of Obtaining Contract [true false]",
        "verboseLabel": "Revenue for practical expedient"
       }
      }
     },
     "localname": "RevenuePracticalExpedientIncrementalCostOfObtainingContract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_RevenueRecognitionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueRecognitionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.",
        "label": "Revolving credit facility"
       }
      }
     },
     "localname": "RevolvingCreditFacilityMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureCreditAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r523",
      "r594"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Non-cash right of use assets obtained in exchange for new operating lease obligations"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesLeaseRelatedAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureNatureOfBusinessAndOperationsDetails",
      "http://www.tactilemedical.com/role/DisclosureStockholdersEquityEmployeeStockPurchasePlanDetails",
      "http://www.tactilemedical.com/role/DisclosureStockholdersEquitySeriesBPreferredStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SalesRevenueNetMember": {
     "auth_ref": [
      "r308",
      "r630"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue"
       }
      }
     },
     "localname": "SalesRevenueNetMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureAccountsReceivableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SalesTypeLeaseLeaseIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sales-type Lease, Lease Income [Abstract]",
        "terseLabel": "Revenue from sale type lease"
       }
      }
     },
     "localname": "SalesTypeLeaseLeaseIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SalesTypeLeaseLeaseIncomeTableTextBlock": {
     "auth_ref": [
      "r277",
      "r529"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of components of income from sales-type lease.",
        "label": "Sales-type Lease, Lease Income [Table Text Block]",
        "terseLabel": "Sales-type lease revenue and the associated cost of goods sold"
       }
      }
     },
     "localname": "SalesTypeLeaseLeaseIncomeTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureRevenueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SalesTypeLeaseRevenue": {
     "auth_ref": [
      "r277",
      "r528"
     ],
     "calculation": {
      "http://www.tactilemedical.com/role/DisclosureRevenueDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_SalesTypeLeaseSellingProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of sales-type lease revenue.",
        "label": "Sales-type Lease, Revenue",
        "terseLabel": "Sales-type lease revenue"
       }
      }
     },
     "localname": "SalesTypeLeaseRevenue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SalesTypeLeaseSellingProfitLoss": {
     "auth_ref": [
      "r277",
      "r528"
     ],
     "calculation": {
      "http://www.tactilemedical.com/role/DisclosureRevenueDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of profit (loss) recognized at commencement from sales-type lease.",
        "label": "Sales-type Lease, Selling Profit (Loss)",
        "totalLabel": "Gross profit"
       }
      }
     },
     "localname": "SalesTypeLeaseSellingProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r67"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureNetLossIncomePerCommonShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r67"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of potentially dilutive securities outstanding"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureNetLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r141"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Schedule of provision (benefit) for income tax expense"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r139"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of components of the Company's deferred tax assets"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r629"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of computation of the basic and diluted net loss per share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureNetLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r137"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of reconciliation of income tax expense (benefit)"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r131",
      "r134"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r131"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]",
        "terseLabel": "Schedule of allocation of total stock-based compensation expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureStockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r501",
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of changes in the earn-out liability"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureFairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r82",
      "r86",
      "r538"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureGoodwillAndIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r82",
      "r86"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of finite lived intangible assets"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureGoodwillAndIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r1",
      "r18",
      "r19",
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Schedule of inventories"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureInventoriesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "auth_ref": [
      "r111"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.",
        "label": "Schedule of Maturities of Long-term Debt [Table Text Block]",
        "terseLabel": "Schedule of maturities of the term note payable"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureCreditAgreementTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock": {
     "auth_ref": [
      "r126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested shares.",
        "label": "Schedule of Nonvested Share Activity"
       }
      }
     },
     "localname": "ScheduleOfNonvestedShareActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureStockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock": {
     "auth_ref": [
      "r109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in the guarantor's aggregate product warranty liability, including the beginning balance of the aggregate product warranty liability, the aggregate reductions in that liability for payments made (in cash or in kind) under the warranty, the aggregate changes in the liability for accruals related to product warranties issued during the reporting period, the aggregate changes in the liability for accruals related to preexisting warranties (including adjustments related to changes in estimates), and the ending balance of the aggregate product warranty liability.",
        "label": "Schedule of Product Warranty Liability [Table Text Block]",
        "terseLabel": "Schedule of warranty reserves"
       }
      }
     },
     "localname": "ScheduleOfProductWarrantyLiabilityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureWarrantyReservesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r97"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosurePropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "auth_ref": [
      "r125"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Schedule of Share-based Compensation, Restricted Stock Units Award Activity [Table Text Block]",
        "terseLabel": "Schedule of stock-settled restricted stock unit activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureStockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r125",
      "r127",
      "r128"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]",
        "terseLabel": "Schedule of stock option activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureStockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r130"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "verboseLabel": "Schedule of estimated fair values and assumptions for stock options granted"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureStockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r113",
      "r114",
      "r115",
      "r117",
      "r118",
      "r119",
      "r120",
      "r121",
      "r122",
      "r123",
      "r215",
      "r216",
      "r217",
      "r279",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r574",
      "r607",
      "r620"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureStockholdersEquityEmployeeStockPurchasePlanDetails",
      "http://www.tactilemedical.com/role/DisclosureStockholdersEquitySeriesBPreferredStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of subsidiary's sales of previously unissued stock made to investors outside the consolidated group. This includes stock issued in a business combination in exchange for shares of an acquired entity.",
        "label": "Schedule of Subsidiary or Equity Method Investee [Table]"
       }
      }
     },
     "localname": "ScheduleOfSubsidiaryOrEquityMethodInvesteeTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureNatureOfBusinessAndOperationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "auth_ref": [
      "r591",
      "r737"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits.",
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "terseLabel": "Schedule of unrecognized tax benefits (\"UTB\")"
       }
      }
     },
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "auth_ref": [
      "r86"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.",
        "label": "Finite-lived Intangible Assets Amortization Expense [Table Text Block]",
        "terseLabel": "Schedule of future amortization expense"
       }
      }
     },
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureGoodwillAndIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Business Segments"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingAndMarketingExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services.",
        "label": "Selling and Marketing Expense",
        "terseLabel": "Sales and marketing"
       }
      }
     },
     "localname": "SellingAndMarketingExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingAndMarketingExpenseMember": {
     "auth_ref": [
      "r38"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling and marketing expense.",
        "label": "Sales and marketing expenses"
       }
      }
     },
     "localname": "SellingAndMarketingExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeriesAPreferredStockMember": {
     "auth_ref": [
      "r610",
      "r611",
      "r645"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A preferred stock.",
        "label": "Series A Preferred Stock"
       }
      }
     },
     "localname": "SeriesAPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureStockholdersEquitySeriesBPreferredStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeriesBPreferredStockMember": {
     "auth_ref": [
      "r610",
      "r611",
      "r645"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series B preferred stock.",
        "label": "Series B Preferred Stock"
       }
      }
     },
     "localname": "SeriesBPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureStockholdersEquitySeriesBPreferredStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Compensation",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation [Abstract]",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Additional General Disclosures [Abstract]",
        "terseLabel": "Stock-based compensation, general disclosures."
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r588"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period (in years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based awards granted",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r427",
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Restricted stock unit awards outstanding at the end of the period (in shares)",
        "periodStartLabel": "Restricted stock unit awards outstanding at the beginning of the period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "verboseLabel": "Units Outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r427",
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Restricted stock unit awards outstanding at the end of the period (in dollars per share)",
        "periodStartLabel": "Restricted stock unit awards outstanding at the beginning of the period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "verboseLabel": "Weighted Average Grant Date Fair Value Per Unit"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Vested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]",
        "verboseLabel": "Estimated fair values and assumptions for stock options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r441"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield (as a percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "verboseLabel": "Expected volatility (as a percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate (as a percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "verboseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized",
        "terseLabel": "Increase in number of shares reserved and available for issuance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureStockholdersEquityEmployeeStockPurchasePlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r590"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized",
        "terseLabel": "Number of shares authorized"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockBasedCompensationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Other information"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Options exercisable number of shares exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Options exercisable, weighted-average exercise price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r434"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "verboseLabel": "Aggregate Intrinsic Value, Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "auth_ref": [
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period",
        "negatedLabel": "Cancelled/Expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Fair value per share of options on the date of grant (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r132"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "verboseLabel": "Aggregate Intrinsic Value, Options outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r419",
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding at end of period",
        "periodStartLabel": "Outstanding at beginning of period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "verboseLabel": "Options Outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r419",
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding at end of period",
        "periodStartLabel": "Outstanding at beginning of period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted Average Exercise Price Per Share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r415",
      "r416",
      "r417",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Equity Award [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureNetLossIncomePerCommonShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails",
      "http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails",
      "http://www.tactilemedical.com/role/DisclosureStockholdersEquityTables"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.",
        "label": "Cancelled",
        "terseLabel": "Cancelled/Expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Tranche one"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Tranche two"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r418",
      "r437",
      "r438",
      "r439",
      "r440",
      "r443",
      "r449",
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by supplier.",
        "label": "Supplier [Axis]"
       }
      }
     },
     "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesMajorVendorsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Specific identification or general nature of (for example, a construction contractor, a consulting firm) the party from whom the goods or services were or are to be received.",
        "label": "Supplier [Domain]"
       }
      }
     },
     "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesMajorVendorsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "verboseLabel": "Stock price"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "auth_ref": [
      "r709"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of vesting of award under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage",
        "verboseLabel": "Compensation arrangement"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value [Abstract]",
        "verboseLabel": "Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding",
        "terseLabel": "Restricted stock unit awards, Average Intrinsic Value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r589"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "terseLabel": "Term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r132"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "verboseLabel": "Aggregate Intrinsic Value, Options exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Options exercisable, weighted-average remaining contractual life"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of non-vested options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares",
        "periodEndLabel": "Non-vested options end of the year",
        "periodStartLabel": "Non vested options beginning of the year"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Number of:"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average grant-date fair value of non-vested options forfeited.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value",
        "terseLabel": "Forfeited options during the year"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average grant-date fair value of non-vested options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Non-vested options end of the year",
        "periodStartLabel": "Non-vested options beginning of the year"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted-average grant date fair value of:"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r129"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average remaining contractual life (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "auth_ref": [
      "r434"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value",
        "terseLabel": "Total grant date fair value of options vested during the period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options vested.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares",
        "terseLabel": "Vested options end of the year"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average grant-date fair value of options vested.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested options end of the year"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent",
        "terseLabel": "Purchase price of common stock under plan (as a percent)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureStockholdersEquityEmployeeStockPurchasePlanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r124",
      "r135"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP).",
        "label": "Shareholders' Equity and Share-based Payments [Text Block]",
        "terseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "ShareholdersEquityAndShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureStockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Shares Issued, Price Per Share",
        "terseLabel": "Share price (in dollars per share)",
        "verboseLabel": "IPO price per share (in dollars per share)"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureNatureOfBusinessAndOperationsDetails",
      "http://www.tactilemedical.com/role/DisclosureStockholdersEquitySeriesBPreferredStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balances at the end (in shares)",
        "periodStartLabel": "Balances at the beginning (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r66",
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureSummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StandardProductWarrantyAccrual": {
     "auth_ref": [
      "r107"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount as of the balance sheet date of the aggregate standard product warranty liability. Does not include the balance for the extended product warranty liability.",
        "label": "Standard Product Warranty Accrual",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "StandardProductWarrantyAccrual",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureWarrantyReservesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StandardProductWarrantyAccrualPayments": {
     "auth_ref": [
      "r103"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in the standard product warranty accrual from payments made in cash or in kind to satisfy claims under the terms of the standard product warranty. Excludes extended product warranties.",
        "label": "Standard Product Warranty Accrual, Decrease for Payments",
        "negatedLabel": "Processed warranty claims"
       }
      }
     },
     "localname": "StandardProductWarrantyAccrualPayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureWarrantyReservesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StandardProductWarrantyAccrualWarrantiesIssued": {
     "auth_ref": [
      "r104"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in the standard product warranty accrual from warranties issued. Excludes extended product warranties.",
        "label": "Standard Product Warranty Accrual, Increase for Warranties Issued",
        "terseLabel": "Warranty provision"
       }
      }
     },
     "localname": "StandardProductWarrantyAccrualWarrantiesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureWarrantyReservesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StandardProductWarrantyDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warranty Reserves",
        "terseLabel": "Product Warranty"
       }
      }
     },
     "localname": "StandardProductWarrantyDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StandardProductWarrantyPolicy": {
     "auth_ref": [
      "r105"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for standard warranties including the methodology for measuring the liability.",
        "label": "Standard Product Warranty, Policy [Policy Text Block]",
        "terseLabel": "Product Warranty"
       }
      }
     },
     "localname": "StandardProductWarrantyPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureIncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r215",
      "r216",
      "r217",
      "r243",
      "r264",
      "r265",
      "r268",
      "r270",
      "r279",
      "r280",
      "r317",
      "r342",
      "r344",
      "r345",
      "r346",
      "r349",
      "r350",
      "r367",
      "r368",
      "r370",
      "r371",
      "r373",
      "r508",
      "r562",
      "r607",
      "r620",
      "r628"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureStockholdersEquitySeriesBPreferredStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r31",
      "r116",
      "r203",
      "r229",
      "r230",
      "r231",
      "r247",
      "r248",
      "r249",
      "r251",
      "r257",
      "r259",
      "r278",
      "r318",
      "r374",
      "r446",
      "r447",
      "r448",
      "r473",
      "r474",
      "r498",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r530",
      "r549",
      "r550",
      "r551"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureStockholdersEquityTables",
      "http://www.tactilemedical.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails",
      "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfOperations",
      "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Statements of Cash Flows"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Balance Sheets"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Statements of Comprehensive Loss"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Statements of Stockholders' Equity"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r247",
      "r248",
      "r249",
      "r278",
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureStockholdersEquityTables",
      "http://www.tactilemedical.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails",
      "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfOperations",
      "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r11",
      "r12",
      "r116",
      "r123"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "verboseLabel": "Common shares issued for employee stock purchase plan (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r11",
      "r12",
      "r116",
      "r123"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Number of shares of common stock sold"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureNatureOfBusinessAndOperationsDetails",
      "http://www.tactilemedical.com/role/DisclosureStockholdersEquitySeriesBPreferredStockDetails",
      "http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockBasedCompensationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r11",
      "r12",
      "r116",
      "r123",
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised",
        "terseLabel": "Exercise of common stock options and vesting of performance and restricted stock units (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails",
      "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r11",
      "r12",
      "r116",
      "r123"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Common shares issued for employee stock purchase plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r31",
      "r116",
      "r123"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercise of common stock options and vesting of performance and restricted stock units"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r12",
      "r15",
      "r16",
      "r77",
      "r595",
      "r622",
      "r634",
      "r749"
     ],
     "calculation": {
      "http://www.tactilemedical.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balances at the end",
        "periodStartLabel": "Balances at the beginning",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/StatementConsolidatedBalanceSheets",
      "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureNatureOfBusinessAndOperationsDetails",
      "http://www.tactilemedical.com/role/DisclosureStockholdersEquityEmployeeStockPurchasePlanDetails",
      "http://www.tactilemedical.com/role/DisclosureStockholdersEquitySeriesBPreferredStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Subsidiary, Sale of Stock"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureNatureOfBusinessAndOperationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental cash flow disclosure"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplierConcentrationRiskMember": {
     "auth_ref": [
      "r70"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that purchases in the period from one or more significant suppliers is to cost of goods or services, as defined by the entity, such as total cost of sales or services, product line cost of sales or services, segment cost of sales or services. Risk is the materially adverse effects of loss of a material supplier or a supplier of critically needed goods or services.",
        "label": "Vendor"
       }
      }
     },
     "localname": "SupplierConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesMajorVendorsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ToolsDiesAndMoldsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used to cut, shape, and form metal and other materials into goods for sale.",
        "label": "Tooling"
       }
      }
     },
     "localname": "ToolsDiesAndMoldsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosurePropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "auth_ref": [
      "r200",
      "r201",
      "r202",
      "r311",
      "r312",
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for accounts receivable.",
        "label": "Trade and Other Accounts Receivable, Policy [Policy Text Block]",
        "terseLabel": "Accounts Receivable"
       }
      }
     },
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TradeNamesMember": {
     "auth_ref": [
      "r146"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof.",
        "label": "Tradenames"
       }
      }
     },
     "localname": "TradeNamesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureAcquisitionsAllocationOfPurchasePriceDetails",
      "http://www.tactilemedical.com/role/DisclosureGoodwillAndIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r453",
      "r462"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Balance end of the year",
        "periodStartLabel": "Balance beginning of the year"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense": {
     "auth_ref": [
      "r461"
     ],
     "calculation": {
      "http://www.tactilemedical.com/role/DisclosureIncomeTaxesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense",
        "terseLabel": "Unrecognized tax benefit"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r74",
      "r75",
      "r76",
      "r282",
      "r283",
      "r284",
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureCreditAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureCreditAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_VehiclesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment used primarily for road transportation.",
        "label": "Vehicles"
       }
      }
     },
     "localname": "VehiclesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureCommitmentsAndContingenciesLeaseObligationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Domain]"
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureStockholdersEquityStockOptionsAndRestrictedStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r263",
      "r270"
     ],
     "calculation": {
      "http://www.tactilemedical.com/role/DisclosureNetLossIncomePerCommonShareBasicAndDilutedNetLossPerShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted (in shares)",
        "totalLabel": "Weighted-average shares used to compute diluted net loss per share"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureNetLossIncomePerCommonShareBasicAndDilutedNetLossPerShareDetails",
      "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r261",
      "r270"
     ],
     "calculation": {
      "http://www.tactilemedical.com/role/DisclosureNetLossIncomePerCommonShareBasicAndDilutedNetLossPerShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Basic (in shares)",
        "verboseLabel": "Weighted-average shares outstanding"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tactilemedical.com/role/DisclosureNetLossIncomePerCommonShareBasicAndDilutedNetLossPerShareDetails",
      "http://www.tactilemedical.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 7
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=77885760&loc=SL35686385-199418",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=126907644&loc=d3e11281-110244",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=126907703&loc=d3e12524-110249",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "((c)(2))",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=126907703&loc=d3e12565-110249",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "((c)(3))",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=126907703&loc=d3e12565-110249",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=126907703&loc=d3e12565-110249",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=126907703&loc=d3e12565-110249",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1),(c)(5)",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=126907703&loc=d3e12565-110249",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(5)",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=126907703&loc=d3e12565-110249",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=126907703&loc=d3e12565-110249",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "460",
   "URI": "https://asc.fasb.org/topic&trid=2155896",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org/topic&trid=2208564",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123586518&loc=d3e1043-128460",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5263-128473",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5333-128473",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6578-128477",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6613-128477",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966325&loc=d3e6819-128478",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "b",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966325&loc=d3e6819-128478",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(20))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "(c)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(11))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "205",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=118262037&loc=d3e9915-115836",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-05(4))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=120401414&loc=d3e604008-122996",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=120401555&loc=SL114874367-224272",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=120401555&loc=SL114874367-224272",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(24))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5212-111524",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5093-111524",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3151-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "https://asc.fasb.org/extlink&oid=126900757&loc=d3e543-108305",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "270",
   "URI": "https://asc.fasb.org/extlink&oid=126900988&loc=SL77927221-108306",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(25))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e4975-111524",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=SL6953401-111524",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "https://asc.fasb.org/topic&trid=2126998",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=126905575&loc=SL51790836-203054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/subtopic&trid=2144439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(13))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868656-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130558-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130561-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130564-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130569-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130550-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "https://asc.fasb.org/topic&trid=49130388",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(26))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(a)",
   "Topic": "720",
   "URI": "https://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(b)",
   "Topic": "720",
   "URI": "https://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(3)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e7008-128479",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918631-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123420820&loc=SL77919306-209978",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL77919372-209981",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL77919372-209981",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "330",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r562": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "217",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126976462&loc=d3e36027-109320",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r598": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r599": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r600": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r601": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r602": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r603": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r604": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r605": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r606": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/subtopic&trid=2196772",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "705",
   "URI": "https://asc.fasb.org/topic&trid=2122478",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(10)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(8)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(9)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(8)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r668": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r669": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r683": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r684": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r685": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r686": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r687": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r688": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r689": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(j)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r690": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r691": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r692": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r693": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r694": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r695": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r696": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r697": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r698": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r699": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(23))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r700": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r701": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r702": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r703": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r704": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r705": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r706": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r707": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r708": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2919-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r709": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r710": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r711": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r712": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r713": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r714": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r715": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r716": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r717": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r718": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r719": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r720": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r721": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r722": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r723": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r724": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r725": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r726": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r727": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r728": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r729": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r730": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r731": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r732": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r733": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r734": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r735": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r736": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r737": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r738": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r739": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r740": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r741": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r742": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r743": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r744": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r745": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(3)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r746": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6911878&loc=d3e8732-128492",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r747": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=124256753&loc=SL5864739-113975",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r748": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r749": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r750": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r751": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r752": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r753": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r754": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r755": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r756": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r757": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r758": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r759": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r760": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r761": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r762": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r763": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r764": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26626-111562",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(24))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "https://asc.fasb.org/topic&trid=2144416",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2420-110228",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "https://asc.fasb.org/topic&trid=2155823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>97
<FILENAME>0001558370-23-001580-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001558370-23-001580-xbrl.zip
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M^Z)OO$M!5_&QXL!J;QT2Y&Z;A;D90#LDS/(0/A I/J54DKD/-E.[?@KG$?F
M2'Z,BZ4;02Y  .VPRQI/R/,L%/QN,^>R5S1>;)R=V+*TL!X;20.*D5SJMN_$
MQ@?1>VPCF@>&()/[5@2W?(_MHAQVD<N2'2UBQ]-K].K=N:X/FD TDW[1\C6C
MQCX0+HE>:,G:97"<#E9CUBKWYAT1 [N;O$YY(?&L>OO ?RD=R-V*[';(CVR:
MY;N-GMX2L(C,>DEM#$ ;9WVV"'$=%%Z/S+:(9O+ T>O_EN/Z!$U\8LQU%TW
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MY-?MMRV4P*[ZV<+410@A6RBHI9X52 S[9;#M"LOA8%:.[/S*ZG%>ADB^.91
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MX9?/&ZR[I1^S7\K?Y5250+V]O?T0LX-T0(\*'KMO\(.+9Y]37*O["G3#$N'
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M,$&K/( LJ1&=#RB'_- ABQ0^A<KL5)2300HV1@1%HC-3ISWVJAY?FZA'IVP
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M\CH@SLBZ E%@L1WJ$U.RD;?<D$JE(BH,(51$6QPB$)8'B>LFLR1@.]CT+,"
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M"]AV.-*F@5.ZNHF+@US6!'I:CB82(;(KF$<G0,LG1.X1_Q5;15D(3IXZ(A'
M 38'5EP<JMGO%H([50U#OF'?6H=J=9Q3U5(E,937 3F^I/)4 .K<WE>A]CYA
M($>3#;.8S\\R9%0=PH*DI70KVZ 1/,C6P@=ZO*%?."](])2FO J$@:4M.CU(
MMAW9RR2*Q?R)9J[LGZJN[&6C R?T!JMFK7FS']TI\I( C2;"E)$R_[9^]0^=
MGUXPU9DR?Y^R_J.GK/\*([RV7LKZKRV$S.Y3UL-)62^<M)2>3ZV:<#R@=>9I
M(ZA Y:CTP6G5!&)D-M!6+?G!\9UV*C^0ZT_W,NUKY3(0\XI*J5VS4@K"F=Y
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MR?Q\JXBKUZMJ+[+>!!H_MEZ]>&UA=+WB165+KR:;F^BE,MRR1Y(C=<HWW<K
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M8C4O/Q TYPJM?C/]"J^I):4^3F AX7=.G%!R?!2-)@R/:8CXL3)$_&"P[F.
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MT62+\^P8)H?I/,].8_/PK2I$0%7+8I" 'J"2&T.V &YCH$"*9T0W @YS2J3
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M00KA)HH2Y%TFQ ]?LN<G,S#WZ"W]26Q<TJL,8;9M2?'+=B@]^)#$G=*6T?Q
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MJW<74<(1B2E[UTF6:'T*F\TNK!!K;95%8_FDU34FV1J(S]%OE+-Q)74; 'H
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M+']J57&JC8-([-FOVE29 %EI6#SSFQ\$F27*"5_\YP!E/^FJAK0)$+D[6U,
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M7CZ]GOWLN-\O L>?M7-Z$K39KUX M._*V0-"*P19B.HJA+"Y?G6A/]MK<\Z
M4(.K=Y>>[]=TC=B6Z3\3)_ G/LL=M[8+TEEM'"6UK6_&_?2K. "ML^8L Z%1
MRY1EE*@LD]FBX5HC:;!?'0%HN97P9LNVKVD<[-#[*XGB="?58,]:;:I?/>G/
MGMN,*X T9(/4B6#17#_L.$N3P3QD;DOZQ1-FAS8_3(MGQJ1HC(/@.LM')-"F
M[KNUNA4V",#KGA. M$UO[ZLL#2&"KJ^!HY' M(?]ASAU*F$9YBY1]O\QBI*
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M+A^S,D@FL=K%K/@51@7_=,O^U&.;?BUI&M&H9APH:72.#\0-@E,&VEG8(YB
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M6-3PRY@10_R!(^"^N3B*?VAYS52?QU!2AHSZ *,KR6V<TF*]N<@I.Y-:2#Z
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M@:XPFR1[PS&T<[:]CQ[9 .=?8U4/O@$,4I*^C-%>3GX78/D4_/'HX[4%8 @
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M H@H>;_P,_FCY*[?X]78Y#%;U#?HG\%CB;;(BBP. .M-T[#K@3[S*S&%C]3
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MBP!-.@0*J7$04H^.$:"9=*Q,7]"1PQUCKV0G"]A"[$ UF>?Y>( >!X8UV84
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MK>I6XC&KLC1K.6GQUSPK5&N.&0VIR):E.+T*6P:<Y<MK63$T?B%27X-![J5
MK!^YP)Z&FQA2E\&I$C%&7N"RBC>#/V$>@,J2KPJF>6]5$5F;NSY+0A[<Q3N)
MK+Q-MZ+BQWVX ZNJEM9Q2BB')H$ A^([4,#K'Y0=(0JR"W)^Q:UT\4#!M^OI
MH^;%8=E>$4&15"01WMO-*?I53Q%.Z)N$[HG24#2ZI\4^@1?FD#CP:Y;_#E4;
M@EW,=A;GT7_NBQ)LPD;V260]\%M'3(?2BTV@Z8=/F\RXRL/E%2E>XH-[JJ+K
MJD2RR)L@34)!FP0-<617-N-TC!U;-4,U==*0)T"?5 .0:@32#N&!HYMO8GY5
M?OM9>YP.^*^WBW7N5';%,YD@D:GZIT\@T2Z)[1(NW>AYX/6F3(#2W;D0\\//
MN7,\/GR_4+)M@*#8?P(O/-A9B><H"N-^.G0*;M:#_J&HD^5@^R8NBAE74/FH
MGSHA2Z]#]H@S3)S$%3;//.MY><S(U5CX%6F)>^ $9YB+1O FB36KOSITBZC_
M62<X8E057#ZSNMZN]S8.GN(D'M54.8J23S%6*Z'-H58M&4\BKA8\JC6Z0XH?
MXBIB_?/<BC3T3F+0PI%>I9%[)':*\$V:6%(#K@A-(]C?/ 4,<AQSFE'*AS+(
M2SPYG^ASG*:G%G5B6'T>(4_\<&B]+U7>TQ+'@XVE2A#M^YDN@A\;1#E7TDU@
MM=7+-GS[1GH:TXWG>1BJLY12LF,#3,)03^R_W39DEN+(O-?HR_BRS>J(=T^3
MH*01E%@UU3^R(>#-ILH@HF$OI<#V80NE9<URY]1-!ZF(\#K!2!=O1TO)H^)0
MZ9?)$\KDF'%1O=GN]HR=FY2)!:5;@H.DO)P3I@<+K%XHY3(K1_-CL=7Q9EAR
M8X'*%E>!"V\W>;_=H"!!R8,K4$H>0'U;?)VDEBS!%3ZI"9"*@@<+L9-H-Y)/
MB/:@P/9&S]0ZV9F,'YF5MN+J$BY---#S,.T8/.IN&K\U\SPR]Q-F2) D57(]
MGG$6GZG6ZL3OB.;497!D)_ CC@&T(X^^,O02/V4V%Z0I&I55P]_)TK;^FF71
M6YPDY]LL+^-_B,8V=;N;Q^ K&WB7%71XVG+$1=@TN@K6;!MM$7$VCF[<*?OA
MM7WPGBN")"Y(1'EF(VP>(5FA#+Z2745OX9WBD6+6Z#S%H"%0=:,CC 1A-$A-
M!&&[>*1\/:DZS<*Z7PQE?;J&>UQZ"RD1;.O+6 9E$L[MX^%3\)]9?I&P4XCF
M=:H3!9PU;H*0W570 7WQ==*9MY%J"@IGG 1I:52K*Z0#<#*$T\%\\:H1M17T
M<[#5E\UVIN*=RNJ$M51;&0F?5%?-GZ/ZKGK*"\1PG]A>[(LRV]*<1QW96@#-
M POMPUHM!HYN6@C1U4,-^.(Z9^1EI%\U!LF[*"C*<TE?:9+M:/1(PY<T2[+G
MPWW\_%+J%<B(A:-$EL)T%<F LK@R6?$S4J@&BY0-&HHZ/>9!1,$EZO5G#(:C
M,"IVNQHRA%E<)>0,R&Z4(IH"F&\[*76DRH3DW3Y)$=/28_BT"U)'ETR;'H:)
M$\,]0AJ2<&GB5IJ@DN9<A'#9C]=!G)._!<G^1#=&IJC?)/'XDV>D&D%]'OD[
MTZNO8;*'_+XZI*&0U189JVJ0BVC]\D$VF AUA.S9DA04&KD CD_>-11(3>)[
M',]PI'P1W6B]!*2@5X(^M['$QG%LP'&\GLQQ6+3%/4I^435A+/0[3F7T19$W
M$5\*NMDGM_%&U1;1#M6W#<58++MM18OGT>9BR)3;%F-%!#X! K[M-(RB715E
MO.5N02/%,K?#HA)$I-E7_$KA2$FC<^9C@F=JM*WC2"+=0<\P#;UKZR/H+7_3
M?32S\HI6D-)1&7&B.B?4A$E%&=^L3S ;C9!!)60POHSSI?-G<9=GUU" MWJ-
MIY@E*TQONG^JA#+T_QRB^= !5,Z390]0ADLX<OTX%#<?VETLL0W-Y<RCFPP[
M@8O"JK?JFET.^/Z9CU1 6R/J(7ME2A+.G T*TL&JJKKO;F5'HJ6.><<*"H*\
M2T "=MP#6)QK2E#4M!2IE_=Q\;NNR;T*&.ER4LMZ[UY2"KG\E:2&C?%M9!>8
M /3\G>X-W5O%W7QU*RI+#%(!+=^O5<UJW:AU#+%HAU;5\.I;Z(5;]<)5UGK3
M8U/9JE<#N_RG-S)>:X 2<%%%,'"AT8?YN_/>I,4^A]?P%]EV%Z30"5/=P44#
MC)!#;&2]21I60N)D"1O8T75MR5+^5 R>C86U5O#44O8/#" N#PNG KO*PN$9
MTPSNA%JL[06M ?9 B]6]E960?FBQ0Z_B&V7?H4:IR[<,5Y%-XM2*_#AF%&?7
M_O'PR(;3Y&YK,3S9OX^%T&[B6W#\G?R0%YOM/&!@9EF/CR-L,&U&M1;#$R4:
M"Z$_"3;@^$HTY,5>B7Q(=!Z)8Y7LK,3"37@V""-+>E:@H"4^:_E1'S/&.N:'
M<_IX^$C3\&4;Y+^[+7,#-$_<E$(<PX+7P\%W6%*&;+Q6@^;5^M=PY;8(CM!\
M43&Y.'H5Z^-XH&(RAAQ5#'-UK,KJ%Z(:-<1OM<NB&APK7T//?C\70PZ+D&>A
M8T220R' 20N/HBH/04+K<KV?J;R7L@$61TFTC'<U1 JXN'IHN)#$+?!NP$>^
M\-;0&E&'X,F:-!)!NQHUT/CKT( 5J^NZVQ/W1[2XI)X@QW8;BPX'O%5H4YXV
MC*<]85($;4>,?=Z#&:XW@U!<+*]OXH2.$-B=(%X3ZG7 Q0G^.C.H"P>KV]"G
MG"JOHU?3)6%->.&;CN-%'CN(%1%$R'I#&C*DH8-0^N1X*3_WOQD;S8^E\X[F
M\ _!,U7U5=6C>+)\2L30+J =>/PE=,2,E8VT6#@YE!/$$,F3NZHN6$'>Q=RU
M55AH"6L3)&DAJD9_+0&D9XYL.\[('MB^W5#D4@Z*]811S7;_P>(8#N%YHHH)
MR35H!<K?(9^ZK*35TSMGWB=N:^=397C_4+S0"!X&JDYV*F!D=9:R+E7H'B2>
M2DO8T"EU#<Y?U-8O;;$>U3J(T/ -#V21U1M:Z-VD=WD64F6NO@H86;VEK$O5
MNP>)I]X2-G3J#>#0^*-"\$._;62 4TB60K\FZ$$L A70IO,L3L]V A,G@ALR
MH]LG=+UA_,-A]G#'^"[/T^CJ[_MX!X=J77J]/3I2G-=1O%[HUQ)W^6BP$V/C
M'7*%Q XJ@,95L4&</V/?01F5XAASQ:PP<5300:BN]EF@+:YXUCRYZ=P*/:],
M;4>F_#(K3,\43Y]O9H'FC^(9\\^L% _SMKUA1GMY.H+"42D%LUWU&8 LKBK2
M\<=5-FHHG.*&6984E^P8SU3Y4Y9$AAJ'*FBD4H=ZYGL5#^6@RQ<^U/$AB85F
MC,@S3MVB?9[&Y3ZGC-/K^"O\2:\<.@2D&D5&$7J5B930R]<C,K RCEG4"'Q5
MJ5%0].:6!@5] =5FS#=_N=FRH^4KY5?C6BVR1\?1*5?QNAIFB[NXOKDQ-M*^
M!@-ZMC4H,^8[7-)MIM^=J,$0\A<T[#9Y"A(8G'P$)2.2]GQQ0;8<@A0E<S0%
M?T 9,0*$UA063BVPYQX@TZ*^'J6HNZX+SLF>M\KDX;IG-BF&^O9:%+0;=J,8
M@QMV)3S&#;N!&=D->X,"H=]=A>17H.#6D.AH@^A9F& DDE64X!8M =*6)=>
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M)1B=?F]A0=*[0Z7U-%@>+XWT?#IH6C([Y3YDU8\U5G2AC&@1!@GY=QKDY%/
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M:;TG94;*S7B39&_^O$1JO$]'I,_T:_GX1I-7^BE+RQ?]>[XIY/S)^G(1WY0
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MV&R*IPY^QRF%*F7"5-@T3C=9OA5G&G8<**O7K65&7CDYPO1GX6JE=G((*,+
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MNOEHFG%Q5BIQ=*\>U/!(2F02H*="*N#E%4C/R;C>/]>41G<0;WFZ#&OO=V2
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M:4BH,M!B[$#2,ED!^'V3'HC'0OV9-WE!?)H?ZZ#F"GO5%?@&"PAV3 8^T%G
M?5Y4^%_4M?G)"AJ*UH4P#$ZH@_?#^YGW;#_#8S'=S<@W,P_<9@;4PJ!VK'Z%
MVT4G#%O39AMJW_-UH>EQL#<7^I3]N;G08O.Z<:&[O,_(A18IYC'VPS(J$CMH
M^5=JZ8P4F? 4^%$R.#.#11_=BF[-HV.C3KHK]KZ\=+?F[;KI;GA[]--=*NC6
M4=_40H3FJ7LUN;OEIY'(WPH4B,U;2]A9A!#S#9[H3_ AOXH*+ QYT0UQ)4K=
MX\ER#ZL*B= &[\E/R3FRR&KS:7I8+DP9HED#YA+T ^QFI.X-XY8LJ'( $6&
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M9$+[!DY[=I^_Q5KSQN,8UQV#@&I[!ES_2[3;_^=E,U3"V'S=XO?HE-,':.-
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MA?1-9>*D4LPA2$](5WSS9Y6R4JD+<(-F&V\MJ[%KOBRVVH$%,DL6I6LD27:
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M<=,9AL6'6%J[53_KP3OE%52Y4)FFY]T[C# T7[;;,R6AV&-R8^J)')C"("I
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M!2RMA3K#Y4YS\17;2#O):U=1P<9,W&"1JJV]GTSB541; RF#4_I]1:O*> W
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MD3*AY]NN$_W^H3_0D?0=?6#\!4F1-TME#(2/J?DJ7&R1.-#J8+C5OEP;8U/
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MA8Y3.+7A.G^S@F3))L=J+)<P4?^<BMPYIW+(I5;UR>M<WW71AH:L_4JAX0#
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M=&'E+4V+E@9#-=DZ4/K02M6DE=FZ23SAJC,81C27-L/^T@SL54PP!8TDZ>N
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M(RLH--$.I!G<)V"%8(&9B/J]^>%QN0K\SS1L%!5JWNH#!KZ5"HCN.U)\,>[
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M#XHF,J^KNF ;G?E'49(<\'E(L1HH#X[S[J>"1NC6^TLUDEV?QY0 (12$>3<
MZI9(5:$7$;S7X:$UQ7XW@",BD/(1@BWO(&._&XHE&XV=*Q,N*<T;W/+=8PT
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M+\^N+WO^'M2$(=-8\9+,TX:-'CDK=EE]&K9J.Q\\C!2U.S(>=2O.,]:_U64
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M=HWM*1<5*$WI(Q+A *@M2'>_7+G^&J02Y\DB\/5S4^(1&SR03Z;BE+X-T4G
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M-=9 (8%-@171>^8'2^PRD5Y14$$EE!XJI"+B#F2;LG'%4;,GJ??T,8$R?=R
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M23*CBU*I$8.L('4EM%GT[[T3Z&S;Y+[]3J!UJ[;H:&+? $UD\K8?K]B6C&Y
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M H^!;%&L-CHU/#4/;>2R0^'VMKXW2+Q8[B8,^X)?A0(D0M8,/[BC!+DN$//
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M@3GJA?=(7'R:"F5HVA)GQ561@11T^")3XE%#KR95)WF,[*=F.<49Y2H^_4%
MQO$H3F$X@<6O')7%A^8#]Q!9W2;A7)V/MROL2,U^>*DTOU'<]3L(#$.0HCS@
MBQV/O*D*O9LHI$\"CR,'1*>..$*V_H^+&WOD+M .$/?,>U<0J8DK D;/-*0V
MSS)BH]W\J#:1./'IZ>X_EY_O*C:TMW75MEZF7TT/KS95N3/0":.CY'4E6:6X
M#WNSB40T@5_0<SUQK^\[)N0Y&XA6!/#D7V[$ P88(4:M\NE_1N <9_AH"HK
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MH*)(&VG 1+-]UYBO%>#06Z$27($I#Q],WI9Q4,F#Q&G#V7PID6=!K6&U)?K
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MQ =5Q;;D]>WC8W]YAUHDJ(M&#NK2FK]UGM<KX%N=A82&'I13HVN__PP*KE=
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M9TCA"JYG,9)/H%O,BVL^_^X!]$6NBP:^@($4I/U=9H!=)UJZ:X/^M&61IS-
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MB^%E*>C -:E0O/Y7I-+?D$;.LG9LY!\O+WY]XS)0&K60K6>Y<%U3.1Q2<'Q
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M5WKL?F4?;U\/%A&I!&5BQP,;$9<,&RI$UNW@M%6#>CV(U3T+4146;3L9]0U
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M09#2%64"TUM;+2*BM>6$++BE]M1X&D"-HH5\BZH8M47>X=&/P+,4^142P1@
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M*KDVMKL5GM5IJC(-RM3%0;^#-O>Z6YA?.)&%AO%@50%U51A:EX.Q75I:E!;
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M,I,/FTI+-3=@M6QXS':@+893.5[]Z\FZ>7.HA;;-8X9%^CH]IF:_N\X,L[+
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M>[S/YNZSN5^>S0T6:'Q^-)P<R[ ?3BO$#RT7=\$)TT5:\0T==HNRS9A$VWQ
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M,5-N#^$>E#)C)3',0TO'Q> T0<)O9$,'H]-JB,GI,5B.,FC7#+$#FP9Q=I(
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MS__J\;$#WQ/W3ZS-K)W?N9$ BW[UQ)8[-[WE'[57A9'';8^&*>RO%0"76(9
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MK:S&2KI)@+K#BX+SG=#Y.+#?"753[-5#;*O33/+U:FICQ&+.DP0WGO)6;.B
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MJ"<@12B8:\E;]>M8Y,,S?(D7\"6]Q-F>9GLB>])^8,@_AS-?IAAC^F!IV?7
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M36/E2DQ:X^0_]&IB_W#EV -F"_S*.^!W@-JZ]0Q6MA4;VXVE!M/%X8 T$N*
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M CAB?,_T&_Z&Z!ZV0'/EHVW%@S_K\"]"#NUOZ1*0;A".%K!33H<1?5S7Q1K
M=!6?:'2O4Z2S]&83AO#\/1)X*T@,3JRK_WY<GL9U*F%*O1EYR$&2G:.ZN%5U
MSN[82Z;S@Q[=OQ.4'45&$"HM.0GB-IW4QOCE^@BL[4JW+.L;_U%YT9&O(X"
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MS<5.8L+ HW9=\"A*+Z"/8<^)6]P_)PIA$!5EPT<ORXSA<6%<6,:YQOY@#'"
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M*M&36SX8\8;7- ?4NKQ9<;J]AKAFO3.5+*LG*H(_.CH<O3'+D,8LA> 4-<G
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MKVU8@]!5-N"55T"*36A\TK/YT#PN3P6478VKT65PCE ^SN,,5S4QW)CQ!>^
M/^*LP$?I7/T4I3B0O,))2"?;E855UPB62Z5;6PD:T(XE]GY##A>*>RA/1[EA
MLPLGRJ+)L'3K;P-%D7!S6C8MFKO?E,+"<4]]I04YGFPT5QD_29( #9PMY9&$
MT1\_ 1UIW.K2PGQRDV//K/5PK7[<^HA4I0@U9*81R^YXA$6$^Q X'KJKTGS+
MGSY[OLSSLW=/GS\[>_<D7[]XMUPM\W>/SLZ=>_YDM=[DCSYF\^V^C;9[8:R
M7"+A)+B]-T3/[]_90\)6(44N[%WN]"Y17RD$MN]C'T?ZDPR>4-+8[JI>!Q3T
M#J<[JB+P32?>-TTRZA^]$BK$?=N2^IT_@N*!0\5?V\*+0\1DD%,_/^0F,'@/
MHDG,EXU"NB^9?KIE5<J"XS+N)\<0/"\O44R]VLK'$&Y3["&ARZ8T\&.G?Y(M
M;B\F(@)Q]G:3XM.I<5C'8-UPN^D.#@^;M,<B'+UK!12 ^<R* 4Q+XUSY+8!B
M<+>G+)= U*@N->_E/S&/@2,DWO&TF3 #NX1=&PZU277"Z%+IDH; C )ZB;TE
M :(HH>.?J4?7RB\;9]79#;4VU0%+X;8EUQCT:[6)Z7U.T<8<):SD]!,E;!E\
MV]N=Z_A$URPVIB2*!D_HY75!],YT?MD^"'_1@G/VU+VZK)C24ARRL@TOJ!$U
M=</*1L-O57];WBSZ>RQ%HI)I_IH4]_"PX?A!P%0?'R3<N+EWBF0$6P>JWK[:
MY$6C(11P6KT\%WZ,KQ7&-_H=O$$JI37ZH-;":>,6K0QL6*M(:4A:2A(H Q^P
MKIM_\;[%!RZTO[YQ(#]UU N(_"?Y>U?=R48R'.HJ9!#MC4*WSF_TG2S/#F]T
M1XG]P!&P;+1 1VE9VI3R6(7*6$QMP>@VW?</>P3IWGR<;\1P/V4'[\#9R'MJ
M <2?SXN*.CD66>N5RM?!J:9,L_)@9@IGB%XR:"MVLS? ^2)@-)V$D\",;OP]
M 4+\[W[C5HR<>WR>41F;?#_8RXDVM_?/]/RY3KWJ'5V6]1*9:T;I.*593Q]Q
MGT8^273N\O&[_]1C<&Q7YN$5.<AGG?[;Q,^_X%\_]NTI^ )7^>EF!X](YXNJ
M_<KEX'=::ABQYUVZ[@8='O\LC^6DER8<XMV\A4#,D[,LH106-B]J'PA(FXX+
M5U%Q8".NI^J'BI:K*V]JN&.[M!QPXUYTQGS@,<:V0G?/@8J/BI_]"BG>)_0%
M/VH<\LG= 6>K9$6&]Y[;;N$>?P0I1*G5XS(SKTO4(.+K\]NV#O#C;WTHY-.G
MB\VFK/_'M5*8"']$MA"QN2E@YXUL#?_YL%J+UR0[HI6T-P$2](/<.IWS%!!.
M@H#J2OGO?$"WD,A!8O;!,\HCQ%5@",GP4W//;+)G]FSNF<T]LP?9,TL\7]C<
MZ((9]^>=QP4$)_Q7<_) _Y7O\BK.(44'=I<K9),8?S#9_?\N+QFLL[;>ZK^]
MC:WK[:FM&&W<YM'9\MFS=_GRJV?OGN3/UN]>K//\W?FCYYL7+S;GJR?/U[\F
M7/O)?:M(YV.W<+2*])8!5DB$/V[IZ(Y/<C\ MP3.4<&QC40<2Y^LQH<Y7;SU
MX;.(\GQ/M11$5OB+\V=?MXMON!RD194+_ZT]@"M^;[T*A TO$\*&'V+Q\74L
M/M(5S[]>F(4\%<D?:TAGSY^_>/'5TZ?OSL^>Y.^>/'K\XEU^]L2]>W'VU7+U
M^/%73UZ\^*BEQ]\"]\\XPI<Y27U@>80ZY;>O0=ZKJDK\<#)UQS5FZCG!F!A7
M!62>CF>U_K0GSJJZ[ WXCWKORHL6)[P< J5\M<^XPN\(?XR:A]4IJ%7/B%15
MA4&":*VX@4GD!P1TTDX]*]4)!"O2*!"22DF@N(OD[XRHJ7ZRJN0TL.^JR^YJ
M)%6HZ-$5N,N:MJL9Q0EY*W<MER7>!.(O.):HH3?UXOFC>.E8A_-F;WX1;4!J
M1 JC7#*GE02."7'.D_.IB_"P'P2P^'*AJM;LH*_HODP)/0")3-*][XNJ<CG*
MA"TJQ?ZL@"(MZE%^73G],W4WJ<1M0:?$@Z>6,TC/$_BA3B%NU3IB3 <2[+S(
M?$D"OOES;+6H*1GD>;)/F)V0)$;/0 0J8S?U3;2?X("YS4YU"1_<-VA-YPTT
MZT:"\WE'Y5G5V;7L*WX[K@MN&.WJ71^KV]ZM<$%?H9<G0C.9U.)4 5-Z2*HF
MTUSF5?&O22IAB[F')5$UI&CY5:!^R91_QOK<SS07B[<E$HPF]P:>A2<**E=2
M?9U6S@G!G2WQDNZGR%C%%D1$ ^-2C5LU/K\/14V_8"A+DA C6PG!/H.=2)M#
M"XU2VV.?5E=<O(W*@^J1MN%,'+Y42KE:=Z=?([D9ZKT4I7__8?6OZ&A8R=%@
M?BN"_2D"(YS"=4[8 EN799R #,^(9I&"-61ZT"\HRUS^\6/O$]D4Q$R<GH8V
M9$?_@<W[CU?%VG^#IFJ>/SI[_/6G+RY\0&VDYD.<Z'C^*$\@?PZ'8;\+,FK#
M4R2.^/K-_E)FVK?>"9=NT')*-D3K0W&A[PW(%*8(8%B<WW0E!'U9)IV\#=?P
MM1?#W1UHLP%+H;>4B+O1263179 ,KF6T07\@_#JSC-,)04,-/!;G'Q<N4%="
M_55T%M'%Z:;%P_KT4[R8[JKP.SJLAZE3'7K0^3)B@NV4%[;-KU5-*SZ@/ZM7
M[X-B&N%4LA0(%;A@%5HD3V:]X5K()?T=<S\MXZ':GL:S*[D&$.W:C?7W3IY?
M!">OBAV+DZFK#S\'JH=BS?1'?K/NO]SI?Z'Z>2W\4Y'_@.4%G6O"3%+ 36@]
M\M$C@5JE_I]^AZ@S_+I=DDZ9MR"M, E^""D!CO,?W+;VAO(37- ;P4<2&R(<
M3BO0_0T*:TBUR5.UJRL?S<D(BH80 XA9.!$!F(R-74)Q^0-CT=2E^Y@'^BV[
M_4/HVY$B_,Z<VC>T34DHXUM M?9L=-]5HIZGSW0LR_DC33&S!VD)Y;>.5W5R
MU4*O*(QDNDM9?7DK0^(FR@X%4)',B_$5#=Z%H_AUWP1GP^<>_= UFZ;?]2O\
M"*ACB=$XT+)00+*S9[:_]3R 2&]B?N (0H1I%)"VV=!.$++LS_Q1CE^OZNOH
M4X5%3%3;N+7.PGXZ+P-X&4LQN')S(FXZM" !_E4F,P "X-7<+H!HX^2NJZ[(
M@_%,)><R;A#J+U8^._=+>;KX4RX PO :-GY3PB<8I#7FD%JA#5 7%$1%;73J
MUIS^D'.!VJF(<H]LP+P>$F$, 4KTMW]\*+OGCOO\84I?W$OG@J*X6>3B;O7E
M[P+3>[#O17X#-7%XA(!@ID,2B1$^/)5PD:3*YZ:H,IO5KV]6(2MEC\XRY7*B
M<457O#K[<H[0$TBW#^4JR8=!@5;D[>EA0_N50RWIGVTVU#^[0T3R.PNO7N5%
ML_@KE33>Z-$94L>?' LC +XE=8]XOIJR7\J6;"AR 2DC3*+/\BJMN*! @C34
MQRXR4M!>:5V.!+K9.W']@5O-2$\NJW!$-S1:T1F8H#"!Y3(8_P,WJ"4Y(-24
MSQ"Y=E2T$O"$ZHQ-4O+%6[DUGP&OM5''4^41D1<>+#X'I0KYUMF+8\(K>8JI
MA=2I<_^'NFGZ70+O8L%RFICV?S'HH?\ZR4AH/7WUY+;M(@Z9&KUG#S#UN!]2
M^_XZT9&/X2UQ+-\]%T%M=DS1/%7:SWU63_D]F;RF'%K7E61#BC6T(73*;H#3
M;&2DOJY,VB&_RWN*X9T)M%-F?2)9'F.(U0688E+.1-%4Y96" R7>AA-RYA<^
M@/EX/F,^9LS'@\1\?/0*-=51I14O(6"(-KZK8BLRTGB1%Y*(T[15LL45'<4:
M$&A_)4X3HMD4>K)=_.$<Y0?,!F(\%(%&4N"+=;_@4UEQ(#9TW 9D%-Q+Y)$M
M#BRX]2$7ER]HL9EO-M*G)'U1KE_'\1 IE02"S3K> %W$OW=JVMRXB?KJN4IJ
M<#VDP$A%Y2 .ML+)3&B^4%0Q-:] U!7T4S(E-\7-M$*CGU-E*IT-EP4QX9CP
M!\>HBF<3&IICU-LG@C5[VG@/YW.CTJU!VL:=U; &2"E=?MG+"R(2%UA6K#U3
MY)B%2IK0QT@2(E= Y!77.<QA-JY@B3!S3/VF><=O&3@=OB<],(L*79.395FO
MWB<NX"SX7G(&.!?HY@:]&>*6]F\G=C^W)"<8QX)ME&,+K+9?:?N]O+6 E&4[
M(A+ G  _)+_!N]OT*%.GT!3M^_!Q";>G?[]OKMT^#E>P'@A2''__ 30!+_41
M4=4/T4A^U;''BT#V8-0W/_W48SSRO3V3["!0^@!M^U,$_.NBJJ&4L4STS-3=
M/[,@D@H/F:&X.+(3X-IOOWW)3MK_1VBJXEL+IK)WF#+N7*RATS\/?HY+U?'J
M\>>S [_/HT)4K\$DA(X%TY-&&6<JUMM;)412U^W^^.67-S<WIZU;G5[6U[_B
MX/B'0O'IU('\H-%K2J; *G=#LS:H8QUZ29&(I!XV)V[<DEX+?(-?B(Z3<:%>
M.?7G$(<*;#3ZNG"95SCMSL]._MM:TL2__W_9T+;"OS['EY6=+O>O>1VX*%D6
M1[^ M[DF#K"^J4!]MV:YRIS+$6]95F=Q_O@/^1?XV/E7?UA_H6GD6];8 D#C
MVY]%4D:$;L]?/'["6(^P0!M,-Q&Q&*&&J&I1M'&9?'Y8,W@E4 "&_@S3 2(Q
M@9\=6-^&J1.<>2QZ]/C8L,_,/"5#YZ!AE.PO^V)E'\GY0\.F%:-.9>A*[]L_
M OKXH.R4-T_ 5!):) (:FD"E1[W@5_T#*[[:-\U9_15-M>-JR]A[E(' 0#&-
M0GRE.JDB'LMO,7$8R1#\D_79\Q?/-N^>GKG-NR=/7CQ]]]RM'KUS2[=\_/BQ
M>W+V:"-(5/[&=]XUG%_\X(_!5TS'\^[QTV>/GIU_;G!5/,?B_.)TP=RW>*"%
M/-'IKXM]OBN;Q6V/1[>\$4XD;N0R]P&S4>0\2*HD"2#F9$[F4'$$F>'*\J;:
MBRA1$<9XA*IH6G?O"!4#-OE@TIZS$B749N!EH2?2*;^+B\A,@7"KE;J_\-.0
M3\%&P,@BDU @UM=19J67I&YTH*G@C4,M[K6JL)HA?]FWH=M-X[6$ XF2@X/U
MY-%G)EUJMK](Y8^?^KL-;U[VG_S@F)M.GGLMG#&ZFK+C\]M7C&\?4_HKORS9
MX(8/O#]"^(P?)5!LJ)J9A#,3C!O6URR?/'NR69TMWSGO6-X]>;Y<OEM^]?C\
MW8MGZZ>/'[U8/7V^>I+XFG=_*=\_?7+V^/&+)Y\='/X'>@\_Z#1M30?ZG\*"
MOTY7^2UG*SQU<>RR'QE.?^LCWKLN\U+"CIJPLWZ#$CK+VTZ]3>#J-BL+E!;9
M0A@$ A5!DXLP:$["$RU7&(XH@R8,,5,RH1\]P;'LZQ]ML.7/(F+.X\MQ =?>
MTX'P39"W^:JIP[\QZ9Q=6"YVNHI*.F&-(Q 7P&- [?*.DL$L7??%INSA->1]
MD>?6WVJ]]\&],'E/>#%PG.Q+X-K!UG!=ZXQY&%0PK'CFE)%WB$FN:CTF$:)?
M_SGW+FV)6VNC>*+&.[3A+-_W+U)>#3("JSL:M-!IJ4G*H:DSW#0.3HLELPS*
M]<)\Y)!XZB+$DD9#1,<>H^OV8([+NW8!GS&]:+^N?/<10O+[NXTI$BL=B4AH
M4O*U^R>!>R/ _S"1U'!![DPBI73>TQQ2#XH[ CK-2KDN<RQB5,+816QE!0\N
M,:O A&0'!XX8'Z(QFI4RC%+]6_E;XDNB$B<=:]X/.*:(QM<<5=PYBYM>?._T
M*,#"X\@ZJQT'."+^\JASO_=NOO#!7#86BE CFE#F\WF:=%493+UU>148=,C[
MA($L*E13CT 2]KKOH%N[JU?PK\JH2J->^HQP%E1@ /-]@2D2;&IFVR:M/+TX
MBZN#BG6\L^?^Y[#_^6+N?\[]S\^M_SE6,QRR+D:1 E63)'[.K8_4BA55KQ(]
MGKHQE(Y,X&H&6650E=A%O2?;74&8B FFE1Z/&;"()([#R'1>E?CV)@8TJQJ
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MGEBMCZ"4I/ J4CJ[?BEZ/\82N+1U+6J=H8<:-F:H0O#H(AO"S;1('.G'P/%
M[^!S 8Z])@4I]KL*@_,[D-RN3!=P.+NE)F\Y#0>EW=-7!=AN'K_XNK69U3 ]
M](G#TF%)^]9M^I(IW1W[B<"I3"_@S@U4$H,\UC\]7?QT591.)'XBLSH>7JQ&
MY'#9&4!>5QIB45*0YU391>.WT:P 2XJ_L.AC^$LA%<#9DLH$&HN#O"8LDF38
M=BZ0SP_(]*D%HIKQ1'?KH\6\"1K&9-'Q*Q1U.U%PSJT,I-S/D%1>[Q>/OG0L
M/1DTQN3O;YR(W0<AMY(51"#1,93Z*RJP*1/Z5UER#6EW#3RL#"P(B9;^MXBM
MJ2))4Y> #_8[\?C^G_[SGWW=?1W43/S)7&P<_R4!?LN> ;]\9Y1&!<%=7-(_
M$P.B=>*8@,/^*Q52>W$80?E)[@Q.P5S\=/%25N? BZ)70',9WA5NG# I.P*;
MNH;AIL%L:"[._VP5:--Y(5G[Q*J*R=_3@6E^F5IF\L-K+H.P@%0O0W?&N##G
M .2GO]I-7H@\1:*L!E<A^6NY/_&1$D#=6 HV!++N/0.P.4#%[QFG[Q;6OQ\5
M6A^[\X?B"0^/-6(T3M\8Y4 ZH]3&.H:F1<-#A,4"EPQ.U"T9&<YEIVE^I1M4
MKZ9G)/0)W;Z6;)6&T79U 4?)5Y!9(EC?G9Y!TA/Q>6YM;M_Z).OW@X</[H*<
M"RYIO%M+T('@*[8NQ_D.-V\0+!:X%,04X_G0$+TS48LBU!J4_Z<+L+0_3%"@
M"YN+![OG.7]0$"56-T2P@&0O26?A=HD(#A7]RYI%W":;TH_GIO3<E/[T(F[Z
MOK3Q_.2V).R#\JX?O?=\^?I_OOOFY/S% KFN _08@U17^3H+XI^V'H5 (;.Y
MY_0<^CU%A91]X#<^B.,^_N._;^C_TA7%^OR]HCCR;4<U1,9G4XV3C]TR9/YQ
MQL]&JA18+9VK%A5&RSBTMX*_W=0[H*.4OMKBJVF>3^E+T<D0NJKK8@Z/*K]R
MOL? -R0T=,Z94:]-OK+E"TYBVR3T8^6M=2_E/1)'66L6 JV VCO UB0'Z$.,
M2]U&[XPJS_R)@U7O4^:GT#7@26,L1-OYI1-E%1\V0%PE6V!G!I9<TRA2*=0(
MLJ=9> J#6.:G8K0\0@W7R.B>,F)H@C+U;BB/^X5%\"A7$TDXXA2];,7&;5E/
M1-(BD6J3D (6P%(M@8T:5[BJ;RCB3R]%T569MV XN'+TW*P(9HOMQ+342K1'
M,7M94DL,UN>C"?\_DF;B[R03XLOX4.]2URVLF;\$I@MRBH90)0V/2%(9?*T1
M$./:1S1A=-J'884/I,C.;T@(Q]^R*Z[%@+8\0PW+1E4;BR 7;">>'^;$Q7X)
M=5D.;50%#(*Y^["THB&O4WM:<AN\L!$=A_0T$"Y_HC3C?!SEO.(13EG^GSM1
M3N;*TJ316QZ+X?N^[1W3RINAZ@\5GDOI&VR!'N/T_+=&\C.E!&$YRK"1V.%Q
MFH(2'";L5Z28<HOB#GG:OI'1W-9_$2>E;@=V;ZEM3*QEM/KVX*?4E.)LVDC@
MM+ C_ZD,NQY*.E#!12?D45$J*:,W*9L-77ENDU%WR=MK7_8MDB>>'J9LA$^L
M.*:,:XGTM^JGL1UYLQ>SXK@KSC71C84^MIDN #0#[QW[A-3-H^><#E&0:?E$
M?QT*ZS9,L:PF@\-3*$/B%HWD+]&;,;U+N.O&R40WTW+0>#)-E=.)"AC"BMHG
M:TTQF5WH-YQ/OG7WFRK#GU6^*ZJ/<520A2?.:()<HIODA>LR'K?N7=VIG!5O
M!FGO3KU,T]/P2]JW<NJU<;?R5@3QQ0=0(MT_%/U,NB9_/WU["@<@U"Q$Y8ZR
M(]X6WJG.]9FF--;E%8FTU;WWC,PTA<U"54>*6<Z?*7U(KZ4&IGAA<I2(): R
M36=7DT8:T3>#PZQRD8VMJ<G-91N+NHFLB@\3<6.6M_WEBWJZ,+ON9VH/)*1?
M\D/90%Q.BF0[:))TPF3C7T$-&B+J#=QV&]3"E;/"M,.$Q"*5\&[]:_,A?.B;
M4JNCX;KVH1] 1%IHI>DNID)=7L.A8L7S #?AG@?1$069Q-/%]W7C\ I46E"O
MB-ZS_#8 $?R@\H_,/64GT]+'+<'LP=02:7MU\+%"":L&EAS9N6(C,6I!*RG/
M^)50T0Y$&J1@:6690[TNO0/>6?Y+J'E2!'97W_<9(09?1JU,PX."2JL+U"9)
M%!J[!YW?DYM-5,B,="4VN<JB(O3$^DVWT&^O6#P4;S4N59A5)&.DBCV< ?X7
M,8N&=,#ED%(1,R1*?5M6?6_7O+!RNPO ,RYKHN_A#@\K)TED)W%V*&HO"\14
M#3=["(%THG_!/Y=?-LY)X*[47.07Y.WB:).+0JH<_<3+NEXG1J$?:'QBKJ_8
M-./Y@T),E#2 C/61W[<KH' +)=ZS<68D^ZHK=@0USR)@TH#:!-119G%1*>DS
M?A.ZE-(, '#()_(,.AL8_#9_3RO?\943]C*,,91[PUSF#Y8A")FK0S6G[U77
M%&Z82,E:#[^'^TI6L>^*D@1-_=?EKM(U_)$\<\@8F#XJ4D%ERC=@?EN9#&41
ML^3,4%XETI['FY;[I*M)T2LQ^=/%6QK*X-LBQJ#(ST'3#%K)8B\QR9Y4;_A&
M\Z:!241H?4K$%!.K</I%6^"3A3=K.VQ3?S)(*GL);(.62VHY4U4U58S.>==I
M:#+A8Z5BF;J:X?,3C9UI7YDOJRRUV")9C7'8;/XW>2JBG2#EQB<>,54MYH;6
M9$/KR=S0FAM:G[ZA=:_H40("">=X>TOGQ3N,.BE;DN>BS]LPD-U, WKE0GA9
M1>]GVH.->7/I( "#!H7_Y-&V\%KT]PRSLZ<C8:'T[+QQ>J1.'U29((W:F+FE
M5U/H]@#>)RA"[O:@8!?3C%@<W-06R$!0<=*K#E==%\2B<D6E,Y/VC,"$-C61
MY]OX )[1Q0,>8'Q6#[R8QB2TD2GTX '$S!%M(_5?#4N2Z$]IZ'QPV\8"H8:^
M;CT*7TUY]A#7ZH_V@ S0[%:/2[J@-5XV&"DR2I,ECX=E%AF+T^+L2AAV UMU
M"*:;\6W#;C0*HG,W+>313$X*(PE6. !499$[.DNM<ZI./=Z-LM?5/!%1]$TU
M,M-?WE/X?(I]WXF#&NJ!4I+;=BE;_*'N_/W6YJ$5Y'Y( O:&FQ6-B[R2[-PW
M#A P_X>>1\&HK;'^8):I[#::J3 5I9=+OI#^)J$<?Q;GT(R>Q[^ #6]M@I$Q
MXZ6TT4MJ>=YRJP=OTQR*@SO"#5-J61;OL:DHJ:6N,XHG*$(15+:$,=*083PH
M)Y^A'=/I3TP]^ ?%\PT:80JIP(BNU$>GC5V9_0N[*R3E&Z,[!^CE,E_6S2),
MPH1<$SBZ7N"A:<I!9 (1B3>\&USJ1FN23@!]M-:IEJ4,6,&1,K9P-+!&0W=8
M;AD;B@-#]!NXL!:@A:>WD"?.C25(M4+._3CA&6JU4HWUGW/5=='47"4:9G$Q
M%^<5HX<=T*(S5GIB4;(4$W)@S;-CH<>$MSI6D'LP(-[7$R:"+; I>^@ =*.X
M*"F)#-N1],(=(RU0,::!9E7*,"2D F$7$Y4WHT49^:(6P&86MIEP(J7 74]/
MN+&S-:V.T53>3+DV&]I=#"V8DB!TN.M DZ8"*MRXO*/",8XS%4Y($EG_CRYO
MX/!("2,@?4RM&%>=37(VR;NR *(91OH&WI>M7*)T%*>QC-4*/S@!%\+09Q=+
M0*US[VW9/$I3QZ%HP36BXW:-[PUFH2)OE$P 4MPSXH;1O!N1@/FVK4'I3>-3
M*WJ6>4O,6^*V+1'*DKO&^1B>DLY-4=+_>NN"[%1'?UB[C:O62F;AH%"UD@%:
MGHG.BS3QY+\?) "Q>0LH^F4N&*:V&_;SF54#.(KXP=F>9WL^9L]PCI$6QW"]
M"O!?!=],A73D9..>4%$S)ZEXW   HFNAF#]K:ZY3)BR_/!OP;,!W<\C35:,!
MHPR-9J!VU,;H!4%"&+$P!9/9]&;3NYOI#?T>4V?DS&:RHGJB=[0SO>EL4G<J
M @S-B2 L&D9:1AY2\*QRR6RX+/5[X#0ENK%818_TD[P"_N&WX'\2/%8<)6I=
MTNN;+)K? ;DZ(Z6FD5)?S4BI&2GUF2&E[@\D^"DV*N-\/_]YT(BZQ!!6%Q";
M..0)DDP0\-!\(L0!$PR9KM=5T79UPPCF>M"CMQ#C2YI#:4P%3AF)UK65"KW*
MF^UHLN%!H1-^-#PU:T>-UR"E6K0Z@&IZKTS[.> ]RY@BJNFR2,4[2>>8='$#
M9C?0;<7:.(X.':2)ZK"J':4BFWEW<H77FHAM?F3QJ W-R3"#[_H?/HBI5H0
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MV#DPDU4Y(S^V+)KH_WO%#F$5^EW8EGP%LJ,(FC.-^^"./BL[_GQ<!/5U\E7
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M[D3"G[9OKEWA7[N/@&RSLW& B@FCP]KEW14U'_&[:)46U3_Z)G+8E)M>\>E
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M(0KK;42J,":NU. 8N^&H]643'RT[MT($;3S #;@(KF>@%K]RR$,<0YGQ4C+
ME8T1Z*(\'C"0S[>U(-!'T*;M)[(\.=+)>3&"\\A$:V/C\VOL8,8M6"$GW9;4
M0B1M;.;I<P="SW2W1L(6[-3.<5?7M%]H3]P@,]OX1IGG.NH2S),-2;IF),W7
M$5FJU/A,=UETE)>YL/+2J9S2X%59_9T&)9:"\K$S90KU"<$?P+;H.DJ-4(HK
MR=#]4GIP3#@$UKKD(1PEW1XP*L\7K+/I(%97(,#<1!@S5LV^-.I*^U>5[HGY
ML&D.^#2G=!Z'))<.%Y41WYU!+H6SX;KM&("SS&%Y#-@F0D?9J [,-0/36\Z!
MK>;05(]F _M)LG2DPEPPLC&)P3(ZU)&9^3IZM,50KG=-1?MN&:/2X!7E\&-H
M%!P\TRS,' "3V,O >4E#E.]F(W<@<?/T/EQ=C 8)DTE%CI3"3TCP1@X_<CSI
M&O",3_2[?'QG&06UN'C*6LNPX9MDH^Z^%]PR(U@91PF$),.QP<6TZ1=C ,.#
MCY&5$PY,!GG]@-YWD\!5!D:%4Y\19W>BS6@1* EUDY2>6S;<OJ+@FG3K_KU$
M:8/WUZ*X)<R'1]S!+SFB,;":\%%;$4B!'.8'E)I\F^<>,HLKU%\84&2&.)Y3
MU= +P5YO)U,^72;SADK5\-6+I6O**Y'0IEWT+;,\SZ2X,?G@'\%',G6DQYTA
M?&L3'[YF3DOE'G.B72 C5:BI?//5]\N4F)!/G-B9X^6?++<,=Q(M+W,K\/=F
M,DVJV1?JA^([9UY&HBJDMD-G[/GL^Y9"W#-[U7HK80#+!RC)H?\7:WUW93AB
M7,0C,TFGC/#4_7" /] !&G&ZMFS.((TK@98V:78&UQ9^Z?JZ='$S9@,9B4>>
MEYR!#9[9X#9G/5%CA*?4N>?('\5'X'8Q$236KR.Y_CI]3(?SGY743<9K%:A-
MJ/UM.+-+NSRBJ/@;ZS;$(G^/EB)):?H\.OL)SY?<4(I/W\I85#*@"M@WP$M-
MMBA,6,E?F?PC-\\(EFF\F$C%]I*4XM$B?FTF#5(8Q1POF>0F.I;I=Y#N$#:X
M)$:TZ'<2VT[#WRPTLQ ZQK>1I6DI55H;+CU)P1&2Z#86S2(7=2(2(['U-+UO
M50,M;7IM<X#;I6]UHF_UNTO?ZM*W>I1]JY\UYDO%)++)'8G'N<L 5AQM..3N
M1YI2-VT=W&7154S[)\/(#+KW1#/!!V/"*)\OH@:%Y/(<:/#7>T3:3!F62OE0
MG<(C).(=)9PK/BV?$K*/CR]^?+.+ CQ*?J:5C]GE,C$>!"BZAAP(1"A7?'T)
MV;$+4<4>Y!3?1K::32D";$+=S/F??H&()(#' DHI]AJM_*JYVMR=%7I?.DU@
M@)P"0]1<E&)C(K2XZG+(6%R[*CR50,1$*:(*$:48SM+>/U<_4/$!<<5:GRN$
MF6E(M=ZU+6O\>?N6>RYBAKP5:%2^8I#$ S*>ME!\?4^$@P+ACU[:+LP&+-H>
M.3Z<E#K6Q'6$-4#U@3HP>"0'B3/2DJ4/P?%?'IY:=EU+@4U\A2ATT3_I:S:*
MBL0.D-AA"](<&[Q$IJ<1VR33')Y9D!)VUG"KX5MKN72NH9 R);D"-'TXION^
M-$>[O.KR&3U5/LDE,0K459Y829RK85YH"SI@8!A5;G=<0PHLL')2'0G?ZU,C
MRDHN68ECF4.?5D2XPBN.+NLI-5RK28BG4RV73&]"_#OS'N@D@UL0TR2F9DOU
MF"KT+T$& F/+"@V3 15*>:AD@P8S&R/K$W1R_O2)!-W1X>\L!8IYM+T^$1HJ
M)UN4B]KQZE/!I4RJ21(QZS0H7:HZ0@_6<V?E@V"!G.8<71N!17A\:0:-(K6@
MHD]6:Q86-^T8?$!U+DX5Y=5$UY@Q>,UDDBGPY_^*\L)K#%&HM)UA-E*/.@>N
M!\M3-QY,ML"75]W.G"!.=/2)R% >7:3R0ZGS#N;S3ZWQE*CJIZQUM_B_K[^/
M3IY.!H4:J-P0.N;M>DQHG3QF7/2EEKK\N+(('BQ-8Z/HI:B[M/.0:++7;XMK
M9LJF@UX5EN@_6_3T$+/MJL/!5:1D_B!VHXMQ P'U;/*0;C(\GLTCL=!1M286
ML'8$[33HS)KXWU4#\%$EW*RI'3IZG&)-WAY-MQ_B--NI=V4(!N645EFP2<;
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M9^N<L(I/8C5"GL*V\+>VDFJ)\E1IPY,)4&BN48G>"DG0MP5D')C,8GIA:?:
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M$CK6R/H85X?Q6KT]/E]V!4KNNBT:P9M&\I=(R93TL7)[L#<M#HII9[96PQ#
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MJ=%MS^DFAW6'ZY(1!TVYK8;D>!73%F_.7<^F5Z4_H4&@"].&/)C@>[Q42UP
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M=CVE!XP('SKE&,H.B036@JDK9IX^T^Q&)S<6Z4^^E.Q]D!GYD\/3%-JZD;V
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M%?Q9,DVP4);+U?C-6+28]B9/+_!\<-F5*$^+M'B<))$QO4Y'BX4H&M->X.0
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M#XQ%Y?T&H-YY1Z1[*[VU;G&RT7:'=,MC#"E_XKG]3SV19]_5(PZ'WGL$<=(
M?^;0@+H)PL]Q;J";\0Y4%A7^T62' .MF\0_$T\]?]Q<*/Y+5>D#TT9\,/^[2
M2?Y@LO5O00]55P4X29ILHTN5I)=*3;\KI$V2,S6CC!$5&U'. 6)=Z#FX;!]+
MG(Q05X5CIC%LNU@?2*N<^/!JRB'M4[='YX&5VN&VC.W$O'95A"7J!Z.-.8%%
M91;MA&4YJ7+1OAX!&1W0M*!]BS>5K^( 9JH]W"[(":9$4W-5-U6F71VYU<5^
MZWRW"\+DU=8Q,D<N:;JOIB=A]/@%RQAYW]IU[ #1$<R\HP86&&F'+?U)EF@
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M>MSF@^N1-^@-_$Z[YT_:+\1;Q2_>%7PV$,$C'OP2)2SQX=9^8@6['@W'X_%
M/KUOFOBCS(LH7-3"CB']WS(@D,DJ0&QK4HXG<08M1S3_^W\_<MC#+0^H8_FV
MW[7^/]W4_'B'I(..=DD-21I$8NW[RP2)&T.?#_Q!MWT]8./Q=:_K^]>3'N &
MG[#!@/=XT.9\!3>&[UD"C 1CC/E/4>Z7>0ZHQY+@3<+B192GX2_1/E%$L0S5
M-[_SB!N]%Z8,%:94!\2K\X:O<Z<ZJ ,G=>BH>90C_6H204H.B [I&4"W,B[H
MD0]SGC'\(M^->_M%O7M>'GT4)8 O4H#NNLW/4^Z$:1RG=["Z$]1OAQFWDY:9
M$^H;\FLWE%4WE.H;<O)I6L:!,^'P/0N<*,%?_5$F/OWN+BJFM"A\2.,3&' I
MXPUY 1\0;M(K"M@G\_UT!JB_P*TF:<%S_#CC10J+^W$9P (\SOD=?HCO*Z:P
M]XS/TZQHG0(H8+<'1%F ,ZP#EP8/&8"&9Q8@CZYP>O(5_N70+6?  . W$U[<
M<9XX."&"EL;!*RUS3_!['&VDD0 ?NM^"GEJP#9!BA8-I#P#6"I@*A&^2I(0S
M?B1(XO9_ >$+"LS5_W5\8*@31&&X5GP>;ZUS4,JG-WBO\66_,=C.NW>N(]B.
M(I,MVPW3C%"9KH4G>,B?N,]G$YXY7<^E6W&!"F+X@B@$'_[T\UM:A4^RDF4+
MI].E!SLM4P1X@V#8F_1[UYVQ/P$1T ^NV3#H7+-NU^L,.OW)8%P7 =?_C+\,
MNKU>N],;'9+-]XS/2/,[ -M_FV8@N6ZCK,R=EV\__/O=3U?>^+O#<N#>'CGP
M_R01<K]/R/-RAP-+3&<+Q+ ;G@#>Q82-B%J3,H\2G@-SG7,_"M'<B1?.E-UR
MH *@JH3?D-X('[(P),W/F2P(B]2U.,!! SZ+_);S.Q<_S?&G+ !ZS8%O JWZ
M2,>Y$Q4.*:+(:%-:).!^#!L0E G46A+F M[/X;7$K(F2IU4>4\A\5&,B+C@#
M_CSR<Z)U4IQQ89 /A1.4] ^>3($68=LY"WFQ<.996J1@%.4NO ,-O#)F&1PO
M*#,4 [,T+R0+$NQ$?HZ["Z,,OOP3:*80FR2B$:J!.CJ+\U2<'P1.&.)/_2E<
M*D]N.+P2E70\+-Y]FMVP)/H/T^P!-HVO44>ZPXL$O=3%JV/ R$ ,.?#=#:<=
MH9SC?Y8<#H=[V022*<ZFP:78G9.G,^[$',")O\@ +P!$A!>"':/MMWI2%YC%
M3;KTRER]4[T*EILQ6 GD,=C-\%?+^4QR4W!A!'Q$ .* US/" 5AAFMXY<2KO
M5R]U%\6Q$[.\<!V0O71ND-+5ANE[X-(YT B\"8 +;) ^S+A .A\N.(>;PV5S
M_ P47WR?6"8OLQMU;_K.8(E;$"HL*0!T&2RKCTA\0*S%B0B ((AHX/M;4"*0
M@B0 BZ@ 28/H?<>R )4%GT>W$H%F+NT3$1K$ %V"7#!?<WY$IQ:R>D$"@-,@
M[UP$)=YHF2AL%U_ OQ;Z:FDUO-8K -],4N *P-*DS@((_4" P1KPXN8SND\1
M@A"/A&A9F,"D:R)Z%%@)& )TSPAR@BD "A!9 $H742)8!0L8V%:2,R6<!UI1
MY;-YG"XX4K"@3D 3 7+%IUK./],[1#1Z-6@1J'BPG%ZS2$M<$M$2>-&-X'ZX
M+.P)*"F7V#//<(-(6A5^^_A]6,9(HS/@>LB-);544*U0N Y18LCF ?DMBTO$
M#WB=ZT1 #G/8PAS 60"MT%M9D,(="%XS \R"_>>*.X=E@<<1+#Q0%Z68@^2O
M][^Q(]O1]W46? "@WD;\KAGV5XT"?A>\@ &D A3=3J%GCSG2M!',(T">G\X5
MGJ6W44!@3=);$N]Z 7B0,%#IE21**6L8X J7B<P5726 R: A 1,!Q1^PA .N
M?0"HSR*A$$>$XE,>SYTY3^<QHC(P.I);89;.5GX.<HU4CJ(@7@_KDZP7NYCE
M>*?$H*8I\J;?N; ]!*:%\%A!5@BH'*AW2P(!V9 $P(5QZ[0<HC&>!Q_8=A:%
M[_@RD!Z%(+D4*0ZNCBL,AK<7<,N2>D%8QE+(Q%%()"8N  DP2T$T13FN8Z@R
M_.N<HWF -";NCR$SEXPZ8W-> B+)H^(/7GK?@<#)2651NW6%7L^<FY216'_
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MPG.^>IQ!QV%K+\)KDEMB6=B1<F2RCB7-0V6V&)Y'G0V#E*-\<XH+R$@GZ6\
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M3"2GA**UIIA$4&,YE7>56"O2?:AJWM4.6C6YMDE$U+99>Z?FZ4H)).=&S45
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MU=C4E4:FKGQS*C'@+<S'Z=9&#-; 9FYZGG'J2@?/.!W/<[N]OHW-/-Q&.2U
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MUS"-X_2.!"!=0E[.X ?PSIRDI^*'H+TH16D;:URC;AM,$J\+U8< WHF_Q6]
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MEG@L\1S!.CE?#&E^C.M?*R7[^>F[9,\TI^#1';2>/2U@WV.(O([;&0S.)E'
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M@XY OY%/2>/$3^.8S7/^2OWQ^K%PK 2E0NA*S%>;H3U<Q6R1EL6K,/K*@W7
MEIHH6"7KP"RVKC"[[EH3O^P/Y;GKJE'M:)^C&2#"K_S.^9C.6 ('HT_P@&MQ
M=$FOHEW#L;8HTJ,5U>FO?QD/AN/7R_M:TJ]6:/615&70>9)F,Q;7Z%Q^].*'
M;W#>I,914W;,>9:G2<+C*\7X$;>!@AC*!T5-#N G ]&0EW&AF&E%7U/. A_
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MC2 ML8G(,Q''CHLZZ/B*8Y_],*959^3VNUWKVG\^U_ZQ\>A9:*B91S],DM+
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M&HUM=0 C7:>J6+:<_5/_VBMB\!4QC/T7R 4"<;5<D)MXX*SV3OE-UY+U@65
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MBGGF!!:4Z<':;0'X[5,@.0]>^ VQ*(U*:Z"447]WL!"$VC([VT5$O\2,?\E
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M8[7_2.Z);W'W<$AF$[UF>Z1K*;OMJE3!G65GD+LYR-T\^X48^(NS 7Q3CFE
M H(]CCU'C<'=E5PP-3]!",>97(V^<W)<Q&E"QQ6$JB$KHXP Q.757MM1D>5T
M"U:VFCPS6]2[.C$I%T;>V&,[TB %FP/[!6%HZ@L9 A@8,#!<@-'CDH!A[S+4
M=X&A*9F<]E@I57.+82XONDKF^=E!7<,Y%((O)+\0.W95II^B"<ZTK\&^JKZ
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M3A#HOWNC/W^G8M)J0G]?,AV"*T.&IS&S;,51S:\<1=%QO ^.8:P^#=A:^;5
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MMHH=??&7@I6'['62,I4O(6="%I.ZN)CR>DE.=MBV.>+&W;K(H@8H%,O$!=P
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M!6Z"+1-(5POL\T)X:>=9?FXH]M-$:P,8VG):]7PVKU3EB:LG*M67829;K1L
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M_.,C,E^*S1H]6V0>GS-M2N,4^S57F'!,ZC<*U2,.N[>M$:P$ ]?<T=Q!QG/
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M</FN<O49N#0+WJQL,.XREWGT=--M+DG]X=0R&5\M,_T:D7UJ4^(PM<RT1:'
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M^'W-V-,H0FKD:&K''&^LW##N*.2J7%:42V4]?KEXY/? Y5R^-!^UI1ENQ>:
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MTH$3T;8]2;&DXFZ/:<:^-FM(+6JI@ Z<$6V_(N#UMAIUK$I$EU;M;JX^ _I
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MZ<DI@=;A\]?AM4L2:!T^9AT +Z%E^/QE0+24CG5 M)2.=4"TE(IE0+24CG5
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MX<%-Z@<P?CG:)5=)-0!_W[G:2@;IDV5D0Z?1<?01&_:%0Y#/[=D)CKNV[$;
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M<S>9;:TL=A<Y'\LI<8]HMPQC6#0DDCM<8;RLBGE/ GZ/D$:)1RZK/!Y"NS.
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MF?]Z&F2= 7QK)[M,XF@%/59C)=DGDGUT$YC)+S!_"U!BHX-!<*?+$RF.^DV
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M+A;P*<'^"%-AY;D)=!Q9I%Y.25NIQEX"_B.\)8/S%'L7J'S!_"L*.MC< ($
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M2[H2Y(I2K-,=M2TT.&4,3:/8-IP*#9Q'4*'H3@B*+8A("]O(@S.=@Y& :PH
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M529Q*60*],&_\FL9D\E-W=XV 9R,!^F1-4^ (2FGR:#ES0UCBCT)%CD^KZ(
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M$*Q;W4=ZOR9+B-KM*R.!IEZ?(V5Z"R1.\P 7*Q@:^+;QF"VLL6')0^%JT-;
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MBP.].,I*)_O__5<NG<G]<SJOXX=."EG_>H@@Q!2G(0(_:@V<#_^'W:VD4S)
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M5DOS5DOSEVII"EC0CIE<1IADA-DXG9F*X^0T+8S1)[%Q;A)+3E+)6"PU@17
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M._*7:EC6WS0>^P6,J.MTYGVPA?&.^LKGR26017_=-))C8818DL"[ZH@MOV%
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M1>%1,[+5>2.O#/E]C#.WB?%#K=WY0.'1E"<=U<XX6:X53\:UR7:9GS[-D?#
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M!F*K9-]C3.R\70G\]__^GZ-F+)[P@1:!AOG=-34#^T?WA4CLN10EO5Z$&9K
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MDV[URU<8A[MGJ= W0EO]_WY0/SY^VD@S]Y1"L5>B^75B)>U31P8')+N,4KZ
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M=/#A\TYHBG4DX@=T9*+!K1E_U9V&E 9;FSK4GF:MU2I#<.EH2>Y-HZ!/+'9
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MBJE1*:(;IHA^?5A.Y-KXJ0<32,U,4$D*_(@K$>62H.G=,#.1CB&*)/+K+C.
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M.>(:+^NH"G*(#T4(\J?R+T36S>(@B#WWOO,M,@O![V(L"^,0@*^7$7\]_TV
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M%,+#0$WP-_,Y,>_=/'LQ+ )39^'_3=\7;KCO]+05?.>#MVG\QU7;KEZ(Y.O
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MY-##&T+00TC_>QN:F:6SC+Q16M0*KQ1M72[TSP^8A_W63$F[V'@V]Y\.P 6
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M/#B*07UG0T7\UIZU?4.1LSRA/1)HW>S56J5:0ZF-D-FTV9\K":(A4'",4C#
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M$^QZAK44:K51OK(H:EQNE)T.9&O0PR5W:9!B$RW>:?)\F;=;[?ITO1C.-CV
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MKPXE]--0ZO>RY'Q4:@U0<4>NA<Q@CM2LT$/)7&W:#H;N#*4V6&<&K5DI)Y(
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MHE*LD' U1#*>N**&&")"C+A1Y#2,%+W;<Z.98_8[]4$&17/JI**Q\U[3LAJ
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M;"E"6T(&^X// 40DPXULX"A&Q^HJ>*HU$ZV8:$C>!N!XEJ6"[1S9F@%\6BP
M[GENEWBL_>:#]Z]X[D'041&#?5-B>P =GQH\>(3(&\2STO[DW?\)D_PFQPS6
M:@J5I4S;R?,=AFJP9V_LD^C[3M58UZ2#,AQ\^0#(( 0.:'CL,/B0Q]PT+*$)
M/4&N;PK^5A$W\L)>^+ZH\SXL:[08"Q!4+HD\48A+() ^S*9IF\^V@!"JBHNC
M';B5#:SF@@8-0Z"^PP40EO[WF&:QS ZS)H**:1I3\TNSF40;)YXO"-$_8]N
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MK?2,KO"&KN!9:Z763$9NE!L!6W$TD\:V*OG#% +(>>XAGJWHWYL;V6J#<Z6
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M-L!G8&9P>$ K0*?C45)S$^RQOQ7 EM>R =0(#BM(D,C@<S97Z1>878>"N%!
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M=#$E4:O;CUI%2)/Z.S% OH(!LE/19PR0X6RU6N.Y? XM-=5RPR7R54&&#QX
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M>1 0<%8$+)6 D0(EXK=-<K)%0#>=O-LGH UU@M78?:IU7H[D#8 A!5K[T \
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M_BND%C8\;ORK;XI/AS&?#2B']@"PU_+P]&*XSH-"""\KQ6-*GR.@$!X6>)'
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M8&S/G7LYC9HOB^7Y.:V3,'E1+F\R5:XF3],K;M61M 9L&1&[Y;K78[0U2JE
MDPUZ.MODY#+#T]$^%UQ)-62-(=%65?-;=F_2;X+1Z2@]QPVA(O3LI8P&I>EV
M@OOK"MN%+2/T%#=SOS>H&B4.8;"U7EMX36/C@Y8'>KX]2JZ1YJP^TVT@4HW.
M6F4TJCP;S!^;X%UY+1N>7+1-'6[$T&0>*NXB#\ZZ)ABS#T;+ 2-=W=^NG/*N
M7T7)?,'TT4!RB'D:=3O5_#YH!L[>LL2XS[2#@NAB/U(R,.DM&/BP/?E2QY5+
MW<F:GDSF]/I5TW3E%):^3^VL_3WU_ON?:9QO70WE%#C30C\[#/#8NSFG9H#E
MNTB>  YBT%EAA[&G0TC/LDUX3RF\]!2&^/8B 0/(X?>@@TJ64CU7<.7]5::9
M">]/P=#>[J:H!0/&ANL<#WRWB_(ZX7QFX>C.\? /S8"Q\G#C,+R_M9_1SY#4
M'ZT8A=^C@[Y:LSVKPV-K5"O\N=9MU]9MA5LUV5S= Q#1+?D?(^='AW_T'GW6
M_OS]3?3U]X#_X)+O;E)0(/<3@@=S<7>@/[5_CA5T9_R@$:/%M0^C[GO#]E=V
M7\H]."0(9ZCG,J:/3(FC_DW0YPP([8$DA]\1>'/WY\Y:A/> 7K32]K 3#GQH
M*DP=4_-<^2.ML]<DL9Q>&/\CK\3^WW>FMV3HA#-QY Q&W&>QA#5Q9 U^3SY;
M "+A3 )G"6<2./LBK$G@++Z<2> LGIR!</9L-=*$->]DS>OK4KW.QKPF&?Z$
M#GNQ!-8\_/#__:!_O%%$2?(>__B"N4_&CI^DT7-.O+$LV"D6WN)Y<-S=FC \
M9/8>K_Q:PA&?LL(7$)[CG(5+B,_UB$._+%U_5XR=H]M=F![H17+^?5Y$\+>*
M"$;=9VY,0G:5_Z:_+E(7YOE#\W40YA*8D@C,B<!@B<!\I,#$JK;]920&O<CF
M$[>*4\^N^G&T]1)F[U7K4KU2$BZI3^_RJR7$>CT&QT^UXD"91.42E4M4+E&Y
M6-)J[V[]5L3ZBCZO>J!;"UF2=>'ADMK%-.4&"JZ^% .]B>JJ+UWR<VR7;^^$
MHV7W9'NMB$?E48N:O%%<TQ,7O<!Q97V?WIHOE:FE/;%MUFL62G-QXE:%5N?-
M=5%?N%O+;O;%;AC'@94XI+ZP.5/.=#AVLEX^/Y>Y$MO&9K16J^4['3Y\^A?'
M\#N<>JZ>Z>UX$CYQNTQ X&N"P./J F\"@<*HQK%4<=WA\F0FW6:-W !KO;TX
M\F5 8)7=&/4MX5O<BFKFMO51=3LLP%PK,G0&W66Q#WIQ*@&!KPT"GQJ;C04(
M/*YX\280*./5C9FV^@;:*JDM7"*R59::7QD$.$$7%IN>5&61X<#!U_7-N#>'
M)P%8UYS.W&%$M.[7S7F(&<7VA2 5)@.'Y8,N;@*\^,34IP</8H>03SNGXA-F
MB048_9E9PLQFF@D?<=FCD)1;:>P\5YRB.-(LVMG&6AT8USZ*:)M62=S,; >5
MZ\6E4JP.K9P"DZ2!/4+ VG+1 CS?Q,-W78=>@E$)1GV"U?08HWBM5.D4FT$?
MI;BM3_<7)2938ZZ,40ND,:F-JFL1;5$S=M-N88T) 3$*F$OD'99.)Q"50-3U
M"?5TP.&K010D#8;_\U7C"E0X2!]6J;^<_%_Y6=K/\S)>>Z5QVU!?6W#@JEND
M4\/JU;S=)5 O2]GZD-.]@(054F!8(4W=9<X\*9)X%!-$2!#A D?L5HU#U#K0
M7A09]M#JUNZ:6_+:B,#[_'HL9IN\*JR;>73>GK=\"58J"V,,]!U*9A)$2!#A
MC6?<!!&>C5)DIHU,W\C7EJR\&#2FNDT/M<FUS6BFY:<WLQ&20ZG54*$\ Z\:
M*V971>V2 8>G9">N,8@+9F!^K5M]<:?+U2[-QITP7\$WE2A2?.B2*%*B2(DB
M?>4[Y9]$F*_EY]T/\ER2X>^G$L/7Z\RCDJ0733R\W92"KW-I]<M0YE-\)%^3
M,(DN);J4Z%*B2Q]_AKM=RMS(U>"/S N,W6)W=9F^LJG_IR[YSW[:_8-2"/'7
MO@?^VQ)Y>'T@\GI[7^1=)<MTZ[BR0DLS>>S*]0;EMWWX< _^XQ<=S0W\ZYMX
M0;ZSVR,!ATN#PR>E%EX:'"KI:LV:,/T&B^C<4I?()M^0PE>]R!^_LM&WB1-P
M2, A_K[-N('#)Z4<7AH<1ORH,NU7V!PGS]*S*<DI#B:&)P<8WT>CL?V_OK;?
M]Q-2!Y,+[B]?!XS];?9X&1I_GA1X:9S(Y9%Z61PC.:Y7TPO<IL4&NN_#1SR!
MA8%%<VDN=XCX;OJ2H$B"(A]CD?QYVMZE481M#7ESXI H&I #3!OJFDS4PJ>
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M0'@.OLX4@=U=Y+7TJQ&'?EFZ_JX8.U>NNS ]T(OD_/N\B.!O%1&,NL_<F(1
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M,-&!;!\IO2,_J ]8F 7D<'_.@@J@V"F FRH8<"UH._P+A>@0/KS; R:8+)3
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M*)DOF#X:2 XQ3Z-NIYKW>=@4NY02OLGD>(7?Y+<5TCWUBKSO,35PLA"@8:F
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MT167C*PT&#ZL54)EHC4'OKB/A1%%^(RLD[)E45;6X?UM>*U>,=:RX9IV /X
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M:(DT8SY#NNV-/P9LVJ82*W&)P>,4K92",.J8[/V2=&OCW%A^=*<KPH)K]-_
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MI9#_?>0J*EX7E8E3[MT,;X%X2\C.[*V16N%%4NXJ\88!F^O^KX3Y\1>*6W;
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M;.B$\U1!_.<F78&B!O$5&[Y_-O$KLKTUF\]RV_;LX?5XFXN0GYEVUPK$:IN
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M,=-P._1)4-YS(*"$F&GOQ5_633GA&%-EI'SNQRK@IWBQ )[)^*016%/!0A8
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MEJ.LE J6H^0 REIL%[0#K!09*\%RE(D_%>S2Z@YH*FHJ6,@"P!RHK /Q@<K
MA@JQ(9\S 9:CJI9CN>K:] W#,7I6O>J:_F[;)EMT;1L.L;U#S'"LG,>Z_)]P
M:IR%._SU_A=]FSXL^I8,O&'1M[0TS19]=YDUZH. 4H(R)0O(1PGT*S3]@C,J
M$R8KV//6'=!4U%2PD 5@.5!9!^ #E8$-%6)#/K4#G%&UG=&'\E'N80,<#5Q1
M2(4I'72#*RHM24,J3,DA&5Q1(%_1R1=<49D06<%>M^Z IJ*F@H4L ,N!RCH
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M%H\-MYJU#6,:<I(O2XX+T@'.BHRS8'7*!+X*=J5U!S05-14L9 %8#E36 ?A
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M>/>6E"^65SM*PP7]9U),XU_^'U!+ P04    " #X2556!CX;5N ]  !!4
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MFXIFTUWDUYA($"=4&M\P/QAS=KP$:AC@B"WJLSV-FLP,&69VF-!I_W*9GUV
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M*%%.*W*J3)M1D7:O1T,=)KQ$T9-6H9K_J$)7_E:A\W^KT Q"&A5@9,!O=D"
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MH1OXCO08;,RIP.C FT+38M-VFA[N[FR@AG<Z60\CW 7<NBV$.[0&07I#-T1
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M88"'YYQ[SSGWW>];[]Z_[EOOU/1>JZI[=^_:NVKO_:OJGIO9FU6 ]*FRFC*
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M*R9'3R3W F9/9$O5'\\X-2M8UHL-[2&SFB-&1W'CN;HIM3"B!94H <M8;26
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M\G3[\?NM<>\>KB-9TOR$OACRLFDED_Y^^!YW+*@&(_;NAD<+^8! F/%*B)4
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MMT/6?+\8;'DI+^"<9*[)& 6FFZOO_O:9JX_Q-&^M-;!9 9X0>P/@>L3QJ/V
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MAFRB__0-<Q]2(,JI6=S2YD/$IQ_1I-Y6U\PGX+2NU&6&*N%GBC\75>[(5-T
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M+1RQOP$03*6S 3!=%.@Z; ETC8X&_4,=0!ZBC*18T&=9-P#&?,(_U%LBKJE
M(3? +[.)&^"P+^^?6MDDS/\DX%_B_B7N?Z:X4G$CY((C\_,,V.S6#VBC"Y_)
MX+UP7Z[;'&'0< -T%"$"K@@: ZY^4P4H(QX$P79':NT;E0I2>I:@;P2!V0-A
M><:9CLHP_6N\ZDNS59,X9YNK]98G\J=*H)_G%P8>Q3O4%QJQ,UXZ^=2($MO$
M8<P@?4=IXU&1&X#,^"I-IR;Z;,'5A5L[Y<_'-^E0#HBF2R1]H['WN"'*GW,5
M^WY^+_(;2_:^0<T( ]A1Y7O\]%11/ ?+\<$<Y^3E3.T_=H\RX!_J&&LKB._O
M0+_W0==8M2Q_K_J2H+D#\&Z T::B&V E4>6?6O+,LC<  :?B[1+RUE"KTMK_
MU#+X]B]I_Y+V?Y&T9(CZF Z-M?>ZJQ!%'SOGQ(,BE!_BXA)N7MQXUES._#[N
M,L,_V)0YY"I+=[G%%<*%")2\ 4+_FBH;,WS!^Z]4+97B.;2^1CZB) Z\"Y2[
MR19&%8DDT=XNKB<XKJ:4,*%VJ#2D0K/WU_NQ[FHVV4^NWE>K)\!9_8.A'Z;?
M,9"0SF>8*4_S#%HJTA;0Z:@4EPG\AW2L_A19%%[CR%%;ZSTN>GCF.<BB>V@
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MAS"[@A$A^>;D*_UYQR$NJO!LX-@8D1E1NC0;6)=&<_%&N-\93X%!*NG'63<
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MDR-:NYQ<#,9J=N,8]OSO-33%7^ST^$:EO X968B2TVUR7(]=19I/()S]O#I
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M]&5\--"/R$P3BX)]8==LX)ZA3G5=Z.M[6Y"(F82_'AO=A1I*0.E>2_6W77=
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MI"<((4J O[_[YIYS[[GWO)BW>ZW9:[[S?)Z]9\]6ZG4Z/6,^Y$>U1/6@'MP
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M#AE8NY]M.8V(]I%HJ_CSH[DP\L%0$Q,?":TI]69>3D_)]8\U]B9ED7EY;LC
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M'5([J[!U![FZVS[M;G2M4/,E#P="'.\WMM6*>R4NM ZH+D?V%5#ZM4L[N]\
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MU 0%IMQ39#!A6KB8R!5I;TLGVW3FC=?(8D[*]K&#?F)AD1G2NW3!A0Y<DV+
M"2<4E^YRVEU8!C:'!C_33R'C1%(1_JE5Z;2TFEZ?_5!="?I7A2I<+@B23FQ4
M78+O*$C!\7XT"C?V2H/[!I#E5G*79KMM] \5P"=G[4\O$D:O44L%-EZ4H:@Q
MGYE Z.[4VC+3Z;CY,/;)J\<]\4DG/1MF+'"]Y,.%H-"#S-8/L')Q>' 02D^2
M4_1BS_A[G-4+5LHTD/5SH]@\TPCR1#NBQ*W6W[ASY'YH?X=F,Y(J2'U>N/8T
MUK>]I+LCBRKQ_(?-4_L/*] *I/J!A@<N".T8 7J)IH"1[ZCP-,Z!U)WLF&69
M-C\A'_YZA[?15HXC/ALII#8-F:0*7=_W[ ^\ 0R(,>/RAU^T)$]QZEL8+DP7
M1[,3&W(+OR/PI]2N$6,)F42P8!$U/@$UP;4'0G4TK=&;3<>$0PN;XX<C5GUJ
M^D^(PL,'3;&P?7;,(K*[7C83!69U#E0I)M)LM+ <>S+ 05B]3M2LS?-;WBA?
MNQQ7=1:#\UI/\N[76L#;E.Y<1&TG%<7KZ "TU1*_/WP4WB";S<V!5>.86VL4
M::E!ZC2ITD+^#E[S:&^VM,V*>=:Z%[?-V+?R#HI\UR"D$;>+F"%9D5=@7(6J
M8D1N !'['AE&V.@N-'M5#*5'\U 82P\+>1RQT9?DWYNCH QKZ V@.?2#9P@W
M;K%GP5]B$ 6D,9<>^=OWJCEO@2DM4KL^+SXWQ.%W8N:J!3QFGWX==@=BT*^8
MG8C7*W9F-O^9;C74TJ@#$BU5#^!1(OI'776/\]6;1'3I[77__2<3N>_S8A&E
MPH/E*__0^:22T\(4$]S\XXE>=YN#26J]!&L:KST5K_.#JGM++ XD,U IS)X!
M!I;4:85R-3NP/AZH<_EKI&TREKC<<]] &$!Z1U-?YW>9HC$P\0;@= .(#J7I
M3-F_ ;#NF >T-:2\"#=_L>5JQAKQDT7-OWQDR7X$8+?N8QHXN6^USLF,*H_"
MT_%7-*Y 8IXKYN6=-H"F%)M2><E9::./GPYFAL.)';U8+<-TL0+K5Y$0']1!
MN6LY&))MB U);3G>_F(Z]7QJ>93#J&] =,C]!A"0&QF9%C^,,[N4-8>$WD)Q
MWQK-'K-)0C7$?&O-JB-'D#%G[P7\IT+F/_?61X4V(LAZMKH$AM>8.N]CNI6T
ML,8PQZ*$>H&EP>5,*0:K'Q4 OEQB&RT!>4#.>,99!,X/V+\-\H!:E87VB8&Z
MGYJ'Y0KQ+BUO/@KO'$W5RF[]UTN2V>HJMU,)146$8LKP"OW*!TMJ)I[S1,@E
M@B2%C32)S1X3HAA5Q6W3 TZ.<T.78@RQ=0/@^-F]G,,XO!*R*\BPY:5-F;5:
M"[SKJ\6#;^]&#@K$'YE1NFEJ>EEW ?=I, @#$CBN C*N Z:QM,R5GN,*KJ]&
M5QND?0P],R6:7<@K"IE2I0'I(G&G75*#@<&(G+_8G1 7*<+6%^*OXE+#QGYH
M][Q1_%T*> T.0P"3H ZI!@'N)/'"[B=[L6_M*#P9))J<[H]ACUJQ'MM"]X[/
M'!LB7S?-@Q30!@PXQ2O?Y>!'1^YLKMYBZ^'OA^QUBM*>A!?D$>;KZ6%A:,L0
MZBD_EDZ%"C,#%*?D#< @XFS!Z4?^4_][^ZP<WJ]DJ2&#GN"0*3#U"8QC>'VY
M@&FG'I*V<:01EWIP+)'&ZN9.K:5$MKJOQC&<"+._$AH,;"D.)4GH?%VH4[4S
M6N9*46K5!X.G/<@T_MCY? PG(,;ZV"=R4!WXIZ[,66K'/X09FQ(/!5:8.Z<Y
MTR.<I9:9NEM2#LBRG.STQI>F!+F:M?2NZO B:"K584'D^'?Y4P-*J^;.@F7-
MH" 3#;^70MK?ZE_SQ1+=:5"TS=GO-+K4@"IA^%OMOT R!B^,,ZI7M-ASG?EY
M-8$'V6\D6&RGVBVG"$/[DF;T6^MV,UQRFN>WF@O%8FI+VC(Y.S-I+GO>._Y0
MFM!!ES-F^U]*X=[> /0QR04^_I4_'9$U_(>:$:HRS),1*+YX _&HB?VJ7JLV
M_F:H[:4V7@H76M6=C0*R.9L;%^8;!05L*<W; 8I3"?IHM29"K -DMEL6):QZ
M.:9&&OH?Q.C01OR'N[2A$]'0-6O(CQS'?C#C-AR'!<>!U+V*=]*W+X);OI[U
M(>#S2^PN)>):Z:#F\SC>O_PMT" ,R6-<9 6D]NCZTJ@U8R!0VIQSI 72D\RR
MNB)I3S/YB=HG+4R^SO!+F/R("HMS/51C%OI6U.,&T.0F[3B%_M!P+D*AW<#$
MX^&_"5@/3\1:Y?UO7+WR7Q6OFX7>?__6%D7-I;VDKAS'4B6=^.XAT48!.9X'
M.X< X-R15N#>23<H'VK[X,"#O[LYA^*[@8H9U< ;;0N (KZ:R/%+3CG6]LP;
MFQ)WNL;F @_)!$VUQOM>>2R,#9NP^5XD&CU^82#J^^;M1_K>M^W#1@O=%9CA
MQ*905@N$P1=$*9XI^X69GK!+K[$=<N[>W7?ZDI+*>QYA*IHM.)IJRVVV8$3F
M>@JMDWDU0GRVV4H-4C!(\16A1TRZ.RL='<#@3@SXNE'P[$PL3(5P#D]ECU;=
M=U<6]O SH ?O2C1T2.D1ISL(O"VY =#8CIPP[IY\), N)ADD>'3+XWVG\1+K
M3[%N.8@D^[+<S#F1_9"Q(W.&NS:"=XK86SES<[F3.K?:87%KA"$RD^NC>(+R
MP:^[U\"8Q_4-WX*9C6;=_FQER4_IBW5/10=0;RH10RS=-_7U@H.#*W$&?5P2
MC3H+LP98YKB5088$#^C>5A1!OV*=TDN6E4#?VNI;47[><-G#)3<+#< ^4 JE
M^%GIK"*"&6#*@G]F/KO5GQ)FHW31IJOS1S],*(NR\[4' [:*+Y5PXT^QS-&G
MXRE4D((!XQF<E/Z4Z!^H  I9O&JZLGP>E66P-I#1=^UI^-OYY5'J4EUSHZX:
M4 4OC!/P6I^,OY#!<[%: ?O.@#1_.E4]*1>K L\:2N=JSQ"V]PX()>VQS=\4
MY&MYU@_[ZF(+R NO"D1KH7RR)7#F#Z)XL5IS\UWC<?Y<X6,S;7[WHSM9,DS5
M[./"*[4,BXO2'PF._?<%0K_N@#E42*R=KCEO !^^7B/^OD[S'6B+1Y@ W[PS
M%\@FY374(8B/G/7^+3.P77#G^@'.Y_7,-4_!W>6UW5!,SJX*;QOFE6)26SX"
ML37J3I?N8$-D69?%9],F>,Q",C)Z@?C;#W<H_KH#SYN/:AXJ+F>ERENI%]+U
ML'JOFC6<N=).PJG%6*P&),=KWA+"3F5_=[2(5E\69A<AB$LIV64*H<VZ8'KX
M;>"!D?!XQWWA*!WYE6*R+'E>WYR_O06QW>)@3L@Z1-TWR=%HT5=/O[^O<=?X
M%KCSE97');+L'*+L,KP GMQW6'E P<Y5D"#=1?.?IYPJ\//JVGL'OU:>UMI\
M"OD35]#17\\17U,(&=;$BI;6[%S8[ZY:.[4^'KOFTWQ)/"23>I\7$*+U,BWM
M)P!:7@M]B/N$O@*C1-L#ULNF+"R[ILKJZPM>M>2 '\&U)#^1*[Q^0_V.C"3Q
MGD_\&J,*"]0%>P-(L48<&LS7-ND:T,-WF=Z.&\V^F4Y*]*AI+Q(Z*_],ZY-%
M5$:V W8R4@,*X J0_@,4,$J\!^8S%T/.EBK=;@$<;ER=D]3ZW]H[KZ\F%RR*
MAQND"!@I4A(I @(*H6EDI"FB@+0@TIL@8B 4N10)16F&+ESD&H8. A>D"@@A
MW!AZ+R*A"804!)2:2+G?$,HP?\&\S:PU:QY^KV>=M5_VV?OE9 9*T$?N00UD
MM9-F"X;$Q@O?VCL!CUBP[F26?7=$6.QCEFU1!FP$/_VO)K\D;CA*5L&L+)/8
M)=>IO%R].D=J*RN&_'V7&E,H.^$.O/<^"(F(1Q="FK^$K/>]4:&,2F;=M5^Y
M^6#%$\;4F2%$7?VB1KS)7.W6=BN'9$:C*@PX60$"#5,@C]],=-.+9^SO@42L
MA6-S&?4OKP%:2-*DWQ9BH*25O*?S0NJ'TQ4-@86U6OY[+4LJDNK!:1\X5U-
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MU=A*M#Y'45]"Y#3K!0G+G;JUR_8BQ,TY\%=H5/$XN;RNZM58^Z.M71"MK],
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M:>GRXG>MJO2P]_\SY>G_^9]%^N3K/P%02P,$%     @ ^$E55EUF H'0L@
M$,8  !@   !T8VUD+3(P,C(Q,C,Q>#$P:S P-RYJ<&?LNV=8%%&[)5H$"1):
MD)R3!)$@.;>2$;%%%"2+Q 8!R0TT07)&0$""!,E9<LY1D9PDTTW.W9)::.#B
M-V?.G._,W.?.F7N?Y_[Y=O?Z4[5J]WYWO?6NM:NJKW]=KP!WGJAJJ (XN "
M<_,!KN<!)0 /%_?O]Z;AWWQO$=VZA8]_ZS8A(0$1Z6U24I+;)"1DY)1WR,@I
MR$E([M#<H;A+14U-30JBI:.AHJ.DHJ;ZVPD.WLTQ^+>(;]TBIB(C(:/Z+[?K
M#H"""*<#UQ8/AP/ I<#!H\"Y[@%8;\9Y"^<?#?BWAH-[,T8"0B+BVR0WA-H[
M "X.'AXN/M[?4=_L];G9#^!3W*)D?_B8X*ZV&2&'$Y7(A[AL(D[%RD[J%V,H
M+M&WS@'$MVEHZ>@9[G'S\/+=%Q.7D)22EE%25E%54]=XHO/RE:[>:WT#<PM+
M*VL;J*V+JYN[!\S3*S H."0T+#PB/N%38E+RYY34KSFY>?D%A47%5=4UM77U
M#8U-7=T]O7W] ]]_C$],3DW/_)J=0R!7U]8W-K>V=]"_CXY/3L\P?\[_QH4#
MX.'\]_:_C(OB)BY<?'P\?,*_<>'@>OPE4.#?8G](0/E8F]#,Z2Z'R <B*L6X
M[,I.8D[1%RCJM\YCMVFXQ!#WT']#^T=D_WN!!?P?1?;O@?V/N.8 4CR<FY.'
M1P& @4N=KQ&\P+_P?X"<+_H(-[7?"P%XJ[*0<OX..2<T/Y+P@WA(54M\+_)=
M#2V_=5"*C]I0)W._+7!.'O%G6BA\^2Y/.%?,^-2J4Z)EO2+1":N\[!6-7L_A
M'W3=-=!A<0T@M_"V(O@W_3#ZIG?;-_OFKP&<A&L@,N=?K'^Q_A.KA$&M[_"N
MC<Q0$ZSXQ\."H4Z;;*+O5Z/==YP6GA..4KVR!S^OG]Q#--4F6M<G*G&%.=.Q
MG)B:AC[/?)KBVOQYW['R<X;-6;X/T7$6&0/_1BMDE3;V./JMEN#VN^Q6M=GU
MVD)Z^;![E8&[>F"$!?;9-9#)Z(@E@%P)^BN$?6WSN :"$]&R5W#[=A0]&-,$
M1EC"_\7Y%^>&T\+?E<E8ZP,V,031=3+7B.)4P9"SZRP]*Q_UML=;?_"]L-!3
M)8_"(]#YJ/:6#%"(X,W"_0_ YQ0/1QX20Z]$QM8G:HGJ^Q9R(\^0#C\+*LM^
M\.*M'[$4H#*-KOJG\;3RU#4-%PK_.%VN7P.SR?5'!QQQ/-$6T8E_:ZLTOM=,
M'J:Y2\8OJL;3]5)1'EW/QX%"2UKI_+H&SDLV^Q@RNZ+?;\UUB$*=*:?/[BN\
M:+P8O-2K/P(.*E7Y*@<25*M4$:MFC?K/'K-\_?*(@+>7ZCE.Q$,5*N!ME+8*
M0)=#I?U?WUA0LDTSMY@PM\B]-9]]4##YZB:@CRC'J!/6(*^!B5K*,QG\_42S
MD>2K\6O@547. Z']6DWU\K)\_?WUY]L<3"$$+89ZXP*US3RU38\&%D%N"E\;
MEV]A!K4Q:J77@-6.RH$K\?S]#FOK"\U+77]Y%Z1UMR:$%9KK7W>>SGE&*W4-
M]!M.LHZW>'0OL36/UO*@KH$PBK(#A'W<=QZ_1Q#XJ?AQ=/0Q0UZZI$15[NB3
M['%E:5+^CY@4U/!(?ZJ[ZB]Q]9=_:-G\5LMVP(F LQ35VX9V$"SD2&DRL_N*
M3;6^.;B.*][C&/_L5'SN__U<_?M&2UAD=]T21Z7P,XF&[S'/I96N6*;T$/4]
MD2. +3]BA**962K=<*%./90GQCO[DM^WJD4%,>](\>NS-:.%B?DG\N?70&@M
MX-WSHK2R)*<DA[2$;X#MF"/35!XK@8GS6&'6@$LC)7B>+49Z)XS$$Z]F;/D]
M.2?@T[704Z2GPRTM8 M<>(ZW]34"X/T/>&KU#6N,8 ;W><DU^6;3;,U_BGO/
MPKWWPYMA,5=NE/ GEZW?;?'N'#NVH7QUS<?..>M]OK]O3ND^]@*6IY&CP?D&
MW;!PTW6LMDDR\AH@@BZ)C*U-G!"=L6](TX:&-XMD]+7Y7 /AF5UE-RDZ '7]
M3FPC^)*YV>4L^;S"<0-G84PK0CE5/%Z"/$J2GV^ <U*G\/_(P11[M<79E_UJ
M+1MW4-U2>Z60LU2N_8@I.5#.NA#.-:V:4N38.&K]KD0(6WT-0/V*9\9T):?/
M$]/U=,=+44^RXV_2@PQ65Y%K:.<.L7--BVN2_)N1AP2PD><8S=)H41TAEZSA
M63VF/W[[0B<&P$E%>";IOIQW_MJM^BEVUH;&_BN9I9P_>K$PCQY)+^ZO5ZQH
M7/'6-8%*KH3V+)[VRD-3]5_+ACM)E4;S3Q(Z[X=JW%D3EN]UN@;N^M+/8LZ>
M/6BV/WE]DY%2NU>#7K'KCY@2J7LQ'CUZJ8+_O2N>MQI"-XGM9[[4_.3FO+6H
MG29?9HN# NT0K81=;:PL_.C-"$&&>8T)KH^Y2HY+\:KX\!QY$1E*=5Q_^::(
M/YK=IC7)O16AF7?A#Q&0Z"62T>-F5JJ?]C5#+MT>W.KF#:L43TC:G0F<90('
MAN6MM2Z+%&AVEN0<"0Q@34N.=_,FIQT+2*#=7'&X%@M]\L59>$?Q5"LKZ<\)
MB[5-[\--+YM;V/,Z<V>Q$FB%8*26%^2. =2C+IGB:8?AP+I%/.=OPLZ.A3S_
M$7F[Z1:[B^=P?HS'JE0+#Q+,"&W2;6=_)1'_)XI#X$>X\<M<3WR?4V8;O$F;
M"F%,Y(46]B%&L[PW!U;=^Q'*D#Y=Y$W=;#C"E\1M7SQ@KDJJL4<LA;_*-.VX
M#T$GO,+PHT@,T#.A;-7-DP(,,P.QVN%S-/H6MS5Y+1U"8U3) &\R:O1TR84M
M)FGF5&6BC:TS%QJ(I.XK/!=+??EMP#ZG(3P76LV:TH!#Y5W9'M"];7S8G3EW
MUIUT#50O!RJPP5_,B+63FMAM"[+7ANCJTW-9*AAI;J@_PG'VQ)/WS )]Y:T0
M;[K,O:+7AX/'L8Y"40_4@L7Y:ROKIEYQV43MQU7Z&V4S/O/PIV5"YF$<+U3@
MDIAF[DK6(+BQ66G;QS9+E!;:\V'4!F3I_KH46.K'Q2CAUS$3/=39:1Y&!ZW7
M&P^S[FH3JYPZZ275'>-,$A4V.G@H^K7T,Y#Y*8/ 3M+HLJJ-!.;R>KJFY*88
MRECHG2OXSE)RC=NS!U3EW*?@Q/5\^4 5Q,0 G-KR_VSC])U@)?6EA.0]1B[3
MZ=O,,.3R.=GAY5:ICTDNQB521+!?';UY[\,'M[_0A MCW"YCECC0&9D%*J6O
MZPH*AI7C>]T<6DTD52RE]QH'*0$"?WF1"+0IQAX<P&HYY@!&F&]S"!A'&*QI
M-MQQSQ1WMZ+(^'VK/!3IM\^.FEB9+C+/QPSVGLIP9WL%J-M_L4A2#%I1[Q*W
M#U.7LNJ0NJDZN6,F;JN.<_R(^NY",9)8"DQ;]].:F;*UI@G!>?A'8^4(^A0+
M%?XHBJBXAH\$&KV>9SV9\Z8="BP84 E6#954 44V[!_00FKK2,0>'\PGQCQZ
M+N?'9CT($!GAQ?/B;=GR!V',T-Z*F$14#@0]%+VS (W73RG/#UEZ]7HM6E2F
M6.20_;4P$]-JU+1;_SX/:GJB.X-R)@_]J@FJ\*#A@CO:9>VIRF1S76+?SWP0
M?L-SV5'"?&T35G3H:<PXG,_#Y:L-"S_J*A,I+Z1;537U=N:=HU7(O09277&;
M.U<G_C^.:MX<]#KI9M:SA)=A=3!I*R5X4.J9T'<.Y%'CW>_W"XT?4\5*^26^
MHI:K$E9?# QPYL7;,>#?-)T]//V)TNL5 L$DM69:=+[.P96GRZ(2;$ZA]U6K
M_L30B)LWOHH(EB4YV"S@:(OXAP,AK:" N<_WN',3]\W2?E['V_@K.88WDI/6
MCG,C.>T4U7[6FW>,,I2EMT=<P7F.NGIA+;+V2-F[^-WO(G\Z?_C!BCK- L$B
M7B92CP66 $HW%7KZK]Z(8Q(\5@14_NH-=[=4?:.#LOX_.O#!HXI\8+O3F1CR
MESKY/\L-/TGOU9T)K'7.8,$.Q8'JGYQ$7RQD]M/Y-2"SF"N&<P3"/FVCMBM0
MG5;2S!^XT9NL_?G+]:N2^3^GZ('J&R/3.>9O^=<112QC$,4PWY&NJGD[BLBT
M\ \2'_L>?50'1[%T>(!#Q3=,R4I/9(UY:^?WJ_U2B=+AW9.QCWS #,#>/PUF
M$&SC.,?3O5QM'60OIX*4)8-H5S<V&XK%:JK//5K7^$Z^\[#ST*3 E->O4[&F
M9KJ%'G7>I3YMT8@V+M5BO)PFI7MSY8JSA-6Y_-9"@4I&Z 6W^!09VB:?0\*Z
MQ!/K,IGLG4(4-]];OV)\_[A3[GRF#"/;,[TDCDJ*1C+RYH>,O*R)^$UW ) 7
M[M 1=')*R8=7_&AG-+15X$>-Q&"I"PT'J0NZM$3U7NL/OU 2'[@3=T 1(R]J
M$HRFV>UL$QN%RW^UK339E:G[L$)B6.E8@DD4L^?4XA;6A07$2B!],WD'MOL-
M@,O[;($!TL>'1K<R^WP8SE95#KO%:MH8UO,_-Y4LBA3,1CW]=9M\?[Y]1>JL
M(FC?-45!",9S^G2\1;/0EC;I/'W&?::*I(@2F@V*#E%A__;27'KX?O*^^(U9
MP;"N'H:Y@D/FX'49K)6H=Q2V[W_]]!TC_UQU]W[/L"8-)Z=<A@W>\0)35&#<
M,G4_]@6F G$-!"ZQAKY&,U7WVLM/ZC[/:^'6X$I5Q7E)ON@5?PO.AZ[3$C)"
M\W1F$F),E:NF?6F68#Z'I:[R2CW6RC4MF4PI#E62Z@65<NDSDFC.CGH/<-55
MB!Q4,*U8*1_3QV_,;2=$D5^<E"320&E8@U8@7TIQ_ QZ EPR!/95::U^AXO?
M&)2->B8^*R&"IM/=R_2U:V"077 O1;X2,_.4P.\+G!TI0*N.&NEO9X2:,!+3
M!$)17>I[\22!8F^%61F-JFG6,ISMAEONHG:Z;T():K=R9-ZF;:HQX9VNA>T+
M'=Z;Y(ZSK+_7[K)>3?V2;@O8<4D%+L4ZC\]RA^V.7'J\/():H*S[9,CV, 7>
MI@DYOVQ3B'4NIQVEP7<H@*\<I\A$J+="41LJS[_G.$L?Z3L$!A'?"Q^?B'?V
M/7I.6#YVXR*U_Q->"9BJUTWO94QO2W(ZT[GI[-S?I\+Y#A/J2PWM,K: IN9?
M1!-8_6B@_WV$O?'1;1&5;8$OJB,VYEZF$K\440]E_W# OWD-,"]!Z\ZYXI8+
M$S,OG]J^GV]5RY>WR[_,J*FXHP\5&?%DCU1)VZBK^T2Y=N9VM7,-*-3@3&*U
M,);0U2$YD?WZ*3.=-:/5B@N!?6Q)/U8:R=_*J.T'VMV:/OM8GQ2OL3QZ%QOK
M=6ZQV@J#[),5;NE![,R8N#=[[G?;=7E&@U#UY=[DDS@YIH)7,VU4:/?(U9&0
M99J6>X@_6",XN]CWPJWI0$E*PP%R$V$1#<:T+*G5**NV2%1M738TYS%+'EO\
M"CDAFG>/^,#.M* R"Q0J/L((RSP=QQ2@E@:5,6Y("!$&W'5>9<=07H'4=*R.
MWZXIU8YY#!:4XDI?\[]E!P=AG$IWYD#[:N;V!2,%=@8'M86&KQ<6%$=3$G,4
M3*;?B.16TC/!^]I&/%F4DMU==GI2Z6<K&R/-/R3<N)\-2%@M],3O0SM!&W,G
MJK_G5($'E1SV3K7"32$$W?GNA59YUQL%/S%L/Y-3PEP>YL,*F!)CBA3J Y'#
MDE^BE]+R8<VZDKJG5W0HN,PDPU!+]&_?*U4R1IXSYX<QPG;' YIL #$33@=C
M+%4D9Q:[\2>6K(? *&&_ @CC[9GM.^M'/HV<>#'YP-4O5,,V-3_'PMQ,Y&..
M)V/<O3GU^W1Q0QZ9J.=D#&>FEXEP??.".:-E8TWYC%\"9M#<-SPOU%_AIY/;
MS;68HVF[P>0U&,&65TACT6YWT0'S"&-=M,!J7,?PU(-'/$S(K!O1826"*T)C
M@UH,<V#A6?UIEW&%:K)J&2E$/1$ AO$51A:I>YDE9X[8F!"*_; O)J_9F]0K
MD#D8?[ZIJ?Z$H(\DE.>V](#8(9[=$A_&$W6T8ER:03EY/"@V+I23T#/G$=17
M5C+_;(;R@_7M)Q*=+7<T1=(/#T1-?6#F2(\@++38=-N7!:V;6&XKX_+V]R"D
M32.OSK[7U_7%D_0 Z8/[T15]RSC+W\M)')FW]$!?^\9MVW2+&!FY='\-*3"N
MX;09U?ORXAW-/$&I5KM<<&XML;:A#LI.,0I\[*T3%6*;E*4J5;UC.@Z+!?$Y
MCMHFRV@\Y:ECO[E!Y'#15XPP+$!:@=Y3]QR>]/3="7%@EUQ(Q^VUPLY'SHK(
MMN":RP*%N\N+G?9V:$A7,JVH2#>5MMW[ZN:[_A%X%FOI;UO9FNWG7N\/NR?T
MV> =>2-JE\.P4/3N"DN)0@J27U9 8?A(*V4=E6IS;A7W_O2 9F[6W+B7(L77
M0XHKZLU!N62?AP<K"&QV#5!C>="@[C(O$!W4H-MHR79\6_GU+<G'\4?[UB$/
M2BMYZ7DXF:S:7Y&.4T(^;\HQ54JSA$ZW4)Z=\F!,BW;X!!;KVMWR\D:;34$C
M%0O?\XCQ'%BW?O;8C\BZQ/SJI\(Y8NUU)(.5=+*RB(]0+NZT"8[*B2(SB:'3
M25ZQ(7 AFB8>8CLJYUGU*K_B[[H.PN2(#/X<C#TJ"4(,=[Q,>D?3;3KI:L^O
M-+5)R\(^[CLDGR/=D$250OV%PY++_E;U&01_9DG[8=!;B8=1YD3NZ.U>W8F3
M2"TM097H8TDHZ9 C>#:?\OZ3AH7HFH]T%A8LJBJ K_TNF/QP]3*A'=H,DQ-U
M;8J>Z2$[C>-.1T+?& Y$T/4M?+H]$M "&"[5M0E@S'M-\#&'-\N.:T ''?(!
M<4@%,X74U;:A1H*S9VZ-QLQ)K5<F6EX#+YQ!3'AQJ9?41[D+91L**\+DJQ_E
MBVC4%-V;V>7=*^FS0($UF4%5,+L^UJIG,4DR!V6Y4&=;/?+SJX0UB$W%Q:]I
MV&13SZNP.1)W@JH6[14R]VN@D[7./B0%<;$9?V%0W5!5'S#4/_?*$LIE$[*<
MZ=^S/[)KFM4Y^Q@GC&P2KS-K8-/!.&:Y.1YV[O6<,!-+@A8OB/:]@['Z3<)_
MH?ZBBY%/X$13HBX-KLWE^'GY2VY@X(+>9DS%A3RLO\>$#1.\XBDVB#F&A.C.
MU54@/%_P40MR9]CD!]]9)7<O DC3$TR+2G]N/NB-+6%*-7TX@.?]QI5>BO4)
M@)UJ1SE&8-4NI UANP9C0J&1<M9HC@G=EEI#:=+1^=X-U0_)#BLYF]*<=)S3
MK<_0AW"!"S7?L2:WT\"RN\C].Q)QG@1?N.JJB?:9ZJRT:ST9'^T81ER8#R4X
M.3X\8REK6+L2"U![-<<<L"E%^F@(\/4$X9K.^@[[57W276)I"KF:Z'T_XA7W
MJVF02&2H=0W'@U?J:5*_RFG%Z"QXNOVB_\_XGXIX>/_@^V>K"2<G^<]Q5*C^
M 0*],*ST7RM*VOVNY-^L:/$U0.;+M8BAU38EAT7'GOHZ.3IK<#PXWFQB':^W
MB\0D>^9'2]L?W!UJ<S C>O_]P*>U>91P'/VCFJ-)V,+L8\<:Q3ZD0AK#GH<)
MU$1]Y:X6.F D@SJR*5AH'/B S.9:&?QO\W[]-^1RX22,^],TLH;YW=F3P\NE
MW^R9J<(5V'_<K;Y4,*;F<@GU9<<J?4.1)YR&#Z3^?J[26B@%!554Q6RT@-7&
M#K'6)9)A6.4^JX\'(01T1NZK53'=[3H'0*I"K-^J@'Z+"E)25"[455BXH]]!
MEG=/]N3\C$K[T:W_B+>PG$X65G2-.U_%UJE7U^L%@<6JQ?X6)9'+6=H,.J_I
M12J< 6,X*TK^"!97+L>7]W2)"["[E[7Y'*\@;60H"O2DH!A^"^-8M@3U,(C]
M($9R\47P5FU5TD8OEQTL.5B%Y]L>N9/Q32=]V\L$<))<,E)]&.1)+0-5A4(2
M1U!LI?JFX)C+[W@U\?QE$%;LBJ<9S6BC*U!A/'<9XJ/<FY)7?PUD//6NX(G2
MO:3"Z5S"XF,<BV OYKLE?0E'#UKD[?@ACOE#MBQTQFU';#S\F6_OK[438(DE
M ]H1(#]"FX*N1K++F =Q]O5X'^?5T-:8IHL9,Q7 *8GU%I8P[\>X/D9-H\Y]
MXAJHBE0A6)ASN8AI=TGH;]6Z!FY'=H)G4PF^W)BYNI13,EQMA43[M2])+T#(
M,.O [^5U$< ?ZU7:O63D87B&T+0;O]\=&+/9Y%0V0TP1XEZR;DUPR&TUF8^E
MCX:9_<TR:H]9NV/QYN!B*)9@A!VQB;<6]YC "WT">O14V'Y"0L36UC_=T?UW
M5,$U;NP$V:^4?-D\!\X@%J-K(+15* RK9H]HYA3KD2OK<<(;S$2=%2HPP,6;
MT<-?V[C0')G?-MU:2T@]V]+='Y^/XJ F$'G+,>+4:)YPZN@D#\-YX8[DB9@!
ML,'9<;39H\+L5ZJX'_QO<7 H1D1D4Y'>PO/G'_+EQ^I!B%5=6Q]$?G$P\Z?=
MN(,W&G=Y^/@1,=H<V033%=IKY;^[FT"6Q;NXAK=P7I]5(8]*#LKXH3IYHBK)
MD-O3*.CQ;L3$.],+0@S3V,NSUWEI[E3\5#.!?4%'WO/JK-7MTW_TESB_8_<W
M<V9A(;LK(<E%!BI^!4N8I:4EY+3E0GS?/!XG^4J BG,[C>]=F.:IWV61+^Z-
M.02)P>3X_,IM7:#UY[Y?&CF:ZKI"[A'+2S*MQN#LFS[R';T&JON^7"C;-%$'
M7P-A;HYD&CG+?C:&)EOS^+N"HSBDRZY1%A3#=HD8I0LZC LB-'8?:U\,*^FY
M!N[ M:SI(_K.>FDS_'YUTG$_')'BLL@0>7^S_+[92R3GE5D]TRM$BWV2DJLE
M^V*R1>VK$>4RSQQ[M(.]VE3F.M8VN>N&MH 14K[,+G6,FWB>B1C*NYSY[&LN
MT/U8=!/]<6;.E^TRJ(49:1J:FAPDY+9HO'<(?WK%(\DA!?^UX3:'YNV3H%@X
M,J8- UM4D.]><6*B2R1JBPSJHVO47?G38#EA>;D/B;IJE*.2>I0.G;[?+)V3
MKP'K:X#0EO84#!KJWW/*'RKXD:2"M9KIJ.;YX;N@XVCD>T1?40&VK6"R,R6[
M(;<SP=*ZD]MGSY>^V%3-+7IJ\"3UV4Q^*;^=01?S>-=$+<>W Y(5R;O7)H-]
M%C ^\B9D7%Z9ZWYD%-OS7R0?HG"B](JOIC/N3,,]+J1@F]U+K!,%4R=INUP1
M<\,+>%REW%$?<3B_\:#$<%9-&#%YZ$#$<JP"Z2)LM??<-+)%%LUUK[3)N#R!
M.0>J(\;'09>KT_3XHF?!,+:U ]E@['>:A4E$Q++"S'5,PV4(PX\O]7KCMI(S
M:$9=U=(TJ^KBM8II7]K,_/PLZ(RS.\)&83*+2CY]/%[#GXF'B>RY4>?PD\$O
M>.HQS)+=35._XF=4D]2!+^8="^KW)G%]3616S#DFKHC_()J91=7'L]'70-1P
M=+;M8,E6ZLL9"@UH_N#&G^@ZD2QI\[Z--=+5HJS;!JSAOL)PW<NB*P&8D!+F
M4P8(U1YT4#K4-G1[^A0^R$I1]!&4+)N>]/U'(1W^S(@IL9PY&K12OZ>RZL>P
MQ2+.;89TLK8TYTYQT%TR=XUTDC@E-1W2!8KHC"R?:?F@5QP#&1S]KQ[ 'Z'W
M\_,\7 HQ/PRAY67<RG?F/U,5APTPQK@,'S[YG7P9W"*GP(*I[T!A9GK&,(8F
MDSHZL<_\.-2/MW6='@JO>SY0+!(8!@X?,0W'H6.1R5V0&-H;-WLS&\?7 */-
MF2]Q,]JVVSSO7GA5$M&<:@!'XX-,3D&C>&<0W>:@+]75G*_"%!RR8F_Z'"T+
MRYCI:4HUL&V[4X_Z5/?-YO1WHW(2R4I[ZWWWA(:X8>FUV$KQ6/\F[E:T]U/T
MR?[ZSS,) _PE%AG#OI Y;T\E0D'?4_6WPE+E>HB9O<),4G%[-IMKX"X6+L>7
M,\0US4)I_U(@B/T[M\1]/ T6C3^,,[N/6.Q0F_U^#+YL\*>8"?GDR*PT111W
MJ[=E <P&*K%^HDHBE/!N J%/\83GI\C/UU%G3#-[NQ=JL'XC3&:6S1484R"1
M4F;:K.2]$DN!X8(V?$95&ABSKVW2B;S)2'MFM^V' R>84&!=P*JE#AI,F4 8
M=YQWDE]PEE+.?F=[HTP>R,F(,8\GHNZW\:MB3F<10 W7(OW"EL306!;Z1LE4
MU12D;,-ZR)Q#"?N;[/2B3GK. H5/.(>3VBH U3_AICI'P@U!(?ONY?=:/_H>
M"$%<]K%;.'*&R"VXI'WE0X'CP#,G+^],QTU#4^*KNT-.SAG<Z/OT#FL*EJVE
M.0?GLJ"UUD(,!)5A5Y*+E@S_-.C&3FDX]T/A,*?A2G.N]1OI<X" S^;K_W /
M:VWL<*5*%'G\Q *%^)I_I/>K&V]0=*R]< T8*+##%;^A:.).(Z.T/+E56K.D
MH(S+?PV%77=--,<UT-?4C(GM>68EPCS:T4U27\_\T9WY//,]GOJXT/\P%8&D
MI,(-^_T6S*&^!<L-?;S_X;?_J_B!9@W;;Y%^:_7Y,+$AYHZGRQ7+,2RV1W>)
ML4KTI]*/!;4[<HTW==VK C5SLX").:&^X4^U=7X9-13N3XM)=X=L/B+L-@V9
M\969U.O)X-(Y)3T(F&V@7"U@_NA;>XSO5*I=G$44(4Q%"O!1T!!U?0U6H;N=
M ]P^<HQDI<Y!?;)^.C[0,,/-J%C! 7A1@ENW>'$4^+&O(<3=E\GY%$[E3X5Q
ML5TW>V1OQ$SVKYB-ZTZ)_S<Q$V'N);ZR7HHEACW1U#!\-46W8)M N=:X\#RC
MY1KP:OKQ3W<>_PF<G(1Q_XO[*?\,ERL!]#L6QMJYAJ33QQ<-K> YA4D 5M_[
M#>,\8XLTG"4\0!Z?*2P/U_G>Q?*F'JS+:2$M1!;5E9-.JV*;MP[ \:>Y-SGS
MU:[Y;\Y\''3YFS-/9;QD8]=J][/>^@/_G#%7-VE1B2+XY"!(I^7!QK$T]8Q!
M]>3T'QFSP[.\UIY<_[-SOCW?VZI%K<</!_L8.61BKZF-OE<S0YD!U/D4MB:J
M'@!9Y#KJ8[6LC+;[2"$*AT\#'DH.'<']9C$#LN27D':G;[$(<*)%[.RR";.<
M+B$6U_1*,!9C'>UW%5)Y#< UKX'>48*ZZ:MM;.'<\N(-\QKHEK.[!H[%8R^0
M_^+^B_O_.;>$O\>7O1ZU&)?JEZJ+E%+3 R,.-:X!4G3%-3 Z#3X,]\,TC:$V
M]WY/S_V4]#HH%;>#-=[!-VLX)=6/99G$B?Y'28H5_T=):J\^^BSP^8WF=K\%
M:YDWUBE7NY@CZ*;6$ !4E<K?OG[E5=;V+Q8&BF6.98*'4\0,+'LDZF.$$X:#
MI^11(&Y_*7#$,G5"U_,O0D\Y-HW2S5ZI'G*Q!,6:/C;Q0 @1:=F)VC:57T2_
M>&N4(LT+T;DZ@8Y<2.WJ2<9Z"(6;>2>_W7_XX8Q&_J@I\S^-'IC^QW0P&EX4
M_"[-_.=)&/L7]U_<_S^X)<AE&B5$B7$.I<D V(.VH/&TS"_H9F7-T]H$N0M+
M(:T7H;C7FIM3\-?>&"@084 TP671$,-V8ZO7W\RB^CJ5_#SK[S8S!WNMT&4!
MY/^D8_\K\/'9_*<7-IX !O]/MN2)P?_NVQ]/1W'_V\,1[L=2(V) S?]D__YO
M$#TZ/NZ6!8IJX[D&.E56,8X7KV>QE HX/HJ:7Q2[^B_>V>$*MT.)/#P5-(87
M+R6/8J9.;38:HO56'+O+7/J(D4-J'1F,[6A%#:;!,J/MYQJP"A8)X<_E>^4$
MY+".7@\JG,W,&K4H<7#H,JX"&RQ-Y8N FP^G8DM;S9=5?1II\^ 4NI+WO]C>
MWQR&L49?*([";Y5CEO4Q8^">$C(AK1"[(8EYS>KH_?R/T<4!1'$ILU41I4X)
MF)DZ['O4O<U>4&";."HFT^E6WFECSB)T%.+2_"-Z/3Q.OR[@/?$FGOBZ+QM&
M PU&AG890SK:'B1TI5(*)#9,N,F3[^SLCQ\01B.AG$F\?3_[B'&JYY?\A=^!
M;?SN@F)I*W>7F-"T0<?10IVT7I-7+),&TQ#Y<5C=DWCE@^  AQ?-(>/OU=AF
MBKLO'F]5\'1KWPM>H\"L/DMX49?XP[XF6D!AO,LTK7Q)P>AHW^A>;$=LF((8
M)KP(EM,_5Q\JD-.&*IL)Z<M$#&R:X20INPC'OR'9A*X$SP?C>7!7R?%?2,%5
M&Z<5&/J1E];=9%D8_J=-8^:AJA$K1B:]]Q(,<@_&W\=&Y_8I:"?)Q@* E] '
M/QO^959HE5VJ7W<L%2L)Q%K@(+'$:O0:@')<+G[T7++U_/S#,Z(1_VZ]>!^F
M_[1\NJ;B-NQ\"038>H%CX."O$O6.N3L>NBYJXG7($%,1^ED%U0MT$MEV^J07
M3T=%Y!TL:PO&S .YB <9?7<L[6HLI#^^TL@0U,$]Z,E]*_'MKP92S@=&OV^[
MEIMV@"OK&O-M380:VFM0D* RMVN 2 .1 UVYT$?=L]8Y33%YGO_BD31/W(1
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MEP5I@U,[0A*<"V7#N&AV'HO[SG0WO0J>NARJ2X,Z.A4*VWU_^X'Z0)V.0)'
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M%;'#I"Q4%Z71+"<IBAU-@T[PZ&1^?65Q+E=4(<MP0#0.6,ZH<*W1HPN@J-H
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M#BL.!J@1ACYT<V""R,EV3))-(I?9HW4/WX*T$.?*%;9.EC*B3[YO/@SBVF[
M":/#K-%Q\3?WW<Z5RG(SL64V@35,-G+@VN=&GS //>SV=7=+O*S"FFX!O;6.
MR+#X3HMZMU8VSN3<@Z<&<4@]79#OB)5TNQ='<EC0OW_Q@)"@*:*4G.%\0U@W
M<.[,@1S,;(RA2BA>IU0VA6=<(DB0A8 ?J0]85+[BL<</VTN_8#Y/;Y\-?;#'
M18=ACO2$J'G6VJEFYX4)E3NK9.@499V*;7IC1  ZCH60%TK$?9-<6.9A+IX[
MOG&&7:KV1/E=&^W#)>U=3_0JK$=Z21UC!N+'6O H-D5VW7]!N*]8P5$#/;00
MR9J)D(T+Z)3?*-2TJJ]X3+9+7T#4?V6EJ<#"7V%$@?,^/C>R9U"-V4VI?D"F
M"R->[L5X#JWO\V=[^7QZH&/,?*2/-%55!(H..%+U(X[KI"_=XV+#2*1">V@'
M@F4K.SN:4U]MZ6@$S@#2JRX?<4KVR?KTW3'Q0CUR?))H0J[-Z=$4E-/ZW.B#
MPJGYL;*9-UBDP <.M<':7,FXK0'@-UQNS&P362NAK,USH#*=KW[2[)_)'Y@8
MXOG\"IHB_-'CM@AU(,;ZGVJB_2LKL.4V<QXRGSJ5!7_2J,@_"JNW$GY[TE__
M6KJ#_UX'=;@#B_B-+%@IQ/]XP!O\9CA0MG#)J3MQ+TEKV?9/6FI1XC^;S?*^
M11RY,Y*3>U )FM42H18/M7N]:=4]]7;N;$1E@\)8GTSJ>V8=?*5*\6_]-[4W
M7>Y&\T V74]@6ME>NV;,84NN_D)FJ6[ILAM38JA>-/1#=K*\JNZDL3K7\O\D
M=%OY(8DD:^>^'E)Q:$6?[&$KL[&EY6+O;IJ?#R\O/\46'Q6I* S 4.CVQWT\
MS*4P,AWB@U:M2]^QT@@N=WNTW^* \']R,K&=])Y412 %T]CQ@)7@#>V=LS)Q
M+S/-+&LMB/MYDJXNKF%#SV?$_!'+QBU=>NQZ:6U!@@F)HS0"1/@4/9+\Y.;#
M1R!0#6+O"!E&Z@84:(/[B>1Q4VE3SCTJJZ;\0>3>Q_^!+YP^YNWHNTI\HJ97
MUU\@>A5@9B/T7/8-'AI4UQI($=2/%=8(Y@<6M$EI]+P7/0F9@0$J?A+I3CCO
M]33"DSNIN>,<^D/OSW1.$CG8"\?6_DUR+4NZ>OC;B%TYUISRTYCX*,V9$8FB
M#)[#'>^RWO#NK3<S1]<<0=AK)WW"D,H="9ULN?E5@YS]JP\32@K#<L([1>[I
MKA 1*QS7JKD<]#! 1*9P3D@) H<##2.ITL'2[6+7\KH"C-PHG6MI2-L:64I$
M4R2843ZNFQI;&2J!#1XN$("?K1J<C ]<L.G/F<L9>M2*YI#?EXR<B#:2P\$:
M]MW'"\\5,)3UT1#JU[DYL2J/U>(\H<H)OO5T>[.V>Q8B 9+I;Q[%$HS3;#"-
M*.>56P,.^:X;1*$IQ,B_.W&=[#7NN7')!3<(N'YB,'@-@9J]]R)KJ>4=Y8_
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M\5LI%@6\2_5N8T2WNZ9@'G13[@,?8*AZ5$<QOQI>BN?8M[<ZI;S)>5TM&D5
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M0G<2X<=:<.G^>;)N+W]R]E[W&=:9.'FCZ0?7(PQ51+U.O[2;KYB4C838^X#
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M+H#H34(_)7/^?WHBM&P_C#ZI94 ]\JK<;F[/HYWB&O>V[6^XKQ?S1H>(4[I
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M"Q<HM:-1,\4;()]M3L[ PWL_?]#;B0IW?>Q,UE9MG;P<,R#?S8AW:1(O*&J
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M@/6/?NPKO[%<4Q^?S>%/NG8*=\85&/('A&NTF7@BKT5@W[:,")+^[9O%%>[
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MM] WQG"12V1,%I!FDYWS*%TM?KWH#NN(W_F_-<O^_[I>;(ICM^=.*#EA=K"
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M#DWH?QF]V6%UO+3>ITC;T3SMU-J4KMZ2.$?4'#D>791+^>Q=DB;#^&?4X/H
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M8SHCS\MI6)%G#EO7DL<\8#Z?[-%G(PO=[=C%H-*]5C&94K>C]\/UR5M%U7<
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M?I^".?9"'DI&PU$DI%&;.9O'QP*='3GG!SN. ";^YNPU,[!K0>BQ]FL-1B,
MP/N%;[G 4U:TQ.O[$Y5W!\CQL\8^$+NOL";.>2362Q,AXW(UU_CI=X#HPBMS
MBG^[/O?').D.@)'RC0$4WU0179^UW@%^ZH1@,Y7^?Q3>?H+0&L@6^]F4Z#QG
M/(U-[F_B#,I2F8[8SU)@5L6A*GVOY_Y.T\WUM9.51<KL^E^L?^*S@<R=Y#K9
M;+>!_X6]]PQKLFG71H,H71 $Z40%0;I2I!-1Z2("TDM41$I$I'>"2J\" @)"
ME"*=2.^$7J672">A]X02 H1D\ZQO'7N_S[N^]]G?6N]:>Z\?Z\?D2(XY9NYK
MSIFKG-?,/3%3#Y7J.>367ZXX96-U2V:]HQ&6-9,(!]9C=R,#9'H=%7FJFY@P
MYHN_L(H3\9R%'0-4E?>5GT*;O ]:V.13@2WIYET^E8BP)B'+CH*95J)C<DAQ
MC-LF4*>-:(;(E^-6_W4WUB9&*D3ZT=.P;T(%40#*^Y<\7?5:_:Y]/3U+7&L:
MW??Q5AJ /(-C?4NWQT]PA#-Z8=31![^[F#XM"#>M;FU8]_2.V$I5DG9D\LZ(
MAK&(SRD=YI+[G^ HK#"&R2<4"LC55[FKW?VP'%$F"(6HD "*.P@,$YC('[MM
M!UI-1Q(O:), [>-3PA(1_]QDT!4>'YP9]4(4IN7$M@7TXUN4HF)B<O.$C"\:
M1\YX@=K!E^!\8P%<.7.5J'P^B5F\\HZ@>A*#R$2\!"$W_[>7,H%LM\+8D.[1
MVIQ"QT[&()$A=9QM+(<C=6NB_^T[(@#?A1H,PS'<2Y9NG5/9FUTO-Z^IK0@(
M?G6?7JY[\(D\TOA/TJ&4>?VNE6$],C-N##O98*JCML<B_1W:GR-.KPIH/CUH
M6>69X8+2$.P;A]QK_(2Q$@/B])N#097CO *G"OK;7Y84>8$[,FL:+,,BBL("
M!K1PKT,KV*^&B<*"C5<%O6G+Q4<'T"42(-L'AJL [@]LD@!DYT$-VHXX\9'H
M/0M=X$,0="PS&T:+_ID%W$<PP<>2 #2(MJHI.,X3!TOWJ&HRABU;W]ZN5S _
M_=*I@/P,;0-#QW)(@$1QXKB5F+A<\_."4RY5;>W*;!* ;]"5.OXUVXG5-(-N
MJM(NRW&%+PGPC^5UX>'!MWW?X*$:):@664S;"7OPW9PP?\]+*)/PJP%4>:P&
M[SX#H1PVYOB/%;E1YOUJ_.OY#N"U*L0N'6% *>2RFV(7;1^[FN>*9G:"8VY5
M)+B1:U.D8U]+(KC67*?JLX$9R+O>_]<NXD\86,R'*8MY&;=)2,F<9/25-E=H
M6/X0^/F;E5<97Z2'V>S@$3IN,$7WO*QV:OQA)XSS:@IYN/\3!TIW5V;#^Z+F
M*6\3NT<<MVTZZ4X]>P-*)ITF<J?0FU :&MJ&2BB>!OHU^;M5%^5#?"77O-T:
M B,HWBL^MIB+CT23 (R(9-0\C4[.5+6.NE7$_;L;-^^;SW"AL\ A7>UTM[#)
M8>ZP*Z^6?K<YBA9_P_V.3#CLAAMGQN:I_:A)D<_0U2 !%H1Z"#O *8G<']=H
M8*D38/S5>K"P#QL'=T@H*LVI?-W,=!2]4X5C$MO-GX[W[[?_D_*5#%M%O6!3
M5:/IX7FU*A3ODE;OW_O7ZE?VGVHKBW:OF*[-"8[>&CTTIW9RY-OD2G+!^*M,
M?_+ODFY4?9S%WM&IM9Y,W?OU\\(6TJ#[1BV6M37\P13_=S2"^H)FB+:W\O1+
MV%8Y@$]E';E& 6G"[,:Z@5G6-WUS+'I\R1:^%"^]##TMNH#Q+_Q>0MX^3]OG
MX 3WTC\B,NY>^>H=]?&,8\M]6LKZ(VR7+.,\2&I,?'.M0FD-*CP+#4:<W2*D
M_CYLK*3S^!+KDKM_*XL$8 *?Z!_GUD[^8_N%Y$9!(R[XZTD!F4VAK0IHWE;5
M&R2 >AUP+N1)*&AV<SIUM[ IY&;&3<6Q>;C;J71=0"X,?-GXLIA9P6S=C_K<
M<JM@\;_M;_A/8-:KNG%U_&4]0/]O54G7R2U92TLD@A+8$'X>K#ZX\..?H'*%
M^1L>/J)!1\BCIY.F]X.7:]);^1SDX[L"A6/PL=C01W@7QZWLJP[$&PT*;RJ4
MY/SZ\G\?'*O/@G&Q39)1QIP__ 2P#!WF:]*("->"W]^9IKSD>Q_B3!B>OF4#
MSB&JGS3&"#<EL<X:0II, L2'W0^G?ZVD.WH+%O9AK. ',S9=[4XL?@YU"4_P
M+M&97O86'>Z+G+\1$_1!9H_>F9  5<ZQN"?4NP%<?@)#RFR3&G6O&)2S7/M7
M"KWF;,:G;6^E#RIY-S?C2NJFIC@5O!:JPZ]_N$45I_;=D/D=@#R0,D=;JT0X
M5;DW8CGT+9R@"U^JNQ[,J>Q=W[=W8 FZDQDA'+3^O\6D&PL.<H-RV26L<^S
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M;OJSZ@5!PN*;4Y_<-UKH7^20>V;\[#!?7=B*=Y?'^,][]_ 8T=!=K 86JY,
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MS'@#0(3WD#\Q98WU^'=WHN#04'GFH4FYV8B#PG0]X9D=(Y46J? 2L_F#:B+
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MJVHBQ(U!1D9OK!_OZ)]E-*WG((FZ+60QHAUHW"UAAFM3OFQMJVO+L9RJ%'Z
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M+X/)U5$$8IP&$D3ZSYW$_?E;6*I6.OLL^$ZSTMVW906O<E4<?@2--:;RQ4=
M[46$>OV?-,YM8V4C?M9D7R'L)QXES1A=(2K&TG\P!(R2A"36C1V?LRW)?GU!
M-J<(@A+_@5** M6DM1B:0UEDZA/,*X0^-4-FF)GG%@N-KD=5VNV3AVM]6[X+
MN$9T@(Z((= !79Q70:,3Q 2/?V>4\>LW*RNGD\NT5NU6[K$+\ZMO;G'*@U^8
M;*CU$9:+BEW(5L_),<_R/ O(>YSFW+,\ BOQ FTW@IAX^/>-N.?;0@C  XE%
MES:\(,2UCQ'Y?=;]P!__HLWOE3YF.=[IC!4D-J7D,9GHNLUV()5DM?6I8@!
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M/')0E.$RJT_G@91H-DJEE@R>NF2C&;C\_>8XC8SW*0J3)3^9]6\ [[?LAFX
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MUX)1[&VW0ZZ83EA@%<1Z$U!-AF F##1T2G]:[(8]&^S98.-LT'HI;,#(@,>
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M:H>-V0KFRNHVP>2. ;7GBI[]'U!+ P04    " #X2556Q7S0DG,*  "T5
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M;)P(.67P=!))YSS0!9(!4MA /%/[_UJ?=U%G/*3$FO^'"A)0)>>5M<C"*8W
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M=HYE=FOA;,OELRL3"+,]Y[_2(43(;7HO>9X%>7=<.VS,5@)WKV[S'>X\3GO
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MQA)V%@B&]D<H(9G@Z>V E%JR)$3A)/1D!!O]0!=6[KQ^ER&]L4J!Z0BOK+-
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MFW-4?L[[-ZP)T0=V2JFCE+XZ/#(HRZ?02B4&&GVX_H?I\.!!,TD>3T"XA\,
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MG]7OE!:G!@;Y\^%1$ :YB1L&7SY:% 47V@0=5W$YJ-QX+<167I+>S=T$T4Q
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M+3(P,C(Q,C,Q7VQA8BYX;6Q02P$"% ,4    " #X2556WNH$*[MJ   _W0<
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M9"TR,#(R,3(S,7@Q,&LP,#8N:G!G4$L! A0#%     @ ^$E55EUF H'0L@
M$,8  !@              ( !>TD' '1C;60M,C R,C$R,S%X,3!K,# W+FIP
M9U!+ 0(4 Q0    ( /A)55;X+F;!&,   .G8   8              "  8'\
M!P!T8VUD+3(P,C(Q,C,Q>#$P:S P."YJ<&=02P$"% ,4    " #X2556$J-
MS.P#  "&"P  &               @ '/O @ =&-M9"TR,#(R,3(S,7AE>#(S
M9#$N:'1M4$L! A0#%     @ ^$E55D0INLJ!"@  *U4  !@
M ( !\< ( '1C;60M,C R,C$R,S%X97@S,60Q+FAT;5!+ 0(4 Q0    ( /A)
M55;%?-"2<PH  +14   8              "  :C+" !T8VUD+3(P,C(Q,C,Q
M>&5X,S%D,BYH=&U02P$"% ,4    " #X2556J4$>$5X&  !%(P  &
M        @ %1U@@ =&-M9"TR,#(R,3(S,7AE>#,R9#$N:'1M4$L! A0#%
M  @ ^$E55O!LZE\_!@  M"(  !@              ( !Y=P( '1C;60M,C R
M,C$R,S%X97@S,F0R+FAT;5!+ 0(4 Q0    ( /A)558(C=PV_D(  !^$ 0 7
M              "  5KC" !T8VUD+3(P,C(Q,C,Q>&5X,V0R+FAT;5!+!08
1    $  0 $D$  "-)@D    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
